From lab to life.
Vigorous research. Uncompromising innovation. Steadfast leadership. For over 150 years, Pfizer has been changing the course of diseases and lives through the introduction of new treatments. Today, with the strength of Pfizer behind us, Pfizer Hemophilia is committed to meeting the unmet needs of the community with conviction and compassion.

Join us on the road to innovation.
A snack will be provided prior to the start of the symposium.

For more information, please visit us at the Novo Nordisk Exhibit/Medical Information Area.

www.haemophilia-events.com

For more information, please visit us at the Novo Nordisk Exhibit/Medical Information Area.
# Table of Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Venue and contacts</td>
<td>2</td>
</tr>
<tr>
<td>Welcome message</td>
<td>3</td>
</tr>
<tr>
<td>Committees</td>
<td>5</td>
</tr>
<tr>
<td>Awards and grants</td>
<td>17</td>
</tr>
<tr>
<td>ISTH information</td>
<td>24</td>
</tr>
<tr>
<td>Other meetings</td>
<td>28</td>
</tr>
<tr>
<td>Programme overview</td>
<td>29</td>
</tr>
<tr>
<td>SSC and educational programme</td>
<td>55</td>
</tr>
<tr>
<td>Nurses forum</td>
<td>89</td>
</tr>
<tr>
<td>Scientific programme</td>
<td>95</td>
</tr>
</tbody>
</table>

### Monday
- Plenary lectures                          | 96   |
- State-of-the-art lectures                  | 97   |
- Symposia                                   | 98   |
- Oral communications                        | 104  |
- ePoster presentations                      | 117  |

### Tuesday
- Plenary lectures                           | 160  |
- State-of-the-art lectures                   | 161  |
- Symposia                                   | 162  |
- Oral communications                        | 168  |
- ePoster presentations                       | 182  |

### Wednesday
- Plenary lectures                           | 224  |
- State-of-the-art lectures                   | 225  |
- Symposia                                   | 226  |
- Oral communications                        | 233  |
- ePoster presentations                       | 246  |

### Thursday
- Plenary lectures (Presidential Symposium)   | 288  |
- State-of-the-art lectures                   | 289  |
- Symposia                                   | 290  |
- Oral communications                        | 296  |
- ePoster presentations                       | 304  |

**ePosters publication only** 348

**Special symposia** 388

**Satellite symposia** 398

**Exhibitors and sponsors** 410

**Exhibition floorplan** 412

**Exhibition and sponsor profiles** 418

**Congress information** 445
- Key information                             | 446  |
- Scientific information                      | 451  |
- ePosters information                        | 454  |
- General information                         | 460  |
- Amsterdam information                       | 462  |
- Future ISTH Congresses                      | 464  |

**Social programme** 470

**Index** 478

**Layout of the congress venue** inside back cover
Venue and contacts

Venue

**Amsterdam RAI**
Europaplein 22 (entrance K)
NL 1078 GZ
Amsterdam, The Netherlands
T: +31 (0) 20 549 12 12
F: +31 (0) 20 646 44 69
W: www.rai.nl/en

Contacts

**ISTH Headquarters**
610 Jones Ferry Road Suite 205
Carrboro, NC 27510
USA
T: +1 919 929 3807
F: +1 919 929 3935
E: headquarters@isth.org
W: www.isth.org

**Hotel Accommodations**
RAI Hotel and Travel Service
P.O. Box 77777
1070 MS Amsterdam
The Netherlands
T: +31 20 549 1927
F: +31 20 549 1946
E: hotelservice@rai.nl

**ISTH 2013 Organising Secretariat**
(logistics, sponsorship, exhibition, abstract handling & registration)
c/o MCI Amsterdam
Jan van Goyenkade 11
1075 HP Amsterdam
The Netherlands
T: +31 20 679 34 11
F: +31 20 673 73 06
E: isth2013@mci-group.com
W: www.isth23013.org
Welcome

It is our privilege to extend to you a warm welcome to The Netherlands, a country with rich cultural heritage, diverse and creative culture and a long and prestigious history of seminal scientific discoveries. Its capital Amsterdam is the perfect location to bring together researchers, scientists, clinicians and allied health professionals from across the globe in the spirit of collaboration, discussion and the translation of science.

The biennial ISTH Congress is the most important event for the advancement of thrombosis and haemostasis. As a global organisation, it is important for us to not only welcome participants from all over the world at our scientific gatherings, but also that the ISTH holds its congresses in different parts of the world to allow for more access. In the past ten years, our congresses brought leading experts together in Kyoto, Japan; Boston, USA; Geneva, Switzerland; Sydney, Australia; and, Birmingham, UK. With our breadth of international experience, we come together to exchange the latest developments in clinical medicine and basic science, and discuss the newest clinical applications designed to improve patient care.

The Congress will traditionally be preceded by the meeting of the Scientific and Standardization Committee of the ISTH on Saturday and Sunday, with progress and final reports on many of the projects of the SSC. In this weekend there will also be an extensive and diverse educational programme, which kicks off with the views of a bibliometrics scientist and science journalist, and ranges from introductions to the specific expertise of the various subcommittees to informal masterclasses where young investigators can interact with the international leaders in the field. On Saturday we also welcome the recipients of the Young Investigator and Reach the World awards for an informal lunch.

The Opening Ceremony on Sunday will give a first glimpse of the concert evening on Tuesday and the party on Wednesday, where internationally renowned musicians and artists will perform, and will be the first of many opportunities to meet colleagues and friends in a relaxing atmosphere. For the scientific programme, there will be 10 plenary lectures, 36 state-of-the-art lectures where the most renowned researchers in the field as well as rising stars will present up-to-date overviews of their field. 45 invited speakers will each introduce an abstract symposium. Focus symposia will highlight specific questions, e.g., from the developing world, and on specific groups e.g., children. And of course, the heart of the meeting will be the oral and poster sessions which offer the best from the nearly 3000 abstracts submitted to the meeting. Both on Monday and Thursday there will be late-breaking abstracts, with the newest results from superb studies. At the large exhibition it is possible to meet representatives from the diagnostic and pharmaceutical industry who have also organised special and satellite symposia.
And finally, on Thursday, there is the Presidential Symposium. Here, we will look again at science in a broader context, and have three presentations on evolution: evolution of altruism, of causal thinking and of music. The survival of the funkiest.

Some innovations will be introduced at this meeting: all posters will be electronic with a special format to allow presentation and discussion at allotted times while all posters can be viewed outside these times with the user-friendly touch-screens. Have you missed a lecture because of parallel sessions? In the Recap lounges the State-of-the-Art lectures and some other presentations will be replayed. The congress app, to be installed on mobile devices, will assist you in finding your way. And, this meeting will also highlight an exciting change for the Society, the unveiling of its new, revitalised brand and logo symbolising the future direction of our organisation.

Enjoy your time in Amsterdam! We look forward to seeing you during the course of the Congress.

Frits Rosendaal
President,
XXIV ISTH Congress

Michael Berndt
Chairman of Council

David Lillicrap
SSC Chairman
ISTH 2013 Committees

ISTH 2013 Organising Committee

Local Organising Committee
Frits Rosendaal, President
Pieter Reitsma, Vice-President
Marcel Levi, Treasurer
Suzanne Cannegieter, Educational Programme
Tilman Hackeng, Innovation

State-of-the-Art Book
Joost Meijers, SOA Book Editor
Jeroen Eikenboom, SOA Book Editor

ISTH 2013 Scientific Programme Committee
Pieter Reitsma, Chairman
Frits Rosendaal
Marcel Levi

Scientific Programme Subcommittee Chairmen
Johan Heemskerk, Platelets
Moniek de Maat, Coagulation and Fibrinolysis
Victor van Hinsbergh, Vascular Biology
Saskia Middeldorp, Venous Thrombotic Disorders
Pieter Willem Kamphuisen, Atherothrombosis
Frank Leebeek, Haemorrhagic Disorders
Flip de Groot, Inflammation and Immunology
Waander van Heerde, New Laboratory Technologies
ISTH 2013 Committees

ISTH 2013 Social Programme Committee
Menno Huisman, Chairman
Mettine Bos
Suzanne Cannegieter
Tilman Hackeng
Ton Lisman
Marjolein Peters

Scientific and Standardisation Committee
David Lillicrap, SSC Chairman
Hugo ten Cate, SSC Liaison

Innovation Committee
Tilman Hackeng
Henri Spronk

Scientific Programme Subcommittee
**ISTH 2013 Committees**

**Scientific Programme Subcommittees**

**Atherothrombosis**  
Pieter Willem Kamphuisen, *Chairman*  
Ale Algra  
Menno Huisman  
Leon Schurgers  
Hugo ten Cate

**Coagulation and fibrinolysis**  
Moniek de Maat, *Chairman*  
Mettine Bos  
Tilman Hackeng  
Ton Lisman  
Joost Meijers  
Dick Rijken  
Shirley Uitte de Willige  
Henri Versteeg

**Haemorrhagic disorders**  
Frank Leebeek, *Chairman*  
Jeroen Eikenboom  
Karin Fijnvandraat  
Marieke Krup  
Karina Meijer  
Jan Voorberg  
Roger Schutgens  
Anske van der Bom

**Inflammation and immunology**  
Flip de Groot, *Chairman*  
Coen Maas  
Arnold Spek  
Rolf Urbanus  
Kees van ’t Veer  
Sacha Zeerleder  
Jan-Jaap Zwaginga

**New technologies**  
Waander van Heerde, *Chairman*  
Piet Meijer  
Gerry Nicolaes  
Guus Sturk  
Chris Reutelingsberger  
Carla Vossen

**Platelets**  
Johan Heemskerk, *Chairman*  
Judith Cosemans  
Rob Fijnheer  
Christian Hackeng  
Mark Roest  
Rienk Nieuwland

**Vascular biology**  
Victor van Hinsbergh, *Chairman*  
Anton Horrevoets  
Esther Lutgens  
Hetty de Boer  
Carlie de Vries  
Jaap van Buul

**Venous thrombotic disorders**  
Saskia Middeldorp, *Chairman*  
Elisabetta Castoldi  
Willem Lijfering  
Astrid van Hylckama Vlieg  
Felix van der Meer  
Heleen van Ommen  
Bart van Vlijmen
ISTH 2013 Committees

Advisory Boards

ISTH 2013 Senior Advisory Board
Harry Büller, Chairman
Jan Willem Akkerman
Rogier Bertina
Bonno Bouma
Pieter Brakman
Ernest Briët
Jan Wouter ten Cate
Coen Hemker
Fredy Loeliger
Jan van Mourik
Hans Pannekoek
Jan Rosing
Jan Sixma

International Advisory Board
Walter Ageno, Italy
Pantep Angchaisuksiri, Thailand
Anne Angelillo-Scherrer, Switzerland
Valder Arruda, USA
Simona Avram, Romania
Trevor Baglin, United Kingdom
Paul Bock, USA
Rodney Camire, USA
Patricia Casais, Argentina
Barry Coller, USA
Javier Corral, Spain
Shaun Coughlin, USA
Mark Crowther, Canada
Björn Dahlbäck, Sweden
Philippe de Moerloose, Switzerland
Hans Deckmyn, Belgium
Cécile Denis, France
Françoise Dignat-George, France
Donna DiMichele, USA
James Douketis, Canada
Etim Essien, Nigeria
Anna Falanga, Italy
Charles Francis, USA
Christian Gachet, France
David Gailani, USA
David Ginsburg, USA
Mike Greaves, United Kingdom
John Griffin, USA
John-Bjarne Hansen, Norway
Paul Harrison, United Kingdom
Philip Hogg, Australia
Keith Hoots, USA
Marc Hoylaerts, Belgium
Beverley Hunt, United Kingdom
James Huntington, United Kingdom
Yasua Ikeda, Japan
Raúl Izaguirre, Mexico
Barry Jacobson, South-Africa
Gerhard Johnson, USA
Steve Kitchen, United Kingdom
Sriram Krishnaswamy, USA
Paul Kyrle, Austria
Bernhard Lämmle, Switzerland
David Lane, United Kingdom
Agnes Lee, Canada
David Lillicrap, Canada
Nigel Mackman, USA
Robert Medcalf, Australia
Diego Mezzano, Chile
Stephan Moll, USA
Laurent Mosnier, USA
Bernhard Nieswandt, Germany
Doyeun Oh, South-Korea
Thomas Ortel, USA
Bjarne Østerud, Norway
Willem Ouwehand, United Kingdom
Ian Peake, United Kingdom
Jaime Pereira, Chile
Flora Peyvandi, Italy
Paolo Prandoni, Italy
Klaus Preissner, Germany
Margaret Ragni, USA
Thomas Renné, Sweden
Alireza Rezaie, USA
Suely Rezende, Brazil
Frederick Rickles, USA
Francesco Rodeghiero, Italy
Wolfram Ruf, USA
Evan Sadler, USA
Per Morten Sandset, Norway
Uri Seligsohn, Israel
Margit Serban, Romania
Vicente Vicente, Spain
Denisa Wagner, USA
Christopher Ward, Australia
Steve Watson, United Kingdom
Hartmut Weiler, USA
Alisa Wolberg, USA
### ISTH 2013 Reviewers

<table>
<thead>
<tr>
<th>Committee</th>
<th>Name</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Ulrich Abildgaard, Norway</td>
</tr>
<tr>
<td></td>
<td>Thomas Abshire, USA</td>
</tr>
<tr>
<td></td>
<td>Yolanda Patricia Adamczuk, Argentina</td>
</tr>
<tr>
<td></td>
<td>Murray Adams, Australia</td>
</tr>
<tr>
<td></td>
<td>Dorothy Adcock, USA</td>
</tr>
<tr>
<td></td>
<td>Walter Ageno, Italy</td>
</tr>
<tr>
<td></td>
<td>Giancarlo Agnelli, Italy</td>
</tr>
<tr>
<td></td>
<td>Josefín Ahsström, United Kingdom</td>
</tr>
<tr>
<td></td>
<td>Ingo Ahrens, Germany</td>
</tr>
<tr>
<td></td>
<td>Masanori Aikawa, USA</td>
</tr>
<tr>
<td></td>
<td>Ramzi Ajjan, United Kingdom</td>
</tr>
<tr>
<td></td>
<td>Nadine Ajzenberg, France</td>
</tr>
<tr>
<td></td>
<td>Lorenzo Alberio, Switzerland</td>
</tr>
<tr>
<td></td>
<td>Marie-Christine Alessi, France</td>
</tr>
<tr>
<td></td>
<td>Ale Algra, The Netherlands</td>
</tr>
<tr>
<td></td>
<td>Hamid Al-Mondhiry, USA</td>
</tr>
<tr>
<td></td>
<td>Kagehiro Amano, Japan</td>
</tr>
<tr>
<td></td>
<td>Robert Andrews, Australia</td>
</tr>
<tr>
<td></td>
<td>Pantep Angchaisuksiri, Thailand</td>
</tr>
<tr>
<td></td>
<td>Anne Angelillo-Scherrer, Switzerland</td>
</tr>
<tr>
<td></td>
<td>Dominick Angiolillo, USA</td>
</tr>
<tr>
<td></td>
<td>Jack Ansell, USA</td>
</tr>
<tr>
<td></td>
<td>Morio Arai, Japan</td>
</tr>
<tr>
<td></td>
<td>Robert Ariëns, United Kingdom</td>
</tr>
<tr>
<td></td>
<td>Valder Arruda, USA</td>
</tr>
<tr>
<td></td>
<td>Roopen Arya, United Kingdom</td>
</tr>
<tr>
<td></td>
<td>Yuijiro Asada, Japan</td>
</tr>
<tr>
<td></td>
<td>Tatsuya Atsumi, Japan</td>
</tr>
<tr>
<td></td>
<td>Simona Avram, Romania</td>
</tr>
<tr>
<td></td>
<td>Cihan Ay, Austria</td>
</tr>
<tr>
<td></td>
<td>Lina Badimon, Spain</td>
</tr>
<tr>
<td></td>
<td>Juan Jose Badimon, USA</td>
</tr>
<tr>
<td></td>
<td>Caroline Baglin, United Kingdom</td>
</tr>
<tr>
<td></td>
<td>Wadie Bahou, USA</td>
</tr>
<tr>
<td></td>
<td>Alessandra Balduini, Italy</td>
</tr>
<tr>
<td></td>
<td>Ivan Bank, The Netherlands</td>
</tr>
<tr>
<td></td>
<td>Trevor Barrowcliffe, United Kingdom</td>
</tr>
<tr>
<td></td>
<td>Shannon Bates, Canada</td>
</tr>
<tr>
<td></td>
<td>Angelika Batorova, Slovakia</td>
</tr>
<tr>
<td></td>
<td>Kenneth Bauer, USA</td>
</tr>
<tr>
<td></td>
<td>Cecilia Becattini, Italy</td>
</tr>
<tr>
<td></td>
<td>Richard Becker, USA</td>
</tr>
<tr>
<td></td>
<td>Joel Bennett, USA</td>
</tr>
<tr>
<td></td>
<td>Wolfgang Bergmeier, USA</td>
</tr>
<tr>
<td></td>
<td>David Bergqvist, Sweden</td>
</tr>
<tr>
<td></td>
<td>Francesco Bernardi, Italy</td>
</tr>
<tr>
<td></td>
<td>Michael Berndt, Australia</td>
</tr>
<tr>
<td></td>
<td>Erik Berntorp, Sweden</td>
</tr>
<tr>
<td></td>
<td>Rogier Bertina, The Netherlands</td>
</tr>
<tr>
<td></td>
<td>Alicia Blanco, Argentina</td>
</tr>
<tr>
<td></td>
<td>Paul Bock, USA</td>
</tr>
<tr>
<td></td>
<td>Michael Boffa, Canada</td>
</tr>
<tr>
<td></td>
<td>Vladimir Bogdanov, USA</td>
</tr>
<tr>
<td></td>
<td>Nuala Booth, United Kingdom</td>
</tr>
<tr>
<td></td>
<td>Julian Borissoff, USA</td>
</tr>
<tr>
<td></td>
<td>Mettine Bos, The Netherlands</td>
</tr>
<tr>
<td></td>
<td>Henri Bounnameaux, Switzerland</td>
</tr>
<tr>
<td></td>
<td>Lawrence Brass, USA</td>
</tr>
<tr>
<td></td>
<td>Paul Bray, USA</td>
</tr>
<tr>
<td></td>
<td>Benjamin Brenner, Israel</td>
</tr>
<tr>
<td></td>
<td>George Broze, USA</td>
</tr>
<tr>
<td></td>
<td>Kathleen Brummel-Ziedins, USA</td>
</tr>
<tr>
<td></td>
<td>Saulius Butenas, USA</td>
</tr>
<tr>
<td></td>
<td>Rodney Camire, USA</td>
</tr>
<tr>
<td></td>
<td>Suzanne Cannegieter, The Netherlands</td>
</tr>
<tr>
<td></td>
<td>Marc Carrier, Canada</td>
</tr>
<tr>
<td></td>
<td>Patricia Casais, Argentina</td>
</tr>
<tr>
<td></td>
<td>Elisabetta Castoldi, The Netherlands</td>
</tr>
<tr>
<td></td>
<td>Marco Cattaneo, Italy</td>
</tr>
<tr>
<td></td>
<td>Elizabeth Chalmers, United Kingdom</td>
</tr>
<tr>
<td></td>
<td>Wayne Chandler, USA</td>
</tr>
<tr>
<td></td>
<td>Beng Chong, Australia</td>
</tr>
<tr>
<td></td>
<td>Frank Church, USA</td>
</tr>
<tr>
<td></td>
<td>Douglas Cines, USA</td>
</tr>
<tr>
<td></td>
<td>Peter Clark, United Kingdom</td>
</tr>
<tr>
<td></td>
<td>Kenneth Clemetson, Switzerland</td>
</tr>
<tr>
<td></td>
<td>Barry Coller, USA</td>
</tr>
<tr>
<td></td>
<td>Michiel Coppens, The Netherlands</td>
</tr>
<tr>
<td></td>
<td>Ramon Corbalan, Chili</td>
</tr>
<tr>
<td></td>
<td>Javier Corral, Spain</td>
</tr>
</tbody>
</table>
ISTH 2013 Reviewers

Judith Cosemans, The Netherlands
Benilde Cosmi, Italy
Dermot Cox, Ireland
Jim Crawley, United Kingdom
Mark Crowther, Canada
Mary Cushman, USA
Martina Daly, United Kingdom
Armando D'Angelo, Italy
Alan Daugherty, United Kingdom
Simon Davidson, United Kingdom
Hetty de Boer, The Netherlands
Raimondo De Cristofaro, Italy
Philip de Groot, The Netherlands
Moniek de Maat, The Netherlands
Philippe De Moerloose, Switzerland
Valerio De Stefano, Italy
Carlie de Vries, The Netherlands
Najet Debili, France
Hans Deckmyn, Belgium
Paul Declerck, Belgium
Jay Degen, USA
Cécile Denis, France
Francesco Dentali, Italy
Karl Desch, USA
Scott Diamond, USA
Françoise Dignat-George, France
James Douketis, Canada
Marie Dreyfus, France
Ludovic Drouet, France
Maura Malone Dumas, USA
Sabine Eichinger, Austria
Jeroen Eikenboom, The Netherlands
Jonas Emsley, United Kingdom
Miguel Escobar, Spain
Naomi Esmon, USA
Anna Falanga, Italy
Dominique Farge, France
Richard Farndale, United Kingdom
Emmanuel Favaloro, Australia
Philip Fay, USA
William Fay, USA
Augusto Federici, Italy
Rob Fijnheer, The Netherlands
Karin Fijnvandraat, The Netherlands
Kathelijn Fischer, The Netherlands
Garrett Fitzgerald, USA
Robert Flaumenhaft, USA
Jonathan Foley, Canada
Kathleen Freson, Belgium
Satoshi Fujii, Japan
Alain Gadisseur, Belgium
David Gailani, USA
Monica Galli, Italy
Alex Gallus, Australia
Sophie Gandrille, France
David Garcia, USA
Chris Gardiner, United Kingdom
Pascale Gaussem, France
William Geerts, Canada
Jonathan Gibbins, United Kingdom
Ann Gils, Belgium
Samuel Goldhaber, USA
Anne Goodeve, United Kingdom
Shinya Goto, Japan
Jenny Goudemand, France
Mike Greaves, United Kingdom
David Green, USA
Ian Greer, United Kingdom
Andreas Greinacher, Germany
Jean-Christophe Gris, France
Peter Gross, Canada
Yves Gruel, France
Sylvia Haas, Germany
Tilman Hackeng, The Netherlands
John-Bjarne Hansen, Norway
Job Harenberg, Germany
Paul Harrison, United Kingdom
John Hartwig, USA
Tatsuya Hayashi, Japan
Cathy Hayward, Canada
Mary Heeb, USA
Johan Heemskerk, The Netherlands
John Heit, USA
Stan Heptinstall, United Kingdom
Katherine High, USA
Andreas Hillarp, Sweden
Philip Hogg, Canada
Keith Hoots, USA
Marie Hélène Horellou, France
Hisanori Horiuchi, Japan
Marc Hoylaerts, Belgium
Menno Huisman, The Netherlands
Beverley Hunt, United Kingdom
Jim Huntington, United Kingdom
Akitada Ichinose, Italy
Masahiro Ieko, Japan
Yasuo Ikeda, Japan
Aida Inbal, Israel
Alfonso Iorio, Canada
Masaru Ishii, Japan
Shaun Jackson, Australia
Marc Jacquemin, Belgium
Joseph Jakubowski, USA
Martine Jandrot-Perrus, France
Bernd Jilma, Austria
Gerhard Johnson, USA
Rezan Kadir, United Kingdom
Ajay Kakkar, United Kingdom
Michael Kalafatis, USA
Farhad Kamali, United Kingdom
Pieter Willem Kamphuisen, The Netherlands
Carol Kasper, USA
Nevine Kassim, Egypt
Clive Kearon, Canada
David Keeling, United Kingdom
Gili Kenet, Israel
Craig Kessler, USA
Nigel Key, USA
Alok Khorana, USA
Manjunatha Kini, Singapore
Steve Kitchen, United Kingdom
Erik Klok, The Netherlands
Tetsuhito Kojima, Japan
Hiroshi Kojima, Japan
Koichi Kokame, Japan
Kimihiro Komori, Japan
Barbara Konkle, USA
Johanna Kremer Hovinga, Switzerland
Steven Kritis, Australia
Sriram Krishnaswamy, USA
Marieke Kruijf, The Netherlands
Nicole Kuderer, USA
Thomas Kuehne, Switzerland
Satya Kunapuli, USA
Shinichiro Kurosawa, USA
Masataka Kuwana, Japan
Paul Kyrlie, Australia
Bernhard Lämmle, Switzerland
Michael Laffan, United Kingdom
David Lane, United Kingdom
Francois Lanza, France
Daniel Lawrence, USA
Bernard Le Bonniec, France
Grégoire Le Gal, Canada
Agnes Lee, Canada
Frank Leebeek, The Netherlands
Peter Lenting, France
Marcel Levi, The Netherlands
Howard Lieberman, USA
Ri Liesner, United Kingdom
Willem Lijfering, The Netherlands
Roger Lijnen, Belgium
David Lillicrap, Canada
Shu-Wha Lin, Taiwan
Ton Lisman, The Netherlands
Rolf Ljung, Sweden
Pete Lollar, USA
Colin Longstaff, United Kingdom
Marie Lordkipanidzé, United Kingdom
<table>
<thead>
<tr>
<th>Name</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>Luca Lotta</td>
<td>Italy</td>
</tr>
<tr>
<td>Gordon Lowe</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Christopher Ludlam</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Brenda Luken</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Florea Lupu</td>
<td>USA</td>
</tr>
<tr>
<td>Jeanne Lusher</td>
<td>USA</td>
</tr>
<tr>
<td>Esther Lutgens</td>
<td>The Netherlands</td>
</tr>
<tr>
<td>Ian Mackie</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Nigel Mackman</td>
<td>USA</td>
</tr>
<tr>
<td>Mike Makris</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Asrar Malik</td>
<td>USA</td>
</tr>
<tr>
<td>Naveen Manchanda</td>
<td>USA</td>
</tr>
<tr>
<td>Maria Elisa Mancuso</td>
<td>Italy</td>
</tr>
<tr>
<td>Christine Mannhalter</td>
<td>Austria</td>
</tr>
<tr>
<td>Pier Mannucci</td>
<td>Italy</td>
</tr>
<tr>
<td>Marina Marchetti</td>
<td>Italy</td>
</tr>
<tr>
<td>Victor Marder</td>
<td>USA</td>
</tr>
<tr>
<td>Maurizio Margaglione</td>
<td>Italy</td>
</tr>
<tr>
<td>Guglielmo Mariani</td>
<td>Italy</td>
</tr>
<tr>
<td>Richard Marlar</td>
<td>USA</td>
</tr>
<tr>
<td>Ida Martinelli</td>
<td>Italy</td>
</tr>
<tr>
<td>Alan Mast</td>
<td>USA</td>
</tr>
<tr>
<td>Yumiko Matsubara</td>
<td>Japan</td>
</tr>
<tr>
<td>Osamu Matsuo</td>
<td>Japan</td>
</tr>
<tr>
<td>Tadashi Matsushita</td>
<td>Japan</td>
</tr>
<tr>
<td>Owen McCarty</td>
<td>USA</td>
</tr>
<tr>
<td>Keith McCrae</td>
<td>USA</td>
</tr>
<tr>
<td>Claire McLintock</td>
<td>New Zealand</td>
</tr>
<tr>
<td>John McVey</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Robert Medcalf</td>
<td>Australia</td>
</tr>
<tr>
<td>Leonid Medved</td>
<td>USA</td>
</tr>
<tr>
<td>Piet Meijer</td>
<td>The Netherlands</td>
</tr>
<tr>
<td>Karina Meijer</td>
<td>The Netherlands</td>
</tr>
<tr>
<td>Joost Meijers</td>
<td>The Netherlands</td>
</tr>
<tr>
<td>Koen Mertens</td>
<td>The Netherlands</td>
</tr>
<tr>
<td>Diego Mezzano</td>
<td>Chili</td>
</tr>
<tr>
<td>Alan Michelson</td>
<td>USA</td>
</tr>
<tr>
<td>Saskia Middeldorp</td>
<td>The Netherlands</td>
</tr>
<tr>
<td>Jonathan Miller</td>
<td>USA</td>
</tr>
<tr>
<td>Jun Mizuguchi</td>
<td>Japan</td>
</tr>
<tr>
<td>Marco Moia</td>
<td>Italy</td>
</tr>
<tr>
<td>Stephan Moll</td>
<td>USA</td>
</tr>
<tr>
<td>Paul Monagle</td>
<td>Australia</td>
</tr>
<tr>
<td>Paul Monahan</td>
<td>USA</td>
</tr>
<tr>
<td>Manuel Monreal</td>
<td>Spain</td>
</tr>
<tr>
<td>Dougald Monroe</td>
<td>USA</td>
</tr>
<tr>
<td>Robert Montgomery</td>
<td>USA</td>
</tr>
<tr>
<td>Karel Moons</td>
<td>The Netherlands</td>
</tr>
<tr>
<td>Pierre-Emmanuel Morange</td>
<td>France</td>
</tr>
<tr>
<td>Massiomo Morfini</td>
<td>Italy</td>
</tr>
<tr>
<td>Takashi Morita</td>
<td>Japan</td>
</tr>
<tr>
<td>James Morrissey</td>
<td>USA</td>
</tr>
<tr>
<td>Laurent Mosnier</td>
<td>USA</td>
</tr>
<tr>
<td>David Motto</td>
<td>USA</td>
</tr>
<tr>
<td>Andrew Mumford</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>László Muszbek</td>
<td>Hungary</td>
</tr>
<tr>
<td>Nicola Mutch</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Khalid Naseem</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Amit Nathwani</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Marguerite Neerman-Arbez</td>
<td>Switzerland</td>
</tr>
<tr>
<td>Claude Negrier</td>
<td>France</td>
</tr>
<tr>
<td>Peter Newman</td>
<td>USA</td>
</tr>
<tr>
<td>Heyu Ni</td>
<td>Canada</td>
</tr>
<tr>
<td>William Nichols</td>
<td>USA</td>
</tr>
<tr>
<td>Timothy Nichols</td>
<td>USA</td>
</tr>
<tr>
<td>Gerry Nicolaes</td>
<td>The Netherlands</td>
</tr>
<tr>
<td>Bernhard Nieswandt</td>
<td>Germany</td>
</tr>
<tr>
<td>Rienk Nieuwland</td>
<td>The Netherlands</td>
</tr>
<tr>
<td>Marina Noris</td>
<td>Italy</td>
</tr>
<tr>
<td>Agata Nowak</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Ulrike Nowak-Göttl</td>
<td>Germany</td>
</tr>
<tr>
<td>Paquita Nurden</td>
<td>France</td>
</tr>
<tr>
<td>Doyeun Oh</td>
<td>South-Korea</td>
</tr>
<tr>
<td>Tsukasa Ohmori</td>
<td>Japan</td>
</tr>
<tr>
<td>Susanne Osanto</td>
<td>The Netherlands</td>
</tr>
<tr>
<td>Bjarne Østerud</td>
<td>Norway</td>
</tr>
<tr>
<td>Hans-Martin Otten</td>
<td>The Netherlands</td>
</tr>
<tr>
<td>Willem Ouwehand</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Ingrid Pabinger</td>
<td>Austria</td>
</tr>
<tr>
<td>Gualtiero Palareti</td>
<td>Italy</td>
</tr>
</tbody>
</table>
### ISTH 2013 Reviewers

<table>
<thead>
<tr>
<th>Name</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joseph Palumbo</td>
<td>USA</td>
</tr>
<tr>
<td>Paola Patrignani</td>
<td>Italy</td>
</tr>
<tr>
<td>Rafal Pawlinski</td>
<td>USA</td>
</tr>
<tr>
<td>Bernard Payrastre</td>
<td>France</td>
</tr>
<tr>
<td>Ian Peake, United Kingdom</td>
<td></td>
</tr>
<tr>
<td>Kathelijne Peerlinck, Belgium</td>
<td></td>
</tr>
<tr>
<td>Vittorio Pengo, Italy</td>
<td></td>
</tr>
<tr>
<td>Jaime Pereira, Chile</td>
<td></td>
</tr>
<tr>
<td>Arnoud Perrier, Switzerland</td>
<td></td>
</tr>
<tr>
<td>Egon Persson, Sweden</td>
<td></td>
</tr>
<tr>
<td>Marjolein Peters, The Netherlands</td>
<td></td>
</tr>
<tr>
<td>Flora Peyandi, Italy</td>
<td></td>
</tr>
<tr>
<td>Helen Philippou, United Kingdom</td>
<td></td>
</tr>
<tr>
<td>Silvia Pierangeli, USA</td>
<td></td>
</tr>
<tr>
<td>Marlien Pieter, The Netherlands</td>
<td></td>
</tr>
<tr>
<td>Steven Pipe, USA</td>
<td></td>
</tr>
<tr>
<td>Eleanor Pollak, USA</td>
<td></td>
</tr>
<tr>
<td>Mortimer Poncz, USA</td>
<td></td>
</tr>
<tr>
<td>Alastair Poole, United Kingdom</td>
<td></td>
</tr>
<tr>
<td>Paolo Prandoni, Italy</td>
<td></td>
</tr>
<tr>
<td>Kathleen Pratt, USA</td>
<td></td>
</tr>
<tr>
<td>Klaus Preissner, Germany</td>
<td></td>
</tr>
<tr>
<td>Martin Prins, The Netherlands</td>
<td></td>
</tr>
<tr>
<td>Margaret Ragni, USA</td>
<td></td>
</tr>
<tr>
<td>Janusz Rak, Canada</td>
<td></td>
</tr>
<tr>
<td>Jacob Rand, USA</td>
<td></td>
</tr>
<tr>
<td>Margaret Rand, Canada</td>
<td></td>
</tr>
<tr>
<td>A. Koneti Rao, USA</td>
<td></td>
</tr>
<tr>
<td>Thomas Rennen, Sweden</td>
<td></td>
</tr>
<tr>
<td>Chris Reutelingsperger, The Netherlands</td>
<td></td>
</tr>
<tr>
<td>Suely Rezende, Brazil</td>
<td></td>
</tr>
<tr>
<td>Frederick Rickles, USA</td>
<td></td>
</tr>
<tr>
<td>Dick Rijken, The Netherlands</td>
<td></td>
</tr>
<tr>
<td>Georges Rivard, Canada</td>
<td></td>
</tr>
<tr>
<td>Francesco Rodeghiero, Italy</td>
<td></td>
</tr>
<tr>
<td>Mark Roest, The Netherlands</td>
<td></td>
</tr>
<tr>
<td>Frits Rosendaal, The Netherlands</td>
<td></td>
</tr>
<tr>
<td>Jan Rosing, The Netherlands</td>
<td></td>
</tr>
<tr>
<td>Changgeng Ruan, China</td>
<td></td>
</tr>
<tr>
<td>Wolfram Ruf, USA</td>
<td></td>
</tr>
<tr>
<td>Evan Sadler, USA</td>
<td></td>
</tr>
<tr>
<td>Jean-Marie Saint-Remy, Belgium</td>
<td></td>
</tr>
<tr>
<td>Yoichi Sakata, Japan</td>
<td></td>
</tr>
<tr>
<td>Marc Samama, France</td>
<td></td>
</tr>
<tr>
<td>Per Morten Sandset, Norway</td>
<td></td>
</tr>
<tr>
<td>Elena Santagostino, Italy</td>
<td></td>
</tr>
<tr>
<td>Sentot Santoso, Germany</td>
<td></td>
</tr>
<tr>
<td>Rüdiger Scharf, Germany</td>
<td></td>
</tr>
<tr>
<td>Inge Scharrer, Germany</td>
<td></td>
</tr>
<tr>
<td>Sebastian Schellong, Germany</td>
<td></td>
</tr>
<tr>
<td>Alvin Schmaier, USA</td>
<td></td>
</tr>
<tr>
<td>Sam Schulman, Canada</td>
<td></td>
</tr>
<tr>
<td>Roger Schutgens, The Netherlands</td>
<td></td>
</tr>
<tr>
<td>Jean-François Schved, France</td>
<td></td>
</tr>
<tr>
<td>Marie Scully, United Kingdom</td>
<td></td>
</tr>
<tr>
<td>Mike Scully, United Kingdom</td>
<td></td>
</tr>
<tr>
<td>Uri Seligsohn, Israel</td>
<td></td>
</tr>
<tr>
<td>Amy Shapiro, USA</td>
<td></td>
</tr>
<tr>
<td>Midori Shima, Japan</td>
<td></td>
</tr>
<tr>
<td>Kazuyuki Shimada, Japan</td>
<td></td>
</tr>
<tr>
<td>Keiko Shinizawa, Japan</td>
<td></td>
</tr>
<tr>
<td>Dirk Sibbing, The Netherlands</td>
<td></td>
</tr>
<tr>
<td>Pierre Sie, France</td>
<td></td>
</tr>
<tr>
<td>Bob Siegerink, The Netherlands</td>
<td></td>
</tr>
<tr>
<td>Roy Silverstein, USA</td>
<td></td>
</tr>
<tr>
<td>Robert Simari, USA</td>
<td></td>
</tr>
<tr>
<td>Paolo Simioni, Italy</td>
<td></td>
</tr>
<tr>
<td>Nicholas Smith, USA</td>
<td></td>
</tr>
<tr>
<td>Kenji Soejima, Japan</td>
<td></td>
</tr>
<tr>
<td>Arnold Spek, The Netherlands</td>
<td></td>
</tr>
<tr>
<td>Catherine Sperlich, Canada</td>
<td></td>
</tr>
<tr>
<td>Henri Spronk, The Netherlands</td>
<td></td>
</tr>
<tr>
<td>Alessandro Squizzato, Italy</td>
<td></td>
</tr>
<tr>
<td>Deborah Stearns-Kurosawa, USA</td>
<td></td>
</tr>
<tr>
<td>Hans Stricker, Switzerland</td>
<td></td>
</tr>
<tr>
<td>Sydney Strickland, USA</td>
<td></td>
</tr>
<tr>
<td>Guus Sturk, The Netherlands</td>
<td></td>
</tr>
<tr>
<td>Katsuo Sueishi, Japan</td>
<td></td>
</tr>
<tr>
<td>Campbell Tait, United Kingdom</td>
<td></td>
</tr>
<tr>
<td>Nobuyuki Takakura, Japan</td>
<td></td>
</tr>
</tbody>
</table>
ISTH 2013 Reviewers

Jerome Teitel, Canada
Hugo ten Cate, The Netherlands
Arina ten Cate-Hoek, The Netherlands
Henrik Toft Sørensen, Denmark
Cheng-Hock Toh, United Kingdom
Mauro Torti, Italy
Alberto Tosetto, Italy
David Trégouet, France
JoAnn Trejo, USA
Hiroko Tsuda, Japan
Alexander Turpie, Canada
Yoshio Uetsuka, Japan
Shirley Uitte de Willige, The Netherlands
Aneta Undas, Poland
Tetsuomi Urano, Japan
Rolf Urbanus, The Netherlands
Elizabeth Van Cott, USA
Ton van den Besselaar, The Netherlands
Anske van der Bom, The Netherlands
Felix van der Meer, The Netherlands
Tom van der Poll, The Netherlands
Waander van Heerde, The Netherlands
Victor van Hinsbergh, The Netherlands
Astrid van Hylckama Vlieg, The Netherlands
Heleen van Ommen, The Netherlands
Kees van ´t Veer, The Netherlands
Bart van Vlijmen, The Netherlands
Thierry Vandendriessche, Belgium
Karen Vanhoorelbeke, Belgium
David Varon, Israel
Douglas Vaughan, USA
Henri Versteeg, The Netherlands
Agnes Veyradier, France
Vicente Vicente, Spain
Bruno Villoutreix, France

Jan Voorberg, The Netherlands
Hideo Wada, Japan
Denisa Wagner, USA
Denis Wahl, France
Hironao Wakabayashi, USA
Christopher Ward, Australia
Theodore Warkentin, Canada
Henry Watson, United Kingdom
Steve Watson, United Kingdom
Jeffrey Weitz, Canada
Phil Wells, Canada
Randal Westrick, USA
Richard White, USA
Samuel Wickline, USA
David Wilcox, USA
Julie Williams, USA
Alisa Wolberg, USA
Tim Woods, United Kingdom
Renchi Yang, China
Masahiro Yasaka, Japan
Yutaka Yatomi, Japan
Neil Zakai, USA
Yongqiang Zhao, China
X. Long Zheng, USA
Ariella Zivelin, Israel
ISTH Council

Chair of Council (2012-2014)
Michael Berndt, Australia

Secretary/Chair-Elect (2012-2014)
Nigel Key, USA

Treasurer (2011-2015)
Nuala Booth, United Kingdom

Class of 2014
Nuala Booth, United Kingdom
Françoise Dignat-George, France
Nigel Key, USA
Robert Montgomery, USA
Hugo ten Cate, The Netherlands

Class of 2016
Marco Cattaneo, Italy
Björn Dahlbäck, Sweden
Andreas Greinacher, Germany
Paula Tracy, USA
Yukio Ozaki, Japan

Class of 2018
Peter Lenting, France
Claire McLintock, New Zealand
James Morrissey, USA
Ingrid Pabinger, Austria
Jeffrey Weitz, Canada

Ex-Officio Council Members
Secretary General (2010-2014): Bruce Furie, USA
Immediate Past Chair (of Council): Henri Bounameaux, Switzerland
President of the XXIV Congress (Amsterdam, 2013): Frits Rosendaal, The Netherlands
Vice-President of the XXIV Congress (Amsterdam, 2013): Pieter Reitsma, The Netherlands
Past President of XXIII Congress (Kyoto 2011): Yasuo Ikeda, Japan
Editors in Chief, Journal of Thrombosis and Haemostasis:
Pieter Reitsma and Frits Rosendaal, The Netherlands
Chairman, Scientific and Standardization Committee: David Lillicrap, Canada
ISTH Awards

ISTH 2013 Awards

Robert P. Grant Medal
The Robert P. Grant Medal is the highest award of the ISTH. Presented at each biennial Congress of the Society, it recognises outstanding service or accomplishments which have promoted the goals of the Society: research achievement, organisational activities, important public recognition and support of research activities, facilitation of institutional cooperation and communications, unusual teaching or educational initiatives, or the development of concepts which result in a clearer understanding of the meaning of research data.

*The ISTH Grant Medal will be presented at the Opening Ceremony on Sunday, June 30.*

Biennial Awards for Contributions to Haemostasis
Initiated in 1982, the Biennial Awards for Contributions to Haemostasis (BACH), recognise individuals who have made significant contributions to research and education in blood coagulation. The awards are presented in two categories:

The Investigator Recognition Awards recognise ISTH members whose accomplishments are internationally regarded as exemplary models of excellence in research and teaching.

The Distinguished Career Awards recognise ISTH members whose career contributions have significantly advanced the scientific community’s understanding of the diseases and disorders affecting haemostasis.

*The ISTH BACH Awards will be presented during the Presidential Dinner [invitation only] on Monday, July 1.*
Congress Awards and Grants

Young Investigator Awards (YIA)
The Young Investigators Awards are provided in the form of grants to young researchers and are intended to assist covering expenses related to their participation at the Congress. The grants, consisting of € 500 each, are awarded to investigators who are first author on an accepted abstract based on the abstract review score. Applicants should be younger than 35 of age as of June 29, 2013. Awards are provided by the ISTH with additional support from Daiichi-Sankyo and Octapharma.

Recipients of a Young Investigator Award

Sonia Aguila, Spain  
Iciar Arbesu, Austria  
Cihan Ay, Austria  
Tamam Bakchoul, Germany  
Sandra Baker, USA  
Dario Balestra, Italy  
Sophia Barbar, Italy  
Geoffrey Barnes, USA  
Paul Basciano, USA  
Zsuzsanna Bereczky, Hungary  
Ewa Bielczyk-Maczynska, United Kingdom  
Jenny Björkqvist, Sweden  
Yacine Boulafitli, USA  
Alessio Branchini, Italy  
Loredana Bury, Italy  
Sara Calzavarini, Switzerland  
Elena Campello, Italy  
Ashley Cartwright, United Kingdom  
Caterina Casari, France  
Lana Castellucci, Canada  
Martijn Chatrou, The Netherlands  
Deya Cherpokova, Germany  
Sebastian Düttig, Germany  
Daan de Boer, The Netherlands  
Karen de Cenynck, Belgium  
Hugoline de Haan, The Netherlands  
Steven de Maat, The Netherlands  
Paul den Exter, The Netherlands  
Carsten Deppermann, Germany  
Jonathan Douxfils, Belgium  
Lucy Duan, Canada  
Cedric Duval, United Kingdom  
Marion Egot, France  
Kristin Enga, Norway  
Chao Fang, USA  
Linda Flinterman, The Netherlands  
Ewelina Golebiowska, United Kingdom  
Nimesh Gupta, France  
Matthew Harper, United Kingdom  
Janneke Hendriksen, The Netherlands  
Catherine Hobbs, United Kingdom  
Daniel Horner, United Kingdom  
Simin Jamaly, Norway  
Carolina Jaquenod De Giusti, Argentina  
Reema Jasuja, USA  
Lining Ju, USA  
Alexandre Kauskot, Belgium  
Miriam Kimpton, Canada  
Marie-Claire Kleinegriss, The Netherlands  
Jorine Koenderman, The Netherlands  
Andras Kovacs, Hungary  
Ketan Kulkarni, Canada  
Romaric Lacroix, France  
Frank Lee, Canada  
Catherine Lemarie, Canada
Congress Awards and Grants

Gunhild Lerstad, Norway
Caroline Lind, Norway
Siuh Ling Wong, USA
Viola Lorenz, Germany
Luca Lotta, Italy
Safiah Mai, Canada
Óscar Marcos-Contreras, France
Maura Marcucci, Canada
Sara Martinez de Lizarondo, France
Kimberly Martinod, USA
Davide Matino, Italy
Maximilian Mauler, Germany
Kelly McGowan, Canada
Simone Merlin, Italy
Cláudia Moreira, Portugal
Joshua Muia, USA
Muhammad Mukhlis Mohd Izam, United Kingdom
Thomas Murray-Rust, United Kingdom
Banne Nemeth, The Netherlands
Katrin Nickel, Sweden
Marisa Ninivaggi, The Netherlands
Francesca Nuzzo, The Netherlands
Farida Omarova, The Netherlands
Dirk Paul, United Kingdom
Laura Pepler, Canada
Sameera Peraramelli, The Netherlands
Carlos Perez-Sanchez, Spain
Irina Pleines, Australia
Cristina Puy, USA
Inge Rietveld, The Netherlands
Nicoletta Riva, Italy
Rachel Roach, The Netherlands
Valeria Rossetto, Italy
Essa Sabi, United Kingdom
Yvonne Sanders, The Netherlands
Mathieu Schaff, France
Henrike Schouten, The Netherlands
Anish Sharda, USA
Nuha Shiltagh, United Kingdom
Bob Siegerink, The Netherlands
Lucia Stefanini, USA
Bernardine Stegeman, The Netherlands
David Stegner, Germany
Sara Stoo, The Netherlands
Simon Stritt, Germany
Ingrid Stroo, The Netherlands
Rosa Suades, Spain
Eriko Suzuki, Japan
Laura Swystun, Canada
Maria Talmon, Italy
Claudia Tersteeg, The Netherlands
Nabil Thalji, USA
Jasmijn Timp, The Netherlands
Federica Tosi, Italy
Wei-Lien Tseng, Taiwan
Raymond van Adrichem, The Netherlands
Maartje van den Biggelaar, The Netherlands
Tom van der Hulle, The Netherlands
Dianne van der Wal, Canada
Josien van Es, The Netherlands
Thijs van Holten, The Netherlands
Kathinka van Hooren, The Netherlands
Nienke van Rein, The Netherlands
Fabian Verbij, The Netherlands
Timo Vögtle, Germany
Trang Vu, Canada
Yiming Wang, Canada
Jiong-Wei Wang, Singapore
Xiaowei Wang, Australia
Jovian Wat, Canada
Matthew Whelihan, USA
Kristien Winckers, The Netherlands
Jonathan Yau, Canada
Calvin Yeh, Canada
Ying Zheng, USA
Anna Zufferey, Switzerland
Congress Awards and Grants

Control of Anticoagulation Awards
These awards are part of an SSC Subcommittee on Control of Anticoagulation project and have been made possible thanks to the SSC and the corporate sponsor Sanofi-Aventis.
The Control of Anticoagulation travel awards are provided in the form of travel grants to young researchers (under 35 years of age as of June 28th, 2013) with highly rated abstracts at the XXIV ISTH Congress in Amsterdam. The awards help subsidise travel to the Congress. In order to be considered for an award, the investigator must be the presenter and first author of an abstract submitted to the Congress.

Recipients of a Control of Anticoagulation Award

Tyler Buckner, USA
Elena Campello, Italy
Pichika Chantrathammachart, Thailand
Xue Chen, China
Shanshan Du, Germany
Maarten Hendrickx, Belgium
Sandra Krämer, Germany
Martin Krejczy, Germany
Abimbola Onasoga, USA
Ivan Stevic, Canada
Dianne van der Wal, Australia
Min Xuan, China
Shabanm Zolfaghari, Germany
Congress Awards and Grants

Reach the World Grants
The ISTH 2013 Congress and the ISTH provide travel grants to clinicians and researchers from developing countries to help subsidise travel to the Congress which includes free registration, travel costs and subsistence. The grants are made possible by the ISTH, with additional support from Bayer, Octapharma and Aryogen.

Recipients of a Reach the World Grant

- Minoo Ahmadinejad, Iran
- Mariam Ahmed Badr El Din, Egypt
- Doa Ahmed Gamal Eissa, Egypt
- María Fabiana Alberto, Argentina
- Rumjana Apostolovska, Macedonia
- Alexey Arsenyev, Russian Federation
- Lena Artemenko, Russian Federation
- Abeer Attia Saadeldin, Egypt
- José Azofeifa Campos, Chile
- Anna Balandina, Russian Federation
- Aline Barnabé, Brazil
- Nwogoh Benedict, Nigeria
- Jeffry Beta Tenggara, Indonesia
- Volha Bichan, Republic of Belarus
- Luis Fernando Bittar Sckayer, Brazil
- Vanesa Bittar Sckayer, Argentina
- Jelena Bodrozic, Serbia
- Munira Borhany, Pakistan
- Anggoro Budi Hartopo, Indonesia
- Valentina Budkova, Russian Federation
- Zorica Bumbaroski, Serbia
- Bolor Buyanbadrakh, Mongolia
- Altantsetseg Buyanbat, Mongolia
- Sumiya Byambasuren, Mongolia
- Fidel Manuel Cáceres-Lóriga, Cuba
- Julio Calderazzo, Argentina
- Agostina Carestia, Argentina
- Roberto Jose Castro Fonseca, Brazil
- Carolina Cervio, Argentina
- Kun Chi, China
- Yingyong Chinthammitr, Thailand
- Ligia Maria Claro, Panama
- Tina Cocica, Serbia
- Marina Colella, Brazil
- Evelyn Cortina de la Rosa, Mexico
- Carolina Costa Lima, Brazil
- Andra Costache, Romania
- Jing Dai, China
- Paola D’Atri, Argentina
- Zelda De Lange, South Africa
- Gabriela de Larrañaga, Argentina
- Maria de Lourdes Herrera, Argentina
- Stephan Nicollas De Oliveira, Brazil
- Samuel De Souza Medina, Brazil
- Bruno Deltreggia Benites, Brazil
- Valentina Djordjevic, Serbia
- Lizaveta Drozd, Russian Federation
- Fernanda Dutra Santiago Bassora, Brazil
- Marion Echenagucia, Venezuela
- Shelest Ekaterina, Russian Federation
- Julia Etulain, Argentina
- Rongfeng Fu, China
- Eduardo Fuentes, Chile
- Temirlan Gamzatov, Russian Federation
- Vanessa Gimenez, Argentina
- Anastasia Golomysova, Russian Federation
- Marina Gracheva, Russian Federation
- Irina Gribkova, Russian Federation
- Elena Gupalo, Russian Federation
- Yang He, China
- Shundong Ji, China
- Tibisay Jiménez, Venezuela
- Zhou Jingyi, China
<table>
<thead>
<tr>
<th>Name</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ivana Jovanovic</td>
<td>Serbia</td>
</tr>
<tr>
<td>Bat-Erdene Jugder</td>
<td>Mongolia</td>
</tr>
<tr>
<td>Natalia Korotina</td>
<td>Russian Federation</td>
</tr>
<tr>
<td>Anatoly Kozlov</td>
<td>Russian Federation</td>
</tr>
<tr>
<td>Huiyuan Li</td>
<td>China</td>
</tr>
<tr>
<td>Jiaming li</td>
<td>China</td>
</tr>
<tr>
<td>Mukhametova Lilia</td>
<td>Russian Federation</td>
</tr>
<tr>
<td>Lucia López Vázquez</td>
<td>Venezuela</td>
</tr>
<tr>
<td>Yeling Lu</td>
<td>China</td>
</tr>
<tr>
<td>Andrea Manzino</td>
<td>Uruguay</td>
</tr>
<tr>
<td>Maria Matveeva</td>
<td>Russian Federation</td>
</tr>
<tr>
<td>Tayana Mello</td>
<td>Brazil</td>
</tr>
<tr>
<td>Pravas Mishra</td>
<td>India</td>
</tr>
<tr>
<td>Daniella Mizurini</td>
<td>Brazil</td>
</tr>
<tr>
<td>Jasone Monasterio Aspíri</td>
<td>Spain</td>
</tr>
<tr>
<td>Silmara Montalvão</td>
<td>Brazil</td>
</tr>
<tr>
<td>Soledad Negrotto</td>
<td>Argentina</td>
</tr>
<tr>
<td>Ivanka Nikoloska</td>
<td>Macedonia</td>
</tr>
<tr>
<td>Ndoumba Nkengue</td>
<td>Cameroon</td>
</tr>
<tr>
<td>Theresa Nwaghia</td>
<td>Nigeria</td>
</tr>
<tr>
<td>Sergey Obydennyy</td>
<td>Russian Federation</td>
</tr>
<tr>
<td>Matvienko Olesya</td>
<td>Russian Federation</td>
</tr>
<tr>
<td>Inolyn Pandjaitan</td>
<td>Indonesia</td>
</tr>
<tr>
<td>Marina Panova-Noeva</td>
<td>Macedonia</td>
</tr>
<tr>
<td>Andreea Pascalau</td>
<td>Romania</td>
</tr>
<tr>
<td>Rucha Patil</td>
<td>India</td>
</tr>
<tr>
<td>Sandra Pekovic</td>
<td>Serbia</td>
</tr>
<tr>
<td>Marija Perisic Bozic</td>
<td>Serbia</td>
</tr>
<tr>
<td>Anton Petrov</td>
<td>Russian Federation</td>
</tr>
<tr>
<td>Marlien Pieters</td>
<td>South Africa</td>
</tr>
<tr>
<td>Alexander Poletaev</td>
<td>Russian Federation</td>
</tr>
<tr>
<td>Dmitry Polokhov</td>
<td>Russian Federation</td>
</tr>
<tr>
<td>Santy Pudjianto</td>
<td>Indonesia</td>
</tr>
<tr>
<td>Ira Puspitawati</td>
<td>Indonesia</td>
</tr>
<tr>
<td>Halimatun Radziah Othman</td>
<td>Malaysia</td>
</tr>
<tr>
<td>Lucia Remotti</td>
<td>Argentina</td>
</tr>
<tr>
<td>Elena Ristovska</td>
<td>Macedonia</td>
</tr>
<tr>
<td>Leonardo Rivadeneyra</td>
<td>Argentina</td>
</tr>
<tr>
<td>Ninoska Roza</td>
<td>Peru</td>
</tr>
<tr>
<td>Aisina Roza</td>
<td>Russian Federation</td>
</tr>
<tr>
<td>Deena Samir Eissa</td>
<td>Egypt</td>
</tr>
<tr>
<td>Marko Saracevic</td>
<td>Serbia</td>
</tr>
<tr>
<td>Milena Šćekić</td>
<td>Serbia</td>
</tr>
<tr>
<td>Mirta Schattner</td>
<td>Argentina</td>
</tr>
<tr>
<td>Elena Seregina</td>
<td>Russian Federation</td>
</tr>
<tr>
<td>Sharda Shanbhag</td>
<td>India</td>
</tr>
<tr>
<td>Olga Smirnova</td>
<td>Russian Federation</td>
</tr>
<tr>
<td>Stanislava Sovilj-Gmizic</td>
<td>Serbia</td>
</tr>
<tr>
<td>Stepan Surov</td>
<td>Russian Federation</td>
</tr>
<tr>
<td>Gevorg Tamamyan</td>
<td>Armenia</td>
</tr>
<tr>
<td>IvanTarandovskiy</td>
<td>Russian Federation</td>
</tr>
<tr>
<td>Vladislava Terentyeva</td>
<td>Russian Federation</td>
</tr>
<tr>
<td>Botheina Thabet</td>
<td>Egypt</td>
</tr>
<tr>
<td>Constanza Torres-Urrutia</td>
<td>Chile</td>
</tr>
<tr>
<td>Thais Helena Trento</td>
<td>Brazil</td>
</tr>
<tr>
<td>Hui-Ju Tsai</td>
<td>Taiwan</td>
</tr>
<tr>
<td>Wei-Lien Tseng</td>
<td>Taiwan</td>
</tr>
<tr>
<td>Ana Maria Uribe</td>
<td>Colombia</td>
</tr>
<tr>
<td>Devenkumar Vasantray Desai</td>
<td>India</td>
</tr>
<tr>
<td>Natalya Vorobyeva</td>
<td>Russian Federation</td>
</tr>
<tr>
<td>Biljana Vučković</td>
<td>Serbia</td>
</tr>
<tr>
<td>Zhenya Wang</td>
<td>China</td>
</tr>
<tr>
<td>Luciana Wermelinger Serrão</td>
<td>Brazil</td>
</tr>
<tr>
<td>Adriana Woods</td>
<td>Argentina</td>
</tr>
<tr>
<td>Shi-tong Xiong</td>
<td>China</td>
</tr>
<tr>
<td>Cao Yanan</td>
<td>China</td>
</tr>
<tr>
<td>Yanhui Yang</td>
<td>China</td>
</tr>
<tr>
<td>Guoling You</td>
<td>China</td>
</tr>
<tr>
<td>Mohammad Zekrullah-Faqirzada</td>
<td>Afghanistan</td>
</tr>
<tr>
<td>Ansar Zhalyalov</td>
<td>Russian Federation</td>
</tr>
<tr>
<td>Donglei Zhang</td>
<td>China</td>
</tr>
</tbody>
</table>
Wiley is proud to publish JTH, the official journal of the International Society of Thrombosis and Haemostasis, and other leading journals in haematology.

Do you have access to these top journals?

Don’t miss out on this renowned content! Recommend a subscription to your library today.

Visit www.wileyonlinelibrary.com/subject/hematology for all of our resources in haematology.
ISTH Information

The ISTH is the leading worldwide organisation dedicated to the advancement of the understanding, prevention, diagnosis and treatment of thrombotic and bleeding disorders.

As a professional membership organisation, the ISTH supports a community of specialists in bleeding and clotting disorders through the creation and promotion of education and outreach initiatives, research activities, scientific meetings, peer-reviewed publications, expert committees and the development of standards allowing a common language and approach to basic and clinical science all over the world. The Society is also dedicated to transformative scientific discoveries and fostering the development of the next generation of scientists, physicians, and allied health professionals, wherever they may live. With over 3,200 members in more than 85 countries, the ISTH is highly regarded as an organisation poised on the leading edge of science.

**ISTH membership benefits include:**
- A professional network of over 3,200 members in more than 85 countries
- Priority registration and discounted fees for ISTH meetings and congresses
- Complimentary print (for regular members only) and online subscription to ISTH’s Journal of Thrombosis and Haemostasis (JTH)
- Access to the ISTH members-only online resources, including educational materials, e-learning and membership directory
- Exclusive access and reduced fees for other educational activities, programmes and publications
- The quarterly ISTH Newsletter, regular e-updates and the ISTH Career Center
- The right to nominate, elect and serve on ISTH committees

**ISTH membership categories include:**

*Regular:* for active researchers, educators and clinicians in the field

*Associate:* for students, trainees, research staff, post-doctoral fellows as well as allied health professionals

*Reach-the-World:* for researchers, educators and clinicians in non-industrialised countries

Continued next page
ISTH membership is an essential investment in your future at every stage in your career. With membership, you receive the ISTH's highly regarded Journal of Thrombosis and Haemostasis (JTH), timely information regarding thrombotic and bleeding disorders, targeted educational programs and networking opportunities.

Visit us online to arrive at your career and education destination today.

ISTH Membership Benefits

- International network that spans more than 85 countries
- Priority registration and meeting discounts
- Complimentary print subscription to JTH
- E-learning opportunities
- Access to the ISTH members-only online resources
- Eligibility to hold elected and/or appointed offices
- Vote on Society matters and serve on subcommittees and working groups
- Career center

Mission

The ISTH is a global not-for-profit organization advancing the understanding, prevention, diagnosis and treatment of thrombotic and bleeding disorders.
ISTH Information

For more information, or to join the Society, please contact:

The International Society on Thrombosis and Haemostasis (ISTH)
Headquarters Office
610 Jones Ferry Road Suite 205
Carrboro, NC 27510
USA
T: +1 919 929 3807
F: +1 919 929 3935
E: headquarters@isth.org
W: www.isth.org

Or visit us at our booth in the Exhibition Area!
for Kazuyoshi, progress starts with access to good haemophilia care

With limited access to doctors and information, Kazuyoshi’s parents formed a local patient association. Today, Kazuyoshi continues their work all over Japan.

At Novo Nordisk, we partner with patient associations, policy-makers and physicians to lead a coordinated response to inadequate haemophilia care. By involving more stakeholders, we facilitate concrete joint actions, including improved access to treatment, support and education resources for people with haemophilia and their families. We also work as a partner to improve access to care in the developing world, driving sustainable solutions that are changing possibilities for people with haemophilia wherever they live.

Find out how Novo Nordisk is changing possibilities in haemophilia at changingpossibilities.com
Other meetings

**Saturday June 29**
16.00-18.30 D203
*International Society of Fibrinolysis and Proteolysis (ISFP) council meeting*

**Monday July 1**
12:00-13:00 E103
*European Thrombosis Research Organisation (ETRO) general assembly*

**Tuesday July 2**
17.00-20.00 E103
*Mediterranean League against Thromboembolic Diseases (MLTD) general assembly*
12:15-12:45 G001
*International Society of Fibrinolysis and Proteolysis (ISFP) general meetings*
<table>
<thead>
<tr>
<th>Time</th>
<th>Saturday</th>
<th>Sunday</th>
<th>Monday</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00</td>
<td>SSC</td>
<td>Oral Communications</td>
<td></td>
</tr>
<tr>
<td>08:30</td>
<td></td>
<td>08:00-09:30</td>
<td></td>
</tr>
<tr>
<td>09:00</td>
<td>SSC</td>
<td>Plenary Lecture</td>
<td></td>
</tr>
<tr>
<td>09:30</td>
<td></td>
<td>09:45-10:30</td>
<td></td>
</tr>
<tr>
<td>10:00</td>
<td>General Educational Session</td>
<td>Coffee/Booth Visit</td>
<td></td>
</tr>
<tr>
<td>10:30</td>
<td>12:00-14:00</td>
<td>Special Symposia</td>
<td></td>
</tr>
<tr>
<td>11:00</td>
<td></td>
<td>12:15-14:15</td>
<td></td>
</tr>
<tr>
<td>11:30</td>
<td>SSC</td>
<td>Master Classes invitation only</td>
<td></td>
</tr>
<tr>
<td>12:00</td>
<td>14:00-18:00</td>
<td>14:00-16:00</td>
<td></td>
</tr>
<tr>
<td>12:30</td>
<td></td>
<td>Special Symposia</td>
<td></td>
</tr>
<tr>
<td>13:00</td>
<td></td>
<td>16:15-18:15</td>
<td></td>
</tr>
<tr>
<td>13:30</td>
<td>General Educational Session</td>
<td>ePoster Sessions</td>
<td></td>
</tr>
<tr>
<td>14:00</td>
<td>12:00-14:00</td>
<td>17:00-18:30</td>
<td></td>
</tr>
<tr>
<td>14:30</td>
<td></td>
<td>Opening Ceremony and Welcome Reception</td>
<td></td>
</tr>
<tr>
<td>15:00</td>
<td>SSC</td>
<td>18:30-21:30</td>
<td></td>
</tr>
<tr>
<td>15:30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:30</td>
<td></td>
<td></td>
<td>Special Symposia</td>
</tr>
<tr>
<td>17:00</td>
<td></td>
<td></td>
<td>18:30-20:00</td>
</tr>
<tr>
<td>17:30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:00</td>
<td>Football match</td>
<td>President’s Dinner invitation only</td>
<td></td>
</tr>
<tr>
<td>18:30</td>
<td>Netherlands - Rest of the World followed by a reception celebrating the 25th anniversary of the Netherlands Society on Thrombosis and Haemostasis (NVTH)</td>
<td></td>
<td>20:30-23:00</td>
</tr>
<tr>
<td>19:00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19:30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20:00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20:30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>21:00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>21:30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>22:00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>22:30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>23:00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>01:00</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Nurses Forum on Saturday and Sunday see pages 92-95
<table>
<thead>
<tr>
<th>Tuesday</th>
<th>June 2, 2013</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Oral Communications</strong></td>
<td>08:00-09:30</td>
<td>08:00</td>
</tr>
<tr>
<td><strong>Plenary Lecture</strong></td>
<td>09:45-10:30</td>
<td>08:30</td>
</tr>
<tr>
<td><strong>State-of-the-Art Lectures</strong></td>
<td>11:00-12:00</td>
<td>09:00</td>
</tr>
<tr>
<td><strong>Lunch/Booth Visit</strong></td>
<td></td>
<td>09:30</td>
</tr>
<tr>
<td><strong>Abstract Symposia</strong></td>
<td>13:00-14:15</td>
<td>10:00</td>
</tr>
<tr>
<td><strong>Oral Communications</strong></td>
<td>14:30-15:30</td>
<td>11:00</td>
</tr>
<tr>
<td><strong>Coffee/Booth Visit</strong></td>
<td></td>
<td>11:30</td>
</tr>
<tr>
<td><strong>Plenary Lecture</strong></td>
<td>16:00-16:45</td>
<td>12:00</td>
</tr>
<tr>
<td><strong>ePoster Sessions</strong></td>
<td>17:00-18:30</td>
<td>12:30</td>
</tr>
<tr>
<td><strong>Satellite Symposia</strong></td>
<td>18:30-20:00</td>
<td>13:00</td>
</tr>
<tr>
<td><strong>Cultural Evening</strong></td>
<td>Ticket needed</td>
<td>13:30</td>
</tr>
<tr>
<td></td>
<td></td>
<td>14:00</td>
</tr>
<tr>
<td></td>
<td></td>
<td>14:30</td>
</tr>
<tr>
<td></td>
<td></td>
<td>15:00</td>
</tr>
<tr>
<td></td>
<td></td>
<td>15:30</td>
</tr>
<tr>
<td></td>
<td></td>
<td>16:00</td>
</tr>
<tr>
<td></td>
<td></td>
<td>16:30</td>
</tr>
<tr>
<td></td>
<td></td>
<td>17:00</td>
</tr>
<tr>
<td></td>
<td></td>
<td>17:30</td>
</tr>
<tr>
<td></td>
<td></td>
<td>18:00</td>
</tr>
<tr>
<td></td>
<td></td>
<td>18:30</td>
</tr>
<tr>
<td></td>
<td></td>
<td>19:00</td>
</tr>
<tr>
<td></td>
<td></td>
<td>19:30</td>
</tr>
<tr>
<td></td>
<td></td>
<td>20:00</td>
</tr>
<tr>
<td></td>
<td></td>
<td>20:30</td>
</tr>
<tr>
<td></td>
<td></td>
<td>21:00</td>
</tr>
<tr>
<td></td>
<td></td>
<td>21:30</td>
</tr>
<tr>
<td></td>
<td></td>
<td>22:00</td>
</tr>
<tr>
<td></td>
<td></td>
<td>22:30</td>
</tr>
<tr>
<td></td>
<td></td>
<td>23:00</td>
</tr>
<tr>
<td></td>
<td></td>
<td>01:00</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Wednesday</th>
<th>June 3, 2013</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Oral Communications</strong></td>
<td>08:00-09:30</td>
<td>08:00</td>
</tr>
<tr>
<td><strong>Plenary Lecture</strong></td>
<td>09:45-10:30</td>
<td>08:30</td>
</tr>
<tr>
<td><strong>State-of-the-Art Lectures</strong></td>
<td>11:00-12:00</td>
<td>09:00</td>
</tr>
<tr>
<td><strong>Lunch/Booth Visit</strong></td>
<td></td>
<td>09:30</td>
</tr>
<tr>
<td><strong>Abstract Symposia</strong></td>
<td>13:00-14:15</td>
<td>10:00</td>
</tr>
<tr>
<td><strong>Oral Communications</strong></td>
<td>14:30-15:30</td>
<td>11:00</td>
</tr>
<tr>
<td><strong>Coffee/Booth Visit</strong></td>
<td></td>
<td>11:30</td>
</tr>
<tr>
<td><strong>Plenary Lecture</strong></td>
<td>16:00-16:45</td>
<td>12:00</td>
</tr>
<tr>
<td><strong>ePoster Sessions</strong></td>
<td>17:00-18:30</td>
<td>12:30</td>
</tr>
<tr>
<td><strong>All Congress Party</strong></td>
<td>Ticket needed 19:00-01:00</td>
<td>13:00</td>
</tr>
<tr>
<td></td>
<td></td>
<td>13:30</td>
</tr>
<tr>
<td></td>
<td></td>
<td>14:00</td>
</tr>
<tr>
<td></td>
<td></td>
<td>14:30</td>
</tr>
<tr>
<td></td>
<td></td>
<td>15:00</td>
</tr>
<tr>
<td></td>
<td></td>
<td>15:30</td>
</tr>
<tr>
<td></td>
<td></td>
<td>16:00</td>
</tr>
<tr>
<td></td>
<td></td>
<td>16:30</td>
</tr>
<tr>
<td></td>
<td></td>
<td>17:00</td>
</tr>
<tr>
<td></td>
<td></td>
<td>17:30</td>
</tr>
<tr>
<td></td>
<td></td>
<td>18:00</td>
</tr>
<tr>
<td></td>
<td></td>
<td>18:30</td>
</tr>
<tr>
<td></td>
<td></td>
<td>19:00</td>
</tr>
<tr>
<td></td>
<td></td>
<td>19:30</td>
</tr>
<tr>
<td></td>
<td></td>
<td>20:00</td>
</tr>
<tr>
<td></td>
<td></td>
<td>20:30</td>
</tr>
<tr>
<td></td>
<td></td>
<td>21:00</td>
</tr>
<tr>
<td></td>
<td></td>
<td>21:30</td>
</tr>
<tr>
<td></td>
<td></td>
<td>22:00</td>
</tr>
<tr>
<td></td>
<td></td>
<td>22:30</td>
</tr>
<tr>
<td></td>
<td></td>
<td>23:00</td>
</tr>
<tr>
<td></td>
<td></td>
<td>01:00</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Thursday</th>
<th>June 4, 2013</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Oral Communications</strong></td>
<td>08:00-09:30</td>
<td>08:00</td>
</tr>
<tr>
<td><strong>Plenary Lecture</strong></td>
<td>09:45-10:30</td>
<td>08:30</td>
</tr>
<tr>
<td><strong>State-of-the-Art Lectures</strong></td>
<td>11:00-12:00</td>
<td>09:00</td>
</tr>
<tr>
<td><strong>Presidential Symposium</strong></td>
<td>11:00-12:30</td>
<td>09:30</td>
</tr>
<tr>
<td><strong>Lunch/Booth Visit</strong></td>
<td></td>
<td>10:00</td>
</tr>
<tr>
<td><strong>ePoster Sessions</strong></td>
<td>13:30-15:00</td>
<td>11:00</td>
</tr>
<tr>
<td><strong>Coffee/Booth Visit</strong></td>
<td></td>
<td>11:30</td>
</tr>
<tr>
<td><strong>Abstract Symposia</strong></td>
<td>15:30-17:00</td>
<td>12:00</td>
</tr>
<tr>
<td><strong>President’s Dinner</strong></td>
<td>Ticket needed 19:30-23:00</td>
<td>12:30</td>
</tr>
<tr>
<td></td>
<td></td>
<td>13:00</td>
</tr>
<tr>
<td></td>
<td></td>
<td>13:30</td>
</tr>
<tr>
<td></td>
<td></td>
<td>14:00</td>
</tr>
<tr>
<td></td>
<td></td>
<td>14:30</td>
</tr>
<tr>
<td></td>
<td></td>
<td>15:00</td>
</tr>
<tr>
<td></td>
<td></td>
<td>15:30</td>
</tr>
<tr>
<td></td>
<td></td>
<td>16:00</td>
</tr>
<tr>
<td></td>
<td></td>
<td>16:30</td>
</tr>
<tr>
<td></td>
<td></td>
<td>17:00</td>
</tr>
<tr>
<td></td>
<td></td>
<td>17:30</td>
</tr>
<tr>
<td></td>
<td></td>
<td>18:00</td>
</tr>
<tr>
<td></td>
<td></td>
<td>18:30</td>
</tr>
<tr>
<td></td>
<td></td>
<td>19:00</td>
</tr>
<tr>
<td></td>
<td></td>
<td>19:30</td>
</tr>
<tr>
<td></td>
<td></td>
<td>20:00</td>
</tr>
<tr>
<td></td>
<td></td>
<td>20:30</td>
</tr>
<tr>
<td></td>
<td></td>
<td>21:00</td>
</tr>
<tr>
<td></td>
<td></td>
<td>21:30</td>
</tr>
<tr>
<td></td>
<td></td>
<td>22:00</td>
</tr>
<tr>
<td></td>
<td></td>
<td>22:30</td>
</tr>
<tr>
<td></td>
<td></td>
<td>23:00</td>
</tr>
<tr>
<td></td>
<td></td>
<td>01:00</td>
</tr>
</tbody>
</table>
## Programme at a Glance

<table>
<thead>
<tr>
<th>Time</th>
<th>Mondriaan II</th>
<th>Mondriaan III</th>
<th>Mondriaan IV</th>
<th>Elicium 1</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>08:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:00</td>
<td><strong>SSC</strong></td>
<td><strong>SSC</strong></td>
<td><strong>SSC</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Platelet Immunology</td>
<td>Fibrinolysis</td>
<td>Predictive Variables in Cardiovascular Disease</td>
<td>Animal Models</td>
</tr>
<tr>
<td>09:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30</td>
<td><strong>SSC</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Fibrinolysis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:00</td>
<td><strong>SSC</strong></td>
<td><strong>SSC</strong></td>
<td><strong>SSC</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Women’s Health Issues in Thrombosis and Haemostasis</td>
<td>Plasma Coagulation Inhibitors</td>
<td>Haemostasis and Malignancy</td>
<td>Fibrinogen and Factor XIII</td>
</tr>
<tr>
<td>14:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:00</td>
<td><strong>SSC</strong></td>
<td><strong>SSC</strong></td>
<td><strong>SSC</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Women’s Health Issues in Thrombosis and Haemostasis</td>
<td>Plasma Coagulation Inhibitors</td>
<td>Haemostasis and Malignancy</td>
<td>Fibrinogen and Factor XIII</td>
</tr>
<tr>
<td>15:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:30</td>
<td><strong>SSC</strong></td>
<td><strong>SSC</strong></td>
<td><strong>SSC</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Plasma Coagulation Inhibitors</td>
<td>Haemostasis and Malignancy</td>
<td>Fibrinogen and Factor XIII</td>
<td></td>
</tr>
<tr>
<td>17:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>21:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- SSC Educational Session
- SSC Business
Programme at a Glance

<table>
<thead>
<tr>
<th>Time</th>
<th>Mondriaan I (Plenary Hall)</th>
<th>Mondriaan II</th>
<th>Mondriaan III</th>
<th>Mondriaan IV</th>
<th>Auditorium</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>08:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:00</td>
<td></td>
<td></td>
<td>Special Symposium</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:30</td>
<td></td>
<td></td>
<td>Bayer</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:00</td>
<td></td>
<td></td>
<td>Special Symposium</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:30</td>
<td></td>
<td></td>
<td>CSL Behring</td>
<td>Special Symposium</td>
<td>Novo Nordisk</td>
</tr>
<tr>
<td>17:00</td>
<td></td>
<td></td>
<td>CSL Behring</td>
<td>Special Symposium</td>
<td>Novo Nordisk</td>
</tr>
<tr>
<td>17:30</td>
<td></td>
<td></td>
<td>CSL Behring</td>
<td>Special Symposium</td>
<td>Novo Nordisk</td>
</tr>
<tr>
<td>18:00</td>
<td></td>
<td></td>
<td>CSL Behring</td>
<td>Special Symposium</td>
<td>Novo Nordisk</td>
</tr>
<tr>
<td>18:30</td>
<td></td>
<td></td>
<td>CSL Behring</td>
<td>Special Symposium</td>
<td>Novo Nordisk</td>
</tr>
<tr>
<td>19:00</td>
<td></td>
<td></td>
<td>CSL Behring</td>
<td>Special Symposium</td>
<td>Novo Nordisk</td>
</tr>
<tr>
<td>19:30</td>
<td></td>
<td></td>
<td>CSL Behring</td>
<td>Special Symposium</td>
<td>Novo Nordisk</td>
</tr>
<tr>
<td>20:00</td>
<td></td>
<td></td>
<td>CSL Behring</td>
<td>Special Symposium</td>
<td>Novo Nordisk</td>
</tr>
<tr>
<td>21:00</td>
<td></td>
<td></td>
<td>CSL Behring</td>
<td>Special Symposium</td>
<td>Novo Nordisk</td>
</tr>
</tbody>
</table>

- SSC Educational Session
- SSC Business
- Sponsored Symposia
<table>
<thead>
<tr>
<th>Time</th>
<th>Mondriaan I (Plenary Hall)</th>
<th>Mondriaan II</th>
<th>Mondriaan III</th>
<th>Mondriaan IV</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00</td>
<td>OC</td>
<td>OC</td>
<td>OC</td>
<td>OC</td>
</tr>
<tr>
<td>08:30</td>
<td>Novel platelet inhibitors</td>
<td>Platelet granule secretion</td>
<td>Platelet ion channels and protein kinases</td>
<td></td>
</tr>
<tr>
<td>09:00</td>
<td>Virchow Lecture</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:30</td>
<td>Coffee break</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00</td>
<td>SOA</td>
<td>SOA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30</td>
<td>Platelets I</td>
<td>Fibrinogen and fibrinolysis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:00</td>
<td>SOA</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:30</td>
<td>Platelets I</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:00</td>
<td>Lunch / Booth visit</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:00</td>
<td>AS</td>
<td>FS</td>
<td>AS</td>
<td>AS</td>
</tr>
<tr>
<td>13:30</td>
<td>Assays for antithrombotic drugs</td>
<td>Antithrombtics and pregnancy</td>
<td>Platelet interactions</td>
<td></td>
</tr>
<tr>
<td>14:00</td>
<td>OC</td>
<td>OC</td>
<td>OC</td>
<td>OC</td>
</tr>
<tr>
<td>14:30</td>
<td>Heparin-induced thrombocytopenia</td>
<td>Platelet and coagulation interaction</td>
<td>Platelets and cancer</td>
<td></td>
</tr>
<tr>
<td>15:00</td>
<td>OC</td>
<td>OC</td>
<td>OC</td>
<td>OC</td>
</tr>
<tr>
<td>15:30</td>
<td>OC</td>
<td>OC</td>
<td>OC</td>
<td>OC</td>
</tr>
<tr>
<td>16:00</td>
<td>Plenary Lecture</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19:00</td>
<td>Special Symposium</td>
<td>Special Symposium</td>
<td>Special Symposium</td>
<td></td>
</tr>
<tr>
<td>19:30</td>
<td>Bayer</td>
<td>LFB Biomedicaments</td>
<td>Biogen Idec / Sobi</td>
<td></td>
</tr>
<tr>
<td>20:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>21:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Programme at a Glance

**Monday, July 1, 2013**

<table>
<thead>
<tr>
<th>Auditorium</th>
<th>G102-103</th>
<th>G104-105</th>
<th>G106-107</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>OC</td>
<td>OC</td>
<td>OC</td>
<td>OC</td>
<td>08:00</td>
</tr>
<tr>
<td>Clinical issues in</td>
<td>Haemostatic factors and arterial vascular disorders</td>
<td>Angiogenesis and arteriogenesis - I</td>
<td>Fibrinogen</td>
<td>08:30</td>
</tr>
<tr>
<td>haemophilia A</td>
<td></td>
<td></td>
<td></td>
<td>09:00</td>
</tr>
<tr>
<td>Auditory G102-103</td>
<td></td>
<td></td>
<td></td>
<td>09:30</td>
</tr>
<tr>
<td>G104-105</td>
<td></td>
<td></td>
<td></td>
<td>10:00</td>
</tr>
<tr>
<td>Coffee break</td>
<td></td>
<td></td>
<td></td>
<td>10:30</td>
</tr>
<tr>
<td>SOA</td>
<td></td>
<td></td>
<td></td>
<td>11:00</td>
</tr>
<tr>
<td>Biology of vWF</td>
<td></td>
<td></td>
<td></td>
<td>11:30</td>
</tr>
<tr>
<td>Lunch / Booth visit</td>
<td></td>
<td></td>
<td></td>
<td>12:00</td>
</tr>
<tr>
<td>AS</td>
<td>AS</td>
<td>AS</td>
<td>AS</td>
<td>13:00</td>
</tr>
<tr>
<td>Late breaking abstracts:</td>
<td>Hormones and thrombosis</td>
<td>New genetic determinants of venous thrombosis</td>
<td>Upcoming anticoagulants</td>
<td>13:30</td>
</tr>
<tr>
<td>Therapy</td>
<td></td>
<td></td>
<td></td>
<td>14:00</td>
</tr>
<tr>
<td>AS</td>
<td>OC</td>
<td>OC</td>
<td>OC</td>
<td>14:30</td>
</tr>
<tr>
<td>ADAMTS13</td>
<td>Coagulation factors XI and XII</td>
<td>Vessel wall</td>
<td>Intrinsic pathway of coagulation</td>
<td>15:00</td>
</tr>
<tr>
<td>AS</td>
<td></td>
<td></td>
<td></td>
<td>15:30</td>
</tr>
<tr>
<td>Coffee break</td>
<td></td>
<td></td>
<td></td>
<td>16:00</td>
</tr>
<tr>
<td>AS</td>
<td></td>
<td></td>
<td></td>
<td>16:30</td>
</tr>
<tr>
<td>Abstract / Focus Symposia</td>
<td></td>
<td></td>
<td></td>
<td>17:00</td>
</tr>
<tr>
<td>Novo Nordisk</td>
<td>Sanofi</td>
<td></td>
<td></td>
<td>17:30</td>
</tr>
<tr>
<td>Special Symposium</td>
<td></td>
<td></td>
<td></td>
<td>18:00</td>
</tr>
<tr>
<td>Sanofi</td>
<td></td>
<td></td>
<td></td>
<td>18:30</td>
</tr>
<tr>
<td>Special Symposium</td>
<td></td>
<td></td>
<td></td>
<td>19:00</td>
</tr>
<tr>
<td>Novo Nordisk</td>
<td></td>
<td></td>
<td></td>
<td>19:30</td>
</tr>
<tr>
<td>Sponsored Symposia</td>
<td></td>
<td></td>
<td></td>
<td>20:00</td>
</tr>
<tr>
<td>Plenary Lectures</td>
<td></td>
<td></td>
<td></td>
<td>21:00</td>
</tr>
<tr>
<td>Oral Communications</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>State-of-the-Art Lectures</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Abstract / Focus Symposia</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sponsored Symposia</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Continued next page*
## Programme at a Glance

<table>
<thead>
<tr>
<th>Time</th>
<th>Emerald</th>
<th>Elicium 1</th>
<th>Elicium 2</th>
<th>Forum</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00</td>
<td>OC Coagulation factors VIII, IX and XI</td>
<td>OC Clinical issues related to cancer and haemostasis</td>
<td>OC Anticoagulant agents - clinical studies I</td>
<td>OC Von Willebrand disease</td>
</tr>
<tr>
<td>08:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:00</td>
<td>Coffee break</td>
<td>SOA Tissue factor biology</td>
<td>SOA Prediction rules bleeding and thrombosis</td>
<td>SOA Coagulation modeling</td>
</tr>
<tr>
<td>11:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:00</td>
<td>Lunch / Booth visit</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:00</td>
<td>AS Inflammation and coagulation in atherosclerosis</td>
<td>AS Post-thrombotic syndrome</td>
<td>AS Antiphospholipid syndrome</td>
<td>AS Flow and von Willebrand factor (VWF)</td>
</tr>
<tr>
<td>13:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:00</td>
<td>OC Anticoagulants: Basic</td>
<td>OC Acquired bleeding disorders</td>
<td>OC Inhibitors in haemophilia A - I</td>
<td>OC Diagnosis of primary venous thrombosis</td>
</tr>
<tr>
<td>15:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:30</td>
<td>Special Symposium: Sanquin Blood Supply</td>
<td></td>
<td></td>
<td>Special Symposium: CSL Behring</td>
</tr>
<tr>
<td>19:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>21:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- **OC**: Oral Communications
- **SOA**: State-of-the-Art Lectures
- **AS**: Abstract Symposia
- **Special Symposium**: Sanquin Blood Supply, CSL Behring
<table>
<thead>
<tr>
<th>Time</th>
<th>E104-107</th>
<th>E102</th>
<th>ePoster Area</th>
<th>Hall 1</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00</td>
<td>OC</td>
<td>OC</td>
<td>ePoster viewing</td>
<td></td>
</tr>
<tr>
<td>08:30</td>
<td>OC</td>
<td>OC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:00</td>
<td>OC</td>
<td>OC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:30</td>
<td>OC</td>
<td>OC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00</td>
<td>OC</td>
<td>OC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30</td>
<td>OC</td>
<td>OC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:00</td>
<td>OC</td>
<td>OC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:30</td>
<td>OC</td>
<td>OC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:00</td>
<td>OC</td>
<td>OC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:30</td>
<td>OC</td>
<td>OC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:00</td>
<td>OC</td>
<td>OC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:30</td>
<td>OC</td>
<td>OC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:00</td>
<td>OC</td>
<td>OC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:30</td>
<td>OC</td>
<td>OC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:00</td>
<td>OC</td>
<td>OC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:30</td>
<td>OC</td>
<td>OC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:00</td>
<td>OC</td>
<td>OC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:30</td>
<td>OC</td>
<td>OC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:00</td>
<td>OC</td>
<td>OC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:30</td>
<td>OC</td>
<td>OC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:00</td>
<td>OC</td>
<td>OC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:30</td>
<td>OC</td>
<td>OC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>19:00</td>
<td>OC</td>
<td>OC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>19:30</td>
<td>OC</td>
<td>OC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>20:00</td>
<td>OC</td>
<td>OC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>21:00</td>
<td>OC</td>
<td>OC</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Programme at a Glance Monday, July 1, 2013**

**E104-107**
- OC: Recurrent venous thrombosis - I
- OC: Coagulation factors VIII, IX and XI
- OC: Clinical issues related to cancer and haemostasis
- OC: Anticoagulant agents - clinical studies I
- OC: Von Willebrand disease
- OC: Recurrent venous thrombosis - I

**E102**
- OC: Inflammation: Clinical studies
- AS: Coagulation and inflammation
- AS: Cardiovascular disease
- OC: Clinical relevance of microparticles
- OC: Coagulation - I

**ePoster Area**
- ePoster viewing

**Hall 1**
- ePoster sessions

**Legend**
- Green: Oral Communications
- Blue: State-of-the-Art Lectures
- Purple: Abstract Symposia
- Light Blue: Sponsored Symposia

**Notes**
- Coffee break
- Lunch / Booth visit
<table>
<thead>
<tr>
<th>Time</th>
<th>Mondriaan I (Plenary Hall)</th>
<th>Mondriaan II</th>
<th>Mondriaan III</th>
<th>Mondriaan IV</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00</td>
<td>OC Platelet disorders - I</td>
<td>OC Megakaryocytes and thrombopoiesis</td>
<td>OC Platelet signaling - I</td>
<td></td>
</tr>
<tr>
<td>08:30</td>
<td>11:00 Sherry-Koller Lecture</td>
<td>11:00 SOA Procoagulant and anti-coagulant mechanisms</td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:00</td>
<td>11:30 SOA Platelets II</td>
<td>13:00 AS Methods and relevance of microparticle detection</td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:30</td>
<td>12:00</td>
<td>13:30 AS New approaches to antiplatelet therapy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00</td>
<td>13:00</td>
<td>15:15 AS Functional characterisation of hereditary platelet disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30</td>
<td>13:30</td>
<td>15:30 OC TTP/thrombotic microangiopathies</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:00</td>
<td>14:00</td>
<td>15:30 OC Glycoprotein Ib functions</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:30</td>
<td>14:30</td>
<td>15:00 OC Infection and coagulation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:00</td>
<td>15:00</td>
<td>16:00 Plenary Lecture</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:30</td>
<td>15:30</td>
<td>16:30 Coffee break</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:00</td>
<td>16:00</td>
<td>17:00 Coffee break</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:30</td>
<td>16:30</td>
<td>17:30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:00</td>
<td>17:00</td>
<td>18:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:30</td>
<td>17:30</td>
<td>18:30 Satellite Symposium Octapharma</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:00</td>
<td>18:30</td>
<td>19:00 Satellite Symposium Pfizer</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:30</td>
<td>19:00</td>
<td>19:30 Satellite Symposium Biogen Idec / Sobi</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:00</td>
<td>19:30</td>
<td>20:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:30</td>
<td>20:00</td>
<td>21:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:00</td>
<td></td>
<td>21:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:30</td>
<td></td>
<td>21:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:00</td>
<td></td>
<td>21:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:30</td>
<td></td>
<td>21:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>19:00</td>
<td></td>
<td>21:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>19:30</td>
<td></td>
<td>21:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>20:00</td>
<td></td>
<td>21:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>21:00</td>
<td></td>
<td>21:00</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Legend:
- Yellow: Plenary Lectures
- Green: Oral Communications
- Blue: State-of-the-Art Lectures
- Blue: Abstract Symposia
- Light Blue: Sponsored Symposia
<table>
<thead>
<tr>
<th>Time</th>
<th>Auditorium</th>
<th>G102-103</th>
<th>G104-105</th>
<th>G106-107</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00</td>
<td>OC</td>
<td>OC</td>
<td>OC</td>
<td>OC</td>
</tr>
<tr>
<td></td>
<td>Therapy in haemophilia A</td>
<td>Tissue factor</td>
<td>Mechanisms of atherosclerosis</td>
<td>Antiphospholipid syndrome</td>
</tr>
<tr>
<td>08:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>21:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Coffee break

- SOA - Common and rare bleeding disorders: Global aspects

Lunch / Booth visit

- AS Inhibitors in haemophilia A
- AS The interplay between coagulation and inflammation
- AS What’s new in fibrinolysis?
- AS Pleiotropic effects of fibrinogen
- OC Bleeding and anticoagulants
- OC Clinical aspects of atherosclerosis
- OC Angiogenesis and arteriogenesis - II
- OC - Animal models of antiphospholipid syndrome

Coffee break

Satellite Symposium

- Daiichi Sankyo Europe
- Stago

Plenary Lectures
Oral Communications
State-of-the-Art Lectures
Abstract Symposia
Sponsored Symposia
<table>
<thead>
<tr>
<th>Time</th>
<th>Elicium 1</th>
<th>Elicium 2</th>
<th>Emerald</th>
<th>Forum</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00</td>
<td>OC Mechanisms in cancer and haemostasis</td>
<td>OC Reversal of anticoagulant agents</td>
<td>OC Coagulation factor VIII</td>
<td>OC Von Willebrand disease: Basic aspects</td>
</tr>
<tr>
<td>08:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:00</td>
<td>SOA Structure function coagulation proteins</td>
<td>SOA Venous thrombosis</td>
<td>SOA Biology of ADAMTS13</td>
<td></td>
</tr>
<tr>
<td>11:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:00</td>
<td>AS Challenges in therapeutic management of VT</td>
<td>AS New developments in treatment of VT</td>
<td>AS Vascular disorders</td>
<td>AS Prevention of recurrent VT</td>
</tr>
<tr>
<td>13:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:30</td>
<td>OC Inhibitors in haemophilia A - II</td>
<td>OC Treatment for haemophilia</td>
<td>OC Inherited risk factors for venous thrombosis - II</td>
<td>OC Prothrombin</td>
</tr>
<tr>
<td>15:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:30</td>
<td>Satellite Symposium Baxter</td>
<td>Satellite Symposium BMS/Pfizer</td>
<td>Satellite Symposium Boehringer Ingelheim</td>
<td>Satellite Symposium CMEducation</td>
</tr>
<tr>
<td>19:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>21:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
## Programme at a Glance

<table>
<thead>
<tr>
<th>Time</th>
<th>Mondriaan I (Plenary Hall)</th>
<th>Mondriaan II</th>
<th>Mondriaan III</th>
<th>Mondriaan IV</th>
<th>Auditorium</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00</td>
<td></td>
<td>OC Immune thrombocytopenic purpura</td>
<td>OC Novel platelet receptors</td>
<td>OC Thrombin generation tests</td>
<td>OC Inhibitor development in haemophilia A</td>
</tr>
<tr>
<td>08:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Mondriaan Lecture</td>
</tr>
<tr>
<td>10:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:00</td>
<td></td>
<td>SOA New and old anticoagulants</td>
<td>SOA Microparticles</td>
<td>SOA Gene therapy</td>
<td></td>
</tr>
<tr>
<td>11:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:00</td>
<td></td>
<td>AS Thrombocytopenia</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:00</td>
<td></td>
<td></td>
<td>OC Platelet signalling - II</td>
<td>OC - Disseminated intravascular coagulation</td>
<td>OC Microparticles</td>
</tr>
<tr>
<td>15:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>OC - Alternative treatments of haemophilia A</td>
</tr>
<tr>
<td>16:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:30</td>
<td></td>
<td>Plenary Lecture</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>21:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Legend:**
- **Yellow**: Plenary Lectures
- **Green**: Oral Communications
- **Blue**: State-of-the-Art Lectures
- **Dark Blue**: Abstract / Focus Symposia
- **Light Blue**: Sponsored Symposia

**Note:**
- Coffee breaks are indicated at 10:30, 11:30, and 15:30.
- Lunch/Booth visit times are at 12:30 and 13:30.
# Programme at a Glance

<table>
<thead>
<tr>
<th>Time</th>
<th>Elicium 1</th>
<th>Elicium 2</th>
<th>Forum</th>
<th>E102</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00</td>
<td>OC</td>
<td>OC</td>
<td>OC</td>
<td>OC</td>
</tr>
<tr>
<td>08:30</td>
<td>Non-inherited risk factors for venous thrombosis</td>
<td>New developments in thrombus formation</td>
<td>Von Willebrand factor - I</td>
<td>Rare bleeding disorders - II</td>
</tr>
<tr>
<td>09:00</td>
<td>OC</td>
<td>OC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:30</td>
<td>OC</td>
<td>OC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00</td>
<td>OC</td>
<td>OC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30</td>
<td>OC</td>
<td>OC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:00</td>
<td>SOA</td>
<td>SOA</td>
<td>SOA</td>
<td></td>
</tr>
<tr>
<td>11:30</td>
<td>Genetics: Humans and mice</td>
<td>Women’s issues in bleeding and thrombosis</td>
<td>Vessel wall biology</td>
<td></td>
</tr>
<tr>
<td>12:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:30</td>
<td>Lunch / Booth visit</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:00</td>
<td>AS</td>
<td>AS</td>
<td>AS</td>
<td>AS</td>
</tr>
<tr>
<td>13:30</td>
<td>Coagulation and complement</td>
<td>Venous thrombosis and cancer</td>
<td>Treatment of von Willebrand disease</td>
<td>Clot structure</td>
</tr>
<tr>
<td>14:00</td>
<td>OC</td>
<td>OC</td>
<td>OC</td>
<td>OC</td>
</tr>
<tr>
<td>14:30</td>
<td>Paediatric thrombosis</td>
<td>Management of venous thrombosis</td>
<td>Haemophilia B</td>
<td>RNA and coagulation</td>
</tr>
<tr>
<td>15:00</td>
<td>OC</td>
<td>OC</td>
<td>OC</td>
<td>OC</td>
</tr>
<tr>
<td>15:30</td>
<td>OC</td>
<td>OC</td>
<td>OC</td>
<td>OC</td>
</tr>
<tr>
<td>16:00</td>
<td>OC</td>
<td>OC</td>
<td>OC</td>
<td>OC</td>
</tr>
<tr>
<td>16:30</td>
<td>OC</td>
<td>OC</td>
<td>OC</td>
<td>OC</td>
</tr>
<tr>
<td>17:00</td>
<td>OC</td>
<td>OC</td>
<td>OC</td>
<td>OC</td>
</tr>
<tr>
<td>17:30</td>
<td>OC</td>
<td>OC</td>
<td>OC</td>
<td>OC</td>
</tr>
<tr>
<td>18:00</td>
<td>OC</td>
<td>OC</td>
<td>OC</td>
<td>OC</td>
</tr>
<tr>
<td>18:30</td>
<td>OC</td>
<td>OC</td>
<td>OC</td>
<td>OC</td>
</tr>
<tr>
<td>19:00</td>
<td>OC</td>
<td>OC</td>
<td>OC</td>
<td>OC</td>
</tr>
<tr>
<td>19:30</td>
<td>OC</td>
<td>OC</td>
<td>OC</td>
<td>OC</td>
</tr>
<tr>
<td>20:00</td>
<td>OC</td>
<td>OC</td>
<td>OC</td>
<td>OC</td>
</tr>
<tr>
<td>21:00</td>
<td>OC</td>
<td>OC</td>
<td>OC</td>
<td>OC</td>
</tr>
</tbody>
</table>

- **OC**: Oral Communications
- **AS**: Abstract / Nurses Symposia
- **SOA**: State-of-the-Art Lectures
Programme at a Glance Wednesday, July 3, 2013

**E104-107**
- OC
  - Recurrent venous thrombosis - II

**E108**
- Coffee break

**ePoster Area**
- Coffee break
- ePoster viewing

**Hall 1**
- Lunch / Booth visit
- ePoster session

- AS
  - Contact activation 2:0
  - AS
  - Coagulation and complement
  - AS
  - Venous thrombosis and cancer
  - AS
  - Treatment of von Willebrand disease
  - AS
  - Clot structure
  - AS
  - Contact activation 2:0
  - NS
  - Nurses Symposium
  - OC
  - Thrombophilia - I
  - OC
  - Thrombophilia - I
  - OC
  - RNA and coagulation
  - OC
  - Thrombophilia - I

- Coffee break
- Lunch / Booth visit
- Abstract / Nurses Symposia
<table>
<thead>
<tr>
<th>Time</th>
<th>Mondriaan I (Plenary Hall)</th>
<th>Mondriaan II</th>
<th>Mondriaan III</th>
<th>Mondriaan IV</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00</td>
<td>OC Platelet disorders - II</td>
<td>OC Platelet collagen receptors</td>
<td>OC</td>
<td></td>
</tr>
<tr>
<td>08:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00</td>
<td>Plenary Lecture</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:00</td>
<td>Presidential Symposium</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:00</td>
<td>AS Thrombotic microangiopathies</td>
<td>AS Regulation of platelet function</td>
<td>AS</td>
<td></td>
</tr>
<tr>
<td>16:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>21:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Yellow:** Plenary Lectures  
**Green:** Oral Communications  
**Blue:** Abstract Symposia
### Programme at a Glance

**Thursday, July 4, 2013**

<table>
<thead>
<tr>
<th>Time</th>
<th>Hall 1</th>
<th>E104-107</th>
<th>E102</th>
<th>ePoster Area</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00</td>
<td></td>
<td>OC Fibrinolysis - II</td>
<td>OC Thrombophilia - II</td>
<td>ePoster viewing</td>
</tr>
<tr>
<td>08:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>21:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- **Coffee break**
- **Lunch / Booth visit**
- **Coffee break**
- **AS Blood coagulation tests**
## Programme at a Glance

<table>
<thead>
<tr>
<th>Time</th>
<th>Emerald</th>
<th>Elicium 1</th>
<th>Elicium 2</th>
<th>Forum</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00</td>
<td>OC Basic Issues in haemophilia A</td>
<td>OC Cancer and thrombosis</td>
<td>OC Anticoagulant agents: Clinical studies II</td>
<td>OC Von Willebrand factor - II</td>
</tr>
<tr>
<td>08:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:00</td>
<td>Coffee break</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:30</td>
<td>Lunch / Booth visit</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:00</td>
<td>Coffee break</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:00</td>
<td>AS Structure-function of factor V</td>
<td>AS Inflammation and coagulation axis</td>
<td>AS Diagnosis of deep vein thrombosis and pulmonary embolism</td>
<td>AS Innovative treatments of haemophilia A and B</td>
</tr>
<tr>
<td>16:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>21:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- **OC** Oral Communications
- **AS** Abstract Symposia
<table>
<thead>
<tr>
<th>Time</th>
<th>E102</th>
<th>E104-107</th>
<th>ePoster Area</th>
<th>Hall 1</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00</td>
<td>OC Fibrinolysis - II</td>
<td>OC Thrombophilia - II</td>
<td>ePoster viewing</td>
<td></td>
</tr>
<tr>
<td>08:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>21:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- Oral Communications
- Abstract Symposia
Massimo looks forward to the next haemophilia breakthrough

When Massimo developed inhibitors, the lack of an effective therapy meant his joints became damaged. Now a solution has been found, he is looking forward to the next life-changing breakthrough.

At Novo Nordisk, we tirelessly pursue every opportunity to improve haemophilia care. Our research and development portfolio is the broadest in the industry, and we are working on compounds that treat bleeds fast and effectively, as well as treatments that offer convenience. Through awards, training and partnerships across the scientific community, we support scientific excellence that will continue changing possibilities for people with haemophilia in the future.

Find out how Novo Nordisk is changing possibilities in haemophilia at changingpossibilities.com
SSC and Educational Programme
INTRODUCTION SSC AND EDUCATIONAL PROGRAMME

The education programme of the ISTH 2013 is set up at two levels: First of all, there will be an educational session during the first hour of each SSC meeting, the level of which is advanced and topic oriented. Secondly, at a more general level, the congress this year has as a topic oriented focus to inspire and stimulate young investigators in their careers and to educate researchers from underprivileged countries who have few opportunities to attend courses and meet established investigators. For this group, Master Classes are offered during which Young Investigators and Reach the World participants have been invited for 3 half-hour sessions with a ‘Master’, who is a well-known and established investigator. Furthermore, all Reach the World Awardees have been invited to visit a Dutch comprehensive haemostasis laboratory affiliated to a Hemophilia Care Centre. Lastly, a general educational session, open to everyone, has been set up on Saturday afternoon, in between the SSC sessions, which offers a broad perspective on the scientific profession. Here, topics will include science citation, science journalism and advice on how to successfully attend a conference, presented by well known authors in the field.
Factor VIII and IX and Rare Coagulation Disorders (part I)  
Elicium 2

Chairman: Flora Peyvandi [Italy]
Co-chairs: Jan Astermark [Sweden], Kathelijn Fischer [Netherlands], Michael Makris [United Kingdom], Danijela Mikovic [Serbia], Steven Pipe [USA], Elena Santagostino [Italy], Midori Shima [Japan] and Leonard Valentino USA

Educational session

Moderators: David Lillicrap [Canada] and Flora Peyvandi [Italy]

08:00 - 08:15  
Inhibitor risk associated with switching products including PUPs and PTPs  
SC01-1.01  
Steven Pipe [USA]

08:15 - 08:30  
Laboratory and clinical phenotype comparison in rare bleeding disorders  
SC01-1.02  
Danijela Mikovic [Serbia]

08:30 - 08:45  
Acquired hemophilia: Diagnosis and treatment  
SC01-1.03  
Peter Collins [United Kingdom]

08:45 - 09:00  
Discussion

Report on SSC-FVIII and IX activity 2012 - 2013

Moderator: Flora Peyvandi [Italy]

09:00 - 09:05  
SSC reorganisation FVIII and IX

09:05 - 09:20  
SOA SSC (report on on-going and closing projects)

Clinical outcome evaluation - methods

Moderators: Kathelijn Fischer [The Netherlands] and Michael Makris [United Kingdom]

09:20 - 09:35  
SSC project: Bleeding score in haemophilia: A prognostic tool for clinical outcome  
SC01-3.01  
Maria Elisa Mancuso and Alberto Tosetto [Italy]

09:35 - 09:50  
SSC project: The definition of mild haemophilia A  
SC01-3.02  
Michael Makris [United Kingdom]

09:50 - 10:05  
Discussion

10:05 - 10:20  
Coffee break
SSC PROGRAMME

Saturday, June 29, 2013

Inhibitor development - methods and results
Moderators: Steven Pipe (USA) and Marijke van den Berg (The Netherlands)

10:20 - 10:35  SSC project: Inhibitor assays standardisation
SC01-4.01  Koen Mertens (The Netherlands)

10:35 - 10:50  Membrane composition can alter results of factor VIII inhibitor assays
SC01-4.02  Gary Gilbert (USA)

10:50 - 11:00  Discussion

11:00 - 11:15  SIPPET study: power and weakness of the study
SC01-4.03  Pier Mannuccio Mannucci (Italy)

11:15 - 11:30  RODIN study: Power and weakness of the study
SC01-4.04  Marijke van den Berg (The Netherlands)

11:30 - 11:45  Inhibitor development in PTP: available registries and harmonisation
SC01-4.05  Alfonso Iorio (Canada)

11:45 - 12:00  Discussion

Animal Models
Elicium 1

Chairman: Susan S. Smyth (USA)
Co-chairs: Cecile Denis (France), Tom Knudsen (Denmark), Toshiyuki Miyata (Japan), David Motto (USA), Eva-Maria Muchitsch (Austria), Timothy Nichols (USA), Denise Sabatino (USA) and Hugo ten Cate (Netherlands)

Educational session: Humanised animal models - their role in drug discovery/validation

08:00 - 08:20  Need for improved models for drug discovery and antidote testing
SC02-1.01  Nigel S. Key (USA)

08:20 - 08:40  Modifications in mice for assessment of human therapies
SC02-1.02  Thomas Diacovo (USA)

08:40 - 09:15  Animal models to validate therapies for antidotes for anticoagulant therapy
SC02-1.03  Henri Spronk (The Netherlands)

Subcommittee session

09:15 - 09:45  Insights into hemostasis and thrombosis from studying murine models
SC02-2.01  David Motto (USA)

09:45 - 10:00  Genetic mouse models of venous thrombosis for Japanese
SC02-2.02  Fumiaki Banno (Japan)

10:00 - 10:15  Temporary cerebral ischemia induced by three-vessel occlusion in mice
SC02-2.03  Hitomi Yamamoto (Japan)

10:15 - 10:45  Optimized bleeding model in mice
SC02-2.04  Tom Knudsen (Denmark)
**SSC PROGRAMME**

**Saturday, June 29, 2013**

08:00 – 12:00

10:45 - 11:15  **Major advances using genetic approaches in pig**  
**SC02-2.05**  Timothy Nichols [USA]

11:15 - 12:00  **SSC discussion**

---

**Lupus Anticoagulant/Phospholipid-Dependent Antibodies Forum**

*Chairman: Thomas Ortel [USA]*  
*Co-chairs: Tatsuya Atsumi [Japan], Bas de Laat [the Netherlands], Katrien Devreese [Belgium], Silvia Pierangeli [USA] and Armando Tripodi [Italy]*

**Educational session**

08:00 - 08:20  **Solid phase assays for the diagnosis of APS**  
**SC03-1.01**  Katrien Devreese [Belgium]

08:20 - 08:40  **The conformation of ß2GPI plays a major role in the diagnosis of APS**  
**SC03-1.02**  Hilde Kelchtermans [The Netherlands]

08:40 - 09:00  **Diagnosis and treatment of pregnancy-related complications of APS**  
**SC03-1.03**  Keith McCrake [USA]

09:00 - 09:10  **Coffee break**

**Subcommittee session**

09:10 - 09:35  **Antiphospholipid database: Impact of ISTH guidelines in a real world setting**  
**SC03-2.01**  Denis Wahl [France]

09:35 - 10:00  **The 1st International Reference Panel for lupus anticoagulant - collaborative study results**  
**SC03-2.02**  Elaine Gray [United Kingdom]

10:00 - 10:20  **Lupus anticoagulant assessment: role of mixing tests**  
**SC03-2.03**  Rolf Urbanus [The Netherlands]

10:20 - 10:30  **Discussion on mixing tests in diagnostic algorithms for lupus anticoagulants**  
**SC03-2.04**  Thomas Ortel [USA]

10:30 - 11:00  **Solid phase assays for the diagnosis of APS: SSC recommendations**  
**SC03-2.05**  Katrien Devreese [Belgium]

11:00 - 11:30  **Update on international units and reference materials for solid phase assays**  
**SC03-2.06**  Silvia Pierangeli [USA]

11:30 - 11:50  **Collaborative proposals**  
1) How to report the diagnostic value of a new test for antiphospholipid antibodies: guidelines for analysis and reports  
2) Thrombin generation and the diagnosis of antiphospholipid syndrome: review of available data and choice of methods  
Denis Wahl [France]

11:50 - 12:00  **Updates and session wrap-up**  
**SC03-2.08**  Thomas Ortel [USA]
### Platelet Immunology

**Mondriaan II**

**Chairman:** Yves Gruel (France)
**Co-chairs:** Donald Arnold (Canada), Tamam Bakchoul (Germany), Sentot Santoso (Germany), Yoshiaki Tomiyama (Japan) and Christopher Ward (Australia)

#### Educational session

**08:00 - 08:05**  
**Welcome**  
SC04.1-1.1  
Yves Gruel (France)

**08:05 - 08:35**  
**New insights on the pathophysiology of heparin-induced thrombocytopenia**  
SC04.1-1.2  
Andreas Greinacher (Germany)

**08:35 - 09:05**  
**Laboratory testing for secondary forms of ITP: What is the evidence?**  
SC04.1-1.3  
Adam Cuker (USA)

#### Autoimmune and drug-induced thrombocytopenia

**Moderators:** Donald Arnold (Canada) and Yoshiaki Tomiyama (Japan)

**09:05 - 09:15**  
**Update on the DITP standardization project**  
SC04.2-1.1  
Donald Arnold (Canada)

**09:15 - 09:25**  
**Anti-GP IIb/IIIa ddab induced by ampicillin and methylprednisolone in patients with sudden-onset thrombocytopenia**  
Volker Kiefel (Germany)

**09:25 - 09:35**  
**Autoantigenic epitopes on GPIIb-IIIa in ITP**  
SC04.2-1.3  
Yoshiaki Tomiyama (Japan)

**09:35 - 09:45**  
**Auto-antibodies to GPVI**  
SC04.2-1.4  
Martine Jandrot-Perrus (France)

#### Alloimmune thrombocytopenia, basic research, diagnosis and treatment

**Moderators:** Tamam Bakchoul (Germany) and Sentot Santoso (Germany)

**09:45 - 09:55**  
**Molecular structure of HPA-1a and -HPA-1b and its consequence on immune response**  
SC04.3-1.1  
Vincent Jallu (France)

**09:55 - 10:03**  
**The implementation of SPR technology in prenatal monitoring of FNAIT**  
SC04.3-1.2  
Sentot Santoso and Tamam Bakchoul (Germany)

**10:03 - 10:11**  
**The relevance of low avidity HPA-1a antibodies on the pathomechanism of NAIT**  
SC04.3-1.3  
J.T. Peterson (USA)

**10:11 - 10:20**  
**Impact of divalent cation on the detection of HPA-1a antibodies**  
SC04.3-1.4  
D.L. Allen (United Kingdom)

**10:20 - 10:30**  
**Detection of platelet alloantibodies using a multiplex bead assay**  
SC04.3-1.5  
Gian Visentin (USA)

**10:30 - 10:36**  
**Development of a prophylactic treatment for the prevention of NAIT**  
SC04.3-1.6  
Bjørn Skogen (Norway)
SSC PROGRAMME

Saturday, June 29, 2013 08:00 – 12:00

10:36 - 10:42  Postnatal treatment of NAIT and new approach
SC04.3-1.7  Tamam Bakchoul and Sentot Santoso (Germany)

10:42 - 10:45  Discussion

10:45 - 10:55  Coffee break

Heparin-induced thrombocytopenia
Moderators: Christopher Ward (Australia) and Yves Gruel (Germany)

10:55 - 11:10  Genomic approaches to variation in platelet activation via FcgRIIa
SC04.4-1.1  Steven McKenzie (USA)

11:10 - 11:20  Novel laboratory assays for heparin-induced thrombocytopenia
SC04.4-1.2  Adam Cuker (USA)

11:20 - 11:30  The 'Rapid Test PF4', a new assay for the diagnosis of HIT
SC04.4-1.3  Gian Visentin (USA)

11:30 - 11:40  Proposal for a standardized method for the whole blood impedance assay
SC04.4-1.4  Christopher Ward (Australia)

11:40 - 11:50  Anti-PF4/heparin serology in the PROTECT-ICU trial
SC04.4-1.5  Theodore Warkentin (Canada)

11:50 - 12:00  Conclusion and perspectives
SC04.4-1.6  Yves Gruel (France)

Fibrinolysis  Mondriaan III

Chairman: Ann Gils (Belgium)
Co-chairs: Jonathan Foley (Canada), Paul Kim (Canada), Nicola Mutch (United Kingdom), Craig Thelwell (United Kingdom), Shirley Uitte de Willige (The Netherlands) and Tetsumei Urano (Japan)

Education session: Unexpected/unconventional factors that partake in upregulation of fibrinolysis

08:00 - 08:20  Effect of cells and flow on fibrinolysis
SC05-1.01  Krasimir Kolev (Hungary)

08:20 - 08:40  Roles of factor Xa cleavage products in upregulation PA by t-PA
SC05-1.02  Ed Pryzdial (Canada)

08:40 - 09:00  The role of microparticles in initiating and regulation clot lysis
SC05-1.03  Eduardo Anglés-Cano (France)
SSC PROGRAMME

Saturday, June 29, 2013

08:00 – 12:00

Subcommittee session

09:00 - 09:15  Detection of fibrinolytic microvesicles using a chemosensor capture assay
SC05-2.01  Laurent Plawinski and Eduardo Angles-Cano [France]

09:15 - 09:30  Improvement of fibrin clot structure after the treatment in hemophilia A. Do TAFI and microparticles play any role?
SC05-2.02  Aleksandra Antovic, Danijela Mikovic, Fariborz Mobarez, Michal Zabczyk, Shu He, Ivo Elezovic, Kjell Hutenby, Barry Woodhams and Jovan Antovic [Sweden]

09:30 - 09:45  The antifibrinolytic function of factor XIII
SC05-2.03  Nicola Mutch [United Kingdom]

09:45 - 09:55  Update on standard development for D-dimer assays
SC05-2.04  Colin Longstaff [United Kingdom]

09:55 - 10:05  Program to replace the WHO 3rd IS for Plasmin
SC05-2.05  Craig Theelwell [United Kingdom]

10:05 - 10:15  Coffee break

10:15 - 10:30  Evaluation of the profibrinolytic effect of TAFI and PAI-1 inhibitors
SC05-2.06  Tine Wyseur, Ann Gils, Paul Declerck [Belgium]

10:30 - 10:45  Interindividual CPU (TAFIa) generation profiles during a standardised clot lysis assay
SC05-2.07  Dorien Leenaerts, Dirk Hendriks [Belgium]

10:45 - 11:00  Extrahepatic TAFI expression and regulation of TAFI gene expression: What does it all mean?
SC05-2.08  Michael Boffa [Canada]

11:00 - 11:10  Nomenclature of TAFI
SC05-2.09  Jonathan Foley [Canada]

11:10 - 11:25  Global haemostasis assays, from bench to bedside
SC05-2.10  Waander van Heerde [The Netherlands]

11:25 - 11:40  Quantifying the added value of a diagnostic test
SC05-2.11  Karel Moons [The Netherlands]

11:40 - 11:55  Clinical utility of D-dimer in the diagnosis and prediction of VTE
SC05-2.12  Shannon Bates [Canada]

11:55 - 12:00  Closing remarks
SC05-2.13  Ann Gils [Belgium]
SSC PROGRAMME

Saturday, June 29, 2013 08:00 – 12:00

Predictive Variables in Cardiovascular Disease  Mondriaan IV
Chairman: James Douketis (Canada)
Co-Chairs: Shinya Goto (Japan), Paul Kyrle (Austria), Karel Moons (The Netherlands), Marc Samama (France), Alex Spyropoulos (USA) and Richard White (USA)

New approaches to predict thrombosis risk + update of SSC research
Moderators: Alex Spyropoulos (USA)

08:00 - 08:05  Session objectives
SC06-1.01  James Douketis (Canada)

Educational session: CHADS2, CHA2DS2VASc and new approaches to predicting thrombosis risk
Moderator: Alex Spyropoulos (USA)

08:05 - 08:25  CHADS2 and CHA2DS2VASc to determine stroke risk in atrial fibrillation: One or both?
SC06-2.01  Michiel Coppens (The Netherlands)

08:25 - 08:45  Platelet function assay: Is there a role to predict adverse cardiovascular events in the PCI setting?
SC06-2.02  Paul Kyrle (Austria)

08:45 - 09:05  Patients receiving new oral anticoagulants who need surgery: How to manage anticoagulation and use coagulation tests to minimize thrombosis and bleeding risk?
SC06-2.03  Marc Samama (France)

09:05 - 09:20  Coffee break

Update of SSC research and related activities
Moderator: James Douketis (Canada)

09:20 - 09:40  D-dimer in atrial fibrillation: Is there a role to combine with CHADS2 to stratify patients according to stroke risk?
SC06-3.01  John Eikelboom (Canada)

09:40 - 10:00  D-dimer and risk for stroke in atrial fibrillation
SC06-3.02  Robert Campbell Tait (United Kingdom)

10:00 - 10:20  SSC Communication: Standardization of perioperative outcomes: Why is this clinically important and implications for clinical trials
SC06-3.03  Alex Spyropoulos (USA)

10:20 - 10:40  D-dimer to predict recurrent VTE: The MORGAGNI study
SC06-3.04  Paolo Prandoni (Italy)

10:40 - 10:55  Coffee break

10:55 - 11:15  Prognosis after unprovoked VTE: Lessons from the REVERSE study
SC06-3.05  Marc Rodger, Grégoire Le Gal (Canada)

11:15 - 11:35  SSC Subcommittee Report: Predictive value of hemostatic variables for first and recurrent arterial events
SC06-3.06  Gordon Lowe (United Kingdom)
Using the CHA2DS2VASC score in clinical practice: A clinical trial [CAFÉ] assessing different approaches
Karel Moons, Geert-Jan Geersing [The Netherlands]

Adjournment
James Douketis [Canada]

Vascular Biology E104-107
Chairman: Francoise Dignat-George [France]
Co-chairs: Elizabeth E. Gardiner [Australia], Nigel Key [USA], Rienk Nieuwland [The Netherlands] and Florence Toti-Orfanoudakis [France]

Educational Session

08:00 - 08:20 Microparticles: Emerging role in cellular therapy and regenerative medicine
SC07-1.01 Florence Toti [France]

08:20 - 08:40 Tetraspanins as new regulators of membrane protein shedding
SC07-1.02 Michael Tomlinson [United Kingdom]

08:40 - 09:00 Endothelial progenitors in cardiovascular diseases studies with blood outgrowth endothelial cells
Anna Randi [United Kingdom]

Subcommittee Session: Shedded protein and receptors

09:00 - 09:15 Measurement of shed vascular proteins in clinical settings
SC07-2.01 Robert Andrews [Australia]

09:15 - 09:30 Shed proteins as biomarkers in acute coronary syndromes
SC07-2.02 Giovanni Davi [Italy]

09:30 - 09:45 Mining the platelet sheddome for biomarkers and insights into mechanism
SC07-2.03 Lawrence Brass [USA]

09:45 - 10:15 Coffee break
SC07-2.04

Circulating endothelial cells and progenitors

10:15 - 10:30 Circulating endothelial cells and progenitors in pulmonary hypertension: potential in diagnosis and treatment monitoring
David Smadja [France]

10:30 - 10:45 Flow cytometry detection of circulating endothelial progenitor cells
Michael Hristov [Germany]
** SSC PROGRAMME  

**Saturday, June 29, 2013**  
**12:00 – 14:00**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>12:00 - 13:00</strong></td>
<td>Welcoming lunch for all recipients of Reach-the-World and Young Investigators Awards (on invitation only)</td>
</tr>
</tbody>
</table>
| **13:00 - 13:10** | The dos and don’ts of attending a conference  
ED 01-01  
Frits Rosendaal (The Netherlands) |
| **13:10 - 13:35** | Cited and be damned: the view of a science impact scientist  
ED 01-02  
Ton van Raan (The Netherlands) |
| **13:35 - 14:00** | From silliness to fraud: the view of a science journalist  
ED 01-03  
Hans van Maanen (The Netherlands) |
SSC PROGRAMME

Saturday, June 29, 2013 12:00 - 14:00

Working Group on Genomics in Hemostasis E102

Chairmen: Anne Goodeve (United Kingdom), Thomas Kunicki (USA), Willem Ouwehand (United Kingdom) and Pieter Reitsma (The Netherlands)

First Session
Moderator: Anne Goodeve (United Kingdom)

12:00 - 12:05 Welcome

12:05 - 12:25 A NGS diagnostic platform for 100 bleeding and platelet disorders
SC08-1.01 Graham Kiddle (United Kingdom)

12:25 - 12:45 Towards a clotting factor mutation database
SC08-1.02 Christopher Ludlam (United Kingdom)

12:45 - 13:00 Coding of patients with bleeding and platelet disorders against HPO terms
SC08-1.03 Kathleen Freson (Belgium)

13:00 - 13:15 Coffee Break

Second Session
Moderator: Willem Ouwehand (United Kingdom)

13:15 - 13:35 Patterns of variation in hemostasis genes in the UK10K samples
SC08-2.01 Augusto Rendon (United Kingdom)

SC08-2.02 Barry Coller (USA)

SC08-2.03 Marta Filizola (USA)

13:55 - 14:00 Towards clinical genomics
SC08-2.04 Willem Ouwehand (United Kingdom)
General educational session

Moderators: Frits Rosendaal (The Netherlands) and Suzanne Cannegieter (The Netherlands)

12:00 - 13:00  Welcoming lunch for all recipients of Reach-the-World and Young Investigators Awards  
(on invitation only)

13:00 - 13:10  The dos and don’t’s of attending a conference  
ED 01-01  Frits Rosendaal (The Netherlands)

13:10 - 13:35  Cited and be damned: the view of a science impact scientist  
ED 01-02  Ton van Raan (The Netherlands)

13:35 - 14:00  From silliness to fraud: the view of a science journalist  
ED 01-03  Hans van Maanen (The Netherlands)
SSC PROGRAMME

Saturday, June 29, 2013

14:00 - 18:00

**Factor VIII and IX and Rare Coagulation Disorders (part II)**

Elicium 2

Chairman: Flora Peyvandi (Italy)

Co-chairs: Jan Astermark (Sweden), Kathelijn Fischer (The Netherlands), Michael Makris (United Kingdom), Danijela Mikovic (Serbia), Steven Pipe (USA), Elena Santagostino (Italy), Midori Shima (Japan) and Leonard Valentino (USA)

New hemostatic drugs: classification, dose standardisation and monitoring

Moderators: Flora Peyvandi (Italy) and David Lillicrap (Canada)

14:00 - 14:15  SSC project: Clinical trial design for hemophilia
SC09-1.01  Donna DiMichel (USA)

14:15 - 14:25  Immunogenicity of novel products and its evaluation
SC09-1.02  Sébastien Lacroix-Desmazes (Switzerland)

14:25 - 14:35  Efficient model of safety evaluation of new products
SC09-1.03  Frits Rosendaal (The Netherlands)

14:35 - 14:45  Timelines of approval of new products: Patients’ view
SC09-1.04  Brian O’Mahony (Ireland)

14:45 - 14:55  Global assays standardization: What is needed?
SC09-1.05  Guy Young (USA)

SC09-1.06  Andrew Lawrie (United Kingdom)

15:10 - 15:30  Discussion

**Assays standardization**

Moderators: Jan Astermark (Sweden) and Midori Shima (Japan)

15:30 - 15:45  Relationship between results with different FIX assays in post concentrate infusion samples
SC09-2.01  Steve Kitchen (United Kingdom)

15:45 - 16:00  SSC project: Standardization of genetic assays for diagnosis of hemophilia
SC09-2.02  Vincent P. Jenkins (Ireland)

16:00 - 16:10  Discussion

16:10 - 16:25  Coffee break

**Orphan drugs in Rare Bleeding Disorders (RBDs)**

Moderators: Elena Santagostino (Italy) and Danijela Mikovic (Serbia)

16:25 - 16:40  SSC project: Factor V deficiency, clinical heterogeneity and treatment
SC09-3.01  Danijela Mikovic (Serbia)

16:40 - 16:50  Novel products for treatment of RBDs: Clinical trial design and methods for efficacy evaluation (antithrombin RNAi)
SC09-3.02  Amy Simon (USA)
**SSC PROGRAMME**

**Saturday, June 29, 2013**

16:50 - 17:00 **Novel Factor V concentrate: Orphan drug and clinical trial**
SC09-3.03 Claudia Nardini [Italy]

17:00 - 17:15 **Discussion**

**Open session in new proposals**

*Moderators: Alok Asrivastava [India] and Leonard Valentino [USA]*

17:15 - 17:20 **Toward long-term clinical outcome evaluation**
SC09-4.01 Alok Srivastava [India]

17:20 - 17:27 **New European pharmacovigilance legislation: First experiences**
SC09-4.02 Anneliese Hilger [Germany]

17:27 - 17:34 **New FDA regulation for post-marketing surveillance**
SC09-4.03 Nisha Jain [USA]

17:34 - 17:39 **Discussion**

**New SSC projects**

17:39 - 17:46 **Consensus definitions and recommendations for immune tolerance induction (ITI) in hemophilia with inhibitors**
SC09-5.01 Elena Santagostino [Italy]

17:46 - 17:53 **Prophylaxis in hemophilic patients with inhibitor**
SC09-5.02 Carmen Escuriola [Germany]

17:53 - 18:00 **Prophylaxis in hemophilic patients without inhibitor**
SC09-5.03 Victor Blanchette [Canada]

**Fibrinogen and Factor XIII**

*Elicium 1*

*Chairman: Helen Philippou [United Kingdom]*

*Co-chairs: Moniek de Maat [The Netherlands], Aida Inbal [Israel], Vytautas Ivaskevicius [Germany], Hans Kohler [Switzerland], Marguerite Neerman-Arbez [Switzerland], Sanj Raut [United Kingdom] and Verena Schroeder [Switzerland]*

**Educational session**

14:00 - 14:30 **In vivo imaging of simultaneous FXIII activity, fibrin formation and fibrinolysis in a murine model**
SC10-1.01 Helen Philippou [United Kingdom]

14:30 - 15:00 **Structural molecular transitions underlying deformation of fibrin clots and thrombi**
SC10-1.02 John Weisel [USA]
SSC PROGRAMME

Saturday, June 29, 2013  14:00 - 18:00

Subcommittee session

15:00 - 15:10  Update on FXIII-B subunit standardisation
   SC10-2.01  Verena Schroeder and Hans Peter Kohler (Switzerland)

15:10 - 15:20  Update on the proposed WHO 2nd International Standard (IS) on fibrinogen concentrates
   SC10-2.02  Sanj Raut (United Kingdom)

15:20 - 15:35  Clottable protein assays for fibrinogen concentrates: the effect of fibrinogen & thrombin concentrations on clot formation, structure and clot opacity/turbidity
   SC10-2.03  Sanj Raut (United Kingdom)

15:35 - 15:50  Misconceptions regarding turbidity and clot density
   SC10-2.04  Robert Ariëns (United Kingdom)

15:50 - 16:05  Stable expression of FXIII variants in flp-in CHO cells
   SC10-2.05  Helena Handrková, Verena Schroeder, Hans Peter Kohler (Switzerland)

16:05 - 16:15  Coffee break

16:15 - 16:30  Modelling fibrinogen disorders in the zebrafish
   SC10-2.06  Marguerite Neerman-Arbez (Switzerland)

16:30 - 16:45  FXIII in Hemophilia A
   SC10-2.07  Catherine Rea, Benny Sorenson (United Kingdom)

16:45 - 17:00  Measurement of the knob-hole interactions of fibrin at the single-molecule level
   SC10-2.08  Rustem Litvinov (USA)

17:00 - 17:15  Free and total FXIII-B subunit assays
   SC10-2.09  Éva Katona, László Muszbek (Hungary)

17:15 - 17:30  An update on Japanese criterion 2012 for the diagnosis and treatment of autoimmune/acquired hemorrhaphilia XIII/13; a proposal of algorithm of laboratory tests and differential diagnosis
   SC10-2.10  Akitada Ichinose (Japan)

17:30 - 17:45  Algorithm to determine inherited FXIII deficiency
   SC10-2.11  Vytautas Ivaskevicius (Germany)

17:45 - 18:00  Discussion
Women's Health Issues in Thrombosis and Haemostasis

Chairman: Sabine Eichinger [Austria]
Co-chairs: Rezan Abdul-Kadir [United Kingdom], Takao Kobayashi [Japan], Ida Martinelli [Italy], Claire McLintock [New Zealand], Saskia Middeldorp [The Netherlands], Claire Phillip [USA] and Rochelle Winikoff [Canada]

Educational session

Moderator: Sabine Eichinger [Austria]

14:00 - 14:20  A user's guide to management of ITP in pregnancy
SC11-1.01  Claire McLintock [New Zealand]

14:20 - 14:40  Risk of thrombosis in postmenopausal women
SC11-1.02  Astrid van Hylckama Vlieg [The Netherlands]

14:40 - 15:00  Thrombosis and haemostasis issues in preeclampsia
SC11-1.03  Benjamin Brenner [Israel]

15:00 - 15:10  Outline of the SSC and overview of activities
SC11-1.04  Sabine Eichinger [Austria]

SC11-1.05  Benjamin Brenner [Israel]

Thrombosis

Moderator: Saskia Middeldorp [The Netherlands]

15:15 - 15:35  Update on studies on VTE diagnosis during pregnancy
SC11-2.01  Melanie Tan, Menno Huisman [The Netherlands]

15:35 - 15:50  Risk of recurrent VTE among women
SC11-2.02  Lisbeth Eischer [Australia]

15:50 - 16:10  Coffee break

Thrombophilia and pregnancy

Moderator: Ida Martinelli [Italy]

16:10 - 16:25  Thrombophilia and pregnancy
SC11-3.01  Maria DeSancho [USA]

16:25 - 16:40  Observational study on anti-Thrombotic prevention in thrombophilia and pregnancy loss. The OTTILIA study
SC11-3.02  Elvira Grandone [Italy]

16:40 - 17:00  Adverse pregnancy outcomes in patients with inherited thrombophilia proven by DNA sequencing in a Japanese population
SC11-3.03  Reiko Neki [Japan]

17:00 - 17:15  Update of the EPPI study [enoxaparin in preeclampsia/ intrauterine growth restriction] study and the Australasian Maternity Outcomes Surveillance Systems (AMOSS)-maternal morbidity studies
SC11-3.04  Claire McLintock [New Zealand]
### SSC PROGRAMME

**Saturday, June 29, 2013**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>17:15 - 17:25</td>
<td><strong>ALIFE 2 and HIGHL OW studies: call for participation</strong>&lt;br&gt;SC11-3.05 Saskia Middeldorp (The Netherlands)</td>
</tr>
</tbody>
</table>

#### Haemostasis

*Moderator: Rezan Abdul Kadir [United Kingdom]*

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>17:25 - 17:35</td>
<td><strong>Prospective observational study on massive transfusion in PPH</strong>&lt;br&gt;SC11-4.01 Claire McLintock (New Zealand)</td>
</tr>
<tr>
<td>17:35 - 17:50</td>
<td><strong>Update on Canadian initiatives in women and girls with bleeding disorders</strong>&lt;br&gt;SC11-4.02 Rochelle Winikoff (Canada)</td>
</tr>
<tr>
<td>17:50 - 18:00</td>
<td><strong>Report from the Bleeding Assessment Tool Standing Committee</strong>&lt;br&gt;SC11-4.03 Sabine Eichinger (Austria)</td>
</tr>
</tbody>
</table>

#### Plasma Coagulation Inhibitors

*Chairman: Steven Kitchen [United Kingdom]*<br>*Co-chairs: Elisabetta Castoldi [The Netherlands], Tilman Hackeng [The Netherlands], Richard Marlar [USA], Piet Meijer [The Netherlands], Laurent Mosnier [USA] and Jun Teruya [USA]*

*Educational session*

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00 - 14:30</td>
<td><strong>Laboratory diagnosis and characterisation of antithrombin deficiency</strong>&lt;br&gt;SC12-1.01 Peter Cooper (United Kingdom)</td>
</tr>
<tr>
<td>14:30 - 15:00</td>
<td><strong>Structure-function of activated protein C: Deficiencies and endogenous anticoagulant activities</strong>&lt;br&gt;SC12-1.02 Laurent Burnier (USA)</td>
</tr>
</tbody>
</table>

#### Laboratory testing

*Moderators: Jun Teruya [USA] and Richard Marlar [USA]*

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:00 - 15:10</td>
<td><strong>Project proposal: Proposed guideline for assays of AT, PC and PS</strong>&lt;br&gt;SC12-2.01 Piet Meijer (The Netherlands)</td>
</tr>
<tr>
<td>15:10 - 15:30</td>
<td><strong>Pre-analytical issues for AT, PC and PS testing</strong>&lt;br&gt;SC12-2.02 Richard Marlar [USA]</td>
</tr>
<tr>
<td>15:30 - 15:50</td>
<td><strong>Diagnosis of AT Budapest variants</strong>&lt;br&gt;SC12-2.03 Ingrid Hrachovinova (Czech Republic)</td>
</tr>
<tr>
<td>15:50 - 16:10</td>
<td><strong>Coffee break</strong></td>
</tr>
</tbody>
</table>

---

**Plasma Coagulation Inhibitors**

*Mondriaan III*

*Chairman: Steven Kitchen [United Kingdom]*

*Co-chairs: Elisabetta Castoldi [The Netherlands], Tilman Hackeng [The Netherlands], Richard Marlar [USA], Piet Meijer [The Netherlands], Laurent Mosnier [USA] and Jun Teruya [USA]*

*Educational session*

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00 - 14:30</td>
<td><strong>Laboratory diagnosis and characterisation of antithrombin deficiency</strong>&lt;br&gt;SC12-1.01 Peter Cooper (United Kingdom)</td>
</tr>
<tr>
<td>14:30 - 15:00</td>
<td><strong>Structure-function of activated protein C: Deficiencies and endogenous anticoagulant activities</strong>&lt;br&gt;SC12-1.02 Laurent Burnier (USA)</td>
</tr>
</tbody>
</table>

#### Laboratory testing

*Moderators: Jun Teruya [USA] and Richard Marlar [USA]*

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:00 - 15:10</td>
<td><strong>Project proposal: Proposed guideline for assays of AT, PC and PS</strong>&lt;br&gt;SC12-2.01 Piet Meijer (The Netherlands)</td>
</tr>
<tr>
<td>15:10 - 15:30</td>
<td><strong>Pre-analytical issues for AT, PC and PS testing</strong>&lt;br&gt;SC12-2.02 Richard Marlar [USA]</td>
</tr>
<tr>
<td>15:30 - 15:50</td>
<td><strong>Diagnosis of AT Budapest variants</strong>&lt;br&gt;SC12-2.03 Ingrid Hrachovinova (Czech Republic)</td>
</tr>
<tr>
<td>15:50 - 16:10</td>
<td><strong>Coffee break</strong></td>
</tr>
</tbody>
</table>
Molecular genetics

Moderators: Elisabetta Castoldi (The Netherlands) and Tilman Hackeng (The Netherlands)

16:10 - 16:25  Subcommittee Project update: Update and maintenance of the antithrombin, protein C and protein S mutation databases
Elisabetta Castoldi (The Netherlands)

16:25 - 16:35  Subcommittee Project proposal: Racial differences in genetic risk factors for venous thromboembolism
Hiroko Tsuda (Japan)

16:35 - 16:55  Can plasma levels of PS, PC and AT predict the presence of an underlying genetic defect?
Anna Pavlova (Germany)

Standardisation of Protein S activity assays (panel)

Moderator: Piet Meijer (The Netherlands)
Panel: Steve Kitchen (United Kingdom), Ian Jennings (United Kingdom) and Richard Marlar (USA)

16:55 - 17:05  The problem: Lack of agreement in PS activity results by different methods
Steve Kitchen (United Kingdom)

17:05 - 17:45  Principles and features of widely used commercial PS activity assays (to incorporate non promotional short presentations on the most widely used commercial kits/assays)
Panel

17:45 - 18:00  Discussion

Hemostasis and Malignancy  Mondriaan IV

Chairman: Alok A. Khorana (USA)
Co-chairs: Marc Carrier (Canada), Agnes Lee (Canada), Howard Liebman (USA), Marina Marchetti (Italy), Ingrid Pabinger (Austria), Joseph Palumbo (USA), Wolfram Ruf (USA) and Jeffrey Zwicker (USA)

Educational session

14:00 - 14:20  LMWHs, VKAs or NOACs in CAT: What’s a clinician to do?
Agnes Lee (Canada)

14:20 - 14:40  Platelets, cancer and thrombosis: Role of anti-platelet agents in cancer clinics
Chris Holmes (USA)

14:40 - 15:00  Bleeding in cancer: An unseen epidemic?
Thomas Ortel (USA)
**Session one: Clinical guidance**  
*Moderators: Agnes Lee [Canada] and Jeffrey Zwicker [USA]*

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:00 - 15:20</td>
<td>Treatment of recurrent VTE and bleeding concerns</td>
<td>Marc Carrier [Canada]</td>
</tr>
<tr>
<td>15:20 - 15:40</td>
<td>Treatment of catheter-related thrombosis</td>
<td>Jeffrey Zwicker [USA]</td>
</tr>
<tr>
<td>15:40 - 16:00</td>
<td>Prevention of VTE in medical outpatients</td>
<td>Alok Khorana [USA]</td>
</tr>
<tr>
<td>16:00 - 16:20</td>
<td>Diagnosis and management of incidental VTE</td>
<td>Adrienne Lee [Canada]</td>
</tr>
<tr>
<td></td>
<td>Coffee break</td>
<td></td>
</tr>
</tbody>
</table>

**Session two: clinical and translational updates**  
*Moderators: Joseph Palumbo [USA] and Ingrid Pabinger [Austria]*

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:30 - 16:50</td>
<td>Role of hemostatic factors in malignancy</td>
<td>Joseph Palumbo [USA]</td>
</tr>
<tr>
<td>16:50 - 17:10</td>
<td>Lessons from Vienna CATS Registry: an update</td>
<td>Ingrid Pabinger and Cihan Ay [Austria]</td>
</tr>
<tr>
<td>17:10 - 17:20</td>
<td>The Inpatient thromboprophylaxis conundrum</td>
<td>Marc Carrier [Canada]</td>
</tr>
<tr>
<td>17:20 - 17:30</td>
<td>Tumoral coagulation factors and VTE: A translational proposal</td>
<td>Henri Versteeg [The Netherlands]</td>
</tr>
<tr>
<td>17:30 - 18:00</td>
<td>Update on active clinical trials</td>
<td>[CATCH-Carrier, PHACS-Khorana, SOME-Carrier, PERIOP-Carrier, LONGHEVA-Kamphuisen, TILT-Meyer, Incidental VTE treatment -DiNisio, CAT IQ - Zwicker]</td>
</tr>
</tbody>
</table>

**Biorheology**  
*Chairman: Michael King [USA]*  
*Co-chairs: Lawrence Brass [USA], Shaun Jackson [Australia], David Ku [USA], Owen McCarty [USA], Keith Neeves [USA], Armin Reininger [Austria] and Mitsuhiko Sugimoto [Japan]*

**Educational Session: Flow-based assays of thrombosis and hemostasis**

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00 - 14:20</td>
<td>Flow-dependent thrombin and fibrin generation</td>
<td>Keith Neeves [USA]</td>
</tr>
<tr>
<td>14:20 - 14:40</td>
<td>Assaying thrombus formation under flow: The role of coagulation</td>
<td>Johan Heemskerk [The Netherlands]</td>
</tr>
<tr>
<td>14:40 - 15:00</td>
<td>Measuring and modeling the thrombus interior microenvironment</td>
<td>Lawrence Brass [USA]</td>
</tr>
</tbody>
</table>
Session 2: Mechanical degradation of VWF in medical devices
Moderators: Michael King and Jorge Di Paola [USA]

15:00 - 15:10 Break and introduction
SC14-2.01 Michael King [USA]

15:10 - 15:30 VWF mechanoenzymatic stability under fluid dynamic conditions germane to LVADs
SC14-2.02 Vincent Turitto, Zoe Demou [USA]

15:30 - 15:50 Force-induced self-association and disruption of von Willebrand factor strands
SC14-2.03 José López [USA]

15:50 - 16:10 Regulation of VWF structure and function by hydrodynamic shear
SC14-2.04 Sriram Neelamegham [USA]

16:10 - 16:30 Fluid shear stress and VWF proteolysis by ADAMTS13
SC14-2.05 X. Long Zheng [USA]

16:30 - 16:50 Thrombosis differences in vascular grafts and ECMO circuits
SC14-2.06 David Ku [USA]

16:50 - 17:10 Acquired von Willebrand syndrome in continuous flow left ventricular assist device recipients
SC14-2.07 Rong He [USA]

Session 3: Emerging Topics in Biorheology
Moderator: Keith Neeves [USA]

17:10 - 17:20 Break and introduction
SC14-3.01 Keith Neeves [USA]

17:20 - 17:40 Live cell imaging of coagulation
SC14-3.02 Owen McCarty [USA]

17:40 - 18:00 Multiscale simulations of blood cell interactions with a microvascular thrombus
SC14-3.03 Michael King [USA]
SSC PROGRAMME

Sunday, June 30, 2013 08:00 – 12:00

Pediatric Neonatal Hemostasis and Thrombosis  Elicium 2

Chairman: Anthony Chan (Canada)
Co-chairs: Mariana Bonduel (Argentina), Leonardo Brandao (Canada), Elizabeth Chalmers (United Kingdom), Neil Goldenberg (USA), Christoph Male (Austria), Paul Monagle (Australia), Paolo Simioni (Italy) and Guy Young (USA)

Educational session

08:00 - 08:20  Protein C and activated Protein C: Is there an indication in children
SC15-1.01  Riten Kumar (Canada)

08:20 - 08:40  Diagnosis and management of CSVT in neonates
SC15-1.02  Mahendranath Moharir (Canada)

08:40 - 09:00  Platelet dysfunction: How to investigate
SC15-1.03  Alan Michelson (USA)

Subcommittee session

09:00 - 09:15  Introduction and update on the work of the SSC
SC15-2.01  Anthony Chan (Canada)

09:15 - 09:45  APLA in children
SC15-2.02  Mariana Bonduel (Argentina)

09:45 - 10:15  Pulmonary embolism in childhood
SC15-2.03  Madhvi Rajpurkar (USA)

10:15 - 10:45  Arterial thrombosis: Diagnosis and management
SC15-2.04  Manuela Albisetti (Switzerland)

10:45 - 11:15  Investigation of the bleeding child
SC15-2.05  Paolo Simioni (Italy)

11:15 - 11:25  FFP use in neonates and children
SC15-2.06  Elizabeth Chalmers (United Kingdom)

11:25 - 11:35  Purpura Fulminans Registry
SC15-2.07  Adrian Minford (United Kingdom)

11:35 - 11:45  Diagnostic criteria for thrombosis in children
SC15-2.08  Leonardo Brandao (Canada)

11:45 - 12:00  Conclusion
SC15-2.09  Anthony Chan (Canada)
SSC PROGRAMME

Sunday, June 30, 2013  08:00 – 12:00

Control of Anticoagulation  Elicium 1
Chairman: Walter Ageno (Italy)
Co-chairs: Rebecca Beyth (USA), Benilde Cosmi (Italy), Mark Crowther (Canada), Ismail Elalamy (France), Elaine M. Hylek (USA), Pieter W. Kamphuisen (The Netherlands), Peter Verhamme (Belgium) and Henry G. Watson (United Kingdom)

Educational session: Predicting and managing bleeding in patients on anticoagulant therapies
Moderators: Walter Ageno (Italy) and Mark Crowther (Canada)

08:00 - 08:05  Introduction
SC16-1.01  Walter Ageno (Italy)

08:05 - 08:20  Risk factors and bleeding scores for AF patients
SC16-1.02  Elaine Hylek (USA)

08:20 - 08:35  Risk factors and bleeding scores for VTE patients
SC16-1.03  Benilde Cosmi (Italy)

08:35 - 08:50  Evidence based management of major bleeding with the old and new anticoagulants
SC16-1.04  Rebecca Beyth (USA)

08:50 - 09:00  Discussion

Update on current SSC registries
Moderators: Peter Verhamme (Belgium) and Steve Watson (United Kingdom)

09:00 - 09:10  Recurrent venous thromboembolism in anticoagulated patients with cancer
SC16-2.01  Sam Schulman (Canada)

09:10 - 09:20  Splanchnic vein thrombosis: Long-term follow-up
SC16-2.02  Walter Ageno (Italy)

09:20 - 09:30  Survey on anticoagulated patients START SSC ISTH register
SC16-2.03  Gualtiero Palareti (Italy)

09:30 - 09:45  Coffee break

Second session
Moderators: Ismail Elalamy (France) and Pieter Willem Kamphuisen (The Netherlands)

09:45 - 10:00  Report on ongoing SSC projects: Evaluation of tests to assess the effect of apixaban
SC16-3.01  Job Harenberg (Germany)

10:00 - 10:15  Evaluation of tests to assess the effect of the ODIs. Comparing in vitro and in vivo results
SC16-3.02  Jovan Antovic (Sweden)

10:15 - 10:30  Control of anticoagulation with the oral direct inhibitors: which patients to monitor which tests which suggestions
SC16-3.03  Ismail Elalamy (France)
SSC PROGRAMME

Sunday, June 30, 2013  08:00 – 12:00

10:30 - 10:45  Inhibition of factor Xla with the ODIs: clinical relevance and methodological issues
SC16-3.04  Cornelis Kluft (The Netherlands)

Third session
Moderators: Mark Crowther (Canada) and Pieter Willem Kamphuisen (The Netherlands)

10:45 - 11:00  Standardizing the definition of clinically relevant bleeding in studies on patients with usual and unusual VTE
SC16-4.01  Scott Kaatz (USA)

11:00 - 11:15  Standardizing the definition of unprovoked VTE
SC16-4.02  Clive Kearon (Canada)

11:15 - 11:35  The need for independent trials in orphan areas
SC16-4.03  Peter Verhamme (Belgium)

11:35 - 11:55  How to design an independent clinical trial to address clinically relevant, unanswered questions in orphan areas
SC16-4.04  Harry Büller (The Netherlands)

11:55 - 12:00  Control of Anticoagulation Awards and closing remarks
SC16-4.05  Walter Ageno (Italy) and Job Harenberg (Germany)

Von Willebrand Factor  Forum
Chairman: Jorge Di Paola (USA)
Co-chairs: Imre Bodo (Hungary), Jeroen Eikenboom (Netherlands), Yoshihiro Fujimura (Japan), Sandra Haberichter (USA), Daniel Hampshire (United Kingdom), Paula James (Canada), Johanna Kremer Hovinga (Switzerland) and Alberto Tosetto (Italy)

Educational Session
Moderators: Jorge Di Paola (USA) and Paula James (Canada)

08:00 - 08:20  Genesis and intracellular processing of VWF
SC17-1.01  Jeroen Eikenboom (The Netherlands)

08:20 - 08:40  VWF molecular interactions and their effect on disease
SC17-1.02  Evan Sadler (USA)

08:40 - 09:00  New developments in VWD diagnosis and treatment
SC17-1.03  Imre Bodo (Hungary)

Registries VWD/TTP
Moderator: Daniel Hampshire (United Kingdom)

09:00 - 09:10  Hereditary TTP registry
SC17-2.01  Magnus Mansour [Switzerland]

09:10 - 09:15  VWF database
SC17-2.02  Daniel Hampshire (United Kingdom)

09:15 - 09:30  Coffee break
## SSC PROGRAMME

**Sunday, June 30, 2013**

### Assays for VWF and ADAMTS13

*Moderators: Yoshihiro Fujimura [Japan] and Johanna Kremer Hovinga [Switzerland]*

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:30 - 09:45</td>
<td>Flow cytometry for the diagnosis of VWD</td>
<td>Mark Roest [The Netherlands]</td>
<td>SC17-3.01</td>
</tr>
<tr>
<td>09:45 - 10:00</td>
<td>Collagen binding types IV/VI</td>
<td>Veronica Flood [USA]</td>
<td>SC17-3.02</td>
</tr>
<tr>
<td>10:00 - 10:15</td>
<td>Multimer analysis quantification</td>
<td>Sandra L. Haberichter [USA]</td>
<td>SC17-3.03</td>
</tr>
<tr>
<td>10:15 - 10:30</td>
<td>Comparison of VWF activity assays</td>
<td>Imre Bodo [Hungary]</td>
<td>SC17-3.04</td>
</tr>
<tr>
<td>10:30 - 10:40</td>
<td>Multimer methodology and minimal diagnostic requirements</td>
<td>Imre Bodo [Hungary]</td>
<td>SC17-3.05</td>
</tr>
</tbody>
</table>

### ADAMTS13/TTP

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:40 - 10:55</td>
<td>Standardization of ADAMTS13 assays</td>
<td>Johanna A. Kremer Hovinga [Switzerland]</td>
<td>SC17-4.01</td>
</tr>
<tr>
<td>10:55 - 11:10</td>
<td>New ADAMTS13 assay, novel substrate and improved sensitivity</td>
<td>Joshua Muia [USA]</td>
<td>SC17-4.02</td>
</tr>
</tbody>
</table>

### Updates on Multicenter Studies

*Moderators: Alberto Tosetto [Italy] and Sandra Haberichter [USA]*

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:25 - 11:35</td>
<td>French Cohort Study</td>
<td>Agnes Veyradier [France]</td>
<td>SC17-5.01</td>
</tr>
<tr>
<td>11:35 - 11:40</td>
<td>EU study</td>
<td>Anne Goodeve [United Kingdom]</td>
<td>SC17-5.02</td>
</tr>
<tr>
<td>11:40 - 11:45</td>
<td>Canadian study</td>
<td>Paula James [Canada]</td>
<td>SC17-5.03</td>
</tr>
<tr>
<td>11:45 - 11:50</td>
<td>Zimmerman project</td>
<td>Robert Montgomery [USA]</td>
<td>SC17-5.04</td>
</tr>
<tr>
<td>11:50 - 11:55</td>
<td>Dutch WIN Study</td>
<td>Frank Leebeek [The Netherlands]</td>
<td>SC17-5.05</td>
</tr>
<tr>
<td>11:55 - 12:00</td>
<td>Brno-VWD (Belgium-Czech Cooperative Study)</td>
<td>Alain Gadisseur [Belgium]</td>
<td>SC17-5.06</td>
</tr>
</tbody>
</table>
SSC PROGRAMME

Sunday, June 30, 2013 08:00 – 12:00

Platelet Physiology

Chairman: Paul Harrison [United Kingdom]
Co-chairs: Christian Gachet [France], Paolo Gresele [Italy], Diego Mezzano [Chile], Andrew Mumford [United Kingdom], Patrizia Noris [Italy] and Alan Nurden [France]

Educational session

Moderators: Paul Harrison [United Kingdom] and Andrew Mumford [United Kingdom]

08:00 - 08:15 Platelets and their progeny
SC18-1.01 Hansjörg Schwertz (Germany)

08:15 - 08:30 Circulating pre-platelets and their role in platelet maturation and size determination
SC18-1.02 Jonathan Thon (USA)

08:30 - 09:00 Platelets and inflammation
SC18-1.03 Meinrad Gawaz (Germany)

Subcommittee session

Moderators: Paul Harrison [United Kingdom] and Paolo Gresele [Italy]

09:00 - 09:10 Introduction and overview
SC18-2.01 Paul Harrison (United Kingdom)

09:10 - 09:35 Guidelines for the diagnosis of platelet disorders
SC18-2.02 Paolo Gresele [Italy]

09:35 - 10:00 LTA standardization in The Netherlands
SC18-2.03 Yvonne Henskens (The Netherlands)

10:00 - 10:30 Coffee break

Second session

Moderators: Patrizia Noris [Italy] and Christian Gachet [France]

10:30 - 11:00 ISTH Bleeding Assessment Tool (BAT): Potential role for platelet function disorders
SC18-3.01 Alberto Tosetto (Italy)

11:00 - 11:15 Assessment of the BAT in the GAPP study
SC18-3.02 Marie Lordkipanidze [United Kingdom]

11:15 - 11:25 Proposal for SSC Evaluation of the BAT for platelet function disorders
SC18-3.03 Paul Harrison (United Kingdom)

11:25- 11:45 Measurement of platelet release
SC18-3.04 Diego Mezzano [Chile]

11:45 - 12:00 Technical investigations resulting in a standardised, clinically diagnostic mepacrine assay
SC18-3.05 Elaine Uhr (Australia)
SSC PROGRAMME

Sunday, June 30, 2013 08:00 – 12:00

Disseminated Intravascular Coagulation Mondriaan III
Chairman: Hideo Wada (Japan)
Co-chairs: Satoshi Gando (Japan), Hyun Kyung Kim (South Korea), Shinichiro Kurosawa (USA), Jorn Nielsen (Denmark) and Jecko Thachil (United Kingdom)

Educational session

08:00 - 08:30  Coagulopathy of the critically ill
SC19-1.01 Gary Kinasewitz (USA)

08:30 - 09:00  Guidance for diagnosis and treatment of DIC
SC19-1.02 Hideo Wada (Japan)

Diagnosis and treatments for DIC

09:00 - 09:20  Chairman’s report
SC19-2.01 Hideo Wada (Japan)

09:20 - 09:40  SISET guidelines for DIC?
SC19-2.02 Marcello Di Nisio (Italy)

09:40 - 10:00  How we understand DIC in Russia
SC19-2.03 Igor Bokarev (Russian Federation)

10:00 - 10:20  Coffee break

Mechanisms for onset of DIC

10:20 - 10:40  Thrombocytopenia in DIC -- causes and consequences
SC19-3.01 Jecko Thachil (United Kingdom)

10:40 - 11:00  Prognostic value of thrombomodulin expression in peripheral monocytes in DIC
SC19-3.02 Hyun Kyung Kim (South Korea)

11:00 - 11:20  DIC Border Patrol: Complement activation
SC19-3.03 Shinichiro Kurosawa (USA)

11:20 - 11:40  DIC: Emerging histones-emerging relevance
SC19-3.04 Cheng-Hock Toh (United Kingdom)

11:40 - 12:00  Massive thrombosis evoked by extracellular histones: Is it DIC?
SC19-3.05 Takashi Ito, Mayumi Nakahara and Ikuro Maruyama (Japan)
# SSC PROGRAMME

**Sunday, June 30, 2013**  
08:00 – 12:00

## Registry of Exogenous Hemostatic Factors  
Mondriaan IV

*Chairman: Jan Rosing (The Netherlands)*  
*Co-chairs: Kenneth Clemetson (Switzerland), Ivo Francischetti (USA), Manjunatha Kini (Singapore), Francis Markland Jr (USA), Mary Ann McLane (USA) and Takashi Morita (Japan)*

### Educational session

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00 - 08:20</td>
<td>Exogenous haemostatic factors: Novel antiplatelet agents</td>
<td>Ivo Francischetti (USA)</td>
</tr>
<tr>
<td>08:20 - 08:40</td>
<td>Exogenous haemostatic factors in cancer therapy</td>
<td>Manjunatha R. Kini (Singapore)</td>
</tr>
<tr>
<td>08:40 - 09:00</td>
<td>Exogenous haemostatic factors as research tools in platelet activation</td>
<td>Kenneth Clemetson (Switzerland)</td>
</tr>
<tr>
<td>09:00 - 09:30</td>
<td>Coffee break</td>
<td></td>
</tr>
</tbody>
</table>

### Subcommittee session

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:30 - 09:50</td>
<td>A proposal to replace the WHO 1st International Standard for Ancrod (74/581)</td>
<td>Craig Thelwell (United Kingdom)</td>
</tr>
<tr>
<td>09:50 - 10:10</td>
<td>Developing a FXa inhibitor (Amblyomin-X) as a new antitumoral molecule</td>
<td>Ana Marisa Chudzinski-Tavassi (Brazil)</td>
</tr>
<tr>
<td>10:10 - 10:30</td>
<td>Ixolaris, a TFPI-like inhibitor from tick saliva, as model for understanding TF-mediated thrombosis, cancer and signalling</td>
<td>Robson Monteiro (Brazil)</td>
</tr>
<tr>
<td>10:30 - 10:50</td>
<td>Regulation of expression of a prothrombin activator in venom</td>
<td>Han Xia (Singapore)</td>
</tr>
<tr>
<td>10:50 - 11:10</td>
<td>King cobra genome</td>
<td>Michael Richardson (The Netherlands)</td>
</tr>
<tr>
<td>11:10 - 11:30</td>
<td>Characterisation of new proteins involved in consumptive coagulopathy in Vipera envenomation</td>
<td>Inn-Ho Tsai (Taiwan)</td>
</tr>
<tr>
<td>11:30 - 11:50</td>
<td>A randomised controlled trial of fresh frozen plasma for treating venom induced consumption coagulopathy in Australia</td>
<td>Michael Seldon (Australia)</td>
</tr>
<tr>
<td>11:50 - 12:00</td>
<td>Closing remarks</td>
<td>Jan Rosing (The Netherlands)</td>
</tr>
</tbody>
</table>
**SSC PROGRAMME**

**Sunday, June 30, 2013**

**Factor XI and the contact system**  
Chairman: Thomas Renné (Sweden)  
Co-chairs: Jonas Emsley (United Kingdom), David Gailani (USA), Jose Govers-Riemsrag (The Netherlands), Christine Mannhalter (Austria), Joost Meijers (The Netherlands), James Morrissey (USA) and Ophira Salomon (Israel)

**Educational session**

08:00 - 08:20  Structures of contact factors  
SC21-1.01  Jonas Emsley (United Kingdom)

08:20 - 08:40  The contact system in diabetes  
SC21-1.02  Edward Feener (USA)

08:40 - 09:00  Polyporphates in coagulation  
SC21-1.03  James Morrissey (USA)

09:00 - 09:20  Coffee break

**Subcommittee session**

09:20 - 09:40  Hereditary angioedema - facts and fiction  
SC21-2.01  Erik Hack (The Netherlands)

09:40 - 10:00  Increased factor XIIa activity in patients on extracorporeal membrane oxygenation - a link to NETs  
SC21-2.02  Simon Davidson (United Kingdom)

10:00 - 10:20  The involvement of coagulation factor XII in fibrinolysis  
SC21-2.03  Joke Konings (The Netherlands)

10:20 - 10:40  Understanding the role of sequence variation in the factor XI gene in the next-generation sequencing era  
SC21-2.04  Stefano Duga (Italy)

10:40 - 11:00  Coffee break

**An update on FXI/FXII inhibitor development: Safe anticoagulation**

11:00 - 11:20  FXI inhibitors  
SC21-3.01  Erik Tucker (USA)

11:20 - 11:40  Allosteric inhibitors of factor XIa  
SC21-3.02  Umesh Desai (USA)

11:40 - 12:00  Factor XIIa inhibitors  
SC21-3.03  Marc Nolte (Germany)
MASTER CLASSES

Sunday, June 30, 2013 14:00 – 16:00

The Master Class sessions are a new educational feature for the ISTH Congress. Young Investigators and Reach-the-World participants are specifically invited for three half-hour sessions with a Master, who is a well-known and established investigator. In small groups (20 per Master), the Master will give a short introduction (5-10 minutes), after which there will be an interactive exchange of questions and a discussion, which will last 30 minutes in total. This way, every participant will be able to meet three Masters.

The following Master Classes have been organised:

Walter Ageno (Italy) - Treatment of venous thrombosis in unusual sites
Giancarlo Agnelli (Italy) - Risk stratification in acute pulmonary embolism
Robert Ariëns (United Kingdom) - Fibrinogen/Fibrinolysis
Trevor Baglin (United Kingdom) - Venous thrombosis: recurrence
Lawrence Brass (USA) - Is there anything new left to be learned about platelets?
Harry Büller (The Netherlands) - Treatment of venous thrombosis
Peter Collins (United Kingdom) - Tailoring prophylaxis for haemophilia A
Mark Crowther (Canada) - Epidemiology and statistics
Mary Cushman (USA) - Venous thrombosis: incidence and risk factors
Sabine Eichinger (Austria) - Predicting the risk of recurrent venous thrombosis
Mike Greaves (United Kingdom) - Getting societal impact from your research
Andreas Greinacher (Germany) - How to manage a patient with a low platelet count?
Tilman Hackeng (The Netherlands) - Natural anticoagulants
Paul Harrison (United Kingdom) - Platelets
Johan Heemskerk (The Netherlands) - Platelet functions and signals
James Huntington (United Kingdom) - Structural biology as a tool for understanding basic mechanisms in blood coagulation
Susan Kahn (Canada) - Venous thrombosis: post thrombotic syndrome
Steve Kitchen (United Kingdom) - Laboratory investigations for bleeding disorders
Sriram Krishnaswamy (USA) - Coagulation system: mechanisms and big unsettled questions
Bernhard Lämmle (Switzerland) - Thrombotic microangiopathy: pathophysiology, diagnosis and treatment
David Lane (United Kingdom) - Flow dependent haemostasis: VWF and ADAMTS13
Marcel Levi (The Netherlands) - Antithrombotic treatment and bleeding risk - practical issues
David Lillicrap (Canada) - Von Willebrand disease: biology, diagnosis and therapy

Continued next page
MASTER CLASSES

Gordon Lowe (United Kingdom) - Epidemiology and statistics
Pier Mannucci (Italy) - Bleeding disorders: haemophilia
Saskia Middeldorp (The Netherlands) - Women’s issues in thrombosis
Pierre-Emmanuel Morange (France) - Genetics of venous thrombosis
Bernhard Nieswandt (Germany) - Mechanisms of platelet adhesion and activation
Yukio Ozaki (Japan) - Platelets research from basic to clinical aspects
Flora Peyvandi (Italy) - Bleeding disorders: rare bleeding disorders
Frits Rosendaal (The Netherlands) - Venous thrombosis: incidence and risk factors
Alberto Tosetto (Italy) - Don’t count your chickens before they are hatched: prognosis is not aetiology
Armando Tripodi (Italy) - New approach to the laboratory investigation of acquired bleeding disorders
Anske van der Bom (The Netherlands) - Inhibitors in haemophilia: appraisal of the evidence and lessons for the future
Waander Van Heerde (The Netherlands) - Laboratory tests
Karen Vanhoorelbeke (Belgium) - Animal models for thrombotic thrombocytopenic purpura
Steve Watson (United Kingdom) - Platelets
Jeffrey Weitz (Canada) - Prevention and treatment of venous thrombosis
Phil Wells (Canada) - Diagnosis of venous thrombosis: can we do better?
Alisa Wolberg (USA) - Investigating fibrinogen and fibrinolysis in health and diseases

Tickets required for admittance. Please check at the Registration Desk whether tickets are still available if you have not ordered them in advance.
Nurses Forum
NURSES FORUM

Saturday, June 29, 2013  09:00 – 18:00

NURSES FORUM  G109

09:00 - 10:40  Nurses abstracts and invited papers - I

Moderator: Maura Malone Dumas (USA)

09:00 - 09:10  Welcome and introduction to Nurses Forum
NF 01.1  Maura Malone Dumas (USA)

09:10 - 09:25  A nurse’s perspective on healthcare practice in the Netherlands
NF 01.2  Marlies Schrijvers (The Netherlands)

09:25 - 09:40  Counselling by healthcare professionals for patients taking oral direct inhibitors as anticoagulant therapy
NF 01.3  Caroline Baglin (United Kingdom)

09:40 - 09:55  Telemedicine: Physician supported rural haemophilia treatment center making a difference for patients
NF 01.4  Michelle Witkop (USA)

09:55 - 10:10  Subcutaneous injection of enoxaparin in neonates
NF 01.5  Rebecca Goldsmith (Canada)

10:10 - 10:25  Discussion

10:25 - 10:40  Coffee break

10:40 - 13:15  Nurses abstracts and invited papers - II

Moderator: Jennifer Maahs (USA)

10:40 - 10:55  Personalised prophylaxis in haemophilia A: How low can you go?
NF 02.1  Allison Greig (United Kingdom)

10:55 - 11:10  Thromboprophylaxis: Analysis of hospital acquired thrombosis
NF 02.2  Gayle Porter (United Kingdom)

11:10 - 11:25  Haemophilia and home treatment: Optimizing skills by an e-learning program
NF 02.3  Greta Mulders (The Netherlands)
NURSES FORUM

Saturday, June 29, 2013 09:00 – 18:00

13:15 - 15:00  Adherence

Moderator: Bunis Packham [United Kingdom]

13:15 - 13:35  Barriers and motivators of adherence to prophylactic treatment in haemophilia
NF 03.1  Marlies Schrijvers [The Netherlands]

NF 03.2  Bunis Packham [United Kingdom]

13:55 - 14:15  Adherence scale in haemophilia
NF 03.3  Natalie Duncan [USA]

14:15 - 14:30  Discussion on session 3
NF 03.4  Bunis Packham [United Kingdom]

14:30 - 14:45  Haemostatic markers and sleep quality among shift work and day work female nurses
NF 03.5  Gleb Saharov [Israel]

14:45 - 15:00  Coffee break

15:00 - 16:15  Identification of risk factors and prevention of VTE

Moderator: Jim Munn [USA]

15:00 - 15:20  Challenges for midwifery in VTE prevention
NF 04.1  Catherine Manning [Ireland]

15:20 - 15:40  Lower limb fractures and VTE: A UK perspective
NF 04.2  Huw Rowswell [United Kingdom]

15:40 - 16:00  Risk of recurrence of VTE assessment following discontinuation of initial treatment of anticoagulation
NF 04.3  Caroline Baqlin [United Kingdom]

16:00 - 16:15  Discussion

16:30 - 18:00  Nurses Networking Reception
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00 - 10:45</td>
<td><strong>Haemophilia care in developing countries</strong></td>
</tr>
<tr>
<td>Moderator</td>
<td>Regina Butler (USA)</td>
</tr>
<tr>
<td>09:00 - 09:30</td>
<td><strong>Haemophilia twinning in Africa: Botswana, Ghana and Kenya</strong></td>
</tr>
<tr>
<td>NF 06.1</td>
<td>Regina Butler and Jennifer Maahs (USA)</td>
</tr>
<tr>
<td>09:30 - 09:40</td>
<td><strong>Management of haemophilia in Northern Cape, South Africa: A nurse’s perspective</strong></td>
</tr>
<tr>
<td>NF 06.2</td>
<td>Suzie Peterson (South Africa)</td>
</tr>
<tr>
<td>09:40 - 09:55</td>
<td><strong>Challenges to diagnosis and treatment of women with bleeding disorders - South Africa Northern Cape (Kimberley)</strong></td>
</tr>
<tr>
<td>NF 06.3</td>
<td>Suzie Peterson (South Africa)</td>
</tr>
<tr>
<td>09:55 - 10:15</td>
<td><strong>Establishing haemophilia care in China: A nurse’s perspective</strong></td>
</tr>
<tr>
<td>NF 06.4</td>
<td>Jessica Kuixing (China)</td>
</tr>
<tr>
<td>10:15 - 10:30</td>
<td><strong>Discussion</strong></td>
</tr>
<tr>
<td>10:30 - 10:45</td>
<td><strong>Coffee break</strong></td>
</tr>
<tr>
<td>10:45 - 11:45</td>
<td><strong>Thrombosis and haemostasis - I</strong></td>
</tr>
<tr>
<td>Moderator</td>
<td>Ann O’Sullivan (Ireland)</td>
</tr>
<tr>
<td>10:45 - 11:05</td>
<td><strong>Care of families with antithrombin deficiency</strong></td>
</tr>
<tr>
<td>NF 07.1</td>
<td>Ann O’Sullivan (Ireland)</td>
</tr>
<tr>
<td>11:05 - 11:25</td>
<td><strong>New innovation - models of care pathway using new oral anticoagulants</strong></td>
</tr>
<tr>
<td>NF 07.2</td>
<td>Jim Munn (USA)</td>
</tr>
<tr>
<td>11:25 - 11:40</td>
<td><strong>Mild bleeding disorders and sports: Risk assessment</strong></td>
</tr>
<tr>
<td>NF 07.3</td>
<td>Maura Malone Dumas (USA)</td>
</tr>
<tr>
<td>11:40 - 11:45</td>
<td><strong>Discussion</strong></td>
</tr>
<tr>
<td>11:45 - 13:30</td>
<td><strong>Thrombosis and haemostasis - II</strong></td>
</tr>
<tr>
<td>Moderator</td>
<td>Bunis Packham (United Kingdom)</td>
</tr>
<tr>
<td>11:45 - 12:15</td>
<td><strong>Select case discussions</strong></td>
</tr>
<tr>
<td>12:15 - 13:30</td>
<td><strong>Lunch</strong></td>
</tr>
</tbody>
</table>
13:30 - 14:45  Bleeding disorder

Modaror: Regina Butler (USA)

13:30 - 13:45  The pharmacokinetics of dosing factor based on ideal body weight in the obese patient
NF 09.1  Anne Graham (USA)

13:45 - 14:00  Treating women while pregnant with high dose of Immunoglobulin G (IVIG) and reducing complications
NF 09.2  Dalia Bashari (Israel)

14:00 - 14:20  Gene therapy in haemophilia
NF 09.3  Leslie Raffini (USA)

14:20 - 14:30  Discussion

14:30 - 14:45  Coffee break

14:45 - 15:40  Thrombosis

Modaror: Caroline Baglin (United Kingdom)

14:45 - 15:05  Nursing approach to smoother transition from inpatient to outpatient follow up
NF 10.1  Marilyn Blumenstien (USA)

15:05 - 15:25  Is inpatient care as good as outpatient care for VTE?
NF 10.2  Niamh Larkin (Ireland)

15:25 - 15:40  Discussion

15:45 - 16:00  Wrap up and evaluations
Bunis Packham (United Kingdom)

16:00 - 16:01  Adjourn

16:00 - 17:30  ISTH Nurses Forum Meeting
Scientific Programme
Monday, July 1, 2013
Monday, July 1, 2013

PLENARY LECTURES 09:45 - 10:30 / 16:00 - 16:45

Virchow Lecture Mondriaan I
Moderator: Marcel Levi (The Netherlands)

09:45 - 10:30 New anticoagulants: a critical analysis of their clinical development
PL 01 John Eikelboom (Canada)

Plenary Lecture Mondriaan I
Moderator: Johan Heemskerk (The Netherlands)

16:00 - 16:45 Platelet activation mechanisms in thrombosis and thrombo-inflammatory disease
PL 02 Bernhard Nieswandt (Germany)
Monday, July 1, 2013

STATE-OF-THE-ART LECTURES  11:00 - 12:00

Prediction rules bleeding and thrombosis  Elicium 2
Moderators: James Douketis (Canada) and Philip Wells (Canada)

11:00 - 11:30  Diagnostic and prognostic prediction models
SOA 01.1  Karel Moons (The Netherlands)

11:30 - 12:00  Bleeders, bleeding rates and bleeding score
SOA 01.2  Alberto Tosetto, Giancarlo Castaman, Francesco Rodeghiero (Italy)

Biology of vWF  Auditorium
Moderators: Jeroen Eikenboom (The Netherlands) and Evan Sadler (USA)

11:00 - 11:30  The secretion of von Willebrand Factor from endothelial cells; an increasingly complicated story
SOA 02.1  Daniel Cutler, Tom Nightingale (United Kingdom)

11:30 - 12:00  Clearance of von Willebrand factor
SOA 02.2  Cécile Denis, C. Casari, P. Lenting, N. Wohner, O. Christophe (France)

Coagulation modeling  Forum
Moderators: Lawrence Brass (USA) and Dougald Monroe (USA)

11:00 - 11:30  Models for thrombin generation and risk of disease
SOA 03.1  Kathleen Brummel-Ziedins (USA)

11:30 - 12:00  Systems biology of coagulation
SOA 03.2  Scott Diamond (USA)

Tissue factor biology  Elicium 1
Moderators: Janusz Rak (Canada) and Wolfram Ruf (USA)

11:00 - 11:30  Encryption and decryption of tissue factor
SOA 04.1  Philip Hogg (Australia)

11:30 - 12:00  Tissue factor-integrin interactions in cancer and thrombosis: Every Jack has his Jill
SOA 04.2  Henri Versteeg (The Netherlands)

Fibrinogen and fibrinolysis  Mondriaan II
Moderators: Nuala Booth (United Kingdom) and Joost Meijers (The Netherlands)

11:00 - 11:30  Fibrinogen and thrombotic disease
SOA 05.1  Robert Ariëns (United Kingdom)

11:30 - 12:00  Insights into TAFI function and regulation
SOA 05.2  Ann Gils (Belgium)

Platelets I  Mondriaan I
Moderators: Judith Cosemans (The Netherlands) and Yukio Ozaki (Japan)

11:00 - 11:30  MicroRNAs in platelet production and activation
SOA 06.1  Paul Bray (USA)

11:30 - 12:00  Genotyping and phenotyping of platelet function disorders
SOA 06.2  Steve Watson (United Kingdom)
Monday, July 1, 2013

ABSTRACT SYMPOSIA 13:00 - 14:15

Cardiovascular disease E102

**Moderator:** Samuel Wickline (USA)

13:00 - 13:30  **Nanomedicines for cardiovascular disease**
*AS 01*  
Samuel Wickline (USA)

13:30 - 13:45  **Von Willebrand factor regulates physiological and pathological angiogenesis through vascular endothelial growth factor receptor-2 signalling**
*AS 01.1*  
Richard Starke, Omary Chillo, Judith Pagel, Maeve Elder, Michael Laffan, Elisabeth Deindl, Anna Randi (United Kingdom)

13:45 - 14:00  **Sign and shape: correlation of clinical findings and clot ultrastructure in arterial thrombi**
*AS 01.2*  
Andras Kovacs, Kiril Tenekedjiev, Nikolett Wohner, László Szabó, Péter Sótonyi, Zsolt Szelid, Anikó Nagy, György Szabó, Béla Merkely, Krasimir Kolev (Hungary)

14:00 - 14:15  **Joint association of elevated factor VIII and low protein C with stroke and coronary heart disease: The reasons for geographic and racial differences in stroke (REGARDS) study**
*AS 01.3*  
Neil Zakai, Suzanne Judd, Brett Kissela, George Howard, Monika Safford, Mary Cushman (USA)

Assays for antithrombotic drugs Mondriaan II

**Moderator:** Wayne Chandler (USA)

13:00 - 13:30  **Assays for antithrombotic drugs**
*AS 02*  
Wayne Chandler (USA)

13:30 - 13:45  **Comparison of the HAS-BLED, ATRIA and HEMORR2HAGES scores to the CHADS2 score for bleeding risk in atrial fibrillation patients on warfarin therapy: The MAQI2 experience**
*AS 02.1*  
Geoffrey Barnes, Xiaokui Gu, Brian Haymart, Eva Kline-Rogers, Steve Almany, Jay Kozlowski, Dennis Besley, Gregory Krol, James Froehlich, Scott Kaatz (USA)

13:45 - 14:00  **Effects of dabigatran on routine tests of haemostasis as determined with a full range of reagents: Results of a UK NEQAS exercise**
*AS 02.2*  
Steve Kitchen, Ian Jennings, Dianne Kitchen, Tim Woods, Anna Lowe, Isobel Walker (United Kingdom)

14:00 - 14:15  **How to monitor Dabigatran- when needed. Comparison of coagulation laboratory methods on Dabigatran concentrations in plasma**
*AS 02.3*  
Jovan Antovic, Mika Skeppholm, Jaak Eintrei, Elisabet Eriksson-Boija, Lisbeth Söderblom, Yuko Rönquist, Olof Beck, Eva-Marie Norberg, Paul Hjemdahl, Rickard Malström (Sweden)
Monday, July 1, 2013

ABSTRACT SYMPOSIA 13:00 - 14:15

Platelet interactions Mondriaan IV

Moderator: Anne Angelillo-Scherrer (Switzerland)

13:00 - 13:30 Homo- and heterotypic platelet interactions
AS 03
Anne Angelillo-Scherrer (Switzerland)

AS 03.1
Sara Calzavarini, Francois Saller, Luca Bologna, Laurent Burnier, Anne Brisset, José Fernández, John Griffin, Tilman Hackeng, Anne Angelillo-Scherrer (Switzerland)

13:45 - 14:00 Toll-like receptor 2 is critical for platelet adhesion to the injured arterial wall
AS 03.2
Sven Jäckel, Klytaimnistra Kiooupts, Marie-Luise Von Brühl, Cora Reiß, Steffen Massberg, Ulrich Walter, Christoph Reinhardt (Germany)

14:00 - 14:15 The activated protein C cofactor activity of protein S is enhanced through extracellular phosphorylation by platelet kinases
AS 03.3
Fabian Stavenuiter, Andrew Gale, Mary Heeb (USA)

Inflammation and coagulation in atherosclerosis Emerald

Moderator: Julian Borissoff (USA)

13:00 - 13:30 The coagulation-inflammation axis in atherosclerosis
AS 04
Julian Borissoff (USA)

13:30 - 13:45 Increased levels of circulating platelet-monocyte complexes and platelet-neutrophil complexes are associated with myocardial infarction
AS 04.1
Bert Rutten, Wouter Jukema, Pieter Doevendans, Nico Pijls, Johannes Waltenberger, Anton-Jan van Zonneveld, Gerard Pasterkamp, Imo Hoefer, Philip de Groot, Mark Roest (The Netherlands)

13:45 - 14:00 Small molecule inhibitors of CD40-TRAF6 interaction reduce atherosclerosis by targeting its inflammatory nature
AS 04.2
Barbara Zarzycka, Tom Seijkens, Oliver Soehnlein, Roy Schrijver, Gert Vriend, Sander Nabuurs, Christian Weber, Esther Lutgens, Gerrit Nikolaes (The Netherlands)

14:00 - 14:15 Platelet CD40 exacerbates atherosclerosis by transcellular activation of endothelial cells and leukocytes
AS 04.3
Dirk Lievens, Tom Seijkens, Marijke Kuipers, Holger Winkels, Linda Beckers, Norbert Gerdes, Johan Heemskerk, Oliver Soehnlein, Christian Weber, Esther Lutgens (Belgium)

Hormones and thrombosis G102-103

Moderator: Mary Cushman (USA)

13:00 - 13:30 Exogenous hormones and thrombosis
AS 05
Mary Cushman (USA)

13:30 - 13:45 The risk of venous thrombosis in oral contraception users with a history of superficial thrombophlebitis
AS 05.1
Rachel Roach, Willem Lijfering, Astrid van Hylckama Vlieg, Frans Helmerhorst, Frits Rosendaal, Suzanne Cannegeieter (The Netherlands)

13:45 - 14:00 Progestin-only contraception after venous thromboembolism: cohort study
AS 05.2
Emmanuelle Le Moigne, Marie-Laure Roudaut-Le Gall, Aurelien Delluc, Emmanuel Nowak, Dominique Mottier, Gregoire Le Gal (France)

14:00 - 14:15 Heparanase procoagulant activity is elevated in women using oral contraceptives
AS 05.3
Yona Nadir, Matan Moshe, Elena Axelman, Benjamin Brenner (Israel)
Monday, July 1, 2013

ABSTRACT SYMPOSIA 13:00 - 14:15

Post-thrombotic syndrome
Moderator: Susan Kahn (Canada)

13:00 - 13:30 Post-thrombotic syndrome: Evidence-based update on prevention and treatment
AS 06 Susan Kahn (Canada)

AS 06.1 Lucy Duan, Maria Avila, Suzan Williams, Leonardo Brandao (Canada)

13:45 - 14:00 Post-thrombotic syndrome after central venous catheter removal in childhood cancer survivors is associated with decreased quality of life
AS 06.2 Esther Polen Mallard, Michael Weintraub, Chanie Stoffer, Dena Jaffe, Ayala Burger, Shoshana Revel-Vilk (Israel)

AS 06.3 Risk factors for severe post-thrombotic syndrome. VTE Epidemiology Group (VEG) Study
Alexander Cohen, Carlos Martinez, Anja Katholing, (United Kingdom)

Upcoming anticoagulants
Moderator: Bruno Villoutreix (France)

13:00 - 13:30 Rational design of future low molecular weight anticoagulant medications: can we get assistance from novel computational drug discovery methods?
AS 07 Bruno Villoutreix (France)

13:30 - 13:45 EP217609, a neutralizable synthetic dual-action FIIa/FXa anticoagulant, has a superior antithrombotic effect compared to its parent compounds in murine models of arterial thrombosis
AS 07.1 Ghina Alame, Pierre Mangin, Monique Freund, Maurice Petitou, Béatrice Hechler, Christian Gachet, (France)

13:45 - 14:00 Identification of novel antagonists of protein disulfide isomerase for inhibition of thrombus formation
AS 07.2 Robert Flaumenhaft, Carol Khodier, Christina Galinski, Partha Nag, Freda Passam, Alissa Scalise, Lotte van Hessem, Suzanne Gunnink, Sivaraman Dandapani, Benito Munoz, Daniel Kennedy (USA)

14:00 - 14:15 Cardioprotective effects of EWE thrombin, a selective protein C activator, in a mouse model of acute focal myocardial ischemia and reperfusion
AS 07.3 Norah Verbout, Zhiping Cao, Liujuan Liu, Owen McCarty, Erik Tucker, Enrico Di Cera, John Griffin, Donna van Winkle, Andras Gruber (USA)

Antiphospholipid syndrome
Moderator: Philip de Groot (The Netherlands)

13:00 - 13:30 Serology and pathophysiology of the antiphospholipid syndrome
AS 08 Philip de Groot (The Netherlands)

13:30 - 13:45 Conformation of f2-glycoprotein I and its effect on coagulation
AS 08.1 Marisa Ninivaggi, Hilde Kelchtermans, Theo Lindhout, Bas de Laat (The Netherlands)

13:45 - 14:00 Human anti-f2-glycoprotein I autoantibodies bind to platelets but not to endothelium in a mouse model of antiphospholipid syndrome
AS 08.2 Valerie Proulle, Barbara Furie, Richard Furie, Bruce Furie (USA)

14:00 - 14:15 Fibrin clot properties in patients with antiphospholipid syndrome
AS 08.3 Magdalena Celinska-Löwenhoff, Teresa Iwaniec, Agnieszka Padjas, Jacek Musial, Anetta Undas (Poland)
Monday, July 1, 2013

**ABSTRACT SYMPOSIA 13:00 - 14:15**

**Flow and von Willebrand factor (VWF) Forum**

*Moderator: Timothy Springer [USA]*

13:00 - 13:30  **Activation of A1 domain adhesiveness in VWF by elongational force**  
*AS 09*  
Timothy Springer, Jongseong Kim [USA]

13:30 - 13:45  **Solution structure and dynamics of the major FVIII binding region on von Willebrand factor: Implications for type 2N von Willebrand disease**  
*AS 09.1*  
Nuha Shiltagh, John Kirkpatrick, Lisa Cabrita, Konstantinos Thalassinos, Edward Tuddenham, Flemming Hansen [United Kingdom]

13:45 - 14:00  **Enhanced binding of von Willebrand factor mutants to LRP1 may explain their reduced circulatory half-life**  
*AS 09.2*  
Nikolett Wohner, Caterina Casari, Olivier Christophe, Cécile Denis, Peter Lenting [France]

14:00 - 14:15  **Fluid shear dependent regulation of von Willebrand factor (VWF) binding to platelet GpIba: Mechanism revealed by MS analysis of cross-linked VWF**  
*AS 09.3*  
Sriram Neelamegham, Sri Madabhushi, Kannayakanahalli Dayananda, Chengwei Shang, Qu Jun [USA]

**Coagulation and inflammation E104-107**

*Moderator: Jay Degen [USA]*

13:00 - 13:30  **Hemostatic factors and innate immunity**  
*AS 10*  
Jay Degen [USA]

13:30 - 13:45  **TLR3 activation is involved in venous thrombosis development**  
*AS 10.1*  
Catherine Lemarie, Sandrine Laurance, Angela Le, Mark Blostein [Canada]

13:45 - 14:00  **High sensitivity C-reactive protein, body mass index, factor VIII levels and risk of venous thrombosis. Results from the MEGA study**  
*AS 10.2*  
Sigrid Braekkan, Willem Lijfering, Frits Rosendaal, Suzanne Kannegieter [The Netherlands]

14:00 - 14:15  **Differential contribution of FXa and thrombin to vascular inflammation in a mouse model of sickle cell disease**  
*AS 10.3*  
Erica Sparkenbaugh, Pichika Chantrathammachart, Robert Hebbel, Joanne van Ryn, Nigel Mackman, Nigel Key, Rafal Pawlinski [USA]
Monday, July 1, 2013

ABSTRACT SYMPOSIA  13:00 - 14:15

New genetic determinants of venous thrombosis  G104-105

Moderator: Tetsuhito Kojima [Japan]

13:00 - 13:30  New genetic determinants of venous thrombosis: A novel mechanism of hereditary thrombosis by antithrombin resistance
Tetsuhito Kojima [Japan]

13:30 - 13:45  Genome-wide association of quantitative trait loci with levels of hemostatic factors and thrombin generation in the GIFT study
Jorine Koenderman, Elisabetta Castoldi, David-Alexandre Tregouet, Pierre-Emmanuel Morange, Mark Lathrop, Hans Vos, Rogier Bertina, Jeanine Houwing-Duistermaat, Pieter Reitsma, Marieke de Visser [The Netherlands]

13:45 - 14:00  Y haplogroup R1b is associated with an increased risk of recurrent venous thrombosis in men
Hugoline de Haan, Astrid van Hylckama Vlieg, Kristiaan van der Gaag, Peter de Knijff, Frits Rosendaal [The Netherlands]

14:00 - 14:15  Whole exome sequencing of >900 individuals provides insight into genetic architecture of venous thromboembolism
Erin Smith, Sigrid Braekkan, Andrew Carson, Kristen Jepsen, Hiroko Matsui, Tom Wilsgaard, Olivier Harismendy, Kelly Frazer, John-Bjarne Hansen [USA]

Late breaking abstracts: Therapy

Auditorium

Moderators: Marcel Levi [The Netherlands] and Pieter Reitsma [The Netherlands]

13:00 - 13:15  The Anticoagulation of Calf Thrombosis (ACT) project: results from the randomized controlled external pilot trial
Daniel Horner, Kerstin Hogg, Richard Body, Michael Nash, Trevor Baglin, Kevin Mackway-Jones [United Kingdom]

Giancarlo Agnelli, Harry Büller, Alexander Cohen, Madelyn Curto, Alexander Gallus, Margot Johnson, Urszula Masiukiewicz, Raphael Pak, John Thompson, Gary Raskob, Jeffrey Weitz [Italy]

13:30 - 13:45  Dalteparin sodium for the long-term management of venous thromboembolism in cancer patients. The DALTECAN Study
Ajay Kakkar, Craig Kessler, Samuel Goldhaber, Michael Kovacs, Alex Spyropoulos, Thomas Ortel, Ingrid Pabinger, Menno Huisman, David Bergqvist, Manuel Monreal, Graham Turpie, Charles Francis [United Kingdom]

13:45 - 14:00  Safety, efficacy and pharmacokinetics of nonacog beta pegol (N9-GP) for prophylaxis and treatment of bleeding episodes in patients with haemophilia B
Peter Collins, Torben Colberg, Guy Young, Faraizah Abdul Karim, Pantep Anghaisuksiri, Turkiz Gursel, Johnny Mahlangu, Tadashi Matsushita, Evelien Mauser-Bunschoten, Johannes Oldenburg, Christopher Walsh, Karin Knobe, Claude Negrier, ParadigmTM2 investigators [United Kingdom]

14:00 - 14:15  An antibody to thrombin’s exosite 1 prevents thrombosis without causing bleeding
Trevor Baglin, Jonathan Langdown, Lacramioara Ivanciu, Rodney Camire, Marfoua Ali, Helen Philippou, James Huntington [United Kingdom]
Monday, July 1, 2013

FOCUS SYMPOSIUM  13:00 - 14:15

Antithrombotics and pregnancy  Mondriaan III

Moderator: Ian Greer [United Kingdom]

13:00 - 13:30  Antithrombotics and pregnancy complications: Is it time for precision medicine?
FS 01  Ian Greer [United Kingdom]

13:30 - 13:45  The Thrombophilia in Pregnancy Prophylaxis Study (TIPPS): A multi-national randomized trial of dalteparin versus no dalteparin to prevent pregnancy complications in pregnant thrombophilic women
FS 01.1  Marc Rodger, William Hague, John Kingdom, Susan Kahn, Alan Karovitch, Philip Wells, Mathew Sermer, Anne Marie Clement, Wee Shian Chan, The TIPPS Investigators (Canada)

13:45 - 14:00  RhuFVIIa reduces the rate of interventional second line therapies in severe primary postpartum haemorrhages resistant to uterotonics: a multicenter, randomised, open controlled trial
FS 01.2  Geraldine Lavigne-Lissalde, Guy Aya, Frederic Mercier, Celine Chauleur, Estelle Morau, Anne-Sophie Ducloy-Bouthors, Alexandre Mignon, Francoise Boehlen, Jean-Christophe Gris (France)

14:00 - 14:15  Polymorphisms in the Annexin A5 promoter, placental Annexin A5 gene expression and risk of preeclampsia
FS 01.3  Paulien de Jong, Gijs Afink, Carrie Ris-Stalpers, Sigrid Fouchier, Joost Meijers, Saskia Middeldorp (The Netherlands)
Monday, July 1, 2013

ORAL COMMUNICATIONS 08:00 - 09:30

Angiogenesis and arteriogenesis - I G104-105

Moderators: Alvin Schmaier (USA) and Henri Versteeg (The Netherlands)

08:00 - 08:15  Prolylcarboxypeptidase promotes angiogenesis and vascular repair
OC 01.1  Gregory Adams, Alona Merkulova, Evi Stavrou, Chao Fang, Alaiti Amer, Kohsuke Nakajima, Daniel Simon, Mukesh Jain, Alvin Schmaier (USA)

08:15 - 08:30  UPAR’s domain 2 regulates single chain urokinase-mediated angiogenesis through beta-1-integrins and VEGFR2
OC 01.2  Alvin Schmaier, Alona Merkulova, Gretchen LaRusch, Fakhri Mahdi, Zia Shariat-Madar, Robert Sitrin, Douglas Cines (USA)

08:30 - 08:45  Junctional adhesion molecule-A modulates angiogenesis through transcriptional regulation of VEGF/VEGFR2 expression
OC 01.3  Meghna Naik, Vesselina Cooke, Sharmila Chatterjee, Ulhas Naik (USA)

08:45 - 09:00  The intestinal microbiota triggers tissue factor-dependent vascular remodelling in the small intestine via the angiopoietin-1 / Tie-2 pathway
OC 01.4  Christoph Reinhardt, Mattias Bergentall, Ines Brandão, Nives Hörmann, Ulrich Walter, Wolfram Ruf, Fredrik Bäckhed (Germany)

09:00 - 09:15  Tissue factor rich endothelial-microparticles induce angiogenesis and post-ischemic revascularization
OC 01.5  Lina Badimon, Gemma Arderiu, Esther Peña (Spain)

09:15 - 09:30  Protease Nexin-1 regulates the retinal vascular development
OC 01.6  Véronique Arocas, Sonia Selbonne, Yacine Bounaftali, Martine Jandrot-Perrus, Marie-Christine Bouton (France)

Anticoagulant agents - clinical studies I Elicium 2

Moderators: Elise Eerenberg (The Netherlands) and Jeffrey Weitz (Canada)

08:00 - 08:15  Antithrombotic treatment of splanchnic vein thrombosis in the ISTH international registry: results of 6-month follow-up
OC 02.1  Nicoletta Riva, Walter Ageno, Sam Schulman, Soo-Mee Bang, Maria Teresa Sartori, Elvira Grandone, Jan Beyer-Westendorf, Giovanni Barilari, Dario Di Minno, Rita Duce, Alessandra Malato, Rita Santoro, Daniela Poli, Peter Verhamme, Francesco Dentali (Italy)

08:15 - 08:30  What is the clinical impact of major bleedings with rivaroxaban? Results from the pooled EINSTEIN studies
OC 02.2  Elise Eerenberg, Saskia Middeldorp, Anthonie Lensing, Harry Büller (The Netherlands)

08:30 - 08:45  Subgroup analysis of the FONDACAST study comparing fondaparinux to low-molecular-weight heparin for the prevention of venous thromboembolism after an isolated, non-surgical below-knee injury
OC 02.3  Charles Marc Samama, Bruno Riou, Pierre-Marie Roy, Alain Sautet, Patrick Mismetti, Alexander van der Veen (France)

08:45 - 09:00  Effect of dabigatran etexilate on the risk of myocardial infarction and other cardiac events: a systematic review and updated dose-response meta-analysis of randomized controlled trials
OC 02.4  Jonathan Douxfils, Fanny Buckinx, François Mullier, Véronique Rabenda, Jean-Yves Reginster, Philippe Hainaut, Olivier Bruyère, Jean-Michel Dogné (Belgium)

09:00 - 09:15  Management of anticoagulation with vitamin K antagonists: can the time in therapeutic range (TTR) be used to optimize the interval between measurements?
OC 02.5  Cláudia Moreira, Paulo Leitão, Vânia Gonçalves, Sara Morais, Fernanda Leite, Manuel Campos, Eugénia Cruz (Portugal)
Monday, July 1, 2013

**ORAL COMMUNICATIONS** 08:00 - 09:30

09:15 - 09:30  **Cost-effectiveness of rivaroxaban for the treatment of pulmonary embolism and secondary prevention of venous thromboembolism - a UK perspective**
OC 02.6  

**Clinical issues in haemophilia A**  
Auditorium

Moderators: Karin Fijnvandraat [The Netherlands] and David Raunig (USA)

08:00 - 08:15  **Impact of sports on children with haemophilia in terms of their health status, health-related quality of life and physical performance**
OC 03.1  
Sylvia Von Mackensen, Kate Khair [Germany]

08:15 - 08:30  **Intracranial haemorrhage in children with haemophilia A and B - interim analysis of the retrospective part of a multicentre study**
OC 03.2  
Nadine Gretenkort Andersson, Rolf Ljung [Sweden]

08:30 - 08:45  **Clinical risk factors in the development of inhibitors in non-severe hemophilia A patients: The first results of the INSIGHT case-control study**
OC 03.3  
Alice van Velzen, Corien Eckhardt, Marjolein Peters, Kathelijne Peerlinck, Johannes Oldenburg, Charles Hay, Maria Elisa Mancuso, Jan Astemark, Anske van der Bom, Karin Fijnvandraat [The Netherlands]

08:45 - 09:00  **Has the inhibitor incidence increased in severe hemophilia A from 1990-2009?**
OC 03.4  
Marijke van den Berg, Rolf Ljung [The Netherlands]

09:00 - 09:15  **Validation of the extended magnetic resonance imaging scale for evaluation of joint status in adult patients with severe hemophilia A**
OC 03.5  
David Raunig, Walter Hong, Björn Lundin [USA]

09:15 - 09:30  **US retrospective database analysis on prevalence of cardiovascular comorbidities among hemophilia A patients**
OC 03.6  
Jennifer Pocoski, Alice Ma, Craig Kessler, Susan Boklage, Thomas Humphries [USA]

**Clinical issues related to cancer and haemostasis**  
Elicium 1

Moderators: Gregory Connolly [USA] and Anna Falanga [Italy]

08:00 - 08:15  **Type 1 plasminogen activator inhibitor (PAI-1) and risk of colorectal cancer in the European prospective investigation into cancer (EPIC)-Italy cohort**
OC 04.1  
Licia Iacoviello, Claudia Agnoli, Amalia De Curtis, Maria Concetta Giurdanella, Vittorio Krogh, Amalia Mattiello, Giuseppe Matullo, Salvatore Panico, Carlotta Sacerdote, Rosario Tumino, Paolo Vineis, Maria Benedetta Donati [Italy]

08:15 - 08:30  **The risk of venous thrombosis in patients with malignancy is largely mediated through levels of factor VIII and von Willebrand factor**
OC 04.2  
Jasmijn Timp, Willem Lijfering, Frits Rosendaal, Henri Versteeg, Suzanne Cannegieter [The Netherlands]

08:30 - 08:45  **Platelet count measured prior to cancer development is a risk factor for venous thromboembolic events in cancer patients - The Tromso Study**
OC 04.3  
Hilde Jensvoll, Kristine Blix, Sigrid Brækkcn, John-Bjarne Hansen [Norway]

08:45 - 09:00  **Chemotherapy-induced hypercoagulability and biomarkers for prediction of thromboembolic events in patients with metastatic testicular cancer**
OC 04.4  
Siouke Lubberts, Hink Boer, Renske Altena, Coby Meijer, Joop Lefrandt, Janine Nuver, André Mulder, Ton Lison, Pieter Willem Kamphuisen, Jouri Kietema [The Netherlands]
Monday, July 1, 2013

ORAL COMMUNICATIONS 08:00 - 09:30

09:00 - 09:15  Prevalence of pulmonary embolism in patients with oncogene addicted advanced lung adenocarcinoma
OC 04.5
Melina Verso, Laura Franco, Stefano Mosca, Matthias Fischer, Rita Chiari, Valeria Marconi, Luca Pagliaiuluca, Giancarlo Agnelli [Italy]

09:15 - 09:30  Using proteomics to identify new biomarkers for cancer-associated thrombosis: A pilot study
OC 04.6
Gregory Connolly, Brian Smith, Fred Hagen, Renuka Iyer, Alok Khorana [USA]

Coagulation factors VIII, IX and XI Emerald

Moderators: Olivier Christophe [France] and Salam Salloum-Asfar [Spain]

08:00 - 08:15  Residues of the 39-Loop Restrict. The plasma inhibitor specificity of factor IXa
OC 05.1
Alireza Rezaie, Likui Yang [USA]

08:15 - 08:30  Activated factor XI enhances procoagulant tissue factor activity on endothelial cells by cleaving tissue factor pathway inhibitor
OC 05.2
Cristina Puy, Erik Tucker, András Gruber, Owen McCarty [USA]

08:30 - 08:45  Role for coagulation factor XI during pneumococcal pneumonia independent of factor XII activation
OC 05.3
Ingrid Stroo, Cornelis van ’t Veer, Joris Roelofs, Joost Meijers, Frank Castellino, Sacha Zeerleder, Tom van der Poll [The Netherlands]

08:45 - 09:00  Regulation of Human Factor XI by a Hepatic MicroRNA
OC 05.4
Salam Salloum-Asfar, Raúl Teruel, Ana B. Arroyo, Nuria Garcia-Barberá, Amarjit Chaudhry, Erin Schuetz, Ginés Luengo-Gil, Vicente Vicente, Rocío González-Conejero, Constantino Martínez [Spain]

09:00 - 09:15  Abnormal plasma clot structure and stability distinguish bleeding risk in patients with severe factor XI deficiency
OC 05.5
Michal Zucker, Ophira Salomon, Uri Seligsohn, Alisa Wolberg [Israel]

09:15 - 09:30  The endothelial lectin CLEC4M is a novel clearance receptor for factor VIII
OC 05.6
Laura Swystun, Colleen Notley, Kate Sponagle, Paula James, David Lillicrap [Canada]

Fibrinogen G106-107

Moderators: Marguerite Neerman-Arbez [Switzerland] and Shirley Uitte de Willige [The Netherlands]

08:00 - 08:15  A new mechanism for modulation of fibrin formation by shear: the knob-hole interactions display ‘catch-slip’ kinetics
OC 06.1
Rustem Litvinov, John Weisel [USA]

08:15 - 08:30  DNA methylation profiling of the fibrinogen gene landscape in human cells and during mouse and zebrafish development
OC 06.2
Marquerite Neerman-Arbez, Silja Vorjohann, Jean-Luc Pitetti, Serge Nef, Carmen Gonelle-Gispert, Leo Bühler, Richard Fish [Switzerland]

08:30 - 08:45  The B subunit for coagulation factor XIII accelerates the crosslinking of fibrin in human plasma
OC 06.3
Masayoshi Souri, Tsukasa Osaki, Akitada Ichinose [Japan]

08:45 - 09:00  Fibrin formation under flow on biomimetic tissue factor microparticles
OC 06.4
Abimbola Onasoga, Keith Neeves [USA]

09:15 - 09:30  Transcriptome analysis of the miR-29-mediated control of fibrinogen gene expression
OC 06.6
Samuel Lukowski, Richard Fish, Emmanouil Dermitzakis, Marguerite Neerman-Arbez [Switzerland]
Monday, July 1, 2013

ORAL COMMUNICATIONS  08:00 - 09:30

Haemostatic factors and arterial vascular disorders  G102-103
Moderators: Menno Huisman [The Netherlands] and Licia Iacoviello [Italy]

08:00 - 08:15 Impact of incident venous thromboembolism on future risk of arterial thrombotic disease
OC 07.1
Caroline Lind, Linda Flinterman, Kristin Enga, Marianne Severinsen, Søren Kristensen, Sigrid Brækkan, Suzanne Cannegieter, Kim Overvad, John-Bjarne Hansen [Norway]

08:15 - 08:30 Procoagulant tumor-derived microparticles: Phenotypic and functional approaches for their detection in an in vitro model of tumor cells-containing blood
OC 07.2
Jérémie Bez, Philippe Poncelet, Tanik Bouriche, Wolfram Ruf [France]

08:30 - 08:45 High on-treatment platelet reactivity in patients with unprotected left main disease treated by percutaneous coronary intervention: The ALMA (Angioplasty of Left Main - LArboisier) registry
OC 07.3
Ludovic Drouet, Jean-Guillaume Dillinger, Iheb Kchaou, Georgios Sideris, Claire Ballot Sollier, Sebastien Voicu, Stephane Manzo Silberman, Damien Logeart, Patrick Henry [France]

08:45 - 09:00 FXIII levels and different major adverse cardiac events (MACEs) in acute myocardial infarction: A potential prognostic biomarker
OC 07.4
Donato Gemmati, Giulia Zeri, Rosella Mari, Elisa Orioli, Stefano Moratelli, Roberto Ferrari, Maria Elena Grossi, Lucia Ansani, Luisa Serino [Italy]

09:00 - 09:15 Effect of factor XIII polymorphisms on the risk of myocardial infarction
OC 07.5
Zsuzsanna Berczy, Zoltan Mezei, Laszlo Balogh, Eva Katona, Emilia Balogh, Istvan Csurgi, Istvan Edes, Laszlo Muszbek [Hungary]

09:15 - 09:30 D-dimer levels are differently associated with the risk of acute coronary syndrome in men and women of the European prospective investigation in the cancer (EPIC)-Italy cohort
OC 07.6
Licia Iacoviello, Claudia Agnoli, Amalia De Curtis, Augusto Di Castelnuovo, Vittorio Krogh, Giuseppe Matullo, Salvatore Panico, Fulvio Riccieri, Carlotta Sacerdote, Rosario Tumino, Paolo Vineis, Giovanni De Gaetano [Italy]

Inflammation: Clinical studies  E102
Moderators: Tom van der Poll [The Netherlands] and Marein Schimmel [The Netherlands]

08:00 - 08:15 Prognostic role of MIR146A polymorphisms in atrial fibrillation
OC 08.1
Vanessa Roldan, Salam Salloum-Asfar, Pillar Gallego, Ana Arroyo, Nuria Garcia-Barbera, Raúl Teruel, Eva Caparros, Vicente Vicente, Rocio Gonzalez-Conejero, Constant Martinez [Spain]

08:15 - 08:30 Inflammatory markers and metalloproteinases profiles predict death in the acute phase of ischemic stroke treated with tissue plasminogen activator thrombolysis
OC 08.2
Anna Maria Gori, Patrizia Nencini, Betti Giusti, Nesi Mascia, Alessandra Armillis, Benedetta Piccardi, Vanessa Palumbo, Giovanni Pracucci, Rosanna Abbate, Domenico Inzitari [Italy]

08:30 - 08:45 Circulating nucleosomes and neutrophil activation as a measure of the formation of Neutrophil Extracellular Traps (NETs) during sickle cell painful crisis
OC 08.3

08:45 - 09:00 Activated Protein C inhibits lung inflammation in asthma patients after intrabronchial allergen challenge
OC 08.4
Daan de Boer, Christof Majoor, Berger Marieke, Joost Meijers, Sacha Zeerleder, Alex de Vos, Cornelis van ’t Veer, Jaring van der Zee, Tom van der Poll [The Netherlands]
Monday, July 1, 2013

ORAL COMMUNICATIONS 08:00 - 09:30

09:00 - 09:15  Increased adhesive properties of neutrophils and inflammatory markers in VTE patients with residual vein occlusion and high D-dimer levels
OC 08.5
Kiara Cristina Zapponi, Fernando Bittar, Bruna Mazetto, Aline Barnabé, Fernanda Santiago-Bassora, Erich De Paula, Fernanda Orsi, Nicola Conran, Joyce Annichino-Bizzacchi (Brazil)

09:15 - 09:30  Does platelet activation mediate pathogenesis of malaria infection?
OC 08.6
Shawn Jobe, Michael Schenk, Chengjing Zhou, Hyojung Choo, Jonathan Gibbins, Tracey Lamb (USA)

Novel platelet inhibitors  Mondriaan II

Moderators: Jan David Hohmann (Australia) and Coen Maas (The Netherlands)

08:00 - 08:15  Discovery of novel GPVI receptor antagonists by structure-based repurposing
OC 09.1
Carmen Coxon, Lewis Taylor, Sridhar Vasudevan, Chris Jones, Grant Churchill, Duncan Campbell (United Kingdom)

08:15 - 08:30  Parmudulins target the intracellular side of PAR1 to selectively interfere with Gaq but not Ga12/13 signaling and block thrombus formation, but not hemostasis
OC 09.2
Omozuanvbo Aisiku, Christian Peters, James Dilks, Suzanne Gunnink, Christopher Dockendorff, Daniel Smith, Bradley Denker, Mingdong Huang, Robert Flaumenhaft (USA)

08:30 - 08:45  Antiplatelet and antithrombotic activity of 2NTX-99, a novel molecular entity combining dual thromboxane inhibition with NO-donor properties
OC 09.3
Stefania Momi, AnnaMaria Mezzasoma, Giuseppe Guglielmini, Cesare Casagrande, Paolo Gresele (Italy)

08:45 - 09:00  Delayed targeting of CD39 to thrombus with an activated-platelet antibody allows for effective antithrombotic treatment without prolonging bleeding times
OC 09.4
Jan David Hohmann, Xiaowei Wang, Stefanie Krajewski, Andreas Straub, Christoph Hagemeyer, Karlheinz Peter (Australia)

09:00 - 09:15  Endocannabinoids limit collagen-induced platelet activation and restrict aggregate formation under flow
OC 09.5
Coen Maas, Valentina De Angelis, Arnold Koekman, Mark Roest, Cees Weeterings, Philip de Groot (The Netherlands)

09:15 - 09:30  Extracellular fibrinogen-binding protein (Efb) from Staphylococcus aureus inhibits fibrinogen binding, platelet aggregation and whole blood thrombus formation
OC 09.6
Giordano Pula, Mareike Posner, Bernhard Merget, Ilaria Canobbio, Abhishek Upadhyay, Stefan Bagby (United Kingdom)

Platelet granule secretion  Mondriaan III

Moderators: Herve Falet (USA) and Marc Hoylaerts (Belgium)

08:00 - 08:15  Role of novel SNARE proteins syntaxin 8, VTI1A and VTI1B in regulating platelet secretion and function
OC 10.1
Ewelina Golebiowska, Matthew Harper, Joshua Savage, Robert Goggs, Christiane Wiegand, Gabriele Von Mollard, Alastair Poole (United Kingdom)

08:15 - 08:30  Alpha-granule proteins are localized in a ‘cap’ on the surface of procoagulant platelets to promote their incorporation into aggregates
OC 10.2
Mikhail Panteleev, Anastasia Abaeva, Matthias Canault, Yana Kotova, Sergei Obydennyi, Alena Yakimenko, Vladimir Kolyadko, Fazly Ataullakhanov, Alan Nurden, Marie- Christine Alessi (Russian Federation)

08:30 - 08:45  Functional regulation of platelet membrane systems by the F-BAR protein PACSIN2
OC 10.3
Herve Falet (USA)
Monday, July 1, 2013

ORAL COMMUNICATIONS 08:00 - 09:30

08:45 - 09:00 Identification of secretion-related PKC substrates in platelets by a proteomic and pharmacological approach
OC 10.4
Marion van den Bosch, Alastair Poole, Ingeborg Hers (United Kingdom)

09:00 - 09:15 Platelet granule release patterns under flow
OC 10.5
Claudia Tersteeg, Cor Seinen, Harry Heijnen (The Netherlands)

09:15 - 09:30 Platelet dense granule secretion is required for infarct progression, but not for intracranial haemostasis in the ischaemic brain
OC 10.6
David Stegner, Carsten Deppermann, Peter Kraft, Martina Morowski, Christian Kleinschnitz, Guido Stoll, Bernhard Nieswandt (Germany)

Platelet ion channels and protein kinases Mondriaan IV

08:00 - 08:15 Chloride channels regulate platelet calcium signalling and procoagulant activity
OC 11.1
Matthew Harper, Alastair Poole (United Kingdom)

08:15 - 08:30 Transient receptor potential channels (TRPCs) contribute to platelet phosphatidylserine exposure
OC 11.2
Matthew Harper, Juan Camacho Londano, Kathryn Quick, Julia Camacho Londano, Stephan Phillip, Lutz Birnbaumer, Alastair Poole (United Kingdom)

08:30 - 08:45 The Scott syndrome protein anoctamin 6 (TMEM16F) regulates multiple cell death responses including membrane phospholipid scrambling in platelets
OC 11.3
Nadine Mattheij, Atilla Braun, Roger van Kruchten, Judith Cosemans, Paola van der Meijden, Constance Baaten, Harald Ehlen, Rainer Schreiber, Andrea Vortkamp, Peter Collins, Edouard Bevers, Jiraporn Ousingsawat, Karl Kunzelmann, Bernard Nieswandt, Johan Heemskerk (The Netherlands)

08:45 - 09:00 Ste20 kinase MINK is involved in platelet function and thrombus formation
OC 11.4
Ming Yue, Shanshan Yu, Lei Jiang, Chunhua Xu, Dongjiao Luo, Pu Liu, Qi Zhou, Linrong Lu, Hu Hu (China)

09:00 - 09:15 Characterisation of platelets lacking the p110a PI3K isoform and its role in primer mediated enhancement of platelet activation
OC 11.5
Thomas Blair, Samantha Moore, Christopher Williams, Elizabeth Aitken, Ingeborg Hers (United Kingdom)

09:15 - 09:30 The Class II PI3K, PI3K-C2a, regulates internal membrane reserves and biomechanical integrin αIIbβ3 adhesive function in platelets
OC 11.6
Justin Hamilton, Jessica Mountford, Claire Petitjean, Simone Schoenwaelder, Ross Dickens, Shaun Jackson (Australia)

Recurrent venous thrombosis - I E104-107

08:00 - 08:15 Secondary prevention of recurrent venous thromboembolism: Systematic review and meta-analysis of bleeding complications among patients receiving anticoagulation
OC 12.1
Lana Castellucci, Gregoire Le Gal, Phil Wells, Esteban Gandara, Marc Rodger, Marc Carrier (Canada)

08:15 - 08:30 Risk profile and clinical outcome of symptomatic isolated subsegmental pulmonary embolism
OC 12.2
Paul den Exter, Josien van Es, Frederikus Klok, Lucia Kroft, Marieke Kruij, Pieter Willem Kamphuisen, Harry Büller, Menno Huisman (The Netherlands)
Monday, July 1, 2013

**ORAL COMMUNICATIONS 08:00 - 09:30**

**08:30 - 08:45  OC 12.3**  The REVERSE I and II studies: Impact of using “Men continue and HERD002” clinical decision rule to guide anticoagulant therapy in patients with first unprovoked venous thromboembolism
Marc Rodger, Michael Kovacs, Gregoire Le Gal, David Anderson, Marc Righini, Tammy Beaudoin, The Reverse Investigators (Canada)

**08:45 - 09:00  OC 12.4**  D-dimer and ultrasound in combination Italian study (DULCIS) to establish the optimal duration of anticoagulation for venous thromboembolism on behalf of the DULCIS investigators
Benilde Cosmi, Cristina Legnani, Nicoletta Erba, Angelo Ghirarduzzi, Daniela Poli, Sophie Testa, Paolo Prandoni, Vittorio Pengo, Anna Falanga, Gualtiero Palareti (Italy)

**09:00 - 09:15  OC 12.5**  D-Dimer levels over time and the risk of recurrent venous thromboembolism: An update of the Vienna Prediction Model
Sabine Eichinger, Georg Heinze, Paul Kyrle (Austria)

**09:15 - 09:30  OC 12.6**  Recurrent venous thrombosis in premenopausal women: effect of hormonal contraceptive use
Jasmijn Timp, Bernardine Stegeman, Linda Flinterman, Frans Helmerhorst, Frits Rosendaal, Suzanne Cannegieter, Astrid van Hylckama Vlieg (The Netherlands)

**Von Willebrand disease**

*Forum*

*Moderators: Agnes Veyradier (France) and Robert Montgomery (USA)*

**08:00 - 08:15  OC 13.1**  Genetic variations determine von Willebrand factor levels in patients with von Willebrand disease from the WiN study
Yvonne Sanders, Anske van der Bom, Marjon Cnossen, Moniek de Maat, Britta Laros-van Gorkom, Karin Fijnvandraat, Karina Meijer, Evelien Mauser-Bunschoten, Jeroen Eikenboom, Frank Leebeek (The Netherlands)

**08:15 - 08:30  OC 13.2**  Incidence of large VWF gene deletions and duplications in the French cohort of 1182 patients with von Willebrand disease (VWD)
Pierre Boisseau, Catherine Ternisien, Claudine Caron, Mathilde Giraud, Patricia Talarmain, Christophe Zawadzki, Stephane Bezieau, Edith Fressinaud, Jenny Goudemand, Agnes Veyradier (France)

**08:30 - 08:45  OC 13.3**  Severity of bleeding tendency in von Willebrand disease is associated with von Willebrand factor string formation
Jiong-Wei Wang, Bieuwke Dragt, Richard Dirven, Eveline Bouwens, Jan Voorberg, Karine Valentijn, Pieter Reitsma, Jeroen Eikenboom (The Netherlands)

**08:45 - 09:00  OC 13.4**  Characterisation of large in-frame deletions contributing to type 1 VWD pathogenesis in the MCDM-1VWD study
Ashley Cartwright, Daniel Hampshire, Lisa Bloomer, Ahlam Al-Buhaieran, Raymon Vijzelaar, Ulrich Budde, Jeroen Eikenboom, Reinhard Schneppenheim, Ian Peake, Anne Goodeve [United Kingdom]

**09:00 - 09:15  OC 13.5**  Distribution of the von Willebrand Disease types in 337 patients followed by a single hemophilia center since 2002: A comparison of von Willebrand Disease patients classification after ten years
Luciano Baronciani, Maria Teresa Canciani, Giovanna Cozzi, Inmaculada Garcia Oya, Francesca Stufano, Maria Teresa Pagliari, Franca Franchi, Augusto Federici, Flora Peyvandi (Italy)

**09:15 - 09:30  OC 13.6**  Type 2N von Willebrand disease (VWD): One variant, two diseases? Analysis of the French cohort
Jenny Goudemand, Christophe Zawadzki, Fabienne Volot, Pierre Boisseau, Marianne Sigaud, Katia Poumayou, Nathalie Itzhar, Claudine Caron, Edith Fressinaud, Agnès Veyradier (France)
Monday, July 1, 2013

ORAL COMMUNICATIONS 14:30 - 15:30

Acquired bleeding disorders  Elicium 1

Moderators: Atsushi Muto [Japan] and Anetta Undas [Poland]

14:30 - 14:45
OC 14.1  Treatment of acute bleeding episodes in acquired haemophilia with recombinant activated factor VII (rFVIIa): Analysis from 10-year Japanese post-marketing surveillance
Ikuo Seita, Kagehiro Amano, Satoshi Higasa, Akihiro Sawada, Mitsuhiro Kuwahara, Midori Shima [Japan]

14:45 - 15:00
OC 14.2  Treatment of bleeding episodes in acquired haemophilia with activated prothrombin complex concentrate: What is the optimal therapy?
Marta Milan, Gabriella Gamba, Chiara Ambaglio, Nadia Montani, Luca Spiezia, Ezio Zanon [Italy]

15:00 - 15:15
OC 14.3  In vivo hemostatic potency of a factor VIII function-mimetic, bispecific antibody to factors IXa and X (ACE910) against on-going bleeds in an acquired hemophilia A model
Atsushi Muto, Takehisa Kitazawa, Kazutaka Yoshihashi, Minako Takeda, Tetsuhiro Soeda, Tomoyuki Igawa, Zenjiro Sampei, Midori Shima, Akira Yoshioka, Kunihiko Hattori [Japan]

15:15 - 15:30
OC 14.4  The prevalence and severity of shear stress-associated acquired von Willebrand factor abnormality in patients with mitral regurgitation
Dong Chen, Joseph Blackshear, Ewa Wysokinska, Robert Safford, Colleen Thomas, Brian Shapiro, Steven Ung, Mark Stark, Gretchen Johns [USA]

ADAMTS-13  Auditorium

Moderators: Colin Kretz [USA] and Brenda Luken [United Kingdom]

14:30 - 14:45
OC 15.1  ADAMTS13 meets von Willebrand factor strings: A single molecule approach

14:45 - 15:00
OC 15.2  Spatially distinct regulation of von Willebrand factor by ADAMTS13 at the sites of platelet accumulation
Yasuaki Shida, Christine Brown, Jeffery Mewburn, Kate Sponagle, Jacob Riches, Christine Hough, David Lillicrap [Canada]

15:00 - 15:15
OC 15.3  ADAMTS13 is autoinhibited by distal thrombospondin-1 (T) or CUB domains and is activated allosterically by VWF or antibodies against ADAMTS13 domain T8
Joshua Muia, Jian Zhu, Sandra Haberichter, Kenneth Friedman, Hendrik Feys, Karen Vanhoorelbeke, Lisa Westfield, Evan Sadler [USA]

15:15 - 15:30
OC 15.4  A comprehensive mutagenesis screen defines the substrate recognition landscape within VWF for ADAMTS13
Colin Kretz, Karl Desch, Andrew Yee, David Siemieniak, Fan Meng, David Ginsburg [USA]

Anticoagulants: Basic  Emerald

Moderators: Jack Stopa [USA] and Gerry Nicolaes [The Netherlands]

14:30 - 14:45
OC 16.1  Effect of rivaroxaban with or without acetylsalicylic acid on thrombus formation in an ex vivo perfusion chamber - an open-label, randomized study in healthy subjects
Michael Wolzt, Ghazaleh Gouya, Stylianos Kapiotis, Michael Becka, Wolfgang Mueck, Dagmar Kubitzka [Austria]

14:45 - 15:00
OC 16.2  Analysis of the interaction of anticoagulants on points of care (POC) tests for urine from patients on therapy with dabigatran and rivaroxaban
Sandra Krämer, Christina Giese, Shanshan Du, Christel Weiss, Job Harenberg [Germany]
Monday, July 1, 2013

ORAL COMMUNICATIONS  14:30 - 15:30

15:00 - 15:15
OC 16.3  Human clinical trials evaluating protein disulfide isomerase as an antithrombotic target: Pharmacodynamic and pharmacokinetic studies of oral quercetin and isoquercetin
Jack Stopa, Bruce Furie, Robert Flaumenhaft, Jeffrey Zwicker (USA)

15:15 - 15:30
OC 16.4  Aptamer inhibition of an exosite of Factor (F)XA or thrombin synergizes with non-aptamer inhibition of the catalytic site of FXa or thrombin, respectively
James Frederiksen, Jens Lohrmann, Kristin Bompiani, Rebecca Smock-Woodruff, Ruwan Gunaratne, Bruce Sullenger (USA)

Clinical relevance of microparticles  E104-107

Moderators: Françoise Dignat-George (France) and Feng Jung Woei-A-Jin (The Netherlands)

14:30 - 14:45
OC 17.1  Circulating microparticles and thrombin generation phenotypes in the Prospective Observational Multicenter Major Trauma Transfusion (PROMMTT) study: Correlation with coagulopathy and survival
Nena Matijevic, Yao-Wei Wang, John Holcomb, Bryan Cotton, Charles Wade, Martin Schreiber, Peter Muscat, John Myers, Mitchell Cohen (USA)

14:45 - 15:00
OC 17.2  Microparticle-dependent plasmin generation predicts the outcome of septic shock patients
Romaric Lacroix, Karim Harti Souab, Sylvie Cointe, Tarik Bouriche, Coralie Judicone, Diane Frankel, Philippe Poncelet, Jacques Albanese, Françoise Dignat-George (France)

15:00 - 15:15
OC 17.3  Characterization of microparticle numbers and cellular origin in human endotoxemia using high-sensitivity flow cytometry
Micah Mooberry, Robert Bradford, Feng-Chang Lin, Bernd Jilma, Nigel Key (USA)

15:15 - 15:30
OC 17.4  Microparticle-associated tissue factor activity is associated with disease severity in patients with E. coli urosepsis
Feng Jung Woei-A-Jin, Willize van der Starre, Margot Tesselaar, Patricia Garcia Rodriguez, Cees van Nieuwkoop, Rogier Bertina, Jaap van Dissel, Susanne Osanto (The Netherlands)

Coagulation factors XI and XII  G102-103

Moderators: David Gailani (USA) and Bob Siegerink (The Netherlands)

14:30 - 14:45
OC 18.1  APC-resistant factor V restores impaired coagulation resulting from deficient factor XI-mediated feedback activation
Inge Rietveld, Rodney Camire, Pieter Reitsma, Mettine Bos (The Netherlands)

14:45 - 15:00
OC 18.2  Two novel inhibiting factor XI antibodies prevent cessation of blood flow in a murine venous thrombosis model
Maurits van Montfoort, Veronique Knaup, Arnoud Marquart, Kamran Bakhtiar, Frank Castellino, Erik Hack, Joost Meijers (The Netherlands)

15:00 - 15:15
OC 18.3  Factor XI acts by mechanisms at least partially independent of thrombin-induced platelet activation in a mouse model of arterial thrombosis
Tovo David, Cherry Concengo, Lisa Wang, Daniel Ha, Ivo Cornelissen, Matthew Flick, Jay Degen, Shaun Coughlin (USA)

15:15 - 15:30
OC 18.4  A model for binding of factor IX to the factor Xla apple 3 domain
David Gailani, Yipeng Geng, Ingrid Verhamme, Mao-fu Sun, Paul Bajaj, Jonas Emsley (USA)
### ORAL COMMUNICATIONS 14:30 - 15:30

**Coagulation - I**

Moderators: Grigoris Gerotziafas [France] and James Morrissey [USA]

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:30 - 14:45</td>
<td>Circulating histone-induced thrombosis leads to circulatory and respiratory failure</td>
<td>Simon Abrams, Joanna Manson, Tingting Liu, Yasir Alhamdi, Karim Brohi, Guozheng Wang, Cheng-Hock Toh [United Kingdom]</td>
</tr>
<tr>
<td>14:45 - 15:00</td>
<td>An essential role of factor XI-feedback activation for hemostasis in embryonic development</td>
<td>Anne Jämsä, Henri Spronk, José Govers-Riemslag, Menno Knetsch, David Gailani, Nigel Mackman, Thomas Renné [Sweden]</td>
</tr>
<tr>
<td>15:00 - 15:15</td>
<td>White blood minimal tissue factor triggered thrombelastometry and calibrated automated thrombogramme are useful tools for the evaluation of the global effect of antithrombotic treatment</td>
<td>Grigoris Gerotziafas, Hela Ketatni, Ismail Elalamy, Vasiliki Galea [France]</td>
</tr>
<tr>
<td>15:15 - 15:30</td>
<td>Human VKORC1 mutations (His28Gln, Trp59Leu, Val66Met) investigated by the new cell-based assay exhibit warfarin resistance phenotypes not detected by the ‘classical’ DTT-driven VKOR assay</td>
<td>Katrin Czogalla, Matthias Watzka, Ann-Chrinstin Wendeln, Carville Bevans, Kerstin Liphardt, Philipp Westhofen, Johannes Oldenburg [Germany]</td>
</tr>
</tbody>
</table>

### Diagnosis of primary venous thrombosis

Moderators: Henri Bounameaux [Switzerland] and Mathilde Nijkeuter [The Netherlands]

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:30 - 14:45</td>
<td>Is it useful to image both legs in patients with suspected deep vein thrombosis? A retrospective chart review</td>
<td>Gregoire Le Gal, Helia Robert-Ebadi, Marc Carrier, Clive Kearon, Henri Bounameaux, Marc Righini [Canada]</td>
</tr>
<tr>
<td>14:45 - 15:00</td>
<td>Safety of ruling out pulmonary embolism (PE) in pregnancy by computed tomography pulmonary angiography (CTPA)</td>
<td>Mathilde Nijkeuter, Melanie Tan, Saskia Middeldorp, Lucia Kroft, Ludo Beenen, Menno Huisman [The Netherlands]</td>
</tr>
<tr>
<td>15:00 - 15:15</td>
<td>Cost-effectiveness of ruling out pulmonary embolism in primary care using the Wells rule and D-dimer testing</td>
<td>Petra Erkens, Arina ten Cate-Hoek, Geert-Jan Geersing, Wim Lucassen, Carl Moons, Martin Prins, Henk van Weert, Jelle Stoffers, Manuela Joore [The Netherlands]</td>
</tr>
<tr>
<td>15:15 - 15:30</td>
<td>D-dimer relevance score</td>
<td>Andrea Penaloza, Christopher Kabrhel, Franck Verschuren, Bruno Vielle, Jeffrey Kline, Grégoire Le Gal, Frédéric Thys, Pierre-Marie Roy [Belgium]</td>
</tr>
</tbody>
</table>
**Monday, July 1, 2013**

**ORAL COMMUNICATIONS**

14:30 - 15:30

**Heparin-induced thrombocytopenia**

Mondriaan II

**Moderators**: Andreas Greinacher (Germany) and Theodore Warkentin (Canada)

14:30 - 14:45

**OC 21.1**

Bimolecular interactions of platelet factor 4 (PF4) with HIT-pathogenic versus non-pathogenic anti-PF4/heparin antibodies

Rustem Litvinov, Bruce Sachais, Serge Yarovoi, Lubica Rauova, Ann Rux, Gowthami Arepally, Douglas Cines, John Weisel (USA)

14:45 - 15:00

**OC 21.2**

Sero logical investigation of 20 patients re-exposed to heparin with a previous history of heparin-induced thrombocytopenia (HIT)

Theodore Warkentin, Jo-Ann Sheppard (Canada)

15:00 - 15:15

**OC 21.3**

Impact of polymorphisms affecting ACP1, which codes for a protein tyrosine phosphatase, on levels of antibodies to platelet factor 4/heparin complexes

Jérome Rollin, Claire Pouplard, Dorothée Leroux, Marc-Antoine May, Yves Gruel (France)

15:15 - 15:30

**OC 21.4**

Endocytotic mechanisms contributing to the internalization of ADAMTS13 by macrophages

Fabian Verbij, Nicoletta Sorvillo, Paul Kaijen, Anja ten Brinke, Rob Fijnheer, Jan Voorberg (The Netherlands)

---

**Inhibitors in haemophilia A - I**

Elicium 2

**Moderators**: Christoph Hofbauer (Austria) and Erik Berntorp (Sweden)

14:30 - 14:45

**OC 22.1**

Exploration of biomarkers for early recognition of FVIII inhibitor development in previously untreated severe hemophilia A patients: Hemophilia Inhibitor PUP Study & beyond

Christoph Hofbauer, Christoph Male, Deborah Brown, Elena Santagostino, Johannes Oldenburg, Friedrich Scheiflinger, Birgit Reipert (Austria)

14:45 - 15:00

**OC 22.2**

European monitoring of inhibitor development in haemophilia A and B

Kathelijn Fischer, Michael Makris, Gabriele Calizzani, Charles Hay, Christopher Ludlam, Thierry Lambert, Riitta Lassila, Pier Mannucci (The Netherlands)

15:00 - 15:15

**OC 22.3**

The change of Treg cells and serum BAFF level in the development of anti-factor VIII antibiotics in hemophilia A mice model

Shin-Nan Cheng, Chiew-Peng Huang, Ming-Shen Dai, Yeu-Chin Chen (Taiwan)

15:15 - 15:30

**OC 22.4**

Restricted specificity of a recombinant anti-idiotypic antibody in protecting human factor VIII against anti-C2 inhibitory antibodies

Jean-Luc Plantier, Jean-Guy Gilles, Christophe De Romeuf, Alexandre Fontayne, Christine Gaucher, Christian Behrens, Rémi Urbain, Jean-François Prost, Jean-Marie Saint-Rémy (France)
**Monday, July 1, 2013**

**ORAL COMMUNICATIONS**  
14:30 - 15:30

**Intrinsic pathway of coagulation**  
G106-107

*Moderators: Thomas Colace (USA) and Thomas Renné (Sweden)*

**14:30 - 14:45**  
OC 23.1  
**Two cleavage sites in factor XII direct its diverging activities**  
Steven de Maat, Dennis Beringer, Loes Kroon-Batenburg, Philip de Groot, Coen Maas  
(The Netherlands)

**14:45 - 15:00**  
OC 23.2  
**FXIIa enhances fibrinolysis in addition to plasminogen activators**  
Joke Konings, Lisa Hoving, Robert Ariëns, Emma Smith, Marisa Ninivaggi, Lewis Hardy,  
Bas de Laat, Hugo ten Cate, Helen Philippou, José Govers-Riemslag (The Netherlands)

**15:00 - 15:15**  
OC 23.3  
**Direct inhibition of FXa by TFPI independent of TF-FVIIa contributes to the down-
regulation of coagulation**  
Maria Christella Thomassen, Alexandra Heinzmann, Linda Herfs, Rudolf Hartmann,  
Michael Dockal, Friedrich Scheiflinger, Tilman Hackeng, Jan Rosing (The Netherlands)

**15:15 - 15:30**  
OC 23.4  
**A microfluidic model of in vitro hemostasis that potentiates thrombin generation via the intrinsic pathway of coagulation**  
Thomas Colace, Patrick Fogarty, Scott Diamond (USA)

**Platelet and coagulation interaction**  
Mondriaan III

*Moderators: Todd Getz (USA) and Mortimer Poncz (USA)*

**14:30 - 14:45**  
OC 24.1  
**A new role for integrin outside-in signaling in the regulation of platelet packing density, solute transport and fibrin deposition following vascular injury in vivo**  
Timothy Stalker, John Welsh, Jie Wu, Scott Diamond, Lawrence Brass (USA)

**14:45 - 15:00**  
OC 24.2  
**Rap signaling is central to the pro-adhesive and pro-coagulant platelet response**  
Todd Getz, Lucia Stefanini, Raymond Piatt, David Paul, Agnieszka Cholka,  
Bethany Walton, Alisa Wolberg, Gilbert White III, Wolfgang Bergmeier (USA)

**15:00 - 15:15**  
OC 24.3  
**Contribution of intrinsic and extrinsic coagulation pathways to whole blood clot and thrombus formation under flow**  
Frauke Swieringa, Marijke Kuipers, Moniek Lamers, Thomas Renné, Johan Heemskerk,  
Paola van der Meijden (The Netherlands)

**15:15 - 15:30**  
OC 24.4  
**The polyphosphate-binding proteins in the human platelet secretome**  
Stephanie Smith, Peter Yau, James Morrissey (USA)
Monday, July 1, 2013

**ORAL COMMUNICATIONS** 14:30 - 15:30

**Platelets and cancer**  
Mondriaan IV  
*Moderators: Agnes Lee (Canada) and Paul Harrison (United Kingdom)*

14:30 - 14:45  
**OC 25.1**  
**A novel and selective proteasome modulate expression of molecules linked to coagulation and angiogenesis independent of NF-κB activation in tumor cells**  
Ana Marisa Chudzinkski-Tavassi, M. Pacheco, C. Berra, K. Moreas, I. Sciani, R. Bosch, J. Onuki (Brazil)

14:45 - 15:00  
**OC 25.2**  
**Prostate cancer cells signal through Syk-FK intracellular molecules to induce platelet secretion**  
Annachiara Mitrugno, Niamh Moran (Ireland)

15:00 - 15:15  
**OC 25.3**  
**A role of CLEC-2 in tumor growth and metastasis**  
Toshiaki Shirai, Osamu Inoue, Kazuyoshi Hirayama, Hiroshi Endo, Hideki Fujii, Hitomi Utida-Sato, Yukio Ozaki, Katsue Suzuki-Inoue (Japan)

15:15 - 15:30  
**OC 25.4**  
**Observational study of alternative platelet parameters to predict bleeding risk in patients with hematological malignancies (ATHENA study)**  
Lise Estcourt, Gillian Powter, Kay Harding, Steve Howgate, Claire Dyer, Andrew Mumford, Simon Stanworth, Paul Harrison, Michael Murphy (United Kingdom)

**Vessel wall**  
G104-105  
*Moderators: William Aird (USA) and Brecht Willems (The Netherlands)*

14:30 - 14:45  
**OC 26.1**  
**Ang-(1-7) and Mas decrease thrombosis in Bdkrb2-/- mice by increasing NO and prostacyclin to reduce platelet spreading and GPVI activation**  
Chao Fang, Evi Stavrou, Alec Schmaier, Nadja Grobe, Andrew Chen, Marvin Nieman, Gregory Adams, Gretchen LaRusch, Matthew Bilodeau (USA)

14:45 - 15:00  
**OC 26.2**  
**GRP/Ucma: A novel member of the class of vitamin K-dependent proteins is involved in osteochondrogenic transdifferentiation of vascular smooth muscle cells**  
Brecht Willems, Martijn Chatrou, Dennis Kusters, Elke Theuwissen, Dina Simes, Cees Vermeer, Chris Reutelingsperger, Leon Schurgers (The Netherlands)

15:00 - 15:15  
**OC 26.3**  
**Accelerated senescence of cord blood endothelial progenitor cells in premature neonates is driven by SIRT1 decreased expression**  
Stéphanie Simoncini, Paula Frizera-Vassallo, Isabelle Ligi, Florence Sabatier, Umberto Simeoni, Frédérique Magdinier, Françoise Dignat-George, Francine Anfosso (France)

15:15 - 15:30  
**OC 26.4**  
**Endothelial progenitor outgrowth cells on ePTFE grafts respond to hemodynamic preconditioning**  
Monica Hinds, Jeremy Glynn, Deirdre Anderson (USA)
ePOSTERS PRESENTATIONS (A)  ePOSTER AREA

Monday, July 1, 2013  17:00 – 18:30

ePOSTER PRESENTATIONS
For the XXIV congress, ISTH has decided to innovate its poster sessions by introducing a new Electronic Poster format. Posters will not be presented in a paper format. Instead, all posters will be presented in the format of ePoster sessions on large touch-screens.

In the sessions, the ePosters will be presented and discussed in the sequence indicated in the programme.

**Antiplatelet agents: ADP receptors - I**  
*Screen 01*

**Moderator**: Martin Reiner (Switzerland)

**PA 1.01-1**  
*Comparison of a new ELISA-based with the flow cytometric assay for vasodilator-associated stimulated phosphoprotein (VASP) phosphorylation to assess P2Y12-inhibition after ticagrelor intake*

Eva-Luise Hobl, Ulla Derhaschnig, Christian Schoergenhofer, Petra Jilma-Stohlwawetz, Michael Schwameis, Bernd Jilma (Austria)

**PA 1.01-2**  
*Impact of body mass index on response to Thienopyridines in patients treated after acute coronary syndrome*

Thomas Cuisset, Mathieu Pankert, Jacques Quilici, Pierre-Emmanuel Morange, Jean-Louis Bonnet, Marie-Christine Alessi (France)

**PA 1.01-3**  
*Evaluation of non-specific agents to control prasugrel-related bleeding in a rabbit model*

Fanny Bonhomme, Anne Godier, Charles-Marc Samama, Pierre Fontana (Switzerland)

**PA 1.01-4**  
*How to test the effect of aspirin and clopidogrel in patients on dual antiplatelet therapy?*

Zsuzsa Bagoly, Emese Kovács, Ferenc Sarkady, Nóra Honoródi, János Kappelmayer, László Csiba, László Muszbek (Hungary)

**PA 1.01-5**  
*Reversal strategy in antagonizing the P2Y12-inhibitor ticagrelor*

Eva-Luise Hobl, Ulla Derhaschnig, Christa Firbas, Christian Schoergenhofer, Michael Schwameis, Bernd Jilma (Austria)

**PA 1.01-6**  
*Ticagrelor and Endothelial Dysfunction: Platelet-Independent Effects*

Martin Reiner, Simona Stivala, Alexander Akhmedov, Remo Spescha, Giovanni Camici, Jürg Beer (Switzerland)

**Platelet activation: Novel proteins - I**  
*Screen 02*

**Moderator**: Marfoua Ali (United Kingdom)

**PA 1.02-1**  
*Disabled-2 is required for efficient platelet activation by thrombin in mouse*

Tsai Hui-Ju, Huang Chien-Ling, Huang Ding-Yuan, Lin Chung-Ching, Jonathan Cooper, Cheng Ju-Chien, Tseng Ching-Ping (Taiwan)

**PA 1.02-2**  
*Human platelet aminophospholipid translocase (APLT) ATP8A1 and TMEM16F are calpain substrates*

Hong Wang, Annie Bang, Eileen McMillan-Ward, Sara Israels, Margaret Rand (Canada)

**PA 1.02-3**  
*Platelet Toll-like receptor 9 stimulation enhances ATP- and ADP-dependent platelet activation and aggregation*

Céline Delierneux, Christelle Lecut, Alexandre Hego, Richard Evans, Paul Massion, André Gothot, Vincent Bours, Cécile Oury (Belgium)

**PA 1.02-4**  
*Regulation of platelet function by Diacylglycerol Kinase*

Olga Konopatskaya, Khalid Naseem, Alastair Poole (United Kingdom)

**PA 1.02-5**  
*A role for histone deacetylases in the regulation of platelet function*

Marfoua Ali, Chris Jones, Jonathan Gibbins, Michael Fry (United Kingdom)
**ePOSTERS (A)**

**Monday, July 1, 2013**

**17:00 – 18:30**

**PA 1.02-6**  
**Regulation of platelet GPCR receptor function by NHERF1 in mouse platelets**  
Robert Pope, Shaista Nisar, Margaret Cunningham, Chris Williams, Josh Savage, Matthew Harper, Robert Goggs, Stuart Mundell (United Kingdom)

**Platelet hyperfunction**  
**Screen 03**

**Moderator: Samantha Moore (United Kingdom)**

**PA 1.03-1**  
**Podoplanin overexpressed rat c6 glioma cells enhances platelet aggregation and lymphatic metastasis**  
Kowit-Yu Chong, Pei-Yun Lin, Pei-Shan Lu, Ching-Ping Tseng. [Taiwan]

**PA 1.03-2**  
**Does loss of insulin signalling lead to a hyperactive platelet phenotype? Studies on Pf4-Cre insulin receptor knock out mice**  
Samantha Moore, Christopher Williams, Elizabeth Aitken, Ingeborg Hers (United Kingdom)

**PA 1.03-3**  
**Hemostasis and thrombosis in JAK2V617F-KI mice**  
Lamia Lamrani, Catherine Lacout, Véronique Ollivier, Benoît Ho Tin Noe, William Vainchenker, Jean-Luc Villeval, Martine Jandrot-Perrus (France)

**PA 1.03-5**  
**Platelet activation and function during dengue virus infection**  
Quirijn de Mast, Meta Michels, Alisjahbana Bachti, Mita Puspita, Panji Rudiman, Mark Roest, Rob Fijnheer, Philip de Groot, André van der Ven (The Netherlands)

**PA 1.03-6**  
**Platelet-mediated angiogenesis is independent of VEGF and fully inhibited by aspirin**  
Julia Etulain, Carlos Fondevila, Soledad Negrotto, Mirta Schattner (Argentina)

**Circulating microparticles**  
**Screen 04**

**Moderator: Simin Jamaly (Norway)**

**PA 1.04-1**  
**Increased levels of P-selectin glycoprotein ligand-1 positive microparticles in patients with unprovoked venous thromboembolism**  
Simin Jamaly, Irina Starikova, Mikhail Sovershaev, John-Bjarne Hansen (Norway)

**PA 1.04-2**  
**Microparticles from monocytes and CFTRΔF508 mutated exocrine cells are deleterious for insulin secreting cells**  
Andrei Alexandru Constantinescu, Celine Gleizes, Alexandre Leclercq, Fatiha Zobairi, Ioan Mitrea, Gheorghe Stoian, Gilles Prevost, Florence Toti, Laurence Kessler (France)

**PA 1.04-3**  
**Circulating MPs show a prothrombotic phenotype in patients with long-life exposure to high LDL levels and directly associate with lipid-rich atherosclerotic plaque burden**  
Rosa Suades, Lina Badimon, Teresa Padro, Rodrigo Alonso, Pedro Mata (Spain)

**PA 1.04-4**  
**Plasmatic levels of leukocyte-derived microparticles predict unstable plaque in asymptomatic patients with high-grade carotid stenosis**  
Florence Sabatier, Gabrielle Sarlon-Bartoli, Youssef Bennis, Romaric Lacroix, Marie-dominique Piercucci-Marti, Michel Bartoli, Aurelie Leroyer, Julien Mancini, Pierre-Edouard Magnan, Françoise Dignat-George (France)

**PA 1.04-5**  
**Circulating microparticle plasma levels in obese patients**  
Elena Campello, Eva Zabeo, Claudia Radu, Luca Spiezia, Sabrina Gavasso, Barry Woodhams, Paolo Prandoni, Roberto Vettor, Paolo Simioni (Italy)

**PA 1.04-6**  
**Variations of procoagulant microparticles during disseminated intravascular coagulopathy and septic shock: A prospective multicentre study**  
Xavier Delabranche, Julie Boisrame-Helms, Asaël Berger, Dominique Desprez, François Lanza, Thierry Lavigne, Pierre Asfar, Florence Toti, Ferhat Meziani (France)
**Immune thrombocytopenic purpura - I**

**Moderator: Philip Choi (Australia)**

**PA 1.05-1** CD8+ regulatory/suppressor T cells in primary immune thrombocytopenia  
Huiyuan Li, Donglei Zhang, Renchi Yang (China)

**PA 1.05-2** Defective proliferation and the Immunosuppressive Function of Bone Marrow-derived Mesenchymal Stem Cells in Patients with Primary Immune Thrombocytopenia  
Donglei Zhang, Huiyuan Li, Li Ma, Xian Zhang, Zeping Zhou, Shaoguang Yang, Renchi Yang (China)

**PA 1.05-3** Detection of circulating B cells producing anti-GP1b autoantibodies in patients with immune thrombocytopenia  
Masataka Kuwana, Yuka Okazaki, Yasuo Ikeda (Japan)

**PA 1.05-4** Is the total 2 g/kg of Intravenous Immunoglobulin G optimal dose for acute immune thrombocytopenic purpura in childhood?  
Kun Lee, Uk Kim (South-Korea)

**PA 1.05-5** Successfully sparing splenectomy in immune thrombocytopenia purpura (ITP)  
Philip Choi, Beng Chong (Australia)

**PA 1.05-6** Cell-based haemostasis assessment to improve disseminated intravascular coagulopathy (DIC) diagnosis during septic shock  
Xavier Delabranche, Julie Boisramé-Helms, Pierre Asfar, Asaël Berger, Yoganaden Mootien, Thierry Lavigne, Fathia Zobairi, Lélia Grunebaum, François Lanza, Christian Gachet, Jean-Marie Freyssinet, Florence Toti, Ferhat Meziani (France)

---

**Fibrinolytic system: Basic - I**

**Moderator: Maarten Hendrickx (Belgium)**

**PA 1.06-1** Identification of a novel, nanobody-induced, mechanism of TAFI inactivation and its in vivo application  
Maarten Hendrickx, Monika Zatloukalova, Gholamreza Hassanzadeh-Ghassabeh, Serge Muyldermans, Ann Gils, Paul Declerck (Belgium)

**PA 1.06-2** Alpha2-antiplasmin is a potential regulator of neuronal morphology  
Eri Kawashita, Yosuke Kanno, Haruka Asayama, Kiyotaka Okada, Shigeru Ueshima, Osamu Matsuo, Hiroyuki Matsuno (Japan)

**PA 1.06-3** Generation and characterization of homozygous plasminogen-Tochigi mutant mice bearing reduced fibrinolytic activity  
Yuko Tashima, Fumiaki Banno, Toshiyuki Kita, Yasuyuki Matsuda, Hiroji Yanamoto, Toshiyuki Miyata (Japan)

**PA 1.06-4** Enhanced t-PA-mediated fibrinolysis through co-administration of a TAFI-inhibiting nanobody  
Maarten Hendrickx, Gholamreza Hassanzadeh-Ghassabeh, Serge Muyldermans, Ann Gils, Paul Declerck (Belgium)

**PA 1.06-5** Clots formed from γ'-fibrinogen are more resistant to lysis than those formed from ΔA-fibrinogen because of delayed plasminogen activation by tissue plasminogen activator  
Paul Kim, Trang Vu, Beverly Leslie, Alan Stafford, James Fredenburgh, Jeffrey Weitz (Canada)

**PA 1.06-6** Structural and biochemical studies of naturally occurring antiplasmin variants  
Anita Horvath, Bernedine Lu, Juara Entrenacao, Qing Wu Etang, Johnes Whisstock, Paul Coughlin, Ruby Law
<table>
<thead>
<tr>
<th>Screen 07</th>
<th>Monday, July 1, 2013 17:00 – 18:30</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Haemophilia A: Basic - I</strong> &lt;br&gt;<strong>Moderator:</strong> Monique van Meegeren [The Netherlands]</td>
<td></td>
</tr>
<tr>
<td><strong>PA 1.07-1</strong></td>
<td>Antiplasmin, but not amiloride, prevents synovitis and cartilage destruction following hemarthrosis in hemophilic mice &lt;br&gt;Laurens Nieuwenhuizen, Goris Roosendaal, Katja Coeleveld, Douwe Biesma, Floris Lafeber, Roger Schutgens [The Netherlands]</td>
</tr>
<tr>
<td><strong>PA 1.07-2</strong></td>
<td>A single intra-articular injection with IL-4 plus IL-10 ameliorates blood-induced cartilage degeneration in haemophilic mice &lt;br&gt;Monique van Meegeren, Goris Roosendaal, Katja Coeleveld, Laurens Nieuwenhuizen, Lize van Vulpen, Simon Mastbergen, Floris Lafeber [The Netherlands]</td>
</tr>
<tr>
<td><strong>PA 1.07-3</strong></td>
<td>Structure of a cyclic peptide binding to Kunitz domain 1 and 2 inhibiting tissue factor pathway inhibitor (TFPI) &lt;br&gt;Michael Dockal, Rudolf Hartmann, M. Fries, K. Prohaska, R. Pachlinger, T. Polakowski, H. Brandstetter, F. Scheiflinger [Austria]</td>
</tr>
<tr>
<td><strong>PA 1.07-4</strong></td>
<td>The effect of a novel TFPI inhibitory fusion peptide on TFPI clearance &lt;br&gt;Michael Dockal, Rudolf Hartmann, C. Redl, E. Panholzer, Andrea Kolm, Werner Höllriegl, F. Scheiflinger [Austria]</td>
</tr>
<tr>
<td><strong>PA 1.07-5</strong></td>
<td>Deferasirox prevents cartilage destruction following hemarthrosis in hemophilic mice &lt;br&gt;Laurens Nieuwenhuizen, Goris Roosendaal, Katja Coeleveld, Douwe Biesma, Floris Lafeber, Roger Schutgens [The Netherlands]</td>
</tr>
<tr>
<td><strong>PA 1.07-6</strong></td>
<td>In vivo blood loss in a TVIII-inhibited rusbit model and its correlation with global hemostatic assays ex vivo &lt;br&gt;Michael Dockal, Sabine Knappe, P. Leidenmüller, M. Resch, S. Tippl, D. Verdino, A. Bauer, F. Scheiflinger, E. Muchitsch, Werner Höllriegl [Austria]</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Screen 08</th>
<th>Rare bleeding disorders - I &lt;br&gt;<strong>Moderator:</strong> Marzia Menegatti [Italy]</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PA 1.08-1</strong></td>
<td>A recurrent Gly43Asp substitution of coagulation Factor X rigidifies its catalytic pocket and impairs catalytic activity and intracellular trafficking &lt;br&gt;Marzia Menegatti, Raimondo De Cristofaro, Anna Vangone, Roberta Palla, Giuseppe Milano, Luigi Cavallo, Romina Oliva, Flora Peyvandi [Italy]</td>
</tr>
<tr>
<td><strong>PA 1.08-2</strong></td>
<td>Mapping of inhibitory antibodies directed to the carboxy-terminus of FVIIa in severe FVII deficiency with elongated C-terminal variant (p.A354V-p.P464Hfs†) &lt;br&gt;Alessio Branchini, Marcello Baroni, Caroline Pfeiffer, Angelika Batorova, Muriel Giainsily-Blaizot, Guglielmo Mariani, Mirko Pinotti, Francesco Bernardi [Italy]</td>
</tr>
<tr>
<td><strong>PA 1.08-3</strong></td>
<td>Association between thrombin generation and bleeding severity in 41 patients with coagulation factor VII deficiency &lt;br&gt;Luca Lotta, Simona Siboni, Laura Lemma, Mariagrazia Clerici, Marzia Menegatti, Flora Peyvandi [Italy]</td>
</tr>
<tr>
<td><strong>PA 1.08-4</strong></td>
<td>Characterization of a primary hemostasis abnormality in patients with OCRL1 gene mutations (Lowe syndrome) &lt;br&gt;Marion Egot, Dominique Lasne, Geneviève Baujat, Bernard Payrastre, Marie-Pierre Gratacap, Tristan Mirault, Caroline Elie, Dominique Baruch, Christilla Bachelot-Loza [France]</td>
</tr>
<tr>
<td><strong>PA 1.08-5</strong></td>
<td>Measurement of the 5- and 7-carbon aglycone vitamin K metabolites in term and preterm neonatal faecal matter using HPLC with electrochemical detection &lt;br&gt;Henk Huisjes, David Card, Karen Few, Paul Clarke, Frits Flesch, Dominic Harrington [United Kingdom]</td>
</tr>
</tbody>
</table>
PA 1.08-6  Novel homozygous mutation Met362Thr identified as a cause of cross-reacting material reduced factor X deficiency in Japanese brother patients
Yushi Chikasawa, Keiko Shinozawa, Kagehiro Amano, Kyoichi Ogata, Takeshi Hagiwara, Takashi Suzuki, Hiroshi Inaba, Katsuyuki Fukutake (Japan)

Screen 09

Von Willebrand factor: Basic
Moderator: Andrea Guilliatt [United Kingdom]

PA 1.09-1  Cysteine 584 is required for correct von Willebrand factor multimerization
Viviana Daidone, Lisa Gallinaro, Elena Pontara, Grazia Cattini, Enrico Zampese, Paola Pizzo, Giovanni Barbon, Antonella Bertomoro, Alessandra Casonato (Italy)

PA 1.09-2  Von Willebrand Factor activity determination using new assay principle ristocetin-free for reliable von Willebrand disease diagnosis
Claudine Caron, Lucia Rugeri, Antoine Rauch, Sophie Susen, Jenny Goudemand (France)

PA 1.09-3  Identification of VWF gene deletions in 9 VWD families using multiplex ligation-dependent probe amplification (MLPA)
Bimal Theophilus, Lesley Baugh, Andrea Guilliatt, Jonathan Wilde, Jayashree Motwani, Michael Williams (United Kingdom)

PA 1.09-4  Characterization of von Willebrand factor and ADAMTS13 in plasma derived factor concentrates
Barbara Konkle, Shelley Fletcher, Kerry Lannert, Jill Johnsen, Garrett Bergman, Gayle Teramura (USA)

PA 1.09-5  Development of the Self-PBQ (Self-administered Pediatric Bleeding Questionnaire): Pre-testing and optimization
Margaret Rand, Angie Tuttle, Julie Grabell, Paul Moorehead, Meghan Deforest, John Wu, MacGregor Steele, Robert Klaassen, Mariana Silva, Paula James (Canada)

PA 1.09-6  Genetic defect of von Willebrand disease in thirty Taiwanese patients
Yeu-Chin Chen, Shin-Nan Cheng, Shu-Hsia Hu, Ya-Feng Yiang (Taiwan)

Screen 10

Anticoagulant agents - I
Moderator: Jan Beyer-Westendorf [Germany]

PA 1.10-1  Observed practice of bridging anticoagulation; guideline adherence and risk factors for perioperative bleeding
Pieter Eijgenraam, Hugo ten Cate, Arina ten Cate-Hoek (The Netherlands)

PA 1.10-2  The coagulation factor XIa inhibitor rHA-Infestin-4 potently improves outcome after cerebral ischemia/reperfusion injury in rats
Jennifer Krupka, Frauke May, Franz Kaspereit, Ingo Pragst, Thomas Weimer, Christoph Kleinschnitz, Guido Stoll, Gerhard Dickneite, Marc Nolte (Germany)

PA 1.10-3  Development of a clinical prediction model for an INR = 4.5 in hospitalized patients treated with vitamin K antagonists
Anouk Lindemans, Nico van Blijderveen, Marieke Kruip, Yvonne Vergouwe, Miriam Sturkenboom, Arnold Vulto, Patricia van den Bemt (The Netherlands)

PA 1.10-4  Inhibiting coagulation factor XIa potently prevents thrombosis in a rabbit arteriovenous shunt model
Marion Fries, Jennifer Krupka, Franz Kaspereit, Veronica Rayzman, Michael Wilson, Ingo Pragst, Thomas Weimer, Kosta Panousis, Gerhard Dickneite, Marc Nolte (Germany)

PA 1.10-5  Treatment of acute VTE with Rivaroxaban. Updated results of the prospective Dresden NOAC Registry (NCT01588119)
Jan Beyer-Westendorf, Franziska Ebertz, Vera Gelbricht, Kati Förster, Christina Köhler, Sebastian Werth (Germany)
The FXIa inhibitor rHA-Infestin-4 safely protects from arterial and venous thrombosis in rodent and non-rodent species
Frauke May, Jennifer Krupka, Ina Thielmann, Sabrina Schenk, Patrick Letmade, Ingo Pragst, Thomas Weimer, Bernhard Nieswandt, Gerhard Dickneite, Marc Nolte (Germany)

Blood coagulation tests - I
Moderator: Hilde Kelchtermans (The Netherlands)

PA 1.11-1 Activated Factor VII Antithrombin Complex plasma concentration in subjects with or without angiographically demonstrated coronary artery disease and myocardial infarction
Federica Tosi, Nicola Martinelli, Marcello Baroni, Domenico Girelli, Patrizia Guarini, Silvia Udalti, Alessio Branchini, Barry Woodhams, Francesco Bernardi, Oliviero Olivieri (Italy)

PA 1.11-2 The appearance of the second peak in platelet rich plasma thrombin generation curve can be provided by antiplatelet compounds: mechanism and possible applications
Ivan Tarandovskiy, Elena Artemenko, Konstantine Kopylov, Maria Kumskova, Mikhail Panteleev, Elena Sinauridze, Fazoil Ataullakhanov (Russian Federation)

PA 1.11-3 Assessment of thrombin formation in patients with ulcerative colitis without a history of thrombotic events
Muzaffer Demir, Sema Halhalli, Ahmet Tezel, Ayten Ustundag, Guray Can, Elif Umit (Turkey)

PA 1.11-4 Simultaneous measurement of thrombin generation and fibrin formation in plasma and whole blood applying continuous flow
Hilde Kelchtermans, Leonie Pelkmans, Marisa Ninivaggi, Raed Al Dieri, Coenraad Hemker, Bas de Laat (The Netherlands)

PA 1.11-5 Preoperative thrombin generation is predictive for the risk of blood loss after cardiac surgery
Yvonne Bosch, Raed Al Dieri, Saartje Bloemen, Bas de Laat, Hugo ten Cate, Patty Nelemans, Hendrik Hemker, Patrick Weerwind, Jos Maessen, Baharansjah Mochtar (The Netherlands)

PA 1.11-6 Fibrin monomers improves CHA2DS2-VASc risk prediction in chronically anticoagulated atrial fibrillation patients
Pilar Gallego, Marta Romera, Francisco Marín, Mariano Valdés, Gregory Lip, Vicente Vicente, Vanessa Roldán (Spain)

Coagulation factor IX - I
Moderator: Eloïse Perot (France)

PA 1.12-1 Quantitative whole body autoradiography (QWBA) study on the effect of albumin fusion on the biodistribution of recombinant factor rIX
Eva Herzog, Stephen Harris, Andrew McEwen, Ingo Pragst, Gerhard Dickneite, Stefan Schulte, Sabine Zollner (Germany)

PA 1.12-2 Expression and characterization of a novel recombinant factor IX molecule with enhanced clotting activity
Eloïse Perot, Nathalie Enjolras, Claude Negrier, Yesim Dargaud (France)
ePOSTERS (A)  ePOSTER AREA

Monday, July 1, 2013  17:00 – 18:30

PA 1.12-3  Pharmacokinetics of buccally and intravenously delivered transgenic recombinant and plasma derived Factor IX
William Velander, Paul Monahan, Tulin Morcol, Timothy Nichols, Nicholas Vanderslice [USA]

PA 1.12-4  Detection of galactose-alpha-1,3-galactose (a-Gal) and N-glycolylneuraminic acid (NGNA) in recombinant and plasma derived FIX products
Mingxuan Zhang, Qi Lu, Baisong Mei, Robert Peters [USA]

PA 1.12-5  Impact of Factor IXa content on function, safety and efficacy of recombinant factor IX products
Hanspeter Rottensteiner, Peter Turecek, Wilfried Auer, Gerald Schrenk, Werner Höllriegl, Alexandra Schiviz, Friedrich Scheiflinger, Hans-Peter Schwarz, Eva-Maria Muchitsch [Austria]

PA 1.12-6  Two phosphatidylserine-positive platelet subpopulations are major in binding of coagulation factor IXa
Anatoly Kozlov, Nadejda Podoplelova, Fazly Ataullakhanov, Michail Panteleev [Russian Federation]

Coagulation factor VIII - I  Screen 13

Moderator: Andrey Sarafanov [USA]

PA 1.13-1  Residues within the B02C11 epitope may participate in FVIII endocytosis by antigen presenting cells
Bagirath Gangadharan, Sandrine Delignat, Pushpa Hegde, Meenu Sharma, Srini Kaveri, Sébastien Lacroix-Desmazes [France]

PA 1.13-2  Impact on healthcare costs and quality of life of secondary prophylaxis in adolescent and adult patients with severe haemophilia A: The POTTER study
Annarita Tagliaferri, Antonio Coppola, Giulio Feola, Angelo Molinari, Cristina Santoro, Fabio Gagliano, Dorina Cultrer, Maria Elisa Mancuso, Ezio Zanon, Lelia Valdrè, Gavino Piseddu, Susanna Amoresano [Italy]

PA 1.13-3  MD Simulation Studies of the membrane binding process of the human blood coagulation Factor VIII C domains
Jiangfeng Du, Kanin Wichapong, Gerry Nicolaes [The Netherlands]

PA 1.13-4  Light chain of coagulation factor VIII contains a site for low-density lipoprotein receptor
James Kurasawa, Svetlana Shestopal, Elena Karnaukhova, Evi Struble, Timothy Lee, Andrey Sarafanov [USA]

PA 1.13-5  Human liver sinusoidal endothelial cells but not hepatocytes contain FVIII
Marc G. Jacquemin, Kris Covens, Nawal Jazouli, Etienne Sokal, Kathelijne Peerlinck, Tina Shahani [Belgium]

PA 1.13-6  Myeloid-Derived Cells a novel target for cell therapy in hemophilia A
Diego Zanolini, Simone Mertin, Maria Feola, Gabriella Ranaldo, Roberto Gherzi, Guido Valente, Maria Prat, Antonia Follenzi [Italy]
**Fibrinogen/Fibrin - I**

**Screen 14**

**Moderator: Rustem Litvinov (USA)**

**PA 1.14-1**  
Kinetics and thermodynamics of knob-hole interactions in fibrin from dynamic force measurements in silico  
Rustem Litvinov, Artyom Zhmurov, Olga Kononova, John Weisel, Valeri Barsegov (USA)

**PA 1.14-2**  
Fibrinogen Birmingham II - a novel variant associated with hypodysfibrinogenemia, due to co-inheritance of Trp334Cys and Asn335Tyr in the fibrinogen Aa chain  
Katie Greenhalgh, Marian Hill, Benjamin Gordon, Robert Aniêns, Mike Williams, Gerry Dolan, Ramzi Ajjan (United Kingdom)

**PA 1.14-3**  
Fibrin structure in subjects with diabetes and aortic aneurysm  
Muhammad Mohd Izam, Ayleen Ofosu-Adjei, Amy Cilia La Corte, Anne Johnson, Soroush Sohrabi, Julian Scott, Robert Aniêns, Kirti Kain (United Kingdom)

**PA 1.14-4**  
Prothrombotic plasma fibrin clot phenotype is predictive of recurrent venous thromboembolism following discontinuation of anticoagulant therapy  
Anetta Undas, Mariola Ciesla-Dul, Tomasz Drzakiewicz, Jerzy Sadowski (Poland)

**PA 1.14-5**  
The impact of diabetes duration on plasma fibrin clot properties in type 2 diabetic patients  
Anetta Undas, Malgorzata Konieczynska, Korneliusz Filip, Marta Bazejek (Poland)

**PA 1.14-6**  
Fluid and solute transport in thrombi as function of platelet and fibrin density  
Adam Wufsus, Keith Neeves (USA)

**Natural anticoagulants - I**

**Screen 15**

**Moderator: Laurent Burnier (USA)**

**PA 1.15-1**  
Effect of coagulation factors and heparin on FXa inhibition by TFPI  
Alexandra Heinzmann, Maria Christella Thomassen, Sameera Peraramelli, Tilman Hackeng, Rudolf Hartmann, Friedrich Scheiflinger, Jan Rosing, Michael Dockal (The Netherlands)

**PA 1.15-2**  
Implication of the protein S/Growth arrest-specific gene 6 pathway in the pathophysiology of purpura fulminans  
Anne Angelillo-Scherrer, Raja Prince, Sara Calzavarini, François Saller, Michael Racine, Monica Azevedo (Switzerland)

**PA 1.15-3**  
In vivo characterization of double deficiency in protein S and growth arrest-specific gene 6  
Anne Angelillo-Scherrer, Raja Prince, Sara Calzavarini, François Saller, Monica Azevedo, Michael Racine (Switzerland)

**PA 1.15-4**  
Autodegradation of murine activated protein C due to cleavage at Lys43  
Laurent Burnier, José Fernandez, John Griffin (USA)

**PA 1.15-5**  
The search for functionally important residues in protein S required for its enhancement of TFPI  
Natalia Reglinska, Helena Andersson, Suely Rezende, Björn Dahlbäck, James Crawley, David Lane, Josefin Ahnström (United Kingdom)

**PA 1.15-6**  
Stabilization of N-glycosylation in Asn135 of antithrombin by an aromatic sequon  
Sonia Aquila, Irene Martinez-Martinez, José Navarro-Fernández, Ricardo Gutiérrez-Gallego, Horacio Pérez-Sánchez, Maria Eugenia De La Morena-Barrio, Vicente Vicente, Javier Corral (Spain)
Cancer and thrombosis - I

Moderator: Mandy Lauw (The Netherlands)

PA 1.16-1 Predictors of factor Xa generation in breast cancer
Susan Lakoski, Maria Bravo, Pamela Wolfe, Mary Cushman, Henry Thompson, Kathleen Brummel-Ziedins [USA]

PA 1.16-2 Clinical course of cerebral venous thrombosis in adults with acute lymphoblastic leukemia
Mandy Lauw, Susanna Zuurbier, Jonathan Coutinho, Charles Majoie, Bronno van der Holt, Jan Cornelissen, Saskia Middeldorp, Bart Biemond, Jan Stam [The Netherlands]

PA 1.16-3 Plasma fibrin clot abnormalities in patients with multiple myeloma: association with thromboembolic events during induction therapy
Anetta Undas, Lidia Usnarska-Zubkiewicz, Grzegorz Helbig, Dariusz Woszczyk, Justyna Kozinska, Anna Dmoszynska, Maria Podolak-Dawidziak, Kazimierz Kuliczkowski [Poland]

PA 1.16-4 Incidental venous thromboembolism in kidney cancer patients: a case-control study
Daniel Yokom, Ryma Ihaddadene, Gregoire Le Gal, Patricia Moretto, Marc Carrier [Canada]

PA 1.16-5 Association of interleukins with venous thromboembolism and mortality in cancer patients
Eva-Maria Reitter, Cihan Ay, Alexandra Kaider, Robert Pirker, Christoph Zielinski, Gerhard Zlabinger, Ingrid Pabinger [Austria]

PA 1.16-6 Prolonged thromboprophylaxis with low molecular weight heparin to prevent venous thromboembolism after abdominal cancer surgery: A systematic review
Morten Rasmussen, Lars Jorgensen, Paolo Prandoni, V. Kakkar [Denmark]

Angiogenesis

Moderator: Rory Koenen (The Netherlands)

PA 1.17-1 Role of α1 integrin subunit in tumor growth and tumor angiogenesis
Dominique Helley, Claire Bouvard, Adèle De Arcangelis, Melyn Nizard, Anne-Marie Fischer, Elisabeth Georges-Labouesse [France]

PA 1.17-2 Intramyocardial release of engineered chemokines from biodegradable hydrogels prevents injury extension after myocardial infarction

PA 1.17-3 Characterization of a reduced form of plasma plasminogen as the precursor for angiostatin formation
Diego Butera, Philip Hogg [Australia]

PA 1.17-4 Targeting VEGFR1 on endothelial progenitors modulates their differentiation potential
Clément D’Audigier, Benoît Gautier, Alexis Yon, Jean-Meidi Alili, Solène Evrard, Nicolas Inguiembert, Michel Vidal, Pascale Gaussem, David Smadja [France]

PA 1.17-5 Imbalances in angiopoietin 1 and 2 levels in steady state sickle cell disease
Marina Colella, Fabiola Traina, Maiara Fiusa, Gleice Souza, Vanessa Faiotto, Fernando Costa, Joyce Maria Annichino-Bizzacchi, Sara Saad, Erich De Paula [Brazil]

PA 1.17-6 Thrombin induces pro-angiogenic signals and disruption of the retinal blood barrier: An in vitro model
Tami Livnat, Rima Dardik, Yael Nisgav, Dov Weinberger, Gili Kenet [Israel]
**Antiphospholipid - I**

Moderator: Nathalie Pequeriaux (The Netherlands)

PA 1.18-2  
A systematic review and meta-analysis of pathogenic mechanisms of the antiphospholipid syndrome  
Vivian Du, Hilde Kelchtermans, Raed Al Dieri, Philip de Groot, Bas de Laat  
(The Netherlands)

PA 1.18-3  
Increased levels of Thrombin Activatable Fibrinolysis Inhibitor - TAFI in patients with the antiphospholipid syndrome  
Aleksandra Antovic, Anna Vikerfors, Jovan Antovic, Barry Woodhams, Mariette Adam, Elisabet Svenungsson (Sweden)

PA 1.18-4  
A novel method for the diluted Russell’s viper venom time (dRVVT) test that abrogates the effects of vitamin K antagonist (VKA) treatment  
Keiko Misasa, Chizuru Morikawa, Akiko Suzuki, Hugh Fryer (Japan)

PA 1.18-5  
Antibodies against domain I of beta2-glycoprotein I are a better predictor for the antiphospholipid syndrome than antibodies to the total protein  
Martine Hollestelle, Martlies van Schagen, Afzal Kariman, Nathalie Pequeriaux  
(The Netherlands)

PA 1.18-6  
Investigation of resistance to exogenous activated protein C and activation of endogenous protein C in thrombotic patients with or without antiphospholipid syndrome  
Deepa Jayakody Arachchillage, Maria Efthymiou, Ian Mackie, Andrew Lawrie, Samuel Machin, Hannah Cohen (United Kingdom)

**Innate and acquired immunity**

Moderator: Cornelis van’t Veer (The Netherlands)

PA 1.19-1  
Plasma endothelial protein C receptor influences innate immune response in ovarian cancer by decreasing the population of natural killer and TH17 helper cells  
Samaher Besbes, Massoud Mirshahi, Dalel Azzazene, Hamda Thawadi, Halema Al Farsi, Shahsoltan Mirshahi, Julia Pardo, Anne Marie Faussat, Amu Therwath, Eric Pujade-Lauraine, Jeannette Soria (France)

PA 1.19-2  
Acute hypoxia induced adhesion of leukocyte are mediated through toll-like receptor3-interferon γ- signal transducers and activators of transcription 1 pathway  
Indranil Biswas, Bandana Singh, Manish Sharma, Paban Agrawala, Gausal Khan (India)

PA 1.19-3  
Protease-activated receptor (PAR) 1 impairs host defense during severe Gram-negative sepsis (meliodosis)  
Liesbeth Kager, Joost Wiersinga, Joost Meijers, Cornelis van ’t Veer, Tom van der Poll  
(The Netherlands)

PA 1.19-4  
Thrombin receptor activation impairs TLR mediated whole blood TNF production by thrombin induced MKP-1 expression and p38 deactivation  
Cornelis van ’t Veer, Jack Yang, Miranda Versloot, Floor van den Boogaard, Danielle Kruijswijk, Tom van der Poll, Jonathan van der Meer, Veer Keizer  
(The Netherlands)

PA 1.19-5  
Thrombelastographic studies reveal a new mechanism in MASP-1-induced fibrin clotting  
Lorenz Jenny, Jozsef Dobo, Peter Gal, Verena Schroeder (Switzerland)
The role of autoantibodies to heat shock proteins (HSP-70) in immune reactions in old-aged patients with chronic generalized periodontitis and coronary heart disease

Lidia Malezhik, Yuri Pinelis, Namzhil Tsybikov, Margarita Malezhik (Russian Federation)

**Recurrent venous thrombosis - I**

**Screen 20**

**Moderator:** Paul den Exter (The Netherlands)

**PA 1.20-1**

**Aspirin for the prevention of recurrent venous thromboembolism (VTE): The INSPIRE collaboration**

Cecilia Becattini, John Simes, Giancarlo Agnelli, John Eikelboom, Adrienne Kirby, Rebecca Mister, Paolo Prandoni, Tim Brighton, The INSPIRE Collaborators (Italy)

**PA 1.20-2**

**Low level of residual thrombotic obstruction following 6 months of anticoagulant treatment for acute pulmonary embolism**

Paul den Exter, Josien van Es, Lucia Kroft, Petra Erkens, Renee Douma, Gé Jonkers, Hugo ten Cate, Ludo Beenen, Pieter Willem Kamphuisen, Menno Huisman (The Netherlands)

**PA 1.20-3**

**The prognostic significance of residual vein obstruction in patients with treated deep vein thrombosis: A patient-level meta-analysis**

Marco Donadini, Walter Ageno, Benilde Cosmi, Daniela Poli, Paolo Prandoni, Marc Rodger, Sergio Siragusa, Laura Young, Matteo Bonzini, James Douketis (Italy)

**PA 1.20-4**

**Complication rates among patients treated for upper extremity thrombosis: A meta-analysis and systematic review**

Melanie Tan, Marc Carrier, Menno Huisman, Marc Rodger (The Netherlands)

**PA 1.20-5**

**The risk of venous thromboembolism in renal cell carcinoma patients with residual and non-resected tumor thrombus**

Ryma Ihaddadene, Daniel Yokom, Gregoire Le Gal, Patricia Morett, Marc Carrier (Canada)

**PA 1.20-6**

**Predictors of recurrent venous thromboembolism in cancer patients: Findings from the worldwide RIETE registry**

Gualberto Gussoni, Stefania Frasson, Pierpaolo Di Micco, Micaela La Regina, Manuel Alejandro Lorente, Elena González, Fabienne Gonçalves, Isabelle Mahe, Manuel Monreal, RIETE For the Study Group (Italy)
<table>
<thead>
<tr>
<th><strong>ePOSTERS (B)</strong></th>
<th><strong>Screen 21</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antiplatelet agents: ADP receptors - II</strong></td>
<td>Monday, July 1, 2013 17:00 – 18:30</td>
</tr>
<tr>
<td><strong>Moderator:</strong> Isobel Ford (United Kingdom)</td>
<td></td>
</tr>
<tr>
<td>PB 1.21-1</td>
<td>Evolving pattern of platelet P2Y12 inhibition during maintenance therapy in acute coronary syndrome patients Rajiv Joshi, Rashed Hossain, Allison Morton, Rosemary Ecob, Heather Judge, Clare Wales, Arun Karunakaran, Robert Storey (United Kingdom)</td>
</tr>
<tr>
<td>PB 1.21-2</td>
<td>Comparison of two platelet function analysers in patients having taken clopidogrel and awaiting cardiac surgery: Single centre experience in 50 unselected patients Simon Davidson (United Kingdom)</td>
</tr>
<tr>
<td>PB 1.21-3</td>
<td>Clopidogrel therapy has additional inhibitory actions on cyclo-oxygenase and thrombin receptor-mediated pathways in platelets Isobel Ford, Neil Scott, Vera Herd, Louise Mitchell, David Williams, Julie Brittenden (United Kingdom)</td>
</tr>
<tr>
<td>PB 1.21-4</td>
<td>The effect of CYP4F2 G1347A polymorphism and of clinical factors on platelet reactivity in patients, treated with dual antiplatelet therapy Vacis Tatarunas, Nora Kupstyte, Laima Jankauskaie, Vilius Skipskis, Vilma Kozlovaite, Vaiva Lesauskaite (Lithuania)</td>
</tr>
<tr>
<td>PB 1.21-6</td>
<td>Antiplatelet activity, P2Y1 and P2Y12 inhibition, and metabolism in plasma of diastereomers of the Ap4A analog diadenosine-5',5''-P1,P4'-dithio-P2,P3-chloromethylenetetraphosphate Andrew Frelinger III, Hung Chang, Edward Dix, Milka Yanachkova, Youfu Li, Marc Barnard, George Wright, Alan Michelson, Ivan Yanachkov (USA)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Screen 22</strong></th>
<th><strong>Standardising platelet function tests</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Moderator:</strong> Jacqueline Glenn (United Kingdom)</td>
<td></td>
</tr>
<tr>
<td>PB 1.22-1</td>
<td>A simplified approach to monitoring changes in VASP phosphorylation in platelets and other blood cells Jacqueline Glenn, Ann White, Natalia Dovlatova, Stanley Heptinstall, Sue Fox (United Kingdom)</td>
</tr>
<tr>
<td>PB 1.22-2</td>
<td>Simultaneously measuring adenosine triphosphate (ATP) release and light transmission aggregation does not potentiate platelet aggregation in participants with clinically diagnosed bleeding disorders Marie Lordkipanidze, Gillian Lowe, Steve Watson (United Kingdom)</td>
</tr>
<tr>
<td>PB 1.22-3</td>
<td>Label-free detection of platelet adhesion to collagenous substrates Richard Farndale, Frauke Swieringa, Matthew Tsim, Joanna Howes, Stephanie Jung, Dominique Bihan, Samir Hamaia (United Kingdom)</td>
</tr>
<tr>
<td>PB 1.22-4</td>
<td>Effect of platelet count on platelet aggregation measured by impedance aggregometry (Multiplate - analyzer) and by light transmission aggregometry Mariangela Scavone, Eti Alessandra Femia, Anna Lecchi, Marco Cattaneo (Italy)</td>
</tr>
<tr>
<td>PB 1.22-5</td>
<td>Thrombin generation and microparticle-associated procoagulant activity as new assays to characterize the hemostatic profile of platelet concentrates Laura Russo, Marina Marchetti, Carmen Tartari, Alfonso Vignoli, Erika Diani, Cinzia Giacherini, Cristina Verzeroli, Chiara Gargantini, Barry Woodhams, Anna Falanga (Italy)</td>
</tr>
<tr>
<td>PB 1.22-6</td>
<td>Subdivision according to size is necessary for correct interpretation of data regarding platelet expression of active GPIIb/IIIa and phosphatidylserine Anna Sodergren, Karin Ollinger, Sofia Ramstrom (Sweden)</td>
</tr>
</tbody>
</table>
Monday, July 1, 2013 17:00 – 18:30

Platelet integrins - I

**Screen 23**

**Moderator:** Chris Jones (United Kingdom)

PB 1.23-1  **The role of the fibrinogen NGR motif in mediating platelet adhesion and activation**
 Dermot Cox, Roisin Moriarty, Thea Tilley, Mathew Lambert, Steven Kerrigan (Ireland)

PB 1.23-2  **Regulation of platelets collagen receptor a2β1 integrin and the possibility of intermediate affinity**
 Samir Hamaja, Dominique Bihan, Richard Farndale (United Kingdom)

PB 1.23-3  **Mass spectrometry of platelet lipid raft fractions reveals a substantial pool of active integrin allß3**
 Chris Jones, Katherine Tucker, Natasha Barrett, Yichuan Wen, David Leake, Jonathan Gibbins (United Kingdom)

PB 1.23-4  **The fibronectin binding partner Msb2 of Candida albicans impairs the platelet-mediated host attack**
 Volker Stoldt, Rüdiger Scharf, Khon Chan Huynh (Germany)

PB 1.23-5  **Involvedment of Protein Disulfide Isomerase (PDI) in beta3 integrin-Mediated Adhesion of Nucleated Cells to Immobilized Fibrinogen**
 Nurit Rosenberg, Vera Sheptovitsky, Olga Romanenco, Judith Lahav (Israel)

PB 1.23-6  **Surface expressions of platelet glycoprotein Iba, GpIIbIIIa, and P-Selectin are Elevated in lung cancer patients**
 Kesheng Dai, Jiansheng Zhang, Lili Zhao, Jianan Huang (China)

Platelet apoptosis

**Screen 24**

**Moderator:** Asuman Mutlu (Canada)

PB 1.24-1  **Arsenic trioxide induces platelet apoptosis**
 Kesheng Dai, Yicun Wu, Jin Dai, Weilin Zhang, Rong Yan, Changgeng Ruan (China)

PB 1.24-2  **Caspase-3 activation regulates platelet lifespan but it is not involved in microparticle (MP) formation and phosphatidylserine (PS) exposure**
 Yukinori Kozuma, Hiroshi Kojima, Yoko Tashiro, Haruhiko Ninomiya (Japan)

PB 1.24-3  **Inner mitochondrial membrane disruption is closely associated with both Bax/Bak and cyclophilin D-mediated platelet phosphatidylserine exposure**
 Hyojung Choo, Shawn Jobe (USA)

PB 1.24-4  **Platelet apoptosis in uremic patients**
 Kesheng Dai, Ming Li, Tongling Ma, Guoyuan Lu, Kun Deng, Rong Yan (China)

PB 1.24-5  **The Effects and mechanisms of Cyanidin-3-glucoside on platelet apoptosis**
 Liyi Chen, Jinju Tian, Fenglin Song, Jing Ren, Xiujuan Deng, Wenhua Ling, Yan Yang (China)
Platelet disorders: Gain-of-function

**Moderator:** Dong Chen (USA)

**PB 1.25-1** Platelet apoptosis and agonist-mediated activation in myelodysplastic syndromes
Nora Butta, Mónica Martín, Raquel De Paz, Ihsosvany Fernández Bello, Elena García Arias Salgado, María Teresa Álvarez, Víctor Jiménez Yuste (Spain)

**PB 1.25-2** H2 haplotype of ADP-P2Y12 receptor gene is associated with increased platelet response to ADP in Taiwanese population
Chao-Zong Liu, Yi-Hsuan Chen, Jia-Li Lin (Taiwan)

**PB 1.25-3** Purified dietary Anthocyanin inhibited platelet secretion in hypercholesterolemia
Fenglin Song, Zhenyin Shi, Yanna Zhu, Jinju Tian, Liyi Chen, Wenhua Ling, Yan Yang (China)

**PB 1.25-4** Polymorphism of human platelets antigens in Tunisian patients with acute ischemic stroke
Rym Houki, Mehdi Ben Said, Imen Sfar, Tarek Dhaouadi, S. Younes, I. Bannour, L. Boughamoura, Sami Guermazi, Taieb Ben Abdallah, Yousr Gorgi (Tunisia)

**PB 1.25-5** Modeling and molecular dynamics simulations: Structural comparison of the V33 variant of the integrin subunit β3 with its L33 (HPA-1a) and P33 (HPA-1b) forms
Vincent Jallu, Pierre Poulain, Patrick Fuchs, Cecile Kaplan, Alexandre De Brevern (France)

**PB 1.25-6** Diagnostic laboratory validation of platelet transmission electron microscopy
Dong Chen, Cindy Uhl, Ryan Barness, Mary Olson, Susan Gossman, Sibel Erdogan, Scott Gamb, Jon Charlesworth, Randal Miller, Jeffrey Salisbury, William Nichols, James White (USA)

Platelet function in disease

**Moderator:** Benoit Decouture (France)

**PB 1.26-1** Enhanced lipid peroxidation and platelet activation as potential contributors to increased cardiovascular risk in the low-HDL phenotype
Natale Vazzana, Antonina Ganci, Angelo Cefalù, Stefano Lattanzio, Davide Noto, Nicole Santoro, Raul Saggini, Luca Puccetti, Maurizio Averna, Giovanni Dati (Italy)

**PB 1.26-2** Platelet activation and thrombin-generation in paediatric patients with acute ITP, chronic ITP and chemotherapy-induced thrombocytopenia
Markus Schmugge, Jeanine Winkler, Sabine Kroiss, Oliver Speer (Switzerland)

**PB 1.26-3** A clinical pilot study to compare T2MR and VerifyNow P2Y12 platelet activity measurements in cardiovascular patients
Yuka-Marie Vinagre, Rabin Niroula, Lovely Chhabra, Walter Massefski, Thomas Lowery (USA)

**PB 1.26-4** Markers of activation haemostasis in patients with psychosis influence of an antipsychotic treatment: Findings from the ANTRE study
Radovan Malý, Jiri Masopust, Ctirad Andrýs, Jan Bažant, Vera Krejšková, Ladislav Hosák (Czech Republic)

**PB 1.26-5** Evaluation of aspirin use on platelet function in essential thrombocythemia and polycythaemia vera patients
Marina Panova-Noeva, Marina Marchetti, Laura Russo, Guido Finazzi, Alessandro Rambaldi, Hugo ten Cate, Anna Falanga (Macedonia)

**PB 1.26-6** Inhibition of MRP4 down regulates platelet activation and prevents pre-clinical arterial thrombosis
Benoit Decouture, Christilla Bachelot-Loza, Tiphaine Belleville, Blandine Dizier, Isabelle Gouin-Thibault, Berard Coqueran, Anne-Marie Lompré, Jean-Sébastien Hulot, Pascale Gaussem (France)
Platelets and cancer

**Screen 27**

**PB 1.27-1** Resistance to aspirin in myeloproliferative neoplasms: Is it a reality? Evaluation of low dose aspirin resistance in a pilot study including 54 patients

*Authors:* Nadine Ajzenberg, Dorothée Faille, Anh Cung, Marie-Genevieve Huisse, Christine Chomienne, Martine Jandrot-Perrus, Christine Dosquet (France)

**PB 1.27-2** Intraplatelet angiogenesis regulators more relevant than serum carcino embryonic antigen (CEA) to colorectal cancer (CRC)?

*Authors:* Anne Bauters, Claire Beugnet-Henaut, Bertrand Vaast, Philippe Zerbib (France)

**PB 1.27-3** Procoagulant microparticles in cancer patients: Prognostic value

*Authors:* Virtudes Vila, Vicenta Martinez-Sales, Tania Fleitas, Gaspar Reynés (Spain)

**PB 1.27-4** Immune thrombocytopenia in patients with chronic lymphocytic leukemia treated with 2 - Cda-based regiments or chlorambucil

*Authors:* Jacek Trelinski, Jerzy Blonski, Tadeusz Robak, Krzysztof Chojnowski, Investigators Polish Adult Leukemia Group (Poland)

**PB 1.27-5** Crosstalk between platelets and inflammation in nasopharyngeal carcinoma

*Authors:* Adi Komala, Andhika Rachman, Asrul Harsal (Indonesia)

**PB 1.27-6** Role of thrombopoietin signalling in murine B-cell lymphoma

*Authors:* Emma Josefsson, Marion Lebois, Ping Cannon, Diane Moujalled, Angelika Rutgersson, Fatme Faraj, Andrew Roberts, Benjamin Kile, Kylie Mason, Warren Alexander (Australia)

Platelet storage and transfusion

**Screen 28**

**PB 1.28-1** Effects of ultraviolet radiation on platelet shape

*Authors:* Chikahiro Terada, Hitoshi Okazaki, Masahiro Satake, Kenji Tadokoro (Japan)

**PB 1.28-2** Reversible blockade of GpIIb-IIIa reduces platelet storage lesions

*Authors:* Lisa Jennings, Melanie White, Shila Cholera, Aditya Tyagi (USA)

**PB 1.28-3** Sonorheometry assessment of aspirin effects on platelet contributions to blood clot stiffness ex vivo in patients undergoing cardiopulmonary bypass procedures

*Authors:* Michael Lawrence, Xiefan Lin-Schmidt, Francesco Viola, Gorav Ailawadi, William Walker (USA)

**PB 1.28-4** Use of high-sensitivity flow cytometry for the characterization of a lyophilized platelet-derived hemostatic agent

*Authors:* Anja Gerrits, Marc Barnard, Michael Fitzpatrick, Michelle Berny-Lang, Alan Michelson, Andrew Frelinger III (USA)

**PB 1.28-5** Refrigerated storage of platelet products for transfusion in dogs

*Authors:* Kazuhito Segawa, Ayumi Fujimoto, Takashi Kato, Sakurako Neo, Masaharu Hisasue, Ryo Tsuchiya (Japan)

**PB 1.28-6** Pneumatic tube transport affects platelet function measured by multiplate electrode aggregometry

*Authors:* Thalén Simon, Ida Forsling, Jaak Eintrei, Lisbeth Söderblom, Jovan Antovic (Sweden)
**Megakaryocytes and thrombopoiesis - I**

**Screen 29**

**Moderator: Tim Thijs (Belgium)**

**PB 1.29-1** Purinergic signalling regulates human megakaryocytes function by inducing store-operated Ca2+ entry

Christian Di Buduo, Francesco Moccia, Monica Battiston, Luigi De Marco, Mario Mazzucato, Marco Cattaneo, Franco Tanzi, Alessandra Balduini [Italy]

**PB 1.29-2** Establishment of conditions for in vitro and in vivo production of genetically modified human megakaryocytes and platelets

Tim Thijs, Katleen Broos, Wim Maes, Aline Vandenbulcke, Juan Fang, David Wilcox, Karen Vanhoorelbeke, Hans Deckmyn [Belgium]

**PB 1.29-3** Protein synthesis in the late stages of megakaryocyte maturation triggers proplatelet formation

Kellie Machlus, Jonathan Thon, Robert Campbell, Andrew Weyrich, Joseph Italiano [USA]

**PB 1.29-4** Human pre-adipocytes differentiate into megakaryocytes and platelets using endogenous thrombopoietin

Yumiko Matsubara, Yukako Ono-Uruga, Yumiko Matsubara, Tatsuya Tanaka, Nobuhiro Goda, Shinichiro Okamoto, Yasuo Ikeda, Mitsuru Murata [Japan]

**PB 1.29-5** Expression and functionality of toll-like receptor 3 in the megakaryocytic lineage

Lina D'Atri, Julia Etulain, Leonardo Rivadeneyra, María Lapponi, Carlos Fondevilla, Mirta Schättner [Argentina]

**PB 1.29-6** Evidence for non-hematopoietic Cre activity in P4-Cre mice

Fabien Pertuy, Catherine Strassel, Anita Eckley, Jean-Noël Freund, Isabelle Duluc, Christian Gachet, François Lanza, Catherine Léon [France]

**Microparticles and disease - I**

**Screen 30**

**Moderator: Anat Aharon [Israel]**

**PB 1.30-1** Increased circulating microparticles and endothelial cells in patients with psoriasis

Vicenta Martínez-Sales, Virtudes Vila, José Ricart, Amparo Vayá, José Todolí, Cornelio Núñez, Carmen Ballester, Teresa Contreras, Edelmiro Reganon [Spain]

**PB 1.30-2** Chemotherapy and anti-angiogenic drugs affect composition and coagulant phenotype of cell-derived vesicles in cancer patients

Ankie Kleinjan, Joost Verhoeff, René Berckmans, Peter Kunst, Frederiek van Doormaal, Marcello Di Nisio, Dick Richel, Pieter Willem Kamphuisen, Harry Büller, Rienk Nieuwland [The Netherlands]

**PB 1.30-3** The role of breast cancer cell microparticles in thrombogenicity, angiogenesis and apoptosis following chemotherapy

Anat Aharon, Shachar Ben-shaul, Hagay Stern, Gil Barsela, David Loven, Benjamin Brenner [Israel]

**PB 1.30-4** Microparticle characterization in patients with acute leukemia at diagnosis and after induction therapy

Inna Tsoran-Rosenthal, Benjamin Brenner, Anat Aharon [Israel]

**PB 1.30-5** Anticoagulant activity of MP in patients with atherosclerosis of the vessels of the lower extremities

Olesya Matvienko, Yury Namestnikov, Olga Golovina, Natalia Saltykova [Russian Federation]

**PB 1.30-6** Granulysin and other inflammatory mediator induced procoagulant response in patients with Stevens Johnson Syndrome/Toxic Epidermal Necrolysis

Omer Iqbal, Julia Malais, Christine Mata, Daniel Kahn, Josephine Cunanan, Amy Lin, Michael Mosier, Charles Bouchard, Debra Hoppensteadt, Jawed Fareed [USA]
**Endothelial function**

**Screen 31**

**Moderator:** Gary Gilbert (USA)

**PB 1.31-1** Procoagulant activity at the margins of TNFα treated endothelial cells leads to pericellular fibrin deposition and anti-streptococcal function in flowing plasma

Gary Gilbert, Valerie Novakovic, Junhong Lu, Jialan Shi, Byungwook Ahn, Wilbur Lam (USA)

**PB 1.31-2** Effects of antiretroviral treatment on endothelial dysfunction and regeneration in HIV-positive patients: 1-year of follow-up

Francesca Cesari, Angela Rogolino, Canio Martinelli, Antonio Carocci, Paola Corsi, GianFranco Gensini, Rosanna Abbate, Anna Maria Gori (Italy)

**PB 1.31-3** Regulation of endothelial cell proliferation and survival by collagen receptors

Sung Kyu Kim, Nicholas Pugh, Dominique Bihan, Samir Hamaia, Richard Farndale (United Kingdom)

**PB 1.31-4** A role of Cilostazol in Alzheimer’s disease treatment: Induction of LRP1 expression in endothelial cells

Yuko Yano, Chihiro Takeshima, Eri Kawashita, Yosuke Kanno, Hiroyuki Matsuno (Japan)

**PB 1.31-5** Closely spaced thiols in integrin are involved in adhesion of endothelial cells

Halszka Ponamarczuk, Marcin Popielarski, Katarzyna Sobierańska, Marta Stasiak, Maria Swiatkowska (Poland)

**PB 1.31-6** Cocaine induces oxidative stress and decreased nitric oxide production in human endothelial cells: beneficial effect of atorvastatin

Jaime Pereira, Claudia Sáez, Karla Pereira-Flores, Roberto Ebensperger, Teresa Massardo, Diego Mezzano (Chile)

**Atherosclerosis: Mouse models**

**Screen 32**

**Moderator:** Xinjie Lu (United Kingdom)

**PB 1.32-1** Liver X receptor (LXR) agonist T0901317 induces regression of early and advanced atherosclerotic lesions under normolipidemic conditions in mice

Marco van der Stoep, Zhaohui Li, Laura Calpe-Berdiel, Ronald van der Sluis, Heather McKinnon, Martin Smit, Theo van Berkel, Miranda van Eck, Menno Hoekstra, Suzanne Korporaal (The Netherlands)

**PB 1.32-2** Replacement of Apob Peptide Sequence with C5ar Peptide Sequence in a recombinant vaccine construct significantly increases the atheroprotective effect of immunization in Apobtm2SglyLdlrtm1Her/J Mouse

Xinjie Lu, Min Xia, Daxin Chen, Valeria Endresz, Ildiko Faludi, Andrea Szabo, Lakshmi Mundkur, Vijay Kakkar (United Kingdom)

**PB 1.32-3** Immune response and gene profiling at different stages of atherosclerotic plaque progression using mouse model

Vrushali Vrushali, Lakshmi Mundkur Lakshmi, Vijay Kakkar (India)

**PB 1.32-4** Oral administration of recombinant multi antigenic construct expressing three peptides induces tolerance to individual peptides and prevents development of atherosclerosis in mice

Lakshmi Mundkur, Philip Sheena, Thiruvelsevan Ponnusamy, Narasimha Rao, Suryakanth Biradar, Meenakshi Varma, Xinjie Lu, Vijay Kakkar (India)
PB 1.32-5 Immunization with a linear peptide derived from tissue factor and protease activated receptor-1 significantly reduces the development of atherosclerotic lesion in ApoBtm2SglyLdlr1tm1Her/J mice
Xinjie Lu, Min Xia, Valeria Endrezs, Daxin Chen, Chris Goodwin, Ildiko Faludi, Andrea Szabo, Lakshmi Mundkur, Vijay Kakkar [United Kingdom]

PB 1.32-6 Aging- and activation-induced platelet microparticles suppress apoptosis in monocytes and differentially signal to proinflammatory mediator release
Johan Heemskerk, Elena Vasina, Sandra Cauwenberghs, Mareike Staudt, Marion Feijge, Christian Weber, Rory Koenen [The Netherlands]

ADAMTS13: Clinical - I

PB 1.33-1 Quantitative PCR assay demonstrated exon deletions of ADAMTS13 in two unrelated patients with Upshaw-Schulman syndrome
Yuka Eura, Koichi Kokame, Toshiro Takaftua, Ryojiro Tanaka, Hikaru Kobayashi, Fumihiro Ishida, Shuichi Hisanaga, Masanori Matsumoto, Yoshihiro Fujimura, Toshiyuki Miyata [Japan]

PB 1.33-2 Kinetics and half-life of plasma ADAMTS13 after plasma infusion in four patients with Upshaw-Schulman Syndrome
Hideo Yagi, Seiji Kato, Mutsuko Konno, Ryojiro Tanaka, Yuki Hasegawa, Rie Kanai, Seiji Yamaguchi, Ayami Isonishi, Masanori Matsumoto, Yoshihiro Fujimura [Japan]

PB 1.33-3 The determination and characterisation of anti-ADAMTS13 autoantibodies
Yusrah Harahsheh, Quintin Hughes, Jasmine Tay, Lisa Holmes, Grace Gilmore, Jim Thom, Ross Baker [Australia]

PB 1.33-4 ADAMTS13 activity is a potential biomarker of thrombotic risk in systemic lupus erythematosus
Susana Martin, Joan Carles Reverter, Dolors Tassies, Ana Galan, Gerard Espinosa, Marcos Pino, Gines Escolar, Maribel Diaz-Ricart [Spain]

PB 1.33-5 Decreased plasma ADAMTS13 activity during moderate to much consumption of ethanol in healthy volunteers: Differences between normal and heterozygous mutant aldehyde dehydrogenase-2 Alleles
Masahito Uemura, Masao Fujimoto, Masaki Hayakawa, Tomomi Matsuyama, Seiji Kato, Hiroaki Takaya, Chie Morioka, Masanori Matsumoto, Yoshihiro Fujimura, Hiroshi Fuhui [Japan]

PB 1.33-6 Levels of the ADAMTS13 metalloprotease and risk of myocardial infarction: Review of the literature and meta-analysis
Luca Lotta, Khaled Musallam, Giacomo Tuana, Eugenia Biguzzi, Raffaella Rossio, Barbara Ferrari, Nita Radhakrishnan, Flora Peyvandi, Frits Rosendaal [Italy]

Fibrinolytic system: Clinical - I

PB 1.34-1 Increased N-terminal cleavage of alpha-2-antiplasmin in liver cirrhosis
Shirley Uitte de Willige, Joyce Malfliet, Harry Janssen, Frank Leebeek, Dingeman Rijken [The Netherlands]

PB 1.34-2 Feasible mechanisms of fibrinolysis impairment in patients with antiphospholipid syndrome
Roza Aisina, Tat’yana Reshetnyak, Lilia Mukhametova, Lev Patrushev, N. Patrusheva, Nataliya Seredavkina, Dmitrii Gulin, Karina Gershkovich [Russian Federation]
Monday, July 1, 2013

**ePOSTER AREA**

**PB 1.34-3**  
**Topical and conjunctival use of fresh frozen plasma in patients with congenital plasminogen deficiency**  
Nihal Ozdemir, Gulen Tuysuz, Ayse Turhan, Guzin Iskeleli, Zeynep Alkin, Tiraje Celkan  
(Turkey)

**PB 1.34-4**  
**Effect of genetic PAI-1 polymorphisms 4G/5G, C428T and G429A on PAI-1 activity and clot lysis time**  
Zelda de Lange, Dingeman Rijken, Tiny Hoekstra, Karin Conradie, Johann Jerling,  
Marlien Pieters (South Africa)

**PB 1.34-5**  
**The hyperfibrinolytic phenotype induced by short-term venous stasis is not triggered by activation of the clotting cascade or thrombin formation**  
Heiko Rühl, Jens Müller, Jana Wäschenbach, Johannes Oldenburg, Bernd Pötzsch  
(Germany)

**PB 1.34-6**  
**Nicotinic acid/laropiprant modulates fibrinolytic system in patients with elevated levels of Lipoprotein(a)**  
Donatella Lami, Gabriele Cioni, Anna Paola Cellai, Elena Sticchi, Claudia Saracini,  
Emilia Antonucci, Agatina Alessandrello Liotta, Angela Rogolino, Rossella Marcucci,  
Rosanna Abbate (Italy)

**Haemophilia A: Clinical - I**

**Screen 35**

**Moderator:** Josephine Li-McLeod (USA)

**PB 1.35-1**  
**A fusion peptide binding to tissue factor pathway inhibitor (TFPI) inhibits both plasma- and platelet TFPI**  
Michael Dockal, Stella Thomassen, Alexandra Heinzmann, Kristien Winckers,  
Rudolf Hartmann, Tilman Hackeng, Jan Rosing, Friedrich Scheiflinger (Austria)

**PB 1.35-2**  
**The incidence and impact of intracranial hemorrhages within a hemophilia and non-hemophilia population**  
Josephine Li-McLeod, Yan Xiong, Diane Ito, Josh Epstein (USA)

**PB 1.35-3**  
**Variation in effect of DDAVP in mild haemophilia patients with an Asn637Ser mutation**  
Eveline Mauser-Bunschoten, Dietje Franssen van de Putte, Kathelijn Fischer,  
Karin van Galen, Goris Rosendaal, Roger Schutgens (The Netherlands)

**PB 1.35-4**  
**Major surgery in haemophiliacs: Istanbul experience**  
Bulent Zulfikar, Gulen Tuysuz, Nihal Ozdemir, Onder Kilicoglu, Necdet Aras, Omer Taser  
(Turkey)

**PB 1.35-5**  
**What we can learn from real-life clinical experience data from a post authorization safety surveillance in PUPs treated with antihaemophilic factor (recombinant), plasma/albumin free method in Japan**  
Masashi Takii, Hideji Hanabusa, Katsuyuki Fukutake, Tadashi Matsushita, Midori Shima,  
Akira Shirahata, Study Group Advate Pass (Japan)

**PB 1.35-6**  
**Costs and utilization of haemophilia A and B patients with and without inhibitors**  
Edward Armstrong, Daniel Malone, Sangeeta Krishnon, Jacob Wessler (USA)
**Haemophilia A: Clinical - II**

**Screen 36**

**Moderator:** Brigitte Brand [Switzerland]

**PB 1.36-1** Cognitive dysfunctions and cerebral microbleeds in adult patients with haemophilia A and B: The role of cardiovascular disease  
Ezio Zanon, Barbara Brandolin, Renzo Manara, Piero Amodio [Italy]

**PB 1.36-2** Decreased FVIIIa stability of mild Hemophilia A mutation R527W explains discrepancy between two chromogenic method applications using different FX activation times  
Pia Bryngelhed, Johannes Oldenburg, Anna Pavlova, Andreas Hillarp, Karin Strandberg, Steffen Rosen [Sweden]

**PB 1.36-3** Clinical outcome of hemophilia patients undergoing major orthopedic surgery without pharmacological thromboprophylaxis  
Brigitte Brand, Bernhard Gerber, Peter Koch, Stefan Rinderknecht Graf [Switzerland]

**PB 1.36-4** Integrated analysis of safety data from 12 clinical interventional studies of a plasma- and albumin-free recombinant factor VIII (rAHF-PFM) in persons with hemophilia A (HemoA)  
Amy Shapiro, Vadim Romanov, Laura Silvati-Fidell, Wing Yen Wong, Claudia Schoenig-Diesing [USA]

**PB 1.36-5** Clinical study in children with severe haemophilia A investigating efficacy, immunogenicity, pharmacokinetics, and safety of human-cl rhFVIII  
Anna Klukowska, Vladimir Vdovin, Tomasz Szczepanski, Martina Jansen, Sigurd Knaub, Ri Liesner [Poland]

**PB 1.36-6** Evaluation of the hemostatic potentials in a mild hemophilia A with a novel factor VIII mutation Thr677Ile  
Koji Yada, Keiji Nogami, Ogiwara Kenichi, Hiroaki Minami, Midori Shima [Japan]

**Haemophilia A: Clinical - III**

**Screen 37**

**Moderator:** Ian Jennings [United Kingdom]

**PB 1.37-1** Molecular genetics of inherited bleeding disorders. External quality assessment identifies errors in genotyping and interpretation  
Ian Jennings, David Perry, Anne Goodeve, Tony Cumming, Marion Hill, Steve Kitchen, Tim Woods, Isobel Walker [United Kingdom]

**PB 1.37-2** Efficient typing of copy number variations in HA and HB families with large deletion/insertion mutations using multiplex competitive amplification  
Yeling Lu [China]

**PB 1.37-3** Ongoing prospective rAHF-PFM immune tolerance induction registry (PAIR): Success rates continue to support published literature  
Amy Shapiro, Kate Khair, Jerry Teitel, Iliana Leony-Lasso, Elizabeth Matovinovic, Claudia Schoenig-Diesing, Gerald Spotts [USA]

**PB 1.37-4** Adherence to clotting factor treatment among patients with haemophilia A or B  
Edward Armstrong, Daniel Malone, Sangeeta Krishnon, Jacob Wessler [USA]

**PB 1.37-5** P.I.S.A. - Safety, immunogenicity and efficacy of a full length DNA rAHF-PMF in patients with hemophilia A in the Italian post-marketing surveillance study  
Michele Schino, Angiola Rocino, Elena Santagostino, Maria Gabriella Mazzucconi [Italy]

**PB 1.37-6** The influence of co-morbidities on annualised bleeding rates in patients with severe haemophilia A: Experiences from the pivotal turoctocog alfa prophylaxis trial (guardianTM1)  
Tatyana Andreeva, Takashi Suzuki, Rasmus Nielsen, Erik Andersen, Anders Lindblom [Russian Federation]
Monday, July 1, 2013 17:00 – 18:30

Haemophilia A: Clinical - IV
Screen 38

Moderator: Perrine Limperg [The Netherlands]

PB 1.38-1 The mechanism of action of prophylactic administration of recombinant factor VIIa may be explained by the presence of hemostatically active FVIIa in plasma throughout the time frame of prophylaxis
Anne Marieke Schut, Agon Hyseni, Jelle Adelmeijer, Joost Meijers, Philip de Groot, Ton Lisman [The Netherlands]

PB 1.38-2 TF-initiated thrombin generation associates with bleeding phenotype in patients suffering from haemophilia A
Marisa Ninivaggi, Yesim Dargaud, René van Oerle, Bas de Laat, Coenraad Hemker, Theo Lindhout [The Netherlands]

PB 1.38-3 Thrombin generation assay by calibrated automated thrombogram (CAT): Application to monitoring severe hemophilia A treatment
Virtudes Vila, Andréts Moret, Noelia Cabrera, Francisco España, Vicenta Martínez-Sales, José Aznar [Spain]

PB 1.38-4 Patient reported outcomes in clinical hemophilia practice
Perrine Limperg, Marjolein Peters, Heleen van Ommen, Karin Fijnvandraat, Martha Grootenhuis, Lotte Haverman [The Netherlands]

PB 1.38-5 Adherence to prophylaxis in the Netherlands: A multicentre study
Liesbeth Schrijvers, Marlene Beijleveld- van der Zande, Marjolein Peters, Janske Lock, Marjon Cnossen, Marieke Schuurmans, Kathelijn Fischer [The Netherlands]

PB 1.38-6 Immuno-monitoring of patients with severe hemophilia A
Sandrine Delignat, Wolfhart Kreuz, Carmen Escuriola, Sébastien Lacroix-Desmazes [France]

Haemophilia B - I
Screen 39

Moderator: Catherine Costa [France]

PB 1.39-1 Treatment of haemophilia B - Comparison study of the in vitro activities of plasma derived and recombinant factor IX
Yao Yu, Michael Laffan, Carolyn Millar [United Kingdom]

PB 1.39-2 Restoration of coagulation factor IX function impaired by different splicing mutations by a unique exon-specific U1 small nuclear RNA (snRNA)
Dario Balestra, Nicola Cavallari, Eugenio Fernandez Alanis, Andrea Dal Mas, Malgorzata Rogalska, Francesco Bernardi, Franco Pagani, Mirko Pinotti [Italy]

PB 1.39-3 Improvement in health-related quality of life with recombinant Factor IX prophylaxis in moderately-severe or severe hemophilia B patients: Results from the BAX326 Pivotal Study
Jerzy Windyga, Vincent Lin, Joshua Epstein, Diane Ito, Yan Xiong, Brigitt Abbuehl, Jorge Ramirez [Poland]

PB 1.39-4 Complex gene rearrangement combining both large F9 gene duplication and exon 6 deletion in severe hemophilia B patients
Catherine Costa, Mathilde Fretigny, Audrey Labalme, Sylvia Letourneau, Caroline Schluth-Bolard, Michel Goossens, Claude Negrier, Damien Sanlaville, Christine Vinciguerra [France]

PB 1.39-5 An amazing 10th century old mutation with a high prevalence in haemophilia B patients of the Rhone-Alpes region, France
Oriane Marmontel, Mathilde Fretigny, Patrice Bouvagnet, Dorothée Pellechia, Hugo Tailhefer, Claude Negrier, Christine Vinciguerra [France]
Superiority of the chromogenic assay specific for activated factor IX over the non-activated partial thromboplastine time (NAPTT) clotting assay in detecting FIXa in recombinant FIX preparations

Michael Dockal, E. Boehm, J. Pilz, Gerald Schrenk, K. Varadi, F. Scheiflinger (Austria)

Heparin-induced thrombocytopenia (HIT): Clinical - I

Moderator: Vinod Bansal (USA)

Evaluation of fondaparinux for the treatment of serotonin release assay positive heparin-induced thrombocytopenia

Snehal Bhatt, May Adra (USA)

Recombinant thrombomodulin as an alternate anticoagulant in the long-term management of patients with heparin-induced thrombocytopenia. Laboratory validation

Jawed Fareed, Jeanine Walenga, Schuharazad Abro, Debra Hoppensteadt, Daneyal Syed, Josephine Cunanan, Rakesh Wahi, Takefumi Matsuo (USA)

Variations in the prevalence of HIT antibodies during the period 2004-2012. Relevance to heparin contaminatns

Vinod Bansal, Debra Hoppensteadt, Walter Jeske, Jeanine Walenga, Ajay Singh, Jawed Fareed (USA)

Improving specificity for diagnosing heparin-induced thrombocytopenia through repeated testing

Usira Vithanarachchi, Lisa Saminaden, Colin Downey, Cheng-Hock Toh, Tina Dutt (United Kingdom)

Further studies on the pro-inflammatory and thrombotic mediators in patients with suspected heparin-induced thrombocytopenia

Jawed Fareed, Jovan Antovic, Jeanine Walenga, Margaret Prechel, Walter Jeske, Debra Hoppensteadt, Bruce Lewis (USA)

Suspicion heparin induced thrombocytopenia in internal medicine: How appropriate are the prescriptions of anti-PF4 antibodies tests?

Jean-Luc Reny, Yan Beauvier, Elena Tessitore, Françoise Bohlen, Eric Gerstel, Mathieu Nendaz, Arnaud Perrier, Jean-Luc Reny (Switzerland)

Update on GGX sequence variations causing combined deficiency of vitamin K-dependent coagulation factors (VKCFD) type 1 with a new case of compound heterozygosity

Aurélien Lebreton, Muriel Giansily-Blaizot, Fanny Chambon, Anne-Françoise Sapin, Patricia Aguilar-Martinez, Xavier Charmes, Alain Marquès-Verdier, Jean-François Schved, Séverine Cunat (France)

Arg69Pro is a novel mutation in Factor VII with defective binding to rabbit thromboplastin

Saravanan Vinayagam, Gillian Mellars, Jun Pie, Paul Thurlow, Anne Riddell, Keith Gomez (United Kingdom)

Influence of Coagulation factor XIII on the severity of the skin affection and endothelial dysfunction in patients with progressive systemic sclerosis

Sonja Alesci, Carolin Dockhorn, Matthias Wahle, Wolfgang Miesbach (Germany)

Intracranial hemorrhage (ICH) in Egyptian children with rare coagulation disorders: A single center experience

Maqy Abdelwahab, Hadeel Seif (Egypt)
Monday, July 1, 2013  
17:00 – 18:30

**PB 1.41-5**  
*Clinical and laboratory manifestation of bleeding diathesis in Noonan syndrome*  
Nicolas Waespe, Seraina Prader, Sabine Kroiss, Walter Knirsch, Manuela Albisetti, Oliver Speer, Markus Schmugge (Switzerland)

**PB 1.41-6**  
*Prospective data collection on patients with fibrinogen and Factor XIII deficiencies: Design of the PRO-RBDD project*  
Flora Peyvandi (Italy)

**Von Willebrand disease: Clinical - I**  
Screen 42  
*Moderator: Yvonne Sanders [The Netherlands]*

**PB 1.42-1**  
*Iatrogenic bleeding is the presenting symptom in children with moderate or severe von Willebrand disease - from the Win study*  
Yvonne Sanders, Karin Fijnvandraat, Evelien Mauser-Bunschoten, Anske van der Bom, Joke de Meris, Jeroen Eikenboom, Britta Laros-van Gorkom, Rienk Tamminga, Marjon Cnossen, Frank Leebeek (The Netherlands)

**PB 1.42-2**  
*Prenatal diagnosis in severe von Willebrand disease using intron 40 markers of VWF gene and phenotypic assays*  
Shrimati Shetty, Kanjaksha Ghosh, Priyanka Kasatkar (India)

**PB 1.42-3**  
*Vicenza bleeding score is correlated with postoperative bleeding and blood transfusion requirement in total knee replacement operation*  
Yingyong Chinthammitr, Sutat Srisawat, Theera Ruchutrakool, Bundarika Suwannawiboon, Keerati Chareancholvanich, Pacharapol Udomkiat, Suwit Soontarinka, Yupa Nakkinkun, Tasneem Binhama (Thailand)

**PB 1.42-4**  
*Screening for type 2 von Willebrand disease in the pediatric population*  
Rabia Shafi, Esther Soundar, Jun Teruya, Lakshmi Srivaths, Shiu-Ki Rocky Hui (USA)

**PB 1.42-5**  
*Von Willebrand factor genotyping for validation of type 2N von Willebrand disease*  
Thomas Mancini, Bas van Haren, Selene Schoormans, T. Hofste, Adinda Diekstra, Britta Laros-van Gorkom, Paul Brons, Lies Hoefsloot, Waander van Heerde (The Netherlands)

**PB 1.42-6**  
*Safety and efficacy of a von Willebrand factor/factor VIII concentrate (Wilate®): A single centre experience*  
Paul Batty, Yun-Han Chen, Sean Platten, Louise Bowles, Daniel Hart, John Pasi (United Kingdom)

**Von Willebrand disease: Clinical - II**  
Screen 43  
*Moderator: Niamh O’Connell [Ireland]*

**PB 1.43-1**  
*Von Willebrand disease patients with associated risk factor(s) of venous thromboembolism: Efficacy and safety of a von Willebrand factor product with a low factor VIII content*  
Jenny Goudemand, Annie Borel-Derlon, Augusto Federici, Catherine Chatelanan, Céline Henriet, Anne Cécile Jaffry, Françoise Bridey, the WILFACTIN (France)

**PB 1.43-2**  
*Validation of a new panel of automated chemiluminescence assays for von Willebrand factor antigen and activity in the screening for von Willebrand disease*  
Charlotte Verfaillie, Katrien Devreese (Belgium)

**PB 1.43-3**  
*Analysis of Factor VIII:c/VWF:Ag ratio in the Brno-von Willebrand Disease study*  
Inge Vangenechten, Petr Smejkal, Ondrej Zapletal, Fatima Bouddount, J. Zavrelova, Jan Blatny, Miroslav Penka, Jan Jacques Michielis, Alain Gadisseur (Belgium)
PB 1.43-4  Efficacy and safety of Wilate® following an en masse switch for patients with inherited von Willebrand disease
Niamh O’Connell, Evelyn Singleton, Mary Byrne, Kevin Ryan, Barry White, James O’Donnell (Ireland)

PB 1.43-5  Biologic response to desmopressin. Is this predictable in patients from the same family?
Lucia Rugeri, Sandrine Meunier, Marine Gierczynski, Angele Garcia, Anne Lienhart, Yesim Dargaud, Patrick Ffrench, Yoann Chevalier, Claude Negrier (France)

PB 1.43-6  Low-dose ristocetin induced platelet aggregation: Which dose is low enough?
Juan Pablo Frontroth, Mirta Hepner, Graciela Pieroni, Silvina Annetta, Gabriela Sciuccati, Aurora Feliu Torres, Mariana Bonduel (Argentina)

Von Willebrand factor - I
Moderator: Lindsey Hawke (Canada)

PB 1.44-1  Alterations in aberrant and alternative endothelial splicing of von Willebrand factor under high laminar shear stress
Lindsey Hawke, Man-Chiu Poon, Mary-Frances Scully, Paula James (Canada)

PB 1.44-2  Potential thiol isomerase activity of conserved CXXC motifs in D3, D4 and C1 domains of von Willebrand factor
Susan Shapiro, Michael Laffan, Thomas McKinnon (United Kingdom)

PB 1.44-3  An evaluation of the age-related quantitative and qualitative pathophysiology of von Willebrand factor
Silvia Albánez, Alison Michels, Kate Sponagle, Julie Grabell, Paula James, David Lillicrap (Canada)

PB 1.44-4  High-resolution, functional mapping by phage display of VWF residues required for platelet binding
Andrew Yee, Manhong Dai, Fan Meng, David Ginsburg (USA)

PB 1.44-5  Investigation of the effect of CLEC4M on plasma von Willebrand factor level in the general population
Ahmad Mufti, David Lillicrap, Ian Peake, Anne Goodeve, Daniel Hampshire (United Kingdom)

PB 1.44-6  Comparative pharmacokinetic analysis of 1200/500 IU VWF/FVIII and 900/800 IU VWF/FVIII concentrate in patient with type 3 von Willebrand disease
Agnes Nagy, Barbara Reger, Orsolya Toth, Hajna Losonczy (Hungary)

Anticoagulant agents - II
Moderator: Scott Kaatz (USA)

PB 1.45-1  Does anticoagulant treatment duration vary by the risk of venous thromboembolism recurrence in clinical practice?
Scott Kaatz, An-Chen Fu, Azza AbuDagga, Joyce LaMori, Brahim Bookhart, C. Damaraju, Hanqiang Tang, Jeff Schein, Edith Nutescu (USA)

PB 1.45-2  Differential stimulation of fibrinolysis by vitamin K-antagonists alone and associated with low-molecular-weight heparin
Mario Colucci, Rita Galasso, Francesca Incampo, Cosme Carriere, Renato Marino, Cosimo Ettorre, Nicola Semeraro (Italy)

PB 1.45-3  Evaluation and introduction of direct thrombin inhibitor assay to assess dabigatran anticoagulant effect in patients undergoing direct current cardioversion
Jane Needham, Helen Lewis, Janet Lock, Carl Brookes, Savita Rangarajan (United Kingdom)
ePOSTERS (B)  ePOSTER AREA

Monday, July 1, 2013  17:00 – 18:30

PB 1.45-4  Outcome of patients treated with plasma or prothrombin complex concentrates for warfarin related intracerebral hemorrhage
Ammar Majeed, Karina Meijer, Ramiro Larrazabal, Fabian Arnberg, Robin Roberts, Sam Schulman (Sweden)

PB 1.45-5  Therapeutic concentrations of dabigatran inhibit factor Xa
Cornelis Kluft, Kees van Leuven, Ria Laterveer, Jacobus Burggraaf (The Netherlands)

PB 1.45-6  Assessment of dabigatran activity using the activated clotting time assay with concomitant heparin in vitro: Comparison of two different point of care tests
Joanne van Ryn, Johanna Schurer, Andreas Clemens (Germany)

Anticoagulant agents - III
Screen 46

Moderator: Wilma Potze (The Netherlands)

PB 1.46-1  Oral and parenteral antithrombotic agents differentially inhibit tissue factor mediated generation of thrombin in prothrombin complex concentrates
Jawed Fareed, Daniel Kahn, Debra Hoppensteadt, Walter Jeske, Jeanine Walenga, Phillip DeChristopher (USA)

PB 1.46-2  Evaluation of edoxaban in Japanese patients with severe renal impairment undergoing lower-limb orthopedic surgery
Takeshi Fuji, Satoru Fujita, Yasuyuki Abe, Shintaro Tachibana, Yohko Kawai (Japan)

PB 1.46-3  Clinical profile of patients with low quality of oral anticoagulation in regular medical care
Meike Coldewey, Karsten Keller, Martin Hendelmeier, Jürgen Prochaska, Göbel Sebastian, Heidrun Lamparter, Alexander Ullmann, Ulrich Walter, Thomas Munzel, Philipp Wild (Germany)

PB 1.46-4  Low intensity and good-controlled anticoagulant therapy can prevent thromboembolism but cannot reduce bleeding in AF patients with both hemodialysis and mechanical valve replacement
Kagari Murasaki, Yukiko Shimatani, Yoshi Uetsuka, Hagiwara Nobuhisa (Japan)

PB 1.46-5  Increased anticoagulant response to drugs targeting thrombin, but not to drugs targeting FXa, in plasma from patients with cirrhosis
Wilma Potze, Freeha Arshad, Jelle Adelmeijer, Hans Blokzijl, Aad van den Berg, Robert Porte, Ton Lisman (The Netherlands)

PB 1.46-6  Risk factors for suboptimal efficacy of 3-factor prothrombin complex concentrates in emergency reversal of anticoagulation with vitamin K antagonists in patients with major bleeding
Francesco Dentali, Davide Imberti, Eleonora Tamborini Permunian, Ezio Croci, Walter Ageno (Italy)

Anticoagulant agents - IV
Screen 47

Moderator: Ingo Ahrens (Germany)

PB 1.47-1  Patients with atrial fibrillation undergoing PCI and subsequent triple therapy with aspirin, clopidogrel and VKA - Results from a single center retrospective study
Michael Kaiser, Christoph Hehrlein, Christoph Bode, Ingo Ahrens (Germany)

PB 1.47-2  Vitamin K Antagonists (VKA) for stroke prevention in Atrial Fibrillation (AF) in very elderly naive patients
Serena Granziera, Giulia Bertozzo, Lucia Marigo, Florinda Petruzzelessi, Katia Rossi, Tiziana Infante, Stefano Pietri, Giovanni Nante, Enzo Manzato, Vittorio Pengo (Italy)
PB 1.47-3 Determination of dabigatran and rivaroxaban in serum samples from patients on treatment
Shanshan Du, Sandra Krämer, Christel Weiss, Roland Krämer, Job Harenberg [Germany]

PB 1.47-4 Assessment of cross-reactivity in three different fecal occult blood test systems with dabigatran and dabigatran etexilate: Identification of useful test methods for gastrointestinal bleeding
Ashley Goss, Joanne van Ryn, Johanna Schurer, Andreas Clemens [USA]

PB 1.47-5 Low molecular weight heparin monitoring
Sophie Testa, Oriana Paoletti, Laura Bassi, Emilia Cancellieri, Anna Cogrossi, Ezio Damilini, Silvia Zambelli, Anke Zimmermann [Italy]

PB 1.47-6 Surgical safety threshold in patient under long term Rivaroxaban treatment: Is Quick PT suitable?
Laurine Dierge, Emmanuel Fosse, Alain Alewaeters, Charles Chevalier, Danielle Govaerts, Philippe Cauchie [Belgium]

Anticoagulant agents - V

PB 1.48-1 Association between CYP2C9, VKORC1 and CYP4F2 genetic variants in anticoagulation related outcomes during initiation period in acenocoumarol therapy
Juan Jose Cerezo-Manchado, Rocio Gonzalez-Conejero, Anton Ana Isabel, Martinez Constatino, Virginia Perez-Andreu, Garcia-Barbera Nuria, Padilla Jose, Vicente Vicente, Roldan Vanessa [Spain]

PB 1.48-2 The effect of dabigatran on the activated partial thromboplastin time and thrombin time as determined by the hemoclot thrombin inhibitor assay in patient plasma samples
Greg Hapgood, Jenny Butler, Erica Malan, Sanjeev Chunilal, Huyen Tran [Australia]

PB 1.48-3 Personalised clopidogrel therapy by teststrip-based CYP2C19 genotyping
Christian Oberkanins, H. Puehringer, B. Rauscher [Austria]

PB 1.48-4 A novel synthetic heparin antagonist neutralizes the anticoagulant actions of branded and generic enoxaparins in the whole blood clotting assay used during interventional cardiology
Omer Iqbal, Debra Hoppensteadt, Bruce Lewis, Hussein Khan, Jeanine Walenga, Richard Scott, Jawed Fareed [USA]

PB 1.48-5 Antidotal effects of non-specific reversal agents on anticoagulant-induced inhibition of thrombin generation
Daniele Pillitteri, Ann-Kathrin Pilgrim-Thorp, Manuela Krause, Thomas Scholz, Cärl Kirchmaier [Germany]

PB 1.48-6 D-dimer levels evolution during Heparin therapy of patients with cerebral venous thrombosis
Bernard Tardy, Emilie Chalayer, Michele Piot, Céline Chapelle, Pierre Garnier, Brigitte Tardy-Pontet [France]
**Anticoagulant agents - VI**

**Moderator:** Laura Franco (Italy)

**PB 1.49-1**  
Short-term prognosis of intracranial haemorrhage in patients on oral anticoagulant and antiplatelet drug: The VAIP study  
Alessandro Squizzato, Remo Melchio, Anna Sironi, Alessia Girando, Francesco Dentali, Luigi Fenoglio, Fulvio Pomerio (Italy)

**PB 1.49-2**  
Risk factors for death and thromboembolic complications in patients with major or clinically relevant non-major bleeding while on oral anticoagulant treatment  
Laura Franco, Cecilia Becattini, Luca Masotti, Rodolfo Sbrojavacca, Cinzia Nitti, Roberto Cappelli, Giancarlo Agnelli (Italy)

**PB 1.49-3**  
The synthetic pentasaccharide fondaparinux attenuates myocardial ischemia-reperfusion injury in rat via STAT-3  
Sophie Guillou, Walid Moussa, Sophie Tamairelle, Delphine Lamon, Delphine Prunier, Fabrice Prunier, Laurent Macchi (France)

**PB 1.49-4**  
A pharmacodynamic comparison of otamixaban and bivalirudin in primates  
Walter Jeske, Jeanine Walenga, Vicki Escalante, Elizabeth McGeehan, Hussein Khan, Jawed Fareed, Mamdouh Bakhos (USA)

**PB 1.49-5**  
Evaluation of the new DG-Chrom Anti-Xa kit from Grifols for detection and quantification of new oral anti-Xa anticoagulants  
Roser Ambros, Virginia Montanini, Georgina Civil (Spain)

**PB 1.49-6**  
Can high quality vitamin K-antagonist treatment be further improved?  
Jane Skov, Else-Marie Bladjbjerg, Jørgen Jespersen (Denmark)

**Blood coagulation system - I**

**Moderator:** Oleg Gorkun (USA)

**PB 1.50-1**  
Association of D-dimer levels with all-cause mortality in a healthy adult population: Findings from the MOLI-SANI study  
Licia Iacoviello, Augusto Di Castelnuovo, Amalia De Curtis, Simona Costanzo, Maria Rosaria Persichillo, Marco Olivieri, Francesco Zito, Maria Benedetta Donati, Giovanni De Gaetano (Italy)

**PB 1.50-2**  
Phosphatidylserine exposure on platelets’ surface upon binding to rigid fibrin scaffold  
Tomasz Brzoska, Yuko Suzuki, Hideo Mogami, Hideto Sano, Tetsumei Urano (Japan)

**PB 1.50-3**  
The effect of Tissue Factor Pathway Inhibitor (TFPI) on thrombin generation and post-operative bleeding in patients undergoing surgery requiring cardiopulmonary bypass  
Charles Percy, Rudolf Hartmann, Erwin Panholzer, Andrea Kolm, Dheeraj Mehta, Subramaniam Balachandran, Judith Hall, Michael Dockal, Friedrich Scheiflinger, Peter Collins (United Kingdom)

**PB 1.50-4**  
Safety and effectiveness of anti inhibitor coagulation complex (AICC) in routine clinical management: A post-authorization safety study (PASS)  
Aaron Novack, Vadim Romanov, Manfred Pirck, Robert Numerof (USA)

**PB 1.50-5**  
Thrombin generation profile of dehydrated solvent/detergent treated plasma and FFP  
Oleg Gorkun, Arthur Bode, Joseph DaCorta (USA)

**PB 1.50-6**  
Comparison of recombinant coagulation factor VII (ARYOSEVEN®) with NOVOSEVEN® in patients with FVIII & IX deficiency with an inhibitor  
Mohammad Faranoush, Abolghassemi Hassan, Mehran Karimi, Gholamreza Toogeh, Peyman Eshghi, Mohammad Managchi, Hoorfar Hamid, Kamran Kamyar, Ramin Heshmat, Mohammad Reza Baghaiepour (Iran)
PB 1.51-1  Control of vitamin-K antagonist treatment by measuring thrombin generation in whole blood - effect of thrombomodulin  
Saartje Bloemen, Marieke de Laat, Arina Cate-Hoek, Hugo ten Cate, Bas de Laat, Coenraad Hemker, Raed Al Dieri [The Netherlands]

PB 1.51-2  False-positive results for a lupus anticoagulants occur in patients on low molecular weight heparin but not fondaparinux, by dilute activated partial thromboplastin time  
Sean Platton, Bilkis Nahar, Christopher Dale, Peter MacCallum [United Kingdom]

PB 1.51-3  Monitoring of parenteral anticoagulant drugs with the prothrombinase induced clotting time (PICT)  
Debra Hoppensteadt, Jeanine Walenga, Josephine Cunanan, Omer Iqbal, Jawed Fareed [USA]

PB 1.51-4  Evaluation of in-house normal pool plasma for activated partial thromboplastin time mixing test as a part of diagnosing protocol for lupus anticoagulant detection  
Sandra Margetic, Tihana Butorac, Nada Vrkic, Renata Novosel [Croatia]

PB 1.51-5  Prothrombin time with Recombiplastin 2G correlates strongly with plasma rivaroxaban levels  
R. Tait, Michael McGurk, Grainne Hickman, Jim Conkie, Caroline Lawrence, Catherine Bagot [United Kingdom]

PB 1.51-6  A global hemostasis assays in laboratory monitoring of low molecular weight heparin treatment in patients after surgery  
Alexandr Poletaev, Anna Balandina, Stanislav Rabotinskiy, Elena Orel, Fazly Ataullakhanov, Elena Shulutko [Russian Federation]

PB 1.52-1  Comparison of Calibrated Automated Thrombogram and chronometric or chromogenic assays for the monitoring of NOACs in patients with non-valvular atrial fibrillation  
Jonathan Douxfils, Jean-François Classen, Justine Baudar, Sébastien Walbrecq, Christian Chatelain, Bernard Chatelain, Jean-Michel Dogné, François Mullier [Belgium]

PB 1.52-2  Minimizing the impact of preanalytical variables on intrinsic coagulation during blood collection improves sample quality for thromboelastography and the calibrated automated thrombogram  
Frank Sinquett, Keith Moskowitz [USA]

PB 1.52-3  Spatial fibrin clot growth dynamics: interlaboratory evaluation of the assay reproducibility and standardization  
Natalia Korotina, Tatiana Vuimo, Anna Balandina, Irina Shcherbina, Luuya Sokolova, Natalia Potapova, Olga Khrapkova, Mikhail Panteleev, Fazoil Ataullakhanov [Russian Federation]

PB 1.52-4  Assessment of rotational thromboelastometry in cardiac surgery: Correct prediction of clinically relevant thrombocytopenia and hypofibrinogenaemia after 5 minutes  
Rik Olde Engberink, Gerhard Kuiper, Rick Wetzels, Patty Nelemans, Marcus Lancé, Erik Beckers, Yvonne Henskens [The Netherlands]

PB 1.52-5  Calibrated Automated Thrombography in identification of patients with high bleeding risk on vitamin K antagonists treatment  
Veronika Shmeleva, Yryi Namestnikov, Olesya Matvienko, Natalia Saltikova, Vitaly Soldatenkov, Ludmila Papayan [Russian Federation]
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>PB 1.52-6</td>
<td>The value of epistaxis as a predictor of a bleeding disorder: A prospective study in an Egyptian cohort of children</td>
<td>Magy Abdelwahab, Rania Ismail, Ahmed Fathy, Ahmed Nancy (Egypt)</td>
</tr>
<tr>
<td>PB 1.53-1</td>
<td>A New Clotting Biomarker for Predicting Sepsis Severity</td>
<td>Gareth Davies, Gavin Mills, Sophie Stanford, Matthew Lawrence, Nia Davies, Robert Aubrey, Rhodri Williams, Dafydd Thomas, Phillip Evans (United Kingdom)</td>
</tr>
<tr>
<td>PB 1.53-2</td>
<td>The impact of reference ranges in platelet aggregation study</td>
<td>Marinez Matos, André Dói, Eliana Taniguchi, Claudia Finazzo, Alberto Duarte (Brazil)</td>
</tr>
<tr>
<td>PB 1.53-4</td>
<td>Results of performance assessment of CoaguChek XS INR monitors by external quality control</td>
<td>Piet Meijer, Cornelis Kluft (The Netherlands)</td>
</tr>
<tr>
<td>PB 1.53-5</td>
<td>Comparison of Biophen DiXa®, Prothrombin time with a reference HPLC-MS/MS method to monitor patients receiving Rivaroxaban</td>
<td>Jonathan Douxfils, Anne Tamigniau, Jean-François Classen, Justine Baudar, Sébastien Walbrecq, Christian Chatelain, Bernard Chatelain, François Mullier, Pierre Wallemacq, Jean-Michel Dogné (Belgium)</td>
</tr>
<tr>
<td>PB 1.53-6</td>
<td>Relationship between thromboelastometry measurements, hemostasis factors and two global hemostasis tests: Thrombin Generation and Thromboplastin-Thrombomodulin-mediated Time</td>
<td>Dolors Llobet, Montserrat Borrell, Montserrat Font, Agnès Morera, Cristina Vallvé, Marina Carrasco, José Mateo, Juan Carlos Souto, Jordi Fontcuberta (Spain)</td>
</tr>
<tr>
<td>PB 1.54-1</td>
<td>Normalized ratio for silica clotting time and dilute Russell venom time is an excellent tool for diagnosis of lupus anticoagulant</td>
<td>Michael Nardi (USA)</td>
</tr>
<tr>
<td>PB 1.54-2</td>
<td>Dynamic APTT characteristics in a case-control study of venous thrombosis</td>
<td>Andrey Ziyatdinov, Agnès Morera, Montserrat Borrell, Vanessa Orantes, Dolors Llobet, José Mateo, Jordi Fontcuberta, Juan Carlos Souto (Spain)</td>
</tr>
<tr>
<td>PB 1.54-3</td>
<td>Comparison between different point of care systems for PT INR testing</td>
<td>Laura Bassi, Oriana Paolotti, Emilia Cancellieri, Ezio Damiolini, Anna Cogrossi, Claudia Dellanoce, Anke Zimmermann, Sophie Testa (Italy)</td>
</tr>
<tr>
<td>PB 1.54-4</td>
<td>Local verification and assignment of ISI values: Recent Mayo Clinic experience and outcome</td>
<td>Julie Tange, Diane Grill, Christopher Koch, Roxanne Ybabez, Benjamin Kreckelberg, Cynthia Wiese, Darci Block, Bradley Karon, Dong Chen, Rajiv Pruthi (USA)</td>
</tr>
<tr>
<td>PB 1.54-5</td>
<td>Thrombin generation and post-operative bleeding in patients undergoing surgery requiring cardiopulmonary bypass</td>
<td>Charles Percy, Rhidian Jones, Dheeraj Mehta, Subramaniam Balachandran, Judith Hall, Valerie O’Donnell, Peter Collins (United Kingdom)</td>
</tr>
<tr>
<td>PB 1.54-6</td>
<td>The overall haemostasis potential: A novel global coagulation assay for use in canine plasma</td>
<td>Anna Dengate, Marie-Christine Morel-Kopp (Australia)</td>
</tr>
</tbody>
</table>
### Coagulation factor VIII - II
**Screen 55**

**Moderator:** Wendela Kappers (Denmark)

| **PB 1.55-1** | **Amino acid sequence epitope mapping of four factor VIII monoclonal antibodies**  
| --- | ---  
|  | Paul Batty, Stuart Skelton, Adrian Shepherd, Daniel Hart (United Kingdom) |

| **PB 1.55-2** | **Excretion and pharmacokinetics of glycopegylated rFVIII (N9-GP) after single intravenous dose administration to rats**  
| --- | ---  
|  | Inga Bjoernsdottir, Wendela Kappers, Ola Sternebring, Hanne Kornoe, Jesper Kristensen, Peter Thygesen, Ruth Stow, Phil Fernyhough, Morten Bagger (Denmark) |

| **PB 1.55-3** | **Accessibility to thrombin cleavage does not limit the circulating half-life of longer-acting factor VIII molecules**  
| --- | ---  
|  | Liang Tang, Peter Kretschmer, Warren Manzana, Wei Xia, Katherine Tran, Derek Sim, Cornell Mallari, David Shiroma, Elena Ho, John Murphy (USA) |

| **PB 1.55-4** | **Evaluation of recombinant canine FVIII production from three cell types transduced with either a B domain deleted or codon optimized and truncated B domain cFVIII transgene**  
| --- | ---  
|  | Bredon Crawford, Margareth Ozelo, Lorianne Harpell, Carol Hegadorn, Sandra Powell, Christine Hough, David Lillicrap (Canada) |

| **PB 1.55-5** | **Instability of the His118Arg mutation in both factor VIII and activated factor VIII causing discrepancy in FVIII assays**  
| --- | ---  
|  | Qiulan Ding, You Guoling, Wang Min, Wang Xuefeng (China) |

| **PB 1.55-6** | **Functional characterization of rVIII-SingleChain and comparison with commercially available recombinant FVIII products**  
| --- | ---  
|  | Carsten Horn, Burkhard Watzka, Hubert Metzner, Gerhard Dickneite, Stefan Schulte (Germany) |

### Tissue factor - I
**Screen 56**

**Moderator:** Beth Bouchard (USA)

| **PB 1.56-1** | **Platelets do not express the oxidized or reduced forms of tissue factor**  
| --- | ---  
|  | Beth Bouchard, Matthew Gissel, Matthew Whelihan, Kenneth Mann, Saulius Butenas (USA) |

| **PB 1.56-2** | **Inflammation and tissue factor expression by acute promyelocytic leukemia cells**  
| --- | ---  
|  | Egbert Kruthof, Sylvie Dunoyer-Geindre (Switzerland) |

| **PB 1.56-3** | **Disulfide reduction abolishes tissue factor cofactor function**  
| --- | ---  
|  | Saulius Butenas, Jolanta Krudysz-Amblo, Mark Jennings, Tyler Knight, Dwight Matthews, Kenneth Mann (USA) |

| **PB 1.56-4** | **Perioperative plasma tissue factor levels in patients with advanced coronary heart disease and heart failure subjected to off-pump coronary bypass grafting**  
| --- | ---  
|  | Mikhail Sovershaev, Timofey Sovershaev, Elena Egorina, Svetlana Sovershaeva, Valentina Gubkina, John-Bjarne Hansen (Norway) |

| **PB 1.56-5** | **Eicosapentaenoic acid and docosahexaenoic acid suppress the release of tissue factor as cell-derived microparticles, from cancer cell lines**  
| --- | ---  
|  | Yupei Xiao, Mary Collier, Maggy Harley, Camille Ettelaie, Jorg Hardege, Anthony Maraveyas (United Kingdom) |

| **PB 1.56-6** | **Plasma tissue levels and risk factors for cardiovascular disease in the cancer (EPIC)-Italy cohort**  
| --- | ---  
|  | Licia Iacoviello, Claudia Agnoli, Simonetta Guarrera, Vittorio Krogh, Amalia Mattiello, Giuseppe Matullo, Salvatore Panico, Carlotta Sacerdote, Rosario Turino, Paolo Vineis, Roberto Lorenzet, Maria Benedetta Donati (Italy) |
**Monday, July 1, 2013**

**ePOSTERS (B)**

**Monday, July 1, 2013**

**17:00 – 18:30**

**Fibrinogen/Fibrin - II**

**Screen 57**

**Moderator: Karl Hawkins [United Kingdom]**

**PB 1.57-1** Dysfibrinogenemia associated with obstetric complications in four unrelated female patients  
Jingyi Zhou, Linlin Jiang, Qiulan Ding, Xiaodong Xi, Xuefeng Wang, Hongli Wang [China]

**PB 1.57-2** Optimisation of fibrin clot microstructure: Mechanical and microstructural properties of fibrin clots, from incipiency to the acquisition of haemostatic functionality  
Karl Hawkins, Irena Chernysh, Daniel Curtis, Nafiseh Badiei, Rowan Brown, Adrian Evans, Matthew Lawrence, John Weisel, Rhodri Williams [United Kingdom]

**PB 1.57-3** Investigation of exogenous fibrinogen substitution on fibrinogen synthesis in a chronic pig model of blunt liver injury  
Christian Zentai, Paola van der Meijden, Rolf Rossaint, Hugo ten Cate, Henri Spronk, Oliver Grottke [Germany]

**PB 1.57-4** Effects of homocysteine-thiolactone on fibrin networks  
Valeria Genoud, Ana Lauricella, Lucia Kordich, Irene Quintana [Argentina]

**PB 1.57-5** The clinically asymptomatic dysfibrinogenemia (FGG H103N) is associated with abnormal polymerization but no thrombin generation impairment  
Michel Hanss, Jean Devignes, Philippe De Mazancourt, Patrick Ffrench [France]

**PB 1.57-6** A new automated D-Dimer assay optimized for minimizing interferences to heterophilic antibodies  
Frédéric Esteve [France]

**Other coagulation factors - I**

**Screen 58**

**Moderator: Siyuan Tan [USA]**

**PB 1.58-1** A platelet-targeted factor VIIa. XTEN fusion protein with increased circulating half-life and improved clotting activity  
Siyuan Tan, Joe Salas, Kai Chen, Elena Kistanova, Tamera Ashworth, Marisol Acosta, Brad Johnson, Bob Pape, Glenn Pierce, David Light, Baisong Mei, Volker Schellenberger, Robert Peters, Haiyan Jiang [USA]

**PB 1.58-2** Hepatocyte growth factor down-regulates protein C inhibitor expression in hepatocytes via MEK pathway  
Nobuyuki Akita, Takayuki Okamoto, Junji Nishioka, Koji Suzuki, Tatsuya Hayashi [Japan]

**PB 1.58-3** Quantitative whole body autoradiography (QWBA) study on the biodistribution of a recombinant factor VIIa linked to human albumin  
Eva Herzog, Stephen Harris, Andrew McEwen, Ingo Pragst, Gerhard Dickneite, Stefan Schulte, Sabine Zollner [Germany]

**PB 1.58-4** Utilization of FXIII concentrates by FXIII deficiency patients in Canadian hemophilia Treatments centers: 10 years national data from the Canadian Hemophilia Assessment and Resource Management System  
Aicha Traore, Anthony Chan, Margaret Warner, Nancy Heddle, Bruce Ritchie, Jean St-Louis, Irwin Walker, John Wu [Canada]

**PB 1.58-5** Ex vivo factor XIII supplementation dose-dependently improves clot stability in blood samples from cardiac and scoliosis surgery patients  
Malin Carling, Caroline Shams Hakimi, Helena Brisby, Vladimir Radulovic, Anders Jeppsson [Sweden]

**PB 1.58-6** Compositional differences in commercially available prothrombin complex concentrates  
Jawed Fareed, Nasir Sadeghi, Daniel Kahn, Josephine Cunanan, Debra Hoppensteadt, Walter Jeske, Job Harenberg, Phillip DeChristopher [USA]
**Coagulation: Miscellaneous - I**

**Screen 59**

**Moderator: Borros Arneth (Germany)**

**PB 1.59-1**  
**Absence of variation in tissue factor and procoagulant phospholipid activity after plasmapheresis in lung transplantation patients**  
Marc Vasse, Marie-Charlotte Bourrienne, Dominique François, François Parquin, Patrick van Dreden, Marc Fischler, Barry Woodhams, Marc Vasse (France)

**PB 1.59-2**  
**Activation of FXII-dependent coagulation pathway by hand heating**  
Jane Skov, Anne Sofie Gram, Thorkil Ploug, Johannes Sidelmann, Bente Merete Stallknecht, Else-Marie Bladbjerg (Denmark)

**PB 1.59-3**  
**Severe Factor XII deficiency presenting as over-heparinisation prior to urgent cardiac surgery for a right atrial myxoma**  
Joyce Low, Patricia Rebeiro, Susan Jarvis, Joanne Joseph (Australia)

**PB 1.59-4**  
**Spectrum of the factor XI mutations in Chinese population and TEG apply to patients with factor XI deficiency**  
Yanan Cao, Leiming Dong (China)

**PB 1.59-5**  
**Understanding platelet-virus interaction**  
Soledad Negrotto, Carolina Jaquenod De Giusti, Lucrecia Alberdi, Carlos Fondevila, Mirta Schattner, Ricardo Gomez (Argentina)

**PB 1.59-6**  
**Regulation of Blood Coagulation by Poly-Phosphate**  
Borros Arneth, Triantafyllos Chavakis, Gabriele Siegert (Germany)

**Cancer and thrombosis - II**

**Screen 60**

**Moderator: Meghedi Aghourian Namagerdy (Canada)**

**PB 1.60-1**  
**Role of Gas6 in cancer-induced venous thrombosis**  
Meghedi Aghourian Namagerdy, Catherine Lemarie, Mark Blostein (Canada)

**PB 1.60-2**  
**Acceleration of lung metastasis of melanoma cells in mice fed a high-fat diet: Changes in circadian expressions of thrombotic factors and cell-adhesion molecules through day-night reversal feeding**  
Shuichi Horie, Sayuri Nakamura, Katsutaka Oishi, Sayuri Hiraishi (Japan)

**PB 1.60-3**  
**Microvesicles bearing Tissue-Factor: A new potential biomarker for thrombosis in acute promyelocytic leukemia**  
Damien Gheldof, François Mullier, Béragère Devalet, Nicolas Bailly, Bernard Chatelain, Jean-Michel Dogné, Christian Chatelain (Belgium)

**PB 1.60-4**  
**Pro-metastatic human breast cancer cell line, MDA-MB-231 (MDA) and platelet interactions in an ‘in vitro’ aggregation assay**  
María Alberto, Emilse Bermejo, Julio Calderazzo, Susana Meschengieser, María Lazzari, Anália Sánchez-Luceros (Argentina)

**PB 1.60-5**  
**Activation of coagulation by lenalidomide-based regimens for multiple myeloma**  
Reina Arai, Yu Isozumi, Kazumi Fujimoto, Takatoshi Koyama (Japan)

**PB 1.60-6**  
**Development of the overall haemostatic potential assay for murine plasma and identification of elevated fibrin and thrombin generation in tumour bearing mice**  
Caroline Reddel, John Allen, Leonard Kritharides, Jennifer Curnow, Graham Robertson (Australia)
Cancer and thrombosis - III

Moderator: Erica Peterson (Canada)

PB 1.61-1 Pathogenesis of hemostatic abnormalities due to L-asparaginase in children with acute leukemia
Atsuki Yamashita, Chiai Nagae, Tomoko Ashikaga, Shinji Muto, Mieko Akita, Satoshi Yamazaki, Shigenobu Takayama, Shinobu Tatsunami, Masashi Taki (Japan)

PB 1.61-2 Simple laboratory variables are prognostic factors in hospitalized cancer patients with acute pulmonary embolism
Nicoletta Riva, Alessandro Squizzato, Sara Turato, Stefano Grazioti, Francesco Dentali, Walter Ageno (Italy)

PB 1.61-3 Bleeding rates and thrombotic complications in patients with hematological malignancies admitted to hospital
Erica Peterson, Hayley Merkeley, Chen Leena, Sarah Hocevar, Janice Yeung, Agnes Lee (Canada)

PB 1.61-4 Management and outcomes of venous thromboembolic events in patients with concomitant cancer-associated thrombocytopenia: a retrospective cohort study
Ilana Kopolovic, Cynthia Wu (Canada)

PB 1.61-5 Patients with advanced stage germ cell tumors have a high risk of thromboembolic events
Lina Gordy, Mary Brames, Lawrence Einhorn, Naveen Manchanda (USA)

PB 1.61-6 Venous thromboembolism-related mortality in cancer patients
Jose Garcia-Garcia, Patricia Parra- Esquivel, Rafael Lopez-Alonso (Spain)

Antiphospholipid - II

Moderator: Karen Breen (United Kingdom)

PB 1.62-1 Autoantibodies against component of complement 1 contribute to the complement activation and to the manifestations of refractory antiphospholipid syndrome (APS)
Kenji Oku, Olga Amengual, Watanabe Toshiyuki, Kanetsuka Yuusaku, Fujieda Yuuichiro, Bohgaki Toshiyuki, Horita Tetsuya, Yasuda Shinsuke, Atsumi Tatsuya (Japan)

PB 1.62-2 Exploring the diagnostic opportunities of the measurement of circulating procoagulant phospholipids by a coagulation based assay in lupus anticoagulant positive samples
Line Coucke, Katrien Devreese (Belgium)

PB 1.62-3 Beta2-glycoprotein I plasma levels are in relation to antiphospholipid antintibody profile in Antiphospholipid Syndrome
Alessandra Banzato, Jessica Traverso, Francesco Buzzanca, Elisa Bison, Alessia Bracco, Gentian Denas, Seena Padayattil, Vittorio Pengo (Italy)

PB 1.62-4 The influence of anti-Tissue Factor Pathway Inhibitor (TFPI) antibodies on Thrombin Generation (TG) in thrombotic patients with and without antiphospholipid syndrome
Maria Efthymiou, Ian Mackie, Andrew Lawrie, Sam Machin, Hannah Cohen (United Kingdom)

PB 1.62-5 Lack of association of serum mannose binding lectin or ficolins with complement activation in patients with antiphospholipid antibodies
Karen Breen, David Kilpatrick, A. Swierzko, M. Cedzynski, Beverley Hunt (United Kingdom)

PB 1.62-6 Resistance to anticoagulant activity of annexin A5 in patients with antiphospholipid syndrome with and without systemic lupus erythematosus receiving hydroxychloroquine
Karen Breen, X Wu, Jacob Rand, Beverley Hunt (United Kingdom)
### Arterial vascular disorders - I

**Screen 63**

**Moderator:** Bob Siegerink (The Netherlands)

<table>
<thead>
<tr>
<th>PB 1.63-1</th>
<th>Effects of exercise stress testing on blood coagulation and fibrinolysis in asymptomatic aortic stenosis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Anetta Undas, Renata Trela, Korneliusz Fil (Poland)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PB 1.63-2</th>
<th>Fibrin clot formation and fibrinolysis in patients with coronary stent thrombosis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Thea Godska1, Joke Konings, José Govers, Jurriën ten Berg, Christian Hackeng,</td>
</tr>
<tr>
<td></td>
<td>Hugo ten Cate (The Netherlands)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PB 1.63-3</th>
<th>Risk of myocardial infarction and ischaemic stroke and the impact of hypercoagulability - the RATIO case control study</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Bob Siegerink, Alberto Maino, Frits Rosendaal, Ale Algra (The Netherlands)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PB 1.63-4</th>
<th>A pig model of primary angioplasty of acute myocardial infarction in human like conditions</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Ludovic Drouet, Georgios Sideris, Nikos Magkoutis, Michel Bonneau, Chantal Kang,</td>
</tr>
<tr>
<td></td>
<td>Claire Bal dit Sollier, Patrick Henry (France)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PB 1.63-5</th>
<th>Increased arterial thrombo-embolic events and major bleeding in patients with atrial fibrillation and chronic kidney disease on vitamin K-antagonist treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Judith Kooman, Bas Spaans, Wilke van de Peppel, Koen van Beers, Suzanne Cannegieter, Felix van der Meer, Ton Rabelink, Menno Huisman (The Netherlands)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PB 1.63-6</th>
<th>Thromboembolic complications or intracerebral haemorrhages in patients with atrial fibrillation in the emergency departments. Complications of atrial fibrillation in Bologna: The CAF-BO Study</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Benilde Cosmi, Luisa Salomone, Mario Cavazza, Giordano Guizzardi, Nicola Binetti, Gaetano Procaccianti, Giovanni Maria Puddu, Gualtiero Palareti (Italy)</td>
</tr>
</tbody>
</table>

### Diagnosis of venous thrombosis - I

**Screen 64**

**Moderator:** Jane Strong (United Kingdom)

<table>
<thead>
<tr>
<th>PB 1.64-1</th>
<th>Clinical validity of a quantitative point of care d-dimer assay in an acute ambulatory DVT service</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Jane Strong, Nayna Patel, H. Briggs, R. Clarke-Drury, K. Coults, J. Dent, J. Eggleston, V. Frimpong, D. Thornton (United Kingdom)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PB 1.64-2</th>
<th>A review of computed tomography pulmonary angiograms in three teaching hospitals: The rise of sub-segmental pulmonary emboli and their management</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Jennifer Goy, Justin Lee, Oren Levine, Salman Chaudhry, Mark Crowther (Canada)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PB 1.64-3</th>
<th>Diagnostic accuracy of lung ultrasound for pulmonary embolism: A systematic review and meta-analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Alessandro Squizzato, Elena Rancan, Francesco Dentali, Matteo Bonzini, Luigina Guasti, Luigi Steidl, Gebhard Mathis, Walter Ageno (Italy)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PB 1.64-4</th>
<th>Diagnosis, management and outcome of non-catheter related proximal upper extremity deep vein thrombosis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Noel Chan, Sanjeev Chunilal, Huyen Tran, Eileen Merriman (Australia)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PB 1.64-5</th>
<th>Development and accreditation of a standardized training program in thrombosis and vascular medicine - a Canadian initiative</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Carol Gonsalves, Shannon Bates, Philip Wells, Susan Kahn, Marc Carrier, James Douketis, Marc Rodger (Canada)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PB 1.64-6</th>
<th>An improved screening system for protein S type II deficiency: Expanded versatility of total protein S activity assay</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Tsuda Tomohide, Jin Xiuri, Tsuda Hiroko, Hamasaki Naotaka (Japan)</td>
</tr>
</tbody>
</table>
Monday, July 1, 2013 17:00 – 18:30

**Diagnosis of venous thrombosis - II**

**Screen 65**

**Moderator: Mazdak Tavoly (Sweden)**

**PB 1.65-1**  
Health-related quality of life after pulmonary embolism - a case-control study  
Mazdak Tavoly, Hilde Skuterud Wik, Firas Nori, Waleed Ghanima (Sweden)

**PB 1.65-2**  
Treatment patterns of venous thromboembolism in a real world population: The Q-VTE study cohort  
Vicky Tagalakis, Valérie Patenaude, Susan Kahn, Samy Suissa (Canada)

**PB 1.65-3**  
Single whole-leg compression ultrasound for exclusion of deep vein thrombosis in symptomatic ambulatory patients: A prospective observational cohort study  
Daniel Horner, Kerstin Hogg, Richard Body, Michael Nash, Kevin Mackway-Jones (United Kingdom)

**PB 1.65-4**  
Retrospective audit of incidental VTE events over three years in a large teaching hospital  
Huw Rowswell, Tim Nokes (United Kingdom)

**PB 1.65-5**  
Provision of an external quality assessment programme for D-dimer point of care testing kits  
Dianne Kitchen, Shelene Munroe-Peart, Steve Kitchen, Ian Jennings, Tim Woods, Isobel Walker (United Kingdom)

**PB 1.65-6**  
Modified strain gauge plethysmography as an additional screening test for patients with suspected deep vein thrombosis  
Andrew Hughes, Ben Hall, Beverley Piper, Katie Jennings, Christine Smith, Florence Charova, Francina Dzora (United Kingdom)

**Hormones, pregnancy, women’s issues - I**

**Screen 66**

**Moderator: Christelle Orlando (Belgium)**

**PB 1.66-1**  
The Pregnancy Health-care Program: A model for the prevention of venous thromboembolism in pregnancy  
Sophie Testa, Serena Passamonti, Oriana Paoletti, Anke Zimmermann, Paolo Bucciarelli, Enrica Ronca, Aldo Riccardi, Ida Martinelli (Italy)

**PB 1.66-2**  
Influence of maternal thrombophilia status on the outcome of assisted reproduction  
Christelle Orlando, Kristin Jochmans (Belgium)

**PB 1.66-3**  
Pelvic vein thrombosis after cesarian-section delivery  
Gustavo Magalhães, Daniel Ribeiro, Suely Rezende, Maíra Reis, Guilherme Costa (Brazil)

**PB 1.66-4**  
The coagulation profile of preterm delivery  
Anat Keren Politansky, Tatiana Breizman, Benjamin Brenner, Galit Sarig, Arieh Drugan (Israel)

**PB 1.66-6**  
The effect of thrombotic markers on severity of bleeding symptoms in women with inherited bleeding disorders  
Joanna Davies, Claudia Chi, Lava Shareif, Edward Tuddenham, Rezan Abdul-Kadir (United Kingdom)
**Inflammation: Basic - I**  
**Screen 67**

**Moderator: Sacha de Stoppelaar (The Netherlands)**

**PB 1.67-1** PI3Kinase is a key regulator of CD40L surface expression and release from activated platelets  
Charlotte Grosdidier, Adrien Chabert, Denis Bernot, Pierre-Emmanuel Morange, Marie-Christine Alessi, Matthias Canault (France)

**PB 1.67-2** T cells, inflammation and tissue factor in gastric malignancy  
Mario D’Elios, Marisa Benagiano, Amedeo Amedei, Chiara Della Bella, Elena Niccolai, Alessia Grassi, Elena Silvestri, Giacomo Emrri, Domenico Prisco (Italy)

**PB 1.67-3** Protease activated receptor 4 contributes to host defense in streptococcus pneumoniae induced pneumonia  
Sacha de Stoppelaar, Cornelis van’t Veer, Florry van den Boogaard, Rienk Nieuwland, Arie Hoogendijk, Onno de Boer, Joris Roelofs, Tom van der Poll (The Netherlands)

**PB 1.67-4** Increased systemic interleukin-1β accelerates the onset of stroke in stroke-prone spontaneously hypertensive rats  
Toru Nakazawa, Chiba Tsuyoshi, Tatsuki Itoh, Masaki Tabuchi, Takao Satou (Japan)

**PB 1.67-5** Diverse roles of alphaMbeta2 integrin in lipopolysaccharide-mediated inflammation  
Yuan-Bin Yu, Kuo-Hui Su, Jyh-Pyng Gau, Hui-Chi Hsu, Cheng-Hwai Tzeng, Tzong-Shyuan Lee (Taiwan)

**PB 1.67-6** Plasmin induces in vivo monocyte recruitment through protease-activated receptor-1, MEK/ERK and CCR2 mediated signaling  
Aline Carmo, Bruno Costa, Juliana Vago, Leonardo Oliviera, Luciana Tavares, Camila Nogueira, Bruno Brasil, Luci Dusse, Luciola Barcelos, Cláudio Bonjardim, Mauro Teixeira, Lirlândia Sousa (Brazil)

**Inherited risk factors venous thrombosis: Basic - I**  
**Screen 68**

**Moderator: Ruth Wheeler (United Kingdom)**

**PB 1.68-1** Identification of rare variants in ADAMTS13 through next generation sequencing implicated in pediatric stroke  
Monika Stoll, Andrei Barysenka, Anika Witten, Astrid Arning, Daniela Manner, Ulrike Nowak-Göttl (Germany)

**PB 1.68-2** Identification of mutations in the protein C gene in a panel of 83 Spanish families with protein C deficiency  
Laura Martos, Pilar Medina, Maria Fernanda López-Fernández, Dolors Tássies, Vanesa Roldán, José Ramón González-Porras, Tomás González-López, Sonia Herrero, Francisco España, Silvia Navarro (Spain)

**PB 1.68-3** What is the origin of Factor V Leiden mutation in East Mediterranean Arabs and has it occurred there first?  
Mehrez Jadaan, Ali Dashti, Hend Lewis (Kuwait)

**PB 1.68-4** Molecular Characterization of PCE29K Missense mutation  
Xu Ye (China)

**PB 1.68-5** Venous thrombosis in adolescent girls on oral contraceptives - association with estrogen gene polymorphisms  
Ayesha Zia, Michael Callaghan, Jeanne Lusher, Meera Chitlur, M. Rajpurkar (USA)

**PB 1.68-6** A common PROS1 variant and its association with reduced free Protein S levels in patients of African ancestry; A risk factor for thrombosis?  
Ruth Wheeler, Jacky Cutler, Mike Mitchell (United Kingdom)
Non-inherited risk factors venous thrombosis - I  
Screen 69

**Moderator:** Kirsten van Langevelde (The Netherlands)

**PB 1.69-1**  
*Obesity measures and future risk of venous thromboembolism and myocardial infarction*  
Sigrid Braekkan, Kristin Enga, Cecilie Nyegaard, Inger Njolstad, John-Bjarne Hansen (Norway)

**PB 1.69-2**  
*Postoperative complication is the main risk factor for venous thromboembolism after bariatric surgery*  

**PB 1.69-3**  
*In-hospital prevention of venous thromboembolism: how should we do it? Comparison of a surveillance project with the use of a validated risk score for thrombotic risk assessment*  
Elena Faioni, Anita Andreano, Federico Lussana, Pasqualina Iannuzzi, Elena Bertinato, Monica Ferraroni, Adriano Decarli, Marco Cattaneo (Italy)

**PB 1.69-4**  
*Impact of chronic obstructive pulmonary disease on future risk of venous thromboembolism in a general population: The Tromsø study*  
Trond Borvik, Kristin Enga, Sigrid Brækkan, Hasse Melbye, John-Bjarne Hansen (Norway)

**PB 1.69-5**  
*The number of venous valves in the legs does not explain the association between body height and risk of venous thrombosis*  
Kirsten van Langevelde, Annelies Segers, Harry Büller, Suzanne Cannegieter (The Netherlands)

**PB 1.69-6**  
*Incidence of Symptomatic Venous Thromboembolism Among Hospitalized Patients With Lung Cancer in China*  
Zhi-Cheng Jing, H. Qi, Lan Wang, Xin Xu, Jing He, Dan-Chen Wu, Wen-Hui Wu, Stavros Konstantinides, Li-Hong Fan (China)

Non-inherited risk factors venous thrombosis - II  
Screen 70

**Moderator:** Gunhild Lerstad (Norway)

**PB 1.70-1**  
*Thyroid function, assessed by thyroid stimulating hormone, and future risk of venous thromboembolism - The Tromsø study*  
Gunhild Lerstad, Kristin Enga, Rolf Jorde, Ellen Brodin, Sigrid Brækkan, Inger Njolstad, Johan Svartberg, John-Bjarne Hansen (Norway)

**PB 1.70-2**  
*Cardiovascular profile of individuals with deep vein thrombosis: Results of the Gutenberg Health Study (GHS)*  
Liana Ariza, Karsten Keller, Andreas Schulz, Tanja Zeller, Mareike Lankeit, Stavro Konstantinides, Christine Espinola-Klein, Thomas Munzel, Philipp Wild (Germany)

**PB 1.70-3**  
*Incidence of venous thromboembolism in patients undergoing laparoscopic surgery for colorectal cancer*  
Michela Giustozzi, Cecilia Becattini, Fabio Rondelli, Michela Boncompagni, Giuseppe Camporese, Ruben Balzarotti, Otello Flamini, Annibale Donini, Maria Cristina Vedovati, Giancarlo Agnelli (Italy)

**PB 1.70-4**  
*Outpatient treatment for PE and risk factors for mortality, recurrent VTE and pulmonary hypertension in a six-month follow-up: Results of a retrospective registry*  
Sebastian Werth, Virginia Kamvissi, Thoralf Stange, Eberhard Kuhlisch, Norbert Weiss, Jan Beyer-Westendorf (Germany)
**Increased incidence of VTE prior to surgery in patients with renal cell carcinoma and tumor thrombus**

Daniel Yokom, Ryma Ihaddadene, Gregoire Le Gal, Patricia Moretto, Marc Carrier [Canada]

**Incidence of Congestive Heart Failure-associated Venous Thromboembolism in Korean Population: From Health Insurance Review and Assessment Service database**

Doyeun Oh, Moon Ju Jang, Sung-Eun Seo, Hyuck-Moon Kwon, Myung-Ho Jeong [South-Korea]

---

**Vitamin K antagonists (VKAs) for venous thromboembolism (VTE) in a pediatric cohort with persistent antiphospholipid antibodies (aPL)**

Mariana Bonduel, Mirta Hepner, Gabriela Sciuccati, Silvina Annetta, Aurora Feliu Torres, Graciela Pieroni, Carolina Cervio, Carolina Pepe, Juan Pablo Fronroth [Argentina]

**Evaluating the Impact Low molecular Weight Heparin on Quality of Life for Children and their Families**

Aisha Bruce, Mary Bauman, Patti Massicotte [Canada]

**Chylothorax in neonates and children: Diagnosis and antithrombotic therapy of a complication associated with upper venous system thrombosis (UVST)**

Carolina Cervio, Gabriela Sciuccati, Mirta Hepner, Sergio Sierre, Aurora Feliu Torres, Juan Fronroth, Graciela Pieroni, Silvina Annetta, Mariana Bonduel [Argentina]

**Evaluating the impact of thrombophilia testing on health-related quality of life in children: Development of an inventory**

Aisha Bruce, Colin Reynolds, Mary Bauman, Patti Massicotte [Canada]

**Warfarin knowledge retention in families participating in a home INR monitoring programme**

Kate Monagle, Paul Monagle, Sophie Jones, Fiona Newall [Australia]

**A successful implementation of a pediatric thrombosis program to promote assistance to children, adolescent and young adults with cancer**

Claudia Terzian, Julianna Gamba, Andreza Senerchia, Leonardo Brandão, Antonio Sergio Petrilli [Brazil]

---

**The F2G1787T prothrombin gene mutation is not present in a representative cohort of Spanish patients with venous thromboembolism or controls**

José Mateo, Isabel Tirado, Imma Coll, Juan Carlos Souto, Amparo Santamaria, Montserrat Borrell, Jordi Fontcuberta [Spain]

**Thrombophilia in young patients with isquemic stroke. A prospective national study**

José Ceresetto, Cristina Duboscq, Valeria Genoud, Claudia Shantey, Germán Stemmelin, Óscar Rabinovich, Silvina Palmer, Eduardo Bullorsky, investigators AISYF [Argentina]

**Prothrombin G20210A and oral contraceptives are risk factors for cerebral venous thrombosis**

Marianne Landau, Gizele Campanate, Vassalo Juliana, Biasoli Irene, Spector Nelson, Gadelha Telma [Brazil]
PB 1.72-4  Thrombophilia screening in Malaysian patients with arterial & venous thrombosis - A cause for concern?
Thiruchelvam Ayadurai, Faridah Alandi, Faraija Karim (Malaysia)

PB 1.72-5  Thrombophilia and cerebral venous thrombosis: A systematic review
Mandy Lauw, Stefano Barco, Jonathan Coutinho, Saskia Middeldorp (The Netherlands)

PB 1.72-6  Thrombin generation in Cushing’s and metabolic syndrome
Luca Spiezia, Lina Koutroumpa, Maria Bon, Sara Maggiolo, Sabrina Gavasso, Barry Woodhams, Carla Scaroni, Paolo Simioni (Italy)

Atherosclerosis: Miscellaneous - I
Screen 73
Moderator: Sascha Meyer dos Santos (Germany)

PB 1.73-1  Metabolic changes in rabbit atherosclerotic arteries: Increased glucose uptake and metabolite levels of glycolysis, pentose phosphate pathway, tricarboxylic acid cycle and nucleotides
Atsushi Yamashita, Yan Zhao, Yunosuke Matsuura, Kazuaki Yamasaki, Chihiro Sugita, Keichi Kawai, Nagara Tamaki, Songji Zhao, Yuji Kuge, Yujiro Asada (Japan)

PB 1.73-2  The transmembrane chemokine CXCL16 mediates platelet adhesion to von Willebrand factor, HUVECs and human arteries under physiologic flow conditions
Sascha Meyer dos Santos (Germany)

PB 1.73-3  Integrative bioinformatics analysis of genomic and proteomic approaches to understand the transcriptional regulatory program in coronary artery disease pathways
Rajani Kanth Vangala, Vandana Ravindran, Ghatge Madan, Jayashree Shankar, Prathima Arvind, Vijay Kakkar (India)

PB 1.73-5  CLL V-1, A synthetic phenanthrene compound, inhibits TNF-a-induced adhesion molecule expression through affecting reactive oxygen species production and NF-κB signaling in human endothelial cells
Wen-Bin Wu, Tsung-Hsuan Lai, Tsong-Long Hwang, Pi-Hui Wu (Taiwan)

PB 1.73-6  Early postoperative thrombosis following bypass surgery and remote endarterectomy in patients with peripheral arterial disease: A comparative analysis
Alexey Arsenyev, Temirlan Gamzatov, Alexey Svetlikov (Russian Federation)

Acquired coagulation disorders - I
Screen 74
Moderator: Michelle Witkop (USA)

PB 1.74-1  Acquired haemophilia: Clinical manifestations and management. A 15 years experience from a single centre
Anna Kouramba, Ioanna Anastasopoulou, Paraskevi Kotsi, Anestis Chanos, Georgia Kanellopoulou, Maria Gavalaki, Olga Katsarou (Greece)

PB 1.74-2  An immunological mechanism underlies the development of acquired von Willebrand syndrome (AvWS): Clinical usefulness of an ELISA system detecting anti-VWF antibodies
Mayuko Kishimoto, Nobuaki Suzuki, Tadashi Matsushita (Japan)

PB 1.74-3  Managing acquired haemophilia A: Relating the European Acquired Haemophilia Registry (EACH2) data to experience in a South London centre, St George’s Hospital
Pu-Lin Luo, Diana Mhonda, James Uprichard, Steve Austin (United Kingdom)
PB 1.74-4  Acquired hemophilia A: Retrospective analysis of 49 cases from a single Chinese hemophilia center
Yanhui Yang, Min Xuan, Feng Xue, Rongfeng Fu, Fangfang Zhou, Lei Zhang, Linxiang Ji, Renchi Yang (China)

PB 1.74-5  Telemedicine: Physician supported rural hemophilia treatment center (HTC) making a difference for patients
Michelle Witkop, Margaret Hall, David Rushlow, Susan Wischman, Judith Andersen, Roshni Kulkarni (USA)

PB 1.74-6  Diagnosis and management of acquired haemophilia A (AHA) patients: Experience of a single center
Caterina Mercanti, Cristina Santoro, Erminia Baldacci, Roberta Abbruzzese, Francesco Barone, Raffaele Angelo Bochicchio, Roberta Di Mauro, Laura Parlanti, Maria Gabriella Mazzucconi (Italy)
Scientific Programme

Tuesday, July 2, 2013
Tuesday, July 2, 2013

**PLENARY LECTURES** 09:45 - 10:30 / 16:00 - 16:45

**Sherry-Koller Lecture**

*Mondriaan I*

*Moderator: Tilman Hackeng [The Netherlands]*

**09:45 - 10:30**  
**Vessel wall, platelets, NETs and venous thrombosis**  
**PL 03**  
*Denisa Wagner [USA]*

**Plenary Lecture**

*Mondriaan I*

*Moderator: Pieter Reitsma [The Netherlands]*

**16:00 - 16:45**  
**ADAMTS13 and the pathogenesis of thrombotic thrombocytopenic purpura**  
**PL 04**  
*Bernhard Lämml[e] [Switzerland]*
Tuesday, July 2, 2013

STATE-OF-THE-ART LECTURES 11:00 - 12:00

Common and rare bleeding disorders: Global aspects Auditorium
Celebrating the 50th anniversary of the WFH
Moderators: Michael Berndt [Australia] and Alain Weill [France]

11:00 - 11:30  Translational medicine advances in von Willebrand disease
SOA 07.1      David Lillicrap [Canada]
11:30 - 12:00  Future of coagulation factor replacement therapy
SOA 07.2      Flora Peyvandi [Italy]

Venous thrombosis Elicium 2
Moderators: Harry Büller [The Netherlands] and Sabine Eichinger [Austria]

11:00 - 11:30  Optimal treatment duration of venous thrombosis
SOA 08.1      Walter Ageno [Italy]
11:30 - 12:00  Venous thrombosis: Understanding the paradoxes of recurrence
SOA 08.2      Suzanne Cannegieter [The Netherlands]

Procoagulant and anticoagulant mechanisms Mondriaan I
Moderators: Charles Esmon [USA] and John Griffin [USA]

11:00 - 11:30  Key molecular and cellular players in venous thrombosis
SOA 09.1      Steffen Massberg [Germany]
11:30 - 12:00  Mechanisms of anticoagulant and cytoprotective actions of the protein C pathway
SOA 09.2      Laurent Mosnier [USA]

Platelets II Mondriaan II
Moderators: Paul Bray [USA] and Bernhard Nieswandt [Germany]

11:00 - 11:30  Antiplatelet therapy: New pharmacological agents and changing paradigms
SOA 10.1      Dominick Angiolillo [USA]
11:30 - 12:00  Platelet receptors activated via multimerization: GPVI, GPIb-IX-V and CLEC-2
SOA 10.2      Yukio Ozaki, Katsue Suzuki-Inoue, Osamu Inoue [Japan]

Structure function coagulation proteins Elicium 1
Moderators: Elsa Bianchini [France] and Mettine Bos [The Netherlands]

11:00 - 11:30  Thrombin Inhibition by the serpins
SOA 11.1      James Huntington [United Kingdom]
11:30 - 12:00  The transition of prothrombin to thrombin
SOA 11.2      Sriram Krishnaswamy [USA]

Biology of ADAMTS13 Forum
Moderators: James Crawley [United Kingdom] and Johanna Kremer Hovinga [Switzerland]

11:00 - 11:30  Animal models for thrombotic thrombocytopenic purpura
SOA 12.1      Karen Vanhoorelbeke [Belgium]
11:30 - 12:00  Structure-function and regulation of ADAMTS13 protease
SOA 12.2      Ying Zheng [USA]
ABSTRACT SYMPOSIA 13:00 - 14:15

Role of FXII activation in mechanism of thrombosis  E102
Moderator: Nicola Mutch (United Kingdom)

13:00 - 13:30  Factor XII: What's new?  Nicola Mutch (United Kingdom)
13:30 - 13:45  Histidine-rich glycoprotein binds to DNA, RNA and fXIIa with high affinity and attenuates contact-mediated coagulation in a mouse model of arterial thrombosis
   Trang Vu, Ji Zhou, Beverly Leslie, Alan Stafford, James Fredenburgh, Jeffrey Weitz (Canada)
13:45 - 14:00  Selective depletion of contact factors with antisense oligonucleotides attenuates catheter thrombosis in rabbits
   Jonathan Yau, Peng Liao, Alan Stafford, James Fredenburgh, Alexey Revenko, Brett Monia, Jeffrey Weitz (Canada)
14:00 - 14:15  Factor XII promotes blood coagulation independent of factor XI in the presence of long chain inorganic polyphosphates
   Cristina Puy, Erik Tucker, Zöe Wong, András Gruber, David Gailani, Stephanie Smith, Sharon Choi, James Morrissey, Owen McCarty (USA)

Methods and relevance of microparticle detection  Mondriaan II
Moderator: Paul Harrisson (United Kingdom)

13:00 - 13:30  Microparticle Detection: Why and how?  Paul Harrisson (United Kingdom)
13:30 - 13:45  The activation pathway determines the properties of platelet-derived microvesicles
   Maria Aatonen, Mikaela Grönholm, Daniela Lopez-Contreras, Pia Siljander (Finland)
13:45 - 14:00  Physical interpretation of the size and concentration of extracellular vesicles measured by advanced techniques
   Edwin van der Pol, Chris Gardiner, Paul Harrison, Auguste Sturk, Ton van Leeuwen, Rienk Nieuwland (The Netherlands)
14:00 - 14:15  Microparticles from blood plasma revealed by cryo-electron microscopy, receptor-specific gold labeling and flow cytometry
   Alain Brisson, Nicolas Arraud, Sisareuth Tan, Romain Linares, Céline Gounou (France)

New approaches to antiplatelet therapy  Mondriaan III
Moderator: Chris Hackeng (The Netherlands)

13:00 - 13:30  Platelet function as a predictor of clinical outcome in patients on anti-platelet therapies
   Chris Hackeng (The Netherlands)
13:30 - 13:45  Clinical implications of very low on-treatment platelet reactivity in patients treated with thienopyridines: The poba study (predictor of bleedings with antiplatelet drugs)
   Thomas Cuisset, Charlotte Grosdidier, Jacques Quilici, Pierre-Emmanuel Morange, Jean-Louis Bonnet, Marie-Christine Alessi (France)
13:45 - 14:00  First ex vivo and in vivo assessment of anfibatide, a novel glycoprotein Ib-IV-V complex antagonist, in healthy human volunteers in phase I clinical trial
   Benjamin Xiaoyi Li, Xiangrong Dai, Zhongqiang Yang, Fang Qian, Guohui Zhang, Zhengyu Xu, Jing Liu, Chaofan Liang, Adili Reheman, Heyu Ni (Hong Kong, SAR China)
14:00 - 14:15  A Network-Biology Based Approach to Elucidate Determinants of Platelet Reactivity in Aspirin-Treated Cardiovascular Patients
   Anne Zufferey, Mark Ibberson, Jean-Luc Reny, Séverine Nolli, Mylène Docquier, Ioannis Xenarios, Jean-Charles Sanchez, Pierre Fontana (Switzerland)
Tuesday, July 2, 2013

ABSTRACT SYMPOSIA 13:00 - 14:15

Functional characterisation of hereditary platelet disorders Mondriaan IV
Moderator: Kathleen Freson [Belgium]

13:00 - 13:30   Genetics, platelet dysfunction and bleeding
AS 16
Kathleen Freson [Belgium]

13:30 - 13:45   Abnormal megakaryocyte development and platelet function in a mouse model of
gray platelet syndrome
Walter Kahr, Wei-Chi Lo, Ran Ni, Ling Li, Fred Pluthero, Nima Vaezzadeh,
Andrew Weyrich, Jorge Di Paola, Carolina Landolt-Marticorena, Peter Gross [Canada]

13:45 - 14:00   Nbeal2-deficient mice reveal a key role of platelet a-granules in arterial thrombosis,
                thrombo-inflammatory brain infarction and wound healing
Carsten Deppermann, Deya Cherpokova, Paquita Nurden, Ina Thielmann, Peter Kraft,
Alan Nurden, Beate Eckes, Guido Stoll, David Stegner, Bernhard Nieswandt [Germany]

14:00 - 14:15   Defective Thrombus Formation in Hermansky Pudlak Syndrome Mice is due to
                Impaired Platelet Granule Exocytosis and Reduced Protein Disulfide Isomerase
                Release
Anish Sharda, Sarah Kim, Robert Flaumenhaft, Sheryl Bowley, Barbara Furie,
Bruce Furie [USA]

Challenges in therapeutic management of venous thrombosis Elicium 1
Moderator: Cecilia Becattini [Italy]

13:00 - 13:30   Aspirin for the prevention and treatment of venous thromboembolism
AS 17
Cecilia Becattini [Italy]

13:30 - 13:45   Risk of bleeding in patients with acute venous thromboembolism treated with
                rivaroxaban or enoxaparin/VKA and concomitant ASA therapy or NSAIDs: Subanalysis
                from EINSTEIN DVT and PE studies
Bruce Davidson, Sara Verheijen, Anthonie Lensing, Martin Gebel [USA]

13:45 - 14:00   Vitamin K antagonist treatment patterns and persistence after venous
                thromboembolism in non-cancer patients: VTE Epidemiology Group (VEG) Study
Alexander Cohen, Carlos Martinez, Christopher Wallenhorst, Luke Bamber [United
Kingdom]

14:00 - 14:15   Elderly patients with venous thromboembolism: Cancer or no cancer, a different
                therapeutic approach?
Isabelle Mahe, Laurent Bertoletti, Raluca Sterpu, Marion Pépin, Sabiha Hennou,
Sebastian Schellong, Ferran Garcia-Bragado, Manuel Monréal, Group RIETE [France]
### Prevention of recurrent venous thrombosis

**Moderator:** Sabine Eichinger [Austria]

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:00 - 13:30</td>
<td>Management and prognosis after a first venous thrombosis</td>
<td>Sabine Eichinger [Austria]</td>
</tr>
<tr>
<td>13:30 - 13:45</td>
<td>Assessment of the risk of recurrent venous thrombosis using a genetic risk score comprising five genetic markers</td>
<td>Astrid van Hylckama Vlieg, Linda Flinterman, Lance Bare, Suzanne Cannegieter, Andre Arellano, Carmen Tong, James Devlin, Frits Rosendaal [The Netherlands]</td>
</tr>
<tr>
<td>13:45 - 14:00</td>
<td>Prevention of pulmonary embolism recurrences by retrievable vena cava filter: Results of the randomized multicenter trial PREPIC 2</td>
<td>Patrick Mismetti, Pierre-Vladimir Ennezat, Isabelle Quéré, Schmidt Jeannot, Fabrice-Guy Barral, Francis Couturaud, Antoine Elias, Christophe Teinturier, Silvy Laporte, Guy Meyer [France]</td>
</tr>
<tr>
<td>14:00 - 14:15</td>
<td>D-dimer to select patients with a first unprovoked venous thromboembolism (VTE) who have anticoagulants stopped at 3-7 months or have treatment continued indefinitely: A multicentre management study</td>
<td>Clive Kearon, Group for the D-dimer Optimal Duration [Canada]</td>
</tr>
</tbody>
</table>

### Vascular disorders

**Moderator:** Irene Lang [Austria]

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:00 - 13:30</td>
<td>Chronic thromboembolic pulmonary hypertension - a model disease for vascular occlusion</td>
<td>Irene Lang [Austria]</td>
</tr>
<tr>
<td>13:30 - 13:45</td>
<td>Risk factors for chronic pulmonary hypertension. VTE Epidemiology Group (VEG) Study</td>
<td>Alexander Cohen, Carlos Martinez, Stephan Rietbrock [United Kingdom]</td>
</tr>
<tr>
<td>13:45 - 14:00</td>
<td>Residual vein thrombosis as a strong predictor of recurrent thromboembolism and post-thrombotic syndrome. A prospective cohort study</td>
<td>Paolo Prandoni, Anthonie Lensing, Martin Prins, Franco Noventa, Raffaele Pesavento, Daniela Tormene, Sabina Villalta [Italy]</td>
</tr>
<tr>
<td>14:00 - 14:15</td>
<td>Health-related quality of life after catheter-directed thrombolysis for deep vein thrombosis; from the CaVenT study</td>
<td>Tone Enden, Hilde Wik, Ann Kristin Kvam, Ylva Haig, Nils Einar Klow, Per Morten Sandset [Norway]</td>
</tr>
</tbody>
</table>

### New developments in treatment of venous thrombosis

**Moderator:** Jeffrey Weitz [Canada]

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:00 - 13:30</td>
<td>New anticoagulants for venous thrombosis: Opportunities and challenges</td>
<td>Jeffrey Weitz [Canada]</td>
</tr>
<tr>
<td>13:30 - 13:45</td>
<td>A phase 2 randomized, double-blind, placebo-controlled trial of PRT064445, a novel, universal antidote for direct and indirect factor Xa inhibitors</td>
<td>Mark Crowther, Michael Kitt, Todd Lorenz, Vandana Mathur, Genmin Lu, Athiwat Hutchaleelaha, Stanley Hollenbach, John Curnutte, Richard Becker [Canada]</td>
</tr>
<tr>
<td>13:45 - 14:00</td>
<td>No need for a rivaroxaban dose reduction in renally impaired patients with symptomatic venous thromboembolism</td>
<td>Rupert Bauersachs, Anthonie Lensing, Akos Pap, Herve Decousus [Germany]</td>
</tr>
<tr>
<td>14:00 - 14:15</td>
<td>Inhibition of coagulation factor XII provides thromboprotection in extracorporeal circulation without increasing bleeding risk</td>
<td>Magnus Larsson, Katharina Theinert, Linda Labberton, Veronika Rayzman, Marc Nolte, Kosta Panousis, Ingo Pragst, Gerhard Dickneite, Thomas Renné [Sweden]</td>
</tr>
</tbody>
</table>
Tuesday, July 2, 2013

ABSTRACT SYMPOSIA 13:00 - 14:15

The interplay between coagulation and inflammation  G102-103

Moderators: Wolfram Ruf [USA]

13:00 - 13:30  Tissue Factor Signaling and Inflammation  
AS 21  
Wolfram Ruf [USA]

13:30 - 13:45  Formation of neutrophil extracellular traps in skin wounds of mice retards healing  
AS 21.1  
Siu Ling Wong, Kimberly Martinod, Melanie Demers, Maureen Gallant, Yanming Wang, Denisa Wagner [USA]

13:45 - 14:00  Protease-activated receptor 1 contributes to early immune responses in the lung after influenza A infection  
AS 21.2  
Silvio Antoniak, Justin Milner, Melinda Beck, Nigel Mackman [USA]

14:00 - 14:15  Activated protein C glycosylation status dictates protease-activated receptor 1 proteolysis and anti-inflammatory signaling efficacy  
AS 21.3  
Elmear Gleeson, Fionnuala Ni Áinle, Bridget-Ann Kenny, James O’Donnell, Roger Preston [Ireland]

Inhibitors in haemophilia A  
Auditorium

Moderator: Anske van der Bom [The Netherlands]

13:00 - 13:30  Haemophilia inhibitors  
AS 22  
Anske van der Bom [The Netherlands]

13:30 - 13:45  Factor VIII gene (F8) mutation and inhibitor development in non-severe hemophilia A  
AS 22.1  
Corien de Groot-Eckhardt, Alice van Velzen, Marjolein Peters, Kathelijne Peerlinck, Johannes Oldenburg, Elena Santagostino, Jan Astermark, Waander van Heerde, Cedric Hermans, Massimo Morfini, Giancarlo Castaman, Saturnino Haya, Simon McRae, Sylvia-Elisabeth Reitter-Pfoertner, Pieter Willem Kamphuisen, Anske van der Bom, Karin Fijnvandraat, For the INSIGHT consortium [The Netherlands]

13:45 - 14:00  Effect of type and intensity of FVIII exposure on inhibitors development in hemophilia A: First results of an individual patient data meta-analytic project  
AS 22.2  
Maura Marcucci, Maria Elisa Mancuso, Elena Santagostino, Gili Kenet, Mohssen Elalfy, Susanne Holzhauer, Christoph Bidlingmaier, Carmen Escuriola Ettingshausen, Alfonso Iorio, Ulrike Nowak-Göttt [Canada]

14:00 - 14:15  Defective indoleamine 2,3-dioxygenase induction is associated with inhibitor development in severe hemophilia A patients carrying F8 gene null mutations  
AS 22.3  
Davide Matino, Alfonso Iorio, Marco Gargaro, Elena Santagostino, Cristina Santoro, Giovanni Di Minno, Massimo Morfini, Paolo Puccetti, Francesca Fallarino [Italy]
## Tuesday, July 2, 2013

### Abstract Symposia 13:00 - 14:15

#### What’s new in fibrinolysis?

**Moderator: Douglas Vaughan (USA)**

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:00 - 13:30</td>
<td>Plasminogen activator inhibitor-1: what’s new?</td>
<td>Douglas Vaughan (USA)</td>
</tr>
<tr>
<td>13:30 - 13:45</td>
<td>PAI-1 is a critical determinant of senescence and survival in klotho mice, a murine model of accelerated aging</td>
<td>Mesut Eren, Amanda Boe, B. Sheila, Aaron Place, Varun Nagpal, Scott Budinger, Gokhan Mutlu, Toshio Miyata, Douglas Vaughan (USA)</td>
</tr>
<tr>
<td>13:45 - 14:00</td>
<td>Hyperfibrinolytic states induce blood-brain barrier disruption by a plasmin-bradykinin dependent mechanism</td>
<td>Óscar Marcos-Contreras, Sara Martinez De Lizarrondo, Cyrille Orset, Pierre Bardou, Isabelle Focault, Axel Montagne, Eric Maubert, Jérôme Parcq, Denis Vivien, Maxime Gauberti (France)</td>
</tr>
<tr>
<td>14:00 - 14:15</td>
<td>The interplay of DNA, histones and neutrophil leukocytes with plasmin dependent lysis of plasma clots</td>
<td>Imre Varjú, Krasimir Kolev, Colin Longstaff, László Szabó, Veronika Varga-Szabó, Adám Zoltán Farkas, Raymund Machovich (Hungary)</td>
</tr>
</tbody>
</table>

#### Pleiotropic effects of fibrinogen

**Moderator: Sidney Strickland (USA)**

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:00 - 13:30</td>
<td>Fibrinogen and β-amyloid association alters thrombosis and fibrinolysis: A possible contributing factor to Alzheimer’s disease</td>
<td>Sidney Strickland, Maria Cortes-Canteli, Hyung Jin Ahn, Daria Zamolodchikov, Karin Hultman, Anna Kruyer, Erin Norris (USA)</td>
</tr>
<tr>
<td>13:30 - 13:45</td>
<td>Fibrinogen promotes obesity and high fat diet-associated diseases through a mechanism linked to its aMβ2 binding motif</td>
<td>Matthew Flick, Carolina Cruz, Harini Raghu, Senad Divanovic, Traci Stankiewicz, Anna Kopec, James Luyendyk (USA)</td>
</tr>
<tr>
<td>13:45 - 14:00</td>
<td>Plasma fibronectin supports hemostasis, controls the diameter of fibrin fibers, and regulates thrombosis</td>
<td>Yiming Wang, Adili Reheman, Jalil Kalantari, Joseph Jin, Peter Gross, Jeffrey Weitz, Margaret Rand, John Freedman, Heyu Ni (Canada)</td>
</tr>
<tr>
<td>14:00 - 14:15</td>
<td>Inhibition of thrombin-mediated factor V activation as a novel anticoagulant mechanism of fibrinogen</td>
<td>Farida Omarova, Shirley Uitte de Willige, Robert Ariëns, Jan Rosing, Rogier Bertina, Elisabetta Castoldi (The Netherlands)</td>
</tr>
</tbody>
</table>
Tuesday, July 2, 2013

FOCUS SYMPOSIUM 13:00 - 14:15

**Thrombosis and haemostasis in children**

**Moderator:** Paul Monagle (Australia)

13:00 - 13:30

**New approaches to unravelling the mysteries of clotting in children**

*FS 02*

Paul Monagle (Australia)

13:30 - 13:45

**Significantly increased risk for venous thrombotic events in long-term pediatric, adolescent and young adult cancer survivors: A population-based study**

*Ketan Kulkarni, Maria Lorenzi, S. Devji, Mary McBride, Mitchell Lesley (Canada)*

13:45 - 14:00

**‘Blood and bone thinning’ in children on long-term oral anticoagulation: What a bone-scan can tell you**

*Maria Avila, Sunayna Gupta, Darlene Castle, Walter Kahr, Suzan Williams, Leonardo Brandao (Canada)*

14:00 - 14:15

**Risk factors for the development of venous thromboembolism in childhood acute lymphoblastic leukaemia**

*Charlotte Zuurbier, Eva Stokhuijzen, Cor van den Bos, Antoinette Schouten-van Meeteren, Heleen van Ommen (The Netherlands)*
Tuesday, July 2, 2013

**ORAL COMMUNICATIONS**

**Antiphospholipid syndrome**

Moderators: Philip de Groot [The Netherlands] and Karim Brandt [Switzerland]

08:00 - 08:15
OC 27.1 **Antiphospholipid antibodies induce NF-κB activation exclusively from endosomal compartments of human monocytes**

Karim Brandt, Céline Fickentscher, Gautier Frizon De Lamotte, Françoise Boehlen, Guido Reber, Egbert Kruithof, Philippe De Moerloose [Switzerland]

08:15 - 08:30
OC 27.2 **Beta2-glycoprotein I selectively inhibits the procoagulant functions of thrombin**

Vincento De Filippis, Laura Acquasaliente, Nicola Pozzi, Roberta Frasson, Raimondo De Cristofaro, Alessandro Arcovito, Alessandra Banzato, Vittorio Pengo [Italy]

08:30 - 08:45
OC 27.3 **High levels of β2-glycoprotein I protects against secondary major adverse cardiovascular events after PTCA**

Thijs van Holten, Rolf Urbanus, Wouter Jukema, Nico Pijls, Anton-Jan van Zonneveld, Gerard Pasterkamp, Imo Hoefer, Mark Roest, Philip de Groot [The Netherlands]

08:45 - 09:00
OC 27.4 **Anti-β2-glycoprotein I antibodies inhibit the prothrombinase complex in a phospholipid-independent manner**

Maarten Pennings, Sandra Drost-Verhoef, Joost Meijers, Philip de Groot, Rolf Urbanus [The Netherlands]

09:00 - 09:15
OC 27.5 **Pathological mechanisms of antiphospholipid antibodies in trophoblastic cell fusion**

Tess Marchetti, Marie Cohen, Philippe De Moerloose [Switzerland]

09:15 - 09:30
OC 27.6 **MicroRNA expression in monocytes and neutrophils from primary antiphospholipid syndrome and systemic lupus erythematosus patients. Potential value as biomarkers of atherothrombotic disease**

Carlos Perez-Sanchez, Patricia Ruiz-Limón, María Angeles Aguirre, Nuria Barbarroja, Antonio Rodriguez-Ariza, Eduardo Collantes, María José Cuadrado, Rocío González-Conejero, Costantino Martínez, Chary López-Pedrera [Spain]

**Coagulation factor VIII**

Emerald

Moderators: Koen Mertens [The Netherlands] and Svetla Stoilova-McPhie [USA]

08:00 - 08:15
OC 28.1 **Factor VIII: Where is it synthesized?**

Scot Fahs, Matthew Hille, Mary Joziwick, Qizhen Shi, Harmut Weiler, Robert Montgomery [USA]

08:15 - 08:30
OC 28.2 **Factor VIII A2 domain stabilization enhances potency and efficacy in hemophilia A mice**

Lilley Leong, Thomas Thompson, Katherine Tran, Perry Liu, Derek Sim, Hironao Wakabayashi, Philip Fay, Peter Kretschmer, Volker Laux, John Murphy [USA]

08:30 - 08:45
OC 28.3 **Activated blood coagulation factor VIII interacts with cluster III complement-type repeats of the low-density lipoprotein receptor-related protein**

James Kurasawa, Svetlana Shestopal, Timothy Lee, Andrey Sarafanov [USA]

08:45 - 09:00
OC 28.4 **Identification of monoclonal antibodies protecting activated Factor VIII against spontaneous inactivation by A2 subunit dissociation**

Henrik Ostergaard, Kasper Lambert, Jes Clausen, Kristoffer Balling, Johan Faber, Stine Reedtz-Runge, Marianne Kjalke, Heidi Holmberg [Denmark]

09:00 - 09:15
OC 28.5 **Clearance of FVIII in a rat perfused liver model and isolated primary liver cells in the presence and absence of VWF**

Rupa Shree Appa, Mette Loftager, Hermann Pelzer, Ditte Karpf, Marianne Kjalke, Henning Stennicke, Bard Smedsrud [Denmark]

09:15 - 09:30
OC 28.6 **Difference in the membrane-bound organization of human and porcine Factor VIII**

Svetla Stoilova-McPhie, Jaimy Miller, Daniela Dalm, Kirill Grushin [USA]
**Tuesday, July 2, 2013**

**ORAL COMMUNICATIONS 08:00 - 09:30**

**Fibrinolysis - I**

Moderators: Moniek de Maat (The Netherlands) and Joanne Mitchell (United Kingdom)

- **08:00 - 08:15**
  - Pharmacological inhibition of PAI-1 activity prolongs the lifespan of klotho mice, a murine model of accelerated aging
  - Mesut Eren, Toshio Miyata, Douglas Vaughan (USA)

- **08:15 - 08:30**
  - Global gene expression profiling in PAI-1 knockout murine heart and kidney: Molecular basis of cardiac-selective fibrosis
  - Asish Ghosh, Sheila Murphy, Raj Kishore, Douglas Vaughan (USA)

- **08:30 - 08:45**
  - Plasmin induces in vivo monocyte recruitment through protease-activated receptor-1, MEK/ERK and CCR2 mediated signaling
  - Aline Carmo, Bruno Costa, Juliana Vago, Leonardo Oliviera, Luciana Tavares, Camila Nogueira, Bruno Brasil, Luci Dusse, Lucília Barcelos, Cláudio Bonjardim, Mauro Teixeira, Lírlândia Sousa (Brazil)

- **08:45 - 09:00**
  - Metalloproteinase-9 higher increase after thrombolysis is associated with hemorrhagic transformation of lesion and with poor stroke outcome
  - Betti Giusti, Patrizia Nencini, Anna Maria Gori, Mascia Nesi, Vanessa Palumbo, Benedetta Piccardi, Alessandra Armillis, Giovanni Pracucci, Rosanna Abbate, Domenico Inzitari (Italy)

**Inherited risk factors for venous thrombosis - I**

Moderators: Maria Bruzelius (Sweden) and Elisabetta Castoldi (The Netherlands)

- **08:00 - 08:15**
  - Towards identification of novel inherited genetic risk factors for venous thromboembolism
  - Marisa Cunha, Sigrid Fouchier, Joost Meijers, Saskia Middeldorp (The Netherlands)

- **08:15 - 08:30**
  - Hidden antithrombin deficiencies
  - José Navarro-Fernández, José Padilla, Irene Martínez-Martínez, Sonia Águila, María De La Morena-Barrio, Antonio Miñano, Nataliya Bohdan, Consuelo Martínez, Vicente Vicente, Javier Corral (Spain)

- **08:30 - 08:45**
  - The risk of venous thrombosis varies in different ethnic groups
  - Suely Rezende, Willem Lijfering, Frits Rosendaal, Suzanne Cannegieter (The Netherlands)

- **08:45 - 09:00**
  - Genetic influence on risk of venous thromboembolism in women
  - Maria Bruzelius, Maria Sabater-Lleal, Rona Strawbridge, Annica Bergendal, Angela Silveira, Anders Sundström, Helle Kieler, Jacob Odeberg, Anders Hamsten (Sweden)

- **09:00 - 09:15**
  - Candidate genetic polymorphisms and their associations with incident and recurrent venous thrombosis
  - Marc Blondin, Kerri Wiggins, Laura Harrington, Barbara McKnight, Kent Taylor, Frits Rosendaal, Susan Heckbert, Bruce Psaty, Nicholas Smith (USA)

- **09:15 - 09:30**
  - Sex difference in incidence of first venous thrombosis: A higher risk in men than in women
  - Rachel Roach, Willem Lijfering, Frits Rosendaal, Suzanne Cannegieter, Saskia Le Cessie (The Netherlands)
Tuesday, July 2, 2013

**ORAL COMMUNICATIONS** 08:00 - 09:30

### Mechanisms in cancer and haemostasis  Elicium 1

**Moderators: Arnold Spek (The Netherlands) and Susan Gilmour (USA)**

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00 - 08:15</td>
<td>Association of mean platelet volume with cancer-associated venous thromboembolism: Results from the vienna cancer and thrombosis study (CATS)</td>
<td>Julia Riedl, Eva-Maria Reitter, Christine Marosi, Ulrich Jäger, Ilse Schwarzinger, Christoph Zielinski, Ingrid Pabinger, Cihan Ay (Austria)</td>
</tr>
<tr>
<td>08:15 - 08:30</td>
<td>Protease-activated receptor-1 in the pancreatic tumor microenvironment favors cancer progression and chemoresistance</td>
<td>Karla Queiroz, Kun Shi, Jan Willem Duitman, Hella Aberson, Johanna Wilmink, Carel van Noesel, Dick Richel, Arnold Spek (The Netherlands)</td>
</tr>
<tr>
<td>08:30 - 08:45</td>
<td>Kinome profiling of coagulation factors VIIa, Xa and thrombin-dependent signaling reveals common and coagulation factor-unique signaling pathways</td>
<td>Keren Borensztajn, Kaushal Parikh, Arie Hoogendijk, Arnold Spek, Maikel Peppelenbosch (France)</td>
</tr>
<tr>
<td>08:45 - 09:00</td>
<td>Elevated aPC levels reduce cancer metastasis independent of aPC’s cytoprotective effect</td>
<td>Julie Crudele, Geerte van Sluis, Paris Margaritis, Joshua Siner, Michael Sliozberg, Armida Faella, Shangzhen Zhou, Katherine High, Arnold Spek, Valder Arruda (USA)</td>
</tr>
</tbody>
</table>

### Mechanisms of atherosclerosis  G104-105

**Moderators: Victor van Hinsbergh (The Netherlands) and Laura West (United Kingdom)**

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00 - 08:15</td>
<td>Role of platelet-specific junctional adhesion molecule-A (JAM-A) in atherosclerosis progression</td>
<td>Rory Koenen, Ela Karshovska, Zhen Zhao, Philipp Von Hundelshausen, Christian Weber (The Netherlands)</td>
</tr>
<tr>
<td>08:15 - 08:30</td>
<td>The role of vessel wall P2Y12 in early atherogenesis is not blocked by ticagrelor or clopidogrel</td>
<td>Laura West, Tanja Steiner, Sheila Francis, Robert Storey (United Kingdom)</td>
</tr>
<tr>
<td>08:30 - 08:45</td>
<td>Deficiency of the anticoagulant annexin A5 attenuates atherosclerotic plaque development in ApoE-/- mice</td>
<td>Dennis Kusters, Martijn Chatrou, Brecht Willems, Kristof Schutters, Leon Schurgers, Chris Reutelingsperger (The Netherlands)</td>
</tr>
<tr>
<td>08:45 - 09:00</td>
<td>Calcium, cholesterol and TLT-1 in atherosclerosis</td>
<td>Marieli Gonzalez, Fiorella Reyes, Deborah Marraro, Carlos Collado, A.V Washington (Puerto Rico)</td>
</tr>
<tr>
<td>09:00 - 09:15</td>
<td>Sphingosine-1-Phosphate induced TNF-a expression in Natural Killer T (NKT) Cell Hybridomas Through S1P2/Gq/PLC/PKC Pathway and mediated migration of NKT Cell Hybridomas</td>
<td>Shiori Ito, Rie Kondo, Soichiro Iwaki, Kazuya Iwabuchi, Satoshi Fujii (Japan)</td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
<td></td>
</tr>
<tr>
<td>--------</td>
<td>-------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>08:00</td>
<td><strong>ORAL COMMUNICATIONS</strong></td>
<td></td>
</tr>
</tbody>
</table>
| 09:15  | Effect of immunization of C5a and C3a released from complement component C5 and C3 respectively on early atherosclerotic lesion in Apobtm2SgyLdlrmt1Her/J Mouse Model  
Xinjie Lu, Min Xia, Daxin Chen, Valeria Endres, Ildiko Faludi, Andrea Szabo, Lakshmi Mundkur, Vijay Kakkar (United Kingdom) |
| 08:00  | **Megakaryocytes and thrombopoiesis**                                    |
| 08:00  | The hepatic Ashwell-Morell receptor regulates thrombopoietin production  
Karin Hoffmeister, Renata Grozoswky, Antonija Jurak Begonja, John Hartwig (USA) |
| 08:15  | Microthrombocytopenia and impaired platelet integrin function in conditional profilin1-deficient mice  
Simon Stritt, Markus Bender, Paquita Nurden, Shuchi Gupta, Ina Thielmann, John Hartwig, Bernhard Nieswandt (Germany) |
| 08:30  | Functional characterisation of novel regulators of haematopoiensis: From GWAS to function  
Ewa Bielczyk-Maczyńska, Nicole Soranzo, Willem Ouwehand, Ana Cvejic (United Kingdom) |
| 08:45  | PEAR1 attenuates megakaryopoiesis via regulation of the PTEN/PI3K pathway  
Alexandre Kauskot, Christophe Vandenbriele, Sophie Louwette, Kathleen Freson, Peter Verhamme, Marc Hoylaerts (Belgium) |
| 09:00  | Tropomyosin 4 is a novel regulator of platelet production in mice and humans  
Irina Pleines, Stephane Chappaz, Rachael Lane, Myrto Kostadima, Galina Schevzov, Cedric Ghevaert, Peter Gunning, Willem Ouwehand, Benjamin Kile (Australia) |
| 09:15  | Redundant functions of RhoA and Cdc42 in platelet biogenesis  
Michael Popp, Deya Cherpokova, Sebastian Dütting, Irina Pleines, Georg Krohne, Paquita Nurden, Cord Brakebusch, Bernhard Nieswandt (Germany) |
| 08:00  | **Platelet disorders - I**                                                |
| 08:00  | Functional studies and proteomics in platelets and fibroblasts reveal a lysosomal defect with increased cathepsin-dependent apoptosis in ATP1A3 defective Alternating Hemiplegia of Childhood  
Michela Di Michele, Christophe Goubau, Etienne Waelkens, Chantal Thys, Lut Overbergh, Gunnar Buyse, Marc Csaer, Chris van Geet, Kathleen Freson (Belgium) |
| 08:15  | Identification of novel FLI1 mutations in two families with a platelet secretion defect  
Jacqueline Stockley, Matthew Jones, Danai Bern, Stuart Mundell, Paul Gissen, Andrew Mumford, Michael Makris, Steve Watson, Martina Daly, GAPP Study group UK (United Kingdom) |
| 08:30  | A mutation in β3 integrin causing macrothrombocytopenia displays constitutive active allbβ3 and aVβ3 and proplatelet-like structures on immobilized fibrinogen  
Hagit Hauschner, Stefania Messineo, Uri Seligsohn, Anna Savoia, Nurit Rosenberg (Israel) |
| 08:45  | Treatment modalities and outcomes in 204 surgical procedures in 96 Glanzmann thrombasthenia (GT) patients: The International Prospective Glanzmann’s Thrombasthenia Registry (GTR)  
Man-Chiu Poon, Roseline D’Oiron, Rainer Zott, Giovanni Di Minno (Canada) |
### ORAL COMMUNICATIONS 08:00 - 09:30

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00 - 09:15</td>
<td>OC 34.5</td>
<td>The β-1 tubulin R307H single nucleotide polymorphism is associated with significantly worse thrombocytopenia and distinct platelet physiology in Bernard Soulier monoallelic 'Bolzano' mutation patients</td>
<td>Paul Basciano, Valeria Bozzi, Elisa Civaschi, Stella Provini, Jason Matakas, Paraskevi Giannakakou, James Bussel, Carlo Balduini, Patrizia Noris (USA)</td>
</tr>
<tr>
<td>09:15 - 09:30</td>
<td>OC 34.6</td>
<td>The BRIDGE bleeding and platelet disorders exome sequencing project: Presentation and first discoveries</td>
<td>Kathleen Freson (Belgium)</td>
</tr>
</tbody>
</table>

**Platelet signaling - I**

***Mondriaan IV***

*Moderators: Paul Bray [USA] and Gianni Guidetti [Italy]*

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00 - 08:15</td>
<td>OC 35.1</td>
<td>A recombinant HPA-1a antibody with abrogated Fcγ receptor binding for treatment of fetomaternal alloimmune thrombocytopenia: Proof of principle in human studies</td>
<td>Cedric Ghevaert, Nina Herbert, Phil Cookson, Steve Garner, Paul Lloyd-Evans, Kottekkaku Ballan, Willem Ouwehand, Kathryn Armour, Mike Clark, Lorna Williamson (United Kingdom)</td>
</tr>
<tr>
<td>08:15 - 08:30</td>
<td>OC 35.2</td>
<td>The P2X1 receptor antagonist NF449 protects mice from experimental Transfusion Related Acute Lung Injury</td>
<td>Blandine Maitre, Cécile Leguay, Henri De La Salle, Béatrice Hechler, Christian Gachet (France)</td>
</tr>
<tr>
<td>08:30 - 08:45</td>
<td>OC 35.3</td>
<td>The mechanical regulation of VWF GPIba dependent platelet triggering on a single cell</td>
<td>Lining Ju, Yunfeng Chen, Miguel Cruz, Cheng Zhu (USA)</td>
</tr>
<tr>
<td>08:45 - 09:00</td>
<td>OC 35.4</td>
<td>The Rap guanine nucleotide exchange factor CalDAG-GEFI is phosphorylated and regulated by protein kinase A</td>
<td>Gianni Guidetti, Daria Manganaro, Alessandra Consonni, Ilaria Canobbio, Cesare Balduini, Mauro Torti (Italy)</td>
</tr>
<tr>
<td>09:00 - 09:15</td>
<td>OC 35.5</td>
<td>Genetic deletion of Vaccinia H1-related (VHR) phosphatase inhibits collagen-induced platelet activation and thrombus formation without affecting bleeding time in mice</td>
<td>Souad Rahmouni, Lucia Musumeci, Lisbeth Maurissen, Marijke Kuijpers, Yotis Senis, Tomas Mustelin, Johan Heemskerk (Belgium)</td>
</tr>
<tr>
<td>09:15 - 09:30</td>
<td>OC 35.6</td>
<td>SHIP1 deficiency affects platelet internal contraction and integrin dynamics during the first steps of platelet activation</td>
<td>Sonia Severin, Alessandra Consonni, Gaëtan Chicanne, Sophie Allart, Bernard Payrastre, Marie-Pierre Gratacap (France)</td>
</tr>
</tbody>
</table>

**Reversal of anticoagulant agents**

***Elicium 2***

*Moderators: Laurent Mosnier [USA] and Nabil Thalji [USA]*

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00 - 08:15</td>
<td>OC 36.1</td>
<td>Early reversal with prothrombin complex concentrate in vitamin K antagonist-treated patients with severe haemorrhage is associated with decreased mortality</td>
<td>Bernard Vigué, Bruno Riou, Benjamin Tremey, Charles-Marc Samama, Eric Vicaut, Karim Tazarourte (France)</td>
</tr>
<tr>
<td>08:15 - 08:30</td>
<td>OC 36.2</td>
<td>In vitro characterization, pharmacokinetics and reversal of supratherapeutic doses of dabigatran-induced bleeding in rats by a specific antibody fragment antidote to dabigatran</td>
<td>Joanne van Ryn, Felix Schiele, Tobias Litzenburger, Johanna Schurer, Herbert Nar (Germany)</td>
</tr>
</tbody>
</table>
**ORAL COMMUNICATIONS**  
08:00 - 09:30

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30 - 08:45</td>
<td>OC 36.3</td>
<td><strong>Active site-mutated thrombin S195A but not active site-blocked thrombin counteracts the anticoagulant activity of dabigatran in plasma</strong></td>
<td>William Sheffield, Melissa Lambourne, Varsha Bhakta, Louise Eltrimingham-Smith, Donald Arnold, Mark Crowther (Canada)</td>
</tr>
<tr>
<td>08:45 - 09:00</td>
<td>OC 36.4</td>
<td><strong>Reversal of direct factor Xa inhibitors using factor Xa zymogen-like variants</strong></td>
<td>Nabil Thalji, Sunita Patel-Hett, Joachim Fruebis, Debra Pittman, Rodney Camire (USA)</td>
</tr>
<tr>
<td>09:00 - 09:15</td>
<td>OC 36.5</td>
<td><strong>Effects of three-factor and four-factor prothrombin complex concentrates on the pharmacodynamics of rivaroxaban</strong></td>
<td>Marcel Levi, Todd Moore, Carlos Castillejos, Scott Berkowitz, Dagmar Kubita, Samuel Goldhaber, Jeffrey Weitz, Jeffrey Levy (The Netherlands)</td>
</tr>
<tr>
<td>09:15 - 09:30</td>
<td>OC 36.6</td>
<td><strong>Reversal of dabigatran effects by factor VIIa in a cell-based model of coagulation</strong></td>
<td>Maureane Hoffman, Zoya Volovyk, Dougald Monroe (USA)</td>
</tr>
</tbody>
</table>

**Therapy in haemophilia A**  
Auditorium

*Moderators: Christopher Ludlam (United Kingdom) and Johnny Mahlangu (South Africa)*

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00 - 08:15</td>
<td>OC 37.1</td>
<td><strong>Targeting Factor VIII expression to platelets by intraosseous delivery of lentiviral vectors into bone marrow corrects murine Hemophilia A with and without pre-existing inhibitors</strong></td>
<td>Xuefeng Wang, Simon Shin, Dao Pan, David Rawlings, Carol Miao (USA)</td>
</tr>
<tr>
<td>08:15 - 08:30</td>
<td>OC 37.2</td>
<td><strong>A-LONG: Results from a phase 3 study of safety, efficacy, and pharmacokinetics of long-lasting Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc)</strong></td>
<td>Johnny Mahlangu, Jerry Powell, Margaret Ragni, Pratima Chowdary, Neil Josephson, Ingrid Pabinger, Hideji Hanabus, Naresh Gupta, Roshni Kulkarni, Patrick Fogarty, David Perry, Amy Shapiro, John Pasi, Shashikant Apte, Snejana Krassova, Haiyan Jiang, Shuanglian Li, Lynda Cristiano, Srividya Neelakantan, Feriandas Greblikas, Jaya Goyal, Jurg Sommer, Jennifer Dumont, Alison Innes, Karen Nugent, Aoife Brennan, Alvin Luk, Glenn Pierce (South Africa)</td>
</tr>
<tr>
<td>08:30 - 08:45</td>
<td>OC 37.3</td>
<td><strong>A novel bispecific antibody (ACE910) against coagulation factors IXa and X improves procoagulant activity of patients with hemophilia A ex vivo to hemostatic level</strong></td>
<td>Kenichi Ogwara, Keiji Nomami, Koji Yada, Shoko Furukawa, Hiroaki Minami, Junka Haku, Takehisa Kitazawa, Kunihiro Hattori, Midori Shima (Japan)</td>
</tr>
<tr>
<td>08:45 - 09:00</td>
<td>OC 37.4</td>
<td><strong>An RNAi therapeutic targeting antithrombin increases thrombin generation and improves hemostasis in hemophilia mice</strong></td>
<td>Akin Akinc (USA)</td>
</tr>
<tr>
<td>09:00 - 09:15</td>
<td>OC 37.5</td>
<td><strong>Engineering a novel rFVIII-VWF D’D3 fusion protein to enhance stability and improve pharmacokinetic properties of FVIII</strong></td>
<td>Ekta Seth Chhabra, Tongyao Liu, John Kulman, Susannah Patarroyo-White, Lily Zhu, Bob Pape, Glenn Pierce, Baisong Mei, Haiyan Jiang, Robert Peters (USA)</td>
</tr>
<tr>
<td>09:15 - 09:30</td>
<td>OC 37.6</td>
<td><strong>Results of haemostatic efficacy, safety, and pharmacokinetics/pharmacodynamics of a plasma-derived factor VIIa and factor X (MC710) in haemophilia patients with inhibitors: Phase II clinical trial</strong></td>
<td>Kagehiro Amano, Akira Shirarahata, Katsuyuki Fukutake, Junki Takamatsu, Midori Shima, Satoshi Higasa, Teruhsita Fujii, Masahiro Migita, Kiyoshi Kawakami, Hidehiko Saito (Japan)</td>
</tr>
<tr>
<td>Time</td>
<td>Title</td>
<td>Authors</td>
<td></td>
</tr>
<tr>
<td>------------</td>
<td>----------------------------------------------------------------------</td>
<td>------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>08:00 - 08:15</td>
<td>Heme-induced vascular permeability leads to the extravascular TF-dependent activation of coagulation</td>
<td>Erica Sparkenbaugh, Pichika Chantrathammachart, Junmei Chen, Daniel Kirchhofer, José López, Nigel Key, Nigel Mackman, Rafal Pawlinski (USA)</td>
<td></td>
</tr>
<tr>
<td>08:15 - 08:30</td>
<td>The insulin-like growth factor 1 receptor mediates tissue factor/FVIIa-induced cell survival</td>
<td>Mikael Åberg, Oskar Eriksson, Dariush Mokhtari, Agneta Siegbahn (Sweden)</td>
<td></td>
</tr>
<tr>
<td>08:30 - 08:45</td>
<td>Red blood cells enhance LPS-induced tissue factor and TNFalpha in monocytes</td>
<td>Mikael Åberg, Oskar Eriksson, Dariush Mokhtari, Agneta Siegbahn (Sweden)</td>
<td></td>
</tr>
<tr>
<td>08:45 - 09:00</td>
<td>Endothelial cells uptake and recycle microparticle-derived tissue factor to the cell surface with augmented procoagulant activity</td>
<td>Camille Ettelaie, Pui-Mah Mei, Mary Collier, Yupei Xiao, Anthony Maraveyas (United Kingdom)</td>
<td></td>
</tr>
<tr>
<td>09:00 - 09:15</td>
<td>Tissue factor expression and signalling in aortic valve interstitial cells: insights into fibro-calcific aortic valve disease</td>
<td>Sophie Susen, Ahmed Elkalioubie, Anais Arbesu Y Mar, Delphine Corseaux, Annabelle Dupont, Christophe Zawadzki, Francis Juthier, David Smadja, Giulia Chinetti, Eric van Belle (France)</td>
<td></td>
</tr>
<tr>
<td>09:15 - 09:30</td>
<td>Increased expression of tissue factor in intra-abdominal adipose tissue in a metabolic syndrome model: A new insight</td>
<td>Delphine Corseaux, Louise Pasquesoone, Ahmed Elkalioubie, Alexandre Ung, Bertrand Vaast, Giulia Chinetti, Bart Staels, Brigitte Jude, Eric van Belle, Sophie Susen (France)</td>
<td></td>
</tr>
</tbody>
</table>
Tuesday, July 2, 2013

ORAL COMMUNICATIONS 08:00 - 09:30

Von Willebrand disease: Basic aspects

Moderators: Mackenzie Bowman [Canada] and Cécile Denis [France]

08:00 - 08:15
OC 39.1 The type 2B p.R1306W von Willebrand factor mutant shows a large enhancement of sensitivity to shear stress that favors its interaction with the platelet receptor
Raimondo De Cristofaro, Stefano Lancellotti, Giovanni Luca Scaglione, Massimiliano Papi, Marco De Spirito, Luciano Baronciani, Maria Teresa Pagliari, Alessandro Arcovito, Enrico Di Stasio, Flora Peyvandi (Italy)

08:15 - 08:30
OC 39.2 The von Willebrand disease type 2B p.V1316M mutation inhibits platelet functions by interfering with Ca2+ mobilization and integrin αIIbβ3 activation pathways
Caterina Casari, Eliane Berrou, Marilyne Lebret, Régis Bobe, Céline Desconclois, Olivier Christophe, Jean-Philippe Rosa, Peter Lenting, Cécile Denis, Marijke Bryckaert (France)

08:30 - 08:45
OC 39.3 Defective angiopoietin-2 release from von Willebrand disease patients’ blood outgrowth endothelial cells
Richard Starke, Koralia Paschalaki, Clare Dyer, Kimberly Harrison-Lavoie, Jacqueline Cutler, Thomas McKinnon, Carolyn Millar, Daniel Cutler, Michael Laffan, Anna Randi (United Kingdom)

08:45 - 09:00
OC 39.4 Applying in silico analysis to the historically reported VWF exon 42 deletion reveals a probable L1 non-autonomous retrotransposition mediated deletion pathomechanism
Ashley Cartwright, Ian Peake, Anne Goodeve (United Kingdom)

09:00 - 09:15
OC 39.5 Investigation of the contribution of von Willebrand factor (VWF) propeptide mutations to type 3 VWD using in vitro cellular studies and patient-derived blood outgrowth endothelial cells (BOEC)
Mackenzie Bowman, Lara Casey, Lisa Morrison, Angie Tuttle, Irwin Walker, Mariana Silva, Paula Jacobi, Sandra Haberichter, David Lillicrap, Paula James (Canada)

09:15 - 09:30
OC 39.6 Novel variations in platelet GPCRs identified in patients with a historical diagnosis of Type 1 von Willebrand disease
Jacqueline Stockley, Shaista Nisar, Vincenzo Leo, Anne Goodeve, Stuart Mundell, Andrew Mumford, Steve Watson, Martina Daly, UK GAPP Study group MCMDM-1VWD Study group (United Kingdom)
**Angiogenesis and arteriogenesis - II**

**Moderators: Lina Badimon [Spain] and Keith McCrae [USA]**

**14:30 - 14:45**

**OC 40.1**

The ability of cleaved high molecular weight kininogen (HKA) to induce endothelial cell apoptosis and inhibit angiogenesis is not dependent on the urokinase-type plasminogen activator receptor (uPAR)

Keith McCrae, Venkaiah Betapudi [USA]

**14:45 - 15:00**

**OC 40.2**

Thrombin receptor PAR-1 activation on endothelial progenitor cells enhances chemotaxis associated gene expression and leukocytes recruitment by a COX-2 dependant mechanism

Clément D’Audigier, Clément Cochain, Ivan Bièche, Laetitia Mauge, Bérengère Marsac, Michel Vidaud, Jean-Sébastien Silvestre, Pascale Gaussem, David Smadja [France]

**15:00 - 15:15**

**OC 40.3**

Peritoneal fluid reduces angiogenesis-related microRNA expression in cell cultures of endometrial and endometriotic tissues from women with endometriosis

Aitana Braza-Boils, Juan Gilabert-Estellés, Josep Mari-Alexandre, Juan Gilabert, Francisco España, Amparo Estellés [Spain]

**15:15 - 15:30**

**OC 40.4**

MicroRNAs expression profile in endometriosis: its relation with angiogenesis and fibrinolytic factors

Aitana Braza-Boils, Josep Mari-Alexandre, Juan Gilabert, Dolors Sánchez-Izquierdo, Francisco España, Amparo Estellés, Juan Gilabert-Estellés [Spain]

**Animal models of antiphospholipid syndrome**

**Moderators: Harshal Nandurkar [Australia] and Rolf Urbanus [The Netherlands]**

**14:30 - 14:45**

**OC 41.1**

Adenosine generation protects in a murine model of antiphospholipid antibody-induced miscarriages

Harshal Nandurkar, Anushka Samudra, Anup Sharma, Xiang Zhang, Carly Selan, Karen Dwyer, Simon Robson, Anthony D’Apice, Peter Cowan [Australia]

**14:45 - 15:00**

**OC 41.2**

In vivo thrombus formation fostered by a human cofactor independent monoclonal anticardiolipin antibody

Davit Manukyan, Sven Jäckel, Nadine Prinz, Ulrich Walter, Christoph Reinhardt, Karl Lackner [Germany]

**15:00 - 15:15**

**OC 41.3**

IgA anti-β2glycoprotein I antibodies are pathogenic in a mouse model of antiphospholipid syndrome

Rohan Willis, Patricia Ruiz-Limon, Zurina Romay-Penabad, Elizabeth Papalardo, Ana Laura Carrera-Marín, Silvia Pierangeli [USA]

**15:15 - 15:30**

**OC 41.4**

Affinity purified antibodies directed against domain I of β2GPI are pathogenic in a mouse model of thrombosis

Rohan Willis, Charis Pericleous, Patricia Ruiz-Limon, Zurina Romay-Penabad, Acely Garza-Garcia, Lucy Murfitt, Ian Giles, Yiannis Ioannou, Anisur Rahman, Silvia Pierangeli [USA]
## Tuesday, July 2, 2013

### ORAL COMMUNICATIONS  14:30 - 15:30

#### Bleeding and anticoagulants  Auditorium

**Moderators:** Willem Lijfering (The Netherlands) and Daniela Poli (Italy)

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:30 - 14:45</td>
<td>Comparison of four scores for the prediction of major bleeding in patients with acute venous thromboembolism. Findings from the RIETE registry</td>
<td>Chiara Piovella, Fabio Dalla Valle, Javier Trujillo-Santos, Raffaele Pesavento, Manuel Monreal, Paolo Prandoni (Italy)</td>
</tr>
<tr>
<td>14:45 - 15:00</td>
<td>Recurrence of intracranial hemorrhage after resumption of anticoagulation in patients who had a first episode occurred during Vitamin K Antagonists anticoagulation. Results Of a Collaborative Study</td>
<td>Daniela Poli, Emilia Antonucci, Sophie Testa, Nicoletta Erba, Giuliana Guazzaloca, Eros Tirapelli, Aurora Giardello, Teresa Lerede, Giovanni Nante, Gualtiero Palareti (Italy)</td>
</tr>
<tr>
<td>15:00 - 15:15</td>
<td>The predictive ability of bleeding risk stratification models in very old patients on VKA treatment for venous thromboembolism. Results of the prospective collaborative EPICA study</td>
<td>Daniela Poli, Emilia Antonucci, Sophie Testa, Benilde Cosmi, Gualtiero Palareti, Walter Ageno (Italy)</td>
</tr>
<tr>
<td>15:15 - 15:30</td>
<td>Statin use and bleeding complications during treatment with vitamin K antagonists: a cohort study in 8188 patients with atrial fibrillation</td>
<td>Nienke van Rein, Willem Lijfering, Suzanne Cannegieter, Frits Rosendaal, Pieter Reitsma, Felix van der Meer (The Netherlands)</td>
</tr>
</tbody>
</table>

#### Clinical aspects of atherosclerosis  G102-103

**Moderators:** Pieter Willem Kamphuisen and Javier Martin Ramirez (The Netherlands)

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:30 - 14:45</td>
<td>Reduced propagation of blood outgrowth endothelial cells in subjects with advanced subclinical atherosclerosis</td>
<td>Javier Martin Ramirez, Menno Hofman, Maayke Kok, Esther Creemers, Joost Meijers, Jan Voorberg, Sara-Joan Pinto (The Netherlands)</td>
</tr>
<tr>
<td>14:45 - 15:00</td>
<td>Plasma levels of matrix metalloproteinases and circulating endothelial cells in patients with peripheral arterial disease: relationship with disease severity and effect of treatment with prostanoids</td>
<td>Valentina Conti, Emanuela Falcinelli, Tiziana Fierro, Massimo Lenti, Paolo Gresele (Italy)</td>
</tr>
<tr>
<td>15:00 - 15:15</td>
<td>Human coronary thrombus formation is associated with degree of plaque disruption and expression of tissue factor and hexokinase II in atherosclerotic plaques</td>
<td>Shuntaro Matsuda, Nozomi Okuyama, Atsushi Yamashita, Sayaka Monguchi, Yuichiro Sato, Kinta Hatakeyama, Kousuke Marutsuka, Yujiro Asada (Japan)</td>
</tr>
<tr>
<td>15:15 - 15:30</td>
<td>Vitamin K-antagonists: a two edged sword. Bi-phasic effect of VKA on atherosclerotic plaque development</td>
<td>Martijn Chatrou, Dennis Kusters, Chris Reutelingsperger, Leon Schurgers (The Netherlands)</td>
</tr>
</tbody>
</table>
Tuesday, July 2, 2013

ORAL COMMUNICATIONS 14:30 - 15:30

Coagulation - II E102

Moderators: Waander van Heerde (The Netherlands) and Matthew Whelihan (USA)

14:30 - 14:45
TALEN-mediated vitamin K epoxide reductase knockout in human cells for vitamin K cycle study
Jian-Ke Tie, Da-Yun Jin, Kevin Tie, Darrel Stafford (USA)

14:45 - 15:00
Recombinant FVIIa acts independently of tissue factor to restore haemostasis and clot dynamics
Christian Sommer, Mikael Tranholm (Denmark)

15:00 - 15:15
The extended reactive centre loop of protein C inhibitor balances its pro- and anti-coagulant functions
Stéphanie Polderdijk, James Huntington (United Kingdom)

15:15 - 15:30
Contribution of Red Cells to Thrombin Generation In Sickle Cell Disease (SCD)
Matthew Whelihan, Micah Mooberry, Kenneth Ataga, Kenneth Mann, Nigel Key (USA)

Glycoprotein Ib functions Mondriaan III

Moderators: Peter Gross (Canada) and Zane Kaplan (Australia)

14:30 - 14:45
Platelet interaction with von Willebrand factor is enhanced by shear-induced clustering of glycoprotein Ibα
Eelo Gitz, Charlotte Koopman, Cornelis Koekman, Dave van den Heuvel, Hans Deckmyn, Jan-Willem Akkerman, Hans Gerritsen, Rolf Urbanus (The Netherlands)

14:45 - 15:00
Distinct roles for platelet GPIba, PAR4 and fibrin in regulating thrombin-dependent recruitment of leukocytes to sites of vascular injury
Zane Kaplan, Imala Alwis, Yuping Yuan, Mehran Ghasemzadeh, Simone Schoenwaelder, Zaverio Ruggeri, Shaun Jackson (Australia)

15:00 - 15:15
Platelet adhesion and activation by the oral colonizer Streptococcus oralis: key roles for platelet receptors GPIba, FcgRIIa and P2Y12
Dorothea Tilley, Monica Albert, Albert Smolenski, Dermot Cox, James O’Donnell, C. Douglas, Steve Watson, Steven Kerrigan (Ireland)

15:15 - 15:30
Macrotrombocytopenias with abnormalities of the VWF/GP Ib-IX/filamin A/myosin 2A axis correspond to defects in megakaryocyte membrane formation and abnormal granule repartition
Paquita Nurden, Xavier Pillois, Johann Denizot, Alan Nurden, Rémi Favier, Nicole Schlegel, Augusto Federici, Najet Debili (France)

Infection and coagulation Mondriaan IV

Moderators: John Morser (USA) and Cornelis van ’t Veer (The Netherlands)

14:30 - 14:45
Platelets control CVB3 infection in vivo
Carolina Jaquenod De Giusti, Lucrecia Alberdi, Emilia Scharrig, Leonardo Rivadeneyra, Ricardo Gomez, Mirta Schattner (Argentina)

14:45 - 15:00
ProCPB2 (TAFI) deficiency protects against polymicrobial sepsis
John Morser, Toshihiko Nishimura, Zhifei Shao, Lawrence Leung (USA)

15:00 - 15:15
Influenza and Dengue Viruses Upregulate Interferon-Induced Transmembrane (IFITM) Proteins in Human Platelets: Novel Immune Sensing of Viral Pathogens
Matthew Rondina, Neal Tolley, Hans Schwertz, Raul Diaz-Ortiz, Robert Hunter-Mellado, Fernando Bozza, Christa DeVette, Guy Zimmerman, Valance Washington, Andrew Weyrich (USA)
### Thrombin-mediated fibrin generation supports innate defense against pulmonary plague in mice

**Moderators:** Anand Chandrasekhar (USA) and Nigel Mackman (USA)

**OC 46.4**

**Tuesday, July 2, 2013**

**14:30 - 15:30**

**ORAL COMMUNICATIONS**

**Emerald**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:30 - 14:45</td>
<td>A Sensitized Whole Genome ENU Mutagenesis Screen Identifies an Arp2 Missense Mutation As a Novel Suppressor of Lethal Thrombosis in the Factor V Leiden Mouse</td>
<td>Randal Westrick, Guojing Zhu, Kart Tomberg, David Siemieniak, Sara Haynes, Jishu Xu, Jun Li, David Ginsburg (USA)</td>
</tr>
<tr>
<td>14:45 - 15:00</td>
<td>Genetic variants in Cell Adhesion Molecule 1 (CADM1): a validation study of a novel endothelial cell venous thrombosis risk factor</td>
<td>Hugoline de Haan, Irene Bezemer, Astrid van Hylckama Vlieg, Carla Vossen, Stefan Böhringer, Sandra Hasstedt, Samuel Levy, Frits Rosendaal, Edwin Bovill (The Netherlands)</td>
</tr>
</tbody>
</table>

### Inherited risk factors for venous thrombosis - II

**Moderators:** Anne Goodeve [United Kingdom] and Randal Westrick [USA]

**Emerald**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:30 - 14:45</td>
<td>Exacerbated venous thromboembolism in mice with the protein S Tokushima mutation</td>
<td>Fumiaki Banno, Toshiyuki Kita, Hiroji Yanamoto, Yuko Tashima, Koichi Kokame, Toshiyuki Miyata (Japan)</td>
</tr>
<tr>
<td>14:45 - 15:00</td>
<td>Functional analysis of the thrombomodulin gene c.1418C&gt;T polymorphism. Its association with venous thrombosis</td>
<td>Elena Bonet, Pilar Medina, Laura Martos, Vicenta Martinez-Sales, Javier Corral, Marta Gurrea, Silvana Aniorte, Rogier Bertina, Francisco España, Silvia Navarro (Spain)</td>
</tr>
</tbody>
</table>

### Inhibitors in haemophilia A - II

**Moderators:** Yesim Dargaud [France] and Roger Schutgens [The Netherlands]

**Elicium 1**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:30 - 14:45</td>
<td>Prediction of the extent and duration of desmopressin response in moderate and mild haemophilia A</td>
<td>Sara Stoof, Moniek de Maat, Marjon Cnossen, Frank Leebeek, Marieke Kruip (The Netherlands)</td>
</tr>
<tr>
<td>14:45 - 15:00</td>
<td>FVIII-targeting specific regulatory T-cell therapy: A novel translational approach for tolerance in Hemophilia A patients</td>
<td>Yong Chan Kim, Aihong Zhang, Robert Rossi, Patrick Adair, Jeong Heon Yoon, Ruth Ettinger, Kathleen Pratt, David Scott (USA)</td>
</tr>
<tr>
<td>15:00 - 15:15</td>
<td>Diagnosis and management challenges in patients with mild hemophilia A and discrepant FVIII measurements</td>
<td>Yesim Dargaud, Marc Trossaërt, Anne Lienhart, Christophe Nougier, Mathilde Fretigny, Claude Negrier (France)</td>
</tr>
<tr>
<td>15:15 - 15:30</td>
<td>Improvement of fibrin clot structure after FVIII injection in hemophilia A patients treated on demand</td>
<td>Aleksandra Antovic, Danijela Mikovic, Michael Zabczyk, Shu He, Ivo Elezovic, Kjell Hutenby, Jovan Antovic (Sweden)</td>
</tr>
</tbody>
</table>
Tuesday, July 2, 2013

14:30 - 15:30

ORAL COMMUNICATIONS

14:30 - 15:30

Prothrombin Forum

Moderators: Maria Aleman (USA) and Sriram Krishnaswamy (USA)

14:30 - 14:45
OC 49.1
Crystal structure of the prothrombinase complex from the venom of Pseudonaja textilis
Thomas Murray-Rust, Bernhard Lechtenberg, Ty Adams, Daniel Johnson, Rodney Camire, Sriram Krishnaswamy, James Huntington (United Kingdom)

14:45 - 15:00
OC 49.2
NMR and crystallographic studies demonstrate that GpIba interacts exclusively with thrombin’s exosite II
James Huntington, Bernhard Lechtenberg, Stefan Freund (United Kingdom)

15:00 - 15:15
OC 49.3
Elevated prothrombin promotes venous, but not arterial, thrombosis in mice: implications for investigating vascular bed-specific mechanisms in humans
Maria Aleman, Bethany Walton, James Byrnes, Jian-Guo Wang, Matthew Heisler, Kellie Machlus, Brian Cooley, Alisa Wolberg (USA)

15:15 - 15:30
OC 49.4
Prothrombin activation intermediates bind thrombomodulin demonstrating sequential capacitation of exosite 1
Calvin Yeh, Michael DeDominicis, Colin Kretz, James Fredenburgh, Jeffrey Weitz (Canada)

Rare bleeding disorders - I

Moderators: Elisabetta Castoldi (The Netherlands) and Flora Peyvandi (Italy)

14:30 - 14:45
OC 50.1
Antisense-based RNA therapy of severe coagulation factor V deficiency: in vitro and ex vivo rescue of a F5 deep-intronic splicing mutation
Francesca Nuzzo, Claudia Radu, Marco Baralle, Luca Spiezia, Paolo Simioni, Elisabetta Castoldi (The Netherlands)

14:45 - 15:00
OC 50.2
Delivery of a modified U1 small nuclear RNA alleviates splicing-defective coagulation Factor VII expression in mouse models
Dario Balestra, Armida Faella, Nicola Cavallari, Paris Margaritis, Franco Pagani, Francesco Bernardi, Valder R. Arruda, Mirko Pinotti (Italy)

15:00 - 15:15
OC 50.3
A very rare simultaneous presence of a ring chromosome 13 and a splicing site mutation on Factor X gene
Marzia Menegatti, Dario Balestra, Benedetta Fabrizzi, Rosanna Asselta, Mirko Pinotti, Flora Peyvandi (Italy)

15:15 - 15:30
OC 50.4
Characterisation of an apparently synonymous F5 mutation causing aberrant splicing and factor V deficiency
Elisabetta Castoldi, Cristiana Bulato, Francesca Nuzzo, Brenda Nielsen, Kristy Lee, Nigel Key, Paolo Simioni (The Netherlands)
Tuesday, July 2, 2013

**ORAL COMMUNICATIONS**

**Treatment for haemophilia**

Elicium 2

**Moderators:** Howard Chan (Canada) and Michael Makris (United Kingdom)

**14:30 - 14:45**

**OC 51.1**  A novel prediction model for inhibitor development in severe hemophilia A

Said Mojtaba Hashemi, Kathelijn Fischer, Marijke van den Berg (The Netherlands)

**14:45 - 15:00**

**OC 51.2**  An in vitro Model Studying the Effects of Rivaroxaban and Dabigatran on Clot Formation in Factor VIII-depleted Plasma Mimicking the Plasma of Hemophilia A Patients

Howard Chan, Frank Lee, Ivan Stevic, Leslie Bery, Keith Lau, Anthony Chan (Canada)

**15:00 - 15:15**

**OC 51.3**  Binding and inhibition of cell surface tissue factor pathway inhibitor by an inhibitory fusion peptide

Michael Dockal, R. Pachlinger, A. Baldin-Stoyanova, F. Knofl, N. Ullrich, Hartmut Ehrlich, F. Scheiflinger (Austria)

**15:15 - 15:30**

**OC 51.4**  Plasma-derived factor IX concentrates, but not rFIX, support direct platelet activation and microparticle formation and, as a result of this, increase platelet mediated endogenous thrombin potential

Anne Bertling, Kerstin Griess, Martin Brodde, Anja Müller, Beate Kehrel (Germany)

**TTP/thrombotic microangiopathies**

Mondriaan II

**Moderators:** Catarina Silva Pinto (Portugal) and X Long Zheng (USA)

**14:30 - 14:45**

**OC 52.1**  Intensive Care Outcomes of patients with Thrombotic Thrombocytopenic Purpura: a single centre study

Joana Alcada, Catherine Hockings, Alice Taylor, Siobhan McGuckin, John-Paul Westwood, David Walker, Marie Scully, Niall MacCallum (United Kingdom)

**14:45 - 15:00**

**OC 52.2**  ADAMTS13 and von Willebrand factor antigen levels in patients with severe leptospirosis

Ekoadhi Pangarsa, Muhammad Hussein Gasem, Nur Forhanah, Catharina Suharti, Bambang Isbandrio (Indonesia)

**15:00 - 15:15**

**OC 52.3**  Very early onset of autoimmune thrombotic thrombocytopenic purpura in five children with polynesian origin in four combined with immunodeficiency

Magnus Mansouri Taleghani, Peter Bradbeer, Nyree Cole, George Chan, Bernhard Lämmle, Johanna Kremer Hovinga (Switzerland)

**15:15 - 15:30**

**OC 52.4**  Genetic predisposing factors in 5 portuguese patients with atypical hemolytic uremic syndrome - identification of a new mutation in the CFH gene

Catarina Silva Pinto, Teresa Fidalgo, Patrícia Martinho, Ramón Salvado, Ana Oliveira, Elsa Gonçalves, Teresa Sevivas, Natália Martins, Maria Letícia Ribeiro (Portugal)
For the XXIV congress, ISTH has decided to innovate its poster sessions by introducing a new Electronic Poster format. Posters will not be presented in a paper format. Instead, all posters will be presented in the format of ePoster sessions on large touch-screens.

In the sessions, the ePosters will be presented and discussed in the sequence indicated in the programme.

**Antiplatelet agents: Aspirin - I**  
*Moderator: Dermot Cox [Ireland]*

**Screen 01**

**PA 2.01-1**  
The response to enteric-coated aspirin is weight-dependent in multiple assays  
Dermot Cox, Meadhbh McCall, Aaron Peace, Ronan Conroy, David Foley [Ireland]

**PA 2.01-2**  
Lack of aspirin resistance in patients with coronary artery disease  
Emese Kovács, Nóra Homoródi, Éva Katona, Zsuzsanna Bereczky, László Balogh, Hajna Péterfy, Róbert Kiss, István Édes, László Muszbek [Hungary]

**PA 2.01-3**  
The relationship between antiplatelet drug therapy and platelet microparticle formation and procoagulant activity in normals and patients with cardiovascular disease  
Ken Ly, Anoosha Aslam, Joyce Low, Susan Jarvis, David Connor, Joanne Joseph [Australia]

**PA 2.01-4**  
Safety and efficacy of dual antiplatelet therapy in transcatheter aortic valve implantation  
Holger Seidel, Tobias Zeus, Mathias Schleicher, Amin Polzin, Malte Kelm, Thomas Höflheld, Elisabeth Kirchhoff, Rüdiger Scharf [Germany]

**PA 2.01-5**  
Twice-daily administration of low-dose aspirin to patients with ischemic cerebrovascular disease  
María Teresa Santos, Aida Lago, Antonio Moscardo, Ana Latorre, Juana Valles [Spain]

**PA 2.01-6**  
Microfluidic assay of platelet deposition on collagen using perfusion of whole blood from healthy subjects taking aspirin  
Ruizhi Li, Susanne Fries, Xuanwen Li, Tilo Grosser, Scott Diamond [USA]

**Platelet activation: Novel proteins - II**  
*Moderator: Brian Branchford [USA]*

**Screen 02**

**PA 2.02-1**  
Mitochondrial permeability transition pore dependent intracellular pH elevation is associated with enhanced calpain activity and integrin αIIbβ3 inactivation  
Fang Liu, Shawn Jobe [USA]

**PA 2.02-2**  
Redundant functions of TRPC6 and Orai1 in murine platelets  
Wenchun Chen, Shuchi Gupta, Ina Thielmann, Sanjeev Gotru, Roger van Kruchten, Alexander Dietrich, Johan Heemskerk, Bernhard Nieswandt, Attila Braun [Germany]

**PA 2.02-3**  
The Chaperone Protein, Heat Shock Protein 47 [Hsp47]: A Novel Platelet Collagen Receptor that Contributes to Thrombosis and Haemostasis  
Parvathy Sasikumar, William Kaiser, Sakthivel Vaiyapuri, Tanya Sage, Leonardo Moraes, Richard Farndale, Jonathan Gibbins [United Kingdom]

**PA 2.02-4**  
Inhibition of the Gas6/Mer Pathway with novel compounds recapitulates the antithrombotic phenotype of Gas6−/− or Mer−/− mice in arterial and venous thrombosis models  

**PA 2.02-5**  
VacA, the vacuolating cytotoxin of Helicobacter pylori, binds to multimerin 1 associated with platelet membranes  
Kaneo Satoh, Hirayama Toshiya, Takano Katsuhiro, Sato Tadashi, Ozaki Yukio [Japan]
Tuesday July 2, 2013  
17:00 – 18:30

PA 2.02-6  Rational targeting of Rac-NOX2 pathway prevents ROS generation and platelet activation involving MLC, Akt and Ca++-PKC signaling induced by diverse agonists  
Huzoor Akbar, Saima Saleem, Ashley Kuenzi, Yi Zheng (USA)

Platelet signal transduction - I  
Moderator: Anne Dominique Terrisse (France)

PA 2.03-1  Antiphospholipid antibodies-mediated platelet activation: a key role of PI3Ks beta and alpha  
Anne Dominique Terrisse, Cédric Garcia, Sonia Séverin, Pierre Alexandre Laurent, Marie Pierre Gratacap, Bart van Haesbroeck, Pierre Sié, Bernard Payrastre (France)

PA 2.03-2  Partial inhibition of serine/threonine phosphatase PP2A blocks clot retraction without reducing alphallbbeta3 receptor activation  
Antonio Moscardó, Juana Vallés, Ana Latorre, Isabel Madrid, María Ángeles Dasí, María Teresa Santos (Spain)

PA 2.03-3  Autocrine amplification of integrin allbβ3 activation and platelet adhesive responses by deoxyribose-1-phosphate  
Giordano Pula, Dina Vara (United Kingdom)

PA 2.03-4  Canonical and non-canonical cleavage patterns for protease-activated receptor (PAR) 1 and 3 by factor Xa reveal novel insights into the allosteric modulation of cytoprotective PAR1 signaling by PAR3  
Fabian Stavenuiter, Laurent Mosnier (USA)

PA 2.03-5  Immobilized heparin enhances allbβ3-dependent outside-in signaling in human platelets  
Marianna Gyenes, Katharina Wildt, Volker Stoldt, Rüdiger Scharf (Germany)

PA 2.03-6  Purinergic receptor modulation of platelet function in vitro and ex vivo  
Stefania Momi, Richard Amison, Stefania Momi, Paolo Gresele, Clive Page, Pitchford Simon (Italy)

Megakaryocytes and thrombopoiesis - II  
Moderator: Laura Gutierrez (The Netherlands)

PA 2.04-1  Microtubule plus-end tracking protein CLASP2 K0 mice phenocopy CAMT: A role for CLASP2 in hematopoiesis and hematopoietic stem cell maintenance  
Laura Gutierrez, Dubravka Drabek, Catherine Robin, Niels Galjart, Marcel Vermeij, Thomas Clapes, Sunita Patel, Jean-Charles Boisset, Jeffrey van Haren, Ana Pereira, Zhe Liu, Umut Akinci, Tatjana Nikolic, Wilfred van Ijcken, Mirjam van den Hout, Marjolein Meinders, Clara Melo, Clara Sambade, Ksenija Drabek, Rudi Hendriks, Sjaak Philipson, Mieke Mommaas, Frank Grosveld, Helder Maiato, Joseph Italiano, Catherine Robin, Niels Galjart (The Netherlands)

PA 2.04-2  The epigenetic landscape of platelet and red blood cell traits  
Dirk Paul, Cornelis Albers, Augusto Rendon, Katrin Voss, Jonathan Stephens, Pim van der Harst, John Chambers, Nicole Soranzo, Willem Ouweland, Panos Deloukas (United Kingdom)

PA 2.04-3  Biogenesis of the Demarcation Membrane System in Megakaryocytes  
Anita Eckly, Harry Heijnen, Fabien Pertuy, Fabienne Proamer, Jean-Yves Rinckel, François Lanza, Christian Gachet (France)

PA 2.04-4  Platelet bioreactor-on-a-chip  
Jonathan Thon, Linas Mazutis, David Weitz, Joseph Italiano (USA)
**Tuesday July 2, 2013 17:00 – 18:30**

**PA 2.04-5**  
**Sp1/Sp3 transcription factors are essential for megakaryopoiesis**  
Divine Kulu, Marjolein Meinders, Guntram Suske, Laura Gutierrez, Sjaak Philipsen  
The Netherlands

**PA 2.04-6**  
**Microtubule plus-end tracking APC negatively regulates proplatelet formation**  
Catherine Strassel, Anne Bull, Cécile Leguay, Anita Eckly, Monique Freund, Bart Williams, Christian Gachet, François Lanza  
France

**Platelets and genes**  
Moderator: Suzanne Korporaal  
The Netherlands

**PA 2.05-1**  
**The platelet response is inherited and dependent on the number of shared alleles**  
Suzanne Korporaal, Frederiek Estourgie-van Burk, Chris Jones, Meike Bartels, Dorret Boomsma, Willem Ouwehand, Alison Goodall, Philip de Groot  
The Netherlands

**PA 2.05-2**  
**Genome-wide association study of aspirin and clopidogrel response in patients with percutaneous coronary intervention**  
Ayse Anil Timur, Gurunathan Murugesan, John Barnard, Sanjay Gandhi, Deepak Bhatt, Kandice Kottke-Marchant  
USA

**PA 2.05-3**  
**Systematic characterization of human platelets by quantitative proteomics**  
Julia Burkhart, Marc Vaudel, Kristin Becker, Stepan Gambaryan, Ulrich Walter, Lennart Martens, Jörg Geiger, Albert Sickmann, René Zahedi  
Germany

**PA 2.05-4**  
**Association between the Microarray-Based CYP2C19 Genotyping Assay and the Platelet Function Test in Cardiovascular Patients Receiving Clopidogrel**  
Jae-Lim Choi, Bo-Ram Kim, Ji-Eun Kim, Kwang-Sook Woo, Kyeoung-Hee Kim, Jeong-Man Kim, Moo-Hyun Kim, Jin-Yeong Han  
South-Korea

**PA 2.05-5**  
**Genes in arterial thrombus formation: a comparison of in vivo and in vitro studies**  
Susanne de Witt, Reyhan Nergiz-Unal, Marion Feige, Anna Wiese, Steve Jupe, Martin Prins, Judith Cosemans, Johan Heemskerk  
The Netherlands

**PA 2.05-6**  
**A new aIIb platelet antigen p.M841 (HPA-27bw) involved in materno-fetal alloimmunization and HPA-27bw genotyping by PCR-HRM (High Resolution Melting) technique**  
Vincent Jallu, Gerald Bertrand, Emilie Le Toriellec, Frederic Bianchi, Christophe Chenet, Pierre Poulain, Cecile Kaplan  
France

**Haemophilia A: Clinical - V**  
Moderator: Annelies Nijdam  
The Netherlands

**PA 2.06-1**  
**Treatment for Life for Severe Haemophilia A. A Cost-Utility Model for Prophylaxis versus On-Demand Treatment**  
Albert Farrugia, Megha Bansal, Josephine Cassar, Mary Clare Kimber, Guenter Auerswald, Kathelijin Fischer, Brian O’Mahony, Declan Noone, Keith Tolley  
USA

**PA 2.06-2**  
**Severe haemophilia a: different regimens for starting prophylaxis (in PedNet)**  
Annelies Nijdam, Pia Petrimi, M. Carcao, Karin Kurnik, Gunter Auerswald, Bearice Nolan, Rolf Ljung, A. Molinari, A. Makipernaa, Kathelijin Fischer  
The Netherlands

**PA 2.06-3**  
**Population pharmacokinetic analysis of long-lasting recombinant factor VIII Fc fusion protein (rFVIIIFc) in patients with severe haemophilia A**  
Srividy Neelakantan, Shuanglian Li, Jerry Powell, Neil Josephson, John Pasi, David Perry, Amy Shapiro, Margaret Ragni, Roshni Kulkarni, Patrick Fogarty, Aoiife Brennan, Glenn Pierce, Haiyan Jiang, Ivan Nestorov  
USA
Tuesday July 2, 2013  
17:00 – 18:30

PA 2.06-4  High-resolution peripheral quantitative computed tomography (HR-pQCT): a novel imaging technology detects microarchitectural skeletal pathology in hemophilia patients
Adrienne Lee, Steven Boyd, Gregory Kline, Man-Chiu Poon (Canada)

PA 2.06-5  Association between predicted FVIII levels and risk of bleeding episodes in clinical trials with turoctocog alfa, a new rFVIII product from Novo Nordisk
Margareth Ozelo, Dobrila Veljkovic, Robert Klarmroth, Mudi Misgav, Rasmus Nielsen, Andreas Groth (Brazil)

PA 2.06-6  Parameters influencing factor VIII half-life and recovery in patients with haemophilia A
Sylvia Kepa, Sylvia Reitter-Pfoertner, Birgit Horvath, Max Heistinger, Peter Neumeister, Sabine Rosenlechner, Gerhard Schuster, Barbara Petz, Christine Mannhalter, Ingrid Pabinger (Austria)

Haemophilia B - II  
Moderator: Hendrika Hazendonk (The Netherlands)

PA 2.07-1  A retrospective observational multicenter cohort study on peri-operative Factor IX consumption in Haemophilia B (‘OPTI-CLOT’ studies)
Hendrika Hazendonk, Janske Lock, Karin Fijnvandraat, Karina Meijer, Rienk Tamminga, Marieke Kruij, Frank Leebeek, Ron Mathôt, Marjon Cnossen (The Netherlands)

PA 2.07-2  Is hemophilia B less severe than hemophilia A in young children with same level of factor deficiency?
Niels Clausen, Maria Elisa Mancuso, Ségolène Claeyssens-Donadel, Pia Pettrini, Ri Liesner, Samantha Gouw (Denmark)

PA 2.07-3  Identification of eleven new mutations in the factor IX gene in patients with haemophilia B
Thais Trento, Lucia Siqueira, Andrey Santos, Marcelo Veiga, Sylvia Thomas, Anelisa Streve, Alessandra Prezzotti, Samuel Medina, Margareth Ozelo (Brazil)

PA 2.07-4  Long-Lasting Recombinant Factor FIXFc Fusion (rFIXFc) for Perioperative Management of Subjects with Haemophilia B in the Phase 3 B-LONG Study
Jerry Powell, Shashikant Apte, Herve Chambost, Cedric Hermans, Shannon Jackson, Neil Josephson, Johnny Mahlangu, Margaret Ozelo, Kathelijine Peertinck, Geoffrey Allen (USA)

PA 2.07-5  Clinical implications of population pharmacokinetics of rFIXFc in routine prophylaxis, control of bleeding and perioperative management for haemophilia B patients
Shuanglian Li, Lei Diao, Jerry Powell, Amy Shapiro, Neil Josephson, John Pasi, David Perry, Margaret Ragni, Roshni Kulkarni, Len Valentino, Aoife Brennan, Glenn Pierce, Ivan Nestorov, Haiyan Jiang (USA)

PA 2.07-6  Treatment of Bleeding Episodes in Subjects with Haemophilia B with the Long-Lasting Recombinant Factor IX Fc Fusion Protein (rFIXFc) in the Phase 3 B-LONG Study
John Pasi, Neil Josephson, Johnny Mahlangu, David Perry, Jerry Powell, Margaret Ragni, Leonard Valentino, Snejana Krassova, Karen Nugent, Aoife Brennan, Alison Innes, Alvin Luk, Glenn Pierce, Geoffrey Allen (United Kingdom)
Von Willebrand factor: Clinical - I

Moderator: Karin van Galen (The Netherlands)

PA 2.08-1  Clinical efficacy and safety of DDAVP with or without tranexamic acid in inherited VWD: final results of the prospective and international study on 229 patients
Augusto Federici, Giancarlo Castaman, Alfonso Iorio, Mariana Bonduel, Elbio D’Amico, Emily Olovecchio, Cristina Santoro, Simona Siboni, Barbara Zieger, Pier Mannucci [Italy]

PA 2.08-2  The Merging Project: A machine learning approach to merge and analyze data from four different bleeding questionnaires
Shamim Mollah, Julie Grabell, Margaret Rand, Dewi Clarke, Pam Christopherson, Andreas Mauer, Robert Montgomery, The Zimmerman Program Investigator, Barry Collier, Paula James [USA]

PA 2.08-3  Hemophilia arthropathy occurs in a significant percentage in von Willebrands disease
Karin van Galen, Yvonne Sanders, Tamara Schaefer, Jeroen Eikenboom, Anske van der Bom, Karin Fijnvandraat, Karina Meijer, Frank Leebeek, Evelien Mauser-Bunschoten [The Netherlands]

PA 2.08-4  Validation of a micro assay for the diagnosis and characterisation of von Willebrand disease
Marije Baaij, Roger Schutgens, Rolf Urbanus, Wailung Leung, Britta Laros, Waander van Heerde, Yvonne Sanders, Frank Leebeek, Philip de Groot, Mark Roest [The Netherlands]

PA 2.08-5  Comparison of two automated latex-based VWF activity assays of differing principles with a standard VWF:RCo platelet aggregometry technique
Gary Moore, Katarzyna Mayger, Bella Madan [United Kingdom]

PA 2.08-6  RNA analysis for Von Willebrand disease; it has a role but it’s not the answer
Medard Hadonou, Steve Austin, Jacky Cutler, Mike Mitchell [United Kingdom]

Von Willebrand factor - II

Moderator: Ruben Bierings (The Netherlands)

PA 2.09-1  Von Willebrand factor as a surrogate marker for coronary artery calcification: the rotterdam study
Michelle Sonneveld, Maryam Kavousi, Janine van Loon, Aad van der Lugt, Frank Leebeek, Albert Hofman, Jacqueline Witteman, Oscar Franco, Moniek de Maat [The Netherlands]

PA 2.09-2  Von Willebrand factor propeptide (VWFpp) a marker useful for identifying adverse platelet activation in murine blood phlebotomy samples
Paula Jacobi, Sachiko Kanaji, Ashley Gehrand, David Jakab, Sandra Habrichter [USA]

PA 2.09-3  Isolation of blood outgrowth endothelial cells from early infantile epileptic encephalopathy 4 (EIEE4) and familial hemophagocytic lymphohistiocytosis 5 (FHL5) patients
Ruben Bierings, Dorothee van Brevoort, Menno Hofman, Timo van den Berg, Sarah Weckhuysen, Peter de Jonghe, Jan Voorberg [The Netherlands]

PA 2.09-4  Active VWF predicts four week mortality in patients with SIRS
Agon Hyseni, Hans Kemperman, Dylan de Lange, Matthijs Linssen, Jozef Kesecioglu, Philip de Groot, Mark Roest [The Netherlands]

PA 2.09-5  Matrix metalloproteinase-13 influences thrombus formation through the cleavage of VWF
Joanna-Marie Howes, Nicholas Pugh, Pete Smethurst, Dominique Bihan, Richard Farndale [United Kingdom]

PA 2.09-6  Von Willebrand factor and ADAMTS-13 in hypertensive disorders of pregnancy
Nervana Bayoumy, Ashwaq Al-Sharaidh, Zainab Babay, Abdulgali Abdulgader [Saudi Arabia]
**Anticoagulant agents - VII**

**Moderator: Todd Moore (USA)**

**PA 2.10-1** Novel vkorC1 variants are associated with the higher acenocoumarol requirements

Anton Ana, Juan Jose Cerezo-Manchado, Martinez Constantino, Padilla Jose, Virginia Perez-Andreu, Corral Javier, Vicente Vicente, Roldan Vanesa, Rocío González-Concejero [Spain]

**PA 2.10-2** Ensuring an efficient transition from rivaroxaban to warfarin: a pharmacodynamic study in healthy subjects

Todd Moore, Seema Vaidyanathan, Jaya Natarajan, Jay Ariyawansa, Kenneth Turner, William Byra [USA]

**PA 2.10-3** Postdischarge mortality risk and risk factors for mortality in acutely ill medical patients following hospitalization

Charles Mahan, Larry Fields, Roger Mills, Judith Stephenson, An-Chen Fu, Maxine Fisher, Alex Spyropoulos [USA]

**PA 2.10-4** A high risk of falls is associated with an increased risk of medically-relevant non-major bleeding in elderly patients receiving anticoagulants

Marie Mêan, Drahomir Aujesky, Andreas Limacher, Pascal Kämpfen [Switzerland]

**PA 2.10-5** Reversal of the effects of new oral anticoagulants by administration of FEIBA

Alexandra Schiviz, Dagmar Verdino, Gerald Schrenk, Marlene Resch, Isabelle Neyens, Barbara Dietrich, Peter Turecek, Friedrich Scheiflinger, Eva-Maria Muchitsch, Werner Höllriegl [Austria]

**PA 2.10-6** Methodological problems in network meta-analysis of studies with the new oral anticoagulants

Job Harenberg, Christel Weiss, Christel Weiss [Germany]

**Blood coagulation tests - VI**

**Moderator: Ganeshram Krishnamoorthy (The Netherlands)**

**PA 2.11-1** Thrombin generation monitored in capillary blood with a calibrated automated thrombogram-based assay

Ganeshram Krishnamoorthy, Arpita De, Marisa Ninivaggi, Rafael Apitz-Castro, Edwin Carlen, Arina ten Cate-Hoek, Coenraad Hemker, Bas de Laat, Theo Lindhout [The Netherlands]

**PA 2.11-2** Optical Tracking of Acoustic Radiation Force Induced Motion in Plasma to Estimate Viscoelastic Measurements of Blood Coagulation

Caroline Wang, Matthew Perez, Francesco Viola, Michael Lawrence [USA]

**PA 2.11-3** Six novel missense mutations causing factor X deficiency and application of thrombin generation test

Qian Liang, Qiong Chen, Qiulan Ding, Fang Wu, Xuefeng Wang, Xiaodong Xi, Hongli Wang [China]

**PA 2.11-4** Fibrinogen activity determined by rotational thromboelastometry is affected by high haematocrit

Sarah Westbury, Kurtis Lee, Christopher Reilly-Stitt, Robert Tulloh, Andrew Mumford [United Kingdom]

**PA 2.11-5** Evaluation of the activated partial thromboplastin time assay for clinical monitoring of PEGylated recombinant factor VIII (BAY 94-9027) for hemophilia A

Jian-Ming Gu, Philip Ramsey, Vince Evans, Liang Tang, Heiner Apeler, Lilley Leong, John Murphy, Volker Laux, Timothy Myles [USA]

**PA 2.11-6** Investigation of the use of a proteomic approach to detect intravascular coagulation

Christopher Goodwin, Michael Scully, Ajay Kakkar [United Kingdom]
**Coagulation factor VIII - III**  
*Screen 12*

**Moderator: Rupa Shree Appa (Norway)**

**PA 2.12-1**  
Enhancing expression of coagulation factor VIII through bioengineering: Strategic introduction of Asn-linked glycan improves secretion  
Sundar Rajan Selvaraj, Hongzhi Miao, Steven Pipe (USA)

**PA 2.12-2**  
Functional consequences and founder effect of a recurrent mutation of F8 (c.6046C>T, p.R2016W) in patients with hemophilia A from Northern Italy  
Isabella Garagiola, Mimosa Mortarino, Maria Elisa Mancuso, Maria Rosaria Fasulo, Sabrina Seregini, Elena Santagostino, Luca Andrea Lotta, Flora Peyvandi (Italy)

**PA 2.12-3**  
Characterization of missense mutations in the B domain of coagulation factor VIII reported to be associated with mild/moderate hemophilia A  
Sundar Rajan Selvaraj, Steven Pipe (USA)

**PA 2.12-4**  
In vivo and hepatocellular distribution of FVIII in rats is independent of high affinity binding to VWF  
Cristina Øie, Ditte Karfp, Carsten Behrens, Jesper Kristensen, Marianne Kjalke, Johan Karlsson, Henning Stennicke, Bard Smedsrod, Rupa Shree Appa (Norway)

**PA 2.12-5**  
A combinatorial library approach to generate rFVIII variants with multiple XTEN insertions and improved pharmacokinetic properties  
Tongyao Liu, John Kulman, Pei-Yun Beth Chang, Susannah Patarroyo-White, Douglas Drager, Sheng Ding, Ekta Seth Chhabra, Sampath Kumar, Bob Pape, Nancy Moore, Sara Bardan, Allison Goodman, Marisol Acosta, Glenn Pierce, Volker Schellenberger, Baisong Mei, Robert Peters, Haiyan Jiang (USA)

**PA 2.12-6**  
B domain-deleted FVIII lacking mannose-ending glycans at Asn239 and Asn2118 retains pro-coagulant activity and corrects bleeding in FVIII-deficient mice  
Julie Rayes, Sandrine Delignat, Ghislaine Cherel, Suryasarathi Dasgupta, Srinivas Kaveri, Cécile Denis, Sébastien Lacroix-Desmazes, Olivier Christophe (France)

---

**Factor II/Prothrombin - I**  
*Screen 13*

**Moderator: Gerry Nicolaes (The Netherlands)**

**PA 2.13-1**  
Structure-function analysis of prothrombin-D519E, a causative mutation in a type 1/2 prothrombin deficient patient with a severe bleeding tendency  
Roy Schrijver, Philip Kuipper, Jan Rosing, Natasja Dors, Gerry Nicolaes (The Netherlands)

**PA 2.13-2**  
Identifying novel thrombin interactions: alpha-synuclein binds to thrombin exosites and inhibits thrombin-mediated platelet aggregation  
Vincenzo De Filippis, Laura Acquasaliente, Giulia Pontarollo, Roberta Frasson, Fabio Maset, Alessandra Banzato, Vittorio Pengo, Alessandro Negro (Italy)

**PA 2.13-3**  
Amino acid sequence 473-487 of human prothrombin is required for timely activation by prothrombinase and optimal thrombin activity  
Joesph Wiencek, Jamila Hirbawi, Michael Kalafatis (USA)

**PA 2.13-4**  
A novel prothrombin c.1787G>A mutation in Serbian family with recurrent thromboembolism- another case of antithrombin resistance  
Djordjevic Valentina, Mirjana Kovac, Iva Pruner, Djordje Francuski, Dragica Radojkovic (Serbia)

**PA 2.13-5**  
Effects of prothrombin Yukuhashi mutation on thrombomodulin-protein C system  
Yuki Takagi, Akira Takagi, Atsuo Suzuki, Moe Murata, Eriko Okuyama, Yumi Ando, Io Kato, Tadashi Matsushita, Hidehiko Saito, Tetsuhito Kojima (Japan)

**PA 2.13-6**  
Evaluation of a new chromogenic method based upon the prothrombinase complex for determination of the functional activity of prothrombin  
Per Rosén, Pia Bryngelheld, Steffen Rosén (Sweden)
Tuesday July 2, 2013  17:00 – 18:30

**Regulation of coagulation and fibrinolysis - I**  
*Screen 14*

**Moderator:** Cong Lin [The Netherlands]

**PA 2.14-1**  
**Inhibitory effects of LDL-associated tissue factor pathway inhibitor**  
Cecilia Augustsson, Ida Hilden, Lars Petersen [Denmark]

**PA 2.14-2**  
**The effect of fibrin(-ogen) on thrombin generation and decay**  
Romy Kremers, Rob Wagenvoord, Coenraad Hemker [The Netherlands]

**PA 2.14-3**  
**Role of the serpin protease Nexin-1 in tissue remodelling occurring during pulmonary fibrosis**  
Déborah François, Joëlle Marchal-Sommé, Bruno Crestani, Marie-Christine Bouton [France]

**PA 2.14-4**  
**Structural and functional studies of a monoclonal high affinity antibody against the human TFPI Kunitz-type protease inhibitor (KPI) 3 domain**  
Anders Svensson, Lars Christian Petersen, Birgitte Kjaer, Berit Olsen Krogh, Jens Breinholt, Chao Tzu-Yuan, Xia Wenjuan, Yang Li, Helle Heibrock Petersen [Denmark]

**PA 2.14-5**  
**Apolipoprotein(a) inhibits the conversion of Glu-plasminogen to Lys-plasminogen on the surface of vascular endothelial and smooth muscle cells**  
Rocco Romagnuolo, Kristen DeMarco, Michael Boffa, Marlys Koschinsky [Canada]

**PA 2.14-6**  
**TF/FVIIa mediated activation of FIX and PAR-2 escapes inhibition by TFPI under conditions of concomitant TFPI blockage of FX activation**  
Lars Petersen, Ida Hilden [Denmark]

---

**Tissue factor - II**  
*Screen 15*

**Moderator:** Martina Schmidt [Germany]

**PA 2.15-1**  
**Increased mortality in SIRS patients with low levels of zymogen and high levels of activated coagulation factor VII**  
Agon Hyseni, Philip de Groot, Hans Kemperman, Dylant de Lange, Matthijs Linssen, Jozef Kesecioglu, Ton Lisman, Mark Roest [The Netherlands]

**PA 2.15-2**  
**Targeting protein C activation to tissue factor: In vivo studies in human tissue factor knock-in mice**  
Martina Schmidt, Andreas Wilmen, Frank Dittmer, Kirk McLean, Volker Laux, Christoph Gerdes [Germany]

**PA 2.15-3**  
**Lung cancer chemotherapy agents induce protein disulphide isomerase dependent tissue factor decyption resulting in increased procoagulant activity in vitro and in vivo**  
Zakhar Lysov, Laura Swystun, Sara Kuruwilla, Andrew Arnold, Patricia Liaw [Canada]

**PA 2.15-4**  
**Tissue factor is not expressed in platelets activated by various agonists**  
Bjarne Østerud, Jan Ole Olsen [Norway]

**PA 2.15-5**  
**PGE2 Cigarette smoke-induced modulates endothelial Tissue Factor: role of EP1 receptor and SIRT1**  
Patrizia Amadio, Silvia Barbieri, Damiano Baldassarre, Eva Tarantino, Mauro Amato, Alessio Ravan, Babette Weksler, Elena Tremoli [Italy]

**PA 2.15-6**  
**Proteomic analysis of tissue factor activation**  
Lena Kask, Anneli Jorsback, Maria Winkvist, Bo Ek, Jonas Bergquist, Agneta Siegbahn [Sweden]
**Cancer and thrombosis - IV**

Moderator: Ankie Kleinjan [The Netherlands]

**PA 2.16-1** Incidence and Predictive Factors of Symptomatic Venous Thromboembolism Related to Port-a-cath in Cancer Patients
Siavash Piran, Vincent Ngo, Sheryl McDiarmid, Grégoire Le Gal, William Petrcich, Marc Carrier [Canada]

**PA 2.16-2** Prediction of venous thromboembolism in cancer patients by tissue factor dependent microparticle coagulant activity, biomarkers and a clinical score
Ankie Kleinjan, Patrick Bossuyt, Gabriela Cesaran-Maus, Marcello Di Nisio, Pieter Willem Kamphuisen, Mark Kramer, Isabelle Mahé, Prabath Nanayakkara, Rienk Nieuwland, Hans-Martin Otten, Alain Stephanian, Harry Büller [The Netherlands]

**PA 2.16-3** High incidence of VTE despite electronic alerts for thromboprophylaxis in hospitalized cancer patients
Ramón Lecumberri, Margarita Marqués, Ana Alfonso, Alberto Fernández del Carril, Martínez Nicolás, Alberto García Mouriz, José Hermida, Sam Schulman, José Antonio Páramo [Spain]

**PA 2.16-4** Clinical presentation, ADAMTS13-related measurements and outcomes in cancer-associated thrombotic thrombocytopenic purpura
Raffaella Rossi, Barbara Ferrari, Silvia Pontiggia, Luca Lotta, Gaetano Giuffrida, Andrea Artoni, Flora Peyvandi [Italy]

**PA 2.16-5** TF expressed by microparticles is associated with mortality but not with thrombosis in cancer patients
José Antonio Paramo, Josune Orbe, Carmen Roncal, Maria Alvarez-Hernandez, Sara Martinez De Lizarondo, Jesus Garcia-Mata, Carmen Hernandez [Spain]

**PA 2.16-6** Association of endothelial protein C receptor (A6936G) haplotype with thrombotic events as a risk factor in acute myeloid leukemia
Dalel Azazene, Shahsoltan Mirshahi, Hamda Thawadi, Hakea Al Farsi, Samaher Besbes, Massoud Mirshahi, Ami Therwath, Ruping Tang, Fanny Fava, Ibtisem Ghedira, Jeannette Soria, Jean Pierre Marie [France]

**Arterial vascular disorders - II**

Moderator: Rinske Loeffen [The Netherlands]

**PA 2.17-1** TM5441, a novel PAI-1 antagonist, prevents hypertension and arteriosclerosis in an experimental model for vascular aging
Amanda Boe, Mesut Eren, Sheila Murphy, Christine Kamide, Toshio Miyata, Douglas Vaughan [USA]

**PA 2.17-2** Vascular smooth muscle cells confer a prothrombotic phenotype within the vessel wall of spontaneously hypertensive rats
Veronique Regnault, Karima Ait Aissa, Jeremy Lagrange, Jean-Pierre Max, Huguette Louis, Simon Thornton, Athanase Benetos, Pascal Challande, Denis Wahl, Patrick Lacolley [France]

**PA 2.17-3** Effect of hyperglycemia and hyperinsulinemia on platelet insulin signaling and coagulation pathways
Koneti Rao, Robert Freishtat, Gauthami Jalagadugula, Anamika Singh, Guangfen Mao, Andrew Wiles, Peter Cheung, Guenther Boden [USA]

**PA 2.17-4** FVII-activating protease (FSAP) confers protection to Primary Astrocytes and Neurons exposed to Oxygen-Glucose deprived conditions
Amit Joshi [Germany]
Intravascular devices and interventions

Screen 18

Moderator: Leslie Berry [Canada]

PA 2.18-1 Survival effects of inferior vena cava filter in patients with acute symptomatic venous thromboembolism: a subgroup analysis from the RIETE registry
David Jimenez, Alfonso Muriel, Drahomir Aujesky, Laurent Bertolotti, Herve Decousus, Silvy Laporte, Patrick Mismetti, Roger Ysen, Manuel Monreal [Spain]

PA 2.18-2 Improving inferior vena cava (IVC) filter retrieval rates using wristband identification in a tertiary care and trauma centre
Erica Peterson, Paul Yenson, Jacobus Kritzinger, Dave Liu, Jay Chi, Agnes Lee [Canada]

PA 2.18-3 Effect of ethanol locks on occlusion of central venous catheters used for administration of total parenteral nutrition
Leslie Berry, Ryan See, Rose-Frances Clause, Brian Cameron, Elyanne Ratcliffe, Anthony Chan [Canada]

PA 2.18-4 A multidisciplinary Pulmonary Embolism Response Team (PERT). Initial clinical experience at Massachusetts General Hospital
Christopher Kabrhel, Michael Jaff, Richard Channick, Joshua Baker, Abdi Jama, Gopi Manthripragada, Beau Hawkins, John O’Dea, Ido Weinberg, Kenneth Rosenfield [USA]

PA 2.18-5 CHA2DS2-VASc Score and risk for reobstruction after endovascular treatment of the superficial femoral artery: differences between balloon angioplasty and stenting
Thomas Gary, Klara Belaj, Philipp Eller, Franz Hafner, Harald Froehlich, Ernst Pilger, Marianne Brodmann [Austria]

PA 2.18-6 Longitudinal investigation of the effect of centrifugal continuous flow left ventricular assist devices (cFLVADS) on haemostatic parameters
Ken Ly, Kavitha Muthiah, David Connor, Elizabeth Gardiner, Robert Andrews, Kumud Dhital, Paul Jansz, Christopher Hayward, Joanne Joseph [Australia]

Paediatric thrombosis - II

Screen 19

Moderator: Monika Stoll [Germany]

PA 2.19-1 Antiphospholipid Antibody Syndrome in Monozygotic Twins
Aisha Bruce, Syama Sinuff, Mary Bauman, Patti Massicotte [Canada]

PA 2.19-2 In vitro assessment of the effect of dabigatran on thrombosis of adult and neonatal plasma using thromboelastography
Fadi Nossair, Jorell Gantioqui, H. Chan, Ivan Stevic, Helen Atkinson, Leslie Berry, A. Chan [Canada]

PA 2.19-3 A deep look at superficial vein thrombosis in hospitalized children
Mattia Rizzi, Suzan Williams, Bairbre Connolly, Leonardo Brandao [Canada]

PA 2.19-4 Portal vein thrombosis in neonates: results of an anticoagulation protocol
Leonardo Brandao, Veerle Labarque, Suzan Williams [Canada]
Clinical presentation and molecular basis of congenital antithrombin deficiency in children: a cohort study
Riten Kumar, Anthony Chan, Darlene Castle, Suzan Williams (Canada)

Characteristics and long-term outcome in children with essential thrombocythemia: an analysis of 61 cases from a single Chinese center
Rongfeng Fu, Lei Zhang, Min Xuan, Cuicui Lv, Feng Xue, Zeng Cao, Renchi Yang (China)

**Thrombophilia - II**

Moderator: Nicholas Beauchamp (United Kingdom)

Thromboelastometric parameters heritability and their relation with thromboembolic disease. Results from GAIT-2 project
Marina Carrasco, Laura Martin-Fernandez, Montserrat Font, Angel Martinez-Perez, Andrey Ziyatdinov, Montserrat Borrell, Jordi Fontcuberta, Jose Manuel Soria, Juan Carlos Souto (Spain)

Evaluation of a genetic analysis service for antithrombin deficiency: experience of Sheffield Diagnostic Genetics Service
Nicholas Beauchamp, Michael Makris, Campbell Tait, Anne Goodeve (United Kingdom)

Who is being screened for hereditary and acquired thrombophilia? A single center experience
Jeremy Whyman, Deborah Ornstein, Donna Robert (USA)

Role of ABO blood group and of thrombophilic abnormalities on the presence of residual vein obstruction after deep-vein thrombosis of the lower limbs
Francesco Dentali, Matteo Di Minno, Sara Turato, Silvia Crestani, Pasquale Ambrosino, Carlo Bonfanti, Giovanni Di Minno, Massimo Franchini, Walter Ageno (Italy)

Genetic determinants of thrombin generation and their relation to thrombosis. Results from GAIT-2 Project
Laura Martin-Fernandez, Marina Carrasco, Andrey Ziyatdinov, Angel Martinez-Perez, Montserrat Borrell, Montserrat Font, Jordi Fontcuberta, Juan Carlos Souto, Juan Carlos Soria (Spain)

Coagulation factor XIII TYR204PHE gene variation and the risk of ischemic stroke
Marianne Landau, Gizele Campanate, Vassalo Juliana, Biasoli Irene, Spector Nelson, Gadelha Telma (Brazil)
**ePOSTERS (B)**

**Tuesday July 2, 2013**  
17:00 – 18:30

**Antiplatelet agents: ADP receptors - III**  
*Screen 21*

**Moderator: Nadezhda Knauer [Russian Federation]**

**PB 2.21-1** Absence of off-target prolongation of the bleeding time in prasugrel-treated rats and mice: additional evidence for selective P2Y12 inhibition by prasugrel  
Atsuhiro Sugidachi, Kousaku Ohno, Joseph Jakubowski, Atsuyuki Tomizawa [Japan]

**PB 2.21-2** Impact of cigarette smoking on clopidogrel antiplatelet effect in diabetic patients  

**PB 2.21-3** The experience of the antiplatelet therapy by clopidogrel in the West-Siberian region of Russia: the effects of CYP2C19 and ABCB1 allelic variants  
Nadezhda Knauer, Elena Voronina, Galina Lifshits [Russian Federation]

**PB 2.21-4** The VerifyNow PRU is Associated with Optimal Duration of Clopidogrel Interruption Prior to CABG surgery: Sub-Analysis of TARGET CABG study  
Paul Gurbel, Elisabeth Mahla, Bliden Kevin, Udaya Tantry, Young-Hoon Jeong, Martin Gesheff, Jeffrey Dahlen [Germany]

**PB 2.21-5** Comparison of the antiplatelet effect of crushed clopidogrel versus whole tablet in diabetic patients presenting with an acute coronary syndrome  

**PB 2.21-6** Rebound of ADP mediated platelet aggregation after abrupt cessation of long-term clopidogrel therapy positively correlate to thrombin and arachidonic-acid dependent platelet aggregation  
Slobodan Obradovic, Nina Djukanovic, Zoran Todorovic, Srdjana Njegomirovic, Milica Prostran, Nemanja Djenic, Modrag Ostojic [Serbia]

**Platelet function tests: Clinical**  
*Screen 22*

**Moderator: Peter Paul Wisman [The Netherlands]**

**PB 2.22-1** Platelet-reactivity tests identify patients at risk of secondary cardiovascular events: a review and meta-analysis  
Peter Paul Wisman, Mark Roest, Folkert Asselbergs, Philip de Groot, Frans Moll, Yolanda van der Graaf, Gert Jan de Borst [The Netherlands]

**PB 2.22-2** The Real World Relationship Between VerifyNow PRU and Device-Reported Percent Inhibition: Analysis from the GRAVITAS Trial  
Jeffrey Dahlen, Matthew Price [USA]

**PB 2.22-3** High platelet reactivity is associated with increased D-dimer levels in acute coronary syndrome patients  
Rossella Marcucci, Anna Maria Gori, Betti Giusti, Rita Paniccia, Sandra Fedi, Ilaria Romagnuolo, Anna Maria Palomba, Raffaella Prior, Rosanna Abbate [Italy]

**PB 2.22-4** Aspirin resistance and C-reactive protein predict long term mortality in STEMI patients  
Rossella Marcucci, Vanessa Cau, Serafina Valente, Marco Chiostri, Chiara Lazzeri, Claudia Saracini, Silvia Galora, Sara Bucherelli, Gian Franco Gensini, Rosanna Abbate [Italy]

**PB 2.22-5** Pharmacogenomic study of clopidogrel poor response  
Beatriz Calderon Cruz, Luis Antonio Manzo Francisco, Aketzali Roman Perez, Karen Rodriguez Galvan, Antonio Herrera Gonzalez, Gilberto Vargas Alarcon, Jose Manuel Fragos, Marco Antonio Peña Duque, Carlos Alberto Reyes Gomez, Aurora De La Peña Diaz [Mexico]
Prevalence of CYP2C19 variant alleles and pharmacodynamic variability of aspirin and clopidogrel in American Indians

Julie Oestreich, Lyle Best, Brody Crowe, Paul Dobesh [USA]

Platelet activation: Receptor changes - I

Moderator: Elizabeth Gardiner [Australia]

Modulation of a-thrombin function by platelet glycoprotein Iba
Zaverio Ruggeri, Alessandro Zarpellon, Antonella Zampolli, James Roberts, Grazia Loredana Mendolicchio (USA)

Thrombin is a selective inducer of heparanase release from platelets via protease-activated receptor-1
Ma’anit Shapira, Elena Axelman, Anat Keren-Politansky, Lilach Bonstein, Yona Nadir [Israel]

Can platelet surface markers synchronize differential platelet secretion?
Xinyan Miao, Zhangsen Huang, Ragnhild Stålesen, NaiLin Li [Sweden]

The effect of omega-3 supplementation on platelet GPVI levels
Elizabeth Gardiner, Chee Wee Tan, Bradley McEwen, Jane Arthur, Marie-Christine Morel-Kopp, Christopher Ward, Robert Andrews [Australia]

Lipid rafts in platelets: their role for TXA2-induced platelet activation
Antonio Moscardó, Juana Vallés, Ana Latorre, Isabel Madrid, Maria Teresa Santos [Spain]

Soluble CLEC-2 was released upon platelet activation and detected in human plasma
Osamu Inoue, Junya Nakamura, Makoto Osada, Mitsuru Oosawa, Yukio Ozaki, Katsue Suzuki-Inoue [Japan]

Platelet mRNA/protein expression

Moderator: Thijs van Holten [The Netherlands]

Differences in platelet microRNA profiles after aspirin use are associated with differences in whole blood aggregation and might identify aspirin resistance
Maayke Kok, Claudia Mandolini, Rienk Nieuwland, Esther Creemers, Joost Meijers, Sara-Joan Pinto [The Netherlands]

Next generation sequencing analysis of human platelet polyA+ mRNAs
Abdimajid Osman, Tomas Lindahl, Antheia Kissopoulou, Jon Jonasson [Sweden]

Mass spectrometry analysis showed comparable releasates and phosphorylation profiles after PAR-1 or PAR-4 stimulation of platelets
Thijs van Holten, Onno Bleijerveld, Patrick Wijten, Philip de Groot, Albert Heck, Arjen Scholten, Mark Roest [The Netherlands]

Protein synthesis in platelets: The key role of platelet receptors
Olga Sirotkina, Anastasiya Laskovets, Pavel Andoskin, Anastasiya Taraskina, Tatiana Vavilova [Russian Federation]

Quantitative PCR of platelet specific mRNA reveals significant upregulation of TLR-2 in patients with non-ST elevation myocardial infarction
Madlin Albrecht, Daniel Duerschmied, Christian Colberg, Andreas Zirlik, Kartheinz Peter, Christoph Bode, Ingo Ahrens [Germany]

Regulatory role of proteasome in determination of platelet life span
Manasa Nayak, Paresk Kulkarni, Debabrata Dash [India]
Platelet disorders: Screening
Screen 25

**Moderator:** Ellinor Peerschke [USA]

**PB 2.25-1**
Evaluation of the diagnostic potential of a whole blood remote assay in assessment of platelet function in bleeding disorders
Natalia Dovlatova, Marie Lordkipanidzé, Gillian Lowe, Jane May, Stan Heptinstall, Sue Fox, Steve Watson [United Kingdom]

**PB 2.25-2**
Investigation of the utility of the ISTH Bleeding Assessment Tool (BAT) in predicting platelet defects in participants with clinically diagnosed bleeding disorders
Gillian Lowe, Marie Lordkipanidzé, Steve Watson [United Kingdom]

**PB 2.25-3**
Five year report of a multicenter project for characterization of inherited platelet disorders (IPD) in the Iberian Peninsula. Diagnosis of 23 severe IPD and identification of 14 new genetic variants
Isabel Sánchez Guiu, Ana Isabel Antón, José Padilla, Consuelo González-Manchón, Vicente Vicente, María Luisa Lozano, José Rivera [Spain]

**PB 2.25-4**
Storage Pool Disorder: A continuous whole blood Flow Cytometric method for the measurement of Platelet calcium flux using an Accuri C6 Cytometer
William Pickering, Anne Riddell, Keith Gomez, Pratima Chowdary [Denmark]

**PB 2.25-5**
Prevalence of disease and relationships between laboratory phenotype and bleeding severity in platelet primary secretion defects
Luca Lotta, Alberto Maino, Giacomo Tuana, Raffaella Rossio, Anna Lecchi, Andrea Artoni, Flora Peyvandi [Italy]

**PB 2.25-6**
Lumi-aggregation is useful for better defining platelet function defects in response to weak agonists
Ellinor Peerschke, Francine Dembitzer [USA]

Platelet procoagulant activity
Screen 26

**Moderator:** Joy Wright [United Kingdom]

**PB 2.26-1**
Targeting platelet GPIbβ decreases GPIb-dependent signaling, platelet procoagulant activity and arterial thrombosis
Eric Maurer, Mathieu Schaff, Catherine Bourdon, Nicolas Receveur, Catherine Ravanat, Béatrice Hechler, Christian Gachet, François Lanza, Pierre Mangin [France]

**PB 2.26-2**
Aggregation of PS exposing platelets and activated (non-PS exposing) platelets
Hyojung Choo, Shawn Jobe [USA]

**PB 2.26-3**
Signalling via CLEC-2 generates a procoagulant response in human platelets
Mohammed Alsaahi, Jacky Appleby, Alice Pollitt, Robert Turnbull, Craig Hughes, Hassan Hamali, Steve Watson, Alison Goodall [United Kingdom]

**PB 2.26-4**
Evidence for necrotic platelets in collagen dependent thrombus formation in vivo
Minh Hua, Philip Hogg, Vivien Chen [Australia]

**PB 2.26-5**
Quantification of the platelet channelome in ultra-purified human platelet samples highlights the high expression level of TMEM16F
Joy Wright, Stefan Amisten, Alison Goodall, Martyn Mahaut-Smith [United Kingdom]

**PB 2.26-6**
Perturbations in local clot hemodynamics triggers intraluminal thrombus contraction
Ryan Muthard, Scott Diamond [USA]
**ePOSTERS (B)**

**ePOSTER AREA**

**Tuesday July 2, 2013**

**Screen 27**

### Platelets in cardiovascular disease

**Moderator: Michael Emerson [United Kingdom]**

**PB 2.27-1**

**Search for a predictive signature of coronary artery disease in platelet transcriptome**  
Marina Camera, Gualtiero Colombo, Marta Brambilla, Luca Piacentini, Laura Rossetti, Paola Canzano, Giovanni Teruzzi, Monica De Metrio, Elena Tremoli [Italy]

**PB 2.27-2**

**Plasma-derived microparticles as a source of biomarkers in acute coronary syndromes: a proteomic study comparing ST-elevation myocardial infarction patients and stable coronary artery disease controls**  
Paula Vélez, Andrés Pariguina, Isaac Rosa, Sergio Alonso-Orgaz, Fernando De La Cuesta, Lilian Grigorian, Maria Baradero, Jose Moreu, José Ramón González-Juanatey, Ángel García [Spain]

**PB 2.27-3**

**P-selectin compared to other tests as a simple-to-use approach for assessing platelet function in cardiac patients**  
Jane May, Sue Fox, Andrew Johnson, Ann White, Jackie Glenn, Natalia Dovlatova, Yanushi Wijeyeratne, Stan Heptinstall [United Kingdom]

**PB 2.27-4**

**Comparison of the Optimul assay with light transmission aggregometry for the detection of aspirin resistance in patients with stable coronary artery disease**  
Christopher Floyd, Tim Warner, Albert Ferro [United Kingdom]

**PB 2.27-5**

**Role of platelets in driving the thrombotic risk and protective processes associated with exposure to diesel exhaust particles**  
Michael Emerson, Antonia Solomon, Erica Smyth, Anupama Vydyanath, Pradeep Luther, Teresa Tetley [United Kingdom]

**PB 2.27-6**

**Platelet and leukocyte ROS production and lipoperoxidation are associated with high platelet reactivity in acute coronary syndrome patients on dual antiplatelet treatment**  
Matteo Becatti, Claudia Fiorillo, Anna Maria Gori, Rossella Marucci, Rita Paniccia, Betti Giusti, Francesco Violi, Pasquale Pignatelli, Gian Franco Gensini, Rosanna Abbate [Italy]

### Platelet activation: Miscellaneous - I

**Moderator: Steve Kerrigan [Ireland]**

**PB 2.28-1**

**Streptococcus pneumoniae triggers platelet activation and platelet-leucocyte complex formation in a strain dependent and toll-like receptor 2 independent manner**  
Sacha de Stoppelaar, Marianne Schaap, Tom van der Poli, Rienk Nieuwland, Cornelis van ’t Veer [The Netherlands]

**PB 2.28-2**

**Multiple sites on Streptococcus gordonii surface protein PadA mediate outside-in signaling in platelets**  
Steve Kerrigan, Ciara Keane, Helen Petersen, Thea Tilley, Jennifer Haworth, Dermot Cox, Howard Jenkinson [Ireland]

**PB 2.28-4**

**Effects of high-amount high-intensity exercise on in vivo platelet activation: modulation by lipid peroxidation and AGE/RAGE axis**  
Francesca Santilli, Natale Vazzana, Pierpaolo Iodice, Stefano Lattanzio, Rossella Liani, Rosa Bellomo, Francesca Perego, Raoul Saggini, Giovanni Davi [Italy]

**PB 2.28-5**

**Effect of hydrogen sulphide (H2S) on human platelet adhesion and clot retraction**  
Emilse Bermejo, Maria Alberto, Daniel Saenz, Ruth Rosenstein, Maria Lazzari [Argentina]

**PB 2.28-6**

**A novel real-time whole blood flow cytometric assay identifies a sub-population of platelets that rapidly bind Annexin-V upon stimulation**  
Chris Jones, Stephen Garner, Jonathan Gibbins [United Kingdom]
Vascular progenitor and stem cells

Moderator: Anna Maria Gori [Italy]

PB 2.29-1 Evaluation of endothelial dysfunction and regeneration in an elderly population: the Mugello Study
Anna Maria Gori, Francesca Cesari, Federica Vannetti, Alice Sereni, Raffaello Molino Lova, Francesco Sofi, Elena Sticchi, Rosanna Abbate, Gian Franco Gensini, Claudio Macchi [Italy]

PB 2.29-2 Adherence to lifestyles’ modifications after a cardiac rehabilitation (CR) program and endothelial progenitor cells (EPCs): a 6-months follow-up study
Francesca Cesari, Rossella Marcucci, Anna Maria Gori, Costanza Burgisser, Sara Francini, Francesco Sofi, GianFranco Gensini, Rosanna Abbate, Francesco Fattorielli [Italy]

PB 2.29-3 Extracellular acidosis inhibits the proangiogenic responses and the tissue regeneration capacity of endothelial progenitor cells
Soledad Negrotto, Carlos Fondevila, Catherine Boisson-Vidal, Mirta Schattner [Argentina]

PB 2.29-4 Down-regulation of TIP2 in Peripheral blood mononuclear cells is associated with low levels of circulating endothelial progenitor cells in patients with type 2 DM
Shilong Xiong, Qian Wang, Lei Zheng, Jie Bao [China]

PB 2.29-5 Mechanistic study of the proangiogenic effect of osteoprotegerin
Zahia Benslimane-Ahmim, Florence Poirier, Claudine Delomenie, Anna Lokajczyk, Isabelle Galy-Fauroux, Amel Mohamadi, Anne Marie Fischer, Dominique Heymann, Didier Lutomski, Catherine Boisson-Vidal [France]

PB 2.29-6 Protease-activated receptor 1 and 2 stimulate endothelial colony forming cell vasculogenesis in a vascular endothelial growth factor- and extracellular signal-regulated kinase-dependent manner
Giordano Pula, Tiago Fortunato, Caroline Wheeler-Jones [United Kingdom]

Microparticles and disease - II

Moderator: Myriam Chalabi [The Netherlands]

PB 2.30-1 Characterization of circulating microparticles in pancreatic and colorectal cancers and chronic inflammatory diseases
Diane Mege, Laurence Panicot-Dubois, Mehdi Ouaiissi, Stéphane Robert, Dominique Farge-Bancel, Bernard Sastre, Françoise Dignat-George, Christophe Dubois [France]

PB 2.30-2 Increased microparticles activities as a marker of platelet activation after percutaneous coronary intervention
Rahajuningsih Setiabudy, Marzuki Suryaatmadja, Yoga Yuniardi, Ay Salim [Indonesia]

PB 2.30-3 Microparticle detection in human plasma using nanoparticle tracking analysis and scanning ion occlusion sensing
Morten Mrk, Shona Pedersen, Sarah Nejlund, Sørøen Risom Kristensen [Denmark]

PB 2.30-4 Microparticles do not modify the antithrombotic properties of brain microvascular cells
Dorothee Faillle, Véronique Ollivier, Marie-Geneviève Huisse, Pierre-Olivier Couraud, Martine Jandrot-Perrus, Mikaël Mazighi, Nadine Ajzenberg [France]

PB 2.30-5 Circulating microparticles in patients with colorectal cancer
Myriam Chalabi, Mathie Leers, Kon-Siong Jie [The Netherlands]

PB 2.30-6 Biological markers in the progression of asymptomatic carotid stenosis
Vicenta Martinez-Sales, Virtudes Vilà, José Tembl, Vera Parkhutik, Teresa Contreras, Cristina Aguilerà, Aida Lago [Spain]
ePOSTERS (B)  

**Endothelium and disease**  
Screen 31  

**Moderator: Betti Giusti (Italy)**

**PB 2.31-1** Circulating endothelial cells in venous thromboembolism  
Manuel Campos, Claudia Torres, Rui Matos, Sara Morais, Margarida Lima (Portugal)

**PB 2.31-2** Endotelial nitric-oxide synthase gene polymorphisms in early and late-onset severe preeclampsia  
Patricia Alpoim, Zoila Carvalho, Lara Carvalho Godoi, Letícia Lemos Jardim, Ana Paula Fernandes, Karina Braga Gomes, Luci Dusse (Brazil)

**PB 2.31-3** Evidence of endothelial dysfunction in patients with major depression: Recovery after treatment with a selective serotonin reuptake inhibitor (SSRI)  
Irene Lopez-Vilchez, Victor Navarro, Montserrat Serra, Patricia Molina, Rosa Hernandez, Maribel Diaz-Ricart, Cristobal Gasto, Gines Escolar, Ana Galan (Spain)

**PB 2.31-4** Endothelial activation in patients with superficial vein thrombosis (SVT) of the lower limbs  
Emanuela Falcinelli, Benilde Cosmi, Massimo Filippini, Eleonora Petito, Cristina Legnani, Michela Cini, Rino Migliacci, Palareti Gualtiero, Paolo Gresele (Italy)

**PB 2.31-5** Toll-like receptor 4 and the inflammasome NALP3 mediate the activation and damage of endothelial cells in advance chronic kidney disease: protective effect of defibrotide  
Susana Martin, Carolina Caballo, Patricia Molina, Gabriela Gutiérrez, Manel Vera, Aleix Cases, Gines Escolar, Maribel Diaz-Ricart (Spain)

**PB 2.31-6** Biomarkers of endothelial dysfunction in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL)  
Francesca Cesari, Francesca Pescini, Anna Maria Gori, Betti Giusti, Ida Donnini, Enza Zicari, Antonio Federico, Maurizio Balestrino, Rosanna Abbate, Domenico Inzitari (Italy)

**Immune thrombocytopenic purpura - II**  
Screen 32  

**Moderator: Doaa Eissa (Egypt)**

**PB 2.32-1** Retrospective analysis of the incidence of refractory ITP and response to second line treatments. Experience in a single centre  
María Gomez-del-Castillo (Spain)

**PB 2.32-2** Differential effects of All-Trans Retinoid on expansion of CD4+CD25+Foxp3 Treg subpopulations in patients with Chronic Immune Thrombocytopenia  
Lan Dai (China)

**PB 2.32-3** Nonclassical monocytes are expanded and involved in the pathogenesis of immune thrombocytopenia  
Yanhui Yang, Donglei Zhang, Xian Zhang, Min Xuan, Rongfeng Fu, Feng Xue, Xiaofan Liu, Lei Zhang, Renchi Yang (China)

**PB 2.32-4** CXCL-10/IP-10 chemokine expression in patients with immune-mediated thrombocytopenia  
Deena Eissa, Nahela Shalaby, Mona Ismail, Doaa Eissa (Egypt)

**PB 2.32-5** Detection of autoantibodies against platelet glycoproteins in patients with Idiopathic Thrombocytopenic Purpura by a Flow Cytometric Bead Array  
Yang He, Yun-xiao Zhao, Ming-qing Zhu, Changgeng Ruan (China)
**Tuesday July 2, 2013**  
**17:00 – 18:30**

**ADAMTS13: Clinical - II**  
**Screen 33**  
**Moderator: Greg Hugenholtz [The Netherlands]**

**PB 2.33-1**  
**Importance of measuring circulating ADAMTS13 immune complexes in addition to free antibodies in patients with acquired TTP**  
Peter Turecek, Silvia Ferrari, Kristina Palavra, Bernadette Gruber, Barbara Plaimauer, Hanspeter Rottensteiner, Friedrich Scheilinger [Austria]

**PB 2.33-2**  
**Mutations and polymorphisms in adult onset pregnancy related TTP**  
Katy Langley, Mary Underwood, Philip Lane, Katarina Lamb, Marie Scully, Samuel Machin [United Kingdom]

**PB 2.33-3**  
**Variability in measurement of ADAMTS13: A UK NEQAS multicentre exercise for ADAMTS13 assays**  
Ian Jennings, Ian Mackie, Rebekah Fretwell, Steve Kitchen, Dianne Kitchen, Tim Woods, Isobel Walker [United Kingdom]

**PB 2.33-4**  
**Decreased ADAMTS13 activity and its clinical significance in patients with idiopathic portal hypertension**  
Hiroaki Takaya, Masahito Uemura, Masao Fujimoto, Sadanobu Ishii, Chie Morioka, Hideto Kawaratani, Masaki Hayakawa, Masanori Matsumoto, Yoshihiro Fujimura, Hiroshi Fukui [Japan]

**PB 2.33-5**  
**An unbalance between von Willebrand factor and its cleaving protease ADAMTS13 in acute liver failure: Implications for hemostasis and correlations with clinical outcome**  
Greg Hugenholtz, Jelle Adelmeijer, Joost Meijers, Robert Porte, Todd Stravitz, Ton Lisman [The Netherlands]

**Fibrinolytic system: Basic - II**  
**Screen 34**  
**Moderator: Tine Wyseure [Belgium]**

**PB 2.34-1**  
**Regulation of fibrinolysis by polyphosphate is dependent on the plasminogen activator**  
Claire Whyte, Nicola Mutch [United Kingdom]

**PB 2.34-2**  
**The Expression Of Plasminogen Activator Inhibitor Type-1 Is Post-Transcriptionally Regulated By Sphingosine-1-Phosphate And SERPINE1 mRNA Binding Protein**  
Satoshi Fujii, Soichiro Iwaki, Shuhei Yamamura, Akimasa Sanagawa, Moyoko Asai, Burton Sobel [Japan]

**PB 2.34-3**  
**Investigation of possible exosite interactions between plasmin(ogen) and antiplasmin**  
Anita Horvath, Bernadine Lu, Ruby Law, Paul Coughlin [Australia]

**PB 2.34-4**  
**Comparison of thrombolytic efficacy of plasmin and rt-PA in an in vitro flow system**  
Nina Bizjak, Franci Bajd, Jernej Vidmar, Ales Blinc, Victor Marder, Valery Novokhatny, Igor Serša [Slovenia]

**PB 2.34-5**  
**Antibody-engineered bispecific inhibitor against TAFI and PAI-1 with improved expression and efficacy**  
Tine Wyseure, Jan Develter, Efi Tziarou, Ann Gils, Paul Declerck [Belgium]

**PB 2.34-6**  
**Plasminogen alterations mediated by N-homocysteinyllation processes**  
Valeria Genoud, Maria Sinito, Silvana Gionco, Irene Quintana, Ana Lauricella [Argentina]
**Haemophilia A: Basic - II**

**Screen 35**

**Moderator:** Martin Brodde (Germany)

**PB 2.35-1** Prediction by Cellular expression of impact of four novel F8 molecular variations identified in isolated female with low FVIII:C levels suspected of being haemophilia A carriers

Mathilde Fretigny, Christophe Nougier, Emilie Talagrand, Catherine Costa, Olivier Roualdes, Dorothee Pellechia, Claude Negrier, Christine Vinciguerra (France)

**PB 2.35-2** Cellular stress in synoviocytes, chondrocytes and osteoblasts and increased osteoclast activity induced by plasma derived factor VIII products in vitro

Martin Brodde, Anja Müller, Beate Kehrel (Germany)

**PB 2.35-3** An aberrant pattern for intron 1 inversion with concomitant large duplication and deletion within the F8 gene in a severe hemophilia A

Kun Chi, Guoling You (China)

**PB 2.35-4** Hemarthrosis-induced heme oxygenase-1 reduces the immune response to FVIII in hemophilic mice

Ivan Peyron, Jordan Dimitrov, Sandrine Delignat, Srinivas Kaveri, Sébastien Lacroix-Desmazes (France)

**PB 2.35-5** The development and binding mechanism of FVIII Trp1707Ser related inhibitors

Yeling Lu (China)

**PB 2.35-6** Functional FVIII assays and bleeding phenotype in 13 patients with mild haemophilia A due to the p.Tyr365Cys mutation

Emily Graves, Kate Talks, Kate Sergeant, Julie Vowles, John Hanley, Tina Biss (United Kingdom)

---

**Haemophilia A: Clinical - VI**

**Screen 36**

**Moderator:** Myriam Dardikh (The Netherlands)

**PB 2.36-1** Low Titre FVIII Inhibitor Assay may substitute the recovery and half-Life measurements in half-Life Induction of Immune Tolerance Therapy

Myriam Dardikh, Ernie Gascoigne, Donna DiMichele, Charles Hay, Waander van Heerde, Bert Verbruggen (The Netherlands)

**PB 2.36-2** A retrospective observational multicenter cohort study on peri-operative Factor VIII consumption in Hemophilia A (‘OPTI-CLOT’ studies)

Janske Lock, Hendrika Hazendonk, Hannan Bouzariouh, Karin Fijnvandraat, Marjolein Peters, Suzanne Polinder, Saskia de Wildt, Frank Leebeek, Ron Mathôt, Marjon Cnossen (The Netherlands)

**PB 2.36-3** Bleeding frequency and consumption of FVIII concentrate during on-demand and prophylactic treatment with Human-cl rhFVIII in prospective clinical studies in adult patients with severe haemophilia A

Andreas Tiede, Johannes Oldenburg, Sigurd Knaub, Johann Bichler (Germany)

**PB 2.36-4** Atrial fibrillation in people with hemophilia: a cross-sectional evaluation in Europe

Roger Schutgens, Robert Klamroth, Ingrid Pabinger, M. Malerba, Gerry Dolan (The Netherlands)

**PB 2.36-5** Beriate® P in the treatment of patients with haemophilia A: update of a long-term pharmacovigilance

Robert Klamroth, Christine Heller, Susanne Holzhauer, Mathias Jürs, Karin Kurnik (Germany)
PB 2.36-6 Comorbidities in patients with haemophilia and other rare bleeding disorders: a cross sectional study
Natascha Marquardt, Cristina Schwerdtfeger, Georg Goldmann, Silvia Horneff, Claudia Klein, Vytautas Ivaskevicius, Hans-Hermann Brackmann, Johannes Oldenburg (Germany)

Haemophilia A: Clinical - VII
Screen 37
Moderator: Catherine Rea (United Kingdom)

PB 2.37-1 FXIII- a novel treatment in haemophilia
Catherine Rea, Jonathan Foley, Jacqueline Mickelson, Dougald Monroe, Benny Sorensen (United Kingdom)

PB 2.37-2 Bleeding pattern and median time interval between bleeding episodes amongst patients receiving on-demand and prophylaxis therapy
Leonard Valentino, Bruce Ewenstein, Norma Guzmán-Becerra, W. Wong, Claudia Schoenig-Diesing, Vadim Romanov (USA)

PB 2.37-3 AURIGA: Study of adherence to prophylaxis in patients with severe haemophilia A
María García-Dási, José Aznar, Víctor Jiménez Yuste, Eva Mingot, Félix Lucía, Carmen Altisent, Francisco Jiménez, Fernanda López, Pascual Marco, Rosario Pérez, Ángeles Fernández, José Paloma, Bernat Galmes, Sonia Herrero, Juan García-Talavera (Spain)

PB 2.37-4 Major surgery in severe haemophilia A with inhibitors using a recombinant factor VIII/activated prothrombin complex concentrate hybrid regimen
Joost van Veen, Rhona Maclean, Andrew Hamer, Kingsley Hampton, Michael Makris (United Kingdom)

PB 2.37-5 Helixate® NexGen for the treatment of hemophilia A: update of a long-term pharmacovigilance project
Johannes Oldenburg, Günter Auerswald, Pia Petrini, Albert Faradji, Ingrid Pabinger, Claudia Niekrens, Marcus Stockschlädner, Zeynep Gutowski-Eckel, Peter Staritz (Germany)

PB 2.37-6 Applicability of the ESC guidelines on management of acute coronary syndromes to people with haemophilia - an assessment by the ADVANCE Working Group
Peter Staritz, Philippe De Moerloose, Roger Schutgens, Angela Huth-Kuehne, Gerard Dolan (Germany)

Haemophilia A: Clinical - VIII
Screen 38
Moderator: Teh-Liane Khoo (Australia)

PB 2.38-1 Heterogeneity of Bleeding Classification among Randomized Studies in Hemophilic Patients
Howard Chan, Chantal Li, Natalie Chan, Keith Lau, Anthony Chan (Canada)

PB 2.38-2 Combined T- and B-cell immunomodulatory therapy for immune tolerance induction in 4 hemophilia patients with poor risk inhibitors
Tyler Buckner, Brenda Nielsen, Brent Weston, Paul Monahan (USA)

PB 2.38-3 On-demand treatment costs of Italian haemophilia patients with inhibitors: an exploratory lifetime economic model
James Weatherall, Won Lee, Allison Petrilla, Pinar Bilir, Karen Trochil (Denmark)
PB 2.38-4 Multi-centre Australia wide study comparing FVIII assay variation in haemophilia A patients receiving two different recombinant FVIII products using the one stage and chromogenic assays
   Teh-Liane Khoo, Geoffrey Kershaw, Stephen Matthews, Waite Clare, Annette Bowyer, Steve Kitchen, Scott Dunkley (Australia)

PB 2.38-5 Introducing the KAPPA prospective registry in hemophilia A: Design, objectives and progress
   Mehdi Osooli, Jan Astermark, Fariba Baghaei, Margareta Holmstrom, Karin Lindvall, Katarina Steen Carlsson, Erik Berntorp (Sweden)

PB 2.38-6 Social status of adult haemophilia patients: Preliminary results of a comparative single-centre Cohort Study with thrombophilia patients
   Sylvia von Mackensen, Katharina Holstein, Jessica Gäsßler, Bernd Lentz, Carsten Bokemeyer, Florian Langer (Germany)

Acquired coagulation disorders - II

Moderator: Sean Platton (United Kingdom)

PB 2.39-1 Heat treatment and immunological testing substantially improves the detection of factor VIII antibodies in acquired haemophilia A
   Sean Platton, Paul Batty, Louise Bowles, John Pasi, Daniel Hart (United Kingdom)

PB 2.39-2 FEIBHAC study: Prospective clinical and biological evaluation of antihemorrhagic treatment with aPPCs (Factor eight inhibitor bypassing activity) in Acquired Hemophilia A (AHA)
   Jeanne-Yvonne Borg, Claude Négrier, Isabelle Durieu, Hervé Lévesque, Edita Dolimier, Béatrice Villette (France)

PB 2.39-3 Treatment characteristics and associated costs of factor replacement and immunosuppressive therapy among patients with acquired hemophilia A
   Miguel Escobar, Kenneth Chong, Aroub Khleif (USA)

PB 2.39-4 Enzyme-linked immunosorbent assay (ELISA) detecting antibodies to von Willebrand factor in patients with acquired von Willebrand Syndrome (AVWS): clinical significance
   Franca Franchi, Francesca Stulano, Maria Teresa Canciani, Giovanna Cozzi, Luciano Baronciani, Simona Siboni, Claudia Mistretta, Eugenia Biguzzi, Flora Peyvandi (Italy)

PB 2.39-5 Haemostatic changes following military trauma and major blood loss
   Beverley Hunt, Thomas Woolley, Kiran Parmar, Mark Midwinter, Victoria Pribul, Chris Peach, Sarah Watts, Jonathon Bishop, Emrys Kirkman (United Kingdom)

PB 2.39-6 Long term follow-up in patients with acquired hemophilia: the role of immunosuppressive therapy
   Giorgia Saccullo, Alessandra Malato, Marco Santoro, Maria Santa Napolitano, Giampaolo Vaccarella, Sergio Siraquisa (Italy)

Heparin-induced thrombocytopenia (HIT): Basic

Moderator: Anne Bertling (Germany)

PB 2.40-1 Staphylococcal Panton-Valentine Leukocidin activates platelets via neutrophil secretion products
   Anne Bertling, Bernhard Schlott, Georg Peters, Christine Heilmann, Bettina Löffler, Beate Kehrel (Germany)

PB 2.40-2 Fibronectin inhibits anti-PF4/heparin antibody induced platelet activation and low fibronectin levels are a potential risk factor for developing clinical HIT
   Krystin Krauel, Patricia Valentin, Birgitt Fürll, Elke Hammer, Sven Brandt, Inga Jensch, Martin Kreimann, Andreas Greinacher (Germany)
Usefulness of a murine monoclonal antibody against human platelet factor 4/heparin complexes to select donor platelets in platelet activation assays for diagnosis of heparin-induced thrombocytopenia

Reiko Asada, Keiko Wanaka, Kumiko Miyashita, Chieko Kaneko, Nobuhiro Hoshino, Mitsuru Oosawa, Utako Okamoto, Miyako Matsuo (Japan)

Evaluation of three new fully automated quantitative immunoassays on diagnosis of heparin-induced thrombocytopenia

Kumiko Miyashita, Keiko Wanaka, Chieko Kaneko, Jeanine Walenga, Margaret Prechel, Vicki Escalante, Reiko Asada, Miyako Matsuo, Utako Okamoto (Japan)

Significance of the measurement of HIT antibodies on diagnosis of heparin-induced thrombocytopenia in the patients with hemodialysis

Keiko Wanaka, Kumiko Miyashita, Chieko Kaneko, Jeanine Walenga, Margaret Prechel, Reiko Asada, Miyako Matsuo, Utako Okamoto (Japan)

In-vitro inhibition of thrombin generation in heparin induced thrombocytopenia by dabigatran and rivaroxaban

Hron Gregor, Steffen Alena, Thiele Thomas, Andreas Greinacher (Germany)

Investigation of medical indications for PNH screening experiment by flow cytometry

Mingqing Zhu, Li Chen, Wenhong Shen, Lan Dai, Changgeng Ruan (China)

Genotype and phenotype relationships in ten unrelated Pakistani patients with inherited FVII deficiency

Munira Borhany, Hugo Bojout, Jean-Luc Pellequer, Tahir Shamji, Hira Fatima, Grégoire Moulin, Jean-François Schved, Muriel Blaizot (Pakistan)

Mild fibrinogen disorders: correlation between genotype and phenotype

Giancarlo Castaman, Sofia Giacomelli, Chiara Biasoli, Dino Veneri, Paolo Radossi, Alessandra Borchiellini, Alberto Tosetto (Italy)

Characterization of adult patients with a mild to moderate bleeding phenotype from the Vienna Bleeding Biobank

Johanna Haselböck, Simon Panzer, Florian Janig, Sylvia Kepa, Christine Mannhalter, Ingrid Pabinger (Austria)

Long-term prophylaxis in patients with severe factor VII deficiency

Simona Maria Siboni, Eugenia Biguzzi, Claudia Mistretta, Isabella Garagiola, Flora Peyvandi (Italy)

Survey of practices: Difficulty of venipuncture practice and contribution of a vein locating device in patients requiring multiple peripheral venipunctures

Patricia Guillou, Malika Makhoulifi, Sylviane Baillie, Christine Roucoulet, Edita Dolimier, Béatrice Villette (France)

Molecular characterisation and discrimination of patients with type 2 von Willebrand disease

Vincent Jenkins, Mary Byrne, Catriona Keenan, Fiona Holden, Beatrice Nolan, Niamh O’Connell, James O’Donnell (Ireland)

Use of double virally inactivated FVII/vWF in 30 children and young people with von Willebrand’s disease – a single centre experience

Kate Khair, Jemma Efford, Mary Mathias, Ri Liesner (United Kingdom)
PB 2.42-3  Results of a prospective, non-interventional clinical study in 170 VWD patients with a new generation of VWF/FVIII concentrate in Germany  
Mario Von Depka, Jennifer Feddern, Susan Halimeh, Janos Kadar, Wolfgang Miesbach, Ulrike Nowak-Göttl, Inge Scharrer (Germany)

PB 2.42-4  Thrombin generation in platelet-rich plasma is sensitive for the activation status of von Willebrand factor  
Hilde Kelchtermans, Leonie Pelkmans, Adam Miszta, Raed Al Dieri, Bas de Laat (The Netherlands)

PB 2.42-5  Comprehensive classification of patients with von Willebrand disease after systematic genotypic analysis  
Selene Schoormans, Clint van Duren, Adinda Diekstra, Lies Hoefsloot, Waander van Heerde (The Netherlands)

PB 2.42-6  Evaluation and clinical application of von Willebrand factor antigen and ristocetin cofactor by chemiliminescence in a new analyzer ACL AcuStar in the diagnosis of von Willebrand disease  
Maria Joana Costa-Pinto, Maria del Carmen Gomez-del-Castillo, Almudena Perez-Rodriguez, Andrea Galego, Esther Lourés, Angela Rodriguez-Trillo, Teresa Martinez-Marini, Teresa Iglesias, Javier Batlle, Maria Fernanda López-Fernández (Spain)

Von Willebrand factor - III  
Screen 43

Moderator: Bieuwke Dragt (The Netherlands)

PB 2.43-1  Dextran sulfate blocks assembly of UL-VWF strings on the surface of endothelial cells  
Bieuwke Dragt, Angela Kragten, Menno Hofman, Bas de Laat, Jan Voorberg (The Netherlands)

PB 2.43-2  Platelet aggregates developed at high shear rate grow rapidly, are unstable, and incorporate vWF  
Thomas Colace, Scott Diamond (USA)

PB 2.43-3  Functional role of von Willebrand factor (VWF) triplet bands in glycoprotein Ib-mediated platelet adhesion and thrombus formation under flow  
Birte Fuchs, Susanne de Witt, Barbara Solecka, Mario Kröning, Tobias Obser, Judith Cosemans, Reinhard Schneppenheim, Johan Heemskerk, Christoph Kannicht (Germany)

PB 2.43-4  Characterization of recombinant VWF73 peptide in different prokaryotic expression systems  
Su Jian, Bai Xia, Ma ZhenNi, Ruan Changgeng (China)

PB 2.43-5  Von Willebrand factor levels are strongly associated with atherosclerosis in patients with ischemic stroke  
Michelle Sonneveld, Anouk van Dijk, Evita van den Herik, Janine van Loon, Lonneke de Lau, Aad van der Lugt, Peter Koudstaal, Moniek de Maat, Frank Leebeek (The Netherlands)

PB 2.43-6  A comparative evaluation of two new automated assays for von Willebrand factor ristocetin cofactor activity and von Willebrand factor antigen  
Francesca Stufang, Andrew Lawrie, Silvia La Marca, Maria Teresa Canciani, Franca Franchi, Giovanna Cozzi, Luciano Baronciani, Flora Peyvandi (Italy)
Tuesday July 2, 2013

Haemophilia: Miscellaneous

Moderator: Greta Mulders [The Netherlands]

PB 2.44-1  Haemophilia and home treatment: Optimizing knowledge and practical skills by an e-learning program
Greta Mulders, Eva de Wee, Monique Vahedi Nikbakht, Marieke Kruij, Erna Elfrink, Frank Leebeek [The Netherlands]

PB 2.44-2  Personalised prophylaxis in haemophilia A: how low can you go?
Allison Greig, Steven Austin, James Uprichard [United Kingdom]

PB 2.44-3  Buprenorphine does not influence the inflammatory response in haemophilia A mice with experimentally induced haemarthrosis
Mette Groth, Annemarie Kristensen, Kirstine Øvlisen, Mikael Tranholm [Denmark]

PB 2.44-4  Identification and characterization of an L1 insertion in intron 16 of F8 in a patient with hemophilia A
Hiroshi Inaba, Keiko Shinozawa, Manabu Otaki, Takeshi Hagiwara, Kagehiro Amano, Katsuyuki Fukutake [Japan]

PB 2.44-5  Haemophilia A with and without historical inhibitors evaluation of T regulatory and memory B lymphocytes populations
Teresa Sevivas, Margarida Coucelo, Sara Domingues, Susana Pedreiro, Manuela Benedito, Ramón Salvado, Natália Martins, Letícia Ribeiro, Ana Sofia Baptista Roda [Portugal]

PB 2.44-6  Stop codon readthrough with PTC-124 and gentamycin in hemophilia B caused by nonsense mutations
Jianfang Chen, Linhua Yang, Yaofang Zhang, Ruijuan Zhang, Baofeng Chai [China]

Acquired coagulation disorders - III

Moderator: Samuel Abegunde [Nigeria]

PB 2.45-1  Hemostasis disorders are indicators of early infectious complications in severe burned
Marina Presniakova, Victoria Kyznetsova, Artem Borisevich, Elena Puchenkina [Russian Federation]

PB 2.45-2  Haemostatic markers predict survival in African patients with burn injuries
Samuel Abegunde, Folake Abikoye, Muna Chira [Nigeria]

PB 2.45-3  Traditional and whole blood coagulative profiles in patients with left ventricle assist devices
Luca Spiezia, Vincenzo Tarzia, Elena Campello, Marco De Franceschi, Jonida Bejco, Giacomo Bortolussi, Francesco Vasques, Tomaso Bottio, Gino Gerosa, Paolo Simioni [Italy]

PB 2.45-4  Comparison between defects of hemostasis and ROTEM parameters in children with dengue infection
Darintr Sosothikul, Pichaya Paisan, Panya Seksarn [Thailand]

PB 2.45-5  The ratios of pro to anticoagulant factors: index of hemostatic imbalance in cirrhotic patients
Asma Labidi, Héla Baccouche, Sonia Mahjoub, Salwa Bssila, Monia Fekih, Azza Filai, Neila Ben Romdhane [Tunisia]

PB 2.45-6  Shortened blood coagulation times in two distinct visceral obesity models, WBN/Kob-Lepr(fal) rats and diet-induced obese mice
Fumitoshi Asai, Dai Nagakubo, Noriyuki Kaji, Saya Takahashi, Mitsuyuki Shirai, Katsuaki Ito [Japan]
**Anticoagulant agents - VIII**

**Screen 46**

**Moderator:** Rita Selby [Canada]

**PB 2.46-1**  
Inhibition of coagulation by the low molecular mass metalloprotease from Indian cobra (Naja naja) venom  
Kemparaju Kempaiah, M. Kumar, K. Girish [India]

**PB 2.46-2**  
Long-term oral anticoagulant management associated with routine medical care (RMC) in patients with non-valvular atrial fibrillation (NVAF) in Canada  
Rita Selby, Nicole Mittmann, Pierre Isogai, Lisa Kaus, Marika Koo, Faith Sealey [Canada]

**PB 2.46-3**  
Edoxaban, an oral direct factor Xa inhibitor, inhibits tissue-factor induced human platelet aggregation and clot-bound factor Xa in vitro  
Yoshiyuki Morishima, Yuko Honda, Chikako Kamisato [Japan]

**PB 2.46-4**  
Antithrombotic effect of direct oral anticoagulants as compared to warfarin evaluated experimentally in treated patients  
Grazia Loredana Mendolicchio, Patrizia Marchese, Anna Colombo, Corrado Lodigiani, Marco Scardino, Matteo Carlo Ferrari, Guido Grappiolo, Lidia Rota, Zaverio Ruggeri [Italy]

**PB 2.46-5**  
The relationship between anti-Xa activity and complications in orthopaedic patients receiving prophylactic fondaparinux  
Takeshi Matsumoto, Hideo Wada, Hasegawa Masahiro, Hiroki Wakebayashi, Kakunoshin Yoshida, Noriki Miyamoto, Kohshi Ohishi, Yuji Shimokariya, Norikazu Yamada, Akihiro Sudo [Japan]

**PB 2.46-6**  
Association of warfarin therapy after prosthetic heart valve replacement with risk of thromboembolic complications, bleeding and mortality  
Kagari Murasaki, Yukiko Shimatan, Kagari Murasaki, Yoshio Uetsuka, Hagiwara Nobuhsa [Japan]

**Anticoagulant agents - IX**

**Screen 47**

**Moderator:** Jawed Fareed [USA]

**PB 2.47-1**  
Biochemical and pharmacological differentiation of dabigatran, apixaban and rivaroxaban  
Jawed Fareed, Daneyal Syed, Daniel Kahn, Walter Jeske, Vicki Escalante, Omer Iqbal, Debra Hoppensteadt, Josephine Cunanan, Jeanine Walenga [USA]

**PB 2.47-2**  
Bone density in patients with VTE treated with VKA. Follow-up of 25 patients over 10 years  
Bogdan Hajduk, Liliana Wawrzynska, Pawel Kuca, Witold Tomkowski [Poland]

**PB 2.47-3**  
Effect of Dabigatran and Rivaroxiban on thrombomodulin mediated activation of protein C and thrombin activated fibrinolysis inhibitor (TAI)  
Debra Hoppensteadt, Josephine Cunanan, Bruce Lewis, Jawed Fareed [USA]

**PB 2.47-4**  
Are global hemostasis assays superior to prothrombin time (INR) for the assessment of hemostatic correction after warfarin withdrawal before invasive procedures?  
Alenka Mavri, Nina Vene, Nina Ostasevski-Fernandez, Maja Vucnik, Mojca Segnar [Slovenia]

**PB 2.47-5**  
Off-label use of recombinant factor VIIa: results from a 10-year university hospital study  
Aroub Khleif, Kenneth Chong, Miguel Escobar [USA]

**PB 2.47-6**  
Measurement of dabigatran and rivaroxaban in primary prevention of venous thromboembolism in 106 patients, who have undergone major orthopedic surgery. An observational study  
Meyer Samama, Celine Guinet, Lena Le Flem, Jean-Marc Debue [France]
**Anticoagulant agents - X**

**Screen 48**

** Moderator: Marc Carrier (Canada)**

**PB 2.48-1** Ambulatory treatment of venous thrombosis in patients older than 85 years  
Monika Stalc, Tjasa Vizintin-Cuderman, Ana Kovac (Slovenia)

**PB 2.48-2** Self-reported adherence with warfarin and new oral anticoagulants in patients on chronic oral anticoagulant therapy.  
Marc Carrier, Katrien van der Salm, Phil Wells, Rosendo Rodriguez, Lloyd Duchesnes, Petra Erkens (Canada)

**PB 2.48-3** Non-clinical safety and efficacy of prothrombin complex concentrates (PCC) for the reversal of dabigatran mediated anticoagulation  
Eva Herzog, Franz Kaspereit, Wilfried Krege, Ryn van Joanne, Gerhard Dickneite, Ingo Pragst (Germany)

**PB 2.48-4** Rivaroxaban for the treatment of symptomatic deep vein thrombosis and/or pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies  
Yuqi Wang, C. Wang, Z. Chen, J. Zhang, Z. Liu, B. Jin, K. Ying, Y. Shao, I. Meng (China)

**PB 2.48-5** Comparison of use of prothrombin complex concentrates vs recombinant factor VIIa (rVIIa) in warfarin related intracranial hemorrhage  
Thomas DeLoughery (USA)

**PB 2.48-6** Is clot structure impaired in patients on warfarin?  
Despoina Adamidou, Anne Riddell, Sagan Aghishi, Linda Mohadam, Paul Priest, Pratima Chowdary (Greece)

**Anticoagulant agents - XI**

**Screen 49**

** Moderator: Niamh Appleby (Ireland)**

**PB 2.49-1** Quality of anticoagulation and bleeding and thrombotic risk in relation to CHADS2 score: Analysis AF cohort of Epica study  
Poli Daniela, Emilia Antonucci, Caterina Cenci, Oriana Paoletti, Walter Ageno, Gualtiero Palareti, Sophie Testa (Italy)

**PB 2.49-2** Fixed versus variable dosing protocols for prothrombin complex concentrate (PCC) for the emergency reversal of warfarin anticoagulation at two university teaching hospitals  

**PB 2.49-3** Chronic anticoagulation: how the population is changing  
Sophie Testa, Oriana Paoletti, Laura Bassi, Emilia Cancellieri, Eizo Damiolini, Silvia Zambelli, Anke Zimmermann (Italy)

**PB 2.49-4** Pilot-scale production and purification of snake venom-derived antiplatelet agents  
Bat-Erdene Jugder, Punsaldulam Dashnyam, Bolor Buyanbadrakh, Sumiya Byambasuren, Altantsetseg Buyanbat (Mongolia)

**PB 2.49-5** Telemedicine via CareOnline-system in patients with vitamin-k-antagonist-therapy  
Bettina Zeiter, Carola Hecking, Martin Hendelmeier, Irene Krämer, Philipp Wild, Ulrich Walter, Helmut Schinzel (Germany)

**PB 2.49-6** First experience of structured introduction of new oral anticoagulants in a Swedish health care district: dabigatran as an alternative to warfarin in atrial fibrillation  
Kerstin Arbring, Roza Chaireti, Magnus Janzon, Srinivas Uppugunduri, Kjell Jansson, Tomas Lindahl (Sweden)
### Blood coagulation system - II

**Screen 50**
**Moderator:** Nafiseh Badiei [United Kingdom]

<table>
<thead>
<tr>
<th>PB 2.50-1</th>
<th>Identification of hypercoagulability in the rat model of microvascular thrombosis using spatial clot growth dynamics</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Stepan Surov, Tatiana Vuimo, Elena Semenova, Irina Kaplanskaia, Fazoil Ataullakhanov, Mikhail Panteleev [Russian Federation]</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PB 2.50-2</th>
<th>Effects of shear flow on the microstructure and elasticity of incipient clots in whole blood and fibrin-thrombin gels</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Nafiseh Badiei, Daniel Curtis, Andrew Campbell, Karl Hawkins, Matthew Lawrence, Ahmed Sowedan, Phillip Evans, Rodri Williams [United Kingdom]</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PB 2.50-3</th>
<th>The alterations of hemostasis and thromboelastometry in children after hematopoietic stem cell transplantation</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Nongnuch Sirachainan, Pornchanok Iamsirirak, Samart Pakakasama, Suradej Hongeng, Praguywan Kadegasem, Somtawin Sirireung, Ampaiwan Chuansumrit [Thailand]</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PB 2.50-4</th>
<th>Self-assessed Villalta score in DVT patients and in matched venous thrombosis-free controls</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Kristin Kornelia Utne, Hilde Wik, Per Morten Sandset, Waleed Ghanima [Norway]</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PB 2.50-5</th>
<th>Oxidized phosphatidylcholine and ethanolamine from 12- and 15-lipoxygenase significantly enhance tissue factor dependent thrombin generation in vitro</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>David Satter, Yoel Garcia-Diaz, Ned Porter, Maceler Aldrovandi, Vince Jenkins, Valerie O'Donnell, Peter Collins [United Kingdom]</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PB 2.50-6</th>
<th>A case with reduced coagulation factor VII level caused by novel compound heterozygous mutations</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Ritsuko Seki, Sogabe Yoko, Yuka Takata, Koiichi Osaki, Koji Nagafuji, Takashi Okamura [Japan]</td>
</tr>
</tbody>
</table>

### Blood coagulation tests - VII

**Screen 51**
**Moderator:** Nathalie Pequeriaux [The Netherlands]

<table>
<thead>
<tr>
<th>PB 2.51-1</th>
<th>Investigation of methodological sources of bias in the measurement of vitamin K1 (phylloquinone) in human serum at endogenous concentrations</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>David Card, Martin Shearer, Leon Schurgers, Patricia Ruwona, Dominic Harrington [United Kingdom]</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PB 2.51-2</th>
<th>The effect of Dabigatran on the PTT, Thrombin Time and Clauss fibrinogen assays</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Artur Szkotak, Susan Nahirniak, Linda Stang [Canada]</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PB 2.51-3</th>
<th>Prediction of unfavourable outcome with Rotational Thromboelastometry in patients with acute liver injury/failure</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mohamed Habib, Lara Roberts, Raj Patel, William Bernal, Roopen Arya [United Kingdom]</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PB 2.51-4</th>
<th>Impact of dabigatran on routine and specific coagulation assays in patients treated by dabigatran.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Eugenie Gemen, Afzal Kariman, Jeroen van Dijk, Martijn van Eck, Nathalie Pequeriaux [The Netherlands]</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PB 2.51-5</th>
<th>The prothrombin time is a poor indicator of plasma rivaroxaban levels in ex-vivo samples from patients taking rivaroxaban</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Diane Zebeljan, Geoffrey Kershaw, Penelope Motum, Beatrice Mui, Danny Hsu, Steven Lang [Australia]</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PB 2.51-6</th>
<th>Impact of sample preparation procedure in the spatial clot growth assay</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Natalia Dashkevich, Tatiana Vuimo, Ruzanna Ovsepyan, Natalia Soshitova, Stepan Surov, Mikhail Panteleev, Fazoil Ataullakhanov, Claude Negrier [Russian Federation]</td>
</tr>
</tbody>
</table>
Tuesday July 2, 2013  17:00 – 18:30

**Blood coagulation tests - VIII**  
Moderator: Matthias Erber [Germany]

- **PB 2.52-1** Validation of methods for determination of procoagulant activities in immunoglobulins using the NIBSC reference reagent for FXa  
  Marta Jose, Berta Pons, Laura López, Merche Faro, Maite López, Juan Jorquera [Spain]
- **PB 2.52-2** Human thrombin liquid reagent for fibrinogen determination in samples containing dabigatran  
  Emma Camacho, Mariona Bono, Daniel Martorell [Spain]
- **PB 2.52-3** The rate of reduction in D-dimer level for patients with venous thromboembolism responding to antithrombotic therapy  
  Howard Chan, Nicole Li, Keith Lau, Anthony Chan [Canada]
- **PB 2.52-4** Specific and global coagulation assays in the diagnosis of mild haemophilia A  
  Annette Bower, Joost van Veen, Anne Goodeve, Steve Kitchen, Michael Makris [United Kingdom]
- **PB 2.52-5** An ECT based assay for thrombelastometry using solid lyophilized pellet reagents  
  Matthias Erber, Geoffrey Lee [Germany]
- **PB 2.52-6** The effect of platelet poor plasma storage time on thrombin generation inter-assay variability using calibrated automated thrombography  
  Sarah Bennett, Lara Roberts, Raj Patel, Roopen Arya [United Kingdom]

**Blood coagulation tests - IX**  
Moderator: Claudia Dellanoce [Italy]

- **PB 2.53-1** Effect of clot detection method on total error calculated by CLSI protocol EP-10  
  Cristina Duboscq, Jose Ceresetto, Sofia Trobo, German Stemmelin, Claudia Shanley, Oscar Rabinovich, Eduardo Bullorsky [Argentina]
- **PB 2.53-2** INR portable monitors: efficacy of a quality control system  
  Oriana Paoletti, Laura Bassi, Emilia Cancellieri, Claudia Dellanoce, Anke Zimmermann, Nika Delpiero, Sophie Testa [Italy]
- **PB 2.53-3** Conventional and new global haemostasis laboratory test reveal hypercoagulation in primary multiple myeloma patients  
  Marina Gracheva, Evdokiya Urnova, Larisa Mendeleeva, Elena Sinauridze, Anna Balandina, Ivan Tarandovskiy, Sergey Vasilyev, Elena Parovichnikova, Valeriy Savchenko, Fazoi Ataullakhanov [Russian Federation]
- **PB 2.53-4** Thrombin generation test: a new and simplified expression of results  
  Claudia Dellanoce, Oriana Paoletti, Laura Bassi, Sophie Testa [Italy]
- **PB 2.53-5** Procoagulant changes in blood plasma as a result of plasmapheresis  
  Stepan Surov, Ruzanna Ovepyan, Igor Vysochin, Ilya Serebriyskiy, Elena Kobzeva, Valery Khvatov, Fazoi Ataullakhanov, Tatiana Vuimo [Russian Federation]
- **PB 2.53-6** Thrombin Dynamics Test: a new global coagulation assay for the evaluation of the propagation phase of thrombin generation  
  Grigoris Gerotziafas, Hela Ketatni, Ismail Elalamy, Vasiliki Galea [France]
### Coagulation factor XI - I

**Screen 54**

**Moderator:** André Mulder [The Netherlands]

<table>
<thead>
<tr>
<th>PB 2.54-1</th>
<th>Ongoing risk of thrombosis with factor XI concentrate: five years experience in two centres</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Paul Batty, Anja Honke, James Uprichard, Louise Bowles, Daniel Hart, John Pasi, Steve Austin [United Kingdom]</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PB 2.54-2</th>
<th>Identification of two novel mutations in sequential nucleotides of the factor XI gene in a Dutch Caucasian family with inherited factor XI deficiency</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>René Mulder, Sophie Wiewel-Verschueren, Karina Meijer, André Mulder [The Netherlands]</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PB 2.54-3</th>
<th>Comparison of thromboelastographic parameters before and after fresh frozen plasma treatment in patients with factor XI deficiency and with ex-vivo samples spiked with FXI concentrate</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Gillian Pike, Jecko Thachil, Anthony Cumming, John Burthem, Paula Bolton-Maggs [United Kingdom]</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PB 2.54-4</th>
<th>Factor XI in the relation to fetal loss: the frequency of the risk alleles</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Juraj Sokol, Biringer Kamil, Chudej Juraj, Skerenova Maria, Antosikova Anna, Stasko Jan, Lisa Lenka, Danko Jan, Kubisz Peter [Slovakia]</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PB 2.54-5</th>
<th>A newly diagnosed with congenital factor XI deficiency in a mild hemophilia A patient by gene analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Manabu Otaki, Keiko Shinozawa, Hiroshi Inaba, Yushi Chikasawa, Ikuo Seita, Kagehiro Amano, Katsuyuki Fukutake [Japan]</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PB 2.54-6</th>
<th>Pharmacodynamic tests for factor XI participation in haemostasis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Cornelis Kluft, Kees van Leuven, Ria Laterveer [The Netherlands]</td>
</tr>
</tbody>
</table>

### Coagulation factor VIII - IV

**Screen 55**

**Moderator:** Denis Noubouossie [Belgium]

<table>
<thead>
<tr>
<th>PB 2.55-1</th>
<th>Factor VIII level correlates with hemolysis and may contribute to the hypercoagulability of children with sickle cell disease</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Denis Noubouossie, Phu-Quoc Lê, Laurence Rozen, Dominique Willems, Malou Ngalula Mujinga, Alina Ferster, Anne Demulder [Belgium]</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PB 2.55-2</th>
<th>Molecular changes in LRP1 and FVIII genes in patients with venous thromboembolism and high FVIII levels</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Luis Bittar, Lúcia Siqueira, Erich De Paula, Joyce Maria Annichino-Bizzacchi [Brazil]</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PB 2.55-3</th>
<th>Effect of unstructured polypeptide insertions on the recombinant expression of human factor VIII</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Sampath Kumar, Tongyao Liu, John Kulman, Pei-Yun Beth Chang, Sheng Ding, Sara Bardan, Nancy Moore, Susannah Patarroyo-White, Glenn Pierce, Volker Schellenberger, Haiyan Jiang, Baisong Mei, Robert Peters [USA]</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PB 2.55-4</th>
<th>Pharmacokinetic results from a Phase I/III study of a novel recombinant single-chain Factor VIII (rVIII-SingleChain) compared to octocog alfa in severe haemophilia A patients</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Ingrid Pabinger, Robert Klamroth, Leonard Valentino, Joan Gill, Howard Levy, Robert Samuels, Ridhi Parasrampuria, For the CSL627_1001 study group [Austria]</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PB 2.55-5</th>
<th>Influence of age on recombinant factor VIII pharmacokinetics: results from clinical pharmacology studies of turoctocog alfa</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Michael Recht, Monica Cerqueira, Faraizah Karim, Judi Mass [USA]</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PB 2.55-6</th>
<th>N-Glycosylation of rVIII-SingleChain, a novel recombinant single-chain factor VIII</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Stefan Schmidbauer, Reinhold Witzel, Lars Robbel, Hubert Metzner, Thomas Weimer, Stefan Schulte [Germany]</td>
</tr>
</tbody>
</table>
Natural anticoagulants - II

Moderator: Romy Kremers (The Netherlands)

PB 2.56-1 Gas6 plasma levels in elderly patients with acute venous thromboembolism (VTE) predict major bleeding under anticoagulation and mortality but not recurrent VTE
Anne Angellino-Scherrer, Sara Calzavarini, Marie Méan, Andreas LImacher, Nicolas Rodondi, Drahomir Ajuesky (Switzerland)

PB 2.56-2 Influence of the 3K3A-activated protein C variant on the in vitro fibrinolytic activity of tPA
José Fernandez, Laurent Mosnier, Thomas Davis, Berislav Zlokovic, John Griffin (USA)

PB 2.56-3 Differences in isoforms of Antithrombin in infants and adults
Vasiliki Karlaftis, Chantal Attard, Paul Monagle, Vera Igijatovic (Australia)

PB 2.56-4 Effect of functional alpha2macroglobulin and antithrombin concentration on thrombin generation and decay in liver cirrhosis patients
Romy Kremers, Marisa Ninivaggi, Saartje Bloemen, Walid Chayouà, Marie-Claire Kleinegris, Ger Koek, Arina ten Cate-Hoek, Rob Wagenvoord, Coenraad Hemker (The Netherlands)

PB 2.56-5 Antithrombin assays can vary in sensitivity to homozygous antithrombin Budapest III, a defect that causes heparin resistance
Peter Cooper, Kieron Hickey, Nicholas Beauchamp, Lishel Horn, Christopher Hughes, Mark Bellamy, Rhona Maclean, Steve Kitchen, Michael Makris (United Kingdom)

PB 2.56-6 Anticoagulant effect of two new estrogens (R- and S-Fenetime)
Mirthala Flores, Juan Manuel Fernández-G, R. Marin-O, Elda Cecilia Uribe-Lezama, Fernando Herrero-Diaz, Teresa Fourtoul van der G, E. Pinzon, Ismael Torres, Victor Salgado, Aurora De La Pena-Diaz (Mexico)

Fibrinogen/Fibrin - III

Moderator: Jelle Adelmeijer (The Netherlands)

PB 2.57-1 Genotype and phenotype of a large series of patients with congenital dysfibrinogenemia
Alessandro Casini, Francoise Boehlen, Marquerite Neerman-Arbez, Philippe De Moerloose (Switzerland)

PB 2.57-2 Proteases in human pancreatic juice degrade both liquid and carrier-bound fibrin sealants in vitro
Jelle Adelmeijer, Robert Porte, Ton Lisman (The Netherlands)

PB 2.57-3 The same mutations in patients with congenital dysfibrinogenemia leading to different clinical manifestations
Jingyi Zhou, Linlin Jiang, Qiulan Ding, Xiaodong Xi, Xuefeng Wang, Hongli Wang (China)

PB 2.57-4 Novel fibrinogen gamma-chain mutation p.Asp342Asn (fibrinogen Pisa) associated with hepatic fibrinogen storage disease and hypofibrinogenaemia
Michela Robusto, Paola Braidotti, Silvia Nastasio, Giuseppe Maggiore, Flora Peyvandi, Rosanna Asselta, Stefano Duga (Italy)

PB 2.57-5 Molecular characterization of the fibrinogen molecule in seven unrelated patients from Cordoba, Argentina
Hugo Guglielmone, Salvador Minoldo, Gustavo Jarchum, Gonzalo Rodriguez, Luis Bastos (Argentina)

PB 2.57-6 Stream with high shear rate decreases tensile strength of plasma clots
Alexander Savushkin (Russian Federation)
Other coagulation factors - II
Screen 58
Moderator: Matthias Watzka (Germany)

PB 2.58-1 Two novel mutations in the gamma carboxylase gene causing VKCFD1
Matthias Watzka, Nancy Blaurock, Silvia Horneff, Johannes Oldenburg (Germany)

PB 2.58-2 Real-life use of high and standard initial doses of activated recombinant Factor VII (rFVIIa) in patients with haemophilia A and B with inhibitors - data from the UKHDCO/NHD registry
Charles Hay, Jens Bjerre, Gerry Dolan (United Kingdom)

PB 2.58-4 Recovery of factor XIII and thromboelastometry during pregnancy in a case of severe factor XIII deficiency
Lone Poulsen, Ole Larsen, Eva Funding (Denmark)

PB 2.58-5 Health-related quality of life in hemophilia patients with inhibitors receiving Prophylaxis with Anti-Inhibitor Coagulant Complex (AICC): Results from AICC Prophylaxis Study
Oleksandra Stasyshyn, Sandra Antunes, Vasily Mamanov, Xiaolan Ye, Yan Xiong, Srilatha Tangada (Ukraine)

PB 2.58-6 Plasma levels of factor VIIa-antithrombin complex in normal pregnancy and in patients with pre-eclampsia
Luca Spiezia, Silvia Visentin, Claudia Radu, Maria Bon, Barry Woodhams, Erich Cosmi, Paolo Simioni (Italy)

Regulation of coagulation and fibrinolysis - II Screen 59
Moderator: Annukka Jouppila (Finland)

PB 2.59-1 Acute atherothrombotic stroke is not associated with systematic enhancement of thrombin generation
Grigoris Gerotziafas, Klearchos Psychogios, Kostas Vemmos, Patrick Vandreden, Ismail Elalamy (France)

PB 2.59-2 A novel methodology for modulation of fibrin clot lysis: the role of fibrinogen-targeted artificial binding proteins
Rhodri King, Christian Tiede, Michael McPherson, Iain Manfield, Coiín Fishwick, Darren Tomlinson, Ramzi Ajjan (United Kingdom)

PB 2.59-3 Bradykinin enhances sympathetic nerve-induced cardiac tPA release possibly by transactivation of the β2-adrenergic receptor
Trude Aspelin, Morten Eriksen, Cathrine Carlson, Arnfinn Ilebekk, Torstein Lyberg (Norway)

PB 2.59-4 Processed versus pooled plasma enhances thrombin generation and reduces tissue factor pathway inhibitor
Annukka Jouppila, Per Morten Sandset, Riitta Lassila (Finland)

PB 2.59-5 Resveratrol and its dimers down-regulate protein S mRNA expression in HepG2 cells
Hiroko Tsuda, Eri Nakazono, Shihoko Sata, Akinobu Kishi, Taiji Matsukawa, Koichiro Ohnuki (Japan)

PB 2.59-6 Twelve weeks of daily exercise reduces thrombin generation in young, overweight males
Anne Sofie Gram, Jane Skov, Else-Marie Bladbjerg, Thorkil Ploug, Anders Sjödin, Bente Merete Stallknecht (Denmark)
Cancer and thrombosis - V
Moderator: Damien Gheldof [Belgium]

PB 2.60-1 High resolution transcriptomic analysis of Trousseau Syndrome
Semih Dalkiliç, Zeynep Ozkeserli, Ozlem Ilk, Ipek Kivilcim Oguzultan, Nejat Akar, Hilal Ozdag [Turkey]

PB 2.60-2 Estrogens downregulate TFPI expression in breast cancer cells
Huda Omar Ali, Benedicte Stavik, Elisabeth Dørum, Nina Iversen, Per Morten Sandset, Grethe Skretting [Norway]

PB 2.60-3 Internalized Protein C inhibitor (PCI) reverses impaired histone modification in Jurkat T-cell lymphoma cells
Margareta Furtmüller, Bettina Sarg, Herbert Lindner, Margarethe Geiger [Austria]

PB 2.60-4 The factor XII-driven intrinsic coagulation cascade contributes to prostate cancer-associated pulmonary embolism
Katrin Nickel, Thomas Renné [Sweden]

PB 2.60-5 Analysis of the expression of RNase in blood cells involved in homeostasis in the vascular system
Aya Murata, Kazumi Fujimoto, Miwako Nishio, Takatoshi Koyama [Japan]

PB 2.60-6 Inhibition of TFPI increases the sensitivity of thrombin generation assay to procoagulant microvesicles
Damien Gheldof, François Mullier, Bernard Chatelain, Jean-Michel Dogné, Christian Chatelain [Belgium]

Cancer and thrombosis - VI
Moderator: Ryma Ihaddadene [Canada]

PB 2.61-1 Poor predictive value of the Pulmonary Embolism Severity Index in hospitalized cancer patients with acute pulmonary embolism
Alessandro Squizzato, Nicoletta Riva, Stefano Grazioli, Sara Turato, Walter Ageno, Francesco Dentoni [Italy]

PB 2.61-2 A retrospective review of myeloma patients over a 6 year period to investigate the prevalence of venous thromboembolism (VTE) and the risk factors associated with it
Maevé Crowley, Oonagh Gilligan, Susan O’Shea [Ireland]

PB 2.61-3 Survival in renal cell carcinoma patients with venous tumor thrombus: a retrospective case-control study
Ryma Ihaddadene, Daniel Yokom, Gregoire Le Gal, Patricia Moretto, Neil Reaume, Christina Canil, Marc Carrier [Canada]

PB 2.61-4 The association of folate-related gene polymorphisms with colorectal cancer risk in Koreans
Nam Keun Kim, Jung O Kim, Moon Ju Jang, Jong Woo Kim, Jeon Young Joo, Doyeun Oh [South-Korea]

PB 2.61-5 Chemotherapy as a risk factor of DIC and thrombophilia in ovarian cancer patients
Alexander Vorobev, Alexander Makatsaria [Russian Federation]

PB 2.61-6 Prophylaxis for venous thromboembolism in patients treated for acute lymphoblastic leukemia - a systematic review
Mandy Lauw, Lowiek Hubers, Stefano Barco, Cornelia van Ommen, Barbara Hutten, Bart Biemond, Saskia Middeldorp [The Netherlands]
**Antiphospholipid - III**

**Moderator:** Rohan Willis [USA]

**PB 2.62-1**  
Myocardial ischaemia and coronary atherosclerosis in patients with antiphospholipid syndrome  
Agnieszka Padjas, Wojciech Plazak, Magdalena Celinska-Löwenhoff, Teresa Iwaniec, Jakub Swadzba, Tomasz Luberda, Piotr Podolec, Jacek Musial (Poland)

**PB 2.62-2**  
Confirmation of the initial antiphospholipid antibody positivity depends on antiphospholipid antibody profile  
Gentian Denas, Amelia Ruffatti, Teresa Del Ross, Marta Tonello, Serena Cuffaro, Ariela Hoxya, Alessandra Banzato, Bison Elisa, Bracco Alessia, Vittorio Pengo (Italy)

**PB 2.62-3**  
Establishment of standardized international units for IgG anti-β2glycoprotein antibody measurement  
Rohan Willis, Claudia Grossi, Maria Orietta Borghi, Pierluigi Meroni, Gabriella Lakos, Maria Crisostomo, Luis Lopez, Nina Olschowka, Michael Watkins, Silvia Pierangeli (USA)

**PB 2.62-4**  
An open-label prospective pilot mechanistic study of fluvastatin in persistently antiphospholipid antibody-positive patients  
Rohan Willis, Doruk Erkan, Vijaya Murthy, Gurjot Basra, JoAnn Vega, Patricia Ruiz-Limon, Ana Laura Carrera-Marin, Shraddha Jatwani, Emilio Gonzalez, Silvia Pierangeli (USA)

**PB 2.62-5**  
Establishment of standardized international units for IgM anti-β2glycoprotein antibody measurement  
Rohan Willis, Claudia Grossi, Maria Orietta Borghi, Pierluigi Meroni, Gabriella Lakos, Nina Olschowka, Luis Lopez, Joel Hardy, Maria Crisostomo, Silvia Pierangeli (Germany)

**PB 2.62-6**  
Laboratory diagnosis of the antiphospholipid syndrome: evaluation of two new automated chemiluminescent assays for anticardiolipin and anti-β2glycoprotein I detection  
Chiara Novelli, Benedetto Morelli, Bruna Bollini, Chiara Grassi (Italy)

**Arterial vascular disorders - III**

**Moderator:** Annie Pedersen [Sweden]

**PB 2.63-1**  
Circulating beta antithrombin glycoform increases during the acute ischemic cerebrovascular event  
María De La Morena-Barrio, Irene Martínez-Martínez, Antonia Miñano, Ana García, Sonia Águila, Jose Navarro-Fernández, Natalya Bohdan, Jose Iniesta, Vicente Vicente, Javier Corral (Spain)

**PB 2.63-2**  
Toll like receptor (TLR)-4 modulates the effects of hyperglycemia and hyperinsulinemia on tissue factor procoagulant activity in blood  
Anamika Singh, Koneti Rao, Guenther Boden (USA)

**PB 2.63-3**  
Hemostatic factors as predictors of recurrent vascular events up to 12 years after ischemic stroke: the Sahlgrenska Academy Study on Ischemic Stroke Outcome  
Annie Pedersen, Petra Redfors, Linnea Lundberg, Ellen Hanson, Christian Blomstrand, Ann Gils, Annika Rosengren, Paul Declerck, Katarina Jood, Christina Jern (Sweden)

**PB 2.63-4**  
Does the immature platelet fraction (IPF) in chest pain patients presenting to the emergency department aid in the diagnosis of acute coronary syndrome?  
Michelle Berny-Lang, Chad Darling, Andrew Frelinger III, Marc Barnard, Anja Gerrits, Alan Michelson (USA)
Fractal Dimension (Df): A novel biomarker to assess change in clot structure in cerebrovascular disease following therapeutic intervention
Sophia Stanford, Ahmed Sabra, Matthew Lawrence, Keith Morris, Karl Hawkins, Phyllip Williams, Sharon Storton, Mushtaq Wani, Phillip Evans [United Kingdom]

MMP-10: a new biomarker in peripheral artery disease?
Carmen Roncal, Esther Martinez-Aguilar, Violeta Gomez-Rodriguez, Leopoldo Fernandez-Alonso, José Antonio Rodríguez, Josune Órbe, José Antonio Paramo [Spain]

Are standardized algorithms used in clinical practice in 7 different European countries to aid in the diagnostic work-up for suspected venous thromboembolism?
Ann Helen Kristoffersen, Eva Ajzner, Dunja Roger, Eser Sozmen, Paolo Carraro, Ana Paula Faria, Joseph Watine, Piet Meijer, Sverre Sandberg [Norway]

Association between treatment regimen and quality of life asessed by EQ-5D-3L and pain interference in adults with haemophilia with and without inhibitors in the global HERO study
Amanda Tricarico [USA]

Performance of fibrin monomer in the evaluation of patients with suspected pulmonary embolism
Shannon Bates, Sameer Parpia, Joanne McGrath, Marilyn Johnston, Hugh Hoogendoorn [Canada]

Assessment of thrombus age with contrast-enhanced MR-Venography
Carsten Arnoldussen, Rick de Graaf, Rob Strijkers, Arina ten Cate-Hoek, Hugo ten Cate [The Netherlands]

Values of pretest probability tests for diagnosis of acute symptomatic proximal DVT in Thai patients
Nuttawut Sermsathanasawadi, Theeraphat Pumpuang, Kiattisak Hongku, Chumpol Wongwanit, Chanean Ruangsetakkit, Kharmin Chinsakchai, Pramook Mutirangura [Thailand]

Using model-based clustering to identify patterns of INR trajectories following warfarin initiation
Vicky Tagalakis, ChangJiang Xu, Antonio Ciampi [Canada]

Clinical impact of findings supporting an alternative diagnosis on computed tomography pulmonary angiography in patients with suspected pulmonary embolism
Josien van Es, Renee Douma, Sanne Schreuder, Saskia Middeldorp, Pieter Willem Kamphuisen, Victor Gerdes, Ludo Beenen [The Netherlands]

Inter-observer Agreement for Wells DVT score and empiric unstructured estimate of pretest probability
Mark Courtney, Krista Brucker, Lexie Dore, Alison Chevrier, Ryan McConnell, Jill Sears [USA]

Accuracy of diagnosing incidental pulmonary embolism on routinely performed contrast-enhanced CT-imaging in patients with malignancy
Tom van der Hulle, Paul den Exter, Frederikus Klok, Lucia Kroft, Menno Huisman, David Jiménez [The Netherlands]
Fibrin monomer (FM) might be used as a marker for venous thromboembolism in pregnancy
Ann Helen Kristoffersen, Per Hyltoft Petersen, Sverre Sandberg (Norway)

Age adjusted D-dimer for exclusion of venous thromboembolism: Results from a hospital emergency department
Peter Scalia, Ruth Padmore, Philip Wells, Antonio Giulivi (Canada)

Patient delay in the diagnosis of acute pulmonary embolism does not lead to higher thromboembolic burden or worse right ventricular function
Sharif Pasha, Frederikus Klok, Noortje van der Bijl, Albert de Roos, Lucia Kroft, Menno Huisman (The Netherlands)

Oral contraceptive formulations with estetrol as an estrogen, in combination with levonorgestrel or drospirenone, show minor effects on haemostasis
Cornelis Kluit, Jacoline Neuteboom, Christine Klipping, Jean-Michel Foidart, Yvette Zimmerman, Herjan Coelingh Bennink (The Netherlands)

Circulating nucleosomes and plasma free DNA are increased in abnormal pregnancies
Sylvie Bouvier, Laurent Grandemange, Guilhem Assie, Eve Mousty, Sylvie Ripart-Neveu, Pierre Marès, Eva Cochery-Nouvellon, Eric Mercier, Jean-Christophe Gris (France)

Could polycythemia vera be a vascular ‘risk factor’ in woman?
Imelda Marton, Éva Pósfai, Zsuzsanna László, Mártta Széll, Zita Borbényi (Hungary)

Carbetocin increases thrombin generation after cesarean section
Sophie Testa, Oriana Paoletti, Claudia Dellanoce, Laura Bassi, Monica Stramezzi, Elisabetta Spotti, Debrah Mammoliti, Aldo Riccardi (Italy)

Changes in haemostatic parameters during the menstrual cycle and drospirenone-containing oral contraceptive use
Svetlana Tchaikovski, Maria Thomassen, Serban Costa, Katarina Bremme, Jan Rosing (Germany)

Venous Thromboembolism (VTE) prophylaxis in hospitalized obstetric patients in Ireland: a multicentre cross-sectional study
Maeve Crowley, Caroline Noone, John Higgins, Susan O’Shea (Ireland)

Factor VII-activating protease in concert with DNase removes nucleosomes from necrotic cells
Gerben Marsman, Femke Stephan, Liza Bakker, Ingrid Bulder, Lucien Aarden, Sacha Zeerleder (The Netherlands)

SMTP-7, a novel small-molecule thrombolytic with an anti-inflammatory potential, improves primate thrombotic stroke with reduced hemorrhage risk
Eriko Suzuki, Naoki Matsumoto, Keiji Hasumi (Japan)

Oral anti-thrombin abrogates microvessel permeability during experimental ischemia
Gregory Del Zoppo, Brian Hawkins, Yu-Huan Gu (USA)
PB 2.67-4  Connective Tissue Growth Factor (CTGF/CCN2) is over-expressed via TGF beta pathway in synoviocytes upon cell-to-cell interaction with platelets
Elisabetta Liverani, Satya Kunapuli, Raul DeLa Cadena, Mario Rico (USA)

PB 2.67-5  Thrombin modulates the expression of a set of proinflammatory genes including tissue factor in human monocytes
Mercedes Lopez Zambrano, Gustavo Bruges, Gustavo Crespo, Joan Pabon, Claudia Alvarado, Victor Salazar, Oliver Dittrich-Breiholz, Heike Schneider, Klaus Preissner, Michael Lienhard Schmitz (Venezuela)

PB 2.67-6  The impact of glycation on aspirin-induced acetylation of human serum albumin: an in vitro study
Francesco Finamore, Feliciano Priego-Capote, Anne Zufferey, Pierre Fontana, Jean-Charles Sanchez (Switzerland)

PB 2.68-1  Rhinovirus infection induces procoagulant changes in parallel with eosinophilic airway inflammation
Christof Majoor, Pieter Willem Kamphuisen, Marianne van de Pol, Joost Meijers, Tom van der Poll, Rienk Nieuwland, Sebastian Johnston, Elisabeth Bel, Rene Lutter, Koen van der Sluijs (The Netherlands)

PB 2.68-2  Role of platelets and MMP2 in osteoarthritis joint inflammation: effect of hyaluronic acid
Eleonora Petito, Emanuela Falcinelli, Stefania Momi, Alessia Alunno, Roberto Gerli, Paolo Gresele (Italy)

PB 2.68-3  Defining platelet function in polytrauma patients upon admission to the emergency department
Donald Brophy, Daniel Contaifer, Bassem Mohammed, Jason Newton, Erika Martin, Gretchen Brophy, Nathan White, Penny Reynolds, Jingmei Song, Kevin Ward (USA)

PB 2.68-4  Changes of platelets status in pts with inflammatory cardiac pathology
Elena Gupalo, Liudmila Buryachkovskaya, Irina Uchitel, Pyotr Chumachenko, Natalia Mironova (Russian Federation)

PB 2.68-5  Protein chip array and thrombotic biomarker profiling of plasma samples undergoing bypass surgery
Jeanine Walenga, Takefumi Matsuo, Keiko Wanaka, Talhah Chaudhry, Debra Hoppensteadt, Jawed Fareed (USA)

PB 2.68-6  Effect of long-term intake of serotonin reuptake inhibitors on neutrophil function in humans
Daniel Duerschmied, Janine Guenther, Armand Kountchou, Daniela Stallmann, Christoph Bode, Claus Normann (Germany)

PB 2.69-1  Haplotypes of the endothelial protein C receptor gene and circulating protein C levels
Laura Martos, Silvia Navarro, Eleno Bonet, Esther Zorio, Fernando Ferrando, Josep Aznar, Amparo Estellés, Rogier Bertina, Francisco España, Pilar Medina (Spain)

PB 2.69-2  Association of haplotypes (H) 1 and 3 of the endothelial protein C receptor gene (PROCR) with venous thromboembolism
Silvia Navarro, Eleno Bonet, Laura Martos, Fernando Ferrando, Josep Aznar, Amparo Vayá, Amparo Estellés, Rogier Bertina, Francisco España, Pilar Medina (Spain)
### Non-inherited risk factors venous thrombosis - III

**Screen 70**

**Moderator:** Ellen Brodin (Norway)

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>PB 2.69-3</td>
<td><em>Sixteen different mutations in the SERPINC1 gene with antithrombin deficiency causing venous thrombosis</em></td>
<td>Keiko Shinozawa, Hiroshi Inaba, Takeshi Hagiwara, Manabu Otaki, Takashi Suzuki, Kagehiro Amano, Fukutake Katsuyuki (Japan)</td>
</tr>
<tr>
<td>PB 2.69-4</td>
<td><em>Novel causative and neutral mutations in a patient with protein C deficiency</em></td>
<td>Jun Yamanouchi, Takaaki Hato, Toshiyuki Niiya, Masaki Yasukawa (Japan)</td>
</tr>
<tr>
<td>PB 2.69-5</td>
<td><em>Vascular tone regulating genes polymorphism can modulate the risk of early-onset venous thromboembolism in individuals with inherited thrombophilia</em></td>
<td>Anastasia Polyakova, Veronika Shmeleva, Vitaly Soldatenkov, Michael Blinov, Viktor Kargin, Sergey Kapustin (Russian Federation)</td>
</tr>
<tr>
<td>PB 2.69-6</td>
<td><em>Mutation analysis of ATIII in a small cohort of Greek patients with VTE</em></td>
<td>Paraskevi Kotsi, Maria Tsousidou, Sotiria Thymianou, Zissis Moschidis, Anestis Chanos, Maria Gavalaki, Olga Katsarou (Greece)</td>
</tr>
</tbody>
</table>

### Socioeconomic status and the risk of venous thromboembolism - the Tromsø study

**Screen 70**

**Session:** PB 2.70-1

**Title:** Socioeconomic status and the risk of venous thromboembolism - the Tromsø study

**Authors:** Kristin Enga, Sigrid Braekkan, Finn-Egil Skjeldestad, John-Bjarne Hansen (Norway)

**Screen 70**

**Session:** PB 2.70-2

**Title:** A study to analyze the utility of PNH screening in patients with intra-abdominal thrombosis

**Authors:** Shano Naseem, Jasmina Ahluwalia, Shano Naseem, Man Updesh Singh Sachdeva, Praveen Bose, Yogesh Chawla, Babu Ram Thapa, Neelam Varma (India)

**Screen 70**

**Session:** PB 2.70-3

**Title:** Impact of different measures of renal impairment on future risk of venous thromboembolism. The Tromsø Study

**Authors:** Ellen Brodin, Kristin Enga, Braekkan Sigrid, Ingrid Toft, Jan Brox, Anders Vik, John-Bjarne Hansen (Norway)

**Screen 70**

**Session:** PB 2.70-4

**Title:** Venous thromboembolism in patients undergoing shoulder surgery: Findings from the Recos registry

**Authors:** Davide Imberti, Nicola Ivaldo, Luigi Murena, Paolo Paladini, Alessandro Castagna, Giovanni Barillari, Enrico Guerra, Federico Castoldi, Giuseppe Camporese, Giuseppe Porcellini (Italy)

**Screen 70**

**Session:** PB 2.70-5

**Title:** Thromboprophylaxis in multiple myeloma - a tale of two cities

**Authors:** Julia Czuprynska (United Kingdom)

**Screen 70**

**Session:** PB 2.70-6

**Title:** Postoperative deep vein thrombosis in patients undergoing general, colorectal and orthopedic surgeries in Taiwan - an institutional experience

**Authors:** Ching Yeh Lin, Ming Ching Shen, Ing Lin Chang, Hung Chang Chen, Ting Ming Huang, Yao Li Chen, Kuo Wei Lee, Hsuan Yu Lin, Han Ni Hsieh, Ya Wun Yang (Taiwan)

### Recurrent venous thrombosis - II

**Screen 71**

**Moderator:** Astrid van Hylckama Vlieg (The Netherlands)

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>PB 2.71-1</td>
<td><em>Factors associated with early and late hypercoagulability after stopping anticoagulation for idiopathic venous thromboembolism</em></td>
<td>Benilde Cosmi, Cristina Legnani, Alberto Tosetto, Vittorio Pengo, Angelo Ghirarduzzi, Sophie Testa, Domenico Prisco, Daniela Poli, Armando Tripodi, Gualtiero Palareti (Italy)</td>
</tr>
<tr>
<td>PB 2.71-2</td>
<td><em>The incidence of recurrent venous thrombosis associated with different clinical risk profiles</em></td>
<td>Astrid van Hylckama Vlieg, Caroline Baglin, Roger Luddington, Frits Rosendaal, Trevor Baglin (The Netherlands)</td>
</tr>
</tbody>
</table>
**ePOSTERS (B)**

**ePOSTER AREA**

**Tuesday July 2, 2013**

**PB 2.71-3**  
**Whole Blood Gene Expression Profiles to Distinguish Venous Thromboembolism Phenotypes**  
Deborah Lewis, Sunil Suchindran, Michele Beckman, John Heit, Stephan Moll, Claire Philipp, Kristy Kenney, Christine De Staercke, Meri Pyle, Thomas Ortel (USA)

**PB 2.71-4**  
**Efficacy and safety of weight-adjusted dosing of low-molecular-weight-heparin for prevention and treatment of acute VTE in obese patients: a systematic review and meta-analysis**  
Rick Ikesaka, Gergoire Le Gal, Marc Carrier (Canada)

**PB 2.71-5**  
**Residual pulmonary embolism as a predictor for recurrent thromboembolic events after a first unprovoked episode: data from the REVERSE cohort study**  
Gergoire Le Gal, Wanzhen Zeng, Marc Righini, Michael Kovacs, Melanie Tan, Marc Carrier, Sadri Bazarjani, Marc Rodger, The REVERSE Study Group (Canada)

**PB 2.71-6**  
**Two years outcome and features of isolated distal vein thrombosis**  
Michelangelo Sartori, Benilde Cosmi, Ludovica Migliaccio, Elisabetta Favaretto, Giuliana Guazzaloca, Lelia Valdrè, Cristina Legnani, Gualtiero Palareti (Italy)

**Thrombophilia - III**  
**Screen 72**

**Moderator:** Wolfgang Miesbach (Germany)

**PB 2.72-1**  
**FIX-Padua increases fibrinolytic resistance through a TAFI-mediated mechanism**  
Fabrizio Semeraro, Concetta Ammollo, Daniela Tormene, Mario Colucci, Paolo Simioni (Italy)

**PB 2.72-2**  
**Audit of requests for thrombophilia laboratory tests post introduction of clinical guidelines in a referral laboratory**  
Mary Byrne, Marie Rafferty, Barry White, Kevin Ryan, James O'Donnell, Niamh O'Connell (Ireland)

**PB 2.72-3**  
**Novel Mutations of Antithrombin Gene in Inherited AT Deficiency**  
Ziqiang Yu, Ling Sun, Chaorong Wang, Wei Zhang, Lijuan Cao, Changgeng Ruan (China)

**PB 2.72-4**  
**Inherited Thrombophilia and Recurrent Pregnancy Loss**  
Mehran Karimi, Jale Zolghadri, Mozghan Nezam, Abdolreza Afrasiabi (Iran)

**PB 2.72-5**  
**Thrombophilia screening in patients with ocular venous thrombosis**  
Mohammed Airilai, Kathrin-Sophie Heidinger, Ronald Fischer, Antje Zimmermann, Bettina Kemkes-Matthes (Germany)

**PB 2.72-6**  
**The Course of vWF multimers and ADAMTS13 in cardiac surgery**  
Wolfgang Miesbach, Imke Reinecke, Christian Weber, Ulrich Budde (Germany)

**TTP/Thrombotic microangiopathies - I**  
**Screen 73**

**Moderator:** Elien de Cock (Belgium)

**PB 2.73-1**  
**Hematologic outcomes at 2 years in eculizumab-treated atypical hemolytic uremic syndrome patients with long disease duration and chronic kidney disease**  
Kenneth Douglas, Richard Furman, Sunil Babu, Camille Bedrosoian (United Kingdom)

**PB 2.73-2**  
**A new heterozygous mutation in the metalloprotease domain of ADAMTS13 in a patient with thrombotic thrombocytopenic purpura**  
Elien de Cock, Cedric Hermans, Nele Vandeputte, Hans Deckmyn, Simon de Meyer, Karen Vanhoorelbeke (Belgium)

**PB 2.73-3**  
**Atypical hemolytic uremic syndrome patients with progressing thrombotic microangiopathy treated with ongoing eculizumab have favorable hematologic outcomes at 2 years**  
Richard Furman, Sunil Babu, Kenneth Douglas, Camille Bedrosoian (USA)
PB 2.73-4  A novel heterozygous missense ADAMTS13 mutation (G3368A) in a patient diagnosed with thrombotic thrombocytopenic purpura due to reduced ADAMTS13 activity and low titer of anti-ADAMTS13 antibody
Julio Calderazzo, Ana Kempfer, Yanina Powazniak, Analía Sánchez-Luceros, Adriana Woods, Juvenal Paiva, Maria Lazari [Argentina]

PB 2.73-5  Release of fibrinolytic microvesicles in atypical haemolytic-uremic syndrome
Kelly Monthé-Sagan, Laurent Plawinski, Valérie Chatellet, Bruno Hurault De Ligny, Eduardo Anglés-Cano [France]

PB 2.73-6  Recurrent disease in patients with thrombotic thrombocytopenic purpura: data from Serbian TTP Registry
Marko Saracevic, Dragica Vucelic, Nebojsa Savic, Zoran Rajic, Slobodan Obradovic, Dragana Jevtic, Danijela Mikovic [Serbia]

Thrombosis: miscellaneous  Screen 74
Moderator: Tobias Bonten [The Netherlands]

PB 2.74-1  Successful management for pregnancy in 3 patients with Upshaw-Schulman syndrome
Masanori Matsumoto, Ayami Isonishi, Michiko Kajiwara, Yoshiyuki Ogawa, Yuko Yamamoto, Yoshihito Fujimura [Japan]

PB 2.74-2  Size of Pulmonary Embolism in Relation to Persisting Symptoms
Anja Mäkelburg, Adrienne Brouwers, Elke Hoendermis, Rudi Dierckx, Nic Veeger, George Nossent, Hanneke Kluin-Nelemans, Karina Meijer [The Netherlands]

PB 2.74-3  D-dimer, factor VIII, and thrombotic burden during the acute phase of leg deep venous thrombosis and early signs and symptoms of post-thrombotic syndrome
Michelangelo Sartori, Elisabetta Favaretto, Benilde Cosmi, Michela Cini, Cristina Legnani, Gualtiero Palareti [Italy]

PB 2.74-4  The effect of initiating combined antiretroviral therapy on endothelial cell activation and coagulation markers in a south african HIV-infected cohort
Susan Louw [South Africa]

PB 2.74-5  Aspirin intake AM or PM?: Effect on platelet reactivity in the morning
Tobias Bonten, Jaap Jan Snoep, Willem Assendelft, Jan Jaap Zwaginga, Menno Huisman, Frits Rosendaal, Jeroen Eikenboom, Anske van der Bom [The Netherlands]

PB 2.74-6  Markers of endothelial damage are associated with successful recanalization in acute stroke
Dorothée Faille, Julien Labreuche, Marie-Geneviève Huisse, Mikaël Mazighi, Nadine Ajzenberg [France]
Scientific Programme

Wednesday, July 3, 2013
Wednesday, July 3, 2013

PLENARY LECTURES 09:45 - 10:30 / 16:45 - 17:30

Ratnoff-MacFarlane Lecture
Moderator: Michael Berndt (Australia)
09:45 - 10:30  Tissue factor pathway inhibitor and protein S
PL 05  Tilman Hackeng (The Netherlands)

Plenary Lecture
Moderator: Frits Rosendaal (The Netherlands)
16:45 - 17:30  A rare view of coding variation and risk for myocardial infarction
PL 06  Sekar Kathiresan (USA)
**Wednesday, July 3, 2013**

**STATE-OF-THE-ART LECTURES**
11:00 - 12:00

**New and old anticoagulants**
Mondriaan I
Moderators: Felix van der Meer (The Netherlands) and Jeffrey Weitz (Canada)

11:00 - 11:30 The role of the laboratory in treatment with new oral anticoagulants (NOACs)
SOA 13.1 Trevor Baglin (United Kingdom)

11:30 - 12:00 Optimisation of anticoagulant treatment in the elderly
SOA 13.2 Elaine Hylek (USA)

**Microparticles**
Mondriaan II
Moderators: Paul Harrison (United Kingdom) and Nigel Key (USA)

11:00 - 11:30 Revisited role of microparticles in arterial and venous thrombosis
SOA 14.1 Francoise Dignat-George (France)

11:30 - 12:00 Innovation in detection of microparticles and exosomes
SOA 14.2 Rienk Nieuwland (The Netherlands)

**Genetics: Humans and mice**
Elicium 1
Moderators: Jay Degen (USA) and Nicholas Smith (USA)

11:00 - 11:30 Novel mouse models for venous thrombosis research
SOA 15.1 Bart van Vlijmen (The Netherlands)

11:30 - 12:00 Current knowledge on the genetics of venous thrombosis
SOA 15.2 Pierre-Emmanuel Morange (France)

**Women’s issues in bleeding and thrombosis**
Elicium 2
Moderators: Ingrid Pabinger (Austria) and Astrid van Hylckama Vlieg (The Netherlands)

11:00 - 11:30 Haemostatic disorders in women
SOA 16.1 Rezan Kadir (United Kingdom)

11:30 - 12:00 Thrombosis in women: what are the knowledge gaps in 2013?
SOA 16.2 Saskia Middeldorp (The Netherlands)

**Vessel wall biology**
Forum
Moderators: Hugo ten Cate (The Netherlands) and Denisa Wagner (USA)

11:00 - 11:30 Evolutionary origins of the blood vascular system and endothelium
SOA 17.1 William Aird (USA)

11:30 - 12:00 Synthetic microvessels
SOA 17.2 José López (USA)

**Gene therapy**
Auditorium
Moderators: Valder Arruda (USA) and Frank Leebeek (The Netherlands)

11:00 - 11:30 Update on AVV-mediated gene therapy for haemophilia B
SOA 18.1 Amit Nathwani (United Kingdom)

11:30 - 12:00 Gene therapy for haemophilia: state of the art
SOA 18.2 Thierry Vandendriessche (Belgium)
Wednesday, July 3, 2013

ABSTRACT SYMPOSIA 13:00 - 14:15

Contact activation 2.0 E104-107

Moderator: Thomas Renné (Sweden)

13:00 - 13:30 Contact activation 2.0
AS 25
Thomas Renné (Sweden)

13:30 - 13:45 Role of cell-free DNA in sepsis pathophysiology: novel studies in murine models of sepsis
AS 25.1
Safiah Mai, Alison Fox-Robichaud, Patricia Liaw (Canada)

13:45 - 14:00 Inhibition of factor XII activation reduces experimental thrombus formation in baboons
AS 25.2
Philberta Leung, Erik Tucker, Anton Matafonov, Thomas Renne, Owen McCarty, David Gailani, Andras Gruber (USA)

14:00 - 14:15 Blood-borne and wall-derived DNA as a kinetically significant contact pathway activator: DNase inhibits thrombin formation in vitro and in vivo
AS 25.3
Scott Diamond, John Welsh, Thomas Colace, Songtao Zhou, Lawrence Brass (USA)

Assays for haemostatic drugs Mondriaan III

Moderator: Steve Kitchen (United Kingdom)

13:00 - 13:30 Assays for haemostatic drugs
AS 26
Steve Kitchen (United Kingdom)

13:30 - 13:45 Evaluation of whole blood clotting activity of recombinant factor VIII Fc fusion protein by ROTEM analysis in a multi-center Phase 3 clinical trial
AS 26.1
Jurg Sommer, Frank Driessler, Maricel Miguelino, Jerry Powell, Alvin Luk, Glenn Pierce, Haiyan Jiang (USA)

13:45 - 14:00 Activated Factor VII. Antithrombin Complex plasma concentration is an independent predictor of total and cardiovascular mortality in patients with angiographically demonstrated coronary artery disease
AS 26.2
Nicola Martinelli, Domenico Girelli, Marcello Baroni, Patrizia Guarini, Federica Tosi, Patrizia Pattini, Barry Woodhams, Francesco Bernardi, Oliviero Olivieri [Italy]

14:00 - 14:15 Evaluation of a recombinant inactive antithrombin to reverse fondaparinux anticoagulant activity by measuring thrombin generation: an asset compared to other non specific hemostatic agents
AS 26.3
Elsa Bianchini, Yasmine Bourt, Marine Armand, Judicael Fazavana, François Saller, Dominique Lasne, Delphine Borgel [France]
Wednesday, July 3, 2013

**ABSTRACT SYMPOSIA** 13:00 - 14:15

**Platelet response to injury** Mondriaan IV

*Moderator: Lawrence Brass (USA)*

13:00 - 13:30  **Re-thinking the platelet response to injury**  
**AS 27** Lawrence Brass (USA)

13:30 - 13:45  **A talin mutant that disrupts talin-integrin binding in platelets decelerates allβ3 activation without pathological bleeding**  
**AS 27.1** Lucia Stefanini, Adam Snider, Raymond Platt, Wolfgang Bergmeier, Brian Petrich (USA)

13:45 - 14:00  **Tetraspanin Tspan18 regulates GPVI-induced platelet activation by interacting with the store-operated Ca2+ entry channel Orai1**  
**AS 27.2** Rebecca Bailey, Dario Colombo, Elizabeth Haining, Jing Yang, Tammy Lloyd, Adam Peall, Steve Watson, Michael Tomlinson (United Kingdom)

14:00 - 14:15  **Integrin α6β1 is the main receptor for vascular laminins and plays a role in platelet adhesion, activation and arterial thrombosis**  
**AS 27.3** Mathieu Schaff, Eric Maurer, Catherine Bourdon, Nicolas Receveur, Béatrice Hechler, Elisabeth Georges-Labouesse, Christian Gachet, François Lanza, Pierre Mangin (France)

**Thrombocytopenia** Mondriaan II

*Moderator: Andreas Greinacher (Germany)*

13:00 - 13:30  **Thrombocytopenia: bridging basic and clinical research**  
**AS 28** Andreas Greinacher (Germany)

13:30 - 13:45  **Impact of an avoid-heparin program on the incidence, clinical consequences and resource use associated with heparin-induced thrombocytopenia (HIT)**  
**AS 28.1** Kelly McGowan, Joy Makari, Peter Rempel, Claudia Bucci, Artemis Diamantouros, William Geerts (Canada)

13:45 - 14:00  **Platelet-monocyte interactions enhance procoagulant activity in heparin induced thrombocytopenia**  
**AS 28.2** Raj Kasuthuri, William Jonas, Marshall Mazepa, Nigel Mackman, Nigel Key, Rafal Pawlinski (USA)

14:00 - 14:15  **A mutation in ANKRD18A is associated with a severe congenital thrombocytopenia**  
**AS 28.3** Neil Morgan, Gillian Lowe, Jayashree Motwani, Mike Williams, Michael Simpson, Gail Kirby, Eamonn Maher, Steve Watson (United Kingdom)

**Genetics in coagulation** G102-103

*Moderator: Elisabetta Castoldi (The Netherlands)*

13:00 - 13:30  **Anticoagulant pathways: genotype-phenotype relationships**  
**AS 29** Elisabetta Castoldi (The Netherlands)

13:30 - 13:45  **Fibrinogen γ’ increases the sensitivity to activated protein C in normal and FV Leiden plasma**  
**AS 29.1** Farida Omarova, Shirley Uitte de Willige, Paolo Simioni, Robert Ariëns, Rogier Bertina, Jan Rosing, Elisabetta Castoldi (The Netherlands)

13:45 - 14:00  **The functional effect of pleotropic mutations on Antithrombin**  
**AS 29.2** Sonia Aguila, José Navarro-Fernández, Nataliya Bohdan, María Eugenia De La Morena-Barrio, José Padilla, Antonia Miñano, Vicente Vicente, Javier Corral, Irene Martinez-Martinez (Spain)

14:00 - 14:15  **Genetic variation in the annexin V gene and the risk for pregnancy related venous thrombosis**  
**AS 29.3** Anders Dahn, Giovanni Tischia, Elvira Grandone, Grethe Skretting, Per Morten Sandset (Norway)
### ABSTRACT SYMPOSIA 13:00 - 14:15

#### Thrombus resolution and stroke  G104-105

**Moderator: Jaimie Grutzendler [USA]**

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:00 - 13:30</td>
<td>Angiophagy: A mechanism of microvascular recanalization after embolic occlusion</td>
<td>Jaimie Grutzendler [USA]</td>
</tr>
<tr>
<td>13:30 - 13:45</td>
<td>The effects of DNA and histones on fibrin clot structure-function and on the regulation of fibrinolysis</td>
<td>Colin Longstaff, Imre Varjú, Péter Sótonyi, László Szabó, Michael Krumrey, Armin Hoell, Attila Bóta, Zoltán Varga, Erzsébet Komorowicz, Krasimir Kolev [United Kingdom]</td>
</tr>
<tr>
<td>14:00 - 14:15</td>
<td>A new effective strategy for thrombolysis in ischemic stroke: Low-dose tPA in combination with MMP-10</td>
<td>Josune Orbe, Carmen Roncal, José Antonio Rodriguez, Agustina Salicio, Joan Montaner, Anna Rosell, Sara Martinez De Lizarrondo, Denis Vivien, José Antonio Paramo [Spain]</td>
</tr>
<tr>
<td>13:45 - 14:00</td>
<td>Kinase activity of TRPM7 enhances PLCγ2 mediated calcium responses in platelets and plays an important role in arterial thrombosis and stroke</td>
<td>Attila Braun, Wenchun Chen, Vladimir Chubanov, Martina Morowski, Peter Kraft, Sanjeev GoTru, Heike Hermanss, Guido Stoll, Thomas Gudermann, Bernhard Nieswandt [Germany]</td>
</tr>
</tbody>
</table>

#### Coagulation and complement  Elicium 1

**Moderator: Marcel Levi [The Netherlands]**

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:00 - 13:30</td>
<td>Coagulation and complement</td>
<td>Marcel Levi [The Netherlands]</td>
</tr>
<tr>
<td>13:30 - 13:45</td>
<td>Human megakaryocytes and platelets contain complement C3 and C5 and release it upon interaction with Escherichia coli</td>
<td>Iciar Arbesu, Michael Fischer, Christine Mannhalter [Austria]</td>
</tr>
<tr>
<td>13:45 - 14:00</td>
<td>Polyphosphate suppresses complement activation</td>
<td>Jovián Wat, Michael Krisinger, Jonathan Foley, Victor Lei, Stephanie Smith, James Morrissey, Edward Conway [Canada]</td>
</tr>
<tr>
<td>14:00 - 14:15</td>
<td>The lectin like domain of Thrombomodulin is involved in the defense against pyelonephritis</td>
<td>Lionel Lattenist, Gwendoline Teske, Nike Claessen, Sandrine Florquin, Joris Roelofs [The Netherlands]</td>
</tr>
</tbody>
</table>

#### Treatment of von Willebrand disease  Forum

**Moderator: Frank Leebeek [The Netherlands]**

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:00 - 13:30</td>
<td>Treatment of von Willebrand disease</td>
<td>Frank Leebeek [The Netherlands]</td>
</tr>
</tbody>
</table>
**Wednesday, July 3, 2013**

### ABSTRACT SYMPOSIA  13:00 - 14:15

**13:45 - 14:00  AS 32.2**  Determinants, frequency, types, and management of bleedings in severe VWD type 3: Final results of the retro/prospective analyses in 86/52 Italian patients  
Augusto Federici, Giancarlo Castaman, Paolo Buccionelli, Emily Oliovecchio, Luciano Baronciani, Maria Gabriella Mazzucchoni, Massimo Morfini, Angiola Rocino, Mario Schiavoni, Flora Peyvandi (Italy)

**14:00 - 14:15  AS 32.3**  High rate of postpartum hemorrhage in women with von Willebrand disease or carriership of hemophilia, despite specialized care  
Sara Stoof, Hanna van Steenbergen, Yvonne Sanders, Suzanne Cannegieter, Johannes Duvekot, Frank Leebeek, Marieke Kruip, Jeroen Eikenboom (The Netherlands)

### Major bleeding  
**Moderator: Ton Lisman (The Netherlands)**

**13:00 - 13:30  AS 33**  Bleeding and thrombosis in patients with liver disease  
Ton Lisman (The Netherlands)

**13:30 - 13:45  AS 33.1**  Comparison of three different prothrombin complex concentrates efficacy, in reversal of anti-vitamin K effect in patients under oral anticoagulant treatment. An in vitro study  
Valeria Rossetto, Maria Teresa Sartori, Sabrina Gavasso, Mariangela Fadin, Elena Campello, Luca Spiezia, Paolo Simioni (Italy)

**13:45 - 14:00  AS 33.2**  Liver cirrhosis is associated with hypercoagulability, decreased clot strength and normal fibrinolysis  
Marie-Claire Kleinegris, Chris Habets, Danny van de Sande, Yvonne Henskens, Arina ten Cate-Hoek, Cees van Deursen, Henri Spronk, Ger Koek, Hugo ten Cate (The Netherlands)

**14:00 - 14:15  AS 33.3**  Prolonged shock phase in a pig model with multiple injuries is associated with a decreased onset of tPA induced fibrinolysis  
Christian Zentai, Henri Spronk, René van Œrle, Hugo ten Cate, Rolf Rossaint, Oliver Grottke (Germany)

### Venous thrombosis and cancer  
**Moderator: Dominique Farge-Bancel (France)**

**13:00 - 13:30  AS 34**  Treatment of venous thromboembolism in cancer patients  
Dominique Farge-Bancel (France)

**13:30 - 13:45  AS 34.1**  The value of CT-scanning for detection of occult cancer in patients with unprovoked venous thromboembolism. The D’Acquapendente study  
Andrea Piccioli, Enrico Bernardi, Fabio Dalla Valle, Adriana Visonà, Pietro Tropeano, Carlo Bova, Eugenio Bucherini, Anna Falanga, Paolo Prandoni (Italy)

**13:45 - 14:00  AS 34.2**  A risk scoring model for cancer-associated venous thromboembolism is predictive for overall survival in patients with cancer  
Cihan Ay, Eva-Maria Reitter, Julia Riedl, Oswald Wagner, Christoph Zielinski, Ingrid Pabinger (Austria)

**14:00 - 14:15  AS 34.3**  Mechanistic insights into zymogen protein C protection against cancer progression  
Julie Crudele, Geerte van Sluis, Paris Margaritis, Joshua Siner, Jenna Maurer, Shangzhen Zhou, Charles Esmon, Katherine High, Arnold C. Spek, Valder Arruda (USA)
### ABSTRACT SYMPOSIA  13:00 - 14:15

#### Clot structure  E102

*Moderator: Alisa Wolberg (USA)*

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:00 - 13:30</td>
<td><strong>Determinants of clot stability</strong></td>
</tr>
<tr>
<td>AS 35</td>
<td>Alisa Wolberg (USA)</td>
</tr>
<tr>
<td>13:30 - 13:45</td>
<td><strong>Fibrinogen a-chain and γ'-chain play specific roles in fibrin clot formation and structure</strong></td>
</tr>
<tr>
<td>AS 35.1</td>
<td>Cedric Duval, Victoria Ridger, Helen Philippou, Robert Ariëns (United Kingdom)</td>
</tr>
<tr>
<td>13:45 - 14:00</td>
<td><strong>Multiscality of the structure and mechanics of fibrin clots</strong></td>
</tr>
<tr>
<td>AS 35.2</td>
<td>Nicholas Kurniawan, Gijsje Koenderink (The Netherlands)</td>
</tr>
<tr>
<td>14:00 - 14:15</td>
<td><strong>Dissolution of tPA-resistant thrombi in occlusive intracranial thrombosis</strong></td>
</tr>
<tr>
<td>AS 35.3</td>
<td>Maxime Gauberti, Audrey Le Béhot, Eloïse Lemarchand, Axel Montagne, Eric Maubert, Denis Vivien, Cyrille Orset (France)</td>
</tr>
</tbody>
</table>
Wednesday, July 3, 2013

FOCUS SYMPOSIA  13:00 - 14:15

Thrombosis and haemostasis in the Asian-Pacific  Emerald
Moderators: Yukio Ozaki (Japan) and Christopher Ward (Australia)

13:00 - 13:15  Asian Pacific Microangiopathic Thrombocytopenic Network (APMAT)
FS 03  Ross Baker, APMAT Steering Committee, APSTH members (Australia)

13:15 - 13:30  Registry of congenital atypical HUS in Japan
FS 03.1  Yoshihiro Fujiyuma, Y. Yoshida, Xinpeng Fan, Toshiyuki Miyata (Japan)

13:30 - 13:45  SMTP-7, a novel thrombolytic with an anti-inflammatory potential, improves primate thrombotic stroke with reduced hemorrhage risk: A role of soluble epoxide hydrolase inhibition
FS 03.2  Eriko Suzuki, Naoki Matsumoto, Hironobu Sawada, Naoko Nishimura, Keiko Hasegawa, Keiji Hasumi (Japan)

13:45 - 14:00  ACTN1 mutations cause congenital macrothrombocytopenia
FS 03.3  Shinji Kunishima, Yusuke Okuno, Masashi Sanada, Koji Miyazaki, Michio Sakai, Akihiro Iguchi, Satoru Miyano, Hidehiko Saito, Seiji Kojima, Seishi Ogawa (Japan)

14:00 - 14:15  Impaired haemostasis in Reelin-deficient mouse: A potential role of plasma Reelin in thrombin generation and fibrin clot formation
FS 03.4  Wei-Lien Tseng, Chia-Chun Huang, Tzu-Hsuan Chen, Yao-Hung Huang, Ju-Chien Cheng, Ching-Ping Tseng (Taiwan)

Thrombosis and haemostasis in the developing world  G106-107
Moderators: Flora Peyvandi (Italy) and Suely Meireles Rezende (Brazil)

13:00 - 13:20  Setting up a clinical facility in Kenya
FS 04.1  Fredrick Asirwa (Kenya)

13:20 - 13:40  Patient care in the developing world
FS 04.2  Mammen Chandy (India)

13:40 - 14:00  Clinical research in the developing world
FS 04.3  Pier Mannucci Mannucci (Italy)

14:00 - 14:15  Education in the developing world
FS 04.4  Suely Meireles Rezende (Brazil)
Wednesday, July 3, 2013

NURSES SYMPOSIUM 13:00 - 14:15

Nurses symposium E108

Moderators: Carolina Baglin (United Kingdom) and Maura Malone Dumas (USA)

13:00 - 13:30
NS 01
The Nurses Forum: Past, present and future direction
Maura Malone Dumas (USA)

13:30 - 13:45
NS 01.1
Adherence to prescribed treatment regimen is related to chronic pain among adolescent and young adults with moderate or severe hemophilia: Early results from the IMPACT QoL survey
Michelle Witkop, John McLaughlin, Angela Lambing, James Munn, Terry Anderson, Bartholomew Tortella (USA)

13:45 - 14:00
NS 01.2
Effectiveness of patient education in VTE prevention: a nurse led collaborative local service improvement project
Rebecca Brown, Carol Law (United Kingdom)

14:00 - 14:15
NS 01.3
An audit of the use of novel anticoagulants: Dabigatran and Rivaroxaban for stroke prevention in AF
Susan Rhodes, Sarah Bond, Jennie Bailey, Karen Curtis, Amanda McMullon, Marie Mowbray, Martin Percival (United Kingdom)
Wednesday, July 3, 2013

**ORAL COMMUNICATIONS**  
08:00 - 09:30

**Contact activation**  
**G106-107**

*Moderators: Katrin Nickel (Sweden) and Thomas Renné (Sweden)*

**08:00 - 08:15**  
**Polyphosphate stimulates FXIIa-mediated fibrinolysis**  
OC 53.1  
Ausra Lionikiene, Nicola Mutch (United Kingdom)

**08:15 - 08:30**  
*A nanobody-based method for tracking factor XII activation in plasma*  
OC 53.2  
Steven de Maat, Sanne van Dooremalen, Philip de Groot, Coen Maas (The Netherlands)

**08:30 - 08:45**  
*Aberrant contact system activity causes hereditary angioedema type III*  
OC 53.3  
Jenny Björkgvist, Anna Sala-Cunill, Sven Cichon, Thomas Renné (Sweden)

**08:45 - 09:00**  
*Identification of leukocyte factor XII: A critical regulator of WBC function*  
OC 53.4  
Evi Stavrou, Chao Fang, Gretchen LaRusch, Matthew Fullana, Howard Meyerson, Cheng-Kui Qu, Gary Wnek, Alvin Schmaier (USA)

**09:00 - 09:15**  
*Targeting the polyphosphate-coagulation factor XII pathway prevents cardiac ischemia-reperfusion injury without influencing bleeding risk*  
OC 53.5  
Katrin Nickel, Stefan Frantz, Charles Esmon, David Gailani, Thomas Renné (Sweden)

**09:15 - 09:30**  
*A pivotal role of regulatory pathways of autophagy during the formation of neutrophil extracellular traps (NETs) in human neutrophils*  
OC 53.6  
Asako Itakura, Owen McCarty (USA)

---

**Endothelial cells**  
**G104-105**

*Moderators: Jaime Pereira (Chile) and Christophe Vandenbriele (Belgium)*

**08:00 - 08:15**  
*Fuellng the knowledge of blood coagulation signaling with time resolved quantitative phosphoproteomics of thrombin-stimulated endothelial cells*  
OC 54.1  
Maartje van den Biggelaar, Juan-Ramon Hernandez, Alexander Meijer, Koen Mertens, Sara Zanivan (The Netherlands)

**08:15 - 08:30**  
*Aldosterone decreases thrombin generation via enhancement of thrombomodulin-mediated protein C activation*  
OC 54.2  
Veronique Regnault, Jeremy Lagrange, Mustapha Bourhim, Celine Fassot, Aurelie Nguyen Dinh Cat, Denis Wahl, Frederic Jaisser, Patrick Lacolley (France)

**08:30 - 08:45**  
*Endothelium but not platelet derived thiol isomerase ERp57 is required for thrombosis in vivo*  
OC 54.3  
Reema Jasuja, Anish Sharda, Sarah Kim, Bruce Furie, Barbara Furie (USA)

**08:45 - 09:00**  
*Parmodulins act at PAR1 to stimulate cytoprotective genetic program in endothelial cells*  
OC 54.4  
Omozuanvo Aisiku, Christian Peters, James Dilks, Jennifer Fitch-Tewfik, Christopher Dockendorff, Robert Flaumenhaft (USA)

**09:00 - 09:15**  
*Endothelial Protease Nexin-1 potentiates the cytoprotective effects of activated Protein C by preventing endothelial Protein C receptor shedding*  
OC 54.5  
Marie-Christine Bouton, Yacine Boulaffal, Déborah François, Laurence Venisse, Martine Jandrot-Perrus, Véronique Arocas (France)

**09:15 - 09:30**  
*Platelet endothelial aggregation receptor-1 is a critical determinant of endothelial cell function*  
OC 54.6  
Christophe Vandenbriele, Alexandre Kauskot, Aernout Luttun, Stefan Janssens, Marc Hoylaerts, Peter Verhamme (Belgium)
**Wednesday, July 3, 2013**

### ORAL COMMUNICATIONS  08:00 - 09:30

#### Immune thrombocytopenic purpura  Mondriaan II

**Moderators: Jan Jaap Zwaginga (The Netherlands) and Sento Santoso (Germany)**

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00 - 08:15</td>
<td><strong>Modified HPA-1a monoclonal antibody to prevent fetal-alloimmune thrombocytopenia</strong></td>
<td>Tamam Bakchoul, Sentot Santoso, Ulrich Sachs, Gregor Bein, Andreas Greinacher, Peter Newman (Germany)</td>
</tr>
<tr>
<td>08:15 - 08:30</td>
<td><strong>Anti-GP Ib antibody induces platelet desialylation: A novel mechanism of Fc-independent immune thrombocytopenia, and a potential new diagnosis and therapy against refractory ITP</strong></td>
<td>Dianne van der Wal, June Li, Guangheng Zhu, Brian Vadasz, Li Ma, Issaka Yougbare, Sean Lang, John Freedman, Heyu Ni (Canada)</td>
</tr>
<tr>
<td>08:30 - 08:45</td>
<td><strong>Dendritic cells differently phagocytose activated or apoptotic blood platelets</strong></td>
<td>Blandine Maître, Marie-Anne Mawhin, Anita Eckly, Véronique Heim, Henri De La Salle, Christian Gachet (France)</td>
</tr>
<tr>
<td>08:45 - 09:00</td>
<td><strong>Autoantibody binding to glycoprotein Ibα induces FcγRIIa-mediated platelet activation in a patient with immune thrombocytopenia</strong></td>
<td>Eelo Gitz, Dianne van der Wal, Cornelis Koekman, Albert Huisman, Dave van den Heuvel, Hans Gerritsen, Hans Deckmy, Jan-Willem Akkerman, Roger Schutgens, Rolf Urbanus (The Netherlands)</td>
</tr>
<tr>
<td>09:00 - 09:15</td>
<td><strong>Therapeutic efficacy of rapamycin in patients with chronic immune thrombocytopenia</strong></td>
<td>Lan Dai (China)</td>
</tr>
<tr>
<td>09:15 - 09:30</td>
<td><strong>A novel monoclonal antibody against GP Ibα/GI10 inhibits human platelet clearance induced by autoantibodies against GPIb/IX from ITP patients in a NOD/SCID mice model</strong></td>
<td>Ulrich Sachs, Tamam Bakchoul, Astrid Giptner, Sentot Santoso (Germany)</td>
</tr>
</tbody>
</table>

#### Inhibitor development in haemophilia A  Auditorium

**Moderators: Anske van der Bom (The Netherlands) and Chao Lien Liu (USA)**

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00 - 08:15</td>
<td><strong>Induction of antigen-specific tolerance upon infusion of Fc-fusion proteins via the Materno-fetal Interface</strong></td>
<td>Nimesh Gupta, Yann Meslier, Sebastien André, Slobodan Culina, Sandrine Delignat, Roberto Mallone, Srini Kaveri, Sebastien Lacroix-Desmazes (France)</td>
</tr>
<tr>
<td>08:15 - 08:30</td>
<td><strong>Role of mannose-ending glycans in the endocytosis and presentation of FVIII to T cell by human and mouse antigen-presenting cells</strong></td>
<td>Sandrine Delignat, Laurent Gilard, Jean-Luc Plantier, Sami Chtourou, Luisa Martinez-Pomares, Yu Chun Lone, John Robinson, Sébastien Lacroix-Desmazes, Srinivas Kaveri (France)</td>
</tr>
<tr>
<td>08:30 - 08:45</td>
<td><strong>Inhibitor eradication therapy in non-severe hemophilia A</strong></td>
<td>Alice van Velzen, Corien Eckhardt, Marjolein Peters, P. Hart, Savita Rangarajan, Charles Hay, Maria Elisa Mancuso, Frans Smiers, Ria Liesner, Pia Petri, Victor Jiménez Yuste, Anske van der Bom, Karin Fijnvandraat, Thynn Yee, For the INSIGHT consortium (The Netherlands)</td>
</tr>
<tr>
<td>08:45 - 09:00</td>
<td><strong>Mechanisms of immune tolerance induction by rFVIIIc in hemophilia A mice</strong></td>
<td>Sriram Krishnamoorthy, Zhan Liu, Douglas Drager, Susannah Patarroyo-White, Tongyao Liu, Arjan van der Flier, Ekta Chhabra, Joe Salas, Lily Zhu, Elena Kistanova, Robert Peters, David Light, Glenn Pierce, Haiyan Jiang (USA)</td>
</tr>
<tr>
<td>09:00 - 09:15</td>
<td><strong>Novel strategies to target long-lived plasma cells for treating Hemophilia A inhibitors</strong></td>
<td>Chao Lien Liu, Meghan Lyle, Simon Shin, Carol Miao (USA)</td>
</tr>
</tbody>
</table>
### Wednesday, July 3, 2013

#### ORAL COMMUNICATIONS 08:00 - 09:30

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:15</td>
<td>Co-administration of factor VIII and dexamethasone prevents anti-factor VIII antibody development in a mouse model of hemophilia A</td>
<td>Paul Moorehead, Alice van Velzen, Kate Sponagle, Katharina Steinitz, Birgit Reipert, David Lillicrap (Canada)</td>
</tr>
</tbody>
</table>

**Modifications in factors VIII, IX and XI**

*Emerald*

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00</td>
<td>Selective mutagenesis of the heparin and antithrombin exosites on human factor IX(a) enhances thrombin generation in human plasma</td>
<td>Pamela Westmark, John Sheehan, (USA)</td>
</tr>
<tr>
<td>08:15</td>
<td>Optimizing factor IX-Triple clotting activity in vitro and in vivo</td>
<td>Chung-Yang Kao, Shu-Wha Lin, Shu-Jhu Yang, Mi-Hua Tao, Yu-Chen Hsu (Taiwan)</td>
</tr>
<tr>
<td>08:30</td>
<td>Increasing the binding affinity between FVIIIa subunits results in higher stability and greater thrombin generation in plasma</td>
<td>Morgan Monaghan, Philip Fay, Hironao Wakabayashi, Jennifer Wintermute (USA)</td>
</tr>
<tr>
<td>08:45</td>
<td>Transcriptional and post-transcriptional targeting of FVIII expression to overcome immunological responses to gene therapy for Hemophilia A</td>
<td>Simone Merlin, Elvira Cannizzo, Maria Feola, Antonia Follenzi [Italy]</td>
</tr>
</tbody>
</table>

**New developments in thrombus formation**

*Elicium 2*

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00</td>
<td>Polo-like kinase 3 regulates in vivo thrombosis through the regulation of thromboxane A2 generation, granular secretion, and integrin aldb3 outside-in signaling</td>
<td>Meghna Naik, Brendan Bachman, John Kostyak, Wei Dai, Ulhas Naik [USA]</td>
</tr>
<tr>
<td>08:15</td>
<td>Disruption of ICAM-4 mediated direct erythrocyte-platelet interaction leads to reduced thrombus formation</td>
<td>Vivian Du, Philip de Groot, Rechard van Wijk, Patrizia Marchese, Zaverio Ruggeri, Bas de Laat [The Netherlands]</td>
</tr>
<tr>
<td>08:30</td>
<td>PDK1 regulates platelet activation and arterial thrombosis</td>
<td>Xue Chen, Yue Zhang, Xinqing Luo, Yanhua Wang, Lin Zhang, Kemin Wang, Zhongzhou Yang, Yi Wu, Junling Liu [China]</td>
</tr>
<tr>
<td>08:45</td>
<td>Thrombus formation in vivo can occur independently of Syk kinase function</td>
<td>Judith van Eeuwijk, David Stegner, Ina Thielmann, Sebastian Königsberger, Friedemann Kiefer, Bernhard Nieswandt [Germany]</td>
</tr>
</tbody>
</table>
Wednesday, July 3, 2013

**ORAL COMMUNICATIONS 08:00 - 09:30**

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00 - 09:15</td>
<td>Hemostasis and thrombosis in JAK2V617F-KI mice</td>
<td>Lamia Lamrani, Catherine Lacout, Véronique Ollvier, Benoît Ho Tin Noe, William Vainchenker, Jean-Luc Villeval, Martine Jandrot-Perrus (France)</td>
</tr>
<tr>
<td>09:15 - 09:30</td>
<td>The JAK2V617F mutation causes an increase in platelet reactivity in a knock-in mouse model of essential thrombocythaemia</td>
<td>Catherine Hobbs, Cavan Bennett, Harriet Manning, Alexandra Mazharian, Lauren Brain, Sonia Severin, Juan Li, Anthony Green, Steve Watson, Cedric Ghevaert (United Kingdom)</td>
</tr>
</tbody>
</table>

### Non-inherited risk factors for venous thrombosis

**Elicium 1**

*Moderators: Mike Greaves (United Kingdom) and Kurt Mahan (USA)*

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00 - 08:15</td>
<td>A randomized study on one week versus four weeks prophylaxis for venous thromboembolism after laparoscopic surgery for colorectal cancer</td>
<td>Maria Vedovati, Cecilia Becattini, Fabio Rondelli, Michela Boncompagni, Giuseppe Camporese, Ruben Balzarotti, Enrico Mariani, Otello Flamini, Saverio Pucciarelli, Giancarlo Agnelli (Italy)</td>
</tr>
<tr>
<td>08:15 - 08:30</td>
<td>Increased risk of venous thrombosis after arterial thrombosis: causal or explained by common risk factors?</td>
<td>Linda Flinterman, Caroline Lind, Marianne Severinsen, Suzanne Cannegieter, John-Bjarne Hansen, Kim Overvad (The Netherlands)</td>
</tr>
<tr>
<td>08:30 - 08:45</td>
<td>Arthroscopy of the knee and risk of venous thrombosis: results from the MEGA study</td>
<td>Raymond van Adrichem, Rob Nelissen, Inger Schipper, Frits Rosendaal, Suzanne Cannegieter (The Netherlands)</td>
</tr>
<tr>
<td>08:45 - 09:00</td>
<td>Optimal risk estimation for DVT requires measurement of coagulation protein concentrations</td>
<td>Bart Bakker, Pieter Reitsma, Henk van Ooijen, René van den Ham, Frits Rosendaal, Willem Lijfering (The Netherlands)</td>
</tr>
<tr>
<td>09:00 - 09:15</td>
<td>Validation study of the IMPACT-ILL venous thromboembolism risk assessment model in the acutely ill medical patient</td>
<td>Charles Mahan, Jennifer Vu, Alex Spyropoulos (USA)</td>
</tr>
</tbody>
</table>
**ORAL COMMUNICATIONS** 08:00 - 09:30

**Novel platelet receptors**  Mondriaan III

Moderators: Wolfgang Bergmeier (USA) and Nicolas Prevost (Japan)

08:00 - 08:15
OC 60.1  
_Syk is essential for anti-CLEC-2 antibody-induced thrombocytopenia, but not receptor depletion_

Viola Lorenz, David Stegner, Friedemann Kiefer, Bernhard Nieswandt (Germany)

08:15 - 08:30
OC 60.2  
_Expression of exogenous proteins in platelets: All you need is Yop_

Nicolas Prevost, Stefan Wölke, Sachiko Kurata, Yoko Morioka, Jürgen Heesemann, Guy Cornelis (Japan)

08:30 - 08:45
OC 60.3  
_A novel double heterozygous substitution p.[Val207Ala; Thr223Arg]) in the P2Y12 receptor is associated with reduced receptor expression and platelet dysfunction_

Shaista Nisar, Matthew Jones, Sherina Murden, Jane Norman, Steve Watson, Stuart Mundell, Andrew Mumford (United Kingdom)

08:45 - 09:00
OC 60.4  
_Endothelial protein C receptor is expressed on activated platelets and contributes to FVIlα binding_

Maureane Hoffman, Dougald Monroe (USA)

09:00 - 09:15
OC 60.5  
_Regulation of the hemostatic and inflammatory responses triggered by ligands of Toll like receptor 2 and 4 is another non-genomic role of nuclear factor-κB in platelets_

Leonardo Rivadeneyra, Mirta Schattner, Agostina Carestia, Carlos Fondevila, Soledad Negrotto (Argentina)

09:15 - 09:30
OC 60.6  
_The newly identified platelet receptor DCBLD2 is involved in platelet activation and thrombus formation_

Benedicte Nuyttens, Katleen Broos, Mehran Sadeghi, Lei Nie, Simon de Meyer, Karen Vanhoorelbeke, Hans Deckmyn (Belgium)

**Pregnancy and coagulation**

_G102-103_

Moderators: Emmanuelle Le Moigne (France) and Saskia Middeldorp (The Netherlands)

08:00 - 08:15
OC 61.1  
_Qualitative Changes in VWF are Acquired During Pregnancy_

Jill Johnsen, Danielle Drury-Stewart, Kerry Lannert, Hilary Gammill, James Zimring, Barbara Konkle (USA)

08:15 - 08:30
OC 61.2  
_Aspirin or anticoagulants for treating recurrent miscarriage in women without antiphospholipid syndrome: an updated systematic review_

Paulien de Jong, Stef Kaandorp, Marcello Di Nisio, Mariëtte Goddijn, Saskia Middeldorp (The Netherlands)

08:30 - 08:45
OC 61.3  
_Calibrated automated thrombography does not reveal hypercoagulability in women with unexplained recurrent pregnancy loss_

Sarah Bennett, Catherine Bagot, Adjoa Appiah, Jemma Johns, Jackie Ross, Lara Roberts, Raj Patel, Roopen Arya (United Kingdom)

08:45 - 09:00
OC 61.4  
_Risk of recurrence during pregnancy after a first VTE: A French cohort_

Emmanuelle Le Moigne, Aurelien Deltuc, Aurore Daoudal, Emmanuel Nowak, Dominique Motter, Gregoire Le Gal (France)

09:00 - 09:15
OC 61.5  
_Risk factors for acute VTE in pregnancy and the postpartum period: A retrospective case control study of 14 years at National Women’s Health, Auckland, New Zealand_

Shannon Emmett, Claire McLintock (Canada)

09:15 - 09:30
OC 61.6  
_Transexamic acid inhibits fibrinolysis-induced coagulopathy associated with post-partum hemorrhage_

Sophie Susen, Antoine Tournys, Alain Duhamel, Ahmed Elkalioubie, Annabelle Dupont, Gisele Debize, Dominique De Prost, Cyril Huissoud, Brigitte Jude, Anne-Sophie Ducloy-Bouthors (France)
Wednesday, July 3, 2013

ORAL COMMUNICATIONS

08:00 - 09:30

Rare bleeding disorders - II

Moderators: David Lillicrap [Canada] and Jonathan Langdown [United Kingdom]

08:00 - 08:15
First report of a CaR DAG-GEF1 gene (RASGRP2) mutation in humans that affects platelet function and causes severe bleeding
Matthias Canault, Dorsaf Ghalloussi, Charlotte Grosdidier, Pierre-Emmanuel Morange, Xavier Pillois, Alan Nurden, Taco Kuijpers, David-Alexandre Tregouet, Marie-Christine Alessi [France]

08:15 - 08:30
A comprehensive approach for the study of a rare bleeding disorder: factor VII deficiency, the IRF7 and STER experiences
Guglielmo Mariani, Study Groups For the IRF7 and STER [Italy]

08:30 - 08:45
The ThromboGenomics Next Generation Sequencing Platform for the DNA-based diagnosis of known inherited rare bleeding and platelet disorders
Graham Kiddle, Pawan Poudel, Paul Bray, Chris van Geet, Anne Goodeve, Thomas Kunicki, Pieter Reitsma, Willem Ouwehand, Augusto Rendon [United Kingdom]

08:45 - 09:00
Constitutive activation of integrin alphabeta3 due to an inherited mutation of integrin beta3 leads to defective receptor function and impaired thrombopoiesis
Loredana Bury, Teresa Corazzi, Silvia Giannini, Emanuela Falcinelli, Anna Savoia, Joseph Italiano, Paolo Gresele [Italy]

09:00 - 09:15
A new type of hereditary bleeding disorder resulting from a premature stop codon in thrombomodulin p.Cys537*
Jonathan Langdown, Roger Luddington, James Huntington, Trevor Baglin [United Kingdom]

09:15 - 09:30
Characterization of four novel beta3 integrin defects associated with Glanzmann's thrombasthenia
Essa Sabi, Jacqueline Stockley, A. Al-Marwani, E. Kiss-Toth, Michael Makris, Martina Daly [United Kingdom]

Recurrent venous thrombosis - II

Moderators: Carlos Martinez [Germany] and Harry Büller [The Netherlands]

08:00 - 08:15
Current statin use and its association with recurrent venous thrombosis
Nicholas Smith, Laura Harrington, Marc Blondon, Kerri Wiggins, Floyd James, Colleen Sittlani, Barbara McKnight, Frits Rosendaal, Susan Heckbert, Bruce Psaty [USA]

08:15 - 08:30
The risk of recurrent venous thromboembolism among women in relation to estrogen intake: results from a prospective cohort study
Lisbeth Eicher, Sabine Eichinger, Paul Kyrle [Austria]

08:30 - 08:45
Safety of dabigatran versus warfarin for acute venous thromboembolism: pooled analyses of RE-COVER and RE-COVER II
Sam Schulman, Henry Eriksson, Samuel Goldhaber, Ajay Kakkar, Clive Kearon, Patrick Mismetti, Sebastian Schellong, Martin Feuring, Nuala Peter, Jeffrey Friedman [Canada]

08:45 - 09:00
Risk factors for recurrent venous thromboembolism: VTE Epidemiology Group (VEG) Study
Carlos Martinez, Anja Katholing, Alexander Cohen [Germany]

09:00 - 09:15
Mortality following Venous thromboembolism: Risk factors from a large cohort. VTE Epidemiology Group (VEG) Study
Alexander Cohen, Stephan Rietbrock, Carlos Martinez [United Kingdom]

09:15 - 09:30
Red cell distribution width and blood monocytes are associated with an increased risk of venous thrombosis
Suely Rezende, Willem Lijfering, Frits Rosendaal, Suzanne Cannegieter [Brazil]
Wednesday, July 3, 2013

ORAL COMMUNICATIONS 08:00 - 09:30

Thrombin generation tests

Moderators: Henri Spronk [The Netherlands] and Howard Chan [Canada]

Mondriaan IV

08:00 - 08:15
Quantitative imaging of thrombus formation under shear
OC 64.1
Sandra Baker, Kevin Phillips, Philberta Leung, Erik Tucker, András Gruber, Owen McCarty [USA]

08:15 - 08:30
Delayed and decreased thrombin generation is associated with stroke in the elderly; results from the prosper study associate
OC 64.2
Rinske Loeffen, Kristien Winckers, Ian Ford, Wouter Jukema, Michele Robertson, David Stott, Henri Spronk, Gordon Lowe, Hugo ten Cate [The Netherlands]

08:30 - 08:45
Evaluation of the thrombin generation potential of a recombinant factor VIII Fc fusion protein (rFVIII Fc) in a phase III multi-national clinical trial
OC 64.3
Yang Buyue, Haiyan Jiang, Alvin Luk, Glenn Pierce, Jurg Sommer [USA]

08:45 - 09:00
Whole blood thrombin generation in aging mice
OC 64.4
Marisa Ninivaggi, Hilde Kelchtermans, Marijke Kuijpers, Bianca Hemmeryckx, Johan Heemskerk, Theo Lindhout, Marc Hoyaerts, Bas de Laat [The Netherlands]

09:00 - 09:15
A systematic review to evaluate thromboelastography for characterization of bleeding patients with advanced liver diseases
OC 64.5
Howard Chan, Xena Li, Keith Lau, Anthony Chan [Canada]

09:15 - 09:30
Increased Thrombin Generation in Patients with Premature Myocardial Infarction Is Linked to Tissue Factor Microparticles in the Circulation
OC 64.6
Mohammed Alsahli, Bhavesh Popat, Joy Wright, Ravi Singh, Nilesam Samani, Alison Goodall [United Kingdom]

Von Willebrand factor - I

Forum

Moderators: Peter Lenting [France] and Yasuki Shida [Japan]

08:00 - 08:15
Accelerated uptake of VWF/platelet complexes in macrophages contribute to VWD-type 2B associated thrombocytopenia
OC 65.1
Caterina Casari, Olivier Christophe, Cécile Denis, Peter Lenting [France]

08:15 - 08:30
The vicinal disulphide bond and calcium coordination site of the von Willebrand factor A2 domain have distinct and additive roles in domain stabilisation that govern proteolysis by ADAMTS13
OC 65.2
Christopher Lynch, David Lane, Brenda Luken [United Kingdom]

08:30 - 08:45
Comprehensive characterization of loss and gain-of-function von Willebrand factor collagen binding variants and the role of GPVI using a mouse model system
OC 65.3
Yasuaki Shida, Natalia Rydz, Christine Brown, Jeffery Mewburn, Kate Sponagle, Ozge Danisment, Bredon Crawford, Barbara Vidal, Carol Hegadorn, David Lillicrap [Canada]

08:45 - 09:00
The role of platelet von Willebrand factor in mice
OC 65.4
Sebastien Verhenne, Sarah Libbrecht, Aline Vandenbulcke, Hans Deckmyn, Karen Vanhoorelbeke, Simon de Meyen [Belgium]

09:00 - 09:15
Common and rare VWF coding variants are associated with von Willebrand factor and Factor VIII phenotypes in African Americans: the NHLBI Exome Sequencing Project
OC 65.5
Jill Johnson, Paul Auer, Mary Cushman, Christopher O’Donnell, Stephen Rich, David Green, Alanna Morrison, Alex Reiner, Exome Sequencing Project NHBLI GO [USA]

09:15 - 09:30
High density lipoprotein and apolipoprotein A1 modulate VWF secretion and self-association
OC 65.6
Dominic Chung, Minhua Ling, Junmei Chen, Xiaoyun Fu, Scott Parsons, Jeff Harris, Jennie Le, José Lopez [USA]
Wednesday, July 3, 2013

**ORAL COMMUNICATIONS  14:30 - 15:30**

**Alternative treatments of haemophilia A**

"Auditorium"

**Moderators: Tilman Hackeng (The Netherlands) and Brigitte Tardy-Poncet (France)**

14:30 - 14:45  
**Fusion of two TFPI inhibitory peptides yields in total inhibition of human TFPI even at highly elevated TFPI levels**  
Michael Dockal, Rudolf Hartmann, T. Polakowski, H. Brandstetter, W. Kammlander, E. Panholzer, C. Redl, F. Osterkamp, F. Scheiflinger [Austria]

14:45 - 15:00  
**Influence of TFPI levels on the different parameters of thrombin generation and impact of a TFPI neutralization on the correction of thrombin generation in haemophilic patients**  
Brigitte Tardy-Poncet, Michèle Piot, Céline Chapelle, Patrick Mismetti, Bernard Tardy [France]

15:00 - 15:15  
**Effect of bypassing agent therapy with and without tranexamic acid in haemophilia A patients with inhibitors, a prospective crossover study using thromboelastography and thrombin generation assay**  
Hoa Tran, Benny Sørensen, Catherine Rea, Stine Bjørnsen, Thor Ueland, Are Hugo Pripp, Geir Tjønnfjord, Pål Andre Holme [Norway]

15:15 - 15:30  
**RISE- Response to DDAVP in moderate/mild haemophilia A patients: in search for determinants**  
Janneke Loomans, Alice van Velzen, Marieke Kruip, Elena Santagostino, Corien Eckhardt, Giancarlo Castaman, Daniel Hart, Marjolein Peters, Ansku van der Bom, Karin Fijnvandraat [The Netherlands]

**Coagulation factor XIII**

**G106-107**

**Moderators: Richard Pease (United Kingdom) and Auguste Sturk (The Netherlands)**

14:30 - 14:45  
**Major roles for FXIII-A and transglutaminase 2 in maintaining cardiovascular tissue integrity**  
Richard Pease, Laura Newell, Kristina Standeven, Peter Grant, Christopher Jackson [United Kingdom]

14:45 - 15:00  
**Functional characteristics of coated platelets**  
Nadine Mattheij, Michelle Berny-Lang, Pieter van de Vijver, Tilman Hackeng, Owen McCarty, Judith Cosemans, Johan Heemskerk [The Netherlands]

15:00 - 15:15  
**Pharmacokinetics of recombinant FXIII at steady-state in patients with congenital FXIII A-subunit deficiency**  
Bryce Kerlin, Brigitte Brand, Aida Inbal, Susan Halimeh, Diane Nugent, Mia Lundblad, Ramin Tehranchi [USA]

15:15 - 15:30  
**Spatial distribution and co-localization of fibrinogen and platelet-derived factor XIIIa on the activated platelet subpopulations**  
Sergey Obydennyy, Yana Kotova, Fazly Ataullakhanov, Mikhail Panteleev [Russian Federation]
Wednesday, July 3, 2013

ORAL COMMUNICATIONS  
14:30 - 15:30

Coagulation factor: Structure and function  
G102-103

Moderators: Rodney Camire (USA) and Dengmin Feng (USA)

14:30 - 14:45  
Molecular and structural determinants of high affinity membrane binding in coagulation factor V  
Shekhar Kumar, Steven Stayrook, James Huntigton, Rodney Camire, Srim Krishnaswamy (USA)

14:45 - 15:00  
Cleavage of factor V by thrombin at Arg709 is dependent on the integrity of amino acid region 1000-1008 of the procofactor  
Mahesheema Na, Joseph Wiencek, Michael Kalafatis (USA)

15:00 - 15:15  
Design of a potent phospholipid membrane-dependent Factor VIIa variant  
Anders Nielsen, Wolfram Ruf, Jens Buchardt, Brit Sørensen, Ole Olsen, Henrik Østergaard (Denmark)

15:15 - 15:30  
A novel chimeric Factor IX-VIIa molecule confers effective hemostasis with reduced thrombogenicity in vivo  
Dengmin Feng, Yacine Boulaftali, Wolfgang Bergmeier, Darrel Stafford (USA)

Disseminated intravascular coagulation  
Mondriaan III

Moderators: Marco Goeijenbier (The Netherlands) and Cheng-Hock Toh (United Kingdom)

14:30 - 14:45  
Histones and DNA infusion in baboons induces inflammation, coagulopathy and complement activation leading to organ failure and death  
Florea Lupu, Robert Silasi-Mansat, Jun Xu, Ravi Keshari, Glenn Peer, Fletcher Taylor, Cristina Lupu, Gary Kinasewitz, Charles Esmon (USA)

14:45 - 15:00  
Hitting the sweet-spot in sepsis: Modulation of histones and CXCL4 (platelet factor 4) effects on activated protein C  
Anna Kowalska, Guohua Zhao, Li Zhai, Stephen Marcus, Srim Krishnaswamy, Mortimer Poncz (USA)

15:00 - 15:15  
Assay method of des-HMGB1, N-terminus cleaved out HMGB1 by thrombin-thrombomodulin, and its clinical significance  
Ikuro Maruyama, Takashi Ito, Yoshio Azuma, Mayumi Nakahara, Teruto Hashiguchi, Shingo Yamada (Japan)

15:15 - 15:30  
Consumptive coagulopathy and tissue fibrin deposition in seasonal-, pandemic- and highly pathogenic avian influenza infection  
Marco Goeijenbier, Judith van den Brand, Koert Stittelaar, Cindy van Haagen, Kamran Bakhtiar, Thjis Kuiken, Albert Osterhaus, Byron Martina, Joost Meijers, Eric van Gorp (The Netherlands)
**Wednesday, July 3, 2013**

**ORAL COMMUNICATIONS  14:30 - 15:30**

**Haemophilia B**

*Moderators: Paul Monahan [USA] and Jerry Powell [USA]*

14:30 - 14:45

**B-LONG: Results from a Phase 3 Study of Safety, Efficacy, and Pharmacokinetics of Long-Lasting Recombinant Factor IX Fc Fusion Protein [rFIXFc]**

Jerry Powell, Margaret Ozelo, John Pasi, Margaret Ragni, Leonard Valentino, Johnny Mahlangu, Marilyn Manco-Johnson, Neil Josephson, David Perry, Glenn Pierce [USA]

14:45 - 15:00

**Efficacy, PK and safety results of a Phase I/II clinical study of recombinant fusion protein linking coagulation factor IX with albumin [rIX-FP] in previously treated patients with hemophilia B**

Uriel Martinowitz, Aaron Lubetsky, Elena Santagostino, Gantcho Jotov, Tami Brutman-Barazani, Christine Voigt, Tina Moises, Iris Jacobs, Toshko Lissitchkov [Israel]

15:00 - 15:15

**Healing defects in both cutaneous and joint wounds are improved by extending factor IX activity during healing using glycoPEGylated factor IX**

Paul Monahan, Junjiang Sun, Baolai Hua, Jacqueline Mickelson, Eric Livingston, Anthony Lau, Ted Bateman, Mirella Ezban, Maureane Hoffman, Dougald Monroe [USA]

15:15 - 15:30

**Ribosome readthrough accounts for secreted full-length factor IX in hemophilia B patients with nonsense mutations**

Matteo Campioni, Pierpaolo Caruso, Alessandro Canella, Giuseppe Tagariello, Giancarlo Castaman, Sofia Giacomelli, Donata Belvini, Mirko Pinotti, Francesco Bernardi [Italy]

---

**Management of venous thrombosis**

*Elicium 2*

*Moderators: Paul den Exter [The Netherlands] and Hiroko Tsuda [Japan]*

14:30 - 14:45

**Clot resolution after three weeks of anticoagulant treatment of pulmonary embolism: comparison of computed tomography and perfusion scintigraphy**

Josien van Es, Renee Douma, Pieter Willem Kamphuisen, Victor Gerdes, Peter Verhamme, Philip Wells, Henri Bounaumeaux, Anthonie Lensing, Harry Büller [The Netherlands]

14:45 - 15:00

**Selective D-dimer thresholds in the diagnostic management for symptomatic pulmonary embolism does not lead to acceptable three months venous thromboembolism recurrence rates**

Tom van der Hulle, Paul den Exter, Frederikus Klok, Petra Erkens, Josien van Es, Pieter-Willem Kamphuisen, Menno Huisman, Inge Mos, Hugo ten Cate [The Netherlands]

15:00 - 15:15

**Factors associated with clinical deterioration shortly after an emergency department diagnosis of pulmonary embolism**

Christopher Kabrhel, Ikenna Okechukwu, Praveen Hariharan, James Takayesu, Elizabeth Temin, Peter MacMahon, Faris Haddad, Yuchiao Chang [USA]

15:15 - 15:30

**Impact of delay in clinical presentation on the diagnostic management and prognosis of patients with suspected pulmonary embolism**

Paul den Exter, Josien van Es, Petra Erkens, Mark Roosmalen, Pim Hoven, Marcel Hovens, Pieter Willem Kamphuisen, Frederikus Klok, Menno Huisman [The Netherlands]
**Wednesday, July 3, 2013**

**ORAL COMMUNICATIONS 14:30 - 15:30**

**Microparticles**

*Mondriaan IV*

*Moderators: Rienk Nieuwland (The Netherlands) and Leonardo Pasalic (Australia)*

14:30 - 14:45

**OC 72.1**

**Microparticles as bioeffectors during experimental septic shock: is there a place for their pharmacological modulation?**

*Julie Boisrame-Helms, Xavier Delabranche, Su Degirmenci, Asaël Berger, Fatiha Zobairi, Bruno Levy, Grégory Meyer, Florence Toti, Ferhat Meziani (France)*

14:45 - 15:00

**OC 72.2**

**Coagulant tissue factor in human wound blood and saliva is not associated with lipid rafts**

*Anita Böing, Chi Hau, Najat Hajji, Jan van Marle, Auguste Sturk, Rienk Nieuwland (The Netherlands)*

15:00 - 15:15

**OC 72.3**

**An improved method for quantitative and qualitative flow cytometric analysis of fluorescently labelled microvesicles**

*Leonardo Pasalic, Minh Hua, Heather Campbell, Christopher Brownlee, Vivien Chen (Australia)*

15:15 - 15:30

**OC 72.4**

**Multicolor flow cytometry analysis of MPs in whole blood: comparison with analysis in platelet free plasma**

*Boselli Daniela, Marta Brambilla, Daniele Manganaro, Elena Tremoli, Marina Camera (Italy)*

**Natural anticoagulants**

*Emerald*

*Moderators: Corral Javier (Spain) and Kristien Winckers (The Netherlands)*

14:30 - 14:45

**OC 73.1**

**The role of the different Kunitz domains of TFPI in the inhibition of TF-FVIIa catalysed FX and FIX activation**

*Sameera Peraramelli, Stella Thomassen, Alexandra Heinzmann, Jan Rosing, Tilman Hackeng, Rudolf Hartmann, Friedrich Scheiflinger, Michael Dockal (The Netherlands)*

14:45 - 15:00

**OC 73.2**

**Relevance of antithrombin A-sheet residues for the internalization of the RCL following interaction with target proteases**

*Sonia Aguila, Irene Martínez-Martínez, Gonzalo Izaguirre, Vicente Vicente, Steve Olson, Javier Corral (Spain)*

15:00 - 15:15

**OC 73.3**

**Low amounts of platelet TFPI and protein S are highly effective in regulating local thrombin generation which is not affected by proteolysis of protein S**

*Kristien Winckers, Maria Christella Thomassen, Hugo ten Cate, Jan Rosing, Tilman Hackeng (The Netherlands)*

15:15 - 15:30

**OC 73.4**

**The serpin Protein C Inhibitor (PCI) interacts with phosphoinositides (PIs) and modulates the activity of the phosphoinositide-specific phosphatase SHIP2 in vitro**

*Felix Wahlmüller, Barbora Sokolikova, Daniela Rieger, Margarethe Geiger (Austria)*
### Wednesday, July 3, 2013

#### ORAL COMMUNICATIONS  
14:30 - 15:30

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:30 - 14:45</td>
<td>Neutrophil histone modification by peptidylarginine deiminase 4 is crucial for deep vein thrombosis in mice</td>
<td>Kimberly Martinod, Melanie Demers, Tobias Fuchs, Siu Ling Wong, Alexander Brill, Maureen Gallant, Yanming Wang, Denisa Wagner (USA)</td>
</tr>
<tr>
<td>14:45 - 15:00</td>
<td>Flow Driven Self-Assembly of Macroscopic Proteins in Microvessels</td>
<td>Ying Zheng, Junmei Chen, José López (USA)</td>
</tr>
<tr>
<td>15:00 - 15:15</td>
<td>In vivo molecular ultrasound imaging for monitoring and efficacy testing of thrombolytic drugs using platelet-targeted microbubbles</td>
<td>Xiaowei Wang, Christoph Hagemeyer, Jan David Hohmann, Ingo Ahrens, Karlheinz Peter (Australia)</td>
</tr>
<tr>
<td>15:15 - 15:30</td>
<td>Cell painting with an engineered membrane-anchoring endothelial protein C receptor (EPCR) improves protein C activation and protease activated receptor-1 and -3 cleavage on EPCR-deprived cells</td>
<td>Eveline Bouwens, Laurent Mosnier (USA)</td>
</tr>
</tbody>
</table>

#### Pediatric thrombosis  
Elicium 1

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:30 - 14:45</td>
<td>Chylothorax in children with congenital heart disease: incidence of upper venous thrombosis</td>
<td>Mary Bauman, Patti Massicotte, Aisha Bruce, Conrad Moher, Stefan Kuhle, Satwinder Kaur (Canada)</td>
</tr>
<tr>
<td>14:45 - 15:00</td>
<td>EmPoWarMent: Five Year Evaluation of Patient Self Management of Vitamin K Antagonist Therapy</td>
<td>Mary Bauman, Patti Massicotte, Aisha Bruce, Stefan Kuhle, Michelle Bauman (Canada)</td>
</tr>
<tr>
<td>15:00 - 15:15</td>
<td>Thrombosis in children: further evaluation of incidence and resolution</td>
<td>Patricia Massicotte, Mary Bauman, Aisha Bruce, Shubham Shan, Michelle Bauman, Laszlo Bazjar (Canada)</td>
</tr>
<tr>
<td>15:15 - 15:30</td>
<td>Traumatic lumbar punctures in children receiving low-molecular-weight heparin during treatment for acute lymphoblastic leukemia or lymphoma</td>
<td>Jeremie Estepp, Matthew Smeltzer, Scott Howard, Ulrike Reiss (USA)</td>
</tr>
</tbody>
</table>
**Wednesday, July 3, 2013**

**ORAL COMMUNICATIONS 14:30 - 15:30**

**Platelet signalling - II**

Mondriaan II

*Moderators: Joel Bennett (USA) and Lucia Stefanini (USA)*

**14:30 - 14:45**

**14-3-3ζ regulates the procoagulant function of platelets**

**OC 76.1**

Dianne van der Wal, Susan Cranmer, Hayley Ramshaw, Simone Schoenwaelder, Yuping Yuan, Elizabeth Gardiner, Michael Berndt, Robert Andrews, Angel Lopez, Shaun Jackson (Australia)

**14:45 - 15:00**

**Kindlin-2 in platelets and in megakaryocytes: a possible role in β integrin activation**

**OC 76.2**

Dorsaf Ghalloussi, Véronique Baccini, Alan Nurden, Marie-Christine Alessi, Matthias Canault (France)

**15:00 - 15:15**

**Protein kinase C mediates Rap1-dependent platelet aggregation in the absence of CalDAG-GEF1 and P2Y12**

**OC 76.3**

Lucia Stefanini, David Paul, Todd Getz, Ashley Beale, Agnieszka Cholka, Patrick Andre, James Stone, Pamela Conley, Wolfgang Bergmeier (USA)

**15:15 - 15:30**

**Grb2 is essential for [hem]ITAM-mediated signalling in platelets**

**OC 76.4**

Sebastian Dütting, Timo Vögtle, Martina Morowski, Carmen Schäfer, Jochen Ackermann, Daniel Radlke, Heike Hermanns, Lars Nitschke, Bernhard Nieswandt (Germany)

**RNA and coagulation**

*Moderators: Pieter Reitsma (The Netherlands) and Irina Starikova (Norway)*

**14:30 - 14:45**

**Factor XI mRNA is spliced upon platelet activation**

**OC 77.1**

Michal Zucker, Hagit Hauschner, Uri Seligsohn, Nurit Rosenberg (Israel)

**14:45 - 15:00**

**The role of microRNA in the pathogenesis of venous thromboembolism**

**OC 77.2**

Irina Starikova, Simin Jamaly, Mikhail Sovsheraev, Thorarinn Blondal, Antonio Sorrentino, John-Bjarne Hansen (Norway)

**15:00 - 15:15**

**Transfection of siRNA in human blood platelets: A high efficiency method for the horizontal transfer of siRNA from platelets to human monocytes and endothelial cells**

**OC 77.3**

Marco Malvestiti, Loredana Bury, Alessandro Marturano, Eleonora Petito, Stefania Momi, Paolo Gresele (Italy)

**15:15 - 15:30**

**Downregulation of Protein S by Oestrogens and miR-494**

**OC 77.4**

Jasmine Tay, Giuliana Romeo, Quintin Hughes, Ross Baker (Australia)

**Thrombophilia - I**

*Moderators: Tyler Smith (Canada) and Luca Lotta (Italy)*

**14:30 - 14:45**

**Reducing inpatient heritable thrombophilia testing using a clinical decision-making tool**

**OC 78.1**

Tyler Smith, David Pi, Monika Hudoba, Jason Pal, Agnes Lee (Canada)

**14:45 - 15:00**

**New diagnostic considerations based on the experience of genetic analysis in Protein C deficiency**

**OC 78.2**

Zsuzsanna Bereczky, Kittı Kovács, Péter Ilonczai, Réka Gindele, Zoltán Boda, György Pfiegenti, László Muszbek, (Hungary)

**15:00 - 15:15**

**Antithrombin Debrecen (p.Leu173Pro): clinical and molecular characterization of a novel mutation associated with severe thrombotic tendency in a large pedigree**

**OC 78.3**

Anna Selmeczi, Zsolt Oláh, Zsuzsanna Bereczky, Réka Gindele, Péter Ilonczai, Agota Schlammadinger, Katalin Rázsó, László Muszbek, Zoltán Boda (Hungary)

**15:15 - 15:30**

**A clinical laboratory test detecting antithrombin-resistance of the new thrombophilia**

**OC 78.4**

Moe Murata, Akira Takagi, Atsuo Suzuki, Yuki Takagi, Yumi Ando, Io Kato, Takashi Murate, Tadashi Matsushita, Hidehiko Saito, Tetsuhito Kojima (Japan)
For the XXIV congress, ISTH has decided to innovate its poster sessions by introducing a new electronic poster format. Posters will not be presented in a paper format. Instead, all posters will be presented in the format of ePoster sessions on large touch-screens.

In the sessions, the ePosters will be presented and discussed in the sequence indicated in the programme.

**Platelet activation: Receptor changes - II**

**Screen 01**

**Moderator:** Stephanie Jung (United Kingdom)

**PA 3.01-1** Tracking of GPVI-dimer cluster formation at the membrane level with live-cell imaging of platelet binding to various collagenous substrates by TIRF (total internal reflection fluorescence) microscopy

Stephanie Jung, Alice Pollitt, Elizabeth Gardiner, Dominique Bihan, Richard Farndale, Masaaki Moroi, Steve Watson (United Kingdom)

**PA 3.01-2** Ligand- and force-induced allosteric shift of the platelet integrin aIIbβ3 to a higher affinity state

Rustem Litvinov, Valeri Barsegov, John Weisel, Joel Bennett (USA)

**PA 3.01-3** Disulfide bond exchange is required for integrin activation and post-ligation signaling during fibrin clot retraction

Ronit Mor-Cohen, Nurit Rosenberg, Yulia Averbukh, Uri Seligsohn, Judith Lahav (Israel)

**PA 3.01-4** Inhibition of platelet aggregation does not prevent endocytosis of tissue factor-rich microvesicles by platelets: involvement of cytoskeleton, scavenger receptor CD36 and serotonin transporter

Irene Lopez-Vilchez, Maribel Diaz-Ricart, Ana Galan, Merce Roque, Carolina Caballo, Patricia Molina, James White, Gines Escolar (Spain)

**PA 3.01-5** First identification and biological characterization of an IgM type platelet cold agglutinin causing temperature-dependent activation, secretion and aggregation of human platelets

Isabel Sánchez Guiu, Irene Martínez Martínez, Eva Plaza, José Navarro Fernández, Constant Martínez, Francisca Ferrer, Roldán Vanessa, Vicente Vicente, María Luisa Lozano, José Rivera (Spain)

**PA 3.01-6** Phosphospecific flow cytometry enables large-scale signaling profiling and compound screening in human platelets

Khalid Naseem, Benjamin Spurgeon (United Kingdom)

**Thrombus formation - I**

**Screen 02**

**Moderator:** Susanne de Witt (The Netherlands)

**PA 3.02-1** Serotonin contributes to platelet calcium signalling and thrombus formation in flowing blood

Monica Battiston, Maria Rita Cozzi, Loredana Mendolicchio, Renzo Deana, Valentina Boz, Zaverio Ruggeri, Mario Mazzuccato, Luigi De Marco (Italy)

**PA 3.02-2** Advanced multi-parameter assessment of microspot thrombus formation: a systems biology approach

Susanne de Witt, Moniek Lamers, Frauke Swieringa, Roger van Kruchten, Tom Mastenbroek, Susan Coort, Rachel Cavill, Nicholas Pugh, Richard Farndale, Kenneth Clementson, Johan Heemskerk, Judith Cosemans (The Netherlands)

**PA 3.02-3** Platelet aggregometry under flow conditions: the rate of change of surface distribution of platelets or thrombi quantifies changes in aIIbβ3 and a2β1 activity in real time

Nicholas Pugh, Dominique Bihan, Richard Farndale (United Kingdom)
**Platelet signal transduction - II**

**Screen 03**

**Moderator: François Bertin [Canada]**

### PA 3.03-1
**Thrombin induces phosphorylation of key components of the mTORC1 pathway via a novel PKC/P2Y12 dependent pathway in human platelets**

*Ingeborg Hers*, Thomas Blair, Roger Hunter, Samantha Moore [United Kingdom]

### PA 3.03-2
**Functional responses and molecular mechanisms involved in platelet activation triggered by histones**

*Agostina Carestia*, Leonardo Rivadeneyra, Albertina Romaniuk, Carlos Fondevila, Soledad Negrotto, Mirta Schattner [Argentina]

### PA 3.03-3
**Regulation of Rap1b activation by cyclic nucleotide-dependent protein kinases in human platelets**

*Harishan Subramanian*, Stepan Gambaryan, René Zahedi, Albert Sickmann, Ulrich Walter [Germany]

### PA 3.03-4
**cGMp signaling pathway regulates platelet shape change through modulation of myosin light chain phosphatase - the role of CPI-17 signalling**

*Khalid Naseem*, Ahmed Aburima [United Kingdom]

### PA 3.03-5
**Small molecule inhibitors of PDK1 inhibit platelet functional response**

*Carol Dangelmaier*, Bhanukanth Manne, Jianquo Jin, Satya Kunapuli [USA]

### PA 3.03-6
**Gas6 regulates thrombin-induced expression of VCAM-1 through a Fox01 in endothelial cells**

*François Bertin*, Catherine Lemarie, Mark Blostein [Canada]

**Microparticles and tissue factor**

**Screen 04**

**Moderator: Anita Böing [The Netherlands]**

### PA 3.04-1
**Human tears and sweat trigger clotting of blood: the role of tissue factor-exposing vesicles**

*Anita Böing*, Jolijn van Leeuwen, Chi Hau, Willemijn Tros, Luca Janssen, Hilde Rinia, Auguste Sturk, Rienk Nieuwland [The Netherlands]

### PA 3.04-2
**Characterisation of the procoagulant properties of microparticles derived from different cell types**

*Mohammed Alsahli*, Hassan Hamali, Alison Goodall [United Kingdom]

### PA 3.04-3
**Microparticle-associated tissue factor activity correlates to plasma levels of bacterial lipopolysaccharides in meningococcal sepsis**

*Marit Hellum*, Reidun Øystebe, Berit Brusletto, Jens Petter Berg, Petter Brandtzaeg, Carola Henriksson [Norway]
PA 3.04-4  Thrombin generation in plasma measured with a commercial reagent for the detection of microparticle-derived tissue factor is heavily influenced by contact activation  
Niklas Boknäs, Lars Faxälv, Sofia Ramström, Tomas Lindahl (Sweden)

PA 3.04-5  Microparticle-associated tissue factor activity in patients with metastatic pancreatic cancer and its effect on fibrin clot formation  
Johannes Thaler, Silvia Koder, Gabriela Kornek, Ingrid Pabinger, Cihan Ay (Austria)

PA 3.04-6  Cell-derived microparticles as novel tools for thrombolytic therapy?  
Sara Martínez De Lizarraondo, Jérôme Parcq, Aurelien Briens, Maxime Gauberti, Denis Vivien (France)

Genetic platelet disorders - I  
Moderator: Cheryl Maier (USA)

PA 3.05-1  Characterization of the second patient with Hermansky-Pudlak Syndrome type-7 (HPS7), and a novel HPS1 mutation. Value of an autozygosity mapping approach to prioritize mutation screening in HPS  
Isabel Sánchez Guiu, Gillian Lowe, Francisco Velasco, Marie Lordkipanidzé, Natalia Dovlatova, Jonathen Wilde, Steve Watson, María Luisa Lozano, Neil Morgan, José Rivera (Spain)

PA 3.05-2  Aberrant mRNA processing in compound heterozygote with glycoprotein IIb gene mutations causing Glanzmann thrombasthenia  
Junko Fujita, Moe Murata, Yoko Kajiura, Akira Takagi, Takashi Murate, Tadashi Matsushita, Shinji Kunishima, Tetsuhiro Kojima (Japan)

PA 3.05-3  Identification of two novel mutations leading to MYH9-related disease and its correlation of genotype/phenotype  
Lucia Siqueira, Vagner Duarte, Samuel Medina, Margareth Ozelo (Brazil)

PA 3.05-4  Variant Glanzmann Thrombasthenia from a newly described Ile282Thr mutation in ITGB3 with functionally defective alpha IIb beta 3 integrin and mild phenotypic presentation  
Cheryl Maier, Alexander Duncan (USA)

PA 3.05-5  Identification of three novel mutations in TUBB1 gene in patients with macrotrombocytopenia  
Béatrice Saposnik, Maud Simansour, Véronique Latger-Cannard, Paquita Nurden, Thomas Lecomppte, Nicole Schlegel (France)

PA 3.05-6  Exome sequencing for causal gene discovery in three patients with primary platelet secretion defect  
Luca Lotta, Giacomo Tuana, Alberto Maino, Raffaella Rossio, Andrea Artoni, Fiola Peyvandi (Italy)

Fibrinolytic system: Clinical - II  
Moderator: Shirley Uitte de Willige (The Netherlands)

PA 3.06-1  The effect of factor XIII and other regulators of fibrinolysis on the outcome of thrombolysis in ischemic stroke patients  
Zsuzsa Bagoly, Gabriella Székely, Katalin Kovács, Zoltán Mezei, Éva Katona, János Kappelmayer, László Csiba, László Muszbek, Zsuzsa Bagoly (Hungary)

PA 3.06-2  Quality of life outcomes in a randomized trial of tenecteplase versus placebo for submassive pulmonary embolism  
Jeffrey Kline, Christopher Kabrhel, Mark Courtney, Deborah Diercks, Alan Jones, Kristen Nordenholz, Matthew Rondina, James Klinger, Jackeline Hernandez (USA)
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>PA 3.06-3</td>
<td>Fibrinolysis impairment in obstructive sleep apnoea syndrome is driven by increased PAI-1 and TAFI activity</td>
<td>Anetta Undas, Anna Borratynska, Katarzyna Stopyra-Pach, Korneliusz Fil (Poland)</td>
</tr>
<tr>
<td>PA 3.06-4</td>
<td>Type 1 plasminogen activator inhibitor (PAI-1) and risk of acute coronary syndrome in the European prospective investigation into cancer (EPIC)-Italy cohort.</td>
<td>Licia Iacoviello, Claudia Agnoli, Amalia De Curtis, Antonella Cutrone, Vittorio Krogh, Amalia Mattiello, Giuseppe Matullo, Salvatore Panico, Carlotta Sacerdote, Rosario Tumino, Paolo Vineis, Giovanni De Gaetano (Italy)</td>
</tr>
<tr>
<td>PA 3.06-5</td>
<td>N-terminal heterogeneity of alpha-2-antiplasmin is associated with plasma clot lysis time and risk of arterial thrombosis</td>
<td>Shirley Uitte de Willige, Joyce Malfliet, Jaap Deckers, Diederik Dippel, Frank Leebeek, Dingeman Rijk (The Netherlands)</td>
</tr>
<tr>
<td>PA 3.06-6</td>
<td>Polymorphisms of matrix metalloproteinase gene and adiposity indices in European children: results of the IDEFICS study</td>
<td>Licia Iacoviello, Daniela Cugino, Francesco Gianfagna, Wolfgang Ahrens, Stefan De Henauw, Stefan Marild, Danesh Molnar, Luis Moreno, Yannis Pitsiladis, Alfonso Siani, Michael Tornaritis, Thomas Veidebaum (Italy)</td>
</tr>
<tr>
<td>PA 3.07-1</td>
<td>Concomitant low doses of activated prothrombin complex concentrate (APCC) and recombinant activated factor VII are efficacious in hemophilic mice and exhibit additive joint action in vitro</td>
<td>Michael Dockal, Sabine Knappe, P. Leidenmüller, R. Palige, M. Resch, S. Tippl, D. Verdino, A. Bauer, Werner Höllriegl, F. Scheiflinger (Austria)</td>
</tr>
<tr>
<td>PA 3.07-2</td>
<td>A single residue in tissue factor pathway inhibitor (TFPI) determines the specificity of an inhibitory peptide to TFPI and guides selection of preclinical models</td>
<td>Michael Dockal, Rudolf Hartmann, R. Pachlinger, H. Brandstetter, Werner Höllriegl, T. Polakowski, F. Scheiflinger (Austria)</td>
</tr>
<tr>
<td>PA 3.07-3</td>
<td>Regulation of plasminogen activator inhibitor -1 promotes immune tolerance to factor VIII in murine hemophilia A</td>
<td>Seiji Madoiwa (Japan)</td>
</tr>
<tr>
<td>PA 3.07-4</td>
<td>The effect of FVIII deficiency on the dynamics of thrombin and fibrin generation under flow on tissue factor–rich surfaces</td>
<td>Abimbola Onasoga, Karin Leiderman, Aaron Fogelson, Marilyn Manco-Johnson, Jorge Di Paola, Keith Neeves (USA)</td>
</tr>
<tr>
<td>PA 3.07-5</td>
<td>Characterization of large deletions in the F8 gene using multiple competitive amplification and genome walking technique</td>
<td>Guoling You (China)</td>
</tr>
<tr>
<td>PA 3.07-6</td>
<td>Role of mannose-ending glycans in the immunogenicity of FVIII in FVIII-deficient mice</td>
<td>Sandrine Delignat, Julie Rayès, Suryasarathi Dasgupta, Ivan Peyron, Luisa Martinez-Pomares, Sami Chtourou, Jean-Luc Plantier, Srinivas Kaveri, Sébastien Lacroix-Desmazes (France)</td>
</tr>
</tbody>
</table>
Wednesday, July 3, 2013  
17:00 – 18:30

**Heparin-induced thrombocytopenia (HIT): Clinical – II**  
Screen 08

**Moderator: Tamam Bakchoul [Germany]**

**PA 3.08-1**  
Off-label use of fondaparinux in suspected acute heparin-induced thrombocytopenia (HIT) – final results from the GerHIT multicentre, retrospective registry study  
Marc Schindewolf, Julia Steindl, Jan Beyer-Westendorf, Sebastian Schellong, Pascal Dohmen, Johannes Brachmann, Katharina Madlener, Bernd Pöttsch, Robert Klamroth, Edelgard Lindhoff-Last [Germany]

**PA 3.08-2**  
Laboratory testing for Heparin Induced Thrombocytopenia (HIT); current practice amongst UK NEQAS and ECAT participants  
Ian Jennings, Piet Meijer, Kevin Horner, Steve Kitchen, Dianne Kitchen, Tim Woods, Isobel Walker [United Kingdom]

**PA 3.08-3**  
Detection and measurement of anti-IL8 IgG antibodies in cardiac surgery patients and heparin-induced thrombocytopenia using a multiplexed fluorimetric assay  
Claire Pouplard, Jean Daniel Abraham, Dorothée Leroux, Priscilla Lapalud, Caroline Pfieffer, Pascale Galea, Daniel Laune, Franck Molina, Yves Gruel [France]

**PA 3.08-4**  
Prospective evaluation of a rapid and IgG specific nanoparticle-based lateral flow immunoassay [Stic Expert HIT®] for the diagnosis of Heparin-Induced Thrombocytopenia  
Dorothée Leroux, Claire Pouplard, Yves Gruel, The HIT Working Group [France]

**PA 3.08-5**  
The clinical impact of anti-protamine/heparin antibodies in patients undergoing cardiac surgery  
Tamam Bakchoul, Heike Zöllner, Jean Amiral, Mihaela Delcea, Simon Panzer, Theodore Warkentin, Ulrich Sachs, Andreas Greinacher [Germany]

**PA 3.08-6**  
Impact of heparin-induced thrombocytopenia on acute coronary artery thrombosis in patients undergoing percutaneous coronary intervention  
Takuma Maeda, Teruo Noguchi, Shin Saito, Rei Yoshio, Eishin Horibe, Shigeki Miyata [Japan]

**Von Willebrand factor: Clinical – II**  
Screen 09

**Moderator: Sophie Susen [France]**

**PA 3.09-1**  
Re-evaluation of sequence variation in type 1 von Willebrand disease in the MCMDM-1VWD cohort  
Anne Goodeve, Daniel Hampshire, Javier Batlle, Ulrich Budde, Giancarlo Castaman, Jeroen Eekenboom, Augusto Federici, Reinhard Schneppenheim, Ian Peake [United Kingdom]

**PA 3.09-2**  
NHLBI Guidelines and the percentile 2.5th of plasma VWF for the diagnosis of type 1 VWD. Comparison in 4517 referred patients and 280 selected patients with conclusive bleeding history  
Teresa Quiroga, Manuela Goycoolea, Pamela Zuñiga, Sabine Belmont, Olga Panes, Jaime Pereira, Diego Mezzano [Chile]

**PA 3.09-3**  
Comparison of Pediatric Bleeding Questionnaire (PBQ) and ISTH/SSC Bleeding Assesment Tool (BAT) scores in pediatric patients referred with mucocutaneous bleeding  
Veerle Labarque, Victor Blanchette, Dewi Clark, Paula James, Margaret Rand [Belgium]

**PA 3.09-4**  
Previously missed mutations in the MCMDM-1VWD type 1 von Willebrand disease study  
Nasher Alyami, Daniel Hampshire, Jenny Goudemand, Giancarlo Castaman, Augusto Federici, Ashley Cartwright, Ian Peake, Anne Goodeve [United Kingdom]

**PA 3.09-5**  
Molecular characterization of 14 italian patients with type 3 von Willebrand disease  
Giancarlo Castaman, Sofia Giacomelli, Maria Messina, Giuseppina Rodorigo, Gina Rossetti, Silvia Linari [Italy]
**ePOSTERS (A)**

**Wednesday, July 3, 2013**

**17:00 – 18:30**

**Anticoagulant agents - XII**

**Screen 10**

**Moderator: Michiel Coppens [The Netherlands]**

**PA 3.10-1**

**DATA III survey. Ten-year follow-up on Dutch orthopedic thromboprophylaxis**

Marieke Struijk-Mulder, Harmen Ettema, Harry Büller, Cees Verheemen [The Netherlands]

**PA 3.10-2**

**First year experience with the German external quality assessment scheme for the new oral anticoagulants (INSTAND e.V.)**

Dirk Peetz, Andrea Dick, Peter Lodemann, Michael Spannagl [Germany]

**PA 3.10-3**

**Case fatality of antithrombotic therapy associated major bleeding or major trauma**

Michiel Coppens, James Douketis, Joseph Mathew, Dillon Da Fonte, Hasib Hanif, Nancy Heddle, John Eikelboom [The Netherlands]

**PA 3.10-4**

**Tissue factor-induced hypercoagulability in rats is increased by low doses of the direct thrombin inhibitor dabigatran but decreased by the Factor Xa inhibitor rivaroxaban**

Elisabeth Perzborn, Stefan Heitmeier, Ulf Buetehorn, Laux Volker [Germany]

**PA 3.10-5**

**Relative lack of effect of steady-state erythromycin on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban in subjects with renal impairment or with normal renal function**

Todd Moore, Seema Vaidyanathan, Jaya Natarajan, Jay Ariyawansa, Kenneth Turner, Lloyd Haskell [USA]

**PA 3.10-6**

**Effects of rivaroxaban and dabigatran on hemostasis and reversion of their antithrombotic effects by different coagulation factors: evidence raised from a clinical study in healthy volunteers**

Ana Galan, Eduardo Arellano-Rodrigo, Veronica Sanz, Patricia Molina, Joan Carles Reverter, Jaume Villalta, Xavier Carne, Maribel Diaz-Ricart, Gines Escolar [Spain]

**Blood coagulation tests - X**

**Screen 11**

**Moderator: Bas de Laat [The Netherlands]**

**PA 3.11-1**

**Capillary electrophoresis improves the selection of DNA-aptamers against activated coagulation factors**

Jens Müller, Rosa Krammer, Nasim Shahidi, Fabian Blümke, Oliver Rudan, Johannes Oldenburg, Günter Mayer, Bernd Pötzschi [Germany]

**PA 3.11-2**

**Endogenous thrombin potential measured in the presence of thrombomodulin as a tool in prediction of thrombotic events**

Veronika Shmeleva, Yryi Namestnikov, Olesya Matvienko, Natalia Saltikova, Vitaly Soldatenkov, Ludmila Papayan [Russian Federation]

**PA 3.11-3**

**Evaluation of the performance characteristics of a diluted thrombin time assay for dabigatran determination using a new thrombin time liquid reagent**

Emma Camacho, Mariona Bono, Daniel Martorell [Spain]

**PA 3.11-4**

**A simplified assay for quantification of circulating activated protein C levels**

Pilar Medina, Silvia Navarro, Elena Bonet, Laura Martos, Yolanda Mira, Amparo Vayá, Fernando Ferrando, José Aznar, Amparo Estellés, Francisco España [Spain]
PA 3.11-5  The use of the new Siemens Innovance VWF activity assay in monitoring treatment for von Willebrand disease  
Annette Bowyer, Fiona Shepherd, Kerensa Leeson, Anna Lowe, Steve Kitchen, Michael Makris (United Kingdom)

PA 3.11-6  Effect of rivaroxaban on clot formation kinetics  
Thomas Siegemund, Ute Scholz, Annelie Siegemund (USA)

**Blood coagulation system - III**  
**Screen 12**

Moderator: John Weisel (USA)

PA 3.12-1  Impact of BDNF Val66Met polymorphism on thrombosis  
Silvia Stella Barbieri, Patrizia Amadio, Sara Gianellini, Eva Tarantino, Cristina Banfi, Francis Lee, Elena Tremoli (Italy)

PA 3.12-2  Mutation of Thr-211 to pro in the activation peptide of factor X in a bleeding patient is associated with a molecular defect in the intrinsic pathway  
Alireza Rezaie, Qiuian Ding, Yiping Shen, Likui Yang, Xuefeng Wang (USA)

PA 3.12-3  Additional effect of BβArg448Lys polymorphism on fibrin clot structure/fibrinolysis and cardiovascular complications in subjects with type 2 diabetes  
Katie Greenhalgh, Saad Alzahrani, Jackie Price, Mark Strachan, Paul Baxter, Zeyad Kurdee, Peter Grant, Ramzi Ajjan (United Kingdom)

PA 3.12-4  Acute and severe coagulopathy in adult mice following silencing of hepatic antithrombin and protein C production  
Huma Safdar, Kelley Cheung, Daniela Salvatori, Henri Versteeg, El Houari Laghmani, Gerry Wagenaar, Pieter Reitsma, Bart van Vlijmen (The Netherlands)

PA 3.12-5  Platelet-derived microparticles attenuate the procoagulant nature of platelet-associated Prothrombinase  
Laura Haynes, Paula Tracy (USA)

PA 3.12-6  Contraction of whole blood clots: platelets and fibrin are on the exterior and compress erythrocytes into close-packed polyhedra on the interior  
John Weisel, Tatiana Lebedeva, Chandrasekaran Nagaswami, Vincent Hayes, Walter Massefski, Lubica Rauova, Thomas Lowery, Douglas Cines (USA)

**Acquired coagulation disorders - IV**  
**Screen 13**

Moderator: Patricia Massicotte (Canada)

PA 3.13-1  Thrombin generation in obese patients  
Elena Campello, Zabeo Eva, Spiezia Luca, Gavasso Sabrina, Woodhams Barry, Prandoni Paolo, Vettor Roberto, Simioni Paolo (Italy)

PA 3.13-2  Predictors of vascular thrombotic events in pediatric liver transplantation  
Patricia Massicotte, Mary Bauman, Aisha Bruce, Mary Bauman (Canada)

PA 3.13-3  A prospective study to evaluate early clauss fibrinogen and fibtem as predictors of progression of major obstetric haemorrhage  
Elizabeth Precious, Raza Alikhan, Graeme Lilley, David Burckett-St.Laurent, Rachel Rayment, Rachel Collis, Peter Collins (United Kingdom)

PA 3.13-4  Early cytokine secretion may predict response to treatment in acquired hemophilia  
Miguel Escobar, Keri Csencsits-Smith, Elizabeth Donnachie (USA)

PA 3.13-5  Real time assessment of hemostatic alterations induced by cardiopulmonary bypass surgery  
Till Hoffmann, Stephan Sixt, Kerstin Urbanski, Alexander Albert, Hiroyuki Kamiya, Markus Barnscheidt, Benedikt Pannen, Artur Lichtenberg, Rüdiger Scharf (Germany)
Novel detection of heparin-like substance as a cause of activated partial thromboplastin time prolongation in dengue hemorrhagic fever
Bundarika Suwanawiboon, Theera Ruchutrakool, Yingyong Chinthammitr, Yupa Nakkinkun (Thailand)

Coagulation factor XI - II
Screen 14
Moderator: Chantal Rothschild (France)

Enhanced factor XI-dependent thrombin generation by nanoparticle-bound polyphosphate
Stephanie Smith, Damien Kudela, Anna May-Masnou, Gary Braun, Alessia Pallaoro, Tracy Chuong, Galen Stucky, James Morrissey (USA)

Identification and characterization of a highly specific FXIa inhibitor from Bungarus fasciatus venom
Wan Chen, Tse Siang Kang, Manjunatha Kini (Singapore)

The type I mutation causing factor XI deficiency in Ashkenazi Jews is a founder mutation of recent Eastern European origin
Hava Peretz, Ophira Salomon, Ronit Mor-Cohen, Sali Usher, Zucker Michal, Ariella Zivelin, Uri Seligsohn (Israel)

Interim results (3-year) of a French non-interventional study to assess the long-term safety and efficacy of BeneFIX
Chantal Rothschild, Marc Trossaert, Ségolène ClaeysSENS-Donadel, Thierry Lambert, Abel Hassoun, Fabienne Volot, Sepideh Attal (France)

FXI deficiency and Gaucher disease: a potentiated bleeding risk?
Alison Thomas, Derralynn Hughes, Atul Mehta, Keith Gomez (United Kingdom)

Structure of coagulation FXI bound to a peptide derived from Laminin
Szu Shen Wong, Jonas Emsley, Henning Stennicke (United Kingdom)

Contact activation - II
Screen 15
Moderator: Joke Konings (The Netherlands)

DNA and RNA promote kallikrein-mediated activation of fXII and are cofactors for FXI feedback activation by thrombin
Trang Vu, Ji Zhou, Beverly Leslie, Alan Stafford, James Fredenburgh, Jeffrey Weitz (Canada)

Ongoing contact activation in patients with hereditary angioedema
Joke Konings, Massimo Cugno, Chiara Suffritti, Hugo ten Cate, Marco Cicardi, José Govers-Riemslag (The Netherlands)

Binding and activation of coagulation factor XII by activated platelet subpopulations and microparticles
Natalia Zakharova, Elena Artemenko, Nadezhda Podoplelova, Fazoil Ataullahkhanov, Mikhail Panteleev (Russian Federation)

Neutrophil extracellular traps (NETs) and factor XII activation; a possible mechanism for increasing thrombotic risk during extracorporeal membrane oxygenation (ECMO)
Simon Davidson, Grace Britton, Sharon Mumby, Mark Griffiths, Gregory Quinlan (United Kingdom)

Activation of coagulation factor XII is on the dextran sulfate surface is predominantly an autoactivation via a free substrate mechanism
Vladislava Terentyeva, Mikhail Panteleev (Russian Federation)
## Cancer and thrombosis - IX

**Screen 16**

**Moderator:** Gregory Adams (USA)

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>PA 3.16-1</td>
<td><strong>Thrombin and fibrinogen support prostate tumor growth in mice</strong></td>
<td>Gregory Adams, Whitney Miller, Leah Rosenfeldt, Keith Kombrinck, Joseph Palumbo (USA)</td>
</tr>
<tr>
<td>PA 3.16-2</td>
<td><strong>Effect of heparins on the progression of tumor growth in mouse lewis lung carcinoma model</strong></td>
<td>Debra Hoppensteadt, Arslan Chaudhry, Angel Gray, Matthew Hejna, Jawed Fareed (USA)</td>
</tr>
<tr>
<td>PA 3.16-3</td>
<td><strong>TFPlα and TFPlβ inhibit tumor growth and associate with invasive tumor phenotypes</strong></td>
<td>Mari Tinholt, Benedicte Stavik, Merete Wiiger, William Louch, Marit Sletten, Grethe Skretting, Gunhild M Mælandsmo, Per Morten Sandset, Nina Iversen (Norway)</td>
</tr>
<tr>
<td>PA 3.16-4</td>
<td><strong>Endothelial cell protein C receptor attenuates tissue factor-promoted tumor growth of malignant pleural mesothelioma</strong></td>
<td>Usha Pendurthi, Usha Pendurthi, Shiva Keshava, Vijaya Mohan Rao (USA)</td>
</tr>
</tbody>
</table>

## Hormones, pregnancy and venous thrombosis

**Screen 17**

**Moderator:** Lakshmi Srivaths (USA)

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>PA 3.17-1</td>
<td><strong>Thrombophilia and outcomes of ART procedures: a prospective Italian cohort study</strong></td>
<td>Michela Villani, Giovanni Tiscia, Francesco Dentali, Donatella Colaizzo, Filomena Cappucci, Lucia Fischetti, Walter Ageno, Maurizio Margaglione, Elvira Grandone (Italy)</td>
</tr>
<tr>
<td>PA 3.17-2</td>
<td><strong>Unfractionated heparin, not enoxaparin, prevents down-regulation of endothelial protein C receptor by a pro-inflammatory cytokine on first trimester trophoblasts</strong></td>
<td>Elena Faioni, Gessica Fontana, Cristina Razzari, Evita Calvi, Laura Avagliano, Gaetano Bulfamante, Anna Maria Marconi (Italy)</td>
</tr>
<tr>
<td>PA 3.17-3</td>
<td><strong>Prospective crossover trial of oral tranexamic acid and combined oral contraceptives in adolescent menorrhagia - interim report of a pilot study</strong></td>
<td>Lakshmi Srivaths, Jennifer Dietrich, Donald Yee, Sangi Sangi-Haghpeykar, Donald Mahoney Jr. (USA)</td>
</tr>
<tr>
<td>PA 3.17-4</td>
<td><strong>Low-molecular-weight heparin added to aspirin in the prevention of recurrent early-onset preeclampsia in women with antiphospholipid antibodies</strong></td>
<td>Marion van Hoorn, William Hague, Marielle van Pampus, P. Bezemer, Johanna de Vries (The Netherlands)</td>
</tr>
<tr>
<td>PA 3.17-5</td>
<td><strong>The minimal effective dose of tranexamic acid in women with menorrhagia</strong></td>
<td>Victoria Price, Susan VanOosten, Rebekah Conlon, Judy Richard, Sue Ann Hawes, Tamara MacDonald, Joan Wenning, Nancy van Eyk, Mohamed Abdolett, Sue Robinson (Canada)</td>
</tr>
</tbody>
</table>
Oral contraceptive use and tamoxifen therapy are not associated with increased levels of thrombin or impaired endogenous APC formation
Heiko Rühl, Lars Schröder, Jens Müller, Rolf Fimmers, Shorena Sukhitashvili, Julia Welz, Walther Kuhn, Johannes Oldenburg, Christian Rudlowski, Bernd Pötzsch (Germany)

Alterations of neutrophils production and functions at early stage of metabolic syndrome in a high fructose rat model
Madjid Tagzirt, Delphine Corseaux, Louise Pasquesoone, Frédéric Mouquet, Alexandre Ung, Ahmed Elkaligoubie, Brigitte Jude, Eric van Belle, Sophie Susen, Annabelle Dupont (France)

The role of plasmin(ogen) in the pathogenesis of inflammatory bowel diseases
Shizuka Inaba, Yosuke Kanno, Eri Kawashita, Kiyotaka Okada, Shigeru Ueshima, Osamu Matsuo, Hiroyuki Matsuno (Japan)

SMTP-7, a novel anti-inflammatory thrombolytic, treats serious cardioembolic stroke in a monkey model
Naoko Nishimura, Nobuhiro Sawada, Keiko Hasegawa, Keiji Hasumi (Japan)

Platelet-mediated innate immunity via toll-like receptor 2 stimulation and subsequent serotonin release
Daniel Duerschmied, Matthias Canault, Pol Koch, Karlheinz Peter, Marie-Christine Alessie, Christoph Bode, Ingo Ahrens (Germany)

The role of a2AP in the development of renal interstitial fibrosis
Yosuke Kanno, Akiko Kokado, Eri Kawashita, Miki Tani, Kiyotaka Okada, Shigeru Ueshima, Osamu Matsuo, Hiroyuki Matsuno (Japan)

Prediction of risk of venous thrombosis after cast immobilization of the lower extremity
Banne Nemeth, Raymond van Adrichem, Saskia Le Cessie, Astrid van Hylckama Vlieg, Paolo Bucciarelli, Ida Martinelli, Trevor Baglin, Frits Rosendaal, Suzanne Cannegieter (The Netherlands)

Chronic VTE treatment VTE with Rivaroxaban. Updated results of the prospective Dresden NOAC Registry (NCT01588119)
Jan Beyer-Westendorf, Franziska Ebertz, Kati Förster, Sebastian Werth, Vera Gelbricht, Luise Tittl, Christina Köhler (Germany)

Physicians’ compliance with the Padua Prediction Score for preventing venous thromboembolism among hospitalized medical patients
Valeria Rossetto, Sofia Barbar, Valentina Vedovetto, Marta Milan, Paolo Prandoni (Italy)

Exposure to air pollution increases the risk of isolated pulmonary embolism relative to deep vein thrombosis
Luca Spiezia, Elena Campello, Elena Pelizzaro, Maria Bon, Sara Maggiolo, Paolo Simioni (Italy)
PA 3.19-5  Cerebral vein thrombosis: long-term recanalization rate and clinical outcome.
Francesco Dentali, Ida Martinelli, Daniela Poli, Umberto Scoditti,
Serena Maria Passamonti, Matteo Di Minno, Emanuele Rezoagli, Valerio De Stefano,
Walter Ageno (Italy)

PA 3.19-6  The contribution of immobility risk factors to the risk of venous thrombosis in the
older population
Marissa Engbers, Jeanet Blom, Mary Cushman, Frits Rosendaal,
Astrid van Hylckama Vlieg (The Netherlands)

Post-thrombotic syndrome  Screen 20
Moderator: Annemieke Bouman (The Netherlands)

PA 3.20-1  Predictive value of the HAS-BLED score for major bleeding in patients with venous
thromboembolism during anticoagulant treatment
Judith Kooiman, Nadja van Hagen, A. Iglesias del Sol, Erwin Planken, Gregory Lip,
Felix van der Meer, Suzanne Cannegieter, Menno Huisman (The Netherlands)

PA 3.20-2  Post-thrombotic syndrome does not confer a hypercoagulable state as measured by
thrombin generation
Lara Roberts, Raj Patel, Lynda Bonner, Roopen Arya (United Kingdom)

PA 3.20-3  Cost-effectiveness of additional catheter-directed thrombolysis for deep vein
thrombosis
Tone Enden, Stephen Resch, Craig White, Hilde Wik, Nils Einar Klow,
Per Morten Sandset (Norway)

PA 3.20-4  Role of inflammation, tissue remodeling, and vascular function in the development of
post thrombotic syndrome: a case-control study
Annemieke Bouman, Yuk Cheung, Casper van Schalkwijk, Henri Spronk, Hugo ten Cate,
Marije ten Wolde, Arina ten Cate-Hoek (the Netherlands)

PA 3.20-5  Venous thromboembolism and subsequent receipt of disability pension -
a population-based prospective cohort study
Finn Egil Skjeldestad, Scott Grosse, Ekwutosi Okoroh, Sigrid Braekkan,
Suzanne Cannegieter, Inger Anne Næss, Steinar Krokstad, John-Bjarne Hansen
(Norway)

PA 3.20-6  Prospective study to identify risk factors for post thrombotic syndrome and evaluate
role of compression ultrasound sonography to decide discontinuation of anticoagulant
Pravas Mishra, Narendra Agrawal, Sanjay Sharma, Tulika Seth, Manoranjan Mahapatra
(India)
### Antiplatelet agents: Aspirin - II

**Screen 21**

**PB 3.21-1** Diabetes modulates the fibrinolytic properties of aspirin without altering the platelet inhibitory actions: a possible mechanism for aspirin treatment failure  
Zeyad Kurdee, Abdullah Mamaniat, Fladia Phonix, Penny Rice, Robert Storey, Peter Grant, Ramzi Ajjan [United Kingdom]

**PB 3.21-2** Anti-platelet effect of aspirin in medically treated patients with acute myocardial infarction: Influence of age and gender  
María Teresa Santos, Juana Valles, Isabel Madrid, Juan Bonastre, Antonio Moscardo, Miguel Ruano, Ana Latorre, María-Teresa Santos [Spain]

**PB 3.21-3** Low-dose acetylsalicylic acid therapy monitored with ultra high performance liquid chromatography  
Peter Rubak, Tore Hardlei, Morten Würtz, Steen Kristensen, Anne-Mette Hvas [Denmark]

**PB 3.21-4** Aspirin response: how to explain striking differences in serum TxB2 levels across clinical studies and what use for serum TxB2  
Jean-Luc Reny, Charlotte Brun, Andrew Frelinger, Youssef Daali, Anne Zufferey, Alan Michelson, Christophe Combescure, Pierre Fontana, Jean-Luc Reny [Switzerland]

**PB 3.21-5** Aspirin efficacy is reduced following off-pump coronary bypass operation  
Morten Würtz, Ivy Modrau, Steen Kristensen, Anne-Mette Hvas [Denmark]

**PB 3.21-6** Association between the GPIIa gene polymorphism and the response to Acetylsalicylic Acid in patients with type 2 diabetes mellitus  
Rita Duarte, Lillian Gonçalves, Michelle Alves, Ana Paula Fernandes, Karina Gomes, Luci Dusse, Adriana Bosco, Maria das Graças Carvalho [Brazil]

### Platelets: Point-of-care tests

**Screen 22**

**Moderator: Gerhardus Kuiper (The Netherlands)**

**PB 3.22-1** A 96 well plate-based whole blood assay assessing multiple platelet activation pathways appears promising in the evaluation of antiplatelet therapy  
Natalia Dovlatova, Mohammad Algahsani, Marie Lordkipanidze, Jane May, Steve Watson, Sue Fox [United Kingdom]

**PB 3.22-2** A simple colorimetric assay provides a novel platelet activation endpoint and distinguishes between responses to different physiological agonists  
Margaret Prechel, Vicki Escalante, Jennifer Lohmeier, Jeanine Walenga [USA]

**PB 3.22-3** Development of a novel high throughput 96 well plate-based whole blood assay for investigation of platelet function in healthy volunteers and patients with clinically diagnosed bleeding disorders  
Marie Lordkipanidze, Natalia Dovlatova, Gillian Lowe, Steve Watson, Sue Fox [United Kingdom]

**PB 3.22-4** Point-of-care platelet testing accurately displays platelet dysfunction in chronic renal insufficiency, but fails to predict bleeding after kidney biopsy  
Gerhardus Kuiper, Rik Houben, Paul Verhezen, Marcus Lancé, Maarten Christiaans, Hugo ten Cate, Yvonne Henskens [The Netherlands]

**PB 3.22-5** Platelet aggregation in whole blood by Multiplate system is a rapid and suitable assay to evaluate platelet function in stored blood for transfusion therapy  
Carmen Tartari, Marina Marchetti, Laura Russo, Alfonso Vignoli, Erika Diani, Cristina Verzeroli, Chiara Gargantini, Nadia Coffetti, Alberto Rosti, Anna Falanga [Italy]
Optimizing whole blood impedance aggregometry in severe thrombocytopenia
Mette Tiedemann Skipper, Peter Rubak, Jesper Stentoft, Anne-Mette Hvas, Ole Halldan Larsen [Denmark]

Platelet inhibition
Screen 23

Prednisolone inhibits platelet function through targeting of the RhoA/ROCK signalling pathway
Khalid Naseem, Sreemoti Banerjee, Mauro Perretti [United Kingdom]

Natriuretic peptides and platelets: evidence of a localised cGMP synthesis
Alessandra Borgognone, Kate Lowe, Stephen Watson, Melanie Madhani [United Kingdom]

Decreased phosphorylation of the Linker for Activated T-cells (LAT) is associated with impaired collagen activation of neonatal platelets
Sara Israels, Eileen McMillan-Ward, Archibald McNicol [Canada]

Tangeretin regulates platelet function through dual inhibition of phosphoinositide 3-kinase and cyclic nucleotide signalling
Sakthivel Vaipuri, Marfoua Ali, Leonardo Moraes, Tanya Sage, Chris Jones, Jonathan Gibbins [United Kingdom]

Targeting of type 1 protein kinase A to lipid rafts is required for competent platelet inhibition by the cAMP-signaling pathway
Khalid Naseem, Zaher Raslan, Ahmed Aburima, Simbarashe Magwenzi, Kjetil Tasken [United Kingdom]

Characterization of the effects of losartan on human platelets
Peng Jiang, Stéphane Loyau, Martine Jandrot-Perrus [France]

Platelet proteomics
Screen 24

Time-resolved phosphorylation patterns of human platelets upon treatment with iloprost reveal novel insights into platelet inhibition
René Zahedi, Florian Beck, Jörg Geiger, Stepan Gambaryan, Ulrich Walter, Albert Sickmann [Germany]

Proteomic comparison of platelets with high and low mean platelet volume
Thomas Thiele, Leif Steil, Stephan Wiersbitzky, Birgit Fuerll, Manuela Gesell Salazar, Elke Hammer, Uwe Völker, Andreas Greinacher [Germany]

A proteomics study of the neonatal platelet plasma membrane
Axel Schlagenhauf, Britta Obrist, Bettina Leschnik, Ruth Birner-Gruenberger, Wolfgang Muntean [Austria]

Towards a better characterization of the platelet secretory granule proteome
Anne Zufferey, Domitille Schwartz, Séverine Nolli, Jean-Luc Reny, Jean Charles Sanchez, Pierre Fontana [Switzerland]

A 2D-DIGE-based proteomic analysis reveals differences in the platelet releasate depending on the platelet stimulus
Paula Vélez, Isaac Rosa, Angel Garcia [Spain]

What do platelets release?
Arjen Scholten, Patrick Wijten, Thijs van Holten, Onno Bleijerveld, Philip de Groot, Albert Heck, Mark Roest [The Netherlands]
**Platelet disorders: Loss-of-function**

**Moderator: Michael Mitchell (United Kingdom)**

**Screen 25**

**PB 3.25-1** Variability in clinical and biological manifestations of anti-GPVI autoantibodies: about four new patients
Stéphane Loyau, Mathieu Fiore, Véronique Latger-Cannard, Véronique Baccini, Bénédicte Dumont, Xavier Pillois, Thomas Lecompte, Marie-Christine Alessi, Martine Jandrot-Perrus (France)

**PB 3.25-2** Platelet dense granule but not alpha granule secretion defect in cystic fibrosis patients
Steve Kerrigan, Tadhg McGivern, Kevin Molloy, Noel McElvaney, Niamh Moran (Ireland)

**PB 3.25-3** Is molecular analysis of the MYH9 gene helpful in the diagnosis of May-Hegglin anomaly and related disorders?
Michael Mitchell, Jayanthi Alamelu, Steve Austin, Jacky Cutler (United Kingdom)

**PB 3.25-4** Increased total platelet TFPI and higher surface expression of TFPI in activated platelets may be involved in the pathogenesis of Mild Bleeding Disorders (MBD) of Undefined Cause (BUC)
Olga Panaes, Pamela Zuniga, Rocio Valencia, Paola Kovacs, Teresa Quiroga, Jaime Pereira, Diego Mezzano (Chile)

**PB 3.25-5** HPLC-based assay to measure platelet serotonin (5-HT) secretion in specialized hemostasis laboratories: comparison with the current 'gold standard' radioisotopic test
Diego Mezzano, Luis Vásquez, Elizabeth Araya, Eduardo Aranda, Manuela Goycoolea, Olga Panaes, Jaime Pereira, Teresa Quiroga (Chile)

**PB 3.25-6** Prevention of intracranial hemorrhage in fetal/neonatal alloimmune thrombocytopenia: Identification of risk factors
Gérald Bertrand, Corinne Martageix, Cécile Kaplan (France)

**Platelet acquired dysfunctions**

**Screen 26**

**Moderator: Paola van der Meißen (The Netherlands)**

**PB 3.26-1** Platelet function and blood loss during coronary artery bypass surgery
Daan van de Kerkhof, Stephanie Mezger, Anton van der Stokker, Patrix Lanen, Bart van Straten (The Netherlands)

**PB 3.26-2** The microstructure of clots formed via the extrinsic pathway: effects of shear induced platelet activation
Rebecca Hambly, H. Chan, C. Thornton, P. Williams, P. Evans, Karl Hawkins (United Kingdom)

**PB 3.26-3** Plasma LDL-cholesterol lowering by LDL apheresis induces acute changes in platelet properties
Suzanne Korporaal, Valentina De Angelis, Barbara Sjouke, Marco van der Stoep, Andrea Bochem, Kees Hovingh, Philip de Groot, Miranda van Eck (The Netherlands)

**PB 3.26-4** The role of platelets in vitamin K antagonist-associated bleeding
Paola van der Meißen, Annemieke Bouman, Marion Feijje, René van Oerle, Henri Spronk, Karly Hamulyak, Arina ten Cate-Hoek, Hugo ten Cate, Johan Heemskerk (The Netherlands)

**PB 3.26-5** An analysis of the hemostatic response using a hybrid computational and experimental approach
Maurizio Tomaiuolo, Tim Stalker, John Welsh, Scott Diamond, Lawrence Brass (USA)
**Pattern and management of bleeding complications with new oral anticoagulants. Results of the Prospective Dresden NOAC Registry (NCT01588119)**

Jan Beyer-Westendorf, Franziska Ebertz, Vera Gelbricht, Kati Förster, Christina Köhler, Luise Tittl, Sebastian Werth (Germany)

**Moderator:** Alexander Bye (United Kingdom)

**Screen 27**

**PB 3.27-1**

*Simultaneous real-time imaging of fibrinogen binding and intracellular calcium reveals a role for Rac1-dependent synergy between P2Y1 and P2Y12 receptors*

Alexander Bye, Richard Evans, Martyn Mahaut-Smith (United Kingdom)

**PB 3.27-2**

*The role of plasma membrane STIM1 and Ca2+entry pathways in platelet aggregation*

Kalwant Authi, Archana Ambily, William Kaiser, Cristina Pierro, Elizabeth Chamberlain, Zhaosu Li, Nick Kassouf, Christopher Jones, Jonathan Gibbins, Kalwant Authi (United Kingdom)

**PB 3.27-3**

*The attachment of integrin αIIbβ3 and GpIb to the platelet cytoskeleton is disrupted in the phosphatidylserine-positive platelets as a result of calpain activation*

Elena Artemenko, Fazoil Ataullakhanov, Mikhail Panteleev (Russian Federation)

**PB 3.27-4**

*Reduced expression of SERCA3 isoform in platelet from patient with morbid obesity inhibits platelet functions*

Régis Bobe, Muriel Coupaye, Jose Javier Lopez, Aurelie Kondratieff, Marion Pepin, France Teillet, Dominique De Prost, Alain Stepanian (France)

**PB 3.27-5**

*Contributing factors influencing the platelet activation time between platelet adhesion on von Willebrand factor, detected by an increase in intraplatelet calcium ion.*

Noriko Tamura, Shinya Goto, Aiko Tomita, Seiji Shiozaki, Yohei Nanazawa (Japan)

**PB 3.27-6**

*Systems biology of platelet activation: a stepped hierarchy of responses arises from the calcium interplay between cytosol, dense tubular system and mitochondria*

Anastasia Golomysova, Mikhail Panteleev (Russian Federation)

**Screen 28**

**PB 3.28-1**

*P21-activated kinase regulate directional migration and cytoskeletal organization in human neutrophils*

Asako Itakura, Joseph Aslan, Branden Kusanto, Kevin Phillips, Xiaolin Nan, Robert Insall, Jonathan Chernoff, Owen McCarty (USA)

**PB 3.28-2**

*Correction of endothelial dysfunction by hepatocyte-specific Dyrk1a gene transfer in hyperhomocysteinemic mice*

Nathalie Janel, Asma Tili, Ana Garcia Perez, Leanne de Koning, Thierry Dubois, Jean-Louis Paul, Bart de Geest, Jean-Maurice Delabar (France)

**PB 3.28-3**

*The novel NOX inhibitor 2-acetylphenothiazine impairs collagen-dependent thrombus formation in a GPVI-dependent manner*

Giordano Pula, Dina Vara (United Kingdom)

**PB 3.28-4**

*The polyamines regulate intestinal epithelial barrier function through AMP-activated protein kinase and the nuclear accumulation of c-Myc*

Lei Xu, Xiaoyu Zhu (China)

**PB 3.28-5**

*Therapeutic application of activated Protein C epigenetically constrains the redox-enzyme p66shc in diabetic nephropathy*

Fabian Bock, Khurram Shahzad, Hongjie Wang, Thati Madhusudhan, Wei Dong, Charles Esmon, Peter Nawroth, Berend Isermann (Germany)
Wednesday, July 3, 2013

PB 3.28-6  Protease-activated receptor-2 triggers epithelial to mesenchymal transition: potential relevance in pulmonary fibrosis and cancer
           Keren Borensztajn, Jan von der Thüsen, Maikel Peppelenbosch, Arnold Spek (France)

**Megakaryocytes and thrombopoiesis - III**

Moderator: Peter Bugert (Germany)

PB 3.29-1  Continuous platelet production in the bloodstream is regulated by von Willebrand factor
           Sonia Poirault-Chassac, Kim Anh Nguyen, Audrey Pietrzyk, Caterina Casari, A. Veyradier, Cécile Denis, Dominique Baruch (France)

PB 3.29-2  IL-21 promotes the expansion of primary human megakaryocytes in vitro
           Salima Benbarche, Catherine Strassel, Christian Gachet, François Lanza, Henri De La Salle (France)

PB 3.29-3  Megakaryocyte regulatory pathway mediated by NMDA receptors
           Maggie Kalev-Zylinska, Tania Kamal, Taryn Green, Marie-Christine Morel-Kopp, Bruce Baguley, Lochie Teague, Ward Christopher, Matthew During (New Zealand)

PB 3.29-4  Effect of three-dimensional hydrogel scaffolds on megakaryocyte differentiation and platelet production
           Audrey Pietrzyk, Sonia Poirault-Chassac, Rachida Aid, Sidi Mohammed Derkaoui, Didier Letourneur, Catherine Le Visage, Dominique Baruch (France)

PB 3.29-5  Impact of COX-2 deletion on platelet and megakaryocyte phenotypes
           Silvia Stella Barbieri, Giovanna Petrucci, Patrizia Amadio, Eva Tarantino, Franco Ranelletti, Sara Gianellini, Bianca Rocca, Carlo Patrono, Elena Tremoli (Italy)

PB 3.29-6  The cholinergic system in cord blood derived megakaryocytes and megakaryocytic lineages
           Peter Bugert, Kerstin Kaiser, Florian Lorenz, Julian Starigk, Anip Sarin, Angelika Schedel (Germany)

**Microparticle assays**

Moderator: Yuana Yuana (The Netherlands)

PB 3.30-1  Towards standardized protocols for preparation and detection of microparticles
           Yuana Yuana, Anita Böing, C. Hau, A. Grootemaat, A. Sturk, Rienk Nieuwland (The Netherlands)

PB 3.30-2  Effect of filtration on the particle concentration and diameter of microparticles
           Yuana Yuana, A. Grootemaat, A. Sturk, Rienk Nieuwland (The Netherlands)

PB 3.30-3  Effect of inflammatory cytokines and coagulation factors on endothelial microparticle formation and content
           Muriel Meiring, Etizette Le Roux, Vernon Louw (South Africa)

PB 3.30-4  The procoagulant phospholipids clotting time assay as a routine functional test for measuring circulating microparticle activity
           Elena Campello, Luca Spiezia, Claudia Radu, Sabrina Gavasso, Barry Woodhams, Paolo Simioni (Italy)

PB 3.30-5  Procoagulant phospholipid in stored erythrocyte concentrates
           Stephanie Smith, Maureen McMichael, Thandeka Ngwenyama, Jennifer Herring, Mauria O’Brien, Rafaela Corsi, Alyssa Galligan, Kelly Swanson (USA)
Wednesday, July 3, 2013
17:00 – 18:30

PB 3.30-6  In vitro microparticle-dependent clot formation mainly depends on platelet-derived microparticles and not on other subtypes
Tarik Bouriche, Coralie Judicone, Romaric Lacroix, Etienne Bernit, Karim Harti, Jacques Albanese, Françoise Dignat-George, Philippe Poncelet (France)

**Endothelium: Miscellaneous**

*Screen 31*

**Moderator: Cormac McDonnell (Ireland)**

**PB 3.31-1**  Molecular mechanisms of *S. aureus* mediated endovascular infection under fluid shear conditions
Cormac McDonnell, Alisha McLoughlin, Phil Cummins, Steve Kerrigan (Ireland)

**PB 3.31-2**  Coagulation profile in patients with acute leukaemia receiving myeloablative or reduced-intensity conditioning regimens for allogeneic hematopoietic stem cell transplantation
Joanna Rupa-Matysek, Anna Czyz, Lidia Gil, Ewelina Wojtasinska, Katarzyna Zajdel, Katarzyna Ciepluch, Mieczyslaw Komarnicki (Poland)

**PB 3.31-3**  Prior intracerebroventricular administration with endothelin-1A receptor antagonists reduces hypercoagulable state and systemic inflammation, and result in survival time prolongation in rat heatstroke
Tsai-Hsiu Yang, Mei-Fen Shih, Mei-Lin Tsai, Chia-Chyuan Liu (Taiwan)

**PB 3.31-4**  Pulmonary embolism that causes tricuspid regurgitation is associated with impaired L-arginine metabolism
Jeffrey Kline, John Watts, Yong-Yook Lee, Sun-il Hwang, Mark Courtney, Mary-Beth Fulkerson (USA)

**PB 3.31-5**  Structure-function relationship and action mechanism of Krait Natriuretic Peptide (KNP)
Sindhuja Sridharan, Manjunatha Kini (Singapore)

**PB 3.31-6**  Increase of angiogenic and angiostatic mediators in patients with idiopathic pulmonary fibrosis
David Smadja, Karine Juvin, Dominique Valeyre, Bruno Crestani, Dominique Israel-Biet (France)

**Atherosclerosis: Expression analysis**

*Screen 32*

**Moderator: Moritz Stolla (USA)**

**PB 3.32-1**  Novel network biomarkers profile based coronary artery disease risk stratification in asian indians.
Rajani Kanth Vangala, Vandana Ravindran, Ghatge Madan, O. Madhavan, Vijay Kakkar (India)

**PB 3.32-2**  Human macrophages spontaneously differentiated from blood monocytes are heterogeneous and show distinct proteome profiling
Sonia Eligini, Maura Brioschi, Mauro Crisci, Elena Tremoli, Cristina Banfi, Susanna Colli (Italy)

**PB 3.32-3**  Detection of protein S in necrotic core of atherosclerotic plaque and of lipoprotein-associated protein S in plasma
Marcello Baroni, Francesco Mascoti, Eleonora Cremonini, Carlo Cervellati, Marina Zagatti, Silvia Meneghetti, Francesco Bernardi, Giovanna Marchetti (Italy)
Fraktalkine is expressed in early and advanced atherosclerotic lesions and supports monocyte recruitment via CX3CR1
Moritz Stolla, Jaroslav Pelisek, Marie-Luise Von Bruehl, Andreas Schaefer, Verena Barocke, Peter Heider, Johann Bauersachs, Paul Bray, Steffen Massberg, Christian Schulz (USA)

UPA/UPAR and vascular repair in atherosclerotic vessel wall
Roberta Lugano, Esther Peña, Laura Casani, Lina Badimon, Teresa Padro (Spain)

Immunological tolerance to a combination of ApoB and HSP60 Peptides Decreases markers known to be associated with plaque instability in mice model of atherosclerosis
Lakshmi Mundkur, Rupak Mukhopadhyay, Meenakshi Varma, Sonia Samson, Daxin Chen, Xinjie Lu, Vijay Kakkar (India)

Pharmacokinetics of a recombinant ADAMTS13 in mice, rats and macaques
Werner Höllriegel, Alexandra Schiviz, Gerald Höbarth, Susan Kubik, Barbara Plaimauer, Friedrich Scheiflinger, Eva-Maria Muchitsch (Austria)

Preclinical safety of Baxter’s recombinant ADAMTS13
Christina Piskernik, Barbara Dietrich, Frank Horling, Susan Kubik, Tanja Ruthsatz, Friedrich Scheiflinger, Hans-Peter Schwarz, Eva-Maria Muchitsch, Alexandra Schiviz (Austria)

Human umbilical vein endothelial cells, platelets and human tumor cell lines express isoforms 2 and 3 of ADAMTS13
Ana Kempfer, Yanina Powazniak, Julio Calderazzo, Juvenal Paiva, Daniel Alonso, Analia Sanchez-Luceros, Maria Lazzari (Argentina)

FRET rather than CBA reflects ADAMTS13 proteolytic activity in thrombotic thrombocytopenic purpura patients with discordant measurements
Ilaria Mancini, Carla Valsecchi, Luca Lotta, Silvia Pontiggia, Maria Teresa Bajetta, Louis Deforche, Roberta Palla, Karen Vanhoorelbeke, Flora Peyvandi (Italy)

The research of ADAMTS13 binding to human microvascular endothelial cells
Anyou Wang, Jingsheng Wu, Kaiyang Ding, Xin Liu, Xiaoyan Cai, Weibo Zhu, Zimin Sun (China)

Characterization of IgG anti-ADAMTS13 autoantibodies isolated from patients with acquired TTP and a healthy donor pool
Peter Turecek, Rana Grillberger, Susanna Skalicky, Gerald Schrenk, Barbara Plaimauer, Paul Knöbl, Long Zheng, Hanspeter Rottensteiner, Friedrich Scheiflinger (Austria)

Fractal kinetic models of plasmin-catalyzed dissolution of fibrin
Imre Varjú, Krasimir Kolev, Zsófia Keresztes, Andrea Pap, Kiril Tenekedjiev, Raymund Machovich (Hungary)

DNA methylation and regulation of t-PA gene expression
Egbert Kruithof, Sylvie Dunoyer-Geindre (Switzerland)

Role for arginine 12 of Thrombin-Activatable Fibrinolysis Inhibitor (TAI) in Thrombin/Thrombomodulin mediated TAI activation?
Tom Plug, Joost Meijers (The Netherlands)
Covalently linking heparin to antithrombin diminishes the protective effect of fibrin on plasmin
Ankush Chander, Helen Atkinson, Leslie Berry, Ivan Stevic, Anthony Chan (Canada)

Zinc inhibits fibrinolysis by attenuating plasminogen activation and fibrin degradation
Sara Henderson, James Fredenburgh, Paul Kim, Alan Stafford, Beverly Leslie, Jeffrey Weitz (Canada)

Plasma proteins and soluble proteins from red blood cells cooperatively regulate wound healing process
Moyuru Hayashi, Miharu Ikeda, Mayuko Asai, Motoyuki Shimonaka (Japan)

DDAVP treatment: clinical efficacy and molecular mechanisms of response in mild haemophilia A patients. A single center experience
Annarita Tagliaferri, Caterina Di Perna, Federica Riccardi, Massimo Franchini, Gianna Franca Rivolta, Corrado Pattacini (Italy)

Clearance during continuous infusion of recombinant factor VIII products to 27 patients with hemophilia A at Nagoya University Hospital
Nobuaki Suzuki, Mayuko Kishimoto, Tadashi Matsushita (Japan)

NO-PEACKS: Non-interventional observations of practical implementation, efficacy, and safety of continuous infusion with full-length recombinant factor VIII formulated with sucrose in surgery
Karina Meijer, Piercarla Schinco, Elena Santagostino, Helen Platokouki, Roger Schutgens, Federica Valeri, Monika Brunn, Claudia Tueckmantel, Stephan Rauchensteiner (The Netherlands)

Knowledge, attitudes, and behaviors of adolescents in developing world hemophilic population: a survey
Anupam Sachdeva, Mohammed Ramzon, Rishabh Gulati, Satya Yadav (India)

Bleeding risks in male patients and carriers with the valine to alanine 2016 form of mild hemophilia A
Chai Wye Phua, Sunkyu Park, Mary-Frances Scully, Brendan Barrett, Yagang Xie (Canada)

Retrospective analysis of 1226 Chinese patients with haemophilia in a single medical centre
Min Xuan, Feng Xue, Rongfeng Fu, Yanhui Yang, Huiyuan Li, Lei Zhang, Tian Mengsu, Renchi Yang (China)

FVIII neutralization kinetics- a complimentary tool for individual assessment of inhibitor patients
Tami Livnat, Shirley Azar- Avivi, Ariella Zivelin, Carmen Altisent Roca, Tami Brutman- Barazani, Uri Martinowitz, Gili Kenet (Israel)

Low inhibitor incidence in previously untreated patients with severe haemophilia A treated with octanate - Update from the PUP-GCP clinical trial
Martina Jansen, Anna Klukowska, Vladimir Komrska, Pavel Laguna, Vladimir Vdovin (Austria)
### ePOSTERS (B)

#### Wednesday, July 3, 2013  
17:00 – 18:30

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>PB 3.36-3</td>
<td>A European certification system for haemophilia centres</td>
<td>Gabriele Calizzani, Ivana Menichini, Fabio Candura, Brian O’Mahoney, Paul Giangrande, Michael Makris (Belgium)</td>
</tr>
<tr>
<td>PB 3.36-4</td>
<td>Patient and parent preferences for efficacy, inhibitor risk, safety, and infusion frequency associated with prophylactic Factor VIII treatment</td>
<td>Ateesha Mohamed, Vincent Lin, Joshua Posner, Joshua Epstein (USA)</td>
</tr>
<tr>
<td>PB 3.36-5</td>
<td>Comprehensive assessment of hemorrhagic phenotype and cardiovascular risk profile in carriers of severe haemophilia</td>
<td>Maria Eva Mingot, Manuel Rodriguez-Martínez, Anabel Heiniger Mazo (Spain)</td>
</tr>
<tr>
<td>PB 3.36-6</td>
<td>Do inhibitors, treatment regimen and bleed frequency impact haemophilia treatment centre and provider utilisation: An analysis of adults with haemophilia in the HERO study</td>
<td>Alfonso Iorio, Diane Nugent, Ann Marie Stain, Matt Gregory, Louisa Pericleous, David Cooper (Canada)</td>
</tr>
</tbody>
</table>

#### Haemophilia A: Clinical - XI

**Screen 37**

**Moderator:** Britt Holderness (USA)

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>PB 3.37-1</td>
<td>Outcomes of total knee and hip arthroplasty for hemophilic arthropathy</td>
<td>Britt Holderness, Yuika Goto, Laurel McKernan, Philip Bernini, Deborah Ornstein (USA)</td>
</tr>
<tr>
<td>PB 3.37-3</td>
<td>Osteoporosis and osteopenia in patient with severe and moderate type hemophilia A</td>
<td>Yeu-Chin Chen, Shin-Nan Cheng, Ru-Yu Pan, Tsung-Ying Li, Shu-Hsia Hu (Taiwan)</td>
</tr>
<tr>
<td>PB 3.37-4</td>
<td>Haemate® P for the treatment of vWD and haemophilia A: New results of a pharmacovigilance project</td>
<td>Manuela Krause, Mario von Depka Prondzinski, Susan Halimeh, Cornelia Wermes, Bettina Kemkes-Matthes, Zeynep Gutowski-Eckel, Günter Auerswald (Germany)</td>
</tr>
<tr>
<td>PB 3.37-5</td>
<td>Safety and pharmacokinetics of a recombinant fusion protein-linking coagulation factor VIII with albumin (rVIII-FP) in healthy volunteers</td>
<td>Alex Veldman, Rachael Easton, Kerstin Jung, Tina Moises, John-Philip Lawo, Christine Joch, Antje Daehler, Debra Bensen-Kennedy (Germany)</td>
</tr>
<tr>
<td>PB 3.37-6</td>
<td>Adherence to hemophilia treatment in the Dutch pediatric population; Reliability and validity of the VERITAS-Pro questionnaire</td>
<td>Janske Lock, Hein Raat, Natalie Duncan, Amy Shapiro, Marjolein Peters, Rienk Tamminga, Frank Leebeek, Henriëtte Moll, Marjon Cnossen (The Netherlands)</td>
</tr>
</tbody>
</table>

#### Haemophilia A: Clinical - XII

**Screen 38**

**Moderator:** Ming Lim (USA)

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>PB 3.38-1</td>
<td>Clinical features and management of hemophilic pseudotumors: A single US center experience</td>
<td>Ming Lim, Brenda Nielsen, Alice Ma, Nigel Key (USA)</td>
</tr>
<tr>
<td>PB 3.38-2</td>
<td>The relationship between specific annual bleed rates and health outcomes among children with severe hemophilia A</td>
<td>Leonard Valentino, Paul Giangrande, Joshua Epstein, Yan Xiong, Diane Ito, Josephine Li-McLeod (USA)</td>
</tr>
<tr>
<td>Session</td>
<td>Title</td>
<td>Authors</td>
</tr>
<tr>
<td>---------</td>
<td>----------------------------------------------------------------------</td>
<td>------------------------------------------------------------------------</td>
</tr>
<tr>
<td>PB 3.38-3</td>
<td>Comparison of factor VIII half-lives in severe haemophilia A following switch to Refacto AF</td>
<td>Jane Needham, Helen Lewis, Karan Rangarajan, Anica Phillott, Savita Rangarajan (United Kingdom)</td>
</tr>
<tr>
<td>PB 3.38-4</td>
<td>Differential patterns of dynamic whole blood platelet aggregation in haemophilia A following in vitro addition of rFVIII and by-passing agents</td>
<td>Maria Sander Jensen, Benny Sørensen, Christian Fenger-Eriksen, Jørgen Ingerslev, Ole Halfdan Larsen (Denmark)</td>
</tr>
<tr>
<td>PB 3.38-5</td>
<td>Qualitative findings contributing to the development of a hemophilia-specific caregiver burden instrument: caregiver and health care professional insights</td>
<td>Sylvia Von Mackensen, Tami Wisniewski, Leonard Valentino (Germany)</td>
</tr>
<tr>
<td>PB 3.38-6</td>
<td>Findings from a conjoint analysis with hemophilia A patients: clinical characteristics and patient preferences for treatment</td>
<td>Anne Rentz, Jennifer Pocoski, Katharine Gries, Christine Thompson, Prasad Mathew, Rahul Sasané (USA)</td>
</tr>
<tr>
<td>PB 3.39-1</td>
<td>Anticoagulant profile studied by thromboelastography of multiple batches of branded enoxaparin and a US generic version of enoxaparin</td>
<td>Jeanine Walenga, Walter Jeske, Vicki Escalante, Debra Hoppensteadt, Talhah Chaudhry, Mamdouh Bakhos (USA)</td>
</tr>
<tr>
<td>PB 3.39-2</td>
<td>Tissue culture based approach to discriminate branded and generic low molecular weight heparins</td>
<td>Christopher Goodwin, Michael Scully, Ajay Kakkar (United Kingdom)</td>
</tr>
<tr>
<td>PB 3.39-3</td>
<td>Pharmacodynamic response to unfractionated heparin used for initial treatment of acute deep vein thrombosis in elderly patients with renal impairment. A substudy of the IRIS clinical trial</td>
<td>Virginie Siguret, Céline Deudon, Jean-Louis Golmard, Alain Leizorovicz, Eric Pautas, Isabelle Gouin-Thibault (France)</td>
</tr>
<tr>
<td>PB 3.39-4</td>
<td>High risk of nadroparin to induce cutaneous delayed-type IV hypersensitivity reactions (DTH)</td>
<td>Marc Schindewolf, Andreas Recke, Detlef Zillikens, Edelgard Lindhoff-Last, Ralf Ludwig (Germany)</td>
</tr>
<tr>
<td>PB 3.39-5</td>
<td>Low incidence of heparin-induced skin lesions in orthopedic surgery patients</td>
<td>Marc Schindewolf, Marco Paulik, Harmut Kroll, Manfred Wolter, Roland Kaufmann, Wolf-Henning Boehncke, Ralf Ludwig, Edelgard Lindhoff-Last (Germany)</td>
</tr>
<tr>
<td>PB 3.40-1</td>
<td>Contribution of the plasminogen activation system during hyperfibrinolysis in trauma-induced coagulopathy</td>
<td>Jessica Cardenas, Nena Matijevic, Bryan Cotton, John Holcomb, Charles Wade (USA)</td>
</tr>
</tbody>
</table>
ePOSTERS (B)  ePOSTER AREA

Wednesday, July 3, 2013  17:00 – 18:30

PB 3.40-2  Principal roles of platelets and fibrinogen in whole-blood fibrin clot formation in dilutional coagulopathy determined by thromboelastometry
Marisa Ninivaggi, Marion Feijge, Gerhardus Kuiper, Constance Baaten, Marco Marcus, Hugo ten Cate, Marcus Lancé, Johan Heemskerk, Paola van der Meijden [The Netherlands]

PB 3.40-3  The use of Preoperative Erythropoiesis-Stimulating Agents (ESAs) in patients who underwent knee or hip arthroplasty a meta-analysis of randomized clinical trials
Ghazi Alotaibi, Khalid Alsaleh, Hind Almodaimegh, Aleem Aamer, Tom Kouroukis [Canada]

PB 3.40-4  Predictive value of the HAS-BLED score in patients with atrial fibrillation and chronic kidney disease using vitamin K-antagonists
Judith Kooiman, Koen van Beers, Jonna Bank, Bas Spaans, Suzanne Cannegieter, Gregory Lip, Felix van der Meer, Ton Rabelink, Menno Huisman [The Netherlands]

PB 3.40-5  Development of an electronic identification tool for in-hospital bleeding
Kerstin Hogg, Phil Wells, Alan Forster [Canada]

PB 3.40-6  Evolution of plasma fibrinogen levels in trauma patients during the first seven days of hospital stay is not influenced by initial treatment with fibrinogen concentrate
Christoph Schlimp, Wolfgang Voelckel, Martin Ponschab, Herbert Schöchl [Austria]

Rare bleeding disorders - IV  Screen 41
Moderator: Tim de Jager [The Netherlands]

PB 3.41-1  Founder effect for a novel GPIIBB mutation in Bernard-Soulier patients from La Réunion island
Marie-Jeanne Baas, Arnaud Dupuis, Hanitra Randrianaivo-Ranjatoelina, Marie-Line Jacquemont, Marie Dreyfus, Cécile Lavenu-Bombled, Christian Gachet, François Lanza [France]

PB 3.41-2  Identification of Novel Mutations causing Congenital Factor XIII deficiency in Pakistan
Munira Borhany, Helena Handrkova, Andrea Cairo, Verena Schroeder, Samina Amanat, Arshi Naz, Tahir Shamsi, Flora Peyvandi, Hans Peter Kohler [Pakistan]

PB 3.41-3  Intracranial hemorrhage in factor XIII deficiency
Majid Naderi, Peyman Eshghi, Mehran Karimi, Akbar Dorgalaleh, Shadi Tabibian [Iran]

PB 3.41-4  Severe FVII-deficiency- a study of geno-phenotype relationship using thromboelastography and thrombin generation assay
Hoa Tran, Stine Bjørnsen, Geir Tjønnfjord, Pål Andre Holme [Norway]

PB 3.41-5  Overcoming barriers to diagnosis of bleeding disorders including Acquired Hemophilia (AH) by healthcare practitioners (HCP): The Coags Uncomplicated iPhone/Android/Web application
David Cooper, Craig Kessler, Ellinor Peerschke, Meera Chitlur, Roshni Kulkarni, Gretchen Eberhart, Robert Gut [USA]

PB 3.41-6  A literature review on the burden of illness and management of congenital FXIII deficiency
Tim de Jager, Louisa Pericleous, Agathe le Lay, Marta Kokot-Kierepa [The Netherlands]
Wednesday, July 3, 2013 17:00 – 18:30

Von Willebrand disease: Clinical - IV

Moderator: Daniel Hampshire (United Kingdom)

Screen 42

PB 3.42-1  Analysis of sequence variation reported within the von Willebrand factor gene locus
Daniel Hampshire, Anne Goodeve (United Kingdom)

PB 3.42-2  Phenotypic and genotypic characterization of 10 Finnish patients with von Willebrand disease type 3: discovery of two main mutations
Vuokko Jokela (Finland)

PB 3.42-3  Bleeding caused by acquired von Willebrand syndrome (AVWS) in adult patients with congenital heart disease (CHD)
Hans Christian Waldow, Mechthild Westhoff-Bleck, Christian Templin, Carsten Detering, Mario von Depka Prondzinski (Germany)

PB 3.42-4  Type 2N von Willebrand disease in the population of Little Poland
Joanna Zdziarska, Teresa Iwaniec, Ulrich Budde, Aleksander Skotnicki, Jacek Musial (Poland)

PB 3.42-5  The usage of pediatric bleeding questionnaire in the diagnosis of von Willebrand disease and thrombocyte function defects among Turkish children
Fatma Burcu Belen, Ülker Koçak, Melek Isik, Ebru Keskin Yilmaz, Nergiz Öner, Ertan Sal, Zuhre Kaya, Idil Yenicesu, Turkiz Gursel (Turkey)

Inge Vangenechten, Petr Smejkal, Ondrej Zapletal, Fatima Bouddount, J. Zavrelova, Jan Blatny, Miroslav Penka, Jan Jacques Michiels, Alain Gadiasseur (Belgium)

Von Willebrand factor - IV

Screen 43

Moderator: Dafna Groeneveld (The Netherlands)

PB 3.43-1  Resistance of C2362F von Willebrand factor to ADAMTS13-induced proteolysis
Alessandra Casonato, Elena Pontara, Margherita Morpurgo, Grazia Cattini, Monica Battiston, Giovanni Barbon, Giorgia Saga, Viviana Daidone, Luigi De Marco (Italy)

PB 3.43-2  Chicken glycoprotein Iba and Ibβ form both GPIb and non-GPIb complexes: implications for the evolution of GPIb-IX
Liang Zhou, Wenjun Yang, Xin Liang, Renhao Li (USA)

PB 3.43-3  Characteristics and angiogenic properties of blood outgrowth endothelial cells from a type 3 von Willebrand disease patient
Dafna Groeneveld, Richard Dirven, Jiongwei Wang, Karine Valentijn, Jan Voorberg, Pieter Reitsma, Jeroen Eikenboom (The Netherlands)

PB 3.43-4  Characterisation of observed changes in vWF target disposition following repeated administration of the anti-vWF Nanobody caplacizumab
Filip Callewaert, Hans Ulrichts, Sandy Jacobs, Stelaan Rossenu, Anne Schoolmeester, Katrien Verschueren, Judith Baumeister, Josefin-Beate Holz (Belgium)

PB 3.43-5  Acquired von Willebrand Disorder in pediatric extracorporeal membrane oxygenation
Nguyen Trung, Hui Shiu-Ki, Kim Nguyen, Esther Soundar, Shilpa Hundalani, Miguel Cruz, Jun Teruya (USA)

PB 3.43-6  Physical fitness determines the von Willebrand factor response to exhaustive physical exercise
Michelle Sonneveld, Janine van Loon, Stephan Praet, Moniek de Maat, Frank Leebeek (The Netherlands)
**Von Willebrand factor - V**  
**Screen 44**

**Moderator:** Marije Baaij (The Netherlands)

**PB 3.44-1**  
*Defining the molecular basis underlying the physiological interaction between von Willebrand Factor and galectins in normal plasma*  
*Orla Rawley, Jamie O’Sullivan, Alain Chion, Niamh O’Regan, Vincent Jenkins, Teresa Brophy, James O’Donnell (Ireland)*

**PB 3.44-2**  
*Free thiol groups in von Willebrand factor (VWF) are required for its proper function under physiological flow conditions*  
*Barbara Solecka, Birte Fuchs, Christoph Weise, Christoph Kannicht (Germany)*

**PB 3.44-3**  
*Detecting the inner-interaction sites of VWF A1 domain and A3 domain*  
*Miao Jiang (China)*

**PB 3.44-4**  
*Oxidized von Willebrand factor is associated with thrombotic micro- and macro-angiopathies in diabetes mellitus*  
*Raimondo De Cristofaro, Laura Oggiuan, Stefano Lancellotti, Dario Pitocco, Francesco Zaccardi, Paola Rizzo, Francesca Martini, Giovanni Ghirlanda (Italy)*

**PB 3.44-5**  
*A single finger prick for the assessment of von Willebrand factor binding to platelets*  
*Marije Baaij, Roger Schutgens, Rolf Urbanus, Tiffany Vu, Philip de Groot, Mark Roest (The Netherlands)*

**PB 3.44-6**  
*Quality specifications for imprecision, bias and total error to be used for measures of von Willebrand factor antigen, activity and multimerisation*  
*Jolan Harsfalvi, Katalin Szekeres-Csiki, Muriel Meiring, Agnes Sandor, Lajos Pataki, Andrea Nemeti, Miklos Udvardy (Hungary)*

**Anticoagulant agents - XIII**  
**Screen 45**

**Moderator:** Jonathan Lancashire (United Kingdom)

**PB 3.45-1**  
*Prothrombin complex concentrate use for the emergency reversal of vitamin K antagonists*  
*Jonathan Lancashire, Neil Smith, Mark Crowther (United Kingdom)*

**PB 3.45-2**  
*Validation of a new questionnaire measuring Satisfaction with Medical Care in Non Valvular Atrial Fibrillation patients (SAFUCA study)*  
*Tomás José González-López, Miguel Ruiz, Fernando Villasante, José Ramón González-Porras, Eduardo Franco, José Luis Aranguren, José Tuñón, Marina De Salas-Cansado, Antonio Pardo, Javier Soto (Spain)*

**PB 3.45-3**  
*Reversal of the oral direct thrombin inhibitor dabigatran captured by visco-elastic and thrombo-imaging techniques*  
*Tomas Lindahl, Andreas Hillarp, Kerstin Gustafsson, Maria Wallstedt (Sweden)*

**PB 3.45-4**  
*Simulation of the international normalized ratio during switching therapy from rivaroxaban to warfarin and its potential clinical implications*  
*Hans-Ulrich Siegmund, Rolf Burghaus, Dagmar Kubitzka, Katrin Coboeken (Germany)*

**PB 3.45-5**  
*Streptokinase affects tissue-type plasminogen activator secretion in HUVEC*  
*Maryna Burlova-Vasylieva, Nataliia Kravchenko, Olexiy Savchuk (Ukraine)*
**Wednesday, July 3, 2013 17:00 – 18:30**

**Screen 46**

**Anticoagulant agents - XIV**

*Screener:* Arina ten Cate-Hoek (The Netherlands)

**PB 3.46-1** Pharmacodynamics and pharmacokinetics during the transition from warfarin to rivaroxaban in healthy subjects: a multicentre, randomized, placebo-controlled study  
**Moderator:** Arina ten Cate-Hoek (The Netherlands)

**PB 3.46-2** Combination effects of edoxaban, an oral direct factor Xa inhibitor, and P2Y12 receptor antagonists on ADP plus tissue-factor induced thrombin generation in human platelet-rich plasma  
**Moderator:** Arina ten Cate-Hoek (The Netherlands)

**PB 3.46-3** Efficacy and safety of weight-adjusted extended duration tinzaparin for prevention of post-operative venous thromboembolism after bariatric surgery  
**Moderator:** Arina ten Cate-Hoek (The Netherlands)

**PB 3.46-4** Effective inhibition of proteases of the coagulation cascade by di-cationic pentamidine-like molecules  
**Moderator:** Arina ten Cate-Hoek (The Netherlands)

**PB 3.46-5** Adherence to oral anticoagulants in an outpatient setting  
**Moderator:** Arina ten Cate-Hoek (The Netherlands)

**PB 3.46-6** Rivaroxaban superior to Nadroparin for thromboprophylaxis in patients receiving hip or knee arthroplasty  
**Moderator:** Arina ten Cate-Hoek (The Netherlands)

**Screen 47**

**Anticoagulant agents - XV**

*Screener:* Herm-Jan Brinkman (The Netherlands)

**PB 3.47-1** A low fixed dose of Prothrombin Complex Concentrate is cost effective in emergency reversal of vitamin K antagonists  
**Moderator:** Herm-Jan Brinkman (The Netherlands)

**PB 3.47-2** Interaction of metformin with the vitamin K antagonist phenprocoumon  
**Moderator:** Herm-Jan Brinkman (The Netherlands)

**PB 3.47-3** Inhibition kinetics of plasma-derived and recombinant activated protein C in human plasma  
**Moderator:** Herm-Jan Brinkman (The Netherlands)

**PB 3.47-4** The clinically relevant interaction of warfarin and capecitabine  
**Moderator:** Herm-Jan Brinkman (The Netherlands)

**PB 3.47-5** Prothrombinase induced clotting time (PICT) for the monitoring of new oral anticoagulants  
**Moderator:** Herm-Jan Brinkman (The Netherlands)

**PB 3.47-6** Ex vivo monitoring of Fenprocoumon reversal by prothrombin complex concentrate using thrombography  
**Moderator:** Herm-Jan Brinkman (The Netherlands)
**Wednesday, July 3, 2013 17:00 – 18:30**

### Anticoagulant agents - XVI

**Screen 48**

**Moderator: Sacheeta Bathija (USA)**

**PB 3.48-1** Impact of pre-injury warfarin use on hospital mortality in elderly United States residents with torso trauma  
Courtney Collins, Heena Santry, Elan Witkowski, Julie Flahive, Fred Anderson Jr (USA)

**PB 3.48-2** Reversal of anticoagulant effects of apixaban with non-specific prohaemostatic agents: an in vitro study  
Anne Godier, Anne-Céline Martin, Charles Samama, Anne-Marie Fischer, Bernard Le BONNIEC (France)

**PB 3.48-3** Determination of dabigatran, rivaroxaban and apixaban using UPLC-MS/MS and comparison with coagulation assays for therapy monitoring  
Daan van de Kerkhof, Ellen Schmitz, Kristel Boonen, Dennis van den Heuvel, Luc Brunsveld (The Netherlands)

**PB 3.48-4** Measurement of anti-Xa activity of apixaban in plasma  
Meyer Samama, Céline Guinet, Lena le Flem, Jean Amiral (France)

**PB 3.48-5** Patient outcomes with anticoagulation therapy after hip and knee replacement: comparison of two models of care  
Sacheeta Bathija, Surrey Walton, Denys Lau, William Galanter, Glen Schumock, Edith Nutescu (USA)

**PB 3.48-6** Psychological influence of the media on patients commencing oral anticoagulation in atrial fibrillation; a qualitative analysis  
Christian Borg Xuereb, Rachel Shaw, Gregory Lip, Deirdre Lane (United Kingdom)

### Coagulation factor IX - II

**Screen 49**

**Moderator: Jurg Sommer (USA)**

**PB 3.49-1** The activity of GlycoPEGylated recombinant FIX (N9-GP) can be measured in two-stage chromogenic and one-stage clotting assays  
Pernille Kaae Holm, Mette Hoegh Sørensen, Mette Brunsgaard Hermit, Mirella Ezban (Denmark)

**PB 3.49-2** Comparative field study evaluating the activity of recombinant Factor IX - Fc fusion protein (rFIXFc) in plasma samples at clinical haemostasis laboratories  
Jurg Sommer, Yang Buyue, Robert Peters, Hayyan Jiang, Elaine Gray, Glenn Pierce (USA)

**PB 3.49-3** The effect of different APTT reagents on the potencies of plasma-derived and recombinant factor IX concentrates in one-stage clotting assays  
Helen Wilmot, John Hogwood, Elaine Gray (United Kingdom)

**PB 3.49-4** Efficacy and safety of a novel rFIX (BAX326): phase III study in previously treated patients with severe or moderately severe hemophilia B undergoing surgical or other invasive procedures  
Jerzy Windyga, Toshko Lissitchkov, Oleksandra Stasyshyn, Vassily Mamonov, Helieh Ghandehari, Miranda Chapman, Sandor Fritsch, Borislava Pavlova, Wing-Yen Wong, BRIGITTE ABBUEHL (Poland)

**PB 3.49-5** Population pharmacokinetic model for a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients  
Ridhi Parasrampuria, Rachael Easton, Zhenling Yao, Debra Bensen-Kennedy, Christine Voigt, Iris Jacobs, MORFINI MASSIMO (USA)
PB 3.49.6  Prospective study of a novel recombinant factor IX in previously treated patients with hemophilia B  
Jerzy Windyga, Toshko Lissitchkov, Oleksandra Stasyshyn, Vassily Mamonov, Myung-Shin Oh, Miranda Chapman, Borislava Pavlova, Wing-Yen Wong, Briiggit Abbuehl (Poland)

PB 3.50-1  Tyrosine phosphorylation of macrophage factor XIII-A: a potential mechanism for controlling intracellular enzyme activation and localization  
Paul Cordell, Kerrie Smith, Richard Pease, Peter Grant (United Kingdom)

PB 3.50-2  Biochemical and numerical simulation of thrombin decay  
Romy Kremers, Laurent Crépin, Sébastien Kerdélo, Rob Wagenvoord, Coenraad Hemker (The Netherlands)

PB 3.50-3  Hemostatic status pre - post intracoronary injection of peripheral blood stem cells in patients with recent myocardial infarction  
Irawan Cosphiadi, Teguh Santoso, Agus Kosasih, Djumhana Atmakusumah, Setiawan Lyana, A. Abdulmuthalib, Reksodiputro Harryanto, Azis Auda, Idrus Alwi, Aru Sudoyo (Indonesia)

PB 3.50-4  Successful use of recombinant activated factor VII for a major surgery in a patient with severe FXI deficiency and severe allergic reaction to fresh frozen plasma  
Aysegul Unuvar, Emre Hocaoglu, Omer Devecioglu (Turkey)

PB 3.50-5  The 78 kDa glucose response protein (GRP78) interacts with ATP to inhibit a modified prothrombin time  
Sarah Kamel, Anup Sharma, Xiang-Ming Zhang, Carly Selan, Anushka Samudra, Evelyn Salavaris, Greg Coia, Tim Adams, Peter Cowan, Harshal Nandurkar (Australia)

PB 3.50-6  Post-operative Bridging Therapy in a Tertiary Hospital in Singapore  
Nihar Pandit, Roland Boey, Jackie, Yu Ling Tan, Theresa Choo, Jam Chin Tay (Singapore)

PB 3.51-1  Sensitivity of various aPTT reagent - instrument combinations to dabigatran concentrations  
Rita Selby, Lesley Black, Sumedha Kulkarni, Dina Piraino (Canada)

PB 3.51-2  Bleeding disorders in children presenting with different bleeding symptoms or abnormal coagulation tests--First evaluation results in an out-patient clinic  
Aysegul Unuvar,伊斯al Yildiz, Ibrahim Kamer, Serap Karaman, Ezgi Uysalol, Ayse Kilic, Emin Unuvar, Fatma Oguz (Turkey)

PB 3.51-3  Studies on thrombin generation and thrombelastometry in haemophilic plasma show good correlation at low FVIII levels and the feasibility to use frozen samples of PRP  
Eva Zetterberg, Karin Knobe, Erik Berntorp (Sweden)

PB 3.51-4  Comparison of Hemoclot Thrombin Inhibitor® and activated partial thromboplastin time with a reference UPLC-MS/MS method to monitor patients receiving Dabigatran Etxelate  
Jonathan Douxfils, Paul Hjemdahl, Rickard Malmström, Yuko Ronquist, Olof Beck, Justine Baudar, Jean-François Classen, Christian Chatelain, Bernard Chatelain, François Mullier, Jean-Michel Dogné (Belgium)
Clot waveform analysis in patients with bleeding disorders
Thomas Siegemund, Ute Scholz, Rosemarie Schobess, Annelie Siegemund (USA)

Laboratory monitoring of unfractionated heparin therapy
Dmitry Polokhov, Nataliya Soshitova, Anna Balandina, Elena Orel, Sergey Vasiliev, Alena Gnedova, Fazail Ataullakhanov, Gennadiy Galstian (Russian Federation)

PB 3.52-1 Platelet aggregometer according to the Born method is not suitable to control biological effectiveness of Minirin in the DDAVP test
Stephanie Wördemann, Berthold Siegmund, Hartmut Pollmann (Germany)

PB 3.52-2 Effect of eculizumab administrations on the haemostatic changes in patients with paroxysmal nocturnal hemoglobinuria
Elena Seregina, Olga Nikulina, Nina Tsvetaeva, Anna Balandina, Fazoi Ataullakhanov (Russian Federation)

PB 3.52-3 Evaluation of assay performance monitoring direct Thrombin Inhibitors with TECHNOCLOT® DTI in plasma samples contaminated with indirect thrombin inhibitors
Lieselottte Wagner, Nikolaus Binder, Martina Leitner, Michael Riha (Austria)

PB 3.52-4 Application of an automated genotyping system (Verigen®) in a thromboembolic disease unit
Pilar Gallego, Ana Martínez, Juan Cerezo-Manchado, José Padilla, Gloria Soler, Noelia Navarro, Vicente Vicente, Vanessa Roldán, Rocio González-Conejero (Spain)

PB 3.52-5 Evaluation of the Grifols Q Analyzer for routine and special hemostasis tests
Silmara Montalvao, Barbara Silva, Alini Camargo, Tania De Fatina, Susan Kely Picoli, Elaine Pereira, Joyce Maria Annichino-Bizzacchi, Erich Vinicius (Brazil)

PB 3.52-6 Apixaban: Safety, usefulness and practical details of laboratory monitoring
Jonathan Douxfils, Jean-François Classen, Justine Baudar, Sébastien Walbrecq, Christian Chatelain, Bernard Chatelain, Jean-Michel Dogné, François Mullier (Belgium)

PB 3.53-1 Haemostatic abnormalities in patients with Noonan syndrome
Andrea Artoni (Italy)

PB 3.53-2 The impact of blood sampling and major surgery on plasma levels of thrombin and activated protein C
Jens Müller, Max Friedrich, Heiko Rühl, Tobias Becher, Tina Kupper, Johannes Oldenburg, Günter Mayer, Bernd Pötzschn (Germany)

PB 3.53-3 Von Willebrand factor and factor VIII inhibitor testing
Thomas Siegemund, Ute Scholz, Annelie Siegemund (USA)

PB 3.53-4 Application of turbidity monitoring by combined activated partial thromboplastin time and waveform analysis to characterize heterogeneity of hemophilia plasma response to recombinant factor VIII
Lilley Leong, Philip Ramsey, Derek Sim, Chandra Patel, John Murphy, Volker Laux (USA)

PB 3.53-5 Six SIGMA metric seems not to be applicable as a good quality tool for most laboratory tests of haemostasis
Marta Martinuzzo, Luis Barrera, María Cheluja, María D’Adamo, Juan Otaso, María Gimenez, Jose Oyhamburu (Argentina)
**ePOSTERS (B)**

**Wednesday, July 3, 2013**

17:00 – 18:30

**PB 3.53-6**

**Whole blood thromboelastometry and aggregometry in obese patients**

Elena Campello, Zabeo Eva, Spiezia Luca, Prandoni Paolo, Vettor Roberto, Simioni Paolo (Italy)

**Factor II/Prothrombin - II**

Screen 54

**Moderator:** Barbara Zarzycka (The Netherlands)

**PB 3.54-1**

**Des-gamma-carboxyprothrombin (PIVKA-II) in fetus and newborns**

Tomizo Nishiguchi, Takakazu Kawamura, Aki Kamo, Midori Sugiyama, Naohiro Kanayama, Takao Kobayashi, Satoshi Ibara (Japan)

**PB 3.54-2**

**The effect of the variant F2C20209T on the detection of the mutation F2G20210A**

Immaculada Coll, Isabel Tirado, Elisabeth Martínez-Sanchez, Juan Carlos Souto, Jordi Fontcuberta (Spain)

**PB 3.54-3**

**Differentiation of newer oral anti-Xa and Anti-IIa agents with a reference to the regulatory function of thrombin**

Jawed Fareed, Debra Hoppensteadt, Jeanine Walenga, Walter Jeske, Omer Iqbal, Angel Gray, Bruce Lewis (USA)

**PB 3.54-4**

**Protein-peptide docking of human thrombin: towards improved imaging in cardiovascular disease**

Barbara Zarzycka, Sander Nabuurs, Pieter van den vijver, Gert Vriend, Tilman Hackeng, Gerry Nicolaes (The Netherlands)

**PB 3.54-5**

**Thrombin generation assay in a patient with acquired factor V deficiency**

Claudia Radu, Sabrina Gavasso, Cristiana Bulato, Elena Campello, Elisabetta Castoldi, Paolo Simioni (Italy)

**PB 3.54-6**

**Effects of camel milk on platelet function and coagulation parameters in streptozotocin diabetic rats**

Abdelgalil Abdelgadir, Aida Korisha, Abdulqader Alhaider (Saudi Arabia)

**Coagulation factor VIII - V**

Screen 55

**Moderator:** Inge Rietveld (The Netherlands)

**PB 3.55-1**

**Elevated plasma factor VIII enhances venous thrombus formation and propagation in rabbits: Contribution of thrombin, factor XI, von Willebrand factor and tissue factor**

Chiihiro Sugita, Atsushi Yamashita, Yunosuke Matsuura, Takashi Iwakiri, Tomoko Matsumoto, Osamu Inoue, Takehisa Kitazawa, Kunihiro Hattori, Midori Shima, Yuiro Asada (Japan)

**PB 3.55-2**

**Risk of venous thrombosis associated with coagulation factor VIII levels and the interrelation of other procoagulant and environmental risk factors**

Inge Rietveld, Willem Lijfering, Mettine Bos, Frits Rosendaal, Pieter Reitsma, Suzanne Cannegieter (The Netherlands)

**PB 3.55-3**

**Characterization of a panel of Anti-FVIII Antibodies by domain specificity assignment, pairwise epitope overlap analysis, and determination of affinities for FVIII and rFVIIIFc**

Zhiqian Lucy Liu, Allison Goodman, Robert Peters, John Kulman (USA)

**PB 3.55-4**

**Preclinical safety of a longer acting recombinant factor VIII (BAX 855)**

Barbara Dietrich, Frank Horling, Margit Spatzenegger, Christina Piskernik, Martin Wolfsegger, Hartmut Ehrlich, Friedrich Scheiflinger, Hans-Peter Schwarz, Birgit Reipert, Eva-Maria Muchitsch (Austria)

**PB 3.55-5**

**Comparing projected prophylactic consumption and effects of recombinant factor VIII Fc Fusion (rFVIIIFc) and shorter half-life FVIII products in haemophilia**

Sangeeta Krishnan, Alec Miners (USA)
ePOSTERS (B)

Wednesday, July 3, 2013  17:00 – 18:30

PB 3.55-6  PEGylated biopharmaceuticals and safety evaluation of polyethylene glycol (PEG) with focus on PEG-rFVIII
Reinhard Stidl, Barbara Dietrich, Frank Horling, Margit Spatzenegger, Eva-Maria Muchitsch, Mary Bossard, Friedrich Schefflinger, Hartmut Ehrlich, Peter Turecek [Austria]

Tissue factor - III
Screen 56
Moderator: Linhua Yang [China]

PB 3.56-1  The retention and release of tissue factor by endothelial cells results in the differential activation of p38-MAPK and influences the fate of the cells
Camille Ettelaie, Azza ElKeeb, Anthony Maraveyas, Mary Collier [United Kingdom]

PB 3.56-2  Human neutrophils express tissue factor in peritonitis
Souad Lakbakbi, Alexandre Debrumetz, Philippe Rieu, Philippe Nguyen [France]

PB 3.56-3  Plasma levels of bone morphogenetic proteins and circulating monocyte tissue factor in individuals with echolucent and echogenic carotid atherosclerosis
Mikhail Sovershaev, Timofey Sovershaev, Elena Egorina, Vladimir Bogdanov, John-Bjarne Hansen, Mikhail Sovershaev [Norway]

PB 3.56-4  Tissue Factor is expressed by osteosarcoma and regulates IL-8 expression
Chris Tieken, Henri Versteeg [The Netherlands]

PB 3.56-5  Detection of tissue factor bearing microparticles and the study of the clinical significance in the haemostatic dysfunction of acute myeloid leukemia
Linhua Yang, Sijun Bai, Zhiping Guo, Yaofang Zhang [China]

PB 3.56-6  Oral anti-factor Xa and factor IIa agent mediated inhibition of tissue-factor mediated generation of thrombin in prothrombin complex concentrates
Daneyal Syed, Debra Hoppensteadt, Daniel Kahn, Job Harenberg, Jawed Fareed [USA]

Fibrinogen/Fibrin - IV
Screen 57
Moderator: Dennis Galanakis [USA]

PB 3.57-1  Fibrinogen Geisinger, γW335C: impaired self-assembly, diminished clot stiffness, accelerated clot lysis, and association with thrombophilia
Dennis Galanakis, Marguerite Neerman-Arbez, Thomas Sheiner, Albert Quiery, Ying Liu, Liudi Zhang, Marilyn Manco-Johnson, Miriam Rafailovich, John Weisel [USA]

PB 3.57-2  The spectrum of mutations associated with hereditary fibrinogen disorders in the UK
Marian Hill, Rashmi Seth, Ben Gordon, N. Patel, Emma Nicholson, Tait Campbell, Gerry Dolan [United Kingdom]

PB 3.57-3  Progression in D-Dimer and biomarkers of fibrin formation correlate with outcome in sepsis
Julien Toh, Gie Ken-Dror, Colin Downey, Simon Abrams [United Kingdom]

PB 3.57-4  Impairment of fibrin properties resulting from coagulopathy at haemodilution and its reverse by a fibrinogen concentrate Haemocomplettan® (RiaStap®)
Shu He, Hans Johnsson, Michal Zabczyk, Kjell Hultenby, Håkan Wallen, Margareta Blomback [Sweden]

PB 3.57-5  Global development plan for a double virus inactivated fibrinogen concentrate for the treatment of congenital fibrinogen deficiency
Oliver Hegener, Bruce Schwartz, Sigurd Knaub [Switzerland]
Acquired hypofibrinogenemia assessed by whole blood thromboelastometry profiles in children with acute lymphoblastic leukemia treated with l-asparaginase
Luca Spiezia, Maria Caterina Putti, Maria Teresa Sartori, Elena Campello, Maria Bon, Sara Maggiolo, Stefania Varotto, Giulia Geranio, Giuseppe Basso, Paolo Simioni (Italy)

Other coagulation factors - III
Screen 58
Moderator: Agon Hyseni (The Netherlands)

Platelet uptake of recombinant factor VIIa takes place in vivo but does not prolong its circulating half-life
Agon Hyseni, Anne Marieke Schut, Mark Roest, Ton Lisman, Philip de Groot (The Netherlands)

A fusion of thrombin-activatable FVII and soluble tissue factor displays improved activity and pharmacokinetic properties compared to activated FVII
Joe Salas, Siyuan Tan, Elena Kistanova, Tamera Ashworth, Kai Chen, Marisol Acosta, Robert Pape, Glenn Pierce, Haiyan Jiang, Robert Peters, Brad Johnson, David Light (USA)

Hemostatic effect of an anti-TFPI peptide in a murine model of hemophilic joint bleeding
Narine Hakoby, Lin Cong, Rudolf Hartmann, Fritz Scheifling, Michael Dockal, Leonard Valentino (USA)

Structure and function of chicken protein C inhibitor
Tatsuya Hayashi, Nobuyuki Akita, Takayuki Okamoto, Junji Nishioka, Koji Suzuki (Japan)

Fibrinogen protects activated factor XIII from early inactivation in human plasma
Jens Müller, Rosa Krammer, Heiko Rühl, Johannes Oldenburg, Bernd Pötzsche (Germany)

Novel mutation of factor XII gene in five Taiwanese families of congenital factor XII deficiency
Ming-Ching Shen, Ching-Yeh Lin, Shyuann-Yuh Lin, Cheng-Shyong Chang, Chuan-Cheng Wang, Bo-Do Lin, Han-Ni Hsieh (Taiwan)

Regulation of coagulation and fibrinolysis - III
Screen 59
Moderator: Katharina Hess (Germany)

An additional pathway for hypofibrinolysis in diabetes: The role of complement C3
Katharina Hess, Saad Alzahrani, Jackie Price, Mark Strachan, Paul Baxter, Toby Gamlen, Nikolaus Marx, Verena Schroeder, Rhodri King, Ramzi Ajjan (Germany)

Specific detection of polyphosphate in cells, tissues, and thrombi
Richard Travers, Sharon Choi, James Morrissey (USA)

Serpins interfering with procoagulant activity and pressure regulation in a basal vertebrate
Hermann Ragg, Yunjie Wang (Germany)

Glycan associated functional changes of desialylated, deglycosylated and recombinant acutobins
Iinn-Ho Tsai, Ying-Ming Wang, Kay-Hooi Khoo, Jin-Mei Chen (Taiwan)

An ex vivo evaluation of the hemostatic effects of plasma-derived C1 inhibitor
Jerold Levy, Fania Szlam, Steven Gelone (USA)

How aspirin inhibits human cyclooxygenase-1 hybrid quantum mechanical/molecular mechanical (QM/MM) calculations on the mechanism
Istvan Komaromi, László Tóth, László Muszbek (Hungary)
Wednesday, July 3, 2013

Cancer and thrombosis - VII

Moderator: Georgios Bozas [United Kingdom]

PB 3.60-1  Coagulation factors V and X gene polymorphisms are associated with breast cancer risk and correlate with phenotype
Mari Tinholt, Marthe Kathrine Viken, (OSBREAC) Oslo Breast Cancer Consortium, Kristine Kleivi Sahlberg, Sandra Nyberg, Grethe Skretting, Anders Erik Dahm, Benedicte Alexandra Lie, Per Morten Sandset, Nina Iversen [Norway]

PB 3.60-2  Biomarkers predictive of venous thromboembolism in patients with high grade gliomas
Johannes Thaler, Cihan Ay, Alexandra Kaider, Eva-Maria Reitter, Johanna Haselböck, Christine Marosi, Christoph Zielinski, Ingrid Pabinger [Austria]

PB 3.60-3  Pre-existing pulmonary thrombi in cancer patients diagnosed with an unsuspected pulmonary embolism
Georgios Bozas, Robert Bradley, Ged Avery, Andrew Stephens, Anthony Maraveyas [United Kingdom]

PB 3.60-4  Different patterns of death among cancer patients and venous thromboembolism
Jose Garcia-Alexandra, Patricia Parra- Esquivel, Rafael Lopez-Alonso [Spain]

PB 3.60-5  TF, TFPi and TAT complexes in myeloproliferative neoplasms
Grazyna Gadomska, Katarzyna Stankowska, Joanna Boinska, Wojciech Swistek, Ewelina Drela, Ewa Zekanowska, Danuta Rosc [Poland]

PB 3.60-6  Prolonged LMWH treatment of venous thromboembolism in patients with cancer-A restrospective observational study
Francesco Cortiula, Gianpiero Fasola, Giovanni Barillari [Italy]

Cancer and thrombosis - VIII

Moderator: Talal Altayeb [United Kingdom]

PB 3.61-1  Cerebral venous thrombosis and myeloproliferative neoplasms: results from a combined analysis of 706 patients with cerebral vein thrombosis and 2267 patients with myeloproliferative neoplasms.
Francesco Dentali, Walter Ageno, Elisa Rumi, Daniela Poli, Umberto Scoditti, Matteo Di Minno, Ilaria Cassetti, Mario Cazzola, Francesco Passamonti [Italy]

PB 3.61-2  Low molecular weight heparin in hospitalized cancer patients: A systematic review and pooled analysis of placebo-controlled randomized trials
Marc Carrier, Patricia Moretto, Alok Khorana, Gregoire Le Gal, Jeffrey Zwicker [Canada]

PB 3.61-3  The impact of combined radiation and hormone therapy on the microparticles and tissue factor generation in patients with prostate cancer
Ewa Zekanowska, Ewelina Drela, Danuta Rystok, Tomasz Wisniewski, Ewa Ziólkowska, Paulina Giumza-Kucharska, Danuta Rosc [Poland]

PB 3.61-4  The impact of prophylactic heparin on survival in cancer patients: A meta-analysis
David Sanford, Abhishek Naidu, Neda Alizadeh, Alejandro Lazo-Langner [Canada]

PB 3.61-5  Pro-coagulant activity of malignant ascites
Talal Altayeb, Leigh Madden, John Edward Hartley, Anthony Maraveyas [United Kingdom]

PB 3.61-6  Clinical profiles of DIC patients with bone marrow carcinoma, aiming for earlier diagnosis and treatment to improve their prognosis
Yoshinobu Seki, Kunihiko Wakaki [Japan]
**Antiphospholipid - IV**  
*Screen 62*

**Moderator: Christine Sabapathy (Canada)**

**PB 3.62-1**  
**Antiphospholipid syndrome in children**  
Christine Sabapathy, Senq-J Lee, Julie Barsalou, Patcharee Komwilaisak, Suzan Williams, Mahendranath Moharir, Earl Silverman, Deborah Levy, Leonardo Brandão (Canada)

**PB 3.62-2**  
**RAPS: A prospective randomised controlled phase II/III clinical trial of rivaroxaban versus warfarin in patients with thrombotic antiphospholipid syndrome, with or without SLE**  
Hannah Cohen, Caroline Dore, Simon Clawson, Beverley Hunt, Munther Khamashta, Samuel Machin, Nicola Muirhead (United Kingdom)

**PB 3.62-3**  
**Contribution of immunoregulatory cytokines in the pathogenesis of primary antiphospholipid syndrome**  
Teresa Iwaniec, Bogdan Jakiela, Magdalena Celinska-Lowenhoff, Jakub Swadzba, Jacek Musial, Agnieszka Padjas (Poland)

**PB 3.62-4**  
**Pro-inflammatory and pro-thrombotic markers in antiphospholipid antibody positive patients: subgroup analysis from an open-label prospective pilot study**  
Rohan Willis, Doruk Erkan, Vijaya Murthy, Gurjot Basra, JoAnn Vega, Patricia Ruiz-Limon, Ana Laura Carrera-Marín, Shradhha Jatwani, Emilio Gonzalez, Silvia Pierangelii (USA)

**PB 3.62-5**  
**Laboratory evaluation of antiphospholipid antibodies: have the recommended guidelines for diagnosing antiphospholipid syndrome been followed**  
Sandra Margetic, Andrea Tesija Kuna, Ines Vukasovic, Nada Vrkic (Croatia)

**Arterial vascular disorders - IV**  
*Screen 63*

**Moderator: Katherine Bridge (United Kingdom)**

**PB 3.63-1**  
**The ABO, non-O blood groups and their association with hematoma growth in acute intracerebral hemorrhage**  
Isabel Tirado, Immaculada Coll, José Mateo, Joan Martí-Fabregas, Montserrat Borrell, Raquel Delgado-Mederos, Jordi Fontcuberta (Spain)

**PB 3.63-2**  
**Pathomechanism of reobstruction after endovascular treatment of the superficial femoral artery: Impact of inflammatory cells**  
Klara Belaj, Martin Pichler, Gerald Hackl, Philipp Eller, Marianne Brodmann, Thomas Gary (Austria)

**PB 3.63-3**  
**Presence of organized thrombus in coronary aspirated materials is a predictor of in-hospital mortality in patients with acute myocardial infarction**  
Kensaku Nishihira, Kinta Hatakeyama, Yoshisato Shibata, Yujiro Asada (Japan)

**PB 3.63-4**  
**Correlation between burst of thrombin and microvascular obstruction (no reflow) during ST Elevation Myocardial Infarction treated by primary percutaneous coronary intervention**  
Ludovic Drouet, Vincent Spagnoli, Emilie Klein, Georgios Sideris, Caren Brumpt, Nikos Magkoutis, Natacha Berge, Claire Bal dit Sollier, Patrick Henry (France)

**PB 3.63-5**  
**Thrombophilic risk factors predisposing to thrombosis in patients suffered from ocular arterial occlusions**  
Jerzy Dropinski, Agnieszka Kubicka-Trzaska, Teresa Domagala, Marek Sanak, Jacek Musial (Poland)
ePOSTERS (B)

**Wednesday, July 3, 2013 17:00 – 18:30**

**Diagnosis of venous thrombosis - V**

**Screen 64**

**Moderator:** Kerry Hitos (Australia)

**PB 3.64-1**

**Hestia criteria with the POMPE-C tool identifies patients with cancer and pulmonary embolism at very low risk for short-term complications**

Jeffrey Kline, Christopher Kabrhel, Daren Beam (USA)

**PB 3.64-2**

**Prevention of venous thromboembolism after major trauma: efficacy of prophylactic measures and associated bleeding complications**

Kerry Hitos, Jeremy Hsu, John Fletcher (Australia)

**PB 3.64-3**

**A swine model for pulmonary embolism with autologous clot mimicking sub-massive PE**

Daren Beam, Johnathan Tune, Michael Sturek, Jeffrey Kline (USA)

**PB 3.64-4**

**Clinical outcome and prognostic factor of cerebral venous sinus thrombosis in Siriraj hospital**

Yingyong Chinthammitr, Thitirat Bhurihirun (Thailand)

**PB 3.64-5**

**Implementation of a venous thromboembolism prophylaxis program in Brazilian hospitals: VTE Safety Zone Brazil**

Ana Rocha, Liane Tandeitinik, Jorge Timi, Alex Macedo, Wille Oigman, Marcelo Paiva, João Pantoja, José Carlos Anjos (Brazil)

**PB 3.64-6**

**The influence of the thrombotic burden on D-dimer plasma levels in acute symptomatic deep vein thrombosis of the lower limbs**

Benilde Cosmi, Cristina Legnani, Michela Cini, Giuliana Guazzaloca, Giuseppina Rodorigo, Lelia Valdrè, Michelangelo Sartori, Gualtiero Palareti (Italy)

**Hormones, pregnancy, women’s issues - III**

**Screen 65**

**Moderator:** Michael Creagh (United Kingdom)

**PB 3.65-1**

**Does systematic risk assessment in pregnancy identify women at risk for venous thromboembolism and so avoid thrombosis? Experience of an 18 month programme based on national guidance**

Michael Creagh, Alexandra Dehnel, Liadin Rider, Andrew McSorley, Philip Carson, Aylur Rajasri (United Kingdom)

**PB 3.65-2**

**Incidence of pregnancy outcomes in the conventionally treated purely obstetric antiphospholipid syndrome, pregnancy loss subtype: the NOH-APS observational study**

Jean-Christophe Gris, Sylvie Bouvier, Eva Cochery-Nouvellon, Géraldine Lissalde-Lavigne, Eric Mercier, Eve Moustic, Jean-Pierre Balducchi, Pierre Marès (France)

**PB 3.65-3**

**Prevalence of hereditary thrombophilia is the highest in women who developed pregnancy related thrombosis during first trimester**

Jelena Bodrozic, Predrag Miljic, Miroslava Gajnic, Valentina Djordjevic (Serbia)

**PB 3.65-4**

**Protein Z deficiency and Lipoprotein [a] increase are the most frequent abnormalities in women with recurrent miscarriage**

Frauke Bergmann, Heike Groening, Sandra Frohne, Florian Guenther, Katrin Luttkus, Andreas Czwalinna (Germany)

**PB 3.65-5**

**Elevated endogenous thrombin potential prior to clinical diagnosis of preeclampsia**

Sabrina Schweinzger, Eva Christine Weiss, Axel Schlagenhauf, Bettina Leschnik, Heike Bernhard, Harald Haidl, Wolfgang Muntean, Uwe Lang (Austria)
PB 3.65-6  Effect of Prophylaxis with LMWH on implantation in women undergoing assisted reproductive procedures (IVF or ICSI): An interim report of a prospective randomized study
Daniela Tormene, Francesca Viganò, Libera Falcone, Stefano Gava, Michele Gangemi, Paolo Simioni [Italy]

PB 3.66-1  New insight on the Systemic Inflammation Response Syndrome (SIRS) in STEMI patients undergoing primary percutaneous intervention: Clinical features, blood markers, and prognostic significance.
Pierre Théroux, The Minh Luong, José Nicolau, Arnaud Bonnefoy [Canada]

PB 3.66-2  Do therapeutic infliximab concentrations influence TAFI and PAI-1 plasma levels in IBD patients?
Lize Bollen, Niels Vande Casteele, Miet Peeters, Paul Declerck, Séverine Vermeire, Ann Gils [Belgium]

PB 3.66-3  Pulmonary tuberculosis is associated with a systemic but not intrapulmonary procoagulant state
Liesbeth Kager, Dana Blok, Ivar Lede, Paul Bresser, Jaring van der Zee, Joost Meijers, Aniruddha Ghose, Cornelis van ’t Veer, Tom van der Poll [The Netherlands]

PB 3.66-4  Blood cell response to a fatty meal in healthy subjects at different degree of cardiovascular risk: Effect of orange juice intake
Chiara Cerletti, Chiara Tamburrelli, Francesco Gianfagna, Marco D’Imperio, Amalia De Curtis, Roberto Lorenzet, Domenico Rottilo, Licia Iacoviello, Giovanni De Gaetano, Maria Benedetta Donati [Italy]

PB 3.66-5  Higher thrombin generation during the luteal phase of a normal menstrual cycle does not depend on inflammatory activity
Roza Chaireti, Anders Larsson, Katarina Bremme, Tomas Lindahl [Sweden]

PB 3.66-6  Coagulation profile in patients with H1N1 influenza A infection undergoing treatment for haematological malignancies
Joanna Rupa-Matysek, Lidia Gil, Ewelina Wojtasinska, Katarzyna Zajdel, Katarzyna Ciepluch, Mieczyslaw Komarnicki [Poland]

Inherited risk factors venous thrombosis: Clinical
Screen 67
Moderator: Antonella Tufano [Italy]

PB 3.67-1  Molecular analysis of SERPINC1 abnormalities in 19 Japanese patients with hereditary antithrombin deficiency
Io Kato, Yumi Ando, Yuki Takagi, Atsu Suzuki, Eriko Okuyama, Moe Murata, Akira Takagi, Tadaaki Matsushita, Tadaaki Nakashima, Tetsuhito Kojima [Japan]

PB 3.67-2  Non-O blood group as a risk factor for cerebral venous thrombosis
Antonella Tufano, Antonio Coppola, Assunta Nardo, Carlo Bonfanti, Silvia Crestani, Francesco Frattini, Matteo Di Minno, Ernesto Cimino, Anna Maria Cerceone, Massimo Franchini [Italy]

PB 3.67-3  Thrombophilic and systemic risk factors in patients with central retinal vein occlusion
Jerzy Dropinski, Marek Sanak, Agnieszka Kubicka-Trzaska, Teresa Iwaniec, Teresa Domagala, Jacek Musial [Poland]
A case of protein S deficiency caused by compound heterozygous mutations in PROS1 gene
Edyta Odnoczko, Beata Baran, Barbara Vertun-Baranowska, Johannes Oldenburg, Jerzy Windyga (Poland)

Antithrombin-deficiency and pregnancy: Report of four cases
Peter Ilonczai, Ágota Schlammadinger, Anna Selmeczi, Zsolt Oláh, Adrienne Kerényi, Zsuzsanna Bereczky, Róbert Póka, Zoltán Boda (Hungary)

Genetic background analysis of protein C deficiency type I and type II in 26 Portuguese families
Teresa Fidalgo, Patricia Martinho, Ramon Salvado, Catarina Silva Pinto, Ana Cristina Oliveira, Elsa Gonçalves, Dalila Marques, Teresa Sevivas, Natália Martins, Maria Letícia Ribeiro (Portugal)

FondaKIDS II: Long-term follow-up data of children receiving Fondaparinux for treatment of venous thromboembolic events
Guy Young, Carlo Michieli, Laura Bernardini, Richard Ko (USA)

Safety and efficacy outcomes of home and hospital warfarin management within a paediatric anticoagulation clinic
Sophie Jones, Siobhan McLoughlin, Dana Piovesan, Helen Savoia, Paul Monagle (Australia)

Pediatric stroke: A single center experience
Elif Sobu, Nihal Ozdemir, Gulen Tuysuz, Zehra Hasiloglu, Ayse Buyru, Serap Uysal, Tiraje Celkan (Turkey)

Demonstration of Construct Validity of the KIDCLOT PAC QL®
Aisha Bruce, Sophie Jones, Patti Massicotte, Mary Bauman (Canada)

Decreased Protein S Activity in Ulcerative Colitis but not Crohn Disease in a pediatric cohort

Antithrombin concentrate in pediatric patients requiring heparin anticoagulation: a retrospective cohort study
Mary Bauman, Lindsay Ryerson, Stefan Kuhle, Aisha Bruce, Patti Massicotte (Canada)

Evaluation of a unique mHealth Web-Based VKA management system
Mary Bauman, Adam Seniuk, Suzanne Siddons, Aisha Bruce, Patti Massicotte (Canada)

Anticoagulation of pulmonary hypertension in children
Kate Monagle, Sophie Jones, Ingrid King, Robert Weintraub, Paul Monagle, Fiona Newall (Australia)

Clinical characteristics of pediatric and adolescent index cases with antithrombin deficiency: results of a cohort study
Verena Limperger, André Franke, Susanne Holzhauer, Daniela Manner, Ralf Junker, Ulrike Nowak-Göttl (Germany)
PB 3.69-4  Clinical experience with recombinant tissue plasminogen activator in the management of intracardiac and arterial thrombosis in children
Mustafa Buyukavci, Hasim Olgun, Zuhal Keskin Yildirim, Ibrahim Caner, Naci Ceviz, Irfan Oguz Sahin (Turkey)

PB 3.69-5  Can we predict poor outcome in neonatal arterial ischemic stroke by testing for the presence of a prothrombotic risk factor (inherited or acquired)?
Veerle Labarque, Leonardo Brandao, Gabrielle DeVeber, Rand Askalan, Daune MacGregor, Mahendranath Moharir (Belgium)

PB 3.69-6  Anticoagulation therapy in pediatric Lemierre’s syndrome
Femke van Herrewegen, Jonathan Coutinho, Jan Stam, Heleen van Ommen (The Netherlands)

Recurrent venous thrombosis - III  Screen 70
Moderator: Richard White (USA)

PB 3.70-1  The use of the REVERSE study clinical prediction rule for risk stratification after initial anticoagulation results in decreased recurrences in patients with idiopathic venous thromboembolism
Alejandro Lazo-Langner, Jameel Abdulrehman, Jay Taylor, Shobha Sharma, Michael Kovacs (Canada)

PB 3.70-2  Outcomes after vena cava filter (VCF) placement in patients with acute venous thromboembolism (VTE)
Richard White, Zhongmin Li, Ann Brunson, Ted Wun, Patrick Romano (USA)

PB 3.70-3  External validation and updating of the Vienna Prediction Model for recurrent venous thromboembolism using a pooled individual patient data database
Maura Marcucci, Sabine Eichinger, Alfonso Iorio, James Douketis, Alberto Tosetto, Trevor Baglin, Mary Cushman, Gualtiero Palareti, Daniela Poli, Tait Campbell, Paul Kyrle (Canada)

PB 3.70-4  Risk factors of recurrent thromboembolism during pregnancy
Päivi Galambosi, Veli-Matti Ulander, Risto Kaaja (Finland)

PB 3.70-5  Risk factors for recurrence after the first venous thromboembolic event in women
Gorana Mitic, Mirjana Kovac (Serbia)

PB 3.70-6  Pulmonary embolism severity index accurately predicts long-term mortality rate in patients hospitalized for acute pulmonary embolism
Francesco Dentali, Nicoletta Riva, Sara Turato, Alessandro Squizzato, Stefano Grazioi, Luigi Steidl, Luigina Guasti, Anna Maria Grandi, Walter Ageno (Italy)

Regulation of gene expression in vascular cells  Screen 71
Moderator: Robert Turnbull (United Kingdom)

PB 3.71-1  Aspirin influences megakaryocytes gene expression leading to MRP4 up-regulation in human platelets
Isabella Massimi, Raffaella Guerriero, Lavinia Vittoria Lotti, Valentina Lulli, Flavia Temperilli, Alessandra Borgognone, Marco Gabbianelli, Fabio Maria Pulcinelli (Italy)

PB 3.71-2  Deteriorative effects of a mutant mitochondrial fission protein on calcium and energy homeostasis
Vincenzo Leo, Thomas Cahill, Houman Ashrafian, Chris Peers, John Boyle, Neil Dear (United Kingdom)
**PB 3.71-3** Diet modification in conjunction with regulatory immune response to a combination of ApoB and HSP60 Peptides controls progression of atherosclerotic lesions in Apobtm2SgylDLrtm1Her/J mice  
Lakshmi Mundkur, Rupak Mukhopadhyay, Meenakshi Varma, Sonia Samson, Daxin Chen, Xinjie Lu, Vijay Kakkar (India)

**PB 3.71-4** Aspirin inhibits the platelet-mediated expression of antithrombotic genes in monocytes  
Robert Turnbull, Julian van Capelleveen, Unni Krishnan, Joy Wright, Nilesh Samani, Mieke Trip, Suthesh Sivapalaratnam, Alison Goodall (United Kingdom)

**PB 3.71-5** Establishment of a Lentiviral vector encoding human HGF and the infection of human ADSCs  
Xiaoyu Zhu, Xin Liu, Jingsheng Wu, Weibo Zhu, Xiaoyan Cai, Zimin Sun (China)

**PB 3.71-6** Monocyte contribution to thrombus mass and stability through gene expression  
Robert Turnbull, Sameer Kumani, Alison Goodall (United Kingdom)

### Thrombophilia – IV

*Screen 72*

**Moderator: Jason Jundt [USA]**

**PB 3.72-1** Peripheral arterial thrombosis and thrombophilia  
Jason Jundt, Thomas DeLoughery, Amir Azarbal, Gregory Landry, Erica Mitchell, Gregory Moneta, Timothy Liem (USA)

**PB 3.72-2** Budd-Chiari syndrome and TIPS: Analysis of etiology and course of the disease  
Petr Dulícek, Ondrej Renc, Petr Hulek, Petr Sadilek, Vrbacký Filip (Czech Republic)

**PB 3.72-3** Thrombophilia Screening as Part of Preventive Medicine? Single Center Experience  
Galit Sarig, Etab Higazi, Ophir Avizohar, Lisa Rubin, Manfred Green, Benjamin Brenner (Israel)

**PB 3.72-4** Aging induces a thrombophilic phenotype independently from acute medical conditions  
Ferdinando De Negri, Franco Carmassi (Italy)

**PB 3.72-5** Congenital antithrombin deficiency-clinical phenotype in 40 patients  
Tatiana Prigancova, Angelika Batorova, Denisa Jankovicova (Slovakia)

**PB 3.72-6** Multicenter evaluation of the INNOVANCE Free PS Ag assay  
Mechthild Merz, Katharina Madlener, Adriana Mendez, Robert Zimmermann (Germany)

### Recurrent venous thrombosis - IV

*Screen 73*

*Moderator: Alev Karasu [The Netherlands]*

**PB 3.73-1** The risk of recurrent venous thromboembolism after a first surgery-related event: A prospective cohort study  
Lisbeth Eischer, Sabine Eichinger, Paul Kyrle (Austria)

**PB 3.73-2** Prolonged Clot Lysis Time as a potential risk factor for recurrent venous thrombosis; results from THE-VTE follow-up study  
Alev Karasu, Trevor Baglin, Roger Luddington, Caroline Baglin, Frits Rosendaal, Astrid van Hylckama Vlieg (The Netherlands)

**PB 3.73-3** Risk factors for recurrent events in subjects with superficial vein thrombosis in the randomized clinical trial steflux (Superficial thromboembolism fluxum)  
Benilde Cosmi, Massimo Filippini, Fausto Campana, Angelo Ghirarduzzi, Giampiero Avruscio, Davide Imberti, Giuseppe Camporese, Gualtiero Palareti (Italy)
PB 3.73-4  Dyslipidemia and thrombotic complications in patients with venous thromboembolic disease (VTE)
Aránzazu García-Raso, Gabriela Ene, Carolina Miranda, Raquel Mata, Pilar Llamas (Spain)

PB 3.73-5  Medical literature and vena cava filters: From weak to worse, with exceptions
Philippe Girard, Patrick Mismetti, Guy Meyer (France)

PB 3.73-6  Vascular’s involvements in Behçet’s disease
Dianette Hakem, Abdelkrim Berrah, Nacer Ouadahi, Abdelhalim Boudjelida, Malika Boucelma, Dalila Zemmour, Moufida Ibrir, Nabila Hamzaoui, Amine Habouchi, Boudjemaa Mansouri (Algeria)

Coagulation: Miscellaneous - II
Moderator: Paresh Kulkarni (India)

PB 3.74-1  Overview of a global clinical trial programme with turoctocog alfa, a new recombinant factor VIII: the guardian™ programme
Pawel Laguna, Vladimir Vdovin, Lina Rageliene, Lydia Abad Franch, Anders Lindblom (Poland)

PB 3.74-2  Coagulation Factor IX deficiency does not afford protection from pulmonary fibrosis in the experimental murine bleomycin model
Keren Borensztajn, Lin Cong, Charlène François, Bruno Crestani, Joost Daalhuisen, Olivier Christophe, Arnold Spek (France)

PB 3.74-3  New anticoagulants and their effect on platelet function
Jessica Busse, Thomas Eller, Marcus Dittrich, Tobias Flieder, Susanne Alban, Cornelius Knabbe, Ingvild Birschmann (Germany)

PB 3.74-5  Significantly Higher Level of Serum Amyloid A among Acute Coronary Syndrome (ACS) than Stable Angina Pectoris (SAP) Patients in Indonesian Population
Ira Puspitawati, Setyawati Setyawati, Dyah Wulan Anggrahini, Rahma Yantari, Ing Sudana (Indonesia)

PB 3.74-6  Elevated plasma microparticles in chronic obstructive pulmonary disease
Paresh Kulkarni, Pavan Yadav, Jai Samaria, Debabrata Dash (India)
Scientific Programme
Thursday, July 4, 2013
Thursday, July 4, 2013

PLENARY LECTURE 09:45 - 10:30

Plenary Lecture Mondriaan I
Moderator: Suzanne Cannegieter (The Netherlands)

09:45-10:30 Haemophilia care in the 21st century
Amy Shapiro (USA)

PRESIDENTIAL SYMPOSIUM 11:00 – 12:30

Presidential Symposium Mondriaan I
Moderators: Frits Rosendaal (The Netherlands) and Sam Schulman (Canada)

11:00 – 11:30 Evolution of music - Survival of the funkiest
Armand Leroi (United Kingdom)

11:30 – 12:00 Evolution of causal inference - Towards the unraveling of paradoxes
Miguel Hernan (USA)

12:00 – 12:30 Evolution of altruism - Prosocial primates: empathy in animals and humans
Frans de Waal (USA)
Thursday, July 4, 2013

**ABSTRACT SYMPOSIA** 15:30 - 17:00

### Structure-function of factor V

*Emerald*

**Moderator: Rodney Camire (USA)**

15:30 - 16:00  
**Molecular Basis of Factor V Procofactor Activation**  
Rodney Camire (USA)

16:00 - 16:15  
**Alternatively spliced factor V isoform in the east Texas bleeding disorder inhibits coagulation by binding and increasing tissue factor pathway inhibitor alpha (TFPIα) plasma levels**  
Lisa Vincent, Sinh Tran, Tracy Bensend, Dianna Milewicz, Björn Dahlbäck (Sweden)

16:15 - 16:30  
**Site-specific glycan trimming in megakaryocyte-endocytosed factor V**  
Paula Tracy, Mark Jemings II, Kimberly Stringer, Jay Silveira, Jeremy Wood, Adam Blanchard (USA)

16:30 - 16:45  
**Functional characterization of a structural element unique to venom factor V from the Australian common brown snake Pseudonaja textilis**  
Daniel Verhoef, Rodney Camire, Pieter Reitsma, Mettine Bos (The Netherlands)

16:45 - 17:00  
**Regulatory sequence 1000-1008 of human coagulation factor V maintains the procofactor in a quiescent state**  
Joesph Wiencek, Mahesheema Na, Jamila Hirbawi, Michael Kalafatis (USA)

### Signal transduction

*Mondriaan IV*

**Moderator: JoAnn Trejo (USA)**

15:30 - 16:00  
**Signaling and trafficking of PARs**  
JoAnn Trejo (USA)

16:00 - 16:15  
**Role of Class I PI3K α and β in platelet activation and functions: New potential antithrombotic targets?**  
Marie-Pierre Gratacap, Sonia Severin, Pierre-Alexandre Laurent, Gaëtan Chicanne, Béatrice Hechler, Christian Gachel, Julie Guillermé-Guibert, Bart Vanhaesebroeck, Bernard Payrastre (France)

16:15 - 16:30  
**The Epac1-Rap1 pathway regulates Weibel-Palade body exocytosis from endothelial cells through the activation of Rac1 via PREX-1**  
Kathinka van Hooren, Mar Fernandez-Broja, Alexander Meijer, Ruben Bierings, Jan Voorberg (The Netherlands)

16:30 - 16:45  
**Endoplasmic reticulum stress in diabetic nephropathy is mechanistically linked to coagulation protease-activated protein C signaling**  
Madhusudhan Thali, Hongjie Wang, Herman-Josef Gröne, Peter Nawroth, Berend Isermann (Germany)

16:45 - 17:00  
**Junctional adhesion molecule-A suppresses platelet integrin αIIbβ3 signaling by recruiting Csk to the integrin-c-Src complex**  
Meghna Naik, Ulhas Naik (USA)
## Thursday, July 4, 2013

### ABSTRACT SYMPOSIA  15:30 - 17:00

#### Blood coagulation tests  E104-107

**Moderator: Waander van Heerde (The Netherlands)**

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:30 - 16:00</td>
<td>Measurement of anticoagulation status in saliva</td>
<td>Waander van Heerde (The Netherlands)</td>
</tr>
<tr>
<td>AS 38</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:00 - 16:15</td>
<td>Endothelial cell-based fluorogenic thrombin generation assay for the evaluation of the protein C anticoagulant system</td>
<td>Enriqueta Coll, Liza Robles-Carrillo, Eduardo Reyes, John Francis, Ali Amirkhosravi (USA)</td>
</tr>
<tr>
<td>AS 38.1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:15 - 16:30</td>
<td>Defining time in therapeutic range for clinicians: Frequency of dose changes and INR testing as surrogate markers for adequate vitamin K antagonist management</td>
<td>Miriam Kimpton, Gregoire Le Gal, Shemina Kherani, Marc Carrier (Canada)</td>
</tr>
<tr>
<td>AS 38.2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:30 - 16:45</td>
<td>Prothrombin fragment 1 + 2 in urine; a new way of analysing blood coagulation activity</td>
<td>Fredrik Wexels, Ola Dahl, Lars Borris, Are Pripp, Anniken Haslund, Tor Gudmundsen, Ferenc Laszlo, Ingebjørg Seljeflot, Michael Lassen (Norway)</td>
</tr>
<tr>
<td>AS 38.3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:45 - 17:00</td>
<td>Real-time dynamic measurement of hemostasis and fibrinolysis and detection of hemostatic and prothrombotic blood disorders by T2 magnetic resonance</td>
<td>Douglas Cines, Tatiana Lebedeva, Anna Kowalska, Adam Cuker, John Weisel, Joseph Whitten, Lynell Skewes, Vyacheslav Papkov, Thomas Lowery (USA)</td>
</tr>
<tr>
<td>AS 38.4</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Regulation of platelet function  Mondriaan III

**Moderator: Judith Cosemans (The Netherlands)**

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:30 - 16:00</td>
<td>Non-redundant roles of kinase isoforms in platelet activation and thrombus formation</td>
<td>Judith Cosemans (The Netherlands)</td>
</tr>
<tr>
<td>AS 39</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:00 - 16:15</td>
<td>Src-like adapter proteins (SLAPs) are critical negative regulators of GPVI/ITAM-signalling in arterial thrombosis and ischaemic stroke</td>
<td>Deya Cherpokova, Markus Bender, Martina Morowski, Peter Kraft, Sarah Akbar, Cheryl Sultan, Leonard Dragone, Steve Watson, Michael Tomlinson, Bernhard Nieswandt (Germany)</td>
</tr>
<tr>
<td>AS 39.1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:15 - 16:30</td>
<td>Connexin40 regulates platelet function and thrombosis</td>
<td>Sakthivel Vaiyapuri, Leonardo Moraes, Tanya Sage, Marfoua Ali, Martyn Mahaut-Smith, Alexander Simon, Jonathan Gibbins (United Kingdom)</td>
</tr>
<tr>
<td>AS 39.2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:30 - 16:45</td>
<td>CalDAG-GEFI deficiency protects mice from FcγRIIa-mediated thrombotic thrombocytopenia induced by CD40L and β2GPI immune complexes</td>
<td>Ali Amirkhosravi, Yacine Boulaftali, Liza Robles-Carrillo, Steven McKenzie, Todd Meyer, John Francis, Wolfgang Bergmeier (USA)</td>
</tr>
<tr>
<td>AS 39.3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:45 - 17:00</td>
<td>Platelet ITAM signaling is critical for maintenance of vascular integrity during inflammation</td>
<td>Yacine Boulaftali, Paul Hess, Todd Getz, Moritz Stolla, Nigel Mackman, Phillip Owens III, Jerry Ware, Mark Kahn, Wolfgang Bergmeier (USA)</td>
</tr>
<tr>
<td>AS 39.4</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
**Thrombotic microangiopathies**

**Mondriaan II**

**Moderator:** Marina Noris (Italy)

**15:30 - 16:00**

**The spectrum of microvascular thrombosis in TTP and (a)HUS**

Marina Noris (Italy)

**16:00 - 16:15**

**A novel CD46 gene mutation in a patient with normal ADAMTS13 activity and microangiopathy**

Raffaella Rossio, Luca Andrea Lotta, Silvia Pontiggia, Roberta Donadelli, Rossella Piras, Isabella Garagiola, Nicolò Ghiringhelli Borsa, Danijela Mikovic, Massimo Cugno, Flora Peyvandi (Italy)

**15:30 - 16:15**

**Complement activation and cytokine response in TTP**

John-Paul Westwood, Edward Heelas, Katy Langley, Samuel Machin, Marie Scully (United Kingdom)

**16:30 - 16:45**

**Plasmin cleavage of von Willebrand factor; a physiological and therapeutic bypass for ADAMTS13 deficiency and thrombotic microangiopathy**

Claudia Tersteeg, Michel Smeets, Mark Roest, Gerard Pasterkamp, Philip de Groot, Coen Maas (The Netherlands)

**16:45 - 17:00**

**The Phenotype of ADAMTS13 Mutation 4143_4144insA - A study of 11 homozygous cases in Norway**

Anne-Sophie Von Krogh, Johanna Kremer Hovinga, Anders Waage, Geir Tjønnfjord, Petter Quist-Paulsen (Norway)

---

**Natural anticoagulants**

**G104-105**

**Moderator:** Javier Corral (Spain)

**15:30 - 16:00**

**Anticoagulant proteins: Function**

Javier Corral (Spain)

**16:00 - 16:15**

**Protease-activated receptor 3 (PAR3) tethered-ligand peptides derived from non-canonical cleavage at Arg41 by activated protein C provide vascular barrier protective effects in vitro and in vivo**

Laurent Burnier, Laurent Mosnier (USA)

**16:15 - 16:30**

**Direct inhibition of factor Vila by TFPI and TFPI constructs**

Sameer Peraramelli, Stella Thomassen, Alexandra Heinzmann, Jan Rosing, Tilman Hackeng, Rudolf Hartmann, Friedrich Scheiflinger, Michael Dockal (The Netherlands)

**16:30 - 16:45**

**Protective effects of non-anticoagulant activated protein C variant (D36A/L38D/A39V) in a murine model of ischaemic stroke**

James Crawley, Maria Efthymiou, Yao Yu, Helena Watts, Faruq Noormohamed, Daqing Ma, David Lane, Anna Andreou (United Kingdom)

**16:45 - 17:00**

**Identification of a novel pathway for encryption of the endothelial protein C receptor (EPCR) by TNFα that results in loss of activated protein C (APC) binding and induction of cellular APC resistance**

Eveline Bouwens, Laurent Mosnier (USA)
### Diagnosis of deep vein thrombosis and pulmonary embolism

**Moderator: Menno Huisman (The Netherlands)**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Authors/Institutions</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:30 - 16:00</td>
<td><strong>Diagnostic management of deep-vein thrombosis and pulmonary embolism</strong></td>
<td>Menno Huisman (The Netherlands)</td>
</tr>
<tr>
<td>16:00 - 16:15</td>
<td><strong>Age-adjusted D-Dimer for venous thromboembolism exclusion in the elderly:</strong> A systematic review and meta-analysis</td>
<td>Gregoire Le Gal, Marc Carrier, David Keeling, Andrea Penaloza, Renée Douma, Marc Righini (Canada)</td>
</tr>
<tr>
<td>16:15 - 16:30</td>
<td><strong>Safety and feasibility of a diagnostic algorithm combining clinical probability, D-dimer and ultrasonography in suspected upper extremity deep vein thrombosis: A prospective management study</strong></td>
<td>Ankie Kleinjan, Marcello Di Nisio, Jan Beyer-Westendorf, Benilde Cosmi, Giuseppe Camporese, Angelo Ghirarduzzi, Pieter Willem Kamphuisen, Hans-Martin Otten, Ettore Porreca, Harry Büller (The Netherlands)</td>
</tr>
<tr>
<td>16:30 - 16:45</td>
<td><strong>Combined pretest probability assessment for acute coronary syndrome and pulmonary embolism in emergency department patients with chest pain and shortness of breath</strong></td>
<td>Jeffrey Kline, Nathan Shapiro, Alan Jones, Jackeline Hernandez, Melanie Hogg, Jennifer Troyer (USA)</td>
</tr>
<tr>
<td>16:45 - 17:00</td>
<td><strong>Validity of the primary care rule for risk stratification in patients with suspected DVT in Auckland New Zealand</strong></td>
<td>Sarah Hyder, Paul Ockelford, Maelen Tagelagi, Sharon Jackson, Laura Young (New Zealand)</td>
</tr>
</tbody>
</table>

### Non-inherited risk factors for venous thrombosis

**Moderator: Roger Lijnen (Belgium)**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Authors/Institutions</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:30 - 16:00</td>
<td><strong>Obesity and thrombosis</strong></td>
<td>Roger Lijnen (Belgium)</td>
</tr>
<tr>
<td>16:00 - 16:15</td>
<td><strong>Impaired glucose metabolism, assessed by HbA1c, and future risk of venous thromboembolism - The Tromsø study</strong></td>
<td>Bånhild Lerstad, Ellen Brodin, Kristin Enga, Sigrid Brækkan, Rolf Jorde, Inger Njølstad, Johan Svartberg, John-Bjarne Hansen (Norway)</td>
</tr>
<tr>
<td>16:15 - 16:30</td>
<td><strong>Insulin resistance is not independently associated with unprovoked venous thromboembolism. Results from the EDITH case-control study</strong></td>
<td>Aurélien Delluc, Hélène Kerspern, Emmanuelle Le Moigne, Cécile Tromeur, Dominique Mottier, Jean-Luc Carré, Grégoire Le Gal, Karine Lacut (France)</td>
</tr>
<tr>
<td>16:30 - 16:45</td>
<td><strong>Lower leg cast immobilisation and risk of venous thrombosis: results from the MEGA study</strong></td>
<td>Raymond van Adrichem, Jan Debeij, Rob Nelissen, Inger Schipper, Frits Rosendaal, Suzanne Cannegieter (The Netherlands)</td>
</tr>
<tr>
<td>16:45 - 17:00</td>
<td><strong>Acute infection, immobility and venous thromboembolism: An analysis from the RIETE Registry</strong></td>
<td>Stefania Frasson, Gualberto Gussoni, Pierpaolo Di Micco, Micaela La Regina, José Bascuñana, María Luisa Peris, Aurora Villalobos, Adel Merah, Manuel Monreal, for the RIETE Group (Italy)</td>
</tr>
</tbody>
</table>
Inflammation and coagulation axis

Moderator: Tom van der Poll (The Netherlands)

15:30 - 16:00 Immunity and the coagulation system
Tom van der Poll (The Netherlands)

16:00 - 16:15 Akt2 plays a critical role in regulating alphaMbeta2 integrin function and heterotypic platelet-neutrophil interactions during vascular inflammation.
Jaehyung Cho, Jing Li, Kyungho Kim, Eunsil Haehm, Xiaoping Du, Nissim Hay (USA)

16:15 - 16:30 Shedding of protease activated receptor 1 (PAR1) by Streptococcus pyogenes pyrogenic exotoxin B (SpeB) - a novel mechanism to evade host immune system
Reto Schuepbach, Miriam Ender, Federica Andreoni, Andrea Tarnutzer, Annelies Zinkernagel (Switzerland)

16:30 - 16:45 CXCL7 (platelet basic protein) and CXCL4 (platelet factor 4) contribute to the pathogenesis of acute lung injury
Khalil Bdeir, Junjie Mei, Marta Stasiak, Guohua Zhao, Dahlia Kenawy, Czeslaw Cierniewski, Douglas Cines, Mortimer Poncz, Anna Kowalska (USA)

16:45 - 17:00 The P2X1 receptor plays a key role in LPS-induced lethal endotoxemia
Béatrice Hechler, Blandine Maitre, Stéphanie Magnenat, Véronique Heim, Catherine Ravanat, Richard Evans, Christian Gachet (France)

Innovative treatments of haemophilia A and B

Moderator: Alan Mast (USA)

15:30 - 16:00 Alternative strategies for haemophilia treatment
Alan Mast (USA)

16:00 - 16:15 A new class of coagulation factor VIII molecules that achieved four-fold longer half-life than recombinant FVIII in hemophilia A mice
Tongyao Liu, Ekta Seth Chhabra, John Kulman, Lily Zhu, Susannah Patarroyo-White, Douglas Drager, Bob Pape, Nancy Moore, Allison Goodman, Glenn Pierce, Volker Schellenberger, Baisong Mei, Robert Peters, Haiyan Jiang (USA)

16:15 - 16:30 IPSC-based Strategy to Correct the Bleeding Phenotype in Haemophilia A
Maria Talmon, Gabriella Ranaldo, Chantal Grosso, Elvira Cannizzo, Simone Merlin, Angelo Lombardo, Angel Raya, Luigi Naldini, Piercarla Schinco, Antonia Follenzi (Italy)

16:30 - 16:45 Platelet-specific expression of FIX induced by lentiviral gene delivery to hematopoietic stem cells restores hemostasis and induces immune tolerance in hemophilia B mice
Yingyu Chen, Jocelyn Schroeder, Erin Kuether, Robert Montgomery, Qizhen Shi (USA)

16:45 - 17:00 A novel mutation that alters an ubiquitination site on adeno-associated virus serotype (AAV) - 8 capsid improves hepatic coagulation factor IX expression in vivo.
Dwaipayan Sen, Ramya Vijay, Sukesh Nair, Alok Srivastava, Giridhara Jayandharan (India)
## ABSTRACT SYMPOSIA

### Tissue factor, cancer and thrombosis

**Moderator:** Janusz Rak (Canada)

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:30 - 16:00</td>
<td><strong>Tissue factor in brain cancer</strong></td>
<td>Janusz Rak (Canada)</td>
</tr>
<tr>
<td>16:00 - 16:15</td>
<td><strong>Neuronal cell tissue factor contributes to microvascular thrombosis in the brain after injury</strong></td>
<td>Erica Sparkenbaugh, Janice Russell, Michael Tencati, Nigel Mackman, Neil Granger, Rafal Pawlinski (USA)</td>
</tr>
<tr>
<td>16:15 - 16:30</td>
<td><strong>Transient phosphorylation of the cytoplasmic domain of tissue factor at serine 253 promotes its interaction with filamin-A and is prerequisite for tissue factor release into microparticles</strong></td>
<td>Mary Collier, Anthony Maraveyas, Camille Ettelaie (United Kingdom)</td>
</tr>
<tr>
<td>16:30 - 16:45</td>
<td><strong>Alternatively spliced Tissue Factor fuels breast cancer growth by binding to a non-canonical site on beta1 integrins</strong></td>
<td>Begüm Kocatürk, Yascha van den Berg, Chris Tieken, Peter Kuppen, Wolfraum Ruf, Pieter Reitsma, Susanne Osanto, Vladimir Bogdanov, Henri Versteeg (The Netherlands)</td>
</tr>
<tr>
<td>16:45 - 17:00</td>
<td><strong>Alternatively spliced tissue factor contributes to tumor spread and activation of coagulation in pancreatic ductal adenocarcinoma</strong></td>
<td>Vladimir Bogdanov, Ramprasad Srinivasan, Kevin Turner, Dusten Unruh, Xiaoyang Qi, Bruce Aronow, Syed Ahmad, Fred Lucas, Henri Versteeg (USA)</td>
</tr>
</tbody>
</table>

### Late breaking abstracts: New insights

**Moderators:** Tilman Hackeng (The Netherlands) and Frits Rosendaal (The Netherlands)

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:30 - 15:45</td>
<td><strong>Antidote for new oral anticoagulants: Mechanism of action and binding specificity of PER977</strong></td>
<td>Bryan Laulicht, Sasha Bakhru, Xuan Jiang, Lirong Chen, Deng Pan, Michael Grosso, Yoshiyuki Morishima, Karen Brown, Hiroshi Masumoto, James Costin, Solomon Steiner (USA)</td>
</tr>
<tr>
<td>15:45 - 16:00</td>
<td><strong>A case of thrombotic thrombocytopenic purpura and two novel mutations on complement system genes: A new etiology of disease?</strong></td>
<td>Flora Peviani, Raffaella Rossio, Luca Lotta, Silvia Pontiggia, Nicolò Ghiringhelli Borsa, M. Pizzuti, Roberta Donadelli, Marina Noris (Italy)</td>
</tr>
<tr>
<td>16:00 - 16:15</td>
<td><strong>Complement is not activated in nonhuman primates during development of hemolytic uremic syndrome and thrombotic microangiopathy induced by E. coli Shiga toxins</strong></td>
<td>Benjamin Lee, C. Mayer, C. Leibowitz, D. Stearns-Kurosawa, Shinichiro Kurosawa (USA)</td>
</tr>
<tr>
<td>16:15 - 16:30</td>
<td><strong>The interaction between complement factor H and von Willebrand factor increases factor H cofactor activity and regulates von Willebrand factor prothrombotic status</strong></td>
<td>Julie Rayes, Lubka Roumenina, Jordan Dimitrov, Yohann Repessé, Mathieu Ing, Olivier Christophe, Sakari Jokiranta, Lise Halbwachs-Mecarelli, Annie Borel-Derlon, Srinivas Kaveri, Véronique Frémeaux-Bacchi, Sébastien Lacroix-Desmazes (France)</td>
</tr>
<tr>
<td>16:30 - 16:45</td>
<td><strong>Thrombin binds to human ceruloplasmin and proteolytically hinders its antioxidant activity</strong></td>
<td>Vincenzo De Filippis, Laura Acquasaliente, Alexej Sokolov, Valeria Kostевич, Elena Zakharova, Vadim Vasilyev (Italy)</td>
</tr>
<tr>
<td>16:45 - 17:00</td>
<td><strong>A novel gene identified at an erythrocyte quantitative trait locus has a profound effect on thromboocyte formation in zebrafish</strong></td>
<td>Jonathan Stephens, Ana Cvejic, Lonneke Haer-Wigman, Pim van der Harst, Ellen van der schoot, Cornelis Albers, Willem Ouwehand (United Kingdom)</td>
</tr>
</tbody>
</table>
**ORAL COMMUNICATIONS**

**Anticoagulant agents: Clinical studies II**

Moderators: Paolo Prandoni (Italy) and Martin Prins (The Netherlands)

08:00 - 08:15
OC 79.1
**Safety, tolerability, and pharmacokinetics of edoxaban in end-stage renal disease subjects undergoing hemodialysis**
Dolly Parasrampuria, Nobuko Matsushima, Shuquan Chen, Prachi Wickremasingha, Ling He, Vic, Karen Brown (USA)

08:15 - 08:30
OC 79.2
**Apixaban: Determination of its anticoagulant effects and influence on coagulation tests: A multicentre French GEHT study**
Isabelle Gouin-Thibault, Claire Flaujac, Sara Quenet, Marie-Hélène Morellou, Xavier Delavenne, Nicole Lacarrrière, Thomas Lecompte (France)

08:30 - 08:45
OC 79.3
**Comparing new oral anticoagulants (dabigatran, rivaroxaban and apixaban) to warfarin in patients with atrial fibrillation, a cost-effectiveness analysis from a German payer perspective**
Martin Krejczy, Martin Wehling, Svetlana Marx, Konrad Obermann, Job Harenberg (Germany)

08:45 - 09:00
OC 79.4
**Incidence of recurrent venous thromboembolism in patients following completion of the EINSTEIN DVT and EINSTEIN PE studies**
Martin Prins, Petra Erkens, Anthonie Lensing (The Netherlands)

09:00 - 09:15
OC 79.5
**Stopping oral anticoagulation and the risk of thrombotic events and mortality in patients with atrial fibrillation**
Pilar Gallego, Francisco Marin, Marta Romero, Mariano Valdés, Vicente Vicente, Gregory Lip, Vanessa Roldán (Spain)

09:15 - 09:30
OC 79.6
**Venous thromboembolism: An annual European Union 27 cost-of-illness model for the burden of the disease**
Charles Mahan, Alex Woersching, Stefano Barco, Mark Holdsworth, Franco Piovella, Scott Kaatz, Jason Barkemeyer, Graham Turpie, Alex Spyropoulos (USA)

**Basic issues in haemophilia A**

Moderators: Kathelijn Fischer (The Netherlands) and Derek Sim (USA)

08:00 - 08:15
OC 80.1
**Genetic targeting of human coagulation factor VIII into platelet α-granules resulted in long-term improvement of hemostatic function in canine hemophilia A**
David Wilcox, Lily Du, Paquita Nurden, Alan Nurden, Timothy Nichols, Dwight Bellinger, Eric Jensen, Sandra Haberichter, Qizhen Shi, Kenneth Corneita (USA)

08:15 - 08:30
OC 80.2
**Allosteric modulation of the structurally related factor VIIa and IXa proteases is responsible for the procoagulant properties of a novel peptide family**
Karina Thorn, Swapnil Rakhe, Lucy Liu, Garabet Toby, Alan Bitonti, Glenn Pierce, Adam Mezo, Robert Peters (USA)

08:30 - 08:45
OC 80.3
**Pharmacological modulation of the uptake of blood coagulation factor VIII by dendritic cells**
Robin Hartholt, Alexandre Wroblewski, Eszter Herczenik, Anja ten Brinke, Jan Voorberg (The Netherlands)

08:45 - 09:00
OC 80.4
**An epitope-dependent increase in clearance of antigen-antibody complexes may increase the pathogenicity of a subset of anti-C2 factor fVIII antibodies in hemophilia A**
Shannon Meeks, Courtney Cox, Ernest Parker (USA)

09:00 - 09:15
OC 80.5
**Identification and characterization of deep intronic variations causing mild hemophilia A**
Behnaz Pezeshkpoor, Nicole Zimmer, Natascha Marquardt, Indrajit Nanda, Thomas Haaf, Ulrich Budde, Johannes Oldenburg, Osman El-Maarri (Germany)
Thursday, July 4, 2013

**ORAL COMMUNICATIONS**  
**08:00 - 09:30**

09:15 - 09:30  
**OC 80.6**  
**Polyphosphates corrected blood loss in a novel acute tail vein transection hemophilia model**  
Derek Sim, Cornell Mallari, Jim Newgren, Chandra Patel, John Murphy, Volker Laux, Stephanie Smith, James Morrissey (USA)

**Blood coagulation tests**  
**G104-105**

**Moderators:** Marjan van Blerk (The Netherlands) and Steve Kitchen (United Kingdom)

08:00 - 08:15  
**OC 81.1**  
**A next generation sequencing approach for genotyping patients with hemophilia**  
Neil Josephson, Beth Martin, Shelley Nakaya, Barbara Konkle, Alvin Luk, Glenn Pierce, Jay Shendure, Brian O’Roak (USA)

08:15 - 08:30  
**OC 81.2**  
**Developmental hemostasis: Preliminary results of a multicenter study aimed at defining the reference ranges for routine coagulation parameters in pediatric populations**  
Pierre Toulon, Micheline Berruyer, François Grand (France)

08:30 - 08:45  
**OC 81.3**  
**Evidence that the effects of rivaroxaban are dependent on the degree of activation of the coagulation system**  
Cornelis Kluft, Kees van Leuven, Ria Laterveer, Riet Kret, Jacoline Neuteboom, Annelieke Krüthof, Jacobus Burggraaf (The Netherlands)

08:45 - 09:00  
**OC 81.4**  
**Development of a quantitative model of systemic procoagulant condition due to bacterial sepsis**  
Zoe Wong, Owen McCarty, Cristina Puy, Erik Tucker, Stephanie Smith, Sharon Choi, James Morrissey, András Gruber (USA)

09:00 - 09:15  
**OC 81.5**  
**A high performance of Nijmegen-Bethesda assay in therapy to induce immune tolerance for hemophilia patients**  
Silmara Montalvão, Alini Tucunduva, Tania Machado, Susan Quaino, Marina Colella, Erich De Paula, Samuel De Souza Medina, Margareth Ozelo (Brazil)

09:15 - 09:30  
**OC 81.6**  
**A nationwide Belgian survey on the influence of the new oral anticoagulants dabigatran and rivaroxaban on commonly used coagulation assays**  
Marjan van Blerk, Els Bailleul, Bernard Chatelain, Anne Demulder, Katrien Devreese, Jonathan Douxfils, Kristin Jochmans, François Mullier, Walter Wijns, Mohamed Soumali (Belgium)

**Cancer and thrombosis**  
**Elicium 1**

**Moderators:** Yunliang Chen (United Kingdom) and Joseph Palumbo (USA)

08:00 - 08:15  
**OC 82.1**  
**The role of a prothrombinase - Fibrinogen-like protein 2 in angiogenesis and tumorigenesis**  
Esther Rabizadeh, Doron Lederfine, Eli Rosenbaum, Ofer Yosipovitz, Aida Inbal (Israel)

08:15 - 08:30  
**OC 82.2**  
**Brain metastasis depends on tumor cell initiated coagulation**  
Laurie Gay, Jonathan Day, Sarah LeBoeuf, Melissa Ritland, Zaverio Ruggeri, Wolfram Ruf, Brunhilde Felding-Habermann (USA)

08:30 - 08:45  
**OC 82.3**  
**The heparin/heparan-sulphate interactome of human breast cancer cells exerts a pro-tumourigenic role associated with activation of the PI3K/Akt and MAPK/ERK signalling pathways**  
Yunliang Chen, Michael Scully, Gloria Dawson, Christopher Goodwin, Xia Min, Lu Xinjie, Ajay Kakkar (United Kingdom)
### Thursday, July 4, 2013

#### ORAL COMMUNICATIONS 08:00 - 09:30

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:45 - 09:00</td>
<td>Systemic venous thrombotic events are associated with significantly increased loss of central venous catheters in pediatric cancer patients: A Multicenter Study</td>
<td>Ketan Kulkarni, Jaqueline Halton, Maria Spavor, Shereck Evan, Israels Sara, Kevin Dietrich, Sharon Abish, Mitchell Lesley (Canada)</td>
</tr>
<tr>
<td>09:00 - 09:15</td>
<td>Coagulant activity and cellular origin of circulating tissue factor exposing microparticles in cancer patients - two forms of TF-exposing microparticles</td>
<td>Ankie Kleinjan, Anita Böing, Marcello Di Nisio, Desiree Twint, Pieter Willem Kamphuisen, Prabath Nanayakkara, Harry Büller, Rienk Nieuwland (The Netherlands)</td>
</tr>
<tr>
<td>09:15 - 09:30</td>
<td>Colon adenocarcinoma cell recruitment to platelets and thrombi under shear</td>
<td>Sandra Baker, Asako Itakura, András Gruber, Owen McCarty (USA)</td>
</tr>
</tbody>
</table>

#### Coagulation factor VII Auditorium

**Moderators:** Giulia Pavani (Italy) and Alizera Rezaie (USA)

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00 - 08:15</td>
<td>Novel insights into the therapeutic mode of action of recombinant FVIIa</td>
<td>Cecilia Augustsson, Egon Persson (Denmark)</td>
</tr>
<tr>
<td>08:15 - 08:30</td>
<td>Multicentre, randomised, double-blinded, active-controlled, cross-over phase 3 trial on safety and efficacy of rFVIIa analogue (vatreptacog alfa) in haemophilia patients with inhibitors (adept™2)</td>
<td>Stephen Lentz, Johnny Mahlangu, Faraizah Abdul Karim, Tatyana Andreeva, Marina Economou, Silke Ehrenforth, Jerzy Windyga (USA)</td>
</tr>
<tr>
<td>08:30 - 08:45</td>
<td>EPCR binding to Factor VIIa enhances its hemostatic function in vivo</td>
<td>Giulia Pavani, Lacramioara Ivanciu, Armida Faella, Paris Margaritis (Italy)</td>
</tr>
<tr>
<td>08:45 - 09:00</td>
<td>Identification of novel platelet-targeting moieties that increase the activity of recombinant factor VIIa without affecting platelet function</td>
<td>Joe Salas, Siyuan Tan, Tamera Ashworth, Elena Kistanova, Kai Chen, Xiangyang Tan, Marisol Acosta, Glenn Pierce, Haiyan Jiang, Robert Peters, Brad Johnson, Bob Pape, David Light (USA)</td>
</tr>
<tr>
<td>09:00 - 09:15</td>
<td>Anti-drug antibody formation induced by recombinant activated FVII analogue (vatreptacog alfa) - results from the phase 3 adept™2 trial in haemophilia patients with inhibitors</td>
<td>Johnny Mahlangu, Faraizah Abdul Karim, Magdalena Gorska-Kosicka, Shipra Kaicker, Tadashi Matsushita, Michael Recht, Margit Serban, Steven Lentz, Karin Nana Weldingh (South Africa)</td>
</tr>
<tr>
<td>09:15 - 09:30</td>
<td>A long-acting FVIIa -CTP proposing an improved prophylactic and on demand treatment for hemophilic patients following SC and IV administration - evaluation in animal models</td>
<td>Gili Hart, Oren Hershkovitz, Ahuva Bar-Ilan, Eyal Fima (Israel)</td>
</tr>
</tbody>
</table>
## Thursday, July 4, 2013

### ORAL COMMUNICATIONS 08:00 - 09:30

#### Fibrinolysis - II  
**E102**

**Moderators: Laura Pepler [Canada] and Dick Rijken [The Netherlands]**

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00 - 08:15</td>
<td>Characterization of knock-in mice harboring a variant of EPCR with impaired ability to bind protein C</td>
<td>Laura Pepler, Dhruva Dwivedi, Patricia Liaw [Canada]</td>
</tr>
<tr>
<td>08:15 - 08:30</td>
<td>Inactivation of FVIIIa in vivo - insights into the physiological down-regulation of haemostasis</td>
<td>Heidi Holmberg, Anne Pastoft, Torben Elm, Gert Bolt, Brian Lauritzen, Henrik Østergaard [Denmark]</td>
</tr>
<tr>
<td>08:30 - 08:45</td>
<td>Modulation of FXa zymogenicity yields variants that improve hemostasis in hemophilia</td>
<td>Lacramioara Ivanciu, Rodney Camire [USA]</td>
</tr>
<tr>
<td>08:45 - 09:00</td>
<td>Thrombosis and Hemostasis in Mice Lacking Factor VII Activating Protease (FSAP)</td>
<td>Saravanan Subramaniam, Ina Thielmann, Michael Etscheid, Martina Morowski, Ingo Pragst, Bernhard Nieswandt, S. Kanse [Germany]</td>
</tr>
<tr>
<td>09:00 - 09:15</td>
<td>Characterization of two monoclonal antibodies that inhibit the antifibrinolytic but not the anti-inflammatory activity of activated TAFI</td>
<td>Fabrizio Semeraro, Concetta Ammollo, Ann Gils, Paul Declerck, Mario Colucci [Italy]</td>
</tr>
<tr>
<td>09:15 - 09:30</td>
<td>Identification of heparin binding sites on TAFI that modulate plasmin-mediated activation, thermal stability and antifibrinolytic potential</td>
<td>Tanya Marar, Anastassia Filipieva, Michael Boffa [Canada]</td>
</tr>
</tbody>
</table>

#### Inflammation: Basic studies  
**G106-107**

**Moderators: Steve Kerrigan [Ireland] and Michael Schenk [United Kingdom]**

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00 - 08:15</td>
<td>Platelets promote immunopathology in Plasmodium berghei infection by inhibiting the development of interleukin-10 and interferon-γ expressing T-helper 1 cells</td>
<td>Michael Schenk, Tracey Lamb, Jonathan Gibbins [United Kingdom]</td>
</tr>
<tr>
<td>08:15 - 08:30</td>
<td>Histones and DNA in complex synergistically promote plasma coagulation</td>
<td>Concetta Ammollo, Fabrizio Semeraro, Paolo Simioni [Italy]</td>
</tr>
<tr>
<td>08:30 - 08:45</td>
<td>Gas6 promotes macrophage recruitment and activation in venous thrombosis</td>
<td>Sandrine Laurance, Catherine Lemarie, Mark Blostein [Canada]</td>
</tr>
<tr>
<td>09:00 - 09:15</td>
<td>Association of cell-free DNA with plasma von Willebrand factor levels in human and mouse models of inflammation</td>
<td>Alison Michels, Silvia Albánez, Laura Swystun, Kate Sponagle, Paula James, David Lillicrap [Canada]</td>
</tr>
<tr>
<td>08:45 - 09:00</td>
<td>Soluble TREM Like Transcript-1 (sTLT-1) enhances thrombin induced actin polymerization through a Rac1 and P38 mediated pathway</td>
<td>Mónica Fernández De Soto, Valance Washington [Puerto Rico]</td>
</tr>
<tr>
<td>09:15 - 09:30</td>
<td>Platelets persistently enhance Treg responses, but biphasically regulate Th1/Th17 responses in platelet-CD4+ T cell co-cultures</td>
<td>Linjing Zhu, Zhangsen Huang, Ragnhild Stålesen, Göran Hansson, Nailin Li [Sweden]</td>
</tr>
</tbody>
</table>
Thursday, July 4, 2013

ORAL COMMUNICATIONS  08:00 - 09:30

Negative regulation of platelet function  G102-103
Moderators: Marco Cattaneo (Italy) and David Stegner (Germany)

08:00 - 08:15  Shedding light on platelet CD84
OC 86.1  Timo Vögtle, Sebastian Hofmann, Peter Kraft, Martina Morowski, Markus Bender, Attília Braun, Guido Stoll, Stefan Rose-John, Bernhard Nieswandt (Germany)

08:15 - 08:30  BAMBI [BMP and activin membrane bound inhibitor]. A novel regulator of thrombus formation
OC 86.2  Isabelle Salles, James Monkman, Josefín Ahsnström, David Lane, James Crawley (United Kingdom)

08:30 - 08:45  Paxillin is an intrinsic negative regulator of platelet activation in mice
OC 86.3  Asuka Sakata, Tsukasa Ohmori, Satoshi Nishimura, Hidenori Suzuki, Seiji Madoiwa, Jun Mimuro, Kazuomi Kario, Yoichi Sakata (Japan)

08:45 - 09:00  Apelin acts as an endogenous antithrombotic factor
OC 86.4  Frédéric Adam, Jose-Javier Lopez-Barba, Camille Vatier, Sabrina Turpin, Adeline Muscat, Philippe Valet, Régis Bobe, Bruno Feve, Géraldine Siegfried (France)

09:00 - 09:15  The role of NADPH oxidase (NOX) 1 and 2 in GpVI-dependent platelet activation and thrombus formation
OC 86.5  Tony Walsh, Naadiya Carrim, Michael Berndt, Pat Metharom (Ireland)

09:15 - 09:30  An essential role of the inhibitory Fc gamma receptor IIb in antibody-induced glycoprotein VI ectodomain shedding in vivo
OC 86.6  David Stegner, Michael Popp, Sebastian Dütting, Viola Lorenz, Johannes Gessner, Bernhard Nieswandt (Germany)

Platelet adhesion and function  Mondriaan IV
Moderators: Kerstin Jurk (Germany) and Christian Gachet (France)

08:00 - 08:15  Beta3 integrin PSI domain has thiol isomerase function: New insights into integrin function and for anti-thrombotic agent development
OC 87.1  Guangheng Zhu, Pingguo Chen, Adili Reheman, June Li, John Freedman, Heyu Ni (Canada)

08:15 - 08:30  A role for CD40L signalling in platelet activation and thrombus formation that is independent of CD40
OC 87.2  Marijke Kuipers, Nadine Mattheij, Lina Cipolla, Judith Cosemans, Dirk Lievens, Marjo Donners, Frauke Swieringa, Tom Mastenbroek, Mauro Torti, Esther Lutgens, Johan Heemskerk (The Netherlands)

08:30 - 08:45  Integrin a5β1 and glycoprotein VI play important roles in mediating activation and aggregation of platelets adhering to fibrillar fibronectin
OC 87.3  Eric Maurer, Nicolas Receveur, Catherine Bourdon, Bernhard Nieswandt, François Lanza, Christian Gachet, Pierre Mangin (France)

08:45 - 09:00  CD40L deficiency protects from a pro-thrombotic phenotype induced by angiotensin-II in mice
OC 87.4  Kerstin Jurk, Michael Hausding, Thomas Münzel, Stephan Grabbe, Andreas Daiber (Germany)

09:00 - 09:15  Differential effects of platelet-derived MMPs on thrombus formation and collagen matrix degradation
OC 87.5  Tom Mastenbroek, Marion Feijge, Romy Kremers, Marion van den Bosch, Jason Johnson, Johan Heemskerk, Judith Cosemans (The Netherlands)

09:15 - 09:30  Role of EphB2-Ephrin signalling in platelet function
OC 87.6  Rekha Rana, Tanya Sage, Neline Kriek, Parvathy Sasikumar, Chris Jones, Jonathan Gibbins (United Kingdom)
**ORAL COMMUNICATIONS**

**Platelet collagen receptors**

**Mondriaan III**

**Moderators:** Elizabeth Haining [United Kingdom] and Kenneth Clemetson [Switzerland]

**08:00 - 08:15**

**Activated STIM1 controls GPVI signaling and enhances calcium store release in platelets**

*OC 88.1*

Atilia Braun, Rommy Rivera-Galdos, Sanjeev Gotru, David Varga-Szabo, Simon Stritt, Heike Hermanns, Bernhard Nieswandt [Germany]

**08:15 - 08:30**

**Novel loci associated with glycoprotein VI expression identified by a genome-wide association study and locus-specific fine-mapping**

*OC 88.2*

Peter Smethurst, Aparna Radhakrishnan, Abeer Al-Subaie, Stephen Garner, Sjoert Jansen, Alison Goodall, Elizabeth Gardiner, Michael Tomlinson, Willem Ouwehand, Augusto Rendon [United Kingdom]

**08:30 - 08:45**

**Disturbed glycoprotein VI-mediated signaling in platelets from hypercholesterolemic mice and humans**

*OC 88.3*

Suzanne Korporea, Valentina De Angelis, Menno Hoekstra, Eelo Gitz, Andrea Bochem, Barbara Sjouke, Kees Hoet, Philip de Groot, Miranda van Eck [The Netherlands]

**08:45 - 09:00**

**Deletion of GPVI and CLEC-2 partially rescues macrothrombocytopenia in G6b-B-deficient mice**

*OC 88.4*

Alexandra Mazharian, Jun Mori, Silke Heising, Bernhard Nieswandt, Steve Watson, Yotis Senis [United Kingdom]

**09:00 - 09:15**

**Regulation of the platelet collagen receptor GPVI by the tetraspanin Tspan9**

*OC 88.5*

Elizabeth Haining, Helen Harris, Marie Lordkipanidze, Jing Yang, Bernhard Nieswandt, Steve Watson, Michael Tomlinson [United Kingdom]

**09:15 - 09:30**

**Combined in vivo depletion of GPVI and CLEC-2 severely compromises hemostasis and abolges arterial thrombosis in mice**

*OC 88.6*

Markus Bender, Frauke May, Viola Lorenz, Ina Thielmann, Ina Hagedorn, Brendan Finney, Timo Voegtle, Atilia Braun, Steve Watson, Bernhard Nieswandt [Germany]

**Platelet disorders - II**

**Mondriaan II**

**Moderators:** Marie-Christine Morel-Kopp [Australia] and Rüdiger Scharf [Germany]

**08:00 - 08:15**

**Non-myeloablative conditioning with busulfan prior to hematopoietic stem cell transplantation leads to phenotypic correction of murine Bernard Soulier Syndrome**

*Sachiko Kanaji, Scot Fahs, Jerry Ware, Robert Montgomery, Qizhen Shi [USA]*

**08:15 - 08:30**

**MYH9-Related disease in France: A growing cohort among inherited macrothrombocytopenias On behalf of the French network on MYH9 Related disorders**

*Nicole Schlegel, Sylvie Binard, Alan Nurden, Paquita Nurden, Marie-Christine Alessi, Béatrice Saposnik [France]*

**08:30 - 08:45**

**Identification of a patient with bleeding diathesis, associated with dysfunctional platelet P2Y12 receptor**

*Anna Lecchi, Cristina Razzari, Silvia Paolotta, Lea Nakamura, Philippe Ohlman, Christian Gachet, Kenneth Jacobson, Marco Cattaneo [Italy]*

**08:45 - 09:00**

**Platelet and megakaryocyte abnormalities in the Gray Platelet Syndrome**

*Erica De Candia, Luigi Sarroca, Paula Heller, Gian Marco Podda, Nuria Pujol-Moix, Ana Glembocky, Alessandro Pecci, Maria Adele Alberelli, Marco Cattaneo, Carlo Balduini [Italy]*

**09:00 - 09:15**

**A new autosomal dominant macrothrombocytopenia maps to chromosome 9**

*Mari-Cristine Morel-Kopp, Qiang Chen, Hai Liang, Catherine Bromhead, Sarah Britton, Rust Turakulov, Melanie Bahlo, William Stevenson, Christopher Ward [Australia]*

**09:15 - 09:30**

**Thrombotic tendencies and bleeding in a thrombocytosis mouse model**

*Catherine Strassel, Pierre Magin, Monique Freund, Jean-Pierre Cazenave, Radek Skoda, Arnaud Dupuis, Raoul Herbrecht, Christian Gachet, François Lanza [France]*
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00 - 08:15</td>
<td>Risk assessment of venous thrombosis in families with known hereditary thrombophilia: The MARseilles-Nimes (MARNI) prediction model</td>
<td>William Cohen, Christel Castelli, Pierre Suchon, Sophie Bouvet, Marie-Francoise Aillaud, Dominique Brunet, Marie Christine Barthen, Marie-Christine Alessi, David-Alexandre Tregouet, Pierre-Emmanuel Morange</td>
<td>France</td>
<td></td>
</tr>
<tr>
<td>08:15 - 08:30</td>
<td>Antithrombin (AT) type II deficiency in Finland caused by a single point mutation - difficulties in detecting AT activity using commercially available assays</td>
<td>Marja Puurunen, Perttu Salo, Markus Perola, Sari Engelbarth, Kaja Javela</td>
<td>Finland</td>
<td></td>
</tr>
<tr>
<td>08:30 - 08:45</td>
<td>Mutation spectrum of antithrombin deficiency in Hungary; prevalence of Antithrombin Budapest 3 mutation in patients with venous and arterial thrombosis</td>
<td>Zsuzsanna Bereczky, Réka Gindele, Zsolt Oláh, György Pfliegler, Hajna Losonczy, Bettina Kovács, Anna Selmecki, Zoltán Boda, László Muszbek, Zsuzsanna Bereczky</td>
<td>Hungary</td>
<td></td>
</tr>
<tr>
<td>08:45 - 09:00</td>
<td>The influence of ABO, Lewis and Secretor genotypes on von Willebrand factor and lipid levels in two population cohorts</td>
<td>Peter Clark, Caroline Hayward, Igor Rudan, James Wilson, Gordon Lowe, Ann Rumley</td>
<td>United Kingdom</td>
<td></td>
</tr>
<tr>
<td>09:00 - 09:15</td>
<td>Identification of dominant thrombosis modifier loci using a sensitized ENU mutagenesis screen</td>
<td>Yang Liu, Catherine Richter, Morgan Maeder, Andy Vo, Michael Huarng, Alok Swaroop, Keith Joung, Jordan Shavit</td>
<td>USA</td>
<td></td>
</tr>
<tr>
<td>09:15 - 09:30</td>
<td>Antithrombin defects in thromboembolism are underestimated when calculated only by Antithrombin activity measurement</td>
<td>Ronald Fischer, Ulrich Sachs, Kathrin Heidinger, Mohammed Alrifai, Christiane Kelm, Anette Kirsch-Altene, Anna Pavlova, Johannes Oldenburg, Bettina Kemkes-Matthes</td>
<td>Germany</td>
<td></td>
</tr>
</tbody>
</table>
Thursday, July 4, 2013

ORAL COMMUNICATIONS 08:00 - 09:30

**Von Willebrand factor - II Forum**

*Moderators: Michael Laffan [United Kingdom] and Marjon Mourik [The Netherlands]*

**08:00 - 08:15**
**OC 91.1**
**Syntaxin binding protein 1 (STXBP1) modulates release of Weibel-Palade bodies from endothelial cells**
Dorothee van Breevoort, Mar Fernandez-Borja, Bram Snijders, Tom Carter, Jeroen Eikenboom, Karine Valentijn, Jan Voorberg, Ruben Bierings [The Netherlands]

**08:15 - 08:30**
**OC 91.2**
**A novel cleavage-resistant and highly prothrombotic von Willebrand factor mutant**
Nicolas Prevost, Yoko Morioka, Caterina Casari, Sachiko Kurata, Olivier Christophe, Cécile Denis [Japan]

**08:30 - 08:45**
**OC 91.3**
**CTL-2 is a new von Willebrand receptor: Role in antibody mediated neutrophil aggregation induced by anti-CTL-2 antibodies**

**08:45 - 09:00**
**OC 91.4**
**Impact of ADAMTS13-mediated regulation of von Willebrand factor multimer (VWF) profile on hemostasis and VWF clearance**
Yasuaki Shida, Christine Brown, Jeffery Mewburn, Kate Sponagle, David Lillicrap [Canada]

**09:00 - 09:15**
**OC 91.5**
**Analysis of ADAMTS13 proteolysis of von Willebrand factor under physiological shear stress conditions**
Agata Nowak, Carol Wooding, Aia Mehdi, Michael Laffan, Thomas McKinnon [United Kingdom]

**09:15 - 09:30**
**OC 91.6**
**Early stages of Weibel-Palade body biogenesis revealed by light and electron microscopy**
Marjon Mourik, Ruben Bierings, Karine Valentijn, Jan Voorberg, Abraham Koster, Jeroen Eikenboom [The Netherlands]
ePOSTER PRESENTATIONS

For the XXIV congress, ISTH has decided to innovate its poster sessions by introducing a new Electronic Poster format. Posters will not be presented in a paper format. Instead, all posters will be presented in the format of ePoster sessions on large touch-screens.

In the sessions, the ePosters will be presented and discussed in the sequence indicated in the programme.

New antiplatelet agents - I

Moderator: Georgina Apostoli [United Kingdom]

PA 4.01-1  Tumor vascular disrupting agent DMXAA inhibits platelet activation and thrombosis via inhibition of TXA2 - TP signaling and PDE
Shenghui Zhang, Yan Zhang, Jian Shen, Si Zhang, Leilei Chen, Jozef Mruk, Li Zhu, Satya Kunapuli, Zhongren Ding [China]

PA 4.01-2  Antiplatelet activity of N,N'-substituted piperazines
Olga Veselkina, Lubov Vasina, Lana Tarkovskaja, Ludmila Papajan, Nikolay Petrishchev [Russian Federation]

PA 4.01-3  PAR-1 antagonists inhibit thrombin-induced platelet activation whilst leaving the PAR4-mediated response intact
Heather Judge, Lisa Jennings, David Moliterno, Edward Hord, Rose Ecob, Pierluigi Tricoci, Susan Smyth, Tyrus Rorick, Jayaprapaksh Kotla, Robert Storey [United Kingdom]

PA 4.01-4  The role of glaucocalyxin A in inhibiting platelet activation and protecting against hypoxic ischemic brain injury
Li Zhu, Xiaorong Tang, Qiang Li, Fei Yang, Xiaohui Liu, Changgeng Ruan, Xingshun Xu, Jian Zhang [China]

PA 4.01-5  Plain pegylated liposomes inhibit platelet activation by HOCl modified albumin, thrombospondin peptide RFYVMWK and high shear modified von Willebrand factor
Martin Brodde, Jerzy-Roch Nofer, Beate Kehrel [Germany]

PA 4.01-6  Sildenafil reduces platelet activity via both NO synthase and NO synthase-independent pathways
Georgina Apostoli, Antonia Solomon, Michael Emerson [United Kingdom]

Platelet activation: New pathways

Moderator: Hansjörg Schwertz [Germany]

PA 4.02-1  Retinoic acids control translational events in platelets
Hansjörg Schwertz, Andrew Weyrich [Germany]

PA 4.02-2  Platelet Rap1 signaling, mediated by CalDAG-GEFI and P2Y12, contributes to atherosclerotic lesion development in mice
Yacine Boulaftali, Phillip Owens III, Ashley Beale, Raymond Piatt, Patrick Andre, Pamela Conley, Nigel Mackman, Wolfgang Bergmeier [USA]

PA 4.02-3  Antithrombotic actions of statins involve PECAM-1 signalling
Leonardo Moraes, Sakthivel Vaijapuri, Parvathy Sasikumar, Neline Kriek, Tanya Sage, Jonathan Gibbins [United Kingdom]

PA 4.02-4  Hydrophobic regions on protein surfaces, an ancient damage-associated molecular pattern, induce platelet activation
Beate Kehrel, Anne Bertling, Kerstin Jurk, Christine Heilmann, Judith Lahav, Jerzy-Roch Nofer, Martin Brodde [Germany]

PA 4.02-5  Amplification of platelet activation by surface pannexin-1 hemichannels
Kirk Taylor, Joy Wright, Catherine Vial, Richard Evans, Martyn Mahaut-Smith [United Kingdom]
PA 4.02-6  PKCδ negatively regulates platelet function in response to thrombin via GPIba
Younes Zaid, Ahmed Hachem, Daniel Yacoub, Walid Mourad, Yahye Merhi [Canada]

Platelets and leukocytes

Moderator: Rory Koenen [The Netherlands]

PA 4.03-1  Membrane fragments from dying platelets promote leukocyte aggregation and
vascular obstruction during ischemia-reperfusion injury
Yuping Yuan, Zane Kaplan, Katrina Ashworth, Imala Alwis, Shaun Jackson [Australia]

PA 4.03-2  Platelets limit the histotoxic activities of infiltrating neutrophils and act as vascular
healing patches in inflamed tissues
Benoît Ho Tin Noe, Veronique Ollivier, Lamia Lamrani, Martine Jandrot-Perrus [France]

PA 4.03-3  Platelet thrombi utilize co-operative biochemical and biophysical mechanisms to
induce excessive leukocyte accumulation to sites of endothelial injury
Imala Alwis, Zane Kaplan, Mehran Ghasemzadeh, Yuping Yuan, David Bark, Francisco Tovar-Lopez, Warwick Nesbitt, Shaun Jackson [Australia]

PA 4.03-4  Platelet Flow-Induced Protrusions (FLIPRs): A landing strip for circulating
monocytes
Claudia Tersteeg, Harry Heijnen, Gerard Pasterkamp, Coen Maas, Rolf Urbanus, Imo
Hoefer, Rienk Nieuwland, Richard Farndale, Philip de Groot, Mark Roest
[The Netherlands]

PA 4.03-5  Zebrafish as a model to investigate the effect of P2Y12 knockdown on leukocyte
migration
Rebecca Bright, Robert Storey, Tim Chico [United Kingdom]

PA 4.03-6  Cell-specific role of Junctional Adhesion Molecule-A in flow-dependent
atherosclerosis
Rory Koenen, Martin Schmitt, Remco Megens, Alma Zernecke, Nynke van den Akker, Timo Rademakers, Marc van Zandvoort, Tilman Hackeng, Christian Weber
[The Netherlands]

Thrombocytopenia models

Moderator: Shawn Jobe [USA]

PA 4.04-1  Only severe thrombocytopenia results in bleeding and defective thrombus formation in mice
Martina Morowski, Timo Vögtle, Peter Kraft, Christoph Kleinschnitz, Guido Stoll, Bernhard Nieswandt [Germany]

PA 4.04-2  A novel non-antibody mediated model of thrombocytopenia allows efficient adoptive transfer of platelets and assessment of platelet function
ChengJing Zhou, Bagirath Gangadharan, Shawn Jobe [USA]

PA 4.04-3  Fucoidan improves adenovirus mediated thrombocytopenia and enhances viral liver transduction
Harmjanpreet Kaur, Mazen Toukh, Kathrynn Corscadden, Alan Parker, Maha Othman
[Canada]

PA 4.04-4  Suspected clopidogrel induced thrombocytopenia - identifying the real culprit
Joanne Joseph, Anoosha Aslam, Romesh Markus, Daniel Bougie, Richard Aster
[Australia]

PA 4.04-5  Megakaryocytes, not only victims, but also participants in ITP
Zeping Zhou, Li Ma, Renchi Yang [China]
Tissue plasminogen activator induced fibrinolysis on rotational thromboelastometry in chemotherapy-induced thrombocytopenia
Rik Olde Engberink, Gerhardus Kuiper, Marcus Lancé, Yvonne Henskens, Erik Beckers [The Netherlands]

Genetic platelet disorders - II
Screen 05
Moderator: Samantha Gouw [The Netherlands]

PA 4.05-1 Proteomic analysis of platelets from patients with X-linked thrombocytopenia with thalassemia (XLT)
Daniel Bergemalm, Edwin Ngoasong, Caroline Kardeby, Jan Palmblad, Maria Åström [Sweden]

Inherited mild bleeding disorders (MBD) of undefined cause (BUC): Platelets express decreased tissue factor-dependent FXa generation and low thrombin generation in platelet-rich plasma
Olga Panes, Pamela Zuniga, Ana Lopez, Gilda Loncon, Teresa Quiroga, Jaime Pereira, Diego Mezzano [Chile]

A novel mutation in the dry motif of the P2Y12 receptor combined with a function-reducing polymorphism in PAR1 in a patient with a bleeding disorder
Steve Austin, Yatin Patel, Mike Mitchell, Marie Lordkipanidze, Gillian Lowe, Shaista Nisar, Kathryn Garner, Martina Daly, Steve Watson, Stuart Mundell [United Kingdom]

PTGS1 compound heterozygosity impairs gene expression and platelet aggregation and is associated with severe bleeding complications
Peter Bugert, Eray Yagmur, Ralf Weiskirchen, Angelika Schedel [Germany]

Platelet defects in congenital variant of Rett syndrome patients with FOXG1 mutations or reduced expression due to a position effect at 14q12
Christophe Goubau, Koenraad Devriendt, Nathalie van der Aa, Dagmar Wieczorek, Tjitske Kleefstra, Anita Rauch, Andreas Tzschach, Gunnar Buyse, Christel van Geet, Kathleen Freson [Belgium]

Demonstration of novel gain-of-function mutations of allbβ3: Association with macrothrombocytopenia and Glanzmann thrombasthenia-like phenotype
Hirokazu Kashiwagi, Shinji Kunishima, Kazunobu Kiyomizu, Yoshiro Amano, Hiroyuki Shimada, Masashi Morishita, Yuzuru Kanakura, Yoshiaki Tomiyama [Japan]

ADAMTS13: Basic - II
Screen 06
Moderator: Nicoletta Sorvillo [The Netherlands]

Anti-idiotypic DARPin molecules - potential new treatment tools for acquired thrombotic thrombocytopenic purpura (aTTP)?
Monica Schaller, Sabine Hiltbrunner, Irmela Sulzer, Monique Vogel, Karim Kentouche, Bernhard Laemmle, Johanna Kremer Hovinga [Switzerland]

Identification of glycosylation sites in plasma derived ADAMTS13 employing tandem mass spectrometry
Nicoletta Sorvillo, Paul Kajjen, Masanori Matsumoto, Yoshiro Fujimura, Fabian Verbij, Carmen van der Zwaan, Rob Fijnheer, Jan Voorberg, Alexander Meijer [The Netherlands]
PA 4.06-3 Prophylactic and therapeutic efficacy of a recombinant ADAMTS13 in a mouse model of thrombotic thrombocytopenic purpura
Alexandra Schiviz, Dagmar Verdino, Marlene Resch, Elisa Farnleitner, Friedrich Scheiflinger, Hans-Peter Schwarz, Eva-Maria Muchitsch, Werner Höllriegl (Austria)

PA 4.06-4 Treatment of reperfusion injury with recombinant ADAMTS13 in a porcine model of acute myocardial infarction
Elise Eerenberg, Paul Teunissen, Bert-Jan van den Born, Joost Meijers, Maurits Hollander, Mohamed Aly, Hans Niessen, Pieter Willem Kamphuisen, Marcel Levi, Niels van Royen (The Netherlands)

PA 4.06-5 A rat model reveals feasibility of rADAMTS13 therapy in the presence of inhibitory antibodies
Alexandra Schiviz, Barbara Plaimauer, Stefan Kaufmann, Susanna Skalicky, Gerald Hobarth, Martin Wolfgesser, Eva-Maria Muchitsch, Peter Turecek, Friedrich Scheiflinger, Hanspeter Rottensteiner (Austria)

PA 4.06-6 ADAMTS13 accelerates the cell engraftment efficacy in mouse model of bone marrow transplantation
Hideto Matsu, Masaaki Doi, Yasunori Matsunari, Maiko Takeda, Kenji Nishio, Midori Shima, Kenji Soejima, Fumiaki Banno, Toshiyuki Miyata, Mitsuhi Sugimoto (Japan)

Haemophilia A: Clinical - XIII
Screen 07
Moderator: Amy Dunn (USA)

PA 4.07-1 Relation between cut-off value of the Bethesda assay and the detection of low titre inhibitors in previously untreated children with severe haemophilia A
Helen Platokouki, Johannes Oldenburg, Rolf Ljung, Elena Santagostino, Marijke van den Berg (Greece)

PA 4.07-2 Long-Lasting Recombinant Factor VIII Fc Fusion (rFVIII:Fc) for Perioperative Management of Subjects with Haemophilia A in the Phase 3 A-LONG Study
Johnny Mahlangu, Jerry Powell, Neil Josephson, Robert Klamroth, Rafael Parra Lopez, Massimo Morfini, Johannes Oldenburg, John Pasi, David Perry, Margaret Ragni, Amy Shapiro, Scott Dunkley, Shashikant Apte, Snejana Krassova, Feriandas Greblikas, Alison Innes, Karen Nugent, Aoife Brennan, Alvin Luk, Glenn Pierce (South Africa)

PA 4.07-3 The importance of biomarkers of joint damage in monitoring the efficacy of different prophylaxis regimens for severe haemophilia A
Irena Djunic, Violeta Dopsaj, Aleksandar Lesic, Predrag Miljic, Nada Suvajdzic-Vukovic, Dragica Tomin, Aleksandra Novkovic, Ivo Elezovic (Serbia)

PA 4.07-4 Factor VIII genotype and correlation with the hemophilia severity score
Amy Dunn, Lauren Taylor, Shawn Jobe (USA)

PA 4.07-5 A new treatment concept for haemophilia: safety, pharmacokinetics and pharmacodynamics of single i.v. and s.c. doses of a monoclonal anti-TFPI antibody in healthy males and haemophilia subjects
Pratima Chowdary, Ute Friedrich, Stefan Lethagen, Pantep Angchaisuksiri (United Kingdom)

PA 4.07-6 Validation of the Colorado adult joint assessment scale in patients with severe haemophilia A
Walter Hong, David Raunig, Sharon Funk (USA)
ePOSTERS (A)  

Thursday, July 4, 2013  
13:30 - 15:00

Heparin and heparinoids - II  
Moderator: Anthony Chan (Canada)

Screen 08

PA 4.08-1  Procoagulant red blood cells diminish the protective effect of prothrombinase on factor Xa inhibition by fondaparinux and low molecular weight heparin  
Ivan Stevic, Howard Chan, Ankush Chander, Leslie Berry, Anthony Chan (Canada)

PA 4.08-2  Binding and inhibition of drug transport proteins by heparin - a significant role in modulation of multidrug resistance in human breast cancer cells  
Yunliang Chen, Michael Scully, Gloria Petralia, Ajay Kakkar (United Kingdom)

PA 4.08-3  Heparin induced apoptosis of breast cancer cells is associated with modulation of endogenous Protein Kinase C (PKC) activities  
Yunliang Chen, Michael Scully, Ajay Kakkar (United Kingdom)

PA 4.08-4  Protamine sulfate neutralization of anticoagulation by a potent antithrombin-heparin covalent complex  
Helen Atkinson, Andrea Rubiano, Leslie Berry, Anthony Chan (Canada)

PA 4.08-5  In vitro immunogenicity assessment of branded enoxaparin and a US generic version of enoxaparin  
Jeanine Walenga, Margaret Prechel, Vicki Escalante, Walter Jeske, Debra Hoppensteadt, Talhah Chaudhry, Mamdouh Bakhos (USA)

PA 4.08-6  Non-anticoagulant heparin analogue protects against ConA-induced acute hepatitis and sepsis  
Karin Wildhagen, Pablo Garcia De Frutos, Oliver Soehnlein, Coen Hemker, Roy Schrijver, Niko Deckers, Chris Reutelingsperger, Gerry Nicolaes (The Netherlands)

Von Willebrand factor - VI  
Moderator: Adam Miszta (The Netherlands)

Screen 09

PA 4.09-1  Acquired von Willebrand factor deficiency and bleeding risk in a rabbit model of aortic stenosis  
Antoine Rauch, Carlo Banfi, Emmanuelle Jean Pierre, Natacha Rousse, Alexandre Ung, Anne Godier, Claudine Caron, Amhed Ekalioubie, Eric van Belle, Sophie Susen (France)

PA 4.09-2  Loss of either Fut1 or Fut2 fucosyltransferase is associated with significantly elevated von Willebrand Factor (Vwf) levels in mice  
Jill Johnsen, Ermias Yohannes, Thomas Walsh (USA)

PA 4.09-3  Incorporation of von Willebrand factor into a fibrin network induces activation of von Willebrand Factor enabling binding of GPIb  
Adam Miszta, Leonie Pelkmans, Zaverio Ruggeri, Read Al Dieri, Vivian Du, Philip de Groot, Wim Hermens, Coenraad Hemker, Hilde Kelchtermans, Bas de Laat (The Netherlands)

PA 4.09-4  Von Willebrand factor acts as a novel antagonist for nitric oxide synthase to promote insulin resistance in hypoxia  
Gausal Khan, Bandana Singh, Indranil Biswas, Iti Garg (India)

PA 4.09-5  Vimentin is a ligand for von Willebrand factor: The role of this interaction in platelet adhesion  
Miguel Cruz, Vinod Vijayan, Ryanne Brown, Juliana Correa (USA)

PA 4.09-6  Conformation and N-linked glycan determinants within the A1A2A3 domains play critical roles in modulating human von Willebrand factor interaction with macrophages  
Alain Chan Kwo Chion, Gudmundur Bergsson, Jamie O’Sullivan, Orla Rawley, Sean Keyes, Vince Jenkins, Tom McKinnon, Michael Lafflan, Teresa Brophy, James O’Donnell (Ireland)
**Anticoagulant agents - XVII**

**Moderator: Pall Onundarson [Iceland]**

**PA 4.10-1** Real-world management, clinical outcome and predictors of thromboembolism during a one-year follow-up in patients with atrial fibrillation: Results from the ATA-AF study
Gualberto Gussoni, Aldo Maggioni, Giorgio Vescovo, Gianna Fabbri, Concetta Baldo, Donata Lucci, Carlo Nozzoli, Massimo Zoni Berisso, Giovanni Mathieu, Giuseppe Di Pasquale [Italy]

**PA 4.10-2** Warfarin monitoring with the Fiix-prothrombin time [Fiix-INR] increases time within target range and reduces dose adjustment need compared to standard monitoring using INR
Pall Onundarson, David Arnar, Einar Bjornsson, Magnus Magnusson, Olafur Indridason, Kristin Einarsdottir, Gunnhildur Magnusdottir, B. Vidarsson, Charles Francis, Brynja Guðmundsdóttir [Iceland]

**PA 4.10-3** Efficacy and safety of weight-adjusted heparin prophylaxis for the prevention of acute venous thromboembolism among obese patients undergoing bariatric surgery: A systematic review and meta-analysis
Rick Ikesaka, Gregoire Le Gal, Marc Carrier [Canada]

**PA 4.10-4** A 7-year outcome study on the effect of warfarin and co-morbidities in critically injured patients. Has the outcome improved?
Mahad Omar [United Kingdom]

**PA 4.10-5** The effect of rivaroxaban and dabigatran on the surface architecture of clots formed from plasma enriched with different levels of autologous platelets
Howard Chan, Jorell Gantioqui, Ivan Stevic, Paul Kim, Keith Lau, Anthony Chan [Canada]

**PA 4.10-6** Determinants for anticoagulant use in patients with first-time venous thromboembolism: VTE Epidemiology Group (VEG) Study
Carlos Martinez, Alexander Cohen, Stephan Rietbrock [Germany]

**Blood coagulation tests - XIV**

**Moderator: Michael Nardi [USA]**

**PA 4.11-1** Increase of INR above 2-2.5 and within therapeutic range does not change the thrombin generation capacity of patients on warfarin
Despoina Adamidou, Anne Riddell, Saman Aghishi, Linda Mohadam, Paul Priest, Pratima Chowdary [Greece]

**PA 4.11-2** The SAW-CT assay: A point-of-care clotting assay based on surface acoustic waves (SAWs) to monitor anticoagulant pharmacotherapy
Sascha Meyer dos Santos [Germany]

**PA 4.11-3** Protein c and factor vii concentrations can predict outcomes of surgical intensive care unit patients
Ning Tang, Yingying Pan [China]

**PA 4.11-4** Changes in hemostasis during the perioperative period of orthopedic surgery
Brandon Oberweis, Michael Nardi, Germaine Cuff, Andrew Rosenberg, Luis Pardo, Yu Guo, Mitchell Marshall, David Steiger, Steven Stuchin, Jeffrey Berger [USA]

**PA 4.11-5** External quality assessment of platelet function by the PFA-100: An update from the RCPAQAP Haematology
Roslyn Bonar, Emmanuel Favaloro [Australia]

**PA 4.11-6** Thrombin generation assay (TGA) is not able to predict hemostatic efficacy of bypassing agents in patients with hemophilia and inhibitors: Results from in vivo studies
Maria Elisa Mancuso, Elena Santagostino, Veena Chantarangkul, Marigrazia Clerici, Maria Rosaria Fasulo, Armando Tripodi [Italy]
ePOSTERS (A)  

Thursday, July 4, 2013  
13:30 - 15:00

Coagulation factor V  
Screen 12

Moderator: Raed Al Dieri (The Netherlands)

PA 4.12-1  
**Isolated decrease of factor v in children treated by 6-mercaptopurine for acute lymphoblastic leukemia**  
Bruno Filhon, Cecile Dumesnil, Patrick van Dreden, Patricia Compagnon, Mariette Adam, Pascale Schneider, Marc Vasse, Jean-Pierre Vannier (France)

PA 4.12-2  
**Cleavage at Arg1018 is not required for factor V activation**  
Mahesheema Na, Joseph Wiencek, Jamila Hirbawi, Michael Kalafatis (USA)

PA 4.12-3  
**Galectin-8 does not function as a factor V receptor on the surface of CMK cells and ex vivo-derived megakaryocytes**  
Jacqueline Gertz, Kyriel Pineault, Beth Bouchard (USA)

PA 4.12-4  
**Molecular characterization of FV deficiency in a large cohort of Italian patients**  
Elvezia Maria Paraboschi, Ilaria Guella, Flora Peyvandi, Stefano Duga, Rosanna Asselta (Italy)

PA 4.12-5  
**Factor V is endocytosed and trafficked to proplatelet extensions by megakaryocytes derived ex vivo from human umbilical cord blood**  
Jacqueline Gertz, Kelley McLean, Beth Bouchard (USA)

PA 4.12-6  
**A new regulatory function of activated factor V: Inhibition of the activation by tissue factor/factor VII(a) of factor X**  
Raed Al Dieri, Saartje Bloemen, Hilde Kelchtermans, Rob Wagenvoord, Bas de Laat, Coenraad Hemker (The Netherlands)

---

Coagulation factor VIII - VI  
Screen 13

Moderator: Arjan van der Flier (USA)

PA 4.13-1  
**Assessment of Structural Comparability between rFVIIIFc and Unmodified B Domain-deleted FVIII by Complementary Biophysical Methods**  

PA 4.13-2  
**Structure of Membrane-bound Porcine Factor VIII**  
Svetla Stoilova-McPhie, Daniela Dalm, Kirill Grushin, Jaimy Miller (USA)

PA 4.13-3  
**Dose response relationship and duration of effect of a PEGylated recombinant FVIII conjugate, N8-GP, in a new tail vein transection bleeding model in anaesthetised FVIII k/o mice**  
Peter Johansen, Mikael Tranholm, Marianne Kjalke, Jesper Haaning, Tom Knudsen (Denmark)

PA 4.13-4  
**Impact of factor VIII A2 domain stabilization on activated factor X generation**  
Lilley Leong, Thomas Thompson, Katherine Tran, Philip Ramsey, Hironao Wakabayashi, Philip Fay, Peter Kretschmer, Chandra Patel, John Murphy, Volker Laux (USA)

PA 4.13-5  
**Increased mortality risk in US Hemophilia A inhibitor patients**  
Christopher Walsh, Connie Miller, Michael Soucie (USA)

PA 4.13-6  
**VWF affects the clearance and biodistribution of recombinant factor VIII Fc fusion (rFVIIIFc)**  
Arjan van der Flier, Siyuan Tan, Zhan Liu, Kai Chen, Tongyao Liu, Susannah Patarroyo-White, David Light, Haiyan Jiang (USA)
Extrinsic pathway of coagulation

Moderator: Grethe Skretting (Norway)

PA 4.14-1  Mechanism by which platelet-bound Prothrombinase maximizes platelet procoagulant activity
Brittany Todd, Jay Silveira, Paula Tracy (USA)

PA 4.14-2  Differential effects on TFPI levels upon exposure of human endothelial cells and cynomolgus monkey vascular beds to TFPI KPI-2 antibody mAb 2021 and TFPI KPI-3 antibody mAb 0001
Cecilia Augustsson, Mette Loftager, Lene Hansen, Lars Petersen, Ida Hilden, Helle Petersen (Denmark)

PA 4.14-3  Increased expression of TFPI by NaBut is due to changes in the acetylation pattern of the TFPI promoter
Grethe Skretting, Christiane Myklebust, Elisabeth Dørum, Benedicte Stavik, Nina Iversen, Per Morten Sandset (Norway)

PA 4.14-4  Sodium butyrate induces TFPI-mediated apoptosis through the AKT/mTOR pathway
Xue Yan Cui, Benedicte Stavik, Christiane Myklebust, Marianne Andresen, Elisabeth Dørum, Nina Iversen, Per Morten Sandset, Grethe Skretting (Norway)

PA 4.14-5  Factor VII antigen levels are differentially associated to etiological subtypes of ischemic stroke
Tara Stanne, Ellen Hanson, Sandra Olsson, Joel Höglund, Katarina Jood, Christian Blomstrand, Christina Jern (Sweden)

PA 4.14-6  Endogenous Tissue Factor Pathway Inhibitor and Tissue Factor expression in rabbit bleeding and clotting models
Kasper Almholt, Brian Lauritzen, Peter Johansen (Denmark)

Factor XIII

Moderator: Verena Schroeder (Switzerland)

PA 4.15-1  Factor XIII deficiency in elective hip or knee surgery
Mario Von Depka Prondzinski, Janßen Imke, Michael Böker, Carsten Detering, Christian Siebert (Germany)

PA 4.15-2  Effects of free factor XIII activation peptide on factor XIII function and fibrin formation and structure
Verena Schroeder, Cedric Duval, Rebecca Brown, Helena Handrkova, Robert Ariëns, Hans Kohler (Switzerland)

PA 4.15-3  Factor XIII and corneal wound healing
László Muszbek, Zsuzsa Orosz, Helga Bárdos, Andrea Facskó, Amir Shemirani, György Vereb, Róza Ádány, Berta András (Hungary)

PA 4.15-4  Pre-clinical safety and prolonged pharmacokinetic/pharmacodynamic (PK/PD) properties of a recombinant fusion protein linking activated coagulation factor VII with albumin (rVIIa-FP)
Sabine Zollner, Daniel Schuermann, Franz Kaspereit, Wilfried Krege, Thomas Weimer, Jochen Müller-Cohrs, Ingo Pragst, Gerhard Dickneite, Stefan Schulte (Germany)

PA 4.15-5  Molecular interaction of factor XIII subunits
Éva Katona, Krisztina Pénzes, Andrea Csapó, Mária Kun, Judit Csapó, Zsuzsa Bagoly, Ferenc Fazakas, László Muszbek (Hungary)

PA 4.15-6  Common FXIII polymorphisms associate with abdominal aortic aneurysms and with overall survival rate
Fraser Macrae, Hannah Lee Evans, Soroush Sohrabi, Anne Johnson, Julian Scott, Robert Ariëns (United Kingdom)
**Diagnosis of venous thrombosis - VI**

**Moderator: Henrike Schouten (The Netherlands)**

**PA 4.16-1** Conventional or age-adjusted D-dimer cut-off values to exclude venous thromboembolism in older patients: A systematic review and meta-analysis
Henrike Schouten, Geert-Jan Geersing, Huiberdina Koek, Nicolaas Zuithoff, Kristel Janssen, Renée Douma, Johannes van Delden, Karel Moons, Johannes Reitsma (The Netherlands)

**PA 4.16-2** Arterial disease in patients with symptomatic venous thromboembolism. Findings from the RIETE Registry
Manuel Monreal, Olga Madridano, Alicia Lorenzo, Jorge Del Toro, Mar Martín, Jorge Gómez-Cerezo, Paolo Prandoni, Alessandra Bura-Riviere, Lidia Rota (Spain)

**PA 4.16-3** Incidence of superficial vein thrombosis: A community-based study
Andrea Buchmuller-Cordier, Paul Frappe, Laurent Bertoletti, Emilie Presles, Serge Couzan, Philippe Preynat, Bernard Tardy, Hervé Decousus (France)

**PA 4.16-4** Exploring decisions to withhold diagnostic investigations in Dutch nursing home patients with a clinical suspicion of venous thromboembolism: A mixed method study
Henrike Schouten, Huiberdina Koek, Marije Kruisman-Ebbers, Geert-Jan Geersing, Ruud Oudega, Marijke Kars, Karel Moons, Johannes van Delden (The Netherlands)

**Disseminated intravascular coagulation**

**Moderator: Debra Hoppensteadt (USA)**

**PA 4.17-1** Increased levels of nucleosome in human plasma in septic patients with DIC
Kazuo Kawasugi, Tadashi Yamamoto, Yoko Oka, Ryousuke Shirasaki, Nobu Akiyama, Naoki Shirafuji (Japan)

**PA 4.17-2** Dysregulation of inflammatory and hemostatic markers in sepsis associated disseminated intravascular coagulation
Jawed Fareed, Kazuhisa Tsuruta, Debra Hoppensteadt, Michael Mosier, Yutaka Osawa, Inder Kaul (USA)

**PA 4.17-3** Thrombin generation mediators and markers in sepsis associated coagulopathy and their modulation by recombinant thrombomodulin
Debra Hoppensteadt, Kazuhisa Tsuruta, Josephine Cunanan, Joe Hirman, Inder Kaul, Yutaka Osawa, Jawed Fareed (USA)

**PA 4.17-4** DIC and DIC in septic shock: Myth or reality? (Why clinical trials failed to improve survival)
Xavier Delabranche, Asaël Berger, Nicolas Lerolle, Laurent Macchi, Maleka Schenck-Dhif, Lélia Grunebaum, Yoganaden Mootien, Achille Kouatchet, Thierry Lavigne, Farhat Meziani (France)

**PA 4.17-5** New diagnostic strategy of sepsis induced disseminated intravascular coagulation (DIC)
Yasumasa Kawano, Hiroyasu Ishikura, Takeshi Nishida, Mariko Mizunuma, Rie Yuge, Reiko Ichiki, Kota Hoshino, Akira Murai (Japan)
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>PA 4.17-6</td>
<td><strong>Heparin inhibits extracellular histones-induced HUVEC apoptosis</strong></td>
<td>Xi Mo, Feifei Wang, Qing Cao (China)</td>
</tr>
<tr>
<td><strong>Inherited risk factors venous thrombosis</strong></td>
<td>Screen 18</td>
<td><strong>Moderator:</strong> Ted Wun (USA)</td>
</tr>
<tr>
<td>PA 4.18-1</td>
<td><strong>Venous thromboembolism risk assessment with a multilocus genetic risk score</strong></td>
<td>Joan Vila, Pierre-Emmanuel Morange, Juan Carlos Souto, Eduardo Salas, David-Alexandre Tregouet, José Mateo, Sara Pich, Roberto Elosua, Jose Manuel Soria (Spain)</td>
</tr>
<tr>
<td>PA 4.18.2</td>
<td><strong>Incidence and risk factors for Venous Thromboembolism (VTE) amongst adults with Sickle Cell Disease</strong></td>
<td>Ted Wun, Ann Brunson, Amy Lei, Richard White (USA)</td>
</tr>
<tr>
<td>PA 4.18-3</td>
<td><strong>Replication and meta-analysis of the association between F11 genetic variants and the risk of incident venous thrombosis by statin use</strong></td>
<td>Laura Harrington, Kerri Wiggins, Colleen Sittani, Marc Blondon, Astrid van Hylckama Vlieg, Frits Rosendaal, Susan Heckbert, Bruce Psaty, Nicholas Smith (USA)</td>
</tr>
<tr>
<td>PA 4.18-4</td>
<td><strong>Height and risk of venous thromboembolism: A mendelian randomization study</strong></td>
<td>Erin Smith, Sigrid Braekkan, Andrew Carson, Kristen Jepsen, Hiroko Matsui, Tom Wilsgaard, Olivier Harismendy, Kelly Frazer, John-Bjarne Hansen (USA)</td>
</tr>
<tr>
<td>PA 4.18-5</td>
<td><strong>Not all factor V Leiden or prothrombin G20210A mutations are equal: Results from a retrospective cohort family study</strong></td>
<td>Paolo Bucciarelli, Valerio De Stefano, Serena Passamonti, Angela Ciminello, Cristina Legnani, Daniela Tormene, Giancarlo Castaman, Ida Martinelli (Italy)</td>
</tr>
<tr>
<td>PA 4.18-6</td>
<td><strong>Association of ABO blood type with cognitive decline: The reasons for geographic and racial differences in stroke study</strong></td>
<td>Kristine Alexander, Leslie McClure, Virginia Wadley, Fred Unverzagt, Neil Zakai, Sarah Gillett, Peter Callas, Mary Cushman (USA)</td>
</tr>
<tr>
<td><strong>TTP/Thrombotic microangiopathies - II</strong></td>
<td>Screen 19</td>
<td><strong>Moderator:</strong> Magnus Mansouri Taleghani (Switzerland)</td>
</tr>
<tr>
<td>PA 4.19-1</td>
<td><strong>International registry for patients with hereditary thrombotic thrombocytopenic purpura (TTP) - Upshaw Schulman syndrome</strong></td>
<td>Magnus Mansouri Taleghani, Yoshihiro Fujimura, James George, Ingrid Hrachovinova, Bernhard Lämmlle, Paul Knoebl, Petter Quist-Paulsen, Reinhard Schneppenheim, Johanna Kremer Hovinga (Switzerland)</td>
</tr>
<tr>
<td>PA 4.19-2</td>
<td><strong>Measurement and prevalence of circulating ADAMTS13-specific immune complexes in autoimmune thrombotic thrombocytopenic purpura</strong></td>
<td>Luca Lotta, Carla Valsecchi, Silvia Pontiggia, Ilaria Mancini, Andrea Artoni, Danijela Mikovic, Silvia Trisolini, Flora Peyvandi (Italy)</td>
</tr>
<tr>
<td>PA 4.19-3</td>
<td><strong>Sequela of chronic relapsing idiopathic thrombotic thrombocytopenic purpura</strong></td>
<td>Tanja Falter, Katharina Alber, Inge Schrarrer (Germany)</td>
</tr>
<tr>
<td>PA 4.19-4</td>
<td><strong>Characterization of hereditary thrombotic thrombocytopenic purpura (TTP) from one of the blood centers in China</strong></td>
<td>Xia Bai, Jian Su, Lijuan Cao, Ziqiang Yu, Zhaoyue Wang, Changgeng Ruan (China)</td>
</tr>
<tr>
<td>PA 4.19-5</td>
<td><strong>Safety and efficacy of cryosupernatant as a replacement fluid for plasmapheresis in thrombotic thrombocytopenic purpura: A single center retrospective evaluation</strong></td>
<td>Bianca Stefanello, Erich De Paula, Fernanda Orsi, José Marques-Junior, Eduardo Roveri, Marina Coletta, Margareth Ozelo, Joyce Maria Annichino-Bizzacchi, Marcelo Addas-Carvalho (Brazil)</td>
</tr>
</tbody>
</table>
ePOSTERS (A)  ePOSTER AREA

Thursday, July 4, 2013  13:30 - 15:00

PA 4.19-6  In vitro characterisation of two ADAMTS13 mutants (I143T, Y570C) identified in two patients with congenital thrombotic thrombocytopenic purpura (TTP)
Mary Underwood, Isabella Garagiola, Ian Mackie, Samuel Machin, Ayse Metin, Aytemiz Gurgey, Flora Peyvandi [United Kingdom]

Vessel wall

Moderator: Joanna Sylman [USA]

PA 4.20-1  Platelet adhesion to collagen under flow conditions is increased in essential thrombocythemia patients
Alfonso Vignoli, Paola van der Meijden, Cinzia Giaccherini, Frauke Swieringa, Marina Marchetti, Hugo ten Cate, Johan Heemsker, Anna Falanga [Italy]

PA 4.20-2  The shear rate dependence of nitric oxide inhibition of platelet aggregation
Joanna Sylman, Sarah Lantvit, Melissa Reynolds, Keith Neeves [USA]

PA 4.20-3  Angiogenesis and permissiveness to invasion in the human endometrium: Role of anticoagulant heparan sulfate distribution during the cycle and in tumorigenesis
Ariane De Agostini, Noémie Bouchet, Anthony Filipe, Jean-Christophe Tille [Switzerland]

PA 4.20-4  Deep vein thrombus formation induced by flow reduction in mice is determined by venous side branches
Moritz Brandt, Tanja Schönfelder, Melanie Schwenk, Christian Becker, Sven Jäckel, Ulrich Walter, Steffen Massberg, Thomas Münzel, Marie-Luise Von Brühl, Philip Wenzel [Germany]

PA 4.20-5  Human platelet activation/secretion and a membrane-associated urokinase-like activity induce the activation of the latent form of platelet transforming growth factor-β1 (TGF-β1)
Olga Panes, Jaime Gutierrez, Mirentxu Iruretagoyena, Enrique Brandan, Diego Mezzano [Chile]

PA 4.20-6  Plasma levels of intercellular cell adhesion molecule-1 (sicam-1) in elderly with and without Alzheimer disease
Mayara Faria, Gisele Gonçalves, Josianne Silveira, Maria das Graças Carvalho [Brazil]
ePOSTERS (B)  

**ePOSTER PRESENTATIONS**

For the XXIV congress, ISTH has decided to innovate its poster sessions by introducing a new Electronic Poster format. Posters will not be presented in a paper format. Instead, all posters will be presented in the format of ePoster sessions on large touch-screens.

In the sessions, the ePosters will be presented and discussed in the sequence indicated in the programme.

**New antiplatelet agents - II**

**Screen 21**

*Moderator: Nima Vaezzadeh (Canada)*

**PB 4.21-1**  
**Different effects of antiplatelet versus anticoagulant agents in mouse bleeding models**  
Nima Vaezzadeh, Ran Ni, Paul Kim, Peter Gross (Canada)

**PB 4.21-2**  
**Relation between the mechanism of antiplatelet action of adenosine from Solanum lycopersicum and its derivate inosine**  
Eduardo Fuentes, Jaime Pereira, Julio Caballero, Marcelo Alarcón, Pablo Pérez, Luis Astudillo, Iván Palomo (Chile)

**PB 4.21-3**  
**Pharmacokinetics, pharmacodynamics, and tolerability of LC23-1306, a novel antiplatelet agent, in healthy subjects**  
Hye Kyung Chang, Dongseong Shin, Donghoon Shin, Howard Lee, Hye Kyung Chang, Hee Dong Park, Young Joo Jung, Mia Song, In-Jin Jang, Kyung-Sang Yu (South-Korea)

**PB 4.21-4**  
**Antiplatelet effect of black soybean mediated by Adenosine-cAMP signaling pathway**  
Keunyoung Kim, Kyung-Min Lim, Ok-Nam Bae, Seojin Kang, Jin-Ho Chung (South-Korea)

**PB 4.21-5**  
**Anopheline anti-platelet protein from a malaria vector mosquito has anti-thrombotic effects in a pulmonary thromboembolism model without compromising hemostasis**  
Hideki Hayashi, Hiroyuki Kyushiki, Keisuke Nagano, Toshiki Sudo, Mitsuhiro Iyori, Hiroyuki Matsuoka, Shigeto Yoshida (Japan)

**PB 4.21-6**  
**Interactions between vascular prostaglandins and antiplatelet agents result in profound inhibition of platelet function**  
Ann White, Stan Heptinstall, David lyu, Jacqueline Glenn, Sue Fox (United Kingdom)

**Antiplatelet agents: Miscellaneous**

**Screen 22**

*Moderator: Arnaud Bonnefoy (Canada)*

**PB 4.22-3**  
**A novel platelet aggregation inhibitor purified from Gloydius blomhoffii brevicaudus venom**  
Altantsetseg Buyanbat, Bolor Buyanbadrakh, Sumiya Byambasuren, Punsalulam Dashnyam, Bat-Erdene Jugder (Mongolia)

**PB 4.22-4**  
**Vipera lebetina (snake) venom components affecting hemostasis**  
Ene Siigur, Katrin Trummal, Külli Tõnismägi, Anu Aaspöllu, Mari Samel, Heiki Vija, Jüri Siigur (Estonia)

**PB 4.22-5**  
**Sodium tungstate as a potential antiplatelet agent**  
Maribel Diaz-Ricart, Rebeca Fernández, Marc Pino, Carolina Caballo, Ginés Escolar, Ramón Gomis (Spain)

**PB 4.22-6**  
**Aspirin induces platelet apoptosis**  
Kesheng Dai, Lili Zhao, Weilin Zhang, Mengxing Chen, Jiansheng Zhang, Mingyi Zhang, Changgeng Ruan (China)
Platelet integrins - II

**Moderator: Ivan Budnik (Israel)**

**PB 4.23-1** The role of platelet actin polymerization and agonist-induced cortactin tyrosine phosphorylation in αIIbβ3 expression, activation, cytoskeleton association and fibrinogen binding
Ivan Budnik, Boris Shenkman, Naphtali Savion [Israel]

**PB 4.23-2** Fibronectin unfolding and assembly: The dual role of fibronectin in platelet adhesion and aggregation
Khon Chan Huynh, Volker Stoldt, Rüdiger Scharf [USA]

**PB 4.23-3** FcγRII mediates the intrinsic platelet activation of disintegrin, probed by αIIbβ3-specific monoclonal antibodies
Tur-Fu Huang, Chun-Chieh Hsu [Taiwan]

**PB 4.23-4** Platelet integrin αIIbβ3 (IIb-IIIa) and cytoskeleton modulate fibrin network formation and clot stiffness
Caroline Wang, Matthew Perez, Brian Helmke, Michael Lawrence [USA]

**PB 4.23-5** The potencies and mechanisms by which engineered nanoparticles induce platelet aggregation are dependent upon their precise physicochemistry
Erica Smyth, Antonia Solomon, Anupama Vydyanath, Pradeep Luther, Simon Pitchford, Terry Tetley, Michael Emerson [United Kingdom]

**PB 4.23-6** The role of heterotrimeric G proteins in regulation of αIIbβ3 fibrinogen affinity and αIIbβ3 cytoskeleton association
Ivan Budnik, Boris Shenkman, Naphtali Savion [Israel]

---

New platelet agonists

**Moderator: Demetrios Braddock (USA)**

**PB 4.24-1** The endothelial cell surface enzyme, NPP-4 stimulates platelet aggregation via hydrolysis of diadenosine triphosphate to ADP and partially overcomes aspirin-mediated platelet inhibition
Deborah Ornstein, Ronald Albright, William Chang, Donna Robert, Wenxiang Cao, Enrique De La Cruz, Demetrios Braddock [USA]

**PB 4.24-2** Histone deacetylase 6 (HDAC6)-mediated deacetylation of α-tubulin coordinates cytoskeletal and signaling events of platelet activation
Joseph Asian, Kevin Phillips, Jiaqing Pang, Owen McCarty [USA]

**PB 4.24-3** Phosphorothioate oligodeoxynucleotides are potent platelet activators acting toll-like receptor 9 independently
Ulrike Flierl, Joy Yao, Nicole Bassler, Kartheinz Peter [Australia]

**PB 4.24-4** High resolution structure determination and small molecule inhibitor identification of NPP4, a procoagulant enzyme localized to brain vascular endothelium
Demetrios Braddock, Ronald Albright, William Chang, Deborah Ornstein, Donna Robert, Wenxiang Cao, Enrique De La Cruz [USA]

**PB 4.24-5** Functional implications of histone deacetylases in platelet activation: A role for α-tubulin acetylation?
Antonio Moscardó, María Teresa Santos, Ana Latorre, Isabel Madrid, María Ángeles Dasi, Juana Vallés [Spain]

**PB 4.24-6** The role of peroxisome proliferator-activated receptor (PPAR)-γ ligands in platelet activation
Jin-Yeong Han, Jae-Lim Choi, Bo-Ram Kim, Ri-Young Goh, Joo-In Park [South-Korea]
Thursday, July 4, 2013  13:30 - 15:00

**Thrombus formation - II**  
**Screen 25**

**Moderator:** Heyu Ni (Canada)

**PB 4.25-1**  
**Kinetics of thrombus formation and further characterization of the bleeding phenotype in PT-VWD hTgG233V mouse model**  
Harmanpreet Kaur, Mazen Toukh, Kathryn Corscadden, Maha Othman (Canada)

**PB 4.25-2**  
**A novel approach to reduce variability in platelet flow chamber experiments by utilizing an internal control**  
Kjersti Claesson, Lars Faxälv, Katarina Bengtsson, Nathaniel Robinson, Tomas Lindahl (Sweden)

**PB 4.25-3**  
**Anfibatide, a novel GPIb complex antagonist inhibits platelet adhesion and thrombus formation in vitro and in vivo murine models of thrombosis**  
Reheman Adili, Xi Lei, Hui Zhou, Yiming Wang, Yan Hou, Xiangrong Dai, Benjamin Xiaoyi Li, Heyu Ni (Canada)

**PB 4.25-4**  
**Tetraspanin CD9 negatively regulates thrombus formation and stability and GPIIb-IIIa outside-in signaling**  
Lisa Jennings, Sarah Hill, Michael Herr, Svetozar Grgurevich, Jayaprakash Kotha (USA)

**PB 4.25-5**  
**The Rho GTPase effector PAK regulates thrombin- and collagen-stimulated platelet aggregation, lamellipodia formation and aggregate stability under shear**  
Joseph Aslan, Asako Itakura, Sandra Baker, Kristina Haley, Garth Tormoen, Jiaqing Pang, Cassandra Loren, Jonathan Chernoff, Owen McCarty (USA)

**PB 4.25-6**  
**Light-controlled coagulation - Aptamer-templated synthesis facilitating masking and photochemical liberation of thrombin function**  
Falk Rohrbach, Franziska Pfeiffer, Florian Schäfer, Jens Müller, Bernd Pöttsch, Alexander Heckel, Günter Mayer (Germany)

---

**Platelet activation mechanisms**  
**Screen 26**

**Moderator:** Jeffrey Berger (USA)

**PB 4.26-1**  
**A critical role of thrombin/PAR-1 in ADP-induced platelet secretion and the second wave of aggregation**  
Lei Jiang, Chunhua Xu, Shanshan Yu, Pu Liu, Dongjiao Luo, Qi Zhou, Cunji Gao, Hu Hu (China)

**PB 4.26-2**  
**Oxidised LDL activates blood platelets through NADPH oxidase-dependent modulation of the cGMP/Protein kinase G signalling cascade**  
Khalid Naseem, Simbarashe Maqwenzi, Katie Wraith (United Kingdom)

**PB 4.26-3**  
**P2X1-mediated p38 signaling enhances U46619-induced platelet secretion and aggregation**  
Zhangsen Huang, Pu Liu, Linjing Zhu, Nainin Li, Hu Hu (Sweden)

**PB 4.26-4**  
**Characterization of losartan effects on platelets**  
Martine Jandrot-Perrus, Peng Jiang, Stéphane Loyau (France)

**PB 4.26-5**  
**Sex-specific differences in platelet activity**  
Jeffrey Berger, Richard C. Becker, Iryna Lobach, Thomas Ortel, Redford Williams (USA)

**PB 4.26-6**  
**The cellular prion protein PrPC regulates platelet signaling and activation**  
Joseph Aslan, Rafael Mariante, Daniella Mizurini, Tatiana Alvez America, Fausto Gomes, Robson Monteiro, Owen McCarty, Rafael Linden (USA)
### Platelet activation: Miscellaneous - II
**Screen 27**

**Moderator:** Kandicie Kottke-Marchant [USA]

| PB 4.27-1 | Non-uniform distribution of coagulation factors on the membrane of activated platelets  
Nadezhda Podoplelova, Anastasia Golomysova, Fazoil Ataullakhanov, Mikhail Panteleev  
[Russian Federation] |
|---|---|
| PB 4.27-2 | Assessment of platelet inhibition and its stability during aspirin and clopidogrel treatment  
Ayse Anil Timur, Gurunathan Murugesan, Li Zhang, John Barnard, Deepak Bhatt,  
Kandice Kottke-Marchant [USA] |
| PB 4.27-3 | Platelet aggregation behavior in the perioperative period of vascular surgery  
Daniela Calderaro, Adriana Pastana, Tania Rocha, Danielle Gualandro, Pai Yu,  
Gabriel Carmo, Elbio D'Amico, Nelson De Luccia, Pedro Puech-Leão, Bruno Caramelli  
[Brazil] |
| PB 4.27-4 | Binding of factor X to the activated platelet membrane demonstrates a multistep dissociation process that allows hysteresis effects  
Nadezhda Podoplelova, Fazoil Ataullakhanov, Mikhail Panteleev [Russian Federation] |
| PB 4.27-5 | Mean platelet volume interactions with glycoprotein IIb-IIIa and Ib content and platelet aggregation in acute coronary syndrome patients and healthy volunteers  
Alexey Mazurov, Svetlana Khaspekova, Ilia Zyuryaev, Vladimir Yakushkin, Olga Sirotkina,  
Natalia Zaytseva, Mikhail Ruda [Russian Federation] |
| PB 4.27-6 | Elevated prevalence and stability over time of high on-treatment platelet reactivity in patients with ischemic cerebrovascular disease  
José Rivera, Eva Jover, Isabel Sánchez Guiu, José Manuel Rodríguez, Agustina Bernal,  
Juan Antonio Iniesta, Ana Isabel Antón, Vicente Vicente, María Luisa Lozano [Spain] |

### Platelet function in health and disease
**Screen 28**

**Moderator:** William Gunning [USA]

| PB 4.28-1 | The platelet delta granule storage pool increases in pregnancy  
William Gunning, Eleonora Cekova, Hermann Simo, Amy Patel, Joseph Karnitits [USA] |
|---|---|
| PB 4.28-2 | Essential thrombocythemia and polycythemia vera thrombotic or bleeding diathesis? flow study results  
Elisabeth Kapfhammer, Petro Petrides, Armin Reininger [Germany] |
| PB 4.28-3 | Risk-stratification of essential thrombocythemia patients for arterial, venous thromboses and for microcirculatory disturbances  
Eva Posfai, Imelda Marton, Márti Széll, Zsuzsanna László, Zita Borbényi [Hungary] |
| PB 4.28-4 | Omega-3 Alpha linolenic acid interferes with platelet rolling and adhesion to von Willebrand factor  
Simona Stivala, Martin Reiner, Thomas Lüscher, Jürg Beer [Switzerland] |
| PB 4.28-5 | Platelet aggregations in thrombus and thrombopoiesis in bone marrows visualized by in vivo molecular imaging and contribution of inflammatory cytokines  
Satoshi Nishimura, Mika Nagasaki [Japan] |
| PB 4.28-6 | Plasma levels of soluble receptor protein-tyrosine kinases Mer and Tyro3 are increased in acute coronary syndrome patients  
Wu Jun, Ma Yuliang, Zhao Jie, Song Ying, Lu Songsong, Zhao Jingzhong, Zhao Lei,  
Liu Ning [China] |
ePOSTERS (B)  ePOSTER AREA

Thursday, July 4, 2013  13:30 - 15:00

Acquired and immune thrombocytopenia  Screen 29
Moderator: Marco van der Stoep (The Netherlands)

PB 4.29-1  The immature platelet fraction is susceptible to the platelet size and useful for screening of macrothrombocytopenia from immune thrombocytopenia
Koji Miyazaki, Yukako Koike, Mikio Danbara, Ryouichi Hori, Masaaki Higashihara (Japan)

PB 4.29-2  Abnormal lipid rafts related signaling in T lymphocytes in immune thrombocytopenia patients
Xian Zhang, Donglei Zhang, Huiyuan Li, Yanhui Yang, Rongfeng Fu, Lei Zhang, Renchi Yang (China)

PB 4.29-3  Alloimmune thrombocytopenia masking a bernard soulier syndrome in a congenital nephrotic syndrome of the Finnish type (nphs1)
Véronique Baccini, Elodie Elkaim, Dorsaf Ghalloussi, Caroline Rouset-Rouviere, Corinne Frere, Hervé Chambost, Pierre-Emmanuel Morange, Michel Tsimaratos, Marie-Christine Alessi (France)

PB 4.29-4  Type I interferon dampen platelet production and function
Leonardo Rivadeneyra, Roberto Pozner, Soledad Negrotto, Carlos Fondevila, Ricardo Gomez, Mirta Schattner (Argentina)

PB 4.29-5  Lack of association between NR3C1 polymorphism and glucocorticoid resistance in Chinese patients with immune thrombocytopenia
Min Xuan, Yanhui Yang, Huiyuan Li, Rongfeng Fu, Donglei Zhang, Xian Zhang, Renchi Yang (China)

PB 4.29-6  Liver X receptor (LXR) activation influences murine platelet count only under normolipidemic conditions
Marco van der Stoep, Zhaosha Li, Ronald van der Sluis, Theo van Berkel, Miranda van Eck, Menno Hoekstra, Suzanne Korporaal (The Netherlands)

Microparticles and disease - III  Screen 30X
Moderator: Anoop Enjeti (Australia)

PB 4.30-1  Thrombin generation caused by microparticles in patients with atherosclerosis of the vessels of the lower extremities
Olesya Matvienko, Yury Namestnikov, Olga Golovina, Natalia Saltykova, Olga Smirnova (Russian Federation)

PB 4.30-2  Circulating microparticle number and function vary with age: A study of 120 healthy blood donors
Anoop Enjeti, Angel D’Cruz, Michael Seldon, Lisa Lincz (Australia)

PB 4.30-3  Microparticles in aneurismal subarachnoid hemorrhage: Role in acute and delayed cerebral ischemia
Andrea Artoni, Valeria Conte, Armando Tripodi, Giuliana Merati, Erika Scalambrino, Serena Maria Passamonti, Paolo Bucciarelli, Ida Martinelli (Italy)

PB 4.30-4  Platelet microparticles: Biomarkers of arterial thrombus formation?
Anita Böing, Chi Hau, Romaric Lacroix, Françoise Dignat-George, Auguste Sturk, Rienk Nieuwland (The Netherlands)

PB 4.30-5  Elevated circulating platelet microparticles determine thrombus occlusion in acute coronary syndrome
Anggoro Hartopo, Ira Puspitawati, Muhammad Muntazhar, Suseno Aji, Putrika Gharini, Budi Setianto, Nahar Taufiq, Lucia Dinarti (Indonesia)

PB 4.30-6  Increased procoagulant microparticle levels in women with recurrent pregnancy loss
Rucha Patil, Kanjaksha Ghosh, Shrimati Shetty, Purnima Satoskar (India)
**Atherosclerosis: Risk factors**

**Screen 31**

**Moderator: François Laliberté (Canada)**

**PB 4.31-1** Can we identify patients at risk of recurrent coronary artery disease?  
Ghatge Madan, M. Sangeeta, Ankit Sharma, Vijay Kakkar, Rajani Kanth Vangala (India)

**PB 4.31-2** Risk Factors Associated with Myocardial Infarction in Venous Thromboembolism Patients  
François Laliberté, Edith Nutescu, Patrick Lefebvre, C. Damaraju, Jonathan Rondeau-Leclaire, Brahim Bookhart, Joyce LaMori, Jeff Schein, Scott Kaatz (Canada)

**PB 4.31-3** Further evidence in support of the association between atherosclerosis and venous thrombosis  
Marta Milan, Valentina Vedovetto, Fabio Dalla Valle, Raffaele Pesavento, Paolo Prandoni (Italy)

**PB 4.31-4** The relationship of FII, FVII, FXIII and fibrinogen levels with conventional risk factors in patients with and without coronary artery disease  
Ana Bronic, Goran Ferencak, Jasna Lenicek Krleza, Robert Bernat (Croatia)

**PB 4.31-5** Subclinical atherosclerosis in patients infected with Human Immunodeficiency Virus Early predictors  
Gabriela De Larrañaga, Federico Aranda, Stella Oliva, Edgardo Bottaro, Karla Bendezú, Roberto Gonzalez, Gabriela Camicia, Analía Lucero, Silvia Perés Wingeyer (Argentina)

**PB 4.31-6** Comprehensive analysis of global gene expression and microRNA profile in coronary artery disease  
Jayashree Shanker, Prathima Arvind, Yogeeshwari Sathyamurthy, Sriarthika Jambunathan, Jiny Nair, Priyanka Setty, Vijay Kakkar (India)

**Atherosclerosis: Miscellaneous - II**

**Screen 32**

**Moderator: Ahmed Elkalioubie (France)**

**PB 4.32-1** Association of obesity markers and atherothrombotic biomarkers in coronary artery disease  
Jayashree Shanker, Vandana Ravindran, Dhanalakshmi Bhasker, Sridhara Hebbagodi, Vijay Kakkar (India)

**PB 4.32-2** Free leptin, carotid plaque phenotype and relevance to related symptomatology: Insights from the OPAL-Lille carotid endarterectomy study  
Ahmed Elkalioubie, Christophe Zawadzki, Giulia Chinetti-Gbaguidi, Delphine Corseaux, Francis Juthier, Stephan Haulon, Bart Staels, Sophie Susen, Eric van Belle, Annabelle Dupont (France)

**PB 4.32-3** Nicotinic acid/laropiprant: Negative effects on vascular function  
Gabriele Cioni, Rossella Marcucci, Giovanna D’Alessandri, Sandra Fedi, Agatina Alessandrello Liotta, Lucia Mannini, Cinzia Fatini, Rosanna Abbate (Italy)

**PB 4.32-4** Oxidized LDL: A link between Atherosclerosis and Alzheimer’s Disease?  
Mayara Faria, Marina Grossi, Gisele Gonçalves, Maria das Graças Carvalho, Lirlândia Sousa, Josianne Silveira, Ieda De Fátima Silva (Brazil)

**PB 4.32-5** Plasma salusin-beta levels in health and atherosclerotic cardio- and cerebro-vascular diseases  
Kazumi Fujimoto, Takuya Watanabe, Masayoshi Shichiri, Takatoshi Koyama (Japan)

**PB 4.32-6** Urinary Biomarker discovery for coronary artery disease risk prediction using global proteomic analysis  
Ghatge Madan, M. Sangeeta, Ankit Sharma, Vijay Kakkar, Rajani Kanth Vangala (India)
EPOSTERS (B)  

Thursday, July 4, 2013  
13:30 - 15:00

Fibrinolytic system: Basic - IV  
Screen 33

**Moderator: Brittany Bannish (USA)**

**PB 4.33-1** Homocysteine plasma levels influence fibrinolytic capacity but not in vitro cleavage of fibrin by exogenous plasmin in patients with pulmonary embolism  
Anna Paola Cellai, Donatella Lami, Emilia Antonucci, Rossella Marcucci, Claudia Fiorillo, Matteo Becatti, Caterina Cenci, Lucia Mannini, Rosanna Abbate, Domenico Prisco (Italy)

**PB 4.33-2** Real time imaging of plasminogen binding to platelet-rich micro-thrombus and its effective lysis by tPA infusion in vivo  
Tetsumei Urano, Aki Tanaka, Tomasz Brzoska, Yuko Suzuki (Japan)

**PB 4.33-3** Kinetic and thrombolytic properties of streptokinase-polyethylene glycol conjugates  
Lilia Mukhametova, Roza Aisina, Dmitrii Gulin, Karina Gershkovich, Sergei Varfolomeyev (Russian Federation)

**PB 4.33-4** Insights from a mathematical model of fibrinolysis  
Brittany Bannish, James Keener, John Weisel, Aaron Fogelson (USA)

**PB 4.33-5** The impact of bradykinin-potentiating peptide on fibrinolytic activity of blood plasma on the model of diabetes mellitus 1 type  
Tatyana Shubina (Russian Federation)

**PB 4.33-6** Diagnosis performance of thromboelastography to assess tissue plasminogen activator induced fibrinolysis  
Anne Godier, Kiran Parmar, Beverley Hunt (France)

Fibrinolytic system: Basic - V  
Screen 34

**Moderator: Michael Etscheid (Germany)**

**PB 4.34-1** Assessing the extent of fibrinogenolysis by t-PA seen in bleeding trauma patients and what is the extent of its inhibition by tranexamic acid using an in vitro model  
Anne Godier, Kiran Parmar, Beverley Hunt (France)

**PB 4.34-2** Quantification of the CPU system in individuals by means of a clot lysis assay in combination with an activity-based assay  
Dorien Leenaerts, Anne-Marie Lambeir, Dirk Hendriks (Belgium)

**PB 4.34-3** Increased Fibrinolysis on Blood Outgrowth Endothelial Cells (BOEC) from Chronic Thromboembolic Pulmonary Hypertension (CTEPH) patients  
Sarah Mangles, Koralia Paschalaki, Richard Starke, Carolyn Millar, Anna Randi, Michael Laffan (United Kingdom)

**PB 4.34-4** Spatial clot lysis rate is regulated by clot growth rate  
Ansar Zhalyalov, Alexey Shibeko, Mikhail Panteleev, Fazoil Ataullakhanov (Russian Federation)

**PB 4.34-5** Hemostatic alterations induced by Micrurus tener tener venom in C57BL/6 mice  
Emelyn Salazar, Ana Salazar, Peter Taylor, Alexis Rodriguez-Acosta, Elda Sanchez, Zoila Carvajal, Belsy Guerrero (Venezuela)

**PB 4.34-6** The Factor VII Activating Protease (FSAP) regulates fibrin clot structure and fibrinolysis by direct interaction with fibrinogen  
Michael Etscheid, Julian Lankes, Nicole Beer, O. Rannou, Sandip Kanse (Germany)
Thursday, July 4, 2013  13:30 - 15:00

Haemophilia A: Basic- IV  Screen 35

**Moderator:** Christine Hough [Canada]

**PB 4.35-1** Analysis of neutralizing and non-neutralizing anti-canine FVIII antibodies in hemophilia A dogs treated with FVIII gene therapy
Christine Hough, Barbara Vidal, James Ahlin, Christine Brown, Lori Harpell, Sandra Powell, Valder Arruda, Margarethe Ozelo, David Lillicrap [Canada]

**PB 4.35-2** Structural and functional characterization of clinical phase 1 and phase 2/3 material of BAX 855, a PEGylated recombinant FVIII
Peter Turecek, Gerald Schrenk, Michael Graninger, Herbert Gritsch, Peter Matthiessen, Hanspeter Rottensteiner, Martin Kaliwoda, Hartmut Ehrlich, Friedrich Scheillinger [Austria]

**PB 4.35-3** Global haemostatic assays in monitoring the effect of bypassing agent therapy in haemophilia A patients with inhibitors- an in-vivo prospective crossover study
Hoa Tran, Stine Bjørnsen, Thor Ueland, Are Hugo Pripp, Geir Tjønnfjord, Pål Andre Holme [Norway]

**PB 4.35-4** Improved strategy for rapid genetic analysis of haemophilia A
Rima Daridik, Ariella Zivelin, Shirley Azar-Avivi, Nurit Kornbrot, Aviya Dvir, Gili Kenet, Uriel Martinowitz [Israel]

**PB 4.35-5** The inhibition mechanism of factor FYIII Trp1707Ser mutation associated inhibitors
Xi Wu, Ye Ling Lu, Xue Feng Wang, Qiu Lan Ding, Jing Dai, Xiao Dong Xi, Hong Li Wang [China]

**PB 4.35-6** Copy number variation (CNV) within the F8 gene causing haemophilia A; gene dosage determination of gross gene deletions/duplications by MLPA
Vincent Jenkins, Catriona Keenan, Eadaoin O’Shea, Barry White, James O’Donnell, Niamh O’Connell [Ireland]

---

Haemophilia A: Clinical - XIV  Screen 36

**Moderator:** Manuel Carcao [Canada]

**PB 4.36-1** Correlation between phenotype and genotype in a large unselected cohort of 621 PUPS (previously untreated patients) with severe haemophilia A
Manuel Carcao, Marijke van den Berg, Rolf Ljung, Maria Elisa Mancuso [Canada]

**PB 4.36-2** Evaluation of unfavourable cardiovascular risk factors and metabolic syndrome in young haemophiles
Melek Erbas, Bulent Zulfikar, Nihal Ozdemir, Ahmet Aydin [Turkey]

**PB 4.36-3** Development of Factor VIII inhibitors and its association with HLA class I and II alleles in Pakistani hemophilia A patients
Arshi Naz, Shariq Ahmed, Muhammad Nadeem, Tahir Shamsi [Pakistan]

**PB 4.36-4** Laboratory control of replacement therapy in severe hemophilia A patients
Anna Balandina, Anastasiya Zaparyi, Dmitry Polokhov, Elena Yakovleva, Alexander Kargaltsev, Nadezhda Konyashina, Tatyana Polysanskaya, Konstantin Kopylov, Fazoi Ataullakhanov [Russian Federation]

**PB 4.36-5** ORTHem 15-25: French retrospective national survey of different treatment regimens in patients with severe (factor VIII or IX = 2%) haemophilia A and B between 15 and 25 years old
Sandrine Meunier, Roseline D’Oiron, Hervé Chambost, Benoît Guillet, Edita Dolimier, Béatrice Villette [France]
Thursday, July 4, 2013 13:30 - 15:00

PB 4.36-6  Implementing pharmacokinetic (PK)-guided dosing in hemophilia; a discrete choice experiment (DCE) in an international cohort of hemophilia professionals ['OPTI-CLOT' studies]
Janseke Lock, Gamze Urhan, Mariette Driessens, Paul Brons, Britta Laros-van Gorkom, Felix van der Meer, Frans Smiers, Esther de Bekker-Grob, Marjon Cnossen [The Netherlands]

Haemophilia A: Clinical - XV
Screen 37

Moderator: Kapil Saxena [USA]

PB 4.37-1  Different neutralizing effects of factor VIII concentrates associated with von Willebrand factor and the inhibitor epitopes
Koji Yada, Keiji Nogami, Ogiwara Kenichi, Hiroaki Minami, Midori Shima [Japan]

PB 4.37-2  Pharmacokinetics, efficacy, and safety of BAY 81-8973, a full-length plasma-protein-free recombinant factor VIII product: Results from the LEOPOLD trial
Kapil Saxena, Shadan Lalezari, Johannes Oldenburg, Heinz Delesen, Anita Shah, Despina Tseneklidou-Stoeter, Monica Maas Enriquez [USA]

PB 4.37-3  Treatment of bleeding episodes in subjects with haemophilia A with long-lasting recombinant factor VIII Fc fusion protein (rFVIIIFc) in the phase 3 A-LONG Study
Margaret Ragni, Neil Josephson, Johnny Mahlangu, John Pasi, David Perry, Jerry Powell, Amy Shapiro, Snejana Krassova, Feriandras Greblikas, Karen Nugent, Aoife Brennan, Alvin Luk, Glenn Pierce [USA]

PB 4.37-4  Does prophylactic factor replacement prevent asymptomatic microscopic haematuria in adult people with severe haemophilia?
Soysal Teoman, Cem Ar, Mahir Cengiz, Derya Kececi, Ahmet Emre Eskazan, Ayse Salihoglu, Emine Gulturk, Seniz Ongoren Aydin, Zafer Baslar [Turkey]

PB 4.37-5  Ageing, haemophilia A and associated bleeding disorders - whose problem is it?
Georgie Robinson, Jackie Schuster, Savita Rangarajan [United Kingdom]

PB 4.37-6  Impact of children with inhibitors on caregiver burden
Mitch DeKoven, Hoa Pham, Won Lee, Julie Powers, Laurie Kelley, David Cooper, Tami Wisniewski [USA]

Haemophilia A: Clinical - XVI
Screen 38

Moderator: Paul Batty [United Kingdom]

PB 4.38-1  Immunological detection of factor VIII antibodies in congenital and acquired haemophilia A
Paul Batty, Gary Moore, Sean Platton, James Maloney, Louise Bowles, John Pasi, Savita Rangarajan, Daniel Hart [United Kingdom]

PB 4.38-2  Long-term anti-FVIII antibody response in Bethesda-negative haemophilia A patients on continuous replacement therapy
Jenny Klintman, Andreas Hillarp, Erik Berntorp, Jan Astermark [Sweden]

PB 4.38-3  Carrier and prenatal diagnosis in sporadic haemophilia A and B families in China
Yeling Lu [China]

PB 4.38-4  Quality of hemophiliacs treatment in India - a survey
Anupam Sachdeva, Mohammed Ramzon, Rishabh Gulati, Veronique Dinand, Satya Yadav [India]

PB 4.38-5  The impact of hemarthropathy on the QoL of Korean patients with severe hemophilia A: The critical level of hemarthropathy for the QoL
Soeun Jun, Chur wu you, Ho Jin Shin, Jung Woo Han [South-Korea]
Social determinants of quality of life in persons with hemophilia
Roya Dolatkhah, Ali Fakhari, Mohammad Zakaria Pezeshki, Reza Shahbanelouei, Mehr Gholchin, Nasrin Tavassoli (Iran)

Peak FVIII levels and time spent in hemostatically effective FVIII range post-infusion correlates with improved efficacy for prophylaxis in hemophilia A: A closer look at the other end of the curve
Leonard Valentino, Peter Collins, Steven Pipe, Victor Blanchette, Philip Schroth, Sandor Fritsch, Bruce Ewenstein, Gerald Spotts (USA)

Self-efficacy in the Dutch pediatric population; reliability and validity of the Hemophilia Self-Efficacy Scale (HSES)
Janske Lock, Hein Raat, Channa Hijnmans, Marjolein Peters, Rienk Tamminga, Frank Leebeek, Henriette Moll, Marjon Cnossen (The Netherlands)

Recombinant activated factor VII use for surgical/invasive procedures in congenital haemophilia with inhibitors and acquired hemophilia: Analysis from 10-year Japanese post-marketing surveillance
Hideyuki Takedani, Midori Shima, Yasuo Horikoshi, Takatoshi Koyama, Katsuyuki Fukutake, Mitsuhiro Kuwahara, Naoki Ishiguro (Japan)

The first review of global spontaneous adverse event reports for a third generation recombinant factor VIII concentrate (Octocog Alfa): 10 years of safety experience
Roger Berg, Alessandro Gringeri, Armin Reininger (Austria)

National Haemophilia Registry of China - a developing registry
Feng Xue, Renchi Yang, Lei Zhang (China)

Comparison of a ELISA FVIII inhibitor assay with the Nijmegen Modified Bethesda assay in patients with inherited and acquired Haemophilia A
Anne Riddell, William Pickering, Pura Lawler, Leyla Yildiz, Anja Drebesh, Thynn Yee (United Kingdom)

Frequent off-label use of fondaparinux in patients with suspected acute heparin-induced thrombocytopenia (HIT) - final results from the GerHIT multi-centre registry study
Marc Schindewolf, Julia Steindl, Jan Beyer-Westendorf, Sebastian Schellong, Pascal Dohmen, Johannes Brachmann, Katharina Madiener, Bernd Pöttsch, Robert Klamroth, Edelgard Lindhoff-Last (Germany)

Apixaban as an alternate anticoagulant for the management of patients with heparin-induced thrombocytopenia
Jeanine Walenga, Margaret Prechel, Debra Hoppensteadt, Vicki Escalante, Talhah Chaudhry, Walter Jeske, Mamdouh Bakhos (USA)

Rapid exclusion of the diagnosis of immune HIT by AcuStar HIT and heparin-induced multiple electrode aggregometry: A prospective monocenter study
Valentine Minet, Nicolas Bailly, Justine Baudar, Sébastien Walbrecq, Christian Chatelain, Bernard Chatelain, Jean-Michel Dogné, François Mullier (Belgium)

Prospective comparison of the HIT expert probability (HEP) score versus the Warkentin’s 4T’s score in a quaternary care center
Navid Farahani, Sumire Kitahara, Oxana Tcherniantchouk (USA)
<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>PB 4.40-5</td>
<td>Cost-effective HIT diagnosis: Utilizing IgG-specific PF4 assays reduces the number of confirmatory serotonin release assays without missing true HIT</td>
<td>Navid Farahani, Oxana Tcherniantchouk, Sumire Kitahara (USA)</td>
</tr>
<tr>
<td>PB 4.40-6</td>
<td>Incidence of Heparin-induced thrombocytopenia in sick children who used unfractioned heparin for prophylaxis in intensive care unit</td>
<td>Kaan Kavakli, Gabil Mursalov, Bulent Karapinar, Deniz Yilmaz Karapinar, Can Balkan, Nihal Karadas (Turkey)</td>
</tr>
<tr>
<td>PB 4.41-1</td>
<td>Variant Bernard Soulier syndrome with ambiguous mutation data: A diagnostic dilemma</td>
<td>Jacky Cutler, Alan Drew, Gary Moore, Bella Madan, Mike Mitchell, Steven Okoli (United Kingdom)</td>
</tr>
<tr>
<td>PB 4.41-2</td>
<td>Mild bleeding diathesis in 10 patients due to functional deficiency of plasminogen activator inhibitor type 1 (PAI-1)</td>
<td>Teresa Iwaniec, Joanna Zdziarska, Ewa Wypasek, Anetta Undas, Agnieszka Padjas, Jacek Musial, Aleksander Skotnicki (Poland)</td>
</tr>
<tr>
<td>PB 4.41-3</td>
<td>Congenital Factor XIII deficiency in women; a systematic review of literature</td>
<td>Lava Sharief, Joanna Davies, Debra Pollard, Christine Lee, Rezan Abdul-Kadir (United Kingdom)</td>
</tr>
<tr>
<td>PB 4.41-4</td>
<td>Solvent-detergent plasma abolished severe bleeding tendency and normalized procoagulant activity in Calibrated Automated Thrombogram both in plasma and platelets of a FVIII deficient patient</td>
<td>Lauri Virtanen, Annukka Jouppila, Lotta Joutsi-Korhonen, Marja Lemponen, Riitta Lassila (Finland)</td>
</tr>
<tr>
<td>PB 4.41-5</td>
<td>An international systematic study for the assessment of bleeding phenotype in platelet type von Willebrand disease</td>
<td>Harmanpreet Kaur, Stephen Scovil, Kimberly MacEachern, Paula James, Maha Othman (Canada)</td>
</tr>
<tr>
<td>PB 4.41-6</td>
<td>Long-term secondary prophylaxis in rare factor deficiencies of children in eight cases</td>
<td>Zafer Salcioğlu, Arzu Akçay, Deniz Tugcu, Hulya Saylan Sen, Gonul Aydoğdu, Ferhan Akıcı, Muge Gökce, Nuray Aktay Ayaz, Rengin Siraneci, Zafer Başlar (Turkey)</td>
</tr>
<tr>
<td>PB 4.42-1</td>
<td>Health-related quality of life and caregivers’ burden in partners of persons with haemophilia</td>
<td>Karin Lindvall, Sylvia Von Mackensen, Sölve Elmståhl, Erik Berntorp (Sweden)</td>
</tr>
<tr>
<td>PB 4.42-2</td>
<td>Congenital FXI deficiency: Evaluation of bleeding phenotype and correlation with FXI activity (FXI:Act)</td>
<td>Cristina Santoro, Roberta Di Mauro, Erminia Baldacci, Caterina Mercanti, Roberta Abbruzzese, Francesco Barone, Raffaele Angelo Bochicchio, Laura Parlanti, Maria Gabriella Mazzucconi (Italy)</td>
</tr>
<tr>
<td>PB 4.42-3</td>
<td>A novel mutation in downstream half of WASP gene correlates with worse clinical presentation of the wiskott-aldrich syndrome</td>
<td>Samuel Medina, Lucia Siqueira, Marina Colella, Maria Marluce Vilela, Margareth Ozelo (Brazil)</td>
</tr>
</tbody>
</table>
Thursday, July 4, 2013  
13:30 - 15:00

**PB 4.42-4** Changes in FXIII levels during various stages of pregnancy  
Lava Sharief, Flora Peyvandi, Andrew Lawrie, Ian Mackie, Colette Smith, Joanna Davies, Rezan Abdul-Kadir (United Kingdom)

**PB 4.42-5** Inhibitor in Congenital Factor VII Deficiency, report of two cases  
Mohammad Reza Baghaipour, Ghassem Rastegar Lari, Mohammadreza Shervinrad, Shirin Ravanbod, Mohammad Jazebi (Iran)

**PB 4.42-6** Laboratory assessment of Hermansky-Pudlak Syndrome: A case report  
Ann-Kathrin Pilgrimm-Thorp, Daniele Pilitteri, Thomas Scholz, Manuela Krause, Carl Kirchmaier (Germany)

**Von Willebrand disease: Clinical - V**  
Screen 43  
Moderator: Dawn Goodyear (Canada)

**PB 4.43-1** The Effectiveness of screening of Exon 28 in patients with type 3 von Willebrand disease  
Shirin Ravanbod, Said Enayat, Maryam Rassoulzadegan, Farzaneh Nasirnejad, Ghassem Rastegar Lari, Arian Chupan, Mohammad Reza Baghaipour, Mohammad Jazebi, Fereydoun Ala (Iran)

**PB 4.43-2** Four novel von Willebrand factor mutations in mild von Willebrand disease  
Giancarlo Castaman, Sofia Giacomelli, Antonio Coppola, Francesco Rodeghiero, Alberto Tosetto (Italy)

**PB 4.43-3** Atorvastatin ameliorates angiodysplasia-associated bleeding in von Willebrand disease  
Dawn Goodyear, Man-Chiu Poon (Canada)

**PB 4.43-4** Predictors of von Willebrand disease diagnosis in individuals with borderline von Willebrand factor plasma levels  
Paolo Bucciarelli, Simona Siboni, Francesca Stufano, Eugenia Biguzzi, Maria Teresa Canciani, Claudia Mistretta, Luciano Baronciani, Luca Lotta, Frits Rosendaal, Flora Peyvandi (Italy)

**PB 4.43-5** Significant improvement of live birth rate in VWD patients with repetitive reproductive failure treated with VWF concentrate  
Mario Von Depka Prondzinski, Anja Henkel-Klene, Stefanie Döpke, Mahnaz Ekhlasi-Hundrieser, Carsten Detering (Germany)

**PB 4.43-6** Analysis of clinical phenotype and genotype in patients with VWD2B, in a single institution of Argentina  
Adriana Woods, Emilse Bermejo, Analía Sánchez-Luceros, Ana Kempfer, Julio Calderazzo, Susana Meschengieser, Maria Lazzari (Argentina)

**Von Willebrand disease: Clinical - VI**  
Screen 44  
Moderator: Jane Needham (United Kingdom)

**PB 4.44-1** Individually tailored prophylaxis in type 3 von willebrand disease patients: Efficacy and safety of a von Willebrand factor concentrate with a low factor VIII content  
Emna Gouider, Kathelijne Peerlinck, Cédric Hermans, Alain Gadiesseur, Anna Klukowska, Nathalie Knuchel, Wil Stevens, Michal Matysiak, Baltis Meddeb, Celine Henriet

**PB 4.44-2** Analysis of clinical severity of VWD2A and VWD2M patients, according to their candidate mutations, in a single institution of Argentina  
Adriana Woods, Analía Sánchez-Luceros, Ana Kempfer, Julio Calderazzo, Susana Meschengieser, Maria Lazzari (Argentina)
ePOSTERS (B)  

Thursday, July 4, 2013  13:30 - 15:00

PB 4.44-3  Evaluation of a commercial von Willebrands factor: Factor VIII binding assay for the identification of von Willebrands disease Normandy variant
Jane Needham, Helen Lewis, Savita Rangarajan [United Kingdom]

PB 4.44-4  Genetic analyses of two patients with von Willebrand disease (VWD) type2B: Implication of type 2B in the differential diagnosis for thrombocytopenic patients
Naomi Sanda, Ryuhei Tanaka, Mayuko Kishimoto, Nobuaki Suzuki, Shini Kunishima, Mayumi Takatsu, Hiroyuki Matsumoto, Shigeo Nakamura, Tadashi Matsushita [Japan]

PB 4.44-5  Analysis of von Willebrand disease in the South Moravian population  [Czech Republic]: The BRNO-vWD Study: An update
Inge Vangenechten, Petr Smejkal, Ondrej Zapletal, Fatima Bouddount, J. Zavrelova, Jan Blatny, Miroslav Penka, Jan Jacques Michiels, Alain Gadisseur [Belgium]

PB 4.44-6  DDAVP use and cardiovascular outcomes in patients with bleeding disorders undergoing invasive procedures
Deepa Suryanarayan, Dawn Goodyear, Man-Chiu Poon [Canada]

Anticoagulant agents - XVIII  Screen 45
Moderator: Joanne van Ryn [Germany]

PB 4.45-1  Factors predicting choice of anticoagulant treatment in elderly patients with VTE - findings from the RITE registry
Raluca Sterpu, Laurent Bertoletti, Isabelle Mahe,Sabiba Henou, Michelle Pinson, Luis Hernandez, Sebastien Schellong, Ferran Garcia-Bragado, Manuel Monreal [Spain]

PB 4.45-2  Association between bleeding risk and persistence on warfarin therapy in patients with VTE in clinical practice
Scott Kaatz, An-Chen Fu, Azza AbuDagga, Joyce LaMori, Brahim Bookhart, C. Damaraju, Hiangkit Tan, Jeff Schein, Edith Nutescu [USA]

PB 4.45-3  Differential effects of dabigatran etexilate and ticagrelor on bleeding as assessed by washed blood and shed blood tests in healthy subjects
Joanne van Ryn, Thomas Giessmann, Ghazaleh Gouya, Michael Wolzt, Johanna Schurer, Maximilian Lobbmeier, Martin Bruackmann [Germany]

PB 4.45-4  A randomized clinical trial for the effects of an anticoagulation clinic in heart disease patients at a Brazilian public hospital
Maria Martins, Cibele César, Daniel Ribeiro, Vandack Nobre, João Oliveira, Daniel Palhares, Gabriela Botelho, Manoel Rocha, Antonio Ribeiro [Brazil]

PB 4.45-5  Correctness of the identification by patients of colour of urine samples obtained a point of care test for dabigatran and rivaroxaban
Job Harenberg, Shanshan Du, Sandra Krämer, Christel Weiss [Germany]

PB 4.45-6  Analysis of the preference of patients to choose conventional or new oral anticoagulants based on a short questionnaire
Shabnam Zolfaghar, Christophe Kremer, Nadja Abou-Ayash, Lutz Frölich, Job Harenberg [Germany]

Anticoagulant agents - XIX  Screen 46
Moderator: Nienke van Rein [The Netherlands]

PB 4.46-1  Asian patients with splanchnic vein thrombosis: A sub-analysis from an international registry
Nicoletta Riva, Soo-Mee Bang, Doyeun Oh, Jeong-Ok Lee, Sam Schulman, Maria Teresa Sartori, Elvira Grandone, Jan Beyer-Westendorf, Giovanni Barillari, Dario Di Minno, Rita Duce, Allessandra Malato, Rita Santoro, Francesco Dentali, Walter Ageno [Italy]
**Anticoagulant agents - XX**

**Moderator: Vicky Tagalakis (Canada)**

<table>
<thead>
<tr>
<th>PB 4.46-2</th>
<th>Vitamin K in oral solution or tablets: A cross-over study and randomized controlled trials to compare effects</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Nienke van Rein, Willem Lijfering, Edward Gebuis, Ernst-Jan Groeneveld, Frits Rosendaal, Felix van der Meer (The Netherlands)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PB 4.46-3</th>
<th>Efficacy and safety of dabigatran in over 75 years old patients with atrial fibrillation</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Alenka Mavri, Petra Sinigoj, Nina Vene, Tjasa Vizintin-Cuderman, Gregor Tratar, Mirjam Gubensek, Marko Mlkič, Nina Ostasevski-Fernandez (Slovenia)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PB 4.46-4</th>
<th>Assessment of apixaban on automated analyzers using a Liquid Anti-Xa assay</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Zhenghua Cao, Chun Kung, Ralph Bottenus, Mark Triscott (USA)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PB 4.46-5</th>
<th>The influence of Novel Oral Anticoagulants (NOAC) on Routine Coagulation Assays</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mary Byrne, Mairead Doyle, Barry White, Kevin Ryan, James O’Donnell, Niamh O’Connell (Ireland)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PB 4.46-6</th>
<th>Moderate-intensity warfarin therapy in extended treatment of venous thromboembolic disease improve patient comfort, decreasing bleeding risk without increasing risk of relapse: a matched-paired study</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Francesc Casals Sole (Spain)</td>
</tr>
</tbody>
</table>

**Anticoagulant agents - XXI**

**Moderator: Plino Alekseeva (Russian Federation)**

<table>
<thead>
<tr>
<th>PB 4.47-1</th>
<th>The effect of venous thromboembolism treatment patterns and clinical outcomes in a real world population: The Q-VTE study cohort</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Vicky Tagalakis, Valerie Patenaude, Susan Kahn, Samy Suissa (Canada)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PB 4.47-2</th>
<th>Coagulation factor concentrates: In vitro experimental studies with steady and circulating human blood</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Eduardo Arellano-Rodrigo, Ana M Galan, Veronica Sanz, Patricia Molina, Joan Carles Reverter, Dolors Tassies, Maribel Diaz-Ricart, Gines Escolar (Spain)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PB 4.47-3</th>
<th>Adherence to anticoagulant treatment with dabigatran in a real-world setting</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Sam Schulman, Brigit Shortt, Marlene Robinson, John Eikelboom (Canada)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PB 4.47-4</th>
<th>Thrombelastometry monitoring of the anticoagulant effect of dabigatran etexilate</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Assia Stancheva (Bulgaria)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PB 4.47-5</th>
<th>Large inter-individual variability of the response to new oral anticoagulants</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Saartje Bloemen, Marieke de Laat, Marisa Ninivaggi, T. Lenderink, Mathie Leers, Bas de Laat, Coenraad Hemker, Raed Al Dieri (The Netherlands)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PB 4.47-6</th>
<th>A single-centre prospective study on fluctuations in INR control for Singapore’s Muslim patients on oral anticoagulation therapy with stable dosing over the months of Ramadan and Hari Raya Aidilfitri</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Yi Feng Lai, Hua Heng Mcvin Cheen, Seng Han Lim, Hui Ing Fiona Yeo, Szu Chin Nah, Ming Chai Kong, Hae Tha Dawn Mya, Lai Heng Lee, Heng Joo Ng (Singapore)</td>
</tr>
</tbody>
</table>

**Anticoagulant agents - XXII**

**Moderator: Plino Alekseeva (Russian Federation)**

<table>
<thead>
<tr>
<th>PB 4.48-1</th>
<th>Aptamer based thrombin inhibitors: Efficacy and functional stability in vitro</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Irina Gribkova, Vera Spiridonova, Alexander Gorbatenko, Elena Sinauridze (Russian Federation)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PB 4.48-2</th>
<th>Laboratory monitoring of novel oral anticoagulants rivaroxaban and dabigatran</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Elise Eerenberg, Pieter Willem Kamphuisen, Meertien Sijpkens, Joost Meijers, Harry Bøller, Marcel Levi (The Netherlands)</td>
</tr>
</tbody>
</table>
**Thurday, July 4, 2013**

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>PB 4.48-3</td>
<td>Thrombin generation assay to monitor the reversal of anticoagulants by FEIBA</td>
<td>Peter Turecek, Gerald Schrenk, Michaela Schaedler, Sylvia Peyrer-Heimstaett, Hanspeter Rottensteiner, Friedrich Scheiflinger (Austria)</td>
</tr>
<tr>
<td>PB 4.48-4</td>
<td>Small-molecule thrombin inhibitors based on derivatives of N-arylbenzamidines</td>
<td>Polina Alekseeva, Elena Fedorova, Elena Kuvaeva (Russian Federation)</td>
</tr>
<tr>
<td>PB 4.48-5</td>
<td>Purification and characterization of fibrinogenolytic serine protease from Agkistrodon brevicaudus venom</td>
<td>Sumiya Byambasuren, Punsaldulam Dashnyam (Mongolia)</td>
</tr>
<tr>
<td>PB 4.48-6</td>
<td>Interaction of defibrotide with dabigatran, rivaroxaban and apixaban in the whole blood, platelet rich plasma and platelet poor plasma studies</td>
<td>Jawed Fareed, Debra Hoppensteadt, Walter Jeske, Omer Iqbal, Daneyal Syed, Evi Kalodiki, Rakesh Wahi (USA)</td>
</tr>
</tbody>
</table>

**Intrinsic pathway of coagulation**

**Screen 49**

**Moderator: Daria Zamolodchikov (USA)**

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>PB 4.49-1</td>
<td>The Alzheimer’s disease-related peptide beta-amyloid accelerates thrombin generation and clot formation in plasma in a factor XII-dependent manner</td>
<td>Daria Zamolodchikov, Thomas Renné, Sidney Strickland (USA)</td>
</tr>
<tr>
<td>PB 4.49-2</td>
<td>Activation of the intrinsic pathway of coagulation without kinin generation in factor XII-deficient chicken plasma</td>
<td>Benedito Prezoto, Mayra Lui, Guacyara Da Motta (Brazil)</td>
</tr>
<tr>
<td>PB 4.49-3</td>
<td>Inhibiting the activation of the intrinsic pathway with a FXII-targeting RNA aptamer</td>
<td>Becky Woodruff, Juliana Layzer, Bruce Sullenger (USA)</td>
</tr>
<tr>
<td>PB 4.49-4</td>
<td>Cycling induces a hypercoagulable state via contact activation</td>
<td>Jelle Posthuma, Rinske Loeffen, René van Oerle, Yvonne Henskens, Hugo ten Cate, Henri Sprok, Paola van der Meijden (The Netherlands)</td>
</tr>
<tr>
<td>PB 4.49-5</td>
<td>Genetic characterization of sever patients effected by FXI deficiency</td>
<td>Giancarlo Castaman, Sofia Giacomelli, Annachiara Giaffrida, Alfredo Dragani, Chiara Biasoli (Italy)</td>
</tr>
<tr>
<td>PB 4.49-6</td>
<td>Novel coumarins with improved solubility as FXIIa inhibitors</td>
<td>Charlotte Bouckaert, Christelle Vancraeynest, Eduard Dolusic, Raphaël Frédérick, Lionel Pochet (Belgium)</td>
</tr>
</tbody>
</table>

**Blood coagulation system - V**

**Screen 50**

**Moderator: Margarethe Geiger (Austria)**

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>PB 4.50-1</td>
<td>Protein C inhibitor and the ambivalent regulation of apoptotic cell removal</td>
<td>Daniela Rieger, Barbora Sokolokova, Margarethe Geiger (Austria)</td>
</tr>
<tr>
<td>PB 4.50-2</td>
<td>Hemostasis in acute respiratory viral infections in often sick children with gene’s polymorphism (asp299gly) toll-4 and (ser 249 pro) toll-6 receptors</td>
<td>Lidia Malezhik, Natalia Karpova, Margarita Malezhik (Russian Federation)</td>
</tr>
<tr>
<td>PB 4.50-3</td>
<td>Developmental Haemostasis: The quantity of haemostatic proteins change with age</td>
<td>Chantal Attard, Tirza van der Straaten, Karlafis Vasiliki, Paul Monagle, Ignjatovic Vera (Australia)</td>
</tr>
<tr>
<td>PB 4.50-4</td>
<td>Effects of rVIIa in thrombocytopenic cord blood derived plasma</td>
<td>Harald Haidl, Gernot Grangl, Axel Schlagenhauf, Bettina Leschnik, Sabrina Schweintzger, Wolfgang Muntean (Austria)</td>
</tr>
</tbody>
</table>
PB 4.50-5  Thrombin generation testing to monitor warfarin anticoagulation in thrombotic antiphospholipid syndrome patients
Maria Efthymiou, Andrew Lawrie, Ian Mackie, Sam Machin, Hannah Cohen [United Kingdom]

PB 4.50-6  Evaluation of a new chromogenic protein C assay (DG-Chrom PC) on the Q Hemostasis Analyzer [Grifols]
Kieron Hickey, Peter Cooper, Steve Kitchen [United Kingdom]

Blood coagulation tests - XV
Moderator: Desiree Coen Herak [Croatia]

PB 4.51-1  Evidence that low protein C is a crucial determinant of the pro-coagulant imbalance in cirrhosis
Veena Chantarangkul, Armando Tripodi, Massimo Primignani, Laura Lemma, Marigrazia Clerici, Flora Peyvandi [Italy]

PB 4.51-2  Effekt of recombinant Factor VIIa BAY 86-6150 on clot formation kinetics
Thomas Siegemund, Natalie Adam, Rosemarie Schobess, Ute Scholz, Annelie Siegemund [USA]

PB 4.51-3  Design and establishment of a biobank for a multicenter and interdisciplinary prospective cohort enrolling elderly patients with venous thromboembolism (SWITCO65+)
Marie Méan, Drahomir Aujesky, Bernhard Laemmle, Christiane Gerschheimer, Sven Trelle, Anne Angelillo-Scherrer [Switzerland]

PB 4.51-4  A simple screening method for the identification of the presence of FVIII and FIX inhibitors by determining the steepness of the routine aPTT reaction curves
Desiree Coen Herak, Marija Milos, Renata Zadro [Croatia]

PB 4.51-5  Laboratory estimation of expanded uncertainty of D dimer measurement by ELISA
Marta Martinuzzo, Ruth Carbone, Luis Barrera, Cecilia Ujhelly, María D’Adamo, Juan Otaso, María Gimenez, Jose Oyhamburu [Argentina]

PB 4.51-6  Validation of rivaroxaban anti-Xa activity measurement
Suman Rathbun, Alfonso Tafur, Karin Mauer, Jana Gausman, Richard Marlà [USA]

Blood coagulation tests - XVI
Moderator: Ihosvany Fernandez-Bello [Spain]

PB 4.52-1  Dilute Russell Viper Venom Time: A useful assay for the monitoring of direct oral anticoagulants in patients?
Jonathan Douxfils, Jean-François Classen, Justine Baudar, Sébastien Walbrecq, Christian Chatelain, Bernard Chatelain, François Mullier, Jean-Michel Dogné [Belgium]

PB 4.52-2  Validation of an assay for determination of anti-xa activity of Rivaroxaban
Xavier Delavenne, Roland Meuley, Denis Baylot, Patrick Mismetti [France]

PB 4.52-3  Point of care heparin monitoring: Combined use of clot rate and clot time
Stephen MacDonald, Roger Luddington, Linda Sharples, Martin Besser [United Kingdom]

PB 4.52-4  Effects of rFVIIa and vatreptacog alfa on clot formation and thrombin generation in blood from patients with haemophilia
Ihosvany Fernandez-Bello, Vivian Lind, Nora Butta Coll, Víctor Jiménez Yuste, Camilla Stenmo, Mirella Ezban [Spain]

PB 4.52-5  Evaluation of the Silica Clotting time (SCT) test as a secondary test for the detection of Lupus Anticoagulant
Tejas Gandhi, Pratima Chowdary, Anne Riddell [United Kingdom]
Hemocompatibility of manufactured nanoparticles: Guidelines proposal
Julie Laloy (Belgium)

Blood coagulation tests - XVII
Screen 53
Moderator: Joachim Stangier (Germany)

Clot waveform analysis in patients with thrombophilia
Thomas Siegumund, Ute Scholz, Annelie Siegumund (USA)

Measurement of dabigatran concentrations by calibrated thrombin clotting time in comparison to LC-MS/MS in human volunteers on dialysis
Joachim Stangier, Michael Schmohl, Dietmar Gansser, Viktoria Moschetti, Ludwin Ley, Stephan Formella (Germany)

Thromboelastometry in liver transplantation of end-stage liver disease and familial amyloidotic polyneuropathy patients
Fernanda Leite, Rui Magathães, Anna Chumakova, Cidália Siva, Eugénia Cruz (Portugal)

Impact of apixaban on haemostasis diagnosis assays: Practical recommendations
Jonathan Douxfils, Jean-François Classen, Justine Baudar, Sébastien Walbrecq, Christian Chatelain, Bernard Chatelain, François Mullier, Jean-Michel Dogné (Belgium)

Thromboelastometry in liver transplantation of end-stage liver disease and familial amyloidotic polyneuropathy patients
Fernanda Leite, Rui Magathães, Anna Chumakova, Cidália Siva, Eugénia Cruz (Portugal)

Blood coagulation tests - XVIII
Screen 54
Moderator: Elena Campello (Italy)

Influence of FIX and FVIII PEGYATION on FIX and FVIII activity based on APTT assays
Anne Lochu, Noura Romari, Jérôme Beltran, Anne Magdetaine, Mirella Ezban, Mette Brunsgaard Hermit (France)

Influence of time delays in sample processing on protein S assays
Kieron Hickey, Peter Cooper, Steve Kitchen, Michael Makris (United Kingdom)

Time-and space-resolved imaging of coagulation as a method for monitoring the effectiveness of LMWH therapy after total hip replacement
Ilya Serebriyskiy, Irina Tararenko, Tatiana Vuimo, Stepan Surov, Ruzanna Ovsepyan, Fazio Ataullakhanov, Andrey Momot (Russian Federation)

Evaluation of TEG® and ROTEM® inter-changeability
Elena Campello, Luca Spiezia, Claudia Radu, Sara Maggiolo, Elena Pelizzaro, Paolo Simioni (Italy)

Unravelling the thrombin generation assay
Joanne Dunster, Helen Byrne, Susan Franks, Jonathan Gibbins, John King (United Kingdom)

Validation of a new liquid fibrinogen assay
Arnaud Berthier, Michelle Blanc, Vincent Foissaud, Elie Khoury (France)
Coagulation factor VIII

Moderator: Qi Lu (USA)

PB 4.55-1 Detection of non-human sialic acid N-glycolylneuraminic acid in Factor VIII products by ultra-performance liquid chromatography with fluorescent labeling
Qi Lu, Baisong Mei, Robert Peters (USA)

PB 4.55-2 Molecular characterization of nine F8 splicing mutations in RNA isolated from patient’s leukocytes. Evaluation of in silico prediction tools accuracy
Lluis Martorell, Irene Corrales, Rafael Parra, Angel Raya, Jordi Barquiner, Francisco Vidal (Spain)

PB 4.55-3 Heat-sensitization allows the detection of anti-FVIII antibodies in patients with acquired hemophilia, who have a negative Bethesda assay
Imre Bodo, Attila Szederjesi, Julia Galgoczi, Kinga Kael, Eszter Nagy, Katalin Pap, Krisztina Szabo, Andrea Varkonyi, Beata Vilimi, Tamas Masszi (Hungary)

PB 4.55-4 Identification of structurally permissive regions in coagulation factor VIII suitable for the insertion of exogenous peptidyl elements
Kulman John, Tongyao Liu, Pei-Yun Beth Chang, Sheng Ding, Susannah Patarroyo-White, Allison Goodman, Sampath Kumar, Deping Wang, Ekta Seth Chhabra, Adam Mezo, Glenn Pierce, Jiang Haiyan, Mei Baisong, Volker Schellenberger, Robert Peters (USA)

Angiogenesis and arterial vascular disorders

Moderator: Zhangsen Huang (Sweden)

PB 4.56-1 A Novel Technetate-99m labeled anti-Intergin Peptide Dimer useful for tumor imaging
Shundong Ji, Yumin Zheng, Changgeng Ruan, Shuang Liu (China)

PB 4.56-2 Optimal antithrombotic strategy in patients undergoing carotid endarterectomy
Temirlan Gamzatov, Aleksei Svetlikov (Russian Federation)

PB 4.56-3 VEGF-A, sVEGFR-1, sVEGFR-2 in myeloproliferative neoplasms
Ewelina Drela, Danuta Rosc, Grazyna Gadomska, Katarzyna Stankowska, Joanna Boinska, Robert Slusarz, Malgorzata Michalska (Poland)

PB 4.56-4 Evaluation of arterial stiffness in β-thalassemia/Hb E patients
Sudarat Satithhunmanid, Noppacharn Uaprasert, Pranee Supharitchanan, Sarinya Puwanant, Suphot Srimahachota, Smonporn Boonyaratavej Songmuang (Thailand)

PB 4.56-5 HDL Cholesterol, Apolipoprotein A-I, and HDL subfractions predict severity of Coronary Artery Disease
Paul Gurbel, Bliden Kevin, Udaya Tantry, Martin Gesheff, Anand Singla, Christopher Franzese, Peter Toth (USA)

PB 4.56-6 Release of PAR1-activated platelets enhances capillary formation of endothelial progenitor cells
Zhangsen Huang, Linjing Zhu, Xinyan Miao, Charlotte Ander, Paul Hjemdahl, Nailin Li (Sweden)
Thursday, July 4, 2013
13:30 - 15:00

Fibrinogen/Fibrin - V
Screen 57

Moderator: Oliver Grottke [Germany]

PB 4.57-1
Combination of haemostatic agents reduces blood loss and enhances survival in a two-hit model of blunt liver injury
Christian Zentai, Rolf Rossaint, Hugo ten Cate, Henri Spronk, Oliver Grottke [Germany]

PB 4.57-2
Detection, localisation and quantification of intracellular phosphorylated human fibrinogen by proximity ligation: A novel approach for the characterisation of fibrinogen phosphorylation
Esther Cooke, Paul Cordell, Richard Pease, Peter Grant, Kerrie Smith [United Kingdom]

PB 4.57-3
Functional aspects of platelets and factor XIII in Hereditary Afibrinogenaemia
Till Hoffmann, Barbara Bomke, Holger Seidel, Klaus Strathmann, Adamantia Alatsaki, Christian Ducker, Rudiger Scharf [Germany]

PB 4.57-4
Fibrinogen clottable protein assays (Clauss assay vs CLOT methods): The effects of fibrinogen & thrombin concentrations on clot formation, structure and clot turbidity
Sanj Raut [United Kingdom]

PB 4.57-5
New liquid quality controls for D-Dimer assays with extended stability
Mathieu Robert, Thomas Vial, Laure Aiello, Thomas Ashwell, Sylvie Langlet, Marc Grimaux [France]

PB 4.57-6
Purification and characterization of a new fibrinogen concentrate: Results at laboratory scale
Hugo Guglielmone, Federico Farias, Ricardo Lombardi, Maria Bernardi, Maria Vitali [Argentina]

Other coagulation factors - IV
Screen 58

Moderator: Egon Persson [Denmark]

PB 4.58-1
Spectroscopic evidence of intrinsic disorder in the activation peptide of coagulation factor X
Egon Persson, Mathilde Kaas Hansen, Birthe Kragelund [Denmark]

PB 4.58-2
Pseudonaja textilis venom FXa is poorly inhibited by human antithrombin
Daniel Johnson, James Huntington [United Kingdom]

PB 4.58-3
Real-life use of activated recombinant Factor VII (rFVIIa) in elderly patients with haemophilia with inhibitors - data from the UK National Haemophilia Database
Gerry Dolan, Jens Bjerre, Charles Hay [United Kingdom]

PB 4.58-4
Ribavirin effects on expression of coagulation factors in HepG2 cells
Yumi Ando, Atsuo Suzuki, Eriko Okuyama, Moe Murata, Io Kato, Yuki Takagi, Akira Takagi, Takashi Murate, Hidehiko Saito, Tetsuhiho Kojima [Japan]

PB 4.58-5
Elimination capacity of Transmissible Spongiform Encephalopathy (TSE) model agents by the production process of therapeutic antithrombin
Francisco Figueras, Magdalena Otegui, Francescisco Belda, Andrea Vincent, Santiago Caballero, Jose Diez, Rodrigo Gajardo, Juan Jorquera [Spain]

PB 4.58-6
A prospective, open-label, randomized, parallel study with AICC to evaluate the efficacy and safety of prophylactic versus on-demand treatment in hemophilia A or B subjects with inhibitors
Sandra Antunes, Srilatha Tangada, Oleksandra Stasyshyn, Vasily Mamonov, Julia Phillips, Norma Guzmán-Becerra, Ani Grigorian, Phillip Schroth, Bruce Ewenstein, Wing Yen Wong [Brazil]
Regulation of coagulation and fibrinolysis - IV

Moderator: William Sheffield (Canada)

PB 4.59-1 Applying phage display to screen a library of α1-protease inhibitor mutants for thrombin inhibitory activity
William Sheffield, Benjamin Scott, Richard Gierczak (Canada)

PB 4.59-4 Peritoneal mesothelium expresses functionally active thrombomodulin
John Morser, Zhifei Shao, Lawrence Leung (USA)

PB 4.59-5 Role of platelets in the regulation of the spatial propagation of fibrin clot
Valentina Budkova, Anna Balandina, Anastasiya Zapariy, Fazli Ataullakhanov, Mikhail Panteleev (Russian Federation)

PB 4.59-6 Coleus forskohlii extract attenuates the anti-coagulation activity of warfarin
Tsuyoshi Chiba, Kaori Yokotani, Yuko Yamazaki, Fumio Shimura, Shizuo Yamada, Kazumasa Shinozuka, Yoko Sato, Keizo Umegaki (Japan)

Cancer and thrombosis - X

Moderator: Judith Kooiman (The Netherlands)

PB 4.60-1 Biomarker profiling of bladder cancer patients undergoing radical cystectomy. Relevance of thrombotic and inflammatory processes
Debra Hoppensteadt, Melanie Clark, Marcus Quek, Omer Iqbal, Daniel Kahn, Josephine Cunanan, Jawed Fareed (USA)

PB 4.60-2 Prevalence of unexpected pulmonary embolism at contrast-enhanced CT scan performed for cancer staging in patients with advanced lung cancer
Melina Verso, Laura Franco, Stefano Mosca, Matthias Fischer, Rita Chiari, Valeria Marconi, Luca Pagliuca, Giancarlo Aghelli (Italy)

PB 4.60-3 Impact of chronic kidney disease and treatment with LMWH on the risk of major bleeding in patients with cancer-associated venous thromboembolism
Judith Kooiman, Paul den Exter, Suzanne Cannegieter, Saskia Le Cessie, Jorge Del Toro, Joan Cartes Sahuquillo, José Maria Pedrajas, Menno Huisman (The Netherlands)

PB 4.60-4 Von Willebrand factor, ADAMTS13 levels and prediction of venous thromboembolism in patients with cancer
Marion Pepin, Ankie Kleinjan, David Hajage, Harry Büller, Marcello Dinisio, Pieter Willem Kamphuisen, Isabelle Mahe, Alain Stepanian (France)

PB 4.60-5 Thrombotic events in children with malignancies in relation to treatment components of chemotherapy
Alexandra Russo, Arthur Wingerter, Johanna Dudda, Jaroslava Feketeova, Inge Scharrer, Jörg Faber (Germany)

PB 4.60-6 Impact of haemophilia on cancer detection and management: a retrospective study
Christine Biron-Andreani, Philippe De Moerloose, Roseline D’Oiron, Hervé Chambost, Jean-François Schved, Cédric Hermans (France)
**Cancer and thrombosis - XI**

**Moderator: Susan Lakoski (USA)**

**PB 4.61-1**
Recombinant thrombomodulin reduces the elevation of some biomarkers after allogeneic hematopoietic stem cell transplantation
Shosaku Nomura, Kazuyoshi Ishii, Shinya Fujita, Hideaki Yoshimura, Masaaki Hotta, Takahisa Nakanishi, Tomoki Ito (Japan)

**PB 4.61-2**
Peak Factor Xa generation as a candidate biomarker for bevacizumab-induced thrombotic and bleeding events
Susan Lakoski, Kathleen Brummel-Ziedins, Gregory Connolly, Maria Bravo, Mary Cushman, Alok Khorana (USA)

**PB 4.61-3**
Anticoagulant treatment of cancer patients with pulmonary embolism in the real world
Ankie Kleinjan, Barbara Hutten, Marcello Di Nisio, Pieter Willem Kamphuisen, Harry Bülter (The Netherlands)

**PB 4.61-4**
L-asparaginase induced laboratory and clinical hemostasis impairments and use of replacement therapy in children treated from acute lymphoblastic leukemia - single center experience
Milena Jovic, Dragan Micic, Milos Kuzmanovic, Olivera Serbic-Nonkovic, Ankica Jovanovic (Serbia)

**PB 4.61-5**
Thrombotic events in acute promyelocytic leukemia - Single center experience
Mitrovic Mirjana, Nada Suvajdzic, Ivo Elezovic, Andrija Bogdanovic, Irena Djunic, Natasa Colovic, Marijana Virijevic, Ana Vidovic, Dragica Tomin (Serbia)

**PB 4.61-6**
Thrombotic complications in hematological malignancies
Pravas Mishra, Manorajan Mahapatra, Tulika Seth (India)

**Antiphospholipid - V**

**Moderator: Leonie Pelkmans (The Netherlands)**

**PB 4.62-1**
Variability in exposure of epitope G40-R43 of domain I in commercial anti-β2-glycoprotein I IgG ELISAs influences the diagnosis of the antiphospholipid syndrome
Leonie Pelkmans, Hilde Kelchtermans, Philip de Groot, Stephane Zuily, Veronique Regnault, Denis Wahl, Vittorio Pengo, Bas de Laat (The Netherlands)

**PB 4.62-2**
Elevated levels of endothelial cell microparticles in patients with antiphospholipid antibodies correlate with levels of anti-beta2-glycoprotein I antibodies
Keith McCrae, Shruti Chaturvedi (USA)

**PB 4.62-3**
False positive results of Lupus Anticoagulant in plasmas of patients receiving LMWH or the new oral anticoagulants
Marta Martinuzzo, Luis Barrera, Maria D´Adamo, Juan Otaso, Maria Gimenez, Jose Oyhamburu (Argentina)

**PB 4.62-4**
Anticoagulation for patients with antiphospholipid antibodies undergoing cardiopulmonary bypass - a novel strategy for optimisation of heparin anticoagulation
Kevin Ryan, Matt Goodyer, Niamh O’Connell, Ruth Gilmore, Fionnuala Ni Ainle, Vince Jenkins, Paul Fagan, Vincent Young, James O’Donnell (Ireland)

**PB 4.62-5**
Anti-β2 Glycoprotein I autoantibodies and atherosclerosis in patients with ischemic stroke
Mehdi Ben Said, Imen Sfar, S. Younes, Farah Chaker, I. Bannour, L. Boughamoura, Taieb Ben Abdallah, Sami Guermazi, Yousr Gorgi (Tunisia)
Antiphospholipid and antinuclear antibodies in schizophrenic patients during antipsychotic treatment: Findings from the ANTRE study
Radovan Malý, Jiří Masopust, Ctirad Andrýs, Jan Bažant, Vera Krejšková, Ladislav Hosák [Czech Republic]

Antiphospholipid - VI
Screen 63

Moderator: Maria DeSancho [USA]

PB 4.63-1 High specificity of Silica clotting time confirm/screen normalized ratio for LA diagnosis
Marta Martinuzzo, Luis Barrera, María D´Adamo, Juan Otaso, María Gimenez, José Oyhamburu [Argentina]

PB 4.63-2 Erythrocyte and platelet microparticles are associated with thrombotic complications of antiphospholipid syndrome
Denis Wahl, Faten Merhi-Soussi, Stephane Zuily, Jean Devignes, Thomas Lecompte, Veronique Laterre-Cannard [France]

PB 4.63-3 Antibody titers and clinical outcomes in patients with single-double or triple positivity antiphospholipid antibodies
Maria DeSancho, Jacqueline Bamme, John Chapin, Paul Christos, Michaela Nguyen, Mikhail Rosshal [USA]

PB 4.63-4 Circulating endothelial cells are increased in patients with antiphospholipid syndrome
Denis Wahl, Stephane Zuily, Marie Heymonet, Frederic Massin, Gilbert Faure [France]

PB 4.63-5 Prevalence of antiphospholipid antibodies in psychiatric patients users and non-users of antipsychotics
Aurélien Delluc, Aurélie Rousseau, Mickael Le Galudec, Olivier Canceil, Barry Woodhams, Sylvie Etienne, Michel Walter, Dominique Mottier, Patrick van Dreden, Karine Lacut [France]

PB 4.63-6 Hypoprothrombinaemic Lupus Anticoagulant Syndrome masquerading as acquired Haemophilia in a 5-year-old child
Ponni Sivaprakasam, Oliver Tunstall, Christopher Reilly-Stitt, John Marshall, Malcolm Hamilton [United Kingdom]

Arterial vascular disorders - V
Screen 64

Moderator: Kristin Enga [Norway]

PB 4.64-1 Increased fibrinogen rises thrombin generation and fibrin clot formation in obese Zucker rats
Veronique Regnault, Jeremy Lagrange, Huguette Louis, Jean-Pierre Max, Simon Thornton, Denis Wahl, Bruno Feve, Athanase Benetos, Patrick Lacolley [France]

PB 4.64-2 Impact of venous thromboembolism on future risk of atrial fibrillation - the Tromsø study

PB 4.64-3 Different role of hypercoagulability in myocardial infarction and ischemic stroke: A systematic review
Alberto Maino, Bob Siegerink, Ale Algra, Flora Peyvandi, Frits Rosendaal [Italy]

PB 4.64-4 A novel and selective proteasome inhibitor modulate expression of molecules linked to coagulation and angiogenesis independent of NF-kB activation in tumor cells
Ana Marisa Chudzinski-Tavassi, M. Pacheco, C. Berra, K. Moraes, J. Sciani, R. Bosch, J. Onuki [Brazil]
Thursday, July 4, 2013
13:30 - 15:00

PB 4.64-5  Correlation between Factor VII-activating protease and metabolic control in children and adolescents with type 1 diabetes
Gernot Grangl, Bettina Leschnik, Jasmin Pansy, Elfriede Schaffer, Elke Fröhlich-Reiterer, Martin Borkenstein, Wolfgang Muntean, Siegfried Gallistl (Austria)

PB 4.64-6  Coronary microvascular dysfunction due to Essential thrombocythemia and Polycythemia vera: The missing piece of the puzzle of their increased cardiovascular risk
Giuseppe Cella, Giulia Famoso, Francesco Tona, Andrea Ballin, Elena Osto, Elisabetta Omenetto, Fabrizio Vianello (Italy)

Hormones, pregnancy, women’s issues - IV
Screen 65
Moderator: Marc Durian (The Netherlands)

PB 4.65-1  Impact on the initial pregnancy loss subtype on pregnancy outcomes in the conventionally treated purely obstetric antiphospholipid syndrome
Jean-Christophe Gris, Sylvie Bouvier, Eva Cochery-Nouvellon, Géraldine Lissalde-Lavigne, Eric Mercier, Jean-Pierre Balducchi, Eve Mousty, Pierre Marès (France)

PB 4.65-2  Severe Preeclampsia: Evaluation of D-Dimer, PAI-1 and Inflammatory Cytokine
Melina Pinheiro, Maria Carvalho, Olindo Martins-Filho, Ana Paula Mota, Lara Godoi, Patrícia Alpoim, Andrea Teixeira-Carvalho, Karina Borges, Luci Dusse (Brazil)

PB 4.65-3  A safe and effective regimen for managing women at intermediate and high risk of pregnancy-related venous thrombosis
Marc Durian, Jeanine Roeters van Lennep, Johannes Duvekot, Frank Leebeek, Marieke Krup (The Netherlands)

PB 4.65-4  No increased fibrinolysis in women with menorrhagia
Sophie Wiewel-Verschueren, Marieke Knol, Ton Lisman, Dick Bogchelman, Hanneke Kluin-Nelemans, Ate van der Zee, André Mulder, Karina Meijer (The Netherlands)

PB 4.65-5  Is rotation thrombelastometry a useful method for monitoring of hemostasis in normal pregnancy and puerperium?
Jan Stasko, Lukas Duraj, Miroslav Hasko, Lenka Lisa, Juraj Sokol, Radka Simonova, Kamit Biringer, Jan Danko, Peter Kubisz (Slovakia)

PB 4.65-6  Anticoagulation in pregnant women with history of unexplained miscarriage
Rene Mahnel, Mohammed Alrifai, Ronald Fischer, Kathrin Heidinger, Christiane Kelm, Anette Kirsch-Altena, Wolfgang Mondorf, Christina Mondorf, Bettina Kemkes-Matthes (Germany)

Hormones, pregnancy, women’s issues - V
Screen 66
Moderator: Svetlana Tchaikovski (Germany)

PB 4.66-2  May-Hegglin anomaly in pregnancy: A systematic review
Joanna Davies, Brwa Hussein, Lava Shareif, Keith Gomez, Rezan Abdul-Kadir (United Kingdom)

PB 4.66-3  Incidence of pregnancy outcomes in women with pregnancy loss subtypes bearing Leiden polymorphisms: Comparison with the purely obstetric antiphospholipid syndrome
Jean-Christophe Gris, Sylvie Bouvier, Eva Cochery-Nouvellon, Géraldine Lissalde-Lavigne, Eric Mercier, Eve Mousty, Jean-Pierre Balducchi, Pierre Marès (France)
**ePOSTERS (B)**

**Thursday, July 4, 2013**

**13:30 - 15:00**

**Inflammation: Basic - III**

**Screen 67**

**Moderator: Ruchira Engel (The Netherlands)**

**PB 4.67-1**

Overexpression of activated protein C improves host defense during pneumococcal pneumonia

Liesbeth Kager, Daan de Boer, Joris Roelofs, Joost Meijers, Berend Isermann, Cornelis van ’t Veer, Tom van der Poll (The Netherlands)

**PB 4.67-2**

SMTP, a novel family of small molecule anti-inflammatory thrombolytic: structure-activity relationships with respect to plasminogen modulation and soluble epoxide hydrolase inhibition

Naoki Matsumoto, Eriko Suzuki, Haruki Koide, Keiko Hasegawa, Naoko Nishimura, Keiji Hasumi (Japan)

**PB 4.67-3**

Acute fluoxetine treatment increases leukocyte-endothelial interactions in murine peritonitis

Nadine Herr, Julius Mezger, Daniela Stallmann, Christoph Bode, Daniel Dürschmied (Germany)

**PB 4.67-4**

Effect of C1-inhibitor glycans on the kinetics of target protease inhibition

Ruchira Engel, Dorina Roem, Ineke Wagenaar-Bos, Marieke van Ham, Sacha Zeerleider, Diana Wouters (The Netherlands)

**PB 4.67-5**

The modulation of astrocyte functions by activated protein C

Lyubov Gorbacheva, Anna Ivanova, Vsevolod Pinelis, Georg Reiser, Shin’ichi Ishiwata, Svetlana Strukova (Russian Federation)

**PB 4.67-6**

Gene Expression of mouse platelet GPCRs under chronic inflammatory conditions

Erica De Candia, Dan Palmer, Shaun Coughlin (Italy)

**Inflammation: Clinical - III**

**Screen 68**

**Moderator: Vladimir Tichelaar (The Netherlands)**

**PB 4.68-1**

Hypercoagulability and hypofibrinolysis in patients with human immunodeficiency virus infection partially resolve after antiretroviral treatment

Herman Sprenger, Johannes Lisman, André Mulder, Tijn van der Werf, Wouter Bierman, Karina Meijer, Ynse Tichelaar (The Netherlands)

**PB 4.68-2**

Thrombomodulin-modified thrombin generation in patients with diffuse peritonitis

Olga Smirnova, Yury Namestnikov, Dmitriy Gurzhiy, Khizry Gamzatov, Vyacheslav Zemlyanoy, Anna Lerner, Ludmila Papayan (Russian Federation)
ePOSTERS (B)  

Thursday, July 4, 2013  
13:30 - 15:00

PB 4.68-3  Elevated platelet count, platelet activation and CRP in gulf war veterans’ illnesses: Evidence of a chronic inflammatory state?  
Gerhard Johnson, Linda Leis, Billie Slater, Ronald Bach [USA]

PB 4.68-4  Gene expression analysis in patients with spontaneous deep venous thrombosis  
Aline Barnabé, Fernanda Santiago-Bassora, Patrícia Severino, Marcelo Carazzolle, Gonçalo Pereira, Fernanda Orsi, Erich De Paula, Nelci Höehr, Joyce Maria Annichino-Bizzacchi [Brazil]

PB 4.68-5  Up-regulation of tissue factor, adhesion molecules, nitric oxide and adiponectin in end stage renal disease: A paradoxical interplay  
Jawed Fareed, Kristiya Kaneva, Debra Hoppensteadt, Josephine Cunanan, Danayat Syed, Ajay Singh, Vinod Bansal [USA]

PB 4.68-6  Increased expression of caspase 4 gene in mononuclear cells from patients with deep venous thrombosis  
Fernanda Santiago-Bassora, Aline Barnabé, Andrey Dos Santos, Ana Deckmann, Marcelo Carazzolle, Gonçalo Pereira, Fernanda Orsi, Erich De Paula, Joyce Maria Annichino-Bizzacchi [Brazil]

Non-inherited risk factors venous thrombosis - V  
Screen 69

Moderator: Marian van Kraaij [The Netherlands]

PB 4.69-1  Prevalence of clonal populations of hematopoietic cells with paroxysmal nocturnal hemoglobinuria phenotype in patients with splanchnic vein thrombosis  
Walter Ageno, Francesco Dentali, Valerio De Stefano, Franco Piovella, Mario Bazzan, Simona Piana, Rita Santoro, Renzo Poggio, Daniela Poli, Alberto Tozetto [Italy]

PB 4.69-2  Systemic hypoxia and risk of venous thromboembolism - the Tromsø study  
Trond Borvik, Kristin Enga, Sigrid Brækkan, Hasse Melbye, John-Bjarne Hansen [Norway]

PB 4.69-3  RDW-CV and MPV as a risk indicators for deep venous thrombosis  
Pieternel Pasker-de Jong, Sanne Hofstraat, Marjo Albers-Akkers, Paul van Noord, Marian van Kraaij [The Netherlands]

PB 4.69-4  Clinical presentation of isolated distal deep vein thrombosis differs significantly from proximal disease states  
Daniel Horner, Kerstin Hogg, Richard Body, Michael Nash, Kevin Mackway-Jones [United Kingdom]

PB 4.69-5  Pulsed methylprednisolone therapy markedly increases thrombin generation potential in a rabbit experiment  
Tomoko Ashikaga, Atsuki Yamashita, Shinji Muto, Chiai Nagae, Mieko Akita, Noriko Suzuki, Satoshi Yamazaki, Shigenobu Takayama, Masashi Taki [Japan]

PB 4.69-6  Incidence of venous thromboembolism (VTE) after major surgeries and proposal of Evidence-based Korean Guidelines for the Prevention of VTE  
Soo-Mee Bang, Moon Ju Jang, Kyoung Ha Kim, Ho-Young Yhim, Yeo-Kyeoung Kim, Sung Hwa Bae, Sung-Hyun Kim, Yeung-Chul Mun, Inho Kim, Chul Won Jung, Nam-Kyong Choi, Doyeun Oh [South-Korea]
Non-inherited risk factors venous thrombosis - VI

**Moderator: Sharif Pasha (The Netherlands)**

**PB 4.70-1** The risk of venous thrombosis after a symptomatic arterial event in an older population
Patricia Casais, Marissa Engbers, Mary Cushman, Suzanne Cannegieter, Frits Rosendaal, Astrid van Hylckama Vlieg (Argentina)

**PB 4.70-2** Risk of atherothrombotic events in patients after deep vein thrombosis
Sharif Pasha, Melanie Tan, Tjalco van Rees Vellinga, Frederikus Klok, Menno Huisman (The Netherlands)

**PB 4.70-3** An age-related prospective cohort study in patients with retinal vein occlusion: Risk factors, antithrombotic treatment and outcome
Maria Teresa Sartori, Sofia Barbar, Annalisa Donà, Stefano Piermarocchi, Elisabetta Pilotto, Graziella Saggiorato, Paolo Prandoni (Italy)

**PB 4.70-4** Association of perioperative inflammation and coagulation status with delayed VTE after major surgery
Sara Cheng, Christine Baird, Elizabeth Luzier, Kristen Nordenholz, David Matero, Martin McCarter, Nathan Pearlman, Csaba Gajdos, Zung Vu Tran, Paul Wischmeyer (USA)

**PB 4.70-5** Root cause analysis of hospital-acquired venous thromboembolism: A quality improvement initiative
Artemis Diamantouros, Valentine Valenzuela, Gunjan Varma, Paula Brown, William Geerts (Canada)

**PB 4.70-6** Splanchnic vein thrombosis in Siriraj hospital: Etiology and outcome
Yingyong Chinthammitr, Chanya Wateperm, Roongthip Chanwanichkulchai (Thailand)

Paediatric thrombosis - V

**Moderator: Pascal Amedro (France)**

**PB 4.71-1** Thromboembolic events emerging during the treatment of childhood acute lymphoblastic leukemia
Gonul Aydogan, Hulya Sayilan Sen, Deniz Tugcu, Arzu Akcay, Nuray Aktay Ayaz, Ferhan Akici, Zafer Salcioglu, Metin Demirkaya, Muge Gokce (Turkey)

**PB 4.71-2** Does management of Warfarin by patients with home INR testing improve health related quality of life in children/families
Aisha Bruce, Patti Massicotte, Mary Bauman (Canada)

**PB 4.71-3** Postthrombotic syndrome in children with limb venous thromboembolic events
Helen Pergantou, Panagiota Xafaki, Maria Avgiri, Anna Komitopoulou, Eltychia Adamtziki, Zoey Kapsimali, Michalis Mazarakis, Helen Platokouki (Greece)

**PB 4.71-4** Epidemiology of thrombosis in children with cancer
Dana Piovesan, Chantal Attard, Paul Monagle, Vera Ignjatovic (Australia)

**PB 4.71-5** Quality of life of children participating to a formalized INR self-monitoring vitamin K antagonist educational program
Pascal Amedro, Fanny Bajolle, Radhia Cheurfi, Erika Nogue, Dominique Lasne, Marie-Christine Picot, Raphaël Dorka, Damien Bonnet (France)

**PB 4.71-6** Portal vein thrombosis in children and adolescents
Suzan Williams, Najwa Fayea, Karima Al Hinai, Leonardo Brandao, Veerle Labarque (Canada)
Thrombophilia - V

Moderator: Olivier Heylen [Belgium]

PB 4.72-1 Clinical characteristics of double heterozygous for factor V Leiden and prothrombin mutation. Findings from the RIETE Registry
Telma Gadelha, Maria Jesús Jaras Hernández, Jana Hirmerova, Mafalda Santos, Manuel Monreal [Brazil]

PB 4.72-2 Challenges in the diagnosis of type II antithrombin deficiency with heparin-binding site defects
Olivier Heylen, Christelle Orlando, Kristin Jochmans [Belgium]

PB 4.72-3 Molecular markers of blood hypercoagulability and values of overall coagulation potential in double heterozygotes for the FV Leiden and FII G20210A mutation
Predrag Miljic, Jelena Bodrozić, Valentina Djordjevic, Aleksandra Antovíc [Serbia]

PB 4.72-4 Role of promoter polymorphisms of Glutathione Peroxidase (GPX3) gene in the development of Deep Vein Thrombosis in Asian Indian population.
Renu Saxena, Mohd Akhter, Hina Rashid, Ravi Ranjan, Amit Sharma [India]

PB 4.72-5 Thromboembolic disease in overweight and obese patients
Hanrry Paredes, Manuel Gonzalez [USA]

PB 4.72-6 Association of JAK2 V617F mutation and tromboembolic events among patients with essential thrombocytemia and idiopathic myelofibrosis in a Brazilian center: Evidence of a retrospective study
Paula Villaca, Audrey Zeinad-Valim, Erica Okazaki, Camila Linardi, Liliana Suganuma, Fernanda Seguro, Dalton Chamone, Elbio D’Amico [Brazil]

Thrombophilia - VI

Moderator: Jacqueline Conard [France]

PB 4.73-1 Identification of a new thrombophilic disorder that affecting a correct N-glycosylation causes antithrombin deficiency
María De La Morena-Barrio, Irene Martínez-Martínez, Carmen De Cos, Teresa Sevivas, Antonia Miñano, José Padilla, Dirk Lefeber, Jaak Jaeken, Vicente Vicente, Javier Corral [Spain]

PB 4.73-2 Long-term follow-up in 4 homozygous protein C deficiencies with late clinical onset
Jacqueline Conard [France]

PB 4.73-3 Inherited thrombophilia as a risk factor for gestational vascular complications
Ana Baptista, Patrícia Martinho, Teresa Fidalgo, Teresa Sevivas, Ana Oliveira, Ana Maçães, Ramón Salvado, Carlos Barata, Natália Martins, Maria Letícia Ribeiro [Portugal]

PB 4.73-4 Effect of genetic variants in the TAFI gene on TAFI levels, the efficiency and safety of anticoagulant therapy in patients with venous thromboembolism in Russian population
Natalya Vorobyeva, Natalya Doroshchuk, Zikhra Khasanova, Anatoly Dobrovolsky, Elena Titaeva, Anton Postnov, Alexandr Kirienko, Elizaveta Panchenko [Russian Federation]

PB 4.73-5 The prevalence of thrombophilia in patients with isolated superficial vein thrombosis
Jana Hirmerova, Jitka Seidlerova, Ivan Subrt, Jitka Slechtova [Czech Republic]

PB 4.73-6 Evaluation of the INNOVANCE Free PS Ag assay: An easy and reliable assay for the automated determination of free protein S
Sabine Pilgrim, Viktoria Esch, Karin Kolbe-Scheu, Matthias Schleifer, Andrea Lichte [Germany]
Fibrinolysis and FXIII

PB 4.74-1  Fibrinolysis wave as a possible cause of rethrombosis
Ansar Zhalyalov, Mikhail Panteleev, Fazoil Ataullakhanov, Alexey Shibeko
[Russian Federation]

PB 4.74-2  Polymorphism thr325ile in thrombin-activable fibrinolysis inhibitor gene in
dyslipidemic subjects from Brazil
Izabela Santos, Maria das Graças Carvalho, Marinez Sousa, Cláudia Ferreira,
Karina Gomes [Brazil]

PB 4.74-3  Residual perfusion defects in patients with Pulmonary Embolism and fibrinolytic
system
Anna Paola Cellai, Donatella Lami, Caterina Cenci, Rossella Marcucci, Claudia Fiorillo,
Matteo Becatti, Lucia Mannini, Daniela Poli, Rosanna Abbate, Domenico Prisco [Italy]

PB 4.74-4  Molecular basis of 21 severe FXIIIa deficiency cases: 11 novel mutations detected
Sharda Shanbhag, Kanjaksha Ghosh, Shrimati Shetty [India]

PB 4.74-5  Mutation analysis in patients with decreased fibrinogen level
Beata Baran, Edyta Odnoczko, Ewa Stefanska-Windyga, Andrzej Mital,
Vytautas Ivaskevicius, Johannes Oldenburg, Jerzy Windyga [Poland]

PB 4.74-6  Role of genotyping in FXIII deficiency
Renée Weerens, Waander van Heerde, Selene Schoormans, Adinda Diekstra, Paul Brons
[The Netherlands]
Name of medicinal product: NovoThirteen 2500 IU, powder and solvent for solution for injection Composition: One vial contains catrisedacog (recombinant coagulation factor XIII) (rDNA): 2500 IU per 3 ml, after reconstitution corresponding to a concentration of 833 IU/ml. The specific activity of NovoThirteen is approximately 165 IU/mg protein. Pharmaceutical form: Powder and solvent for solution for injection. The powder is white and the solvent is clear and colourless. Therapeutic indications: Long term prophylactic treatment of bleeding in patients 6 years and above with congenital factor XIII A-subunit deficiency. Posology and method of administration: Treatment should be initiated under the supervision of a doctor experienced in the treatment of rare bleeding disorders. The congenital factor XIII A-subunit deficiency should be confirmed by appropriate diagnostic procedures including factor XIII activity and immunoassay and if applicable genotyping. Posology: The potency of this medicinal product is expressed in international units (IU). Although expressed in the same unitage (IU), the posology of NovoThirteen is different from the dosing schedule of the other FXIII containing products. The recommended dose is 35 IU/kg body weight (bw) once monthly (every 28 days +/- 2 days), administered as an intravenous bolus injection. Based on the actual concentration of NovoThirteen, the dose volume (in millilitres) to be administered can be calculated from the formula below: Dose volume in ml = 0.042 x subject bw (kg). Dose adjustment can be considered necessary by the physician in certain situations where the prevention of bleeding is not appropriately covered by the recommended 35 IU/kg/month dose. Monitoring NovoThirteen activity levels using a standard FXIII activity assay is recommended. The safety and efficacy of NovoThirteen in children less than 6 years have not yet been established. Method of administration: Following reconstitution the product should be administered separately and not mixed with infusion solutions nor be given in a drip. The preparation should be administered as a slow bolus intravenous injection at a rate not higher than 2 ml/minute. Contraindications: Hypersensitivity to the active substance or to any of the excipients Special warnings and precautions for use: In patients with FXIII deficiency, NovoThirteen is not effective if used for monthly prophylactic treatment of bleeding in patients with congenital FXIII B-subunit deficiency. FXIII B-subunit deficiency is associated with a much reduced half-life of the administered pharmacologically active A-subunit. The subunit deficiency of patients should be determined prior to treatment by appropriate diagnostic procedures including factor XIII activity and immunoassay and if applicable genotyping. The on-demand treatment of acute bleeds or breakthrough bleeds with NovoThirteen has not been studied in clinical trials. An alternative treatment should be considered in such situations. Considering that the posology and the FXIII concentration in NovoThirteen are different from those of the other FXIII containing products, careful attention should be paid to the calculation of the appropriate dose for the individual. As NovoThirteen contains a recombinant protein it may cause allergic reactions including anaphylactic reactions. Patients should be informed of the early signs of hypersensitivity reactions (including hives, generalised urticaria, tightness of the chest, wheezing, hypotension) and anaphylaxis. If allergic or anaphylactic-type reactions occur, the administration should be immediately discontinued and further treatment with NovoThirteen should not be given. Inhibitor formation: Inhibitor formation to NovoThirteen therapy has not been detected in clinical trials. Inhibitors may be suspected in the event of lack of therapeutic response which is observed as bleeding or demonstrated by laboratory findings including FXIII activity that fails to reach expected levels. In the event that inhibitors are suspected analysis for antibodies should be performed. Patients known to have neutralising antibodies to FXIII should not be treated with NovoThirteen without close monitoring. Thromboembolic risk: The reconstituted product must be handled accordingly. Incorrect storage of the product after reconstitution must be avoided as it may result in loss of sterility and in increased levels of activated NovoThirteen. Increased levels of activated NovoThirteen may increase the risk of thrombosis. In case of predisposition to conditions of thrombosis, caution should be exercised due to the fibrin-stabilising effect of NovoThirteen. A stabilisation of the thrombus might occur, resulting in increased risk of vessel occlusions. Patients with hepatic impairment have not been studied. NovoThirteen may not be effective in patients with hepatic impairment if the hepatic impairment is not severe enough to result in decreased levels of FXIII B-subunits. FXIII activity levels should be monitored in patients with severe hepatic impairment. There is limited clinical experience in administering NovoThirteen to elderly patients with congenital FXIII deficiency. Patients with renal insufficiency requiring dialysis have not been studied in clinical trials. Interaction with other medicinal products and other forms of interaction: There are no clinical data available on interaction between NovoThirteen and other medicinal products. Based on the non-clinical study it is not recommended to combine NovoThirteen and rFVIIa. Fertility, pregnancy and lactation: There are no clinical data on the use of NovoThirteen in pregnant women. The risk to humans is not known. No effects on reproductive organs have been seen in non-clinical studies. There are no human data on potential effects on fertility. Effects on ability to drive and use machines: NovoThirteen has no influence on the ability to drive and use machines. Undesirable effects: Frequency descriptions of all adverse reactions identified from 51 patients with congenital FXIII deficiency exposed in clinical trials: common (≥ 1/100 to < 1/10): leucopenia and aggravated neutropenia; headache; pain in extremity; injection site pain; non-neutralising antibodies; fibrin D-dimer increased. One patient with pre-existing neutropenia experienced a mild aggravation of neutropenia and leucopenia during treatment with NovoThirteen. Following discontinuation of NovoThirteen the patient’s neutrophil count returned to levels similar to those prior to treatment with NovoThirteen. Non-neutralising antibodies have been seen in 4 of the 51 exposed patients with congenital FXIII deficiency. The four events of non-neutralising antibodies occurred in patients below the age of 18 (age 8, 8, 14 and 16). These antibodies were seen at the start of treatment with NovoThirteen. All 4 patients received at least 2 doses of NovoThirteen. 3 of the patients discontinued the study and returned to their previous treatment. One continued to receive rFIII and the antibodies decreased below detection limit. The antibodies had no inhibitory action and the patients did not experience any adverse events or bleeding in association with these antibodies. Antibodies were transient in all patients. One healthy subject developed low-titer, transient non-neutralising antibodies after receiving the first dose of NovoThirteen. The antibodies had no inhibitory activity, and the subject did not experience any adverse events or bleeding in association with these antibodies. The antibodies disappeared in the 6-month follow up. Overdose: In the reported cases of NovoThirteen overdose up to 2.3 times, no clinical symptoms have been observed. List of excipients: Powder: Sodium chloride, Sucrose, Polysorbate 20, L-histidine, Hydrochloric acid (for pH-adjustment), Sodium hydroxide (for pH-adjustment) Solvent: Water for injections Incompatibilities: In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products. Shelf life: 2 years. After reconstitution, the medicinal product should be used immediately due to the risk of microbial contamination. Reconstituted NovoThirteen is a clear, colourless solution. Special precautions for storage: Store in a refrigerator (2°C - 8°C). Store in the original package in order to protect from light. Do not freeze. Authorisation holder: Novo Nordisk A/S, Novo Allé, DK-2880 Bagsvaerd, Denmark. Date of last revision: September 2012. For more detailed information please consult the EMEA product information. Reference: 1. World Federation of Hemophilia. Report on the Annual Global Survey 2010. http://www1.wfh.org/publications/files/pdf-1427.pdf NovoThirteen®_4367_Sep2012
purely because he’s one in a million

Manny Sandow has factor XIII congenital deficiency; Michigan, USA

With around 900 identified patients worldwide,¹ people with congenital factor XIII A-subunit deficiency are special.

Their treatment should be too.

Thanks to the innovation of Novo Nordisk, this small group of patients now has the option of a fully recombinant replacement therapy, so that they and their treating physicians can experience the same confidence and peace of mind enjoyed by those with more common bleeding disorders.
ePosters Publication Only
The posters below can be viewed in the ePoster area during all congress hours, except during moderated ePoster session hours, which are at Monday-Wednesday from 16:30-18:00 hours and Thursday from 13:00-14:30 hours.

**PO 001**  
Correlation of hemostatic parameters with age in patients with myocardial infarction  
Nebojsa Antonijevic, Ivana Zivkovic, Ljubica Jovanovic, Dragana Vukosavljevic, Nebojsa Radovanovic, Jovan Perunicic, Aco Radanovic, Dragan Matic, Valentina Djordjevic, Slobodan Obradovic (Serbia)

**PO 002**  
Diagnosis of acquired hemophilia due to pregnancy  
Rumjana Apostolovska, Violeta Dejanova-Ilijevska, Ivanka Nikolova, Violeta Neceva, Tatjana Bojadjieva-Makarovska (Macedonia)

**PO 003**  
Haemostatic changes in cirrhotic patients  
Hela Baccouche, Asma Labidi, Sonia Mahjoub, Ahlem Raissi, Wafa Ben Mohamed, Azza Filali, Neila Ben Romdhane (Tunisia)

**PO 004**  
Factor VIII inhibitor and pulmonary embolism developing in a patient after meningoia resection: clinical and laboratory aspects  
Adam Bryant, Geoffrey Kershaw, Diane Zebeljan, Penelope Motum, Riton Das (Australia)

**PO 005**  
Unusual thrombotic complications in patients with acute promyelocytic leukemia  
Natasa Colovic, Nada Suvajdic, Natalija Kosanovic-Jakovic, Ana Vidovic, Predrag Miljic, Irena Djunic, Mirjana Mitrovic, Marijana Virijevic, Dragica Tomin (Serbia)

**PO 006**  
Transiently prolonged prothrombin times with reduced factor VII levels in acutely ill children  
Michael Creagh, Laura Benyon, Arisa Takada, Sarah Johns, Philip Carson, Sian Harris (United Kingdom)

**PO 007**  
Assessing the range of dietary vitamin K intake in children undergoing tonsillectomy  
Michael Creagh, Laura Benyon, Arisa Takada, Sarah Johns, Philip Carson, Gemma Burley, Sian Harris, Phil Flanagan (United Kingdom)

**PO 008**  
Acquired hemophilia A with severe anemia  
Bouhadjar Dahmani, Séverine Lascar, Cristel Fissore-Magdelein, Philippe Sorlin, Xavier Magdelein, Christophe Robino (France)

**PO 009**  
Multiple myeloma presenting with acquired factor VIII inhibitor: A case report  
Flavia Fidelis, Roberta Oliveira, Joao Paulo Guimaraes, Emanuella Graciott, Gizelli Pires, Patricia Rezende, Daniel Ribeiro (Brazil)

**PO 010**  
Factor X inhibitor: An unexpected bleeding disorder with a therapeutic challenge  
Marc Fouassier, Ghislaine Cherel, Julie Graveleau, Amine Bezaa, Marc Trossaërt, Cécile Loubiere, Laurent Ardillon, Peter Lenting, Catherine Ternisien, Cécile Denis, Marianne Sigaud, Olivier Christophe (France)

**PO 011**  
Recombinant activated factor VII in treatment of bleeding complications in thrombocytopenic patients  
Gennady Galstyan, Polina Makarova, Dimitriy Polokhov, Elena Orel (Russian Federation)

**PO 012**  
Long-term follow up in acquired hemophilia A: Clinical courses and outcomes observed in a single Hemophilia Centre  
Gabriella Gamba, Nicola Ghidelli, Fabio Lodo, Nadia Montani, Chiara Ambaglio (Italy)

**PO 013**  
Haemostatic parameters including Factor VIII levels in different types of tuberculosis in Northern India  
Naresh Gupta, Aditya Kutiyal, Sandeep Garg (India)
| PO 014 | Snake venom induced coagulopathy | Vilas Hiremath (India) |
| PO 015 | Bleeding into the tongue - case history of acquired haemophilia A | Radomira Hrdlickova, Zuzana Cermakova, Sarka Blahutova, Marketa Ryzi (Czech Republic) |
| PO 016 | Acquired hemophilia A: Literature review and report of two cases | Rafael Lluch-Garcia, Marta Valero-Nuñez, Inmaculada García-Navarro, Aurelio López-Martínez, María del Mar Luis-Hidalgo, Teresa Bautista-Claver, Reyes Sancho-Tello, Francisco Mena, José Reinaldo Mayans-Ferrer (Spain) |
| PO 017 | Our experience in the use of prothrombin complex concentrate in patients with acute haemorrhage | Lidija Lokar, Marko Lokar, Bojana Bizjak, Marija Šega (Slovenia) |
| PO 018 | Acquired haemophilia: why the delay in diagnosis? | Susan Louw (South Africa) |
| PO 019 | Bleeding tendency associated with a coagulation inhibitor in two patients with monoclonal gammopathy of undetermined significance | Joyce Low, Susan Jarvis, Shrinivas Desai, Joanne Joseph (Australia) |
| PO 020 | Acquired von Willebrand syndrome: About one observation | Reda Messaoudi, Touhami Hadj, Driss Benlaledj, Yasmina Rahal, A. Chérif-Hosni, M. Bensahli, M. Bekadja, A. Arabi (Algeria) |
| PO 021 | Inhibitor characterization in acquired haemophilia and its influence on bleeding profiles and treatment response: CIHA-01 project | María Eva Mingot, Pascual Marco, Jose Antonio Aznar, Carmen Altisent, Spanish group for the prevention and treatment of acquired haemophilia (Spain) |
| PO 022 | Accuracy of thromboelastometry analysis in detecting patients treated with vitamin K antagonists | Michael Nagler, Lucas Bachmann, Walter Wuillemin (Switzerland) |
| PO 023 | Haemodilution with NaCl Solutions Below 600 mOsm/L Induce Hypercoagulability While Concentrations Above 1200 mOsm/L Progressively Impair Coagulation as Evaluated with Thrombelastography in Vitro | Gordon Ogweno, Samson Gwer (Kenya) |
| PO 024 | Monitoring anticoagulation during Extra-Corporeal Membrane Oxygenation (ECMO) in patients with acute respiratory failure | Serena Maria Passamonti, Mauro Panigada Panigada, Andrea Artoni, Cristina Mietto, Paolo Bucciarelli, Ida Martinelli (Italy) |
| PO 025 | Multiple inhibitory effects associated with IgG kappa multiple myeloma | Lucia Remotti, Marcelo Ingratti, Analía Sánchez Luceros, Silvia Grosso, Susana Meschengieser, Alicia Blanco, Maria Lazzari (Argentina) |
| PO 026 | A sensitive mixing test to screen for clotting factor inhibitors | Ponlapat Rojnuckarin, Benjaporn Akkawat (Thailand) |
| PO 027 | Two cases of acquired haemophilia A associated with chronic myelomonocytic leukaemia | Noppacharn Uaprasert, Supakanya Wongrakpanich, Ponlapat Rojnuckarin (Thailand) |
| PO 028 | Haemostatic function in hypothyroid state | Tatiana Vavilova, Andrey Ivanov, Elisaveta Egorova (Russian Federation) |
PO 029  Acquired factor VIII inhibitor associated to prostate cancer in elderly
Paula Villaca, Erica Okazaki, Audrey Zeinad-Valim, Tania Rocha, Dalton Chamone, Elbio D'Amico (Brazil)

PO 030  Parameters of hemostasis in patients with deep frostbites and malnutrition
Yuri Vitkovsky, Valery Konnov, Konstantin Shapovalov (Russian Federation)

PO 031  Some hemostatic parameters in patients with severe influenza A/H1N1, requiring artificial ventilation
Yuri Vitkovsky, Andrey Malyarchikov, Konstantin Shapovalov (Russian Federation)

PO 032  A retrospective study of treatment and outcome of consecutive patients with acquired haemophilia A
Eng Soo Yap, Suat Ying Lee, Stephanie Saw, Yen Lin Chee (Singapore)

PO 033  Activated prothrombin complex concentrate in acquired haemophilia A: An Italian registry-the F.A.I.R. study
Ezio Zanon, Marta Milan, Michele Schino (Italy)

PO 034  Evaluation of an automated method for the measurement of dabigatran in plasma
Mary Byrne, Mairead Doyle, Barry White, Kevin Ryan, James O’Donnell, Niamh O’Connell (Ireland)

PO 035  Level ranges for a new latex agglutination immunoassay for free protein S antigen in a pregnant women cohort
Beatriz Delgado, Helena Gomes, Manuela Carvalho, Luciana Goncalves, Fernando Araujo, Nuno Montenegro, Gabriela Namora (Portugal)

PO 036  At what time derived fibrinogen must replace the Clauss assay
Isabel Freire, Ana Azevedo, Teresa Gago (Portugal)

PO 037  Effect of primary tube underfilling and hemolysis on PT, APTT, antithrombin and D-Dimer assays; implementing the pre-analytical sample integrity checks of the Sysmex CS-2100i System
Hugh Hoogendoorn, Jacob de Haan, Joanne McGrath, Eman Ali (Canada)

PO 038  A modified coagulation time (activated partial thromboplastin time) assay for the measurement of very low levels of factor VIII activity
Makoto Kaneko, Yukari Saito, Nobuko Kanno, Yutaka Yatomi (Japan)

PO 039  Interference in von Willebrand factor latex immunoturbidometric assays, lupus anticoagulant assays and one-stage factor assays in a patient with splenic marginal zone lymphoma
Geoffrey Kershaw, Beatrice Mui, Ilona Cunningham (Australia)

PO 040  Hypercoagulability markers in renal transplanted patients: Association to inflammatory response
Ana Mota, Karina Gomes, Olimdo Martins-Filho, Melina Pinheiro, Maria das Graças Carvalho, Luci Dusse (Brazil)

PO 041  Correlation between hemostatic molecular markers under warfarin anticoagulation
Takehiko Nagao, Tsuyoshi Shiga, Shinichiro Uchiyama (Japan)

PO 042  Use of the thrombin generation test in patients with ischemic cerebral pathologies
Chiara Novelli, Benedetto Morelli, Andrea Giorgetti (Italy)

PO 043  Is it necessary to monitor dabigatran efficacy?
Pavlata Sigutova, Zdenka Hajsmanova, Ivana Korelusova (Czech Republic)
### ePOSTERS PUBLICATION ONLY

<table>
<thead>
<tr>
<th>PO 044</th>
<th>Evaluation of assay performance of the rivaroxaban screening assay Technoclot® rivaroxaban screen</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Lieselotte Wagner, Nikolaus Binder, Annelie Siegemund [Austria]</td>
</tr>
<tr>
<td>PO 045</td>
<td>New immunodepleted plasmas for determination of Factor VIII and IX activity</td>
</tr>
<tr>
<td></td>
<td>Chris Watson, Siegmund Gehrisch, G. Siegert [United Kingdom]</td>
</tr>
<tr>
<td>PO 046</td>
<td>Coagulation profile in polycythemia vera and essential thrombocythemia patients in Medan Indonesia</td>
</tr>
<tr>
<td></td>
<td>Sry Suryani Widjaja, Karmel Tambunan, Yahwardiah Siregar, Stephen Koh [Indonesia]</td>
</tr>
<tr>
<td>PO 047</td>
<td>Adverse effects of PEG-Asparaginase treatment in paediatric population and relation with APOE polymorphisms and hereditary thrombophilia</td>
</tr>
<tr>
<td></td>
<td>Joana Azevedo, Margarida Coucelo, Conceição Constanço, Teresa Sevivas, Susana Santos, Manuel Brito, Manuela Benedito, Natália Martins, Leticia Ribeiro [Portugal]</td>
</tr>
<tr>
<td>PO 048</td>
<td>Long-term use of low-molecular-weight heparins (LMWH) for cancer-associated venous thromboembolism: Clinical practice and patients’ perception in the TROPIQUE study</td>
</tr>
<tr>
<td></td>
<td>Francis Cajfinger, Dominique Farge Bancel [France]</td>
</tr>
<tr>
<td>PO 049</td>
<td>Evidence of the ‘off-label’ usefulness of FEIBA® to manage the critical gastrointestinal bleeding in patients with haematological malignancies</td>
</tr>
<tr>
<td></td>
<td>Dorina Cultrera, Antonino Cipolla, Maria Rita Caraci, Francesco Di Raimondo [Italy]</td>
</tr>
<tr>
<td>PO 050</td>
<td>Association of factor V Leiden mutation with thrombosis in newly diagnosed cases of acute leukemia in Pakistan</td>
</tr>
<tr>
<td></td>
<td>Arshi Naz, Shariq Ahmed, Muhammad Nadeem, Tahir Shamsi [Pakistan]</td>
</tr>
<tr>
<td>PO 051</td>
<td>Thrombotic complications associated with chemotherapy: An analysis of 356 patients</td>
</tr>
<tr>
<td></td>
<td>Gevorg Tamamyan, Samvel Danielyan, Davit Zohrabyan, Liana Safaryan, Astghik Voskanyan, Lilit Sargsyan, Lusine Hakobyan, Armen Avagyan, Lilit Harutyunyan [Armenia]</td>
</tr>
<tr>
<td>PO 052</td>
<td>Diagnosis of functional and structural platelet disorders - implication for oncology</td>
</tr>
<tr>
<td></td>
<td>Irina Vasilenko, Alesia Matveeva, Pavel Polyakov, Oleg Bichenkov, Andrey Balkanov [Russian Federation]</td>
</tr>
<tr>
<td>PO 053</td>
<td>LMWH generics as first line drugs in prophylaxis of thrombotic complications in cancer patients</td>
</tr>
<tr>
<td></td>
<td>Alexander Vorobev [Russian Federation]</td>
</tr>
<tr>
<td>PO 054</td>
<td>Diffuse intracranial haemorrhage in factor V deficiency: Two case reports</td>
</tr>
<tr>
<td></td>
<td>Mehran Karimi, Mohammad Moghaddam, Javad Gerdabi, Abdoreza Afrasiabi, Javad Dehbozorgian, Rezvan Ardehshiri, Zohreh Zahedi [Iran]</td>
</tr>
<tr>
<td>PO 055</td>
<td>Congenital combined deficiency VII and V associated with thrombocytopenia</td>
</tr>
<tr>
<td></td>
<td>Reda Messaoudi, Touhami Hadj, Driss Benlamedj, K. Moulasserdoune, Yasmina Rahal, A. Chérif-Hosni, Fatima Seghier, F. Touhami [Algeria]</td>
</tr>
<tr>
<td>PO 056</td>
<td>Registry of inhibitors in mild and moderate haemophilia A patients in Spain</td>
</tr>
<tr>
<td></td>
<td>Ana Cid, Víctor Jiménez Yuste, Ramiro Nuñez, Eva Mingot, Carmen Sedano, Angeles Palomo, María Fernanda López-Fernández, María José Paloma, Carmen Altisent, Manuel Prieto [Spain]</td>
</tr>
<tr>
<td>PO 057</td>
<td>Fluctuation in factor VIII levels in a patient with hemophilia B</td>
</tr>
<tr>
<td></td>
<td>Nil Guler, Piltan Büyükkaya [Turkey]</td>
</tr>
</tbody>
</table>
PO 058  Structural comparison of a new recombinant rFVIII molecule, turoctocog alfa, and commercially available FVIII products  
Anne Kristensen, Marianne Kjalke, Niels Klausen, Mirella Ezban, Knud Vad (Denmark)

PO 059  The activity of glycoPEGylated recombinant FVIII (N8-GP) can be measured in both two-stage chromogenic and one-stage clotting assays  
Thomas Krogh-Meibom, Eva Olsen, Marianne Kjalke, Mirella Ezban (Denmark)

PO 060  Selective measurement of PEGylated human recombinant factor VIII (BAX 855) in laboratory animal plasma  
Peter Turecek, Alfred Weber, Andrea Engelmaier, Eva Minibeck, Sandra Hainzelmayer, Hans Peter Schwarz, Friedrich Scheiflinger (Austria)

PO 061  Modification-dependent activity assay: A new assay type for selective activity measurement of PEGylated human factor VIII (BAX 855)  
Peter Turecek, Alfred Weber, Andrea Engelmaier, Sonja Haindl, Gabriele Mohr, Hans Peter Schwarz, Friedrich Scheiflinger (Austria)

PO 062  Differentiation of the natural, full length recombinant FVIII molecule from B-domain deleted recombinant FVIII with respect to its hemostatic potency  
Peter Turecek, Gerald Schrenk, Herbert Gritsch, Stefan Romeder-Finger, Sabine Knappe, Michael Dockal, Friedrich Scheiflinger (Austria)

PO 063  Factor XI deficiency: A family report  
Driss Benlaldj, Mourir Bougherza, Fatima Seghier (Algeria)

PO 064  Factor XI deficit: Cases report  
Maria Amanda Ruades Ninfea, Cristina Dubosq, Jose Ceresetto, Sebastian Prieto, Claudia Shanley, Germán Stemmelin, Oscar Rabinovich, Silvina Palmer, Eduardo Bullorsky (Argentina)

PO 065  Prevalence of venous thrombo-embolism & related morbidity and mortality among hospitalized patients in Saudi Arabia (SAVTE Registry)  
Essam Abo-El-nazar, Fahad Al-Hameed, Savte Research Group Savte Research Group (Saudi Arabia)

PO 066  Acute deep venous thrombosis secondary to May-Thurner Syndrome: A case report  
Katherine Rose Acosta, Marie Simoastte Ganzon, Rommel Carino, Evelyn Esposo (Philippines)

PO 067  The role of clinical scores in the diagnosis of pulmonary thromboemboli  
Sevda Comert, Benan Caglayan, Sukran Mutlu, Ali Fidan, Nesrin Kiral (Turkey)

PO 068  Retrospective evaluation of pulmonary thromboembolism cases  
Sevda Comert, Benan Caglayan, Sukran Mutlu, Ali Fidan, Nesrin Kiral (Turkey)

PO 069  D-dimer, P-selectin and microparticles are superior to duplex ultrasound in the diagnosis of DVT  
Doaa Eissa, Manal Ghozlan, Amany Osman, Hanan Mahmoud (Egypt)

PO 070  Normalized activated protein C sensitivity ratio and protein S-specific activity are useful predictive markers for venous thromboembolism  
Takao Kobayashi, Kyuya Hirai, Norio Kasamatsu, Masakazu Kobayashi, Toshiki Iwase, Toshikazu Kanai, Toshihiko Matsuoka, Kazuko Sugiyama, Tomohide Tsuda (Japan)

PO 071  DVT to VTE: A nursing evolution or revolution?  
Rosemary Lavery, Hilary Speers (Northern Ireland)
<table>
<thead>
<tr>
<th>PO 072</th>
<th>Thromboses of unusual localization and pregnancy</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Aleksander Makatsaria, Victoria Bitsadze, Evgeniy Kitsenko, Dzhamilya Khizroeva, Olga Panfilova [Russian Federation]</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PO 073</th>
<th>A comparative study of two automated assays for D-Dimer used in patients admitted in the Emergency Department in a university hospital</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Alain Marques-Verdier [France]</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PO 074</th>
<th>Inferior vena cava agenesis as cause of deep venous thrombosis in a young patient: case report and literature review</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Tayana Mello, Julia Giovelli, Alfredo Lopes, Alexandre Borges [Brazil]</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PO 075</th>
<th>Role of D-dimer monitoring for the diagnosis of deep vein thrombosis in patients undergoing neurosurgery for brain tumor</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Maria Teresa Sartori, Emiliano De Bon, Alessandro Della Papuda, Fabio Dalla Valle, Chiara Piovella, Andrea Padoan, Pietro Ciccarino, Daniela Bernardi, Renato Scienza, Paolo Prandini [Italy]</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PO 076</th>
<th>Prevalence of perioperative asymptomatic proximal deep vein thrombosis following gynecological cancer surgery in Thai patients</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Nuttawut Sermthananawadi, Rattana Thangrod, Kiattisak Hongku, Chumpol Wongwanit, Chanean Ruangsetaktik, Kharmin Chinsakchai, Pramook Mutirangura [Thailand]</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PO 077</th>
<th>Evaluating the effectiveness of warfarin therapy in patients with deep vein thrombosis of the lower limbs</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Faina Verkhomolova, Ishkhan Manukyan, Ilya Serebrijskiy, Aleksey Krylov, Fazly Ataullahianov, Aleksander Shulutko [Russian Federation]</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PO 078</th>
<th>How we understand DIC today in Russia</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Igor Bokarev [Russian Federation]</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PO 079</th>
<th>Normal prothrombinase activity, systemic thrombin activation, and lower antithrombin levels in patients with DIC at an early phase of trauma: Comparison with acute coagulopathy of trauma-shock (ACOTS)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Satoshi Gando, Yuichiro Yanagida, Atsushi Sawamura, Mineji Hayakawa, Nobuhiko Kubota, Takeshi Wada, Yuichi Ono, Hiroshi Yamamoto [Japan]</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PO 080</th>
<th>New diagnostic strategy of sepsis induced disseminated intravascular coagulation (SEDIC); a validation study</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Reiko Ichiki, Hiroyasu Ishikura, Takeshi Nishida, Yoshihiko Nakamura, Yasumasa Kawano, Akira Murai, Takehiro Umemura [Japan]</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PO 081</th>
<th>Serum des-R prothrombin activation peptide fragment 2: A novel prognostic marker for disseminated intravascular coagulation</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Ji Eun Kim, Soie Chung, Hyun Kyung Kim, Eun Hee Yeon, Yong Sung Shin, Chul Woo Kim [South-Korea]</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PO 082</th>
<th>Kasabach Merritt Syndrome (KMS) in infant with hepatoblastoma</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Patcharee Komvilaisak, Junya Jirapradittha, Pakapnan Kiatchoosakun, Arunee Jetsrisuparb, Surapon Wiangnon [Thailand]</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PO 083</th>
<th>Coagulation abnormalities in adult hemophagocytic lymphohistiocytosis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Naveen Manchanda [USA]</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PO 084</th>
<th>Catastrophic evolution of disseminated intravascular coagulation as initial manifestation of recurrent prostate cancer</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Tayana Mello, Patricia Gama, Simara Mantalvo, Joyce Maria Annichino-Bizzacchi [Brazil]</td>
</tr>
</tbody>
</table>
| PO 085 | Evaluation of two automated soluble fibrin assays for use in the routine hospital laboratory  
Eli Westerlund, Barry Woodhams, Jaak Eintrei, Lisbeth Söderblom, Jovan Antovic  
(Sweden) |
| PO 086 | The expression and secretion of ADAMTS13 in human microvascular endothelial cells  
Anyou Wang, Jingsheng Wu, Kaiyang Ding, Xin Liu, Xiaoyan Cai, Weibo Zhu, Zimin Sun,  
Ziqiang Yu, Changgeng Ruan  
(China) |
| PO 087 | Twin pregnancy with a very low ADAMTS13 activity and existence of schistocytes together with thrombocytopenia  
Nil Guler, Piltan Büyükkaya, Engin Kelkitli, Duzgun Ozatli  
(Turkey) |
| PO 088 | Alterations of plasma VWF and ADAMTS13 activity in patients receiving bone marrow transplantation  
Yue Han, Luping Hu, Jian Su, Qian Wang, Xia Bai, Zhaoyue Wang, Depei Wu,  
Changgeng Ruan  
(China) |
| PO 089 | Von Willebrand factor, ADAMTS13 activity, inflammatory marker and their relationships with risk factors of coronary artery disease  
Supakanya Lasom, Nantarit Komanasin, Nongnuch Settasatian, Chatri Settasatian,  
Upa Kukongviriyapan, Paisal Mongkolwongroj, Pongsak Intharapetch,  
Kasem Tantipanichetrearakul, Vichai Senthom, Pyatat Tatsanavivat  
(Thailand) |
| PO 090 | Fibrinogen concentration and tensile strength of clots  
Alexander Savushkin  
(Russian Federation) |
| PO 091 | Elimination of coagulation factor XIII from fibrinogen preparations  
Emma Smith, Barbara Cardinali, Lifang Ping, Robert Ariëns, Helen Philippou  
(United Kingdom) |
| PO 092 | Fibrinogen deficiency and surgical hemostasis-our first experience  
Deniza Stambolieva, Tatjana Timova, Tanja Malinova, Meri Sorova  
(Macedonia) |
| PO 093 | Detection of alpha-2-antiplasmin heterogeneity in plasma by immunoprecipitation and SDS-PAGE/western blotting  
Shirazkhan Abdul, Joyce Malfliet, Robert Ariëns, Frank Leebeek, Dingeman Rijken,  
Shirley Uitte de Willige  
(The Netherlands) |
| PO 094 | T-PA and PAI-1 levels in Tunisian Behçet patients  
Hela Baccouche, Nabil BelFeki, Monia Khanfir, Sonia Mahjoub,  
Mohamed Habib Houman, Neila Ben Romdhane  
(Tunisia) |
| PO 095 | Functional characterization of metalloproteinases (colombienases) with fibrinolytic activity from Bothrops colombiensis venom  
Belsy Guerrero, María Girón, Ana Salazar, Alexis Rodríguez-Acosta  
(Venezuela) |
| PO 096 | Plasminogen activity in patients with linceous conjunctivitis and hydrocephalus in Indonesia  
Santy Pudjianto, Rahajuningsih Setiabudy, Irawan Mangunatmadja, Made Susiyanti  
(Indonesia) |
| PO 097 | Computational study of Textilinin as an anti-bleeding agent to improve the stability and activity  
Hamzeh Rahimi, Shahriar Abdoli, Reza Mahdian  
(Iran) |
| PO 098 | Circumcision in patients with haemophilia: A single centre experience  
Arzu Akçay, Zafer Salcioglu, Deniz Tugcu, Hulya Sayilan Sen, Gonül Aydogan,  
Ferhan Akici, Muge Gokce, Nuray Aktay Ayaz, Unal Guvenc, Serdar Sander  
(Turkey) |
Iliopsoas hemorrhage in congenital factor deficiencies: The experience of Çukurova University, Adana, Turkey
Bulent Antmen, Ilgen Sasmaz, Barbaros Karagun, Goksel Leblebisatan, Yurdanur Kilinc [Turkey]

The effect of water exercise on atrophic muscles associated with limited range of motion in severe haemophilia A patients
Bulent Antmen [Turkey]

How well is haemophilia known among non-hematologists?
Cem Ar, Simge Erdem, Ahmet Sarici, Ayse Salihoglu, Osman Yokus, Fettah Sametoglu, Berna Yurttas [Turkey]

Hematuria in congenital coagulation factor deficiencies
Can Balkan, Nihal Karadas, Deniz Karapinar, Kaan Kavakli [Turkey]

SNC Bleeding: Experience on a Single Haemophilia Center (1990-2013)
Alejandra Baques, Raul Peres Bianco, Gabriela Guerrero, Miguel Candela [Argentina]

Primary prophylaxis in Venezuelan cohort: 5-year experience
Apsara Boadas, Mercedes Mijares, Luisa Hernandez, Marion Echenagucia, Naiari Fernandez, Arlette Ruiz-Saez [Venezuela]

Incidence of reduced bone mineral density among patients with hemophilia
Ana Boban, Silva Zupancic Satek, Darko Kaštelan, Damir Nemet [Croatia]

Feasibility study of a randomized control trial to evaluate an internet-based self-management program for adolescents with hemophilia: Preliminary results and observations
Vicky Breakey, Danial Ignas, Ashley Warias, Meghan White, Victor Blanchette, Jennifer Stinson [Canada]

Ischemic stroke and haemophilia A: What therapy?
Elena Campello, Spiezia Luca, Brandolin Barbara, Manara Renzo, Zanon Ezio [Italy]

Physical and mental quality-of-life in patients with haemophilia in Belgium: The impact of financial issues and of patients’ understanding of their condition
Ana Carvalhosa, Séverine Henrard, Cedric Hermans [Belgium]

Treatment of acute abdomen resulting from hematoma of the jejunum in severe haemophilia A
Ana Chalkling, Sandra Pias, Florenca Perera [Uruguay]

Hemophilia children receiving immune tolerance induction with adjuvant rituximab: 5-year long-term follow-up
Ampaiwan Chuansumrit, Nongnuch Sirachainan, Pakawan Wongwerawattanakoon, Duantida Songdej, Praguwan Kadegasem, Werasak Sasanaakul [Thailand]

Challenging diagnosis of haemophilia
Maia De luca, Francesca Ippolita Calò Carducci, Maria Patrizia Bicocci, Maura Acquila, Valentina Coletti, Giorgio Persano, Marco Cirillo, Massimiliano Soldati, Patrizia D’Argenio, Matteo Luciani [Italy]

Valeria De Padua, Cristina Santoro, Domenico Gaglioti, Riccardo Bosco, Francesco Riva, Erminia Baldacci, Caterina Mercanti, Laura Parlanti, Maria Gabriella Mazzucconi [Italy]

Rituximab plus prednisolone for managing hemophilia A with FVIII-inhibitor
Kaiyang Ding, Jingsheng Wu, Lei Zhang [China]
PO 114 Evaluation of quality of life in adult patients with hemophilia in northwest of Iran
Roya Dolatkhah, Ali Fakhari, Mohammad Zakaria Pezeshki, Reza Shabanlouei,
Mehri Gholchin, Nasrin Tahassoli (Iran)

PO 115 A possibility of relation between weather to joint bleedings in haemophic patients.
Teruhisa Fujii, Seiji Saito, Tomie Fujii (Japan)

PO 116 A prospective post-authorization safety surveillance study in 384 hemophilia A
patients with antihemophilic factor (recombinant) plasma/albumin free method
demonstrates safety and efficacy in Japan
Katsuuyuki Fukutake, Hideji Hanabusa, Masashi Taki, Tadashi Matsushita, Midori Shima,
Akira Shirahata, J-PASS Study group Advate (Japan)

PO 117 Treatment of hemophiliacs with inhibitors
Nemra Gaid Mehalhal, F. Arbaoui, H. Chalabi, E. Yessad Khaled (Algeria)

PO 118 retrospective study of sporadic haemophilia in the region of Murcia, Spain
Faustino García-Candel, Eduardo Tizzano, M. Majado, Valentín Cabañas,
Antonio García-Candel, Manuel Moreno, José Maria Moraleda (Spain)

PO 119 Physiotherapy is an important element of the modern haemophilia treatment
Susan Halimeh, Hannelore Rott, Guenther Kappert, Carola Kindermann, Marc Rosenthal
(Germany)

PO 120 Assessment of QoL in Korean hemophiliacs: The impact of health-related factors,
social state and a treatment factor on QoL of Korean hemophiliacs.
Jung Woo Han, So Eun Jeon, Shin Ho Jin, Lee Sun Ah, You Chur woo (South-Korea)

PO 121 Participation for innovation: Survey of motivation for clinical studies evaluating new
treatments for haemophilia
Séverine Henrard, Niko Speybroeck, Cedric Hermans (Belgium)

PO 122 Do inhibitors, treatment regimen and bleed frequency impact parent-directed
haemophilia treatment centre and provider utilisation: An analysis of parents of
children with haemophilia in the HERO study
Alfonso Iorio, Diane Nugent, Ann Marie Stain, Matt Gregory, Louisa Pericleous,
David Cooper (Canada)

PO 123 Potential relationships between negative impacts on employment or relationships
with haemophilia centre/provider utilisation: An analysis of parents of children with
haemophilia from the HERO study
Alfonso Iorio, Frederica Cassis, Matt Gregory, Werner Kalnins, Tami Wisniewski,
David Cooper (Canada)

PO 124 Potential relationships between negative impacts on employment or relationships
and haemophilia treatment centre/provider utilisation: An analysis of adults with
haemophilia from the HERO study
Alfonso Iorio, Frederica Cassis, Matt Gregory, Werner Kalnins, Tami Wisniewski,
David Cooper (Canada)

PO 125 Relationship of quality of life, pain and self-reported arthritis with activity, bleed rate
and haemophilia treatment centre/provider utilisation: Results from the HERO study
Alfonso Iorio, Angela Forsyth, Christine Guelcher, Andrea Buzzi, Tami Wisniewski,
David Cooper (Canada)

PO 126 Does higher risk activity change bleed frequency and haemophilia treatment center/
provider utilisation in children with haemophilia: An analysis from the HERO study
Alfonso Iorio, Angela Forsyth, Felipe Querol, Ann Marie Stain, Louisa Pericleous,
David Cooper (Canada)
PO 127  Do bleed rates and haemophilia treatment centre/provider utilisation vary with physical activity risk in adults with haemophilia: An analysis from the HERO study
Alfonso Iorio, Angela Forsyth, Felipe Querol, Ann Marie Stain, Louisa Pericleous, David Cooper (Canada)

PO 128  Association of treatment regimen and location with bleed frequency, quality of life and comorbidities in adults and children with haemophilia from the HERO study
Alfonso Iorio, Andrea Buzzi (Canada)

PO 129  Association between treatment regimen and quality of life assessed by EQ-5D-3L and pain interference in adults with haemophilia with and without inhibitors in the HERO study
Alfonso Iorio, Andrea Buzzi, Soraya Benchikh El Fegoun, David Cooper (Canada)

PO 130  Patient survey - pain therapy in haemophilia in Germany
Werner Kalnins, Günter Schelle, Katrin Jost, Wolfgang Eberl, Andreas Tiede (Germany)

PO 131  An experience of use of Traumastem P in control of spontaneous mucosal bleeding in patients with inherited bleeding disorders in Southern Iran
Mehran Karimi, Sezaneh Haghpanah, Zohreh Zahedi (Iran)

PO 132  Areas of concern for caregivers of children with hemophilia A and B: Results of a cross-sectional survey in the US
Laurie Kelley, Hoa Pham, Mitch DeKoven, Won Lee, Julie Powers, David Cooper, Tami Wisniewski (USA)

PO 133  Immune tolerance induction in children with severe hemophilia A and inhibitor in Poland
Anna Klukowska, Pawel Laguna, Grzegorz Dobaczewski, Anna Janik-Moszant, Elzbieta Kamienska, Andrzej Koltan, Danuta Pietrys, Beata Waleszkiewicz-Majewska (Poland)

PO 134  A systematic review of treatment patterns in Japanese haemophilia patients
Sangeeta Krishnan, Keiko Wada, Bruce Crawford, Chia Wen Lee-Grossman (USA)

PO 135  Treatment strategy and outcomes among US haemophilia patients: Results of a patient survey
Sangeeta Krishnan, Jeffrey Vietri, Roberto Furlan (USA)

PO 136  Regional factors influencing participation in clinical trials in hemophilia in the United States of America and South Africa
Rebecca Kruse-Jarres, Adam Rodman, Johnny Mahlangu (USA)

PO 137  The use of central venous catheters in children with haemophilia in Poland
Pawel Laguna, Anna Klukowska, Marcin Rawicz, Slawomir Puchalski, Michal Matysiak (Poland)

PO 138  Is venous or arterial thrombosis a clinical problem in patients with haemophilia? Experience from a Danish haemophilia centre
Julie Larsen, Karen Nielsen, Lone Poulsen, Mustafa Bor (Denmark)

PO 139  The importance of taking the In Vivo Recovery Test as a Routine Evaluation for Hemophilia Patients
Kun Lee, Jinkyung Suh, Uk Kim (South Korea)

PO 140  Clinical study to investigate the immunogenicity, efficacy and safety of treatment with human-cl rhFVIII in previously untreated patients with severe haemophilia A
Ri Liesner, Martina Jansen, Sigurd Knaub (United Kingdom)
PO 141  A new board game to assess coping and perception of children with hemophilia: Validation and evaluation
Perrine Limperg, Lotte Haverman, Vivian Colland, Heleen van Ommen, Marjolein Peters, Martha Grootenhuis (The Netherlands)

PO 142  Satisfaction with self-reported annual bleed rates within a severe hemophilia A population
Vincent Lin, Joshua Epstein (USA)

PO 143  Immune tolerance induction (ITI) according to the Bonn protocol in haemophilia A patients with inhibitors using a plasma-derived VWF-containing factor VIII concentrate: Two paediatric case reports
Judith Lohse, Siegmund Gehrisch, Carmen Escuriola-Ettingshausen, Wolfhart Kreuz, Ralf Knoeller (Germany)

PO 144  Identification of carriers of mutations in the factor VIII gene that cause severe hemophilia A: first study in Venezuela
Lucía López-Vásquez, Arlette Ruiz-Sáez, Apsara Boadas, Antonietta Porco, Silvia Albánez (Venezuela)

PO 145  Implementation of a mobile haemophilia outpatient’s care in Germany: Results of the HomeMHA Project
Sylvia Von Mackensen, Christian Schleicher, Karin Freidinger, Sabine Heine, Norbert Graf, Hermann Eichler (Germany)

PO 146  Sub-visible particles in recombinant FVIII products: Increased risk for immunogenicity?
Mantas Malisauskas, Christian Lubich, Thomas Prenninger, Peter Matthiessen, Peter Turecek, Friedrich Scheiflinger, Birgit Reipert (Austria)

PO 147  Evaluation causes of deaths among individuals with inherited haemophilia A & B in North-eastern Iran
Hassan Mansouritorghabeh, Manavifar Lida, Alireza Modaresi (Iran)

PO 148  Meta-analysis of post authorization safety studies: Worldwide postmarketing surveillance of hemophilia A patients treated with antihemophilic factor recombinant plasma/Albumin-free method rAHF-PFM
Maura Marcucci, Ji Cheng, Johannes Oldenburg, Claudia Schoenig-Diesing, Elizabeth Matovinovic, Vadim Romanov, Lehana Thabane, Alfonso Iorio (Canada)

PO 149  Mortality and cardiovascular disease in patients with haemophilia. A pilot study in a single centre
Teresa Martínez-Marini, Maria Joana Costa-Pinto, Maria del Carmen Gomez-del-Castillo, Andrea Galego, Julia Carnero, Pilar Echevarría, Javier Batlle, Maria Fernanda López-Fernández (Spain)

PO 150  Effectiveness and safety of long-term treatment with recombinant factor VIII formulated with sucrose for hemophilia A in clinical practice of emerging-market countries
Balkis Meddeb, Emna Gouider, Tatyana Andreeva, Azzam Al Zoebie, Tatyana Chernova, Senada Mehadzic, Nefyodova Lyudmila, Monika Brunn, Claudia Tueckmantel, Stephan Rauchensteiner (Tunisia)

PO 151  Utility of thrombin generation test in laboratory management of hemophilia A patients
Marija Milos, Desiree Coen Herak, Silva Zupancic-Salek, Renata Zadro (Croatia)
PO 152  Progress report on the experience of immune tolerance induction with a VWF/FVIII concentrate in haemophilia A patients in Colombia  
Cesar Montano, Gabriel David, Ernesto Rueda, Diego Estupiñan, Alexy Maza, Iliana De Los Reyes, Leila Martínez, Catalina Gutierrez, Carmen Escuriola, Wolfhart Kreuz [Colombia]

PO 153  Rapid immune tolerance induction following primary immunologic prophylaxis in a hemophilia A patient with high-titre inhibitor  
Paul Moorehead, Lisa Thibeault, Angie Tuttle, Julie Grabell, Louise Dwyre, Mariana Silva, Paula James, David Lillicrap [Canada]

PO 154  Frequency of FVIII inhibitor in patients treated with plasma derived FVIII concentrates  
Anna Morongova, Angelika Batorova, Eva Bubanska, Denisa Jankovicova, Tatiana Prigancova [Slovakia]

PO 155  Situation with haemophilia in Ukraine - the first results of work of regional haemophilia center  
Galyna Moroz, Iryna Gartovska, Natalia Derbeneva, Stanislav Vyduborets [Ukraine]

PO 156  Moba-Roku - a new internet assisted monitoring system of home infusion program for hemophilia care in Japan  
Hisaya Nakadate, Akira Ishiguro, Chiharu Namiki, Yuna Furuoya, Saori Mastmoto, Junko Saito [Japan]

PO 157  Causes of death in a cohort of patients with haemophilia in a Haemophilia Care Center in the last five years  
Ramiro Nuñez, Rosario Perez-Garrido [Spain]

PO 158  Filling the gap on long-term joint health and HRQoL outcomes data in hemophilia A using a single product (rAHF-PFM), non-interventional registry, AHEAD  
Johannes Oldenburg, Dimitrios Tsakiris, Ingo Abraham, Holger Brondke, Manfred Pirck, Werner Engl, Alexandra Loew-Baselli, Pedro Pina, Gerald Spotts [Germany]

PO 159  A study of risk factors for the development of FVIII inhibitors in Indian severe haemophilia A patients  
Patricia Pinto, Kanjaksha Ghosh, Shrimati Shetty [India]

PO 160  Impact of rAHF-PFM prophylactic Treatment on annual bleeding rate and health-related quality of life of adults with severe hemophilia A  
Doris Quon, Amy Shapiro, Elena Santagostino, Leonard Valentino, Joshua Epstein, Norma Guzman-Becerra, Phillip Schroth, Wing-Yen Wong [USA]

PO 161  Prophylaxis in adults hemophilic patients with severe arthropathy  
Carlos Ramirez, Gloria Valencia, Diana Arias, Ana Arteaga, Martha Madrid [Colombia]

PO 162  Immune tolerance induction in adult severe haemophilia A patients with a single FVIII/VWF product. The UK experience  
Savita Rangarajan, Thyn Thyn Yee, Ashok Roy [United Kingdom]

PO 163  Intracranial hemorrhage in hereditary bleeding disorders: The experience of Çukurova University Hemophilia Center  
Ilgen Sasmaz, Bulent Antmen, Barbaros Karagun, Göksel Leblebisatan, Dervis Yilmaz, Yurdanur Kilinc [Turkey]

PO 164  Treatment of outpatient dental extractions in persons with inherited bleeding disorders  
Kim Schafer, Elizabeth Funke, Jonathan Ducore, Jerry Powell [USA]
Surgery in hemophilia - a real therapeutic challenge for a low-resource country
Margit Serban, Dan Poenaru, Hortensia Ionita, Jenel Marian Patrascu, Cristina Emilia Ursu, Delia Savescu, Cristian Jinca, Serban Talpos-Niculescu, Alina Lacatusu, Ladislau Rittli [Romania]

Quality of life and well-being of haemophilia patients and parents in China: Subgroup analysis of the HERO study
Jing Sun, Renchi Yang, Yongqiang Zhao, Xuefeng Wang, Jingsheng Wu, Xinsheng Zhang, Tao Guan, Alfonso Iorio [China]

Adult onset high titer inhibitor disappeared in a patient with congenital hemophilia A after immune tolerance induction therapy
Takashi Suzuki [Japan]

Surgery in FVIII inhibitor patients: single center experience of 13 procedures in 8 patients
Jerome Teitel, Michelle Sholzberg, Georgina Floros [Canada]

Use of factor VIII after inhibitor clearance in patients with moderate hemophilia
Duc Tran, Donald Harvey, Shannon Meeks, Robin Chapman, Christine Kempton [USA]

Outcome of liver transplantation haemophilia patients in the Nordic countries
Hoa Tran, Ina Andersen, Aksel Foss, Lone Poulsen, Riitta Lassila, Geir Tjønnfjord, Pål Andre Holme [Norway]

Experience of home prophylactic treatment of inhibitory form of haemophilia A in children using recombinant activated FVII
Vladimir Vdovin, Pavel Svirin, Ekaterina Shiller, Elena Luchinkina, Oksana Malkova, Elina Ageenkova [Russian Federation]

Diagnosis of inherited coagulation disorders - when and why?
Nada Vukelic-Damijani, Sanja Balen, Edita Ivankovic, Natasa Katalinic [Croatia]

Successful anticoagulation with concomitant factor VIII replacement in a severe haemophilia A patient suffering a life threatening thrombotic event
Frederico Xavier, Jennifer Maahs, Rich Hallett, Charles Nakar, Angeli Rampersad, Sweta Gupta, Amy Shapiro [USA]

Clinical experience with new third generation recombinant B-domain deleted factor VIII concentrate (beroctocog alpha) in a single center
Ki-Young Yoo, Hwi-Joong Yoon [South-Korea]

Spectrum of molecular events encountered in Hemophilia B in a referral hospital in North India
Reena Das, Jasmina Ahluwalia, Jasbir Kaur, Hari Senee, Gunjan Chopra, Amita Trehan, Pankaj Malhotra, Ram Marwaha [India]

Real-life use of activated recombinant Factor VII (rFVIIa) in patients with haemophilia B with inhibitors - data from the UKHCD0/NHD registry
Charles Hay, Jens Bjerre, Gerry Dolan [United Kingdom]

RFVIIa prophylaxis for hemophilia B with recurrent high-titer inhibitors: A single patient experience
Zhanna Kovalova, Marika Grutupa, Elizabete Cebura, Zelma Vishnevsksa-Preciniece, Sergey Nikulshin, Gunita Medne [Latvia]

Treatment strategy and outcomes among US haemophilia B patients: results of a patient survey
Sangeeta Krishnan, Roberto Furlan, Jeffrey Vietri [USA]
ePOSTERS PUBLICATION ONLY

**PO 179** Identification of mutations in the Factor IX gene in patients with Hemophilia B in Venezuela
Liset Latorre, A. Ruiz-Sáez, Apsara Boadas, N. de Bosch, A. Porco (Venezuela)

**PO 180** Mitroaortic valve replacement in a haemophilic B patient with an intracardiac abscess and cerebral septic embolism. Case report
Susana Nobre Fernandes, Manuela Carvalho, Manuela Lopes, Fernando Araújo (Portugal)

**PO 181** Linkage analysis coupled with direct mutational screening in carrier detection and prenatal diagnosis of hemophilia B
Ravi Ranjan, Suhail Akhter, Amit Sharma, Sunil Kumar, Deepika Deka, Renu Saxena (India)

**PO 182** The efficacy and safety of Benefix in severe and moderate Hemophilia children in China: a signal centre observation study
Runhui Wu, Xinyi Wu, Gang Li, Yinzi Zhen, Ningning Zhang, Yan Wang, Wenwen He, Koon-Hung Luke, Man-chiu Poon (China)

**PO 183** Persistence of circulating heparin levels during maintenance hemodialysis in end stage renal disease patients
Vinod Bansal, Kristiyana Kaneva, Debra Hoppensteadt, Josephine Cunanan, Daneyal Syed, Ajay Singh, Jawed Fareed (USA)

**PO 184** The effect of empiric systemic anticoagulation prior to imaging for pulmonary embolism on mortality
Daren Beam, Christopher Kabrhel, Jeffrey Kline (USA)

**PO 185** Comparison of adherence to three times a day low dose unfractionated heparin for venous thromboembolism prophylaxis between surgical and medical ward patients
Snehal Bhatt, Enrique Seoane-Vazquez (USA)

**PO 186** Effects of novel oral anticoagulants on venous thrombosis model and bleeding time assay
Roberto José Fonseca, Raffaela Cortez, Paulo Antonio Mourao (Brazil)

**PO 187** No clinically relevant interaction between sugammadex and heparin (enoxaparin and unfractionated heparin) on coagulation
Annelieke Kruithof, Pieter-Jan de Kam, Rachid El Gahta, Matthijs Moerland, Cornelis Kluft, Marie-José van Lierop, Justin Dennie, Matt Troyer, David Gutstein, Jacobus Burggraaf (The Netherlands)

**PO 188** Biosimilar enoxaparins available for clinical use in Brazil
Stephan De Oliveira, Bianca Glauser, Gabriel Almeida, Gustavo Dos Santos, Mariana Pereira, Paulo Mourão (Brazil)

**PO 189** A comprehensive evaluation of factors effecting range and precision for heparin Anti-IIa and Anti-Xa chromogenic assays
Patrick Shaklee, Margaret Shaklee (USA)

**PO 190** The assessment of patients with heparin-PF4 antibody positivity: the importance of expert haematological input remains
Jenny Bosworth, Steven Austin, James Uprichard (United Kingdom)

**PO 191** Serotonin release assay (SRA) results for confirmation of heparin induced thrombotic thrombocytopenia (HITT)
Timothy Brighton, Mayu Kondo, Dea Prawitha, Sarah Just (Australia)
| PO 192 | Detection of heparin-induced thrombocytopenia antibodies by functional and immunological methods and comparison with genetic risk factor (polymorphism of FCγ receptor) | Ludek Slavik, Gabriela Svobodova, Jana Ulehlova, Vera Krcova, Antonin Hlusi, Jana Prochazkova [Czech Republic] |
| PO 193 | A Rheological Study of Incipient Clots Formed by Heparinized Plasma: Assessing the health risk associated with HIT and exploring the use of Gel Point detection for therapeutic management | Bethan Thomas, Adrian Evans, Weisel John, Lubica Rauova, Doug Cines, Rhodri Williams, Karl Hawkins [United Kingdom] |
| PO 194 | The utility of ELISA optical density as a prognostic tool in patients with confirmed heparin-induced thrombocytopenia | Elona Turley, Irwindie Sandhu, Cynthia Wu, Artur Szkotak [Canada] |
| PO 195 | Recurrence of heparin-induced thrombocytopenia induced by the re-administration of heparin after negative conversion of HIT antibodies in a patient with hemodialysis | Keiko Wanaka, Hiroyuki Matsushima, Chieko Kaneko, Kumiko Miyashita, Jeanine Walenga, Miho Otani, Yoshihiko Nakajima [Japan] |
| PO 196 | Inherited thrombophilia and other risk factors in women with thrombotic complications of oral contraceptives | Angelika Batorova, Denisa Jankovicova, Tatiana Prigancova, Anna Morongova [Slovakia] |
| PO 197 | Gynaecological problems in women with severe inherited platelet disorders - a single centre experience | Louise Bowles, Archana Depala, Shohreh Beski [United Kingdom] |
| PO 198 | Prenatal diagnosis in haemophilia A and B families: Combine cordocentesis and gene diagnosis | Jing Dai, Ye Ling Lu, Lan Qiu Ding, Li Hong Wang, Feng Wang [China] |
| PO 199 | Antiplatelet effect of Tyrane \([N-(3-hydroxy-1:3:5(10)-estratrien-17\beta-yl)-4-hydroxyphenethylamine]\) | Aurora De La Peña, Juan Manuel Fernandez-G, Mirthala Flores-Garcia, Roberto Marin-Ocampo, Cecilia Uribe-Lezama, Enrique Pinzon, Teresa Fortoul, Ismael Torres, Victor Salgado [Mexico] |
| PO 200 | Successful pregnancy outcome in a patient with factor XII deficiency and recurrent fetal loss | Cosimo Ettorre, Giuseppe Malcangi, Rita Scarafili, Valeria Landolo, Francesco Romano, Renato Marino [Italy] |
| PO 201 | Mutations within exon 8 of Protein Z gene of women with fetal loss: Structural implications assessed by molecular dynamic simulations | Giovanni Favuzzi, Giovanni Tiscia, Rocco Calandrino, Giovanni Nico, Valerio De Stefano, Elena Rossi, Tommaso Za, Elvira Grandone, Maurizio Margaglione [Italy] |
| PO 203 | Successful anticoagulation to prevent recurrent miscarriage in two women with severe thrombophilia and von Willebrand disease | Kathrin Heidinger, Ronald Fischer, Mohammed Alrifai, Christiane Kelm, Anette Kirsch-Altena, Bettina Kemkes-Matthes [Germany] |
| PO 204 | Platelet hyperaggregability in patients with fetal loss: The selected gene polymorphisms | Peter Kubisz, Juraj Sokol, Kamil Biringer, Lenka Lisa, Ingrid Skornova, Jela Ivankova, Maria Skerenova, Jan Danko, Jan Stasko [Slovakia] |
PO 205  Thrombophilia in ethiopathogenesis of IVF failure  
Aleksander Makatsaria, Dzhамиlya Khizroeva, Natalia Makatsariya, Olga Panfilova, Nadezhda Stuleva, Victoria Bitsadze [Russian Federation]

PO 206  LMWH and natural progesterone in patients with multiple pregnancy and thrombophilia  
Aleksander Makatsaria, Natalia Makatsariya, Victoria Bitsadze, Dzhамиlya Khizroeva, Olga Panfilova [Russian Federation]

PO 207  Biosimilar LMWH in prevention of repeated thromboses at pregnant women with thrombophilia  
Aleksander Makatsaria, Victoria Bitsadze, Olga Panfilova, Natalia Makatsariya, Ekaterina Yashenina [Russian Federation]

PO 208  Pregnancy and arterial thrombosis  
Aleksander Makatsaria, Svetlana Akinshina, Victoria Bitsadze, Dzhамиlya Khizroeva, Zumrad Gadaeva, Nadezhda Stuleva [Russian Federation]

PO 209  Different clinical manifestations of APS in obstetric practice  
Aleksander Makatsaria, Dzhамиlya Khizroeva, [Russian Federation]

PO 210  Antithrombotic prophylaxis in pregnant patients with prosthetic heart valves  
Aleksander Makatsaria, Svetlana Akinshina, Victoria Bitsadze, Dzhамиlya Khizroeva, Olga Panfilova, Natalia Makatsariya [Russian Federation]

PO 211  Multiple pregnancy, chorion and placental abruption and thrombophilia  
Aleksander Makatsaria, Victoria Bitsadze, Olga Panfilova, Natalia Makatsariya [Russian Federation]

PO 212  Massive obstetric bleedings and pathology of hemostasis system  
Aleksander Makatsaria [Russian Federation]

PO 213  Successful pregnancy outcome in women with bad obstetric history and recurrent fetal loss due to thrombophilia: Efficacy of combination of aspirin and heparin  
Alessandra Malato, Giorgia Saccullo, Marisanta Napolitano, Lucio Lo Coco, Simona Raso, Marco Santoro, Giuseppe Tarantino, Gianpaolo Vaccarella, Sergio Siragusa [Italy]

PO 214  Excessive menstrual blood losses can cause severe iron deficient anemia in women with inherited or acquired coagulation disorder for oral anticoagulant treatment  
Marisanta Napolitano, Giorgia Saccullo, Dolce Alberto, Assunta Orecchioni, Elvira Grandone, Alessandra Malato, Alessandro Lucchesi, Guglielmo Mariani, Sergio Siragusa [Italy]

PO 215  D-Dimer and pregnancy  
Ivanka Nikoloska, Violeta Neceva, Rumjana Apostolovska, Tatjana Bojadzieva-Makaroska, Ema Velkova, Julija Samonikov-Tosevksa [Macedonia]

PO 216  Evaluation of protein C activity in pregnant Nigerians  
Theresa Nwagha, Uchenna Nwagha, Obike Ibegbulam, Sunday Ocheni [Nigeria]

PO 217  Thrombocytopenia and pregnancy  
Dalila Tadlaoui, Hafida Bendaoud, Z’Hor Guechi [Algeria]

PO 218  Plasma Thrombin generation and circulating nucleosomes in women with early abortions  
Daniela Tormene, Tiziana Ammollo, Fabrizio Semeraro, Mirvana Gjergji, Martina Camerin, Silvia Visentin, Giovanni Nardelli, Paolo Simioni [Italy]
ePOSTERS PUBLICATION ONLY

PO 219  The features platelet hemostasis in pregnant women with missed abortion
         Irina Vasilenko, Susanna Gasparyan, Marina Nalgieva, Roman Lifenko, Alexandr Topuzov
         [Russian Federation]

PO 220  The clinical outcome of 103 pediatric ITP patients in one center
         Ali Bay, Ozlem Karaoglu [Turkey]

PO 221  The serum TPO levels, not a good biomark in children immune thrombocytopenia
         Zhenping Chen, Jingyao Ma, Jin Jiang, Ling Jin, Li Zhang, Jun Yang, Runhui Wu [China]

PO 222  Safety and efficacy of laparoscopic splenectomy in children with chronic Immune
         thrombocytopenic purpura
         Irina Evstafyeva, Igor Poddubnyi, Kirill Tolstov, Elena Donyush, Pavel Svirin,
         Vladimir Vdovin [Russian Federation]

PO 223  Comparison of length of stay for inpatients with immune thrombocytopenia treated
         with anti-Rh(D) versus those treated with intravenous immunoglobulin or steroids
         Hrvoje Melinscak, Ilan Shapira, Michael Grossbard, Mala Varma [USA]

PO 224  Successful management of ITP during pregnancy: Weekly IVIg is an option
         Paula Villaca, Erica Okazaki, Audrey Zeinad-Valim, Dalton Chamone, Elbio D’Amico
         [Brazil]

PO 225  CXCR4 gene variation is associated with minimal platelet count of childhood primary
         immune thrombocytopenia
         Jiaan-Der Wang, Ku Fan-Chen, Tsai Chi-Ren, Chang Te-Kau [Taiwan]

PO 226  Decreased interleukin–7 in peripheral blood is due to the negative feedback of
         apoptosis-resistance and over-expression of pro-inflammatory cytokines of
         lymphocytes in primary immune thrombocytopenia
         Donglei Zhang, Huiyuan Li, Xian Zhang, Xiaofan Liu, Feng Xue, Renchi Yang [China]

PO 227  Experience in treatment with alpha interferon in children with hemangioma in
         Srinagarind Hospital
         Patcharee Komvilaisak, Arunee Jetsrisuparb, Surapon Wiangnon,
         Kannika Choksantisook [Thailand]

PO 228  APC and PAR-antagonists’ protective effects on inflamed mast cells and mast
         cells co-cultivated with rat neurons
         Anna Erukhimovich, Lubov Gorbacheva, Zhanna Bespalova, Vsevolod Pinelis,
         Svetlana Strukova, Georg Reiser [Russian Federation]

PO 229  Splitomicin inhibits fMLP-induced superoxide anion production in human neutrophils
         by activate cAMP/PKA signaling inhibition of ERK pathway
         Hsiang Ruei Liao, Fu-Chao Liu, Jiin-Tarng Liou, Yuan-Ji Day, Huang-Ping Yu [Taiwan]

PO 230  Prospective study of inflammatory biomarkers in patients undergoing peritoneal
         dialysis
         Danyelle Romana Rios, Marina Velloso, Silvia Lima, Sylvia Turani, Laiise Rodrigues,
         Melina Pinheiro, Lucci Dusse, Adriano Sabino, Karina Gomes, Sergio Pinto [Brazil]

PO 231  Role of protein S in murine model of allergic asthma
         Takehiro Takagi, Masahiro Onishi, Ayshwarya Chelakko-Govindalayathil, Koa Hosoki,
         Kobayashi Tetsu, Corina D’Alessandro-Gabazza, John Morser, Osamu Taguchi,
         Esteban Gabazza [Japan]

PO 232  Protective effect of thrombomodulin in murine asthma is dose dependent
         Takehiro Takagi, Masahiro Onishi, Ayshwarya Chelakko-Govindalayathil, Masaaki Toda,
         Kobayashi Tetsu, Corina D’Alessandro-Gabazza, John Morser, Osamu Taguchi,
         Esteban Gabazza [Japan]
**The role of ETX in the pathogenesis of vascular complications of diabetes**
Natsumi Wakabayashi, Maako Kimura, Yosuke Kanno, Eri Kawashita, Hiroyuki Matsuno [Japan]

**Venous thrombosis and the incidence of factor V Leiden and factor II A20210 mutation in the cardiac pacing patients**
Teresa Domagala, Jacek Lelakowski, Mirosław Janczura, Sylwia Dziedzina, Teresa Iwaniec, Anna Rydlewska, Jacek Musial [Poland]

**Impact of inherited thrombophilia on the risk of recurrence venous thromboembolism (VTE) in Georgian population**
Levani Makhaldiani, Nino Pirtskheliani, Nino Kochiashvili, Nugzari Pargalava, Eka Gaprindashvili, Ketevani Kartvelishvili [Georgia]

**Familial screening in the case of Budd-Chiari syndrome with multiple thrombi due to Arg42Ser mutation in the protein C gene**
Jun Muratsu, Atsuyuki Morishima, Masayoshi Kukida, Anzu Tanaka, Xinpeng Fan, Toshiyuki Miyata, Katsuhiko Sakaguchi [Japan]

**Protein C deficiency: A case study**
Tatjana Timova, Emilija Kocovska, Deniza Stambolieva, Tanja Malinova, Lile Maninska, Violeta Gorgevska, Slavica Ortakovska, Jordanka Vitarova [Macedonia]

**Platelets function as enhancers of the dendritic cell-mediated allergic response**
Tomoki Ito, Takahisa Nakanishi, Muneo Inaba, Shosaku Nomura [Japan]

**Modern Approach for the detection of Pulmonary Embolism and our results of it surgical cure**
Alexandr Medvedev, Svetlana Nemirova, N. Melnikov, Vladimir Pichugin, Igor Bokarev [Russian Federation]

**Treatment of occluded stented segments in the venous system by ultrasound accelerated catheter directed thrombolysis**
Rob Strijkers, Mark de Wolf, Carsten Arnoldussen, Rick de Graaf, Arina ten Cate-Hoek, Cees Wittens [The Netherlands]

**Polyphosphatethe phosphate is an haemostatic agent in vivo**
Magnus Larsson, Linda Labberton, Cecilia Österholm Corbascio, Katrin Nickel, Thomas Renné [Sweden]

**Hemorrhagic diathesis in patient with multiple myeloma - case report**
Lenka Lisá, Ivana Plamenová, Pavol Holíč, Juraj Sokol, Ján Staško, Peter Kubisz [Slovakia]

**The effect of adenosine/lidocaine/Mg2+ on correcting coagulopathy following traumatic hemorrhagic shock**
Natalie Pecheniuk, Hayley Letson, Shauna French, Geoffrey Dobson [Australia]

**Fibrinogen therapy of severe bleeding based on whole blood rotational thromboelastometry**
Luca Spiezia, Sara Maggiolo, Elena Campello, Maria Bon, Elena Pelizzaro, Paolo Simioni [Italy]

**BDNF acts as an autocrine cell proliferation factor in TPO stimulated megakaryocytic cell line**
Shogo Tamura, Takanori Moriyama, Kazuhiko Matsuno, Katsue Suzuki-Inoue, Yukio Ozaki [Japan]
<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>PO 247</td>
<td>Comparison of platelet microparticles quantification between patients with Alzheimer disease and individuals without cognitive impairment</td>
<td>Gisele Gonçalves, Fernanda Campos, Rita Duarte, Olindo Martins-Filho, Lorena Caixeta, Luci Dusse, Josianne Silveira, Maria das Graças Carvalho [Brazil]</td>
</tr>
<tr>
<td>PO 248</td>
<td>Identification and isolation methodologies for blood microparticles</td>
<td>Xavier Sauder, Paul Monagle, Vera Ignjatovic  [Australia]</td>
</tr>
<tr>
<td>PO 249</td>
<td>Prothrombotic microparticles concentration after percutaneous coronary intervention and stent implantation</td>
<td>Krystyna Zawilska, Justyna Wachowiak  [Poland]</td>
</tr>
<tr>
<td>PO 250</td>
<td>Anticoagulant activity of sulfated polysaccharides from the green seaweed Cladophora falklandica</td>
<td>Paula Arata, Marina Ciancia, Lucia Kordich, Irene Quintana  [Argentina]</td>
</tr>
<tr>
<td>PO 251</td>
<td>Purification method thrombin-like enzyme and fibrinogenolytic enzyme from Agkistrodon blomhoffii ussuriensis snake venom</td>
<td>Bolor Buyanbadrakh, Punsaldulam Dashnyam, Sumiya Byambasuren  [Mongolia]</td>
</tr>
<tr>
<td>PO 252</td>
<td>Alterations in natural coagulation inhibitors in acute leukemias</td>
<td>Marzena Galar, Anna Szumowska, Agnieszka Kostur, Lukasz Bolkun, Janusz Kloczko  [Poland]</td>
</tr>
<tr>
<td>PO 253</td>
<td>Venous thromboembolism prophylaxis with rivaroxaban subsequent to enoxaparin in major orthopaedic surgery</td>
<td>Faik Altintas, Cagatay Ulucay, Turhan Ozler, Volkan Kilincoglu, Tevfik Guzelbey, Burak Aksu  [Turkey]</td>
</tr>
<tr>
<td>PO 254</td>
<td>Start-register (Survey on anticoagulated patients register): The first year of activity</td>
<td>Emilia Antonucci, Nicola Magrini, Francesco Marongiu, Vittorio Pengo, Daniela Poli, Armando Tripodi, Gualtiero Palareti  [Italy]</td>
</tr>
<tr>
<td>PO 255</td>
<td>Dabigatran overdose vs disseminated intravascular coagulation</td>
<td>Ana Azevedo, Teresa Gago, Isabel Freire  [Portugal]</td>
</tr>
<tr>
<td>PO 256</td>
<td>Efficacy and safety of thromboprophylaxis with use of LMWH and warfarin in the traumatology-orthopedic hospital</td>
<td>Svetlana Bozhkova, Alexey Borisov, Rashid Tikhilov, Anna Novokshonova, Alexandr Cibin  [Russian Federation]</td>
</tr>
<tr>
<td>PO 257</td>
<td>Identification of brodifacoum exposure and subsequent monitoring of treatment and recovery using functional markers of vitamin K status</td>
<td>Anniesharon Christian, David Card, Ruth Gilmore, Dominic Harrington  [United Kingdom]</td>
</tr>
<tr>
<td>PO 258</td>
<td>In vitro assessment, using thrombin generation, of the applicability of prothrombin complex concentrate as an antidote for Rivaroxaban</td>
<td>Jasper Dinkelaar, Pascal Molenaar, Marisa Ninivaggi, Bas de Laat, Herm-Jan Brinkman, Anja Leyte  [The Netherlands]</td>
</tr>
<tr>
<td>PO 259</td>
<td>Defibrotide interactions with newer oral anticoagulants and antithrombotic agents</td>
<td>Jawed Fareed, Debra Hoppensteadt, Omer Iqbal, Josephine Cunanan, Vinod Bansal, Schuharazad Abro, Rakesh Wahi  [USA]</td>
</tr>
<tr>
<td>PO 260</td>
<td>Dabigatran etexilate overdose and life-threatening gastrointestinal bleeding</td>
<td>Zdenka Hajsmanova, Jitka Slechtova, Pavla Sigutova, Alena Lavickova  [Czech Republic]</td>
</tr>
</tbody>
</table>
| PO 261 | Incidence of thromboembolic and bleeding events according to the timing of prophylaxis after orthopedic major surgery  
Hun Gyu Hwang, Myung Shin Kim, Gune Il Lim, Ho Hyung Lee, Hyun Uk Lee, Jung Woo Ji  
(South-Korea) |
| PO 262 | Profiling anticoagulants from hematophagous animals: An on-line post-column bioactivity assay with parallel mass spectrometric identification  
Janaki Iyer, Mirko Slovak, Jeroen Kool, Manjunatha Kini  
(Singapore) |
| PO 263 | Are the complications of anticoagulant treatment with vitamin K antagonists in atrial fibrillation gender dependent?  
Jelena Kovacev, Sladjana Novakovic-Anucin, Sanja Gnip, Pavica Radovic, Visnja Canak, Predrag Filipov, Gorana Mitic  
(Serbia) |
| PO 264 | Laboratory coagulation assays and ROTEM thromboelastography in monitoring the reversal of dabigatran with FEIBA and haemofiltration  
Jean Leong, Eric Thomson, Abreen Ali, Una Jarrold, Pamala Kanagasabapathy  
(United Kingdom) |
| PO 265 | Are point-of-care devices useful for monitoring bleeding risk under rivaroxaban treatment?  
Helen Mani, Natalie Herth, Alexander Kasper, Gundolf Schuettfert, Yvonne Weil, Birgit Linnemann, Edelgard Lindhoff-Last  
(Germany) |
| PO 266 | Topical use of antithrombotics  
Leanne Ng, Kate Monagle, Vera Ignjatovic, Paul Monagle  
(Australia) |
| PO 267 | Improving vitamin K antagonists management through daily low dose vitamin K supplementation  
Oriana Paoletti, Emilia Cancellieri, Anke Zimmermann, Laura Bassi, Ezio Damiolini, Silvia Zambelli, Sophie Testa  
(Italy) |
| PO 268 | A personalized system to enhance INR monitoring  
Oriana Paoletti, Mark Linder, Anke Zimmermann, Laura Bassi, Nika Delpero, Roger Jr Valdes, Claudia Dellanoce, Sophie Testa  
(Italy) |
| PO 269 | The effect of application of fresh frozen plasma on prothrombin time in the patients overdosed with oral anticoagulant medicaments  
Marina Paunovic, Biljana Jankovic-Orešcanin, Ljiljana Šuput-Tomaš  
(Serbia) |
| PO 270 | Use of prothrombin complex concentrates for urgent reversal of Dabigatran in the emergency department: A pilot study  
Manuel Quintana, Alberto Borobia, Ana Martinez Virto, Sara Fabra, Angelica Rivera, Marcelino Sánchez Casado, Jose Antonio García Erce  
(Spain) |
| PO 271 | Comparative study of medication compliance to two anticoagulants in the prevention of venous thromboembolism in orthopaedic surgery  
Maria João Ribeiro, Manuel Morgado, Sandra Morgado, Jorge Martinez  
(Portugal) |
| PO 272 | The course of D-Dimer levels in patients getting Rivaroxaban in therapeutical doses  
Hannelore Rott, Susan Halimeh, Guenther Kappert, Manuela Siebert  
(Germany) |
| PO 273 | Safety of enoxaparin sodium (subcutaneous injection kit) used in clinical settings in patients undergoing abdominal surgery (general surgery and gynecology) - specified drug-use survey  
Masato Sakon, Takao Kobayashi, Hideo Wada, Norimasa Seo  
(Japan) |
| PO 274 | Availability of laboratory monitoring of new oral anticoagulant (rivaroxaban)  
Vladimir Sukhanov, Olga Petrova  
(Russian Federation) |
| PO 275 | **New treatments and old effects: Dabigatran-induced leukocytoclastic vasculitis**  
Marta Valero Núñez, Inmaculada García Navarro, Francisco Mena Rodríguez, Carmen Benet Campos, María del Mar Luis Hidalgo, Teresa Bautista Claver, José Reinaldo Mayans Ferrer (Spain) |
| PO 276 | **Laboratory testing in new oral anticoagulants**  
Tatiana Vavilova, Olga Belyavskaya, Olga Sirotkina, Vera Samokhovetz (Russian Federation) |
| PO 277 | **Influence pharmacogenetics analysis on adequacy and safety of therapy by indirect anticoagulants**  
Nadezda Vorobyeva, Aleksandra Rogozina, Alyona Vorobyeva (Russian Federation) |
| PO 278 | **Intensity of bleeding following tooth extraction is moderated by personality traits independently of anticoagulant therapy**  
Shabnam Zollahzari, Job Harenberg, Svetlana Marx, Parastoo Hassani, Jeelka Fischer, Marinella Damiam, Lutz Frölich (Germany) |
| PO 279 | **Deep vein thrombosis of the penis: an unusual but severe complication of prostatic abscess. Case-report and review of the literature**  
Adriano Alatri, Luca Calanca, Marie-Denise Schaller, Alain Sermier, Lucia Mazzolai (Switzerland) |
| PO 280 | **Over-representation of thoracic outlet obstruction in patients with unprovoked upper extremity deep vein thrombosis**  
Howard Chan, Shuoyan Ning, Anthony Chan, Ryan Rebello, Keith Lau (Canada) |
| PO 281 | **Venous thrombosis and plasma homocysteine levels in the cardiac pacing patients**  
Teresa Domagała, Jacek Lelakowski, Katarzyna Kotula-Horowitz, Mirosław Janczura, Sylwia Dziedzina, Jacek Musial (Poland) |
| PO 282 | **Ageing of the venous valves as a new risk factor for venous thrombosis in the elderly - the BATAVIA pilot study**  
Alev Karasu, Alexandr Srámek, Frits Rosendaal, Astrid van Hylckama Vlieg (The Netherlands) |
| PO 283 | **Management and treatment outcomes of venous thromboembolism (VT)**  
Firas Salah Nori, Siv Foyn, Eli Førsund, Johannes Kahrs, Waleed Ghanima (Norway) |
| PO 284 | **Non-inherited causes of newly diagnosed venous thromboembolism in Croatia in 2011. Croatian Cooperative Group for Hematologic Diseases (CROHEM) study**  
Drazen Pulanic, Velka Gveric-Krecak, Zlatka Nemet-Lojan, Hrvoje Holik, Bozena Coha, Renata Babok-Flegaric, Mili Komljenovic, Mladen Petrovecki, Silva Zupancic Salek, Boris Labar, Damir Nemet (Croatia) |
| PO 285 | **Audit of completion of compulsory documented risk assessment for venous thrombosis**  
Kathryn Quinn, Rosemary Lavery, Hilary Speers, Gary Benson (Northern Ireland) |
| PO 286 | **Is MTHFR 677 genotyping a link that can be missed from the chain of assessment of the venous thrombosis risk?**  
Biljana Vuckovic, Gorana Mitic, Tatjana Ilic (Serbia) |
| PO 287 | **Factor VII levels and genetic polymorphisms in severe preeclampsia**  
Lara Godoi, Karina Gomes, Maria Carvalho, Luci Dusse (Brazil) |
| PO 288 | **Investigation on expression pattern of VKORC1 in mouse brain**  
Kerstin Liphardt, Katrin Czogalla, Stephan Baader, Matthias Watzka, Johannes Oldenburg (Germany) |
Establishment of a reference interval for canine FVIIa level in healthy client owned dogs
Karin Lövgren, Annemarie Kristensen, Bo Winberg, Mikael Tranholm, Tom Knudsen (Denmark)

Congenital factor VII deficiency and surgery in a single center experience
Young Shil Park, Ji Kyoung Park, Eun Jin Choi (South-Korea)

Pharmacodynamic effects of escalating dosages of a new recombinant human Factor VIIa (LR769) in congenital hemophilia A or B patients
Jerry Powell, Cornelius Kluft, Matthijs Moerland, Johan Frieling, Leonard Valentino (USA)

Pharmacodynamic effects of two recombinant FVIIa products in anticoagulated healthy volunteers
Joannes Reijers, Matthijs Moerland, Johan Frieling, Marcel Levi, Cornelis Kluft, Zheng Guan, Jan Freijer, Jan Freijer, Johannes Burggraaf (The Netherlands)

The evaluation of cases with Factor X deficiency in Southern East of Turkey
Murat Soker, Musemma Karabel, Aysen Yildirim, Yesim Oymak, Selvi Kelekci, Duran Karabel (Turkey)

Safety and pharmacokinetics of three doses of a new recombinant human Factor VIIa (LR769) in congenital hemophilia A or B patients
Leonard Valentino, Joannes Reijers, Jan Freijer, Johan Frieling, Jerry Powell (USA)

Extracorporeal shockwave lithotripsy (ESWL) in a patient with congenital factor VII deficiency and von Willebrand disease
Paula Villaca, Erica Okazaki, Audrey Zeinad-Valim, Tania Rocha, Eliane Sandoval, Raphael Kato, Elias Chedid-Neto, Dalton Chamome, Elbio D’Amico (Brazil)

Antiphospholipid antibody syndrome in monozygotic twins
Aisha Bruce, Syama Sinuff, Mary Bauman, Patti Massicotte (Canada)

Non-catheter deep venous thrombosis in pediatric patients: Data from a single hospital.
Vanessa Gimenez, Monica Martinez, Alejandra Costa, Liliana Alba, Alcira Fynn, Fernanda Cuello, Virginia Schuttemberg, Marcela Aznar, Ramiro Fernandez, Sandra Formisano (Argentina)

Successful bivalirudin use in a child post liver transplant
Patricia Massicotte, Aisha Bruce, Mary Bauman (Canada)

A case of extensive recalcitrant IVC thrombosis in a teenager with Behçet disease
Charles Nakar, Sweta Gupta, Frederico Xavier, Angeli Rampersad, Kannan Natarajan (USA)

Splenic infarction in a teenager associated with oral contraceptives, elevated lipoprotein a, and median arcuate ligament syndrome
Charles Nakar, Frederico Xavier (USA)

Inherited antithrombin deficiency: Description of a pediatric series in a single center
Gabriela Sciuccati, Graciela Pieroni, Mirta Hepner, Carolina Pepe, Silvina Annetta, Aurora Felui Torres, Carolina Cervio, Juan Fronroth, Mariana Bonduel (Argentina)

The assessment of risk factors for rhrombosis in children
Skrzypczyk Smalisz, Anna Klukowska (Poland)

Clinical utility of age specific natural anticoagulant levels in children with thrombosis
Esther Soundar, Vadim Kostousov, Purvi Jariwala, Ozlem Bilin, Jun Teruya (USA)
ePOSTERS PUBLICATION ONLY

PO 306  Antiphospholipid antibodies in neonates and babies with clinically significant thrombosis
Pavel Svirin, Pavel Zharkov, Lubov Larina, Vladimir Vdovin, Ekaterina Shiller, Nadezhda Podcherniaeva (Russian Federation)

PO 307  Neonatal cerebral sinus venous thrombosis associated with congenital chylothorax and congenital nephrosis: report of two unusual cases
Ivanna Yau, Yaser Diab, Mahendranath Moharir (Canada)

PO 308  Analysis of different mechanisms through hydrogen sulphide (H2S) would inhibit platelet aggregation
Emilse Bermejo, Daniel Saenz, Maria Alberto, Ruth Rosenstein (Argentina)

PO 309  Platelet activation and abnormal Ca2+ homeostasis in women with gestational diabetes mellitus
Volha Bichan, Zoya Zabarovskaya (Republic of Belarus)

PO 310  Detection of high platelet reactivity induced by release reaction by light transmission aggregatometry and the ways to prevent it
Liudmila Buryachkovskaya, Irina Uchitel, Alexander Sumarokov, Nikita Lomakin (Russian Federation)

PO 311  Impedance aggregation comparing three different anticoagulant matrices performed on whole blood samples from healthy subjects
Donna Castellone, A. Stroobants, Andrea Dummermuth (USA)

PO 312  Changes in platelet aggregation after impact with vipoxin and its components isolated from Vipera ammodytes venom
Dobri Danchev, Yana Goranova, Vassil Atanasov, Svetla Petrova (Bulgaria)

PO 313  New approach to determination of the intravascular platelets activation in patients with ischemic heart disease
Lizaveta Drozd, Inga Markava, Elena Miadzvedzeva, Ludmila Gelis, Sergei Syroezhkin (Republic of Belarus)

PO 314  Inhibition of platelet aggregation in Dengue infection does not correlate with anti DV-NS1 and anti PDI
Andhika Effendi (Indonesia)

PO 315  Impedance aggregometric analysis of thrombocyte function in pooled platelet concentrates in relation to storage time
Michael Glas, Janine Bauer, Sven Schneider, Thomas Volk, Sascha Kreuer (Germany)

PO 316  Increased platelet activity associates with clinical severity of ST-elevation acute myocardial infarction
Anggoro Hartopo, Budi Setianto, Deddy Achadiono, Putrika Gharini (Indonesia)

PO 317  Mechanisms for Ang-(1-7) on the expression of talin1 induced by AngII in human umbilical vein endothelial cells
Xiaofan He, Wenzhuo Ran, Zhibin Wen (China)

PO 318  Differential platelet activation: granule release without aIIbβ3 activation indicates platelet functions independent of aggregation
Thijs van Holten, Peter-Paul Wisman, Philip de Groot, Jasper Remijn, Frans Moll, Martin Teraa, Marianne Verhaar, Rolf Urbanus, Mark Roest (The Netherlands)

PO 319  Evaluation of activation states of small GTPases in patient platelets
Hisanori Horiuchi, Nobuhiro Yaoita, Ryutaro Shirakawa (Japan)
PO 320   Necrotic cell material from human renal tubular cells dose dependently stimulate platelet activation, aggregation and platelet-leukocyte complex formation
Marcel Jansen, Joris Roelofs [The Netherlands]

PO 321   Comparison of different brands of agonists for light transmission aggregometry using a multichannel analyser
Daan van de Kerkhof, Anton van der Stokker, Cisca Hudig, Paul Verhezen, Ed van Wijk, An Stroobants, Yvonne Henskens [The Netherlands]

PO 322   Technical validation of light transmission aggregometry using Chrono-Log, PAR8 and PAP8e
Irene Körver-Keularts, René van Oerle, Laura van Thoor, Paul Verhezen, Yvonne Henskens [The Netherlands]

PO 323   Fractal and euclidian geometrical descriptors of platelet shape
Max-Joseph Kraus, Heiko Neeb, Erwin Strasser [Germany]

PO 324   Absence of clinically relevant interaction between sugammadex and aspirin on platelet aggregation and coagulation
Annelieke Kruithof, Pieter-Jan de Kam, Rachid El Gatta, Jacobus Burggraaf, Cornelis Kluit, Hein Fennema, Marie-José van Lierop, Katsuhiro Mihara, Marjan Jagt-Smook, Matthijs Moerland [The Netherlands]

PO 325   A standardized flow chamber model for real-time visualization of whole blood platelet aggregation
Peter Laursen, Catherine Rea, Benny Sorensen [Denmark]

PO 326   Automation of Light Transmission Platelet Aggregation
Andrew Lawrie, Katsushi Kobayashi, Philip Lane, Ian Mackie, Samuel Machin [United Kingdom]

PO 327   Measuring platelet aggregation integrals to predict thromboembolic complications in patients undergoing pipeline embolization for treatment of cerebral aneurysms
Cheryl Maier, Thomas Schneider, Geoffrey Smith, William Rutledge, Jeannette Guarner, Alexander Duncan, Anne Winkler [USA]

PO 328   Platelet activation might facilitate the immunogenicity of stressed biotherapeutics
Mantas Malisauskas, Christine Lenk, Thomas Wurz, Christian Lubich, Friedrich Scheiflinger, Birgit Reipert [Austria]

PO 329   A novel flow cytometry-based platelet aggregation assay
Marjolein Meinders, Iris de Cuyper, Masha de Haas, Karl Seeger, Sergio Rutell, Taco Kuijpers, Arthur Verhoeven, Timo van den Berg, Laura Gutierrez, Edith van de Vijver, Dirk de Korte, Leendert Porcelijn, Johannes Eble, Daria Pagliara [The Netherlands]

PO 330   Ex vivo and in vivo effect of aspirin on different platelet activity pathways
Emilie Montenont, Nardi Michael, Jeffrey Berger [USA]

PO 331   Clinical features and bleeding patterns in children with Glanzmann thrombasthenia: Single center experience
Nihal Ozdemir, Busra Kutlubay, Gulen Tuysuz, Hilmi Apak, Tiraje Celkan [Turkey]

PO 332   Influence of angiotensin-(1-7) on the expression of talin 1 induced by angiotensin II in endothelial cells
Wenzhuo Ran, Xiaofan He, Zhibin Wen [China]

PO 333   Molecular study on the interactions between extracellular fragments of platelet thrombin receptor PAR4 and thrombin exosites and functional effects on platelet activation
Daniel Sanchez Centellas, Robert Selegård, Karin Enander, Tomas Lindahl [Sweden]
The influence of neurotropic drugs on platelet aggregation in vitro
Marina Shamanskaya, Stas Pradun, Ivan Darensky, Nadezda Shamanskaya (Russian Federation)

Antidepressant suppresses collagen-induced platelet activation
Naoko Sugita, Hideo Hirakata, Shuji Kawamoto, Toshiya Murai (Japan)

Platelet aggregation pattern amongst multiracial healthy blood donors performed in National Blood Centre (NBC), Malaysia
Eusni Tohit, Azlina Muhsin, Sabariah Noor, Roshida Hassan, Faraizah Karim (Malaysia)

Prasugrel shows less intraday variability in its antiplatelet effect compared to ticagrelor in cynomolgus monkeys
Atsuyuki Tomizawa, Kousaku Ohno, Joseph Jakubowski, Makoto Mizuno, Atsuhiro Sugidachi (Japan)

Methods for detection ASA resistance in vitro
Jana Ulehlova, Ludek Slavik, Vera Krcova, Jan Vaclavik, Jana Kucerova (Czech Republic)

The influence of different types of TRAP peptides on platelet aggregation, using different light transmission aggregometry devices
Paul Verhezen, Irene Körver-Keularts, René van Oerle, Laura van Thoor, Yvonne Henskens (The Netherlands)

Platelet aggregation in patients with chronic cerebral ischemia, carried the AGT-174T/M, AGT-235M/T, AGTR1-1166F/C, ACEI/D polymorphisms
Yuri Vitkovsky, Natalya Strambovskaya, Anna Knyazeva (Russian Federation)

Reduced platelet reactivity in critical limb ischemia patients
Peter Paul Wisman, Martin Teraa, Gert Jan de Borst, Frans Moll, Marianne Verhaar, Mark Roest (The Netherlands)

The use of a rapid, whole blood platelet factor 4 clotting assay for the early detection of hypercoagulability and guide to heparin therapy in equines
E. Yin, Crystal Sousa, David McCarroll, John McCarroll, Dave Morgan, Tanya Rozin (USA)

Evaluation study of a new, direct whole blood platelet function assay and its application
Yiming Zhao, Youtao Zhang, Shixiu Yao, Shundong Ji, Changgeng Ruan (China)

Evaluation of 195 referral cases with suspected hereditary platelet function disorders using platelet aggregometry and ATP release
Minoo Ahmadianejad, Ali Rajabi, Maryam Mashkooli, Mohammad Reza Tabatabaei, Seyedeh Ladan Seyed Mortaz, Somayeh Balooch, Maryam Mokhtari (Iran)

The efficacy of anti-Rh D, and vincristine sulphate in immune thrombocytopenic purpura
Saadet Akarsu, Erdal Kurnaz (Turkey)

Thrombotic complications in patients with adult chronic immune thrombocytopenic purpura
Natasa Colovic, Irena Djunic, Nada Suvajdzic, Ana Vidovic, Predrag Miljic, Dragica Tomin, Milica Colovic (Serbia)

Successful use of Recombinant Factor VIIa for menorrhagia control in a patient with Glanzmann’s thrombasthenia
Soeun Jun, Chur woo You, Ho Jin Shin, Jung Woo Han (South-Korea)
PO 348  Evaluation of laboratory desmopressin testing and clinical effects in patients with hereditary and acquired thrombocytopathies: Results of a retrospective multicenter study  
Ralf Knoefler, Anne Gneuß, Dirk Franke, Karim Kentouche, Jürgen Koscielny, Beate Krammer-Steiner, Sirak Petros, Uwe Platzbecker, Karl Seeger, Robert Klamroth  
(Germany)

PO 349  Congenital amegakaryocytic thrombocytopenia - the first case diagnosed in the Czech Republic and successfully treated by means of hematopoietic stem cell transplantation from matched unrelated donor  
Tomas Kuhn, Bohumir Blazek, Petra Keslova, Radek Cmejla, Petra Kovarova, Matthias Ballmaier  
(Czech Republic)

PO 350  Haemostatic management of pregnant women with platelet function disorders: Utility of PFA-100  
Claire Lentaigne, Vinnie Sodhi, Nusrat Usman, Andrew McCarthy, Carolyn Millar  
(United Kingdom)

PO 351  Use of recombinant factor VIIa in the management of 3 bleeding episodes in a patient with Bernard-Soulier syndrome  
Reda Messaoudi, Touhami Hadj, Benhadji Zahia  
[Algeria]

PO 352  Availability of a microchip flow chamber system as a screening test of platelet storage pool disease  
Hiroaki Minami, Keiji Nogami, Kenichi Ogiwara, Yosihiko Sakurai, Koji Yada, Kazuhiro Kashiwagi, Hidenori Suzuki, Kazuya Hosokawa, Midori Shima  
(Japan)

PO 353  Features of patients with immune thrombocytopenic purpura South-East of Turkey  
Murat Soker, Feride Akyüz, Selvi Kelekci, Velat Sen, Müsemma Karabel, Hülya Üzel, Ilyas Yolbas, Ali Günes  
(Turkey)

PO 354  Successful IVF and pregnancy in Glanzmann’s thrombasthenia under cover of recombinant factor VIIa  
Peter Staritz, Rainer Zimmermann, Christoph Domschke, Thomas Strowitzki, Christof Sohn, Angela Huth-Kuehne  
(Germany)

PO 355  Course of pregnancy, labour and perioperative management of a patient with Bernard-Soulier Syndrome - case report and literature review  
Justyna Teliga-Czajkowska, Anna Sikorska, Ksenia Bykowska, Krystyna Maslanka, Izabella Kopec, Wieslaw Schubert, Ewa Dmoch-Gajlerska, Jerzy Windyga, Krzysztof Czajkowski  
(Poland)

PO 356  Spontaneous duodenal hematoma in a patient with Glanzmann’s thrombasthenia  
Huseyin Tokgoz, Umran Caliskan  
(Turkey)

PO 357  RFVIIa inhalation for life threatening pulmonary hemorrhage in a case with refractoriness to platelet transfusion  
Abdulkareem Almomen, Aamer Aleem, Hana Saad  
(Saudi Arabia)

PO 358  Time dependent effect of aspirin intake on circadian rhythm of platelet reactivity: A pilot study  
Tobias Bonten, J. Snoep, J. Zwaginga, Frits Rosendaal, Jeroen Eikenboom, Anske van der Bom  
(The Netherlands)

PO 359  Can abnormal high mean platelet volume be used as a screening factor for detection of metabolic syndrome and coronary heart disease?  
Andrei Braester, Lev Dorosinsky, Alex Shturman, Tommy Hershkovitz, Luiza Akria, Celia Suriu, Moshe Shay, Shaul Atar  
(Israel)
| PO 360 | Metabolomics response of human platelets to collagen interaction  
Alexandra Bussey, Julian Griffin, Richard Farndale (United Kingdom) |
| PO 361 | Whole blood aggregometry and platelet derived microparticles enumeration in acute leukemia patients  
Andra Costache, Delia Mut Popescu, Silvana Angelescu, Doina Barbu, Anca Lupu (Romania) |
| PO 362 | A systems biology study of platelet GPVI signalling  
Joanne Dunster, Françoise Mazet, Mike Fry, Chris Jones, Marcus Tindall, Jonathan Gibbins (United Kingdom) |
| PO 363 | Immature platelet fraction and mean platelet volume in diabetes mellitus  
Eunyoung Lee (South-Korea) |
| PO 364 | Responses of different platelet activation pathways in health volunteers with Aspirin/Clotidogrel administration  
Jian Li, Jian Cao, Chengbin Wang, Yu-long Cong (China) |
| PO 365 | ELISA-VASP assay: Preanalytical stability of whole blood samples  
Maxime Moulard, Drifa Beroual, Aurélie Maguer, Guillaume Haquette, Paul Barragan, Nicolas Bourguet (France) |
| PO 366 | The participation of gamma/delta and alpha/beta T-lymphocytes in coaggregates forming with platelets in patients with coronary artery disease  
Alexey Solpov, Pavel Tereshkov, Marine Avetisyan, Olga Bolshakova, Svetlana Romanyuk, Igor Topolev, Yuri Vitkovsky (Russian Federation) |
| PO 370 | Guideline for diagnosis of inherited diseases of platelet function: Interdisciplinary S2K guideline of the GTH  
Werner Streif, Wolfgang Eberl, Harald Schulze, Ralf Knoeferl (Austria) |
| PO 371 | Lymphocyte-Platelet Adhesion in patients with chronic viral hepatitis C  
Yuri Vitkovsky, Darya Sakharova, Antony Petrov (Russian Federation) |
| PO 372 | Comparison of TRAP-stimulated platelet releasate between children and adults using two dimensional-Differential-In-Gel Electrophoresis (DIGE)  
Christina Yip, Vasiliki Karlaftis, Chantal Attard, Matthew Linden, Paul Mongale, Vera Ignatovic (Australia) |
| PO 373 | Platelet-derived growth factor (PDGF-BB) and platelets in myeloproliferative neoplasms  
Danuta Rosc, Joanna Boinska, Katarzyna Stankowska, Ewelina Drela, Grazyna Gadomska (Poland) |
| PO 374 | Biomarkers for post thrombotic syndrome: A systematic review and meta-analysis  
Annemiek Bouman, Selma Atalay, Hugo ten Cate, Marije ten Wolde, Arina ten Cate-Hoek (The Netherlands) |
| PO 375 | Diagnosis and prevention of post-thrombotic syndrome (PTS)  
Kristin Kornelia Utne, Hilde Wik, Waleed Ghanima (Norway) |
| PO 376 | Spontaneous acute cerebral hematoma in a child with F XIII deficiency  
Ali Bay, Akif Sirikci, Alper Dogan (Turkey) |
| PO 377 | Major surgery in emergency in a patient with deep factor X homozygous deficiency: Use of the thrombin generation test for management  
Sylvia Bellucci, Patricia Appaplaizza, Sophie Lubrano, Ludovic Drouet (France) |
ePOSTERS PUBLICATION ONLY

PO 378  The rare coagulation disorders in the west Algeria: Diagnosis and screening
Driss Benlaldj, Amine Mouadene, Reda Messaoudi, Khedidja Moulasserdoun, Yasmina Rahal, Mohammed Chakib Rahal, Hadj Touhami, Fatima Seghier [Algeria]

PO 379  Prenatal diagnosis for rare bleeding disorders
Jing Dai, Ye Ling Lu, Fang Xin, Lan Qiu Ding, Li Hong Wang, Feng Wang [China]

PO 380  Inherited factor VII deficiency in three Moroccan pedigrees
Chahrazad Guedira, Muriel Giansily, Souad Benkiran, Dallal Jeddi, Nezha Messoudi, Mohamed Mikdame, Jean-François Schved [Morocco]

PO 381  Effect of social factors on high prevalence of factor XIII deficiency in southeast Iran
Majid Naderi, Akbar Dorgalaleh, Peyman Eshghi, Shaban Alizadeh, Shadi Tabibian, Esmaeil Sanei Moghaddam [Iran]

PO 382  Rare Inherited Clotting Factor Deficiencies (RICFD) in pediatric population: King Faisal Specialist Hospital and Research Centre Riyadh Experience
Mahasen Saleh, Rubina Jamil, Abdulrahman Al Musa, Haza Zahrani, Tariq Owaidah, Tariq Hassan Hassan, Vigaruddin Mohammed, Mahmoud Abu-Riyash, Khawar Siddiqui [Saudi Arabia]

PO 383  Handling of a neonate with severe congenital factor VII deficiency and severe bleeding episodes
Gesa Wiegand, Ralf Rauch, Vanja Icheva, Günter Auerswald, Michael Hofbeck [Germany]

PO 384  Congential afibrinogenemia
Elena Yakovleva, Irina Tentsova, Anna Balandina, Nadegda Konyashina, Natalya Soboleva, Vladimir Zorenko [Russian Federation]

PO 385  Dysfibrinogenemia and pregnancy - a case report
Lucia Remotti, Maria Vera Morandini, Marcelo Ingratti, Analía Sánchez Luceros, Silvia Grosso, Adriana Woods, Susana Meschengieser, Alicia Blanco, Maria Lazzari [Argentina]

PO 386  The laboratory profile of the thrombotic Antiphospholipid Syndrome-experience from a North Indian tertiary care referral centre
Jasmina Ahluwalia, Joseph Masih, Sunil Bose, Varma Neelam [India]

PO 387  Anti-annexin V antibodies and clinical manifestations of antiphospholipid syndrome
Mehdi Ben Said, Rym Ellouze, Imen Sfar, Hajer Kallel, Yousr Gorgi, Taieb Ben Abdallah, Sami Guermazi [Tunisia]

PO 388  Hemolytic anemia and chronic non-healing ulcer on the right foot in a 27-year old female: A case of SLE antiphospholipid antibody positive responsive to cyclophosphamide therapy
Jose Bernardo Calatrava, Paul Santos-Estrella, Melissa Villamin, Evelyn Esposo [Philippines]

PO 389  Antiphospholipid syndrome and arterial thrombosis
Fatima Ibañez, Fernandez Harberth, Bermejo Nuria, Arcos Maria Jose, Martin Carolina, Carnicero Fernando, Martin Maria Luisa, Bañas Helena, Bergua Juan, Siguencia Raul [Spain]

PO 390  Comparison of six dilute Russell viper venom time lupus anticoagulant screen/confirm assay kits
George Fritsma, David McGlasson [USA]

PO 391  Prevalence of antiphospholipid antibodies in adults with ischaemic stroke
Benedict Nwogoh, Augustina Awodu, Obununbi Ogunrin [Nigeria]
PO 392 Incidence of antiphospholipid antibodies in women with preeclampsia seen at the University of Benin Teaching Hospital
Benedict Nwogoh, Augustina Awodu, Micheal Aziken [Nigeria]

PO 393 Frequency of Antiphospholipid Syndrome in 600 of Czech Females with Venous Thromboembolism in Association with Oral Contraceptive Use
Petr Sadilek, Petr Dulicek [Czech Republic]

PO 394 Lupus anticoagulant and anticardiolipin antibodies in polytransfused beta thalassemia major
Te-Fu Weng, Kang-Hsi Wu, Ching-Tien Peng, Ming-Ching Shen [Taiwan]

PO 395 Lupus anticoagulants sensitivity of Siemens APTT reagents
Thomas Wissel, Carola Wagner [Germany]

PO 396 Overweight, obesity and body composition and risk thrombotic complications
Aránzazu García-Raso, Gabriela Ene, Carolina Miranda, Raquel Mata, Rosa Vidal, Pilar Llamas [Spain]

PO 397 Measuring quality of life in acute venous thromboembolism
Kerstin Hogg, Joseph Shaw, Parvaneh Fatlah, Douglas Coyle, Marc Carrier, Phil Wells [Canada]

PO 398 Initiation of evidence-based guidelines in hemostaseology in a local hospital in southern germany
Andreas Kessler, Joerg Bickeboeller-Friedrich, Joana Knoeller, Gerhard Fischer [Germany]

PO 399 A rare cause of recurrent and serious venous thromboembolism: Klinefelter’s syndrome
Nihal Ozdemir, Beyhan Tuysuz, Olcay Evliyaoglu, Ozge Avar, Gulen Tuysuz, Tiraje Celkan [Turkey]

PO 400 Cancer-related thrombosis shows refractory to anticoagulant treatment
Xu Ye [China]

PO 401 Automated assay of plasminogen activator inhibitor-1 (PAI-1) activity on STA-R®
Claire Dunois, Vincent Juif, David Guimbard, Elodie Goulas, Geneviève Contant [France]

PO 402 Protective anticoagulation effects of peptide Arg-Pro-Gly-Pro and complex heparin with Arg-Pro-Gly-Pro in conditions of immobilization stress
Marina Grigorjeva, Ludmila Lyapina [Russian Federation]

PO 403 Flow conditions modulate fibrillogenesis of plasma fibronectin
Huong Nguyen, Khon Chan Huynh, Rüdiger Scharf, Volker Stoldt [Germany]

PO 404 Functional constituents in Natto: Nattokinase, vitamin K2 and polyamine contents
Mitsuru Serata, Sawa Naito, Chieko Yatagai, Tadanori Ohsugi, Yasuhide Yanagisawa, Josuke Saito, Hiroyuki Sumi [Japan]

PO 405 Thrombotic risk factors in cirrhotic patients
Hela Baccouche, Asma Labidi, Houda Kaabi, Sonia Mahjoub, Khadouja Hsouna, Monia Fekih, Hmida Slama, Azza Filali, Neila Ben Romdhane [Tunisia]

PO 406 Unusual thrombosis and thrombophilia: A difficult problem to address. 4 years experience
Claudia Casas, Luis Buitrago, María Helena Solano [Colombia]

PO 407 New automated chromogenic assay for Protein C activity in Q Hemostasis Analyzer
Eva Lambea, Cristina Lebrero, Maite Muñoz, Ana Chiva, Daniel Martorell [Spain]
The level of β-thromboglobulin and thrombophilia
Maria Matveeva, Ekaterina Shelest, Ludmila Popova, Lev Patrushev, Igor Bokarev
(Russian Federation)

Thrombophilia as a cardiovascular risk factor for acute myocardial infarction in a young patient-case report
Laurentiu Pascalau, Andreea Pascalau (Romania)

Inherited thrombophilia - accidental discovery at patients with neoplastic diseases from IIIrd Pediatric Clinic, Department of Hematology Oncology and Bone Marrow Transplantation Timisoara
Andreea Pascalau, Smaranda Arghirescu, Andrada Oprisoni, Anca Isac, Oana Ciocirlie, Bogdana Zoica, Ada Maria Balan, Cristian Jinca, Margit Serban (Romania)

The intensity of the intravascular coagulation and thrombophilia
Ludmila Popova, Maria Matveeva, Ekaterina Shelest, Lev Patrushev, Igor Bokarev (Russian Federation)

Plasminogen activator inhibitor type 1 (PAI-1) level and activity at patients with PAI-1 polymorphism
Ekaterina Shelest, Maria Matveeva, Ludmila Popova, Lev Patrushev, Evgeny Shuganov, Tatiana Gneusheva, Igor Bokarev (Russian Federation)

Observational analysis of genetic risk factors in patients with a documented diagnosis of cerebral sinus vein thrombosis
Gianpaolo Vaccarella, Mariasanta Napolitano, Giorgia Saccullo, Alessandra Malato, Sergio Siragusa (Italy)

About hemostasis system genes polymorphisms in patients with acute ischemic stroke
Nadezda Vorobyeva, Natali Shemakina (Russian Federation)

VKORC1 gene polymorphisms distribution features in native population of European Russia
Nadezda Vorobyeva, Petr Lavrinov, Natali Belova, Aleksandra Rogozina, Alyona Vorobyeva (Russian Federation)

The difference of homocysteine plasma in acute myocardial infarction depending on genetic polymorphisms of the enzyme methyltetrahydrofolate reductaza
Nadezda Vorobyeva, Polina Muchina (Russian Federation)

MTHFR C677T and A1298C as a hyperhomocysteinemia risk factor in native population of Nenets Autonomous District
Nadezda Vorobyeva, Petr Lavrinov, Natali Belova (Russian Federation)

The value of hyperhomocysteinemia on the severity of acute myocardial infarction
Nadezda Vorobyeva, Polina Muchina, Alyona Vorobyeva (Russian Federation)

Alllicin inhibits tissue factor expression in thrombin-induced endothelial cells by blocking MAPK and NF-κB
Junling Li, Feng Gao, Wenhui Zhu, Ping Zhou (China)

At equivalent biologic units, commercially available prothrombin complexes are not the same. Differential generation of thrombin and factor Xa upon tissue factor mediated activation
Arthur Only, Josephine Cunanan, Debra Hoppensteadt, Daniel Kahn, Nasir Sadeghi, Jawed Fareed (USA)
ePOSTERS PUBLICATION ONLY

PO 421 Influence of D-1208I gene polymorphism on tissue factor expression in healthy and influenza
Anton Petrov, Olga Petrova, Yuri Vitkovsky (Russian Federation)

PO 422 Mycophenolate mofetil for treatment of relapsed, refractory thrombotic thrombocytopenic purpura
Anyou Wang, Jingsheng Wu, Kaiyang Ding, Xin Liu, Zimin Sun, Jian Su, Ziqiang Yu, Changgeng Ruan (China)

PO 423 Diagnosis of von Willebrand disease: Use of bleeding score
Driss Benlaldj, Brahim Khachaa, Amine Mouadene, Khedidja Moulasserdong, Mohammed Chakib Rahal, Fatima Seghier (Algeria)

PO 424 A simplified assay for von Willebrand factor multimers analysis
Arnaud Bonnefoy, Annie Fontaine, Marie Lafayette, Carolina Dubois, Anik Cormier, Georges Rivard (Canada)

PO 425 A de novo type 2A von Willebrand factor mutation (Ser1517Arg)
Giancarlo Castaman, Sofia Giacomelli, Antonio Coppola (Italy)

PO 426 The first successful treatment of trauma in von Willebrand disease with a specific von Willebrand Factor Concentrate (VWF) in Paysandú, Uruguay - Treatment of fractured unstable lumbar vertebrae
Ana Chalkling, Sandra Pias, Florenca Perera (Uruguay)

PO 427 Severe periodical menorrhagia, corpus luteum rupture, haemoperitoneum with acute abdomen, laparoscopic ovariectomy, WILFACTIN® substitutive therapy in young female with type IIA von Willebrand disease
Dorina Cullrera, Antonino Cipolla, Francesco Di Raimondo (Italy)

PO 428 Management of severe coronary artery disease in a patient with type Vicenza von Willebrand disease
Emiliano De Bon, Sofia Barbar, Irene Di Pasquale, Alessandra Casonato, Antonella Bertomoro (Italy)

PO 429 Dental invasive procedures in von Willebrand disease (VWD) outpatients treated with high purity VWF/FVIII complex concentrate: experience of a single center
Valeria De Padua, Cristina Santoro, Domenico Gaglioti, Riccardo Bosco, Francesco Riva, Erminia Baldacci, Caterina Mercanti, Laura Parlanti, Maria Gabriella Mazzucconi (Italy)

PO 430 Successful percutaneous coronary intervention in a patient with von Willebrand disease
Cosimo Ettorre, Giuseppe Malcangi, Rita Scarafino, Valeria Iandolo, Renato Marino (Italy)

PO 431 Acquired von Willebrand syndrome secondary to a functional defect of von Willebrand factor
Kenny Galvez, Juan Combariza, Mauricio Gomez (Colombia)

PO 431 Bleeding score and fibrinolysis after DDAVP in possible type 1 VWD patients
Adriana Woods, Analia Sánchez-Luceros, Alicia Blanco, Susana Meschengieser, Maria Lazzari (Argentina)

PO 432 Changes in von Willebrand parameters during the menstrual Cycle
Susan Halimeh, Hannelore Rott, Guenther Kappert (Germany)

PO 433 Feno- and genotyping von Willebrand disease type 2A patient because of spontaneous tonsillar haemorrhage
Jolan Harsfalvi, Miklos Udvardy, Judit Kallai, Adrienne Kerenyi, Istvan Szegedi, Erzsebet Marjan, Csongor Kiss (Hungary)
PO 434 Treatment of a high thrombosis risk von Willebrand disease type 3 patient with high-purity von Willebrand factor during last trimester, cesarean delivery and post partum - a Case Report
Pål Holme [Norway]

PO 435 Automated ristocetin cofactor assay on STA-R®
Olivier Mathieu, Claire Dunois, David Guimbard, Didier Beaufere, Lucie Poncet, Vincent Juif, Geneviève Contant [France]

PO 436 Case study: Rare laboratory presentation of type IIB von Willebrand disease
Jane Needham, Helen Lewis, Savita Rangarajan, John de Vos, Mike Mitchell [United Kingdom]

PO 437 Von Willebrand disease a common inherited bleeding disorder after haemophilia A in Pakistan

PO 438 Update on laboratory findings in a prospective cohort of childbearing women with bleeding history
Anaïs Sánchez Luceros, Susana Meschengieser, Adriana Woods, Emilse Bermejo, Maria Alberto, Alicia Blanco, Maria Lazzari [Argentina]

PO 439 De novo mutation in von Willebrand disease type III in two siblings of Surinamese origin
Sheldon Simson [Surinam]

PO 440 Clinical presentation and laboratory findings of von Willebrand disease in a tertiary center in Saudi Arabia
Owaidah Tarek, Karima Al Hinai, Mahasen Al Saleh, Alsahbahi Amal, Alzahrani Hazzaa, Abdulrahman Almusa [Saudi Arabia]

PO 442 Operative management and outcomes in patients with von willebrand disease
Bulent Zulfikar, Basak Koc, Gulsum Ak, Fatih Dikici, Ihsan Karaman, Atacan Atalar, Fikret Bezgal [Turkey]

PO 443 Resistance to anti-platelet therapy in Saudi patients with coronary heart disease
Abdelgalil Abdelgadir, Mustafa Al Shimairi, Nervana Buyomi [Saudi Arabia]

PO 444 Frequencies of CYP2C19 in mexican-mestizo patients with coronary or cerebral atherosclerosis, and their association with high on-treatment platelet reactivity to adenosine diphosphate
Evelyn Cortina De La Rosa, Elias Merlin González, Beatriz Villegas Torres, Raul Izaguirre Avila [Mexico]

PO 445 Comparative effectiveness of the verifyNow P2Y12 test and light transmittance aggregometry for detecting the antiplatelet effect of clopidogrel
Jeffrey Dahlen, Victor Serebruany [USA]

PO 446 An optimal approach to selecting the appropriate cutoff for platelet function tests
Jeffrey Dahlen, Somjot Brar [USA]

PO 447 Urinary levels of 11-dehydro-TxB2 are not an accurate marker of inhibition of platelet thromboxane A2 production by aspirin
Eti Alessandra Femia, Viviana Cavalc, Mariateresa Pugliao, Cristina Razzari, Isabella Squellerio, Benedetta Porro, Gian Marco Podda, Federico Lombardi, Elena Tremoli, Marco Cattaneo [Italy]
ePOSTERS PUBLICATION ONLY

PO 448 Usefulness of light transmission aggregometry to optimize aspirin regimen in patients with left ventricular assist devices
Mathieu Fiore, Chloé James, Marie-Christine Boiteux, Christine Mouton, François Picard, Joachim Calderon, Laurent Barandon [France]

PO 449 Antithrombotic activity of synthetic compound LASSBio-752
Flávia Frattani [Brazil]

PO 450 First European performance evaluation of the VerifyNow II System
Thea Godschalk, Thomas Bergmeijer, Jeffrey Dahlen, Merel Kühbauch, Christian Hackeng, Jurriën ten Berg [The Netherlands]

PO 451 Effects of Platelet Reactivity on Long-term Clinical Outcomes and Bleeding Events in Japanese Patients Receiving Aspirin therapy
Hisanori Horiuichi, Keiichiro Yamane, Toru Kita, Takeshi Kimura [Japan]

PO 452 Coagulation markers and platelet reactivity after dual antiplatelet therapy in patient with acute myocardial infarction treated with primary percutaneous coronary intervention
Tina Kocica, Nebojsa Antonijevic, Lazar Davidovic [Serbia]

PO 453 Non-invasive method for study aggregation properties of the platelet, leukocyte, erythrocyte and hemostasis state
Boris Kuznik, Ilya Fine, Olga Maksimova, Evgeniya Kustovskaya, E. Martynova, Olga Rodnina, Natalia Khasanova [Russian Federation]

PO 454 Comparison of P2Y12-receptor blockade in cardiovascular disease patients undergoing antiplatelet therapy by Innovaance PFA P2Y assay and light transmission aggregometry using ADP agonist
Sandra Margetic, Biserka Getaldic, Ivana Vuga, Nada Vrkic [Croatia]

PO 455 Identification of patients less sensitive to Aspirin treatment through arachidonic acid stimulated platelet marker
Fabio Pulcinelli, Flavia Temperilli, Aldona Rina, Isabella Massimi, Anna Lisa Montemari, Guarino Maria Luisa, Maria Teresa Cardillo [Italy]

PO 456 Platelet-dependent thrombin generation assay provides new insights into the monitoring of antiplatelet therapy effectiveness
Olga Smirnova, Yury Namestnikov, Gelena Berezovskaya, Elena Klokova, Mikhail Karpenko, Olga Golovina, Olesya Matvienko, Ludmila Papayan [Russian Federation]

PO 457 Possibilities to assess compliance with low-dose aspirin treatment using a highly sensitive assay for salicylic acid in plasma?
Ragnhild Stålesen, Galia Spectre, Claes-Göran Östensson, Charlotte Ander, Erik Hedman, Olof Beck, Paul Hjemdahl [Sweden]

PO 458 Anti-platelet aggregation activity observed in Honkaku shochu
Hiroyuki Sumi, Satoshi Fujii, Syun Tokudome, Etsuo Yoshida, Chieko Yatagai, Sawa Naito, Masugi Maruyama [Japan]

PO 459 The effect of clopidogrel with and without aspirin on hemostatic system activation in vivo in man
Ludwig Traby, Marietta Kollars, Alexandra Kaider, Sabine Eichinger, Paul Kyrle [Austria]

PO 460 Sulforaphane induces ubiquitination of p85 and PDK1 and inhibits phosphatidylinositol 3-kinase signaling in human platelets
Chin-Chung Wu, Wen-Ying Chuang, Po-Hsiung Kung, Chih-Yun Kuo [Taiwan]
Could von Willebrand’s disease be overlooked in women using combined oral contraceptives?
Julie Larsen, Mustafa Bor, Anne-Mette Hvas (Denmark)

Association of methionine synthase and thymidylate synthase genetic polymorphisms with idiopathic recurrent pregnancy loss
Nam Keun Kim, Jung O. Kim, Jeon Young Joo, Bo Eun Lee, Dong Hee Choi, Woo Sik Lee, Ji Hyang Kim, Doyeun Oh (South-Korea)

Association study of Paraoxonase-1 gene polymorphisms and Homocysteine Levels in Patients with Ischemic Strokes
Nam Keun Kim, Jung O. Kim, Jeon Young Joo, Doyeun Oh (South-Korea)

Effects of hypertonic saline hydroxyethyl starch solution on heatstroke-induced damage in a rat model
Chen Kuen Bor, Huang Wu-Tien, Yang Tsai-Hsiu, Tsai Hsin-Mao, Liu Chia-Chyuan (Taiwan)

Children’s playbook validation for cardiovascular disease prevention
Luciana Lima, Mariana Oliveira Ferreira, Samuel Henrique Vieira Oliveira, Gustavo Antonio Oliveira, Flávia Euzébio Domingues, José Reinaldo Oliveira Junior, Marina Tarbes, Polylana Rezende Castilho (Brazil)

Coagulation factor VII gene polymorphisms and cardiovascular diseases in Iran
Nader Cohan (Iran)

Compound folate deficiency, elevated homocysteine and pseudo-homozygosity for MTHFR677T as predisposing factors in TIA: A case study
Jacky Cutler, Agata Sobczynska-Malefora, Paul Holmes, Robin Howard, Yusof Rahman (United Kingdom)

Individuals with coronary artery disease at a young age and features of the metabolic syndrome have an increased prothrombotic potential
Maayke G. Kok, Joost Meijers, Sara-Joan Pinto (The Netherlands)

Prevalence of risk factors for cardiovascular disease in Thai rural elderly
Nantarat Komanasin, Nisarat Neamsam, Anongnart Weerachai, Paisal Mongkolwongroj, Montien Puntumetakul, Nongnuch Settasatian (Thailand)

Immunization with a peptide containing two epitopes derived from chlamydia pneumoniae (Cpn) significantly reduces atherosclerotic lesion In Apobtm2SgyLdrtm1Her/J mice infected with the Cpn bacteria
Xinjie Lu, Min Xia, Daxin Chen, Valeria Endresz, Ildiko Faludi, Andrea Szabo, Eva Gonczol, Lakshmi Mundkur, Vijay Kakkar (United Kingdom)

Association of serum gamma-glutamyl transferase (GGT) and other markers with extent of coronary artery disease in angiographically proven patients and its potential use as risk indicator
M. Sangeeta, Ankit Sharma, Ghatge Madan, Vijay Kakkar, Rajani Kanth Vangala (India)

The hemostatic system status in chronic generalized periodontitis in the elderly people with coronary heart disease
Lidia Malezhik, Yurii Pinelis, Margarita Malezhik (Russian Federation)

Mucosal tolerance to multiple peptides ameliorates atherosclerosis in rabbits
Lakshmi Mundkur, Suryakanth Biradar, Narasimha Rao, Philip Sheena, Thiruvelselvan Ponnusamy, Deshpande Vrushali, Xinjie Lu, Vijay Kakkar (India)
| PO 474 | A genetic risk score for coronary artery disease in Asian Indians  
Jayashree Shanker, Prathima Arvind, Jiny Nair, Yogeshwari Sathyamurthy, Vandana Ravindran, Priyanka Setty, Sriarthika Jambunathan, Vijay Kakkar [India] |
| PO 475 | Non-invasive surrogate markers of coronary artery disease in Asian Indians  
Jayashree Shanker, Satish Govind, Dhanalakshmi Bhasker, Pruthvi Vaz, Vandana Ravindran, Vinoth Kumar, Vijay Kakkar [India] |
| PO 476 | Non-invasive assessment of extent of atherosclerotic disease, CVD risk factors and atherothrombotic biomarkers in Asian Indians  
Jayashree Shanker, Satish Govind, Dhanalakshmi Bhasker, Pruthvi Vaz, Vandana Ravindran, Vinoth Kumar, Vijay Kakkar [India] |
| PO 477 | Association of periodontal disease, extent of peripheral vascular changes, oral pathogens and risk of coronary artery disease in Asian Indians  
Jayashree Shanker, Priyanka Setty, Prathima Arvind, Jiny Nair, Dhanalakshmi Bhasker, Vijay Kakkar [India] |
| PO 478 | A comprehensive genetic analysis of the 9p21.3 CAD risk locus in Asian Indians  
Jayashree Shanker, Prathima Arvind, Sriarthika Jambunathan, Jiny Nair, Priyanka Setty, Vijay Kakkar [India] |
| PO 479 | The polymorphism SstI in APOC3 gene is not associated with abnormal lipid profile in Brazilian dyslipidemic children  
Franciele Silva, Marinez Sousa, Maria das Graças Carvalho, Cláudia Ferreira, Karina Gomes [Brazil] |
| PO 480 | Improvement of risk assessment with multi-pathway representative markers for coronary artery disease in the Indian population  
Rajani Kanth Vangala, Ghatge Madan, Vandana Ravindran, Ankit Sharma, Jayashree Shankar, Vijay Kakkar [India] |
| PO 481 | The comparison of efficacy between recombinant activated factor VII (ARYOSEVEN®) and NOVOSEVEN® in patients with congenital factor VII deficiency  
Mohammad Faranoush, Abolghassemi Hassan, Gholamreza Toogeh, Mehran Karimi, Peyman Eshghi, Mohammad Managchi, Hoofar Hamid, Kamran Kamyar, Ramin Heshmat, Bijan Keykhahi [Iran] |
| PO 482 | New data on the non-invasive method for the study of the haemostatic system  
Boris Kuznik, Ilya Fine, Olga Maksimova, Evgeniya Kustovskaya, Natalia Khasanova [Russian Federation] |
| PO 483 | Relationship of HLA-phenotype with some hemostasis profiles  
Dulma Nimaeva, Valentina Tsyrendorzhiieva [Russian Federation] |
| PO 484 | Variations of coagulation parameters during orthotopic liver transplantation - single center experience  
Sladjana Novakovic-Anucin, Sanja Gnip, Visnja Canak, Pavica Radovic, Djurdjina Jurišić, Svetlana Erdeljan, Zoran Milošević, Gorana Mitic [Serbia] |
| PO 485 | Implication of post-translational modifications on the function of key haemostatic proteins.  
Sachin Perera, Paul Monagle, Ignjatovic Vera [Australia] |
| PO 486 | Proteomics of defined platelets  
Fahrad Rezaee, B. Badlou, M. de Vries [The Netherlands] |
| PO 487 | A dual role for monocytes in coagulation and fibrinolysis cascades: Non-canonical coagulation factor production |
| PO 488 | Hemostatic alterations in mice model produced by mapanare snake venom (Bothrops isabelae) from Venezuelan Andes |
| PO 489 | Anaemic comorbidity is associated with coagulation dysfunction in patients with heart failure |
| PO 490 | Counselling by healthcare professional for patients taking oral direct inhibitors as anticoagulant therapy |
| PO 491 | Subcutaneous injection of enoxaparin in neonates |
| PO 492 | Risk of recurrence of venous thromboembolism assessment following discontinuation of initial treatment of anticoagulation |
| PO 493 | Treating pregnant women with high dose immunoglobulin (IVIG) in a single skilled Center reduce side effects |
| PO 494 | Hemostatic markers and sleep quality among shift work and day work female nurses |
| PO 495 | The PLD inhibitor, 5-Fluoro-2-indolyl des-chlorohalopemide, protects from occlusive thrombus formation and ischaemic stroke without impairing haemostasis |
| PO 496 | Brachial artery endothelium-dependent flow-mediated dilation and carotid artery intima-media thickness in the cardiac pacing patients |
| PO 497 | Talin and Src protein phosphorylation in hyperreactive platelets |
| PO 498 | Treatment modalities and outcomes in 870 non-surgical bleeds in 184 Glanzmann thrombasthenia (GT) patients. The International Prospective Glanzmann’s Thrombasthenia Registry (GTR) |
| PO 499 | The significance of TEG and TGA in the evaluation of hemostasis in children with cyanotic and acyanotic congenital heart diseases |
| PO 500 | Caspase-8 activation can be triggered in platelets through the intrinsic apoptosis pathway |
**Octapharma cordially invites you to attend our symposia**

### The first truly Human recombinant FVIII – a natural choice to satisfy unmet needs of haemophilia A patients

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker/Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:15</td>
<td>Welcome and introduction</td>
<td></td>
</tr>
<tr>
<td>16:25</td>
<td>Human-cl rFVIII: Functional insights gleaned from structure</td>
<td>Christoph Kannicht, Germany</td>
</tr>
<tr>
<td>16:45</td>
<td>Pharmacokinetics, efficacy and safety of Human-cl rhFVIII in adult patients: on-demand vs prophylaxis</td>
<td>Andreas Tiede, Germany</td>
</tr>
<tr>
<td>17:05</td>
<td>Human-cl rhFVIII in children: Results from the phase I/II study</td>
<td>Ri Liesner, UK</td>
</tr>
<tr>
<td>17:25</td>
<td>Can new research techniques enable future strategies to avoid inhibitor formation?</td>
<td>Daniel Hart, UK</td>
</tr>
<tr>
<td>17:45</td>
<td>Bringing Human-cl rFVIII to PUPs and personalized prophylaxis</td>
<td>Sigurd Knaub, Switzerland</td>
</tr>
<tr>
<td>18:05</td>
<td>Concluding remarks / Questions and answers</td>
<td></td>
</tr>
</tbody>
</table>

**Date:** Sunday, June 30, 2013  
**Time:** 16:15 - 18:15  
**Location:** Forum room

### Specific patients, specific solutions – beyond the clinical routine of von Willebrand disease

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker/Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>18:30</td>
<td>Welcome and introduction</td>
<td>Frank Leebeek, Netherlands</td>
</tr>
<tr>
<td>18:35</td>
<td>Von Willebrand disease and pregnancy</td>
<td>Mario v. Depka, Germany</td>
</tr>
<tr>
<td>18:55</td>
<td>Relevance of physiological VWF:FVIII complex in clinical setting</td>
<td>John Pasi, UK</td>
</tr>
<tr>
<td>19:15</td>
<td>Bleeding scores: How do they help with type 1 VWD?</td>
<td>Paula James, Canada</td>
</tr>
<tr>
<td>19:35</td>
<td>The role of continuous infusion during surgical procedures in VWD patients</td>
<td>Charlotte Grimley, UK</td>
</tr>
<tr>
<td>19:55</td>
<td>Concluding remarks / Questions and answers</td>
<td>All</td>
</tr>
</tbody>
</table>

**Date:** Tuesday, July 2, 2013  
**Time:** 18:30 - 20:00  
**Location:** Mondriaan II room

Come and visit our booth 6.
Special Symposia
SPONSORED SYMPOSIA

SPECIAL SYMPOSIA

Sunday, June 30  12:15 – 14:15

Special Symposium Bayer: Prophylaxis in action: its expanding role in hemostasis and thrombosis  Mondriaan II

Moderators: Gerry Dolan [United Kingdom] and Craig Kessler [USA]

12:15 - 12:20  Opening remarks  
SPS01-01  Gerry Dolan [United Kingdom]

12:20 - 12:50  Developments in prophylaxis for hemostatic and thrombotic disorders  
SPS01-02  Jerry Powell [USA]

12:50 - 13:20  Thromboprophylaxis for persons with hemophilia  
SPS01-03  Gerry Dolan [United Kingdom]

13:20 - 13:50  FXa primary and secondary thromboprophylaxis: where are we now?  
SPS01-04  Sebastian Schellong [Germany]

13:50 - 14:10  DEBATE: FVIII trough levels in prophylaxis should be kept above 5%  
SPS01-05  For: Cedric Hermans [Belgium]  
Against: Gili Kenet [Israel]

14:10 - 14:15  Summary  
SPS01-06  Craig Kessler [USA]

Special Symposium Baxter: Prophylaxis in hemophilia: Towards a world without bleeds  Elicium 1

Moderators: Jan Astermark [Sweden] and Bruce Ewenstein [USA]

12:15 - 12:20  Welcome  
SPS02-01  Bruce Ewenstein [USA]

12:20 - 12:45  The burden of bleeds: Is one bleed too many?  
SPS02-02  Alessandro Gringeri [Austria]

12:45 - 13:15  Individualizing hemophilia care: Pharmacokinetics and beyond  
SPS02-03  Steven Pipe [USA]

13:15 - 13:40  FEIBA Prophylaxis for hemophilia patients with inhibitors: Evidence from two prospective clinical studies  
SPS02-04  Wing Yen Wong [USA]

13:40 - 14:05  Insights into real world practice in hemophilia  
SPS02-05  Johannes Oldenberg [Germany]

14:05 - 14:15  Panel discussion and question & answer session  
SPS02-06  Jan Astermark [Sweden]
**SPONSORED SYMPOSIA**

**SPECIAL SYMPOSIA**

**Sunday, June 30**

**16:15 - 18:15**

Special Symposium CSL Behring: Spotlight on the future: new options for our patients

Mondriaan IV

**Moderators:** Kathelijn Fischer (The Netherlands) and Barbara Konkle (USA)

- **16:15 - 16:20** Introduction and welcome
- **16:20 - 16:30** Innovation in recombinant coagulation factors
  - SPS03-01 Stefan Schulte (Germany)
- **16:30 - 16:45** PROLONG-9FP: Results of the clinical program of the recombinant fusion protein linking coagulation FIX with albumin (rIX-FP)
  - Elena Santagostino (Italy)
- **16:45 - 17:00** PROLONG-9FP: Population PK modeling
  - SPS03-03 Massimo Morfini (Italy)
- **17:00 - 17:15** Affinity: Modern treatment of hemophilia A
  - SPS03-04 Ingrid Pabinger (Austria)
- **17:15 - 17:35** The challenge of inhibitors
  - SPS03-05 Jerzy Windyga (Poland)
- **17:35 - 17:45** PROLONG-7FP: New treatment options for hemophilia patients with inhibitors - phase I study investigating recombinant fusion protein linking coagulation FVIIa with albumin (rVIIa-FP)
  - SPS03-06 Alex Veldman (Germany)
- **17:45 - 18:10** Q & A session
- **18:10 - 18:15** Concluding remarks
**SPONSORED SYMPOSIA**

**SPECIAL SYMPOSIA**

Sunday, June 30 16:15 - 18:15

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:15 - 16:20</td>
<td>Welcome and introduction</td>
</tr>
<tr>
<td>SPS04-01</td>
<td>Eveline Mauser-Bunschoten [The Netherlands]</td>
</tr>
<tr>
<td>16:20 - 16:30</td>
<td>Challenges faced by inhibitor patients today - what have we learned?</td>
</tr>
<tr>
<td>SPS04-02</td>
<td>Stephanie Seremetis [USA]</td>
</tr>
<tr>
<td>16:30 - 16:45</td>
<td>NovoSeven® efficacy: latest results from the largest pivotal trial in haemophilia with inhibitors</td>
</tr>
<tr>
<td>SPS04-03</td>
<td>Johnny Mahlangu [South Africa]</td>
</tr>
<tr>
<td>16:45 - 17:00</td>
<td>Safety in numbers: evidence from NovoSeven® in children and adults</td>
</tr>
<tr>
<td>SPS04-04</td>
<td>Ellis Neufeld [USA]</td>
</tr>
<tr>
<td>17:00 - 17:15</td>
<td>Immunogenicity: small molecular changes - what are the potential risks?</td>
</tr>
<tr>
<td>SPS04-05</td>
<td>Silke Ehrenforth [Denmark]</td>
</tr>
<tr>
<td>17:15 - 17:30</td>
<td>Navigating a complex landscape: successful data collection in rare bleeding disorders</td>
</tr>
<tr>
<td>SPS04-06</td>
<td>Guy Young [USA]</td>
</tr>
<tr>
<td>17:30 - 17:40</td>
<td>Congenital FXIII deficiency: a rare and under-diagnosed bleeding disorder</td>
</tr>
<tr>
<td>SPS04-07</td>
<td>Andrew Mumford [United Kingdom]</td>
</tr>
<tr>
<td>17:40 - 17:55</td>
<td>Investigation and diagnosis of FXIII deficiency: improving patient outcomes</td>
</tr>
<tr>
<td>SPS04-08</td>
<td>Hans-Peter Kohler [Switzerland]</td>
</tr>
<tr>
<td>17:55 - 18:10</td>
<td>NovoThirteen®: charting a new course in the treatment of congenital FXIII deficiency</td>
</tr>
<tr>
<td>SPS04-09</td>
<td>Manuel Carcao [Canada]</td>
</tr>
<tr>
<td>18:10 - 18:15</td>
<td>Concluding remarks</td>
</tr>
<tr>
<td>SPS04-10</td>
<td>Eveline Mauser-Bunschoten [The Netherlands] and Andrew Mumford [United Kingdom]</td>
</tr>
</tbody>
</table>
Special Symposium Octapharma: The first truly Human recombinant FVIII - a natural choice to satisfy unmet needs of haemophilia A patients

Moderators: Claude Negrier (France) and Leonard Valentino (USA)

16:15 - 16:25 Welcome and introduction
SPS05-01 Leonard Valentino (USA) and Claude Negrier (France)

16:25 - 16:45 Human-cl rhFVIII: Functional insights gleaned from structure
SPS05-02 Christoph Kannicht (Germany)

16:45 - 17:05 Efficacy and safety of Human-cl rhFVIII in adult patients: on-demand vs prophylaxis
SPS05-03 Andreas Tiede (Germany)

17:05 - 17:25 Human-cl rhFVIII in children: Results from the phase III study
SPS05-04 Ri Liesner (United Kingdom)

17:25 - 17:45 Can new research techniques enable future strategies to avoid inhibitor formation?
SPS05-05 Daniel Hart (United Kingdom)

17:45 - 18:05 Bringing Human-cl rFVIII to PUPs and personalized prophylaxis
SPS05-06 Sigurd Knaub (Switzerland)

18:05 - 18:15 Concluding remarks / Questions and answers
SPS05-07 Leonard Valentino (USA) and Claude Negrier (France)
**SPONSORED SYMPOSIA**

**SPECIAL SYMPOSIA**

**Monday, July 1**

18:30 – 20:00

**Special Symposium Bayer: Treatment with Rivaroxaban - Real Life Aspects that Matter**

*Mondriaan II*

*Moderators: Rhona Maclean (United Kingdom) and Phil Wells (Canada)*

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>18:30 - 18:35</td>
<td>Welcome and introduction</td>
<td>Phil Wells (Canada)</td>
</tr>
<tr>
<td>18:35 - 18:50</td>
<td>Breadth of indication matters...One drug for multiple indications</td>
<td>Freerk Verheugt (The Netherlands)</td>
</tr>
<tr>
<td>18:50 - 19:00</td>
<td>Single-drug solution matters...EINSTEIN pooled analysis</td>
<td>Phil Wells (Canada)</td>
</tr>
<tr>
<td>19:00 - 19:20</td>
<td>Experience matters...Practical management with rivaroxaban</td>
<td>Rupert Bauersachs (Germany)</td>
</tr>
<tr>
<td>19:20 - 19:35</td>
<td>Confirming study results matters...The Dresden Registry</td>
<td>Jan Beyer-Westendorf (Germany)</td>
</tr>
<tr>
<td>19:35 - 19:55</td>
<td>Moderated discussion</td>
<td>Rhona Maclean (United Kingdom)</td>
</tr>
<tr>
<td>19:55 - 20:00</td>
<td>Summary and close</td>
<td>Phil Wells (Canada)</td>
</tr>
</tbody>
</table>
**SPONSORED SYMPOSIA**

**SPECIAL SYMPOSIA**

**Monday, July 1**

**18:30 – 20:00**

**Special Symposium Biogen Idec / Sobi: Microphysiology of joint damage: Surrogate measures of joint damage and inflammation**

Mondriaan IV

*Moderators: Kathelijn Fischer (The Netherlands) and Glenn Pierce (USA)*

18:30 - 18:35

**Introduction**

Kathelijn Fischer (The Netherlands)

18:35 - 18:55

**Microphysiology of joint damage and induction of a chronic inflammatory state following haemarthrosis in patients with haemophilia**

Leonard Valentino (USA)

18:55 - 19:15

**Biomarkers: Surrogate measures of joint damage**

Anne Bay-Jensen (Denmark)

19:15 - 19:30

**Challenges in understanding early joint damage using MR imaging: Experience from the joint outcome study**

Marilyn Manco-Johnson (USA)

19:30 - 19:50

**Personalised treatment to prevent haemarthrosis**

Pia Petrini (Sweden)

19:50 - 20:00

**Panel discussion**

Glenn Pierce (USA)

**Special Symposium CSL Behring: Bleeding emergencies: Strategies for the reversal of old and new generation oral anticoagulants**

Forum

*Moderators: Jerold Levy [USA] and Ingrid Pabinger [Austria]*

18:30 - 18:33

**Introduction**

Ingrid Pabinger (Austria)

18:33 - 18:55

**Efficacy of prothrombin complex concentrate (Beriplex) compared to plasma in emergency warfarin reversal: Insights from a randomized trial**

Ravindra Sarode (USA)

18:55 - 19:05

**Pharmacology and safety of new oral anticoagulants: The challenge of bleeding persists**

Jerold Levy (USA)

19:05 - 19:20

**Prothrombin complex concentrate as a reversal agent for the new oral anticoagulants - lessons from models**

Gerhard Dickneite (Germany)

19:20 - 19:35

**Bleeding with new oral anticoagulants - clinical presentation and approach**

Elise Eerenberg (The Netherlands)

19:35 - 19:50

**Treatment of ICH due to new oral anticoagulants - a neurologists view**

Roland Veitkamp (Germany)

19:50 - 20:00

**Panel discussion**
## SPONSORED SYMPOSIA

### SPECIAL SYMPOSIA

**Monday, July 1**

**18:30 – 20:00**

#### Special Symposium LFB Biomedicaments: Issues and emerging challenges in bleeding disorders

**Mondriaan III**

**Moderators:** Marcel Levi (The Netherlands) and Jean-François Schved (France)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Presenter(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>18:30 - 18:35</td>
<td>Welcome and introduction</td>
<td>Marcel Levi (The Netherlands), Jean-François Schved (France)</td>
</tr>
<tr>
<td>18:35 - 18:55</td>
<td>Challenges and unmet needs in bleeding disorders</td>
<td>Flora Peyvandi (Italy)</td>
</tr>
<tr>
<td>18:55 - 19:15</td>
<td>Specific approach for von Willebrand Disease patients</td>
<td>Wolfgang Miesbach (Germany)</td>
</tr>
<tr>
<td>19:15 - 19:35</td>
<td>Congenital fibrinogen deficiency: an update</td>
<td>Jean-François Schved (France)</td>
</tr>
<tr>
<td>19:55 - 20:00</td>
<td>Concluding remarks</td>
<td>Jean-François Schved (France), Marcel Levi (The Netherlands)</td>
</tr>
</tbody>
</table>

#### Special Symposium Novo Nordisk: Harmonising experience and technology: evolving new possibilities for haemophilia patients

**Auditorium**

**Moderators:** Claude Négrier (France) and Stephanie Seremetis (USA)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Presenter(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>18:30 - 18:40</td>
<td>Welcome &amp; introduction</td>
<td>Claude Négrier (France) and Stephanie Seremetis (USA)</td>
</tr>
<tr>
<td>18:40 - 19:00</td>
<td>New perspectives on risk factors for inhibitor development in severe haemophilia A: the results of the RODIN Study</td>
<td>Samantha Gouw (The Netherlands)</td>
</tr>
<tr>
<td>19:00 - 19:20</td>
<td>Realising the potential of recombinant technology: reliability by design</td>
<td>Robert Klamroth (Germany)</td>
</tr>
<tr>
<td>19:20 - 19:35</td>
<td>Clinical outcomes with turoctocog alfa: reviewing the guardian™ trials</td>
<td>Maria Elisa Mancuso (Italy)</td>
</tr>
<tr>
<td>19:35 - 19:55</td>
<td>Advancing the treatment of haemophilia B: a paradigm shift with recombinant glycoPEGylated FIX?</td>
<td>Claude Négrier (France)</td>
</tr>
<tr>
<td>19:55 - 20:00</td>
<td>Closing remarks</td>
<td>Claude Négrier (France) and Stephanie Seremetis (USA)</td>
</tr>
</tbody>
</table>
SPONSORED SYMPOSIA

SPECIAL SYMPOSIA

Monday, July 1  18:30 – 20:00

Special Symposium Sanofi: Advancing Patient Safety in the Prevention of VTE  G102-103

Moderator: Lord Kakkar [United Kingdom]

18:30 - 18:40  Opening remarks and welcome
SPS11-01  Lord Kakkar [United Kingdom]

18:40 - 18:55  Is immobility a real risk factor for VTE?
SPS11-02  Jean-François Bergmann [France]

18:55 - 19:10  How should we anticoagulate fragile populations?
SPS11-03  Sylvia Haas [Germany]

19:10 - 19:25  HIT: A relevant complication?
SPS11-04  Yves Gruel [France]

19:25 – 19:55  Patient case studies
SPS11-05  Panel

19:55 – 20:00  Closing remarks
SPS11-06  Lord Kakkar [United Kingdom]

Special Symposium Sanquin Blood Supply: Rapid reversal of oral anticoagulation  Emerald

Moderator: Paul Strengers [The Netherlands]

18:30 - 18:45  Over 60 years of experience with PCC for acute VKA reversal: What do we really know?
SPS12-01  Nakisa Khorsand [The Netherlands]

18:45 - 19:00  Acute reversal of VKA in ICH
SPS12-02  Lawrence Tim Goodnough [USA]

19:00 - 19:15  Ex vivo monitoring of VKA and NOAC reversal by PCC
SPS12-03  Herm-Jan Brinkman [The Netherlands]

19:15 - 19:30  NOAC in atrial fibrillation, needs and options for reversal
SPS12-04  Riitta Lassila [Finland]

19:30 - 19:45  In vivo reversal of NOAC
SPS12-05  Gilles Pernod [France]

19:45 - 20:00  Registry of the reversal of NOAC bleedings
SPS12-06  Michiel Coppens [The Netherlands]
Satellite Symposia
**Satellite Symposium Baxter: Concept to clinic: innovative treatments for coagulation disorders**

**Elicium 1**

 Moderators: Peter Lenting (France) and Friedrich Scheiflinger (Austria)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Presenter</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>18:30 - 18:35</td>
<td>Opening comments</td>
<td>Friedrich Scheiflinger</td>
<td>Austria</td>
</tr>
<tr>
<td>18:35 - 19:00</td>
<td>Phase I study results for BAX855, a full-length longer-acting rFVII</td>
<td>David Bevan</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>19:00 - 19:25</td>
<td>A novel approach for the treatment of hemophilia B: Factor IX Gene Therapy</td>
<td>Paul Monahan</td>
<td>USA</td>
</tr>
<tr>
<td>19:25 - 19:50</td>
<td>The therapeutic potential of ADAMTS13 and VWF</td>
<td>Evan Sadler</td>
<td>USA</td>
</tr>
<tr>
<td>19:50 - 20:00</td>
<td>Panel discussion and question &amp; answer session</td>
<td>Peter Lenting</td>
<td>France</td>
</tr>
</tbody>
</table>
CMEducation symposium: New frontiers and emerging therapeutic paradigms for comprehensive thrombosis management: The role of oral Factor Xa inhibition for thromboprophylaxis and treatment across the arterial venous continuum

Moderator: Samuel Goldhaber (USA)

18:30 - 18:40 Programme chairman’s introduction and welcome: Factor Xa inhibition for oral anticoagulation across the arteriovenous thrombosis risk continuum: scientific rationale and clinical opportunities
Samuel Goldhaber (USA)

18:40 - 19:00 Optimizing stroke prevention in nonvalvular atrial fibrillation (NVAF): What do the clinical trials with Factor Xa inhibitors teach us? Where are the guidelines directing us?
John Camm (United Kingdom)

19:00 - 19:20 New management paradigms for pulmonary embolism (PE) and DVT: Implementing Factor Xa-Based Strategies for Risk-Directed Treatment of PE. For which patients? In which settings? For what duration? Which settings? For what duration?
Harry Büller (The Netherlands)

19:20 - 19:35 The evolving landscape of thrombosis treatment and prevention: The rationale and evidence for Factor Xa inhibition as a foundational strategy for SPAF, VTE treatment, and residual CV risk reduction in patients with CAD
Graham Turpie (Canada)

19:35 - 19:55 Chairman’s summary: The Foundation role of oral, Factor Xa inhibition for optimizing thrombosis management across the arteriovenous risk spectrum. The search for simplicity, singularity, and synthesis
Samuel Goldhaber (USA) and Lord Ajay Kakker (United Kingdom)

19:55 - 20:00 Question and answer session

This symposium is supported by an independent educational grant from Bayer
### SATELLITE SYMPOSIA

#### Satellite Symposium Biogen Idec / Sobi: Novel therapy development in haemophilia

**Mondriaan IV**

**Moderators:** Erik Berntorp (Sweden) and George Scangos (USA)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>18:30 - 18:35</td>
<td><strong>Introduction</strong>&lt;br&gt;<strong>SAS03-01</strong>&lt;br&gt;<strong>George Scangos</strong> (USA)</td>
</tr>
<tr>
<td>18:35 - 18:50</td>
<td><strong>Exploring the FcRn natural pathway to extend half-life of therapeutic proteins</strong>&lt;br&gt;<strong>SAS03-02</strong>&lt;br&gt;<strong>Richard Blumberg</strong> (USA)</td>
</tr>
<tr>
<td>18:50 - 19:05</td>
<td><strong>Advances in understanding FcRn-mediated trafficking and cycling of IgG</strong>&lt;br&gt;<strong>SAS03-03</strong>&lt;br&gt;<strong>Pamela Bjorkman</strong> (USA)</td>
</tr>
<tr>
<td>19:05 - 19:20</td>
<td><strong>Clinical development of recombinant factor VIII Fc fusion protein</strong>&lt;br&gt;<strong>SAS03-04</strong>&lt;br&gt;<strong>Patrick Fogarty</strong> (USA)</td>
</tr>
<tr>
<td>19:20 - 19:35</td>
<td><strong>Clinical development of recombinant factor IX Fc fusion protein</strong>&lt;br&gt;<strong>SAS03-05</strong>&lt;br&gt;<strong>Erik Berntorp</strong> (Sweden)</td>
</tr>
<tr>
<td>19:35 - 19:50</td>
<td><strong>Future directions in development of novel therapies</strong>&lt;br&gt;<strong>SAS03-06</strong>&lt;br&gt;<strong>Robert Peters</strong> (USA)</td>
</tr>
<tr>
<td>19:50 - 20:00</td>
<td><strong>Panel discussion</strong>&lt;br&gt;<strong>SAS03-07</strong>&lt;br&gt;<strong>Erik Berntorp</strong> (Sweden)</td>
</tr>
</tbody>
</table>

#### Satellite Symposium Bristol-Myers Squibb / Pfizer: New oral factor Xa inhibitors: Latest evidence on clinical benefits across the spectrum

**Elicium 2**

**Moderator:** Giancarlo Agnelli (Italy)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>18:30 - 18:50</td>
<td><strong>What's behind different dosing strategies of new oral factor Xa inhibitors?</strong>&lt;br&gt;<strong>SAS04-01</strong>&lt;br&gt;<strong>Patrick Mismetti</strong> (France)</td>
</tr>
<tr>
<td>18:50 - 19:10</td>
<td><strong>New insights on key benefits from trials in atrial fibrillation</strong>&lt;br&gt;<strong>SAS04-02</strong>&lt;br&gt;<strong>Stefan Hohnloser</strong> (Germany)</td>
</tr>
<tr>
<td>19:10 - 19:30</td>
<td><strong>New data on the treatment of DVT and PE: the AMPLIFY programme</strong>&lt;br&gt;<strong>SAS04-03</strong>&lt;br&gt;<strong>Giancarlo Agnelli</strong> (Italy)</td>
</tr>
<tr>
<td>19:30 - 19:50</td>
<td><strong>What more can we do for patients? The apixaban case</strong>&lt;br&gt;<strong>SAS04-04</strong>&lt;br&gt;<strong>Bernard Vrijens</strong> (Belgium)</td>
</tr>
<tr>
<td>19:50 - 20:00</td>
<td><strong>Interactive panel discussion</strong>&lt;br&gt;<strong>SAS04</strong>&lt;br&gt;<strong>All speakers</strong></td>
</tr>
</tbody>
</table>
### SATELLITE SYMPOSIAS

**Satellite Symposium Boehringer Ingelheim: Novel oral anticoagulants for venous and arterial thrombosis - long-term data and real-world experience**

*Emerald*

**Moderators:** John Eikelboom (Canada) and Menno Huisman (The Netherlands)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>18:30 - 18:40</td>
<td><strong>Introduction and welcome</strong></td>
<td>John Eikelboom (Canada)</td>
</tr>
<tr>
<td>18:40 - 19:00</td>
<td><strong>Defending against ischaemic stroke in patients with AF: optimizing the use of novel oral anticoagulants in clinical practice</strong></td>
<td>Elaine Hylek (USA)</td>
</tr>
<tr>
<td>19:00 - 19:20</td>
<td><strong>Treatment and long-term management of venous thromboembolism</strong></td>
<td>Alex Spyropoulos (USA)</td>
</tr>
<tr>
<td>19:20 - 19:40</td>
<td><strong>Improving safety outcomes in patients receiving oral anticoagulants: what can we learn from real-world and long-term data?</strong></td>
<td>Sam Schulman (Canada)</td>
</tr>
<tr>
<td>19:40 - 20:00</td>
<td><strong>Panel discussion: Will the positive data and increasing experience with NOACs encourage physicians to switch patients from warfarin?</strong></td>
<td>Menno Huisman (The Netherlands)</td>
</tr>
</tbody>
</table>

* Closing remarks by John Eikelboom
Satellite Symposium Daiichi Sankyo Europe: Anticoagulation strategies in VTE - what changes, what stays the same?  
Moderators: Alexander Cohen [United Kingdom] and Jeffrey Weitz [Canada]

18:30 - 18:35  
**Introduction**  
Jeffrey Weitz [Canada]

18:35 - 18:55  
**Novel oral anticoagulants in VTE - a first inventory of evidence**  
Jeffrey Weitz [Canada]

18:55 - 19:10  
**registries in VTE - insights, benefits and shortcomings**  
Alexander Cohen [United Kingdom]

19:10 - 19:25  
**Can pharmacology of novel oral anticoagulants predict clinical outcomes?**  
Peter Verhamme [Belgium]

19:25 - 19:40  
**Hokusai VTE - what can the study add to the management of VTE?**  
Gary Raskob [USA]

19:40 - 19:55  
**Panel discussion**  
Jeffrey Weitz [Canada] and Alexander Cohen [United Kingdom]

19:55 - 20:00  
**Close**  
Alexander Cohen [United Kingdom]

Satellite Symposium GlaxoSmithKline: Bringing home the international guidelines on antithrombotic therapy and prevention of thrombosis  
Moderator: Saskia Middeldorp [The Netherlands]

18:30 - 18:35  
**Welcome from the Moderator**  
Saskia Middeldorp [The Netherlands]

18:35 - 18:50  
**Recap of recent innovations and key recommendations**  
Mark Crowther [Canada]

18:50 - 19:05  
**Extended VTE treatment - When do we stop?**  
Michiel Coppens [The Netherlands]

19:05 - 19:20  
**The art of modeling: Risk assessment in medical prevention**  
Alex Gallus [Australia]

19:20 - 19:35  
**Bringing it home: One country’s approach to national guideline development**  
Mike Greaves [United Kingdom]

19:35 - 19:55  
**Panel discussion/Q&A**

19:55 - 20:00  
**Moderator’s conclusions**
**SATELLITE SYMPOSIA**

**Satellite Symposium Octapharma: Specific patients, specific solutions - beyond the clinical routine of von Willebrand disease**

**Mondriaan II**

*Moderator: Frank Leebeek (The Netherlands)*

- **18:30 - 18:35** Welcome and introduction  
  SAS08-01 Frank Leebeek (The Netherlands)

- **18:35 - 18:55** Von Willebrand disease and pregnancy  
  SAS08-02 Mario Depka (Germany)

- **18:55 - 19:15** Relevance of physiological VWF:FVIII complex in clinical setting  
  SAS08-03 John Pasi (United Kingdom)

- **19:15 - 19:35** Bleeding scores: How do they help with type 1 VWD?  
  SAS08-04 Paula James (Canada)

- **19:35 - 19:55** The role of continuous infusion during surgical procedures in VWD patients  
  SAS08-05 Charlotte Grimley (United Kingdom)

- **19:55 - 20:00** Concluding remarks / Questions and answers

**Satellite Symposium Pfizer Inc.: The European principles of haemophilia care: Application, adherence & practice**

**Mondriaan III**

*Moderators: Brian Colvin (Pfizer, Europe) and Brian O’Mahony (Ireland)*

- **18:30 - 18:40** Welcome and introduction  
  SAS09-01 Brian Colvin (Pfizer, Europe) and Brian O’Mahony (Ireland)

- **18:40 - 19:00** The European principles of haemophilia care: A five year review  
  SAS09-02 Brian Colvin (Pfizer, Europe)

- **19:00 - 19:20** Results from the EHC survey of 35 European countries  
  SAS09-03 Brian O’Mahony (Ireland)

- **19:20 - 19:40** Specialist services in haemophilia care: The role of ultrasound in joint disease  
  SAS09-04 Matteo Di Minno (Italy)

- **19:40 - 19:55** Panel discussion

- **19:55 - 20:00** Meeting summary  
  SAS09-05 Brian Colvin (Pfizer, Europe) and Brian O’Mahony (Ireland)
**SATELLITE SYMPOSIA**

**Satellite Symposium Stago: New antithrombotics: practical aspects for the clinician and the laboratory**  

**Moderator:** Walter Ageno (Italy)  

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>18:30 - 18:35</td>
<td>Welcome and introduction</td>
<td>Walter Ageno (Italy)</td>
</tr>
<tr>
<td>18:35 - 19:00</td>
<td>Practical management of patients on NOACs</td>
<td>Walter Ageno (Italy)</td>
</tr>
<tr>
<td>19:00 - 19:25</td>
<td>Measurement of NOACs and influence on coagulation assays</td>
<td>Edelgard Lindhoff-Last (Germany)</td>
</tr>
<tr>
<td>19:25 - 19:50</td>
<td>Antiplatelet therapy</td>
<td>Alan Michelson (USA)</td>
</tr>
<tr>
<td>19:50 - 20:00</td>
<td>Concluding remarks</td>
<td>Walter Ageno (Italy)</td>
</tr>
</tbody>
</table>
Thrombosis and Haemostasis is the official Organ of the Working Groups "Thrombosis" and "Atherosclerosis and Vascular Biology" of the European Society of Cardiology (ESC) and Società Italiana per lo Studio dell’Emostasi e della Trombosi (SISET) and the Sociedad Española de Trombosis y Hemostasia (SETH).

Subscribers to and readers of Thrombosis and Haemostasis enjoy:
- Reliable publication platform in vascular biology and medicine
- Renowned authors – leaders in their field of research
- Electronic Table of Contents – register online today!
- Online submission and PrePrint publications: TH First
- A broad scope covering expanded areas of interest including:
  - Blood coagulation, fibrinolysis and cellular haemostasis
  - Platelets and blood cells
  - Endothelium and vascular development
  - Wound healing and inflammation/infection
  - Cardiovascular biology and cell signalling
  - Cellular proteolysis and oncology
  - Animal models
  - New technologies, diagnostic tools and drugs

Thrombosis and Haemostasis

Today’s Science for Tomorrow’s Results

Thrombosis and Haemostasis is an international journal for vascular biology and medicine. It publishes original contributions of basic and original research and clinical studies in vascular biology and medicine, serving as an international platform for the dissemination and debate of scientific information. The Journal appears monthly in both print and online.

Visit our homepage and register for eTOC today at:

www.thrombosis-online.com
THROMBOSIS: The leading cause of death in Paroxysmal Nocturnal Hemoglobinuria (PNH)\(^1,2\)

- Complement-mediated systemic THROMBOTIC MICRO-ANGIOPATHY (TMA) resulting in sudden and premature death in atypical haemolytic uremic syndrome (aHUS)\(^4-17\)

- Of patients with PNH die within 5 years of diagnosis despite best supportive care\(^1\)

**PNH**

- 35% of patients with PNH die within 5 years of diagnosis despite best supportive care\(^1\)

- 35% PNH of patients with PNH die within 5 years of diagnosis despite best supportive care\(^1\)

**aHUS**

- 70% of aHUS patients (with the most common mutation*\(^\)\) die, require dialysis, or have permanent renal damage within 1 year\(^4\)

- 70% aHUS of aHUS patients (with the most common mutation*\(^\)\) die, require dialysis, or have permanent renal damage within 1 year\(^4\)

PNH and aHUS are two diseases due to chronic uncontrolled complement activation

- Chronic, complement-mediated hemolysis is the underlying cause of progressive morbidities and mortality in PNH: 40% to 67% of deaths are due to venous or arterial thrombosis.\(^3,18\)

- In aHUS, chronic uncontrolled complement activation leads to systemic thrombotic microangiopathy (TMA), to inflammation and multiple thrombi with occlusion of small blood vessels throughout the body (systemic TMA)\(^5-10,12-17\)

**References:**

Exhibitors and Sponsors
# Sponsors

## Silver Sponsors
- Daiichi-Sankyo
- GlaxoSmithKline
- LFB
- SIEMENS
- Sysmex

## Bronze Sponsors
- GRIFOLS
- HYPHEN BioMed
- Instrumentation Laboratory
- Roche
- Sanquin Blood Supply
- SANOFI
The exhibition is held in conjunction with the ISTH 2013 Congress. The coffee break and lunch areas are located within the exhibition area. Thanks to the exhibiting companies from all over the world, attendees will have a complete overview of new findings in the domain of thrombosis and haemostasis.
Exhibition List

(In alphabetical order, as of June 12, 2013)

<table>
<thead>
<tr>
<th>Company</th>
<th>Booth number</th>
</tr>
</thead>
<tbody>
<tr>
<td>4S Dawn Clinical Software</td>
<td>443</td>
</tr>
<tr>
<td>Accumetrics Inc.</td>
<td>440</td>
</tr>
<tr>
<td>Affinity Biologicals</td>
<td>445</td>
</tr>
<tr>
<td>Asahi Kasei Bioprocess Europe N.V. / S.A.</td>
<td>702</td>
</tr>
<tr>
<td>ASD Healthcare</td>
<td>700</td>
</tr>
<tr>
<td>Baxter International Inc.</td>
<td>100</td>
</tr>
<tr>
<td>Bayer Healthcare Pharmaceuticals, Bayer Pharma AG</td>
<td>310</td>
</tr>
<tr>
<td>Blue Print Research Group</td>
<td>522</td>
</tr>
<tr>
<td>Biogen Idec Hemophilia</td>
<td>204, 255</td>
</tr>
<tr>
<td>bioMérieux</td>
<td>340</td>
</tr>
<tr>
<td>Biotest AG</td>
<td>143</td>
</tr>
<tr>
<td>BluePrint Research Group</td>
<td>522</td>
</tr>
<tr>
<td>Boehringer Ingelheim</td>
<td>157</td>
</tr>
<tr>
<td>CEDARLANE®</td>
<td>322</td>
</tr>
<tr>
<td>Chrono-log Corp.</td>
<td>338</td>
</tr>
<tr>
<td>CSL Behring GmbH</td>
<td>450</td>
</tr>
<tr>
<td>DiaPharma Group, Inc.</td>
<td>442</td>
</tr>
<tr>
<td>Enzyme Research Laboratories</td>
<td>216</td>
</tr>
<tr>
<td>Ferrer inCode S.L.</td>
<td>670</td>
</tr>
<tr>
<td>GlaxoSmithKline</td>
<td>540, 550</td>
</tr>
<tr>
<td>Grifols</td>
<td>530</td>
</tr>
<tr>
<td>Haematologic Technologies, Inc.</td>
<td>444</td>
</tr>
<tr>
<td>Helena Biosciences Europe</td>
<td>671</td>
</tr>
<tr>
<td>HemaCore LLC</td>
<td>610</td>
</tr>
<tr>
<td>Hemostasis Reference Laboratory Inc.</td>
<td>445</td>
</tr>
<tr>
<td>HYPHEN BioMed</td>
<td>600</td>
</tr>
<tr>
<td>Immucor Inc.</td>
<td>323</td>
</tr>
<tr>
<td>Instrumentation Laboratory</td>
<td>257</td>
</tr>
<tr>
<td>Intelligent Imaging Innovations</td>
<td>217</td>
</tr>
<tr>
<td>International Society on Thrombosis and Haemostasis (ISTH)</td>
<td>500</td>
</tr>
<tr>
<td>ISTH 2015/SSC 15, Toronto, Canada</td>
<td>500</td>
</tr>
<tr>
<td>ITC</td>
<td>524</td>
</tr>
<tr>
<td>Kantar Health UK</td>
<td>704</td>
</tr>
<tr>
<td>Kedrion S.p.A.</td>
<td>253</td>
</tr>
<tr>
<td>Kogenate</td>
<td>310</td>
</tr>
<tr>
<td>Laboratorios Farmacéuticos Rovi S.A.</td>
<td>511</td>
</tr>
</tbody>
</table>
## Exhibition List

<table>
<thead>
<tr>
<th>Company</th>
<th>Booth number</th>
</tr>
</thead>
<tbody>
<tr>
<td>LFB BIOMEDICAMENTS</td>
<td>411</td>
</tr>
<tr>
<td>MediRox AB</td>
<td>215</td>
</tr>
<tr>
<td>Novo Nordisk Health Care AG</td>
<td>421</td>
</tr>
<tr>
<td>Novo Nordisk Haemophilia Foundation</td>
<td>380</td>
</tr>
<tr>
<td>Octapharma AG</td>
<td>321</td>
</tr>
<tr>
<td>Pentapharm, DSM Nutritional Products Ltd</td>
<td>538</td>
</tr>
<tr>
<td>Pfizer Inc.</td>
<td>350</td>
</tr>
<tr>
<td>BMS/Pfizer, Inc.</td>
<td>645</td>
</tr>
<tr>
<td>pharma-insight GmbH</td>
<td>539</td>
</tr>
<tr>
<td>Precision Biologic Inc</td>
<td>214</td>
</tr>
<tr>
<td>R2 Diagnostics, Inc.</td>
<td>216</td>
</tr>
<tr>
<td>Roche Diagnostics International Ltd</td>
<td>620</td>
</tr>
<tr>
<td>Sanquin Blood Supply Foundation</td>
<td>145</td>
</tr>
<tr>
<td>Schattauer Publishers</td>
<td>673</td>
</tr>
<tr>
<td>Sekisui Diagnostics</td>
<td>324</td>
</tr>
<tr>
<td>SINTESI RESEARCH</td>
<td>652</td>
</tr>
<tr>
<td>Siemens</td>
<td>630</td>
</tr>
<tr>
<td>Sobi</td>
<td>204, 255</td>
</tr>
<tr>
<td>Sysmex Corporation</td>
<td>630</td>
</tr>
<tr>
<td>Sinnowa Medical Science &amp; Technology Co.</td>
<td>213</td>
</tr>
<tr>
<td>SSC 2014, Milwaukee, USA</td>
<td>500</td>
</tr>
<tr>
<td>Stago</td>
<td>520</td>
</tr>
<tr>
<td>Technoclone</td>
<td>441</td>
</tr>
<tr>
<td>Tem International</td>
<td>325</td>
</tr>
<tr>
<td>Wiley</td>
<td>651</td>
</tr>
<tr>
<td>Wisepress Medical Bookshop</td>
<td>669</td>
</tr>
<tr>
<td>World Federation of Hemophilia</td>
<td>672</td>
</tr>
<tr>
<td>Xarelto</td>
<td>400</td>
</tr>
</tbody>
</table>
Exhibition and Sponsor Profiles
EXHIBITION AND SPONSOR PROFILES

4S Dawn Clinical Software

4 The Square
LA7 7QJ Milnthorpe
United Kingdom
T: +44 153 9563091
E: sales@4s-dawn.com
www.4s-dawn.com/dawnac

Established in 1984, 4S DAWN Clinical Software is trusted by over 300 healthcare organisations across the world to deliver reliable, disease specific solutions that increase patient safety, facilitate productivity gains and improve quality of care.

- Anticoagulation [DAWN AC] – including Induction, Maintenance and Bridging of patients, New Oral Anticoagulants and VTE diagnosis assessment. DAWN AC is a complete anticoagulation decision support package designed to support the management of large anticoagulation clinics.
- Clinical Haematology [DAWN CH] – including Myeloproliferative Disease (MPD), Venesection, Haemochromatosis, MGUS, Stable Chronic Leukemia and ITP patients. DAWN CH enables nurse-led monitoring, freeing up clinic slots.

Accumetrics Inc.

3985 Sorrento Valley Blvd
92121 San Diego, CA
USA
T: +1 858 6431600
E: support@accumetrics.com
www.accumetrics.com

Accumetrics is committed to advancing medical understanding of platelets and enhancing quality of care for patients who are at risk of cardiovascular disease by providing industry-leading diagnostic tests to assess response to every major type of antiplatelet therapy, including aspirin, P2Y12 inhibitors (Plavix® and Effient®) and GP IIb/IIIa inhibitors [e.g. ReoPro® and Integrilin®]. Accumetrics’ family of VerifyNow® tests provides physicians with rapid, easy and valuable tools to help make informed treatment decisions.

Affinity Biologicals

1395 Sandhill Dr.
L9G 4V5
Ancaster, ON
Canada
T: +1 905 3049896
E: greg.fullerton@affinitybiologicals.com
www.affinitybiologicals.com

Affinity Biologicals, Inc. is a primary manufacturer of products used worldwide in thrombosis and haemostasis research and medical diagnostics. Products include an extensive line of antibodies, conjugates, antibody pairs for immunoassay of human and animal analytes, the VisuLize™ line of complete ELISA kits, and a full line of immuno-depleted human plasma products, VisuCal™ Calibrator Plasma, VisuCon™ Normal, Abnormal and Low Fibrinogen Control Plasmas and VisuDep™ Factor Deficient Plasmas. Services include protein purification, antibody production, assay development, custom lyophilization and custom plasma production.
Asahi Kasei Bioprocess Europe N.V. / S.A.  Booth no. 702

Rue Colonel Bourg 122
1140 Brussels
Belgium
T: +32 2 52605 00
E: info.eu@ak-bio.com
www.ak-bio.com

Asahi Kasei Bioprocess is the established global market leader in virus filtration, with Planova filter range having an unrivalled 20 year history of trusted use in the production of biotherapeutics. From 2010, Asahi Kasei Bioprocess is also providing innovative hollow fiber membranes for cell culture clarification and anion exchange chromatography to improve upstream and downstream processes to lower costs of production and enhance product quality. Asahi Kasei Bioprocess seeks to deliver the very best in not only the products we manufacture, but also in the technical support we provide through our worldwide technical support network of specialists.

ASD Healthcare  Booth no. 700

3101 Gaylord Pkwy
75034 Frisco
USA
T: +1 469 3657844
E: marketing@asdhealthcare.com
www.asdhealthcare.com

Healthcare organizations nationwide rely on ASD Healthcare for plasma derivatives, specialty pharmaceuticals, influenza vaccine, oncolytics, contrast media and other injectables. They depend on us for the selection, service and accessibility ASD Healthcare delivers. Our business innovation group has developed the only patented RFID solution for consignment tracking of products in this space. Additionally, our novel approach to in-home compliance monitoring using real time data gathering thru RFID, is unique in the world.

Baxter International Inc  Booth no. 100

One Baxter Parkway
60015 Deerfield, IL
USA
T: +1 224 9481812
www.baxter.com

Baxter develops, manufactures and markets products with the aim of saving and sustaining the lives of people with hemophilia and other chronic medical conditions. Baxter provides therapies for hemophilia A and B, for management of bleeding in patients with inhibitors and is investigating possible therapies for von Willebrand disease and other hematologic disorders.
EXHIBITION AND SPONSOR PROFILES

Bayer Healthcare Pharmaceuticals, Bayer Pharma AG  
Booth no. 310, 400

Muellerstr. 178  
13353 Berlin  
Germany  
T: +49 30 4681111  
www.healthcare.bayer.com

The Bayer Group is a global enterprise with core competencies in the fields of health care, agriculture and high-tech materials. Bayer HealthCare, a subgroup of Bayer AG with annual sales of EUR 18.6 billion (2012), is one of the world’s leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. Bayer HealthCare’s aim is to discover, develop, manufacture and market products that will improve human and animal health worldwide. Bayer HealthCare has a global workforce of 55,300 employees (Dec 31, 2012) and is represented in more than 100 countries. More information at www.healthcare.bayer.com.

BluePrint Research Group  
Booth no. 522

5 Vaughn Drive  
08540 Princeton, NJ  
USA  
T: +1 609 4545929  
E: ryan@blueprintrg.com  
www.blueprintrg.com

BluePrint Research Group provides strategy and consulting services to medical, healthcare, and pharmaceutical companies and advocacy groups. Specializing in rare diseases, hemophilia, and bleeding disorders. We are glad to be a part of the ISTH this year. We would like to thank all doctors, nurses, and others throughout the world who have been a part of our research this past year. Should you be interested in partaking in our future market research projects, please stop by our booth to sign up.

Biogen Idec Hemophilia  
Booth no. 204, 255

133 Boston Post Road, Weston, MA  
02493 Weston, Mass.  
USA  
T: +1 781 4644409  
E: joe.slyman@biogenidec.com  
www.biogenidechemophilia.com

Our mission is to empower people with hemophilia to live the lives they choose. Our goal is to transform hemophilia management by researching long-lasting, fully recombinant clotting factors. In a word, Biogen Idec Hemophilia is dedicated. We’re dedicated to improving the lives of people with hemophilia and dedicated to the community in which our team is so deeply rooted. To learn more, visit www.biogenidechemophilia.com.
**EXHIBITION AND SPONSOR PROFILES**

**bioMérieux**  
Booth no. 340

Chemin de l’Orme  
69280 Marcy l’Etoile  
FRANCE  
T: +33 4 78872000  
www.biomerieux.com

bioMérieux, a world leader in the field of in vitro diagnostic, was the first to clinically demonstrate the use of high-sensitivity VIDAS® D-Dimer Exclusion assay to safely exclude venous thromboembolism (VTE) in outpatients (NPV > 99.9%) and 1st FDA cleared for this claim. VIDAS D-Dimer Exclusion is the gold standard assay and we support the pioneering of D-Dimer clinical research such as optimized duration of oral anticoagulant therapy in patients with unprovoked VTE [REVERSE* study].

* Recurrent Venous thromboembolism Risk Stratification Evaluation

**Biotest AG**  
Booth no. 143

Landsteinerstr. 5  
63033 Dreieich  
Germany  
T: +49 6103 8014716  
E: barbara_rueth@biotest.de  
www.biotest.com

Biotest is a provider of pharmaceutical and biotherapeutic drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of application of clinical immunology, haematology and intensive medicine. In its Plasma Protein portfolio Biotest develops and markets immunoglobulins, coagulation factors and albumins based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. Biotest also researches into the development of monoclonal antibodies, including in the indications of rheumatoid arthritis and cancer of plasma cells. Biotest has more than 1,600 employees worldwide.

**Boehringer Ingelheim**  
Booth no. 157

Binger Str 173  
55216 Ingelheim  
Germany  
T: +49 6132 77141590  
E: birgit.akerfors@boehringer-ingelheim.com

The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 44,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine.

In 2011, Boehringer Ingelheim achieved net sales of about 13.2 billion euro. R&D expenditure in the business area Prescription Medicines corresponds to 23.5% of its net sales.
EXHIBITION AND SPONSOR PROFILES

CEDARLANE®

CEDARLANE® (ISO 9001, ISO 13485 registered) specializes in providing high quality research & diagnostic reagents to the life science community. We offer one of the most extensive product listings in the world both domestically & internationally. Cedarlane products include Monoclonal, Polyclonal and Paired Antibodies for Hemostasis, Cell Separation media, Complement for tissue typing, Immunocolumns, Neuronal cell lines & More! Delivering Today’s Innovations for the Science of Tomorrow™

Chrono-log Corp.

Manufacturer of high quality platelet aggregometers. The versatile Model 700 is an easy-to-use Lumi-Aggregation System for: Measuring ATP release with LTA and WBA Aggregometry ...quickly, accurately and cost effectively; Monitoring anti-platelet drugs such as Aspirin and Plavix and screening for vWD and sub-types. Visit with us at Booth No. 338 to discuss your platelet testing needs and to see which Chrono-log system is best for you.

CSL Behring GmbH

CSL Behring is a leader in the plasma protein therapeutics industry. Committed to saving lives and improving the quality of life for people with rare and serious diseases, the company manufactures and markets a range of plasma-derived and recombinant therapies worldwide.

CSL Behring therapies are used around the world to treat coagulation disorders including hemophilia and von Willebrand disease, primary immune deficiencies, hereditary angioedema and inherited respiratory disease, and neurological disorders in certain markets. CSL Behring is a global biopharmaceutical company and a member of the CSL Group of companies. For more information, visit http://www.cslbehring.com/.
EXHIBITION AND SPONSOR PROFILES

Daiichi Sankyo Europe GmbH

Zielstattstrasse 48
81379 Munich
Germany
T: +49 8978080
service@daiichi-sankyo.eu
www.daiichi-sankyo.eu

The Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets. With net sales of nearly €7.3 billion, Daiichi Sankyo is one of the world’s 20 leading pharmaceutical companies. While maintaining its portfolio of marketed pharmaceuticals for hypertension and hyperlipidemia, the Group is engaged in the development of treatments for thrombotic disorders and focused on the discovery of novel oncology products. Daiichi Sankyo Europe has affiliates in 12 European countries.

For more information, please visit: www.daiichi-sankyo.eu

DiaPharma Group, Inc.

Booth no. 442

8948 Beckett Road
45069 West Chester, OH
USA
T: +1 800 5265224
E: info@diapharma.com
www.diapharma.com

DiaPharma supplies laboratory products for thrombophilia testing, anticoagulation monitoring, bleeding disorder management, and hemostasis research. We pride ourselves in providing helpful customer support and highly trained technical support teams for unsurpassed service. Please visit Diapharma, and see our newest assays for thrombin generation, ADAMTS13, microparticles, and platelet function.

Enzyme Research Laboratories

Booth no. 216

1801 Commerce Drive
46628 South Bend, IN
USA
T: +1 574 2882268

Enzyme Research Laboratories provides coagulation and fibrinolytic proteins from human plasma, other source plasmas and platelets. Additionally, we offer monoclonal and polyclonal antibodies, immunodepleted plasmas and ELISA reagents. Custom purifications and contract services are also available.
EXHIBITION AND SPONSOR PROFILES

**Ferrer inCode S.L.**

Diagonal 549, 5th floor  
E-08029 Barcelona  
Spain  
T: +34 936 003700  
E: customerservice@ferrerincode.com  
www.ferrerincode.com

The goal of Ferrer inCode is genetic analysis to facilitate decision-making in the prevention, diagnosis or prognosis of genetic diseases. This focus allows the patient to receive optimal, accurate and personalized treatment.

Ferrer inCode puts the most advanced genomics and proteomics technology at your disposal offering services that enhance the therapeutic goals of treatment and, ultimately, improve the quality of life of patients.

Our services are based on advanced technologies because we know that genetic information is highly sensitive and requires the highest standards of quality:

- Test clinically validated and meets international quality standards.
- Comprehensive and relevant information.
- Team of experts working in the development and improvement of our services.

**GlaxoSmithKline**

GSK House, Great West Road, Brentford  
TW9 8GS Middlesex  
United Kingdom  
T: +44 207 0475000  
www.gsk.com

GlaxoSmithKline is a science-led global healthcare company that researches and develops a broad range of innovative medicines and brands. Our products are used by millions of people around the world, helping them to do more, feel better and live longer. We have three primary areas of business in pharmaceuticals, vaccines and consumer healthcare.

Research is vitally important to the success of our business, and we spent just under £4 billion in 2012 in our search to develop new medicines, vaccines and innovating consumer products. We are one of the few healthcare companies researching medicines and vaccines for the World Health Organisation’s three priority diseases - HIV/AIDS, tuberculosis and malaria.

Our pharmaceuticals business researches, develops and makes available medicines that treat a variety of serious and chronic diseases.

**Grifols**

Parc Empresarial Can San Joan  
Av. De la Generalitat, 152-158  
08174 Sant Cugat del Valles  
Spain  
T: +34 935 710822  
E: marketing.diagnostics@grifols.com  
www.grifols.com

Grifols improves people’s lives with high quality innovative hospital products and services. Our plasmaderived therapies have outstanding records of efficacy and safety and we are also a world-leading manufacturer of medical devices, analyzers and reagents used by blood banks, transfusion centers and clinical laboratories.
Haematologic Technologies, Inc.
Booth no. 444
57 River Road, Unit 1021
05452 Essex Junction, Vermont
USA
T: +1 802 8781777
E: hti@haemtech.com
www.haemtech.com

Haematologic Technologies, Inc. (HTI) is a primary manufacturer of research reagents, specializing in the isolation and characterization of plasma proteins involved in the regulation of blood coagulation and fibrinolysis. Our product line of highly purified proteins includes zymogens, enzymes, cofactors, and inhibitors as well as monoclonal and polyclonal antibodies. Services available by contract include: cGMP stability, release and other QC testing, ADA and TGA assay development and custom blood collection tube manufacturing.

Helena Biosciences Europe
Booth no. 671
Queensway South, Team Valley Trading Estate
NE11 0SD Gateshead
United Kingdom
T: +44 191 4828440
E: info@helena-biosciences.com
www.helena-biosciences.com

Helena Biosciences’ unparalleled clinical diagnostics experience extends over thirty years, driven by a commitment to excellence, value and the best customer service. Specialising in Clinical Electrophoresis and Haemostasis, Helena Biosciences manufacture and market the most innovative diagnostic products, providing clinicians worldwide with a comprehensive portfolio of blue-chip instrumentation, software and assays.

Helena Biosciences Europe delivers integrated capillary and agarose gel electrophoresis systems - in addition to a range of haemostasis instrumentation and reagents.

HemaCore LLC
Booth no. 610
3 4th 8 Marta street
125319 Moscow
Russia
T: + 7 495 2582538
E: mail@hemacore.com
www.hemacore.com

HemaCore
HemaCore LLC is a biotech company, developing medical devices and methods for hematology.

Thrombodynamics
new global assay for monitoring and prognosis of blood coagulation disorders - finding out risks of bleeding and thrombosis.
Hemostasis Reference Laboratory Inc.  
711 Concession St  
L8V 1C3 Hamilton, ON  
Canada  
T: +1 905 5212100 ext. 42667  
E: dmoreno@hemostasislab.com  
www.Hemostasislab.com  

Hemostasis Reference Laboratory (HRL) is a Canadian Laboratory with over 20 years of experience in providing quality coagulation testing services to customers internationally. HRL offer’s a complete range of testing for clinical trials, sample analysis, research projects, product evaluation, value assignments, instrument validation, and more servicing pharmaceutical companies, diagnostic manufacturers, veterinarians, and researchers.

HYPHEN BioMed  
155 Rue d’Eragny  
95000 Neuville sur Oise  
France  
T: +33 134 406510  
E: jamiral@hyphen-biomed.com  
www.hyphen-biomed.com  

HYPHEN BioMed is a biotechnology company, highly specialized for developing, manufacturing and distributing laboratory diagnostic and research reagents. A unique expertise in the field of thrombosis and hemostasis has been developed, and is acknowledged. Reagents are available worldwide through a network of specialized distributors, such as Aniara, Coachrom, Endotell, Diagnostica, Nodia, or Quadrature. HYPHEN BioMed is a major supplier of laboratory reagents and biological to pharmaceutical industry for development and manufacturing of anticoagulant/anti-thrombotic drugs and of recombinant or blood derived products for coagulation disorders. The company is fully committed to convey quality, innovation and service for meeting its customers’ needs.

Immucor Inc.  
Heuvelstraat 60  
2560 Nijlen  
Belgium  
T: +32 4 79853672  
E: bconway@immucor.com  
www.immucor.com/lifecodes  

LIFECODES is now part of Immucor. LIFECODES was acquired by Immucor in March of 2013 and specializes in diagnostic assays designed for the blood bank, special coagulation and transplantation labs. We provide clinicians with reliable and innovative products serving the unique needs of today’s modern diagnostic testing labs. Some of the newest tests offered by LIFECODES include ATS-13, an assay intended to detect decreased levels of the ADAMTS-13 enzyme. Also available is our PF4 Enhanced ELISA, an industry leading kit for the detection of antibodies suspected in heparin induced thrombocytopenia (HIT).
**EXHIBITION AND SPONSOR PROFILES**

**Instrumentation Laboratory**

180 Hartwell Road  
01730 Bedford  
USA  
T: +1 800 9559525  
www.ilww.com

Instrumentation Laboratory (IL) is passionate about delivering the most innovative solutions to address a range of hemostasis testing needs. The advanced ACL™ family of systems brings complete automation to the hemostasis lab—including the ACL TOP® Family of Hemostasis Testing Systems, featuring the new ACL TOP 300 CTS; and, the ACL AcuStar®, the first fully automated, chemiluminescent analyzer for hemostasis specialty testing. Combined with the HemosIL line of reagents, a comprehensive panel of fully automated assays, IL offers complete disease state management for the hemostasis lab.

**Intelligent Imaging Innovations**

Königsallee 9-21  
37081 Göttingen  
Germany  
T: +49 551 50839266  
E: info@intelligent-imaging.com  
www.intelligent-imaging.com

Intelligent Imaging Innovations (3i) designs and builds fluorescence imaging systems. Our multi-dimensional microscopy systems are intuitive to use. They are designed to meet the continually evolving needs of investigators. We configure our systems to our customer’s needs for optimal productivity. Techniques include 2-Photon, Intravital Imaging and Ablation. 3i’s VIVO imaging system is designed specifically for the most demanding intravital applications. The system is built for speed, sensitivity, and flexibility of fluorescence imaging within a living animal in real time.

**International Society on Thrombosis and Haemostasis (ISTH)**

610 Jones Ferry Road, Suite 205  
Carrboro, North Carolina 27510  
USA  
T: +1 919 929 3807  
E: headquarters@isth.org  
www.isth.org

The International Society on Thrombosis and Haemostasis (ISTH) is a global not-for-profit organization advancing the understanding, prevention, diagnosis and treatment of thrombotic and bleeding disorders. ISTH is an international membership organization with over 3,500 clinicians, researchers and educators working together to improve the lives of patients in more than 85 countries around the world. Among its highly regarded activities and initiatives are education and standardization programs, research activities; meetings and conferences, peer-reviewed publications and expert committees. Become an ISTH member today at www.isth.org.
EXHIBITION AND SPONSOR PROFILES

ISTH 2015 in Toronto, Canada

ISTH Headquarters
610 Jones Ferry Road, Suite 205
Carrboro, North Carolina 27510
USA
T: +1 919 929 3807
E: headquarters@isth.org
www.isth.org

The XXVth Congress of the International Society on Thrombosis and Haemostasis (ISTH) will take place in Toronto from June 20 through June 25, 2015. At the Congress, thousands of the world’s leading experts on thrombosis, haemostasis and vascular biology come together to present the most recent advances, exchange the latest science and discuss the newest clinical applications designed to improve patient care. Through an extensive lineup of educational sessions, poster and oral communications, state-of-the-art lectures, exhibits and professional networking opportunities, the Congress promotes important scientific discourse and advancement. Learn more at www.isth.org and visit our booth at ISTH 2013!

ITC

20 Corporate Place South
08854 Piscataway
NJ USA
T: +1 732 548 5700
E: customerservice@itcmed.com
www.itcmed.com

ITC is a global leader in hemostasis management and point-of-care testing and monitoring. ITC’s product portfolio includes solutions for hemostasis management, blood gas and co-oximetry testing. Our leading brands include, the Hemochron® for hemostasis management, ProTime® Microcoagulation System for monitoring patients on warafin therapy, IRMA TruPoint® for blood gas and electrolyte and Avoximeter® CO-Oximetry systems.

ITC will feature the ProTime InRhythm™ which provides clinicians with the accuracy and precision to help patients on anticoagulant therapy remain in designated therapeutic range. (ProTime InRhythm is not cleared for the US market by the FDA; the system is not for sale in the US.)

Kantar Health UK

The Kirkgate, 19-31 Church Street
KT17 4PF Epsom
United Kingdom
T: +44 1372 825825
E: tracy.machado@kantarhealth.com
www.kantarhealth.com

Kantar Health is a global, evidence-based decision support partner to the world’s leading pharmaceutical, biotech, device and diagnostic companies. Having united industry leaders Consumer Health Sciences, MattsonJack, TNS Healthcare, and Ziment to form Kantar Health in 2009, we offer a wide range of expertise in both emerging and established markets. As a collective, we have been operating globally since the mid-1940s. As part of WPP, the largest marketing agency in the world, we leverage the power of the global group.
Kedrion S.p.A. Booth no. 253

Località ai Conti
55051 Castelvecchio Pascoli
Italy
T: +390 5831969224
E: s.vaselli@kedrion.com
www.kedrion.com

Kedrion is a leading global biopharmaceutical company specialized in the development, production and distribution of plasma-derived products.

Based in Italy, Kedrion operates in the manufacture and sale of plasma-derivatives, the sale of flu vaccines and synthetic pharmaceuticals, the collection and sale of plasma on foreign markets.

Its main products include coagulation factors (Factor VIII, Factor IX), coagulation inhibitors (antithrombin), immunoglobulins (standards and hyperimmunes) and albumin.

The company’s competitive edge relies on product quality and the commitment to research and development.

Laboratorios Farmacéuticos ROVI S.A. Booth no. 511

Julián Camarillo, 35
28037 Madrid
Spain
T: +349 13756230
E: internationaloperations@rovi.es
www.rovi.es

ROVI is a fully-integrated, profitable Spanish specialty pharmaceutical company engaged in the research, development, in-licensing, manufacturing and marketing of small molecule and specialty biologic drugs. The Company has a diversified portfolio of products that it markets in Spain through its specialized sales force, calling on specialist physicians, hospitals and pharmacies. ROVI’s portfolio of 30 principal marketed products is currently anchored by the internally-developed, second generation low molecular weight heparin, Bemiparin which is also out-licensed and marketed in 50 countries thanks to a network of partners. ROVI’s research and development pipeline is focused primarily on addressing currently unmet medical needs by developing new bemiparin indications and a novel ISM (“in-situ microparticles”) technology for injectable forms.

LEO Pharma A/S

Industriparken 55
DK-2750 Ballerup
Denmark
E: susanne.lehmann-rasmussen@leo-pharma.com
www.leo-pharma.com

LEO Pharma is an independent, research-based specialty pharmaceutical company with 70 years’ experience in helping healthcare professionals meet their daily clinical challenges in thrombosis. LEO Pharma is fully owned by the LEO Foundation and is totally independent of outside capital. Headquartered in Denmark, we have employees in 61 countries and our products are sold in more than 100 countries.

innohep® (tinzaparin sodium) is a leading low molecular weight heparin (LMWH) offering convenient once daily treatment of deep vein thrombosis [DVT] and pulmonary embolism [PE].
**EXHIBITION AND SPONSOR PROFILES**

**LFB BIOMEDICAMENTS**

3, Avenue des Tropiques – BP 305 Les Ulis
91958 Courtaboeuf cedex
France
T: +33 1 69827010
E: communication@lfb.fr
www.lfb.fr/Accueil.html

LFB is a biopharmaceutical group that develops, manufactures and markets medicinal products for the treatment of serious and often rare diseases in several major therapeutic fields, namely Hemostasis, Immunology and Intensive Care. The LFB Group is the leading manufacturer of plasma-derived medicinal products in France and 6th worldwide and is also among the leading European companies for the development of new-generation proteins and treatments based on biotechnologies.

**MediRox AB**

Studsvik nuclear plant
SE-61182 Nyköping
Sweden
T: +46 155 454410
E: info@medirox.se
www.medirox.se

Since over 10 years MediRox is one of the dominant supplier of routine coagulation reagent and controls to the Scandinavian market. Most famous is our production technology for Owrens PT as well as our coagulation multi-controls with D-dimer and protein S and C included with all the ordinary coagulation parameters. The uniqueness of these products has made them preferred and distributed by both Siemens and Instrumentation Laboratory in Scandinavia. MediRox Multi controls are currently the routine coagulation control of 7 of 8 Swedish University hospitals.

We offer international sales to distributors, end-users, OEM and bulk clients, for most of our products.

**Novo Nordisk Health Care AG**

Thurgauerstrasse 36/38
8050 Zurich
Switzerland
T: +41 43 2224300
E: muhe@novonordisk.com
www.novonordisk.com

Novo Nordisk is a global healthcare company with 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 35,000 employees in 75 countries, and markets its products in more than 180 countries. For more information about our products and initiatives, please visit our exhibit and our website at www.novonordisk.com.
Novo Nordisk Haemophilia Foundation

Thurgauerstrasse 36/38
8050 Zurich
Switzerland
T: +41 43 2224376
E: info@nnhf.org
www.nnhf.org

Founded in 2005 and situated in Zurich, Switzerland, Novo Nordisk Haemophilia Foundation (NNHF) is a non-profit organisation dedicated to define and fund sustainable programmes which improve access to quality care benefiting people with haemophilia and allied bleeding disorders in the developing world. With local partners and renowned experts, we address three focus areas; capacity building, diagnosis and registry as well as education and awareness. For more information, please visit www.nnhf.org

Octapharma AG

Seidenstrasse 2
8853 Lachen
Switzerland
T: +41 55 4512121
E: Corinne.landolt@octaphama.com
www.octapharma.com

Octapharma specializes in the development and production of high quality human proteins derived from blood plasma and recombinant technologies. Our hematology product portfolio consists of: wilate®, a modern treatment for patients with von Willebrand disease. octanate®, VWF-stabilized FVIII for factor replacement in Haemophilia A and for the prevention and treatment of FVIII-Inhibitors. octanine F® a high purity SD-treated and nano-filtered Factor IX. The development of the first truly human and unmodified recombinant FVIII concentrate is a further demonstration of Octapharma living by its mission statement for “the safe and optimal use of human proteins”.

Pentapharm, DSM Nutritional Products Ltd

Dornacherstrasse 112
4147 Aesch
Switzerland
T: +41 61 7064848
E: pentapharm@pentapharm.com
www.pentapharm.com

Pentapharm, since 2007 part of DSM, is a swiss manufacturer of specialized haemostasis Pefakit® diagnostics kits, e.g. APC-R Factor V Leiden, PiCT® (for UFH, LMWH and NOACS [anti-FIIa and -FXa drugs] monitoring), Reptilase Time, in-TDT® [for thrombin generation], TAFI. Pentapharm can also develop upon request OEM products, based on its extensive portfolio of reagents (from research to bulk quantities), such as synthetic chromogenic, fluorogenic and amperogenic substrates, protease inhibitors and snake venom enzymes. Pentapharm offers as well active pharmaceutical ingredients: aprotinin, peptides and snake venom derived enzymes [Batroxobin, Haemocoagulase, Ecarin, Protac®], synthesis of peptides and small organic molecules.
**EXHIBITION AND SPONSOR PROFILES**

**Pfizer Inc.**  
Booth no. 350

235 E. 42nd Street  
10017 New York  
USA  
T: 212-733-2323  
www.pfizer.com

At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines for people and animals. Our diversified global health care portfolio includes human and animal biologic and small molecule medicines and vaccines, and many of the world’s best-known consumer products.

Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.

**BMS/Pfizer, Inc.**  
Booth no. 645

Bristol-Myers Squibb  
P.O. Box 4000  
Princeton, NJ 08540 – 4000  
USA  
www.bms.com

Pfizer Inc.  
235 E. 42nd Street  
New York, New York 10017-5703  
USA  
www.pfizer.com

In 2007, Pfizer and Bristol-Myers Squibb entered into a worldwide collaboration to develop and commercialize apixaban, an investigational oral anticoagulant discovered by Bristol-Myers Squibb. This global alliance combines Bristol-Myers Squibb’s long-standing strengths in cardiovascular drug development and commercialization with Pfizer’s global scale and expertise in this field.

**pharma-insight GmbH**  
Booth no. 539

Merscheider Str. 3  
42699 Solingen  
Germany  
T: +49 212 383520  
E: Guido.Baus@pharma-insight.com  
www.pharma-insight.com

pharma-insight GmbH is an international full-service market research agency specialized in the health care, medical device and pharmaceutical market.

We offer insights and products that deliver proven results for marketing insights, brand marketing, business development and health economics and outcome. We believe in a holistic view of business issues, which includes assessing perceptions of different stakeholders and customers, interpreting this in the context of healthcare structure and understanding the impact this has on brand development and performance.

pharma-insight combines scientific healthcare expertise with strong business know-how, ensuring that solutions are both evidence-based and commercially focused.
**Precision Biologic Inc**

Booth no. 214

140 Eileen Stubbs Avenue  
B3B 0A9 Dartmouth, NS  
Canada  
T: +1 902 4686422  
E: info@precisionbiologic.com  
www.precisionbiologic.com

Precision BioLogic develops, manufactures and markets diagnostic products used for testing in routine and special coagulation laboratories as well as research organizations around the globe. Our unique approach to doing business is built on our superior products, commitment to customer service and attention to detail. Over the past 20 years, our CRYOcheck™ frozen controls, calibrators and reagents have become synonymous with quality. Today, we are growing our product base to help meet customers’ needs by adding more in vitro diagnostics, including our line of clot-based diagnostic kits. For more information, visit www.precisionbiologic.com.

**R2 Diagnostics, Inc.**

Booth no. 216

1801 Commerce Drive  
46628 South Bend, IN  
USA  
T: +1 574 2884377

R2 Diagnostics focuses on the production of high quality, innovative products for the hemostasis market. We have put a major emphasis on the production of products for the detection of thrombophilia, including kits for PC, PS and lupus anticoagulants.

**Roche Diagnostics International ltd**

Booth no. 620

Forrenstrasse 2  
6343 Rotkreuz  
Switzerland  
www.roche.com

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, infectious diseases, inflammation, metabolism and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2012 Roche had over 82,000 employees worldwide and invested over 8 billion Swiss francs in R&D. The Group posted sales of 45.5 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.
Sanofi
54, Rue La Boétie
75008 Paris
France
T: +33 1 53774000
E: christopher.hunter-ward@sanofi.com
http://en.sanofi.com/home.asp

Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme.

Sanquin Blood Supply Foundation
Booth no. 145

Plesmanlaan 125
1066 CX Amsterdam
The Netherlands
www.sanquin.nl

Sanquin Blood Supply Foundation ensures the safe and efficient blood supply in the Netherlands. Sanquin also develops and produces pharmaceutical products, conducts high-quality scientific research, and develops and performs a multitude of diagnostic services. Sanquin supplies in cooperation with partners plasma-derived products for patients in The Netherlands, Belgium, Finland and certain other territories. Sanquin has several coagulation products available including Cofact, Aafact and Nonafact. The Sanquin HomeService, consisting of a team of specialized nurses, pharmacists and back office, provides home therapy in The Netherlands.

Schattauer Publishers
Booth no. 673

Hölderlinstr. 3
70174 Stuttgart
Germany
T: +49 711 2298727
E: info@schattauer.de
www.thrombosis-online.com

Thrombosis and Haemostasis publishes reports on basic and clinical research dedicated to novel results and highest quality in any area of thrombosis and haemostasis, vascular biology and medicine, inflammation and infection, platelet and leukocyte biology, from genetic, molecular & cellular studies, diagnostic, therapeutic & preventative studies to high-level translational and clinical research.

Thrombosis and Haemostasis provides position and guideline papers, state-of-the-art papers, expert analysis and commentaries, and dedicated Theme issues covering recent developments and key topics in the field.

Thrombosis and Haemostasis provides a forum for the exchange of ideas and concepts fostering cross-disciplinary insights in basic and clinical research.
Sekisui Diagnostics

50 Gibson Drive
ME19 4AF Kings Hill, West Malling
United Kingdom
T: +44 1732 220022
E: eeva.slattery@sekisuidiagnostics.com
www.sekisuidiagnostics.com

Sekisui Diagnostics offers the CoaprestaTM 2000 coagulation instrument and reagent system and specialty coagulation reagents as part of their wide portfolio of diagnostic products, which also includes clinical chemistry reagents, point of care rapid tests and critical raw materials. Our global network of commercial and manufacturing facilities allows us to distribute our products to patients around the world. For more information about Sekisui Diagnostics, please visit our web site at www.sekisuidiagnostics.com

SINTESI RESEARCH

Via Ripamonti, 89
20141 Milan
Italy
T: +39 02873512
E: info@sintesiresearch.com
www.sintesiresearch.com

Sintesi Research is a CRO headquartered in Milan, with regional offices in Valencia (Spain), Los Angeles (USA), Buenos Aires (Argentina), Santiago (Chile) and international strategic partnerships, offering full support in planning, managing and evaluating Phase I-IV Clinical Trials. Sintesi Research provides fully therapeutic areas expertise in planning, running and reporting phase I-IV trials and supports pharmaceutical, biotechnology and medical device companies with a broad range of professional services and technological solutions. For further information please contact Valeria Chiarella: v.chiarella@sintesiresearch.com

Siemens

Emil-von-Behring-Straße 76
35041 Marburg
Germany
T: +49 6421 394601
E: michael.noehl@siemens.com
www.siemens.com/diagnostics

Siemens Healthcare Diagnostics, a global leader in clinical diagnostics, provides healthcare professionals in hospital, reference, and physician office laboratories and point-of-care settings with the vital information required to accurately diagnose, treat, and monitor patients. Our innovative portfolio of performance-driven solutions and personalized customer care combine to streamline workflow, enhance operational efficiency, and support improved patient outcome.
EXHIBITION AND SPONSOR PROFILES

Sobi

Booth no. 204, 255

Tomtebodavägen 23A Solna
112 76 Stockholm
Sweden
T: +46 8 6972000
E: communication@sobi.com
www.sobi.com

Sobi is an international specialty healthcare company dedicated to rare diseases. Our mission is to develop and deliver innovative therapies and services to improve the lives of patients. Sobi has a long tradition of haemophilia innovation, which now includes two late-stage biological treatments in development. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. Our commitment drives us towards innovations in treatment of haemophilia with the simple goal – to ensure that people with haemophilia live full and healthy lives. Sobi is listed on NASDAQ OMX Stockholm (STO: SOBI). For more information: www.sobi.com.

Sysmex Corporation

Booth no. 630

1-5-1, Wakinohama-kaigandori, Chuo-ku
651-0073 Kobe
Japan
T: +81 78 2650500
www.sysmex.co.jp/en

Sysmex is a world leader in clinical laboratory systemization and solutions, including laboratory diagnostics, laboratory automation and clinical information systems. Serving customers for more than 40 years, Sysmex focuses on technological leadership in diagnostic science and information tools that make a difference in the health of people worldwide. Its R & D efforts focus on the development of high-value-added testing and diagnostic technologies that are innovative, original and optimize individual health. At present, Sysmex’s products and services are being used at medical institutions in over 170 countries around the world.

Sinnowa Medical Science & Technology Co.

Booth no. 213

Qilin Industrial Park
211135 Nanjing
China
E: zhao@sinnowa.com

Discover a better solution and a better analyzer for successful PLT function test, with our new product PL-11 Platelet Function Analyzer!
SINNOWA is one of the leading developers and manufacturers of clinical Lab equipment & Reagents from China, under CE and ISO quality system.
EXHIBITION AND SPONSOR PROFILES

SSC 2014 in Milwaukee, USA  
Booth no. 500

ISTH Headquarters  
610 Jones Ferry Road, Suite 205  
Carrboro, North Carolina 27510  
USA  
T: +1 919 929 3807  
E: headquarters@isth.org  
www.isth.org

The 60th Annual Scientific and Standardization Committee (SSC) Meeting of the International Society on Thrombosis and Haemostasis (ISTH) will take place in Milwaukee from June 23 through June 26, 2014. The ISTH’s SSC holds annual meetings devoted to the discussion of diagnostic standards, disease nomenclature and classification, and the latest research on bleeding and thrombotic disorders. Learn more at www.isth.org and visit our booth at ISTH 2013!

Stago  
Booth no. 520

9, Rue des Frères Chausson  
92600  
Asnières sur Seine  
France  
T: +33 01 46882020  
E: webmaster@stago.com  
www.stago.com

Stago, created in 1945, is an IVD Company which develops and markets reagents and automated systems for the investigation of blood coagulation disorders. Stago is a leading player in Haemostasis. Headquarters, as well as R&D, manufacturing and logistics activities are located mainly in the Paris area (France). In 2012, Stago has significantly improved its direct presence by opening 8 new subsidiaries in Europe. Its products are also available in more than 110 countries throughout the world through a network of selected partners. In 2013, Stago has more than 2,000 employees worldwide.

Technoclone  
Booth no. 441

Brunnerstr. 67  
1230 Vienna  
Austria  
T: +43 1863730  
E: sales@technoclone.com  
www.technoclone.com

Technoclone is a world leading producer of global and special coagulation tests. Ceveron® alpha [www.ceveron.com], is not only a fully automated coagulation analyzer for clotting, photometric and immunological, latex based coagulation tests but also offers the unique feature of fully automated thrombin generation measurement in the routine: CV <5% and assay times <20min Peak Thrombin. Furthermore Technoclone provides a complete range of ADAMTS13 ELISAs and FXIII assays, as well a complete portfolio for the new anticoagulants such as for Xa inhibitors and direct thrombin inhibitors.
**Tem International**

Martin-Kollar-Strasse 13  
81829 Munich  
Germany  
T: +49  89 4542950  
E: ariane.becker@tem-international.de  
www.rotem.de

Tem International provides patient diagnostic devices for acute bleeding. The ROTEM® system provides rapid results in whole blood. It gives an overview about the coagulation status after 10 minutes allowing controlled targeted therapies and avoiding unnecessary transfusion. Thus, it does not only save blood products, treatment costs and time, but also human lives.

**Wiley**

9600 Garsington Road  
OX4 2DQ Oxford  
United Kingdom  
T: +1 515 2920140  
E: lerhart@wiley.com  
www.wileyonlinelibrary.com

Founded in 1807, John Wiley & Sons, Inc. has been a valued source of information and understanding for more than 200 years, helping people around the world meet their needs and fulfill their aspirations. Wiley and its acquired companies have published the works of more than 450 Nobel laureates in all categories: Literature, Economics, Physiology or Medicine, Physics, Chemistry, and Peace.

Wiley is a global provider of content and content-enabled workflow solutions in areas of scientific, technical, medical, and scholarly research; professional development; and education. Our core businesses produce scientific, technical, medical, and scholarly journals, reference works, books, database services, and advertising; professional books, subscription products, certification and training services and online applications; and education content and services including integrated online teaching and learning resources for undergraduate and graduate students and lifelong learners. Wiley’s global headquarters are located in Hoboken, New Jersey, with operations in the U.S., Europe, Asia, Canada, and Australia. The Company’s Web site can be accessed at http://www.wiley.com. The Company is listed on the New York Stock Exchange under the symbols JWa and JWb.

**Wisepress Medical Bookshop**

25 High Path, Merton Abbey  
SW19 2JL London  
United Kingdom  
T: +44  20 8715 1812  
F: +44  20 8715 1722  
E: bookshop@wisepress.com  
www.wisepress.com

Wisepress.com, Europe’s leading conference bookseller, has a complete range of books and journals relevant to the themes of the meeting. Books can be purchased at the stand or, if you would rather not carry them, posted to you – Wisepress will deliver worldwide. In addition to attending 200 conferences per year, Wisepress has a comprehensive medical and scientific bookshop online with great offers.
World Federation of Hemophilia

Booth no. 672

1425, Boul. René-Lévesque Ouest, bureau 1010
H3G 1T7 Montréal
Québec
T: +1 514 8757944
E: wfh@wfh.org
www.wfh.org

For 50 years, the World Federation of Hemophilia (WFH) has provided global leadership to improve and sustain care for people with inherited bleeding disorders, including hemophilia, von Willebrand disease, rare factor deficiencies, and inherited platelet disorders.

Come visit our booth and enter a draw for a trip to the WFH 2014 World Congress in Melbourne, Australia, May 11-15, 2014. The WFH World Congress is the largest international meeting for the global bleeding disorders community.

Learn about our global efforts to close the gap in care and achieve treatment for all people with inherited bleeding disorders. Meet staff and volunteers, pick up publications, find out more information about the WFH’s new Clinical Research Grants Program, and support our Close the Gap campaign.
Come to the Biogen Idec and Sobi booths to find out more about developments in haemophilia.

Booths: 204 & 255
Arteriosclerosis, Thrombosis, and Vascular Biology

The forum for publication of basic, translational, clinical, and population research in the area of arteriosclerosis, thrombosis, and vascular biology

Submit Your Manuscript
http://atvb-submit.aha-journals.org

With an Impact Factor of 6.368, ATVB ranks 3rd among 68 journals in Peripheral Vascular Disease and 7th among 68 journals in Hematology subject categories. It is the #1 journal dedicated to the study of atherosclerosis and thrombosis in relation to vascular biology.

2011 Journal Citation Reports® (Thomson Reuters, 2012)

RAPID ONLINE PUBLICATION WITHIN 5 TO 10 DAYS OF ACCEPTANCE

Join the AHA†
Call: 1-800-787-8984 (United States)
+1-301-223-2307 (Rest of World)
Visit my.americanheart.org/membership

Subscribe†
Call: 1-800-638-3030 (United States)
+44 (0) 20 7981 0525 (Europe)
+1-301-223-2300 (Rest of World)
Visit http://lww.com/atvb

†Non-member individual and resident subscriptions are ordered via LWW. Institutional print subscriptions are ordered via LWW, and institutional online access is available via Ovid. Visit www.ovid.com or contact your Ovid Sales Representative directly.

‡Premium Professional Plus Members receive full access to all 11 AHA journals online and for their iPad as a benefit of membership. Premium Professional, Early Career, and Student/Trainee Members have limited access to journals and features as indicated by their selected level. Full-access options are available for each level of membership when you join. To have access to the iPad edition, Members with online journal benefits must indicate ATVB as one of their online selections.

Apple and iPad are trademarks of Apple Inc., registered in the U. S. and other countries. App Store is a service mark of Apple Inc.
Congress Information
## Key Information

### Opening hours

<table>
<thead>
<tr>
<th>Date</th>
<th>Saturday</th>
<th>Sunday</th>
<th>Monday</th>
<th>Tuesday</th>
<th>Wednesday</th>
<th>Thursday</th>
</tr>
</thead>
<tbody>
<tr>
<td>Speaker Ready Room [main entrance 1st floor, K101]</td>
<td>07:00–19:00</td>
<td>07:00–19:00</td>
<td>07:00–20:00</td>
<td>07:30–20:00</td>
<td>07:30–18:00</td>
<td>07:30–18:00</td>
</tr>
<tr>
<td>Registration [registration area]</td>
<td>07:00–18:00</td>
<td>07:00–19:00</td>
<td>07:00–20:00</td>
<td>07:30–20:00</td>
<td>07:30–18:00</td>
<td>07:30–17:00</td>
</tr>
<tr>
<td>Exhibition [exhibition area]</td>
<td>08:30–18:30</td>
<td>08:30–18:30</td>
<td>10:00–18:30</td>
<td>10:00–18:30</td>
<td>10:00–18:30</td>
<td>10:00–15:30</td>
</tr>
<tr>
<td>ePoster centre [ePoster area]</td>
<td>08:30–18:30</td>
<td>08:30–18:30</td>
<td>08:30–18:30</td>
<td>08:30–18:30</td>
<td>08:30–18:00</td>
<td>08:30–17:00</td>
</tr>
<tr>
<td>Press room Forum Centre [E001]</td>
<td>09:00–18:00</td>
<td>09:00–19:00</td>
<td>09:00–19:00</td>
<td>09:00–18:00</td>
<td>09:00–18:00</td>
<td>09:00–17:00</td>
</tr>
<tr>
<td>Cloak room [Main Entrance]</td>
<td>07:00–18:30</td>
<td>07:00–22:00</td>
<td>07:00–20:30</td>
<td>07:30–20:30</td>
<td>07:30–18:30</td>
<td>07:30–18:00</td>
</tr>
</tbody>
</table>
Venue
Amsterdam RAI, Europaplein 22, 1078 GZ, Amsterdam, The Netherlands

Registration hours
Registration will start on Saturday morning. The Registration Area at the Amsterdam RAI will be open during the following hours:
- Saturday, June 29: 07:00 – 18:00
- Sunday, June 30: 07:00 – 19:00
- Monday, July 1: 07:00 – 20:00
- Tuesday, July 2: 07:30 – 20:00
- Wednesday, July 3: 07:30 – 18:00
- Thursday, July 4: 07:30 – 17:00

Exhibition hours
- Monday, July 1: 10:00 – 18:30
- Tuesday, July 2: 10:00 – 18:30
- Wednesday, July 3: 10:00 – 18:30
- Thursday, July 4: 10:00 – 15:30

Badges
All participants and accompanying persons will receive a personal badge upon registration. You are expected to wear your name badge when attending any scientific session or Congress related event. Only participants who are wearing their name badge will be admitted to the meeting rooms, the exhibition area, special and satellite symposia.

Please note:
- Accompanying persons and exhibitors will not be admitted to the scientific sessions.
- Accompanying persons will not be admitted to the exhibition area and the ePoster area.

Name badges have been colour-coded as follows:
- WHITE: Regular delegates
- RED: Local organising committee, invited speakers and other invited individuals
- YELLOW: Press
- BLACK: Accompanying persons
- BLUE: Exhibitors
- GREEN: Special and satellite symposia guests
- ORANGE: SSC only

The charge for the replacement of lost badges will be € 25.
Certificates of attendance
Certificates of attendance will be available in the Registration Area as of Tuesday, July 2 (from 12:00) until Thursday, July 4 (until 12:00).

Internet
WIFI is available throughout the Amsterdam RAI.
Username: isth-2013
Password: innovation

Cloakroom and luggage
The cloakroom (free of charge) is located at the main entrance (see floor plan, back cover).

Opening hours:
Saturday, June 29 07:00 – 18:30
Sunday, June 30 07:00 – 22:00
Monday, July 1 07:00 – 20:30
Tuesday, July 2 07:30 – 20:30
Wednesday, July 3 07:30 – 18:30
Thursday, July 4 07:30 – 18:00

Lost and found
Information Desk at the main entrance.

Insurance
It is recommended that participants obtain adequate coverage for travel, health and accident insurance before they depart from their countries. MCI Amsterdam as the Congress planner, the ISTH and committee members and officers of ISTH 2013 claim no liability for the act of any supplier to this meeting, nor liability for: personal injury, the safety of any attendee while in transit to or from this event, for any loss or damage, for delays in transport by air, sea, rail, road, weather, in case of strikes, sickness, war, end of the world or other causes.
Key Information

Press room
The Press room is located in room E001 at the Forum Centre. Press inquiries prior to and after the Congress should be directed to ISTH Headquarters: T: +1 919 929 3807, F: +1 919 929 3935, E: headquarters@isth.org

Opening hours:
Saturday, June 29 09:00 – 18:00
Sunday, June 30 09:00 – 19:00
Monday, July 1 09:00 – 19:00
Tuesday, July 2 09:00 – 18:00
Wednesday, July 3 09:00 – 18:00
Thursday, July 4 09:00 – 15:00

Praying room
A praying room is located at Elicium level -1 (see floor plan, back cover).

Lunch & refreshments
Lunch is provided during the scientific and educational programme of the Congress. Lunch tickets will be available in the registration package. The tickets are valid on Saturday, June 29 and Monday, July 1 – Thursday, July 4.

Services provided during congress

<table>
<thead>
<tr>
<th>Services</th>
<th>Name</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Check in slides/presentations</td>
<td>Speaker Ready Room</td>
<td>Above main entrance (K101)</td>
</tr>
<tr>
<td>City, Hotel and Excursion information</td>
<td>City Information, Hotel Information and Excursions</td>
<td>Registration Area</td>
</tr>
<tr>
<td>Cloakroom and luggage</td>
<td>Cloakroom</td>
<td>Main entrance</td>
</tr>
<tr>
<td>Copying service</td>
<td>Business Centre</td>
<td>Elicium level -1</td>
</tr>
<tr>
<td>Excursion tickets</td>
<td>Excursion Desk</td>
<td>Registration Area</td>
</tr>
<tr>
<td>Exhibition information</td>
<td>Exhibitor Desk</td>
<td>Registration Area</td>
</tr>
<tr>
<td>First Aid</td>
<td>First Aid</td>
<td>Next to hall 2</td>
</tr>
<tr>
<td>Lost and found</td>
<td>Message Desk</td>
<td>Information Desk at main entrance</td>
</tr>
<tr>
<td>Money withdrawal</td>
<td>Cash dispenser</td>
<td>Main entrance</td>
</tr>
<tr>
<td>ePoster information</td>
<td>ePoster Desk</td>
<td>ePoster Area</td>
</tr>
<tr>
<td>Restaurant reservations</td>
<td>City Information Desk</td>
<td>Registration Area</td>
</tr>
<tr>
<td>Tickets Party</td>
<td>Social Event Desk</td>
<td>Registration Area</td>
</tr>
</tbody>
</table>
## Key Information

### Useful telephone numbers

<table>
<thead>
<tr>
<th>Name</th>
<th>Location</th>
<th>Telephone</th>
</tr>
</thead>
<tbody>
<tr>
<td>ISTH Executive Office</td>
<td>ISTH Office</td>
<td>+31 (0)20 549 3404</td>
</tr>
<tr>
<td>Hotel Information Desk</td>
<td>RAI visitor service Desk</td>
<td>+31 (0)20 549 1927</td>
</tr>
<tr>
<td>Registration Desk</td>
<td>Registration Area</td>
<td>+31 (0)20 549 3401</td>
</tr>
<tr>
<td>Press Room</td>
<td>Forum Centre</td>
<td>+31 (0)20 549 3405</td>
</tr>
</tbody>
</table>

### ISTH Mobile App

A mobile app allows access to the Congress programme. Use the app to find sessions of interest, create your own itinerary and locate meeting rooms. Download the app from the Apple App store or the Google Playstore, or scan the QR codes below with your smartphone and download the app. Need a code reader for your phone? http://get.neoreader.com

If you are using an iPhone, iPod Touch or iPad, please scan this code:

If you are using an Android device, please scan this code:

For all devices, you can also scan this code:
Abstracts
Abstracts are available on-line via the Wiley website, on the Congress app and on the congress website.

CME

EACCME/AMA
ISTH 2013 is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS), www.uems.net.

ISTH 2013 is designated for a maximum of 35 hours of European external CME credits. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

EACCME credits are recognised by the American Medical Association towards the Physician’s Recognition Award (PRA). To convert EACCME credit to AMA PRA category 1 credit, contact the AMA.

EHA Accreditation
ISTH 2013 has been accredited by the European Hematology Association (EHA) with 35 credit points.

All participants may print a European Hematology Association CME System approved CME certificate indicating the number of EHA-CME Credit Points awarded, directly from the system on the CME section of the EHA website at www.ehaweb.org.

An EHA-CME Credit Point account will be used by all interested participants. Participants will receive a login after the meeting which will allow them to complete the online evaluation in order to obtain the EHA credits.
**Social media**
ISTH 2013 encourages the use of social media, such as Facebook, Twitter, LinkedIn, and other social media platforms at the conference as a way to summarise, highlight, excerpt, review or promote the presented materials, or the Congress in general, provided that: 1) copyright law is observed; 2) verbatim information is limited to a few quotes, and; 3) the author or speaker is referenced and cited appropriately. To get the latest updates throughout the Congress, follow the ISTH online via the following links. Use the Congress hashtag via twitter: #isth2013.
Facebook: www.facebook.com/internationalsocietythrombosisandhaemostasis
Twitter: www.twitter.com/isth
Linkedin: http://www.linkedin.com/groups/International-Society-on-Thrombosis-Haemostasis-3953570/about

**Online disclosures**
As part of the CME accreditation procedures, all speakers are obliged to provide disclosure of potential conflicts of interest. On the first slide of every presentation, these disclosures must be presented. The Speaker Ready Room can assist you with drafting this slide.

**Programme changes**
Programme changes will be made public via the app and the website.

**Recap lounges**
In the recap lounges participants can view presentations which have taken place during the previous days. Come and watch the State-of-the-Art Sessions and other presentations you have missed. Please check the app or the website for the exact time schedule.
Speaker Ready Room (SRR)
Speakers are asked to check in at the SRR at least three hours before their presentation to check the presentation, to copy the presentation onto the network, to fill in the disclosure slide, and to review the demo of the presentation with the technical staff. Please note that embedded videos in a presentation may not work appropriately. The videos can be converted at the SRR to a PowerPoint compatible format, with the Procoder® video programme. All meeting rooms contain state-of-the-art technical equipment. The use of your own laptop during your presentation is prohibited.

The Speaker Ready Room is located on the first floor of the Main Entrance K in room K101.

Opening hours:
Saturday, June 29  07:00 – 19:00
Sunday, June 30  07:00 – 19:00
Monday, July 1    07:00 – 20:00
Tuesday, July 2   07:30 – 20:00
Wednesday, July 3 07:30 – 18:00
Thursday, July 4  07:30 – 18:00

Website
Up-to-date information regarding the Congress programme, including all abstracts, is available on the website: www.isth2013.org.
ePoster presentations
All posters are presented in an electronic poster (ePoster) format. The Posters will be presented and discussed in the order indicated in the programme on Monday, Tuesday, Wednesday and Thursday.

ePoster Area and ePoster Desk
ePoster sessions will take place in the ePoster Area behind the Exhibition Area. The ePoster Area and ePoster Desk will be open during the following hours:
Monday, July 1 08:30-18:30
Tuesday, July 2 08:30-18:30
Wednesday, July 3 08:30-18:30
Thursday, July 4 08:30-17:00

ePoster Area floor plan with screen and session numbers
<table>
<thead>
<tr>
<th>Screen no.</th>
<th>Session title</th>
<th>Screen no.</th>
<th>Session title</th>
</tr>
</thead>
<tbody>
<tr>
<td>01</td>
<td>Antiplatelet agents: ADP receptors - I</td>
<td>21</td>
<td>Antiplatelet agents: ADP receptors - II</td>
</tr>
<tr>
<td>02</td>
<td>Platelet activation: Novel proteins - I</td>
<td>22</td>
<td>Standardising platelet function tests</td>
</tr>
<tr>
<td>03</td>
<td>Platelet hyperfunction</td>
<td>23</td>
<td>Platelet integrins - I</td>
</tr>
<tr>
<td>04</td>
<td>Circulating microparticles</td>
<td>24</td>
<td>Platelet apoptosis</td>
</tr>
<tr>
<td>05</td>
<td>Immune thrombocytopenic purpura - I</td>
<td>25</td>
<td>Platelet disorders: Gain-of-function</td>
</tr>
<tr>
<td>06</td>
<td>Fibrinolytic system: Basic - I</td>
<td>26</td>
<td>Platelet function in disease</td>
</tr>
<tr>
<td>07</td>
<td>Haemophilia A: Basic - I</td>
<td>27</td>
<td>Platelets and cancer</td>
</tr>
<tr>
<td>08</td>
<td>Rare bleeding disorders - I</td>
<td>28</td>
<td>Platelet storage and transfusion</td>
</tr>
<tr>
<td>09</td>
<td>Von Willebrand factor: Basic</td>
<td>29</td>
<td>Megakaryocytes and thrombopoiesis - I</td>
</tr>
<tr>
<td>10</td>
<td>Anticoagulant agents - I</td>
<td>30</td>
<td>Microparticles and disease - I</td>
</tr>
<tr>
<td>11</td>
<td>Blood coagulation tests - I</td>
<td>31</td>
<td>Endothelial function</td>
</tr>
<tr>
<td>12</td>
<td>Coagulation factor IX - I</td>
<td>32</td>
<td>Atherosclerosis: Mouse models</td>
</tr>
<tr>
<td>13</td>
<td>Coagulation factor VIII - I</td>
<td>33</td>
<td>ADAMTS13: Clinical - I</td>
</tr>
<tr>
<td>14</td>
<td>Fibrinogen/Fibrin - I</td>
<td>34</td>
<td>Fibrinolytic system: Clinical - I</td>
</tr>
<tr>
<td>15</td>
<td>Natural anticoagulants - I</td>
<td>35</td>
<td>Haemophilia A: Clinical - I</td>
</tr>
<tr>
<td>16</td>
<td>Cancer and thrombosis - I</td>
<td>36</td>
<td>Haemophilia A: Clinical - II</td>
</tr>
<tr>
<td>17</td>
<td>Angiogenesis</td>
<td>37</td>
<td>Haemophilia A: Clinical - III</td>
</tr>
<tr>
<td>18</td>
<td>Antiphospholipid - I</td>
<td>38</td>
<td>Haemophilia A: Clinical - IV</td>
</tr>
<tr>
<td>19</td>
<td>Innate and acquired immunity</td>
<td>39</td>
<td>Haemophilia B - I</td>
</tr>
<tr>
<td>20</td>
<td>Recurrent venous thrombosis - I</td>
<td>40</td>
<td>Heparin-induced thrombocytopenia (HIT): Clinical - I</td>
</tr>
<tr>
<td>21</td>
<td>Antiplatelet agents: ADP receptors - II</td>
<td>41</td>
<td>Rare bleeding disorders - II</td>
</tr>
<tr>
<td>22</td>
<td>Standardising platelet function tests</td>
<td>42</td>
<td>Von Willebrand disease: Clinical - I</td>
</tr>
<tr>
<td>23</td>
<td>Platelet integrins - I</td>
<td>43</td>
<td>Von Willebrand disease: Clinical - II</td>
</tr>
<tr>
<td>24</td>
<td>Platelet apoptosis</td>
<td>44</td>
<td>Von Willebrand factor - I</td>
</tr>
<tr>
<td>25</td>
<td>Platelet disorders: Gain-of-function</td>
<td>45</td>
<td>Anticoagulant agents - II</td>
</tr>
<tr>
<td>26</td>
<td>Platelet function in disease</td>
<td>46</td>
<td>Anticoagulant agents - III</td>
</tr>
<tr>
<td>27</td>
<td>Platelets and cancer</td>
<td>47</td>
<td>Anticoagulant agents - IV</td>
</tr>
<tr>
<td>28</td>
<td>Platelet storage and transfusion</td>
<td>48</td>
<td>Anticoagulant agents - V</td>
</tr>
<tr>
<td>29</td>
<td>Megakaryocytes and thrombopoiesis - I</td>
<td>49</td>
<td>Anticoagulant agents - VI</td>
</tr>
<tr>
<td>30</td>
<td>Microparticles and disease - I</td>
<td>50</td>
<td>Blood coagulation system - I</td>
</tr>
<tr>
<td>31</td>
<td>Endothelial function</td>
<td>51</td>
<td>Blood coagulation tests - II</td>
</tr>
<tr>
<td>32</td>
<td>Atherosclerosis: Mouse models</td>
<td>52</td>
<td>Blood coagulation tests - III</td>
</tr>
<tr>
<td>33</td>
<td>ADAMTS13: Clinical - I</td>
<td>53</td>
<td>Blood coagulation tests - IV</td>
</tr>
<tr>
<td>34</td>
<td>Fibrinolytic system: Clinical - I</td>
<td>54</td>
<td>Blood coagulation tests - V</td>
</tr>
<tr>
<td>35</td>
<td>Haemophilia A: Clinical - I</td>
<td>55</td>
<td>Coagulation factor VIII - II</td>
</tr>
<tr>
<td>36</td>
<td>Haemophilia A: Clinical - II</td>
<td>56</td>
<td>Tissue factor - I</td>
</tr>
<tr>
<td>37</td>
<td>Haemophilia A: Clinical - III</td>
<td>57</td>
<td>Fibrinogen/Fibrin - II</td>
</tr>
<tr>
<td>38</td>
<td>Haemophilia A: Clinical - IV</td>
<td>58</td>
<td>Other coagulation factors - I</td>
</tr>
<tr>
<td>39</td>
<td>Haemophilia B - I</td>
<td>59</td>
<td>Coagulation: Miscellaneous - I</td>
</tr>
<tr>
<td>40</td>
<td>Heparin-induced thrombocytopenia (HIT): Clinical - I</td>
<td>60</td>
<td>Cancer and thrombosis - II</td>
</tr>
<tr>
<td>41</td>
<td>Rare bleeding disorders - II</td>
<td>61</td>
<td>Cancer and thrombosis - III</td>
</tr>
<tr>
<td>42</td>
<td>Von Willebrand disease: Clinical - I</td>
<td>62</td>
<td>Antiphospholipid - II</td>
</tr>
<tr>
<td>43</td>
<td>Von Willebrand disease: Clinical - II</td>
<td>63</td>
<td>Arterial vascular disorders - I</td>
</tr>
<tr>
<td>44</td>
<td>Von Willebrand factor - I</td>
<td>64</td>
<td>Diagnosis of venous thrombosis - I</td>
</tr>
<tr>
<td>45</td>
<td>Anticoagulant agents - II</td>
<td>65</td>
<td>Diagnosis of venous thrombosis - II</td>
</tr>
<tr>
<td>46</td>
<td>Anticoagulant agents - III</td>
<td>66</td>
<td>Hormones, pregnancy, women's issues - I</td>
</tr>
<tr>
<td>47</td>
<td>Anticoagulant agents - IV</td>
<td>67</td>
<td>Inflammation: Basic - I</td>
</tr>
<tr>
<td>48</td>
<td>Anticoagulant agents - V</td>
<td>68</td>
<td>Inherited risk factors venous thrombosis: Basic - I</td>
</tr>
<tr>
<td>49</td>
<td>Anticoagulant agents - VI</td>
<td>69</td>
<td>Non-inherited risk factors venous thrombosis - I</td>
</tr>
<tr>
<td>50</td>
<td>Blood coagulation system - I</td>
<td>70</td>
<td>Non-inherited risk factors venous thrombosis - II</td>
</tr>
<tr>
<td>51</td>
<td>Blood coagulation tests - II</td>
<td>71</td>
<td>Paediatric thrombosis - I</td>
</tr>
<tr>
<td>52</td>
<td>Blood coagulation tests - III</td>
<td>72</td>
<td>Thrombophilia - I</td>
</tr>
<tr>
<td>53</td>
<td>Blood coagulation tests - IV</td>
<td>73</td>
<td>Atherosclerosis: Miscellaneous - I</td>
</tr>
<tr>
<td>54</td>
<td>Blood coagulation tests - V</td>
<td>74</td>
<td>Acquired coagulation disorders - I</td>
</tr>
<tr>
<td>55</td>
<td>Coagulation factor VIII - II</td>
<td>75</td>
<td></td>
</tr>
<tr>
<td>56</td>
<td>Tissue factor - I</td>
<td>76</td>
<td></td>
</tr>
<tr>
<td>57</td>
<td>Fibrinogen/Fibrin - II</td>
<td>77</td>
<td></td>
</tr>
<tr>
<td>58</td>
<td>Other coagulation factors - I</td>
<td>78</td>
<td></td>
</tr>
<tr>
<td>59</td>
<td>Coagulation: Miscellaneous - I</td>
<td>79</td>
<td></td>
</tr>
<tr>
<td>60</td>
<td>Cancer and thrombosis - II</td>
<td>80</td>
<td></td>
</tr>
<tr>
<td>61</td>
<td>Cancer and thrombosis - III</td>
<td>81</td>
<td></td>
</tr>
<tr>
<td>62</td>
<td>Antiphospholipid - II</td>
<td>82</td>
<td></td>
</tr>
<tr>
<td>63</td>
<td>Arterial vascular disorders - I</td>
<td>83</td>
<td></td>
</tr>
<tr>
<td>64</td>
<td>Diagnosis of venous thrombosis - I</td>
<td>84</td>
<td></td>
</tr>
<tr>
<td>65</td>
<td>Diagnosis of venous thrombosis - II</td>
<td>85</td>
<td></td>
</tr>
<tr>
<td>66</td>
<td>Hormones, pregnancy, women's issues - I</td>
<td>86</td>
<td></td>
</tr>
<tr>
<td>67</td>
<td>Inflammation: Basic - I</td>
<td>87</td>
<td></td>
</tr>
<tr>
<td>68</td>
<td>Inherited risk factors venous thrombosis: Basic - I</td>
<td>88</td>
<td></td>
</tr>
<tr>
<td>69</td>
<td>Non-inherited risk factors venous thrombosis - I</td>
<td>89</td>
<td></td>
</tr>
<tr>
<td>70</td>
<td>Non-inherited risk factors venous thrombosis - II</td>
<td>90</td>
<td></td>
</tr>
<tr>
<td>71</td>
<td>Paediatric thrombosis - I</td>
<td>91</td>
<td></td>
</tr>
<tr>
<td>72</td>
<td>Thrombophilia - I</td>
<td>92</td>
<td></td>
</tr>
<tr>
<td>73</td>
<td>Atherosclerosis: Miscellaneous - I</td>
<td>93</td>
<td></td>
</tr>
<tr>
<td>74</td>
<td>Acquired coagulation disorders - I</td>
<td>94</td>
<td></td>
</tr>
<tr>
<td>75</td>
<td></td>
<td>95</td>
<td></td>
</tr>
<tr>
<td>76</td>
<td></td>
<td>96</td>
<td></td>
</tr>
<tr>
<td>77</td>
<td></td>
<td>97</td>
<td></td>
</tr>
<tr>
<td>78</td>
<td></td>
<td>98</td>
<td></td>
</tr>
<tr>
<td>79</td>
<td></td>
<td>99</td>
<td></td>
</tr>
</tbody>
</table>

**Colorcode for ePoster Themes:**

- **Platelets**
- **Bleeding**
- **Coagulation**
- **Thrombosis**
**Screen no.** | **Session title** | **Screen no.** | **Session title**
--- | --- | --- | ---
01 | Antiplatelet agents: Aspirin - I | 21 | Antiplatelet agents: ADP receptors - III
02 | Platelet activation: Novel proteins - II | 22 | Platelet function tests: Clinical
03 | Platelet signal transduction - I | 23 | Platelet activation: Receptor changes - I
04 | Megakaryocytes and thrombopoiesis - II | 24 | Platelet mRNA/protein expression
05 | Platelets and genes | 25 | Platelet disorders: Screening
06 | Haemophilia A: Clinical - V | 26 | Platelet procoagulant activity
07 | Haemophilia B - II | 27 | Platelets in cardiovascular disease
08 | Von Willebrand Factor: Clinical - I | 28 | Platelet activation: Miscellaneous - I
09 | Von Willebrand factor - II | 29 | Vascular progenitor and stem cells
10 | Anticoagulant agents - VII | 30 | Microparticles and disease - II
11 | Blood coagulation tests - VI | 31 | Endothelium and disease
12 | Coagulation factor VIII - III | 32 | Immune thrombocytopenic purpura - II
13 | Factor II/Prothrombin - I | 33 | ADAMTS13: Clinical - II
14 | Regulation of coagulation and fibrinolysis - I | 34 | Fibrinolytic system: Basic - II
15 | Tissue factor - II | 35 | Haemophilia A: Basic - II
16 | Cancer and thrombosis - IV | 36 | Haemophilia A: Clinical - VI
17 | Arterial vascular disorders - II | 37 | Haemophilia A: Clinical - VII
18 | Intravascular devices and interventions | 38 | Haemophilia A: Clinical - VIII
19 | Paediatric thrombosis - II | 39 | Acquired coagulation disorders - II
20 | Thrombophilia - II | 40 | Heparin-induced thrombocytopenia (HIT): Basic

**Colorcode for ePoster Themes:**
- Platelets
- Bleeding
- Coagulation
- Thrombosis

**Screen Session no. title**

- **A**
  - 01: Antiplatelet agents: Aspirin - I
  - 02: Platelet activation: Novel proteins - II
  - 03: Platelet signal transduction - I
  - 04: Megakaryocytes and thrombopoiesis - II
  - 05: Platelets and genes
  - 06: Haemophilia A: Clinical - V
  - 07: Haemophilia B - II
  - 08: Von Willebrand Factor: Clinical - I
  - 09: Von Willebrand factor - II
  - 10: Anticoagulant agents - VII
  - 11: Blood coagulation tests - VI
  - 12: Coagulation factor VIII - III
  - 13: Factor II/Prothrombin - I
  - 14: Regulation of coagulation and fibrinolysis - I
  - 15: Tissue factor - II
  - 16: Cancer and thrombosis - IV
  - 17: Arterial vascular disorders - II
  - 18: Intravascular devices and interventions
  - 19: Paediatric thrombosis - II
  - 20: Thrombophilia - II

- **B**
  - 21: Antiplatelet agents: ADP receptors - III
  - 22: Platelet function tests: Clinical
  - 23: Platelet activation: Receptor changes - I
  - 24: Platelet mRNA/protein expression
  - 25: Platelet disorders: Screening
  - 26: Platelet procoagulant activity
  - 27: Platelets in cardiovascular disease
  - 28: Platelet activation: Miscellaneous - I
  - 29: Vascular progenitor and stem cells
  - 30: Microparticles and disease - II
  - 31: Endothelium and disease
  - 32: Immune thrombocytopenic purpura - II
  - 33: ADAMTS13: Clinical - II
  - 34: Fibrinolytic system: Basic - II
  - 35: Haemophilia A: Basic - II
  - 36: Haemophilia A: Clinical - VI
  - 37: Haemophilia A: Clinical - VII
  - 38: Haemophilia A: Clinical - VIII
  - 39: Acquired coagulation disorders - II
  - 40: Heparin-induced thrombocytopenia (HIT): Basic
  - 41: Rare bleeding disorders - III
  - 42: Von Willebrand disease: Clinical - III
  - 43: Von Willebrand factor - III
  - 44: Haemophilia: Miscellaneous
  - 45: Acquired coagulation disorders - III
  - 46: Anticoagulant agents - VIII
  - 47: Anticoagulant agents - IX
  - 48: Anticoagulant agents - X
  - 49: Anticoagulant agents - XI
  - 50: Blood coagulation system - II
  - 51: Blood coagulation tests - VI
  - 52: Blood coagulation tests - VII
  - 53: Blood coagulation tests - VIII
  - 54: Coagulation factor XI - I
  - 55: Coagulation factor VIII - IV
  - 56: Natural anticoagulants - II
  - 57: Fibrinogen/Fibrin - III
  - 58: Other coagulation factors - II
  - 59: Regulation of coagulation and fibrinolysis - II
  - 60: Cancer and thrombosis V
  - 61: Cancer and thrombosis - VI
  - 62: Antiphospholipid - III
  - 63: Arterial vascular disorders - III
  - 64: Diagnosis of venous thrombosis - III
  - 65: Diagnosis of venous thrombosis - IV
  - 66: Hormones, pregnancy, women’s issues - II
  - 67: Inflammation: Basic - II
  - 68: Inflammation: Clinical - I
  - 69: Inherited risk factors venous thrombosis: Basic - II
  - 70: Non-inherited risk factors venous thrombosis: III
  - 71: Recurrent venous thrombosis - II
  - 72: Thrombophilia - III
  - 73: TTP/Thrombotic microangiopathies - I
  - 74: Thrombosis: Miscellaneous
<table>
<thead>
<tr>
<th>Screen no.</th>
<th>Session title</th>
<th>Screen no.</th>
<th>Session title</th>
</tr>
</thead>
<tbody>
<tr>
<td>01</td>
<td>Platelet activation: Receptor changes - II</td>
<td>21</td>
<td>Antiplatelet agents: Aspirin - II</td>
</tr>
<tr>
<td>02</td>
<td>Thrombus formation - I</td>
<td>22</td>
<td>Platelets: Point-of-care tests</td>
</tr>
<tr>
<td>03</td>
<td>Platelet signal transduction - II</td>
<td>23</td>
<td>Platelet inhibition</td>
</tr>
<tr>
<td>04</td>
<td>Microparticles and tissue factor</td>
<td>24</td>
<td>Platelet proteomics</td>
</tr>
<tr>
<td>05</td>
<td>Genetic platelet disorders - I</td>
<td>25</td>
<td>Platelet disorders: Loss-of-function</td>
</tr>
<tr>
<td>06</td>
<td>Fibrinolytic system: Clinical - II</td>
<td>26</td>
<td>Platelet acquired dysfunctions</td>
</tr>
<tr>
<td>07</td>
<td>Haemophilia A: Basic - III</td>
<td>27</td>
<td>Platelet calcium signaling</td>
</tr>
<tr>
<td>08</td>
<td>Heparin-induced thrombocytopenia (HIT): Clinical - II</td>
<td>28</td>
<td>Signal transduction: Miscellaneous</td>
</tr>
<tr>
<td>09</td>
<td>Von Willebrand factor: Clinical - II</td>
<td>29</td>
<td>Megakaryocytes and thrombopoiesis - III</td>
</tr>
<tr>
<td>10</td>
<td>Anticoagulant agents - XII</td>
<td>30</td>
<td>Microparticle assays</td>
</tr>
<tr>
<td>11</td>
<td>Blood coagulation tests - X</td>
<td>31</td>
<td>Endothelium: Miscellaneous</td>
</tr>
<tr>
<td>12</td>
<td>Blood coagulation system - III</td>
<td>32</td>
<td>Atherosclerosis: Expression analysis</td>
</tr>
<tr>
<td>13</td>
<td>Acquired coagulation disorders - IV</td>
<td>33</td>
<td>ADAMTS13: Basic - I</td>
</tr>
<tr>
<td>14</td>
<td>Coagulation factor XI - II</td>
<td>34</td>
<td>Fibrinolytic system: Basic - III</td>
</tr>
<tr>
<td>15</td>
<td>Contact activation - II</td>
<td>35</td>
<td>Haemophilia A: Clinical - IX</td>
</tr>
<tr>
<td>16</td>
<td>Cancer and thrombosis - IX</td>
<td>36</td>
<td>Haemophilia A: Clinical - X</td>
</tr>
<tr>
<td>17</td>
<td>Hormones, pregnancy and venous thrombosis</td>
<td>37</td>
<td>Haemophilia A: Clinical - XI</td>
</tr>
<tr>
<td>18</td>
<td>Inflammation</td>
<td>38</td>
<td>Haemophilia A: Clinical - XII</td>
</tr>
<tr>
<td>19</td>
<td>Non-inherited risk factors venous thrombosis - IV</td>
<td>39</td>
<td>Heparin and heparinoids - I</td>
</tr>
<tr>
<td>20</td>
<td>Post-thrombotic syndrome</td>
<td>40</td>
<td>Massive blood loss</td>
</tr>
<tr>
<td></td>
<td></td>
<td>41</td>
<td>Rare bleeding disorders - IV</td>
</tr>
<tr>
<td></td>
<td></td>
<td>42</td>
<td>Von Willebrand disease: Clinical - IV</td>
</tr>
<tr>
<td></td>
<td></td>
<td>43</td>
<td>Von Willebrand factor - IV</td>
</tr>
<tr>
<td></td>
<td></td>
<td>44</td>
<td>Von Willebrand factor - V</td>
</tr>
<tr>
<td></td>
<td></td>
<td>45</td>
<td>Anticoagulant agents - XIII</td>
</tr>
<tr>
<td></td>
<td></td>
<td>46</td>
<td>Anticoagulant agents - XIV</td>
</tr>
<tr>
<td></td>
<td></td>
<td>47</td>
<td>Anticoagulant agents - XV</td>
</tr>
<tr>
<td></td>
<td></td>
<td>48</td>
<td>Anticoagulant agents - XVI</td>
</tr>
<tr>
<td></td>
<td></td>
<td>49</td>
<td>Coagulation factor IX - II</td>
</tr>
<tr>
<td></td>
<td></td>
<td>50</td>
<td>Blood coagulation system - IV</td>
</tr>
<tr>
<td></td>
<td></td>
<td>51</td>
<td>Blood coagulation tests - X</td>
</tr>
<tr>
<td></td>
<td></td>
<td>52</td>
<td>Blood coagulation tests - XII</td>
</tr>
<tr>
<td></td>
<td></td>
<td>53</td>
<td>Blood coagulation tests - XIII</td>
</tr>
<tr>
<td></td>
<td></td>
<td>54</td>
<td>Factor II/Prothrombin - II</td>
</tr>
<tr>
<td></td>
<td></td>
<td>55</td>
<td>Coagulation factor VIII - V</td>
</tr>
<tr>
<td></td>
<td></td>
<td>56</td>
<td>Tissue factor - III</td>
</tr>
<tr>
<td></td>
<td></td>
<td>57</td>
<td>Fibrinogen/Fibrin - IV</td>
</tr>
<tr>
<td></td>
<td></td>
<td>58</td>
<td>Other coagulation factors - III</td>
</tr>
<tr>
<td></td>
<td></td>
<td>59</td>
<td>Regulation of coagulation and fibrinolysis - III</td>
</tr>
<tr>
<td></td>
<td></td>
<td>60</td>
<td>Cancer and thrombosis - VII</td>
</tr>
<tr>
<td></td>
<td></td>
<td>61</td>
<td>Cancer and thrombosis - VIII</td>
</tr>
<tr>
<td></td>
<td></td>
<td>62</td>
<td>Antiphospholipid - IV</td>
</tr>
<tr>
<td></td>
<td></td>
<td>63</td>
<td>Arterial vascular disorders - IV</td>
</tr>
<tr>
<td></td>
<td></td>
<td>64</td>
<td>Diagnosis of venous thrombosis - V</td>
</tr>
<tr>
<td></td>
<td></td>
<td>65</td>
<td>Hormones, pregnancy, women’s issues - III</td>
</tr>
<tr>
<td></td>
<td></td>
<td>66</td>
<td>Inflammation: Clinical - II</td>
</tr>
<tr>
<td></td>
<td></td>
<td>67</td>
<td>Inherited risk factors venous thrombosis: Clinical</td>
</tr>
<tr>
<td></td>
<td></td>
<td>68</td>
<td>Paediatric thrombosis - III</td>
</tr>
<tr>
<td></td>
<td></td>
<td>69</td>
<td>Paediatric thrombosis - IV</td>
</tr>
<tr>
<td></td>
<td></td>
<td>70</td>
<td>Recurrent venous thrombosis - III</td>
</tr>
<tr>
<td></td>
<td></td>
<td>71</td>
<td>Regulation of gene expression in vascular cells</td>
</tr>
<tr>
<td></td>
<td></td>
<td>72</td>
<td>Thrombophilia - IV</td>
</tr>
<tr>
<td></td>
<td></td>
<td>73</td>
<td>Recurrent venous thrombosis - IV</td>
</tr>
<tr>
<td></td>
<td></td>
<td>74</td>
<td>Coagulation: Miscellaneous - II</td>
</tr>
</tbody>
</table>

Colorcode for ePoster Themes:

- Platelets
- Bleeding
- Coagulation
- Thrombosis
### ePosters information

**Thursday**

#### Screen no. | Session title
--- | ---
01 | New antiplatelet agents - I
02 | Platelet activation: New pathways
03 | Platelets and leukocytes
04 | Thrombocytopenia models
05 | Genetic platelet disorders - II
06 | ADAMTS13: Basic - II
07 | Haemophilia A: Clinical - XIII
08 | Heparin and heparinoids - II
09 | Von Willebrand factor - VI
10 | Anticoagulant agents - XVII
11 | Blood coagulation tests - XIV
12 | Coagulation factor V
13 | Coagulation factor VIII - VI
14 | Extrinsic pathway of coagulation
15 | Factor XIII
16 | Diagnosis of venous thrombosis - VI
17 | Disseminated intravascular coagulation thrombosis
18 | Inherited risk factors venous thrombosis
19 | TTP/Thrombotic microangiopathies - II
20 | Vessel wall

#### Screen no. | Session title
--- | ---
21 | New antiplatelet agents - II
22 | Antiplatelet agents: Miscellaneous
23 | Platelet integrins - II
24 | New platelet agonists
25 | Thrombus formation - II
26 | Platelet activation mechanisms
27 | Platelet activation: Miscellaneous - II
28 | Platelet function in health and disease
29 | Acquired and immune thrombocytopenia
30 | Microparticles and disease - III
31 | Atherosclerosis: Risk factors
32 | Atherosclerosis: Miscellaneous - II
33 | Fibrinolytic system: Basic - IV
34 | Fibrinolytic system: Basic - V
35 | Haemophilia A: Basic - IV
36 | Haemophilia A: Clinical - XIV
37 | Haemophilia A: Clinical - XV
38 | Haemophilia A: Clinical - XVI
39 | Haemophilia A: Clinical - XVII
40 | Heparin-induced thrombocytopenia (HIT): Clinical - III
41 | Rare bleeding disorders - V
42 | Rare bleeding disorders - VI
43 | Von Willebrand disease: Clinical - V
44 | Von Willebrand disease: Clinical - VI
45 | Anticoagulant agents - XVIII
46 | Anticoagulant agents - XIX
47 | Anticoagulant agents - XX
48 | Anticoagulant agents - XXI
49 | Intrinsic pathway of coagulation
50 | Blood coagulation system - V
51 | Blood coagulation tests - XV
52 | Blood coagulation tests - XVI
53 | Blood coagulation tests - XVII
54 | Blood coagulation tests - XVIII
55 | Coagulation factor VIII
56 | Angiogenesis and arterial vascular disorders
57 | Fibrinogen/Fibrin - V
58 | Other coagulation factors - IV
59 | Regulation of coagulation and fibrinolysis - IV
60 | Cancer and thrombosis - X
61 | Cancer and thrombosis - XI
62 | Antiphospholipid - V
63 | Antiphospholipid - VI
64 | Arterial vascular disorders - V
65 | Hormones, pregnancy, women’s issues - IV
66 | Hormones, pregnancy, women’s issues - V
67 | Inflammation: Basic - III
68 | Inflammation: Clinical - III
69 | Non-inherited risk factors venous thrombosis - V
70 | Non-inherited risk factors venous thrombosis - VI
71 | Paediatric thrombosis - V
72 | Thrombophilia - V
73 | Thrombophilia - VI
74 | Fibrinolysis and FXIII

### Colorcode for ePoster Themes:

- **Green**: Platelets
- **Blue**: Bleeding
- **Red**: Coagulation
- **Orange**: Thrombosis
**General Information**

**Banking service**
The official currency in The Netherlands is the Euro (€). Foreign currencies can be exchanged to Euros at banks, which are usually open from Monday to Friday from 09:00 to 17:00. Cash dispensers are located inside the Congress centre and at the airport and railway stations.

**Business center**
Amsterdam RAI has its own Business Centre that provides the following services:
- Printing (including posters and business cards)
- Copying
- Faxing
- Scanning
- Laminating
- Binding
Furthermore, the Business Centre sells a wide range of office and ICT supplies. You can also ship small packages there.

The Business Centre is located in RAI Elicium’s passageway on Level -1 and is open from Monday to Friday from 09:00 – 17:00 hours
T : +31 (0)20 549 1602
E: businesscentre@rai.nl

**Climate**
The weather in Amsterdam in June/July is usually mild. The average temperature is around 19-25°C. However, a raincoat or umbrella for occasional showers may be useful.

**Congress bag**
The Congress bag will be distributed to registered participants at the Congress bag desk in the registration area.

**Congress news daily**
The ISTH 2013 Congress will feature a newspaper that will include Congress highlights. A new issue will be distributed each day from Monday to Thursday. It will also be available online and within the app.
Duplicating/recording
Any form of duplication (recording, audio taping, photography and video) of sessions, including ePoster presentations, is prohibited without the expressed written consent of the author and Congress organisers.

Electricity supply
Electricity in The Netherlands is supplied at 220V - 50Hz AC.

ISTH secretariat
The ISTH secretariat is located in room D201 (Elicium first floor)

ISTH 2013 President’s Room
The ISTH 2013 President’s Room is located in the Amsterdam Suite (1st floor Auditorium Centre)

Language
The official language during the congress is English.

Notepad & pen
A notepad & pen are included in the Congress bag.

Pocket programme
A pocket programme will be provided to participants upon registration.

Rules
Smoking policy: the ISTH 2013 congress is a non-smoking event. Mobile phones: delegates are expected to keep their mobile phones silenced in the room where scientific and educational sessions are being held, as well as during ePoster sessions.

State-of-the-Art book
Non-member participants can collect a State-of-Art book at the JTH stand in the exhibition area. ISTH members will receive the book via mail.
Shopping in Amsterdam
Most shops in Amsterdam are open from 09:00 to 18:00, Monday through Saturday. Shops in the city centre (around Dam Square) are also open on Sunday from 12:00 to 17:00. For more information about Amsterdam, please visit www.iamsterdam.com.

Amsterdam City Guide App
Make sure you don’t miss a thing during your visit to Amsterdam with the complete I Amsterdam City Guide app. This comprehensive guide puts the whole of the city at your fingertips. Easily find internationally renowned museums and attractions, explore local markets and quirky boutiques, or sample the local delicacies at Amsterdam’s best restaurants. From top tourist destinations and cultural events to the city’s hidden gems, the I Amsterdam City Guide is like having a local by your side as you discover everything the city has to offer. You can download the I Amsterdam app in the App Store or Android Market.

City, hotel and excursion information
For hotel, city and restaurant information, please visit the Welcome Desk. For excursion bookings go to the Social Events Desk. These desks are located in the Registration Area and will be open during the following hours:
Saturday, June 29 07:00 – 18:00
Sunday, June 30 07:00 – 19:00
Monday, July 1 09:00 – 20:00
Tuesday, July 2 09:00 – 18:00
Wednesday, July 3 09:00 – 18:00
Thursday, July 4 09:00 – 15:00

Dining out in Amsterdam & tipping
Restaurants usually open at 18:00, with busiest times between 20:00 and 22:00. Booking is recommended, particularly on Thursday, Friday and Saturday nights. It is customary to leave a gratuity of no more than 10% of the bill when eating out. For more information on booking restaurants, please visit: http://www.diningcity.com/en/amsterdam
Transportation in Amsterdam

Public transport ticket
A public transport ticket is included in your registration package and is valid on all public transport in Amsterdam. Your public transport ticket will be valid from Sunday until Thursday and allows you unlimited travel through Amsterdam - day or night - using the bus, tram, and metro (except trains). For more information about the public transportation in Amsterdam, please refer to the public transport map which is included in your Congress bag or visit http://en.gvb.nl/pages/home.aspx.

How to reach Amsterdam RAI?

By train
The Amsterdam RAI railway station is 300 metres from the RAI and offers direct connections with Duivendrecht, Amsterdam Amstel, Amsterdam Zuid and Schiphol railway stations.

By tram, metro and bus
Take the tram route 4 between the centre of Amsterdam, Amsterdam Central and the RAI (stop at Europaplein). From Amsterdam Central Station and Amsterdam Amstel station you can reach the RAI via metro 51 or bus 65.

Car parking
RAI parking stands are available for convenient and affordable parking. There is a car park situated directly alongside the A10 ring road. The car park is covered and can accommodate 2,300 vehicles. A one day pass costs €16.00.
## Future ISTH Congresses

<table>
<thead>
<tr>
<th>Meeting</th>
<th>President</th>
<th>Date</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>60th Annual SSC Meeting</td>
<td>Robert Montgomery</td>
<td>June 23 - 26, 2014</td>
<td>Milwaukee, WI, USA</td>
</tr>
<tr>
<td>XXV ISTH Congress and the 61st Annual SSC Meeting</td>
<td>Sam Schulman</td>
<td>June 20 - 25, 2015</td>
<td>Toronto, Canada</td>
</tr>
<tr>
<td>62nd Annual SSC Meeting</td>
<td>Jean-François Schved</td>
<td>2016</td>
<td>Montpellier, France</td>
</tr>
<tr>
<td>XXVI ISTH Congress and the 63rd Annual SSC Meeting</td>
<td>Johannes Oldenburg</td>
<td>2017</td>
<td>Berlin, Germany</td>
</tr>
<tr>
<td>XXVII ISTH Congress with 64th Annual SSC Meeting</td>
<td>Robert Medcalf</td>
<td>2019</td>
<td>Melbourne, Australia</td>
</tr>
</tbody>
</table>
Visit Us at Booth 500!

ISTH
2015 Congress
TORONTO JUNE 20-25
Reaching for Unprecedented Peaks
Advancing the future of care

Visit Baxter booth #100
See how Baxter has been leading advancements in the bleeding disorder community for the last 60 years.
Learn about our innovative portfolio of therapies and resources for clinicians and patients.

Join us for the ISTH Satellite Symposia
Learn new strategies to improve patient outcomes and advance standards of care for those living with haemophilia or haemophilia with inhibitors. Plus, discover innovative treatment options for coagulation disorders.

Sunday, June 30, 12:15–14:15
Prophylaxis in Haemophilia: Towards a World Without Bleeds
Amsterdam RAI Convention Centre, Elicium 1

Tuesday, July 2, 18:30–20:00
Concept to Clinic: Innovative Treatments for Coagulation Disorders
Amsterdam RAI Convention Centre, Elicium 1
Social Programme
Social Programme

Opening Ceremony and Welcome Reception
Sunday, June 30, 2013
Time: 18:30 – 21:30
Venue: Amsterdam RAI Congress Centre

The opening ceremony takes place in the plenary hall (Mondriaan I) in the congress centre. Besides official opening speeches, there will be a selection of typical Dutch entertainment and performance.

Cultural Evening
Tuesday, July 2, 2013
Time: 21:00 – 22:30
Venue: Concertgebouw/Concerthall (Concertgebouwplein 10)
Price per person: € 60.- (Please check at the Social Event Desk for tickets)

The cultural evening will be held in the Concertgebouw, which was built in 1888 and is considered one of the finest concert halls in the world. During the evening, classical and jazz music will be performed.
Social Programme

All Congress Party  
Wednesday, July 3, 2013  
Time: 19:00 – 01:00  
Venue: Beurs van Berlage [Damrak 243]  
Price per person: € 50.- [Please check at the Social Event Desk for tickets]

At the end of three days of sharing ideas, discussions will continue during the ‘All Congress Party’ in a typical Dutch venue. During this event there will be music from lounge to rock, there will be all types of entertainment and Dutch food will be served. The evening will take place in the Beurs van Berlage, the former Amsterdam Stock Exchange. The building was designed by the famous Dutch architect Hendrik Berlage (1856-1934).

Notes:
- None of the listed events are industry supported
- Social events are only open to individuals who are registered [including accompanying persons] with a ticket [if applicable]
Since 1972, *Thrombosis Research* has rapidly disseminated new information on thrombosis, hemostasis, and vascular biology to advance science and clinical care. Alongside original research, the journal has gained a reputation for publishing insightful review articles and the editors welcome new review article submissions.

Rapid publication, fast peer-review, established editorial expertise and a large online readership mark this journal out as one of the primary resources for both basic and clinical studies.

**Sign up for free article alerts!**

Stay up-to-date with the latest articles in your field, visit the journal website and register your preferences.

---

**Top 5 Most Cited Articles – 2008–2011**

*Provided by Scopus*

1. Enoxaparin for neonatal thrombosis: A call for a higher dose for neonates • Review article

2. Retrievable vena cava filters: Key considerations • Review article
   Volume 122, Issue 4, 2008 • Imberti, D., Prisco, D.

3. Emerging roles of fibronectin in thrombosis • Review article
   Volume 125, Issue 4, 2010 • Maurer, L.M., Tomasini-Johansson, B.R., Mosher, D.F.

4. Assessing outcome measures of oral anticoagulation management in children • Review article
   Volume 127, Issue 2, 2011 • Jones, S., Newall, F., Manias, E., Monagle, P.

5. History of rFVIIa therapy • Review article
   Volume 125, Suppl. 1, 2010 • Hedner, U.
Bleeding emergencies: strategies for the reversal of old- and new-generation oral anticoagulants

Please visit us at booth 450

Chairs’ welcome

Ingrid Pabinger (Austria) and Jerrold Levy (USA)

Efficacy of prothrombin complex concentrate (Beriplex®) compared with plasma in emergency warfarin reversal: insights from a randomised trial

Ravi Sarode (USA)

Pharmacology and safety of new oral anticoagulants – the challenge of bleeding persists

Jerrold Levy (USA)

Prothrombin complex concentrate as a reversal agent for new oral anticoagulants – lessons from preclinical models

Gerhard Dickneite (Germany)

Bleeding with new oral anticoagulants – clinical presentation and approach

Elise Eerenberg (the Netherlands)

Treatment of ICH due to new oral anticoagulants – a neurologist’s view

Roland Veltkamp (Germany)

Closing remarks

Ingrid Pabinger (Austria) and Jerrold Levy (USA)

Monday 1 July 2013, 18:30–20:00
The Forum, Amsterdam RAI, Amsterdam, the Netherlands

CSL Behring-sponsored satellite symposium at the XXIV Congress of the International Society on Thrombosis and Haemostasis
INDEX

Akita N., PB 1.58-2, PB 3.58-4
Akita M., PB 1.61-1, PB 4.69-5
Akiyama N., PA 4.17-1
Akkawat B., PO 026
Akkerman J.W.N., OC 45.1, OC 55.4
Akría L., PO 359
Aksu B.C., PO 253
Aktay Ayaz N., PB 4.41-6, PB 4.71-1, PO 098
Akyüz F., PO 353
Al Dieri R., PA 1.11-4, PA 1.11-5, PA 1.18-2, PA 4.09-3, PA 4.12.6, PB 1.51-1, PB 2.42-4, PB 4.47-5
Al Farsi H., PA 1.19-1, PA 2.16-6
Al Hinai K., PB 4.71-6, PO 440
Al Musa A., PO 382
Al Saleh M., PO 440
Al Shimairi M., PO 443
Al Zoebie A., PO 150
Ala F., PB 4.43-1
Alame G., AS 07.1
Alamelu J., PB 3.25-3
Alanis E.F., PB 1.39-2
Alarcón M., PB 4.21-2
Alatri A., PO 279
Alatsaki A., PB 4.57-3
Alba L., PO 299
Alban S., PB 3.74-3
Albanese J., OC 17.2, PB 3.30-6
Albánész S., OC 65.5, PB 1.44-3, PO 144
Alber K., PA 4.19-3
Alberdi L., OC 46.1, PB 1.59-5
Alberelli M.A., OC 89.4
Albers C.A., PA 2.04-2, AS 47.6
Albers-Akkers M., PB 4.69-3
Albert A., PA 3.13-5
Albert M.A., OC 45.3
Alberto M.F., PB 1.60-4
Alberto D., PO 214
Alberto M.F., PB 2.28-5, PO 308, PO 438
Albisetti M., SC15-2.04, PB 1.41-5
Albrecht M., PB 2.24-5
Albright A.R., PB 4.24-1, PB 4.24-4
Al-Buhairan A.M., OC 13.4
Alcada J., OC 52.1
Aldrovandi M., PB 2.50-5
Aleem A., PO 357
Aleksandrova E., PA 1.18-1
Aleksseva P., PB 4.48-4
Aléman M., OC 49.3
Alectrona S., PB 2.40-6
Alews R., PO 214
Alewaeters A., PB 1.47-6
Alewaeters A., PB 4.32-3
Alessandrello Liotta A., PB 1.34-6, PB 4.32-3
Alessi M-C., AS 15.1, OC 10.2, OC 62.1, OC 76.2, OC 89.2, OC 90.1, PA 1.01-2, PB 1.67-1, PA 3.18-4, PB 3.25-1, PB 4.29-3
Alessia B., PB 2.62-2
Alewaeters A., PB 4.32-3
Alews R., PO 214
Alikhan R., PA 3.13-3
Alili J-M., PA 1.17-4
Alizadeh N., PB 3.61-4
Alizadeh S., PO 381
Alkin Z., PB 1.34-3
Allart S., OC 35.6
Allen G., PA 2.07-4, PA 2.07-6
Allen J., PB 1.60-6
Allen D.L., SC04.3-1.4
Almany S., AS 02.1
Al-Marwani A., OC 62.6
Almeida G.B.F., PO 188
Almholt K., PA 4.14-6
Almodaimegh H., PB 3.40-3
Almomen A.K., PO 357
Almusia A., PO 440
Alonso D., PB 3.33-3
Alonso R., PA 1.04-3
Alonso-Orza S., PB 2.27-2
Alotaibi G., PB 3.40-3
Alpoim P.N., PB 2.31-2, PB 4.65-2
Airifai M., OC 90.6, PB 2.72-5, PB 4.65-6, PO 203
Alsahi M.A., OC 64.6, PA 3.04-2, PB 2.26-3
Alsalm A., PB 3.40-3
Al-Sharaidh A., PA 2.09-6
Al-Subaie A., OC 88.2
Altayeb T., PB 3.61-5
Altsen Roca C., PB 3.36-1
Alunno A., PB 2.68-2
Alvarado C., PB 2.67-5
Alvarez M.T., PB 1.25-1
Alvarez-Hernandez M., PA 2.16-5
Alves M.T., PB 3.21-6
Alvez America R., PB 4.26-6
Alwis I., PB 3.50-3
Alwis I., OC 45.2, PA 4.03-1, PA 4.03-3
Aly M., PA 4.04-4
Alyami N.H., PA 3.09-4
Alzahrani S., PA 3.12-3, PB 3.59-1
Amadio P., PA 2.15-5, PA 3.12-1, PB 3.29-5
Amal A., PO 440
Amanat S., PB 3.41-2, PO 437
Amano K., OC 14.1, OC 37.6, PA 1.08-6
Amano Y., PA 4.05-6
Amano K., PB 2.44-4, PB 2.54-5, PB 2.69-3
Amato M., PA 2.15-5
Ambaglio C., OC 14.2, PO 012
Ambly A., PB 3.27-2
Ambros R., PB 1.49-5
Ambrosino P., PA 2.20-4
<table>
<thead>
<tr>
<th>Name</th>
<th>Page Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amedei A.</td>
<td>PB 1.67-2</td>
</tr>
<tr>
<td>Amedro P.</td>
<td>PB 4.71-5</td>
</tr>
<tr>
<td>Ámengual O.</td>
<td>PB 1.62-1</td>
</tr>
<tr>
<td>Amer A.</td>
<td>OC 01.1</td>
</tr>
<tr>
<td>Amiral J.</td>
<td>PA 3.08-5, PB 3.48-4</td>
</tr>
<tr>
<td>Amirkhosravi A.</td>
<td>AS 38.1, AS 39.3</td>
</tr>
<tr>
<td>Amison R.</td>
<td>PA 2.03-6</td>
</tr>
<tr>
<td>Amisten S.</td>
<td>PB 2.26-5</td>
</tr>
<tr>
<td>Ammollo C.T.C.</td>
<td>OC 84.5, OC 85.2, PB 2.72-1</td>
</tr>
<tr>
<td>Ammollo T.</td>
<td>PO 218</td>
</tr>
<tr>
<td>Amoio P.</td>
<td>PB 1.36-1</td>
</tr>
<tr>
<td>Amoresano S.</td>
<td>PA 1.13-2</td>
</tr>
<tr>
<td>AMUSE study group</td>
<td>PA 4.16-6</td>
</tr>
<tr>
<td>Anastasopoulou I.</td>
<td>PB 1.74-1</td>
</tr>
<tr>
<td>Ander C.</td>
<td>PB 4.56-6, PO 457</td>
</tr>
<tr>
<td>Andersen E.</td>
<td>PB 1.37-6</td>
</tr>
<tr>
<td>Andersen G.</td>
<td>PB 1.21-5</td>
</tr>
<tr>
<td>Andersen I.</td>
<td>PO 170</td>
</tr>
<tr>
<td>Andersen J.</td>
<td>PB 1.74-5</td>
</tr>
<tr>
<td>Andersen J.F.</td>
<td>PB 4.59-2</td>
</tr>
<tr>
<td>Anderson D.</td>
<td>OC 12.3</td>
</tr>
<tr>
<td>Anderson E.J.D.</td>
<td>OC 26.4</td>
</tr>
<tr>
<td>Anderson L.T.</td>
<td>NS 01.1</td>
</tr>
<tr>
<td>Anderson Jr A.F.</td>
<td>PB 3.48-1</td>
</tr>
<tr>
<td>Andersson H.M.H.</td>
<td>PA 1.15-5</td>
</tr>
<tr>
<td>Andjelkovic N.</td>
<td>PB 4.66-5</td>
</tr>
<tr>
<td>Ando Y.</td>
<td>OC 78.4, PA 2.13-5, PB 3.67-1, PB 4.58-4</td>
</tr>
<tr>
<td>Andoskin A.P.</td>
<td>PB 2.24-4</td>
</tr>
<tr>
<td>András B.</td>
<td>PA 4.15-3</td>
</tr>
<tr>
<td>André P.</td>
<td>OC 76.3, PA 4.02-2</td>
</tr>
<tr>
<td>André S.</td>
<td>OC 56.1</td>
</tr>
<tr>
<td>Andreano A.</td>
<td>PB 1.69-3</td>
</tr>
<tr>
<td>Andreeva T.</td>
<td>OC 83.2, PB 1.37-6, PO 150</td>
</tr>
<tr>
<td>Androni F.</td>
<td>AS 44.2</td>
</tr>
<tr>
<td>Andreou A.P.</td>
<td>AS 41.3</td>
</tr>
<tr>
<td>Andresen M.</td>
<td>PA 4.14-4</td>
</tr>
<tr>
<td>Andrews R.K.</td>
<td>SC07-2.01, OC 76.1, PA 2.18-6, PB 2.23-4</td>
</tr>
<tr>
<td>Andrýs C.</td>
<td>PB 1.26-4, PB 4.62-6</td>
</tr>
<tr>
<td>Anfosso F.</td>
<td>OC 26.3</td>
</tr>
<tr>
<td>Anghaisuksiri P.</td>
<td>PA 4.07-5</td>
</tr>
<tr>
<td>Angelescu S.</td>
<td>PO 361</td>
</tr>
<tr>
<td>Angelillo-Scherrer A.</td>
<td>AS 03, AS 03.1, PA 1.15-2, PA 1.15-3, PB 2.56-1, PB 4.51-3</td>
</tr>
<tr>
<td>Anggahini D.W.</td>
<td>PB 3.74-5</td>
</tr>
<tr>
<td>Angiolillo D.J.</td>
<td>SOA 10.1, SOA 10</td>
</tr>
<tr>
<td>Anglés-Canó E.</td>
<td>SC05-1.03, SC05-2.01, PB 2.73-5</td>
</tr>
<tr>
<td>Aniorte S.</td>
<td>OC 47.4</td>
</tr>
<tr>
<td>Anjos J.C.</td>
<td>PB 3.64-5</td>
</tr>
<tr>
<td>Anna A.</td>
<td>PB 2.54-4</td>
</tr>
<tr>
<td>Anneta E.S.</td>
<td>PB 1.43-6, PB 1.71-1, PB 1.71-3, PO 303</td>
</tr>
<tr>
<td>Annichino-Bizzacchi J.M.</td>
<td>OC 08.5, PA 1.17-5, PA 4.19-5, PB 2.55-2, PB 4.68-4, PB 4.68-6, PO 084</td>
</tr>
<tr>
<td>Anonucci E.</td>
<td>OC 42.2, OC 42.3, PB 1.34-6, PB 2.49-1, PB 4.33-1, PO 254</td>
</tr>
<tr>
<td>Antonic A.</td>
<td>SC05-2.02, OC 48.4, PA 1.18-3, PB 4.72-3</td>
</tr>
<tr>
<td>Antonic J.P.</td>
<td>SC05-2.02, SC16-3.02, AS 02.3, OC 48.4, PA 1.18-3, PB 1.28-6, PB 1.40-5, PB 4.66-5, PO 085</td>
</tr>
<tr>
<td>Antunes S.</td>
<td>PB 2.58-5, PB 4.58-6</td>
</tr>
<tr>
<td>Anvari M.</td>
<td>PB 3.46-3</td>
</tr>
<tr>
<td>Apak H.</td>
<td>PO 331</td>
</tr>
<tr>
<td>Æpeler H.</td>
<td>PA 2.11-5</td>
</tr>
<tr>
<td>Apitz-Castro R.</td>
<td>PA 2.11-1</td>
</tr>
<tr>
<td>Apostoli G.</td>
<td>PA 4.01-6</td>
</tr>
<tr>
<td>Apostolovska R.</td>
<td>PO 002, PO 215</td>
</tr>
<tr>
<td>Appa R.S.</td>
<td>OC 28.5, PA 2.12-4</td>
</tr>
<tr>
<td>Appapiazza P.</td>
<td>PO 377</td>
</tr>
<tr>
<td>Appiah A.</td>
<td>OC 61.3</td>
</tr>
<tr>
<td>Appleby J.</td>
<td>PB 2.26-3</td>
</tr>
<tr>
<td>Appleby N.</td>
<td>PB 2.49-2</td>
</tr>
<tr>
<td>Apte S.</td>
<td>OC 37.2, PA 2.07-4, PA 4.07-2</td>
</tr>
<tr>
<td>Ar C.M.</td>
<td>PB 4.37-4, PO 101</td>
</tr>
<tr>
<td>Arabi A.</td>
<td>PO 020</td>
</tr>
<tr>
<td>Arai R.</td>
<td>PB 1.60-5</td>
</tr>
<tr>
<td>Aranda E.</td>
<td>PB 3.25-5</td>
</tr>
<tr>
<td>Aranda F.</td>
<td>PB 4.31-5</td>
</tr>
<tr>
<td>Aranguren J.L.</td>
<td>PB 3.45-2</td>
</tr>
<tr>
<td>Aras N.</td>
<td>PB 1.35-4</td>
</tr>
<tr>
<td>Arata P.</td>
<td>PO 250</td>
</tr>
<tr>
<td>Araujo F.</td>
<td>PO 035, PO 180</td>
</tr>
<tr>
<td>Araya E.</td>
<td>PB 3.25-5</td>
</tr>
<tr>
<td>Arbues I.</td>
<td>AS 31.1</td>
</tr>
<tr>
<td>Arbues Y Mar A.</td>
<td>OC 38.5</td>
</tr>
<tr>
<td>Arbring K.</td>
<td>PB 2.49-6</td>
</tr>
<tr>
<td>Archer R.</td>
<td>PB 3.62-6</td>
</tr>
<tr>
<td>Arcos M.J.</td>
<td>PO 389</td>
</tr>
<tr>
<td>Arcovito A.</td>
<td>OC 27.2, OC 39.1</td>
</tr>
<tr>
<td>Arderiu G.</td>
<td>OC 01.5</td>
</tr>
<tr>
<td>Ardeshiri R.</td>
<td>PO 054</td>
</tr>
<tr>
<td>Ardillon L.</td>
<td>PO 010</td>
</tr>
<tr>
<td>Arellano A.R.</td>
<td>AS 18.1</td>
</tr>
<tr>
<td>Arellano-Rodrigo E.</td>
<td>PA 3.10-6, PB 4.47-2</td>
</tr>
<tr>
<td>Arepally G.M.G.</td>
<td>OC 21.1</td>
</tr>
<tr>
<td>Arghirescu S.</td>
<td>PO 410</td>
</tr>
<tr>
<td>Arias D.</td>
<td>PO 161</td>
</tr>
<tr>
<td>Ariyawansa J.</td>
<td>PA 2.10-2, PA 3.10-5</td>
</tr>
<tr>
<td>Ariza L.</td>
<td>PB 1.70-2</td>
</tr>
<tr>
<td>Armand M.</td>
<td>AS 26.3</td>
</tr>
<tr>
<td>Armillis A.</td>
<td>OC 08.2, OC 29.4</td>
</tr>
<tr>
<td>Armour L.K.</td>
<td>OC 35.1</td>
</tr>
<tr>
<td>Armstrong P.E.</td>
<td>PB 1.35-6, PB 1.37-4</td>
</tr>
<tr>
<td>Arnar D.O.</td>
<td>PA 4.10-2</td>
</tr>
<tr>
<td>Arnborg F.</td>
<td>PB 1.45-4</td>
</tr>
<tr>
<td>Arndt J.</td>
<td>PA 4.13-1</td>
</tr>
<tr>
<td>Arnesen H.</td>
<td>PB 1.21-5</td>
</tr>
<tr>
<td>Arnett B.</td>
<td>PB 1.59-6</td>
</tr>
<tr>
<td>Arning A.</td>
<td>PB 1.68-1</td>
</tr>
<tr>
<td>Arnold A.</td>
<td>PA 2.15-3</td>
</tr>
<tr>
<td>Arnold M.D.</td>
<td>SC04.2-1.1, OC 36.3</td>
</tr>
<tr>
<td>Arnoldussen C.W.K.P.</td>
<td>PB 2.64-4, PO 241</td>
</tr>
<tr>
<td>Arocas V.</td>
<td>OC 01.6, OC 54.5</td>
</tr>
<tr>
<td>Aronow B.</td>
<td>AS 46.4</td>
</tr>
</tbody>
</table>
INDEX

Arraud N., AS 14.3
Arroyo A.B., OC 05.4, OC 08.1
Arruda V.R., AS 34.3, OC 31.4, OC 50.2, PB 4.35-1
Arsenyev A., PB 1.73-5
Arshad F., PB 1.46-5
Arteaga A., PO 161
Artemenko E., PA 1.11-2, PA 3.15-3, PB 3.27-3
Arthur J.F.J., PB 2.23-4
Artoni A., PA 2.16-4, PA 3.05-6, PA 4.19-2, PB 2.25-5, PB 3.53-1, PB 4.30-3, PO 024
Arvind P., PB 1.73-3, PB 4.31-6, PO 474, PO 477, PO 478
Arya R., OC 61.3, PA 3.20-2, PB 2.51-3, PB 2.52-6
Asada Y., OC 43.3, PA 3.02-5, PB 1.73-1
Asada Y., PB 3.55-1, PB 3.63-3
Asai F., PB 2.45-6
Asai M., PB 2.34-2, PB 3.34-6
Asayama H., PA 1.06-2
Asfar P., PB 1.46-5
Ashby S., PB 1.66-5
Ashikaga T., PB 1.61-1, PB 4.69-5
Ashrafian H., PB 3.71-2
Ashwell T., PB 4.57-5
Ashworth K., PA 4.03-1
Ashworth T., OC 83.4, PB 1.58-1, PB 3.58-2
Askanlan R., PB 3.69-5
Aslam A., PA 2.01-3, PA 4.04-4
Aspenberg W.F., PB 2.59-3
Asselbergs W.F., PB 2.22-1
Asselma R., OC 50.3, PA 4.12-4, PB 2.57-4
Assendelft W.J., PB 2.74.5
Assie G., PB 2.66-2
Aster R., PA 4.04-4
Astermark J., AS 22.1, OC 03.3, PB 2.38-5, PB 4.38-2, SPS02-06
Åström M., PA 4.05-1
Astudillo L., PB 4.21-2
Ataga K.I.K., OC 44.4
Atalar A., PO 442
Atalay S., PB 374
Atanasov V., PB 312
Atar S., PO 359
Ataullakhanov F., OC 10.2, OC 67.4, PA 1.12-6, PB 1.51-6, PB 4.59-2, PB 4.59-5, PO 077, PA 1.11-2, PA 3.15-3, PB 1.52-3, PB 2.50-1, PB 2.51-6, PB 2.53-3, PB 2.53-5, PB 3.27-3, PB 3.51-6, PB 3.52-2, PB 4.27-4, PB 4.34-4, PB 4.36-4, PB 4.54-3, PB 4.74-1, PB 4.74-1
Atkinson H.M., PA 2.19-2, PA 4.08-4, PB 3.34-4
Aubrey R., PO 474, PO 477, PO 478
Auda A., PB 3.50-3
Auer P., OC 65.5
Auer W., PA 1.12-5
Averswald G., PA 2.06-2, PB 2.37-5, PB 3.37-4, PO 383
Augustsson C., OC 83.1, PA 2.14-1, PA 4.14-2
Aujesky D., PA 2.10-4, PA 2.18-1, PB 2.56-1, PB 4.51-3
Auserswald G., PA 2.06-1
Austin S., PA 2.08-6, PA 4.05-3, PB 1.74-3, PB 2.44-2, PB 2.54-1, PB 3.25-3, PO 190
Authi K.S., PB 3.27-2
Avagliano L., PA 3.17-2
Avagyan A., PB 4.71-3
Avetisyan M., PO 399
Avila M., AS 06.1, FS 02.2
Averbukh Y., PA 3.01-3
Avery G., PB 3.60-3
Avdak O., PB 4.36-2
Aviño A., PB 3.72-1
Ayakata T., PB 1.72-4
Aydin A., PB 4.36-2
Aydin S.O., PB 4.37-4
Aydogan G., PB 4.41-6, PB 4.71-1, PO 098
Azadi A., PB 293
Azar-Avivi S., PB 3.36-1, PB 4.35-4
Azarbal A.F., PB 3.72-1
Azevedo A.P., PO 036, PO 255
Azevedo J., PO 047
Azevedo M., PA 1.15-2, PA 1.15-3
Aziken M., PO 392
Aznar J.A., PA 3.11-4, PB 1.38-3, PB 2.37-3, PB 2.69-1, PB 2.69-2, PO 021
Aznar M., PO 299
Azuma Y., OC 69.3
Azzazene D., PA 1.19-1, PA 2.16-6
Baader S., PO 288
Baaij M., PA 2.08-4, PB 3.44-5
Baas M-J., PA 3.41-1
Baaten C., OC 11.3, PB 3.60-2
Babay Z.A.H., PA 2.09-6
Babok-Flegaric R., PO 284
Babu S., PB 2.73-1, PB 2.73-3
Baccini V., OC 76.2, PB 3.25-1, PB 4.29-3
Baccouche H., PB 2.45-5, PO 003, PO 094, PO 405
Bach R., PB 4.68-3
Bachelot-Loza C., PA 1.08-4, PB 1.26-6
Bachman B., OC 58.1
Bachmann L.M., PO 022
Bachti A., PA 1.03-5
Bäckhed F., OC 01.4
Badiei N., PB 1.57-2, PB 2.50-2
Badimon L., OC 01.5, PA 1.04-3, PB 3.32-5
Badlou B., PO 486
Bae O-N., PB 4.21-4
Bae S.H., PB 4.69-6
Bagby S., OC 09.6
<table>
<thead>
<tr>
<th>Name</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bagger M.</td>
<td>PB 1.55-2</td>
</tr>
<tr>
<td>Bagheai F.</td>
<td>PB 2.38-5</td>
</tr>
<tr>
<td>Baghaipour M.R.</td>
<td>PB 1.50-6, PB 4.42-5, PB 4.43-1</td>
</tr>
<tr>
<td>Baglin C.A.C.</td>
<td>SOA 13.1, PB 2.71-2, PB 3.73-2, PO 490, PO 492</td>
</tr>
<tr>
<td>Bagoly Z.</td>
<td>PA 1.01-4, PA 3.06-1, PA 4.15-5</td>
</tr>
<tr>
<td>Bagot C.</td>
<td>OC 61.3, PB 1.51-5</td>
</tr>
<tr>
<td>Baguley B.</td>
<td>PB 3.29-3</td>
</tr>
<tr>
<td>Bahlo M.</td>
<td>OC 89.5</td>
</tr>
<tr>
<td>Bai X.</td>
<td>PA 4.19-4, PO 088</td>
</tr>
<tr>
<td>Bai S.</td>
<td>PB 3.56-5</td>
</tr>
<tr>
<td>Bailey R.L.</td>
<td>AS 27.2</td>
</tr>
<tr>
<td>Bailey J.</td>
<td>NS 01.3</td>
</tr>
<tr>
<td>Baillie E.</td>
<td>OC 81.6</td>
</tr>
<tr>
<td>Bailleil S.</td>
<td>PB 2.41-6</td>
</tr>
<tr>
<td>Bailly N.</td>
<td>PB 1.60-3, PB 4.40-3</td>
</tr>
<tr>
<td>Baird C.</td>
<td>PB 4.70-4</td>
</tr>
<tr>
<td>Baisong M.</td>
<td>PB 4.55-4</td>
</tr>
<tr>
<td>Bajaj P.</td>
<td>OC 18.4</td>
</tr>
<tr>
<td>Bajd F.</td>
<td>PB 2.34-4</td>
</tr>
<tr>
<td>Bajetta M.T.</td>
<td>PB 3.33-4</td>
</tr>
<tr>
<td>Bajolle F.</td>
<td>PB 4.71-5</td>
</tr>
<tr>
<td>Bakchoul T.</td>
<td>SC04.3-1.2, SC04.3.1.7, OC 55.1, OC 55.6, PA 3.08-5</td>
</tr>
<tr>
<td>Baker J.N.</td>
<td>PA 2.18-4</td>
</tr>
<tr>
<td>Baker R.</td>
<td>OC 77.4, PB 1.33-3</td>
</tr>
<tr>
<td>Baker S.</td>
<td>OC 64.1, OC 82.6, PB 4.25-5</td>
</tr>
<tr>
<td>Bakhos M.</td>
<td>PA 4.08-5, PB 1.49-4, PB 3.39-1, PB 4.40-2</td>
</tr>
<tr>
<td>Bakhru S.</td>
<td>AS 47.1</td>
</tr>
<tr>
<td>Bakhtiari K.</td>
<td>OC 18.2, OC 69.4</td>
</tr>
<tr>
<td>Bakker B.</td>
<td>OC 59.4</td>
</tr>
<tr>
<td>Bakker L.</td>
<td>PB 2.67-1</td>
</tr>
<tr>
<td>Bal dit Sollier C.</td>
<td>OC 07.3, PB 1.63-4, PB 3.63-4</td>
</tr>
<tr>
<td>Balachandran S.</td>
<td>PB 1.50-3, PB 1.54-5</td>
</tr>
<tr>
<td>Balan A.M.</td>
<td>PO 410</td>
</tr>
<tr>
<td>Balandina A.</td>
<td>PB 1.51-6, PB 1.52-3, PB 2.53-3, PB 3.51-6, PB 3.52-2, PB 4.36-4, PB 4.59-5, PO 384</td>
</tr>
<tr>
<td>Baldacci E.</td>
<td>PB 1.74-6, PB 4.42-2, PO 112, PO 429</td>
</tr>
<tr>
<td>Baldassarre D.</td>
<td>PA 2.15-5</td>
</tr>
<tr>
<td>Baldwin-Stoyanova A.</td>
<td>OC 51.3</td>
</tr>
<tr>
<td>Baldo C.</td>
<td>PA 4.10-1</td>
</tr>
<tr>
<td>Balducchi J-P.</td>
<td>PB 3.65-2, PB 4.65-1, PB 4.66-3</td>
</tr>
<tr>
<td>Balduini A.</td>
<td>PB 1.29-1</td>
</tr>
<tr>
<td>Balduini C.</td>
<td>OC 34.5, OC 89.4, OC 35.4</td>
</tr>
<tr>
<td>Balen S.</td>
<td>PO 172</td>
</tr>
<tr>
<td>Balestra D.</td>
<td>OC 50.2, OC 50.3, PB 1.39-2</td>
</tr>
<tr>
<td>Balestrino M.</td>
<td>PB 2.31-6</td>
</tr>
<tr>
<td>Balkan C.</td>
<td>PB 499, PB 4.40-6, PO 102</td>
</tr>
<tr>
<td>Balkanov A.</td>
<td>PO 052</td>
</tr>
<tr>
<td>Ballan K.</td>
<td>OC 35.1</td>
</tr>
<tr>
<td>Ballester C.</td>
<td>PB 1.30-1</td>
</tr>
<tr>
<td>Ballin A.</td>
<td>PB 4.66-4</td>
</tr>
<tr>
<td>Balling K.</td>
<td>OC 28.4</td>
</tr>
<tr>
<td>Ballmaier M.</td>
<td>PO 349</td>
</tr>
<tr>
<td>Balogh E.</td>
<td>OC 07.5</td>
</tr>
<tr>
<td>Balogh L.</td>
<td>OC 07.5, PA 2.01-2</td>
</tr>
<tr>
<td>Balooch S.</td>
<td>PO 344</td>
</tr>
<tr>
<td>Balzarotti R.</td>
<td>OC 59.1, PB 1.70-3</td>
</tr>
<tr>
<td>Bamber L.</td>
<td>AS 17.2, OC 02.6</td>
</tr>
<tr>
<td>Bamme J.</td>
<td>PB 4.63-3</td>
</tr>
<tr>
<td>Banerjee S.</td>
<td>PB 4.23-1</td>
</tr>
<tr>
<td>Banfi C.</td>
<td>PA 3.12-1, PB 3.32-2, PA 4.09-1</td>
</tr>
<tr>
<td>Bang A.</td>
<td>PA 1.02-2</td>
</tr>
<tr>
<td>Bang S-M.</td>
<td>OC 02.1, PB 4.46-1, PB 4.69-6</td>
</tr>
<tr>
<td>Bangertner M.</td>
<td>PO 202</td>
</tr>
<tr>
<td>Bank J.R.J.</td>
<td>PB 3.40-4</td>
</tr>
<tr>
<td>Bannish B.</td>
<td>PB 4.33-4</td>
</tr>
<tr>
<td>Banno F.</td>
<td>SC02-2.02, OC 47.3, PA 1.06-3, PA 4.06-6</td>
</tr>
<tr>
<td>Bannour I.</td>
<td>PB 1.25-4, PB 4.62-5</td>
</tr>
<tr>
<td>Bansal M.</td>
<td>PA 2.06-1</td>
</tr>
<tr>
<td>Bansal V.</td>
<td>PB 1.40-3, PB 4.68-5, PO 183, PO 259</td>
</tr>
<tr>
<td>Bao J.</td>
<td>PB 2.29-4</td>
</tr>
<tr>
<td>Baptista A.</td>
<td>PB 4.73-3</td>
</tr>
<tr>
<td>Baques A.</td>
<td>PO 103</td>
</tr>
<tr>
<td>Baralle M.</td>
<td>OC 50.1</td>
</tr>
<tr>
<td>Baran B.</td>
<td>PB 3.67-4, PB 4.74-5</td>
</tr>
<tr>
<td>Barandon L.</td>
<td>PO 448</td>
</tr>
<tr>
<td>Barata C.</td>
<td>PB 4.73-3</td>
</tr>
<tr>
<td>Barbar S.</td>
<td>PA 3.19-3, PA 4.16-5, PB 4.70-3, PO 428</td>
</tr>
<tr>
<td>Barbara B.</td>
<td>PO 107</td>
</tr>
<tr>
<td>Barbarroja N.</td>
<td>OC 27.6</td>
</tr>
<tr>
<td>Barbieri S.S.</td>
<td>PA 2.15-5, PA 3.12-1, PB 3.29-5</td>
</tr>
<tr>
<td>Barbon G.</td>
<td>PA 1.09-1, PB 3.43-1</td>
</tr>
<tr>
<td>Barbu D.</td>
<td>PO 361</td>
</tr>
<tr>
<td>Barco S.</td>
<td>OC 79.6, PB 1.72-5, PB 2.61-6</td>
</tr>
<tr>
<td>Bardan S.</td>
<td>PB 2.12-5, PB 2.55-3</td>
</tr>
<tr>
<td>Barderas M.G.</td>
<td>PB 2.27-2</td>
</tr>
<tr>
<td>Bárdos H.</td>
<td>PA 4.15-3</td>
</tr>
<tr>
<td>Bardou P.</td>
<td>AS 23.2</td>
</tr>
<tr>
<td>Bare L.A.L.</td>
<td>AS 18.1</td>
</tr>
<tr>
<td>Bar-Ilvan A.</td>
<td>OC 83.6</td>
</tr>
<tr>
<td>Barillari G.</td>
<td>OC 02.1, PB 2.70-4, PB 3.60-6, PB 4.46-1</td>
</tr>
<tr>
<td>Bark D.</td>
<td>PA 4.03-3</td>
</tr>
<tr>
<td>Barkemeyer J.</td>
<td>OC 79.6</td>
</tr>
<tr>
<td>Barnabé A.</td>
<td>OC 08.5, PB 4.68-4, PB 4.68-6</td>
</tr>
<tr>
<td>Barnard R.</td>
<td>PB 1.21-6, PB 1.28-4, PB 2.63-4</td>
</tr>
<tr>
<td>Barnard J.</td>
<td>PA 2.05-2, PB 4.27-2</td>
</tr>
<tr>
<td>Barnes D.</td>
<td>AS 02.1</td>
</tr>
<tr>
<td>Barness R.</td>
<td>PB 1.25-6</td>
</tr>
<tr>
<td>Barnscheidt M.</td>
<td>PA 3.13-5</td>
</tr>
<tr>
<td>Barocci V.</td>
<td>PB 3.32-4</td>
</tr>
<tr>
<td>Baronciani L.</td>
<td>AS 32.2, OC 13.5, OC 39.1, PB 2.39-4, PB 2.43-6, PB 4.43-4</td>
</tr>
<tr>
<td>Barone F.</td>
<td>PB 1.74-6, PB 4.42-2</td>
</tr>
<tr>
<td>Baroni M.</td>
<td>AS 26.2, PA 1.08-2, PA 1.11-1, PB 3.32-3</td>
</tr>
<tr>
<td>Barquinero J.</td>
<td>PB 4.55-2</td>
</tr>
<tr>
<td>Barragan P.</td>
<td>PO 365</td>
</tr>
<tr>
<td>Barral F.-G.</td>
<td>AS 18.2</td>
</tr>
<tr>
<td>Barrera H.L.</td>
<td>PB 3.53-5, PB 4.51-5, PB 4.62-3, PB 4.63-1</td>
</tr>
<tr>
<td>Barrett E.N.</td>
<td>PB 1.23-3</td>
</tr>
<tr>
<td>Barrett B.</td>
<td>PB 3.35-5</td>
</tr>
<tr>
<td>Barry W.</td>
<td>PA 1.04-5, PA 3.13-1, PB 3.30-4</td>
</tr>
</tbody>
</table>
INDEX

Barsalou J., PB 3.62-1
Barsegov V., PA 1.14-1, PA 3.01-2
Barsela G., PB 1.30-3
Bartels M., PA 2.05-1
Barthet M.C., OC 90.1
Bartoli M., PA 1.04-4
Baruch D., PA 1.08-4, PB 3.29-1, PB 3.29-4
Barysenka A., PB 1.68-1
Basciano P., OC 34.5
Bascuñana J., AS 43.4
Bashari D., PO 492
Baslar Z., PB 4.37-4, PB 4.41-6
Basra G., PB 2.62-4, PB 3.62-4
Bassi L., PB 1.47-5, PB 1.54-3, PB 2.49-3, PB 2.53-2, PB 2.53-4, PB 2.66-4, PO 267, PO 268
Basler N., PB 4.24-3
Basso G., PB 3.57-6
Bastos L., PB 2.57-5
Bateman A.T., OC 70.3
Bates S.M., PB 1.64-5, PB 2.64-3
Bathija S., PB 3.48-5
Batlle J., PA 3.09-1, PB 2.42-6, PO 149
Batorova A., PA 1.08-2, PB 3.72-5, PO 154, PO 196
Battiston M., PA 3.02-1, PA 3.02-4, PB 1.29-1, PB 3.43-1
Batty P., PB 1.42-6, PB 1.55-1, PB 2.39-1, PB 2.54-1, PB 4.38-1
Becatti M., PB 2.27-6, PB 4.33-1, PB 4.74-3
Becattini C., AS 17, OC 59.1, PA 1.20-1, PB 1.49-2, PB 1.70-3
Becker T., PB 3.53-2
Beck F., PB 3.24-1
Beck O., AS 02.3, PB 3.51-4, PO 457
Becker C., PA 4.20-4
Becker K., PA 2.05-3
Becker R.C., AS 20.1, PB 4.26-5
Beckers L., AS 04.3
Beckers A.M., PA 4.04-6, PB 1.52-4
Beckman M.G., PB 2.71-3
Bedrosian C.L.C., PB 2.73-1, PB 2.73-3
Beenen L., OC 20.2, PA 1.20-2, PB 2.65-1
Beer J.H.J., PA 1.01-6, PB 4.28-4
Beer N., PB 4.34-6
Behrens C., OC 22.4, PA 2.12-4
Beijleveld- van der Zande M., PB 1.38-5
Bein G., OC 55.1
Bejo J., PB 2.45-3
Bekadja M.A., PO 020
Bel E.H., PB 2.68-1
Belaj K., PA 2.18-5, PB 3.63-2
Belda J.F., PB 4.58-5
Belen F.B., PB 3.42-5
BelFeki N., PO 094
Bell C., PB 1.66-5
Bellamy M., PB 2.56-5
Belleville T., PB 1.26-6
Bellinger D., OC 80.1
Bellomo R., PB 2.28-4
Bellucci S., PO 377
Belmont S., PA 3.09-2
Belova N., PO 415, PO 417
Beltran J., PB 4.54-1
Belvini D., OC 70.4
Belyavskaya O, PO 276
Bem D., OC 34.2
Ben Abdallah T., PB 1.25-4, PB 4.62-5, PO 387
Ben Halima A., PB 2.21-2, PB 2.21-5
Ben Mohamed W., PO 003
Ben Romdhane N., PB 2.45-5, PO 003, PO 094, PO 405
Ben Said M., PB 1.25-4, PB 4.62-5, PO 387
Benagiano M., PB 1.67-2
Benbarche S., PB 3.29-2
Benbir G., PB 4.64-4
Benchikh El Fegoun S., PO 129
Bendaoud H., PO 217
Bender M., AS 39.1, OC 33.2, OC 86.1, OC 88.6
Bendezú K., PB 4.31-5
Benedik-Dolnicar M., PO 298
Benedito M., PB 2.44-5, PO 047
Beneke H., PB 4.66-1, PO 202
Benet Campos C., PO 275
Benetos A., PB 2.17-2, PB 4.64-1
Bengtsson K., PB 4.25-2
Benkirane S., PO 380
INDEX

Bentaledj D., PO 020, PO 055, PO 063, PO 378, PO 423
Bennett A.S., OC 61.3, PB 2.52-6
Bennett C., OC 58.6
Bennett J.S., PA 3.01-2
Bennis Y., PA 1.04-4
Bensahli M., PO 020
Bensend T.A.T., AS 36.1
Bensen-Kennedy D., PB 3.37-5, PB 3.49-3
Ben-Shaul S., PB 1.30-3
Benslimane-Ahmim Z., PB 2.29-5
Benson G., PO 285
Benyon L., PO 006, PO 007
Benziane O., OC 19.3
Berckmans R., PB 1.30-2
Bereczky Z., OC 07.5, OC 78.2, OC 78.3, OC 90.3, PA 2.01-2, PB 3.67-5
Berezovskaya G., PO 456
Berg J.P., PA 3.04-3
Berg R., PB 4.39-4
Berge N., PB 3.63-4
Bergemalm D., PA 4.05-1
Bergendal A., OC 30.4
Bergentall M., OC 01.4
Berger A., OC 72.1, PA 1.04-6, PA 4.17-4
Berger J.S., PA 4.11-4, PB 4.26-5, PO 330
Berghöfer H., OC 91.3
Bergman G.E.G., PA 1.09-4
Bergmann F., PB 3.65-4, SPS11-02
Bergmeier W., AS 29.1, OC 17.4, OC 47.4, AS 11.1, AS 24.3, PB 2.69-1, PB 2.69-2
Berteluch A., PB 4.54-6
Bertin F.R., PA 3.03-6
Bertinato E., PB 1.69-3
Bertling A., PB 4.02-4, OC 51.4, PB 2.40-1
Bertoletti L., AS 17.3, PA 2.18-1, PA 4.16-3, PB 4.45-1
Bertomoro A., PA 1.09-1, PO 428
Bertozzo G., PB 1.47-2
Bertrand G., PA 2.05-6, PB 3.25-6
Bery L.R., OC 51.2
Besbes S., PA 1.19-1, PA 2.16-6
Beski S., PO 197
Besley D., AS 02.1
Bespalova Z., PO 228
Besser M., PB 4.52-3
Best G.L., PB 2.22-6
Bernal A., PB 4.27-6
Bernal W., PB 2.51-3
Bernardi D., PO 075
Bernardi E., AS 34.1
Bernardi F., AS 26.2, OC 50.2, OC 70.4, PA 1.08-2, PA 1.11-1, PB 1.39-2, PB 3.32-3
Bernardi M., PB 4.57-6
Bernardini L., PB 3.68-1
Bernat R., PB 4.31-4
Berndt M.C., OC 76.1, OC 86.5
Bernhagen J., PA 1.17-2
Bernhard H., PB 3.65-5
Bernini Ph.M., PB 3.37-1
Bert E., PB 3.30-6
Bernet D., PB 1.67-1
Berntorp E., PB 2.38-5, PB 3.51-3, PB 4.38-2, PB 4.42-1, PO 170, SAS03-05, SAS03-07
Berny-Lang M.A., OC 67.2, PB 1.28-4, PB 2.63-4
Beroald D., PO 365
Berra C.M., OC 25-1
Berrah A., PB 3.73-6
Berrou E., OC 39.2
Berruyer M., OC 81.2
Berry L.R., PA 2.18-3, PA 2.19-2, PA 4.08-1, PA 4.08-4, PB 3.34-4
Berthier A., PB 4.54-6
Berti R., PB 3.03-6
Bertinato E., PB 1.69-3
Bertling A., PB 4.02-4, OC 51.4, PB 2.40-1
Bertoletti L., AS 17.3, PA 2.18-1, PA 4.16-3, PB 4.45-1
Bertomoro A., PA 1.09-1, PO 428
Bertozzo G., PB 1.47-2
Bertrand G., PA 2.05-6, PB 3.25-6
Bery L.R., OC 51.2
Besbes S., PA 1.19-1, PA 2.16-6
Beski S., PO 197
Besley D., AS 02.1
Bespalova Z., PO 228
Besser M., PB 4.52-3
Best G.L., PB 2.22-6
Betapudi V., OC 40.1
Beugnet-Henaut C., PB 1.27-2
Bevan D., SAS01-02
Bevans C., OC 19.4
Bevers E.M., OC 11.3
Beyer-Westendorf J., AS 42.2, OC 02.1, PA 1.10-5, PA 3.08-1, PA 3.19-2, PB 1.70-4, PB 3.26-6, PB 4.40-1, PB 4.46-1, SPS06-05
Beyth R., SC16-1.04
Bez J., OC 07.2
Bezaa A., PO 010
Bezemer I.D., OC 47.2
Bezemer P., PA 3.17-4
Bezgal F., PO 442
Bezieau S., OC 13.2
Bhakta V., OC 36.3
Bhasker D., PB 4.32-1, PO 475, PO 476, PO 477
Bhatt D.L., PA 2.05-2, PB 4.27-2
Bhatt S.H., PO 185, PB 1.40-1
Bhurhirun T., PB 3.64-4
Bianchi F., PA 2.05-6
Bianchini E.P., AS 26.3
Biasoli C., PB 2.41-3, PB 4.49-5
Biasoli I., PA 2.20-6, PB 1.72-3
Bichan V.D., PO 309
Bichenkov O., PO 052
Bichler J., PB 2.36-3
Bickeboeller-Friedrich J., PO 398
Bicocchi M.P., PO 111
Biddingmaier C., AS 22.2
Bièche I., OC 40.2
Bielczyk-Maczynska E.K., OC 33.2
Biemond B.J., OC 08.3, PA 1.16-2, PB 2.61-6
Bierings R., AS 37.2, OC 91.1, OC 91.6, PA 2.09-3
Bierman W.F., PB 4.68-1
Biesma D.H., PA 1.07-1, PA 1.07-5
Biguzzi E., PB 3.09-6, PB 1.33-6, PB 2.39-4, PB 2.41-5, PB 4.43-4
Bihan D., PA 2.09-5, PA 3.02-3, PA 3.02-3, PB 1.22-3, PB 1.31-3
Bihan D.G., PB 1.23-2
INDEX

Bilen O., PO 305
Bilir P., PB 2.38-3
Bilodeau M.L., OC 26.1
Bilora F., PA 4.16-5
Binard S., OC 89.2
Binder N.B., PB 3.52-3, PO 044
Binetti N., PB 1.63-6
Binhama T., PB 1.42-3
Biradar S., PB 1.32-4, PO 473
Biringer K., PB 2.54-4, PB 4.65-5, PO 204
Birnbaumer L., OC 11.2
Birner-Gruenberger R., PB 3.24-3
Biron-Andreani C., PB 4.60-6
Birschmann L., PB 3.74-3
Bishop J., PB 2.39-5
Bison E., PB 1.62-3, PB 2.62-2
Biss T., PB 2.35-6
Biswas I., PA 1.19-2, PA 4.09-4
Bitonti A.J., OC 80.2
Bitsadze V., PO 017
Bode C., OC 78.2, OC 78.3
Bode A., PA 3.18-6, PA 4.12-6
Bode H., OC 77.2
Bode J., PA 3.16-6
Boekema E., PO 438
Boe A.E., AS 23.1, PA 2.17-1
Boehlen F., FS 01.2, OC 27.1, PB 1.40-6, PB 2.57-1
Boehm E., PB 1.39-6
Boehncke W.-H., PB 3.39-5, PB 3.39-6
Boer H., OC 04.4
Boey R., PB 3.50-6
Boffa M.B., SC05-2.08, OC 84.6, PA 2.14-5
Bogdanic D.H., PB 4.65-4
Bogdanov V.Y., AS 46.3, AS 46.4, PB 3.56-3
Bogdananic A., PB 4.61-5
Bohdan N., AS 29.2, OC 30.2, PB 2.63-1
Böhinger S., OC 4.72
Bojilov H., PB 2.41-2
Boing A.N., OC 77.2, OC 82.5, PA 3.04-1, PB 3.30-1, PB 4.30-4
Boinska J., PB 3.60-5, PB 4.56-3, PO 373
Boismare-Helms J., OC 72.1, PA 1.04-6
Boisvieux P., OC 13.2, OC 13.6
Boisset J.-C., PA 2.04-1
Boisson-Vidal C., PB 2.29-3, PB 2.29-5
Boiteux M.-Ch., PO 448
Bojadzieva-Makarovska T., PO 002, PO 215
Bokarev I.N., SC19-2.03, PO 078, PO 240, PO 408, PO 411, PO 412
Bokemeyer C., PA 3.16-6, PB 2.38-6
Böker M., PA 4.15-1
Boklage S., OC 03.6
Boknäss N., PA 3.04-4
Bolkun L., PO 252
Bollen L., PB 3.66-2
Bollini B., PB 2.62-6
Bologna L., AS 03.1
Bolshakovskova O., PB 369
Bolt G., OC 84.2

Blanchette V.S., SC09-5.03, PA 3.09-3, PB 4.39-1, PO 106
Blanco A.N., PO 025, PO 385, PO 431, PO 438
Blatny J., PB 1.43-3, PB 3.42-6, PB 4.44-5
Blauert N., PB 2.58-1
Blazek B., PO 349
Bliejerveld O.B., PB 2.24-3, PB 3.24-6
Blinc A., PB 2.34-4
Blinov M., PB 2.69-5
Blix K., OC 04.3
Block D.R., PB 1.54-4
Bloem E., OC 57.5
Bloemen S., PA 1.11-5, PA 4.12.6, PB 1.51-1, PB 2.56-4, PB 4.47-5
Blok D., PB 3.66-3
Blomkiel H., PB 1.46-5
Blom J.W., PA 3.19-6
Blom Back M., PB 3.57-4
Blomstrand C., PA 4.14-5, PB 2.63-3
Blondal T., OC 77.2
Blondon M., OC 30.5, OC 63.1, PA 4.18-3
Blonski J., PB 1.27-4
Bloomer L., OC 13.4
Blöstein M.D., AS 10.1, OC 85.3, PA 3.03-6, PB 1.60-1
Blumberg R., SAS03-02
Blümke F., PA 3.11-1
Boadas A., PO 104, PO 144, PB 179
Bogdanov V.Y., PB 4.44-5
Boe R., OC 39.2, OC 86.4, PB 3.27-4
Bochem A.E., OC 88.3, PB 3.26-3
Bocchiuca R.A., PB 1.74-6, PB 4.42-2
Bock F., PB 3.28-5
Boda Z., OC 78.2, OC 78.3, OC 90.3, PB 3.67-5
Bode A., PB 1.50-5
Bode C., PA 3.02-6, PA 3.18-4, PB 1.47-1, PB 2.24-5, PB 2.68-6, PB 4.67-3
Boden G., PA 2.17-3, PB 2.63-2

Bodo I., SC17-1.03, SC17-3.04, SC17-3.05, PB 4.55-3
Bodrozic J., PB 3.65-3, PB 4.72-3
Body R., AS 12.1, PB 1.65-3, PB 4.69-4
Boe A.E., AS 23.1, PA 2.17-1
Boehlken F., FS 01.2, OC 27.1, PB 1.40-6, PB 2.57-1
Boehm E., PB 1.39-6
Boehncke W.-H., PB 3.39-5, PB 3.39-6
Boer H., OC 04.4
Boey R., PB 3.50-6
Bofha M.B., SC05-2.08, OC 84.6, PA 2.14-5
Bogdalanic D.H., PB 4.65-4
Bogdanov V.Y., AS 46.3, AS 46.4, PB 3.56-3
Bogdananic A., PB 4.61-5
Bohdan N., AS 29.2, OC 30.2, PB 2.63-1
Bohndor S., OC 47.2
Boejlou H., PB 2.41-2
Böing A.N., OC 72.2, OC 82.5, PA 3.04-1, PB 3.30-1, PB 4.30-4
Boinska J., PB 3.60-5, PB 4.56-3, PO 373
Boisrame-Helms J., OC 72.1, PA 1.04-6
Boisvieux P., OC 13.2, OC 13.6
Boisset J.-C., PA 2.04-1
Boisson-Vidal C., PB 2.29-3, PB 2.29-5
Boiteux M.-Ch., PO 448
Bojadzieva-Makarovska T., PO 002, PO 215
Bokarev I.N., SC19-2.03, PO 078, PO 240, PO 408, PO 411, PO 412
Bokemeyer C., PA 3.16-6, PB 2.38-6
Böker M., PA 4.15-1
Boklage S., OC 03.6
Boknäss N., PA 3.04-4
Bolkun L., PO 252
Bollen L., PB 3.66-2
Bollini B., PB 2.62-6
Bologna L., AS 03.1
Bolshakovskova O., PB 369
Bolt G., OC 84.2
INDEX

Bradley R.L., PB 3.60-3


Braeister A., PO 359

Braga Gomes K., PB 2.31-2

Braidotti P., PB 2.57-4

Brain L., OC 58.6

Braekbusch C., OC 33.6

Brambilla M., OC 72.4, PB 2.27-1

Brambes M.J., PB 1.61-5

Branchford B.R., PA 2.02-4

Branchini A., PA 1.08-2, PA 1.11-1

Brand B., OC 67.3, PB 1.36-3

Brandan E., PA 4.20-4

Brandão I., OC 01.4

Brandão L.R., PA 2.19-3, PA 3.07-2

Brandjes D.P.M., OC 08.3, PB 1.69-2

Brandolin B., PB 1.36-1

Brandsdter H., OC 66.1, PA 1.07-3, PA 3.07-2

Brandt K.J., OC 27.1

Brandt M., PA 4.20-4

Brandt S., PB 2.40-2

Brandtzaeg P., PA 3.04-3

Brar S., PO 446


Braun A., AS 30.2, OC 11.3, OC 86.1, OC 88.1, OC 88.6, PA 2.02-2

Braun G., PA 3.14-1

Bravo M.C., PA 1.16-1, PB 4.61-2

Bray P.F., SOA 06.1, OC 62.3, PB 3.32-4

Braza-Boils A., OC 40.3, OC 40.4

Breakey V.R., PO 106

Breen K.A., PB 1.62-5, PB 1.62-6

Breinholt J., PA 2.14-4

Breizman T., PB 2.66-5, PB 3.66-5, PB 4.66-6

Bremme K., PB 2.66-5, PB 3.66-5, PB 4.66-6

Brennan A., OC 37.2, PA 2.06-3, PA 2.07-5, PA 2.07-6, PA 4.07-2, PB 4.37-3

Brenner B., SC11-1.03, SC11-1.05, AS 05.3, PA 1.30-3, PA 1.30-4, PB 1.66-4, PB 3.72-3, PO 494

Bresser P., PB 3.66-3

Bridie F., PA 1.43-1

Bridge K.I., PB 3.63-6

Briens A., PA 3.04-6

Briens A., PA 3.04-6

Briggs H., PB 1.64-1

Bright R., PA 2.07-5

Brighton T.A., PA 2.07-6, PA 4.07-2, PB 4.37-3

Brenner B., SC11-1.03, SC11-1.05, AS 05.3, PB 1.30-3, PB 1.30-4, PB 3.72-3, PO 494

Brenner B., PA 2.07-6, PA 4.07-2, PB 4.37-3

Brennan A., OC 37.2, PA 2.06-3, PA 2.07-5, PA 2.07-6, PA 4.07-2, PB 4.37-3

Brenner B., SC11-1.03, SC11-1.05, AS 05.3, PA 1.30-3, PA 1.30-4, PB 1.66-4, PB 3.72-3, PO 494

Bresser P., PB 3.66-3

Bridie F., PA 1.43-1

Bridge K.I., PB 3.63-6

Briens A., PA 3.04-6

Briens A., PA 3.04-6

Briggs H., PB 1.64-1

Bright R., PA 2.07-6, PA 4.07-2, PB 4.37-3

Brighton T.A., PA 2.07-6, PA 4.07-2, PB 4.37-3

Brennan A., OC 37.2, PA 2.06-3, PA 2.07-5, PA 2.07-6, PA 4.07-2, PB 4.37-3

Brenner B., SC11-1.03, SC11-1.05, AS 05.3, PA 1.30-3, PA 1.30-4, PB 1.66-4, PB 3.72-3, PO 494

Bresser P., PB 3.66-3

Bridie F., PA 1.43-1

Bridge K.I., PB 3.63-6

Briens A., PA 3.04-6

Briens A., PA 3.04-6

Briggs H., PB 1.64-1

Bright R., PA 2.07-6, PA 4.07-2, PB 4.37-3

Brighton T.A., PA 2.07-6, PA 4.07-2, PB 4.37-3

Brennan A., OC 37.2, PA 2.06-3, PA 2.07-5, PA 2.07-6, PA 4.07-2, PB 4.37-3

Brenner B., SC11-1.03, SC11-1.05, AS 05.3, PA 1.30-3, PA 1.30-4, PB 1.66-4, PB 3.72-3, PO 494

Bresser P., PB 3.66-3

Bridie F., PA 1.43-1

Bridge K.I., PB 3.63-6

Briens A., PA 3.04-6

Briens A., PA 3.04-6

Briggs H., PB 1.64-1

Bright R., PA 2.07-6, PA 4.07-2, PB 4.37-3

Brighton T.A., PA 2.07-6, PA 4.07-2, PB 4.37-3

Brennan A., OC 37.2, PA 2.06-3, PA 2.07-5, PA 2.07-6, PA 4.07-2, PB 4.37-3
INDEX

Budinger G.R., AS 23.1
Budkova V., PB 4.59-5
Budnik I., PB 4.23-1, PB 4.23-6
Buetehorn U., PA 3.10-4
Bugert P., PB 4.05-5, PB 3.29-6
Bugger H., PA 3.02-6
Buhler L., OC 06.2
Buitrago L., PO 406
Bulato C., OC 50.4, PB 3.54-5
Bulder I., PB 2.67-1
Bulfamante G., PA 3.17-2
Bull A., PA 2.04-6
Büller H.R., OC 06.2, OC 12.2, OC 71.1, OC 82.5, PA 2.16-2, PA 3.10-1, PB 4.60-4, PB 4.61-3, SAS01-03
Bullorsky E.O., PB 1.72-2, PB 1.72-3, PB 120, PB 128, PB 129
Byambasuren S., PB 2.49-4, PB 4.22-3, PB 4.48-5, PO 251
Bye A.P., PB 3.27-1
Bykowska K., PO 355
Byra W., PA 2.10-2
Byrne M.B., PB 1.43-4, PB 2.42-1, PB 4.46-5, PO 034
Byrne H., PB 4.54-5
Byrnes J.R., OC 49.3
Caballero J., PB 4.21-2
Caballero S., PB 4.58-5
Caballo C., PA 3.01-4, PB 2.31-5, PB 4.22-5
Cabañas V., PB 3.11-3, PB 2.52-2
Cabrera N., PB 1.38-3
Cabrera S., PB 4.58-5
Caballo C., PB 2.31-5, PB 4.22-5
Cacałowicz S., OC 11.2
Camacho E., PA 3.11-3, PB 2.52-2
Camacho M., OC 11.2
Camacho M., OC 72.4, PB 2.27-1
Camerin M., PA 218
Camerón B.H., PB 2.18-3
Camichi G., PA 1.01-6
Camia G., PB 4.31-5
Camp R.M., AS 36, AS 36.3, OC 18.1, OC 36.4, OC 49.1, OC 68.1, OC 84.3
Cammm J.A.J., SAS12-02
Campana F., PB 3.73-3
Campanate G., PA 2.20-6, PB 1.72-3
Campbell A.I., PB 2.50-2
Campbell D., OC 09.1
Campbell H., OC 72.3
Campbell R.A., PB 1.29-3
Campbell T.R., PB 3.57-2, PB 3.70-3
Campello E., AS 33.1, PA 1.04-5, PA 3.13-1, PA 3.19-4, PB 2.45-3, PB 3.30-4, PB 3.53-6, PB 3.54-5, PB 3.57-6, PB 4.64-4, PO 245
Campioni M., OC 70.4
Camporese G., AS 42.2, OC 59.1, PB 1.70-3, PB 2.70-4, PB 3.73-3
Campos M., OC 02.5, PB 2.31-1
Campos M.F., PB 247
Can G., PA 1.11-3
Canak V., PB 263, PO 484
Canau M., OC 10.2, OC 62.1, OC 76.2, PA 3.18-4, PB 1.67-1
Cancel O., PB 4.63-5
Cancelliere E., PB 1.47-5, PB 1.47-5, PB 2.49-3, PB 2.53-2, PO 267
Canciani M.T., OC 13.5, PB 2.39-4, PB 2.43-6, PB 4.43-4
INDEX

Cande M., PO 103
Candura F., PB 3.36-3
Canella A., OC 70.4
Caner I., PB 3.69-4
Canil C., PB 2.61-3
Cannizzaro E.S., AS 45.2, OC 57.4
Cannon P., PB 1.27-6
Canobbio I., OC 09.6, OC 35.4
Canzano P., PB 2.27-1
Cao J., PO 364
Cao L., PA 4.19-4, PB 2.72-3
Cao Q., PA 4.17-6
Cao W., PB 4.24-1, PB 4.24-4
Cao Y., PB 1.59-4
Cao Z., AS 07.3, PA 2.19-6, PB 4.46-4
Caparros E., OC 08.1
Cappelli R., PB 1.49-2
Cappucci F., PA 3.17-1
Caraci M.R., PO 049
Caramelli B., PB 4.27-3
Carazze M.F., PB 4.68-4, PB 4.68-6
Carbone R.J., PB 2.71-5, PB 3.61-2, PO 397
Carbone R.J., PB 2.71-4, PB 2.71-4, PB 1.64-5, PB 1.70-5, PB 2.48-2, PB 2.61-3, PB 2.71-4, PB 2.71-4, PB 2.71-5, PB 3.61-2, PB 397
Carriero C., PB 1.45-2
Carrei M.N., OC 86.5
Carson A.R., AS 11.3, PA 4.18-4
Carson P., PA 4.65-1, PO 006, PO 07
Carter T., OC 91.1
Cartwright A., OC 13.4, OC 39.4, PA 3.09-4
Caruso P., OC 70.4
Carvalhal Z., PB 4.34-5, PO 488
Carvalho M., PO 035, PA 180, PB 4.65-2, PB 4.66-4, PB 287
Carvalho M.G., PA 4.20-6, PB 2.33-6, PB 3.21-6, PB 4.32-4, PB 4.74-2, PO 040, PB 247, PO 479
Carvalho Z., PB 2.31-2
Carvalho Godoi L., PB 2.31-2
Carvalhosha A.M., PO 108
Casaer P., OC 34.1
Casagrande C., OC 09.3
Casais P., PB 4.70-1
Casais Sole F.J., PB 4.46-6
Casani L., PB 3.32-5
Casari C., AS 09.2, OC 39.2, OC 65.1, OC 91.2, PB 3.29-1
Casas C., PO 406
Cases A., PB 2.31-5
Casey L., OC 39.5
Casini A., PB 2.57-1
Casonato A., PA 1.09-1, PB 3.43-1, PO 428
Cassar J., PA 2.06-1
Cassetti I., PB 3.61-1
Cassisi F., PO 123, PO 124
Castagna A., PB 2.70-4
Castaman G., AS 22.1, AS 32.2, OC 66.4, OC 70.4, PA 2.08-1, PA 3.09-1, PA 3.09-4, PA 3.09-5, PA 4.18-5, PB 2.41-3, PB 4.49-5, PO 425
Castel A., PB 3.47-6
Castelli C., OC 90.1
Castellino F.J., OC 05.3, OC 18.2
Castellone D., PO 311
Castellucci L.A., OC 12.1
Castilhejos C.F., OC 36.5
Castle D., FS 02.2, PA 2.19-5
Castoldi F., PB 2.70-4
Castoldi E., SC12-3.01, AS 11.1, AS 24.3, AS 29, AS 29.1, OC 50.1, OC 50.4, PB 3.54-5
Cattaneo M., OC 89.3, OC 89.4, PB 1.22-4, PB 1.29-1, PB 1.69-3, PO 447
Cattini G.M., PA 1.09-1, PB 3.43-1
Cau V., PB 2.22-4
Cauchie Ph., PB 1.47-6
Cauwenberghs S., PB 1.32-6
Cavallar V., PO 447
Cavallari N., OC 50.2, PB 1.39-2
Cavallo L., PA 1.08-1
Cavazza M., PB 1.63-6
Cavill R., PA 3.02-2
Cavazza R., OC 89.6
Cazzola M., PB 3.61-1
Cebura E., PO 177
Cedzynski M., PB 1.62-5
Cefatà A.B., PB 1.26-1
Cekova E., PB 4.28-1
Celik F., PB 1.69-2
Celsinska-Löwenhoff M., AS 08.3, PB 2.62-1, PB 3.62-3
Celkan T., PB 1.34-3, PB 3.68-3, PO 399
Cella G., PB 4.64-6
Cella A.P., PB 1.34-6, PB 4.33-1, PB 4.74-3
<table>
<thead>
<tr>
<th>Name</th>
<th>Index Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cenci C.</td>
<td>PB 2.49-1, PB 4.33-1, PB 4.74-3</td>
</tr>
<tr>
<td>Cengiz M.</td>
<td>PB 4.37-4</td>
</tr>
<tr>
<td>Cense H.A.</td>
<td>PB 1.69-2</td>
</tr>
<tr>
<td>Cerbone A.M.</td>
<td>PB 3.67-2</td>
</tr>
<tr>
<td>Ceresetto J.</td>
<td>PB 2.53-1, PO 0.064</td>
</tr>
<tr>
<td>Ceresetto J.M.</td>
<td>PB 1.72-2</td>
</tr>
<tr>
<td>Cerezo-Manchado J.J.</td>
<td>PA 2.10-1, PB 1.48-1, PB 3.52-4</td>
</tr>
<tr>
<td>Cerbone A.M.</td>
<td>PB 3.67-2</td>
</tr>
<tr>
<td>Ceresetto J.M.</td>
<td>PB 1.72-2</td>
</tr>
<tr>
<td>Cerezo-Manchado J.J.</td>
<td>PA 2.10-1, PB 1.48-1, PB 3.52-4</td>
</tr>
<tr>
<td>Cerevo C.</td>
<td>PB 1.71-1, PB 1.71-3, PO 0.303</td>
</tr>
<tr>
<td>César C.</td>
<td>PB 4.45-4</td>
</tr>
<tr>
<td>Cesari F.</td>
<td>PB 1.31-2, PB 2.29-1, PB 2.29-2, PB 2.31-6</td>
</tr>
<tr>
<td>Cesarman-Maus G.</td>
<td>PA 2.16-2</td>
</tr>
<tr>
<td>Ceviz N.</td>
<td>PB 3.69-4</td>
</tr>
<tr>
<td>Chabert A.</td>
<td>PB 1.67-1</td>
</tr>
<tr>
<td>Chai B.</td>
<td>PB 2.44-6</td>
</tr>
<tr>
<td>Chaireti R.</td>
<td>PB 2.49-6, PB 3.66-5</td>
</tr>
<tr>
<td>Chaker F.</td>
<td>PB 4.62-5</td>
</tr>
<tr>
<td>Chalabi M.</td>
<td>PB 2.30-5</td>
</tr>
<tr>
<td>Chalayer E.</td>
<td>PB 1.48-6</td>
</tr>
<tr>
<td>Chalkele A.G.</td>
<td>PO 109, PO 426</td>
</tr>
<tr>
<td>Challande P.</td>
<td>PA 2.17-2</td>
</tr>
<tr>
<td>Chalmers E.V.</td>
<td>SC 15-2.06</td>
</tr>
<tr>
<td>Chamberlain E.V.</td>
<td>PB 3.27-2</td>
</tr>
<tr>
<td>Chambers J.C.</td>
<td>PA 2.04-2</td>
</tr>
<tr>
<td>Chambers F.</td>
<td>PB 1.41-1</td>
</tr>
<tr>
<td>Chambost H.</td>
<td>PA 2.07-6, PB 4.29-3, PB 4.36-5, PB 4.60-6</td>
</tr>
<tr>
<td>Chan B.</td>
<td>PB 4.31-5</td>
</tr>
<tr>
<td>Chan A.K.</td>
<td>OC 51.2, OC 64.5, PA 2.18-3, PA 2.19-2, PA 2.19-5, PA 4.08-1, PA 4.08-4, PA 4.10-5, PB 1.58-4, PB 2.38-1, PB 3.34-4, PO 2.80, PO 491, SC 15-2.01, SC 15-2.09</td>
</tr>
<tr>
<td>Chan G.</td>
<td>OC 52.3</td>
</tr>
<tr>
<td>Chan H.H.</td>
<td>PA 2.19-2, PB 3.26-2</td>
</tr>
<tr>
<td>Chan H.W.</td>
<td>OC 51.2, OC 64.5, PA 4.08-1, PA 4.10-5, PB 2.38-1, PB 2.52-3, PO 280</td>
</tr>
<tr>
<td>Chan N.</td>
<td>PB 2.38-1, PB 1.64-4</td>
</tr>
<tr>
<td>Chan W.S.</td>
<td>FS 01.1</td>
</tr>
<tr>
<td>Chan Kwo Chion A.</td>
<td>PA 4.09-6</td>
</tr>
<tr>
<td>Chanden M.</td>
<td>FS 04.2</td>
</tr>
<tr>
<td>Chandler A.</td>
<td>PA 4.08-1, PB 3.34-4</td>
</tr>
<tr>
<td>Chandler W.</td>
<td>AS 02</td>
</tr>
<tr>
<td>Chang C.S.</td>
<td>PB 3.58-6</td>
</tr>
<tr>
<td>Chang H.</td>
<td>PB 1.21-6</td>
</tr>
<tr>
<td>Chang H.K.</td>
<td>PB 4.21-3</td>
</tr>
<tr>
<td>Chang I.L.</td>
<td>PB 2.70-6</td>
</tr>
<tr>
<td>Chang P-Y.B.</td>
<td>PA 2.12-5, PB 2.55-3, PB 4.55-4</td>
</tr>
<tr>
<td>Chang W.C.</td>
<td>PB 4.24-1, PB 4.24-4</td>
</tr>
<tr>
<td>Chang Y.</td>
<td>OC 71.3</td>
</tr>
<tr>
<td>Chiang R.</td>
<td>PB 2.43-4</td>
</tr>
<tr>
<td>Channick R.</td>
<td>PA 2.18-4</td>
</tr>
<tr>
<td>Chen A.</td>
<td>OC 26.1</td>
</tr>
<tr>
<td>Chen D.</td>
<td>OC 32.6, PB 1.32-2, PB 3.32-6, PB 3.71-3, PO 470, OC 14.4, PB 1.25-6, PB 1.54-4</td>
</tr>
<tr>
<td>Chen H.</td>
<td>PB 2.70-6</td>
</tr>
<tr>
<td>Chen J.</td>
<td>PB 2.44-6, OC 38.1, OC 65.6, OC 74.2</td>
</tr>
<tr>
<td>Chen J-M.</td>
<td>PB 3.59-4</td>
</tr>
<tr>
<td>Chen K.</td>
<td>OC 83.4, PB 4.13-6, PB 1.58-1, PB 3.58-2</td>
</tr>
<tr>
<td>Chen L.</td>
<td>AS 47.1 PA 4.01-1, PB 2.41-1, PB 1.24-5, PB 1.25-3</td>
</tr>
<tr>
<td>Chen M.</td>
<td>PB 4.22-6</td>
</tr>
<tr>
<td>Chen N.</td>
<td>PB 2.59-1</td>
</tr>
<tr>
<td>Chen P.</td>
<td>OC 87.1</td>
</tr>
<tr>
<td>Chen Q.</td>
<td>OC 89.5</td>
</tr>
<tr>
<td>Chen Q.</td>
<td>PA 2.11-3</td>
</tr>
<tr>
<td>Chen S.</td>
<td>OC 97.1</td>
</tr>
<tr>
<td>Chen T.H.</td>
<td>FS 03.4</td>
</tr>
<tr>
<td>Chen V.M.</td>
<td>OC 72.3, PB 2.26-4</td>
</tr>
<tr>
<td>Chen W.</td>
<td>PA 3.14-2, AS 30.2, PA 2.02-2</td>
</tr>
<tr>
<td>Chen X.</td>
<td>OC 58.3</td>
</tr>
<tr>
<td>Chen Y.L.</td>
<td>PB 2.70-6</td>
</tr>
<tr>
<td>Chen Y.C.</td>
<td>OC 22.3, PA 1.09-6, PB 3.37-3</td>
</tr>
<tr>
<td>Chen Y.</td>
<td>AS 45.3, OC 35.3, OC 82.3, PA 4.08-2, PA 4.08-3</td>
</tr>
<tr>
<td>Chen Y.H.</td>
<td>PB 1.25-2</td>
</tr>
<tr>
<td>Chen Y.W.</td>
<td>PO 489</td>
</tr>
<tr>
<td>Chen Y.H.</td>
<td>PB 1.42-6</td>
</tr>
<tr>
<td>Chen Z.</td>
<td>PB 2.48-4, PO 221</td>
</tr>
<tr>
<td>Chenet C.</td>
<td>PA 2.05-6</td>
</tr>
<tr>
<td>Cheng J.</td>
<td>PO 148</td>
</tr>
<tr>
<td>Cheng J-Ch.</td>
<td>FS 03.4</td>
</tr>
</tbody>
</table>
INDEX

Cheng S., PB 4.70-4
Cheng S.-N., OC 22.3, PA 1.09-6, PB 3.37-3
Cherel G., PA 2.12-6, PO 101
Chérif-Hosni A., PO 020, PO 055
Chernoff J., PB 3.28-1, PB 4.25-5
Chernova T., PO 150
Chernysh I., PB 1.57-2
Cherpokova D., AS 16.2, AS 39.1, OC 33.6
Cheung K., PA 3.12-4
Cheung P., PA 2.17-3
Cheung Y.W., PA 3.20-4
Cheurfi R., PB 4.71-5
Chevalier C., PB 1.47-6
Chevalier Y., PB 1.43-5
Chevrier A., PB 2.65-2
Chhabra E.S., OC 56.4, PA 2.12-5
Chhabra L., PB 1.26-3
Chi C., PB 1.66-6
Chi J., PA 2.18-2
Chi K., PB 2.35-3
Chia-Chyuan L., PO 464
Chiari R., OC 04.5, PB 4.60-2
Chiba T., PB 4.59-6
Chicanne G., AS 37.1, OC 35.6
Chico T., PA 4.03-5
Chien-Ling H., PA 1.02-1
Chikasawa Y., PA 1.08-6, PB 2.54-5
Chillo O., AS 01.1
Chinetti G., OC 35.6
Chinetti-Gbaguidi G., PB 4.32-2
Ching-Ping T., PA 1.02-1
Chinksakchai K., PB 2.64-5, PO 076
Chinthammitr Y., PA 3.13-6, PB 1.42-3, PB 3.64-4, PB 4.70-6
Chion A., PB 3.44-1
Chiostr M., PB 2.22-4
Chira M.K., PB 2.45-2
Chi-Ren T., PO 225
Chite Asirwa F., FS 04.1
Chittur M., PB 1.68-5, PB 3.41-5
Chiu P-L., PA 4.13-1
Chiva A., PO 407
Cho J., AS 44.1

Choi D.H., PO 462
Choi E.-J., PO 290
Choi J.L., PA 2.05-4, PB 4.24-6
Choi N.-K., PB 4.69-6
Choi P.Y., PA 1.05-5
Choi S.H., AS 13.3, OC 81.4, PB 3.59-2
Chojnowski K., PB 1.27-4
Chokantsisook K., PO 227
Cholera S., PB 1.28-2
Cholka A., OC 24.2, OC 76.3
Chomienne C., PB 1.27-1
Chong B.H., PA 1.05-5
Chong K., PB 2.39-3, PB 2.47-5
Chong K.Y., PA 1.03-1
Choo H., OC 08.6, PB 1.24-3, PB 2.26-2
Choo T., PB 3.50-6
Chopra G., PO 225
Chowdary P., OC 37.2, PA 4.07-5, PA 4.11-1, PB 2.25-4, PB 2.48-6,
PB 4.52-5
Christiaans M.H.L., PB 3.22-4
Christian A.D., PO 257
Christophe O.D., AS 44.3, OC 39.2, OC 65.1, OC 91.2,
PB 2.12-6, PO 3.74-2, PO 010
Christopher W., PB 3.29-3
Christopherson P., PA 2.08-2
Christos P., PB 4.63-3
Chourouck S., OC 56.2, PA 3.07-6
Chuang W-Y., PO 460
Chuansamwit K.V., PB 2.50-3, PO 110
Chubanov V., AS 30.2
Chudzinski-Tavassisi A.M., PB 4.64-4, OC 25.1, SC20-2.02
Chumachenko P., PB 2.68-4
Chumakova A., PB 4.53-3
Chung D.W., OC 65.6
Chung J.-H., PB 4.21-4
Chung S., PO 081
Chung-Ching L., PA 1.02-1
Chunial S., PB 1.48-2, PB 1.64-4
Chuong T., PA 3.14-1
Chupan A., PB 4.43-1
Chur woo Y., PO 120

Church F.C., PB 3.46-4
Churchill G.C., OC 09.1
Ciampi A., PB 2.64-6
Ciancia M., PO 250
Ciardiello A., OC 42.2
Cibin A.V., PB 256
Cicardi M., PA 3.15-2
Ciccarino P., PO 075
Cichon S., OC 53.3
Cid A.R., PO 056
Ciepluch K., PB 3.31-2, PB 3.66-6
Cierciawski C.S., AS 44.3
Ciesla-Dul M., PA 1.14-4
Cilia La Corte A., PA 1.14-3
Ciminello A., PA 4.18-5
Cimino E., PB 3.67-2
Cines D.B., AS 38.4, AS 44.3, OC 01.2, OC 21.1, PA 3.12-6,
PO 193
Cini M., PB 2.31-4, PB 2.74-3, PB 3.64-6
Cicoriette O., PO 410
Cioni G., PB 1.34-6, PB 4.32-3
Cipolla A., PO 049, PO 427
Cipolla L., OC 87.2
Cirillo M., PO 111
Civaschi E., OC 34.5
Civit G., PB 1.49-5
Claessen N., AS 31.3
Claessen K., PB 4.25-2
Claeysens-Donatell S., PA 2.07-2, PA 3.14-4
Clapess T., PA 2.04-1
Clare W., PB 2.38-4
Clark D.S., PA 3.09-3
Clark M., PB 4.60-1
Clark M.R., OC 35.1
Clark P., OC 90.4
Clarke D., PA 2.08-2
Clarke P., PA 1.08-5
Clarke-Drury R., PB 1.64-1
Clases J.-F., PB 1.52-1, PB 3.51-4, PB 3.52-6, PB 4.52-1, PB 4.53-4
Claude R.-F., PA 2.18-3
Clausen J.T., OC 28.4
Clausen N., PA 2.07-2
INDEX

Cosmi E., PB 2.58-6
Cosphiadi I., PB 3.50-3
Costa A., PO 299
Costa C., PB 1.39-4, PB 2.35-1
Costa F., PA 1.17-5
Costa G.A.R., PB 1.66-3
Costa S.D., PB 2.66-5, PB 4.66-6
Costache A., PO 361
Costanzo S., PB 1.50-1
Costa-Pinto M.J., PB 2.42-6, PO 149
Costin J., AS 47.1
Cotton B.A., OC 17.1
Cotton B., PB 3.40-1
Coucelo M., PB 2.44-5, PO 047
Coucke L., PB 1.62-2
Coughlin P.B., PB 2.34-4, PB 3.34-3
Coultas K., PB 1.64-1
Coupaye M., PB 3.27-4
Couraud P.O., PB 2.30-4
Courtney M.D., PB 2.65-2, PA 3.06-2, PB 3.31-4
Coutinho J.M., PA 1.16-2, PB 1.72-5, PB 3.69-6
Couraud F., AS 18.2
Couzan S., PA 4.16-3
Covens K., PA 1.13-5
Cowan P., OC 80.4
Cox C.L., OC 09.1
Cox D., OC 45.3, PA 2.01-1, PB 1.23-1, PB 2.28-2
Coxon C.H., OC 09.1
Coyle D., PO 397
Cozzi G., OC 13.5, PB 2.39-4, PB 2.43-6
Cozzi M.R., PA 3.02-1, PA 3.02-4
Cranmer* S.L., OC 76.1
Crawford B.A., OC 65.3, PB 1.55-4
Crawford B., PO 134
Crawley J.T.B., AS 41.3, OC 86.2, PA 1.15-5
Creagh M.D., PB 3.65-1, PO 006, PO 007
Creemers E., OC 43.1, PB 2.24-1
Cremonini E., PB 3.32-3
Crépin L., PB 3.50-2
Crespo G., PB 2.67-5
Crestani B., PA 2.14-3, PB 3.31-6, PB 3.74-2
Crestani S., PA 2.20-4, PB 3.67-2
Crisi M., PB 3.32-2
Crisostomo M., PB 2.62-3, PB 2.62-5
Cristiano L., OC 37.2
Croci E., PB 1.46-6
Crowe B.W., PB 2.22-6
Crowley M.P., PB 2.61-2, PB 2.66-6
Crowther M., AS 20.1, OC 36.3, PB 1.64-2, PB 3.45-1, PB 3.46-3, SAS07-02
Crukey J.M., AS 34.3, OC 31.4
Cruce M.A., OC 35.3, PA 4.09-5, PB 3.43-5
Csapó A., PA 4.15-5
Csapó J., PA 4.15-5
Csencsits-Smith K., PA 3.13-4
Csipa L., PA 1.01-4, PA 3.06-1
Cuadrado M.J., OC 27.6
Cuff G., PA 4.11-4
Cuffaro S., PB 2.62-2
Cugno M., AS 40.1, PA 3.15-2
Cui X.Y., PA 4.14-4
Cuisset T., AS 15.1, PA 1.01-2
Cuker A., SC04.1-1.3, SC04.4-1.2
Culina S., OC 56.1
Culturera D., PA 1.13-2, PO 049, PO 427
Culyba E., PA 4.13-1
Cumming A., PB 2.54-3
Cumming T., PB 1.37-1
Cummins P.M., PB 3.31-1
Cunanan J., PA 4.17-3, PB 1.30-6, PB 1.40-2, PB 1.51-3, PB 1.58-6, PB 2.47-1, PB 2.47-3, PB 3.47-5, PB 4.60-1, PB 4.68-5, PO 259, PO 420
Cunat S., PB 1.41-1
Cung A., PB 1.27-1
Cunha M., OC 30.1
Cunningham I., PO 039
Cunningham M.R., PA 1.02-6
Curnow J., PB 1.60-6
Curnute J., AS 20.1
Curtis D.J., PB 1.57-2, PB 2.50-2
Curtis K., NS 01.3
Cushman M., AS 01.3, AS 05, OC 65.5, PA 1.16-1, PA 3.19-6, PA 4.18-6, PB 3.70-3, PB 4.61-2, PB 4.70-1
Cutler D.F., SOA 02.1, OC 39.3
Cutler J., OC 39.3, PA 2.08-6, PB 1.68-6, PB 3.25-3, PB 4.41-1, PO 467
Cutrone A., PA 3.06-4
Cvejic A., OC 33.2
Cvejic A., AS 47.6
Czajkowski K., PO 355
Czogalik K.J., OC 19.4, PO 288
Czuprynska J., PB 2.70-5
Czuriga I., OC 07.5
Czwalinna A., PB 3.65-4
Czyz A., PB 3.31-2
D’Imperio M., PB 3.66-4
Da Fonte D., PA 3.10-3
Da Motta G., PB 4.49-2
Daalhuisen J., PB 3.74-2
Daali Y., PB 3.21-4
DaCort A.J.A., PB 1.50-5
Daehler A., PB 3.37-5
Dahl O.E., AS 38.3
Dahlbäck B., AS 36.1, PA 1.15-5
Dahlen J.R., PB 2.21-4, PB 2.22-2, PO 445, PO 446, PO 450
Dahm A.E.A., AS 29.3, PB 3.60-1
Dahmani B., PO 008
Dai J., PB 1.24-1, PB 4.35-5, PO 198, PO 379
Dai K., PB 1.23-6, PB 1.24-4, PB 4.22-6
Dai L., OC 55.5, PB 2.32-2, PB 2.41-1
Dai M., PB 1.44-4
Dai M-S., OC 22.3
INDEX

Dai W., OC 58.1
Dai X., AS 15.2, PB 4.25-3
Daiber A., OC 87.4
Daidone V., PA 1.09-1, PB 3.43-1
Dal Mas A., PB 1.39-2
Dale C., PB 1.51-2
D’Alessandri G., PB 4.32-3
D’Alessandro-Gabazza C.N., PO 231, PO 232
Dalkilic S., PB 2.60-1
Dalla Valle F., AS 34.1, OC 42.1, PB 4.31-3, PO 075
Dalm D., OC 28.6, PA 4.13-2
Daly M.E., OC 34.2, OC 39.6, OC 62.6, PA 4.05-3
Damaraju C.V., PB 1.45-1, PB 4.31-2, PB 4.45-2
Damian M., PO 278
D’Amico E.A., PA 1.03-4, PA 2.08-1, PB 4.27-3, PB 4.72-6, PA 029, PA 224, PA 296
Damiolini E., PB 1.47-5, PB 1.54-3, PB 2.49-3, PB 267
Danbara M., PB 4.29-1
Danchev D., PO 312
Dandapani S., AS 07.2
Dangelmaier C., PA 3.03-5
Daniela B., OC 72.4
Danielyan S., PO 051
Danisment O., OC 65.3
Danko J., PB 2.54-4, PB 4.65-5, PO 204
Daoudal A., OC 61.4
D’Apice A., OC 41.1
Dardik R., PA 1.17-6, PB 4.35-4
Dardikh M., PB 2.36-1
Daresky I., PO 334
Dargaud Y., OC 48.3, PA 1.12-2, PB 1.38-2, PB 1.43-5
D’Argenio P., PO 111
Darling C.E., PB 2.63-4
Das R., PO 175, PO 004
Dasgupta S., PA 2.12-6, PA 3.07-6
Dash D., PB 2.24-6, PB 3.74-6
Dashkevich N.M., PB 2.51-6
Dashnyam P., PB 2.49-4, PB 4.22-3, PB 4.48-5, PO 251
Dashti A., PB 1.68-3
Dashty M., PO 487
Dasi M.A., PA 2.03-2, PB 4.24-5
D’Atri L.P., PB 1.29-5
D’Audigier C., OC 40.2, PA 1.17-4
Davi G., SC07-2.02
Davi G., PB 1.26-1, PB 2.28-4
David G., PO 152
Davidovic L., PO 452
Davidson B.L., AS 17.1
Davidson S.J., SC21-2.02, PA 3.15-4, PB 1.21-2
Davies G.R., PB 1.53-1
Davies J.S., PB 1.66-6, PB 4.41-3, PB 4.42-4, PB 4.66-2
Davies N., PB 1.53-1
Davis T.P., PB 2.56-2
Day J.L., OC 82.2
Day Y.J., PO 229
Dayananda K., AS 09.3
D’Cruz A., PB 4.30-2
De A., PB 2.11-1
De Agostini A.L., PA 4.20-3
De Angelis V., OC 09.5, OC 88.3, PB 3.26-3
De Arcangelis A., PA 1.17-1
De Bas L., PA 2.11-1
De Bekker-Grob E.W., PB 4.36-6
De Boer D.J., OC 08.4, PB 4.67-1
De Boer O.J., PB 1.67-3
De Bon E., PO 075, PO 248
De Borst G.J., PB 2.22-1, PO 341
De Bosch N., PO 179
De Breverin A.G., PB 1.25-5
De Candia E., OC 89.4
De Ceunynck K.E.P., OC 15.1
De Cock E., PB 2.73-2
De Cos C., PB 4.73-1
De Cristofaro R., OC 27.2, OC 39.1, PA 1.08-1, PB 3.44-4
De Curtis A., OC 04.1, OC 07.6, PA 3.06-4, PB 1.50-1, PB 3.66-4
De Cuyper I.M., PO 329
De Fatina T., PB 3.52-5
De Filippis V., AS 47.5, OC 27.2, PA 2.13-2
De Franceschi M., PB 2.45-3
De Gaetano G., OC 07.6, PA 3.06-4, PB 1.50-1, PB 3.66-4
De Geest B., PB 3.28-2
De Graaf R., PB 2.64-4, PO 241
De Groot P.G., AS 04.1, AS 08.1, AS 40.3, OC 09.5, OC 23.1, OC 27.3, OC 27.4, OC 53.2, OC 58.2, OC 88.3, PA 1.18-2, PA 2.05-1, PA 2.08-4, PA 2.09-4, PA 2.15-1, PA 2.15-1, PA 4.03-4, PB 1.38-1, PB 2.22-1, PB 2.24-3, PB 3.24-6, PB 3.26-3, PB 3.44-5, PB 3.58-1, PA 4.09-3, PB 4.62-1, PA 318, PO 318
De Groot-Eckhardt C.L., AS 22.1
De Haan H.G., AS 11.2, OC 47.2
De Haan J., PO 037
De Haas M., PO 329
De Henauw S., PA 3.06-6
De Jager T., PB 3.41-6
De Jong P.G., FS 01.3, OC 61.2
De Jonghe P., PA 2.09-3
De Kam P.J., PO 187, PO 324
De Krijn P., AS 11.2
De Koning L., PB 3.28-2
De Korte D., PO 329
De La Cruz E.M., PB 4.24-1, PB 4.24-4
De La Cuesta F., PB 2.27-2
De La Morena-Barrio M.E., AS 29.2, OC 30.2, PA 1.15-6, PB 2.63-1, PB 4.73-1
De La Peña Diaz A., PB 2.22-5, PB 2.56-6, PO 199
De La Salle H., OC 35.2, OC 55.3, PB 3.29-2
De Laat B., AS 08.1, OC 23.2, OC 58.2, OC 64.4, PA 1.11-4, PA 1.11-5, PA 1.18-2, PA 4.09-3, PA 4.12.6, PB 1.38-2, PB 2.42-4, PB 2.43-1, PB 4.47-5, PB 4.62-1, PA 258, PO 258
De Laat M., PB 1.51-1, PB 4.47-5
De Lange D.W., PA 2.09-4, PA 2.15-1
De Lange Z., PB 1.34-4
De Larrañaga G.F., PB 4.31-5
De Lau M.L., PB 2.43-5
De Los Reyes I., PO 152
De Luca M., PO 111
De Luccia N., PB 4.27-3
<table>
<thead>
<tr>
<th>Name</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>De Maat P.M.</td>
<td>OC 13.1, OC 48.1, PA 2.09-1, PB 2.43-5, PB 3.43-6</td>
</tr>
<tr>
<td>De Maat S.</td>
<td>OC 53.2, OC 23.1</td>
</tr>
<tr>
<td>De Marco L.</td>
<td>PA 3.02-1, PB 1.29-1, PB 3.43-1</td>
</tr>
<tr>
<td>De Mast Q.</td>
<td>PA 1.03-5</td>
</tr>
<tr>
<td>De Mazancourt Ph.</td>
<td>PB 1.57-5</td>
</tr>
<tr>
<td>De Meris J.</td>
<td>PB 1.42-1</td>
</tr>
<tr>
<td>De Meyer S.F.</td>
<td>AS 32.1, OC 15.1, OC 60.6, OC 65.4, PB 2.73-2</td>
</tr>
<tr>
<td>De Moerloose Ph.</td>
<td>PA 3.02-1, PB 2.57-1, PB 4.60-6</td>
</tr>
<tr>
<td>De Negri F.</td>
<td>PB 3.72-4</td>
</tr>
<tr>
<td>De Oliveira S.</td>
<td>PO 188</td>
</tr>
<tr>
<td>De Oliveira V.</td>
<td>PO 497</td>
</tr>
<tr>
<td>De Palma V.</td>
<td>PO 112, PO 429</td>
</tr>
<tr>
<td>De Paula E.V.</td>
<td>OC 85.5, OC 81.5, PA 1.17-5, PA 4.19-5, PA 2.55-2, PB 4.68-4, PB 4.68-6</td>
</tr>
<tr>
<td>De Paz R.</td>
<td>PB 1.25-1</td>
</tr>
<tr>
<td>De Prost D.</td>
<td>OC 61.6, PB 3.27-4</td>
</tr>
<tr>
<td>De Romeuf C.</td>
<td>OC 22.4</td>
</tr>
<tr>
<td>De Roos A.</td>
<td>PB 2.65-6</td>
</tr>
<tr>
<td>De Salas-Cansado M.</td>
<td>PB 3.45-2</td>
</tr>
<tr>
<td>De Souza Medina S.</td>
<td>OC 81.5</td>
</tr>
<tr>
<td>De Spirito M.</td>
<td>OC 39.1</td>
</tr>
<tr>
<td>De Staercke C.</td>
<td>PB 2.71-3</td>
</tr>
<tr>
<td>De Stefano V.</td>
<td>PA 3.19-5, PB 4.69-1, PO 201</td>
</tr>
<tr>
<td>De Stoppelaar S.F.</td>
<td>PB 1.67-3, PB 2.28-1</td>
</tr>
<tr>
<td>De Visser M.C.H.</td>
<td>AS 11.1</td>
</tr>
<tr>
<td>De Vos A.F.</td>
<td>OC 08.4</td>
</tr>
<tr>
<td>De Vos J.</td>
<td>PO 436</td>
</tr>
<tr>
<td>De Vries J.J.</td>
<td>PA 3.17-4</td>
</tr>
<tr>
<td>De Vries M.</td>
<td>PO 486</td>
</tr>
<tr>
<td>De Wea F.</td>
<td>PL 08.03</td>
</tr>
<tr>
<td>De Wee E.</td>
<td>PB 2.44-1</td>
</tr>
<tr>
<td>De Wildt S.N.</td>
<td>PB 2.36-2</td>
</tr>
<tr>
<td>De Witt S.M.</td>
<td>PA 2.05-5, PA 3.02-2, PB 2.43-3</td>
</tr>
<tr>
<td>De Wolf M.A.</td>
<td>PO 241</td>
</tr>
<tr>
<td>Deana R.</td>
<td>PA 3.02-1</td>
</tr>
<tr>
<td>Dear T.N.</td>
<td>PB 3.71-2</td>
</tr>
<tr>
<td>Debbas V.</td>
<td>PA 0497</td>
</tr>
<tr>
<td>Debeij J.</td>
<td>AS 43.3</td>
</tr>
<tr>
<td>Debili N.</td>
<td>OC 45.4</td>
</tr>
<tr>
<td>Debize G.</td>
<td>OC 61.6</td>
</tr>
<tr>
<td>Debrumetz A.</td>
<td>PB 3.56-2</td>
</tr>
<tr>
<td>Debuie J.-M.</td>
<td>PB 2.47-6</td>
</tr>
<tr>
<td>Decartl A.</td>
<td>PB 1.69-3</td>
</tr>
<tr>
<td>DeChristopher Ph.</td>
<td>PB 1.46-1, PB 1.58-6</td>
</tr>
<tr>
<td>Deckers J.W.</td>
<td>PA 3.06-5</td>
</tr>
<tr>
<td>Deckers N.</td>
<td>PA 4.08-6</td>
</tr>
<tr>
<td>Deckmann A.C.</td>
<td>PB 4.68-6</td>
</tr>
<tr>
<td>Deckmyn H.</td>
<td>AS 32.1, OC 15.1, OC 45.1, OC 55.4, OC 60.6, OC 65.4, OC 91.3, PB 1.29-2, PB 2.73-2</td>
</tr>
<tr>
<td>Declercck P.J.</td>
<td>SC05-2.06, OC 84.5, PA 1.06-1, PA 1.06-4, PB 2.34-5, PB 2.63-3, PB 3.66-2</td>
</tr>
<tr>
<td>Decousus H.</td>
<td>AS 20.2, PA 2.18-1, PA 4.16-3</td>
</tr>
<tr>
<td>Decouture B.</td>
<td>PB 1.26-6</td>
</tr>
<tr>
<td>DeDominicis M.D.</td>
<td>OC 49.4</td>
</tr>
<tr>
<td>Deforche L.</td>
<td>PB 3.33-4</td>
</tr>
<tr>
<td>Deforest M.</td>
<td>PA 1.09-5</td>
</tr>
<tr>
<td>Degen J.L.</td>
<td>AS 10, OC 18.3</td>
</tr>
<tr>
<td>Dehbozorgian J.</td>
<td>OC 72.1</td>
</tr>
<tr>
<td>Delabar J-M.</td>
<td>PB 3.28-2</td>
</tr>
<tr>
<td>Delavenne X.</td>
<td>OC 72.1, PA 1.04-6, PA 1.05-6, PA 4.17-4</td>
</tr>
<tr>
<td>Delavalle X.</td>
<td>OC 79.2, PB 4.52-2</td>
</tr>
<tr>
<td>Delcea M.</td>
<td>PA 3.08-5</td>
</tr>
<tr>
<td>Deleeson H.</td>
<td>PB 4.37-2</td>
</tr>
<tr>
<td>Delgado B.R.C.</td>
<td>PB 035</td>
</tr>
<tr>
<td>Delgado-Mederos R.</td>
<td>PB 3.63-1</td>
</tr>
<tr>
<td>Delierneux C.</td>
<td>PA 1.02-3</td>
</tr>
<tr>
<td>Delignat S.</td>
<td>OC 56.1, OC 56.2, PA 1.13-1, PA 2.12-6, PA 3.07-6, PB 1.38-6, PB 2.35-4</td>
</tr>
<tr>
<td>D’Elios M.</td>
<td>PB 1.67-2</td>
</tr>
<tr>
<td>Della Bella C.</td>
<td>PB 1.67-2</td>
</tr>
<tr>
<td>Della Puppa A.</td>
<td>PO 075</td>
</tr>
<tr>
<td>Dellanoce C.</td>
<td>PB 1.54-3, PB 2.53-2, PB 2.64-4, PO 268</td>
</tr>
<tr>
<td>Deluc A.</td>
<td>AS 05.2, AS 43.2, OC 61.4, PB 4.63-5</td>
</tr>
<tr>
<td>Delomenie C.</td>
<td>PB 2.29-5</td>
</tr>
<tr>
<td>Deloukas P.</td>
<td>PA 2.04-2</td>
</tr>
<tr>
<td>Delpero N.</td>
<td>PB 2.53-2, PO 268</td>
</tr>
<tr>
<td>DeMarco K.</td>
<td>PA 2.14-5</td>
</tr>
<tr>
<td>Dembitzer F.R.</td>
<td>PB 2.25-6</td>
</tr>
<tr>
<td>Demers M.</td>
<td>PA 21.1, OC 74.1</td>
</tr>
<tr>
<td>Demir M.</td>
<td>PA 1.11-3</td>
</tr>
<tr>
<td>Demirkaya M.</td>
<td>PB 4.71-1</td>
</tr>
<tr>
<td>Demou Z.</td>
<td>SC14-2.02</td>
</tr>
<tr>
<td>Demulder A.</td>
<td>OC 81.6, PB 2.55-1</td>
</tr>
<tr>
<td>Den Exter P.L.</td>
<td>OC 12.2, OC 71.2, OC 71.4, PA 1.20-2, PB 2.65-3, PB 4.60-3</td>
</tr>
<tr>
<td>Denas G.</td>
<td>PB 1.62-3, PB 2.62-2</td>
</tr>
<tr>
<td>Deng K.</td>
<td>PB 1.24-4</td>
</tr>
<tr>
<td>Deng X.</td>
<td>PB 1.24-5, PB 2.59-1</td>
</tr>
<tr>
<td>Dengate A.</td>
<td>PB 1.54-6</td>
</tr>
<tr>
<td>Denis C.V.</td>
<td>SOA 02.2, AS 09.2, OC 39.2, OC 65.1, OC 91.2, PA 2.12-6, PO 3.29-1, PO 010</td>
</tr>
<tr>
<td>Denizot J.</td>
<td>OC 45.4</td>
</tr>
<tr>
<td>Denker B.</td>
<td>OC 09.2</td>
</tr>
<tr>
<td>Dennie J.</td>
<td>PO 187</td>
</tr>
<tr>
<td>Dent J.</td>
<td>PB 1.64-1</td>
</tr>
<tr>
<td>Dentali F.</td>
<td>OC 02.1, PA 2.20-4, PA 3.17-1, PA 3.19-5, PB 1.46-6, PB 1.49-1, PB 1.61-2, PB 2.64-3, PB 3.31-1, PB 3.46-1, PB 4.69-1</td>
</tr>
<tr>
<td>Depka M.V.</td>
<td>SAS08-02, PO 197</td>
</tr>
<tr>
<td>Deppermann C.N.</td>
<td>AS 16.2, OC 10.6</td>
</tr>
<tr>
<td>Derbeneva N.</td>
<td>PO 155</td>
</tr>
<tr>
<td>Derhaschnig U.</td>
<td>PA 1.01-1, PA 1.01-5</td>
</tr>
<tr>
<td>Derkaoui S.M.</td>
<td>PB 3.29-4</td>
</tr>
<tr>
<td>Dermitzakis E.</td>
<td>OC 06.6</td>
</tr>
<tr>
<td>DeRyckere D.</td>
<td>PA 2.02-4</td>
</tr>
<tr>
<td>Desai S.</td>
<td>PO 019</td>
</tr>
<tr>
<td>Desai U.</td>
<td>SC21-3.02</td>
</tr>
</tbody>
</table>
INDEX

DeSancho M.T., SC11-3.01, PB 4.63-3
Desch K.C., OC 15.4
Desconclois C., OC 39.2
Desprez D., PA 1.04-6
Detering C., PA 4.15-1, PB 3.42-3, PB 4.43-5
Deudon C., PB 3.39-3
Devalet B., PB 1.60-3
DeVeber G., PB 3.69-5
Devecioglu O., PB 3.50-4
Develter J., PB 2.34-5
DeVette C., OC 46.3
Devignes J., PB 1.57-5, PB 4.63-2
Devji S., FS 02.1
Devlin J., AS 18.1
Devriendt K., PA 4.05-5
Dhaouadi T., PB 1.25-4
Dhital K., PA 2.18-6
Di Buduo C.A., PB 1.29-1
Di Castelnuovo A., OC 07.6, PB 1.50-1
Di Cera E., PB 3.35-1
Di Raimondo F., PB 4.58-5
Diab Y., PO 307
Diako T., SC02-1.02
Diamantouros A., AS 28.1, PB 4.70-5
Diamond S.L., SOA 03.2, AS 25.3, OC 23.4, OC 24.1, PA 2.01-6, PB 2.26-6, PB 2.43-2, PB 3.26-5
Diani E., PB 1.22-5, PB 3.22-5
Diao L., PA 2.07-5
Diaz-Ortiz R., OC 46.3
Díaz-Ricart M., PA 3.01-4, PA 3.10-6, PB 2.31-3, PB 2.31-5, PB 4.22-5, PB 4.47-2
Dick A., PA 3.10-2
Dickins R.A., OC 11.6
Dickneite G., PA 1.04-4, PB 2.30-1, PB 3.30-6, PB 4.30-4
Dikici F., PO 442
Dilks J.R., OC 09.2, OC 54.4
Dillinger J-G., SC07-5.03, SOA 14.1, OC 23.4, OC 24.1, PA 1.04-4, PB 2.30-1, PB 3.30-6, PB 4.30-4
Dikici F., PO 442
Dilks J.R., OC 09.2, OC 54.4
Dillinger J-G., OC 07.3
DiMichele D., PB 4.58-5
Dignat-George F., SC07-5.03, SOA 14.1, OC 17.2, OC 26.3, PA 1.04-4, PB 2.30-1, PB 3.30-6, PB 4.30-4
Dikici F., PO 442
Dilks J.R., OC 09.2, OC 54.4
Dillinger J-G., OC 07.3
DiMichele D., PB 2.36-1
Dimitrov J.D., PA 4.01-6
Dinand V., PB 4.35-5
Dinart L.K., PA 4.30-5
Ding K., PB 3.33-5, PO 086, PO 113, PO 422
Ding Q., PB 2.11-3, PA 3.12-2, PB 1.55-5, PB 1.57-1, PB 2.57-3, PB 3.58-3, PO 062, PO 062
Ding Q.L., PA 4.35-5
Ding S., PA 2.12-5, PB 2.55-3, PB 4.55-4
Ding Z., PA 4.01-1
Ding-Yuan H., PA 1.02-1
DiNisio M., PB 4.60-4
Dinkelaar J., PO 258
Dippel D.W., PA 3.06-5
Dirven R.J., OC 13.3, PB 3.43-3
Dishy V., OC 79.1
Dittmer F., PA 2.15-2
Dittrich M., PB 3.42-3
Dittrich-Breiholz O., PB 2.67-5
Divanovic S., AS 24.1
Dix E.J., PB 1.21-6
Dizier B., PB 1.26-6
Djenic A., PA 4.05-5
Djukanovic N., PB 2.21-6
Djukic A., PB 4.66-5
Djukic S., PB 4.66-5
Djunic I., PA 4.07-3, PB 4.61-5, PO 005, PO 346
Dmoch-Gajzierska E., PO 355
Dmoszynska A., PA 1.16-3
D'Oiron R., PO 498
Dobaczewski G., PO 133
Dobesh P., PB 2.22-6
Dob J., PO 1.19-5
Dobrovolsky A., PB 4.73-4
Dobson G.P., PO 244
Dockal M., AS 41.2, OC 23.3, OC 51.3, OC 66.1, OC 73.1, PA 1.07-3, PA 1.07-4, PA 1.07-6, PA 1.15-1, PA 3.07-1, PB 1.35-1, PB 1.39-6, PB 3.58-3, PO 062, PO 062
Dockendorff C., OC 09.2, OC 54.4
Dockhorn C., PB 1.41-3
Docquier M., AS 15.3
Doevendans P.A., AS 04.1
Dogan A., PO 376
Dogné J-M., OC 02.4, PA 1.52-1, PB 1.53-5, PB 1.60-3, PB 2.60-6, PB 3.51-4, PB 3.52-6, PB 4.40-3, PB 4.52-1, PB 4.53-4
Dohmen P.M., PA 3.08-1, PB 4.60-1
Doi M., PA 4.06-6
Dógi A.M., PB 1.53-2
D'Oiron R., OC 34.4, PB 4.36-5, PB 4.60-6, PO 496
INDEX

Dyer C.E.F., OC 25.4, OC 39.3
Dziedzina S., PO 234, PO 281
Dzora F., PB 1.65-6
Earp S.H., PA 2.02-4
Easton R., PB 3.37-5, PB 3.49-3
Ebensperger R., PB 1.31-6
Eberhart G., PB 3.41-5
Eber W., PO 130, PO 370
Ebert F., PA 1.10-5, PA 3.19-2, PB 3.26-6
Eble J.A., PO 329
Echenagucia M., PO 104
Echevarría P., PO 149
Eckes B., AS 16.2
Eckhardt C.L., OC 03.3, OC 56.3, OC 66.4
Ecky A., OC 55.3, PA 2.04-3, PA 2.04-6, PB 1.29-6
Ecob R., PA 4.01-3, PB 1.21-1
Economou M., OC 83.2
Édes I., OC 07.5, PA 2.01-2
Eerenberg E.S., OC 02.2, PA 4.06-4, PB 4.48-2, SPS08-05
Effendi A.R., PO 314
Efford J., PB 2.42-2
Efthymiou M., AS 41.3, PA 1.18-6, PB 1.62-4, PB 4.50-5
Eggleston J., PB 1.64-1
Egorina E., PB 1.56-4, PB 3.56-3
Egorova E.N., PO 028
Egot M., PA 1.08-4
Ehlen H.W.A., OC 11.3
Ehrenforsth S., OC 83.2, SPS04-05
Ehrlich H.J., OC 51.3, PB 3.55-4, PB 3.55-6, PB 4.35-2
Eichinger S., SC11-1.04, SC11-4.03, AS 18, OC 12.5, OC 63.2, PB 3.70-3, PB 3.73-1, PO 459
Eichler H., PO 145
Eijgenraam P., PA 1.10-1
Eikelboom J.W., SC06-3.01, PL 01, PA 1.20-1, PA 3.10-3, PB 4.47-3, SAS05-01
Eikenboom H.C.J., SC17-1.01, AS 32.3, OC 13.1, OC 13.3, OC 13.4, OC 91.1, OC 91.6, PA 2.08-3, PA 3.09-1, PB 1.42-1, PB 3.43-3, PO 358
Einarsdóttir K.A., PA 4.10-2
Einhorn L.H., PB 1.61-5
Eintrei J., AS 02.3, PB 1.28-6, PO 085
Eischer L., Sc11-2.02, OC 63.2, PB 3.73-1
Eissa D.G., PB 2.32-4, PO 069
Eissa D.S., PB 2.32-4
Ek B., PA 2.15-6
Ekhlas-Hundrieser M., PB 4.43-5
El Gahta R., PO 187, PO 324
Elalamy I., PB 2.53-6, OC 19.3, SC16-3.03
Elafy M., AS 22.2
Elder M.J., AS 01.1
Elena P., PB 4.54-4
Elezovic I., SC05-2.02, OC 48.4, PA 4.07-3, PB 4.61-5
Elfrink E., PB 2.64-1
Elia A., AS 18.2
Elie C., PA 1.08-4
Eligini S., PB 3.32-2
Elkaim E., PB 4.29-3
Elkaloui-Ba A., OC 38.5, OC 38.6, OC 61.6, PA 3.18-1, PA 4.09-1, PB 4.32-2
ElKeeb A.M., PB 3.56-1
Ellder Ph., PB 2.18-5, PB 3.63-2
Eller T., PB 3.74-3
Ellouze R., PO 387
Elm T., OC 84.2
El-Maarri O., OC 80.5
Elmståhl S., PB 4.42-1
Elouel R., PA 4.18-1
Eltringham-Smith L.J., OC 36.3
Emerson M., PA 4.01-6, PB 2.27-5, PB 4.23-5
Emmett S.C., OC 61.5
Emmi G., PB 1.67-2
Emsley J., SC21-1.01, OC 18.4, PA 3.14-6
Enander K., PO 333
Enayat S., PB 4.43-1
Encarnacao J.A., PB 3.34-3
Ender M., AS 44.2
Endo H., OC 25.3
Endresz V., OC 32.6, PB 1.32-2, PB 1.32-5, PO 470
Ene G., PB 3.73-4, PO 396
Eng K.F., AS 43.1, OC 07.1, OC 59.6, PB 1.69-1, PB 1.69-4, PB 1.70-1, PB 2.70-1, PB 2.70-3, PB 4.64-2, PB 4.69-2
Engbers M.J., PA 3.19-6, PB 4.70-1
Engel R., PB 4.67-4
Engelbarth S., OC 90.2
Engelmaier A., PO 060, PO 061
Engl W., PO 158
Enjeti A., PB 4.30-2
Enjolras N., PA 1.12-2
Ennevat P-V., AS 18.2
Enright H., PB 2.49-2
Epstein J., PB 1.35-2
Epstein J.D., PB 1.39-3, PB 3.36-4, PB 3.38-2, PO 142, PO 160
Erba N., OC 12.4, OC 42.2
Eras M., PB 4.36-2
Erber M., PB 2.52-5
Erdeljan S., PO 484
Erdem S., PO 101
Erdogan S., PB 1.25-6
Eren M., AS 23.1, OC 29.1, PA 2.17-1
Ergül S., PB 3.46-5
Eriksen M., PB 2.59-3
Ericksson H., OC 63.3
Ericksson O., OC 38.2
Ericksson-Boij E., AS 02.3
Eritsland J., PB 1.21-5
Erkan D., PB 2.62-4, PB 3.62-4
Erkens P.G.M., OC 20.3, OC 71.2, OC 71.4, OC 79.4, PA 1.20-2, PB 2.48-2, PB 3.46-5
Erkholmovich A., PO 228
Escalante V., PA 4.08-5, PB 1.49-4, PB 2.40-4, PB 2.47-1, PB 3.22-2, PB 3.39-1, PB 4.40-2
Esch V., PB 4.73-6
Escolar G., PA 3.01-4, PA 3.10-6, PB 1.33-4, PB 2.31-3, PB 2.31-5, PB 4.22-5, PB 4.47-2
INDEX

Faber J., PB 4.60-5
Faber J.H., OC 28.4, OC 57.5, OC 57.6
Fabra S., PO 270
Fabrizzi B., OC 50.3
Facskó Á., PA 4.15-3
Fadin M., AS 33.1
Faella A., OC 31.4, OC 50.2, OC 83.3
Fagan P., PB 4.62-4
Faganot Kotnik B., PO 298
Faies S.A., OC 28.1, OC 89.1
Falet H., OC 10.3
Fan L-H., PB 1.69-6
Fan X., FS 03.2, PO 236
Fan-Chen K., PA 225
Fang C., OC 01.1, OC 26.1, OC 53.4
Fang J., PB 1.29-2
Faradji A., PB 2.37-5
Faraj F., PB 1.27-6
Faranoush M., PB 1.50-6, PO 481
Fareed J., PA 3.16-2, PA 4.17-2, PA 4.17-3, PB 1.30-6, PB 1.40-2, PB 1.40-3, PB 1.40-5, PB 1.46-1, PB 1.48-4, PB 1.49-4, PB 1.58-6, PB 2.47-1, PB 2.47-3, PB 2.68-5, PB 3.47-5, PB 3.54-3, PB 3.56-6, PB 4.48-6, PB 4.60-1, PB 4.68-5, PO 183, PO 259, PO 420
Farge-Bancel D., A 34, PB 2.30-1, PO 048
Faria A.P., PB 2.64-1
Faria M.C., PA 4.20-6, PB 4.32-4
Farias F., PB 4.57-6
Farkas A.Z., AS 23.3
Farndale R.W., PA 2.02-3, PA 2.09-5, PA 3.01-1, PA 3.02-2, PA 3.02-3, PA 4.03-4, PB 1.22-3, PB 1.23-2, PB 1.31-3, PO 360
Farnleitner E., PA 4.06-3
Faro M., PB 2.52-1
Farrugia A., PA 2.06-1
Fasola G., PB 3.60-6
Fassot C., OC 54.2
Fasulo M.R., PA 2.12-2, PA 4.11-6
Fathy A., PB 1.52-6
Fatima H., PB 2.41-2
Fatini C., PB 4.32-3
Fattolle R.F., PB 2.29-2
Fautre G.C., PB 4.63-4
Fauquais A.M., PB 1.19-1
Fava F., PA 2.16-6
Favalo E.J., PA 4.11-5
Favaretto E.J., PB 2.71-6, PB 2.74-3
Favier R., OC 45.4
Favuzzi G., PO 201
Faxälv L., PA 3.04-4, PB 4.25-2
Fay Ph.J., OC 28.2, OC 57.3, PA 4.13-4
Fayea N., PB 4.71-6
Fazakas F., PA 4.15-5
Fazavana J., AS 26.3
Federico A., PB 2.31-6
Fedi S., PB 2.22-3, PB 4.32-3
Fedora E., PB 4.48-4
Feener E., SC21-1.02
Feijge M.A.H., OC 87.5, OC 2.05-5, PB 1.32-2, PB 3.26-4, PB 3.40-2
Feketeova J., PB 4.60-5
Fekih M., PB 2.45-5, PO 405
Felding-Habermann B., OC 82.2
<table>
<thead>
<tr>
<th>Name</th>
<th>Page Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Feliu Torres A.S.</td>
<td>PB 1.43-6, PB 1.71-1, PB 1.71-3, PO 303</td>
</tr>
<tr>
<td>Femia E.A.</td>
<td>PB 1.22-4, PO 447</td>
</tr>
<tr>
<td>Feng D.</td>
<td>OC 68.4</td>
</tr>
<tr>
<td>Fenger-Eriksen C.</td>
<td>PB 3.38-4</td>
</tr>
<tr>
<td>Fennema H.</td>
<td>PO 324</td>
</tr>
<tr>
<td>Fenoglio L.M.</td>
<td>PB 1.49-1</td>
</tr>
<tr>
<td>Fennema H.</td>
<td>PO 324</td>
</tr>
<tr>
<td>Feola G.</td>
<td>PA 1.13-2</td>
</tr>
<tr>
<td>Feola M.</td>
<td>OC 57.4, PA 1.13-6</td>
</tr>
<tr>
<td>Ferencak G.</td>
<td>PB 4.31-4</td>
</tr>
<tr>
<td>Fernandes A.P.</td>
<td>PB 2.31-2, PB 2.33-6, PB 3.21-6</td>
</tr>
<tr>
<td>Fernandez A.</td>
<td>PB 2.37-3</td>
</tr>
<tr>
<td>Fernandez J.A.</td>
<td>AS 03.1, PA 1.15-4, PB 2.56-2</td>
</tr>
<tr>
<td>Fernandez N.</td>
<td>PO 104</td>
</tr>
<tr>
<td>Fernandez R.</td>
<td>PB 4.22-5, PO 299</td>
</tr>
<tr>
<td>Fernandez Bello I.</td>
<td>PB 1.25-1, PB 4.52-4</td>
</tr>
<tr>
<td>Fernandez de Soto M.</td>
<td>OC 85.5</td>
</tr>
<tr>
<td>Fernandez B.</td>
<td>OC 91.1, AS 37.</td>
</tr>
<tr>
<td>Fernandez-G J.M.</td>
<td>PA 2.56-6, PO 199</td>
</tr>
<tr>
<td>Fernando C.</td>
<td>PO 389</td>
</tr>
<tr>
<td>Fernyhough P.</td>
<td>PB 1.55-2</td>
</tr>
<tr>
<td>Ferrando F.</td>
<td>PA 3.11-4, PB 2.69-1, PB 2.69-2</td>
</tr>
<tr>
<td>Ferrari B.</td>
<td>PA 2.16-4, PB 1.33-6</td>
</tr>
<tr>
<td>Ferrari M.C.</td>
<td>PB 2.46-4</td>
</tr>
<tr>
<td>Ferrari R.</td>
<td>OC 07.4</td>
</tr>
<tr>
<td>Ferrari S.</td>
<td>PB 2.33-1</td>
</tr>
<tr>
<td>Ferraroni M.</td>
<td>PB 1.69-3</td>
</tr>
<tr>
<td>Ferreira C.N.</td>
<td>PB 4.76-2, PO 479</td>
</tr>
<tr>
<td>Ferrer P.</td>
<td>PA 3.01-5</td>
</tr>
<tr>
<td>Ferro A.</td>
<td>PB 2.27-4</td>
</tr>
<tr>
<td>Ferster A.</td>
<td>PB 2.55-1</td>
</tr>
<tr>
<td>Feuring M.</td>
<td>OC 63.3</td>
</tr>
<tr>
<td>Feussner A.</td>
<td>PB 4.55-6</td>
</tr>
<tr>
<td>Feve B.</td>
<td>OC 86.4, PB 4.64-1</td>
</tr>
<tr>
<td>Few K.</td>
<td>PA 1.08-5</td>
</tr>
<tr>
<td>Feyes H.</td>
<td>OC 15.3</td>
</tr>
<tr>
<td>Ffrench P.</td>
<td>PB 1.43-5, PB 1.57-5</td>
</tr>
<tr>
<td>Fickentscher C.</td>
<td>OC 27.1</td>
</tr>
<tr>
<td>Fidalgo T.</td>
<td>OC 52.4, PB 3.67-6, PB 4.73-3</td>
</tr>
<tr>
<td>Fidan A.</td>
<td>PO 067, PO 068</td>
</tr>
<tr>
<td>Fidelis F.</td>
<td>PO 009</td>
</tr>
<tr>
<td>Fields L.E.</td>
<td>PA 2.10-3</td>
</tr>
<tr>
<td>Fierro T.</td>
<td>OC 43.2</td>
</tr>
<tr>
<td>Figueras F.J.</td>
<td>PB 4.58-5</td>
</tr>
<tr>
<td>Fijnheer R.</td>
<td>OC 21.4, PA 1.03-5, PA 4.06-2</td>
</tr>
<tr>
<td>Fijnvandraat K.J.</td>
<td>AS 22.1, OC 03.3, OC 13.1, OC 56.3, OC 66.4, PA 2.07-1, PA 2.08-3, PB 1.38-4, PB 1.42-1, PB 2.36-2</td>
</tr>
<tr>
<td>Fil K.</td>
<td>PB 1.14-5, PA 3.06-3, PB 1.63-1</td>
</tr>
<tr>
<td>Filai A.</td>
<td>PB 2.45-5</td>
</tr>
<tr>
<td>Filali A.</td>
<td>PO 003, PO 405</td>
</tr>
<tr>
<td>Filhon B.</td>
<td>PA 4.12-1</td>
</tr>
<tr>
<td>Filipieva A.</td>
<td>OC 84.6</td>
</tr>
<tr>
<td>Filipov P.</td>
<td>PB 263</td>
</tr>
<tr>
<td>Filippi L.</td>
<td>PA 4.16-5</td>
</tr>
<tr>
<td>Filippini M.</td>
<td>PB 2.31-4, PB 3.73-3</td>
</tr>
<tr>
<td>Fima E.</td>
<td>OC 83.6</td>
</tr>
<tr>
<td>Fimmers R.</td>
<td>PA 3.17-6</td>
</tr>
<tr>
<td>Finamore F.</td>
<td>PB 2.67-6</td>
</tr>
<tr>
<td>Finazzi G.</td>
<td>PB 1.26-5</td>
</tr>
<tr>
<td>Finazzo C.</td>
<td>PB 1.53-2</td>
</tr>
<tr>
<td>Fine I.</td>
<td>PO 453, PO 482</td>
</tr>
<tr>
<td>Finney B.A.</td>
<td>OC 88.6</td>
</tr>
<tr>
<td>Fiore M.</td>
<td>PB 3.25-1, PO 448</td>
</tr>
<tr>
<td>Fiorillo C.</td>
<td>PB 2.27-6, PB 4.33-1, PB 4.74-3</td>
</tr>
<tr>
<td>Firbas C.</td>
<td>PA 1.01-5</td>
</tr>
<tr>
<td>Fischer A.M.</td>
<td>PA 1.17-1, PB 2.29-5, PB 3.48-2</td>
</tr>
<tr>
<td>Fischer G.</td>
<td>PO 398</td>
</tr>
<tr>
<td>Fischer J.</td>
<td>PB 278</td>
</tr>
<tr>
<td>Fischer K.</td>
<td>OC 22.2, OC 51.1, PA 2.06-1, PA 2.06-2, PA 1.35-3, PB 1.38-5, PB 3.37-2, SPS 03-07, SPS07-01, SPS02-07</td>
</tr>
<tr>
<td>Fischer M.</td>
<td>PB 4.60-2, OC 04.5</td>
</tr>
<tr>
<td>Fischer M.B.</td>
<td>AS 31.1</td>
</tr>
<tr>
<td>Fischer R.</td>
<td>OC 90.6, PB 2.72-5, PB 4.65-6, PO 203</td>
</tr>
<tr>
<td>Fischetti L.</td>
<td>PA 3.17-1</td>
</tr>
<tr>
<td>Fischler M.</td>
<td>PB 1.59-1</td>
</tr>
<tr>
<td>Fish R.J.</td>
<td>OC 06.2, OC 06.6</td>
</tr>
<tr>
<td>Fisher D.</td>
<td>PA 2.10-3</td>
</tr>
<tr>
<td>Fishwick C.</td>
<td>PB 2.59-2</td>
</tr>
<tr>
<td>Fissore-Magdelin C.</td>
<td>PO 008</td>
</tr>
<tr>
<td>Fitch-Tewfik J.L.</td>
<td>OC 54.4</td>
</tr>
<tr>
<td>Fitzpatrick M.G.</td>
<td>PB 1.28-4</td>
</tr>
<tr>
<td>Fiusa M.L.</td>
<td>PA 1.17-5</td>
</tr>
<tr>
<td>Flahive J.M.</td>
<td>PB 3.48-1</td>
</tr>
<tr>
<td>Flamini O.</td>
<td>OC 59.1, PB 1.70-3</td>
</tr>
<tr>
<td>Flanagan P.</td>
<td>PO 007</td>
</tr>
<tr>
<td>Flaujac C.</td>
<td>OC 79.2</td>
</tr>
<tr>
<td>Flaumenhaft R.</td>
<td>AS 07.2, AS 16.3, OC 09.2, OC 16.3, OC 54.4</td>
</tr>
<tr>
<td>Fleitas T.</td>
<td>PB 1.27-3</td>
</tr>
<tr>
<td>Flesch F.M.</td>
<td>PA 1.08-5</td>
</tr>
<tr>
<td>Fletcher J.P.</td>
<td>PB 5.64-2</td>
</tr>
<tr>
<td>Fletcher S.N.</td>
<td>PA 1.09-4</td>
</tr>
<tr>
<td>Flickr M.J.</td>
<td>AS 24.1, OC 18.3</td>
</tr>
<tr>
<td>Flieder T.</td>
<td>PB 3.74-3</td>
</tr>
<tr>
<td>Fliert U.</td>
<td>PB 4.24-3</td>
</tr>
<tr>
<td>Flinterman L.E.</td>
<td>AS 18.1, OC 07.1, OC 12.6, OC 59.2</td>
</tr>
<tr>
<td>Flood V.</td>
<td>SC17-3.02</td>
</tr>
<tr>
<td>Flores-Garcia M.</td>
<td>PB 2.56-6, PO 199</td>
</tr>
<tr>
<td>Floros G.</td>
<td>PO 168</td>
</tr>
<tr>
<td>Florquin S.</td>
<td>AS 31.3</td>
</tr>
<tr>
<td>Floyd C.N.</td>
<td>PB 2.27-4</td>
</tr>
<tr>
<td>Fogarty P.</td>
<td>OC 23.4, OC 37.2, PA 2.06-3, SAS03-04</td>
</tr>
<tr>
<td>Fogelson A.L.</td>
<td>PA 3.07-4, PB 4.33-4</td>
</tr>
<tr>
<td>Foidart J-M.</td>
<td>PB 2.66-1</td>
</tr>
<tr>
<td>Foissaud V.</td>
<td>PB 4.54-6</td>
</tr>
<tr>
<td>Foley D.</td>
<td>PA 2.01-1</td>
</tr>
<tr>
<td>Foley J.H.</td>
<td>SC05-2.09, AS 31.2, PB 2.37-1</td>
</tr>
<tr>
<td>Follenzi A.</td>
<td>OC 45.2, OC 57.4, PA 1.13-6</td>
</tr>
<tr>
<td>Fondevila C.</td>
<td>OC 60.5, PA 1.03-6, PA 3.03-2, PB 1.29-5, PB 1.59-5, PB 2.29-3, PB 4.29-4</td>
</tr>
<tr>
<td>Fonseca R.J.C.</td>
<td>PO 186</td>
</tr>
<tr>
<td>Font M.</td>
<td>PA 2.20-1, PA 2.20-5, PB 1.53-6</td>
</tr>
<tr>
<td>Fontaine A.</td>
<td>PO 424</td>
</tr>
<tr>
<td>Fontana G.</td>
<td>PA 3.17-2</td>
</tr>
</tbody>
</table>
Fontana P., AS 15.3, PA 1.01-3, PB 2.67-6, PB 3.21-4, PB 3.24-4
Fontayne A., OC 22.4
Fontcuberta J., PA 2.20-1, PA 2.20-5, PB 1.53-6, PB 1.54-2, PB 1.72-1, PB 3.54-2, PB 3.63-1
Ford I., OC 64.2
Ford I., PB 1.21-3
Fontcuberta J., PA 2.20-1, PA 2.20-5, PB 1.53-6, PB 1.54-2, PB 1.72-1, PB 3.54-2, PB 3.63-1
Ford I., OC 64.2
Formella S., PB 4.53-2
Formisano S., PO 299
Forster A., PB 3.40-5
Förster K., PA 1.10-5, PA 3.19-2, PB 3.26-6
Førsund A., PO 283
Forsyth A., PO 125, PO 126, PO 127
Fortoul T., PB 2.56-6
Fox S.C., PB 1.22-1, PB 2.25-1, PB 2.27-3, PB 3.22-1, PB 3.22-3, PB 4.21-6
Fox-Robichaud A., AS 25.1
Foyn S., PO 283
Fragoso J.M., PB 2.22-5
Franchi F., OC 13.5, PB 2.39-4, PB 2.43-6
Franchini M., PB 2.29-2
Francis C.W., PA 4.10-2
Francis J.L., AS 38.1, AS 39.3
Francis S.E., OC 32.2
Francischetti I., SC20-1.01
Franco E., PB 3.45-2
Franco L., PB 1.49-2, PB 4.60-2, OC 04.5
Franco O.H., PA 2.09-1
François C., PB 3.74-2
François D., OC 54.5, PA 2.14-3, PB 1.59-1
Francuski D., PA 2.13-4
Franke A., PB 3.69-3
Franke D., PO 348
Frankel D., OC 17.2
Franks S., PB 4.54-5
Franssen van de Putte D.E., PB 1.35-3
Franz S., OC 53.5
Franzese C., PB 4.56-5
Frappe P., PA 4.16-3
Fraser S.R., OC 29.6
Frasson R., OC 27.2, PA 2.13-2
Frasson S., AS 43.4, PA 1.20-6
Freichel M., OC 11.2
Freidinger K., PA 1.29-6
Freijer J., PO 292, PO 295
Freire I., PO 036, PO 255
Freishtat R., PA 2.17-3
Freitas L.G., OC 16.4
Freedman J., AS 24.2, OC 55.2, OC 87.1, PO 500
Freichel M., OC 11.2
Freidinger K., PO 145
Freijer J., PO 292, PO 295
Freire I., PO 036, PO 255
Freishtat R., PA 2.17-3
Freitas L.G., PB 4.66-4
Freilinger III A.L., PB 1.21-6, PB 1.28-4, PB 2.63-4, PB 3.21-4
Frémeaux-Bacchi V., AS 47.4
French S., PO 244
Frezinaud E., OC 13.2, OC 13.6
Fretwell R., PB 2.33-3
Fretigny M., OC 48.3, PB 1.39-4, PB 1.39-5, PB 2.35-1
Fritsch S., OC 53.5
Friso S.M., PB 2.29-2
Fritsch S., OC 49.2
Fritsch S., OC 53.5
Frohn S., PA 3.65-4
Fröhlich, PB 4.45-6, PO 278
Fronroth J.P., PB 1.43-6, PB 1.71-1, PB 1.71-3, PO 303
Fruhbeis J., OC 36.4
Fry M., PA 1.02-5, PO 362
Frye S., PA 2.02-4
Fryer H., PA 1.18-4
Fu A.C., PA 2.10-3, PB 1.45-1, PB 4.45-2
Fu R., PB 2.19-6, PB 1.74-4, PB 2.32-3, PB 3.35-6, PB 4.29-2, PB 4.29-5
Fu X., OC 65.6
Fuchs B., PB 2.43-3, PB 3.44-2
Fuchs P.F.J., PB 1.25-5
Fuchs T.A., OC 74.1
Fuentes E., PB 4.21-2
Fuerll B., PB 3.24-2
Fuji H., OC 25.3
Fujii S., OC 32.5, PB 2.34-2, PO 458
Fujii T., PB 1.46-2, OC 37.6, PO 115, PO 115
Fujimoto A., PB 1.28-5
Fujimoto K., PB 1.60-5, PB 2.60-5, PB 4.32-5
Fujimoto M., PB 1.33-5, PB 2.33-4
Fujimoto Y., FS 03.2, PA 4.06-2, PA 4.19-1, PB 1.33-1, PB 1.33-2, PB 1.33-5, PB 2.33-4, PB 2.74-1
Fujita J., PA 3.05-2
Fujita S., PB 1.46-2, PB 4.61-1
INDEX

Fukui H., PB 1.33-5, PB 2.33-4
Fukutake K., OC 37.6, PA 1.08-6, PB 1.35-5, PB 2.44-4, PB 2.54-5, PB 4.39-3, PO 116
Fulkerson M-B., PB 3.31-4
Fullana M.J., OC 53.4
Funding E., PB 2.58-4
Funk S., PA 4.07-6
Funke E.A., PO 164
Furie B.C., AS 08.2, AS 16.3, OC 54.3
Furie B., AS 08.2, AS 16.3, OC 54.3
Furukawa S., OC 37.3
Furuoya Y., PO 156
Fynn A., PO 299
Gabazza E.C., PO 231, PO 232
Gabbianelli M., PB 3.71-1
Gachet C., AS 07.1, AS 27.3, AS 37.1, AS 44.4, OC 35.2, OC 55.3, OC 87.3, OC 89.3, OC 89.6, PA 1.11-6, PB 3.29-2, PB 3.41-1
Gadaeva Z., PO 208
Gadelha T., PB 4.72-1
Gadisseur A., SC17-5.06, PB 1.43-3, PB 3.42-6, PB 4.44-1, PB 4.44-5
Gadomska G., PB 3.60-5, PB 4.56-3, PO 373
Gaglino F., PA 1.13-2
Gaglioti D., PO 112, PO 429
Gaid Mehalhal N., PO 117
Gajardo R., PB 4.58-5
Gajdos C., PB 4.70-4
Gal P., PA 1.19-5
Galambosi P., PB 3.70-4
Galan A.M., PA 3.01-4, PA 3.10-6, PB 1.33-4, PB 2.31-3, PB 4.47-2
Galanakis D.K., PB 3.57-1
Galanter W.L., PB 3.48-5
Galar M., PO 252
Galasso R., PB 1.45-2
Gal A.J., AS 03.3
Galea P., PA 3.08-3
Galea V., OC 19.3, PB 2.53-6
Galego A., PB 2.42-6, PO 149
Galgoczi J., PB 4.55-3
Galinski C.N., AS 07.2
Gallant M., AS 21.1, OC 74.1
Galligan A., PB 3.30-5
Gallinaro L., PA 1.09-1
Gallistl S., PB 4.64-5
Gallus A., SAS07-04
Galmes B., PB 2.37-3
Galora S., PB 2.22-4
Galstyan G., PB 3.51-6, PO 011
Galvez K.M., PO 431
Galpintashvili E., PO 235
Garagiola I., AS 40.1, PA 2.12-2, PA 4.19-6, PB 2.41-5
Garcia A., PB 1.43-5
Garcia C., PA 2.03-1
Garcia Arias Salgado E., PB 1.25-1
Garcia de Frutos P., PA 4.08-6
Garcia Erce J.A., PO 270
Garcia Mouriz A., PA 2.16-3
Garcia Oya I., OC 13.5
Garcia Perez A., PB 3.28-2
Garcia Rodriguez P., OC 17.4
Garcia-Barberá N., OC 05.4, OC 08.1, PB 4.58-1
Garcia-Bragado F., AS 17.3, PB 4.45-1
Garcia-Candel A., PO 118
Garcia-Candel F., PO 118
Garcia-Dasi M., PB 2.37-3
Garcia-Diaz Y., PB 2.50-5
Garcia-Garcia J.A., PB 1.61-6, PB 3.60-4
Garcia-Mata J., PA 2.16-5
Garcia-Navarro I., PO 016, PO 275
Garcia-Raso A., PB 3.73-4, PO 396
Garcia-Talavera J.A., PB 2.37-3
Gardiner C., AS 14.2, SC07-4.02, OC 76.1, OC 88.2, PA 2.18-6, PA 3.01-1, PB 2.23-4
Garg I., PA 4.09-4
Garg S., PO 013
Gargenti C., PB 1.22-5, PB 3.22-5
Gartovska I., PO 155
Gary T., PA 2.18-5, PB 3.63-2
García-Garcia A., OC 41.4
Gascoigne E., PB 2.36-1
INDEX

Gasparyan S., PO 219
Gässler J., PB 2.38-6
Gasto C., PB 2.31-3
Gatt A., PB 3.37-2
Gau J-P., PB 1.67-5
Gauberli M., AS 23.2, AS 35.3, PA 3.04-6, PA 3.04-6
Gau C., OC 22.4
Gart A., PB 3.37-2
Gautier B., PA 1.17-4
Gava S., PB 3.65-6
Gavalaki M., PB 1.74-1, PB 2.69-6
Gavasso S., AS 33.1, PA 1.04-5, PA 3.13-1, PB 1.72-6, PB 3.30-4, PB 3.54-5
Gawaz M., SC18-1.03
Gay L.J., OC 82.2
Gebel M., AS 17.1
Gebers E.P.A., PB 4.46-2
Geersing G.J., OC 20.3, PA 4.16-1, PA 4.16-4, PA 4.16-6
Geerts W.H., AS 28.1, PB 4.70-5
Gehrand A., PA 2.09-2
Gehrisch S., PO 045, PO 143
Gelder M., OC 73.4, PA 2.60-3, PA 4.50-1
Gelbracht V., PA 1.10-5, PA 3.19-2, PB 3.26-6
Gelis L., PO 313
Gelone S., PB 3.59-5
Gemina E., PB 2.51-4
Gemmati D., OC 07.4
Geng Y., OC 18.6
Genoud V., PB 1.57-4, PB 1.72-2, PB 2.34-6
Gensini G.F., PB 1.31-2, PB 2.22-4, PB 2.27-6, PB 2.29-1, PB 2.29-2
George J.N., PA 4.19-1
Georges-Labouesse E., AS 27.3, PA 1.17-1
Gerano G., PB 3.57-6
Gerber B., PB 1.36-3
Gerdabi J., PO 054
Gerd C., PA 2.15-2
Gerd N., AS 04.3
Gerd V.E.A., OC 71.1, PB 1.69-2, PB 2.65-1
Gerhardt A., PO 4.66-1, PO 202
Gertil R., PB 2.68-2
Gerossa G., PB 2.45-3
Geritziasfas G.T., OC 19.3, PB 2.53-6, PB 2.59-1
Gerrits A.J., PB 1.28-4, PB 2.63-4
Gerritson H.C., OC 45.1, OC 55.4
Gesler C., PA 2.15-2
Gerdes N., AS 04.3
Gibbins J.M., AS 39.2, OC 08.6, OC 85.1, OC 87.6, PA 1.02-5, PA 2.02-3, PA 4.02-3, PA 1.23-3, PB 2.28-6, PB 3.23-4, PB 4.54-5, PO 362
Giemza-Kucharska P., PB 3.61-3
Giempans L., PB 3.47-1
Gierczak R.F., PB 4.59-1
Gierczynski M., PB 1.43-5
Giese C., OC 16.2
Giessmann L., PA 4.43-5
Gigant Estellés J., OC 40.3, OC 40.4
Gil A., PO 188
Gil L., PB 3.31-2, PB 3.66-6
Gilbert G.E., SC01-4.02, PB 1.31-1
Giles I., OC 41.4
Gill J.C., PB 2.55-4
Gilles J-G., OC 22.4
Gillett S., PA 4.18-6
Gilligan O., PB 2.61-2
Gilmore G., PB 1.33-3
Gilmore R., PB 4.62-4, PO 257
Gilmour S.K., OC 31.5
Gils A., SC05-2.06, SC05-2.13, SOA 05.2, OC 84.5, PA 1.06-1, PA 1.06-4, PB 2.34-5, PB 2.63-3, PB 3.66-2
Gimenez M.I, PB 3.53-5, PB 4.51-5, PB 4.62-3, PB 4.63-1
<table>
<thead>
<tr>
<th>Name</th>
<th>Page(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gimenez V.</td>
<td>PO 299</td>
</tr>
<tr>
<td>Gindele R.</td>
<td>OC 78.2, OC 78.3, OC 90.3</td>
</tr>
<tr>
<td>Ginsburg D.</td>
<td>OC 15.4, OC 47.1, PB 1.44-4</td>
</tr>
<tr>
<td>Gionco S.</td>
<td>PB 2.34-6</td>
</tr>
<tr>
<td>Giorgetti A.</td>
<td>PO 042</td>
</tr>
<tr>
<td>Giovelli J.</td>
<td>PO 074</td>
</tr>
<tr>
<td>Giptner A.</td>
<td>OC 55.6</td>
</tr>
<tr>
<td>Girando A.V.</td>
<td>PB 1.49-1</td>
</tr>
<tr>
<td>Girard P.</td>
<td>PB 3.73-5</td>
</tr>
<tr>
<td>Giraud M.</td>
<td>OC 13.2</td>
</tr>
<tr>
<td>Giron M.</td>
<td>PB 2.65-5</td>
</tr>
<tr>
<td>Gironi M.T.</td>
<td>PB 1.56-1</td>
</tr>
<tr>
<td>Gissen P.</td>
<td>OC 34.2</td>
</tr>
<tr>
<td>Gitz E.</td>
<td>OC 45.1, OC 55.4, OC 88.3</td>
</tr>
<tr>
<td>Giuffrida A.</td>
<td>PB 1.11-1</td>
</tr>
<tr>
<td>Giuffrida G.</td>
<td>PA 2.04-6</td>
</tr>
<tr>
<td>Giulivi A.</td>
<td>PB 3.67-6</td>
</tr>
<tr>
<td>Gjergji M.</td>
<td>PO 218</td>
</tr>
<tr>
<td>Glas M.</td>
<td>PO 315</td>
</tr>
<tr>
<td>Glauser B.</td>
<td>PB 3.73-5</td>
</tr>
<tr>
<td>Gleeson E.</td>
<td>AS 21.3</td>
</tr>
<tr>
<td>Gleizes C.</td>
<td>PA 1.04-2</td>
</tr>
<tr>
<td>Glembocky A.</td>
<td>OC 89.4</td>
</tr>
<tr>
<td>Glenn J.R.</td>
<td>PB 1.22-1, PB 2.27-3, PB 4.21-6</td>
</tr>
<tr>
<td>Gloria D.</td>
<td>OC 82.3</td>
</tr>
<tr>
<td>Gloria P.</td>
<td>PA 4.08-2</td>
</tr>
<tr>
<td>Glynn J.</td>
<td>OC 26.4</td>
</tr>
<tr>
<td>Gnedova A.</td>
<td>PB 3.51-6</td>
</tr>
<tr>
<td>Gneusheva T.Y.</td>
<td>PO 412</td>
</tr>
<tr>
<td>Gneuß A.</td>
<td>PO 348</td>
</tr>
<tr>
<td>Gnip S.</td>
<td>PO 263, PO 484</td>
</tr>
<tr>
<td>Goda N.</td>
<td>PB 1.29-4</td>
</tr>
<tr>
<td>Goddijn M.</td>
<td>OC 61.2</td>
</tr>
<tr>
<td>Godier A.</td>
<td>PA 1.01-3, PA 4.09-1, PB 3.48-2, PB 4.33-6, PB 4.34-1</td>
</tr>
<tr>
<td>Godoi L.C.</td>
<td>PB 4.65-2, PO 287</td>
</tr>
<tr>
<td>Godschalk T.C.</td>
<td>PA 2.17-6, PB 1.63-2, PO 450</td>
</tr>
<tr>
<td>Goeijenbier M.</td>
<td>OC 69.4</td>
</tr>
<tr>
<td>Goggs R.</td>
<td>OC 10.1, PA 1.02-6</td>
</tr>
<tr>
<td>Goh R-Y.</td>
<td>PB 4.24-6</td>
</tr>
<tr>
<td>Goinic M.</td>
<td>PB 3.65-3</td>
</tr>
<tr>
<td>Gokce M.</td>
<td>PB 4.41-6, PB 4.71-1, PO 098</td>
</tr>
<tr>
<td>Gokce S.</td>
<td>PO 500</td>
</tr>
<tr>
<td>Goldhaber S.Z.</td>
<td>OC 36.5, OC 63.3, SAS01-01, SAS01-05</td>
</tr>
<tr>
<td>Goldmann G.</td>
<td>PB 2.36-6</td>
</tr>
<tr>
<td>Goldsmith R.E.</td>
<td>PO 491</td>
</tr>
<tr>
<td>Golebiewska E.M.</td>
<td>OC 10.1</td>
</tr>
<tr>
<td>Golmard J-L.</td>
<td>PB 3.39-3</td>
</tr>
<tr>
<td>Golomysova A.</td>
<td>PB 3.27-6, PB 4.27-1</td>
</tr>
<tr>
<td>Golovina O.</td>
<td>PB 1.30-5, PB 4.30-1, PO 456</td>
</tr>
<tr>
<td>Gomes F.</td>
<td>PB 4.26-6</td>
</tr>
<tr>
<td>Gomes H.C.</td>
<td>PO 035</td>
</tr>
<tr>
<td>Gomes K.B.</td>
<td>PB 3.23-6, PB 3.21-6, PB 4.74-2, PO 040, PO 230, PO 287, PO 479</td>
</tr>
<tr>
<td>Gomez K.</td>
<td>PA 3.14-5, PB 1.41-2, PB 2.25-4, PB 4.66-2</td>
</tr>
<tr>
<td>Gomez L.</td>
<td>PB 488</td>
</tr>
<tr>
<td>Gomes M.</td>
<td>PB 431</td>
</tr>
<tr>
<td>Gomes R.M.</td>
<td>OC 46.1, PB 1.59-5, PB 4.29-4</td>
</tr>
<tr>
<td>Gómez-Cerezo J.</td>
<td>PA 4.16-2</td>
</tr>
<tr>
<td>Gomez-del-Castillo M.</td>
<td>PB 2.32-2, PB 2.62-6, PO 149</td>
</tr>
<tr>
<td>Gomez-Rodriguez V.</td>
<td>PB 2.63-6</td>
</tr>
<tr>
<td>Gomis R.</td>
<td>PB 4.22-5</td>
</tr>
<tr>
<td>Gonçalves E.</td>
<td>OC 52.4, PB 3.67-6</td>
</tr>
<tr>
<td>Gonçalves F.</td>
<td>PA 1.20-6</td>
</tr>
<tr>
<td>Gonçalves G.S.</td>
<td>PB 4.20-6, PB 4.32-4, PO 247</td>
</tr>
<tr>
<td>Gonçalves L.H.</td>
<td>PB 3.21-6</td>
</tr>
<tr>
<td>Gonçalves L.R.</td>
<td>PO 035</td>
</tr>
<tr>
<td>Gonçalves V.</td>
<td>OC 02.5</td>
</tr>
<tr>
<td>Gonçalves E.</td>
<td>PA 1.20-6</td>
</tr>
<tr>
<td>González-Conejero R.</td>
<td>OC 05.4, OC 08.1, OC 27.6, PA 2.10-1, PB 1.48-1, PB 3.52-4</td>
</tr>
<tr>
<td>González-Juanatey J.R.</td>
<td>PB 2.27-2</td>
</tr>
<tr>
<td>Gonzalez-López T.J.</td>
<td>PB 1.68-2, PB 3.45-2</td>
</tr>
<tr>
<td>Gonzalez-Manchón C.</td>
<td>PB 2.25-3</td>
</tr>
<tr>
<td>Gonzalez-Porras J.R.</td>
<td>PB 1.68-2, PB 3.45-2</td>
</tr>
<tr>
<td>Goodall A.H.</td>
<td>OC 64.6, OC 88.2, PA 2.05-1, PA 3.04-2, PB 2.26-3, PB 2.26-5, PB 3.71-4, PB 3.71-6</td>
</tr>
<tr>
<td>Gooden A.C.</td>
<td>SC17-5.02, OC 13.4, OC 39.4, OC 39.6, OC 62.3, PA 2.20-2, PA 3.09-1, PA 3.09-4, PB 1.37-1, PB 1.44-5, PB 3.42-1</td>
</tr>
<tr>
<td>Goodale A.C.</td>
<td>PB 1.22-1, PB 4.27-3, PB 4.55-4</td>
</tr>
<tr>
<td>Goodnough L.T.</td>
<td>SP12-02</td>
</tr>
<tr>
<td>Goodwin C.</td>
<td>OC 82.3, PA 2.11-6, PB 3.39-2</td>
</tr>
<tr>
<td>Goodwin C.</td>
<td>PB 1.32-5</td>
</tr>
<tr>
<td>Goodyear D.M.</td>
<td>PB 4.43-3, PB 4.44-6</td>
</tr>
<tr>
<td>Goodyer M.</td>
<td>PB 4.62-4</td>
</tr>
<tr>
<td>Goossens M.</td>
<td>PB 1.39-4</td>
</tr>
<tr>
<td>Goranova Y.</td>
<td>PO 312</td>
</tr>
<tr>
<td>Gorbacheva L.</td>
<td>PB 4.67-5, PO 228</td>
</tr>
<tr>
<td>Gorbatenko A.</td>
<td>PO 4.48-1</td>
</tr>
<tr>
<td>Gordon B.</td>
<td>PA 1.14-2 , PB 3.57-2</td>
</tr>
<tr>
<td>Gordy L.</td>
<td>PB 1.61-5</td>
</tr>
<tr>
<td>Gorgevska V.</td>
<td>PO 237</td>
</tr>
<tr>
<td>Gorgi Y.</td>
<td>PB 1.25-4, PB 4.62-5, PO 387</td>
</tr>
<tr>
<td>Gori A.M.</td>
<td>OC 08.2, OC 29.4, PB 1.31-2, PB 2.22-3, PB 2.27-6, PB 2.29-1, PB 2.29-2, PB 2.31-6</td>
</tr>
<tr>
<td>Gorkun O.</td>
<td>PB 1.50-5</td>
</tr>
<tr>
<td>Gorska-Kosicka M.</td>
<td>OC 83.5</td>
</tr>
<tr>
<td>Goss A.M.</td>
<td>OC 31.5, PB 1.47-4</td>
</tr>
<tr>
<td>Gossman S.</td>
<td>PB 1.25-6</td>
</tr>
<tr>
<td>Gotthot A.</td>
<td>PA 1.02-3</td>
</tr>
<tr>
<td>Goto S.</td>
<td>PB 2.28-3, PB 3.27-5</td>
</tr>
<tr>
<td>Goto Y.</td>
<td>PB 3.37-1</td>
</tr>
<tr>
<td>Gotru S.K.</td>
<td>AS 30.2, OC 88.1, PA 2.02-2</td>
</tr>
<tr>
<td>Gouba C.</td>
<td>OC 34.1, PA 4.05-5</td>
</tr>
<tr>
<td>Name</td>
<td>Index</td>
</tr>
<tr>
<td>-----------------------</td>
<td>-------------</td>
</tr>
<tr>
<td>Gouder E.</td>
<td>PB 4.44-1,</td>
</tr>
<tr>
<td>Goulas E.</td>
<td>PO 401</td>
</tr>
<tr>
<td>Gounou C.</td>
<td>AS 14.3</td>
</tr>
<tr>
<td>Gourley M.</td>
<td>PB 1.53-3</td>
</tr>
<tr>
<td>Gouya G.</td>
<td>OC 16.1, PB 4.45-3</td>
</tr>
<tr>
<td>Govaerts D.</td>
<td>PB 1.47-6</td>
</tr>
<tr>
<td>Govers J.</td>
<td>PB 1.63-2</td>
</tr>
<tr>
<td>Govind S.</td>
<td>PO 475, PO 476</td>
</tr>
<tr>
<td>Goy J.</td>
<td>PB 1.64-2</td>
</tr>
<tr>
<td>Goyal J.</td>
<td>OC 65.5</td>
</tr>
<tr>
<td>Goycoolea M.</td>
<td>PB 3.25-5</td>
</tr>
<tr>
<td>Gracie E.</td>
<td>PO 009</td>
</tr>
<tr>
<td>Graf N.</td>
<td>PO 145</td>
</tr>
<tr>
<td>Graham D.K.</td>
<td>PA 2.02-4</td>
</tr>
<tr>
<td>Grae A.</td>
<td>PB 4.38-6</td>
</tr>
<tr>
<td>Grazioli S.</td>
<td>PB 3.15-4</td>
</tr>
<tr>
<td>Gruenwald</td>
<td>SC18-1.01</td>
</tr>
<tr>
<td>Greig A.L.</td>
<td>PB 2.44-2</td>
</tr>
<tr>
<td>Greinacher A.</td>
<td>SC04.1-1.2, AS28, OC 55.1, PA 3.08-5, PB 2.40-2, PB 2.40-6, PB 3.24-2</td>
</tr>
<tr>
<td>Gresele P.</td>
<td>SC18-2.02, OC 09.3, OC 43.2, OC 62.4, OC 77.3, PA 2.03-6, PB 2.31-4, PB 2.68-2</td>
</tr>
<tr>
<td>Gretenkort Andresson N.</td>
<td>OC 03.2</td>
</tr>
<tr>
<td>Grigurevich S.</td>
<td>PB 4.25-4</td>
</tr>
<tr>
<td>Gribkova I.</td>
<td>PB 4.48-1</td>
</tr>
<tr>
<td>Gries K.S.</td>
<td>PB 3.38-6</td>
</tr>
<tr>
<td>Griess K.</td>
<td>OC 51.4</td>
</tr>
<tr>
<td>Griffin J.H.</td>
<td>AS 03.1, AS 07.3, PA 1.15-4, PB 2.56-2</td>
</tr>
<tr>
<td>Griffin J.I.</td>
<td>PO 360</td>
</tr>
<tr>
<td>Griffiths M.</td>
<td>PA 3.15-4</td>
</tr>
<tr>
<td>Grigorian A.</td>
<td>PB 4.58-6</td>
</tr>
<tr>
<td>Grigorian L.</td>
<td>PB 2.27-2</td>
</tr>
<tr>
<td>Grigorjeva M.E.</td>
<td>PO 402</td>
</tr>
<tr>
<td>Grill D.</td>
<td>PB 1.54-4</td>
</tr>
<tr>
<td>Grillberger R.</td>
<td>PB 3.33-6</td>
</tr>
<tr>
<td>Grimala M.</td>
<td>PB 4.57-5</td>
</tr>
<tr>
<td>Grimley C.</td>
<td>SAS08-05</td>
</tr>
<tr>
<td>Gringeri A.</td>
<td>PB 4.39-4, SPS02-03</td>
</tr>
<tr>
<td>Gris J-C.</td>
<td>FS 01.2, PB 2.66-2, PB 3.65-2, PB 4.65-1, PB 4.66-3</td>
</tr>
<tr>
<td>Grissl H.</td>
<td>PB 4.35-2, PO 062</td>
</tr>
<tr>
<td>Grobe N.</td>
<td>OC 26.1</td>
</tr>
<tr>
<td>Groeneveld D.J.</td>
<td>PB 3.43-3</td>
</tr>
<tr>
<td>Groeneveld E-J.</td>
<td>PB 4.46-2</td>
</tr>
<tr>
<td>Groening H.</td>
<td>PB 3.65-4</td>
</tr>
<tr>
<td>Groll J.</td>
<td>PA 1.17-2</td>
</tr>
<tr>
<td>Gröne H.J.</td>
<td>AS 37.3</td>
</tr>
<tr>
<td>Grönholm M.</td>
<td>AS 14.1</td>
</tr>
<tr>
<td>Grootemaat A.E.</td>
<td>PB 3.30-1, PB 3.30-2</td>
</tr>
<tr>
<td>Grootenhus M.A.</td>
<td>PA 2.07-2, PA 2.08-2, PB 1.44-3, PO 153</td>
</tr>
<tr>
<td>Grose S.D.</td>
<td>PA 3.20-5</td>
</tr>
<tr>
<td>Grosser T.</td>
<td>PA 2.01-6</td>
</tr>
<tr>
<td>Gross C.</td>
<td>PB 2.62-3, PB 2.62-5</td>
</tr>
<tr>
<td>Grossi M.</td>
<td>OC 07.4</td>
</tr>
<tr>
<td>Grossi M.F.</td>
<td>PB 4.32-4</td>
</tr>
<tr>
<td>Grosso C.</td>
<td>AS 45.2</td>
</tr>
<tr>
<td>Grosso M.</td>
<td>AS 47.1</td>
</tr>
<tr>
<td>Gross S.H.</td>
<td>PO 025, PO 385</td>
</tr>
<tr>
<td>Grosved F.</td>
<td>PB 2.04-1</td>
</tr>
<tr>
<td>Groth A.</td>
<td>PA 2.06-5</td>
</tr>
<tr>
<td>Groth M.P.</td>
<td>PB 2.44-3</td>
</tr>
<tr>
<td>Grotte O.</td>
<td>AS 33.3, PB 1.57-3, PB 4.37-1</td>
</tr>
<tr>
<td>Grozoswky R.</td>
<td>OC 33.1</td>
</tr>
<tr>
<td>Gruber A.</td>
<td>AS 07.3, AS 13.3, AS 25.2, OC 05.2, OC 46.4, OC 64.1, OC 81.4, OC 82.6</td>
</tr>
<tr>
<td>Gruber B.</td>
<td>PB 2.33-1</td>
</tr>
<tr>
<td>Gruber G.</td>
<td>PB 3.46-6</td>
</tr>
<tr>
<td>Gruel Y.</td>
<td>SC04.1-1.1, SC04.4-1.6, OC 21.3, PA 3.08-3, PA 3.08-4, SPS11-04</td>
</tr>
<tr>
<td>Grunebaum L.</td>
<td>PA 4.17-4</td>
</tr>
<tr>
<td>Grushin K.</td>
<td>OC 28.6, PA 4.13-2</td>
</tr>
<tr>
<td>Grutupa M.</td>
<td>PO 177</td>
</tr>
<tr>
<td>Grutzendler J.</td>
<td>AS 30</td>
</tr>
<tr>
<td>GTHI group</td>
<td>PO 021</td>
</tr>
<tr>
<td>Gu J-M.</td>
<td>PA 2.11-5</td>
</tr>
<tr>
<td>Gu X.</td>
<td>AS 02.1</td>
</tr>
<tr>
<td>Guay L.</td>
<td>PA 1.11-1</td>
</tr>
<tr>
<td>Guarini P.</td>
<td>AS 26.2, PA 1.11-1</td>
</tr>
<tr>
<td>Guarino M.L.</td>
<td>PO 455</td>
</tr>
</tbody>
</table>
INDEX

Guarner J., PO 327
Guarrera S., PB 1.56-6
Guasti L., PB 1.64-3, PB 3.70-6
Guazzaloca G., OC 42.2, PB 2.71-6, PB 3.64-6
Gubensek M., PB 4.46-3
Gubkina V., PB 1.56-4
Gudermann T., AS 30.2
Gudmundsdottir B.R., PA 4.10-2
Gudmundsen T.E., AS 38.3
Guechi Z., PO 217
Guedira C., PO 380
Guelcher C., PO 125
Guella I., PA 4.12-4
Guenther J., PB 2.68-6
Guenther F., PB 3.65-4
Guermazi S., PB 1.25-4, PB 4.62-5, PO 387
Guerra E., PB 2.70-4
Guerrero J.A., PA 2.17-5
Guerrero B., PB 4.34-5, PO 095, PO 488
Guerrero G., PO 103
Guerrero R., PB 3.71-1
Guglielmini G., OC 09.3
Guglielmine H., PB 2.57-5, PB 4.57-6
Guidetti G.F., OC 35.4
Guillermet-Guibert J., AS 37.1
Guillermin A., OC 02.6
Guillet B., PO 4.36-5
Guilliat A.M., PA 1.09-3
Guillon P., PB 2.41-6
Guillou S., PB 1.49-3
Guimaraes J.P., PO 009
Guimbard D., PO 401, PO 435
Guinet C., PB 2.47-6, PB 3.48-4
Guizzardi G., PB 1.63-6
Gulati R., PB 3.35-4, PB 4.38-4
Guler N., PO 057, PO 087
Gulin D., PB 1.34-2, PB 4.33-3
Gültürk E., PB 4.37-4
Gunaratne R.B.A., OC 16.4
Günes A., PO 353
Gunning P., OC 33.5
Gunning W.T., PB 4.28-1
Gunnink S., AS 07.2, OC 09.2
Guo Y., PA 4.11-4
Guo Z., PB 3.56-5
Guoling Y., PB 1.55-5
Gupalo E., PB 2.68-4
Gupta N., OC 37.2, OC 56.1
Gupta S., FS 02.2, OC 33.2, PA 2.02-2, PO 173, PO 301
Gurbel P.A., PB 2.21-4, PB 4.56-5
Gurgey A., PA 4.19-6
Gurrea M., OC 47.4
Gursel T., PB 3.42-5
Gurzhiy D., PB 4.68-2
Gussoni G., AS 43.4, PA 1.20-6, PA 4.10-1
Gustafsson K.M., PB 3.45-3
Gut R., PB 3.41-5
Gutierrez C., PO 152
Gutierrez J., PA 4.20-5
Gutierrez L., PA 2.04-1, PA 2.04-5, PO 329
Gutiérrez G., PB 2.31-5
Gutiérrez-Gallego R., PB 1.15-6
Gutowski-Eckel Z., PB 2.37-5, PB 3.37-4
Gutstein D., PO 187
Guvenc U., PO 098
Guzelbey T., PO 253
Guzmán-Becerra N., PB 2.37-2, PB 4.58-6, PO 160
Gveric-Kreca K., PO 284
Gwer S., PO 023
Gynes M., PA 2.03-4
Gyulkhandanyan A.V., PO 500
Ha D., OC 18.3
Haaf T., OC 80.5
Haaning J.T., PA 4.13-3
Haas S., SP511-03
Haberichter S.L., SC17-3.03, OC 15.3, OC 39.5, OC 80.1, PA 2.09-2
Habets C.A.M., AS 33.2
Habib M., PB 2.51-3
Habouchi A., PB 3.73-6
Hachem A., PA 4.02-6
Hackett S.C., SC21-2.01, OC 18.2

Hackeng C.M., AS 15.1, PA 2.17-6, PB 1.63-2, PO 450
Hackeng T.M., PL 05, AS 03.1, AS 41.2, OC 23.3, OC 67.2, OC 73.1, OC 73.3, PA 1.15-1, PA 4.03-6, PB 1.35-1
Hackl G., PB 3.63-2
Haddad F., OC 71.3
Hadji T., PO 020, PO 055, PO 351
Hadonou M.A., PA 2.08-6
Haer-Wigman L., AS 47.6
Hafner F., PA 2.18-5
Hagedorn I., OC 88.6
Hagemeyer C., OC 09.4, OC 74.3
Hagen F., OC 04.6
Haghnaran S., PO 131
Haghiwar T., PA 1.08-6, PB 2.44-4, PB 2.69-3
Hague W.M., FS 01.1, PA 3.17-4
Hahm E., AS 44.1
Haidl H., PB 3.65-5, PB 4.50-4
Haig Y., AS 19.3
Hainaut P., OC 02.4
Haindl S., PO 061
Haining E.J., AS 27.2, OC 88.5
Hainzelmayer S., PO 060
Haiyan J., PA 4.13-1, PB 4.55-4
Hajage D., PB 4.60-4
Hajduk B., PB 2.47-2
Haji N., OC 72.2
Hajsmanova Z., PO 043, PA 260
Hakem D., PB 3.73-6
Hakobyan L., PO 051
Hakobyan N., PB 3.58-3
Haku J., OC 37.3
Halbwachs-Mecarelli L., AS 47.4
Haley K.M., PB 4.25-5
Halhalli S., PA 1.11-3
Halimsek S., OC 67.3, PB 2.42-3, PB 3.37-4, PO 119, PO 272, PO 432
Hall B., PB 1.65-6
Hall J.E., PB 1.50-3, PB 1.54-5
Hall M., PB 1.74-5
Hallett R.L., PO 173
Halton J., OC 82.4
Halvorsen S., PB 1.21-5
INDEX

Hamahata A., PA 3.20-4
Hamaia S.W., PB 1.22-3, PB 1.23-2, PB 1.31-3
Hamali H.A., PA 3.04-2, PB 2.26-3
Hambly R.J., PB 3.26-2
Hamer A., PB 2.37-4
Hamid H., PB 1.50-6, PO 481
Hamilton J.R., OC 11.6
Hamilton M., PB 4.63-6
Hammami N., PB 2.21-2, PB 2.21-5
Hammer E., PB 2.40-2, PB 3.24-2
Hampshire D., SC17-2.02, SC 13.4, PA 3.09-1, PA 3.09-4, PB 1.44-5, PB 3.42-1
Hampton K., PB 2.37-4
Hamsten A., OC 30.4
Hamulyak K., PB 3.26-4
Hamzaoui N., PB 3.73-3
Han J.-Y, PA 2.05-4, PB 4.24-6
Han J.W., PB 4.38-5, PO 120, PO 347
Han Y., PO 088
Hanabus H., OC 37.2, PB 1.35-5, PO 116
Handa P., PB 3.46-3
Handrkova H., PA 4.15-2, PB 3.41-2
Handrková H., SC10-2.05
Hanif H., PA 3.10-3
Hanley J., PB 2.35-6
Hansen D.F., AS 09.1
Hansen J.B., AS 11.3, AS 43.1, OC 04.3, OC 07.1, OC 59.2, OC 59.6, OC 77.2, PA 1.04-1, PA 3.20-5, PA 4.18-4, PB 1.69-1, PB 4.19-4, PB 1.70-1, PB 2.70-1, PB 2.70-3, PB 2.70-3, PB 3.56-3, PB 4.64-2, PB 4.69-2
Hansen L., PA 4.14-2
Hanson E., PA 4.14-5, PB 2.63-3
Hanss M., PB 1.57-5
Hansson G., OC 85.6
Happgoog G., PB 1.48-2
Haquette G., PO 365
Harahsheh Y., PB 1.33-3
Harberth F., PO 389
Hardege J.D., PB 1.56-5
Harding K., OC 25.4
Hardlei T.F., PB 3.21-3
Hardy J., PB 2.62-5
Hardy L., OC 23.2
Harenberg J., SC16-3.01, SC16-4.05
Harenberg MD J., OC 16.2, OC 79.3, PA 2.10-6, PB 1.47-3, PB 1.58-6, PB 3.56-6, PB 4.45-5, PB 4.45-6, PO 278
Harirahan P., OC 71.3
Harismendy O., AS 11.3, PA 4.18-4
Harley M.A., PB 1.56-5
Harmelin A., PB 4.53-5
Harpell L., PB 1.55-4, PB 4.35-1
Harper M.T., OC 10.1, OC 11.1, OC 11.2, PA 1.02-6, PA 3.03-5
Harrington L.B., OC 30.5, OC 63.1, PA 4.18-3
Harrington D.J., PA 1.08-5, PB 2.51-1, PO 257
Harris H.J, OC 88.5
Harris J., OC 65.6
Harris S., PA 1.12-1, PB 1.58-3, PO 006, PO 007
Harrison P., SC18-2.01, SC18-3.03, AS 14, AS 14.2, OC 25.4
Harrison-Lavoie K.J., OC 39.3
Harrisson P., AS 14
Harryanto R., PB 3.50-3
Harsal A., PB 1.27-5
Harsfali J., PO 433, PB 3.44-6
Hart D.P., OC 66.4, PB 1.42-6, PB 1.55-1, PB 2.39-1, PB 2.54-1, PB 4.38-1, SP505-05
Hart G., OC 83.6
Hart P., OC 56.3
Hartholt R.B., OC 80.3
Harti K., PB 3.30-6
Harti Souab K., OC 17.2
Hartley J.E., PB 3.61-5
Hartmann R., AS 41.2, OC 23.3, OC 66.1, OC 73.1, PA 1.07-3, PA 1.07-4, PA 1.15-1, PA 3.07-2, PB 1.35-1, PB 1.50-3
Hartopo A.B., PB 4.30-5, PO 316
Hartwig J.H., OC 33.1, OC 33.2
Harudova M., PB 3.47-4
Harutyunyan L., PO 051
Harvey D.R., PO 169
Hasegawa K., FS 03.3, PA 3.18-3, PB 4.67-2
Hasegawa Y., PB 1.33-2
Hasselböck J., PB 2.41-4, PB 3.60-2
Hashemi S.M., OC 51.1
Hashiguchi T., OC 69.3
Hasilgolu Z., PB 3.68-3
Haskell L., PA 3.10-5
Hasko M., PB 4.65-5
Haslund A., AS 38.3
Hassan A., PB 1.50-6, PO 481
Hassan R., PO 336
Hassan T.H., PO 382
Hassani P., PO 278
Hassanzadeh-Ghassabeh G., PA 1.06-1, PA 1.06-4
Hassoun A., PA 3.14-4
Haststedt S.J., OC 47.2
Hasumi K., FS 03.3, PA 3.18-3, PB 2.67-2, PB 4.67-2
Hatakeyama K., OC 43.3, PA 3.02-5, PB 3.63-3
Hatmi N., OC 19.3
Hato T., PB 2.69-4
Hattori K., OC 14.3, OC 37.3, PB 3.55-1
Hau C., OC 72.2, PA 3.04-1, PB 4.30-4
Hau C.M., PB 3.30-1
Haulon S., PB 4.32-2
Hauschner H., OC 34.3, OC 77.1
Hausding M., OC 87.4
Haverman L., PB 1.38-4, PO 141
Hawes S.A., PA 3.17-5
Hawke L.K., PB 1.44-1
Hawkins B., PA 2.18-4
Hawkings K.M., PB 1.57-2, PB 2.50-2, PB 2.63-5, PB 3.26-2, PO 193
Haworth J., PB 2.28-2
Hay C.R.M., OC 03.3, OC 22.2, OC 56.3, PB 2.36-1, PB 2.58-2, PB 4.58-3, PO 176
Hay N., AS 44.1
Haya S., AS 22.1
<table>
<thead>
<tr>
<th>INDEX</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hayakawa M., PB 1.33-5, PB 2.33-4</td>
</tr>
<tr>
<td>Hayakawa M., PO 079</td>
</tr>
<tr>
<td>Hayashi H., PB 4.21-5</td>
</tr>
<tr>
<td>Hayashi M., PB 3.34-6</td>
</tr>
<tr>
<td>Hayashi T., PB 1.58-2, PB 3.58-4</td>
</tr>
<tr>
<td>Hayes C.S., OC 31.5</td>
</tr>
<tr>
<td>Hayes V., PA 3.12-6</td>
</tr>
<tr>
<td>Haynes L.M., PA 3.12-5</td>
</tr>
<tr>
<td>Haynes S.A., OC 47.1</td>
</tr>
<tr>
<td>Hayward C., OC 90.4, PA 2.18-6</td>
</tr>
<tr>
<td>Hazendonk H.C.A.M, PA 2.07-1, PB 2.36-2</td>
</tr>
<tr>
<td>Hazzaa A., PO 440</td>
</tr>
<tr>
<td>He J., PB 1.69-6</td>
</tr>
<tr>
<td>He L., OC 79.1</td>
</tr>
<tr>
<td>He S., OC 48.4, PB 3.57-4, SC05-2.02</td>
</tr>
<tr>
<td>He R., SC14-2.07</td>
</tr>
<tr>
<td>He W., PO 182</td>
</tr>
<tr>
<td>He X., PO 317, PO 332</td>
</tr>
<tr>
<td>He Y., PB 2.32-5</td>
</tr>
<tr>
<td>Hebbagodi S., PB 4.32-1</td>
</tr>
<tr>
<td>Hebbel P., AS 10.3</td>
</tr>
<tr>
<td>Hechler B., AS 07.1, AS 27.3, AS 37.1, AS 44.4, OC 35.2, PB 2.26-1</td>
</tr>
<tr>
<td>Heck A.J.R., PB 2.24-3, PB 3.24-6</td>
</tr>
<tr>
<td>Heckbert S.R., OC 30.5, OC 63.1, PA 4.18-3</td>
</tr>
<tr>
<td>Hecking C., PB 2.49-5</td>
</tr>
<tr>
<td>Heckmann F., PB 3.46-6</td>
</tr>
<tr>
<td>Heckmann M.B., PB 3.46-6</td>
</tr>
<tr>
<td>Heddle N., PA 3.10-3, PB 1.58-4</td>
</tr>
<tr>
<td>Hedman E., PO 457</td>
</tr>
<tr>
<td>Heeb M.J., AS 03.3</td>
</tr>
<tr>
<td>Heelas O., AS 40.2</td>
</tr>
<tr>
<td>Heemskerk J.W.M., SC14-1.02, AS 04.3, OC 11.3, OC 24.3, OC 35.5, OC 64.4, OC 67.2, OC 87.2, OC 87.5, PA 2.02-2, PA 3.02-2, PA 4.20-1, PB 1.32-6, PB 2.43-3, PB 3.26-4, PB 3.26-4, PB 3.40-2</td>
</tr>
<tr>
<td>Heesemann J., OC 60.2</td>
</tr>
<tr>
<td>Hegadorn C., OC 65.3, PB 1.55-4</td>
</tr>
<tr>
<td>Hegde P., PA 1.13-1</td>
</tr>
<tr>
<td>Hegener O., PB 3.57-5</td>
</tr>
<tr>
<td>Hego A., PA 1.02-3</td>
</tr>
<tr>
<td>Hehrlein C., PB 1.47-1</td>
</tr>
<tr>
<td>Heider P., PB 3.32-4</td>
</tr>
<tr>
<td>Heidinger K., OC 90.6, PB 4.65-6, PB 203</td>
</tr>
<tr>
<td>Heidinger K-S., PB 2.72-5</td>
</tr>
<tr>
<td>Heijnen H.F., OC 10.5, PA 2.04-3, PA 4.03-4</td>
</tr>
<tr>
<td>Heilmann C., PA 4.02-4</td>
</tr>
<tr>
<td>Heiniger Mazo A., PB 3.36-5</td>
</tr>
<tr>
<td>Heinze G., OC 12.5</td>
</tr>
<tr>
<td>Heinzmann C.A., AS 41.2, OC 23.3, OC 73.1, PA 1.15-1, PB 1.35-1</td>
</tr>
<tr>
<td>Heising S., OC 88.4</td>
</tr>
<tr>
<td>Heisser M.J., OC 49.3</td>
</tr>
<tr>
<td>Heistinger M., PA 2.06-6</td>
</tr>
<tr>
<td>Heit J.A., PB 2.71-3</td>
</tr>
<tr>
<td>Heitmeier S., PA 3.10-4</td>
</tr>
<tr>
<td>Hejna M., PA 3.16-2</td>
</tr>
<tr>
<td>Helbig G., PA 1.16-3</td>
</tr>
<tr>
<td>Helena B., PO 389</td>
</tr>
<tr>
<td>Helis L., PB 4.22-2</td>
</tr>
<tr>
<td>Heller C., PB 2.36-5</td>
</tr>
<tr>
<td>Heller P.G., OC 89.4</td>
</tr>
<tr>
<td>Helley D., PA 1.17-1</td>
</tr>
<tr>
<td>Hellum M., PA 3.04-3</td>
</tr>
<tr>
<td>Helmerhorst F.M., AS 05.1, OC 12.6</td>
</tr>
<tr>
<td>Helmke B.P., PB 4.23-4</td>
</tr>
<tr>
<td>Hemker C.H., PA 1.11-4, PA 2.11-1, PA 4.08-6, PA 4.09-3, PA 4.12.6, PA 1.38-2, PA 1.51-1, PA 2.56-4, PB 3.50-2, PB 4.47-5</td>
</tr>
<tr>
<td>Hemker H.C.H., PA 1.11-5</td>
</tr>
<tr>
<td>Hemmeryckx B., OC 64.4</td>
</tr>
<tr>
<td>Hendelmeier M., PB 1.46-3, PB 2.49-5</td>
</tr>
<tr>
<td>Henderson S.J., PB 3.34-5</td>
</tr>
<tr>
<td>Hendrickx M.L., PA 1.06-1, PA 1.06-4</td>
</tr>
<tr>
<td>Hendriks R.W., PA 2.04-1</td>
</tr>
<tr>
<td>Hendriks D., SC05-2.07, PB 2.34-3, PB 4.34-2</td>
</tr>
<tr>
<td>Hendriksen J., PA 4.16-6</td>
</tr>
<tr>
<td>Henkel-Klene A., PB 4.43-5</td>
</tr>
<tr>
<td>Henrou S., AS 17.3, PB 4.45-1</td>
</tr>
<tr>
<td>Henrard S., PO 108, PO 121</td>
</tr>
<tr>
<td>Henriet C., PB 1.43-1, PA 4.44-1</td>
</tr>
<tr>
<td>Henriksson C., PA 3.04-3</td>
</tr>
<tr>
<td>Henrique Vieira Oliveira S., PO 465</td>
</tr>
<tr>
<td>Henry P., OC 07.3, PB 1.63-4, PB 3.63-4</td>
</tr>
<tr>
<td>Henskens Y.M.C., SC18-2.03, AS 33.2, PA 4.04-6, PB 1.52-4, PB 3.22-4, PB 4.49-4, PO 321, PO 322, PO 339</td>
</tr>
<tr>
<td>Hepner M.D., PB 1.43-6, PB 1.71-1, PB 1.71-3, PB 303</td>
</tr>
<tr>
<td>Heptinstall S., PB 2.25-1, PB 2.27-3, PB 4.21-6</td>
</tr>
<tr>
<td>Heptinstall S., PB 1.22-1</td>
</tr>
<tr>
<td>Herbert N., OC 35.1</td>
</tr>
<tr>
<td>Herbrecht R., OC 89.6</td>
</tr>
<tr>
<td>Herzegen E., OC 80.3</td>
</tr>
<tr>
<td>Herd V., PA 1.21-3</td>
</tr>
<tr>
<td>Herfs L., OC 23.3</td>
</tr>
<tr>
<td>Hermanns H.M., AS 30.2, OC 76.4, OC 88.1</td>
</tr>
<tr>
<td>Hermans C., AS 22.1, PA 2.07-4, PB 2.73-2, PB 4.44-1, PB 4.60-6, PO 108, PO 121, SPS01-05</td>
</tr>
<tr>
<td>Hermens W.Th., PA 4.09-3</td>
</tr>
<tr>
<td>Hermida J., PA 2.16-3</td>
</tr>
<tr>
<td>Hermit M.B, PB 3.49-1, PB 4.54-1</td>
</tr>
<tr>
<td>Hernan M., PL 08.02</td>
</tr>
<tr>
<td>Hernandez C., PA 2.16-5</td>
</tr>
<tr>
<td>Hernandez J., AS 42.3, PA 3.06-2, PA 3.15-6</td>
</tr>
<tr>
<td>Hernandez J.-R., OC 54.1</td>
</tr>
<tr>
<td>Hernandez L., PB 4.45-1, PO 104</td>
</tr>
<tr>
<td>Hernandez R., PB 2.31-3</td>
</tr>
<tr>
<td>Herpers R., PB 3.47-6</td>
</tr>
<tr>
<td>Herr M., PB 4.25-4</td>
</tr>
<tr>
<td>Herr N., PB 4.67-3</td>
</tr>
<tr>
<td>Herrera Gonzalez A., PB 2.22-5</td>
</tr>
<tr>
<td>Herrero S., PB 1.68-2, PB 2.37-3</td>
</tr>
<tr>
<td>Herrero-Diaz F., PB 2.56-6</td>
</tr>
<tr>
<td>Herring J.M., PB 3.30-5</td>
</tr>
<tr>
<td>Hers I., OC 10.4, OC 11.5, PA 1.03-2, PA 3.03-1</td>
</tr>
</tbody>
</table>
INDEX

Hershkovitz O., OC 83.6
Hershkovitz T., PO 359
Herth N., PO 265
Herzog E., PA 1.12-1, PB 1.58-3, PB 2.48-3
Heshmat R., PB 1.50-6, PO 481
Hess K., PB 3.59-1
Hess P.R., AS 39.4
Heylen O., PB 4.72-2
Heymann D., PB 2.29-5
Heymonet M., PB 4.63-4
Hickey K.P., PB 2.56-5, PB 4.50-6, PB 4.54-2
Hickman G.M., PB 1.51-5
Higasa S., OC 14.1, OC 37.6
Higashihara M., PB 4.29-1
Higazi E., PB 3.72-3
Higgins J.R., PB 2.66-6
High K.A., AS 34.3, OC 31.4
Hijmans C.T., PB 4.39-2
Hilden I., PA 2.14-1, PA 2.14-6, PA 4.14-2
Hilger A., SC09-4.02
Hill M., PA 1.14-2, PB 3.57-2
Hill S.N., PB 4.25-4
Hillarp A., PB 3.46-2
Hille M., OC 28.1
Hillebrand I., PB 3.46-6
Hilgerova J., PB 4.72-1, PB 4.73-5
Hiroko T., PB 1.64-6
Hirono T., PB 1.28-5
Hitos K., PB 3.64-2
Hjemo P., AS 02.3, PB 3.51-4, PB 4.56-6, PO 457
Hluši A., PO 192
Ho E., PB 1.55-3
Ho Jin S., PA 120
Ho Tin Noe B., AS 36.4, PA 2.13-3, PA 4.12-2
Hirman J., PA 4.17-3
Hirmerova J., PB 4.72-1, PB 4.73-5
Hiroko T., PA 4.14-5
Hogwood J., PB 3.49-3
Hohlfeld T., PA 2.01-4
Hohmann J.D., OC 09.4, OC 74.3
Hokamura K., PA 3.02-5
Holcomb J.B., OC 17.1, PB 3.40-1
Holden F., PB 2.42-1
Holderness B.M., PB 3.37-1
Holdsworth M.T., OC 79.6
Holik H., PO 284
Hollander M., PA 4.06-4
Hollenbach S., AS 20.1
Hollestelle M.J., PA 1.18-5
Hollingsworth R., PB 3.37-2
Hollréigl W., PA 1.07-4, PA 1.07-6, PA 2.10-5, PA 3.07-1, PA 3.07-2, PA 1.12-5, PB 4.06-3, PB 3.33-1
Holly P., PO 243
Holm P.K., PB 3.49-1
Holmberg H.L., OC 28.4, OC 68.3, OC 84.2
Holme P.A., OC 66.3, PB 3.41-6, PB 4.35-3, PO 170, PO 434
Holmes C., SC13-1.02
Holmes L., PB 1.33-3
Holmes P., PO 467
Holmstrom M., PB 2.38-5
Holstein K., PB 2.38-6
Holz J.B., PB 3.43-4
Holzhauser S., AS 22.2, PB 2.36-5, PB 3.69-3
Homoródi N., PA 1.01-4, PA 2.01-2
Honda Y., PB 2.46-3, PB 3.46-2
Honecker F., PA 3.16-6
Hong W., OC 03.5, PA 4.07-6
Hongeng S., PB 2.50-3
Hongku K., PB 2.64-5, PO 076
Honke A., PB 2.54-1
Hoogendijk A.J., OC 31.3, PB 1.67-3
Hoogendoorn H., PB 2.64-3, PO 037
INDEX

Hord E., PA 4.01-3
Horellou M.H., OC 79.2
Horibe E., PA 3.08-6
Horie R., PB 4.29-1
Horie S., PB 1.60-2
Horikoshi Y., PB 4.39-3
Horii F., PB 2.63-4, PB 3.55-4,
PB 3.55-6
Hörmann N., OC 01.4
Horn C., PB 1.55-6
Horn L., PB 2.56-5
Horneff S., PB 2.36-6, PB 2.58-1
Horner D., AS 12.1, PB 1.65-3,
PB 4.69-4
Horner K., PA 3.08-2
Horvath A.J., PB 2.34-3,
PB 3.34-3
Horvath B., PA 2.06-6
Hosák L., PB 1.26-4, PB 4.62-6
Hoshino K., PA 4.17-5
Hoshino N., PB 2.40-3
Hosokawa K., PO 352
Hosoki K., PO 231
Hossain R., PB 1.21-1
Hotta M., PB 4.61-1
Hou Y., PB 4.25-3
Houben R., PB 3.22-4
Hough C.A., OC 15.2, PB 1.55-4,
PB 4.35-1
Houki R., PB 1.25-4
Houman M.H., PO 094
Houwing-Duistermaat J., AS 11.1
Hoven P., OC 71.4
Hovens M., OC 71.4
Hoving L., OC 23.2
Hovingh K., OC 88.3, PB 3.26-3
Howard G., AS 01.3
Howard R., PO 094
Howard S.C., OC 75.4
Howe N., PB 4.66-1
Howes J.M., PA 2.09-5, PB 1.22-3
Howgate S., OC 25.4
Hoxha A., PB 2.62-2
Hoylaerts M.F., OC 33.3, OC 54.6,
OC 64.4
Hrachovinova I., SC12-2.03,
PA 4.19-1
Hrdlickova R., PO 015
Hristov M., SC07-3.02
Hsieh H.N., PB 2.70-6, PB 3.58-6
Hsin-Mao T., PO 464
Hsouna K., PO 405
Hsu C.C., PB 4.23-3
Hsu D., PB 2.51-5
Hsu H.C., PB 1.67-5
Hsu J., PB 3.64-2
Hsu Y.C., OC 57.2
Hu H., OC 11.4, PB 4.26-1,
PB 4.26-3
Hu L., PO 088
Hu S.H., PA 1.09-6, PB 3.37-3
Hua B., OC 70.3
Hua M., OC 72.3, PB 2.26-4
Huang C.H., FS 03.4
Huang C.P., OC 22.3
Huang J., PB 1.23-6
Huang T.F., PB 4.23-3
Huang T.M., PB 2.70-6
Huang Y.H., FS 03.4
Huang Z., OC 85.6, PB 2.23-3,
PB 4.26-3, PB 4.56-6
Huang M., SC08-2.02, OC 09.2
Huang M., OC 90.5
Hubers L.M., PB 2.61-6
Hudig C., PO 321
Hudoba M., OC 78.1
Hudsen R., OC 02.6
Hugenholtz G.C.G., PB 2.33-5
Hughes J., PA 3.14-5
Hughes A.S., PB 1.65-6
Hughes C., PB 2.56-5
Hughes C.E., PB 2.26-3
Hughes Q., OC 77.4, PB 1.33-3
Hu S.K.R., PB 1.42-4
Hui S.K.R., PA 1.02-1
Huisjes H.R., PA 1.08-5
Huisman M.V., SC11-2.01, AS 42,
OC 12.2, OC 20.2, OC 71.2,
OC 71.4, PA 1.20-2, PA 1.20-4,
PB 1.63-5, PB 2.65-3, PB 2.74-5,
PA 3.20-1, PB 3.40-4, PB 4.60-3,
PB 4.70-2, PB 4.70-2, SAS05-05
Huisse M.G., PB 1.27-1,
PB 2.30-4, PB 2.74-6
Huisse M.G., PB 1.27-1,
PB 2.30-4, PB 2.74-6
Huissoud C., OC 61.6
Hulek P., PB 3.72-2
Hulot J.S., PB 1.26-6
Hultenb K., PB 3.57-4
Hultman K., AS 24
Humphries J., OC 03.6
Hundalani S.G., PB 3.43-5
Hunt B.J., PB 1.62-5, PB 1.62-6,
PB 2.39-5, PB 3.62-2, PB 4.33-6,
PB 4.34-1
Hunter R.W., PA 3.03-1
Hunter-Mellado R., OC 46.3
Huntington J.A., SOA 11.1,
OC 44.3, OC 49.1, OC 49.2,
OC 62.5, OC 68.1, PB 4.58-2
Hurault de Ligny B., PB 2.73-5
Hussein B., PB 4.66-2
Hutchaleelaha A., AS 20.1
Huteny K., SC05-2.02, OC 48.4
Huth-Kuehne A., PB 2.37-6,
PO 354
Hutten B.A., PB 2.61-6, PB 4.61-3
Huynh K.C., PB 1.23-4,
PB 4.23-2, PO 403
Hvas A.M., PB 3.21-3, PB 3.21-5,
PB 3.22-6, PO 461
Hwang H.G., PO 261
Hwang S., PB 3.31-4
Hwang T.L., PB 1.73-4
Hyder S.J., AS 42.4
Hylek E., SC16-1.02, SOA 13.2,
SAS05-02
Hyttolf Petersen P., PB 2.65-4
Hyten S., PA 2.09-4, PA 2.15-1,
PB 1.38-1, PB 3.58-1
Iacoviello L., OC 04.1, OC 07.6,
PA 3.06-4, PA 3.06-6, PB 1.50-1,
PB 1.56-6, PB 3.66-4
Iamsirirak P., PB 2.50-3
Iandolo V., PO 200, PO 430
Iannuzzi P., PB 1.69-3
Ibañez F., PO 389

510
INDEX

Ibara S., PB 3.54-1
Ibarra C., PO 488
Ibberson M., AS 15.3
Ibegbulam O.G., PO 216
Ibn El Hadj Z., PB 2.21-2, PB 2.21-5
Ibri M., PB 3.73-6
Icheva V., PO 383
Ichiki R., PA 4.17-5, PO 080
Ichinose A., SC10-2.10, OC 06.3
Igawa T., OC 14.3
Iglesias T., PB 2.42-6
Iglesias del Sol A., PA 3.20-1
Ignas D.M., PO 106
Ignjatovic V., PB 2.56-3, PB 4.50-3, PB 4.71-4, PO 248, PO 266, PO 372, PO 485
Iguchi A., FS 03.4
Ihaddadene R., PA 1.16-4, PA 1.20-5, PB 1.70-5, PB 2.61-3
Ikeda Y., PB 1.29-4
Ikeda M., PB 3.34-6
Ikesaka T., PA 4.10-3, PB 2.71-4
Illebekk A., PB 2.59-3
Ilc T.A., PB 286
Ilk O., PB 2.60-1
Ilonczai P., OC 78.2, OC 78.3
Imberti D., PB 1.46-6, PB 2.70-4, PB 3.73-3
Imke J., PA 4.15-1
Imran A., PO 437
Inaba H., PA 1.08-6, PB 2.44-4, PB 2.54-5, PB 2.69-3
Inaba M., PO 239
Inaba S., PA 3.18-2
Inbal A., OC 67.3, OC 82.1
Incampo F., PB 1.45-2
Ince B., PB 4.64-4
Indrajit N., OC 80.5
Indridason S., PA 4.10-2
Infante T., PB 1.47-2
Ing M., AS 47.4
Ingerslev J., PB 3.38-4
Ingratti M.F., PO 025, PO 385
Inguimbert N., PA 1.17-4
Iniesta J.A., PB 2.63-1, PB 4.27-6
Innes A., OC 37.2, PA 2.07-6, PA 4.07-2
Inoue O., SC01-4.05, AS 22.2, AS 22.3, PA 2.08-1, PB 3.36-6, PB 3.70-3, PO 122, PO 123, PO 127, PO 128, PO 129, PO 148, PO 166, PO 168
Iqbal O., PB 1.30-6, PB 1.48-4, PB 1.51-3, PB 2.47-1, PB 3.47-5, PB 3.54-3, PB 4.48-6, PB 4.60-1, PO 259
Iruretagoyena M., PA 4.20-5
Irfan A., PO 410
Isermann B., AS 37.3, PB 3.28-5, PB 4.67-1
Ishida F., PB 1.33-1
Ishiguro A., PA 156
Ishiguro N., PB 4.39-3
Ishii K., PB 4.61-1
Ishii S., PB 3.42-5
Ishikawa H., PA 4.17-5, PO 080
Ishii A., PB 2.46-2
Ivankovic E., PO 172
Ivanov A.M., PO 028
Iwase T., PO 070
Iyori M., PB 3.29-1
Izsvak Z., AS 32.1
Jäckel S., AS 03.2, OC 41.2, PA 4.20-4
Jackson C.L., OC 67.1
Jackson S., PA 2.07-4
Jackson S.P., OC 11.6, OC 42.2, OC 76.1, PA 4.03-1, PA 4.03-3
Jackson S.R., PA 44.4
Jacobi P.M., OC 39.5, PA 2.09-2
Jackson S., OC 70.2, PB 3.49-3
Jacobs B., PO 37.2
Jacobs C., PA 3.16-6
Jacobs S., PB 3.43-4
Jacobsen C., PA 3.16-6
Jaff M., PB 2.18-4
Jaff M., PA 2.18-4
Jaff M., SC19-3.05, OC 69.3
Jaff M., PA 1.67-4
Itzhak R., OC 13.6
Ivaldo N., PB 2.70-4
Ivan T., PA 1.11-2
Ivanucci L., OC 83.3, OC 84.3
Ivanova J., PO 204
Ivanov A., PB 4.67-5
Ivaskevicius V., SC10-2.11, PB 2.36-6, PB 4.74-5
Iversen N., PA 3.16-3, PA 4.14-3, PA 4.14-4, PB 2.60-2, PB 3.60-1
Iwabuchi K., OC 32.5
Iwaki S., OC 32.5, PB 2.34-2
Iwakiri T., PB 3.55-1
<table>
<thead>
<tr>
<th>Name</th>
<th>OC/PA/PB/AE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jiyi X.</td>
<td>OC 25.1</td>
</tr>
<tr>
<td>Jobe S.M.</td>
<td>OC 08.6, PA 2.02-1, PA 4.04-2, PA 4.07-4, PB 1.24-3, PB 2.26-2</td>
</tr>
<tr>
<td>Joch C.</td>
<td>PB 3.37-5</td>
</tr>
<tr>
<td>Jochmans K.</td>
<td>OC 81.6, PB 1.66-2, PB 4.72-2</td>
</tr>
<tr>
<td>Johansen P.B.</td>
<td>PA 4.13-3, PA 4.14-6</td>
</tr>
<tr>
<td>Johns G.</td>
<td>OC 14.4</td>
</tr>
<tr>
<td>Johns J.</td>
<td>OC 61.3</td>
</tr>
<tr>
<td>Johns S.</td>
<td>PO 006, PO 007</td>
</tr>
<tr>
<td>Johnsen J.M.</td>
<td>OC 61.1, OC 65.5, PA 1.09-4, PA 4.09-2</td>
</tr>
<tr>
<td>Johnson A.</td>
<td>PA 1.14-3, PA 4.15-6</td>
</tr>
<tr>
<td>Johnson A.</td>
<td>PB 2.27-3</td>
</tr>
<tr>
<td>Johnson A.</td>
<td>PB 3.63-6</td>
</tr>
<tr>
<td>Johnson B.</td>
<td>OC 83.4, PB 1.58-1, PB 3.58-2</td>
</tr>
<tr>
<td>Johnson D.J.</td>
<td>OC 49.1, PB 4.58-2</td>
</tr>
<tr>
<td>Johnson G.J.</td>
<td>PB 4.68-3</td>
</tr>
<tr>
<td>Johnson J.L.</td>
<td>OC 87.5</td>
</tr>
<tr>
<td>Johnsson H.</td>
<td>PB 3.57-4</td>
</tr>
<tr>
<td>Johnston M.</td>
<td>PB 2.64-3</td>
</tr>
<tr>
<td>Johnston S.L.</td>
<td>PB 2.68-1</td>
</tr>
<tr>
<td>Jokela V.</td>
<td>PB 3.42-2</td>
</tr>
<tr>
<td>Jonas J.</td>
<td>AS 28.2</td>
</tr>
<tr>
<td>Jonasson J.</td>
<td>PB 2.24-2</td>
</tr>
<tr>
<td>Jones A.E.</td>
<td>AS 42.3, PA 3.06-2, PA 3.15-6</td>
</tr>
<tr>
<td>Jones C.I.</td>
<td>OC 09.1, OC 87.6, PA 1.02-5, PA 2.05-1, PB 1.23-3, PB 2.28-6, PB 3.23-4, PB 3.27-2, PO 362</td>
</tr>
<tr>
<td>Jones M.</td>
<td>OC 34.2, PB 1.54-5</td>
</tr>
<tr>
<td>Jones M.L.</td>
<td>OC 60.3</td>
</tr>
<tr>
<td>Jones S.</td>
<td>PB 1.71-5, PB 3.68-2, PB 3.68-4, PB 3.69-2</td>
</tr>
<tr>
<td>Jonkers G.</td>
<td>PA 1.20-2</td>
</tr>
<tr>
<td>Jood K.</td>
<td>PA 4.14-5, PB 2.63-3</td>
</tr>
<tr>
<td>Joore M.</td>
<td>OC 20.3</td>
</tr>
<tr>
<td>Jorde R.</td>
<td>AS 43.1, PA 1.70-1</td>
</tr>
<tr>
<td>Jorgensen L.N.</td>
<td>PA 1.16-6</td>
</tr>
<tr>
<td>Jorquera J.I.</td>
<td>PB 2.52-1, PB 4.58-5</td>
</tr>
<tr>
<td>Jorsback A.</td>
<td>PA 2.15-6</td>
</tr>
<tr>
<td>Jose M.</td>
<td>PB 2.52-1</td>
</tr>
<tr>
<td>Jose P.</td>
<td>PA 2.10-1, PB 1.48-1</td>
</tr>
<tr>
<td>Josefsson E.C.</td>
<td>PB 1.27-6</td>
</tr>
<tr>
<td>Joseph J.E.</td>
<td>PA 2.01-3, PA 2.18-6, PA 4.04-4, PB 1.59-3, PO 019</td>
</tr>
<tr>
<td>Josephson N.</td>
<td>OC 37.2, OC 70.1, OC 81.1, PA 2.06-3, PA 2.07-4, PA 2.07-5, PA 2.07-6, PA 4.07-2, PB 4.37-3</td>
</tr>
<tr>
<td>Joshi A.U.</td>
<td>PA 2.17-4</td>
</tr>
<tr>
<td>Joshi R.</td>
<td>PB 1.21-1</td>
</tr>
<tr>
<td>Jost K.</td>
<td>PO 130</td>
</tr>
<tr>
<td>Jotov G.</td>
<td>OC 70.2</td>
</tr>
<tr>
<td>Jouppila A.</td>
<td>PB 2.59-4, PB 4.41-4</td>
</tr>
<tr>
<td>Joutsi-Korhonen L.</td>
<td>PB 4.41-4</td>
</tr>
<tr>
<td>Jovanovic A.</td>
<td>PB 4.61-4</td>
</tr>
<tr>
<td>Jovanovic L.</td>
<td>PO 001</td>
</tr>
<tr>
<td>Jover E.</td>
<td>PB 4.27-6</td>
</tr>
<tr>
<td>Jovic M.</td>
<td>PB 4.61-4</td>
</tr>
<tr>
<td>Jozwiak M.</td>
<td>OC 28.1</td>
</tr>
<tr>
<td>Ju L.</td>
<td>OC 35.3</td>
</tr>
<tr>
<td>Juan B.</td>
<td>PO 389</td>
</tr>
<tr>
<td>Ju-Chien C.</td>
<td>PA 1.02-1</td>
</tr>
<tr>
<td>Judd S.</td>
<td>AS 01.3</td>
</tr>
<tr>
<td>Jude B.</td>
<td>OC 38.6, OC 61.6, PA 3.18-1</td>
</tr>
<tr>
<td>Judge H.M.</td>
<td>PA 4.01-3, PB 1.21-1</td>
</tr>
<tr>
<td>Judicone C.</td>
<td>OC 17.2, PB 3.30-6</td>
</tr>
<tr>
<td>Jugder B.E.</td>
<td>PB 2.49-4, PB 4.22-3</td>
</tr>
<tr>
<td>Juif V.</td>
<td>PO 401, PO 435</td>
</tr>
<tr>
<td>Jukema W.J.</td>
<td>AS 04.1, OC 27.3, OC 64.2</td>
</tr>
<tr>
<td>Juliana V.</td>
<td>PB 1.72-3, PA 2.20-6</td>
</tr>
<tr>
<td>Jun Q.</td>
<td>AS 09.3</td>
</tr>
<tr>
<td>Jun S.</td>
<td>PB 4.38-5, PO 347</td>
</tr>
<tr>
<td>Jun W.</td>
<td>PB 4.28-6</td>
</tr>
<tr>
<td>Jundt J.P.</td>
<td>PB 3.72-1</td>
</tr>
<tr>
<td>Jung C.W.</td>
<td>PB 4.69-6</td>
</tr>
<tr>
<td>Jung K.</td>
<td>PB 3.37-5</td>
</tr>
<tr>
<td>Jung S.M.</td>
<td>PA 3.01-1, PB 1.22-3</td>
</tr>
<tr>
<td>Jung Y.</td>
<td>PB 4.21-3</td>
</tr>
<tr>
<td>Junker R.</td>
<td>PB 3.69-3</td>
</tr>
<tr>
<td>Jupe S.</td>
<td>PA 2.05-5</td>
</tr>
<tr>
<td>Juraj C.</td>
<td>PB 2.54-4</td>
</tr>
<tr>
<td>Jurak Begonja A.</td>
<td>OC 33.1</td>
</tr>
<tr>
<td>Jurišic D.</td>
<td>PO 484</td>
</tr>
<tr>
<td>Jurk K.</td>
<td>OC 87.4, PA 4.02-4</td>
</tr>
<tr>
<td>Jürs M.</td>
<td>PB 2.36-5</td>
</tr>
<tr>
<td>Just S.</td>
<td>PO 191</td>
</tr>
<tr>
<td>Juthier F.</td>
<td>OC 38.5, PB 4.32-2</td>
</tr>
<tr>
<td>Juvin K.</td>
<td>PB 3.31-6</td>
</tr>
<tr>
<td>Kaabi H.</td>
<td>PO 405</td>
</tr>
<tr>
<td>Kaaja R.</td>
<td>PB 3.70-4</td>
</tr>
<tr>
<td>Kaandorp S.P.</td>
<td>OC 61.2</td>
</tr>
<tr>
<td>Kaas Hansen M.J.</td>
<td>PB 4.58-1</td>
</tr>
<tr>
<td>Kaatz S.</td>
<td>OC 16-4,01, AS 02.1, OC 79.6, PB 1.45-1, PB 4.31-2, PB 4.45-2</td>
</tr>
<tr>
<td>Kabrehel C.</td>
<td>OC 20.4, OC 71.3, PA 2.18-4, PA 3.06-2, PB 3.64-1, PO 184</td>
</tr>
<tr>
<td>Kachboura S.</td>
<td>PB 2.21-2, PB 2.21-5</td>
</tr>
<tr>
<td>Kadar J.</td>
<td>PB 2.42-3</td>
</tr>
<tr>
<td>Kadegasem P.</td>
<td>PB 2.50-3, PO 110</td>
</tr>
<tr>
<td>Kadir R.A.</td>
<td>SOA 16.1</td>
</tr>
<tr>
<td>Kael K.</td>
<td>PB 4.55-3</td>
</tr>
<tr>
<td>Kager L.M.</td>
<td>PA 1.19-3, PB 3.66-3, PB 4.67-1</td>
</tr>
<tr>
<td>Kahn D.</td>
<td>PB 1.30-6, PB 1.46-1, PB 1.58-6, PB 2.47-1, PB 3.56-6, PB 4.60-1, PO 420</td>
</tr>
<tr>
<td>Kahn M.L.</td>
<td>AS 39.4</td>
</tr>
<tr>
<td>Kahn S.</td>
<td>AS 06, FS 01.1, PB 1.64-5, PB 1.65-2, PB 4.47-1</td>
</tr>
<tr>
<td>Kahr W.H.A.</td>
<td>AS 16.1, FS 02.2</td>
</tr>
<tr>
<td>Kahrs J.</td>
<td>PO 283</td>
</tr>
<tr>
<td>Kaicker S.</td>
<td>OC 83.5</td>
</tr>
<tr>
<td>Kaidor A.</td>
<td>PA 1.16-5, PB 3.60-2, PO 459</td>
</tr>
<tr>
<td>Kaijen P.</td>
<td>OC 21.4, PA 4.06-2</td>
</tr>
<tr>
<td>Kain K.</td>
<td>PA 1.14-3</td>
</tr>
<tr>
<td>Kaiser J.</td>
<td>PA 2.02-3, PB 3.27-2</td>
</tr>
<tr>
<td>Kaiser K.</td>
<td>PB 3.29-6</td>
</tr>
<tr>
<td>Kaiser M.</td>
<td>PB 1.47-1</td>
</tr>
<tr>
<td>Kaji N.</td>
<td>PB 2.45-6</td>
</tr>
<tr>
<td>Kajura Y.</td>
<td>PA 3.05-2</td>
</tr>
<tr>
<td>Kajiwara M.</td>
<td>PB 2.74-1</td>
</tr>
<tr>
<td>Kakkar A.</td>
<td>AS 12.3, OC 63.3, PA 2.11-6, PB 3.39-2, SPS11-01, SAS02-05, SPS11-06</td>
</tr>
</tbody>
</table>
INDEX

Kaus L., PB 2.46-2
Kausskot A., OC 33.3, OC 54.6
Kavakli K., PO 499, PB 4.40-6, PO 102
Kaveri S.V., AS 47.4, OC 56.1, OC 56.2, PA 2.12-6, PA 3.07-6, PB 2.35-4
Kavousi M., PA 2.09-1
Kawakami K., PO 499, PB 4.40-6, PO 102
Kawarani H., PB 2.33-4
Kawashita E., PA 1.06-2, PA 3.18-2, PA 3.18-5, PB 1.31-4, PO 233
Kawasugi K., PA 4.17-1
Kaya Z., PB 3.42-5
Kchaou I., OC 07.3
Kenawy D., PB 1.73-1
Keane C., PB 2.28-2
Keane N., PB 2.49-2
Kearon C., SC16-4.02, AS 18.3, OC 20.1, OC 63.3
Kececi D., PB 4.37-4
Keeling D., AS 42.1
Keenan C., PB 2.42-1, PB 4.35-6
Keener J.P., PB 4.33-4
Kehrel B.E., PA 4.01-5, PA 4.02-4, PB 2.35-2, PB 2.40-1
Keizer V., PA 1.19-4
Kelchtermans H., SC03-1.02, AS 08.1, OC 64.4, PA 1.11-4, PA 1.18-2, PA 4.09-3, PA 4.12.6, PB 2.42-4, PB 4.62-1
Kellekci S., PO 294, PO 353
Kellkiti E., PO 087
Keller K., PB 1.46-3, PB 1.70-2
Kelemayr R., PB 3.68-5
Kelley L., PB 4.37-6, PO 132
Kelm C., OC 90.6, PB 4.65-6, PO 203
Kelm M., PA 2.01-4
Kempkes-Matthes B., OC 90.6, PB 2.72-5, PB 3.37-4, PB 4.65-6, PO 203
Kempaiah K., PB 2.46-1
Kemperman H., PA 2.09-4, PA 2.15-1
Kempfer A.C., PB 2.73-4, PB 3.33-3, PB 4.43-6, PB 4.44-2
Kempton C., PO 169
Kenawy D., AS 44.3
Ken-Dror G., PB 3.57-3
Kennedy D.R., AS 07.2
Kenney K., PB 2.71-3
Kenny B.A., AS 21.3
Kentouche K., PO 348
Kepa S., PB 2.41-4
Kerdélo S., PB 3.50-2
Keren-Politansky A., PB 3.67-5, PO 433
Keresztes Z., PB 3.34-1
Kershaw G., PB 2.51-5, PO 004, PO 039
Kerspern H., AS 43.2
Kesecioglu J., PA 2.09-4, PA 2.15-1
Keshlan A., OC 69.1
Keshava S., PA 3.16-4
Keskin Yildirim Z., PB 3.69-4
Keskin Yilmaz E., PB 3.42-5
Keslova P., PO 349
Kessler A., PO 398
Kessler A., PA 1.04-2
Kessler L.P., PA 1.06-6
Kessler P., PO 081
Khair K., OC 03.1, PB 1.37-3, PB 2.42-2
Khamashta M., PB 3.62-2
Khan G.A., PA 1.19-2, PA 4.09-4
Khan H., PB 1.48-4, PB 1.49-4
Khanfir M., PO 094
Khasanov A., PB 453, PB 482
Khasanov Z., PB 4.73-4
Khaspekova S., PB 4.27-5
Kheirandish M., PO 293
Kherani S., AS 38.2
Khizegrova D., PO 072, PO 205, PO 206, PO 208, PO 209, PO 210
Kheif A., PB 2.39-3, PB 2.47-5
Khoody C., AS 07.2
Khoon K.H., PB 3.59-4
Khoon T.L., PB 2.38-4
Khorana A., SC13-2.03, OC 04.6, PB 3.61-2, PB 4.61-2
Khorsand N., PB 3.47-1, SPS11
Khoury E., PB 4.56-6
Khrapkova O., PB 1.52-3
Khwatov V.B., PB 2.35-3
Kiatchoosakun P., PO 082
Kiddle G.R., SC08-1.01, OC 62.3
Kiefer F., OC 58.4, OC 60.1
Kieler H., OC 30.4
Kile B.T., OC 33.5, PB 1.27-6
Kilic A., PB 3.51-2
Kilicoglu O., PB 1.35-4
Kilinc Y., PO 099, PO 163
Kilincoglu V., PO 253
Kilpatrick D., PB 1.62-5
Kim B.R., PA 2.05-4, PB 4.24-6
Kim C.W., PO 081
Kim H.K., SC19-3.02, PO 081
Kim I., PB 4.69-6
Kim J., AS 09
Kim J.E., PA 2.05-4, PO 081
Kim J.H., PO 462
Kim J.M., PA 2.05-4
Kim J.O., PB 4.26-4, PO 462, PO 463
Kim J.W., PB 2.61-4
Kim K., AS 44.1, PB 4.21-4
INDEX

Kim K.H., PA 2.05-4, PB 4.69-6
Kim M.H., PA 2.05-4
Kim M.S., PO 261
Kim N.K., PB 2.61-4, PO 462, PO 463
Kim P.Y., PA 1.06-5, PA 4.10-5, PB 3.34-5, PB 4.21-1
Kim S.H., AS 16.3, OC 54.3, PB 4.69-6
Kim S.K.P., PB 1.31-3
Kim S.H., OC 48.2
Kim Y.C., OC 48.2
Kim Y.K., PB 4.69-6
Kimber M.C., PA 2.06-1
Kimpton M., AS 38.2
Kimura M., PO 233
Kimura T., PO 451
Kinasewitz G.T., SC19-1.01, OC 69.1
Kindermann C., PO 119
King R., PB 2.59-2, PB 3.59-1
King I., PB 3.69-2
King M., SC14-3.03, SC14-2.01
Kingdom J., FS 01.1
Kini M.R., SC20-1.02, PA 3.14-2, PB 3.31-5, PO 262
Kiouptsi K., AS 03.2
Kirby A., PA 1.20-1
Kirby G., AS 28.3
Kirchhofer D., OC 38.1
Kirchhoff E., PA 2.01-4
Kirchmaier C.M., PB 1.48-5, PB 4.42-6
Kirienko A., PB 4.73-4
Kirkman E., PB 2.36-6
Klein C., PB 2.36-6
Klein E., PB 3.63-4
Kleinegris M.C., AS 33.2, PB 2.56-4
Klinski T., PA 1.10-2, PA 2.16-2, PB 1.30-2, PB 4.60-4, PB 4.61-3
Klingmann M., AS 16.3, OC 54.3, PB 4.69-6
Klukowska A., PB 1.36-5, PB 3.57-5, PB 4.50-6, PB 4.54-2
Kloos K., PB 1.36-5, PB 2.36-3, PB 3.64-1, PB 3.64-3, PO 184
Klontz B., PB 4.65-6
Klokov A., PA 2.05-4, PB 4.69-6
Klokova E., PO 456
Knabbe C., PB 3.74-3
Knappe S., PA 1.07-6, PA 3.07-1, PO 062
Knaub S., PA 1.36-5, PB 2.36-3, PB 3.57-5, PB 4.50-6, PB 4.54-2
Knauer N., PB 2.21-3
Knaupe L., OC 18.2
Knoetsch M.L., OC 19.2
Knight T., PB 1.56-3
Knirsch W., PB 1.41-5
Knöbl P., PO 4.19-1, PB 3.33-6
Knoeffler R., PO 143, PB 348, PO 370
Knoeller J., PO 398
Knofl F., OC 53.1
Knoel M.H., PB 4.65-4
Knuchel N., PB 4.44-1
Knudsen T., SC02-2.04, PA 4.13-3, PO 289
Knyazeva A., PO 340
Ko R., PB 3.68-1
Kobayashi H., PB 1.33-1
Kobayashi K., PO 326
Kobayashi N., PO 070
Kobayashi T., PB 3.54-1, PO 070, PO 273
Kobezva N., PB 2.53-5
Koc B., PO 442
Kocak U., PB 3.42-5
Kocatürk B., AS 46.3
Koch C., PB 1.54-4
Koch P., PB 1.36-3
INDEX

Koch P., PA 3.18-4
Kochiashvili N., PO 235
Kocica T., PO 452
Kocovska E., PO 237
Koder S., PA 3.04-5
Koek G.H., AS 33.2, PB 2.56-4
Koek H.L., PA 4.16-1, PA 4.16-4
Koekman A.C., OC 09.5
Koekman C.A., OC 45.1, OC 55.4
Koenderink G.H., AS 35.2
Koenderman J.S., AS 11.1
Koenen R.R., PA 1.17-2, PA 4.03-6, PB 1.32-6
Koentges C., PA 3.02-6
Koh S., PO 046
Kohler H.P., SC10-2.01, SC10-2.05, PA 4.15-2, PB 3.41-2, SPS04-08
Köhler C., PA 1.10-5, PA 3.19-2, PB 3.26-6
Koide H., PB 4.67-2
Koike Y., PB 4.29-1
Kojima H., PB 1.24-2
Kojima S., FS 03.4
Kojima T.R., OC 78.4, PA 2.13-5, PA 3.05-2, PB 3.67-1, PB 4.58-4
Kok M.G., OC 43.1, PB 2.24-1, PO 468
Kokado A., PA 3.18-5
Kokame K., SC17-4.03, OC 47.3, PB 1.33-1
Kokot-Kierepa M., PB 3.41-6
Kolbe-Scheu K., PB 4.73-6
Kolev K., SC03-1.01, AS 01.2, AS 23.3, AS 30.1, PB 3.34-1
Kollars M., PO 459
Kolm A., PA 1.07-4, PB 1.50-3
Koltan A., PO 133
Kolyadko V.N., OC 10.2
Komala A.S., PB 1.27-5
Komanasin N., PO 089, PO 469
Komarnicki M., PB 3.31-2, PB 3.66-6
Komaromi I., PB 3.59-6
Kombrinck K.W., PA 3.16-1
Komitopoulou A., PB 4.71-3
Komišanovic M., PO 284
Komorowicz E., AS 30.1
Komrska V., PB 3.36-2
Komvilašak P., PB 3.62-1, PO 082, PO 227
Kondo M., PO 191
Kondo R., OC 32.5
Kondratieff A., PB 3.27-4
Kong M.C., PB 4.47-6
Konieczynska M., PA 1.14-5
Konigsberger S., OC 58.4
Konkle B.A., OC 61.1, OC 81.1, PA 1.09-4
Konnov V., PO 030
Konoeda H., PA 3.20-4
Kononova O., PA 1.14-1
Konopatskaya O., PA 1.02-4
Konstantinides S., PB 1.69-6, PB 1.70-2
Kontchou A., PB 2.68-6
Konyashina N.I., PB 4.36-4
Konyashina N., PO 384
Koo M., PB 2.46-2
Kooiman J., PB 1.63-5, PA 3.20-1, PB 3.40-4, PB 4.60-3
Kool J., PO 262
Koopman C.D., OC 45.1
Kopec A.K., AS 24.1
Kopac I., PO 355
Kopelović I., PB 1.61-4
Kopylov K., PA 1.11-2
Kopylov K.G., PB 4.36-4
Kordich L., PB 1.57-4, PO 250
Korelusic V., PO 043
Korisha A. A., PB 3.54-6
Kornbrot N., PB 4.35-4
Kornek G., PA 3.04-5
Kornev H.T., PB 1.55-2
Korotina N., PB 1.52-3
Korporaal S.J.A., OC 88.3, PA 2.05-1, PB 1.32-1, PB 3.26-3, PB 4.29-6
Körver-Keularts I.M.L.W., PO 322, PO 339
Kosanovic-Jakovic N., PO 005
Kosasih A., PB 3.50-3
Koschinsky M.L., PA 2.14-5
Kosieleny J., PO 348
Kostadima M.A., OC 33.5
Koster A., OC 91.6
Kostevich V., AS 47.5
Kostosov V., PB 3.68-5, PO 305
Kostur A., PO 252
Kostyak J.C., OC 58.1
Kotha J., PA 4.01-3, PB 4.25-4
Kotova Y.N., OC 10.2, OC 67.4
Kots P., PB 1.74-1, PB 2.69-6
Kottke-Marchant K., PB 2.05-2, PB 4.27-2
Kotula-Horowitz K., PO 281
Kotze R.C., OC 06.5
Kouatchet A., PA 4.17-4
Kouderla A., PB 2.43-5
Kouramba A., PB 1.74-1
Kouroukis T., PB 3.40-3
Koutroumpe L., PB 1.72-6
Kovalova P., PB 2.48-1
Kovac M., PA 2.13-4, PB 3.70-5
Kovacev J.B., PO 263
Kovacs A., AS 01.2
Kovacs M.J., OC 12.3, PB 2.71-5, PB 3.70-1
Kovacs P., PB 3.25-4
Kovács B., OC 90.3
Kovács E.G., PA 1.01-4, PB 2.01-2
Kovács K., OC 78.2
Kovács K.R., PA 3.06-1
Kovalova Z., PO 177
Kovarova P., PO 349
Kowalska M.A., AS 38.4, AS 44.3, OC 69.2
Koyama T., PB 1.60-5, PB 2.60-5, PB 4.32-5, PB 4.39-3
Kozinska J., PA 1.16-3
Kozlov A., PA 1.12-6
Kozlovaite V., PB 1.21-4
Kozlowski J., AS 02.1
Kozuma Y., PB 1.24-2
Kragelund B., PB 4.58-1
INDEX

Kristensen A.K., PO 058
Kristensen A.T., PB 2.44-3, PO 289
Kristensen J.B., PA 2.12-4, PB 1.55-2
Kristensen S.D., PB 3.21-3, PB 3.21-5
Kristensen S.R., OC 07.1, PB 2.30-3
Kristoffersen A.H., PB 2.64-1, PB 2.65-4
Kritharides L., PB 1.60-6
Krogh B., PA 2.14-4
Krogh-V. Meibom T., PB 4.55-5, PO 059
Krogh-V., OC 04.1, OC 07.6, PA 3.06-4, PB 1.56-6
Krogh-Meibom T., PB 4.55-5, PO 059
Krohn G., OC 33.6
Kroiss S., PB 1.26-2, PB 1.41-5
Kroistad S., PA 3.20-5
KroJ D.G., AS 02.1
KroJ H., PB 3.39-5, PB 3.39-6
KroJning M., PB 2.43-3
Kroon-Batenburg M.J., OC 23.1
Krudysz-Amblo M., PA 1.10-2, PA 1.10-4, PA 1.10-6
KruJ D., PB 2.55-4, PB 3.50-2
KruJ C.A., OC 15.4, OC 49.4
KruJ S., PO 315
Kruize W., PA 1.38-6, PO 143, PO 152
Kruk A., OC 87.6, PA 4.02-3
Krishnamoorthy G., PA 2.11-1
KrishnaP.othy G., OC 56.4
Krishnan S., PB 3.55-5, PO 134, PO 135, PO 178
Krishnan U., PB 3.71-4
Krishnaswamy S., OC 11.2, OC 48.1, OC 68.1, OC 69.2
Krishnnon S., PB 1.35-6, PB 1.37-4
Krisinger M.J., AS 31.2
Kubisz P., PB 2.54-4, PB 4.65-5, PO 204, PO 243
Kubitz D., OC 16.1, OC 36.5, PB 3.45-4, PB 3.46-1
Kubota N., PO 079
Kuka P.J., PB 2.47-2
Kucerova J., PO 338
Kudela D., PA 3.14-1
Kuen Bor C., PO 464
Kuenzi A., PA 2.02-6
Kuether L., AS 45.3
Kuge Y., PB 1.73-1
Kühbauch M., PO 450
Kuhle S., OC 75.1, OC 75.2, PB 3.68-6
Kuhtisch E., PB 1.70-4
Kuhn T., PO 349
Kuhn W., PA 3.17-6
Kuijper P., PA 2.13-1
Kuijpers J.E., AS 04.3, OC 24.3, OC 35.5, OC 64.4, OC 87.2
Kuijpers T.W., OC 62.1, PO 329
Kuiken T., OC 69.4
Kuijer J.A.J.M., PB 2.30-5
Kuijer G.T.W., OC 12.2, OC 20.2, PA 1.20-2, PB 2.65-3, PB 2.65-6
Kuijer J., OC 07.1, PB 2.30-3
Kurcik B., AS 31.2
Kurcik-Ebbers M., PB 4.66-1
Kurkiewicz D., PB 1.19-4
Krupka J., PA 2.06-3, PB 1.74-5, PB 3.41-5
Kulska J., PB 3.51-1
Kulkarni K., FS 02.1, OC 82.4
Kulkarni P., PB 2.24-6, PB 3.74-6
Kulkarni R., OC 37.2, PA 2.06-3, PA 2.07-5, PB 1.74-5, PB 3.41-5
Kulkarni S., PB 3.51-1
Kulman J., AS 45.1, OC 37.5, PA 2.12-5, PA 4.13-1, PB 2.55-3, PB 3.55-3, PB 4.55-4
Kulu I., PA 2.04-5
Kumari S., PB 3.71-6
Kumar M.S., PB 2.46-1
Kumar M., PB 2.19-5, SC 15-1.0, SC15-1.01
Kumar S., OC 68.1, PA 2.12-5, PB 2.55-3, PB 4.55-4, PO 181
Kumar V., PB 475, PO 476
Kumskova M., PA 1.11-2
Kun M., PA 4.15-5
INDEX

Kunapuli S.P., PA 4.01-1, PB 2.67-4
Kung C., PB 4.46-4
Kung P.H., PO 460
Kunicki T., OC 62.3
Kunishima S., FS 03.4, PA 3.05-2, PA 4.05-6, PB 4.44-4
Kunst P., PB 1.30-2
Kunzelmann K., OC 11.3
Kuo C.Y., PO 460
Kuppen P.J.K., AS 46.3
Kupper T., PB 3.47-3, PB 3.53-2
Kupstyte N., PB 1.21-4
Kurasawa J.H., OC 28.3, PA 1.13-4
Kurata S., OC 60.2, OC 91.2
Kurdee Z., PA 3.12-3, PB 3.21-1
Kurnaz E., PO 345
Kurniawan N.A, AS 35.2
Kurnik K., PA 2.06-2, PB 2.36-5
Kurosawa S., AS 47.3, SC 19-3.03
Kuruvilla S., PA 2.15-3
Kusters H.M., OC 26.2, OC 32.3, OC 43.4
Kustovskaya E., PO 453, PO 482
Kutily A., PO 013
Kutlubay B., PO 331
Kuvaeva E., PB 4.68-4
Kuwahara M., OC 14.1, PB 4.39-3
Kuwana M., PA 1.05-3
Kuzmanovic M., PB 4.61-4
Kuznetsov Y., PB 4.53-5
Kuznik B., PO 453, PO 482
Kvam A.K., AS 19.3
Kwon H.M., PB 1.70-6
Kyrle P.A., SC 06-2.02, OC 12.5, OC 63.2, PB 3.70-3, PB 3.73-1, PO 459
LaMarca S., PB 2.43-6
Labalme A., PB 1.39-4
Labar B., PO 284
Labarque V., PA 2.19-4, PA 3.09-3, PB 3.69-5, PB 4.71-6
Labberton L., AS 20.3, PO 242
Labidi A., PB 2.45-5, PO 003, PO 405
Labrosse J., PB 2.74-6
Lacatérière N., OC 79.2
Lacatusu A., PO 165
Lackner K.J., OC 41.2
Lacolley P., OC 54.2, PA 2.17-2, PB 4.64-1
Lacout C., OC 58.5, PA 1.03-3
Lacroix R., SC 07-5.02, OC 17.2, PA 1.04-4, PB 3.30-6, PB 4.30-4
Lacroix-Desmasez S., SC 09-1.02, AS 47.4, OC 56.1, OC 56.2, PA 1.13-1, PA 2.12-6, PA 3.07-6, PB 1.38-6, PB 2.35-4
Lacut K., AS 43.2, PB 4.63-5
Lafayette M.G., PO 424
Lafeber P.J.G., PA 1.07-1, PA 1.07-2, PA 1.07-5
Laffan M.A., AS 01.1, OC 39.3, OC 91.5, PA 4.09-6, PB 1.39-1, PB 1.44-2, PB 4.34-3
Laghmani E.H., PA 3.12-4
Lago A., PA 2.01-5, PB 2.30-6
Lagrange J., OC 54.2, PA 2.17-2, PB 4.64-1
Laguna P., PB 3.36-2, PB 3.74-1, PO 133, PO 137
Lahav J., PA 3.01-3, PA 4.02-4, PB 1.23-5
Lai T.H., PB 1.73-4
Lai Y.F., PB 4.47-6
Lakbakbi S., PB 3.56-2
Lakoski S.G., PA 1.16-1, PB 1.52-4, PB 3.22-4, PB 3.40-2
Lallemand F., PB 4.63-5
Laliberté F., PB 4.31-2
Laloy J., PB 4.52-6
Lam W.A., PB 1.31-1
Lam J., PB 4.52-6
Lamb K., PB 2.33-2
Lamrani L., PA 2.09-2
Landau M., PB 1.72-3
Landolt-Marticorena C., AS 16.1
Landry G.J., PB 3.72-1
Lanée D.A., AS 43.3, OC 65.2, OC 86.2, PA 1.15-5
Lanerie D.A., PB 3.48-6
Lange D., PB 2.33-2, PO 326
Lane R., OC 33.5
Langlois E., AS 19
Lang S., OC 55.2, PB 2.51-5
Lang U., PB 3.65-5
Langdown J., OC 62.5
Langer F., PA 3.16-6, PB 2.38-6
Langlet S., PB 4.57-5
Langley K.M., AS 40.2, PB 2.33-2
Lanke M., PB 1.70-2
Lankes J., PB 4.34-6
Lannert K.W., OC 61.1, PA 1.09-4
Lantvit S.M., PA 4.20-2
Lanza F., AS 27.3, OC 87.3, OC 89.6, PA 1.04-6, PA 2.04-3, PA 2.04-6, PB 1.29-6, PB 2.26-1, PB 3.29-2, PB 3.41-1
Lapalud P., PB 3.08-3
Laporte S., AS 18.2, PA 2.18-1
Lapponi M.J., PB 2.31-6
Larina L., PO 306
Larocca L.M., OC 89.4
INDEX

Laros-van Gorkom B.A.P.,
OC 13.1, PA 2.08-4, PB 1.42-1, PB 1.42-5, PB 4.36-6
Larrazabal R., PB 1.45-4
Larsen J.B., PB 1.45-4
Larsen O.H., PB 2.58-4, PB 3.22-6, PB 3.38-4
Larsson A., PB 3.66-5
Larsson M., AS 20.3, PO 242
LaRus G.A., OC 01.2, OC 26.1, OC 53.4
Lascar S., PO 008
Laskovets A., PB 2.22-4
Lasne D., AS 26.3, PA 1.08-4, PB 4.71-5
Lasom S., PO 089
Lassen M.R., AS 38.3
Lassila R., OC 22.2, PB 2.59-4, PB 3.37-2, PB 4.41-4, PB 170, SP512-04
Laszlo F., AS 38.3
László Z., PB 2.66-3, PB 4.28-3
Laterveer R., OC 81.3, PA 1.45-5, PB 2.54-6
Latger-Cannard V., PA 3.05-5, PB 3.25-1, PB 4.63-2
Latorre A.M., PA 2.01-5, PA 2.03-2, PB 2.23-5, PB 3.21-2, PB 4.24-5
Latorre L., PO 179
Lattanzio S., PB 1.26-1, PB 2.28-4
Lattenist L., AS 31.3
Lau A.G., OC 70.3
Lau D.T., PB 3.48-5
Lau K., OC 51.2, OC 64.5, PA 4.10-5, PB 2.38-1, PB 2.52-3, PO 280
Laulicht B., AS 47.1
Laune D., PA 3.08-3
Laura S., PA 4.13-1
Laurance S., AS 10.1, OC 85.3
Laurent P.A., AS 37.1, PA 2.03-1
Lauricella A.M., PB 1.57-4, PB 2.34-6
Lauritzen B., OC 84.2, PA 4.14-6
Laursen P.N., PO 325
Laux M.N., PA 1.16-2, PB 1.72-5, PB 2.61-6

Laux V., OC 28.2, OC 80.6, PA 2.11-5, PA 2.15-2, PA 4.13-4, PA 5.33-4
Lavenu-Bombled C., PB 3.41-1
Lavery R.C., PO 071, PO 285
Lavickova A., PO 260
Lavigne T., PA 1.04-6, PA 4.17-4
Lavigne-Lissalde G., FS 01.2
Lavrinov P.A., PO 415, PO 417
Law C., NS 01.2
Law L., PA 2.02-4
Law R.H.P., PB 2.34-4, PB 3.34-3
Lawler P., PB 4.39-6
Lawo J.P., PB 3.37-5
Lawrence C., PB 1.51-5
Lawrence M.B., PB 1.28-3
Lawrence M.B., PB 4.23-4, PA 2.11-2
Lawrence M.J., PB 1.53-1, PB 1.57-2, PB 2.50-2, PB 2.63-5
Lawrie A.S., SC09-1.06, PA 1.18-6, PB 1.62-4, PB 2.43-6, PB 4.42-4, PB 4.50-5, PO 326
Layzer J., PB 4.49-3
Lazo-Lannger A., PB 3.61-4, PB 3.70-1
Lazzari M.A., PB 1.60-4, PB 2.28-5, PB 2.73-4, PB 3.33-3, PB 4.43-6, PB 4.44-2, PO 025, PO 385, PO 431, PO 438
Lazzeri C., PB 2.22-4
Le A.N., AS 10.1
Le J., OC 65.6
Lè P.Q., PB 2.55-1
Le Béhot A., AS 35.3
Le Bonnic B., PB 3.48-2
Le Cessie S., OC 30.6, PA 3.19-1, PB 4.60-3
Le Flem L., PB 2.47-6, PB 3.48-4
Le Gal G., SC06-3.05, AS 05.2, AS 38.2, AS 42.1, AS 43.2, OC 12.1, OC 12.3, OC 20.1, OC 20.4, OC 61.4, PA 1.20-5, PA 2.16-1, PA 4.10-3, PB 1.70-5, PB 2.61-3, PB 2.61-3, PB 2.71-4, PB 2.71-5, PB 3.61-2
Le Galudec M., PB 4.63-5
Le Lay A., PB 3.41-6
Le Moigné E., AS 05.2, AS 43.2, OC 61.4
Le Roux E., PB 3.30-3
Le Toriellec E., PA 2.05-6
Le Visage C., PB 3.29-4
Leahey M., PB 2.49-2
Leake D.S., PB 1.23-3
Lebedeva T., AS 38.4, PA 3.12-6
Leblebisat G., PO 099, PO 163
LeBoeuf S.E., OC 82.2
Lebois M., PB 1.27-6
Lebrero C., PO 407
Lebret M., OC 39.2
Lebreton A., PB 1.41-1
Lecchi A., OC 89.3, PA 1.22-4, PB 2.25-5
Lechtenberg B.C., OC 49.1, OC 49.2
Leclercq A., PA 1.04-2
Lecompte T.P., OC 79.2, PA 3.05-5, PB 3.25-1, PB 4.63-2
Lecumberri R., PA 2.16-3
Lecut C., PA 1.02-3
Lede I., PB 3.66-3
Lederfine D., OC 82.1
Lee A., PA 2.06-4
Lee A.Y.Y., OC 78.1, PA 2.18-2, PB 1.61-3
Lee B.C., AS 47.3
Lee B.E., PO 462
Lee C.A., PB 4.41-3
Lee E., PO 363
Lee F.M.H., OC 51.2
Lee F.S., PA 3.12-1
Lee G., PB 2.52-5
Lee H., PB 4.21-3
Lee H.H., PO 261
Lee H.U., PO 261
Lee J., PB 1.64-2
Lee J.O., PB 4.46-1
Lee K., OC 50.4
Lee K., PA 2.11-4
Lee K.S., PA 1.05-4, PO 139
Lee K.W., PB 2.70-6
Lee L.H., PB 4.47-6
Lee S.J., PB 3.62-1
Lee S.Y., PO 032
INDEX

Lee T.S., PB 1.67-5
Lee W., PB 2.38-3, PB 4.37-6, PO 132
Lee W.S., PO 462
Lee Y.Y., PB 3.31-4
Lee B.C., AS 47.3
Lee A., SC13-2.04
Lee A.Y.Y., SC13-1.01
Lee Evans H., PA 4.15-6
Leebeek F.W.G., SC17-5.05, AS 32, AS 32.3, OC 13.1, OC 48.1, PA 2.07-1, PA 2.08-3, PA 2.08-4, PA 2.09-1, PA 3.06-5, PA 1.42-1, PA 2.36-2, PB 2.43-5, PB 2.44-1, PB 3.37-6, PB 3.37-6, PB 3.43-6, PB 4.39-2, PB 4.65-3, PO 093, SA08-01
Lee-Grossman C.W., PO 134
Leena C., PB 1.61-3
Leenaerts D., SC05-2.07, PB 2.34-3, PB 4.34-2
Leers M.P.G., PB 2.30-5, PB 4.47-5
Leeson K., PA 3.11-5
Lefebvre P., PB 4.31-2
Lefrandt J.D., OC 04.4
LeFrapper L., PB 3.46-6
Legnani C., OC 12.4, PA 4.18-5, PB 2.31-4, PB 2.71-1, PB 2.71-6, PB 2.74-3, PB 3.64-6
Leguay C., OC 35.2, PA 2.04-6
Lei A., PA 4.18-2
Lei V., AS 31.2
Lei X., PB 4.25-3
Lei Z., PB 4.28-6
Leibowitz C.S., AS 47.3
Leidenmüller P., PA 1.07-6, PA 3.07-1
Leiderman K., PA 3.07-4
Lei L.A., PB 4.68-3
Leitão P., OC 02.5
Leite F., OC 02.5, PB 4.53-3
Leitner M., PB 3.52-3
Leizorovicz A., PB 3.39-3
Lelakowski J., PO 234, PO 281, PO 496
Lemarchand E., AS 35.3

Lemarie C.A., AS 10.1, OC 85.3, PA 3.03-6, PB 1.60-1
Lemaria L., PA 1.08-3, PB 4.51-1
Lemmas Jardim L., PB 2.31-2
Lennon M., PB 4.41-4
Lenderink T., PB 4.47-5
Lenicek Krieza J., PB 4.31-4
Lenk C., PO 328
Lenka L., PB 2.54-4
Lensing A.W.A., AS 17.1, AS 19.2, AS 20.2, OC 02.2, OC 02.6, OC 71.1, OC 79.4
Lentaigne C.E., PO 350
Lenti M., OC 43.2
Letting P.J., AS 09.2, OC 39.2, OC 65.1, PO 010, SA01-05
Lentz B., PB 2.38-6
Lentz S.R., OC 83.2, OC 83.5
Leo V., OC 39.6, PB 3.71-2
Léon C., PB 1.29-6
Leong J., PO 264
Leong L., OC 28.2, PA 2.11-5, PA 4.13-6, PB 3.53-4
Leony-Lasso L., PB 1.37-3
Lerede T., OC 42.2
Lerner A., PB 4.68-2
Leroi A., PL 08.01
Lerolle N., PA 4.17-4
Leroux D., OC 21.3, PA 3.08-3, PA 3.08-4
Leroyer A., PA 1.04-4
Lerstad G., AS 43.1, PB 1.70-1
Lesauskaite V., PB 1.21-4
Leschik B., PB 3.24-3, PB 3.65-5, PB 4.50-4, PB 4.64-5
Lesic A., PA 4.07-3
Leslie M., FS 02.1, OC 82.4
Lethagen S., PA 4.07-5
Letmade P., PA 1.10-6
Letourneau S., PB 1.39-4
Letouerneur D., PB 3.29-4
Letson H.L., PO 244
Leung L., OC 46.2, PB 4.59-4
Leung P.Y., AS 25.2, OC 64.1
Leung W., PA 2.08-4

Lévesque H., PB 2.39-2
Levi M., AS 31, OC 02.2, OC 36.5, PA 4.06-4, PB 4.48-2, PO 292, SP09-01, SP09-05, SP10-06
Levinas M., PO 492
Levine O., PB 1.64-2
Levy B., OC 72.1
Levy D.M., PB 3.62-1
Levy H., PB 2.55-4
Levy J., OC 36.5
Levy J.H., PB 3.59-5, SP08-03
Levy S., OC 47.2
Lewis B., PB 1.40-5, PB 1.48-4, PB 2.47-3, PB 3.54-3
Lewis D.A., PB 2.71-3
Lewis H., PB 1.45-3, PB 3.38-3, PB 4.44-3, PO 436
Lewis H.L., PB 1.68-3
Ley L., PB 4.53-2
Leyte A., PO 258
Leytin V., PO 500
Li B.X., AS 15.2, PB 4.25-3
Li C., PB 2.38-1
Li G., PO 182
Li H., PA 1.05-1, PA 1.05-2, PB 3.35-6, PB 4.29-2, PB 4.29-5, PO 226
Li J., AS 44.1, OC 55.2, OC 58.6, OC 87.1 PO 364, PO 419
Li J.Z., OC 47.1
Li L., AS 16.1
Li M., PB 1.24-4
Li N., OC 85.6, PB 2.23-3, PB 2.52-3, PB 4.26-3, PB 4.56-6
Li Q., PA 4.01-4
Li R., PA 2.01-6, PB 2.59-1, PB 3.43-2
Li S., OC 37.2, PA 2.06-3, PA 2.07-5
Li T.Y., PB 3.37-3
Li X., OC 64.5, PA 2.01-6
Li Y., PA 2.14-4, PB 1.21-6
Li Z., PB 1.32-1, PB 3.27-2, PB 3.70-2, PB 4.29-6
Liang C., AS 15.2
Liang H.P., OC 89.5
Liang Q., PA 2.11-3
Liang X., PB 3.43-2
INDEX

Liani R., PB 2.28-4
Liao H.R., PO 229
Liao P., AS 13.2
Liaw P., AS 25.1, OC 84.1, PA 2.15-3
Libbrecht S., OC 65.4
Lichte A., PB 4.73-6
Lichtenberg A., PA 3.13-5
Lida M., PO 147
Lie B.A., PB 3.60-1
Liehn E.A.M., PA 1.17-2
Liem T.K., PB 3.72-1
Lienhart A., OC 48.3, PB 1.43-5
Liesner R., OC 56.3, PA 2.07-2, PB 1.36-5, PB 2.42-2, PO 140, PO 054-04
Lievens D., AS 04.3, OC 87.2
Lievens D., AS 04.3, OC 87.2
Lifenko R., PO 219
Ligi I., OC 26.3
Lijfering W.M., AS 05.1, AS 10.2, OC 04.2, OC 30.3, OC 30.6, OC 42.4, OC 59.4, OC 63.6, PB 3.47-2, PB 3.55-2
Lijnen R., AS 43
Lilley G., PA 3.13-3
Lillicrap D., AS 15.2, AS 10.2, OC 04.2, OC 30.3, OC 30.6, OC 42.4, OC 59.4, OC 63.6, PB 3.47-2, PB 3.55-2
Lim G., PO 261
Lim K.M., PB 4.21-4
Lim M.Y., PB 3.38-1
Lim P., PB 4.47-6
Lim G., PO 261
Lim C.Y., PB 2.70-6, PB 3.58-6
Lin F.C., OC 17.3
Lin H.Y., PB 2.70-6
Lin J.L., PB 1.25-2
Lin J.S., OC 46.4
Lin P.Y., PA 1.03-1
Lin S.W., OC 57.2
Lin S.Y., PB 3.58-6
Lin V.W., PB 3.39-3, PB 3.36-4, PO 142
Lindblom A., PB 1.37-6, PB 3.74-1
Lindemans A.D., PA 1.10-3
Lind C., OC 07.1, OC 59.2
Lind V., PB 4.52-4
Lindahl T., PA 3.04-4, PB 2.24-2, PB 2.49-6, PB 3.45-3, PB 3.66-5, PB 4.25-2, PO 333
Lindblom A., PB 1.37-6, PB 3.74-1
Linden M., PO 372
Linden R., PB 4.26-6
Linder M., PB 4.26-6
Lindvall K., PB 2.38-5, PB 4.42-1
Ling C.Y., PB 4.65-5, PO 204, PO 243
Lisman J.A., PB 4.65-5
Lisman T., AS 33, OC 04.4, PA 2.15-1, PB 1.38-1, PB 1.46-5, PB 2.33-5, PB 2.57-2, PB 3.58-1, PB 4.65-4
Lissalde-Lavigne G., PB 3.65-2, PB 4.66-3
Lissitchkov T., OC 70.2, PB 3.49-4, PB 3.49.6
Litvinov R.I., SC 10.2-08, OC 06.1, OC 21.1, PA 1.14-1, PA 3.01-2
Litzenburger T., OC 36.2
Liu C.C., PB 3.31-3
Liu C.L., OC 56.5
Liu C.Z., PB 1.25-2
Liu D., PA 2.18-2
Liu F., PA 2.02-1
Liu F.C., PO 229
Liu J., AS 15.2
Liu J., OC 58.3
Liu L., AS 07.3
Liu L., OC 80.2
Liu P., OC 28.2
Liu P., OC 11.4, PB 4.26-1, PB 4.26-3
Liu S., PB 4.56-1
Liu T., OC 19.1
Liu T., AS 45.1, OC 37.5, OC 56.4, PA 2.12-5, PA 4.13-6, PB 2.55-3, PB 4.55-4
Liu X., PA 4.01-4
Liu X., PB 2.32-3, PO 226
Liu X., PB 3.33-5, PB 3.71-5, PO 086, PO 422
Liu Y., OC 90.5
Liu Y., PB 3.57-1
Liu Z., OC 56.4, PA 4.13-6
Liu Z., PA 2.04-1
Liu Z., PB 2.48-4
Liu Z.L., PA 4.13-1, PB 3.55-3
Liverani E., PB 2.67-4
Livingston E.W., OC 70.3
Livnat T., PA 1.17-6, PB 3.36-1
Ljung R., OC 03.2, OC 03.4, PA 2.06-2, PA 4.07-1, PB 4.36-1
Llamas P., PB 3.37-6, PO 396
Llobet D., PB 1.53-6, PB 1.54-2
Lloyd T., AS 27.2
Lloyd-Evans P., OC 35.1

522
INDEX

Lluch-Garcia R., PO 016
Lo W.C., AS 16.1
Lo Coco L., PO 213
Lobach I., PB 4.26-5
Lobmeyer M., PB 4.45-3
Löchen M.L., OC 59.6, PB 4.64-2
Lochu A., PB 4.54-1
Lock J., PA 2.07-1, PB 1.38-5, PB 1.45-3, PB 2.36-2, PB 3.37-6, PB 4.36-6, PB 4.39-2
Lodemann P., PA 3.10-2
Lodigiani C., PB 2.46-4
Lodo F., PO 012
Loeffen R., OC 64.2, PA 2.17-6, PB 4.49-4
Loew-Baselli A., PO 158
Löffler B., PB 2.40-1
Loftager M., OC 28.5, PA 4.14-2
Logeart D., OC 07.3
Lohmeier J., PB 3.22-2
Lohrmann J., OC 16.4
Lohse J., PO 143
Lokajczyk A., PB 2.29-5
Lokar L., PO 017
Lokar M., PO 017
Lomakin N.V., PO 310
Lombardi F., PO 447
Lombardi R., PB 4.57-6
Lombardo A., AS 45.2
Lompré A.M., PB 1.26-6
Loncon G., PA 4.05-2
Lone Y.C., OC 56.2
Long Zheng X., SC14-2.05
Longstaff C., SC05-2.04, AS 23.3, AS 30.1, OC 29.5
Loomans J.I., OC 66.4
Lopes A.D., PO 074
Lopes M., PO 180
Lopez A., PA 4.05-2
Lopez A.F., OC 76.1
Lopez L., PB 2.62-3, PB 2.62-5
López F., PB 2.37-3
López J.A., SOA 17.2, OC 38.1, OC 65.6, OC 74.2, SC14-2.03
López L., PB 2.52-1
López M., PB 2.52-1
Lopez Zambrano M., PB 2.67-5
Lopez-Alonso R.J., PB 1.61-6, PB 3.60-4
Lopez-Barba J.J., OC 86.4, PB 3.27-4
Lopez-Contreras D., AS 14.1
López-Fernández M.F., PB 1.68-2, PB 2.42-6, PO 056, PO 149
López-Martínez A., PO 016
López-Pedrera C., OC 27.6
López-Vásquez L., PO 144
Lopez-Vilchez I., PA 3.01-4, PB 2.31-3
Lordkipanidze M., SC18-3.02, OC 88.5, PA 3.05-1, PA 4.05-3, PB 1.22-2, PB 2.25-1, PB 2.25-2, PB 3.22-1, PB 3.22-3
Loren C., PB 4.25-5
Lorenz F., PB 3.29-6
Lorenz J., PA 1.19-5
Lorenz T., OC 60.1, OC 86.6
Lorenz V., OC 61.0, OC 86.6
Lorenzef M., FS 02.1
Lorenzo A., PA 4.16-2
Losonczy H., OC 90.3, PB 1.44-6
Lotta L.A., AS 40.1, AS 47.2, PA 1.08-3, PA 2.12-2, PA 2.16-4, PA 3.05-6, PA 4.19-2, PB 1.33-6, PB 2.25-5, PB 3.33-4
Lotti L.V., PB 3.71-1
Louch W.E., PA 4.16-2
Lo Conte M.L., OC 05.6
Lotchey S., OC 11.4
Louis H., PA 2.17-2, PB 4.64-1
Loure Rê S., PB 2.42-6
Louth S., PB 2.74-4, PO 018, PO 366
Louv V., PB 3.30-3
Louxette S., OC 33.3
Loven D., PB 1.30-3
Lövgren K.M., PO 289
Low J., PA 2.01-3, PB 1.59-3, PO 019
Lowe A., AS 02.2, PA 3.11-5
Lowe G.D.O., SC06-3.06, OC 64.2, OC 90.4
Lowery T.J., AS 38.4, PA 3.12-6, PB 1.26-3
Loayu S., PB 3.23-6, PB 3.25-1, PB 4.26-4
Lozano M.L., PA 3.01-5, PA 3.05-1, PB 2.25-3, PB 4.27-6
Lu B., PB 2.34-4, PB 3.34-3
Lu G., AS 20.1, PB 1.24-4
Lu J., PB 1.31-1
Lu L., OC 11.4
Lu P.S., PA 1.03-1
Lu Q., PA 1.12-4, PB 4.55-1
Lu X., OC 32.6, PB 1.32-2, PB 1.32-4, PB 1.32-5, PB 3.32-6, PB 3.71-3, PO 470, PO 473
Lu Y., PB 1.37-2, PB 2.35-5, PB 4.38-3
Lu Y.L., PB 4.35-5, PO 198, PO 379
Lu B., PB 2.34-4
Lubber S., OC 4.4
Luberda T., PB 2.62-1
Lubetsky A., OC 70.2
Lubich C., PO 146, PO 328
Lubrano S., PO 377
Lucas F.V., AS 66.4
Lucassen W., OC 20.3
Lucchesi A., PO 214
Lucchi D., PA 4.10-1
Lucero A., PB 4.31-5
Luchinkina E., PB 4.35-5, PO 198, PO 379
Lu B., PB 2.34-4
Lubberts S., OC 4.4
Luberda T., PB 2.62-1
Lubetsky A., OC 70.2
Lubich C., PO 146, PO 328
Lubrano S., PO 377
Lucas F.V., AS 66.4
Lucassen W., OC 20.3
Lucchesi A., PO 214
Lucchi D., PA 4.10-1
Lucero A., PB 4.31-5
Luchinkina E., PO 171
Lucia F., PB 2.37-3
Luciani M., PO 111
Luddington R., OC 62.5, PB 2.71-2, PB 3.73-2, PB 4.52-3
Ludlam C.A., SC08-1.02, OC 22.2
Luengo-Gil G., OC 05.4
Lugano R., PB 3.32-5
Lui M.S., PB 4.49-2
Luis-Hidalgo M.M., PO 016, PO 275
Luk A., AS 26.1, OC 37.2, OC 64.3, OC 81.1, PA 2.07-6, PA 4.07-2, PB 4.37-3
Luke K.H., PO 182
INDEX

Maloney J.C., PB 4.38-1
Malone D.C., PB 1.35-6, PB 3.68-1
Makari J., AS 28.1
Makarova P., PO 011
Makatsaria A., PB 2.61-5, PO 127, PO 205, PO 206, PO 207, PO 208, PO 209, PO 210, PO 211, PO 212
Makatsariya N., PO 205, PO 206, PO 207, PO 210, PO 211
Mäkelburg A.B.U., PB 2.74-2
Makhalidani L., PO 235
Makhloifi M., PB 2.41-6
Makipernea A., PB 2.06-2
Makris M., SC01-3.02, OC 22.2, OC 34.2, OC 62.6, PA 2.20-2, PA 3.11-5, PB 2.37-4, PB 2.52-4, PB 2.56-5, PB 3.36-3, PB 4.54-2
Maksimova O., PO 453, PO 482
Malais J., PB 1.30-6
Malen E., PB 1.48-2
Malato A., OC 02.1, PB 2.39-6, PB 4.46-1, PO 213, PO 214, PO 413
Malcangi G., PO 200, PO 430
Male C., OC 22.1
Malerba M., PB 2.36-4
Malezhik L., PA 1.19-6, PB 4.50-2, PO 472
Malezhik M., PA 1.19-6, PB 4.50-2, PO 472
Malfflet J.M.C., PA 3.06-5, PB 1.34-1, PO 093
Malhotra P., PO 175
Malina T., PO 092, PO 237
Malisauskas M., PO 146, PO 328
Malkova O., PO 171
Mallari C., OC 80.6, PB 1.55-3
Mallone R., OC 56.1
Malmström R.E., PB 3.51-4
Malone D.C., PB 1.35-6, PB 1.37-4
Maloney J.C., PB 4.38-1
Malström R.E., AS 02.3
Malvestiti M., OC 72.3
Malý R., PB 1.26-4, PB 4.62-6
Malyarchikov A., PO 031
Mamianiat A., PB 3.21-1
Mamakov V., PB 2.58-5
Mammolit D., PB 2.66-4
Mamakov V., PB 3.49-4, PB 3.49.6, PB 4.58-6
Managchi M.R., PB 1.50-6, PO 481
Manara R., PB 1.36-1
Manchanda N., PB 1.61-5, PO 083
Mancini L., PA 4.19-2, PB 3.33-4
Mancini J., PA 1.04-4
Mancini T., PB 1.42-5
Manco-Johnson M., OC 70.1, PA 3.07-4, PB 3.57-1, SP09-04
Mancuso M.E., SC01-3.01, AS 22.2, OC 03.3, OC 56.3, PA 1.13-2, PA 2.07-2, PA 2.12-2, PA 4.11-6, PB 4.36-1, SP09-04
Mandolini C., PB 2.24-1
Manel V., PB 2.31-5
Manfield I., PB 2.59-2
Manganaro D., OC 35.4, OC 72.4
Mangin P.H., AS 07.1, AS 27.3, OC 87.3, OC 89.6, PB 2.28-1
Mangles S.E., PB 4.34-3
Munganmadaj I., PO 096
Mani H., PO 265
Maninska L., PO 237
Mann K.G., OC 44.4, PB 1.56-1, PB 1.56-3
Manner D., PB 1.68-1, PB 3.69-3
Mannhalter C., AS 31.1, PA 2.06-6, PB 2.41-4
Manning H., OC 58.6
Mannini L., PB 4.32-3, PB 4.33-1, PB 4.74-3
Mannucci P.M., OC 22.2, FS 04.3, PA 2.08-1, PB 3.37-2, SC01-4.03
Manson J., OC 19.1
Mansouri B., PB 3.73-6
Mansouri M., SC17-2.01
Mansouri Taleghani M., OC 52.3, PA 4.19-1
Mansouritaghbeh H., PO 147
Mantelvão S.L., PO 084
Manthripragada G.K., PA 2.18-4
Manukyan D., OC 41.2
Manukyan I., PO 077
Manzana W., PB 1.55-3
Manzato E., PB 1.47-2
Manzo Francisco L.A., PB 2.22-5
Manzo Silberman S., OC 07.3
Mao L., OC 25.1
Mao G., PA 2.17-3
Marar T., OC 84.6
Maraveyas A., AS 46.2, PB 1.56-5, OC 38.4, PB 3.56-1, PB 3.60-3, PB 3.61-5
Marchal-Somme J., PA 2.14-3
Marchese P., OC 58.2, PB 2.46-4
Marchetti T., OC 27.5
Marchetti G., PB 3.32-3
Marchetti M., PA 4.20-1, PB 1.22-5, PB 1.26-5, PB 3.22-5
Marco P., PB 2.37-3, PO 021
Marconi A.M., PA 3.17-2
Marconi V., OC 04.5, PB 4.60-2
Marcos-Contreras O.A., AS 23.2
Marcucci M., AS 22.2, PB 3.70-3, PO 148
Marcucci R., PB 1.34-6, PB 2.22-3, PB 2.22-4, PB 2.27-6, PB 2.29-2, PB 4.32-3, PB 4.33-1, PB 4.74-3
Marcus M.A.E., PB 3.40-2
Marcus S., OC 69.2
Marder V.J., PB 2.34-4
Marës P., PB 2.66-2, PB 3.65-2, PB 4.65-1, PB 4.66-3
Margaglione M., PA 3.17-1, PO 201
Margaritis P., AS 34.3, OC 31.4, OC 50.2, OC 83.3
Margetic S., PB 1.51-4, PB 3.62-5, PO 454
Mari R., OC 07.4
Mari-Alexandre J., OC 40.3, OC 40.4
Mariani E., OC 59.1
Mariani G., OC 62.2, PA 1.08-2, PO 214
Mariante R.M., PB 4.26-6
Marie J.P., PA 2.16-6
<table>
<thead>
<tr>
<th>Name</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Martinez J.,</td>
<td>PB 1.47-2</td>
</tr>
<tr>
<td>Martino R.,</td>
<td>PB 3.10-3</td>
</tr>
<tr>
<td>Marín F.,</td>
<td>OC 74.6</td>
</tr>
<tr>
<td>Mariano R.,</td>
<td>PO 200, PO 430</td>
</tr>
<tr>
<td>Marín-OCampo R., PB 2.56-6, PO 199</td>
<td></td>
</tr>
<tr>
<td>Marjan E.,</td>
<td>PO 433</td>
</tr>
<tr>
<td>Markavicius I., PB 3.74-4, PB 4.22-2, PO 313</td>
<td></td>
</tr>
<tr>
<td>Markwitz R.,</td>
<td>PA 3.12-6</td>
</tr>
<tr>
<td>Marqués-Junior J.F.C., PA 4.19-5</td>
<td></td>
</tr>
<tr>
<td>Marqués-Verdier A., PB 1.41-1, PO 707</td>
<td></td>
</tr>
<tr>
<td>Marrero D., OC 32.4</td>
<td></td>
</tr>
<tr>
<td>Marsac B., OC 40.2</td>
<td></td>
</tr>
<tr>
<td>Marshall J., PB 4.63-6</td>
<td></td>
</tr>
<tr>
<td>Marshall, PA 4.11-4</td>
<td></td>
</tr>
<tr>
<td>Marsman G., PB 2.67-1</td>
<td></td>
</tr>
<tr>
<td>Martageix C., PB 3.25-6</td>
<td></td>
</tr>
<tr>
<td>Martens L., PA 2.05-3</td>
<td></td>
</tr>
<tr>
<td>Martí-Fabregas J., PB 3.63-1</td>
<td></td>
</tr>
<tr>
<td>Martin A.C., PB 3.48-2</td>
<td></td>
</tr>
<tr>
<td>Martin B., OC 81.1</td>
<td></td>
</tr>
<tr>
<td>Martin S., PB 1.33-4, PB 2.31-5</td>
<td></td>
</tr>
<tr>
<td>Martin, PO 389</td>
<td></td>
</tr>
<tr>
<td>Martín M., PA 4.16-2, PB 1.25-1</td>
<td></td>
</tr>
<tr>
<td>Martín Ramirez J., OC 43.1</td>
<td></td>
</tr>
<tr>
<td>Martina B.E., OC 69.4</td>
<td></td>
</tr>
<tr>
<td>Martinelli C., PB 1.31-2</td>
<td></td>
</tr>
<tr>
<td>Martinelli I., PA 3.19-1, PA 3.19-5, PB 4.18-5, PB 1.66-1, PB 4.30-3, PO 224</td>
<td></td>
</tr>
<tr>
<td>Martinelli N., AS 26.2, PA 1.11-1</td>
<td></td>
</tr>
<tr>
<td>Martínez C., AS 06.3, AS 17.2, AS 19.1, OC 63.4, OC 63.5, PA 4.10-6</td>
<td></td>
</tr>
<tr>
<td>Martínez J., PO 271</td>
<td></td>
</tr>
<tr>
<td>Martínez L., PO 152</td>
<td></td>
</tr>
<tr>
<td>Martínez M., PO 299</td>
<td></td>
</tr>
<tr>
<td>Martínez A., PB 3.52-4</td>
<td></td>
</tr>
<tr>
<td>Martínez C., OC 08.1, OC 05.4, OC 27.6, OC 30.2 PA 3.01-5</td>
<td></td>
</tr>
<tr>
<td>Martínez de Lizarraondo S., AS 23.2, AS 30.1, PA 2.16-5, PA 3.04-6</td>
<td></td>
</tr>
<tr>
<td>Martínez Virto A., PO 270</td>
<td></td>
</tr>
<tr>
<td>Martínez-Aguilar E., PB 2.63-6</td>
<td></td>
</tr>
<tr>
<td>Martínez-Marinelli T., PB 2.42-6, PO 149</td>
<td></td>
</tr>
<tr>
<td>Martínez-Martínez L., AS 29.2, OC 30.2, OC 73.2, PA 1.15-6, PA 3.01-5, PB 2.63-1, PB 4.73-1</td>
<td></td>
</tr>
<tr>
<td>Martínez-Perez A., PA 2.20-1, PA 2.20-5</td>
<td></td>
</tr>
<tr>
<td>Martínez-Pomares L., OC 56.2, PA 3.07-6</td>
<td></td>
</tr>
<tr>
<td>Martínez-Sales V., OC 47.4, PB 1.27-3, PB 1.30-1, PB 1.38-3, PB 2.30-6</td>
<td></td>
</tr>
<tr>
<td>Martínez-Sanchez E., PB 3.54-2</td>
<td></td>
</tr>
<tr>
<td>Martín-Fernandez L., PA 2.20-1, PA 2.20-5</td>
<td></td>
</tr>
<tr>
<td>Martinho P., OC 52.4, PB 3.67-6, PB 4.73-3</td>
<td></td>
</tr>
<tr>
<td>Martini F., PB 3.44-4</td>
<td></td>
</tr>
<tr>
<td>Martinod K., AS 21.1, OC 74.1</td>
<td></td>
</tr>
<tr>
<td>Martinowicz U., PA 3.36-1</td>
<td></td>
</tr>
<tr>
<td>Martinowicz U., OC 70.2, PB 4.35-4</td>
<td></td>
</tr>
<tr>
<td>Martins M.A.P., PB 4.45-4</td>
<td></td>
</tr>
<tr>
<td>Martins N., OC 52.4, PB 2.44-5, PB 3.67-6, PB 4.73-3, PO 047</td>
<td></td>
</tr>
<tr>
<td>Martins-Filho O.A., PB 4.65-2, PB 4.66-4, PO 040, PO 247</td>
<td></td>
</tr>
<tr>
<td>Martinuzzo M.E., PB 3.53-5, PB 4.51-5, PB 4.62-3, PB 4.63-1</td>
<td></td>
</tr>
<tr>
<td>Marton I., PB 2.66-3, PB 4.28-3</td>
<td></td>
</tr>
<tr>
<td>Martorell D., PA 3.11-3, PB 2.52-2</td>
<td></td>
</tr>
<tr>
<td>Martorell D., PO 407</td>
<td></td>
</tr>
<tr>
<td>Martorell L., PB 4.55-2</td>
<td></td>
</tr>
<tr>
<td>Martos L., OC 47.4, PA 3.11-4, PB 1.68-2, PB 2.69-1, PB 2.69-2</td>
<td></td>
</tr>
<tr>
<td>Marturano A., OC 77.3</td>
<td></td>
</tr>
<tr>
<td>Martynova E., PO 453</td>
<td></td>
</tr>
<tr>
<td>Marutsuka K., OC 43.3</td>
<td></td>
</tr>
<tr>
<td>Maruyama M., PO 458</td>
<td></td>
</tr>
<tr>
<td>Maruyama I., SC19-3.05, OC 69.3</td>
<td></td>
</tr>
<tr>
<td>Marwaha R.K., PO 175</td>
<td></td>
</tr>
<tr>
<td>Marx N., PB 3.59-1</td>
<td></td>
</tr>
<tr>
<td>Marx S., OC 79.3, PO 278</td>
<td></td>
</tr>
<tr>
<td>Masahiro H., PB 2.46-5</td>
<td></td>
</tr>
<tr>
<td>Mascia N., OC 08.2</td>
<td></td>
</tr>
<tr>
<td>Mascoli F., PB 3.32-3</td>
<td></td>
</tr>
<tr>
<td>Maset F., PA 2.13-2</td>
<td></td>
</tr>
<tr>
<td>Mashkooli M., PO 344</td>
<td></td>
</tr>
<tr>
<td>Masih, PO 386</td>
<td></td>
</tr>
<tr>
<td>Maslanka K., PO 355</td>
<td></td>
</tr>
<tr>
<td>Mason K., PB 1.27-6</td>
<td></td>
</tr>
<tr>
<td>Masopust J., PB 1.26-4, PB 4.62-6</td>
<td></td>
</tr>
<tr>
<td>Masotti L., PB 1.49-2</td>
<td></td>
</tr>
<tr>
<td>Massardo T., PB 1.31-6</td>
<td></td>
</tr>
<tr>
<td>Massberg S., SOA 09.1, AS 03.2, PA 4.20-4, PB 3.32-4</td>
<td></td>
</tr>
<tr>
<td>Massefski W., PA 3.12-6, PB 1.26-3</td>
<td></td>
</tr>
<tr>
<td>Massicotte P., OC 75.1, OC 75.2, OC 75.3, PA 2.19-1, PA 3.13-2, PO 300, PB 1.71-2, PB 1.71-4, PB 3.68-4, PB 3.68-6, PB 3.69-1, PB 4.71-2, PO 297</td>
<td></td>
</tr>
<tr>
<td>Massimi I., PB 3.71-1, PO 455</td>
<td></td>
</tr>
<tr>
<td>Massimo M., PB 3.49-3</td>
<td></td>
</tr>
<tr>
<td>Massin F., PB 4.63-4</td>
<td></td>
</tr>
<tr>
<td>Massion P., PA 1.02-3</td>
<td></td>
</tr>
<tr>
<td>Masszi T., PB 4.55-3</td>
<td></td>
</tr>
<tr>
<td>Mast A., AS 45</td>
<td></td>
</tr>
<tr>
<td>Mastbergen S.C., PA 1.07-2</td>
<td></td>
</tr>
<tr>
<td>Mastenbroek T.G., OC 87.2, OC 87.5, PA 3.02-2</td>
<td></td>
</tr>
<tr>
<td>Mastmoto S., PO 156</td>
<td></td>
</tr>
<tr>
<td>Masumoto H., AS 47.1</td>
<td></td>
</tr>
<tr>
<td>Mata C., PB 1.30-6</td>
<td></td>
</tr>
<tr>
<td>Mata P., PA 1.04-3</td>
<td></td>
</tr>
<tr>
<td>Mata R., PB 3.73-4, PO 396</td>
<td></td>
</tr>
<tr>
<td>Matafonov A., AS 25.2</td>
<td></td>
</tr>
<tr>
<td>Matákas J., OC 34.5</td>
<td></td>
</tr>
<tr>
<td>Mateo J., PA 4.18-1, PB 1.53-6, PB 1.54-2, PB 1.72-1, PB 3.63-1</td>
<td></td>
</tr>
<tr>
<td>Mateo D., PB 4.70-4</td>
<td></td>
</tr>
<tr>
<td>Mathew J., PA 3.10-3</td>
<td></td>
</tr>
<tr>
<td>Mathew P., PB 3.38-6</td>
<td></td>
</tr>
<tr>
<td>Mathias M., PB 2.42-2</td>
<td></td>
</tr>
</tbody>
</table>
INDEX

Mathiesen E.B., OC 59.6, PB 4.64-2
Mathiesen E.H., OC 59.6, PB 4.64-2
Mathieu G., PA 4.10-1
Mathieu O., PO 435
Mathis G., PB 1.64-3
Mathôt R.A.A., PA 2.07-1, PB 2.36-2
Mathur V., AS 20.1
Matic D., PO 001
Matijevic N., OC 17.1, PB 3.40-1
Matino D., AS 22.3
Matos M.F., PB 1.53--2
Matos R., PB 2.31-1
Matovinovic E., PB 1.37-3, PO 148
Matsubara Y., PB 1.29-4
Matsuda S., OC 43.3
Matsuda Y., PA 1.06-3
Matsui H., PA 4.06-6
Matsui H., AS 11.3, PA 4.18-4
Matsunari Y., PB 2.59-5
Matsuda S., OC 43.3
Matsuda Y., PA 1.06-3
Matsui H., PB 2.67-2, PB 4.67-2
Matsunari Y., PA 4.06-6
Matsuno H., PA 1.06-2, PA 3.18-2, PA 3.18-5, PB 1.31-4, PO 233
Matsuno K., PO 246
Matsuo M., PB 2.40-3, PB 2.40-4, PB 2.40-5
Matsuo O., PA 1.06-2, PA 3.18-2, PA 3.18-5
Matsuo T., PB 1.40-2, PB 2.68-5
Matsuoka H., PB 4.21-5
Matsuoka T., PO 070
Matsushima H., PO 195
Matsushita N., OC 79.1
Matsushita T., OC 78.4, OC 83.5, PA 2.13-5, PA 3.05-2, PB 1.35-5, PB 1.74-2, PB 3.35-2, PB 3.67-1, PB 4.44-4, PO 116
Matsuura Y., PB 1.73-1, PB 3.55-1
Matsuyama T., PB 1.33-5
Mattheij N., OC 11.3, OC 67.2, OC 87.2
Matthews D.E., PB 1.56-3
Mathiessen P., PB 4.35-2, PO 146
Mattiello A., OC 04.1, PA 3.06-4, PB 1.56-6
Matulko G., PA 04.1, OC 07.6, PB 1.56-6
Matveeva A., OC 11.3, OC 67.2, OC 87.2
Mattheij N., OC 11.3, OC 67.2, OC 87.2
Mathiessen P., PB 4.35-2, PO 146
Mattiello A., OC 04.1, PA 3.06-4, PB 1.56-6
Matulko G., PA 04.1, OC 07.6, PB 1.56-6
Matveeva A., PO 052
Matveeva M.A., PO 408, PO 411, PO 412
Matvienko O., PA 3.11-2, PB 1.30-5, PB 1.52-5, PB 4.30-1, PO 456
Matsumoto H., AS 27.3, OC 87.3, PB 2.26-1, SPS03-01
Maurer J., AS 34.3
Maurissen L., OC 35.5
Mauser-Bunschoten E., OC 13.1, PA 2.08-3, PB 1.35-3, PB 1.42-1
Mauser-Bunschoten E., SPS03-01, SPS03-10
Mavri A., PB 2.47-4, PB 4.46-3
Mawhin M.A., OC 55.3
May J.A., PB 2.25-1, PB 2.27-3, PB 3.22-1
May M.A., OC 21.3
Mayans-Ferrer J.R., PO 016, PB 275
Mayer C.L., AS 47.3
Mayer G., PA 3.11-1, PB 3.53-2
Mayer K., PA 2.08-5
May-Masnou A., PA 3.14-1
Maze A., PO 152
Mazarakis M., PB 4.71-3
Mazepa M., AS 28.2
Mazet F., PO 362
Mazetto B.M., OC 08.5
Mazharian A., OC 58.6, OC 88.4
Mazighi M., PB 2.30-4, PB 2.74-6
Mazuvur A., PB 4.27-5
Mazutis L., PA 2.04-4
Mazzolai L., PO 279
Mazzucato M., PA 3.02-1, PB 1.29-1
Mazzuconi M.G., AS 32.2, PB 1.37-5, PB 1.74-6, PB 4.42-2, PO 112, PO 429
McBride M., FS 02.1
McCall M., PA 2.01-1
McCarroll D.G., PO 342
McCarroll J., PO 342
McCart M., PB 4.70-4
McCarthy A., PO 350
McCarty O.T., SC14-3.02, AS 07.3, AS 13.3, AS 25.2, OC 05.2, OC 53.6, OC 64.1, OC 67.2, OC 81.4, OC 82.6, PB 4.24-2, PB 4.25-5, PB 4.26-6
McClore L., PA 4.18-6
McConnell R., PB 2.65-2
McCrae K.R., SC03-1.03, OC 40.1, PB 4.62-2
McDiarmid S., PA 2.16-1
McDonnell C., PB 3.31-1
McElvaney N.G., PB 3.25-2
McEwen A., PA 1.12-1, PB 1.58-3
McEwen B.J., PB 2.23-4
McGeehan E., PB 1.49-4
McGivern T.J.P., PB 3.25-2
McGowan K., AS 28.1
McGrath J., PB 2.64-3, PO 037
McGuckin S., OC 52.1
McGurk M., PB 1.51-5
McHugh J., PB 2.49-2
McKenzie S.E., SC04.4-1.1, AS 39.3
McKernan L.J., PB 3.37-1
McKinnon H.J., PB 1.32-1
McKinnon T., OC 91.5, PA 4.09-6
McKinnon T.A.J., OC 39.3, PB 1.44-2
McKnight B., OC 30.5, OC 63.1
McLaughlin J.M., NS 01.1
INDEX

McLean K., PA 2.15-2, PA 4.12-5
McLeod E., OC 02.6
McLintock C., OC 61.5, SC11-1.01, SC11-3.04, SC11-4.01
McLoughlin A., PB 3.31-1
McLoughlin S., PB 3.68-2
MCMDM-1VWD Study group, OC 39.6
McMichael M.A., PB 3.30-5
McMillan-Ward E., PA 1.02-2, PB 3.23-3
McMullen A., NS 01.3
McNicol A., PB 3.23-3
McPherson M., PB 2.59-2
McRae S., AS 22.1
McSorley A., PB 3.65-1
Méan M., PA 2.10-4, PB 2.56-1, PB 4.51-3
Meddeb B., PB 4.44-1, PO 150
Medina P., OC 47.4, PA 3.11-4, PB 1.68-2, PB 2.69-1, PB 2.69-2
Medina S., PA 2.07-3, PA 3.05-3, PB 4.42-2
Medne G., PO 177
Medvedev A.P., PO 240
Meeks S.L., OC 80.4, PO 169
Mege D., PB 2.30-1
Megens R.T., PA 4.03-6
Mequlinski i., PB 4.53-5
Mehadzic S., PO 150
Mehdi A., OC 91.5
Mehta A.B., PA 3.14-5
Mehta D., PB 1.50-3, PB 1.54-5
Mei B., AS 45.1, OC 37.5, PA 1.12-4, PA 2.12-5, PB 1.58-1, PB 2.55-3, PB 4.55-1
Mei J., AS 44.3
Mei P.M., OC 38.4
Meijer A.B., AS 37.2, OC 54.1, OC 57.5, OC 57.6, PA 4.06-2
Meijer C., OC 04.4
Meijer K., OC 13.1, PA 2.07-1, PA 2.08-3, PB 1.45-4, PB 2.54-2, PB 2.74-2, PB 3.35-3, PB 3.47-1, PB 4.65-4, PB 4.68-1
Meijer P., SC12-2.01, PA 3.08-2, PB 1.53-4, PB 2.64-1
Meijers J.C., FS 01.3, OC 05.3, OC 08.4, OC 18.2, OC 27.4, OC 30.1, OC 43.1, OC 69.4, PA 1.06-6, PA 1.19-3, PB 1.38-1, PB 2.24-1, PB 2.33-5, PB 2.68-1, PB 3.66-3, PB 3.66-3, PB 4.48-2, PB 4.67-1, PO 468
Meinders M., PA 2.04-1, PA 2.04-5, PO 329
Meiping R., OC 25.1
Meireles Rezende S., FS 04.4
Meiring M.S., PB 3.30-3, PB 3.44-6
Melbye H., PB 1.69-4, PB 4.69-2
Melchio R., PB 1.49-1
Melinscak H., PO 223
Mellars G., PB 1.41-2
Mello T.B.T., PO 074, PO 084
Melnikov N.Y., PO 240
Melo C., PA 2.04-1
Mena F., PO 016
Mena Rodriguez F., PO 275
Mendeleeva L.P., PB 2.53-3
Mendez A., PB 3.72-6
Mendolicchio G.L., PA 3.02-1, PB 2.23-1, PB 2.46-4
Menegatti M., OC 50.3, PA 1.08-1, PA 1.08-3
Meneghetti S., PB 3.32-3
Meng F., OC 15.4, PB 1.44-4
Meng I.L., PB 2.48-4
Mengs T., PB 3.35-6
Menichini L., PB 3.36-3
Merah A., AS 43.4
Merati G., PB 4.30-3
Mercanti C., PA 1.74-6, PB 4.42-2, PO 112, PO 429
Mercier E., PB 2.66-2, PB 3.65-2, PB 4.65-1, PB 4.66-3
Mercier F., FS 01.2
Merget B., OC 09.6
Merhi Y., PB 4.02-6
Merhi-Soussi F., PB 4.63-2
Merceley H., PB 1.61-3
Merkely B., AS 01.2
Merkulova A., OC 01.1, OC 01.2
Merton M., AS 45.2, OC 57.4, PA 1.13-6
Merton Gonzalez E., PO 444
Meroni P., PB 2.62-3, PB 2.62-5
Merriman E., PB 1.64-4
Mertens K., SC01-4.01, OC 54.1, OC 57.5, OC 57.6, PB 3.47-6
Merz M., PB 3.72-6
Meschengers I., PB 1.60-4, PB 4.43-6, PB 4.44-2, PO 025, PO 385, PO 431, PO 438
Meslier Y., OC 56.1
Messaud R., PO 020, PO 055, PO 351, PO 378
Messina M., PA 3.09-5
Messinee S., OC 34.3
Messoudi N., PO 380
Metham R., OC 86.5
Metin A., PA 4.19-6
Metzner H.J., PB 1.55-6, PB 2.55-6, PB 4.55-6
Meuley R., PB 4.52-2
Meunier S., PB 1.43-5, PB 4.36-5
Mewburn J., OC 15.2, OC 65.3, OC 91.4
Meyer G., AS 18.2, OC 72.1, PB 3.73-5
Meyer T., AS 39.3
Meyer dos Santos S., PA 4.11-2, PB 1.73-2
Meyerson H., OC 53.4
Mezei Z.A., OC 07.5, PA 3.06-1
Mezger J., PB 4.67-3
Mezger S., PB 3.26-1
Meziani F., OC 72.1, PA 1.04-6, PA 4.17-4
Mezo A., OC 80.2, PA 4.13-1, PB 4.55-4
Mezzano D., SC18-3.04, PA 3.09-2, PA 4.05-2, PA 4.20-5, PB 1.31-6, PB 3.25-4, PB 3.25-5
Mezzasoma A.M., OC 09.3
Mhonda D., PB 1.74-3
Mjadzvedze A., PB 4.22-2
Mjadzvedze E., PO 313
Miao C.H., OC 37.1, OC 56.5
Miao H., PA 2.12-1
Miao X., PB 2.23-3, PB 4.56-6
Michalska M., PB 4.56-3
Michels A., OC 85.5, PB 1.44-3
Michels M., PA 1.03-5
INDEX

Michelson A., SC15-1.03, PB 1.21-6, PB 1.28-4, PB 2.63-4, PB 3.21-4, SAS10-04
Micheli C., PB 3.68-1
Michiels J.J., PB 1.43-3, PB 3.42-6, PB 4.44-5
Micic D., PB 4.61-4
Mickelson J., OC 70.3, PB 2.37-1
Middeldorp S., SC11-3.05, SOA 16.2, FS 01.3, OC 02.2, OC 20.2, OC 30.1, OC 61.2, PA 1.16-2, PB 1.72-5, PB 2.61-6, SAS07-01
Midwinter M., PB 2.39-5
Miesbach W., PB 1.41-3, PB 2.42-3, PB 2.72-6, SPS09-03
Mietto C., PO 024
Migita M., OC 37.6
Migliacci R., PB 2.31-4
Migliaccio L., PB 2.71-6
Mignon A., FS 01.2
Miguelinio M., AS 26.1
Mihara K., PO 324
Mijares M.E., PO 104
Mikdame M., PO 380
Mlkic M., PB 4.46-3
Mikovic D., AS 40.1, OC 48.4, PA 4.19-2, PB 2.73-6
Mikovic D., SC01-1.02, SC05-2.02, SC09-3.01
Milan M., OC 14.2, PA 3.19-3, PB 4.31-3, PO 033
Milano G., PA 1.08-1
Milewicz D.M., AS 36.1
Miljic P., PA 4.07-3, PB 3.65-3, PB 4.72-3, PO 005, PO 346
Miltar C.M., OC 39.3, PB 1.39-1, PB 4.34-3, PO 350
Miller C.H., PA 4.13-5
Miller J.L., OC 28.6, PB 4.13-2
Miller R.S., PB 1.25-6
Miller W.M., PA 3.16-1
Mills G.M., PB 1.53-1
Mills R.M., PA 2.10-3
Milner J., AS 21.2
Milos M., PB 4.51-4, PO 151
Milosevic Z., PO 484
Mimuro J., OC 86.3
Min W., PB 1.55-5
Min X., OC 82.3
Minami H., OC 37.3, PB 1.36-6, PB 4.37-1, PO 352
Minano A., AS 29.2, OC 30.2, PB 2.63-1, PB 4.73-1
Miners A., PB 3.55-5
Minet V., PB 4.40-3
Minford A., SC15-2.07
Mingot E., PB 2.37-3, PO 056
Mingot M.E., PB 3.36-5, PO 021
Minibek E., PO 060
Minoldo S., PB 2.57-5
Mir S., PB 3.68-5
Mira Y., PA 3.11-4
Miranda C., PB 3.73-4, PO 396
Miranda M., PB 4.53-6
Mirault T., PA 1.08-4
Mirjana M., PB 4.61-5
Mironova N., PB 2.68-4
Mirshahi M., PA 1.19-1, PA 2.16-6
Mirshahi S., PA 1.19-1, PA 2.16-6
Misasa K., PA 1.18-4
Misgav M., PA 2.06-5
Mishra P., PA 3.20-6, PB 4.61-6
Mismetti P., AS 18.2, OC 02.3, OC 63.3, OC 66.2, PA 2.18-1, PB 3.73-5, PB 4.52-2
Mister R., PA 1.20-1
Mistretta C., PA 3.09-6, PB 2.39-4, PB 2.41-5, PB 4.43-4
Misztia A., PA 4.09-3, PB 2.42-4
Mital A., PB 4.74-5
Mitchell E., PB 3.72-1
Mitchell J.L., OC 29.6
Mitchell L., PB 1.21-3
Mitchell M., PB 2.08-6, PB 4.05-3, PB 1.68-6, PB 4.41-1, PO 436
Mitchell M.J., PB 3.25-3
Mitic G., PB 3.70-5, PO 263, PO 286, PO 484
Mitrea I.L., PA 1.04-2
Mitrovic M., PO 005
Mitrugno A., OC 25.2
Mittmann N., PB 2.46-2
Miyamoto N., PB 2.46-5
Miyano S., FS 03.4
Miyashita K., PB 2.40-3, PB 2.40-4, PB 2.40-5, PO 195
Miyata S., PA 3.08-6
Miyata T., AS 23.1, FS 03.2, OC 29.1, OC 47.3, PA 1.06-3, PA 2.17-1, PA 4.06-6, PB 1.33-1, PO 236
Miyazaki K., FS 03.4, PB 4.29-1
Mizuno M., PO 337
Mizunuma M., PA 4.17-5
Mizurini D.M., PB 4.26-6
Mo X., PA 4.17-6
Mobarrez F., SC05-2.02
Mocci F., PB 1.29-1
Mochtar B., PA 1.11-5
Modaresi A., PO 147
Modrau I.S., PB 3.21-5
Moerland M., PO 187, PO 291, PO 292, PO 324
Mogami H., PB 1.50-2
Moghaddam M., PO 054
Mohadam L., PA 4.11-1, PB 2.48-6
Mohamadi A., PB 2.29-5
Mohamed A.F., PB 3.36-4
Mohammed V., PO 382
Moharir M., SC15-1.02, PB 3.62-1, PB 3.69-5, PO 307
Mohi Izam M.M., PA 1.14-3
Moher C., OC 75.1
Mohr G., PO 061
Moises T., OC 70.2, PB 3.37-5
Mokhtari D., OC 38.2
Mokhtari M., PO 344
Molenaar P.J., PO 258
Molina F., PA 3.08-3, PB 2.31-3
Molina P., PA 3.01-4, PA 3.10-6, PB 2.31-5, PB 4.47-2
Molinar A.C., PA 1.13-2, PA 2.06-2
Molino Lova R., PB 2.29-1
Moliterno D., PA 4.01-3
Moll F.L., PB 2.22-1, PO 318, PO 341
Moll S., PB 2.71-3
Mollah S., PA 2.08-2
Molloy K., PB 3.25-2
Molnar D., PA 3.06-6
Momi S., OC 09.3, OC 77.3, PA 2.03-6, PB 2.68-2
Mommaas M., PA 2.04-1
Momot A.P., PB 4.54-3
Monaghan M., OC 57.3
Monagle K.E., PB 1.71-2, PB 3.69-2, PO 248, PO 266, PO 485
Monagle P., FS 02, PB 1.71-5, PB 2.56-3, PB 3.68-2, PB 3.69-2, PB 4.50-3, PB 4.71-4, PO 248, PO 266, PO 485
Monahan P.E., OC 70.3, PA 1.12-3, PB 2.38-2, SAS01-03
Mondorf C., PB 4.65-6
Mondorf W., PB 4.65-6
Moneta G.L., PB 3.72-1
Mongale P., PO 372
Mongkolwongroj P., PO 089, PO 469
Monia B., AS 13.2
Monkman J.H., OC 86.2
Monreal M., AS 17.3, AS 43.4, OC 42.1, PA 1.20-6, PA 2.18-1, PA 4.16-2, PB 4.45-1, PB 4.72-1
Monroe D., OC 36.6, OC 60.4, OC 70.3, PB 2.37-1, PB 3.46-4
Montagne A., AS 23.2, AS 35.3
Montalvão S.L., OC 81.5, PB 3.52-5
Montaner J., AS 30.1
Montani N., OC 14.2, PO 012
Montanini V., PB 1.49-5, PB 4.53-6
Monteiro Q., PA 3.16-5, PB 4.26-6
Monteiro A., SC20-2.03, PA 3.16-5, PB 4.26-6
Montemari A.L., PO 455
Montenegro N., PO 035
Montenont E., PB 2.73-5
Mooberry M.J., OC 17.3, OC 44.4
Moons C., OC 20.3
Moons K.G.M., SC05-2.11, SC06-3.07, SOA 01.1, PA 4.16-1, PA 4.16-4, PA 4.16-6
Moore G.W., PA 2.08-5, PB 3.62-6, PB 4.38-1, PB 4.41-1
Moore N., AS 45.1, PA 2.12-5, PB 2.55-3
Moore S.F., OC 11.5, PA 3.03-3, PA 3.03-3
Moore T., OC 36.5, PA 2.10-2, PA 3.10-5
Moorehead P.C., OC 56.6, PA 1.09-5 PO 153
Mootien Y., OC 11.5, PA 1.03-2, PB 2.55-3
Moraes L.A., AS 39.2, PA 2.02-3, PA 4.02-3, PB 3.23-4
Morais S., OC 02.5, PB 2.31-1
Moraleda J.M., PO 118
Moran N., OC 25.2, PA 3.25-2
Morange P.E., SOA 15.2, AS 11.1, AS 15.1, OC 62.1, OC 90.1, PA 1.01-2, PA 4.18-1, PB 1.67-1, PB 4.29-3
Moratelli S., OC 07.4
Morau E., FS 01.2
Mor-Cohen R., PA 3.01-3, PA 3.14-3
Morcol T., PA 1.12-3
Morales J.G.M., OC 2.05-5
Moraleda J.M., PO 118
Moran N., OC 25.2, PA 3.25-2
Morange P.E., SOA 15.2, AS 11.1, AS 15.1, OC 62.1, OC 90.1, PA 1.01-2, PA 4.18-1, PB 1.67-1, PB 4.29-3
Moratelli S., OC 07.4
Morau E., FS 01.2
Mor-Cohen R., PA 3.01-3, PA 3.14-3
Morcol T., PA 1.12-3
Moreira C.S., OC 2.05-5
Morales J.G.M., OC 2.05-5
Moroe-Kopp M.C., OC 89.5, PB 2.23-4, PB 3.29-3
Morrelli B., PB 2.62-6, PO 042
Moreno L., PB 3.06-6
Moreno M., PO 118
Morera A., PB 1.53-6, PB 1.54-2
Mored J., PA 1.38-3
Mortarino M., PA 2.12-2
Morton A.C., PO 342
Morikawa C., PA 1.18-4
Mori J., OC 88.4
Moriarty R., OC 89.1, PA 2.08-2
Morioka Y., OC 60.2, OC 91.2
Morioka C., PB 1.33-5, PB 2.33-4
Morishima A., PO 236
Morishima Y., AS 47.1, PB 2.46-3, PB 3.46-2
Morishita M., PA 4.05-6
Moriya M., PA 2.04-1
Mørk M., PA 3.01-1
Morongova A., OC 10.6, OC 76.4, OC 84.4, OC 86.1, PA 4.04-1
Moroz G., PO 155
Morpurgo M., PB 3.43-1
Morris K., PB 2.63-5
Morrison A.C., OC 65.5
Morrison L., OC 39.5
Morser J., OC 46.2, PB 4.59-4, PO 231, PO 232
Mortalino M., PA 2.12-2
Morton A.C., PB 1.21-1
Morrison L., OC 71.2
Mosca S., OC 04.5, PB 4.60-2
Moscardó A., PA 2.01-5, PA 2.03-2, PB 2.23-5, PB 3.21-2, PB 4.24-5
Moscetti V., PB 4.53-2
Moschidis Z.M., PB 2.69-6
Moshe M., AS 05.3
Mosier M., PA 4.17-2, PB 1.30-6
Moskowitz K.A., PB 1.52-2
Mosnier L., PB 4.60-2
Mosnier L.O., SOA 09.2, AS 41.1, AS 41.4, OC 74.4, PA 2.03-4, PB 2.56-2
Møss J., PB 2.55-5, PB 4.55-5
Mota A., PB 4.65-2
Mota A.P.L., PA 036
Mottier D., AS 05.2, AS 43.2, OC 61.4, PB 4.65-2
Motto D., SC02-2.01
Motum P., PA 2.51-5, PO 004
Motwani J., AS 28.3, PA 1.09-3
Mouadene A., PA 378, PO 423
Moujalled D., PB 1.27-6
Moulard M., PB 3.46-2
Mouaddib M., PA 2.03-6
Mouaddib N., PA 2.22-6
Mouaddib S., PA 2.22-6
Mouadene A., PA 378, PO 423
Mouaddib M., PA 2.03-6
Mouaddib N., PA 2.22-6
Mouaddib S., PA 2.22-6
INDEX

Moulasserdou K., PO 378, PO 423
Moulasseroune K., PO 055
Moulis G., PB 2.41-2
Mountford J.K., OC 11.6
Mouquet F., PA 3.18-1
Mourad W., PA 4.02-6
Mourao P.A.S., PO 186
Mourão P., PO 188
Mourik Mr., OC 91.6
Moussa W., PB 1.49-3
Mouste E., PB 2.66-2, PB 3.65-2, PB 4.65-1, PB 4.66-3
Mouton C., PO 448
Mowbray M., NS 01.3
Mruk J.M., PA 4.01-1
Muchina P.N., PO 416, PO 418
Muchitsch E.M., PA 1.07-6, PA 1.12-5, PA 2.10-5, PA 4.06-3, PA 4.06-5, PB 3.33-1, PB 3.33-2, PB 3.55-4, PB 3.55-6
Mueck W., OC 16.1, PB 3.46-1
Mufti A., PB 1.44-5
Muhammad N., PO 437
Muhsin A., PO 336
Mui B., PB 2.51-5, PO 039
Muia J., SC17-4.02, OC 15.3
Muirhead N., PB 3.62-2
Mukhametova L., PB 1.34-2, PB 4.33-3
Mukhopadhyay R., PB 3.32-6, PB 3.71-3
Mulder A.B., OC 04.4, PB 2.54-2, PB 4.65-4, PB 4.68-1
Mulder R., PB 2.54-2
Mulders G., PB 2.44-1
Müller A., OC 51.4, PB 2.35-2
Müller J., PA 3.11-1, PA 3.17-6, PB 1.34-5, PB 3.47-3, PB 3.53-2, PB 3.58-5
Müller-Cohrs J., PA 4.15-4, PB 4.55-6
Muller F., OC 02.4, OC 81.6, PB 1.52-1, PB 1.53-5, PB 1.60-3, PB 2.60-6, PB 3.51-4, PB 3.52-6, PB 4.40-3, PB 4.52-1
Mumby S., PA 3.15-4
Mumford A.D., OC 25.4, OC 34.2, OC 39.6, OC 60.3, PA 2.11-4, PB 1.21-5, SPS04-07, SPS04-10
Mun Y.C., PB 4.69-6
Mundell S.J., OC 34.2, OC 39.6, OC 60.3, PA 1.02-6, PA 4.05-3
Mundkur L.A., OC 32.6, PB 1.32-2, PB 1.32-3, PB 1.32-4, PB 1.32-5, PB 3.32-6, PB 3.71-3, PO 470, PO 473
Munn J.E., NS 01.1
Munoz B., AS 07.2
Muñoz M., PO 407
Munroe-Pearl S., PB 1.65-5
Muntazhar M.Z., PB 4.30-5
Muntean W., PB 3.24-3, PB 3.65-5, PB 4.50-4, PB 4.64-5
Münzel T., OC 87.4, PA 4.20-4, PB 1.46-3, PB 1.70-2
Murai A., PA 4.17-5, PO 080
Murai T., PO 335
Murasaki K.M., PB 1.46-4, PB 2.46-6
Murata A., PB 2.60-5
Murata M., OC 78.4, PA 2.13-5, PA 3.05-2, PB 1.29-4, PB 3.67-1, PB 4.58-4
Murate T., OC 78.4, PA 3.05-2, PB 4.58-4
Muratsu J., PO 236
Murden S.L., OC 60.3
Murena L., PB 2.70-4
Murfitt L., OC 41.4
Muriel A., PA 2.18-1
Murphy J.E., OC 28.2, OC 80.6, PA 2.11-5, PA 4.13-4, PB 1.55-3, PB 3.53-4
Murphy M., OC 25.4
Murphy S.B., OC 29.2, PA 2.17-1
Murray-Rust T.A., OC 49.1
Mursalov G., PB 4.40-6
Murthy V., PB 2.62-4, PB 3.62-4
Murugesan G., PB 2.05-2, PB 4.27-2
Musallam K.M., PB 1.33-6
Muscat A., OC 86.4
Muscat P., OC 17.1
Mustelin T., OC 35.5
Muston D., OC 02.6
Musumeci L., OC 35.5
Muszbek L., SC10-2.09, OC 07.5, OC 78.2, OC 78.3, OC 90.3, PA 1.01-4, PA 2.01-2, PA 3.06-1, PA 4.15-3, PA 4.15-5
Mut Popescu I., PO 361
Mutch N.J., SC05-2.03, AS 13, OC 29.6, OC 53.1, PB 2.34-1
Muthard R.W., PB 2.26-6
Muthiah K., PA 2.18-6
Mutirangura P., PB 2.64-5, PO 076
Mutlu A., PO 500
Mutlu G.M, AS 23.1
Mutlu S., PO 067, PO 068
Muto A., OC 14.3
Muto S., PB 1.61-1, PB 4.69-5
Muyldermans S., PA 1.06-1, PA 1.06-4
Mya H.T.D., PB 4.47-6
Myers J.G, OC 17.1
Myklebust C.F., PA 4.14-3, PA 4.14-4
Myles T., PA 2.11-5
Na M., AS 36.4, OC 68.2, PA 4.12-2
Nabuurs S., AS 04.2, PB 3.54-4
Nadeem M., PB 4.36-3, PO 050
Naderi M., PB 3.41-3, PO 381
Nadir Y., AS 05.3, PB 2.23-2, PO 494
Nass I.A., PA 3.20-5
Nag P., AS 07.2
Nagae C., PB 1.61-1, PB 4.69-5
Nagafuji K., PB 2.50-6
Nagakubo D., PB 2.45-6
Nagano K., PB 4.21-5
Nagao T., PO 041
Nagasaki M., PB 4.28-5
Nagashwami C., PA 3.12-6
Nagel K., PO 491
Nagler M., PO 022
Nappal V., AS 23.1
Nagy A., AS 01.2, PB 1.44-6
Nagy E., PB 4.55-3
Nah S.C., PB 4.47-6
Nahar B., PB 1.51-2
Nahirniak S., PB 2.51-2
<table>
<thead>
<tr>
<th>Name</th>
<th>Index</th>
</tr>
</thead>
<tbody>
<tr>
<td>Naidoo S.</td>
<td>PO 366</td>
</tr>
<tr>
<td>Naidu A.</td>
<td>PB 3.61-4</td>
</tr>
<tr>
<td>Naik M.U.</td>
<td>AS 37.4, OC 01.3, OC 58.1</td>
</tr>
<tr>
<td>Naik U.P.</td>
<td>AS 37.4, OC 01.3, OC 58.1</td>
</tr>
<tr>
<td>Nair J.</td>
<td>PB 4.31-6, PO 474, PO 477, PO 478</td>
</tr>
<tr>
<td>Nair S.</td>
<td>AS 45.4</td>
</tr>
<tr>
<td>Nakamura J.</td>
<td>PB 2.23-6</td>
</tr>
<tr>
<td>Nakamura L.</td>
<td>OC 89.3</td>
</tr>
<tr>
<td>Nakamura S.</td>
<td>PB 1.60-2, PB 4.44-4</td>
</tr>
<tr>
<td>Nakamura Y.</td>
<td>PO 080</td>
</tr>
<tr>
<td>Nakar C.</td>
<td>PB 3.67-1</td>
</tr>
<tr>
<td>Nakazawa T.</td>
<td>PB 1.67-4</td>
</tr>
<tr>
<td>Nakazawa Y.</td>
<td>SC 19-3.05, OC 69.3</td>
</tr>
<tr>
<td>Nakayama S.</td>
<td>OC 81.1</td>
</tr>
<tr>
<td>Nakayama Y.</td>
<td>AS 31.3, PB 1.42-3</td>
</tr>
<tr>
<td>Naldi L.</td>
<td>AS 45.2</td>
</tr>
<tr>
<td>Nalgieva M.</td>
<td>PO 219</td>
</tr>
<tr>
<td>Namestnikov Y.</td>
<td>PA 3.11-2, PB 1.52-5</td>
</tr>
<tr>
<td>Namestnikov Y.</td>
<td>PB 1.30-5, PB 4.30-1, PB 4.68-2, PO 456</td>
</tr>
<tr>
<td>Namiki C.</td>
<td>PC 156</td>
</tr>
<tr>
<td>Namora G.</td>
<td>PC 035</td>
</tr>
<tr>
<td>Nan X.</td>
<td>PB 3.28-1</td>
</tr>
<tr>
<td>Nana Weldingh K.</td>
<td>OC 83.5</td>
</tr>
<tr>
<td>Nanayakkara P.</td>
<td>OC 82.5, PA 2.16-2</td>
</tr>
<tr>
<td>Nanazawa Y.</td>
<td>PB 3.27-5</td>
</tr>
<tr>
<td>Nandurkar H.</td>
<td>OC 41.1, PB 3.50-5</td>
</tr>
<tr>
<td>Nante G.</td>
<td>OC 42.2, PB 1.47-2</td>
</tr>
<tr>
<td>Naotaka H.</td>
<td>PB 1.64-6</td>
</tr>
<tr>
<td>Napolitano M.</td>
<td>PB 2.39-6, PO 213, PO 214, PO 413</td>
</tr>
<tr>
<td>Nar H.</td>
<td>OC 36.2</td>
</tr>
<tr>
<td>Nardelli G.</td>
<td>PO 218</td>
</tr>
<tr>
<td>Nardi M.A.</td>
<td>PA 4.11-4, PB 1.54-1, PO 330</td>
</tr>
<tr>
<td>Nardini C.</td>
<td>SC09-3.03</td>
</tr>
<tr>
<td>Nardo A.</td>
<td>PB 3.67-2</td>
</tr>
<tr>
<td>Naseem K.M.</td>
<td>PA 1.02-4, PA 3.01-6, PA 3.03-4, PB 2.33-5, PB 2.43-1, PB 2.46-2</td>
</tr>
<tr>
<td>Naseem S.</td>
<td>PB 2.70-2</td>
</tr>
<tr>
<td>Nash M.J.</td>
<td>AS 12.1, PB 1.65-3, PB 4.69-4</td>
</tr>
<tr>
<td>Nasirnejad F.</td>
<td>PB 4.43-1</td>
</tr>
<tr>
<td>Nasonov E.</td>
<td>PA 1.18-1</td>
</tr>
<tr>
<td>Nastasio S.</td>
<td>PB 2.57-4</td>
</tr>
<tr>
<td>Natarajan J.</td>
<td>PA 2.10-2, PA 3.10-5</td>
</tr>
<tr>
<td>Natarajan K.</td>
<td>PO 301</td>
</tr>
<tr>
<td>Nathwani A.C.</td>
<td>AS 18.1</td>
</tr>
<tr>
<td>Navarro N.</td>
<td>PB 3.52-4</td>
</tr>
<tr>
<td>Navarro S.</td>
<td>OC 47.4, PA 3.11-4, PB 1.68-2, PB 2.69-1, PB 2.69-2</td>
</tr>
<tr>
<td>Navarro V.</td>
<td>PB 2.31-3</td>
</tr>
<tr>
<td>Navarro Fernández J.</td>
<td>AS 29.2, OC 30.2, PA 1.15-6, PA 3.01-5, PB 2.63-1</td>
</tr>
<tr>
<td>Nawroth P.P.</td>
<td>AS 37.3, PB 3.28-5</td>
</tr>
<tr>
<td>Nayak M.K.</td>
<td>PB 2.24-6</td>
</tr>
<tr>
<td>Naz A.</td>
<td>PB 3.41-2, PB 4.36-3, PO 050, PO 437</td>
</tr>
<tr>
<td>Neamsum N.</td>
<td>PO 469</td>
</tr>
<tr>
<td>Neceva V.</td>
<td>PO 002, PO 215</td>
</tr>
<tr>
<td>Neef H.</td>
<td>PC 323</td>
</tr>
<tr>
<td>Needham J.</td>
<td>PB 1.45-3, PB 3.38-3, PB 4.44-3, PO 436</td>
</tr>
<tr>
<td>Neelakantan S.</td>
<td>OC 37.2, PB 2.06-3</td>
</tr>
<tr>
<td>Neelam V.</td>
<td>PO 386</td>
</tr>
<tr>
<td>Neeltingham S.</td>
<td>SC14-2.04, AS 09.3</td>
</tr>
<tr>
<td>Neerman-Arbez M.</td>
<td>SC10-2.06, OC 06.2, OC 06.6, PB 2.57-1, PB 3.57-1</td>
</tr>
<tr>
<td>Neeyes K.B.</td>
<td>SC14-1.01, SC14-3.01, OC 06.4, PA 1.14-6, PA 3.07-4, PA 4.20-2</td>
</tr>
<tr>
<td>Nef S.</td>
<td>OC 06.2</td>
</tr>
<tr>
<td>Négrier C.</td>
<td>OC 48.3, PA 1.12-2, PB 1.39-4, PB 1.39-5, PB 1.43-5, PB 2.35-1, PB 2.39-2, PB 2.51-6, SPS04-07, SPS10-10, SPS10-05, SPS10-06</td>
</tr>
<tr>
<td>Negro A.</td>
<td>PA 2.13-2</td>
</tr>
<tr>
<td>Negrotto S.</td>
<td>OC 60.5, PA 1.03-6, PA 3.03-2, PB 1.59-5, PB 2.29-3, PB 4.29-4</td>
</tr>
<tr>
<td>Neiva T.J.C.</td>
<td>PO 497</td>
</tr>
<tr>
<td>Nejlund S.</td>
<td>PB 2.30-3</td>
</tr>
<tr>
<td>Nek R.</td>
<td>SC11-3.03</td>
</tr>
<tr>
<td>Neleman P.J.</td>
<td>PA 1.11-5, PB 1.52-4</td>
</tr>
<tr>
<td>Nelissen G.H.H.</td>
<td>AS 43.3, OC 59.3</td>
</tr>
<tr>
<td>Nelson S.</td>
<td>PA 2.20-6, PB 1.72-3</td>
</tr>
<tr>
<td>Nemet D.</td>
<td>PO 105, PO 284</td>
</tr>
<tr>
<td>Nemeth B.</td>
<td>PA 3.19-1</td>
</tr>
<tr>
<td>Nemeti A.</td>
<td>PB 3.44-6</td>
</tr>
<tr>
<td>Nemeto-Lojan Z.</td>
<td>PO 284</td>
</tr>
<tr>
<td>Nemirova S.V.</td>
<td>PO 240</td>
</tr>
<tr>
<td>Nencini P.</td>
<td>OC 08.2, OC 29.4</td>
</tr>
<tr>
<td>Nendaz M.</td>
<td>PB 1.40-6</td>
</tr>
<tr>
<td>Neo S.</td>
<td>PB 1.28-5</td>
</tr>
<tr>
<td>Nergiz-Únal R.</td>
<td>PA 2.05-5</td>
</tr>
<tr>
<td>Nesbitt W.</td>
<td>PA 4.03-3</td>
</tr>
<tr>
<td>Nesi M.</td>
<td>OC 29.4</td>
</tr>
<tr>
<td>Nestorov I.</td>
<td>PA 2.06-3, PA 2.07-5</td>
</tr>
<tr>
<td>Neufeld E.</td>
<td>SPS04-04</td>
</tr>
<tr>
<td>Neumeister P.</td>
<td>PA 2.06-6</td>
</tr>
<tr>
<td>Neutebboom J.</td>
<td>OC 81.3, PB 2.66-1</td>
</tr>
<tr>
<td>Newall F.</td>
<td>PB 1.71-5, PB 3.69-2</td>
</tr>
<tr>
<td>Newell L.M.</td>
<td>OC 67.1</td>
</tr>
<tr>
<td>Newgren J.</td>
<td>OC 80.6</td>
</tr>
<tr>
<td>Newman P.</td>
<td>OC 55.1</td>
</tr>
<tr>
<td>Neyens I.</td>
<td>PA 2.10-5</td>
</tr>
<tr>
<td>Nezam M.</td>
<td>PB 2.72-4</td>
</tr>
<tr>
<td>Ng H.J.</td>
<td>PB 4.47-6</td>
</tr>
<tr>
<td>Ng L.</td>
<td>PO 266</td>
</tr>
<tr>
<td>Ngalula Mujinga M.</td>
<td>PB 2.55-1</td>
</tr>
<tr>
<td>Ngo V.</td>
<td>PA 2.16-1</td>
</tr>
<tr>
<td>Ngoasong E.</td>
<td>PA 4.05-1</td>
</tr>
<tr>
<td>Nguyen H.</td>
<td>PO 403</td>
</tr>
<tr>
<td>Nguyen K.</td>
<td>PB 3.68-5</td>
</tr>
<tr>
<td>Nguyen K.A.</td>
<td>PB 3.29-1</td>
</tr>
<tr>
<td>Nguyen K.T.</td>
<td>PB 3.43-5</td>
</tr>
<tr>
<td>Nguyen M.</td>
<td>PB 4.63-3</td>
</tr>
<tr>
<td>Nguyen P.</td>
<td>PB 3.56-2</td>
</tr>
<tr>
<td>Nguyen Dinh Cat A.</td>
<td>OC 54.2</td>
</tr>
<tr>
<td>Ngwenyama T.</td>
<td>PB 3.30-5</td>
</tr>
<tr>
<td>NHBLI GO</td>
<td>OC 65.5</td>
</tr>
</tbody>
</table>
INDEX

Ni C., OC 25.1
Ni H., AS 15.2, AS 24.2, OC 55.2, OC 87.1, PB 4.25-3
Ni R., AS 16.1, PB 4.21-1
Ni Áinke F., AS 21.3, PB 4.62-4
Niccolai E., PB 1.67-2
Nichols L., PB 1.25-6
Nichols T.C., SC02-2.05, OC 80.1, PA 1.12-3
Nicholson E., PB 3.57-2
Nickel K.F., OC 53.5, PB 2.60-4, PO 242
Nico G., PO 201
Nicolaes G.A.F., AS 04.2, PA 1.13-3, PA 1.21-1, PB 4.08-6, PB 3.54-4
Nicolás M., PA 2.16-3
Nicolaou J.C., PB 3.66-1
Nie L., OC 60.6
Niekrens C., PB 2.37-5
Nielsen A.L., OC 68.3
Nielsen B.I., OC 50.4, PB 2.38-2, PB 3.38-1
Nielsen K.B.J., PO 138
Nielsen R., PA 2.06-5, PB 1.37-6
Nieman T., OC 26.1
Niessen H.W.M., PA 4.06-4
Nieswandt B., PL 02, AS 16.2, AS 30.2, AS 39.1, OC 10.6, OC 11.3, OC 33.2, OC 33.6, OC 58.4, OC 60.1, OC 84.4, OC 86.1, OC 86.6, OC 87.3, OC 88.1, OC 88.1, OC 88.4, OC 88.5, OC 88.6, PA 1.10-6, PA 2.02-2, PA 4.04-1, PO 495
Nieuwenhuizen L., PA 1.07-1, PA 1.07-2, PA 1.07-5
Nieuwland R., SC07-5.01, SOA 14.2, AS 16.2, OC 72.2, OC 82.5, PA 2.16-2, PA 3.04-1, PA 4.03-4, PB 1.30-2, PB 1.67-3, PB 2.28-1, PB 2.68-1, PB 3.30-1, PB 3.30-2, PB 4.30-4, PB 4.30-4
Niiya T., PB 2.69-4
Nijdam A., PA 2.06-2
Nikau-Tau M., OC 20.2
Nikolic T., PA 2.04-1
Nikoloska I., PO 215
Nikolova I., PO 002
Nikulina O., PB 3.52-2

Nikulshin S., PO 177
Nimaeva D., PO 483
Ning L., PB 4.28-6
Ning S., PO 280
Ninavaggi M., AS 08.1, OC 23.2, OC 64.1, PA 1.11-4, PA 2.11-1, PB 1.38-2, PB 2.56-4, PB 3.40-2, PB 4.47-5, PO 258
Ninomiya H., PB 1.24-2
Niroul S., PB 1.26-3
Nisar S.P., PA 2.06-5, PB 1.37-6
Nisgav Y., PA 1.17-6
Nitschke L., OC 76.4
Nitti C., PB 1.49-2
Notley C., OC 05.6
Noto D., PB 2.67-1
Noubsou S., PB 2.55-1
Nougier C., OC 48.3, PB 2.35-1
Novack A., PB 1.50-4
Novakovic V.A., PB 1.31-1
Novakovic-Anucin S.L., PO 263, PO 484
Novelli C., PB 2.62-6, PO 042
Noventi F., AS 19.2, PA 4.16-5
Novkovic A., PA 4.07-3
Novkhatny V., PB 2.34-4
Novokshonova A., PB 256
Novosel R., PB 1.51-4
Nowak A., OC 91.5
Nowak E., OC 05.2, OC 61.4
Nowak-Götti U., AS 22.2, PB 1.68-1, PB 2.42-3, PB 3.69-3
Nowzoli C., PA 4.10-1
Nugent D., OC 67.3, PB 3.36-6, PO 122
Nugent K., OC 37.2, PA 2.07-6, PA 4.07-2, PB 4.37-3
Numerof R.P., PB 1.50-4
Nuñez R., PO 056, PO 157
Nuñez C., PA 1.30-1
Nur E., OC 08.3
Nurden A.T., AS 16.2, OC 10.2, OC 45.4, OC 62.1, OC 76.2, OC 80.1, OC 89.2
Nurden P., AS 16.2, OC 33.2, OC 33.6, OC 45.4, OC 80.1, OC 89.2, PA 3.05-5
Nutescu E., PB 1.45-1, PB 3.48-5, PB 4.31-2, PB 4.45-2

Noormohamed H., AS 41.3
Nordberg E-M., AS 02.3
Nordenholz K.N., PA 3.06-2, PB 4.70-4
Nori F., PB 1.65-1
Nori F.S., PO 283
Noris M., AS 40, AS 47.2
Noris P., OC 34.5
Norman J.E., OC 60.3
Normann C., PB 2.68-6
Norris E.H., AS 24
Nossair F., PA 2.19-2
Nossent G.D., PB 2.74-2
Notley C., OC 05.6
Noto D., PB 1.26-1
Noubaouissou D., PB 2.55-1
Nouguier C., OC 48.3, PB 2.35-1
Novack A., PB 1.50-4
Novakovic V.A., PB 1.31-1
Novakovic-Anucin S.L., PO 263, PO 484
Novelli C., PB 2.62-6, PO 042
Noventi F., AS 19.2, PA 4.16-5
Novkovic A., PA 4.07-3
Novkhatny V., PB 2.34-4
Novokshonova A., PB 256
Novosel R., PB 1.51-4
Nowak A., OC 91.5
Nowak E., OC 05.2, OC 61.4
Nowak-Götti U., AS 22.2, PB 1.68-1, PB 2.42-3, PB 3.69-3
Nowzoli C., PA 4.10-1
Nugent D., OC 67.3, PB 3.36-6, PO 122
Nugent K., OC 37.2, PA 2.07-6, PA 4.07-2, PB 4.37-3
Numerof R.P., PB 1.50-4
Nuñez R., PO 056, PO 157
Nuñez C., PA 1.30-1
Nur E., OC 08.3
Nurden A.T., AS 16.2, OC 10.2, OC 45.4, OC 62.1, OC 76.2, OC 80.1, OC 89.2
Nurden P., AS 16.2, OC 33.2, OC 33.6, OC 45.4, OC 80.1, OC 89.2, PA 3.05-5
Nutescu E., PB 1.45-1, PB 3.48-5, PB 4.31-2, PB 4.45-2
INDEX

Ouysingwat J., OC 11.3
Ouwender W.H., SC08-2.05, AS 47.6, OC 33.2, OC 33.5, PA 41.3, OC 35.1, OC 62.3, OC 89.2, PA 2.04-2, PA 2.05-1
Overbirg L., OC 34.1
Ovend K., OC 71.1, OC 59.2
Øvliken K.A., PB 2.44-3
Ovsepyan R.A., PB 2.51-6, PB 2.53-5, PB 4.54-3
Øvstebø R., PA 3.04-3
Owaïdah T., PO 382
Owens III A.P., PA 39.4, PA 4.02-2
Oy-hamburu J., PB 3.53-5, PB 4.51-5, PB 4.62-3, PB 4.63-1
Oymak Y., PO 294
Ozaki Y., FS 03, SOA 10.2, OC 25.3, PA 3.02-5, PA 2.23-6, PO 246
Ozatti D., PO 087
Ozdog H., PB 2.60-1
Ozdemir N., PB 1.34-3, PB 1.35-4, PB 3.68-3, PB 4.36-2, PO 331, PO 399
Ozelo M.C., OC 25.1
Ozekeseli Z., PB 2.60-1
Ozler T., PO 253
Pabinger I., SC13-3.02, AS 34.2, OC 31.1, OC 37.2, PA 1.16-5, PA 2.06-5, PA 2.07-3, PA 2.07-4, PA 3.05-3, PA 4.19-5, PB 1.55-4, PB 4.35-1, PB 4.42-3
Pabo V., PA 4.11-3
Pacheco J.F.F., OC 25.1
Pachler R., OC 51.3, PA 1.07-3, PO 3.07-2
Padayatt S., PB 1.62-3
Padilla J., AS 29.2, OC 30.2, PB 2.25-3, PB 3.52-4, PB 4.73-1
Padmore R., PB 2.65-5
Padoan A., PO 075
Padro T., PA 1.04-3, PB 3.32-5
Paes B., PO 491
Paes Leme A.F., PO 497
Pagan F., OC 50.2, PB 1.39-2
Page C.P., PA 2.03-6
Pagel J.J., AS 01.1
Pagliuca L., OC 04.5, PB 4.60-2
Pagliara D., PO 329
Pagliari M.T., OC 13.5, OC 39.1
Paisan P., PB 2.45-4
Paiva J.H., PB 2.73-4, PB 3.33-3
Paiva M., PB 3.64-5
Pakakasama S., PB 2.50-3
Pal J., OC 78.1
Paladini P., PB 2.70-4
Palareti G., SC16-2.03, OC 12.4, OC 42.2, OC 42.3, PB 1.63-6, PB 2.49-1, PB 2.71-1, PB 2.71-6, PB 2.74-3, PB 3.64-6, PB 3.73-3, PO 254
Palavra K., PB 2.33-1
Palhares D.M.F., PB 4.45-4
Palige R., PA 3.07-1
Palla R., PA 1.08-1, PB 3.33-4
Pallarao A., PA 3.14-1
Palmblad J., PA 4.05-1
Palmer S., PB 1.72-2, PO 064
Paloma J., PB 2.37-3
Paloma M.J., PO 056
Palombella A.M., PB 2.22-3
Palomo A., PO 056
Palomo I., PB 4.21-2
Palmullo V., OC 08.2, OC 29.4
Palmumo J., SC13-3.01, PA 3.16-1
Pan D., AS 47.1, OC 37.1
Pan R-Y., PB 3.37-3
Pan Y., PA 4.11-3
Panchenko E., PB 4.73-4
Pandit N., PB 3.50-6
Panes O., PB 3.09-2, PA 4.05-2, PB 4.20-5, PB 3.25-4, PB 3.25-5
Panfilova O., PO 072, PO 205, PB 206, PO 207, PO 064, PB 210, PO 211
Pang J., PB 4.24-2, PB 4.25-5
Pangara E.A., PB 2.49-1
Pandrea J., PA 4.11-3
Pandrea J., PA 4.11-3
Pandrea J., PA 4.11-3
Pandrea J., PA 4.11-3
Pandrea J., PA 4.11-3
INDEX

Panigada M.P., PO 024
Pankert M., PA 1.01-2
Pannen B., PA 3.13-5
Panousis K., AS 20.3, PA 1.10-4
Panova-Noeva M., PB 1.26-5
Pansy J., PA 3.08-5, PB 2.41-4
Paoletta S., OC 89.3
Paoletti O., PB 1.47-5, PB 1.54-3, PB 1.66-1, PB 2.49-1, PB 2.49-3, PB 2.53-2, PB 2.53-4, PB 2.66-4, PO 267, PO 268
Pap A., AS 20.2, PB 3.34-1
Pap K., PA 4.12-4
Papajan L., PA 4.01-2
Papalardo E., OC 41.3
Papayon L., PA 3.11-2, PB 1.52-5, PB 4.68-2, PO 456
Paraboschi E.M., PA 4.12-4
Páramo J.A., AS 20.3, PA 2.16-3, PA 2.16-5, PB 2.63-6
Parasrampuria D., OC 83.4, PA 2.12-5, PA 2.15-2, PB 2.54-1, PB 4.30-1, PB 4.37-3, SAS08-03
Pasalic L., PB 2.30-6
Parальнikova E.N., PB 2.53-3
Parpia S., PB 2.64-3
Parra R., PB 2.65-6, PB 4.70-2
Parsi M., PA 4.07-2
Parsins S., OC 65.6
Parunov L.A., PB 4.59-2
Pascalau A., PO 409, PO 410
Pascalau L., PO 409
Paschalaki K.E., OC 39.3, PB 4.34-3
Paschoakaki L.E., PB 4.69-3
Patel A., PA 4.05-3
Patel C., OC 80.6, PA 4.13-4, PB 3.53-4
Patel H., PO 437
Patel N., PB 1.64-1, PB 3.57-2
Patel R.K., OC 61.3, PA 3.20-2, PB 2.51-3, PB 2.52-6
Patel S., PA 2.04-1
Patel Y.M., PA 4.05-3
Patel-Hett S., OC 36.4
Patenaude V., PB 1.65-2, PB 4.47-1
Patil R.K., PB 4.30-6
Patrascu J.M., PO 165
Patrono C., PB 3.29-5
Patrushev L.I., PB 1.34-2, PO 408, PO 411, PO 412
Patrusheva N.L., PB 1.34-2
Pattacini C., PB 3.35-1
Pattini P., AS 26.2
Paul D.S., OC 24.2, OC 76.3
Paul D., PA 2.04-2
Paul J-L., PB 3.28-2
Paulik M., PB 3.53-4
Paunovic M., PO 269
Pautas E., PB 3.39-3
Pavani G., OC 83.3
Pavlova A., SC12-3.03, OC 90.6, PB 1.36-2
Pavlova B.G., PB 3.49-4, PB 3.49.6
Pawlinski R., AS 10.3, AS 28.2, AS 46.1, OC 38.1
Payrastre B., AS 37.1, OC 35.6, PA 1.08-4, PA 2.03-1
Peace A., PA 2.01-1
Peach C., PB 2.39-5
Peake I.R., OC 13.4, OC 39.4, PA 3.09-1, PA 3.09-4, PB 1.44-5
Peail A., AS 27.2
Pearlmanc N., PB 4.70-4
Pease R.J., OC 67.1, PB 3.50-1, PB 4.57-2
Pecchi A., OC 89.4
Pecheniuk N.M., PO 244
Pedersen A., PB 2.63-3
Pedersen S., PB 2.30-3
Pedrajas J.M., PB 4.60-3
Pedreiro S., PB 2.44-5
INDEX

Pezeshkpoor B., OC 80.5
Pfeiffer C., PA 1.08-2, PA 3.08-3
Pfliiger G., OC 78.2, OC 90.3
Pham H., PB 4.37-6, PO 132
Philipp C.S., PB 2.71-3
Philippou H., SC10-1.01, AS 35.1, OC 23.2, PO 091
Philipsen S., PA 2.04-1, PA 2.04-5
Phillip S.E., OC 11.2
Phillips J., PB 4.58-6
Phillips K.G., OC 64.1, PB 3.28-1, PB 4.24-2
Philott A., PB 3.38-3
Phonix F., PB 3.21-1
Phua C.W., PB 3.35-5
Pi D., OC 78.1
Piacentini L., PB 2.27-1
Piana S., PB 4.69-1
Pias S.N., PO 109, PO 426
Platt R., AS 27.1, OC 24.2, PA 4.02-2
Picard P., PO 448
Piccardi B., OC 08.2, OC 29.4
Piccoli A., AS 34.1
Pich S., PA 4.18-1
Pichler M., PB 3.63-2
Pichugin V., PO 240
Pickering W.M., PB 2.25-4, PB 4.39-6
Picolli S.K., PB 3.52-5
Picot M-Ch., PB 4.71-5
Pie J., PB 1.41-2
Pierangelis S., SC03-2.06, OC 41.3, OC 41.4, PB 2.62-3, PB 2.62-4, PB 2.62-5, PB 3.62-4
Pieraccini-Mari M-D., PA 1.04-4
Piermarocchi S., PB 4.70-3
Pieroni G., PB 1.43-6, PB 1.71-1, PB 1.71-3, PO 303
Pierro C., PB 3.27-2
Pieters M., OC 06.5, PB 1.34-4
Pietrys D., PO 133
Pietrzyk A., PB 3.29-1, PB 3.29-4
Pignatelli P., PB 2.27-6
Pijls H.J., AS 04.1, OC 27.3
Pike G.N., PB 2.54-3
Pilger E., PA 2.18-5
Pilgrim S., PB 4.73-6
Pilgrim-Thorp A.K., PB 1.48-5, PB 4.42-6
Pillitteri D., PB 1.48-5, PB 4.42-6
Pillois X., OC 45.4, OC 62.1, PB 3.25-1
Pilotto E., PB 4.70-3
Pilz J., PB 1.39-6
Pina P., PO 158
Pineault K.M., PA 4.12-3
Pinelis V., PB 4.67-5, PO 228
Pinelis Y., PA 1.19-6, PO 472
Ping L., PO 091
Pinheiro M.B., PB 4.65-2, PO 040, PO 230
Pino M., PB 1.33-4, PB 4.22-5
Pinotti M., OC 50.2, OC 50.3, OC 70.4, PA 1.08-2, PB 1.39-2
Pinson M., PB 4.45-1
Pinto S-J., OC 43.1, PB 2.24-1, PO 468
Pinto P., PO 159
Pinto S.W., PO 230
Pinzon E., PB 2.56-6, PO 199
Piot M., OC 66.2, PB 1.48-6
Piovella C., OC 42.1, PO 075
Piovella F., OC 79.6, PB 4.69-1
Piovesan D., PB 3.68-2, PB 4.71-4
Pipe S., SC01-1.01, PA 2.12-1, PA 2.12-3, PB 4.39-1, SPS02-04
Piper B., PB 1.65-6
Piraino D., PB 3.51-1
Piran S., PA 2.16-1
Piras R., AS 40.1
Pirck M., PB 1.50-4, PO 158
Pires G., PO 009
Pirker R., PA 1.16-5
Piritskhelani N., PO 235
Pisceddu G., PA 1.13-2
Piskernik C., PB 3.33-2, PB 3.55-4
Pitchford S., PA 2.03-6, PB 4.23-5
Pitetti J-L., OC 06.2
Pitocco D., PB 3.44-4
Pitsiladis Y., PA 3.06-6
Pittman D., OC 36.4
Pizzo P., PA 1.09-1
Pizzuti M., AS 47.2
Place A.T., AS 23.1
Plaimauer B., PA 4.06-5, PB 2.33-1, PB 3.33-1, PB 3.33-6
Plamenova L., PO 243
Planken E., PA 3.20-1
Plantier J-L., OC 22.4, OC 56.2, PA 3.07-6
Platokouki H., PA 4.07-1, PB 3.35-3, PB 4.71-3
Platton S.J., PB 1.42-6, PB 1.51-2, PB 2.39-1, PB 4.38-1
Platzecker U., PO 348
Plawinski L., SC05-2.01, PB 2.73-5
Plaza E., PA 3.01-5
Plazak W., PB 2.62-1
Pleines I., OC 33.5, OC 33.6
Pletti S., PB 1.47-2
Ploug T., PB 1.59-2, PB 2.59-6
Plug T., PA 1.06-6
Pluthero F.G., AS 16.1
Pochet L., PB 4.49-6
Pocoski J., OC 03.6, PB 3.38-6
Podcherniaeva N., PO 306
Podda G.M., OC 89.4, PO 447
Poddubny I., PO 222
Podolak-Dawidziak M., PA 1.16-3
Podolec P., PB 2.62-1
Podolepova N.A., PA 1.12-6, PA 3.15-3, PB 4.27-1, PB 4.27-4
Poenaru D., PO 165
Poggio R., PB 4.69-1
Poirault-Chassac S., PB 3.29-1, PB 3.29-4
Poirier F., PB 2.29-5
Poká R., PB 3.67-5
Polakowski T., OC 66.1, PA 1.07-3, PA 3.07-2
Polderdijk S.G.I., OC 44.3
Polen Mallard E., AS 06.2
INDEX

Poletaev A.V., PB 1.51-6
Polgrees R., PB 3.62-6
Polli D., OC 02.1, OC 12.4, OC 42.2, OC 42.3, PA 1.20-3, PA 3.19-5, PB 2.49-1, PB 2.71-1, PB 3.61-1, PB 3.70-3, PB 4.74-3, PO 254
Polinder S., PB 2.36-2
Polish Adult Leukemia Group, PB 1.27-4
Pollard D., PB 4.41-3
Pollitt A.Y., PA 3.01-1, PB 2.26-3
Pollmann H., PB 3.52-1
Polokhov D.M., PB 3.51-6, PB 4.36-4, PO 011
Polyakov P., PO 052
Polyakova A., PB 2.69-5
Polyanskaya T.U., PB 4.36-4
Polzin A., PA 2.01-4
Pomero F., PB 1.49-1
Ponamarczuk H., PB 1.31-5
Poncelet Ph., OC 07.2, OC 17.2, PB 3.30-6
Poncet L., PO 435
Poncz M., AS 44.3, OC 69.2
Ponnusamy T., PB 1.32-4, PO 473
Pons B., PB 2.52-1
Ponschab M., PB 3.40-6
Pontara E., PA 1.09-1, PB 3.43-1
Pontarollo G., PA 2.13-2
Pontiggia S., AS 47.2, AS 40.1, PA 2.16-4, PA 4.19-2, PB 3.33-4
Potapova N., PB 1.52-3
Poulsen L.H., PB 2.58-4, PO 138, PO 170
Poulard C., OC 21.3, PA 3.08-3, PA 3.08-4
Pouymayou K., OC 13.6
Powazniak Y., PB 3.33-3
Powell J., AS 26.1, OC 37.2, OC 70.1, PA 2.06-3, PA 2.07-4, PA 2.07-5, PA 2.07-6, PA 4.07-2, PA 4.37-3, PO 164, PO 295, SPS01-02
Powell S., PB 1.55-4, PB 4.35-1
Powers J., PB 4.37-6, PO 132
Powter G., OC 25.4
Poznań K., PB 3.33-3
Powell J., AS 26.1, OC 37.2, OC 70.1, PA 2.06-3, PA 2.07-4, PA 2.07-5, PA 2.07-6, PA 4.07-2, PA 4.37-3, PO 164, PO 295, SPS01-02
Power J., PB 4.37-6, PO 132
Powier G., OC 25.4
Pozner G., PB 4.29-4
Pozzi N., OC 27.2
Pracucci G., OC 08.2, OC 29.4
Pradner S., PA 1.41-5
Pradru S., PO 334
Prael S.F.E., PB 3.43-6
Pragst I., AS 20.3, OC 84.4, PA 1.10-2, PA 1.10-4, PA 1.10-6, PA 1.12-1, PA 4.15-4, PB 1.58-3, PB 2.48-3, PB 4.55-6
Prandoni P., SC06-3.04, AS 19.2, AS 34.1, OC 12.4, OC 42.1, PA 1.04-5, PA 1.16-6, PA 1.20-1, PA 1.20-3, PA 3.13-1, PA 4.16-2, PA 4.16-5, PB 3.53-6, PB 4.31-3, PB 4.70-3, PO 075
Prat M., PA 1.13-6
Pratt K.P., OC 48.2
Prawitha D., PO 191
Precious E.M., PA 3.13-3
Preissner K.T., PB 2.67-5
Prenninger T., PO 146
Presles E., PA 4.16-3
Presniakova M., PB 2.45-1
Preston R.J.S., AS 21.3
Prevost G., PA 1.04-2
Prevost N., OC 60.2, OC 91.2
Preynat Ph., PA 4.16-3
Prezoto B.C., PB 4.49-2
Prezotti A., PA 2.07-3
Pribul V., PB 2.39-5
Price J.F., PA 3.12-3, PB 3.59-1
Price M.J., PB 2.22-2
Price V.E., PA 3.17-5
Prieo-Capote F., PB 2.67-6
Priest P., PA 4.11-1, PB 2.48-6
Priet M., PO 056
Priet S., PO 064
Pigancova T., PB 3.72.5, PO 154, PO 176
Primignani M., PB 4.51-1
Prince R., PA 1.15-2, PA 1.15-3
Prins M.H., AS 19.2, OC 20.3, OC 79.4, PA 2.05-5
Prinz N., OC 41.2
Piorst S., PB 2.22-3
Pripp A.H., AS 38.3, OC 66.3, PB 4.35-3
Prisco D., PB 1.67-2, PB 2.71-1, PB 4.33-1, PB 4.74-3
Proamer F., PA 2.04-3
Procaccianti G., PB 1.63-6
Prochaska J., PB 1.46-3
Prochazkova J., PO 192
Prohaska K., PA 1.07-3
Projahn D., PA 1.17-2
Prost J-F., OC 22.4
Prostran M., PB 2.21-6
Proulle V., AS 08.2
Provini S., OC 34.5
Pruner I., PA 2.13-4
Pruner D., PB 1.69-3
Prunier F., PB 1.49-3
INDEX

Pruthi R., PB 1.54-4
Pryzdzial E., SC05-1.02
Psaty B., OC 30.5, OC 63.1, PA 4.18-3
Puccetti L., PB 1.26-1
Puccetti P., AS 22.3
Pucciarelli S., OC 59.1
Puchalski S., PO 137
Puddu G.M., PB 1.63-6
Pudyk S., PO 096
Puech-Leão P., PB 4.27-3
Puehringer H., PB 1.48-3
Pugh N., PA 2.09-5, PA 3.02-2, PA 3.02-3, PB 1.31-3
Pugliano M., PO 447
Pujade-Lauraine E., PA 1.19-1
Pula G., OC 09.6, PA 2.03-1, PB 2.29-6, PB 3.28-3
Pulanic D., PO 284
Pulcinelli F.M., PB 3.71-1, PO 455
Pumpuang T., PB 2.64-5
Raat H., PB 3.37-6, PB 4.39-2
Rabinovich O., PB 1.72-2, PB 2.53-1, PO 064
Rabenda V., OC 02.4
Rabotinskiy S., PB 1.51-6
Racine M., PA 1.15-2, PA 1.15-3
Radanovic A., PO 001
Radermachers T., PA 4.03-6
Radhakrishnan A., OC 88.2
Radhakrishnan N., PB 1.33-6
Radhakrishnan S., PB 2.73-6
Rafaelovich M., PB 3.57-1
Rafferty M., PB 2.72-2
Rageliene L., PB 3.74-1
Ragg H., PB 3.59-3
Raghou H., AS 24.1
Raghib M., OC 70.1
Raghibi H., PA 2.06-3, PA 2.07-5, PA 2.07-6, PA 4.07-2, PB 4.37-3
Rahel Y., PO 020, PO 055
Rahel Y., PO 378
Rahal A., OC 41.4
Rahal Y., PO 467
Rahmani S., OC 35.5
Rajabi A., PO 344
Rajasri A., PB 3.65-1
Rajic Z., PB 2.73-6
Rajpurkar M., SC15-2.03, PB 1.68-5
Rak J., AS 46
Rakhe S., OC 80.2
Rambaldi A., PB 1.26-1
Ramos C., PO 161
Ramirez J.H., PB 1.39-3
Rampersad A.G., PO 173, PO 301
Ramshaw H.S., OC 76.1
Ramström S., PA 3.04-4, PB 1.22-6
Ramzon M., PB 3.35-4, PB 4.38-4
Ran W., PO 317, PO 332
Rana R.H., OC 87.8
Ranaldo G., AS 45.2, PA 1.13-6
Rancan E., PB 1.64-3
Rand J.H., PB 1.62-6
Rand M.L., AS 24.2, PA 1.02-2, PA 1.09-5, PA 2.08-2, PA 3.09-3
Randi A.M., SC07-1.03, AS 01.1, OC 39.3, PB 4.34-3
Randrianaivo-Ranjatoelina H., PB 3.41-1
Ranelletti F., PB 3.29-5
Rangarajan K., PB 3.38-3
Ranj R., PB 4.72-4, PO 181
Rannou O., PB 4.34-6
Rao A.K., PB 2.17-3, PB 2.63-2
Rao L.V.M., PA 3.16-4
Rao N., PB 1.32-4, PO 473
Raquet E., PB 4.55-6
Rashid H., PB 4.72-4
Raskob G., SC06-05
Raslan Z., PB 3.23-5
Rasmussen M.S., PA 1.16-6
Raso S., PO 213
Rassoulzadeh M., PB 4.43-1
Rastegar Lari G., PB 4.42-5, PB 4.43-1
INDEX

Richel D., OC 31.2, PB 1.30-2
Riches J., OC 15.2
Richter C., OC 90.5
Rico M., PB 2.67-4
Riddell A., PA 4.11-1, PB 1.41-2, PB 2.25-4, PB 2.48-6, PB 4.39-6, PB 4.52-5
Rider L., PB 3.65-1
Ridger V.C., AS 35.1
Riedl J., AS 34.2, OC 31.1
Rietbrock S., AS 19.1, OC 63.5, PA 4.10-6
Rietveld I.M., OC 18.1, PB 3.55-2
Rieu Ph., PB 3.56-2
Righini M., AS 42.1, OC 12.3, OC 20.1, PB 2.71-5
Riha M., PB 3.52-3
Rijken D.C., PA 3.06-5, PB 1.34-1, PB 1.34-4, PO 093
Rina A., PO 455
Rinckel J-Y., PA 2.04-3
Rinderknecht Graf S., PB 1.36-3
Rinia H., PA 3.04-1
Rios D.R.A., PO 230
Riou B., OC 02.3, OC 36.1
Ripart-Neveu S., PB 2.66-2
Ris-Stalpers C., FS 01.3
Ritchie B., PB 1.58-4
Ritland M., OC 82.2
Ritti L., PO 165
Ritscel V., PB 1.21-5
Riva F., PO 112, PO 429
Riva N., OC 02.1, PB 1.61-2, PB 2.61-1, PB 3.70-6, PB 4.46-1
Rivadeneyra L., OC 46.1, OC 60.5, PA 3.03-2, PB 1.29-5, PB 4.29-4
Rivard G.E., PO 424
Rivera A., PB 270
Rivera J., PA 3.01-5, PA 3.05-1, PB 2.25-3, PB 4.27-6
Rivera-Galdos R., OC 88.1
Rivolta G.F., PB 3.35-1
Rizzi M., PA 2.19-3
Rizzo P., PB 3.44-4
Roach R.E.J., AS 05.1, OC 30.6

Robak T., PB 1.27-4
Robbel L., PB 2.55-6
Robert D.M., PA 2.20-3, PB 4.24-1, PB 4.24-4
Robert S., PB 2.30-1
Robert M., PB 4.57-5
Robert-Ebadi H., OC 20.1
Roberto V., PA 1.04-5, PA 3.13-1, PB 3.53-6
Roberts A., PB 1.27-6
Roberts J.R., PB 2.23-1
Roberts L., PB 2.51-3, PB 2.52-6
Roberts R.S., PB 1.45-4
Robertson G., PB 1.60-6
Robertson M., OC 64.2
Robinson G.J., PB 4.37-5
Robinson J., OC 56.2
Robinson K.S., PA 3.17-5
Robinson M., PB 4.47-3
Robinson N.D., PB 4.25-2
Robles-Carrillo L., AS 38.1, AS 39.3
Robson S., OC 41.1
Robusto M., PB 3.52-6
Rocca B., PB 3.29-5
Rocha A.T., PB 3.64-4
Rocha M.O., PB 4.45-4
Rocha R.F., PO 029, PO 296
Rocha S.N., OC 15.1
Rocha T.R.F., PO 497, PB 4.27-3
Rocino A., AS 32.2, PB 1.37-5
Rodriguez J.M., PB 4.27-6
Rodriguez Galvan K., PB 2.22-5
Rodriguez-Acosta A., PB 4.34-5, PO 095, PO 488
Rodriguez-Ariz a., OC 27.6
Rodriguez-Martinez M., PB 3.36-5
Rodriguez-Trillo A., PB 2.42-6
Roelofs J.T.H., AS 31.3, OC 05.3, PB 1.67-3, PB 4.67-1, PO 320
Roem D., PB 4.67-4
Roest M., SC17-3.01, AS 04.1, AS 40.3, OC 09.5, OC 27.3, PA 1.03-5, PA 2.08-4, PA 2.09-4, PA 2.15-1, PA 4.03-4, PB 2.24-3, PB 3.24-6, PB 3.44-5, PB 3.58-1, PO 318, PO 318, PO 341
Roeters van Lennep J.E., PB 4.65-3
Rogalska M.E., PB 1.39-2
Rogler D., PB 2.64-1
Rogolino A., PB 1.31-2, PB 1.34-6
Rogozina A.S., PO 277, PO 415
Rohrbach F., PB 4.25-6
Rojnuckarin P., PO 026, PO 027
Roldán V., OC 08.1, OC 79.5, PA 1.11-6, PB 1.68-2, PB 3.52-4
Rollin J., OC 21.3
Romagnuolo I., PB 2.22-3
Romagnuolo R., PA 2.14-5
Roman Perez A., PB 2.22-5
Romanenco O., PA 1.23-5
Romaniuk A., PA 3.03-2
Romano F., PO 200
Romano P.S., PB 3.70-2
Romanov V., PB 1.36-4, PB 1.50-4, PB 2.37-2, PO 148
Romanyuk S., PO 369
Romari N., PB 4.54-1
Romay-Penabad Z., OC 41.3, OC 41.4
Romeder-Finger S., PO 062
Romeo G., OC 77.4
Romera M., OC 79.5, PA 1.11-6
Ronca E., PB 1.66-1
Roncal C., AS 30.1, PA 2.16-5, PB 2.63-6
Rondeau-Leclaire J., PB 4.31-2
INDEX

Rondina M.T., OA 46.3, PA 3.06-2
Rong L., OA 25.1
Rönquist Y., AS 02.3, PB 3.51-4
Roosendaal G., PA 1.07-1, PA 1.07-2, PA 1.07-5
Roosmalen M., OA 71.4
Roque M., PA 3.01-4
Rorick T., PA 4.01-3
Rosa I., PB 2.27-2, PB 3.24-5
Rosa J-P., OA 39.2
Rosc D., PB 3.60-5, PB 3.61-3, PB 4.56-3, PO 373
Rose-Orange S., OA 86.1
Rosell A., AS 30.1
Rosén P., PA 2.13-6
Rosén S., PA 2.13-6, PB 1.36-2
Rosenbaum E., OA 82.1
Rosenberg A., PA 4.11-4
Rosenberg N., OC 34.3, OC 77.1, PA 3.01-3, PB 1.23-5
Rosendaal G., PB 1.35-3
Rosendaal F.R., SC09-1.03, AS 05.1, AS 10.2, AS 11.2, AS 18.1, AS 43.3, OC 04.2, OC 12.6, OC 30.3, OC 30.5, OC 42.4, OC 47.2, OC 59.3, OC 59.4, OC 63.1, OC 63.1, OC 63.6, PA 3.19-1, PA 3.19-6, PA 4.18-3, PB 1.33-6, PB 1.63-3, PB 2.71-2, PB 2.74-5, PB 3.55-2, PB 3.73-2, PB 4.43-4, PB 4.43-4, PB 4.43-4, PB 4.44-2, PB 4.64-3, PB 4.70-1, PO 282, PO 358
Rosenfeld L., PA 3.16-1
Rosenfield K., PA 2.18-4
Rosengren A., PB 2.63-3
Rosenlechner S., PA 2.06-6
Rosenstein R.E., PB 2.28-5, PO 308
Rosenthal M., PO 119
Roshal M., PB 4.63-3
Rosing J., SC20-2.08, AS 24.3, AS 29.1, AS 42.1, OC 23.3, OC 73.1, OC 73.3, PA 1.15-1, PA 2.13-1, PB 1.35-1, PB 4.66-6
Ross J., OA 61.3
Rossaint R., AS 33.3, PB 1.57-3, PB 4.57-1
Rossen S., PB 3.43-4
Rossetti G., PA 3.09-5
Rossetti L., PB 2.27-1
Rossetto V., AS 33.1, PA 3.19-3
Rossi E., PO 201
Rossi K., PB 1.47-2
Rossi R.J., OC 48.2
Rossio R., AS 40.1, AS 47.2, PA 2.16-6, PA 3.05-6, PB 1.33-6, PB 2.25-5
Rossi T., PB 3.22-5
Rota L., PA 4.16-2, PB 2.46-4
Rothschild C., PA 3.14-4
Rottilio D., PB 3.66-4
Roth H., PO 119, PO 272, PO 432
Rottensteiner H., PA 1.12-5, PB 2.33-1, PB 3.33-6, PA 4.06-5, PB 4.35-2, PB 4.48-3
Roualdes O., PB 2.35-1
Roucoulet C., PB 2.41-6
Roudaut-Le Gall M-L., AS 05.2
Roumenina R.T., AS 47.4
Rousse N., PA 4.09-1
Rousseau A., PB 4.63-5
Rousselot C., PB 4.29-3
Rovescani E.G., PA 4.19-5
Rosewell H.R., PB 1.65-4
Roy A., PO 162
Roy P-M., OC 02.3, OC 20.4
Rozen L., PB 2.55-1
Rozin T., PO 342
Ruedas Ninfa M.A., PO 064
Ruan C., PA 4.01-4, PA 4.19-4, PB 1.24-1, PB 2.32-5, PB 2.41-1, PB 2.72-3, PB 4.22-6, PB 4.56-1, PO 086, PO 088, PO 422
Ruangsakulak C., PB 2.64-5, PO 076
Ruano M., PB 3.21-2
Rubak P., PB 3.21-3, PB 3.22-6
Rubiano A., PB 4.08-4
Rubin L., PB 3.72-3
Ruchkroko T., PA 3.13-6, PB 1.42-3
Ruda M., PB 4.27-5
Rudan I., OC 90.4
Rudan O., PA 3.11-1
Rudiman P.I.F., PA 1.03-5
Rudowski C., PA 3.17-6
Rueda E., PO 152
Ruf W., AS 21, AS 46.3, OC 01.4, OC 07.2, OC 68.3, OC 82.2, PA 3.16-6
Ruffatti A., PB 2.62-2
Ruggeri L., PA 1.09-2, PB 1.43-5
Ruggeri Z.M., OC 45.2, OC 58.2, OC 82.2, PA 3.02-1, PA 4.09-3, PB 2.23-1, PB 2.46-4
Rühl H., PA 3.17-6, PB 1.34-5, PB 3.53-2, PB 3.58-5
Ruiz M., PB 3.45-2
Ruiz-Limón P., OC 27.6, OC 41.3, OC 41.4, PB 2.62-4, PB 3.62-4
Ruiz-Sánchez A., PO 104, PO 144, PO 179
Rumi E., PB 3.61-1
Rumley A., OC 90.4
Rupa-Matisek J., PB 3.31-2, PB 3.66-6
Rushlow D., PB 1.74-5
Russell J., AS 46.1
Russo A., PB 4.60-5
Russo L., PB 1.22-5, PB 1.26-5, PB 3.22-5
Rutell S., PO 329
Rutgersson A., PB 1.27-6
Ruthsatz T., PA 3.33-2
Rutledge W.C., PO 327
Rutten B., AS 04.1
Ruwna P., PB 2.51-1
Rux A.H., OC 21.1
Ryan K., PB 1.43-4, PB 2.72-2, PB 4.46-5, PB 4.62-4, PO 034
Rydlewski A., PO 234
Rydz N., OC 65.3
Ryerson L., PB 3.68-6
Rystok D., PB 3.61-3
Ryzi M., PO 015
Saad H., PO 357
Saad S.T.O., PA 1.17-5
Sabapathy C.A., PB 3.62-1
Sabater–Lleal M., OC 30.4
Sabatier F., OC 26.3, PA 1.04-4
Sabi E.M., OC 62.6
Sabino A.P., PO 230
Sabra A., PB 2.63-5
<table>
<thead>
<tr>
<th>Author</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saccullo G.</td>
<td>PB 2.39-6, PO 213, PO 214, PO 413</td>
</tr>
<tr>
<td>Sacerdote C.</td>
<td>OC 04.1, OC 07.6, PA 3.06-4, PB 1.56-6</td>
</tr>
<tr>
<td>Sachais B.S.</td>
<td>OC 21.1</td>
</tr>
<tr>
<td>Sachdeva A.</td>
<td>PB 3.35-4, PB 4.38-4</td>
</tr>
<tr>
<td>Sachdeva M.U.S.</td>
<td>PB 2.70-2</td>
</tr>
<tr>
<td>Sachs U.J.</td>
<td>OC 55.1, OC 55.6, OC 90.6, OC 91.3, PA 3.08-5</td>
</tr>
<tr>
<td>Sadeghi M.</td>
<td>OC 60.6</td>
</tr>
<tr>
<td>Sadeghi N.</td>
<td>PB 1.58-6, PO 420</td>
</tr>
<tr>
<td>Sadílek P.</td>
<td>PB 3.72-2, PO 393</td>
</tr>
<tr>
<td>Sadler J.E.</td>
<td>OC 15.3, SC17-1.02, SAS01-04</td>
</tr>
<tr>
<td>Sadowsky J.</td>
<td>PA 1.14-4</td>
</tr>
<tr>
<td>Saenz D.A.</td>
<td>PB 2.28-5, PO 308</td>
</tr>
<tr>
<td>Sáez C.</td>
<td>PB 1.31-6</td>
</tr>
<tr>
<td>Safaryan L.</td>
<td>PO 051</td>
</tr>
<tr>
<td>Safford M.</td>
<td>AS 01.3</td>
</tr>
<tr>
<td>Safford R.E.</td>
<td>OC 14.4</td>
</tr>
<tr>
<td>Saga G.</td>
<td>PB 3.43-1</td>
</tr>
<tr>
<td>Sage T.</td>
<td>AS 39.2, OC 87.6, PA 2.02-3, PA 2.03-4, PA 4.02-3</td>
</tr>
<tr>
<td>Saggini R.</td>
<td>PB 1.26-1, PB 2.28-4</td>
</tr>
<tr>
<td>Saggiorato G.</td>
<td>PB 4.70-3</td>
</tr>
<tr>
<td>Saharor G.</td>
<td>PO 494</td>
</tr>
<tr>
<td>Sahin I.O.</td>
<td>PB 3.69-4</td>
</tr>
<tr>
<td>Sahlberg K.K.</td>
<td>PB 3.60-1</td>
</tr>
<tr>
<td>Sahquillo J.C.</td>
<td>PA 1.15-2, PA 1.15-3</td>
</tr>
<tr>
<td>Saint-Rémy J-M.</td>
<td>OC 22.4</td>
</tr>
<tr>
<td>Saito H.</td>
<td>FS 03.4, OC 37.6, OC 78.4, PA 2.13-5, PA 4.58-4</td>
</tr>
<tr>
<td>Saito J.</td>
<td>PO 156, PO 404</td>
</tr>
<tr>
<td>Saito S.</td>
<td>PA 3.08-6, PO 115</td>
</tr>
<tr>
<td>Saito Y.</td>
<td>PO 038</td>
</tr>
<tr>
<td>Sajjadi S.M.</td>
<td>PO 293</td>
</tr>
<tr>
<td>Sakaguchi K.</td>
<td>PO 236</td>
</tr>
<tr>
<td>Sakakai M.</td>
<td>FS 03.4</td>
</tr>
<tr>
<td>Sakari Jokiranta T.</td>
<td>AS 47.4</td>
</tr>
<tr>
<td>Sakata A.</td>
<td>OC 86.3</td>
</tr>
<tr>
<td>Sakata Y.</td>
<td>OC 86.3</td>
</tr>
<tr>
<td>Sahkarova D.</td>
<td>PO 371</td>
</tr>
<tr>
<td>Sakon M.</td>
<td>PO 273</td>
</tr>
<tr>
<td>Sakurai H.</td>
<td>PA 3.20-4</td>
</tr>
<tr>
<td>Sakurai Y.</td>
<td>PO 352</td>
</tr>
<tr>
<td>Sal E.</td>
<td>PB 3.42-5</td>
</tr>
<tr>
<td>Sala-Cunill A.</td>
<td>OC 53.3</td>
</tr>
<tr>
<td>Salas E.</td>
<td>PA 4.18-1</td>
</tr>
<tr>
<td>Salas J.</td>
<td>OC 56.4, OC 83.4, PA 1.58-1, PA 3.58-2</td>
</tr>
<tr>
<td>Salavaris E.</td>
<td>PB 3.50-5</td>
</tr>
<tr>
<td>Salazar V.</td>
<td>PB 2.67-5</td>
</tr>
<tr>
<td>Salazar A.M.</td>
<td>PB 4.34-5, PO 095, PO 488</td>
</tr>
<tr>
<td>Salazar E.</td>
<td>PB 4.34-5, PO 488</td>
</tr>
<tr>
<td>Salioglu Z.</td>
<td>PB 4.41-6, 4.71-1, PO 098</td>
</tr>
<tr>
<td>Salem M.</td>
<td>PO 382</td>
</tr>
<tr>
<td>Salgado V.</td>
<td>PB 2.56-6, PO 199</td>
</tr>
<tr>
<td>Salicio A.</td>
<td>AS 30.1</td>
</tr>
<tr>
<td>Salihoglu A.</td>
<td>PB 4.37-4, PO 101</td>
</tr>
<tr>
<td>Salim A.K.</td>
<td>PB 3.20-2</td>
</tr>
<tr>
<td>Salisburn J.L.</td>
<td>PB 1.25-6</td>
</tr>
<tr>
<td>Saller F.</td>
<td>AS 03.1, AS 26.3, PA 1.15-2, PA 1.15-3</td>
</tr>
<tr>
<td>Salles I.</td>
<td>OC 86.2</td>
</tr>
<tr>
<td>Sallov-Asfar S.</td>
<td>OC 05.4, OC 08.1</td>
</tr>
<tr>
<td>Salo P.</td>
<td>OC 90.2</td>
</tr>
<tr>
<td>Salomon O.</td>
<td>OC 05.5, PA 3.14-3</td>
</tr>
<tr>
<td>Salomone L.</td>
<td>PB 1.63-6</td>
</tr>
<tr>
<td>Saltikova N.</td>
<td>PA 3.11-2, PA 1.30-4, PA 1.30-5, PB 1.52-5, PB 4.30-1</td>
</tr>
<tr>
<td>Salvado R.</td>
<td>OC 52.4, PB 2.44-5, PB 3.67-6, PB 4.73-3</td>
</tr>
<tr>
<td>Salvatori D.</td>
<td>PA 3.12-4</td>
</tr>
<tr>
<td>Samama M.M.</td>
<td>PB 2.47-6, PB 3.48-3</td>
</tr>
<tr>
<td>Samani N.J.</td>
<td>OC 64.6, PB 3.71-4</td>
</tr>
<tr>
<td>Samaria J.</td>
<td>PB 3.74-6</td>
</tr>
<tr>
<td>Sambade C.</td>
<td>PA 2.04-1</td>
</tr>
<tr>
<td>Samel M.</td>
<td>PB 4.22-4</td>
</tr>
<tr>
<td>Sametoglu F.</td>
<td>PO 101</td>
</tr>
<tr>
<td>Samiei S.</td>
<td>PO 293</td>
</tr>
<tr>
<td>Saminaden L.</td>
<td>PB 1.40-4</td>
</tr>
<tr>
<td>Sanei Moghadam E.</td>
<td>PO 381</td>
</tr>
<tr>
<td>Sanford D.</td>
<td>PB 3.61-4</td>
</tr>
<tr>
<td>Sangeeta M.</td>
<td>PB 4.31-1, PB 4.32-6, PO 471</td>
</tr>
<tr>
<td>Sandoval E.P.N.</td>
<td>PO 296</td>
</tr>
<tr>
<td>Sandset P.M.</td>
<td>AS 19.3, PA 3.16-3, PA 3.20-3, PA 4.14-4, PB 2.50-4, PB 2.59-4, PB 2.60-2, PB 3.60-1</td>
</tr>
<tr>
<td>Sandhui I.</td>
<td>PO 194</td>
</tr>
<tr>
<td>Sandor A.</td>
<td>PB 3.44-6</td>
</tr>
<tr>
<td>Sandor A.</td>
<td>PB 3.44-6</td>
</tr>
<tr>
<td>Sandor A.</td>
<td>PB 3.44-6</td>
</tr>
<tr>
<td>Sangi-Haghepyak S.</td>
<td>PA 3.17-3</td>
</tr>
<tr>
<td>Sanlaville D.</td>
<td>PB 1.39-4</td>
</tr>
<tr>
<td>Sano H.</td>
<td>PB 1.50-2</td>
</tr>
<tr>
<td>Santomino E.</td>
<td>AS 22.1, AS 22.2, AS 22.3, OC 22.1, OC 66.4, OC 70.2, PA 2.12-2, PA 4.07-1, PA 4.11-6, PB 1.37-5, PB 160, SC09-5.01, SPS03-02</td>
</tr>
<tr>
<td>Santamaria A.</td>
<td>PB 1.72-1</td>
</tr>
<tr>
<td>Santiago-Bassora F.D.</td>
<td>OC 08.5, PB 4.68-4, PB 4.68-6</td>
</tr>
<tr>
<td>Santill F.</td>
<td>PB 2.28-4</td>
</tr>
<tr>
<td>Santoro C.</td>
<td>AS 22.3, PA 1.13-2, PA 2.08-1, PB 1.74-6, PB 4.42-2, PO 112, PO 429</td>
</tr>
</tbody>
</table>
INDEX

Santoro M., PB 2.39-6, PO 213
Santoro M.L., PO 497
Santoro N., PB 1.26-1
Santoro R., OC 02.1, PB 4.46-1, PB 4.69-1
Santos A., PA 2.07-3
Santos I.R., PB 4.74-2
Santos M., PB 4.72-1
Santos M.T., PA 2.01-5, PA 2.03-2, PB 2.23-5, PB 3.21-2, PB 4.24-5
Santos S., PO 047
Santos-Estrella P.V., PO 388
Santoso T., PB 3.50-3
Santoso S., SC04.3-1.2, SC04.3.1.7, OC 55.1, OC 55.6, OC 91.3
Santry H.P, PB 3.48-1
Sanz V., PA 3.10-6, PB 4.47-2
Sapin A.F., PB 1.41-1
Saposnik B., OC 89.2, PA 3.05-5
Sarici A., PO 101
Sarig G., PB 1.66-4, PB 3.72-3
Sarrafan A.G., OC 28.3, PA 1.13-4
Sarg B., PB 2.60-3
Sargsyan L., PO 051
Saric A., PO 101
Sarig G., PB 1.66-4, PB 3.72-3
Sarin A., PB 3.29-6
Sarkady F., PA 1.01-4
Sarlon-Bartoli G., PA 1.04-4
Sarode R., SPS08-02
Sartori M.T., AS 33.1, OC 02.1, PB 3.57-6, PB 4.46-1, PB 4.70-3, PO 075
Sartori M., PB 2.71-6, PB 2.74-3, PB 3.64-6
Sasanakul W., PO 110
Sasané R., PB 3.38-6
Sasikumar P., OC 87.6, PA 2.02-3, PA 4.02-3
Sasmaz I., PO 099, PO 163
Sastre B., PB 2.30-1
Sata S., PB 2.59-5
Satake M., PB 1.28-1
Sather S., PA 2.02-4
Sathler-Avelar R., PB 4.66-4
Sathyamurthy Y., PB 4.31-6, PO 474
Satitthummanid S., PB 4.56-4
Sato Y., OC 43.3, PB 4.59-6
Satoh K., PA 2.02-5
Satoskar P., PB 4.30-6
Satou T., PB 1.67-4
Saugstrup T., PB 4.55-5
Saunder X., PO 248
Sautet A., OC 02.3
Savage J.S., OC 10.1, PA 1.02-6, PA 3.03-5
Savchenko V.G., PB 2.53-3
Savchuk O., PB 3.45-5
Savescu D., PO 165
Savic N., PB 2.73-6
Savion N., PB 4.23-1, PB 4.23-6
Savoia A., OC 34.3, OC 62.4
Savoia H., PB 3.68-2
Savete Research Group, PO 065
Savushkin A.V., PB 2.57-6, PO 090
Saw S., PO 032
Sawada A., OC 14.1
Sawada H., FS 03.3
Sawada N., PA 3.18-3
Sawamurah A., PO 079
Saxena K., PB 4.37-2
Saxena R., PB 4.72-4, PO 181
Sayilan Sen H., PB 4.41-6, PO 471-1, PO 098
Sbrojavacca R., PB 1.49-2
Scaglione G.L., OC 39.1
Scalambrino E., PB 4.30-3
Scalia P., PB 2.65-5
Scalise A., AS 07.2
Scangos G., SAS04-01
Scarafile R., PO 200, PO 430
Scarino C., PB 1.72-6
Scavone M., PB 1.22-4
Schaap M.C.L., PB 2.28-1
Schaefer M., PB 3.32-4
Schafer T.M., PA 2.08-3
Schafer K.L., PO 164
Schäfer C., OC 76.4
Schaff M., AS 27.3, PB 2.26-1
Schaffer E., PB 4.64-5
Schaller M., PA 4.06-1
Schaller M-D., PO 279
Scharf R.E., PA 2.01-4, PA 2.03-4, PA 3.13-5, PB 1.23-4, PB 4.23-2, PB 4.57-3, PB 4.66-1, PO 403
Scharrer I., PA 4.19-3, PB 2.42-3, PB 4.60-5
Scharrig E., OC 46.1
Schattner M., OC 46.1, OC 60.5, PA 1.03-6, PA 3.02-2, PB 1.59-5, PB 2.29-3, PB 4.29-4
Schedel A., PA 4.05-4, PB 3.29-6
Scheiflinger F., AS 41.2, OC 22.1, OC 23.3, OC 51.3, OC 66.1, OC 73.1, PA 1.07-3, PA 1.07-4, PA 1.07-6, PA 1.12-5, PA 2.10-5, PA 3.07-1, PA 3.07-2, PA 4.06-3, PA 4.06-5, PA 4.06-6, PB 1.35-1, PB 1.39-6, PB 1.50-3, PB 2.33-1, PB 3.33-1, PB 3.33-2, PB 3.33-3, PB 3.55-4, PB 3.55-6, PB 3.58-3, PB 4.35-2, PB 4.48-3, PB 4.48-3, PO 060, PO 061, PO 062, PO 146, PO 328, SAS01-01
Schein J., PB 1.45-1, PB 4.31-2, PB 4.45-2
Schelle G., PO 130
Schellenberger V., AS 45.1, PA 2.12-5, PB 1.58-1, PB 2.55-3, PB 4.55-4
Scheller G., PB 3.46-6
Schellong S., AS 17.3, OC 63.3, PA 3.08-1, PB 4.40-1, PB 4.45-1, SPS01-04
Schenck-Dhif M., PA 4.17-4
Schenk M.P., OC 08.6, OC 85.1
Schenk S., PA 1.10-6
Schevzov G., OC 33.5
Schiavoni M., AS 32.2
Schiele F., OC 36.2
Schimmelt M., OC 08.3
Schinco P., AS 45.2, PB 3.35-3
Schindewolf M., PA 3.08-1, PB 3.39-4, PB 3.39-5, PB 3.39-6, PB 4.40-1
Schino M., PB 1.37-5, PO 033
<table>
<thead>
<tr>
<th>Name</th>
<th>Page Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Schinzel H.</td>
<td>PB 2.49-5</td>
</tr>
<tr>
<td>Schipper I.B.</td>
<td>AS 43.3, OC 59.3</td>
</tr>
<tr>
<td>Schiviz A.</td>
<td>PA 1.12-5, PA 2.10-5, PA 4.06-3, PA 4.06-5, PB 3.33-1</td>
</tr>
<tr>
<td>Schlagenhauf A.</td>
<td>PB 3.24-3, PB 3.65-5, PB 4.50-4</td>
</tr>
<tr>
<td>Schlammadinger A.</td>
<td>OC 78.3, PB 3.67-5</td>
</tr>
<tr>
<td>Schlegel N.</td>
<td>OC 45.4, OC 89.2, OC 26.1</td>
</tr>
<tr>
<td>Schleifer M.</td>
<td>PB 4.73-6</td>
</tr>
<tr>
<td>Schlimp C.J.</td>
<td>PB 3.40-6</td>
</tr>
<tr>
<td>Schlott B.</td>
<td>PB 2.40-1</td>
</tr>
<tr>
<td>Schmaier A.</td>
<td>OC 26.1</td>
</tr>
<tr>
<td>Schmaier A.H</td>
<td>OC 01.1, OC 01.2, OC 26.1, OC 53.4</td>
</tr>
<tr>
<td>Schneider H.</td>
<td>PB 2.67-5</td>
</tr>
<tr>
<td>Schneider P.</td>
<td>PA 4.12-1</td>
</tr>
<tr>
<td>Schneider S.O.</td>
<td>PO 315</td>
</tr>
<tr>
<td>Schneider T.</td>
<td>PO 327</td>
</tr>
<tr>
<td>Schneeppenheim R.</td>
<td>OC 13.4, PA 3.09-1, PA 4.19-1, PB 2.43-3</td>
</tr>
<tr>
<td>Schnog J-J.</td>
<td>PA 2.15-2</td>
</tr>
<tr>
<td>Schobess R.</td>
<td>PB 4.51-2</td>
</tr>
<tr>
<td>Schoenig-Diesing C.K.</td>
<td>PB 1.36-4, PB 1.37-3, PB 2.37-2, PO 148</td>
</tr>
<tr>
<td>Schoenwaelder S.M.</td>
<td>OC 11.6, OC 45.2, OC 76.1</td>
</tr>
<tr>
<td>Schoergenhofer C.</td>
<td>PA 1.01-1, PA 1.01-5</td>
</tr>
<tr>
<td>Scholten A.</td>
<td>PB 2.24-3, PB 3.24-6</td>
</tr>
<tr>
<td>Scholzer T.</td>
<td>PA 1.01-2</td>
</tr>
<tr>
<td>Scholtz U.</td>
<td>PB 2.24-3, PB 3.24-6</td>
</tr>
<tr>
<td>Schröder E.</td>
<td>OC 46.3</td>
</tr>
<tr>
<td>Schröder M.</td>
<td>OC 13.1</td>
</tr>
<tr>
<td>Schwegel A.</td>
<td>PB 1.12-5, PA 2.10-5, PA 3.33-6, PB 4.35-2, PB 4.48-3, PO 062</td>
</tr>
<tr>
<td>Schrefler M.</td>
<td>PB 1.40-1</td>
</tr>
<tr>
<td>Schueren A.</td>
<td>OC 13.1</td>
</tr>
<tr>
<td>Schwerdtfeger C.</td>
<td>PB 2.36-6</td>
</tr>
<tr>
<td>Schütte C.</td>
<td>PB 3.65-5</td>
</tr>
<tr>
<td>Schüttefort G.</td>
<td>PO 265</td>
</tr>
<tr>
<td>Schweinzer S.</td>
<td>OC 31.1</td>
</tr>
<tr>
<td>Schwegel M.</td>
<td>PB 3.65-5, PB 4.50-4</td>
</tr>
<tr>
<td>Schwenk M.</td>
<td>PA 4.20-4</td>
</tr>
<tr>
<td>Schuwescher M.</td>
<td>PB 1.36-5, PB 2.37-2, PB 4.35-2, PB 4.48-3, PO 062</td>
</tr>
<tr>
<td>Schuster J.</td>
<td>PB 1.48-5</td>
</tr>
<tr>
<td>Schuster K.</td>
<td>OC 32.3</td>
</tr>
<tr>
<td>Schuurmans M.J.</td>
<td>PB 3.37-5</td>
</tr>
<tr>
<td>Schwartz D.</td>
<td>PA 4.15-4</td>
</tr>
<tr>
<td>Schwartz H.</td>
<td>PA 4.15-4</td>
</tr>
<tr>
<td>Schwarting F.</td>
<td>PB 1.36-5, PB 2.37-2, PB 4.35-2, PB 4.48-3, PO 062, PO 061</td>
</tr>
<tr>
<td>Schweitzer L.</td>
<td>OC 25.1</td>
</tr>
<tr>
<td>Sciama K.</td>
<td>PO 075</td>
</tr>
<tr>
<td>Sciaretti G.B.</td>
<td>PB 1.43-6, PB 1.71-1, PB 1.71-3, PO 303</td>
</tr>
<tr>
<td>Scuderi U.</td>
<td>PA 3.19-5, PB 3.61-1, PB 4.12-1, PB 4.15-4, PB 4.50-4</td>
</tr>
<tr>
<td>Scott B.M.</td>
<td>PB 4.59-1</td>
</tr>
<tr>
<td>Scott D.J.A.</td>
<td>PA 4.15-6, PB 3.63-6, PB 4.59-1</td>
</tr>
<tr>
<td>Scott D.W.</td>
<td>OC 48.2</td>
</tr>
<tr>
<td>Scott J.A.</td>
<td>PA 1.14-3</td>
</tr>
<tr>
<td>Scott N.</td>
<td>PA 1.21-3</td>
</tr>
<tr>
<td>Scott R.</td>
<td>PB 1.48-4</td>
</tr>
<tr>
<td>Scofield S.</td>
<td>PB 4.41-5</td>
</tr>
<tr>
<td>Scully M.</td>
<td>AS 40.2, OC 52.1, OC 82.3, PB 2.33-2, PA 2.11-6, PA 4.08-3, PB 4.48-3, PB 4.50-4, PB 3.35-5, PB 3.39-2</td>
</tr>
<tr>
<td>Sealey F.</td>
<td>PB 2.46-2</td>
</tr>
<tr>
<td>Sears J.</td>
<td>PB 2.65-2</td>
</tr>
<tr>
<td>Sebastian G.</td>
<td>PB 1.46-3</td>
</tr>
<tr>
<td>Sedano C.</td>
<td>PO 056</td>
</tr>
<tr>
<td>See R.</td>
<td>PA 2.18-3</td>
</tr>
<tr>
<td>Seeger K.</td>
<td>PO 329, PO 348</td>
</tr>
<tr>
<td>Šega M.</td>
<td>PO 017</td>
</tr>
<tr>
<td>Segawa K.</td>
<td>PB 1.28-5</td>
</tr>
<tr>
<td>Segers A.E.</td>
<td>PB 1.69-5</td>
</tr>
<tr>
<td>Segier F.</td>
<td>PO 055, PO 063, PO 378, PO 423</td>
</tr>
<tr>
<td>Segner M.</td>
<td>PB 2.47-4</td>
</tr>
<tr>
<td>Seguro F.</td>
<td>PB 4.72-6</td>
</tr>
</tbody>
</table>
INDEX

Seidel H., PA 2.01-4, PB 4.57-3
Seidlerova J., PB 4.73-5
Seif H., PB 1.41-4
Seijkens T., AS 04.2, AS 04.3
Seinen C., OC 10.5
Seita I., OC 14.1, PB 2.54-5
Sek R., PB 2.50-6
Seki Y., PB 3.61-6
Sekarn P., PB 2.45-4
Selan C., OC 41.1, PB 3.50-5
Selby R., PB 2.46-2, PB 3.51-1
Seldon M., PB 4.30-2, SC20-2.07
Selegård R., PO 333
Seligsohn U., OC 05.5, OC 34.3, OC 77.1, PA 3.01-3, PA 3.14-3
Seljeflot I., AS 38.3, PB 1.21-5
Selmeczi A., OC 78.3, OC 90.3, PB 3.67-5
Selvaraj S.R., PA 2.12-1, PA 2.12-3
Semenova E.A., PB 2.50-1
Semeraro F., OC 84.5, OC 85.2, PB 2.72-1, PO 218
Semeraro N., PB 1.45-2
Sen D., AS 45.4
Sen V., PO 353
Senee H.K., PO 175
Senerchia A., PB 1.71-6
Senis Y.A., OC 35.5, OC 88.4
Seniuk A., PB 3.69-1
Senthong V., PO 089
Shabanlouei R., PB 4.38-6, PO 114
Shah A., PB 4.37-2
Shahani T., PA 1.13-5
Shahidi N., PA 3.11-1
Shahzad K., PB 3.28-5
Shaker M.J., PO 189
Shaker P., PO 189
Shams Hakimi C., PB 1.58-5
Shamsi T., PB 2.41-2, PB 3.41-2, PB 4.36-3, PO 050, PO 437
Shan S., OC 75.3
Shanbhag S.D., PB 4.74-4
Shang C., AS 09.3
Shankar J., PB 1.73-3, PO 480
Shanker J., PB 4.31-6, PB 4.32-1, PO 474, PO 475, PO 476, PO 477, PO 478
Shanley C., PB 1.72-2, PB 2.53-1, PO 064
Shao Z., OC 46.2, PB 4.59-4
Shao Y., PB 2.48-4
Shapira I., PO 223
Shapira M., PB 2.23-2
Shapiro B.P., OC 14.4
Shapiro N., AS 42.3, PA 3.15-6
Shapiro S.E., PB 1.44-2
Shapovalov K., PO 030, PO 031
Sharda A.V., AS 16.3, OC 54.3
Shareif L., PB 1.66-6, PB 4.66-2
Shariat-Madar Z., OC 01.2
Sharief L., PB 4.41-3, PB 4.42-4
Sharma A., OC 41.1, PB 3.50-5, PB 4.72-4, PB 4.31-1, PB 4.32-6, PO 471, PO 480, PO 181
Sharma M., PA 1.13-1, PA 1.19-2
Sharma S., PB 3.20-6, PB 3.70-1
Sharplies L., PB 4.52-3
Shavit J.A., OC 90.5
Shaw J., PO 397
Shaw R.L., PB 3.48-6
Shay M., PO 359
Shcherbina I., PB 1.52-3
Shearer M.J., PB 2.51-1
Sheehan J.P., OC 57.1
Sheena P., PB 1.32-4, PB 4.36-3, PO 387
Sheila B.M., AS 23.1
Sheiner T., PB 3.57-1
Shelast A., PO 408, PO 411, PO 412
Shemakina N., PO 414
Shemirani A.H., PA 4.15-3
Shen J., PA 4.01-1
INDEX

Shen M.C., PB 2.70-6, PB 3.58-6, PO 394
Shen W., PB 2.41-1
Shen Y., PA 3.12-2
Shendure J., OC 81.1
Shenkman B., PB 4.23-1, PB 4.23-6
Shepherd A.J., PB 1.55-1
Shepherd M., PA 3.11-5
Sheppard J.I., OC 81.1
Sheptovitsky V., PB 1.23-5
Shervinrad M., PB 4.42-5
Shestopal S.A., OC 28.3, PA 1.13-4
Shetty S.D., PB 1.42-2, PB 4.30-6, PB 4.74-1, PO 159
Shi J., PB 1.31-1
Shi K., OC 31.2, OC 31.6
Shi Q.K., AS 45.3, OC 28.1, OC 80.1, OC 89.1
Shi Z., PB 1.25-3
Shibata Y., PB 3.63-3
Shibeko A.M., PB 4.34-4, PB 4.74-1
Shichiri M., PB 4.32-5
Shicora A., OC 31.5
Shida Y., OC 15.2, OC 65.3, OC 91.4
Shiga T., PO 041
Shih M.F., PB 3.31-3
Shiller E., PO 171, PO 306
Shittagh N., AS 09.1
Shima M., OC 14.1, OC 14.3, OC 37.3, OC 37.6, PA 4.06-6, PB 1.35-5, PB 1.36-6, PB 3.55-1, PB 3.57-6, PB 3.65-6, PB 4.54-4, PO 218, PO 245
Shimatani Y., PB 1.46-4, PO 352
Shimada H., PA 4.05-6
Shimatani Y., PB 1.46-4, PB 2.46-6
Shimokariya Y., PB 2.46-5
Shimonaka M., PB 3.34-6
Shimura F., PB 4.59-6
Shin D., PB 4.21-3
Shin H.J., PB 4.38-5, PO 347
Shin S., OC 37.1, OC 56.5
Shin S., PB 4.21-3
Shin Y.S., PO 081
Shinozawa K., PA 1.08-6, PB 2.44-4, PB 2.54-5, PB 2.69-3
Shinozuka K., PB 4.59-6
Shinsuke Y., PB 1.62-1
Shiozaki S., PB 2.28-3, PB 3.27-5
Shirafuji N., PA 4.17-1
Shihara A., OC 37.6, PB 1.35-5, PO 116
Shirai M., PB 2.45-6
Shirai T., OC 25.3
Shirakawa R., PO 319
Shirasaki R., PA 4.17-1
Shiroma D., PB 1.55-3
Shi-Ki H., PB 3.43-5
Shimada H., PA 4.05-6
Shimatani Y., PB 1.46-4, PB 2.46-6
Shin D., PB 4.21-3
Shin S., OC 37.1, OC 56.5
Shin S., PB 4.21-3
Shin Y.S., PO 081
Shimerink B., PB 1.63-3, PB 4.64-3
Sieger G., PB 1.59-6, PO 045
Siegfried G., OC 86.4
Siegmund B., PB 3.52-1
Siegmund H.U., PB 3.45-4
Siemieniak D.R., OC 15.4, OC 47.1
Siffer S., PB 1.71-3
Siad M., OC 13.6, PO 010
Sigutter V., PB 3.39-3
Sigutova P., PO 043, PO 260
Siligur E., PB 4.22-4
Siligur J., PB 4.22-4
Sijbrands E., PO 487
Sijpksens M.K., PB 4.48-2
Sikorska A., PO 355
Silasi-Mansat R., OC 69.1
Silay H., PB 3.46-6
Siljander P.R.M., AS 14.1
Silva B., PB 3.52-5
Silva F., PO 479
Silva I.O., PB 4.32-4
Silva M., OC 39.5, PA 1.09-5, PO 153
Silva Pinto C., OC 52.4, PB 3.67-6
Silvati-Fidel L., PB 1.36-4
Silveria A., OC 30.4
Silveria J.R., AS 36.2, PA 4.14-1
Silveria J.N., PA 4.20-6, PB 4.32-4, PO 247
Silverman E.D., PB 3.62-1
Silvestre J.S., OC 40.2
Silvestre E., PB 1.67-2
Sim D., OC 28.2, OC 80.6, PB 1.55-3, PB 3.53-4
Simansour M., PA 3.05-5
Simonei U., OC 26.3
Simes D., OC 26.2
Simes J., PA 1.20-1
Simioni P., SC15-2.05, AS 29.1, AS 33.1, OC 50.1, OC 50.4, OC 85.2, PA 1.04-5, PA 3.13-1, PA 3.19-4, PB 1.72-6, PB 2.58-6, PB 2.72-1, PB 3.30-4, PB 3.35-6, PB 3.54-5, PB 3.54-5, PB 3.57-6, PB 3.65-6, PB 4.54-4, PO 218, PO 245
INDEX

Simo H., PB 4.28-1
Simon A.M., AS 39.2
Simon D.I., OC 01.1
Simon T., PB 1.28-6
Simoncini S., SC09-3.02
Simonova R., PB 4.65-5
Simpson M., AS 28.3
Simsekyilmaz S., PA 1.17-2
Simson S.G., PO 439
Sinauridze E., PB 2.53-3, PB 4.48-1, PB 1.40-3, PB 2.63-2, PB 4.68-5, PO 183
Singh A., PA 2.17-3, PA 4.09-4
Singh B., PA 1.19-2, PA 4.09-4
Singh R.J., OC 64.6
Singla A., PB 4.56-5
Singleton E., PB 1.43-4
Sinigoj P., PB 4.46-3
Sinito M.A., PB 2.34-6
Sinquett F.L., PB 1.52-2
Sinuff S., PA 2.19-1, PO 297
Siqueira L.H., PA 3.05-3, PB 2.55-2, PB 4.42-3
Sirachainan N., PB 2.50-3, PO 110
Siragusa S., PA 1.20-3, PB 2.39-6, PO 213, PO 214, PO 413
Siraneci R., PB 4.41-6
Siregar Y., PO 046
Sirikci A., PO 376
Sirireung S., PB 2.50-3
Sironi A., PB 1.49-1
Sirotkina O.V., PB 2.24-4, PB 4.25-7, PO 276
Sittlani C., OC 63.1, PA 4.18-3
Sitinin R.G., OC 01.2
Siva C., PB 4.53-3
Sivapalaratnam S., PB 3.71-4
Sivaprakasam P., PB 4.63-6
Sixt S.U., PA 3.13-5
Sjödin A., PB 2.59-6
Sjouke B., OC 88.3, PB 3.26-3
Skalicky S., PA 4.06-5, PB 3.33-6
Skelton S., PB 1.55-1
Skeppholm M., AS 02.3
Skerenova M., PB 2.54-4, PO 204
Skevis L.R., AS 38.4
Skipper M.T., PB 3.22-6
Skipskis V., PB 1.21-4
Skjeldstad F.E., PB 2.70-1
Skoda R., OC 89.6
Skogen B., SC04.3.1.6
Skornova I., PO 204
Skotnicki A.B., PB 3.42-4, PB 4.41-2
Skov J., PB 1.49-6, PB 1.59-2, PB 2.59-6
Skotnicki A.B., PB 3.42-4, PB 4.41-2
Slama H., PO 405
Slater B.C.S., PB 4.68-3
Slatter D.A., PB 2.50-5
Slavik L., PA 192, PO 338
Slechtova J., PA 4.18-3
Slawik L., PB 3.42-6, PB 4.44-5
Smith B.H., OC 04.6
Smith C., PB 1.65-6, PB 4.42-4
Smith D.A., OC 09.2
Smith E.A., OC 23.2, PO 091
Smith E.N., AS 11.3, PA 4.18-4
Smith G., PO 327
Smith K.A., PB 3.50-1, PB 4.57-2
Smith N., PB 3.45-1
Smith N.L.U., OC 30.5, OC 63.1, PA 4.18-3
Smith T.W., OC 78.1
Smock-Woodruff R.B.S., OC 16.4
Smolenski A., OC 45.3
Smith S., PA 4.01-3
Smidt E., PB 2.27-5, PB 4.23-5
Smits M., PA 3.13-5
Smits M.W.J., AS 40.3
Smiet M.J., PB 1.32-1
Smiley S.T., OC 75.4
Smirnova O., PB 4.30-1, PB 4.68-2, PO 456
Smith E.A., PB 1.32-1
Smith B.H., OC 04.6
Sobczynska-Malefora A., PO 467
Soboleva N., PO 384
Sobu E., PB 3.68-3
Soderblom L., AS 02.3, PB 1.28-6, PO 085
Sodergren A.L., PB 1.22-6
Sodhi V., PO 350
Sodea T., OC 14.3
Soejima K., PA 4.06-6
Sofi F., PB 2.29-1, PB 2.29-2
Sohn C., PO 354
Soheir S., PA 1.14-3, PA 4.15-6
Sokol E., PA 1.13-5
Soker M., PO 294, PO 353
Sokol J., PB 2.54-4, PB 4.65-5, PO 204, PO 243
Sokolikova B., OC 73.4, PB 4.50-1
Sokolov A., AS 47.5
Sokolova L., PB 1.52-3
Solano M.H., PO 406
Solati S., OC 08.3
Soldatenkov V., PA 3.11-2, PB 1.52-5, PB 2.69-5
Soldati M., PO 111
Soleckova B.A., PB 2.43-3, PB 3.44-2
Soler G., PB 3.52-4
Stavrou E., OC 01.1, OC 26.1, OC 53.4
Stayrook S., OC 68.1
Stearns-Kurosawa D.J., AS 47.3
Steele McG., PA 1.09-5
Steen Carlsson K., PB 2.38-5
Stefanelli B., PA 4.19-5
Stefanini L., AS 27.1, OC 24.2, OC 76.3
Stefanska-Windyga E., PB 4.74-5
Stegeman B.H., OC 12.6
Stegner D., AS 16.2, OC 10.6, OC 58.4, OC 86.6, PO-495
Steidl L., PB 1.64-3, PB 3.70-6
Steiger D., PA 4.11-4
Steil L., PB 3.24-2
Steindl J., PA 3.08-1, PB 4.40-1
Steiner T., OC 32.2
Steiner S., AS 47.1
Steinitz K.N., OC 56.6
Stemmelin G., PB 1.72-2, PB 2.53-1, PO 064
Stenmo C., PB 4.52-4
Stenning D.J., OC 62.6
Stenin-Durand A., PB 1.66-5
Stinson J.N., PO 106
Stittelaar K., OC 69.4
Stivala S., PA 1.01-6, PB 4.28-4
St-Louis J., PB 1.58-4
Stockley J., OC 34.2, OC 39.6, OC 62.6
Stockschläder M., PB 2.37-5
Stoffler C.R.N., AS 06.2
Stoffers J.I., OC 20.3
Stoilova-McPhie S., OC 28.6, PA 4.13-2
Stokhuijzen E., FS 02.3
Stoldt V.R., PB 1.23-4, PB 4.23-2, PO 403
Stoll G., AS 16.2, AS 30.2, OC 10.6, OC 86.1, PA 1.10-2, PA 4.04-1, PO-495
Stoll M., PB 1.68-1
Stolla M., PB 3.32-4
Stone J.C., OC 76.3
Stoof C.M., AS 32.3, OC 48.1
Stoja J.D., OC 64.2
Stopyra-Pach K., PA 3.06-3
Storey R.F., OC 32.2, PA 4.01-3, PA 4.03-5, PB 1.21-1, PB 3.21-1
Storton S., PB 2.63-5
Stott D.J., OC 64.2
Stow R., PB 1.55-2
Strachan M., PA 3.12-3, PB 3.59-1
Strambovskaya N., PO 340
Stramezzi M., PB 2.66-4
Strandberg K., PA 1.36-2
Strassel C., OC 89.6, PA 2.04-6, PB 1.29-6, PB 3.29-2
Strasser F., PO 323
Strathmann K., PB 4.57-3
Staub A., OC 94.9
Stravitz T.R., PB 2.33-5
Strawbridge R.J., OC 30.4
Streif W., PO 370
Strengers W.F., PB 3.47-6
Streva A., PA 2.07-3
Strickland S., AS 24, PB 4.49-1
Strijkers H.W., PB 2.64-4, PO 241
Stringer K.M., AS 36.2
Stritt S., OC 33.2, OC 88.1
Strong J., PB 1.64-1
Stroo I., OC 05.3
Stroobants A., PO 321
Stroobants A.K., PO 311
Strowitzki T., PO 354
Strubbe E.B., PA 1.13-4
Struijk-Mulder M.C., PA 3.10-1
Strukova S., PB 4.67-5, PO 228
Stuchin S., PA 4.11-4
Stucky G.D., PA 3.14-1
Stufano F., OC 13.5, PB 2.39-4, PB 2.43-6, PB 4.43-4
Stuleva N., PB 205, PO 208
Sturek M., PB 3.64-3
Sturk A., AS 14.2, OC 72.2, PA 3.04-1, PB 3.30-1, PB 3.30-2, PB 4.30-4
Sturkenboom M.C.J.M., PA 1.10-3
Su J., PA 4.19-4, PO 088, PO 422
Su K.H., PB 1.67-5
Suades R., PA 1.04-3
Subramaniam S., OC 84.4
Subramanian H., PA 3.03-3
Subrt I., PB 4.73-5
Suchindran S., PB 2.71-3
Suchon P., OC 90.1
Sudana I., PB 3.74-5
Sudo A., PB 2.66-5
Sudo T., PB 4.21-5
Sudoyo A.W., PB 3.50-3
Suffritti C., PA 3.15-2
Suganuma L.M., PB 4.72-6
Sugidachi A., PB 2.21-1, PO 337
Sugimoto M., PA 4.06-6
Sugita C., PB 1.73-1, PB 3.55-1
Sugita N., PO 335
Sugiyama K., PO 070
Sugiyama M., PB 3.54-1
Suh J., PO 139
Suisse S., PB 1.65-2, PB 4.47-1
Sukhanov V., PO 274
Sukhishvili S., PA 3.17-6
Sullenger B.A., OC 16.4, PB 4.49-3
Sultan C., AS 39.1
Sulzer I., PA 4.06-1
Sumarokov A.B., PO 310
Sumi H., PO 404, PO 458
INDEX

Sun J., OC 70.3, PO 166
Sun L., PB 2.72-3
Sun M.F., OC 18.4
Sun Z., PB 3.33-5, PB 3.71-5, PO 086, PO 422
Sun Ah L., PO 120
Sundström A., OC 30.4
Šuput-Tomaš L., PO 269
Suriu C., PO 359
Surow S., PB 2.50-1, PB 2.51-6, PB 2.53-5, PB 4.54-3
Suryaatmadja M., PB 2.30-2
Suryanarayan D., PB 4.44-6
Susen S., OC 38.5, OC 38.6, OC 61.6, PA 1.09-2, PA 3.18-1, PA 4.09-1, PB 4.32-2
Suske G., PA 2.04-5
Sutcharitchan P., PB 4.56-4
Suvajdzic N., PB 4.61-5, PO 005, PO 346
Suvajdzic-Vukovic N., PA 4.07-3
Suwanawiboon B., PA 3.13-6, PB 1.42-3
Suzuki A., PA 1.18-4
Suzuki A., OC 78.4, PA 2.13-5, PB 3.67-1, PB 4.58-4
Suzuki E., FS 03.3, PB 2.67-2, PB 4.67-2
Suzuki H., OC 86.3, PO 352
Suzuki K., PA 1.58-2, PB 3.58-4
Suzuki N., PB 1.74-2, PB 3.35-2, PB 4.44-4, PB 4.69-5
Suzuki T., PA 1.08-6, PB 1.37-6, PB 2.69-3, PO 167
Suzuki Y., PA 1.50-2, PB 4.33-2
Suzuki-Inoue K., OC 25.3, PA 3.02-5, PB 2.23-6, PO 246
Swartberg J., AS 43.1, PB 1.70-1
Svensson A., PA 2.14-4
Svenungsson E., PA 1.18-3
Svetlikov A., PB 1.73-5, PB 4.56-2
Swirin P., PO 171, PO 222, PO 306
Svobodova G., PO 192
Swadzba J., PB 2.62-1, PB 3.62-3
Swanson K.S., PB 3.30-5
Swaroop A., OC 90.5
Światkowska M., PB 1.31-5
Świeringa F., OC 24.3, OC 87.2, PA 3.02-2, PA 4.20-1, PB 1.22-3
Świerko A.S., PB 1.62-5
Świstek W., PB 3.60-5
Śwystun L., OC 05.6, OC 85.5, PA 2.15-3
Syed D., PB 1.40-2, PB 2.47-1, PB 3.56.6, PB 4.48-6, PB 4.68-5, PO 183
Sylman J.L., PA 4.20-2
Szabo A., OC 32.6, PB 1.32-2, PB 1.32-5, PO 470
Szabó L., AS 01.2, AS 23.3, AS 30.1
Szczepanski T., PB 1.36-5
Szederjesi A, PB 4.55-3
Szegedi I., PO 433
Székely E., PA 3.06-1
Szekeres-Csiki K., PB 3.44-6
Szelid Z., AS 01.2
Széll M., PB 2.66-3, PB 4.28-3
Szigeti R., PB 3.68-5
Szkotak A., PB 2.51-2, PO 194
Szlam F., PB 3.59-5
Szumowska A., PO 252
Tabataebei M.R., PO 344
Tabataebei S.M.R., PO 293
Tabibian S., PB 1.67-4
Tachibana S., PB 1.46-2
Tadashi S., PA 2.02-5
Tadaouï D., PB 217
Tadokoro K., PB 1.28-1
Tafur A.J., PB 1.46-6
Tagalakis V., PB 1.65-2, PB 2.64-6, PB 4.47-1
Tagariello G., OC 70.4
Taglialeri A., PA 1.13-2, PB 3.35-1
Taguchi O., PO 231, PO 232
Tagzirot M., PA 3.18-1
Tailhefer H., PB 1.39-5
Tainer J., PA 4.13-1
Tait C., PA 2.20-2
Tait R.C., SC06-3.02, PB 1.51-5
Takada A., PO 006, PO 007
Takafuta T., PB 1.33-1
Takagi A., OC 78.4, PA 2.13-5, PA 3.05-2, PB 3.67-1, PB 4.58-4
Takagi S., PB 2.28-3
Takagi T., PO 231, PO 232
Takagi Y., OC 78.4, PA 2.13-5, PB 3.67-1, PB 4.58-4
Takahashi S., PB 2.45-6
Takamatsu J., OC 37.6
Takata Y., PB 2.50-6
Takatsu M., PB 4.44-4
Takaya H., PB 1.33-5, PB 2.33-4
Takayama S., PB 1.61-1, PB 4.69-5
Takayesu J.K., OC 71.3
Takeda M., OC 14.3, PA 4.06-6
Takedani H., PB 4.39-3
Takeshima C., PB 1.31-4
Taki M., PB 1.35-5, PB 1.61-1, PB 4.69-5, PO 116
Talagrand E., PB 2.35-1
Talarmain P., OC 13.2
Talks K., PB 2.35-6
Talmon M., AS 45.2
Telpos-Niculescu S., PO 165
Tamaki N., PB 1.73-1
Tamamyan G., PO 051
Tamareille S., PB 1.49-3
Tamborini Permunian E., PB 1.46-6
Tambunan K.L., PO 046
Tamburrelli C., PB 3.66-4
Tamigniau A., PB 1.20-4, PB 2.71-5, PB 4.70-2
Tan C.W., PB 2.23-4
Tan H., PB 1.45-1, PB 4.45-2
Tan M., SC11-2.01, OC 20.2, PA 1.20-4, PB 2.71-5, PB 4.70-2
INDEX

Tan J.Y.L., PB 3.50-6
Tan X., OC 83.4
Tanaka A., PO 236, PB 4.33-2
Tanaka R., PB 1.33-1, PB 1.33-2, PB 4.44-4
Tanaka T., PB 1.29-4
Tandeitinik L.S., PB 3.64-5
Tang L., PA 2.11-5, PB 1.55-3
Tang N., PA 4.11-3
Tang R., PA 2.16-6
Tang X., PA 4.01-4
Tangada S., PB 2.58-5, PB 4.58-6
Tange I., PB 1.54-4
Tani M., PA 3.18-5
Taniguchi E., PB 1.53-2
Tantipanichteerakul K., PO 089
Tantry U.S., PB 2.21-4, PB 4.56-5
Tanzi F., PB 1.29-1
Tao M.H., OC 57.2
Tarandovskiy I.D., PB 2.53-3
Taranenko I.A., PB 4.54-3
Tarantino E., PA 2.15-5, PA 3.12-1, PB 3.29-5
Tarantino G., PO 213
Taraskina A., PB 2.24-4
Tarbes M., PO 465
Tardy B., OC 66.2, PA 4.16-3, PB 1.48-6
Tardy-Poncet B., OC 66.2, PB 1.48-6
Tarek O., PO 440
Tarique S., PO 437
Tarkovskaja L., PA 4.01-2
Tarnutzer A., AS 44.2
Tartari C.J., PB 1.22-5, PB 3.22-5
Taylor A., OC 52.1
Taylor B., OC 69.1
Taylor F., PA 4.07-4
Taylor J.E, PB 3.70-1
Taylor K., OC 30.5
Taylor K.A., PA 4.02-5
Taylor L., OC 09.1
Taylor P., PB 4.34-5
Tazarourte K., OC 4.01-2
Tazarovski S.N., PB 2.66-5, PB 4.66-6
Tcherniantchouk O., PB 4.40-4, PB 4.40-5
Teague L., PB 3.29-3
Teillet , PB 3.27-4
Teinturier C., AS 18.2
Teitel J., PB 1.37-3
Teitel J., PO 168
Teixeira-Carvalho A., PB 4.65-2
Te-Kau C., PO 225
Teliga-Czajkowska J.H., PO 355
Telma G., PA 2.20-6, PB 1.72-3
Tembl J., PB 2.30-6
Temin E., OC 71.3
Temperilli F., PB 3.71-1, PO 455
Templin C., PB 3.42-3
Ten Berg J.M., PA 2.17-6, PB 1.63-2, PO 450
Ten Brinke A., OC 21.4, OC 80.3
Ten Cate-Hoek A.J., AS 33.2, OC 20.3, PA 1.10-1, PA 2.11-1, PA 3.20-4, PB 1.51-1, PB 2.56-4, PB 2.64-4, PB 3.26-4, PB 3.46-5, PO 374
Ten Wolde M., PA 3.20-4, PO 374
Tencati M., AS 46.1
Tenekedijev K., AS 01.2, PB 3.34-1
Tentsova I., PO 384
Teoman S., PB 4.37-4
Teraa M., PO 318, PO 341
Terada C., PA 1.28-1
Teramura G., PA 1.09-4
Terentjeva V., PA 3.15-5
Tereshkov P., PO 369
Ternisien C., OC 13.2, PO 010
Terrisse A.D., PA 2.03-1
Tersteeg C., AS 40.3, OC 10.5, PA 4.03-4
Teruel R., OC 05.4, OC 08.1
Teruya J., PB 1.42-4, PB 3.43-5, PB 3.68-5, PO 305
Teruzzi G., PB 2.27-1
Terzian C.N., PB 1.71-6
Tesija Kuna A., PB 3.62-5
Teske G., AS 31.3
Tesselaar E.T., OC 17.4
Tessitore E., PB 1.40-6
Testa S., OC 12.4, OC 42.2, OC 42.3, PB 1.47-5, PB 1.54-3, PB 1.66-1, PB 2.49-1, PB 2.49-3, PB 2.53-2, PB 2.53-4, PB 2.71-1, PO 267, PO 268
Tetley T.D., PB 2.27-5
Tetley T.D., PB 4.23-5
Tetsu K., PO 231, PO 232
Tetsuya H., PA 1.62-1
Teunissen P.F.A., PA 4.06-4
Tezel A., PA 1.11-3
Thabane L., PO 148
Thachit J., SC19-3.01, PB 2.54-3
Thalassinos K., AS 09.1
Thaler J., PA 3.04-5, PB 3.60-2
Thalji N., OC 36.4
Thangrod R., PO 076
Thapa B.R., PB 2.70-2
Thati M., AS 37.3
INDEX

Thawadi H., PA 1.19-1, PA 2.16-6
Theinert K., AS 20.3
Thelwell C., SC20-2.01, SC05-2.05, OC 29.5
Theophilus B.D., PA 1.09-3
Thermann H., PB 3.46-6
Théroux P., PB 3.66-1
Therwath A., PA 1.19-1, PA 2.16-6
Theuwissen E., OC 26.2
Thibeault L., PO 153
Thiele T., PB 2.40-6, PB 3.24-2
Thielmann I., AS 16.2, OC 33.2, OC 58.4, OC 84.4, OC 88.6, PA 1.10-6, PA 2.02-2, PO 495
Thijs T., PB 1.29-2
Thom J., PB 1.33-3
Thomas A.S., PA 3.14-5
Thomas B., PO 193
Thomas C.S., OC 14.4
Thomas D., PB 1.53-1
Thomas S., PA 2.07-3
Thomassen C.L.G.D., PB 2.66-5, PB 4.66-6
Thomassen L.G.D., OC 23.3, OC 73.3, PA 1.15-1
Thomassen S., AS 41.2, OC 73.1
Thomassen S.T., PB 1.35-1
Thompson C., PB 3.38-6
Thompson H., PA 1.16-1
Thompson T., OC 28.2, PA 4.13-4
Thomson E., PO 264
Thon J., SC18-1.02, PA 2.04-4, PB 1.29-3
Thorn K., OC 80.2
Thornton D., PB 1.64-1
Thornton C.A., PB 3.26-2
Thornton S.N., PA 2.17-2, PB 4.64-1
Thurlow P., PB 1.41-2
Thygesen P., PB 1.55-2
Thymianos S., PB 2.69-6
Thys C., OC 34.1
Thys F., OC 20.4
Tian J., PB 1.24-5, PB 1.25-3
Tiboni M., PB 3.46-3
Tichelaar Y.I., PB 4.68-1
Tidwell R., PB 3.46-4
Tie J.K., OC 44.1
Tie K., OC 44.1
Tiede A., PB 2.36-3, PB 4.55-5, PO 130, SP505-03
Tiede C., PB 2.59-2
Tieken C., AS 46.3, PB 3.56-4
Tikhilov R.M., PO 256
Tille J-C., PA 4.20-3
Tilley O., OC 45.3
Tilley T., PB 1.23-1, PB 2.28-2
Tim J.R.R., PB 3.64-5
Timova T., PO 092, PO 237
Timp J.J., OC 12.6, OC 04.2
Timur A.A., PA 2.05-2, PB 4.27-2
Tindall M., PO 362
Tinholt M., PA 3.16-3, PB 3.60-1
Tipp S., PA 1.07-6, PA 3.07-1
Tirado I., PB 1.72-1, PB 3.54-2, PB 3.63-1
Tiraferrer E., OC 42.2
Tisch G., AS 29.3, PA 3.17-1, PO 201
Titaeva E., PB 4.73-4
Tittl L., PA 3.19-2, PB 3.26-6
Tizzano E., PO 118
Tjahyono Y., OC 91.3
Tjännfjord G.E., AS 40.4, OC 66.3, PB 3.41-4, PB 4.35-3, PO 170
Tlili A., PB 3.28-2
Toby G., OC 80.2
Toda M., PO 232
Todd B.L., PA 4.14-1
Todoli J., PB 1.30-1
Todorovic Z., PB 2.21-6
Toft I., PB 2.70-3
Toh C.H., SC19-3.04, OC 19.1, PB 1.40-4
Toh J.M.H., PB 3.57-3
Tohit E.R., PO 336
Tokgoz H., PO 351
Tokudome S., PO 458
Tolley K., PA 2.06-1
Tolley N.D., OC 46.3
Tolstov K., PO 222
Tomaiuolo M., PB 3.26-5
Tomberg K., OC 47.1
Tomita A., PB 3.27-5
Tomiyama Y., SC04.2-1.3, PA 4.05-6
Tomizawa A., PB 2.21-1, PO 337
Tomkowsi W.Z., PB 2.47-2
Tomlinson D., PB 2.59-2
Tomlinson M.G., SC07-1.02, AS 27.2, AS 39.1, OC 88.2, OC 88.5
Tomohide T., PA 1.64-6
Tona F., PB 4.64-6
Tonello M., PB 2.62-2
Tong C.H., AS 18.1
Tönnsmägi K., PB 4.22-4
Tooge G., PB 1.50-6, PO 481
Topolev I., PO 369
Topuzov A., PO 219
Tormene D., AS 19.2, PA 4.18-5, PB 2.72-1, PB 3.65-6, PO 218
Tormoen G.W., PB 4.25-5
Tornaritis M., PA 3.06-6
Torres C., PB 2.31-1
Torres I., PB 2.56-6, PO 199
Tortella B., NS 01.1
Torti M., OC 35.4, OC 87.2
Tosetto A., SC01-3.01, SC 18-3.01, SOA 01.2, PB 2.41-3, PB 2.71-1, PA 3.70-3, PB 4.43-2, PB 4.69-1
Toshiya H., PA 2.02-5
Toshiyuki B., PB 1.62-1
Toshiyuki W., PB 1.62-1
Tosi F., AS 26.2, PA 1.11-1
Toth O., PB 1.44-6
Toth P., PB 4.56-5
Tóth L., PB 3.59-6
Toti F., SC07-1.01, OC 72.1, PA 1.04-2, PA 1.04-6
Touhami F., PO 055
Touhami H., PO 378
Toukh M., PA 4.04-3
Toulon P.A., OC 81.2
Tournoya A., OC 61.6
Tovar–Lopez F.J., PA 4.03-3
Traby K., PO 459
Tracy P.B., AS 36.2, PA 3.12-5, PA 4.14-1
INDEX

Traina F., PA 1.17-5
Tran H., PB 1.48-2, PB 1.64-4
Tran H.T.T., OC 66.3, PB 3.41-4, PB 4.35-3, PO 170
Tran K., OC 28.2, PA 4.13-4, PB 1.55-3
Tran Q., PO 169
Tran S., AS 36.1
Tran Z.V., PB 4.70-4
Tranhholm M., OC 44.2, PA 4.13-3, PB 2.44-3, PO 289
Traore A.N., PB 1.58-4
Tratar G., PB 4.46-3
Travers R.J., PB 3.59-2
Traverso J., PB 1.62-3
Tregouet D.A., AS 11.1, OC 62.1, OC 90.1, PA 4.18-1
Trehan A., PO 175
Trela R., PB 1.63-1
Trelinski J., PB 1.27-4
Trelle S., PB 4.51-3
Tremey B., OC 36.1
Tremoli E., OC 72.4, PA 2.15-5, PA 3.12-1, PB 2.27-1, PB 3.29-5, PB 3.32-2, PO 447
Trento T.H., PA 2.07-3
Tricarico A., PB 2.64-2
Tricoci P., PA 4.01-3
Trip M., PB 3.71-4
Tripodi A., PA 4.11-6, PB 2.71-1, PB 4.30-3, PB 4.51-1, PO 254
Triscott M., PB 4.46-4
Trisolini S., PA 4.19-2
Trobo S., PB 2.53-1
Trocilii K., PB 2.38-3
Tromeur C., AS 43.2
Tropiano F., AS 34.1
Tros W., PA 3.04-1
Trossaërt M., OC 48.3, PA 3.14-4, PO 010
Troyer J.L., AS 42.3
Troyer M., PO 187
Trujillo-Santos J., OC 42.1
Trummal K., PB 4.22-4
Trung N.C., PB 3.43-5
Tsai I.H., SC 20.2-6, PB 3.59-4
Tsai M.L., PB 3.31-3
Tsai-Hsiu Y., PO 466
Tsakiris D., PO 158
Tsaoisidou M., PB 2.69-6
Tseneklidou-Stoeter D., PB 4.37-2
Tseng C.P., FS 03.4, PA 1.03-1
Tseng W-L., FS 03.4
Tsim M., PB 1.22-3
Tsimaratos M., PB 4.29-3
Tsonar-Rosenthal I., PB 1.30-4
Tsuchiya R., PB 1.28-5
Tsuda H., SC 12-3.02, PB 2.59-5
Tsuda T., PO 070
Tsuruta K., PA 4.17-2, PA 4.17-3
Tsutakawa S., PA 4.13-1
Tsuyoshi C., PB 1.67-4
Tsvetavae N., PB 3.52-2
Tsybikov N., PA 1.19-6
Tsyrendorzhieva V., PO 483
Tuana G., PB 3.50-5, PB 1.33-6, PB 2.25-5
Tucker E., SC 21-3.01, AS 07.3, AS 13.3, AS 25.2, OC 05.2, OC 46.4, OC 64.1, OC 81.4, PB 4.59-2
Tucker K.L., PB 1.23-3
Tucunduva A., OC 81.5
Tuddenham G.D., AS 09.1, PB 1.66-7
Tueckmantel C., PB 3.35-3, PO 150
Tufano A., PB 3.67-2
Tugcu D., PB 4.41-6, PB 4.71-1, PO 098
Tulloh R., PA 2.11-4
Tumino R., OC 04.1, OC 07.6, PA 3.06-4, PB 1.56-6
Tune J.D., PB 3.64-3
Tuńon J., PB 3.45-2
Tunstall O., PB 4.63-6
Turakulov R., OC 89.5
Turani S.A.D., PO 230
Turato S., PA 2.20-4, PB 1.61-2, PB 2.61-1, PB 3.70-6
Turecek P.L., PA 1.12-5, PA 2.10-5, PB 4.06-5, PB 2.33-1, PB 3.35-6, PB 3.55-6, PB 4.35-2, PB 4.48-3, PO 060, PO 061, PO 146
Turhan A.B., PB 1.34-3
Turitto V., SC 14-2.02
Turley E., PO 194
Turnbull E., PB 2.26-3, PB 3.71-4, PB 3.71-6
Turner K., AS 46.4
Turner K.C., PA 2.10-2, PA 3.10-5
Turner K., AS 46.4
Turpie A.G., OC 79.6, SAS 02-04
Turpin S., OC 86.4
Tuttle A.M., OC 39.5, PA 1.09-5, PO 153
Tuysuz B., PO 399
Tuysuz G., PB 1.34-3, PB 1.35-4, PB 3.68-3, PO 331, PO 399
Twint D., OC 82.5
Tyagi A., PB 1.28-2
Tzeng C.H., PB 1.67-5
Tziarou E., PB 2.34-5
Tzschach A., PA 4.05-5
Tzu-Yuan C., PA 2.14-4
Uaprasert N., PB 4.56-4, PO 027
Uchitel I.A., PB 2.68-4, PO 310
Uchiyama S., PO 041
Udali S., PA 1.11-1
Udokmiate P., PB 1.42-3
Udvardy M.L., PB 3.44-6, PO 433
Ueland T., OC 66.3, PB 4.35-3
Uemura M., PB 1.33-5, PB 2.33-4
Ueshima S., PA 1.06-2, PA 3.18-2, PA 3.18-5
Uetsuka Y., PB 1.46-4, PB 2.46-6
Uhl C.B., PB 1.25-6
Uhr E., SC 18-3.05
Uitte de Willige S., AS 24.3, AS 29.1, PA 3.06-5, PB 1.34-1, PO 093
Ujelly C., PB 4.51-5
Uji-i H., OC 15.1
UK, OC 34.2
Ulander V.M., PB 3.70-4
Ulehlova J., PO 192, PO 338
Ulger Z., PO 500
Ullmann A., OC 34.2
Ulrich N., OC 51.3
Ulrichts H., PB 3.43-4
Uluçay C., PB 253
INDEX

Umegaki K., PB 4.59-6
Umemura K., PA 3.02-5
Umemura T., PO 080
Umit E., PA 1.11-3
Undas A., AS 08.3, PA 1.14-4, PA 1.16-3, PA 3.06-3, PB 1.63-1, PB 4.41-2
Underwood M., PB 4.19-6, PB 2.33-2
Ung A., OC 38.6, PA 3.18-1, PA 4.09-1
Ung S., OC 14.4
Unruh D., AS 46.4
Unuvar A., PB 3.50-4, PB 3.51-2
Unuvar E., PB 3.51-2
Unverzagt F., PA 4.18-6
Upadhyay A., OC 09.6
Uppugunduri S., PB 2.49-6
Uprichard J.N., PB 1.74-3, PB 2.44-2, PB 2.54-1, PO 318
Urano T., PB 1.50-2, PB 4.33-2
Urbanus R.T., OC 27.3, OC 27.4, OC 45.1, OC 55.4, PA 2.08-4, PA 4.03-4, PB 3.44-5, PO 318
Urhan G., PB 4.36-6
Uribe-Lezama C., PA 199
Uribe-Lezama E.C., PB 2.56-6
Urnowa E.S., PB 2.53-3
Usman N., PO 350
Usnarska-Zubkiewicz L., PA 1.16-3
Ustundag A., PA 1.11-3
Utida-Sato H., OC 25.3
Utne K.K., PB 2.50-4, PO 375
Uysal S., PB 3.68-3
Uysalol E., PB 3.51-2
Üzel H., PO 353
Vaast B., OC 38.6, PB 1.27-2
Vaccarella G., PB 2.39-6, PO 213, PO 413
Vaclavik J., PO 338
Vad K., PO 058
Vadasz B., OC 55.2
Vaezzadeh N., AS 16.1, PB 4.21-1
Vahedi Nikbakht M., PB 2.44-1
Vaidyanathan S., PA 2.10-2, PA 3.10-5
Vainchenker W., OC 58.5, PA 1.03-3
Vaiyapuri S., AS 39.2, PA 2.02-3, PA 4.02-3, PB 3.23-4
Valdes R., PO 268
Valdés M., OC 79.5, PA 1.11-6
Valdrè L., PA 1.13-2, PB 2.71-6, PB 3.64-6
Valencia G., PO 161
Valencia R., PB 3.25-4
Valente G., PA 1.13-6
Valente S., PB 2.22-4
Valentijn K.M., OC 13.3, OC 91.1, OC 91.6, PB 3.43-3
Valentin P., PB 2.40-2
Valentina D., PA 2.13-4
Valenzuela V., PB 4.70-5
Valeri F., PB 3.35-3
Valero-Nuñez M., PO 016, PO 275
Valenska-Zubkiewicz L., PA 1.16-3
Vandezende D., PB 3.26-1, PB 3.48-3, PO 321
Van de Kerkhof D., PB 3.26-1, PB 3.48-3, PO 321
Van de Laar A., PB 1.69-2
Van de Peppel R., PB 1.63-5
Van der Poel M.A., PB 2.68-1
Van de Riet I., PB 3.47-2
Van de Sande A.J.P., AS 33.2
Van den Vijver E., PO 329
Van den Vijver P., OC 67.2
Van Delden J.M., PA 4.16-1, PA 4.16-4
Van den Akker M., PA 4.03-6
Van den Bemt P., PA 1.10-3
Van den Berg A., PB 1.46-5
Van den Berg H.M., OC 03.4, OC 51.1, PA 4.07-1, PB 4.36-1
Van den Berg T.K.T., PA 2.09-3, PO 329
Van den Berg Y.W., AS 46.3
Van den Berg M., SC01-4.04, OC 54.1, OC 57.5, OC 57.6
Van den Boogaard E., PB 1.67-3
Van den Boogaard F., PA 1.19-4
Van den Born B.J., PA 4.06-4
Van den Bos C., FS 02.3
Van den Bosch M.T.J., OC 10.4, OC 87.5
Van den Brand J.M.A., OC 69.4
Van den Ham R., OC 59.4
Van den Herik E.G., PB 2.43-5
Van den Heuvel D., PB 3.48-3
Van den Heuvel D.J., OC 45.1, OC 55.4
Van den Hout M., PB 2.04-1
Van den Vijver P., PB 3.54-4
Van der Aa N., PA 4.05-5
Van der Bijl N., PB 2.65-6
Van der Bom J.G., AS 22, AS 22.1, OC 03.3, OC 13.1, OC 56.3, OC 66.4, PA 2.08-3, PB 1.42-1, PB 2.74.5, PO 358
Van der Flier A., OC 56.4, PA 4.13-6
Van der Gaag K.J., AS 11.2
Van der Graaf V., PB 2.22-1
Van der Harst P., AS 47.6, PA 2.04-2
Van der Holt B., PA 1.16-2
INDEX

Van der Hulle T., OC 71.2, PB 2.65-3
Van der Lugt A., PA 2.09-1, PB 2.43-5
Van der Meer J., PA 1.19-4
Van der Meer F.J.M., OC 42.4, PB 2.65-3, PA 3.20-1, PB 3.40-4, PB 3.47-2, PB 4.36-6, PB 4.46-2
Van der Pol E., SC07-4.01, AS 14.2
Van der Poll T., AS 44, OC 05.3, OC 08.4, PA 1.19-3, PA 1.19-4, PB 1.67-3, PB 2.28-1, PB 2.68-1, PB 3.66-3, PB 4.67-1
Van der Salm K., PB 2.48-2
Van der Schoot E., AS 47.6
Van der Sluijs K.F., PB 2.68-1
Van der Sluis R.J., PB 1.32-1, PB 4.29-6
Van der Starre E., OC 17.4
Van der Stoep M., PB 1.32-1, PB 3.26-3, PB 4.29-6
Van der Stokker A., PB 3.26-1, PO 321
Van der Straaten T., OC 55.2, OC 55.4, OC 76.1
Van der Werf T.S., PB 4.68-1
Van der Zwaan C., OC 57.6, PA 4.06-2
Van Deursen C., AS 33.2
Van Dielen F.M.A., PB 1.69-2
Van Dijk A.C., PB 2.43-5
Van Dijk J., PB 2.51-4
Van Dissen T., OC 17.4
Van Dooremalen S., OC 53.2
Van Doormaal F., PB 1.30-2
Van Dreden P., PA 4.12-1, PB 1.59-1, PB 4.63-5
Van Duren C., PB 2.42-5
Van Eck M., OC 88.3, PB 1.32-1, PB 2.51-4, PB 3.26-3, PB 4.29-6
Van Eeuwijk J.M.M., OC 58.4
Van Es J., OC 12.2, OC 71.1, OC 71.2, OC 71.4, PA 1.20-2, PB 2.65-1
Van Eyk N., PA 3.17-5
Van Galen K.P.M., PA 2.08-3, PB 1.35-3
Van Geet C., OC 34.1, OC 62.3, PA 4.05-5
Van Gorp E.C.M., OC 69.4
Van Haagen C., OC 69.4
Van Haesebroeck B., PA 2.08-3
Van Geet C., OC 34.1, OC 62.3, PA 4.05-5
Van Haren B., PA 1.42-5
Van Haren J., PB 2.51-4
Van Herrewegen F., PB 3.69-6
Van Hessem L., AS 07.2
Van Hest R., PB 3.47-1
Van Holten T.C., OC 27.3, PB 2.24-3, PB 3.24-6, PO 318
Van Hooren W.E.M., AS 37.2
Van Hoorn M., PA 3.17-4
Van Hylckama Vlieg A., SC05-2.10, AS 22.1, AS 38, PA 2.08-4, PB 1.42-5, PB 2.36-1, PB 2.42-5, PB 4.74-6
Van IJcken W., PA 2.04-1
Van Knijff J., PB 1.67-3
Van Kruithof K., PA 1.67-3
Van Langevelde K., PA 3.04-1
Van Leuven K., OC 81.3, PA 1.45-5, PB 2.54-6
Van Lierop M.J., PO 187, PO 324
Van Loon J.E., OC 69.4
Van Marle J., OC 72.2
Van Mierlo G.J., OC 81.3, PB 1.45-5, PB 2.54-6
Van Nosel C.J.M., OC 81.3, PB 1.45-5, PB 2.54-6
Van Oerle R., AS 33.3, PA 2.17-6, PB 1.38-2, PB 3.26-4, PB 4.49-4, PO 322, PO 339
Van Ommen C.H., PB 2.61-6
Van Ommen H.C., FS 02.3, PB 3.18-4, PB 3.69-6, PO 141
Van Ooijen H.J., OC 59.4
Van Pampus M.G., PA 3.17-4
Van Rees Vellinga T.F.D., PB 4.70-2
Van Ren R., OC 42.4, PB 4.46-2
Van Rooy E., PO 366
Van Rossum A.P., PB 3.47-6
Van Royen N., PA 4.06-4
Van Ryn J., AS 10.3, OC 31.5, OC 36.2, PB 1.45-6, PB 1.47-4, PB 2.68-3, PB 4.45-3
Van Schagen M., PA 1.18-5
Van Schalkwijk C.G., PA 2.20-4
Van Sluis G.L., AS 34.3, OC 31.4
Van Steenenbergen H.W., AS 32.3
Van Straten B., PB 3.26-1
Van ’t Veer C., OC 05.3, OC 08.4, PA 1.19-3, PA 1.19-4, PB 1.67-3, PB 2.28-1, PB 2.68-1, PB 3.66-3, PB 4.67-1
Van Thoor L., PO 322, PO 339
Van Veen J., PB 2.37-4, PB 2.52-4
Van Velzen A.S., AS 22.1, OC 03.3, OC 56.3, OC 56.6, OC 66.4
Van Vlijmen B.J.M., SOA 15.1, PA 3.12-4
Van Vulten F., PA 1.07-2
Van Weert H., OC 20.3
Van Wijk E., PO 321
Van Wijk R., OC 58.2
Van Winkle D., AS 07.3
Van Zandvoort M.A.M.J., PA 4.03-6
Van Zonneveld A., OC 27.3
Van Zonneveld A., AS 04.1
Van Zonneveld A., OC 27.3
Van Zonneveld A., AS 04.1
Vancraeynest C., PB 4.49-6
Vande Casteele N., PB 3.66-2
Van den Berg J., OC 20.3
Van Den Berg J., OC 20.3
Van den Berg J., PA 2.09-1
Van den Berg J., PA 2.09-1
Van den Berg J., PB 2.43-5
Van den Berg J., PB 2.51-4
Van den Berg J., PB 2.51-4
Van den Berg J., PB 2.51-4
Van den Berg J., PB 2.51-4
INDEX

Vija H., PB 4.22-4
Vijay R., AS 45.4
Vijay V.K., PB 1.32-3
Vijayan V., PA 4.09-5
Vijzelaar N.C.P., OC 13.4
Vik A., PB 2.70-3
Viken M.K., PB 3.60-1
Vikerfors A., PA 1.18-3
Vila J., PA 4.18-1
Vila V., PB 1.27-3, PB 1.30-1, PB 1.38-3, PB 2.30-6
Vilela M., PB 4.42-3
Vilimi B., PB 4.55-3
Villaca P.R., PB 4.72-6, PO 029, PO 224, PO 296
Villalobos A., AS 43.4
Villalta J., PA 3.10-6
Villalta S., AS 19.2
Villamin M.A., PO 388
Villani M., PA 3.17-1
Villasante F., PB 3.45-2
Villegas Torres B., PO 444
Villette B., PB 2.39-2, PB 2.41-6, PB 4.36-5
Villeval J.L., OC 58.5, PA 1.03-3
Villoutreix B., SC08-2.04, AS 07
Vinagre Y.M., PB 1.26-3
Vinayagam S., PA 1.41-2
Vincent L.M., AS 36.1
Vinciguerra C., PB 1.39-4, PB 1.39-5, PB 2.35-1
Vineis P., OC 04.1, OC 07.6, PA 3.06-4, PB 1.56-6
Vincent A., PB 4.58-5
Vinicius E., PB 3.52-5
Viola F., PA 2.11-2, PB 1.28-3
Viol F., PB 2.27-6
Virijevic M., PB 4.61-5, PO 005
Virtanen L., PB 4.41-4
Visentin S., PB 2.58-6, PO 218
Visentin G.P., SC04.3-1.5, SC04.4-1.3
Vishnevska-Preciniece Z., PO 177
Visonà A., AS 34.1
Vitali M., PB 4.57-6
Vithanarachchi S., PB 1.40-4
Vitkovsky Y., PO 030, PO 031, PO 340, PO 369, PO 371, PO 421
Vitlarova J., PO 237
Vivien D., AS 23.2, AS 30.1, AS 35.3, PA 3.04-6
Vizintin-Cuderman T., PB 2.48-1, PB 4.46-3
Vo A., OC 90.5
Voegtle T., OC 88.6
Voelckel W., PB 3.40-6
Vogel M., PA 4.06-1
Vögtle T., OC 76.4, OC 86.1, PA 4.04-1
Voicu S., OC 07.3
Voigt C., OC 70.2, PB 3.49-3
Volk T., PO 315
Volker L., PA 3.10-4
Völker U., PB 3.24-2
Volot F., OC 13.6, PA 3.14-4
Volovyk Z., OC 36.6
Von Brühl M.-L., AS 03.2, PA 4.20-4, PB 3.32-4
Von Depka M., PB 2.43-2
Von Der Thüsen J.H., PB 3.28-6
Von Hundelshausen P., OC 32.1
Von Krogh A.S., AS 40.4
Von Mackensen S., OC 03.1, PB 2.38-6, PB 3.38-5, PB 4.42-1, PO 145
Von Mollard G.M.F., OC 10.1
Voorberg J., AS 37.2, OC 13.3, OC 21.4, OC 43.1, OC 57.5, OC 80.3, OC 91.1, OC 91.6, PA 2.09-3, PA 4.06-2, PB 3.43-3
Vorjohann S., OC 06.2
Vorobev A., PB 2.61-5, PO 053
Vorobyeva A.I., PO 277, PO 415, PO 418
Vorobyeva N., PB 4.73-4
Vorobyeva N.A., PO 277, PO 414, PO 415, PO 416, PO 417, PO 418
Voronina E., PB 2.21-3
Vortkamp A., OC 11.3
Vos H.L., AS 11.1
Voskanyan A., PO 454
Voss K., PA 2.04-2
Vossen C.Y., OC 47.2
Vowles J., PB 2.35-6
Vrbačky F., PB 3.72-2
Vriend G., AS 04.2, PB 3.54-4
Vrkić N., PB 1.51-4, PB 3.62-5, PO 454
Vrushihi D., PO 473
Vrushihi V.D., PB 1.32-3
Vu J., OC 59.5
Vu T., AS 13.1, PA 1.06-5, PA 3.15-1
Vu T.D.N., PB 3.44-5
Vucetic D., PB 2.73-6
Vuckovic B.A., PO 286
Vucnik M., PB 2.47-4
Vuga I., PO 454
Vuimo T.A., PB 1.52-3, PB 2.50-1, PB 2.51-6, PB 2.53-5, PB 4.54-3
Vukasovic I., PB 3.62-5
Vukelic-Damijani N., PO 172
Vukosavljevic D., PO 001
Vulto A.G., PA 1.10-3
Vydyanath A., PB 2.27-5, PB 4.23-5
Vydyborets S., PO 155
Vysochin I., PB 2.53-5
Waae A., AS 40.4
Wachowiak J., PO 249
Wada K., PO 134
Wada T., PO 079
Wada H., SC19-1.02, SC19-2.01, PB 2.46-5, PO 273
Wade C.E., OC 17.1, PB 3.40-1
Wadley V., PA 4.18-6
Waekens E., OC 34.1
Waespe N., PB 1.41-5
Wagenaar G.T.M., PA 3.12-4
Wagenaar-Bos I., PB 4.67-4
Wagensveld B.A., PB 1.69-2
Wagenvoord R., PA 4.12.6, PB 2.56-4, PB 3.50-2
Wagner C., PO 395
Wagner D., PL 03, AS 21.1, OC 74.1
Wagner L., PB 3.52-3, PO 044
Wagner O., AS 34.2
<table>
<thead>
<tr>
<th>Name</th>
<th>Index Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wahi R.</td>
<td>PB 1.40-2, PB 4.48-6, PO 259</td>
</tr>
<tr>
<td>Wahl D.</td>
<td>SC03-2.01, SC03-2.07, OC 54.2, PA 2.17-2, PB 4.62-1, PB 4.63-2, PB 4.63-4, PB 4.64-1</td>
</tr>
<tr>
<td>Wahle M.</td>
<td>PB 1.41-3</td>
</tr>
<tr>
<td>Wahlmüller F.C.</td>
<td>OC 73.4</td>
</tr>
<tr>
<td>Wakabayashi H.</td>
<td>OC 28.2, OC 57.3, PA 2.05-3, PA 3.01-2, PA 3.01-3, PA 3.02-2, PA 3.03-3, PB 4.35-2, PO 088, PO 198, PO 379</td>
</tr>
<tr>
<td>Wakebayashi H.</td>
<td>PA 1.02-2</td>
</tr>
<tr>
<td>Waldow H.C.</td>
<td>PB 3.42-3</td>
</tr>
<tr>
<td>Walbrecq S.</td>
<td>PB 1.52-1, PB 1.53-5, PB 3.52-6, PB 4.40-3, PB 4.52-1, PB 4.53-4</td>
</tr>
<tr>
<td>Wallen H.</td>
<td>PA 1.09-2</td>
</tr>
<tr>
<td>Wallenhorst C.</td>
<td>AS 17.2</td>
</tr>
<tr>
<td>Wallstedt M.</td>
<td>PB 3.45-3</td>
</tr>
<tr>
<td>Walsh C.</td>
<td>PA 1.17-2</td>
</tr>
<tr>
<td>Walsh T.G.</td>
<td>OC 86.5</td>
</tr>
<tr>
<td>Walsh T.W.</td>
<td>PA 4.09-2</td>
</tr>
<tr>
<td>Waltenberger J.</td>
<td>AS 41.4</td>
</tr>
<tr>
<td>Walter M.</td>
<td>PB 4.63-5</td>
</tr>
<tr>
<td>Walter U.</td>
<td>AS 03.2, OC 01.4, OC 41.2, PA 2.05-3, PA 3.03-3, PA 4.20-4, PB 1.46-3, PB 2.49-5, PB 3.24-1</td>
</tr>
<tr>
<td>Walton B.L.</td>
<td>OC 24.2, OC 49.3</td>
</tr>
<tr>
<td>Walton S.M.</td>
<td>PB 3.48-5</td>
</tr>
<tr>
<td>Waltz T.</td>
<td>PA 4.13-1</td>
</tr>
<tr>
<td>Wanaka K.</td>
<td>PB 2.40-3, PB 2.40-4, PB 2.40-5, PB 2.68-5, PO 195</td>
</tr>
<tr>
<td>Wärkenstein T.E.</td>
<td>SC04.4-1.5, OC 21.2, PA 3.08-5</td>
</tr>
<tr>
<td>Wäschenbach J.</td>
<td>PB 1.34-5</td>
</tr>
<tr>
<td>Washington A.V.</td>
<td>OC 32.4, OC 46.3, OC 85.5</td>
</tr>
<tr>
<td>Wat J.</td>
<td>AS 31.2</td>
</tr>
<tr>
<td>Watanabe T.</td>
<td>PB 4.32-5</td>
</tr>
<tr>
<td>Waterperm C.</td>
<td>PB 4.70-6</td>
</tr>
<tr>
<td>Watine J.</td>
<td>PB 2.64-1</td>
</tr>
<tr>
<td>Watkins M.</td>
<td>PB 2.62-3</td>
</tr>
<tr>
<td>Watson C.</td>
<td>PO 045</td>
</tr>
<tr>
<td>Watson S.P.</td>
<td>SOA 06.2, AS 27.2, AS 28.3, AS 39.1, OC 34.2, OC 39.6, OC 45.3, OC 58.6, OC 60.3, OC 88.4, OC 88.6, PA 3.01-1, PA 3.05-1, PA 4.05-3, PB 1.22-2, PB 1.22-2, PB 2.25-1, PB 2.25-2, PB 2.26-3, PB 3.22-1, PB 3.22-3, PB 3.23-2</td>
</tr>
<tr>
<td>Watt H.</td>
<td>AS 41.3</td>
</tr>
<tr>
<td>Watts J.A.</td>
<td>PB 3.31-4</td>
</tr>
<tr>
<td>Watts S.</td>
<td>PB 2.39-5</td>
</tr>
<tr>
<td>Watzka B.</td>
<td>PB 1.55-6</td>
</tr>
<tr>
<td>Watzka M.</td>
<td>OC 19.4, PB 2.58-1, PO 288</td>
</tr>
<tr>
<td>Wawrzynska L.</td>
<td>PB 2.47-2</td>
</tr>
<tr>
<td>Weatherall J.H.</td>
<td>PB 2.38-3</td>
</tr>
<tr>
<td>Weber A.</td>
<td>PO 060, PO 061</td>
</tr>
<tr>
<td>Weber C.</td>
<td>AS 04.2, AS 04.3, OC 32.1, PA 1.17-2, PA 4.03-6, PB 1.32-6, PB 2.72-6</td>
</tr>
<tr>
<td>Weertyns C.</td>
<td>OC 9.5</td>
</tr>
<tr>
<td>Weil Y.</td>
<td>PO 265</td>
</tr>
<tr>
<td>Weiler H.</td>
<td>OC 28.1</td>
</tr>
<tr>
<td>Weimer T.</td>
<td>PA 1.10-2, PA 1.10-4, PA 1.10-6, PA 4.15-4, PB 2.55-6, PB 4.55-6</td>
</tr>
<tr>
<td>Weinberg I.</td>
<td>PA 2.18-4</td>
</tr>
<tr>
<td>Weinberger D.</td>
<td>PA 1.17-6</td>
</tr>
<tr>
<td>Weintrab M.</td>
<td>AS 06.2</td>
</tr>
<tr>
<td>Weintrab R.</td>
<td>PB 3.69-2</td>
</tr>
<tr>
<td>Weise C.</td>
<td>PB 3.44-2</td>
</tr>
<tr>
<td>Weisel J.</td>
<td>SC10-1.02, AS 38.4, OC 06.1, OC 21.1, PA 1.14-1, PA 3.01-2, PA 3.12-6, PB 1.57-2, PB 3.57-1, PB 4.33-4</td>
</tr>
<tr>
<td>Weiskirchen R.</td>
<td>PA 4.05-4</td>
</tr>
</tbody>
</table>
INDEX

Weiss C., OC 16.2, PA 2.10-6, PB 1.47-3, PB 4.45-5
Weiss E.C., PB 3.65-5
Weiss N., PB 1.70-4
Weitz D., PA 2.04-4
Weksler B., PA 2.15-5
Wells P., OC 12.1, FS 01.1, OC 71.1, PB 1.64-5, PB 2.48-2, PB 2.65-5, PB 3.40-5, PO 397, SPS06-01, SPS06-06
Welsh J., AS 25.3, OC 24.1, PB 3.26-5, SPS 06-03
Welz J., PA 3.17-6
Wen Y., PB 1.23-3
Wen Z., PO 317, PO 332
Wendeln A.C., OC 19.4
Weng T.F., AS 38.3
Wenjuan X., PA 2.14-4
Wenning J., PA 3.17-5
Wenzel P., PA 4.20-4
Wermes C., PB 3.37-4
Werth S., OC 91.3, PA 1.10-5, PA 3.19-2, PB 1.70-4, PB 3.26-6
Wessler J., PB 1.35-6, PB 1.37-4
West L.E., OC 32.2
Westbury S., PA 2.11-4
Westerdijk E., PO 085
Westfield L.A., OC 15.3
Westhofen P., OC 19.4
Westhoff-Bleck M., PB 3.42-3
Westmark P.R., OC 57.1
Weston B., PB 2.38-2
Westrick R.J., OC 47.1
Westwood J.P., AS 40.2, OC 52.1
Wetzels J.H., PB 1.52-4
Wexel A., AS 38.3
Weyrich A.S., AS 16.1, OC 46.3, PA 4.02-1, PB 1.29-3
Wheeler R.B., PB 1.68-6
Wheeler-Jones C., PB 2.29-6
Whelihan M.F., OC 44.4, PB 1.56-1
Whinna H., PB 3.46-4
Whisstock J., PB 3.34-3
White A.E., PB 1.22-1, PB 2.27-3, PB 4.21-6
White B., PB 1.43-4, PB 2.72-2, PB 4.35-6, PB 4.46-5, PO 034
White C., PA 3.20-3
White J.G., PA 3.01-4, PA 1.25-6
White M., PB 1.28-2, PO 106
White R.H., PA 4.18-2, PB 3.70-2
White III G.C., OC 24.2
Whitlow M., PA 4.13-1
Whitten J., AS 38.4
Whyman J.D., PA 2.20-3
Whyte C.S., PB 2.34-1
Wiangnon S., PO 082, PO 227
Wichapong K., PA 1.13-3
Wickline S.A., AS 01, AS 01
Wickremasingha P.K., OC 79.1
Widjaja S.S., PO 046
Wieczorek D., PA 4.05-5
Wiegand C., OC 10.1
Wiegand G., PO 383
Wiersbitzky S., PB 3.24-2
Wiersinga W.J., PA 1.19-3
Wiese A., PA 2.05-5
Wiese C., PB 1.54-4
Wiewel-Verschueren S., PB 2.54-2, PB 4.65-4
Wiggins K.L., OC 30.5, OC 63.1, PA 4.18-3
Wiiger M.T., PA 3.16-3
Wiinberg B., OC 24.2
Wijayan K., PA 1.13-3
Wijten P., PB 2.24-3, PB 3.24-6
Wiggin K.L., OC 30.5, OC 63.1, PA 4.18-3
Wilger M.T., PA 3.16-3
Wienberg B., PO 289
Wijeyeratne Y., PA 4.18-3
Williams B., OC 41.3, OC 41.4, PB 2.62-3, PB 2.62-4, PB 2.62-5, PB 3.62-4
Wilmen A., PA 2.15-2
Wilmink J.W., OC 31.2
Wilmot H.V., PB 3.49-3
Wilsag Y., AS 11.3, OC 59.6, PA 4.18-4, PB 4.66-2
Wilson J.F., OC 90.4
Wilson M.J., PA 1.10-4
Winckers K., OC 64.2, OC 73.3, PB 1.35-1
Windjug W., OC 83.2, PB 1.39-3, PB 3.37-2, PB 3.49-4, PB 3.49.6, PB 3.67-4, PB 4.74-5, PO 355
Windjug J., SPS03-05
Wingerter A., PB 4.60-5
Winkoff R., SC11-4.02
Winkels H., AS 04.3
Winkler A.M., PO 327
Winkler J., PB 1.26-2
Winkvist M., PA 2.15-6
Wintermute J., OC 57.3
Wiseman S., PB 1.74-5
Wischmeyer P., PB 4.70-4
Wiseman P.P., PB 2.22-1, PO 318, PO 341
Wisniewski T., PB 3.38-5, PB 4.37-6, PO 123, PO 124, PO 125, PO 132
Wisniewski T., PB 3.61-3
Wissel T., PO 395
Witkop M.L., NS 01.1, PB 1.74-5
Witkowski E.R., PB 3.48-1
INDEX

Witteman J.C.M., PA 2.09-1
Witten A., PB 1.68-1
Wittens C.H.A., PO 241
Witzel R., PB 2.55-6
Wnek G., OC 53.4
Woei-A-Jin F.J.S.H., OC 17.4
Woersching A.L., OC 79.6
Wohner N., AS 01.2, AS 09.2
Wojtasinska E., PB 3.31-2, PB 3.66-6
Wolberg A.S., AS 35, OC 05.5, OC 24.2, OC 49.3
Wolfe P., PA 1.16-1
Wolfsegger M., PA 4.06-5, PB 3.55-4
Wölke S., OC 60.2
Wolter M., PB 3.39-5, PB 3.39-6
Wolz M., OC 16.1, PB 4.45-3
Wong S.L., AS 21.1, OC 74.1
Wong S.S., PA 3.14-6
Wong W.Y., PB 1.36-4, PB 2.37-2, PB 3.49-4, PB 3.49.6, PB 4.58-6, PO 160, SPS 04-04
Wong Z.C., AS 13.3, OC 81.4
Wongkapanich S., PO 027
Wongwanit C., PB 2.64-5, PO 076
Wongwetaawanakoon P., PO 110
Woo K.S., PA 2.05-4
Wood J.P., AS 36.2
Woodhams B., SC05-2.02, AS 26.2, PA 1.11-1, PA 1.18-3, PB 1.22-5, PB 1.59-1, PB 1.72-6, PB 2.58-6, PB 4.63-5, PO 085
Wooding C., OC 91.5
Woodle A., PB 1.53-3
Woodruff B.S., PB 4.49-3
Woods A.I., PB 2.73-4, PB 4.43-6, PB 4.44-2, PO 385, PO 431, PO 438
Woods T.A.L., AS 02.2, PA 3.08-2, PB 1.37-1, PB 1.65-5, PB 2.33-3
Woolley T., PB 2.39-5
Wörediumann S., PB 3.52-1
Working group, PA 3.08-4
Woszczynk D., PA 1.16-3
Wouters D., PB 4.67-4
Wraith K., PB 4.26-2
Wright E., PB 1.21-6
Wright J.R., OC 64.6, PA 4.02-5, PB 2.26-5, PB 3.71-4
Wroblewskas A., OC 57.5, OC 80.3
Wu C., PB 1.61-4, PO 194
Wu C.C., PO 460
Wu D., PO 088
Wu D.C., PB 1.69-6
Wu F., PA 2.11-3
Wu J., OC 24.1, PA 1.09-5, PB 1.58-4, PB 3.33-5, PB 3.71-5, PO 086, PO 113, PO 166, PO 422
Wu K.H., PO 394
Wu P.H., PB 1.73-4
Wu R., PO 182, PO 221
Wu W.B., PB 1.73-4
Wu W.H., PB 1.69-6
Wu X., PB 1.62-6
Wu X., PB 4.35-5
Wu X., PO 182
Wu Y., OC 58.3
Wu Y., PB 1.24-1
Wufusas A.R., PA 1.14-6
Wuilemin A., PO 022
Wun T., PA 4.18-2, PB 3.70-2
Würtz M., PB 3.21-3, PB 3.21-5
Wurz T., PO 328
Wu-Tien H., PO 464
Wypasek E., PB 4.41-2
Wyseure T., SC05-2.06, PB 2.34-5
Wysokinska M., OC 14.4
Xafaki P., PB 4.71-3
Xavier F., PO 173
Xavier F., PO 301, PO 302
Xenarios I., AS 15.3
Xi X., PA 2.11-3, PB 1.57-1, PB 2.57-3
Xi X.D., PB 4.35-5
Xia B., PB 2.43-4
Xia J., PB 2.59-1
Xia M., OC 32.6, PB 1.32-2, PB 1.32-5, PO 470
Xia W., PB 1.55-3
Xia H., SC20-2.04
Xiao Y., OC 38.4, PB 1.56-5
Xie Y., PB 3.35-5
Xin D., OC 25.1
Xin Z.F., PO 379
Xinjie L., OC 82.3
Xiong S., PB 2.29-4
Xiong Y., PB 1.35-2, PB 1.39-3, PB 2.58-5, PB 3.38-2
Xiuri J., PB 1.64-6
Xu C., OC 11.4, PB 4.26-1
Xu C.J., PB 2.64-6
Xu J., OC 47.1, OC 69.1
Xu L., PB 3.28-4
Xu X., PA 4.01-4, PB 1.69-6
Xu Z., AS 15.2
Xuan M., PA 2.19-6, PB 1.74-4, PB 2.32-3, PB 3.35-6, PB 4.29-5
Xue F., PA 2.19-6, PB 1.74-4, PB 2.32-3, PB 3.35-6, PB 4.39-5, PO 226
Xuefeng W., PB 1.55-5
Yaalaoui S., PB 2.21-5
Yacoub D., PA 4.02-6
Yada K., OC 37.3, PB 1.36-6, PB 4.37-1, PO 352
Yadav P., PB 3.74-6
Yadav S., PB 3.35-4, PB 4.38-4
Yagi H., PB 1.33-2
Yagmur E., PA 4.05-4
Yakimeno A.O., OC 10.2
Yakovleva V., PB 4.36-4, PO 384
Yakushkin V., PB 4.27-5
Yamada N., PB 2.46-5
Yamada S., OC 69.3
Yamada S., PB 4.59-6
Yamaguchi S., PB 1.33-2
Yamaki T., PA 3.20-4
Yamamoto T., PA 4.17-1
Yamamoto Y., PB 2.74-1
Yamamoto H., SC02-2.03, PO 079
Yamamura S., PB 2.34-2
Yaman H., PO 451
Yamanouchi J., PB 2.69-4
Yamasaki K., PB 1.73-1
Yamashita A., OC 43.3, PB 1.61-1, PB 4.69-5, B 1.73-1, PB 3.55-1
Yamazaki K., PB 1.61-1, PB 4.69-5
Yamazaki Y., PB 4.59-6
Yan K., PB 2.59-1
INDEX

Yen R., PB 1.24-1, PB 1.24-4
Yanachkov I.B., PB 1.21-6
Yanachkova M., PB 1.21-6
Yanagida Y., PO 079
Yanagisawa Y., PO 404
Yanamoto H., OC 47.3, PA 1.06-3
Yang F., PA 4.01-4
Yang J., AS 27.2, OC 88.5, PA 1.19-4, PO 221
Yang L., OC 05.1, PA 3.12-2, PA 3.16-5, PB 2.44-6, PB 3.56-5
Yang R., PA 1.05-1, PA 1.05-2, PA 2.19-6, PA 4.04-5, PB 1.74-4, PB 2.32-3, PB 3.35-6, PB 4.29-2, PB 4.29-5, PB 4.39-5, PO 226
Yang S., PA 1.05-2
Yang S.-J., OC 57.2
Yang T.H., PB 3.31-3
Yang W., PB 3.43-2
Yang Y., PB 1.24-5, PB 1.25-3, PB 1.74-4, PB 2.32-3, PB 3.35-6, PB 4.29-2, PB 4.29-5
Yang Y.W., PB 2.70-6
Yang Z., AS 15.2, OC 58.3
Yano Y., PA 1.31-4
Yao J., PB 4.24-3
Yao S., PO 343
Yao Z., PB 3.49-3
Yaoita N., PO 319
Yap E.S., PO 032
Yarovo S., OC 21.1
Yashenina E., PO 207
Yasukawa M., PB 2.69-4
Yatagai C., PO 404, PO 458
Yatomi Y., PO 038
Yau I., PO 307
Yau J.W., AS 13.2
Yau P.M., OC 24.4
Ybabez R., PB 1.54-4
Ye X., PB 2.58-5, PB 1.68-4, PO 400
Yee A., OC 15.4, PB 1.44-4
Yee D.L., PA 3.17-3
Yee T., OC 56.3, PB 4.39-6
Yee T.T., PO 162
Yeh C.H., OC 49.4
Yen Wong W., SPS01-01
Venicesu I., PB 3.42-5
Yenson R., PA 2.18-2
Yeo H.I.F., PB 4.47-6
Yeon E.H., PO 081
Yeung J., PB 1.61-3
Yhim H.Y., PB 4.69-6
Yang Y.F., PA 1.09-6
Yildirim A., PO 294
Yildiz I., PB 3.51-2
Yildiz L., PB 4.39-6
Yilmaz M., PA 163
Yin E.T., PO 342
Ying K., PB 2.48-4
Ying S., PB 4.28-6
Yip C., PO 372
Yohannes E., PA 4.09-2
Yoko S., PB 2.50-6
Yokom D.W., PA 1.16-4, PA 1.20-5, PA 1.70-5, PB 2.61-3
Yokotani K., PB 4.59-6
Yokus O., PO 101
Yolbas I., PO 353
Yon A., PA 1.17-4
Yoon K.Y., PO 174
Yoon H.J., PO 174
Yoon J.H., OC 48.2
Yoshida E., PO 458
Yoshida K., PB 2.46-5
Yoshida S., PB 4.21-5
Yoshida Y., FS 03.2
Yoshihashi K., OC 14.3
Yoshimura H., PB 4.61-1
Yoshioka A., OC 14.3
Yoshioka R., PA 3.08-6
Yosipovitz O., OC 82.1
You C.W., PB 4.38-5, PO 347
You G., PA 3.07-5, PB 2.35-3
Youghare I., OC 55.2
Younes S., PB 1.25-4, PB 4.62-5
Young G., PB 3.68-1, SPS 04-05
Young L.K., AS 42.4, PA 1.20-3
Young V., PB 4.62-4
Young G., SC09-1.05, SPS03-06
Young Joo J., PB 2.61-4, PO 462, PO 463
Yu H.P., PO 229
Yu K-S., PB 4.21-3
Yu P.C., PB 4.27-3
Yu S., OC 11.4, PB 4.26-1
Yu Y., AS 41.3, PB 1.39-1
Yu Y.B., PB 1.67-5
Yu Z., PA 4.19-4, PB 2.72-3, PO 086, PO 422
Yuan Y., OC 45.2, OC 76.1, PA 4.03-1, PA 4.03-3
Yuana Y., PB 3.30-1, PB 3.30-2
Yuantari R., PB 3.74-5
Yue M., OC 11.4
Yuge R., PA 4.17-5
Yukio O., PA 2.02-5
Yuliang M., PB 4.28-6
Yuniaidy Y., PB 2.30-2
Yurttas B., PO 101
Yusen R., PB 2.18-1
Yuichiyo F., PB 1.62-1
Yuusaku K., PB 1.62-1
Yvan Frigout, Orset C., AS 23.2
Za T., PO 201
Zabarovskaya Z.V., PO 309
Zabczyk M., SC05-2.02, OC 48.4, PB 3.57-4
Zabo E., PA 1.04-5, PA 3.13-1, PB 3.53-6
Zaccher F., PB 3.44-4
Zadok O., PO 492
Zadro R., PB 4.51-4, PO 151
Zagatti M., PB 3.32-3
Zahedi R., PA 2.05-3, PA 3.03-3, PB 3.24-1
Zahedi Z., PO 054, PO 131
Zahlia B., PO 351
Zahangi H., PO 382
Zaid Y., PA 4.02-6
Zajdel K., PB 3.31-2, PB 3.66-6
Zakai N., AS 01.3, PA 4.18-6
Zakaria Peveshki M., PB 4.38-6, PO 114
Zakharova N.V., PA 3.15-3
Zakharova E., AS 47.5
Zambelli S., PB 1.47-5, PB 2.49-3, PO 267
Zamolodchikov D., AS 24, PB 4.49-1
INDEX

Zampese E., PA 1.09-1
Zampolli A., PB 2.23-1
Zanivan S., OC 54.1
Zanolini D., PA 1.13-6
Zanon E., OC 14.2, PA 1.13-2, PB 1.36-1, PO 033
Zapariy A., PB 4.36-4, PB 4.59-5
Zapletal O., PB 1.43-3, PB 3.42-6, PB 4.44-5
Zapponi K.C., OC 08.5
Zatloukalova M., PA 1.06-1
Zavrelova J., PB 1.43-3, PB 3.42-6, PB 4.44-5
Zawadzki C., OC 13.2, OC 13.6, OC 38.5, PB 4.32-2
Zawilska K.M., PO 249
Zaytseva N., PB 4.27-5
Zdziarska J., PB 3.42-4, PB 4.41-2
Zebeljan D., PB 2.51-5, PO 004
Zeebregts C., PO 487
Zeerleder S., OC 05.3, OC 08.3, OC 08.4, PB 2.67-1, PB 4.67-4
Zelter T., PB 1.70-2
Zemlyanoy V., PB 4.68-2
Zemmour D., PB 3.73-6
Zeng M., OC 69.2
Zeng W., PB 2.71-5
Zentai C., AS 33.3, PB 1.57-3, PB 4.57-1
Zerbib P.F., PB 1.27-2
Zeri G., OC 07.4
Zernecke A., PA 4.03-6
Zetterberg E., PB 3.51-3
Zeus T., PA 2.01-4
Zhai L., OC 69.2
Zhalayalov A.S., PB 4.34-4, PB 4.74-1
Zhang A., OC 48.2
Zhang D., PA 1.05-1, PA 1.05-2, PB 2.32-3, PB 4.29-2, PB 4.29-5, PO 226
Zhang G., AS 15.2
Zhang J., PA 4.01-4, PB 1.23-6, PB 2.48-4, PB 4.22-6
Zhang L., OC 58.3, PA 2.19-6, PB 1.74-4, PB 2.32-3, PB 3.35-6, PB 3.57-1, PB 4.27-2, PB 4.29-2, PB 4.39-5, PO 113, PO 221
Zhang M., PA 1.12-4, PB 4.22-6
Zhang N., PO 182
Zhang Q.W., PB 3.34-3
Zhang R., PB 2.44-6
Zhang S., PA 4.01-1
Zhang W., PB 1.24-1, PB 4.22-6
Zhang X., PA 1.05-2, PB 2.32-3, PB 4.29-2, PB 4.29-5, PO 166, PO 226
Zhang X.M., OC 41.1, PB 3.50-5
Zhang Y., OC 58.3, PA 4.01-1, PB 2.44-6, PB 3.56-5, PO 343
Zhang Y., OC 69.2
Zhao G., AS 44.3
Zhao L., PB 1.23-6, PB 4.22-6
Zhao S., PB 1.73-1
Zhao Y., PB 1.73-1
Zhao Y., PO 166
Zhao Y., PO 343
Zhao Y.X., PB 2.32-5
Zhao Z., OC 32.1
Zharkov P., PO 306
Zhen N., OC 69.2
ZhenNi M., PB 2.43-4
Zherkov P., PO 306
Zhen Y., PO 182
Zheng L., PB 2.29-4
Zheng L.X., PB 3.33-6
Zheng Y., OC 74.2, PA 2.02-6, PB 4.56-1, SOA 12.2
ZhenNi M., PB 2.43-4
Zhmurov A., PA 1.14-1
Zhou C.J., OC 08.6, PA 4.04-2
Zhou F., PB 1.74-4
Zhou H., PB 4.25-3
Zhou J., AS 13.1, PA 3.15-1, PB 1.57-1, PB 2.57-3
Zhou L., PB 3.43-2
Zhou P., PO 419
Zhou Q., OC 11.4, PB 4.26-1
Zhou S., AS 25.3, AS 34.3, OC 31.4
Zhou T., PA 1.05-2, PA 4.04-5
Zhu C., OC 35.3
Zhu G., OC 47.1, OC 55.2, OC 87.1
Zhu J., OC 15.3
Zhu L., AS 45.1, OC 37.5, OC 56.4, OC 85.6, PA 4.01-1, PA 4.01-4, PB 4.26-3, PB 4.56-6
Zhu M., PB 2.41-1
Zhu M.Q., PB 2.32-5
Zhu W., PO 419, PB 3.33-5, PB 3.71-5, PO 086
Zhu X., PB 3.28-4, PB 3.71-5
Zhu Y., PB 1.25-3
Zia A., PB 1.68-5
Zicari E., PB 2.31-6
Zieger B., PA 2.08-1
Zielinski C., AS 34.2, OC 31.1, PA 1.16-5, PB 3.60-2
Zillikens D., PB 3.39-4
Zimmer N., OC 80.5
Zimmerman G.A., OC 46.3
Zimmerman Y., PB 2.66-1
Zimmerman Program Investigator, PA 2.08-2
Zimmermann A., PB 1.47-5, PB 1.54-3, PB 1.66-1, PB 2.49-3, PB 2.53-2, PB 2.72-5, PO 267, PO 268
Zimmermann J., PB 3.47-3
Zimmermann R., PB 3.72-6, PO 354
Zimring J.C., OC 61.1
Zinkernagel A.S., AS 44.2
Ziółkowska E., PB 3.61-3
Zirlik A., PB 2.24-5
Zito F., PB 1.50-1
Zivelin A., PA 3.14-3, PB 3.36-1, PB 4.35-4
Zivkovic I., PO 001
Ziyatdinov A., PA 2.20-1, PA 2.20-5, PB 1.54-2
Zlabinger G., PA 1.16-5
Zloko B.V., PB 2.56-2
Zobairi F., OC 72.1, PA 1.04-2
Zohrabyan D., PO 051
Zoica B., PO 410
<table>
<thead>
<tr>
<th>Name</th>
<th>Page Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zolfaghari S.</td>
<td>PB 4.45-6, PO 278</td>
</tr>
<tr>
<td>Zolghadri J.</td>
<td>PB 2.72-4</td>
</tr>
<tr>
<td>Zollner S.</td>
<td>PA 1.12-1, PA 4.15-4, PB 1.58-3, PB 4.55-6</td>
</tr>
<tr>
<td>Zöllner H.</td>
<td>PA 3.08-5</td>
</tr>
<tr>
<td>Zoni Berisso M.</td>
<td>PA 4.10-1</td>
</tr>
<tr>
<td>Zorenko V.</td>
<td>PO 384</td>
</tr>
<tr>
<td>Zorio E.</td>
<td>PB 2.69-1</td>
</tr>
<tr>
<td>Zotz R.</td>
<td>OC 34.4, PB 4.66-1, PO-498</td>
</tr>
<tr>
<td>Zucker M.</td>
<td>PA 3.14-3, OC 05.5, OC 77.1</td>
</tr>
<tr>
<td>Zufferey A.</td>
<td>AS 15.3, PB 2.67-6, PB 3.21-4, PB 3.24-4</td>
</tr>
<tr>
<td>Zuliy S.</td>
<td>PB 4.62-1, PB 4.63-2, PB 4.63-4</td>
</tr>
<tr>
<td>Zuithoff N.P.A.</td>
<td>PA 4.16-1</td>
</tr>
<tr>
<td>Zulfikar B.</td>
<td>PB 1.35-4, PB 4.36-2, PO 442</td>
</tr>
<tr>
<td>Zuñiga P.</td>
<td>PA 3.09-2, PA 4.05-2, PB 3.25-4</td>
</tr>
<tr>
<td>Zupancic Salek S.</td>
<td>PO 105, PO 151, PO 284</td>
</tr>
<tr>
<td>Zuurbier C.M.</td>
<td>FS 02.3</td>
</tr>
<tr>
<td>Zuurbier S.M.</td>
<td>PA 1.16-2</td>
</tr>
<tr>
<td>Zuurveld M.</td>
<td>OC 57.6</td>
</tr>
<tr>
<td>Zwaginga J.J.</td>
<td>PB 2.74.5, PO 358</td>
</tr>
<tr>
<td>Zwicker J.</td>
<td>SC13-2.02, OC 16.3, PB 3.61-2</td>
</tr>
<tr>
<td>Zyuryaev I.</td>
<td>PB 4.27-5</td>
</tr>
</tbody>
</table>
Guillermo Nicolás Pirazzi

A positive attitude is a great help

Guillermo has severe haemophilia A with inhibitors

Scientific Programme

Wednesday, 3 July 2013 · 18:30 – 20:00

Welcome & introduction

Chairs: Eveline Mauser-Bunschoten, NL, Andrew Mumford, UK

Challenges faced by haemophilia patients with inhibitors today – what have we learned?

Stephanie Seremetis, US

NocFactor® efficacy: latest results from the largest pivotal trial in haemophilia with inhibitors among children and adults

Eli Neufeld, US

Safey in numbers: evidence from NocFactor® in children and adults

Eli Neufeld, US

Haemoglobinopathy: small molecular changes – what are the potential risks?

Silke Ehrenforth, DK

Navigating a complex landscape: successful data collection in rare bleeding disorders

Guy Young, US

Immunogenicity: small molecular changes – what are the potential risks?

Silke Ehrenforth, DK

Concluding remarks


www.haemophilia-events.com

For more information, please visit us at the Novo Nordisk Exhibit/Medical Information Area

Scientific Programme

Welcome & introduction

Chairs: Claude Negrier, FR, Stephanie Seremetis, US

New perspectives on risk factors for inhibitor development in severe haemophilia A: the results of the RODIN study

Samantha Gouw, NL

Realising the potential of recombinant technology: reliability by design

Robert Klamroth, DE

Clinical outcomes with turoctocog alfa: reviewing the guardian™ trials

Maria Elisa Manuso, IT

Advancing the treatment of haemophilia B: a paradigm shift with recombinant glycoPEGylated FIX?

Claude Negrier, FR

Closing remarks


Please join us for a light meal after the symposium

A snack will be provided prior to the start of the symposium

More information on: www.haemophilia-events.com

For more information, please visit us at the Novo Nordisk Exhibit/Medical Information Area.
Scientific Programme
Welcome & introduction
 chairs:  claude Negrier, FR, stephanie seremetis, US
New perspectives on risk factors for inhibitor development in severe haemophilia A: the results of the RODIN Study
samantha Gouw, NL
Realising the potential of recombinant technology: reliability by design
robert Klamroth, DE
Clinical outcomes with turoctocog alfa: reviewing the guardian ™ trials
maria elisa mancosu, IT
Advancing the treatment of haemophilia B: a paradigm shift with recombinant glycoPEGylated FIX?
claude Negrier, FR
Closing remarks
chairs
A snack will be provided prior to the start
of the symposium
Please join us for a light meal after the symposium
For further information, please visit us at the Novo Nordisk Exhibit/Medical Information Area
From lab to life.

Vigorous research. Uncompromising innovation. Steadfast leadership. For over 150 years, Pfizer has been changing the course of diseases and lives through the introduction of new treatments. Today, with the strength of Pfizer behind us, Pfizer Hemophilia is committed to meeting the unmet needs of the community with conviction and compassion.

Join us on the road to innovation.

Visit us at stand #350
Vigorous research. Uncompromising innovation. Steadfast leadership. For over 150 years, Pfizer has been changing the course of diseases and lives through the introduction of new treatments. Today, with the strength of Pfizer behind us, Pfizer Hemophilia is committed to meeting the unmet needs of the community with conviction and compassion.

Join us on the road to innovation.